<SEC-DOCUMENT>0001055726-22-000008.txt : 20220301
<SEC-HEADER>0001055726-22-000008.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220301155908
ACCESSION NUMBER:		0001055726-22-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		22697793

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ino-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:91a42a7e-9c16-46a4-89e4-78ae514a2e8d,g:17ea50c5-1e55-4356-a463-d0e13f29ef69,d:e30ae5fecfcc4388997084d44bc65ac3--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ino="http://www.inovio.com/20211231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl80LTEtMS0xLTEzMDc5_8755cd1d-91d1-41b9-abbe-2c7dcd95375a">false</ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl82LTEtMS0xLTEzMDc5_3c2d0efc-7cbd-4670-9985-b27825f9e973">2021</ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl83LTEtMS0xLTEzMDc5_4bcde891-53ea-43e2-a319-ae32be777286">FY</ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl85LTEtMS0xLTEzMDc5_e9c89ecb-12ca-4003-996e-8b503292b952">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="i6fbf1d83933c4796bd3e5b9f8257c137_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i6fbf1d83933c4796bd3e5b9f8257c137_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4c6e93100cda41698c2d90ac7b3add33_D20190219-20190228" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzItMS0xLTEtMTMwNzk_4423523c-0ff7-4e62-b292-9db84deb65f4">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i064aac05f8624a0389f91fa023f36ad6_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzUtMi0xLTEtMTMwNzk_2f8efbb9-e559-4a7b-b12a-9f582b3a1bc3">0.0002110595</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i338ace46836e41128cd3590125bfb51c_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzYtMi0xLTEtMTMwNzk_664055f3-c0b4-4d80-b686-ce098cb9815e">0.0002756873</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id595b8847ae94191b14b7d82020a700e_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzktMi0xLTEtMTMwNzk_2cc082c1-a41a-4200-844a-a4ec8f0df4e6">0.0002147766</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2b7d314600cf45488694aa3608c2b239_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzEwLTItMS0xLTEzMDc5_af3f5804-0a5a-4fe4-9efb-f66657e69664">0.0003579611</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38a5c1786aa4218ab4b1daf6b02098d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i463a7ab03b6446db9e60c8b7ad87def3_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia60088662e644556a450fd3a05824f9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b698702e82d457c8216eac55fae002d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i347d60d556c2498fb9d80645b9a706b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04336b766df84aa2a42f4abf68368421_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64eac47556245f8b42cc012f2ffe0ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ecae667f48745ad9fd43b801e35b9c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i92ed9e2d8d23416fa2216a18597af29a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6ed30dc86a4b31b83a17f1a97066df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea5902416e14a1a8963131a95b4e349_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28851dd7ca34c3cb482d22189f39e47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3f177a526c4d6e9937328cb2042e27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402a2216be6243d79489c5e44b694136_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87e8afe51e242b296534833ed309ce2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44dd97a11a2748a98bed361bca96dcc5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1adaf3d29db647be821417221977869b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54e996352a04ec28cb7e31c037d184e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4990fae62ff441f4acf38817077260d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbcf710c43f435cb1efd59b9274f753_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe285a056e84e7690752bb6bae44144_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411612102a3e4c9e911d58c817263069_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d1df5b1c5b4cc3b96a485c772c8fc7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib319c6f186cc48f394c757bf041fbc05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00acd8f0e9248db874b93cb6b3eb23a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c6f4ee12934a40a1ea728d479c1b02_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a77f36ff44452d920fe5904cb46826_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac56a7bfee5749ab9ef8c4fb331f0dd3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d85a8106cf746239de37759928ef0f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ef69988114421e91fd39d86626a033_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92f9fbbfaa2469dbe870606abca1b9d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0209f8c94d740adaa36dd67c48d6a20_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a501ec111d47fbb2c02a92d18044b8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i934d7a839de6474e9b47fe4f2dde4862_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba84c3ae05e74f7b95113a5d797a1b3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38bba6f63c734bfb8d21fd427b61fbe7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c45e9e8670742aabe1a2097889e1003_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9737ecdffd44d1b2551cce0509fa59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b5dcddd0d942b9afa00d1eb75fd3fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cada50c939e412c9ab1db2da9a0465e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59302a922e4f4aca836ef50c844fef86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b91df562f874655a19dab108f20fb24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3c8a7e151648fa9963ae445b27955e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ad737a11be4f09bde8169850c3ab12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd975f309a74bc9830110950e77a982_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636993c134064180ad2590c08fa52072_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d08995f70474651a10b743f24c3decc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a0eee5ee74422dbf15e46a3b2632fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01da3ab01f954252bc6510f0dbd029c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb449b556844657b6e6671a8579fde4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c72b6e9e8eb4b8ea4fdb38d60151ad5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib722279b8997488c897a37f118e63061_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11f8a3ab55d49a8bb586876044a035e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019963c050f847419c1846c58634267e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5e9f8d356d417887e0a2ce250b61f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c5137421a60479cb080a26e2eb6d08c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f35c89987a74786896285ad7ae13979_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13876df5a7d44b1a938e8ee19872763d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie453dc0fe621472f991c3336fea7f4cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2aed4a0d2c3496d81638d7203fff95f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcee4832a056439890bc22cca53ebf0a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755387a3bd2040869919d38bac155975_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5f38759d4c94c9c9f578011dc9fc2d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64e7bfdf2294cae86cf31ff7714dac5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d91dffb8ff14276905969cb9451fbd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416413e6f44e49bf9af9f5ca9c4a9d19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386a00e8a13746fa9abf8ea15747827d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3348c69519f04942adeb29a5daf412ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic404b3bf911d46e48fef168a1506f7d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbb09860a3f4b019d6e6f2db9a0996b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61571339f1d34229a32dd11283124d8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2f6172e00ae438dba3e872301590376_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3b5941f67f4dd7839d1d0ee8b932e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3185052214d241188760405d062c3a93_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb066154a0b4e63a1b45dee6f783336_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iec094623890140ecbe43e62d969a9e6e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="ia4b54e7447e843b785376b2edd00a1df_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ino:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6fbf1d83933c4796bd3e5b9f8257c137_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef43783aafd41bcbd015396830a6453_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22218578fe146a690414073c1055f9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie75672a5cd7f4ee7b50fd63d1effb9b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib858b60634554cfeb353213f382d8701_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1619b504fabd4b03803cf6d1bd43cdf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf57bbc765a648e88af4e001faf909bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d7d0e03523439aa100b18e4b73ea8f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfd184b5e79415896cd4f9f6baac7f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf52c18686740578bf1f8f9c8cbaa61_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5417c1b5a9294d67b2ece5b90e913521_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153bb9c9446b45eb8aa80f75f7399f3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie80d43743e6a4d668eea6d7bee8e1496_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef6a305f4c7456382cbb6d2f1e80f0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58bb2dd8a4143a19908c58b705c40c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0ab257a6974dcdaba93f9ed07ea5f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818c9cc8d85740b2bf619cb778985673_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8eca20d5f34697abb3f086dc268f34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c7a36858de4d50ad50b6fa093cd1a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia57b862418ed4691a1094727113e9132_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d211e27d9de438bae12df540aefb132_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c100e0e5d064a128da83ec7e1d7bdb0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c4d94d9b204b7b9bfcdd26fabbc2c7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985caa6fe2204c79885e3f347c621473_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ebf37c07fc64f66897dbd181366f4f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i161b5c6c81dd4f91ba0ee787fa80afde_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfdf8c8894d47eaa3893a5f0fb45ab8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93761468f4d2413c9fbddde17352101f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i656c17b4e38a4ee491d602bf63aa7c19_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i919eacd755534f7f903fe6245b2c707c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e0b5e7a72c42b1895acaf229856efe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40e1d2d136dc4c518979cf57c6a1b20b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4a0ade4f3147fc8b24dc411f419712_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873c90e08f654501a8ad20a07c60193f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a1ac7d82334e4baf6955ef04815ce4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57fe04684f046938af512e85a6ba191_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ec58bb67dc470a99951e5275067d10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206cac58be234c169495b0e1f07f3b28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if59018c846e149458509f9c8cd25b24c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99bde567bfb41acbc76d3e0b885ec12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb847a1857fb4bf8b3cbe776dd9e29ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e0404405254e2e98e726f09230deb6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567cdce8ec3f4d2eab6aec7e81bd94f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b628859583d45a886cbba8bc22a2f8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01b088cd46a48608cf5867ab6b78956_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08cf4a688e1e4557bbe98d00332e150f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e4662477174747a0d272e1d8792a76_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f9c1676db542ada5764c97da93a468_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee4ca6918ae4fa796d41036cae115ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia77dac3a01a74815904a03fe7971a7d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b35ca32ad6b49038d3962c931ab0301_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad521f20e6d42869f7f73948ebbd477_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14838e9bc6fc4c4487a1c7f9172258a4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c6acd539524f568bd5b29f3c45c3ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb2df8412c044c118cdb9553e4cf95ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52aca042d6ff42d1ba348dd26d66cffd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59968761470a4f2d802618f91010f7b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6262eab5b3c948d69de6a49741df2b15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if71d5ef52a394d6797808af8b5299731_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ec222c4b76432ca9ce78c095a00f5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06bbd4127d1e42a6b45c7cdf18fc01b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f4b2524a6745389ebfd4167248f100_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2613d428a449579acc6b28ca21928c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ded10e0f0e44a2bb4ece994cc771846_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef8fd46f8504fc48eaafd248555647c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ec0f7d61a247a29e6f8b976b92fdd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e94d242541e4769b9580dca20dd055f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c6068a0d87f4fa585046b88cd0c29e1_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345933f791f148b9ab11262a4e3fabc8_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae7a6139749478dae2789fde984a73d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib423f4e3e0a948d1a2df6de8efddc903_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a9f6f4af6b431f8ca5510726bbceba_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc3a56b04444e0ea7504b1ecbc37e79_D20171231-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-31</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3823ff3500456ebdf2aa61528c8e05_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4218b3818f30409db7b03360c59d6a05_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60c9823b100427ba62081e1ce28130e_D20180411-20180411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-11</xbrli:startDate><xbrli:endDate>2018-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6f8e470b114624a1428d5fe05d2883_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeaaf2a45e274b08822dc97c5f1d6548_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i627a7ce3c55f4c9bac1b8724c31a2b9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b9f355c6d44067b5c91a145b75b3d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3fab37e71394ac2af69e86ac41d336a_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad38c575aa2469a960d1b3021807208_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1057c5132f4610b04adc365c092be4_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02735771448f4559ad8ad7eb771f42a0_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e5d35d7de44a078dff01c3cfa43227_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia081c81a473a4f3399c27e4703bbc7ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd977534e815463fb781c4067853b53b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i781f7721feee4c4ca2ff6d186fcffbf3_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fde4b781ebe4327bf969f8140d88ecf_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1e6c89e8ca49e9b134471c2d4cd4c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie34b4d8f0d4e4a1d973ed63d51a51649_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbf0edc36f446378983dc8302caa4d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0b58a07e594872a449c2f8a64d1f50_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd3cbd20ab142cca107c1f4cf711e83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00eb7864be0441e898f5a5f77d203ff1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4af1a162cd4deda134bce933897a10_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b7af31bd224297994ebe728b26c780_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5575e68486ee4cd5b43dde605b161a50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128585ac13474b3091b72cd864723b37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e2d517b98c4e12bb4ac8e2131fe365_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4422f4760ee74f3ba71d8253cc93cf53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf6fb5f859b42d78d7c7a430a42ff42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0732cac3e67f42b28ba168e6b4b35a13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib71562a57439406ab96e0f74edd9d947_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9327b185da7843ef8a8df8e03d20d44f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib292d78a61bd4623a795a93607e5c9ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003f22a5fb7445d89be30a83788b0272_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b0d42be39843d9b1022921606edc04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ac4c61823a437d8c9b6aee26cf229b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156d5ef8518844db95ef4f40d37d1035_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id939b4ea33cc496d933ef0fa32e5168b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ino:investment</xbrli:measure></xbrli:unit><xbrli:context id="i7071211447db4c3e8f228036ebc64654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26fd2f2ca1804cf8b78f9f97fc906ec9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6f0020516c4a6497376d5f1359cbd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39b5179785c4f0d952c95c50da89619_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3f9b2236a74d2da2c502071722bc13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15cdf0125f0d414b83d3aa528c069939_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c910afcfe76477c8adf69b6afc36738_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb11ec937978481798d9a2fa621b2545_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674ddfb5b1174eab854007ba42538368_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b606f8ce6104231abbb11b014a54bb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7104e94d6b6402b8ad5ba5ea9a6dcf3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78b7886eb8f4368bd3e159d7be11563_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c4fc55ad384a2d90e87c0e989d38c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1effe86d89143f3aded22e7fd8fd339_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4c0a4f24f64339938c89d15957c736_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1245efc94094f599b7d7d3c818aa250_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f0a0b420ecc4a6b936201d1941936bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d04338821da4044877e4bf707d5526b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2231094e244b4b8f8d798ed1d5a673_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5b914f5f74342a2862d941121e5a48f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i395742f3d6cc49d3b3f55b2c752865d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d61d6b3e5354708ac4bab1f051af74a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6d60d841db49b884995b9d409a2699_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1fcbe29e328435f900b5cf60bf4ffb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9693506cef01463bb3c7d6635695bba9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32393fe851fd43879b59a162035f2f85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56064b8e76fe40919fd24d219d24a453_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8277afd2efb5453b93534cade2d9ce8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c766e601044c378ac2db7f87cde480_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922af379e03e4956a28c8f5c205b7dc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ca8c127c9f48b3b63c86430c68e46d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c565cc3c44415ead62595cf93e70f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32dc71cb0364baaaed730794f9f6ac8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1784296ad78e4c20af0d84835cef9888_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7877ab15bcd4dac8a499d3c7b9e7072_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a0e2b2399a434d9a99f30233dc02a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b384928838488791c262caec9215b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab11fde10c2c4d87b33e70d030ae1653_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff4fbe1fd8cc41b6947d447b6a6c741d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d84e84f3c84c92a7c4176575b1dc22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd535af4c12849f0934bcc1b955d369d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c32f98e31846aaa2d17068ee0b3b77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ab88df768e4ba68e5d2e3d4e747e2b_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d4ecd562014440beb00576acad3efd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb6a32bee874e46833ded3ae075b6b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea32134d65f94c16977562bd8ec30416_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f5e0d4976d341d89e231839c5c36c4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eeb3ced61044408997e1d8f8a05e001_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a39711823f44fd6ac0aae903ff997dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45f7a28571f47f4bd640ad228eaafca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0adccf4f6d64811a0e0d98da2637677_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfadc7f8c124e2897d43453679cc488_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147d28db95ca40d8a9e71dd47520fcf3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e398f1b0e24f15973a8336cc567723_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0e15729cf93490bab53bb5b3743cc9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9792ca724094babb1ceaaaf9e7f9699_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb405ddb59694654918b5c478e9d869e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eef2a859d2a4a548cea3f9cc63a809a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6e93100cda41698c2d90ac7b3add33_D20190219-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916cd8866e36499abf272f07df39ec4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="i64bb83c1af53463db93165f16058040b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34a66f65e034d328e08870d700f693e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90a45ddead5f4816a5c59b73845dad0e_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51416fb82fda4188a3a2a2e3f710d077_D20190801-20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3478042f83d6449ead46d859f7d60ffe_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd20ef4b33f94e01bf76d24ff90685b4_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8579f0882d4dc59ef160f7c64b5672_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba0ea858d9c46c78c2859dc92d5033e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5bcadd2c7245faa4cb1ac2870fd0ab_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353adf10991e4196a4b209b6a5267e9c_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6039cba34e8c4be6a904174d99de85a8_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85915c3d427b495197df94d39dff08ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fceb3f6f682487baf3242c63275edbd_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23bc4609abe8422ca6b1d83a291a407a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2fc5c2b195e47d38f45dbda9f77eb42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064aac05f8624a0389f91fa023f36ad6_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338ace46836e41128cd3590125bfb51c_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id595b8847ae94191b14b7d82020a700e_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7d314600cf45488694aa3608c2b239_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98fcd21abb664100b8f5b38c37fe8294_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40a8e6a6790645be83c7f3d6ff04f333_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d15f4eda32428fa3a38009bc9b503f_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0beb8343704b4e66bf518dc68c5d9e59_D20211109-20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b51ec2c12f42e7a12b929edad6ac3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f555fa92724b73a79e6f05d158c07e_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4c0934496e4fd69eff228d86ee8f98_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753fd66a6adf4a97a3cb8ca8d0b01238_D20200512-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-12</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3ea451d4a04b0abec238235c56f2be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a1d23049ec4dc7a76ba1a881242cad_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5029be83e87418db970ef84ed1a4011_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7880a35a7d84470b865daeee2cd2fc5c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b2929e55be54db5a11cf6c1aae0b709_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e80425e56b494380b3ac92a6bad40b_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a43045796d477a93feae3365556de6_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368a7f5ff9214108a0ffca3a870b9948_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631230ffee974729a0560f9e16c5f441_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6791f3241d2d4b26860e5a3f33455b90_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i407c6b8fb0da42379265bd134df26349_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768073d462a746ae9a55cb59ee67fdff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c52650eb05d4d77a1dc769d4513b048_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b6f9125f4245038f3ccc1233da0d79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55226aff8520430581c928fb4cdbc54f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d51be8fd474946a4d6832b362af324_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8d2335ada94a8d968b2b3a1caa5fdf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8a9cd7d8fa44d79020983a83a16598_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5b1cda2b6d4b0b901a301aea31851b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib54d8bf639154cb89c4ba6de26467b78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie18a5ae792de49a48808b18a814cd872_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3954ccf6ef6747ef8feb9744b59bb557_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccbaf36a42a44229ce94ccb6af44093_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99beda0a9bac415092a4c08da1889be8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd750ff594294f0c811ec9edaa677c38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59bd8fb3a94a4250b276d32d4de3f266_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38954b11aa549609db2fb805ac849ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f81ea99dba400ca4654757465a0324_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c01a40e2f44c378fc95b4edf730f2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607dff749d1b494aa307f2fde9568207_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7b6cf865ace43d59c4d9b8cd23d0762_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99399af4f2764839b791a9aff6806132_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768661574b0047a8978ccb5a91644538_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie684f486c3914e20a06a7b5a84e49ca3_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72efe8598cfb48c48cb1d6f2d4c6fdd6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i940ff9e4c5b74f5581133846dcd72463_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764e102832c147288be14730f1429377_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5174769188e48278fd87c450cdc20d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>ino:lease</xbrli:measure></xbrli:unit><xbrli:context id="i553b47824270463b81580d012b8326f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2629ea83a447d48947801594c4a4f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28ea7f8947e74ae483e59fef6fba3c42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170db3d65ef54746a1f01e2eeb793898_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb481c2e100c4b24ab6801fa143fc5a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:KoreanStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8600df4b8cfa4198a900a673aaa25e5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f662a8f3a3462b9e7192ba6281596b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc560e22c9154ac688112e684c7e03ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016abb4ce4ae41eb96f478d01ecb4c74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ecadc9f1fe848b199e3eebeee7aec5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662f61a3c3334b0e9a41c8358963d412_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i882b0a38e1f2460195c1411955ee5cbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a55572cadc4c63ad76c5efc89aa4aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83fbb635f5946a4b9deeceae49cb099_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7373234a664045788a5b334e1076415e_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fa3d23bcb34cf791cf9f42fd01a6fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3814c1b2e66949a0bd31251687136440_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7798242f3b4c25b6738d30fa118ce1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7365de7ee2a44bdbaf064109d873902_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852044bbe3424614962d40fb0b43db9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b9a94f7b494158a6d83627c08f021c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9609157af4444ad383c75696d8f21624_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b9648133c14f64986de131ff9b55c1_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c28778c30d04e92b3843a48a585dbb4_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0ce816abac42bdabeaed537ab884e8_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14abd64fd4ca460b8acf05ac1d77a2c2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ffdc36023f54e9fa96891a1aedfccaa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a5d5fed4e84bfaaaa1da165905d43b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6afcb9b96a3643e394e9339a35bf52eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923c4d838e73472daff6f5c2a0b66af9_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic982a0927e6846e8873518def396e93c_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic828dfae01914c5dadca776a2dbad2ad_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c92f1527c04f16bf9084ab8878ced9_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f7e5188b3845c9ab32ff4a6346e973_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie564892056a949fe9b105cc382205542_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ba584f59334065a632c11588572f53_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30ef1cfdaf874c749abaf0297c07f342_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aaedc813254497f95ad1fb1461a99b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01459eec92d4ada9c407fd1befdf459_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657942a14f6441a2bd23b51205eae9a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa18a071c4404f868cef43212fce1e2c_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a42fdc8de284579bf2e8654f3f26a01_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f23c07d6cfb47f2a060dfee7b1f5455_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377ac441325e467a8c00a33146b64c62_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI0_6863daf9-0139-4de0-a905-a6d4bd1f1e4c">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6ZWU0MmM2NjU3YTUyNGE2Mzg0ZTVlZWY3NDk0MTY0MjkvdGFibGVyYW5nZTplZTQyYzY2NTdhNTI0YTYzODRlNWVlZjc0OTQxNjQyOV8wLTAtMS0xLTEzMDc5_dce53dcd-fc38-4836-9c07-8268f3b5e3bf">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8xMjQ_f457bb89-8a96-47a7-a2cb-baf00510802c"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8xMjQ_6b645f4d-2f65-46a9-8ae0-920ad43db61c">DECEMBER 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6ZTI5ZTliOThiOTlkNDhhZDg3ZDk5YWQxODk4YTI1NmUvdGFibGVyYW5nZTplMjllOWI5OGI5OWQ0OGFkODdkOTlhZDE4OThhMjU2ZV8wLTAtMS0xLTEzMDc5_26530c64-2106-49c0-afa3-530b51c00274">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDMy_73de356a-7c80-4a12-af08-be1c4d6a9ec7">001-14888</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20211231_g1.jpg" alt="ino-20211231_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDIx_2e6435c1-6a09-4fb4-9246-0ccd7a9f673d">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8wLTAtMS0xLTEzMDc5_fb064926-ab91-4c78-b3a4-6a60caf1c7a7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8wLTItMS0xLTEzMDc5_777d8d1c-e0b3-4aaa-bae0-72702932199b">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfNA_6a05842b-90e9-492d-8be2-82c1d4a77fe1">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfOA_102b23d4-0fc0-4f63-90cc-53898117ef95">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfMTE_7b249baf-600f-4c1d-afe6-8cb7a4a09766">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfMTU_91c56e0c-0991-4e15-afa1-7b55a30d9f8e">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTItMS0xLTEzMDc5_7e0a9b2e-30e7-4b2f-85f8-c53d1cd6eb78">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI4_fe1ce93a-5bf6-4bd3-9380-06138860c2c4">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI5_7c4ebbf6-3f4e-4a15-bee2-21ad6ba74ac9">440-4200</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6M2MyY2JhOTZjYTQyNGU5YTg0ZWQzYThjMDViMDBkYTkvdGFibGVyYW5nZTozYzJjYmE5NmNhNDI0ZTlhODRlZDNhOGMwNWIwMGRhOV8xLTAtMS0xLTEzMDc5_9304f695-8932-410b-bb29-61386a5cab3d">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6M2MyY2JhOTZjYTQyNGU5YTg0ZWQzYThjMDViMDBkYTkvdGFibGVyYW5nZTozYzJjYmE5NmNhNDI0ZTlhODRlZDNhOGMwNWIwMGRhOV8xLTEtMS0xLTEzMDc5_30ba976c-a7e1-4fbe-a000-2922e7c876c0">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6M2MyY2JhOTZjYTQyNGU5YTg0ZWQzYThjMDViMDBkYTkvdGFibGVyYW5nZTozYzJjYmE5NmNhNDI0ZTlhODRlZDNhOGMwNWIwMGRhOV8xLTItMS0xLTEzMDc5_f507c043-fc4a-4a2b-8dd7-082aa328611a">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDIy_e6253f52-9f73-48c1-8f76-5f7b1356722a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI2_814f0741-8b1e-48e0-8eda-02d48cf4f9b7">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDMw_6757a2b0-0b91-4670-a71e-2e199a772796">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDMx_fb814bb6-216c-4658-8079-8bd0717c8feb">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6MzkyNTM5YWUxMjAxNDllOWEyMWI4OWVlZmFjODk2ZGEvdGFibGVyYW5nZTozOTI1MzlhZTEyMDE0OWU5YTIxYjg5ZWVmYWM4OTZkYV8wLTAtMS0xLTEzMDc5_ba6bc444-acd6-408e-875b-629fcd027114">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6MzkyNTM5YWUxMjAxNDllOWEyMWI4OWVlZmFjODk2ZGEvdGFibGVyYW5nZTozOTI1MzlhZTEyMDE0OWU5YTIxYjg5ZWVmYWM4OTZkYV8yLTQtMS0xLTEzMDc5_ed07a27b-dc5c-41e1-a5a0-3f285b0ec392">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6MzkyNTM5YWUxMjAxNDllOWEyMWI4OWVlZmFjODk2ZGEvdGFibGVyYW5nZTozOTI1MzlhZTEyMDE0OWU5YTIxYjg5ZWVmYWM4OTZkYV8zLTQtMS0xLTEzMDc5_6270cffb-f10c-4d31-b222-2acf2b323760">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDIz_16d12cce-38ae-4157-a21f-1ff7ef7b2844">&#9746;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI1_cb800a51-d772-49cd-93b8-7b4ad99f3243">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June&#160;30, 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="id38a5c1786aa4218ab4b1daf6b02098d_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8yNzQ2_9f258804-352d-4652-b1f8-7db0b394f270">1.9</ix:nonFraction> billion based on $9.27 per share, the closing price on that date of the Registrant&#8217;s Common Stock on the Nasdaq Global Select Market.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i463a7ab03b6446db9e60c8b7ad87def3_I20220225" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8yOTYx_d6d50bd9-b767-4770-9d9b-e93109fa8fa2">217,403,287</ix:nonFraction> as of February&#160;25, 2022.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI3_b26fc995-338a-404a-b9f9-7fd48d436e50" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_10">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_13">ITEM&#160;1. BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_16">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_16">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_19">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_19">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_22">ITEM&#160;2. PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_22">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_25">ITEM&#160;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_25">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_28">ITEM&#160;4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_28">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_31">PART II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_31">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_34">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_34">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_37">ITEM&#160;6. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_37">[</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_37">RESERVED]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_37">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_40">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_40">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">ITEM&#160;7A. QUA</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">N</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">T</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">IT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">ATIVE AND QUA</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">LI</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">TATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_58">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_61">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_61">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_64">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_64">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_67">ITEM&#160;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_67">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_73">ITEM 9B. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_73">7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669">TE</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669">M 9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669">C.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_1669">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_76">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_76">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_79">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_79">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_82">ITEM&#160;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_82">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_85">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_85">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_88">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_88">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_91">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_91">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_94">PART IV</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_94">71</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_97">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_97">71</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_100">ITEM 16. FORM 10-K SUMMARY</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_100">74</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_103">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_103">75</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_106">CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_106">1</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless stated to the contrary, or unless the context otherwise requires, references to &#8220;INOVIO,&#8221; &#8220;the company,&#8221; &#8220;our company,&#8221; &#8220;our,&#8221; or &#8220;we&#8221; in this report include Inovio Pharmaceuticals, Inc. and its subsidiaries.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K (including the following section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report includes trademarks and registered trademarks of INOVIO Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to INOVIO&#8217;s product candidates for precancerous conditions, cancer and infectious diseases in development.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Part I, Item 1A., "Risk Factors" herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Omicron SARS-CoV-2 variant and newly emerging SARS-CoV-2 variants will likely require us to modify our COVID-19 vaccine strategy, which will result in new and added risks, including whether there will continue to be a need for a COVID-19 vaccine.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There can be no assurance that any of the products we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. The option of seeking an Emergency Use Authorization may no longer exist for our primary vaccine candidates, and if we cannot obtain such authorization or, if granted, it is terminated, we will be unable to sell our product in the near future and instead will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies, which are subject to termination and uncertain future funding.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our participation in the WHO Solidarity Trial Vaccines (STV) could result in adverse consequences. We do not have any control over clinical data, progress, and decisions regarding INO-4800's participation in STV, and as such, decisions regarding the clinical pathway for INO-4800 between the WHO and the Company may not always align.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by of our competitors, such as the introduction of a new, disruptive technology, may impede our ability to successfully commercialize our DNA medicines.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus ("HPV"). We have shown in clinical trials that our DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of our integrated platform, SynCon&#174; and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices facilitate uptake of our DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA&#174; smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to develop, seek regulatory approval for, and commercialize our novel DNA medicines to address unmet global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. We aim to advance our product candidates through commercialization and, where applicable, with third-party resources through collaborations and partnerships, including product license agreements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corporation, AstraZeneca, Advaccine Biopharmaceuticals Suzhou Co, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), Defense Advanced Research Projects Agency ("DARPA"), The U.S. Department of Defense ("DoD"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently evaluating the feasibility of, conducting or planning clinical studies of our DNA medicines for COVID-19, which includes both homologous and heterologous boosting approaches; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our DNA Medicines Platform </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Our Platform </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary design and optimization process for our DNA plasmids is called SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These plasmids are delivered into cells intramuscularly or intradermally via our proprietary CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices, which use brief electrical pulses to reversibly open small pores in the cell, enabling DNA plasmids to enter. Once inside the cell, the plasmids instruct the body&#8217;s cellular machinery to produce the target antigen or monoclonal antibody. We believe our DNA medicines platform offers </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">versatile capabilities, both in terms of addressing several disease targets as well as providing us with several product development opportunities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The characteristics and core components of our DNA medicines platform include:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. SynCon Design Process: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SynCon uses a proprietary computer algorithm that has been designed to identify and optimize the DNA sequence of the target antigen, whether it is from a virus or a tumor.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. CELLECTRA Smart Device: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once our DNA medicines are injected, the DNA medicines instruct the cell to produce the target antigen, monoclonal antibody, or therapeutic protein. The antigens are then processed naturally in the cell and induce the immune system to generate antibodies and T cells that perform preventive or therapeutic functions. Similarly, dMAbs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or dBTAs generated in this manner can also trigger desired immune system functions. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Our DNA medicines have generated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (within the body) immune responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our core platform technology, we have developed a pipeline of clinical-stage product candidates that have generated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> immune responses, in particular CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells that may be responsible for eliminating cancerous or infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Our DNA medicines work naturally with the immune system: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to some other technologies, our DNA medicines are designed to work with the immune system with reduced risk of unwanted inflammatory responses.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mechanism of action for our DNA medicines and the process for administration of our DNA medicines are summarized in the following graphic: </span></div><div style="margin-top:5pt"><img src="ino-20211231_g2.jpg" alt="ino-20211231_g2.jpg" style="height:386px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleic Acid Vaccines: Similarities and Differences between DNA and mRNA-based Approaches </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of nucleic acid-based vaccines (DNA or mRNA) as an alternative to traditional immunization is a strategy that has been under development for many years. We believe that the U.S. Food and Drug Administration's (FDA) approval for emergency use authorization (EUA) of two messenger RNA (mRNA)-based vaccines for COVID-19 in 2020, as well as an EUA by Indian regulators for a DNA vaccine in 2021, suggests the benefit of using nucleic acids as vaccines.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past decade, the scientific community and the vaccine industry have been asked to respond urgently to various epidemics, including but not limited to: H1N1 influenza, Ebola, Zika virus and, most recently, SARS-CoV-2, the virus that causes COVID-19. Today, multiple platforms have been used or are under development in the fight against COVID-19. Among those are DNA- and mRNA-based platforms, along with those developing viral vector and recombinant-subunit vaccines.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to develop a DNA vaccine candidate for COVID-19 is based on the suitability and scalability of our DNA medicines platform, as well as our track record of generating clinical candidates to combat pandemic threats such as Ebola, Zika </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">virus, and Lassa Fever. We were the first company to advance a vaccine against MERS-CoV, a related coronavirus, into clinical evaluation in humans.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our DNA Medicines&#8217; Differentiation from mRNA</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While DNA and mRNA both use fragments of genetic materials that, once injected, instruct the body to fight pathogens, which cause cancer and infectious disease, there are key differentiating features of DNA vaccines. mRNA vaccines require colder storage temperature for transportation, necessitate complex LNP formulations for scaling, and are on average more expensive when considering manufacturing and distribution. We believe that our DNA vaccines offer several key potential advantages: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Tolerability: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA vaccines appear to be well-tolerated when evaluated against multiple disease targets. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Stability of Product: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA vaccines are stable for more than a year at room temperature or for more than a month at 37&#186; C, have a five-year projected shelf life at normal refrigeration temperature and do not require frozen cold storage or shipping. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Rapid Design and Manufacture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to mRNA vaccines, our DNA vaccines can be rapidly designed and scaled, which are critical aspects in addressing global pandemics like COVID-19. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">T Cell Responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA vaccines have demonstrated the ability to generate high levels of T cell (CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) responses along with antibody responses. The CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cell responses, in particular, are regarded to be very important in their propensity to clear tumor cells in the body as well as to fight off infections. In the context of SARS-CoV-2 infection, CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells generated by our vaccine resemble those that the scientific and medical community have profiled and associated with mild COVID illness as opposed to severe illness, as well as convalescence. Furthermore, cellular responses have been preserved across different variants of SARS-CoV-2, suggesting that INO-4800 can elicit a cross-reactive immune profile.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Ability to Readminister: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA vaccines have been used in clinical trials to boost our vaccines&#8217; immunity profile via repeat administration, suggesting that our DNA vaccines could be readministered if immunity wanes, offering the possibility for seasonal boosting usage without any concerns of generating an anti-vector response. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our DNA Medicines Platform in Detail</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of our DNA medicines platform is to generate and deliver safe and effective therapeutics and preventive vaccines. Our technologies allow us to enable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> generation of functional immune responses to achieve desired therapeutic and preventive outcomes. Historically, we have focused primarily on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> production of disease-specific antigens in order to stimulate prophylactic or therapeutic immune responses. More recently, we have explored an additional new application for the platform:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> generation of monoclonal antibodies to achieve preventive and therapeutic outcomes complementary to our antigen-generating immunotherapies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two components to our DNA medicines platform. The first is a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> biological component (SynCon)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, by which we encode proteins (antigens, monoclonal antibodies, antibody fragments, and cytokines such as IL-12) into closed-circular DNA plasmids that are translated into proteins that are expressed to generate an immune response. The second component is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> our proprietary CELLECTRA smart devices technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which facilitates delivery of the DNA plasmids. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resulting immune responses from DNA medicine administration are designed to neutralize or eliminate infectious agents, such as&#8239;viruses, bacteria, and other microorganisms, or abnormal cells, such as&#8239;malignant tumors or infected cells. T cells can be &#8220;trafficked&#8221; to parts of the body where cells are displaying the target antigen. Memory cells are also created for durable effects. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> DNA Medicines Design </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses. Based on extensive due diligence and pre-clinical and clinical data that we have evaluated, we first identify one or more antigens that we believe are the best targets, for directing the immune system toward a particular cancer or infectious disease. We then apply our SynCon design process, which uses the genetic make-up of the selected antigens from multiple variants of a cancer or strains of a virus. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each antigen, we create a new genetic sequence that represents a nucleotide consensus sequence of the targeted antigen from multiple virus variants or strains. We can create a differentiated SynCon sequence to help the immune system better recognize a cancer self-antigen (from a cancerous cell grown in the body) and &#8220;break the tolerance&#8221; of those cancer cells within the body. We have generated immune responses with SynCon DNA medicines against different strains of certain infectious diseases in human clinical trials. Because the engineered SynCon sequences are substantially similar to the original sequences, without matching them exactly we believe they are patentable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a SynCon sequence is engineered, it is then inserted into a circular DNA plasmid with its own promoter. The plasmid is optimized at the DNA level for codon usage and improved stability of mRNA and provided with enhanced and proprietary leader sequences for ribosome loading. It is optimized at the genetic level to enable high expression in human cells. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of the coded antigen compared to traditional approaches, potentially enhancing the overall ability of the immunotherapy to induce the desired immune response. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plasmids are then manufactured in a bacterial fermentation process using scalable manufacturing technology. Ultimately, the manufactured DNA medicines are designed to be stable under normal environmental conditions for extended periods of time. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines platform allows for rapid design, pre-clinical testing, manufacturing at scale, and clinical development of both our DNA vaccine and DNA immunotherapy product candidates. Speed is an important feature, particularly as it relates to developing a response to globally emerging infectious diseases such as COVID-19. Responses to emerging infectious diseases that we have explored are described in more detail below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Delivery Technology </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines are delivered directly into cells of the body intramuscularly (IM) or intradermally (ID) in a small, localized area of tissue using our proprietary CELLECTRA smart devices. CELLECTRA smart devices use brief electrical pulses to reversibly open small pores in the cell, enabling DNA plasmids to enter. Through this process, the cellular uptake of the DNA plasmids increases by more than 1,000-fold compared to the injection of a DNA plasmid alone without this delivery mechanism. This improved cellular uptake has enabled the immune responses observed in our clinical trials along with the efficacy results generated by these immune responses. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CELLECTRA portfolio consists of three devices. CELLECTRA 2000 is our clinical device that can perform both IM and ID injections. CELLECTRA 2000 has been used in almost all clinical trials to date. CELLECTRA 5PSP is our new IM device utilizing a prefilled drug CELLECTRA 5PSP is used in our Phase 3 (REVEAL1/REVEAL2) trials for cervical high squamous epithelial lesions (HSIL). Finally, CELLECTRA 3PSP is our next generation ID delivery device.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternative delivery approaches which typically involve or rely on virus-based vectors, bacteria, nanoparticles and lipids may be complex and expensive and, in some cases, may raise safety concerns. For example, because alternative delivery vectors themselves may possess additional antigens specific to the vector, they can attract unwanted immune responses that could compromise the vectors&#8217; ability to deliver their genetic &#8220;payload&#8221; and produce the desired immune response. In contrast, a DNA plasmid vector possesses no antigens of its own, as the plasmid results in production of only the target antigen. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have published preclinical data in which we observed improved immune responses generated by our SynCon&#174; DNA medicines delivered using CELLECTRA smart devices compared to a viral vector-based approach (Adenovirus type 5). The delivery of DNA medicines using CELLECTRA smart devices to date has shown a favorable tolerability and safety profile in clinical trials. Our CELLECTRA-based approach is designed to be tolerable without the need for an anesthetic. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several configurations in the CELLECTRA smart device family. The first configuration covers intramuscular (IM) delivery, while the second covers intradermal/subcutaneous (ID) delivery. Smart devices with these configurations have been validated, manufactured under Current Good Manufacturing Practices (cGMP) and are being used in human clinical trials. We have filed device master files with the FDA covering the use of the CELLECTRA smart devices in human clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CELLECTRA smart devices combine the functionality of our current generation of ID and IM devices in clinical testing with enhanced form, design and portability. All components of the pulse generator and applicator are integrated into a cordless, rechargeable device. The rechargeable battery can enable immunization of several hundred participants, making the device useful for mass vaccinations. The devices are designed to accommodate different electrode arrays to meet the requirements of the particular DNA medicine and targeted tissue for delivery. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Next-Generation Smart Device Development </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing a new generation of small, portable, battery-powered ID delivery devices called CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3PSP. Currently used ID devices penetrate no more than 3 mm into the target tissue, compared to IM devices that go deeper.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical arm of the U.S. Defense Threat Reduction Agency (DTRA) agreed to fund the further development of our CELLECTRA-3PSP device. DTRA provided $8.14 million of grant funding to support the development of CELLECTRA-3PSP, to be used in the administration of our vaccines and therapies, including DTRA-developed products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 we were awarded funding expected to be approximately $65.2 million from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the CELLECTRA-3PSP smart device, the production of doses and the procurement of CELLECTRA 2000 devices. The DoD contract, from the JPEO-CRBND-EB through funding provided by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense Health Program, builds upon two separate prior $5 million grants from the Bill &amp; Melinda Gates Foundation and CEPI, to accelerate the testing of CELLECTRA-3PSP. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background on DNA Medicines and Immuno-Oncology </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple technology advancements and product approvals have demonstrated the ability of immunotherapies to treat cancer. Monoclonal antibodies such as Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (anti-HER2) and its analogs have demonstrated therapeutic benefit in clinical trials and have been approved for use in a variety of cancers. While a significant step forward, monoclonal antibodies with ideal clinical characteristics have been difficult to design or identify and are expensive to produce, and the technology does not lend itself to designing mAbs for many diseases. Dendritic, or other cell-based therapies such as chimeric antigen receptor (CAR) T-cell therapies, are highly personalized medicines involving removing cells from the patient, modifying, manipulating and multiplying them, and then returning them to the body, which can be complex and costly.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress in the field of immune checkpoint inhibitors (ICIs) has resulted in optimism regarding the potential for new immunotherapies against a spectrum of cancers, specifically solid tumors, where cell-based therapies have not previously succeeded. The immune system relies on checkpoint mechanisms to prevent excessive or incorrectly directed immune responses. Many cancer cells can &#8220;hijack&#8221; these checkpoints and neutralize T cells sent by the immune system to eliminate them. ICIs prevent cancer cells from interfering with these safeguards and enable T cells (especially CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> killer T cells) to complete their killing function against cancer cells. Clinical trials of ICIs have shown notable therapeutic impact against many cancers and have led to several approvals. However, ICIs may be less effective if there is not a high enough pre-existing level of antigen-specific CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells in the tumor micro-environment, meaning that the tumor is &#8220;cold&#8221; rather than &#8220;hot&#8221; (with a significant level of CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells). More recently, scientists have recognized that T cell-generating &#8220;active&#8221; immunotherapies may be able to transform a "cold" tumor into a "hot" tumor and in combination with ICIs may possess significant therapeutic potential to fight cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, a new category of immunotherapies called adoptive cell transfer, for example CAR-T technology, has provided further evidence of the merit of providing an enhanced T cell presence to fight cancer. CAR-T therapies have achieved dramatic results, most notably in B cell cancers. Unfortunately, they have also been associated with significant side effects. Additionally, these complex therapeutic products need to be manufactured and released for each patient, leading to expensive and timely manufacturing, as well as increased supply chain complexity. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there have been significant clinical advances in recent years that better harness or activate capable killer T cells, we believe there is still significant potential to develop additional immunotherapies to fight cancers and infectious diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to advance product candidates that: </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Target disease-specific antigens or proteins unique to a cancer or infectious disease; </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Do not depend on complex manufacturing processes; </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Activate functional killer T cells; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Generate robust T cell responses or a significant number of T cells that are persistent and durable over time (memory response); </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Do not induce toxic inflammatory responses; and </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Are capable of &#8220;breaking tolerance&#8221; of cancer cells in the body. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from our Phase 2b and REVEAL1 Phase 3 trial of VGX-3100, discussed below, suggest that our approach to activating significant antigen-targeted T cells may achieve these characteristics. Accordingly, we are advancing a pipeline of pre-clinical and clinical immunotherapy product candidates. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our DNA Medicines in Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The chart below summarizes the status of our active DNA medicines development programs, each of which is described in more detail following the chart. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><img src="ino-20211231_g3.jpg" alt="ino-20211231_g3.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of HPV-Associated Precancerous Lesions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview and Background</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human papilloma virus (HPV) is a sexually-transmitted, persistent viral infection with one or more high-risk (HR) genotypes that can lead to pre-cancers and cancers, such as cervical, head and neck, anal and vulvar dysplasia and cancer. It is estimated that approximately 43% of the U.S. adult population is infected with HPV, and about 25% of adult men and 20% of adult women in the U.S. have a genital infection with one or more HR-HPV genotypes such as HPV-16 and HPV-18. HPV is the most common viral infection of the reproductive tract and HPV-16 and HPV-18 infections specifically are the major causes of cervical cancers globally. Almost 300 million women globally are estimated to be infected with HPV, with another 30 million additional cases that have progressed to the pre-cancerous stage. While most genital HPV infections are cleared naturally by the body's own immune system, persistent cervical infection with one or more HR-HPV genotypes can eventually lead to cervical high-grade dysplasia (HSIL) and eventually to cervical cancer. Researchers have estimated the global prevalence of clinically pre-cancerous cervical HSILs at between 28 and 40 million.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current management options for cervical HSIL are limited and are associated with potential unwanted side effects. The &#8220;watch-and-wait&#8221; process associated with low-grade squamous intraepithelial lesions (LSIL, formerly called low-grade dysplasia or CIN 1) and in some young women with higher grade lesions (though only for the CIN 2 level of cervical HSIL) can be a stressful approach. The only available current treatment option for cervical HSIL is surgery, which involves ablating or cutting into a women&#8217;s cervix to remove the pre-cancerous or cancerous lesions. These treatments may lead to short-term adverse effects including cervical scarring, excess bleeding, and infection, or to longer-term reproductive risks such as pre-term birth, miscarriage, and perhaps infertility. More importantly, because surgery does not clear the underlying systemic HPV infection, there is a chance of high-grade pre-cancer lesion recurrence after surgery as a result of persistent HPV infection and/or incomplete removal of the lesion. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there is currently a vaccine available to prevent HPV infection, challenges with acceptance, accessibility and compliance of vaccines to prevent HPV infection and their resulting pre-cancers and cancers have resulted in many vaccine-eligible people remaining unvaccinated and at risk; it is estimated that even in the United States, only 60% of the eligible population has been vaccinated against HPV. In addition, preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes, which is a large population. Currently there is no viable immunotherapy or drug available to fight incident, prevalent, or persistent HPV infection or to treat cervical HSIL. We therefore believe that there is a significant market opportunity for our therapeutic product candidate VGX-3100. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VGX-3100 is designed to increase T cell immune responses against the E6 and E7 oncogenic proteins of high-risk HPV types 16 and 18 that can be present in both precancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into precancerous and cancerous cells, thus making them appealing targets for T cell directed immunotherapy. The goal of VGX-3100 is to stimulate the body's immune system to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generate a T cell response strong enough to kill the cells producing the E6/E7 protein. The potential of such an immunotherapy would be to treat HSIL caused by these HPV types. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Cervical HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed randomized, blinded, placebo-controlled Phase 2b and Phase 3 clinical trials of VGX-3100 compared to placebo, in women with HPV-16 and HPV-18 cervical HSIL. Data from the Phase 2b trial supported our Phase 3 development program; in the Phase 2b trial, women treated with VGX-3100 were more likely to demonstrate resolution of cervical HSIL and HPV clearance from cervical lesions than those women receiving placebo. In addition, antigen-specific T cell levels in women treated with VGX-3100 were greater than those treated with placebo. All women were monitored for an additional 52 weeks following the primary endpoint to assess for safety; VGX-3100 was considered to be well-tolerated and there were no safety concerns observed. Immune endpoints were also assessed and women whose lesions regressed also had higher frequencies of HPV-specific CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells which co-expressed key molecules important in the T cell killing cascade and directly correlated with clinical efficacy. To our knowledge, this Phase 2b trial was the first study from which data was published indicating a direct correlation between antigen-specific CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells generated in vivo and clinical efficacy.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Trials (REVEAL1 and REVEAL2)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparation for Phase 3 development and potential commercialization, we completed a manufacturing technology-transfer to a commercial manufacturing facility and scaled up manufacturing of VGX-3100. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designed and manufactured a new smart delivery device, CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5PSP, which is being used in our global Phase 3 clinical trial of VGX-3100. This smart device uses a cordless applicator and charges cordlessly in an improved base station that has been optimized for ease of use in the clinic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 3 program, named REVEAL, consists of a primary trial (REVEAL1; HPV-301) and confirmatory trial (REVEAL2; HPV-303), being conducted in parallel. The REVEAL trials are prospective, randomized (2:1), double-blind, placebo-controlled trials evaluating adult women with HPV 16/18 positive biopsy-proven cervical&#8239;HSIL (CIN 2/3). The primary endpoint is regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix, which was a secondary endpoint that was achieved in our Phase 2b trial. Overall, the Phase 3 trials are evaluating cervical tissue changes at approximately 9 months after beginning a three-dose regimen of VGX-3100 administered at months 0, 1 and 3.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced the result of the REVEAL1 trial of VGX-3100. The trial protocol-defined intention to treat (ITT) population (N=201) includes all randomized participants regardless of availability of endpoint data and defines those without endpoint data as non-responders. There were eight such participants (seven in the treatment group, one in the placebo group) in the ITT population. Including participants with missing endpoint data, the percentage of participants meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 95%CI: -0.4,21.2), which was not statistically significant. All secondary endpoints were achieved except for regression of cervical HSIL alone (95%CI: -0.6,24.5). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the protocol-defined mITT population (N=193) which includes all participants with endpoint data, we announced that VGX-3100 had achieved the primary and secondary endpoints among all evaluable participants. For the primary endpoint of histopathological regression of HSIL and virologic clearance of HPV-16 and/or HPV-18 at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo group (p=0.022; 95%CI: 0.4,22.5), thus achieving statistical significance. All secondary efficacy endpoints were achieved in this population. These endpoints were: a) regression of cervical HSIL to normal tissue combined with HPV16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical HSIL to normal tissue, and d) HPV 16/18 viral clearance alone. There were no treatment-related serious adverse events (SAEs) and most adverse events (AEs) were self-resolving and were considered to be mild to moderate, consistent with earlier clinical trials. These data were presented at the 2021 American Society for Colposcopy and Cervical (ASCCP) annual scientific meeting, and at the 34th International Papillomavirus Conference (IPVC) in November 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the 52-week safety follow-up of participants in REVEAL1 and showed that VGX-3100 remained well-tolerated through Week 88. In addition, participants treated with VGX-3100 who met the primary endpoint at Week 36 remained clear of HPV-16 and/or HPV-18 at Week 88.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REVEAL2 is the second of two Phase 3 trials and the confirmatory trial agreed upon by INOVIO and FDA. Endpoints for REVEAL2 are identical to those for REVEAL1; participants will be followed for up to 40 weeks. Enrollment of REVEAL2 was completed in the fourth quarter of 2021. Top-line efficacy and safety data are expected to be available in the second half of 2022. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Vulvar HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-16 and HPV-18 can cause precancerous and cancerous lesions of the vulva. These precancerous lesions, or vulvar HSIL, have less than a 5% rate of spontaneous or natural regression and there are no&#8239;FDA-approved non-surgical treatments. Surgery, the most common treatment, is associated with high rates of disease recurrence and can cause disfigurement, long-term </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pain, and psychological distress for women who undergo the procedure. Vulvar HSIL recurs in approximately one-half of patients who undergo surgical treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed a Phase 2 trial (HPV-201) to evaluate the efficacy of VGX-3100 in participants with vulvar HSIL. This randomized, open-label Phase 2 clinical trial assessed the efficacy of VGX-3100 in 33 women with vulvar HSIL. VGX-3100 was administered with our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -5PSP smart device. The primary endpoint of the trial was histologic clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue samples. The trial also evaluated the safety and tolerability of VGX-3100. In January 2021, we announced positive efficacy results from this trial. A 25% or more reduction in HPV-16/18-associated vulvar HSIL was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment. Three of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. VGX-3100 was well-tolerated in the Phase 2 trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating future clinical steps for the vulvar HSIL program, including the potential for applying for U.S. FDA Orphan Drug Designation (ODD) for this indication. ODD is intended to encourage drug development for rare diseases by providing tax credits for qualified clinical trials, an exemption from user fees related to the New Drug Application or Biological License Application, and a potential of up to seven years of market exclusivity after approval. The FDA grants orphan drug status to medicines intended for the prevention, diagnosis, and treatment of rare diseases or conditions, as defined as a disease or condition with a prevalence of less than 200,000 patients in the United States annually.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Anal or Perianal HSIL </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-16 and HPV-18 can also cause precancerous lesions of the anus (anal HSIL). Left untreated, anal HSIL may progress to cancer. Spontaneous regression of anal HSIL is observed in approximately 20% of patients. Persistent infection with one or more high-risk HPV genotypes is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/18 specifically. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no validated screening tests or a general screening recommendation consensus for anal HSIL. Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, recurrence rates are high, up to 49% one year after treatment, resulting in an unmet medical need. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 2 clinical trial (HPV-203) to evaluate VGX-3100 in participants who are HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV-16 and/or HPV-18. This open-label trial enrolled 24 participants who received three doses of VGX-3100 delivered by our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5PSP device. The primary endpoint of the trial was histologic clearance of the high-grade lesions and virologic clearance of the HPV-16/18 virus in anal/perianal tissue samples. In December 2020, we announced positive Phase 2 efficacy results from this trial. One-half of participants treated with VGX-3100 (11/22) showed resolution of HPV-16/18-associated anal HSIL at six months following the start of treatment. VGX-3100 was well-tolerated in the trial. We plan to pursue a registrational Phase 3 clinical trial for HPV-16-/18-associated anal HSIL as well as to apply for ODD from the U.S. FDA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Phase 2 anal HSIL trial sponsored by us, a separate ongoing Phase 2 trial sponsored by the AIDS Malignancy Consortium (AMC-103) is evaluating VGX-3100 in participants with histologically confirmed anal or perianal HSIL associated with HPV-16 and/or HPV-18 who are HIV-positive. This open-label single-arm trial plans to enroll approximately 75 participants who will receive up to four doses of VGX-3100 delivered by CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5PSP smart device. The primary endpoint of the trial is histological regression of high-grade anal lesions to low-grade SIL or normal histology.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 Immune Correlates and Biomarker Signatures </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing a biomarker signature for our VGX-3100 program. In May 2019, we entered into a collaboration with QIAGEN N.V. to co-develop a liquid biopsy-based diagnostic for this biomarker signature to identify women with HPV-16/18 cervical HSIL most likely to respond to VGX-3100. In February 2021, we announced an extension of our partnership with QIAGEN with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement our therapies. QIAGEN is utilizing the Illumina NextSeq&#8482; 550Dx platform for this biomarker, the first development based on a partnership QIAGEN and Illumina signed in October 2019. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced that we and QIAGEN have identified candidate biomarker signatures for VGX-3100 with the intent of selecting a final signature of a pre-treatment in vitro diagnostic to meet the specific characteristics desired to identify women with HPV-16/18 cervical HSIL most likely to respond to VGX-3100. This biomarker, if validated, may have the potential to identify those women who are more likely to have a favorable treatment outcome, specifically the regression of cervical HSIL and clearance of virus.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Collaboration Agreement for VGX-3100 within Greater China </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement providing&#8239;ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100 within&#8239;Greater China&#8239;(defined as China,&#8239;Hong Kong,&#8239;Macao and&#8239;Taiwan). Additional details on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloBio Agreement are provided below under "License, Collaboration and Supply Agreements." In December 2021, ApolloBio dosed its first participant in a separate Phase 3 trial in China (HPV-303CHN). </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis (RRP)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP is a rare disease (estimated at about 7,000 active prevalent cases in the United States in 2018, including both juvenile and adult cases) that is characterized by the growth of tumors in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, such papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of this disease is the tendency for the papilloma to recur after surgical procedures to remove them. If RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In extremely rare cases (less than 1%), RRP can develop into squamous cell carcinoma. Additional symptoms of RRP can include hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults. In children, the disorder is most often diagnosed at or around the age of four years. In adults, the disorder occurs most often in the third or fourth decade, though evidence exists for some incidence of new diagnoses in the sixth decade. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we commenced an open-label, multicenter Phase 1/2 trial that is evaluating the efficacy, safety, tolerability and immunogenicity of INO-3107, a DNA medicine candidate similar to INO-3106, but targeting HPV-6 and HPV-11 associated RRP and including INO-9112, encoding IL-12, in participants with HPV-6 and/or HPV-11-associated RRP. For this trial, adult participants will first undergo surgical removal of their papilloma(s) and then receive up to four doses of INO-3107, once every three weeks. The primary endpoint of this trial is safety and tolerability. The trial is also assessing efficacy as a function of the number of treatments required to treat RRP relative to the number of treatments required to control disease prior to enrollment in the trial. We began enrollment in November 2020, and completed enrollment of the first 32 participants in December 2021. All 32 adult participants first underwent surgical removal of their papilloma(s) and then received four doses of INO-3107, one every three weeks. We expect preliminary efficacy data from a portion of participants from this Phase 1/2 trial in the second half of 2022.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we announced that the U.S. FDA granted ODD for INO-3107. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Treatment of Glioblastoma Multiforme (GBM) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glioblastoma multiforme (GBM) is the most common and aggressive type of brain cancer. In the United States, the median age at diagnosis is 65 years, and the incidence rate increases thereafter. Prognosis is extremely poor, and a limited number of new therapies have been approved over the last 10 years; median overall survival for U.S. patients receiving standard of care therapy was approximately eight months and the five-year survival was 6.8% for all ages combined. The annual incidence of GBM is estimated to be approximately 12,000 cases per year and increasing. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate INO-5401 is an immunotherapy consisting of three synthetic DNA plasmids encoding for three tumor-associated antigens: human telomerase (hTERT), Wilms tumor gene-1 (WT1) and PSMA. The National Cancer Institute previously highlighted WT1, hTERT and PSMA among a list of important cancer antigens, designating them as high priorities for cancer immunotherapy development, as these three tumor-associated antigens are commonly expressed in human cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we reported data indicating that our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WT1 cancer antigen was capable of breaking immune tolerance, a major challenge to researchers striving to develop potent cancer therapies and induced neo-antigen-like T cell responses to cause tumor regression in pre-clinical studies. The results were published in the scientific journal Molecular Therapy. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While mice in the preclinical study did not mount an immune response to native mouse WT1 antigens, mice immunized with our SynCon WT1 antigen broke tolerance and generated robust neo-antigen-like T cells. The immunized mice also exhibited smaller tumors and prolonged survival in a tumor challenge study. SynCon WT1 DNA vaccination also broke tolerance and generated neo-antigen-like T cell immune responses in Rhesus monkeys, a species whose immune system closely resembles that of humans. The ability to overcome the immune system&#8217;s usual tolerance of WT1 antigen suggests the potential of our SynCon WT1 antigen to address multiple WT1-expressing cancer in humans. We previously reported similar results for our SynCon hTERT and PSMA cancer antigens. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1/2 immuno-oncology trial of INO-5401 and INO-9012 (IL-12 plasmid) in participants with newly diagnosed GBM, in combination with cemiplimab (Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a PD-1 inhibitor developed jointly by Regeneron Pharmaceuticals and Sanofi. This open-label trial began in 2018 and enrolled 52 newly diagnosed GBM participants. The primary endpoint was safety and tolerability, and the trial also evaluated immunogenicity and efficacy (overall survival). Data from the trial has been presented at several medical conferences. In November 2019, we provided interim results showing that 80% (16 of 20) of MGMT gene promoter methylated participants and 75% (24 of 32) of unmethylated participants, the more difficult to treat group, were progression-free at six months (PFS6) measured from the time of their first dose, exceeding historical standard-of-care data. This immunotherapy combination with a PD-1 checkpoint inhibitor also exhibited supportive safety, tolerability, and immunogenicity data and suggested a safety profile consistent with that of Libtayo as well as our other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. Most participants assessed had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401, and immune responses to all three tumor-associated antigens were also observed in this trial. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we updated these results, showing that 85% (44 out of 52) of the participants in this trial were alive for at least 12 months following treatment. The updated results showed that 84.4% percent (27 of 32) of participants with MGMT promoter unmethylated tumors, and 85% (17 of 20) of participants with MGMT promoter methylated tumors, were alive at 12 months. Activated killer T cells directed towards one, two or all three cancer antigens in INO-5401 were detected in almost all participants tested.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, additional data from the trial were presented at the Society for Neuro-Oncology (SNO) Annual Meeting. Survival data at 18 months showed that 70% (14/20) of MGMT promoter methylated GBM participants were alive, and 50% (16/32) of MGMT promoter unmethylated participants were alive after 18 months. Median overall survival in the unmethylated GBM participants was 17.9 months, which compares favorably to historical controls. An update on immunology data showed that in the MGMT promoter unmethylated cohort, 19 of 22 (86%) participants had an IFN-gamma T cell response that increased over baseline to one or more of the antigens encoded by INO-5401. In the MGMT promoter methylated cohort, 16 of 17 (94%) participants had an IFN-gamma response that increased over baseline to one or more of the antigens encoded by INO-5401.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, updated data was presented at the Society for Immunotherapy of Cancer pre-conference workshop from the GBM-001 Phase 2 trial. Overall survival at 24 months was 22% (7/32) for the MGMT unmethylated cohort and 55% (11/20) for the MGMT methylated cohort. The trial showed that INO-5401+INO-9012 with cemiplimab and radiation/TMZ have an acceptable safety profile, are immunogenic, and may improve survival in newly diagnosed GBM. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5151 (INO-5150 + INO-9012) for the Treatment of Prostate Cancer </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-5151, which consists of DNA plasmids targeting Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSMA), combined with INO-9112, the IL-12 plasmid, for the treatment of prostate cancer. In the United States in 2022, there will be an estimated 268,490 new cases of prostate cancer and about 34,500 deaths due to this cancer. We previously completed a Phase 1 trial of INO-5150, DNA plasmids targeting PSA and PSMA. Data from this trial have been presented at several annual meetings, most recently at the 2018 European Society for Medical Oncology (ESMO) congress and have suggested that men treated with INO-5150 on the trial experienced a slowing of PSA doubling time, an important indicator of potential clinical benefit. Data presented at these conferences also showed immunogenicity and tolerability of INO-5150.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we announced a clinical collaboration with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) as part of which INO-5151 is being combined with an immune modulator (CDX-301, FLT3 ligand, a dendritic cell mobilizer) and a PD-1 immune checkpoint inhibitor (nivolumab) in participants with metastatic castration-resistant prostate cancer (mCRPC), in a PICI-sponsored platform trial (PORTER). This combination trial is an open-label, non-randomized, exploratory platform trial designed to assess the safety and antitumor activity of multiple immunotherapy-based combinations in participants with mCRPC who have received prior secondary androgen inhibition. This trial will evaluate biomarkers of immune activity and clinical outcomes using a multi-omic, multi-parameter approach. Our immunotherapy is one arm of this PICI-supported trial, and recruitment is ongoing. Under the agreement, PICI will design and conduct the clinical trial, working in collaboration with its established network of clinical academic and industry cancer centers, with funding support from CRI. We will provide financial contributions based on the actual costs of the trial, if INO-5151 reaches the initiation of a Phase 3 trial. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Disease Product Candidates</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development platform also allows for rapid design, pre-clinical testing, manufacturing and clinical development of our vaccine and immunotherapy product candidates. In 2016, we were the first entity able to advance a Zika virus vaccine into human clinical trials, 4.5 months after the World Health Organization, or WHO, declared the emerging Zika virus infections to be a Pandemic Health Emergency of International Concern. Previously, we led the development of the first MERS vaccine in human clinical trials. More recently, our DNA medicines platform and SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capabilities allowed us to rapidly respond to the SARS-CoV-2 coronavirus outbreak in early 2020. We believe that our development platform is well positioned to support global health agencies to develop preparedness countermeasures against bioterrorism and/or emerging pandemic agents. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4800 for COVID-19 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A novel strain of coronavirus emerged in the human population in Wuhan City, China in late 2019. The new virus is a member of the genus of Coronaviruses, which is comprised of seven known viruses that can infect and make humans ill, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(SARS-CoV), as well as four other lower risk coronaviruses which can cause the common cold. The disease caused by the SARS-CoV-2 novel coronavirus was subsequently named COVID-19.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The virus quickly spread throughout China, Asia, and worldwide. As of February 2021, almost every country on earth had reported confirmed cases. As of January 2022, a total of nearly 320 million confirmed cases had been reported worldwide, with a total of more than 5,510,000 reported deaths directly due to this disease. Both the numbers of reported and estimated actual cases began to rise significantly in 2022 with the emergence of the Omicron variant of concern of the SARS-CoV-2 virus.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently, several major variants of concern (VOCs) of SARS-CoV-2 have evolved and spread significantly from several portions of the globe and quickly to many countries. These VOCs have the characteristics of at least having a significantly increased transmission rate compared to the original/main SARS-CoV-2 strain. Currently authorized vaccines may not be as effective at preventing disease due to these variants.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Clinical Trial </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants receiving INO-4800. In this trial, INO-4800 was immunogenic in all vaccinated participants, generating an immune response of humoral (including neutralizing antibodies) and/or cellular responses (both CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cells). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported. Six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. These only occurred on the day of the first or second dosing, and the AEs did not increase in frequency with the second administration.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2/3 Clinical Trial &#8211; INNOVATE </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the dosing of the first participant in our Phase 2 clinical trial evaluating INO-4800, as part of our Phase 2/3 clinical trial, called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy). The Phase 2 segment of the trial has enrolled approximately 400 participants who are 18 years or older at 17 U.S. sites to evaluate safety and immunogenicity in order to confirm the dose(s) for the subsequent efficacy evaluation as part of the Phase 3 segment of the trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 segment of the trial, funded by the DoD, evaluated safety, tolerability and immunogenicity of INO-4800 in a two-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo to confirm the more appropriate dosing level(s) for each of three age groups (18-50 years, 51-64 years and 65 years and older) at high risk of SARS-CoV-2 exposure for the subsequent Phase 3 efficacy evaluation. Results from the Phase 2 segment provided us with the information to select the dose level for the Phase 3 segment.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global Phase 3 segment of INNOVATE is a randomized, blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed symptomatic COVID-19. The Phase 3 segment has received authorization to proceed in seven countries: Mexico, Brazil, Colombia, Thailand, India, Philippines, and the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted an in vitro assessment of the cross-reactivity of INO-4800 vaccine-induced immune responses against the Omicron variant of SARS-CoV-2. Testing was observed to provide full maintenance of T cell responses against the Omicron variant in clinical samples from participants who has received INO-4800, including CD8+ responses, in line with results observed with the vaccines of other developers, significantly decreased levels of both neutralizing and binding antibodies against Omicron. The maintenance and preservation of T cell responses continue to remain a consistent observation for INO-4800 against the ancestral COVID-19 virus and across all variants of concern (VOCs) tested to date, including Omicron. We believe this is a critical observation as T cell responses are thought to play an important role in protection against severe disease and death and may be central to the durability of vaccine protection. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the dominance of the Omicron variant globally and the persistence of cross-reactive T cell responses generated by INO-4800, including CD8+, across all variants of concern to date, we plan to seek regulatory approval to amend the primary endpoint of INNOVATE from prevention of virologically confirmed COVID-19 disease to prevention of severe disease due to COVID-19. We believe INO-4800's ability to generate T cell responses could be critical in meeting the proposed amended primary endpoint.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to reflect the potential impact of the Omicron variant on INNOVATE, the Data Safety Monitoring Board (DSMB) recommended that we pause enrollment of new patients in the global Phase 3 clinical trial of INO-4800 in order to update the Informed Consent Form and Investigator Brochure. As a result of the DSMB&#8217;s recommendation, as well as our plans to seek approval to amend the trial&#8217;s primary endpoint, we have paused enrollment of new patients in INNOVATE. Interim efficacy data from INNOVATE will therefore not be available in the first half of 2022 as previously expected. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also evaluating the feasibility of an additional ex-US heterologous boost (vaccination with a different vaccine from the previous administration) trial with our COVID-19 DNA vaccine candidate, INO-4800, as a booster in a non-inferiority </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial compared to approved viral vector and inactivated COVID-19 vaccines. Viral vector and inactivated COVID-19 vaccines have been the vaccine of choice, particularly in low-to-middle income countries where thermostability of a vaccine can be critical. Moreover, global demand for heterologous boosters may not be met with currently licensed vaccines (EUA or full authorization) or those not currently licensed but with Phase 3 efficacy data. While a clear regulatory pathway for a heterologous boost trial has not been defined, regulatory agencies in some countries have expressed consideration towards the use of heterologous boost vaccines in clinical trials, given the logistical challenges as well as vaccine hesitancy associated with some approved vaccines. We believe that second generation vaccines are needed to address issues such as vaccine equity and logistical challenges that are still left to be solved. At the same time, we recognize that there are regulatory hurdles to be cleared. Key features of our DNA vaccine technology which make it a potentially favorable booster candidate include generating T-cell responses against multiple variants of concern, lack of anti-vector immunity, tolerability of re-administration, thermostability for transport, storage, and distribution. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2/3 Clinical Trial &#8211; SOLIDARITY TRIAL VACCINES (STV)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INO-4800 is one of two initial COVID-19 vaccine candidates included in the WHO's Solidarity Trial Vaccines, which is designed to "rapidly evaluate the efficacy and safety of promising new candidate vaccines selected by an independent vaccine prioritization advisory group composed of leading scientists and experts." Recruitment for the trial has begun in Colombia, Mali and the Philippines; enrollment is expected at more than 40 sites across the three countries. According to the WHO, the trial "has the additional potential to uncover second-generation vaccines with greater efficacy, conferring greater protection against variants of concern offering longer duration of protection, and/or using needle-free routes of administration.&#8221; The trial is sponsored by the WHO. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800 in China </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the dosing of the first participant in our Phase 2 clinical trial of INO-4800 in China. The Phase 2 clinical trial being conducted in China is independent of the INNOVATE Phase 2/3 clinical trial of INO-4800 and will enroll approximately 640 participants who are 18 years or older. Our collaborator Advaccine is conducting and funding the Phase 2 trial in China. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Phase 2 clinical trial of INO-4800 in China has enrolled both 18-59 years old adults and older adults (60 years and older) with the primary endpoints of evaluating safety and immunogenicity within the Chinese population. The dosing regimen involves two vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of the INNOVATE trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous boost trials in China. The trials are designed to evaluate safety, tolerability, and immunogenicity of INO-4800 as a homologous boost where INO-4800 was administered as the primary vaccine and as heterologous boost where an inactivated vaccine was administered as the primary vaccine. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that we along with a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the DoD and the JPEO-CBRND, to use our dMAb technology to develop anti-SARS-CoV-2-specific dMAbs that function as both a therapeutic and preventive treatment for COVID-19. See &#8220;Synthetic DNA-based Monoclonal Antibodies Program&#8221; below for more information about our dMAb technology. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of DARPA's two-year grant, our and Wistar's teams have constructed COVID-19 dMAb candidates mirroring AstraZeneca's traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19. These dMAb candidates can be quickly developed and produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offering a cost-effective and scalable therapeutic and preventive option for treatment of SARS-CoV-2 virus infection. The dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates will then be advanced into preclinical studies and then potentially into human clinical trials. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Manufacturing Consortium for INO-4800 </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received a $5 million grant from the Bill &amp; Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP proprietary smart devices for the intradermal delivery of INO-4800. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced an agreement to expand our manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH &amp; Co. KG, to support large-scale manufacturing of INO-4800. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we announced that Thermo Fisher Scientific signed a letter of intent to manufacture INO-4800. Thermo Fisher plans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, for Eurogentec to manufacture INO-4800 at their GMP plasmid production site in Belgium.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Variants of Concern (VOC)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been closely monitoring the development and evolution of SARS-CoV-2, with a particular focus on the Alpha (aka B.1.1.7 or &#8220;UK&#8221;), Beta (aka B.1.351 or original &#8220;South African&#8221;), Gamma (aka B.1.1.28.1 or &#8220;Brazilian&#8221;), Delta (aka B.1.617.2 or &#8220;Indian&#8221;), and Omicron (aka B.1.1.529 or newer &#8220;South African&#8221;) variants of concern (VOCs) of the SARS-CoV-2 virus. We have been and are continuing to evaluate the impact of newly circulating strains of the SARS-CoV-2 virus on the immune profile of INO-4800 through an assessment of binding antibodies, neutralizing antibodies in both live and pseudo-type neutralization assays as well as assessing the impact of the INO-4800-generated T cell responses on these variants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing next-generation, pan-COVID vaccine candidates, that could be tailored to the known and potentially the unknown SARS-CoV-2 variants. Using our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene optimization algorithm to analyze the available sequence data from all existing circulating variants, we are seeking to create a synthetic SAR-CoV-2 spike protein gene design intended to protect against the known VOC as well the future unknown strains. Our DNA vaccines generate a balanced immune response, including T cell responses, which we believe could make our pan-COVID vaccine candidates less susceptible to changes in the genetic sequence of the virus. DNA vaccines can also be used for multiple boosts without being impacted by anti-vector immunity or an increase in reactogenicity. Moreover, pre-clinical studies and clinical trials have shown that DNA vaccines could also be used to boost the initial immune responses generated by multiple other vaccine platforms. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4700 for Middle East Respiratory Syndrome (MERS)</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on MERS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Middle East Respiratory Syndrome or MERS is a viral respiratory illness first reported in Saudi Arabia in 2012. MERS appears to have been transmitted from an animal reservoir to humans but human to human transmission has been confirmed. The virus for this disease belongs to the Coronaviradea family (or a coronavirus &#8211; MERS-CoV), and was not shown to be a communicable virus spreading in a sustained way in communities, but rather via rapid spread in the nosocomial setting, such as emergency rooms and/or hospitals without adherence to state-of-the-art infection control practices, which can result in outbreaks with many cases, including super-spreading events. Like the severe acute respiratory syndrome (SARS) outbreak in 2003 linked to another coronavirus (SARS-CoV-1), which made approximately 8,000 people ill and was fatal in nearly 10% of those cases, MERS-CoV appears to cause severe lung infections. However, the case-fatality rate (death rate) of MERS has typically been between 30% and 40%, which is significantly higher than that of SARS. While the SARS epidemic in 2003 killed 10% of those who became ill from the SARS virus, MERS has killed approximately 34% of people who people who became ill from the MERS virus from 2012 to October 2021. MERS differs in that it also causes rapid kidney failure. Its high death rate has caused serious concern among global health officials. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the continuing threat of MERS outbreaks, there are no approved vaccines or treatments for MERS.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development &#8211; MERS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we announced a collaboration with CEPI under which we are developing vaccine candidates against MERS. CEPI will fund up to $56 million of costs to support our pre-clinical and clinical advancement through Phase 2 of our vaccine candidate INO-4700. The goal of the collaboration is for our MERS vaccine to be available as soon as possible for emergency use. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700. Vaccine recipients had strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg, delivered intradermally with our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device. The vaccination regimen was well-tolerated with no vaccine-associated SAEs. The researchers at the Wistar Institute, Seoul National University Hospital, and the International Vaccine Institute (IVI) collaborated on this trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those receiving 0.6 mg of INO-4700, 88% seroconverted after a two-dose regimen at 0 and 8 weeks, while for those receiving a three-dose regimen given at 0, 4 and 12 weeks, 84% seroconverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a pseudotype-based neutralization assay. Robust T cell responses were observed in 60% of vaccine recipients after the two-dose regimen and 84% of those in the three-dose group (ELISpot assay). A single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dosed and completed enrollment for the first part (dose finding stage) of the Phase 2 trial (192 participants) of INO-4700. The multi-center Phase 2 trial is a randomized, double-blinded, placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of INO-4700 administered with CELLECTRA 2000 in approximately 500 healthy adult participants. The trial, which is sponsored by INOVIO and fully funded by CEPI, is being conducted at sites in Jordan, Lebanon, and Kenya where MERS cases have been reported.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4201 for Ebola Virus Disease</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on Ebola</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ebola virus causes one of the most virulent viral diseases, with case fatality rates averaging 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. Ebola can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within two to twenty-one days of exposure. In November 2019, the first conditional approval was issued for a preventive vaccine against Ebola virus. This approval was from the European Medicines Agency (EMA) for the vaccine ERVEBO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. That same month, the WHO pre-qualified that vaccine for use in high-risk countries. In the next month, the FDA approved that vaccine. However, there are no proven effective therapeutic treatments for Ebola. In addition, various experimental approaches have already been associated with undesirable side effects and limited ability to scale manufacturing.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, two Ebola outbreaks occurred, both in the Democratic Republic of Congo (DRC). The second Ebola outbreak of 2018 in the DRC became the second largest Ebola outbreak in world history. This particular outbreak had a 66% case-fatality ratio (aka case-fatality rate) as of February 2020. On June 1, 2020 an additional Ebola outbreak was declared in the DRC, before the outbreak was declared over on November 18, 2020. More recently, Ebola outbreaks have occurred in Guinea (February to June, 2021) and in the DRC (October 2021 and still ongoing). </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development - Ebola </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Phase 1 clinical data of our Ebola vaccine candidate INO-4201 was published in The Journal of Infectious Diseases. We believe that this trial, which is being fully funded by DARPA, further supports the advancement of the intradermal delivery platform for emerging infectious diseases. Significantly, intradermal (skin) administration with our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery device resulted in 100% of evaluable participants in the trial generating antigen-specific antibody responses that persisted for more than one year in most participants and generated T cell responses equivalent to or better than the group that received intramuscular delivery. We believe these published data further validate the tolerability, potency, and product stability advantages of our vaccine and immunotherapy platform. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ebola vaccine candidate was evaluated in five groups of healthy participants. Of 70 evaluated participants, 67 (96%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 52 participants (74%) seroconverted after only two doses. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the trial arm using intradermal (skin) administration, 13 of 13 evaluable participants (100%) generated antigen-specific antibody responses after only two doses and all remained seropositive after three immunizations. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced complete enrollment of a 46-participant Phase 1b trial in which INO-4201 will be assessed as a heterologous booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (Ervebo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an FDA- and EMA- approved viral vector-based Ebola vaccine. To date INO-4201 has been well-tolerated and has not demonstrated systemic SAEs, such as fever, joint pain, and low white blood cell counts, that have been reported in association with some viral vector-based Ebola vaccines currently in development.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4500 for Lassa Fever</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on Lassa Fever</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lassa fever, also known as Lassa hemorrhagic fever, is an acute viral disease which occurs mostly in West Africa. The disease can cause a range of outcomes including fever, vomiting, diarrhea, cough, swelling of the face, pain in the muscles, chest, back and abdomen, bleeding of various parts of the body including the eyes and nose, vagina, and gastrointestinal tract, and death. Of the survivors of Lassa fever, about one-third have sudden-onset hearing loss, with more than half of those cases resulting in permanent hearing loss. This infection is spread through contact with infected rodents. Person to person transmission is also possible, via bodily fluids, albeit less common. Lassa virus infection in West Africa is estimated to affect 100,000 to 300,000 people annually, resulting in approximately 5,000 deaths, as disease and infection surveillance has been poor. Because of difficulties in diagnosing Lassa fever and the remoteness of many areas in which the disease occurs, the numbers of cases and deaths are likely significantly under-reported. Though the majority (about 80%) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious to fatal in others. There are no approved vaccines or treatments specifically for Lassa. The case-fatality ratio (aka case-fatality rate) (CFR) among patients hospitalized for Lassa fever is about 15% to 20%, and in some epidemics the CFR has reached 50% in hospitalized patients, such as in the 2015-2016 Nigeria portion of the West Africa outbreak. In lab confirmed cases in Nigeria from 2019 through 2020, the CFR was 21%. The CFR among pregnant women is particularly high, and in pregnant women infected with Lassa virus the fetal death rate due to spontaneous abortion rate is estimated to be about 95%. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we dosed our first participant in our Phase 1, first-in-human clinical trial to evaluate INO-4500, a DNA candidate vaccine to prevent infection from the Lassa virus. In 2019, we fully enrolled 60 volunteers in this placebo controlled, blinded, dose escalation trial evaluating INO-4500 for safety, tolerability and immune responses. This trial represents the first Lassa candidate vaccine to enter the clinic. Our sponsored trial, as well as our INO-4500 program, is fully funded through the global partnership with CEPI that we entered into in April 2018. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we announced that we have completed enrollment of a 220 participant Phase 1b trial in Accra, Ghana, which is the first vaccine clinical trial for Lassa Fever conducted in West Africa, where the viral illness is endemic. The dosing regimen involved two intradermal vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg doses. In addition to providing insights on the INO-4500 safety and immunogenicity profile, this trial will inform dose selection for subsequent Phase 2 trials in West Africa. If the result of this trial is positive, we expect to advance INO-4500 into a Phase 2 trial. If satisfactory Phase 2 data are achieved, CEPI, in cooperation with local regulatory authorities and the WHO, could elect to stockpile the vaccine for future use throughout the region.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Synthetic DNA-based Monoclonal Antibody Programs</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on recombinant Monoclonal Antibodies (mAbs)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recombinant mAbs have become one of the most valuable therapeutic technologies of recent years. In 2020, global sales of mAbs exceeded $100 billion.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mAbs are designed to bind to a very specific epitope (area) of an antigen or cell surface target and can bind to almost any selected target. They have the ability to alert the immune system to attack and kill specific cancer cells (as in the case of Yervoy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or block certain biochemical pathways (such as those leading to rheumatoid arthritis, as in the case of Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). However, mAb technology has limitations. mAbs are manufactured outside the body and require costly large-scale laboratory development and production. Additional limitations include high cost to develop and manufacture, their limited duration of in vivo potency, and a pharmacokinetic profile that can result in toxicity. We have created DNA encoded monoclonal antibodies that we believe may overcome many of the limitations associated with conventional mAb technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our core platform technology, we insert the DNA sequence for a specific monoclonal antibody in a DNA plasmid. We deliver the plasmid directly into cells of the body using our CELLECTRA smart delivery system, enabling the electroporated cells to manufacture those mAbs in vivo, - unlike conventional mAb technology that requires manufacture outside of the body. We believe this approach provides potentially significant advantages in terms of design simplicity, rapidity of execution and lower production costs.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to design dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates not only for new disease targets not currently addressable with conventional recombinant mAbs, but also targets of existing, commercially available mAb products. We have already designed and produced dMAb product candidates targeting cancer mechanisms including checkpoint inhibition, anti-cancer pathways and anti-Tregs, as well as prophylactic and therapeutic dMAb product candidates for infectious diseases including COVID-19, Ebola, influenza, antibiotic resistant bacteria, dengue and Chikungunya.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we announced that in collaboration with The Wistar Institute and the University of Pennsylvania, the first participant was dosed as part of the first-ever human trial of our dMAb technology. Funded fully by the Bill &amp; Melinda Gates Foundation, this trial's focus is on the safety and tolerability of DNA plasmid encoding for a human anti-Zika antibody. This open-label trial is a single center, dose escalation trial that enrolled 24 healthy volunteers who received from one to four doses of INO-A002, our DNA plasmid encoding for a human anti-Zika antibody. Doses ranging from 0.5 mg to 4 mg of plasmids were injected per participant, independent of their body weight.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, in December 2020, we and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from DARPA to use our DNA-encoded monoclonal antibody (dMAb) technology to develop anti-SARS-CoV-2-specific dMAbs which could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License, Collaboration, Supply and Other Agreements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various arrangements with corporate, academic, and government collaborators, licensors, licensees and others. The most material of these arrangements are summarized below.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, we entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, we granted to Advaccine the exclusive right to develop, manufacture and commercialize our vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without our express prior written consent. As part of the collaboration, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine also granted to us a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to our collaboration with Advaccine to jointly conduct the global Phase 3 segment of our ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the global Phase 3 trial. We will jointly participate in the trial and will equally share the global development costs for the trial, including our manufacturing costs to supply INO-4800. In certain instances, we will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay us its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China. We will be fully responsible for our costs and expenses, if any, incurred solely as a result of our activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, we are permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine made an upfront payment to us of $3.0&#160;million in January 2021. In addition to the upfront payment, we are entitled to receive up to an aggregate of $206.0&#160;million, payable upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. In December 2020 we earned a $2.0&#160;million milestone payment based on the enrollment of the first participant in the Phase 2 clinical trial for the product in the Advaccine territory. We are also entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay us an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, we will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, we may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by us to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to us, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that we may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an Amended and Restated License and Collaboration Agreement with Beijing Apollo Saturn Biological Technology Limited, a corporation organized under the laws of China, or ApolloBio. Under the terms of this License and Collaboration Agreement, which became effective in March 2018, we granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, our DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories. As part of the collaboration, ApolloBio will fund all clinical development costs within the licensed territory.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment that we received in 2018, we are entitled to receive up to an aggregate of $20.0&#160;million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the Amended and Restated License and Collaboration Agreement. In the event that&#160;VGX-3100&#160;is approved for marketing in these territories, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. The License and Collaboration Agreement, once effective, will continue in force until ApolloBio has no remaining royalty obligations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major pharmaceutical companies, broadly engaged in vaccine/immunotherapy research and development. These include Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline&#8239;plc, Merck, Pfizer, and AstraZeneca. There are also various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies including but not limited to Advaxis, Bavarian Nordic, CureVac, Dynavax, Hookipa, Iovance, Nektar, Translate Bio, Zydus, and Vir Biotechnology. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low- grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. Advaxis and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to GBM, prostate, breast, lung and other cancers we are targeting. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large number of companies are actively advancing COVID-19 vaccines through the clinic. Pfizer and BioNtech, Moderna Therapeutics, Janssen (J&amp;J), Novavax, Zydus, and AstraZeneca have received conditional or complete approval for their COVID-19 vaccines from either the U.S., WHO, or European regulatory authorities. Additionally, several companies such as CanSino Biologics and Bharat Biotech are currently developing vaccine candidates in Phase 2 or Phase 3 clinical trials. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other DNA delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their unique obstacles to overcome. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Vaccine Delivery </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology utilizes a virus as a carrier or vector to deliver genetic material into target cells. The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy. The greatest limitation of the technology stems from problems with unwanted immune responses against the viral vector, limiting its use to patients who have not been previously exposed to the viral vector and making repeated administration difficult. In addition, complexity and safety concerns increase their cost and complicate regulatory approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lipid DNA/RNA Delivery</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies. These work by either increasing uptake of the DNA/RNA into cells or by acting as an adjuvant, alerting the immune system. While there has been significant progress in this field, including emergency use authorization of COVID-19 mRNA vaccines in 2020, lipid nanoparticle delivery of mRNA has thermal stability issues as well as the potential of adverse events from the lipid nanoparticle formulations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA Immunotherapy Delivery with Electroporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other companies with electroporation intellectual property and devices. We believe we have significant competitive advantages over other companies focused on electroporation for multiple reasons: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA-based agents. This experience has been validated with multiple sets of interim data from multiple clinical studies assessing DNA-based immunotherapies and vaccines against cancers and infectious disease.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a broad product line of electroporation instruments designed to enable DNA delivery in tumors, muscle, and skin. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will be affected by the disease indications addressed by our product candidates and those of our competitors, the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include efficacy, safety, ease of use, reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization and Manufacturing</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the broad potential applications of our technologies, we intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as infectious diseases and cancer. Where appropriate, we intend to rely on strategic marketing and distribution alliances.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable clinical investigations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets. Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property portfolio covers our proprietary technologies, including CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery systems as well as immunotherapy and vaccine construct related technologies. As of December 31, 2021, our patent portfolio included 99 issued United States patents and over 651 issued foreign counterpart patents. We also have a number of patent applications pending in the United States and various foreign jurisdictions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us. These third parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system. We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Combination Products in the United States</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action, with the device component reviewed under a Device Master File.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Biological Product Development</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of a BLA;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the product candidate to healthy participants under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, participant selection and exclusion criteria, and the parameters to be used to monitor participant safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial participant or his or her legal representative and must monitor the clinical trial until completed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand participants) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may grant conditional approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials, such as these post-approval trials, to further assess the biologic&#8217;s safety and effectiveness after BLA approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA and FDA Review Process</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA&#8217;s </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review process again, including the initial sixty-day review to determine if the application is sufficiently complete to permit substantive review.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the FDA will ultimately approve a product for marketing in the United States and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Requirements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and vaccines. Accordingly, a pharmaceutical company&#8217;s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products and vaccines can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably.&#160;In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax, and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2031 with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule and guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Laws</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company&#8217;s ability to operate include:</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; and</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">State law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:47.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers and Research and Development</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we derived 43% of our revenue from the procurement contract with the DoD that we entered into in June 2020 and 14% of our revenue from our collaborator Plumbline Life Sciences, a company of which we are an approximately 19% stockholder. During the year ended December 31, 2020, we derived 68% of our revenue from Advaccine and 18% our our revenue from Plumbline Life Sciences. During the year ended December 31, 2019, we derived 78% of our revenue from AstraZeneca. Our collaboration agreement with AstraZeneca was terminated in 2021.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $249.2 million in 2021, $94.2 million in 2020 and $88.0 million in 2019. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue for the years ended December&#160;31, 2021, 2020 and 2019 was earned in the United States. All of our long-lived assets are located in the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our main telephone number is (267) 440-4200. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inovio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, our Corporate Governance Policy and information for contacting our board of directors is available on our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 2022, we employ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed 317 p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eople on a full-time basis. Of the tot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al, 256 were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in product research, which includes research and development, quality assurance, clinical, engineering and manufacturing, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 61 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were in general and administrative functions, which includes corporate development, information technology, legal, commercial, investor relations, finance and corporate administration. About 50% of our workforce is comprised of women and approximately 50% is comprised of individuals with ethnically diverse backgrounds. In addition, three of the eight members of our board of directors are women. None of our employees are subject to collective bargaining agreements. We con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sider our relationship with our employees to be good. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the highly competitive biotechnology industry. Attracting, developing and retaining talented people in research, quality assurance, clinical, engineering, manufacturing and other positions is crucial to executing our strategy and our ability to compete effectively. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and work environment. To that end, we invest in our employees to be an employer of choice.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work to make an impact on how healthcare is delivered, we believe it is critical that our employees are informed and engaged. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, employee surveys and our company intranet, and acknowledge individual contributions to INOVIO through several rewards and recognition initiatives. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work. As a result of the COVID-19 pandemic, we also further strengthened our digital communication platform. Our employee communications during the pandemic have kept our employees informed on critical priorities and important actions being taken by management in response to the pandemic.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical health, financial well-being, life balance and mental health of our employees is vital to our success. In 2021, we launche</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d a company wide comprehensive wellness program inclusive of financial, physical, and mental well-being.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The environmental, health and safety team stays abreast of local, regional and global concerns and trends and ensures safety procedures are in place to mitigate workplace injuries and safety risks. Employees are required to complete training in various safety procedures for the laboratories and manufacturing facilities and specialized safety training based on particular job duties. Designated Safety Officers and response teams oversee safety-related initiatives and a safety committee provides input on safety procedures, practices, and policies. Employees are required to wear personal protective equipment relevant for their particular job duties. Occupational injuries at the workplace are extremely low and are always investigated to determine if any environmental or other changes need to be implemented.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the onset of the COVID-19 pandemic, strict safety protocols have been put in place for employees working on-site, including following federal and local guidelines and mandates to ensure the safety of the workforce. In addition to providing the necessary personal protective equipment, special engineering controls have been installed at the facilities to further protect workers. Regular communication and training about the virus and how individuals can protect themselves and others is ongoing with employees. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of December 31, 2021 our accumulated deficit was $1.2 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine and DNA immunotherapy product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing our electroporation-based DNA delivery technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts currently account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products and product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">debt service obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of the COVID-19 pandemic and geopolitical turmoil, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. To the extent that our product candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval, for example, the results for the ITT population in the REVEAL 1 Phase 3 clinical trial were not statistically significant, which could result in the FDA requiring that we conduct another clinical trial before submitting a BLA for VGX-3100; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications or, with respect to our clinical trials for INO-4800, mass vaccination efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human vaccine programs, which includes our COVID-19 vaccine candidate INO-4800, our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates, including INO-4800. The success of our efforts to develop and commercialize our product candidates, including INO-4800, could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of INO-4800 on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our planned Phase 3 clinical trial of INO-4800 in the United States as a potential COVID-19 vaccine was previously placed on partial clinical hold by the U.S. FDA. Even though the hold has been lifted, we may experience delays in our ability to conduct clinical trials in the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our planned clinical development of INO-4800 in the United States as a potential COVID-19 vaccine was previously placed on partial clinical hold by the U.S. FDA until we satisfactorily resolved the FDA&#8217;s questions relating to our CELLECTRA 2000 device to be used in the trial. This clinical hold meant that we were not permitted to commence a Phase 3 clinical trial in the United States until the hold was lifted. The FDA notified us in November 2021 that the clinical hold had been lifted, allowing us to proceed with the Phase 3 segment of our INNOVATE trial. Although the partial clinical hold did not prevent us from starting our planned Phase 3 clinical trials outside of the United States, foreign regulatory authorities may impose similar requirements before we can commence or complete the portion of our Phase 3 clinical trial to be conducted in foreign countries. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delays in completion of ongoing clinical testing for INO-4800, because of a clinical hold, our current pause on enrolling new patients for INNOVATE, our ability to obtain regulatory approval to amend the primary endpoint of INNOVATE or otherwise, could significantly affect our product development costs. We do not know whether our planned Phase 3 clinical trial will be completed on schedule, if at all. In addition, our ongoing clinical trials for INO-4800 may not be completed on schedule, or at all, and could be placed on additional holds by regulators either in the United States or in foreign jurisdictions for reasons unrelated to our current hold. If we experience delays in completion of, or if we terminate, any of our clinical trials relating to INO-4800, the commercial prospects for our product candidate may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Omicron SARS-CoV-2 variant and newly emerging SARS-CoV-2 variants has required us to modify our COVID-19 vaccine strategy, which will result in new and added risks, including whether there will continue to be a need for a COVID-19 vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The emergence and current dominance of the Omicron SARS-CoV-2 variant may reduce the effectiveness of INO-4800 in preventing COVID-19. We conducted an in vitro assessment of the cross-reactivity of INO-4800 vaccine-induced immune responses against Omicron. Testing demonstrated a maintenance of T cell responses, including CD8+ responses, but significantly decreased levels of both neutralizing and binding antibodies against Omicron.  As a consequence, we plan to seek regulatory approval to amend the protocol for the INNOVATE clinical trial by changing the primary endpoint from prevention of virologically confirmed COVID-19 disease to prevention of severe disease due to COVID-19. There can be no assurance that we will receive regulatory approval for such amendment and we do not know what other requirements and conditions may be imposed on the conduct of INNOVATE that may affect its timing, cost and outcome.  If we are not able to obtain regulatory approval to amend the primary endpoint, INO-4800 may not achieve the primary endpoint of the INNOVATE trial, making marketing approvals less likely. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our COVID-19 vaccine strategy and prospects would be adversely affected if a weakened version of SARS-CoV-2 becomes the dominant variant, obviating the need for any vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our modified COVID-19 vaccine strategy, we are also evaluating the feasibility of an additional ex-US heterologous boost (vaccination with a different vaccine from the primary series) trial with INO-4800. However, a clear regulatory pathway for a heterologous boost trial has not been defined and such a regulatory strategy may be difficult to navigate and ultimately may not be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There can be no assurance that any of the products we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. The option of seeking an Emergency Use Authorization may no longer exist for our primary vaccine candidates, and if we cannot obtain such authorization or, if granted, it is terminated, we will be unable to sell our product in the near future and instead will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, such as conditional marketing authorization from the EMA. If we apply for an EUA and it is granted, an EUA would authorize us to market and sell our COVID-19 vaccine under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 vaccines will proceed to licensure of their vaccine products under a full Biologics License Application. The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. For example, we may no longer be able to obtain an EUA for INO-4800 as a primary vaccine, since several of our competitors&#8217; COVID-19 vaccines have already obtained full approval. As a result, we may only be able to seek an EUA for INO-4800 as a heterologous booster vaccine candidate, which strategy may not be successful. We would need to seek full biologics licensure for INO-4800 as a primary vaccine, which is a lengthy and expensive process. Even if an EUA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other authorization is ultimately granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. An EUA authorizing the marketing and sale of our product will terminate upon expiration of the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 vaccine, which could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our product candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have engaged several additional third-party contract manufacturers to support the planned large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity on commercially reasonable terms. Our inability to secured sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for INO-4800 or any of our other product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are devoting significant resources to the scale-up, development and commercialization of our COVID-19 vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work toward the large-scale technical development, manufacturing scale-up and larger scale deployment of our COVID-19 vaccine candidates. The number of doses of these vaccines that we are able to produce and distribute is dependent on our ability, and the ability of our contract manufacturers, to successfully and rapidly scale up manufacturing capacity. To support the scale-up, we have expended and will need to continue to expend significant resources and capital. We may need to divert resources and capital from our other programs. We may also seek and secure significant additional funding </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through contractual arrangements and collaborations with third parties. We may be unable to enter into such arrangements on favorable terms, or at all, which would adversely affect our ability to develop, manufacture and distribute the COVID-19 vaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our products, development candidates and investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our products, development candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our products, development candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our products or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates, or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. For example, in connection with our planned Phase 3 clinical trials of INO-4800 to be conducted outside of the United States, some regulatory authorities have indicated concerns with placebo-controlled efficacy trials of a COVID-19 vaccine, which means that we would not be able to open clinical trial sites in those countries. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA medicines are a novel approach, and negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our large pipeline of development candidates and investigational medicines could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are developing some of our development candidates or investigational medicines for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our product candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional product candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of recurrent respiratory papillomatosis. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, including but not limited to VGX-3100 for the treatment of HPV-16-/18-associated anal dysplasia, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of recurrent respiratory papillomatosis, and even if we obtain Orphan Drug Designation for our other product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation enacted in 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This reduction could further limit the advantage of, and may impact our future business strategy with respect to, seeking the Orphan Drug Designation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek a breakthrough therapy designation for one or more of our investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in April 2021 we were notified by the DoD that they will discontinue funding for the Phase 3 segment of our INNOVATE trial.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our participation in the WHO Solidarity Trial Vaccines (STV) could result in adverse consequences. We do not have any control over clinical data, progress, and decisions regarding INO-4800's participation in STV, and as such, decisions regarding the clinical pathway for INO-4800 between the WHO and the Company may not always align.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine candidate INO-4800 is one of two vaccine candidates initially selected by the WHO for its randomized, global Phase 3 clinical trial, STV, being conducted initially in Columbia, Mali and the Philippines.  We are supplying INO-4800 to WHO for the STV clinical trial.  Because STV and our other ongoing Phase 2/3 global clinical trial of INO-4800, INNOVATE, have similar protocols and endpoints, we believe that the data generated by STV could support a potential EUA or licensure application for INO-4800. STV is entirely independent of INNOVATE and is being conducted at different clinical trial sites with separate investigators, IRBs and DSMBs. We have no influence on the conduct of STV other than providing INO-4800 for the trial. As a result, we do not have any control over clinical data, clinical trial progress or decisions regarding INO-4800's inclusion in STV.  All decisions regarding STV are and will be made by the WHO, which has the ability to terminate, pause or otherwise control the conduct of STV without seeking our consent. If WHO does not modify the endpoints of STV, or modifies the endpoints in such a manner that results in INO-4800 not showing efficacy in STV, it could negatively affect the prospects of INO-4800 as a vaccine candidate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a small sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our biomarker being developed to identify women with HPV 16/18 cervical HSIL, may not be validated by the FDA or other regulatory bodies, which could adversely affect the commercial viability ofVGX-3100;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our electroporation equipment by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement, including with respect to COVID-19 vaccines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Growth and Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, during 2020, numerous purported shareholder class action complaints were filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of our INO-4800 vaccine candidate against COVID-19 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigation matters, described in this report, are ongoing, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even though we intend to vigorously defend ourselves in these actions, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines could be negatively affected by COVID-19, which could then materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. We have also implemented a mask-wearing mandate for all on-site activities. Non-essential business travel has been suspended and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as local jurisdictions continue to put restrictions in place or reinstitute restrictions they had previously lifted, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The COVID-19 pandemic has caused supply chain disruptions and supply shortages globally. As a result, we have experienced delays and disruptions in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtaining clinical supplies, manufacturing supplies and components, and have had to secure new vendors for certain supplies and components at higher prices. Some manufacturing supplies and components remain in limited supply with uncertain delivery dates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we have raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negative affect our future liquidity. In addition, if a global economic recession results following the spread of COVID-19, including newly emerging SARS-CoV-2 variants, its impact could materially affect our business and the value of our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19, including newly emerging SARS-CoV-2 variants globally, has affected and could continue to adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, COVID-19 adversely impacted the timeline for data collection for our VGX-3100 program. An increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for this trial. As a result, it is taking longer than anticipated to complete the data collection process. Further, the COVID-19 outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of participants to comply with clinical trial protocols as quarantines and travel restrictions impede participant movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. These restrictions may delay the conduct of multiple clinical trials including our Phase 1 through 3 clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furloughs of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including travel restrictions to, from and within the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our products and introduce new, disruptive technology, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Some of our competitors have already received regulatory approval for their COVID-19 vaccines and have mass vaccination efforts underway in our target markets. For example, multiple COVID-19 vaccines and boosters have been approved by regulators in the United States and Europe and in August 2021 the world's first DNA vaccine against COVID-19 was approved for emergency use by India's regulators. The earlier market entry of these other vaccines, and their actual or perceived efficacious or success relative to our own, has led to and may continue to lead to diversion of funding away from us, a declining market for COVID-19 vaccines, decreased demand for INO-4800, if approved, and difficulty in finding participants for our clinical trials. All of these factors could substantially impact our ability to complete the development of, commercialize and generate revenues from INO-4800. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAb candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage, and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Further, Congress is considering additional health reform measures as part of the budget reconciliation process.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule and guidance in September 2020, providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation (MFN) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinded the MFN model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct research and development activities in China through our collaboration with Advaccine, which is conducting and funding the Phase 2 trial of INO-4800 in China. In addition, we are party to a license and collaboration agreement with China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to increased costs for clinical materials that are manufactured in China. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">given the nature of the COVID-19 pandemic, governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of INO-4800 as a potential vaccine candidate against COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other product candidates to address COVID-19 or other diseases; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 pandemic. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Furthermore, our operating expenses have significantly increased due to development and manufacturing activities for our COVID-19 vaccine program, and we may not deploy our expanded capital base effectively. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our investigational medicines. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in laws and regulations, including changes proposed or implemented by the current U.S. presidential administration, such as alternative minimum taxes or suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In December 2017, tax legislation commonly known as the Tax Cuts and Jobs Act was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or changes proposed or implemented by the current U.S. presidential administration or otherwise, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own no real property and have no plans to acquire any real property in the future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Diego Leases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2013, we entered into a lease, or the First San Diego Lease, for office space in San Diego, California. The term of the First San Diego Lease commenced on December 1, 2013. The initial term of the First San Diego Lease is ten years, with an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option to extend the term by five years, subject to specified conditions. In June 2015, we amended the First San Diego Lease to increase the total leased space to 31,207 square feet and occupy the entire building. The commencement of the amended First San Diego Lease was in January 2016. As of December 31, 2021, rent payments under the First San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. We had an option to terminate the First San Diego Lease on December 1, 2019, which we did not exercise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, we entered into an office lease, or the Second San Diego Lease, for a second property in San Diego, California. The total space under the Second San Diego Lease is approximately 51,000 square feet. We are using the facility for office, manufacturing and research and development purposes. The term of the Second San Diego Lease commenced on June&#160;1, 2017. The initial term of the Second San Diego Lease is ten years, with a right to terminate on November&#160;30, 2023, subject to specified conditions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Second San Diego Lease. As of December 31, 2021, rent payments under the Second San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth Meeting Lease </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We occupied the space in June 2014. The initial term of the Plymouth Meeting Lease was 11.5 years, with a right to extend the term by five years, subject to specified conditions. We use the space for office purposes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Plymouth Meeting Lease. As of December 31, 2021, rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately 2 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $49,000. In July 2015, we amended the Plymouth Meeting Lease to increase the total leased space to 27,583 square feet. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we entered into another amendment to the Plymouth Meeting Lease to increase the total leased space to 57,361 square feet and extend the lease term through December 31, 2029. In connection with this amendment, we paid the landlord an additional security deposit of $75,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, we entered into two agreements to sublease a total of approximately 13,500 square feet in our Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Securities Litigation</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss. The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, Plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#8217; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. Defendants intend to move to dismiss the new allegations in the amended complaint.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend these actions vigorously.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. On January 29, 2021, we filed preliminary objections to the complaint. On August 23, 2021, the Court overruled our preliminary objections to the complaint. On September 13, 2021, we filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement, and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 11, 2022, we had approximately 100 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price per share of our common stock on February 11, 2022 was $3.32, as reported on the Nasdaq Global Select Market.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&amp;P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, 2021. The graph assumes a $100 investment on December 31, 2016 in our common stock and in each index, with the reinvestment of all dividends, if any.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><img src="ino-20211231_g4.jpg" alt="ino-20211231_g4.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:558px"/></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*$100 invested on 12/31/16 in stock or index, including reinvestment of dividends.<br/>Fiscal year ended December 31.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NYSE American</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Composite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P SuperCap Biotechnology Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Parties </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;I of this Annual Report under the Caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_43"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus ("HPV"). We have shown in clinical trials that our DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of our integrated platform, SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA nucleic-acid delivered gene products smart delivery devices facilitate uptake of our DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA&#174; smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to develop, seek regulatory approval for and commercialize our novel DNA medicines to address unmet global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corporation, AstraZeneca, Advaccine Biopharmaceuticals Suzhou Co, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), Defense Advanced Research Projects Agency ("DARPA"), The U.S. Department of Defense ("DoD"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently evaluating the feasibility of, conducting or planning clinical studies of our DNA medicines for COVID-19, which includes both homologous and heterologous boosting approaches; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had an accumulated deficit of $1.2 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities. </span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 on Our Business </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operationally, we have experienced some disruptions as a result of the COVID-19 pandemic. Our clinical trial operations have been adversely affected, including our ability to initiate and conduct our planned trials on our expected timelines and our ability to recruit and retain participants in our trials. Our data collection timelines have also been impacted, as an increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples. As a result, it is taking longer than anticipated to complete the data collection process. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused supply chain disruptions and supply shortages globally. As a result, we have experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and have had to secure new vendors for certain supplies and components at higher prices. Some manufacturing supplies and components remain in limited supply with uncertain delivery dates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. We have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. We have also implemented a mask-wearing mandate for all on-site activities. Non-essential business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity has also not been negatively impacted to date by the pandemic. During the years ended December 31, 2021 and 2020, we raised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $47.7 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$454.5 million, respectively,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net proceeds from the sale of shares of our common stock through "at-the-market" equity offering programs and in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> January 2021 we closed an underwritten public offering with net proceeds to us of $162.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which further enhanced our liquidity and capital resources. As of December 31, 2021, our cash and cash equivalents and short-term investments were $401.3 million, compared to $411.6 million as of December 31, 2020. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to closely monitor the impact of the COVID-19 pandemic on our employees, collaborators and service providers. The extent to which the pandemic will impact our business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain. For additional information on the potential effects of the COVID-19 pandemic on our business, financial condition and results of operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see the &#8220;Risk Factors&#8221; section above in Part I, Item 1A of this Form 10-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC defines critical accounting policies as those that are, in management&#8217;s view, important to the portrayal of our financial condition and results of operations and require management&#8217;s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. Our significant accounting policies are outlined in Note 2 to the Consolidated Financial Statements included in this Form 10-K. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. We believe the following accounting policies to be critical to the judgements and estimates used in the preparation of our consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and we conclude that our collaboration partner is not a customer, we present such payments as a reduction of research and development expense. If payments from our collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, we assess the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that include license fees, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that include milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on our past experience with our collaboration partner, market insight and partner communication. Milestone payments that are not within our or our collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue in the period the underlying sales occur. To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations.</span></div><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;2 to the consolidated financial statements, included elsewhere in this report.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial data for the years ended December&#160;31, 2021, 2020 and 2019 is presented in the following table and the results of these periods are used in the discussion thereafter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2020 vs. 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements, including from affiliated entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,147,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,624,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,872,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,476,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,751,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(159,716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,636,462)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,240,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,245,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,017,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,994,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,228,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,752,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,247,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,203,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,504,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,044,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,992,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,493,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,220,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,499,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,272,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(301,217,919)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,082,044)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111,108,545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177,135,875)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,973,499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,605,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,936,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,702,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,948,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,766,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(753,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,670,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,763,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,670,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,907,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(553,570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,556,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,090,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,110,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,647,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,222,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,918,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(704,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,048,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,201,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,177,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,762,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,762,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,762,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss before income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,334,019)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,081,192)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(257,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,658,710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,474,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,551,777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136,183,796)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,923,137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192,558&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,063,757)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,801)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributed to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,658,710)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166,411,157)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119,359,219)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,247,553)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,051,938)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Not meaningful</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2021 and 2020 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our year over year total revenue decreased $5.6 million, or 76%. The decrease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was primarily due to revenue earned from Advaccine in connection with upfront and milestone payments, and milestone revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earned from our affiliated entity Plumbline Life Sciences, Inc. ("PLS"), for the year ended December 31, 2020 that did not occur for the year ended December 31, 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $155.0 million increase in research and development expenses for the year ended December&#160;31, 2021 as compared to 2020 was primarily due to increases of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$39.5 million in drug manufacturing, outside services and clinical study expenses related to INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$35.0 million in expenses related to manufacturing capacity access fees;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$21.9 million related to the acquisition and installation of manufacturing equipment related to INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$13.6 million in engineering services and expensed equipment and inventory related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device array automation project;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$12.8 million in expensed materials purchased in preparation for the manufacturing of INO-4800; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$12.1 million in employee and contractor compensation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These increases were primarily offset by an increase in contra-research and development expense recorded from grant agreements of $6.2 million, among other variances. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $53.7 million and $47.5 million for the years ended December&#160;31, 2021 and 2020, respectively. The increase year over year was primarily due to increases of $5.9 million, $3.6 million and $2.4 million earned from the DoD OTA Agreement, CEPI Lassa and MERS grant and reimbursements from Advaccine, respectively, partially offset by decreases of $3.2 million and $3.2 million, earned from CEPI and Gates, respectively, related to INO-4800 and device development activities, among other variances. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The $16.5 million increase in general and administrative expenses for the year ended December&#160;31, 2021 as compared to 2020 was primarily due to increases of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">$5.3 million in employee and consultant stock-based compensation;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$3.9 million in employee compensation;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$2.7 million in insurance expenses; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$2.2 million in legal expenses.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was also due to less contra-general and administrative expense recorded related to gain on foreign exchange of $2.8 million, among other variances.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended December&#160;31, 2021 and 2020 was $25.0 million and $14.5 million, of which $13.4 million and $8.0 million was included in research and development expenses and $11.6 million and $6.5 million was included in general and administrative expenses, respectively. The increase for 2021 compared to 2020 was primarily due to an increase in options granted and a higher weighted average grant date fair value for the awards granted in the first quarter of 2021 and grants vesting during the period. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $51,000 increase in interest income for the year ended December&#160;31, 2021 as compared to 2020 was primarily due to more interest earned on our higher balance of short-term investment holdings.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $6.8 million decrease in interest expense for the year ended December&#160;31, 2021 as compared to 2020 was primarily due to less interest expense recorded from our convertible senior notes, or the Notes, due to the partial conversions of the Notes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into shares of our common stock in the third and fourth quarters of 2020 and the full conversion of the December 2019 Bonds into shares of our common stock in March 2021, as well as no interest expense recorded on our August 2019 Bonds due to their full conversion into shares of our common stock in August 2020. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) on Investment in Affiliated Entity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) on investment in affiliated entity for the year ended December&#160;31, 2021 was $(554,000) resulting from the change in the fair market value of our investment in PLS, and for the year ended December 31, 2020 was $36.6 million,  resulting from the change in the fair market value of our investments in GeneOne and PLS. During the third quarter of 2020, we sold our full equity interest in GeneOne. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Unrealized Gain (Loss) on Available-for-Sale Equity Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain (loss) on available-for-sale equity securities for the years ended December&#160;31, 2021 and 2020 was $(3.2) million and $1.7 million, respectively, resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in Net Loss of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation in June 2020. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of December&#160;31, 2021, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $864.5 million, $146.5 million and $89.0 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. We also had U.S. federal and state research and development tax credits of $35.1 million and $4.4 million, respectively, net of the federal research and development credits that will expire due to IRC Section&#160;383 limitations. The net operating losses and credits began to expire during 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2020 and 2019</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comparison of the years ended December 31, 2020 and 2019, you may refer to Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 1, 2021.</span></div><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and short-term investments of $401.3 million and working capital of $382.7 million, as compared to $411.6 million and $429.5 million as of December&#160;31, 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $215.7 million and $178.0 million for the years ended December&#160;31, 2021 and 2020, respectively. The variance was primarily due to increased research and development expenses offset by the timing and changes in working capital balances.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $175.3 million and $58.8 million for the years ended December&#160;31, 2021 and 2020, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities, offset by the proceeds from the sale of our investment in GeneOne in 2020 of $40.1 million. Our capital expenditures were $1.2 million and $1.5 million, respectively, and we do not expect our capital expenditure requirements to increase materially.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financing Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $211.5 million and $465.3 million for the years ended December&#160;31, 2021 and 2020, respectively. The decrease was primarily due to less proceeds from the sale of common stock under ATM sales agreements in 2021 compared to 2020, offset by the net proceeds from the January 2021 underwritten public offering. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221;. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us, including any price, time or size limits or other customary parameters or conditions we may impose. We will pay the Sales Agents a commission of up to three percent (3.0%) of the gross sales proceeds of any common stock sold through the Sales Agents under the Sales Agreement, and we have provided the Sales Agents with certain indemnification rights. During the year ended December 31, 2021, we sold 6,955,341 shares of common stock under the Sales Agreement for aggregate net proceeds of $47.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, were $162.1&#160;million. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement, or the 2018 Sales Agreement, with an outside placement agent, or the Placement Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. In the first quarter of 2020, we entered into amendments to the&#160;2018 Sales Agreement to increase the amount of our common stock that could be sold through the Placement Agent under the 2018 Sales Agreement to an aggregate offering price of up to $250.0 million. During the three months ended March 31, 2020, we sold 43,148,952 shares of common stock under the 2018 Sales Agreement for aggregate net proceeds of $208.2 million. Following these sales, there was no remaining capacity under the 2018 Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, we entered into a sales agreement, or the 2020 Sales Agreement, with the same Placement Agent to sell shares of our common stock. On that same day, we filed a prospectus supplement for the offer and sale of our common stock pursuant to the 2020 Sales Agreement for aggregate gross proceeds of up to $150.0 million. On May 12, 2020 we filed an additional prospectus supplement for the offer and sale of our common stock pursuant to the 2020 Sales Agreement for an additional $100.0 million of gross proceeds, bringing the maximum gross proceeds of sales under the 2020 Sales Agreement to $250.0 million. Through December 31, 2020, we sold 22,915,934 shares of common stock under the 2020 Sales Agreement for aggregate net proceeds of $246.2 million. On November 8, 2021, we terminated the 2020 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, stock options to purchase 1,310,263 shares of common stock were exercised for aggregate net proceeds of $6.7 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.6 million. During the year ended December&#160;31, 2020, stock options to purchase 2,178,252 shares of common stock were exercised for aggregate net proceeds of $12.3 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.0 million. During the year ended December&#160;31, 2019, stock options to purchase 42,969 shares of common stock were exercised for aggregate net proceeds of $113,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $893,000.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had an accumulated deficit of $1.2 billion and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. These activities will require additional financing. If these activities are successful and if we receive approval from the FDA to market our product candidates, then we will need to raise additional funding to market and sell the approved products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, future minimum payments due under our contractual obligations are set forth in the table below. We expect to be able to satisfy these obligations, both in the short-term and in the longer-term, with cash on hand and proceeds from sales of our common stock under the Sales Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1&#160;year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;&#8211;&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,082,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,139,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing commitments (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,427,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,427,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent remaining contractual amounts due under our Notes, including interest based on the fixed rate of 6.5% per year. Although these Notes mature in March 2024, they may be converted into shares of our common stock prior to maturity if certain conditions are met. We may also redeem the Notes prior to their maturity if certain conditions are met. Any redemption prior to maturity would result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. See Note 9, "Convertible Debt&#8221; in the Consolidated Financial Statements section of this report for further discussion.</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) We have entered into operating leases for our facilities, which expire from 2023 to 2029, and operating leases for office equipment, which expire in 2024. In the fourth quarter of 2019, we entered into two subleases for a portion of our Plymouth Meeting corporate headquarters facility through December 31, 2022 and March 31, 2025. As of December&#160;31, 2021, we expect to receive aggregate future minimum lease payments totaling $814,000 (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above.&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) We have entered into agreements with contract manufacturers for INO-4800 that contain minimum purchase requirements by us in 2022.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_58"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at December&#160;31, 2021, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness is fixed and not subject to fluctuations in interest rates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment in affiliated entity at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents our ownership interest in the Korean-based company PLS. We report this investment at fair value on the consolidated balance sheet using the closing price of PLS shares of common stock as reported on the date of determination on the Korea New Exchange Market.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the year ended December&#160;31, 2021 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page&#160;F-1 of this report.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of December&#160;31, 2021 at the reasonable assurance level.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of December&#160;31, 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended December&#160;31, 2021, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attestation Report of Independent Registered Public Accounting Firm</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent registered public accounting firm that audited the consolidated financial statements that are included in this Annual Report on Form 10-K has issued an audit report on the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. The report appears below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and Stockholders of Inovio Pharmaceuticals,&#160;Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Inovio Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework (the COSO criteria). In our opinion, Inovio Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2021, based on the COSO criteria.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December&#160;31, 2021 and related notes and our report dated March&#160;1, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for designing, implementing, and maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process effected by those charged with governance, management, and other personnel, designed to provide reasonable assurance regarding the preparation of reliable financial statements in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and those charged with governance; and (3) provide reasonable assurance regarding prevention, or timely detection and correction of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent, or detect and correct, misstatements. Also, projections of any assessment of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, our Board of Directors adopted resolutions (the &#8220;Resolutions&#8221;) ratifying pursuant to Section 204 of the Delaware General Corporation Law (the &#8220;Ratification&#8221;) the grant to employees of certain options to purchase common stock and restricted stock units (collectively, the &#8220;Grants&#8221;). The Board has determined that the Grants were defective corporate acts because they did not fully comply with the requirements of Section 157(c) of the Delaware General Corporation Law. A copy of the Resolutions adopted by the Board setting forth the information with respect to the Ratification required under Section 204 of the Delaware General Corporation Law is attached hereto as Exhibit 99.1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any claim that the defective corporate acts (including all options and restricted stock units and putative common stock issued upon the exercise of such options or the settlement of such restricted stock unit awards) identified in the Resolutions are void or voidable due to the failure of authorization, or any claim that the Court of Chancery of the State of Delaware should declare in its discretion that the Ratification not be effective or be effective only on certain conditions, must be brought within 120 days from the date of the filing of this Annual Report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional detail of the relevant statutory provisions refer to Sections 157, 204 and 205 of the Delaware General Corporation Law.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_1669"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.            DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_76"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2021 fiscal year, under the captions &#8220;Election of Directors&#8221; and &#8220;Executive Officers and Other Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2021 fiscal year, under the captions &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Compensation of Directors&#8221; and &#8220;Director Compensation Table.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2021 fiscal year, under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director independence and other information required by this Item&#160;13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2021 fiscal year, under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2021 fiscal year, under the caption &#8220;Ratification of Appointment of Registered Public Accounting Firm.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_97"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated financial statements required to be filed hereunder are indexed on Page&#160;F-1 hereof.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report on Form&#160;10-K:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit&#160;3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August&#160;10, 2011 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Form&#160;8-K current report filed on August&#160;12, 2011).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Indenture, dated as of February 19, 2019, by and between the registrant and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on February 20, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Form of Note representing the registrant&#8217;s 6.50% Convertible Senior Notes due 2024 (included as Exhibit A to the Indenture filed as Exhibit 4.1).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.9 to the registrant&#8217;s annual report on Form 10-K filed with the SEC on March 12, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">10.1&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">R&amp;D Alliance Agreement dated December&#160;19, 2005 by and between Ganial Immunotherapeutics,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by Novation and Amendment Agreement by and between VGX Pharmaceuticals, Inc., Ganial Immunotherapeutics, Inc., and Onconox (incorporated by reference to Exhibit&#160;10.31 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">10.2&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">R&amp;D Collaboration and License Agreement dated December&#160;18, 2006 by and between VGX International,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated October&#160;31, 2007 and as amended by Second Amendment dated August&#160;4, 2008 (incorporated by reference to Exhibit&#160;10.39 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">10.3&#8224;&#160;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">Patent License Agreement dated April&#160;27, 2007 by and between The Trustees of the University of Pennsylvania and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated June&#160;12, 2008 (incorporated by reference to Exhibit&#160;10.50 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">10.4&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">License Agreement dated May&#160;9, 2007 by and between Baylor University and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.34 as filed with the registrant&#8217;s registration statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">TM Equity Offering</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm"> Sales Agreement dated November 9, 2021 by and among Inovio Pharmaceuticals, Inc., </a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer &amp; Co. Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">(incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">as filed with the registrants Form 10-Q quarterly report for the quarter ended September 30, 2021 filed on November 9, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">10.6&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">License and Collaboration Agreement dated March&#160;24, 2010 between Inovio Pharmaceuticals, Inc. and VGX International, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended March&#160;31, 2010 filed on May&#160;17, 2010).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">10.7&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">Collaborative Development and License Agreement dated October 7, 2011 between VGX International, Inc. and Inovio Pharmaceuticals, Inc., as amended by First Amendment dated August 21, 2013, and Second Amendment dated October 7, 2013 (incorporated by reference to Exhibit 10.1 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended September&#160;30, 2011 filed on November&#160;7, 2011).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">10.10&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">Amended and Restated License and Collaboration Agreement, dated December 29, 2017, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.12 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2017 filed on March 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200622dodnatickotaagr.htm">10.11</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">&#8224;&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200622dodnatickotaagr.htm">Other Transaction Authority For Prototype Agreement dated June 22, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2020 filed on August 10, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200618dodnatickawarde.htm">10.12</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">&#8224;&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200618dodnatickawarde.htm">Award Agreement dated June 18, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2020 filed on August 10, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000055/ino-63021x10xqex101.htm">10.13&#8224;&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000055/ino-63021x10xqex101.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000055/ino-63021x10xqex101.htm">Collaboration and License Agreement dated June 7, 2021 between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (incorporated by reference to Exhibit 10.1 as filed with the registrants Form 10-Q quarterly report for the quarter ended June 30, 2021 filed on August 9, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm">Lease dated April 9, 2013 by and between BMR-Wateridge LP and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to registrant's quarterly report for the quarter ended March 31, 2013, filed on May 10, 2013).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">Lease Agreement dated as of March 5, 2014 between Brandywine Operating Partnership L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.36 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2014 filed on March 17, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">Office Lease Agreement dated October 10, 2016 by and between 6759 Mesa Ridge Road Holdings, LLC and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2016 filed on November 9, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">Sublease dated June 21, 2017 between Accolade, Inc. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">Second Amendment to the Lease Agreement dated June 22, 2017 between Brandywine Operating Partnership, L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm">10.19+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm">Employment Agreement dated March&#160;31, 2008 by and between J. Joseph Kim, Ph.D. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment of Employment Agreement dated March&#160;31, 2008 (incorporated by reference to Exhibit&#160;10.43 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm">10.20+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and J. Joseph Kim, PhD. (incorporated by reference to Exhibit&#160;10.41 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">10.21+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">Employment Agreement dated as of December&#160;27, 2010 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Form 10-K report for the year ended December&#160;31, 2010 filed on March&#160;16, 2011).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">10.22+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit&#160;10.42 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">10.23+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">Second Amendment to Employment Agreement dated November 7, 2014 by and between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.2 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2014 filed on November 10, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">10.24+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">Employment Agreement dated March 8, 2019 between Inovio Pharmaceuticals, Inc. and Jacqueline E. Shea (incorporated by reference to Exhibit 10.26 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">10.25+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">Employment Agreement dated as of March 4, 2019 between Inovio Pharmaceuticals, Inc. and Laurent M. Humeau (incorporated by reference to Exhibit 10.27 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">10.26</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">Form of Indemnification Agreement for Directors and Officers of Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 to the registrant&#8217;s Form&#160;10-Q quarterly report for the quarterly period ended June&#160;30, 2009, filed on August&#160;19, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">10.27+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">Amended and Restated 2007 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.12 to the registrant's Form 10-K report for the year ended December 31, 2015 filed on March 14, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">10.28+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.4 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">10.29+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on May 10, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">10.30+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">Form of Incentive Stock Option Agreement under 2016 Omnibus Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm"> (incorporated by reference to Exhibit 10.55 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">10.31+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">Form of Nonqualified Stock Option Agreement under 2016 Omnibus Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm"> (incorporated by reference to Exhibit 10.56 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">10.32+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">Form of Restricted Stock Units Award Agreement under 2016 Omnibus Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm"> (incorporated by reference to Exhibit 10.54 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex211.htm">Subsidiaries of the registrant (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex231.htm">Consent of Independent Registered Public Accounting Firm (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_103">24.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_103">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex311.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex312.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex321.htm">32.1&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex312.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm">Resolutions adopted by the Board of Directors Ratifying Option </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm">and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm">Restricted S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm">tock Unit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312021x10kex991.htm">Grants (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designates management contract, compensatory plan or arrangement.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain confidential portions of this exhibit (indicated by asterisks) were omitted because the identified confidential portions are not material and are of the type that the registrant treats as private or confidential. </span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March&#160;1, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSEPH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints J. Joseph Kim and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form&#160;10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SIMON X. BENITO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Simon X. Benito</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ROGER DANSEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Roger Dansey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ANN MILLER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ann Miller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAY SHEPARD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jay Shepard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DAVID WEINER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">David Weiner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;WENDY YARNO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wendy Yarno</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;LOTA ZOTH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lota Zoth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_109"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_112">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMDkvZnJhZzoyNGZmYjA0ZDFhOWM0ZmRhOGNiNzU5YmVjMmNmOTZiMy90YWJsZTowNDRkNzU1YjIwNzA0YzMzYjI3ZWJjZWY4NDZmNjNkNi90YWJsZXJhbmdlOjA0NGQ3NTViMjA3MDRjMzNiMjdlYmNlZjg0NmY2M2Q2XzEtMC0xLTEtMjg4NzEvdGV4dHJlZ2lvbjozYTJmNDJjMDNlZGY0YzVmODJhMmY2NWE2ODMwNjE1OF8zODQ4MjkwNjk3MzA0_286d6b76-2307-4acf-91e5-982d93bf0804">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_112">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_115">Consolidated Balance Sheets </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_115">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_118">Consolidated Statements of Operations </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_118">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_121">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_121">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_124">Consolidated Statements of Stockholders' Equity </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_124">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_127">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_127">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_130">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie30ae5fecfcc4388997084d44bc65ac3_130">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders and the Board of Directors of Inovio Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for each of the three years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated March&#160;1, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrual of Clinical Trial Expenses</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2021, the Company incurred $249.2 million for research and development expenses and as of December 31, 2021 accrued $10.3 million for clinical study costs. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including clinical research organizations (&#8220;CROs&#8221;). External costs to be paid to CROs are accrued and expensed based upon actual work completed in accordance with signed agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s accounting for accrued clinical study costs is especially challenging because the evaluation is dependent upon a high-volume of data and input exchanged between clinical personnel and third-party service providers, such as the number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">How We Addressed the Matter in our Audit</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical trial expenses. For example, we tested controls over management&#8217;s assessment and measurement of estimated accrued clinical study costs, including patient enrollment and total cost incurred to date from third-parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the completeness of the Company&#8217;s accrued clinical trial expenses, we obtained from third-parties confirmation of patient enrollment and direct service cost to date for significant clinical trials. We attended internal clinical trial and project status meetings with accounting personnel and the clinical project manager to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#8217;s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements. </span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTIvZnJhZzo5OTZiMzRmZWVkMWE0NTQ3YjMyYjgxNTQ2NGMxOTc3Yi90YWJsZTozMDkwOTFhNDMwMzM0YTc3YWY1NjE0NDMyNjU1YTJkMC90YWJsZXJhbmdlOjMwOTA5MWE0MzAzMzRhNzdhZjU2MTQ0MzI2NTVhMmQwXzAtMC0xLTEtMjg0NDIvdGV4dHJlZ2lvbjozZTYzZmRiNWY4Yzg0YWJlYmM5ZjZmZmUwNGU4MWMxMV84MjQ2MzM3MjA4MzYy_a228d8e0-c756-4b43-8023-87efcf72bb8b">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2002.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTIvZnJhZzo5OTZiMzRmZWVkMWE0NTQ3YjMyYjgxNTQ2NGMxOTc3Yi90YWJsZTozMDkwOTFhNDMwMzM0YTc3YWY1NjE0NDMyNjU1YTJkMC90YWJsZXJhbmdlOjMwOTA5MWE0MzAzMzRhNzdhZjU2MTQ0MzI2NTVhMmQwXzMtMC0xLTEtMjg0MzI_23657c10-dbfd-4d31-9795-f2bbf405e7e9">San Diego, California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQtMS0xLTEtMTMwNzk_0e57253f-11cb-4047-b241-521c0eae63b9">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQtMy0xLTEtMTMwNzk_1c8ba4f8-f401-4ade-8e22-f632e64edddf">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUtMS0xLTEtMTMwNzk_5b023ccd-3044-43f5-b1e3-099b6be62186">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUtMy0xLTEtMTMwNzk_b933ddc4-dd54-48c3-b991-c5ad1560a8de">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzYtMS0xLTEtMTMwNzk_af974c7f-1815-4e56-9f6d-ac9bb5dd1987">5,466,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzYtMy0xLTEtMTMwNzk_f83c45fd-f1c6-479e-b0c5-89e87aff427c">18,559,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzctMS0xLTEtMTMwNzk_180ab256-209c-4937-b3be-f7cfdec2d8fe">2,565,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzctMy0xLTEtMTMwNzk_a425dd53-14f0-4dc1-95f9-44d5270d4442">503,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzgtMS0xLTEtMTMwNzk_3270a8da-2b5f-4dec-ae10-069f90900566">38,836,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzgtMy0xLTEtMTMwNzk_99646a74-770b-49b5-ac2d-50c3d61d7399">40,357,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzktMS0xLTEtMTMwNzk_1e1eb32d-2a65-4e08-8814-813cf59981d0">261,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzktMy0xLTEtMTMwNzk_7a06f0d8-7f92-46b1-91c7-58df88e59746">106,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzExLTEtMS0xLTEzMDc5_524a9c27-8b1a-46e0-a09c-0478aa3fad7e">448,444,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzExLTMtMS0xLTEzMDc5_edb34346-c628-4fe1-ab5d-d674b7564bed">471,170,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzEzLTEtMS0xLTEzMDc5_0a08bf59-d18c-4e3b-acbf-6a62549e219a">17,453,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzEzLTMtMS0xLTEzMDc5_d439d933-6ca8-4f19-924f-b0400251502e">11,348,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in affiliated entity </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE0LTEtMS0xLTEzMDc5_092b5617-21ff-4e68-b925-df199674cb8c">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE0LTMtMS0xLTEzMDc5_8f7b1698-8824-4586-bf80-d50cd9682cda">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE1LTEtMS0xLTEzMDc5_c977c1eb-62dc-4333-b5b0-b1fceced086e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE1LTMtMS0xLTEzMDc5_c8239d6d-7068-46d8-b44c-61217cf98e1c">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE2LTEtMS0xLTEzMDc5_4a15d924-5dbe-44c6-a83c-5769013cb117">2,626,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE2LTMtMS0xLTEzMDc5_6ec05d9c-5e62-4183-9300-8ce72d38ccf9">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE3LTEtMS0xLTEzMDc5_71375df8-37db-4bba-bf7a-a72b563f5d55">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE3LTMtMS0xLTEzMDc5_40b765fd-d1b0-40d3-87d1-d8d23b4414b7">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE4LTEtMS0xLTEzMDc5_88f53c0c-6afb-4ba0-b235-a628d466ae62">11,571,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE4LTMtMS0xLTEzMDc5_1540dc56-0861-43a5-97cd-c52eced479bb">12,741,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE5LTEtMS0xLTEzMDc5_f8d87c53-4a8f-42f9-8d11-9679de0d52c8">1,425,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE5LTMtMS0xLTEzMDc5_fff8d83a-7555-4b42-b1dc-086d06523f64">25,957,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIwLTEtMS0xLTEzMDc5_742645ea-1d54-4e31-a28d-4cf8a9205bd7">495,941,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIwLTMtMS0xLTEzMDc5_7118ef1b-223b-4d70-b05d-a6db8bcb6f31">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIzLTEtMS0xLTEzMDc5_1dcf4d7d-7844-4f33-8d69-0ce205fcdc1c">47,644,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIzLTMtMS0xLTEzMDc5_7c68c2cc-c1da-466b-b662-0f7ac2423297">21,203,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI0LTEtMS0xLTEzMDc5_8ac24c35-d7d0-4b95-bdfc-8460e8549f04">548,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI0LTMtMS0xLTEzMDc5_b1fb56d3-103a-4477-829c-42cdc7b348a3">642,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI1LTEtMS0xLTEzMDc5_ab037b34-fd37-40bb-bfd5-e6f02b60a1fd">10,326,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI1LTMtMS0xLTEzMDc5_10ad3662-991f-41fd-8450-dbad7ce9d2e0">9,950,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI2LTEtMS0xLTEzMDc5_2eb37e5c-32f9-4ddb-845c-c34d44a82fda">21,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI2LTMtMS0xLTEzMDc5_ade49475-ad65-4df8-9337-9345ba8b9c95">46,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI5LTEtMS0xLTEzMDc5_c0e8da5b-3bc4-4848-b0df-94c69457bb57">2,603,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI5LTMtMS0xLTEzMDc5_fa46d9cf-6bda-48a7-b6eb-6caad6d6f974">2,329,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMwLTEtMS0xLTEzMDc5_897def91-a838-4f82-994a-7905d6c649b8">4,559,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMwLTMtMS0xLTEzMDc5_92d0b999-ccea-4023-bdac-be787f357efc">7,474,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMxLTEtMS0xLTEzMDc5_c60c4e7c-e1b7-45be-9bca-229b72e67055">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMxLTMtMS0xLTEzMDc5_ef9fa9e3-6ce5-4b8c-9ea9-8a194f8ad55c">58,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMyLTEtMS0xLTEzMDc5_3516df00-af5d-4fed-bc68-ab02299d6eef">65,741,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMyLTMtMS0xLTEzMDc5_ef5b5115-068a-400d-82a0-fdc520be988e">41,705,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMzLTEtMS0xLTEzMDc5_0d857260-3bff-4742-80a5-25139fa56cd8">64,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMzLTMtMS0xLTEzMDc5_4f43e89b-3a7b-40a7-9e4c-4ebec0436c27">79,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM1LTEtMS0xLTEzMDc5_8004978e-3098-4871-a877-3a3af0c11f52">14,959,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04336b766df84aa2a42f4abf68368421_I20201231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM1LTMtMS0xLTEzMDc5_f5625ca3-d7e1-4ccb-bf3c-b752b4268650">14,139,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64eac47556245f8b42cc012f2ffe0ff_I20211231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM2LTEtMS0xLTEzMDc5_dad645be-7060-4992-ae35-af5023f6b0eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ecae667f48745ad9fd43b801e35b9c4_I20201231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM2LTMtMS0xLTEzMDc5_1d122093-60a9-40c9-bfca-db7fd97c9f73">4,515,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQwLTEtMS0xLTEzMDc5_54fd8535-752d-4176-9ffe-8d90299b80b0">15,459,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQwLTMtMS0xLTEzMDc5_07e689eb-ac66-4acf-b67a-2acdf6417f23">18,063,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQxLTEtMS0xLTEzMDc5_bfe38dfd-b183-448b-861f-04c408ca5d9b">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQxLTMtMS0xLTEzMDc5_aa55e4da-5861-4a71-8234-4227d8b0c953">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQyLTEtMS0xLTEzMDc5_db31ca23-8b12-4286-bf59-e13499a485e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQyLTMtMS0xLTEzMDc5_771e3cf7-8971-4f17-b149-797c652c4ba1">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQzLTEtMS0xLTEzMDc5_97b737c6-7b11-4c06-b251-9976e7f333f4">14,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQzLTMtMS0xLTEzMDc5_f5da52c8-6140-44c4-97d1-b9428f4b89a4">57,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ0LTEtMS0xLTEzMDc5_67e1788f-bbdf-4977-ae98-06f922f8196c">96,272,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ0LTMtMS0xLTEzMDc5_c451fdac-5486-4d1f-bd58-a92ab9bb1215">78,631,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ1LTEtMS0xLTEzMDc5_3a1d1497-ddf7-45e5-bf30-dd469a38a2b5"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ1LTMtMS0xLTEzMDc5_55f421fb-6c8a-4426-a11b-09faa3a3ebf7"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfMzA_567c02d2-af95-4412-9d6f-e1a75986e046"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfMzA_f77625d6-187c-4b77-992a-5818eacb0d5f">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfNTM_a15b3bb1-a137-484d-a9a0-b5c665bd49c2"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfNTM_e6be87c6-dd36-4a4a-a6bb-6a80210cf7ee">10,000,000</ix:nonFraction></ix:nonFraction>, issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_023a1652-d22a-48ab-b5a3-043c382457af"><ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_440f6976-ad42-419d-9bc4-8e5e52a8877d"><ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_7f8158c6-bfac-4658-9888-3a9a2fea6948"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_ce63adce-88be-4dd5-982a-f323b7582681">9</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at December&#160;31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTEtMS0xLTEzMDc5_775bf9d6-b673-408f-9422-623563e61c31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTMtMS0xLTEzMDc5_2918d987-70a0-4fc5-9e27-166eed4f1456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMjc_86528556-127d-48b8-99b9-cf5732ebff12"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMjc_c19573c1-40f9-4be6-bcbf-f9a83e661431">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfNTA_4258b446-6c40-4730-a55c-d0f72ba4521e"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfNTA_9200e9c3-8224-4e30-8182-3a3ff47ae3d8">600,000,000</ix:nonFraction></ix:nonFraction> at December 31, 2021 and 2020, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTIx_1a626fd3-238d-4486-8673-132bb64d8221"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTIx_5e1b45ea-ab21-4b2b-a831-b35145244053">217,382,887</ix:nonFraction></ix:nonFraction> at December&#160;31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTQ5_1df94c8a-844f-4ac9-baef-59e95e9bec84"><ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTQ5_7ce6e63b-904b-45a6-839c-09d596cf903d">186,851,493</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTEtMS0xLTEzMDc5_e360496a-b1d6-4767-a25a-c94092b26702">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTMtMS0xLTEzMDc5_b154c3de-49bc-480b-9520-2ca5aa8a8ca4">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ5LTEtMS0xLTEzMDc5_0f37b658-1411-4977-a2bc-437139e56d02">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ5LTMtMS0xLTEzMDc5_60233695-002a-40a9-8fb1-2978ef12ba5f">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUwLTEtMS0xLTEzMDc5_dc07fd03-85ae-4f6e-9665-76542ae7daca">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUwLTMtMS0xLTEzMDc5_32ba93d1-9077-4782-b994-c929f1b446a5">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUxLTEtMS0xLTEzMDc5_4c5c1c2c-bbd5-48f7-8ffb-2b4c295039c4">282,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUxLTMtMS0xLTEzMDc5_8df758b3-c4fe-4e11-9f46-7ec156315047">256,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUyLTEtMS0xLTEzMDc5_c711a586-cd92-4e63-a08d-f155adc80de8">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUyLTMtMS0xLTEzMDc5_a26bad17-417c-4e38-a232-7b116d8f2671">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzU1LTEtMS0xLTEzMDc5_ae35feef-f829-4f05-b49f-c7bd72549191">495,941,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzU1LTMtMS0xLTEzMDc5_21bbddee-cfae-43a8-b248-4d872426563b">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ed9e2d8d23416fa2216a18597af29a_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzUtMS0xLTEtMTMwNzk_62d750d7-ba6a-4390-90c3-5218a30c1441">902,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c6ed30dc86a4b31b83a17f1a97066df_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzUtMy0xLTEtMTMwNzk_1b292e2d-28de-404f-b8d1-6255bdd65c34">5,170,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea5902416e14a1a8963131a95b4e349_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzUtNS0xLTEtMTMwNzk_14a13c71-f5c8-4f69-9362-5b7bb73b315b">3,636,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28851dd7ca34c3cb482d22189f39e47_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzYtMS0xLTEtMTMwNzk_647de6ed-0173-4bd4-99fa-10990e5077e4">245,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3f177a526c4d6e9937328cb2042e27_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzYtMy0xLTEtMTMwNzk_765b3b78-f020-4a2a-9c17-d1e2ca0b4190">1,453,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402a2216be6243d79489c5e44b694136_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzYtNS0xLTEtMTMwNzk_41b3521b-4d1a-4d4d-b1cf-d875082fe714">235,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87e8afe51e242b296534833ed309ce2_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzctMS0xLTEtMTMwNzk_49eeba6a-458d-4164-8fd0-1897410dddb1">627,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dd97a11a2748a98bed361bca96dcc5_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzctMy0xLTEtMTMwNzk_2ee55f0e-6b82-43d0-bdbf-543893878753">786,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1adaf3d29db647be821417221977869b_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzctNS0xLTEtMTMwNzk_3d521754-d89e-4999-9e71-f0991f276cc2">237,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54e996352a04ec28cb7e31c037d184e_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzgtMS0xLTEtMTMwNzk_30565b8f-c3e3-4bda-ba65-2ed95a1179d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4990fae62ff441f4acf38817077260d8_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzgtMy0xLTEtMTMwNzk_21ffcb64-50f6-4ece-bb00-823c8bce4406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbcf710c43f435cb1efd59b9274f753_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzgtNS0xLTEtMTMwNzk_2147afe4-efd5-4a82-836b-505d5e1b178d">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzktMS0xLTEtMTMwNzk_f81b6d8a-015b-4900-9edf-f6ddc46db3ad">1,774,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzktMy0xLTEtMTMwNzk_b1a1d7ef-52ec-4876-989d-9b29de605d9d">7,411,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzktNS0xLTEtMTMwNzk_3c039756-fe26-41e4-b53d-83c882968dd3">4,111,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzExLTEtMS0xLTEzMDc5_e8bee94c-073c-4464-bf1d-3063704292f5">249,240,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzExLTMtMS0xLTEzMDc5_ffa13d5f-3456-49ea-8963-6f9604c263c8">94,245,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzExLTUtMS0xLTEzMDc5_7081c732-262b-4726-abea-df8ce1cacdb3">88,017,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzEyLTEtMS0xLTEzMDc5_21d60819-1991-4b13-ad28-e59a5da85b42">53,752,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzEyLTMtMS0xLTEzMDc5_69d89fc3-44c5-4f10-bd2b-a9ee6be26392">37,247,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzEyLTUtMS0xLTEzMDc5_7186b9a3-976e-4aa2-8e26-d250bec82545">27,203,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE1LTEtMS0xLTEzMDc5_158b96af-ed1e-4525-bd5a-9aa1c7125e1c">302,992,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE1LTMtMS0xLTEzMDc5_f633836e-e70c-4538-9b60-af7f60d81903">131,493,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE1LTUtMS0xLTEzMDc5_451f172e-b7de-4f12-857d-2828ec48f6be">115,220,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE2LTEtMS0xLTEzMDc5_56c1d656-e6d0-4ffd-b629-efbef9fa6061">301,217,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE2LTMtMS0xLTEzMDc5_65b22f89-01fc-4421-8612-c660691f398a">124,082,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE2LTUtMS0xLTEzMDc5_80132179-1bf3-48c7-81a1-242fdc1ce51a">111,108,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE4LTEtMS0xLTEzMDc5_39d36f0d-6851-433b-96ff-739b851731b2">3,363,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE4LTMtMS0xLTEzMDc5_cc3cf863-8eb1-494b-8aba-3ef1f51e9779">3,311,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE4LTUtMS0xLTEzMDc5_2f36c3c4-cc03-41f5-ab2b-c0ca3612457d">2,605,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE5LTEtMS0xLTEzMDc5_45a60334-2472-4044-8571-4807d3aeccca">1,936,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE5LTMtMS0xLTEzMDc5_e9bfdb9c-f1cc-401a-8e14-b5277892d04d">8,702,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE5LTUtMS0xLTEzMDc5_38076ee7-f990-4e1a-bcef-552a89f160fc">7,948,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIxLTEtMS0xLTEzMDc5_f4524e3a-08a1-4131-a11e-09fdb6274b1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIxLTMtMS0xLTEzMDc5_36e88b32-7550-4247-87f4-e6a4ad7b8fe8">75,670,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIxLTUtMS0xLTEzMDc5_5124fe33-5d44-4de7-9b9f-31f08c5cc440">1,763,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIyLTEtMS0xLTEzMDc5_05c2176b-1c45-4f13-9e57-4da45785ea07">553,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIyLTMtMS0xLTEzMDc5_48b65a14-47bd-414a-b31a-e7f254af7c6c">36,556,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIyLTUtMS0xLTEzMDc5_5a41cef4-98b0-4a9b-a2bb-b409a79e9d0f">3,090,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIzLTEtMS0xLTEzMDc5_7386d331-f1c5-4b57-bdf8-bf601710062d">3,222,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIzLTMtMS0xLTEzMDc5_a8eb97cf-997d-4854-95ee-5133dea73a3f">1,695,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIzLTUtMS0xLTEzMDc5_92dca74d-e09b-472d-b806-0b86e7365272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI0LTEtMS0xLTEzMDc5_61906a26-f5f9-4e21-b1c8-ce213372a480">343,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI0LTMtMS0xLTEzMDc5_0dc6b938-d0e3-4026-91f2-10003cdd46bc">704,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI0LTUtMS0xLTEzMDc5_066e2d36-3947-441a-a527-2408523c6962">496,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI1LTEtMS0xLTEzMDc5_702bff14-f2a3-4cee-963d-9af3efdc3285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI1LTMtMS0xLTEzMDc5_04211f76-af9e-411d-9196-a99af564c9b0">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI1LTUtMS0xLTEzMDc5_d8fa3c97-5b48-4a99-95e6-cdae23b47876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe285a056e84e7690752bb6bae44144_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI2LTEtMS0xLTEzMDc5_41d73eae-b168-448a-bad9-9f5010bd7e25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i411612102a3e4c9e911d58c817263069_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI2LTMtMS0xLTEzMDc5_652d93cc-4c71-4682-80dc-46009fdb6b8d">8,177,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d1df5b1c5b4cc3b96a485c772c8fc7_D20190101-20191231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI2LTUtMS0xLTEzMDc5_83779823-cb57-4bb5-b8ed-2ca5dbf1b00d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib319c6f186cc48f394c757bf041fbc05_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI3LTEtMS0xLTEzMDc5_fc892cc0-6f64-44ef-adf5-46551cb6e999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI3LTMtMS0xLTEzMDc5_78504ff7-3c24-47f1-9856-09357476738b">8,762,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00acd8f0e9248db874b93cb6b3eb23a_D20190101-20191231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI3LTUtMS0xLTEzMDc5_8c965b26-0278-4b74-b6d4-27633f7053cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI4LTEtMS0xLTEzMDc5_36f66860-81ee-45bc-81b7-720dfd3509ab">303,224,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI4LTMtMS0xLTEzMDc5_f71558f9-6bd3-4e84-b13c-1cddf6318792">162,890,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI4LTUtMS0xLTEzMDc5_21a34a1f-f983-4234-b0b0-a9d2cad78e01">120,809,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI5LTEtMS0xLTEzMDc5_334c485e-2aa1-498c-98f0-c0ee79eebf05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI5LTMtMS0xLTEzMDc5_f3dbacca-74d4-479a-87b6-2889da38a5f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI5LTUtMS0xLTEzMDc5_54e10ba2-4a5e-40ee-9189-5353070b5c40">257,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMwLTEtMS0xLTEzMDc5_470e614f-2832-40c9-b806-7b99d7d88fa8">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMwLTMtMS0xLTEzMDc5_5f4da069-21e3-4ab5-a828-b5ae430e14cc">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMwLTUtMS0xLTEzMDc5_90390f9f-e3ba-4ae0-a891-02b8fb12fc82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMxLTEtMS0xLTEzMDc5_968f648a-088f-4ff2-a513-dce5e864cf0c">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMxLTMtMS0xLTEzMDc5_c99f6566-0229-4530-96f4-177519e4b07c">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMxLTUtMS0xLTEzMDc5_4fff3d64-c4c6-4278-a9f9-bce7fa2e459d">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMyLTEtMS0xLTEzMDc5_7de85d60-1bae-4ccd-a52d-56f1a47806bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMyLTMtMS0xLTEzMDc5_a5460dd8-c13b-4e99-a702-57e4be06eb89">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMyLTUtMS0xLTEzMDc5_25020c43-f2fb-4cf7-b9df-c98cdc00247f">1,192,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMzLTEtMS0xLTEzMDc5_457ccdf4-5e04-4c96-9a1d-aa513df791d7">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMzLTMtMS0xLTEzMDc5_2ac17756-8249-4721-a011-a6ca348246b9">166,411,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMzLTUtMS0xLTEzMDc5_0d76f51f-fed7-427f-8f2a-b127bbf78843">119,359,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTEtMS0xLTEzMDc5_58bc7676-2a5d-446c-9966-a65d6affe243"><ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTEtMS0xLTEzMDc5_e9b1d62e-b6c3-4e0a-ae5d-859622023ce9">1.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTMtMS0xLTEzMDc5_0460868f-30cc-4d1c-a746-d378ce994a99"><ix:nonFraction unitRef="usdPerShare" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTMtMS0xLTEzMDc5_a766b946-257a-48e4-9e58-cdf9cb9fab64">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTUtMS0xLTEzMDc5_5d72c847-77d6-451d-b87a-4f4b3e0b6752"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTUtMS0xLTEzMDc5_f65541e8-e252-4fdb-8282-efc198818062">1.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTEtMS0xLTEzMDc5_b4881f4b-c928-4acf-b1ea-59fba2d3e1d1"><ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTEtMS0xLTEzMDc5_b4a21adb-74cf-46f2-9380-02f1021fa434">208,829,801</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTMtMS0xLTEzMDc5_3dca35c6-770d-4b9a-9e24-7b1d463308a4"><ix:nonFraction unitRef="shares" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTMtMS0xLTEzMDc5_91bf1802-8156-4ec0-bf62-d5e476e38f01">155,126,857</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTUtMS0xLTEzMDc5_591c67fb-ad93-401e-b2ee-7dd3f9767bbc"><ix:nonFraction unitRef="shares" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTUtMS0xLTEzMDc5_910ea4fd-699f-45aa-9e4a-77679ce8f77f">98,717,999</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzItMS0xLTEtMTMwNzk_18300cfa-81d6-4f3a-b26a-9e10bff7e2f2">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzItMy0xLTEtMTMwNzk_c2b55eeb-a642-40bf-b032-473a0bfdb248">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzItNS0xLTEtMTMwNzk_413b70bf-5d48-4172-8f71-f3f94b7b9a69">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzUtMS0xLTEtMTMwNzk_b7c044b1-2f50-4392-aa6b-92223ac04dd5">30,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzUtMy0xLTEtMTMwNzk_515536e1-ba28-4053-af57-5e4d3519322f">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzUtNS0xLTEtMTMwNzk_05f0c623-0cb3-430f-b82f-e2805fc87e71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzYtMS0xLTEtMTMwNzk_2aa1994f-ebac-4116-812d-99b7a99be5ce">4,048</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzYtMy0xLTEtMTMwNzk_d28a0ee2-4cc0-49c3-949f-205950917b1d">755,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzYtNS0xLTEtMTMwNzk_23de3233-d0bd-489c-96f4-66deab1af767">1,001,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzctMS0xLTEtMTMwNzk_e59e1b22-7c17-4f65-84a8-5c47aceb4d59">303,684,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzctMy0xLTEtMTMwNzk_5c5ecbda-c448-4ee7-a838-f8832f38eaf7">168,203,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzctNS0xLTEtMTMwNzk_07726299-2d55-4521-8925-be72afc48733">119,550,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzgtMS0xLTEtMTMwNzk_4dc0cbd6-197d-4f0a-a1b0-5e9fb2739f39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzgtMy0xLTEtMTMwNzk_6685e19e-2565-44eb-9137-e3e0fa4323f6">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzgtNS0xLTEtMTMwNzk_8b4d3fb9-cc02-4479-9ff1-4403d9f402b7">1,192,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzktMS0xLTEtMTMwNzk_e46831c7-9c5c-4fc6-8280-a1ad95653cdf">303,684,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzktMy0xLTEtMTMwNzk_c9390cbb-b324-47c4-8393-75159ee5978d">167,139,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzktNS0xLTEtMTMwNzk_274be3d7-9236-440c-a0b8-1b49abf94cde">118,357,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_124"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:25.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36c6f4ee12934a40a1ea728d479c1b02_I20181231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTEtMS0xLTEzMDc5_94e384e9-62a9-4c32-bb9d-bf3fc86c6b6d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c6f4ee12934a40a1ea728d479c1b02_I20181231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTMtMS0xLTEzMDc5_ff57598c-90db-4964-8c09-541323c1e1a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a77f36ff44452d920fe5904cb46826_I20181231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTUtMS0xLTEzMDc5_cef3ab44-fe17-42c1-aabd-d1964d802e9d">97,225,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a77f36ff44452d920fe5904cb46826_I20181231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTctMS0xLTEzMDc5_caedd1e0-a121-4ead-bc4c-213236d31eb9">97,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac56a7bfee5749ab9ef8c4fb331f0dd3_I20181231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTktMS0xLTEzMDc5_191c9563-e090-402c-a4ce-c31b48708311">707,794,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d85a8106cf746239de37759928ef0f3_I20181231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTExLTEtMS0xMzA3OQ_62bb87dd-f1b3-4111-b114-54b37732a47d">620,426,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ef69988114421e91fd39d86626a033_I20181231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTEzLTEtMS0xMzA3OQ_6c020b5d-5876-4ca3-9f91-212706c0b96a">528,867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92f9fbbfaa2469dbe870606abca1b9d_I20181231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTE1LTEtMS0xMzA3OQ_c3db4bcc-f566-4c28-9051-db16322f442e">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0209f8c94d740adaa36dd67c48d6a20_I20181231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTE3LTEtMS0xMzA3OQ_6a746abf-ffd5-4d16-9fae-9d9807126506">87,032,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of capital raising related expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTUtMS0xLTEzMDc5_6f034c1c-9841-441a-b406-ce7ee25d7050">3,340,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTctMS0xLTEzMDc5_69c35c3c-796d-4846-afc1-4d029ddf13d0">3,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTktMS0xLTEzMDc5_cceaebd8-b53c-43ae-b800-6155f590573b">9,085,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTE3LTEtMS0xMzA3OQ_d3408998-92ee-4cc5-b4ac-9cccd05818cd">9,089,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTUtMS0xLTEzMDc5_59067d9d-1795-472d-9767-6f6b856ea7b4">794,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTctMS0xLTEzMDc5_c5a02126-23c1-4218-ad4a-99498a3cd608">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTktMS0xLTEzMDc5_e6a57da7-a533-4199-a385-bfffea965bab">781,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTE3LTEtMS0xMzA3OQ_acf34a84-a991-4dd8-a719-bac45ee5be98">780,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of issuance of convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg2LTktMS0xLTEzMDc5_79744570-798d-4563-a496-fac6126f09d6">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg2LTE3LTEtMS0xMzA3OQ_ed0a9fbf-3dc6-4803-adda-3851ae927e7e">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg3LTktMS0xLTEzMDc5_02c81920-b852-4f2a-bd27-ab9708c3ba92">10,795,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg3LTE1LTEtMS0xMzA3OQ_8d47f526-ad83-4e16-9dbf-b7ea4e2f2372">105,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg3LTE3LTEtMS0xMzA3OQ_4c7013d7-56ba-400a-af65-c29425e97539">10,901,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231" decimals="0" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg4LTE1LTEtMS0xMzA3OQ_420d873c-5803-4d92-9307-2aa01c3971a9">2,960,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg4LTE3LTEtMS0xMzA3OQ_272d7387-5ebf-4c2b-aea3-a86ed6bc1044">2,960,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0a501ec111d47fbb2c02a92d18044b8_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg5LTExLTEtMS0xMzA3OQ_2828838e-2144-4bd2-814d-f0f7e9474382">119,359,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg5LTE1LTEtMS0xMzA3OQ_03c8cde0-807b-4c30-9348-dc8bcd663cf2">1,192,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg5LTE3LTEtMS0xMzA3OQ_8320f7b9-ab68-4d49-bc50-65eb029496ef">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934d7a839de6474e9b47fe4f2dde4862_D20190101-20191231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkwLTEzLTEtMS0xMzA3OQ_17829c3f-d2a5-4b6a-8ddb-b06e4d1d1b28">1,001,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkwLTE3LTEtMS0xMzA3OQ_5224f4f8-5449-4b70-b207-60cf6905d56c">1,001,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba84c3ae05e74f7b95113a5d797a1b3e_I20191231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTEtMS0xLTEzMDc5_222e65de-187d-481b-b170-06069f6f0e8b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba84c3ae05e74f7b95113a5d797a1b3e_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTMtMS0xLTEzMDc5_5f939573-4c67-48e0-921e-3ce435eaa794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38bba6f63c734bfb8d21fd427b61fbe7_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTUtMS0xLTEzMDc5_8cd3fbf5-e980-4125-b901-ee18ad00bc64">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38bba6f63c734bfb8d21fd427b61fbe7_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTctMS0xLTEzMDc5_56bf3c13-4651-40d9-97f0-ba978d4da506">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c45e9e8670742aabe1a2097889e1003_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTktMS0xLTEzMDc5_eceb4ca3-61c1-422c-b8dc-a385b97ea276">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a9737ecdffd44d1b2551cce0509fa59_I20191231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTExLTEtMS0xMzA3OQ_be38b762-3fe5-4ccb-b02a-36d76e0ad678">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b5dcddd0d942b9afa00d1eb75fd3fc_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTEzLTEtMS0xMzA3OQ_45841a98-7edd-49f6-98c8-58386a73b73a">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cada50c939e412c9ab1db2da9a0465e_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTE1LTEtMS0xMzA3OQ_61e71b54-09af-460e-9701-d1a420713e5f">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTE3LTEtMS0xMzA3OQ_14ac31b3-7b88-447a-8ba2-6235224cb393">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of capital raising related expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTUtMS0xLTEzMDc5_7af8defd-9b0e-458d-ba59-6f6c91fac661">66,064,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTctMS0xLTEzMDc5_8badaf6c-a552-4426-a73d-dc6685e65f93">66,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTktMS0xLTEzMDc5_5061400a-e918-4f7f-a0ef-e749cffc62de">454,420,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTE3LTEtMS0xMzA3OQ_2e25d209-c3f7-4822-a2ad-31039058a1ea">454,486,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee3c8a7e151648fa9963ae445b27955e_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTEtMS0xLTEzMDc5_38174794-66a2-41bb-9f97-ed9d07c3cc59">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTUtMS0xLTEzMDc5_b71b08c1-25e9-4ea5-ba62-fe02a40e9ac6">5,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTctMS0xLTEzMDc5_00222deb-8e6d-4e30-9ba2-68c88ed37de9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTktMS0xLTEzMDc5_881273e2-acc9-469f-ba93-e8291786a084">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTE3LTEtMS0xMzA3OQ_8e4d727c-701e-46e4-a9a8-4f535a441371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of senior notes to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98ad737a11be4f09bde8169850c3ab12_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTUtMS0xLTEzMDc5_4c6d6565-b809-4a3c-9cfd-ea69ba7254d6">11,535,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ad737a11be4f09bde8169850c3ab12_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTctMS0xLTEzMDc5_0514ef75-6e43-4bef-aefb-63b80a3ebf1a">11,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd975f309a74bc9830110950e77a982_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTktMS0xLTEzMDc5_7e5a8431-1f43-4ee1-b0e6-89f5c1fe00c7">43,682,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTE3LTEtMS0xMzA3OQ_db5c7712-58fd-4bcc-b201-aa8b7398c9ab">43,694,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of August 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i636993c134064180ad2590c08fa52072_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTUtMS0xLTEzMDc5_01ff68df-9f61-4914-87a8-a5655606898e">4,962,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636993c134064180ad2590c08fa52072_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTctMS0xLTEzMDc5_f0ad43c0-d197-443e-883e-93a3e29a9245">4,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d08995f70474651a10b743f24c3decc_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTktMS0xLTEzMDc5_e5b13658-5051-425e-9776-597e3624d7d6">102,666,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a0eee5ee74422dbf15e46a3b2632fc_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTE3LTEtMS0xMzA3OQ_abd351ce-9660-47bf-b687-b770c3a09962">102,671,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTUtMS0xLTEzMDc5_7664d697-1678-4ed3-82e1-dc8dccfba6a0">2,922,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTctMS0xLTEzMDc5_42b0414d-f337-48ed-8ab4-17d1fb87b7ea">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTktMS0xLTEzMDc5_f461b43c-8cdc-4b46-9383-aadd5f672b26">8,238,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTE3LTEtMS0xMzA3OQ_bc97f397-92e2-4417-abf4-a500f4152017">8,241,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk3LTktMS0xLTEzMDc5_1e76f6b2-3041-4415-b4b1-0bda196cb24c">15,655,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231" decimals="0" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk3LTE1LTEtMS0xMzA3OQ_09559b45-171f-4484-afd5-ccff318812d2">8,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk3LTE3LTEtMS0xMzA3OQ_e9a99872-2f92-48d5-8de8-689c3e05d9cc">15,647,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk4LTE1LTEtMS0xMzA3OQ_ad91289d-a5fc-4762-913b-593459c29bc2">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk4LTE3LTEtMS0xMzA3OQ_dca4c51d-8d80-42ea-83f7-f8142df17d10">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk5LTE1LTEtMS0xMzA3OQ_3ded8841-0467-4d3a-8aa2-050f89d2c52b">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk5LTE3LTEtMS0xMzA3OQ_fc29bee1-02c3-480b-b729-3eb7d1e95f4f">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01da3ab01f954252bc6510f0dbd029c0_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMC0xMS0xLTEtMTMwNzk_ab981bec-38de-4f26-98e9-51fcee5a4ca2">166,411,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMC0xNS0xLTEtMTMwNzk_86c9df0d-ff85-42ba-9eb0-c8494f41a1d2">1,063,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMC0xNy0xLTEtMTMwNzk_d9a06dc8-8892-4599-8721-da53cb65d14e">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231" decimals="0" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMS05LTEtMS0xMzA3OQ_6212b1c6-2f37-43da-866e-ed62859d3fbd">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231" decimals="0" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMS0xNS0xLTEtMTMwNzk_c685ffc9-e692-4067-ae43-fcc3e35c1560">96,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMS0xNy0xLTEtMTMwNzk_5d303c60-68a0-46f9-9007-ab29155453d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceb449b556844657b6e6671a8579fde4_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMi0xMy0xLTEtMTMwNzk_98321154-076a-4de1-aafe-85fc78ed0d14">755,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMi0xNy0xLTEtMTMwNzk_998b17b0-c264-40ef-89d4-47c42d3074d9">755,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb449b556844657b6e6671a8579fde4_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMy0xMy0xLTEtMTMwNzk_21e4e689-07b6-452c-bbe4-f26c3e5ba84f">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMy0xNy0xLTEtMTMwNzk_5c7b1ddd-18ab-4014-9555-74ae4e681833">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c72b6e9e8eb4b8ea4fdb38d60151ad5_I20201231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xLTEtMS0xMzA3OQ_9a7818e7-9d80-416d-9606-cae144525a29">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c72b6e9e8eb4b8ea4fdb38d60151ad5_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0zLTEtMS0xMzA3OQ_033aa943-82b2-4d5f-b1ae-13b382cf40e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib722279b8997488c897a37f118e63061_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC01LTEtMS0xMzA3OQ_9ed6bc27-cb11-4834-ac26-ef0c9402a37c">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib722279b8997488c897a37f118e63061_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC03LTEtMS0xMzA3OQ_a489d9bd-cd68-4c66-ad34-00125eadf73b">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11f8a3ab55d49a8bb586876044a035e_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC05LTEtMS0xMzA3OQ_ae02a2b8-1234-48fc-8faa-68e22c28dcf5">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i019963c050f847419c1846c58634267e_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xMS0xLTEtMTMwNzk_2028754f-1f48-4274-b3d9-242b42cdac4f">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f5e9f8d356d417887e0a2ce250b61f5_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xMy0xLTEtMTMwNzk_f588d13b-cda6-4baf-b5ce-b22692ee0f92">256,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5137421a60479cb080a26e2eb6d08c_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xNS0xLTEtMTMwNzk_76c214fb-db0a-48d6-bb6c-a785a1384a5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xNy0xLTEtMTMwNzk_696cf5a0-d99b-4bcf-9e1f-5ccb8adfa1e7">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of capital raising related expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS01LTEtMS0xMzY4MA_463b58d5-1ca6-4b7d-96a9-907324038b29">27,310,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS03LTEtMS0xMzY4MA_4a65c3bb-5adf-4786-8562-8b10b6042b7e">27,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f35c89987a74786896285ad7ae13979_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS05LTEtMS0xMzY4MA_4e58ddca-4f2c-419a-8325-2edaefa49ab6">209,414,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS0xNy0xLTEtMTM2ODA_40c6129b-e78c-4658-9671-2730e0c93eb0">209,441,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of December 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13876df5a7d44b1a938e8ee19872763d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi01LTEtMS0xMzY4MA_0c8d3307-6d7b-4909-b532-268914b21862">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13876df5a7d44b1a938e8ee19872763d_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi03LTEtMS0xMzY4MA_f37b03c4-1e09-425a-b673-92295ef7b364">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie453dc0fe621472f991c3336fea7f4cb_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi05LTEtMS0xMzY4MA_6f68b860-bc3e-483e-a25c-008d5b93b361">4,376,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aed4a0d2c3496d81638d7203fff95f_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi0xNy0xLTEtMTM2ODA_68dd05c5-7f8a-420c-8eb1-401ad8934061">4,377,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy01LTEtMS0xMzY4MA_8b329dd4-f62a-4f2d-9d1f-f70f543da61c">2,211,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy03LTEtMS0xMzY4MA_0de21051-aa29-447b-8a4a-a73dae440fab">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f35c89987a74786896285ad7ae13979_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy05LTEtMS0xMzY4MA_786de3bc-72c7-490c-a854-2fdf1c8c055e">2,055,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy0xNy0xLTEtMTM2ODA_3fd07372-2a76-4c45-96f8-ee4a6586d461">2,057,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f35c89987a74786896285ad7ae13979_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOC05LTEtMS0xMzY4MA_d6c97d5b-c11b-4866-9fbd-a69d6e8ca6b2">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcee4832a056439890bc22cca53ebf0a_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOC0xNS0xLTEtMTM2ODA_9c643418-35fe-4af3-a300-99380ef369d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOC0xNy0xLTEtMTM2ODA_073d3e85-059e-4619-b728-352d014bb3cd">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i755387a3bd2040869919d38bac155975_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOS0xMS0xLTEtMTM2ODA_cb7bb454-e693-4318-bdba-9748182e7c3b">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcee4832a056439890bc22cca53ebf0a_D20210101-20211231" decimals="0" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOS0xNS0xLTEtMTM2ODA_890b773c-c703-43ef-83f7-17613dffaadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOS0xNy0xLTEtMTM2ODA_4f9ace36-abc4-4ae7-b26d-b65628d56ad9">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f38759d4c94c9c9f578011dc9fc2d9_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMC0xMy0xLTEtMTM2ODA_0649d123-97e7-4e71-acba-066455f20084">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMC0xNy0xLTEtMTM2ODA_038d901c-4e10-4034-9c21-45ccab12fe9a">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5f38759d4c94c9c9f578011dc9fc2d9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMS0xMy0xLTEtMTM2ODA_71d53824-0cf6-4cdc-91a4-b71543cb4c24">30,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMS0xNy0xLTEtMTM2ODA_b000bcf5-a4b4-4515-ab1d-4b5002c5f9a7">30,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if64e7bfdf2294cae86cf31ff7714dac5_I20211231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xLTEtMS0xMzY4MA_30beb8bb-244c-43b0-b4b2-6f828a245709">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64e7bfdf2294cae86cf31ff7714dac5_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0zLTEtMS0xMzY4MA_6c4f11ac-174c-4ddb-8bf3-9eb7c351993b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d91dffb8ff14276905969cb9451fbd4_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi01LTEtMS0xMzY4MA_9923f90d-3492-4444-a519-9f4cfa528eb8">217,382,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d91dffb8ff14276905969cb9451fbd4_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi03LTEtMS0xMzY4MA_53c012ce-37ec-42c7-9b43-c6e1385a5ba2">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416413e6f44e49bf9af9f5ca9c4a9d19_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi05LTEtMS0xMzY4MA_0a130e80-4591-4b3a-a9ae-aca2ee6db192">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i386a00e8a13746fa9abf8ea15747827d_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xMS0xLTEtMTM2ODA_d69beacd-b54e-492b-b3c7-b700a73864d8">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3348c69519f04942adeb29a5daf412ac_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xMy0xLTEtMTM2ODA_6d927326-9f85-4bbe-a5a1-524777a2ab31">282,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic404b3bf911d46e48fef168a1506f7d1_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xNS0xLTEtMTM2ODA_4042e617-76e5-4d65-80ca-e544f739f138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xNy0xLTEtMTM2ODA_11acfeca-4e7f-4577-abf6-7f41c653c1ed">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_127"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMtMS0xLTEtMTMwNzk_9c793b06-62b3-4f23-a3da-e9331ebd1ce7">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMtMy0xLTEtMTMwNzk_8e80ba74-1cc3-4452-965e-4af6743026f0">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMtNS0xLTEtMTMwNzk_6e824d16-7feb-4fe3-a45d-b04a54a68495">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUtMS0xLTEtMTMwNzk_fab2decd-536d-465c-a869-13428ca3298b">3,040,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUtMy0xLTEtMTMwNzk_6f510c7c-aa3e-41ea-9801-d4bc898a783c">3,038,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUtNS0xLTEtMTMwNzk_1b27fa0a-8756-4163-a183-ee0a4d7494d8">3,598,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYtMS0xLTEtMTMwNzk_3bd9f2dc-b872-4008-9141-82494b95e044">520,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYtMy0xLTEtMTMwNzk_d082fe67-2c2a-430c-af9a-d55926ccd376">547,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYtNS0xLTEtMTMwNzk_aeecc233-130f-4299-9d51-c866c783acff">1,066,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzctMS0xLTEtMTMwNzk_c835c1dd-f8ff-4fcd-9c07-02b873142c82">1,170,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzctMy0xLTEtMTMwNzk_1013137a-8954-491f-b302-4bc460248641">1,041,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzctNS0xLTEtMTMwNzk_d9946a4e-5b6e-496c-81b0-f84792e2aadd">851,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzktMS0xLTEtMTMwNzk_b37c4053-92cf-4b1a-9377-37024b9ad973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzktMy0xLTEtMTMwNzk_2cac3514-86d8-4142-b173-71bdbb518856">75,670,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzktNS0xLTEtMTMwNzk_e09b4121-010a-451c-a3fe-54ca50bfe427">1,763,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzExLTEtMS0xLTEzMDc5_20d29bc8-2965-4124-87ef-439bfafeaf1d">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzExLTMtMS0xLTEzMDc5_ec9f5a2d-0204-4277-8b2b-3f394efe7bc2">15,647,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzExLTUtMS0xLTEzMDc5_9f7110a9-fcb2-40fc-9f1b-7bcd0d305577">10,901,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:NonCashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEyLTEtMS0xLTEzMDc5_28dbc904-fe56-4b06-a5a2-48be37c71537">858,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:NonCashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEyLTMtMS0xLTEzMDc5_37a68eba-a60d-4701-bd12-010a00db1161">4,077,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:NonCashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEyLTUtMS0xLTEzMDc5_06e61952-8bef-47a0-bab1-100bf94c2eaa">5,230,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premiums on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:InvestmentIncomeAmortizationOfPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEzLTEtMS0xLTEzMDc5_b51a8215-05a7-47e1-845e-1074add96da4">1,633,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:InvestmentIncomeAmortizationOfPremium" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEzLTMtMS0xLTEzMDc5_98a2dfc5-465a-4bec-89ce-df78815f2367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:InvestmentIncomeAmortizationOfPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEzLTUtMS0xLTEzMDc5_42e597ea-22c4-457d-8370-289d677bf1eb">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE1LTEtMS0xLTEzMDc5_6011391d-7475-4a5a-b43e-d910d050facd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE1LTMtMS0xLTEzMDc5_de466f6e-8dc1-4f67-8ada-a9912e7e6557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE1LTUtMS0xLTEzMDc5_52971d60-a22f-4a6b-ae62-104c2face96f">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE4LTEtMS0xLTEzMDc5_f862feb0-8feb-448c-b9e6-54f8e2a80fea">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE4LTMtMS0xLTEzMDc5_c6cfb47b-0be6-46fe-9f80-4d065fee9ab6">588,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE4LTUtMS0xLTEzMDc5_3190f4a9-be0b-4730-af63-7c116441408d">476,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE5LTEtMS0xLTEzMDc5_78abfc15-a5ac-4246-87f2-427275d08e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE5LTMtMS0xLTEzMDc5_acde1310-cfed-441b-b042-5cf4c47ababd">1,713,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE5LTUtMS0xLTEzMDc5_635a1841-338c-42f8-8b69-aeee36d749d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIwLTEtMS0xLTEzMDc5_f483ecfa-6f02-4a98-9e2f-6ad8e51c6964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIwLTMtMS0xLTEzMDc5_56336769-684e-46fb-8ab1-a27645f96a60">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIwLTUtMS0xLTEzMDc5_88d5639d-7793-4d7c-9ffc-c527568a39c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIxLTEtMS0xLTEzMDc5_836ce064-d337-4f70-acf5-c73162431958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIxLTMtMS0xLTEzMDc5_245e3bfe-d67c-4a49-b702-b932c0be8ea4">26,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIxLTUtMS0xLTEzMDc5_cb69c731-a6ec-4976-8fb7-2aa2f87147bf">5,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIyLTEtMS0xLTEzMDc5_a1cab045-4352-4f5b-be27-80eee6d6a950">553,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIyLTMtMS0xLTEzMDc5_88b44acd-be76-4f06-a8f7-46aee3c7a34a">36,556,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIyLTUtMS0xLTEzMDc5_fb011310-da22-4f9b-b086-3fe21fb4c5a4">3,090,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIzLTEtMS0xLTEzMDc5_da4e9da7-ff10-46f4-82bf-71fc82289458">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIzLTMtMS0xLTEzMDc5_31d04ac0-5616-41dc-be8c-89e4e078ce02">4,584,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIzLTUtMS0xLTEzMDc5_101d1df4-be62-4634-9ac7-3d78c69f3331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible August 2019 bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2aed4a0d2c3496d81638d7203fff95f_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI0LTEtMS0xLTEzMDc5_41cd9362-1785-4a51-9858-a447a80b3711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a0eee5ee74422dbf15e46a3b2632fc_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI0LTMtMS0xLTEzMDc5_0387913a-b4b6-4464-ba3d-3db860d1a077">8,177,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbb09860a3f4b019d6e6f2db9a0996b_D20190101-20191231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI0LTUtMS0xLTEzMDc5_bc0cb04e-0211-49dd-b7a6-f5d05cbbf45f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib319c6f186cc48f394c757bf041fbc05_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI1LTEtMS0xLTEzMDc5_ba6909de-7e66-4ec4-ac1c-10cb9f541522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI1LTMtMS0xLTEzMDc5_5e0055e6-4710-46ca-9af9-471264fddbed">8,762,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00acd8f0e9248db874b93cb6b3eb23a_D20190101-20191231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI1LTUtMS0xLTEzMDc5_36ea4104-cb64-4467-a9d2-f1c6fc367fb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss (gain) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI2LTEtMS0xLTEzMDc5_e452529c-1c12-4008-b5f1-23ffbc102aa7">3,222,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI2LTMtMS0xLTEzMDc5_ac87d7a9-dd14-4d34-9b3b-7571fe24c655">1,695,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI2LTUtMS0xLTEzMDc5_f2030ccb-f848-4c4d-8870-76c882a33d5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit from other unrealized gains on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI3LTEtMS0xLTEzMDc5_0eb26d45-bad5-4938-88ac-3659b916e485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI3LTMtMS0xLTEzMDc5_6321484f-7e68-4b9f-91ab-1f16e0092bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI3LTUtMS0xLTEzMDc5_43be4500-b5cf-42ed-b5bf-5019041d3c2f">266,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized transaction (gain) loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI4LTEtMS0xLTEzMDc5_a8748968-0182-4431-b477-7099ba2f9e35">176,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI4LTMtMS0xLTEzMDc5_50725b1c-1998-47a6-abae-55369e3cbc8f">15,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI4LTUtMS0xLTEzMDc5_ee318d3d-8a1a-4e92-adb3-23c415368e7f">471,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMwLTEtMS0xLTEzMDc5_12208846-7178-426a-b42a-006a03abc73d">13,093,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMwLTMtMS0xLTEzMDc5_41122633-6020-44a5-8a5a-bf2b53267f0e">17,859,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMwLTUtMS0xLTEzMDc5_d5b7e338-7504-4a1a-8aea-c9a2efd85175">2,616,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMxLTEtMS0xLTEzMDc5_25761609-f21a-4aca-9bce-f44c1dec59e8">2,061,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMxLTMtMS0xLTEzMDc5_eb03c9f2-ca20-47d6-95d4-9bdb647f81a8">844,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMxLTUtMS0xLTEzMDc5_42534321-b072-4a13-8de3-b161767c7d55">593,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMyLTEtMS0xLTEzMDc5_7dedf7d8-60a6-49cd-947f-86fff1a81dec">6,188,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMyLTMtMS0xLTEzMDc5_912910a6-e19f-4ee5-ace3-5a10a5d4fadd">38,849,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMyLTUtMS0xLTEzMDc5_4093b412-1a31-49c7-aad7-6f3aca9b9c89">178,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMzLTEtMS0xLTEzMDc5_a77dad24-64a2-43d2-b4e0-1ab4e4ee70d4">154,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMzLTMtMS0xLTEzMDc5_78067fb6-9cf1-4263-8aac-4dc0a6858977">374,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMzLTUtMS0xLTEzMDc5_b168dad9-246b-4081-9a13-b3678e7f8249">70,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM1LTEtMS0xLTEzMDc5_686ae1a6-2655-4a8f-96df-bacc994c96bd">24,531,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM1LTMtMS0xLTEzMDc5_e509d62a-fffc-4f1f-8799-1c1cb6724e95">23,285,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM1LTUtMS0xLTEzMDc5_b7c53faf-a8df-47a8-85a8-1c6a3a5c5df9">2,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM2LTEtMS0xLTEzMDc5_196afeb8-214e-49f7-aee7-a006302f61de">26,235,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM2LTMtMS0xLTEzMDc5_692d21b6-5d4e-4ec4-a6dd-365379a08f7e">3,115,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM2LTUtMS0xLTEzMDc5_0ea74c1a-9c86-46a2-a275-846b63b96a13">4,337,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM3LTEtMS0xLTEzMDc5_bff4de95-6f14-4e79-8a73-88f06806e623">375,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM3LTMtMS0xLTEzMDc5_abf25c70-ce57-439b-ac34-4a6978d21c2b">5,962,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM3LTUtMS0xLTEzMDc5_62514984-1260-4328-8233-46a74b1aa2f6">1,622,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM4LTEtMS0xLTEzMDc5_12367082-31d4-4ea0-93ea-dfd757932f89">94,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM4LTMtMS0xLTEzMDc5_8d33424b-5c0c-4ad1-867d-45628b69c9cc">135,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM4LTUtMS0xLTEzMDc5_91e1393d-6570-43cb-8255-0d8e36e05acb">248,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM5LTEtMS0xLTEzMDc5_659c3d9b-376a-4a96-9ff7-53be76a8cb38">39,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM5LTMtMS0xLTEzMDc5_cf6e0a26-2b48-4559-bb89-a6dc3aa2b806">68,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM5LTUtMS0xLTEzMDc5_c5b01ca7-5cca-45c4-8f61-5bb12850823b">180,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQwLTEtMS0xLTEzMDc5_3b053406-0eec-4706-9bf5-e9ab5453e302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQwLTMtMS0xLTEzMDc5_28edd639-edb8-4ebf-9d6c-37037c947a2c">5,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQwLTUtMS0xLTEzMDc5_ed7b1f94-c8b9-4927-bfdc-db2cb2cb3c94">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQyLTEtMS0xLTEzMDc5_aea4d04f-d855-41dd-b6dc-ba48686de627">2,329,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQyLTMtMS0xLTEzMDc5_84e15327-cd84-4f69-ae88-dd0f8440657d">2,091,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQyLTUtMS0xLTEzMDc5_f56335da-4753-47bb-b968-3bd07a666842">1,733,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQzLTEtMS0xLTEzMDc5_f4253e26-7075-42fd-8e21-1ff74a8bb9c1">2,914,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQzLTMtMS0xLTEzMDc5_759a9069-b1b5-4fcb-a9ae-d4abce89532c">1,409,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQzLTUtMS0xLTEzMDc5_a674bbb7-6ea1-414f-972e-16c3b5dd914a">1,899,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ0LTEtMS0xLTEzMDc5_dcb736c0-4f95-47c5-b227-01104615f25b">58,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ0LTMtMS0xLTEzMDc5_4667bd6b-a880-4374-a9d8-18ced0954ed5">784,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ0LTUtMS0xLTEzMDc5_2f5fdac5-cbd2-4ebe-ab01-11e99bd87014">816,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ1LTEtMS0xLTEzMDc5_7ae6790c-7bbc-4a98-9ed2-72350b9e9adc">42,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ1LTMtMS0xLTEzMDc5_1302f98c-040e-4b23-bb45-b05ff2a136b0">20,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ1LTUtMS0xLTEzMDc5_57c3d169-4a92-4eeb-a4ba-d76a123ecd26">48,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ2LTEtMS0xLTEzMDc5_eea1f715-ce12-42aa-a02b-8ff7eaae931f">215,708,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ2LTMtMS0xLTEzMDc5_616b69a8-1998-427e-b518-ff7f6323997b">177,979,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ2LTUtMS0xLTEzMDc5_f188878a-dd46-4f18-94e9-c708b08ba065">97,850,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ4LTEtMS0xLTEzMDc5_72bb8c52-9033-40de-a46a-01cb8e92c7f3">348,953,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ4LTMtMS0xLTEzMDc5_656adc18-62de-4573-a215-609456a4d95b">156,216,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ4LTUtMS0xLTEzMDc5_4f55c30c-6e26-434e-b262-00db7944b6eb">100,950,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ5LTEtMS0xLTEzMDc5_463c5d1e-259c-4007-95f3-19f2d451b9b1">174,839,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ5LTMtMS0xLTEzMDc5_105d075a-51aa-433f-9f9d-044bc5a0a8e3">62,991,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ5LTUtMS0xLTEzMDc5_f5567ace-644d-4f23-8b6d-89858d6e3aee">92,893,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUwLTEtMS0xLTEzMDc5_ec452f9f-4d70-470c-bd5a-9bfe97c7e590">1,231,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUwLTMtMS0xLTEzMDc5_2e3496db-8631-4354-9f3b-96118964a6f5">1,520,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUwLTUtMS0xLTEzMDc5_8d014997-a17b-4338-a144-75087c36249b">987,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of investment of GeneOne</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUxLTEtMS0xLTEzMDc5_8f746e7a-9bc3-4ff0-b706-406f3eb6c1c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUxLTMtMS0xLTEzMDc5_1dfe871d-e44d-4dd1-9997-4f4df9768f17">40,125,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUxLTUtMS0xLTEzMDc5_77a6a8f8-d34a-434f-8a88-cf6bddaaaa64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUyLTEtMS0xLTEzMDc5_663855cb-42c7-4e74-ba7c-fb983be0dbab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUyLTMtMS0xLTEzMDc5_b1845fd6-a1a4-4ac8-9fda-9a0634520e08">2,774,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUyLTUtMS0xLTEzMDc5_688b9b52-135c-4044-bda3-ad3649395c2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUzLTEtMS0xLTEzMDc5_1d1496d1-fd8c-408a-9649-086ba05b7c5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUzLTMtMS0xLTEzMDc5_cd1bd62e-2614-4fb5-a58c-fdc72dad4672">1,399,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUzLTUtMS0xLTEzMDc5_82c156d8-b9ec-4f52-b516-ffe88d764b46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU1LTEtMS0xLTEzMDc5_81e572be-0328-4917-8003-1a803adf7e58">175,344,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU1LTMtMS0xLTEzMDc5_fa636975-2757-406c-bcf1-cc607ec3be2f">58,795,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU1LTUtMS0xLTEzMDc5_144b3de5-e591-433e-a658-0a1a0c608b3e">9,044,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuances of convertible senior notes and convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU3LTEtMS0xLTEzMDc5_f3504f33-ea41-4eff-8384-ed7c39e31652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU3LTMtMS0xLTEzMDc5_a6404b99-2c0a-4ff7-89f8-8769b3327af4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU3LTUtMS0xLTEzMDc5_245ecec5-bf4b-4b69-8c20-97f571d14a9a">97,443,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs related to issuances of convertible senior notes and convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU4LTEtMS0xLTEzMDc5_9fa07ac7-1cd4-4fbe-8a10-786a804f9c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU4LTMtMS0xLTEzMDc5_e0f5013a-af5b-4526-a417-2373a4c4d023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU4LTUtMS0xLTEzMDc5_3dca36f9-da7b-4eca-a95f-f013e2001832">3,314,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU5LTEtMS0xLTEzMDc5_9b7e9692-ced4-47a2-ba8e-df97ce12cc44">209,441,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU5LTMtMS0xLTEzMDc5_016188c3-a292-4805-886c-0fc672f16ace">454,486,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU5LTUtMS0xLTEzMDc5_ae15a57e-9431-40ca-8edf-d0d58ab224ad">9,089,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock option exercises, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYwLTEtMS0xLTEzMDc5_34808601-bb3f-4e0c-89cb-6df23e37648c">6,668,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYwLTMtMS0xLTEzMDc5_f5c8176c-6e28-4734-a518-1e4d490e7ce2">12,269,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYwLTUtMS0xLTEzMDc5_00fbbacb-68ff-4ab6-8250-f1958e2f9c55">112,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYxLTEtMS0xLTEzMDc5_7b4b05ef-a47f-4fcb-92b5-81fce0c32f83">4,611,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYxLTMtMS0xLTEzMDc5_2e65332c-d37b-43c4-b353-3ace20584559">4,028,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYxLTUtMS0xLTEzMDc5_b3be5d89-5163-4da5-8cd1-9814a50301c3">892,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYyLTEtMS0xLTEzMDc5_8a96dc1a-07c6-4dc0-8fb0-e678577f5a00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYyLTMtMS0xLTEzMDc5_595d8892-16d5-4b9e-8cf6-456fb8ecf2c9">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYyLTUtMS0xLTEzMDc5_c95b976b-6d5f-43f4-afcc-7f6e79bc1c64">2,960,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from Geneos issuance of note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYzLTEtMS0xLTEzMDc5_1d0c4c6f-f09d-4249-a877-25a51e2ea432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYzLTMtMS0xLTEzMDc5_98d216e9-a0bc-4cbd-9e72-5b252929eb64">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYzLTUtMS0xLTEzMDc5_1bfd7876-e428-402c-bbd6-2a2f376ad5cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY0LTEtMS0xLTEzMDc5_8b330cb5-9964-4ea1-b44e-dbac4edfb98c">211,498,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY0LTMtMS0xLTEzMDc5_e0b994c3-28da-4019-baa5-15ebac4c5002">465,279,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY0LTUtMS0xLTEzMDc5_c72c63e9-fc2f-4e08-9b7f-f53a01a4789a">105,397,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY1LTEtMS0xLTEzMDc5_76813332-d436-4359-a268-d191265a62bc">30,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY1LTMtMS0xLTEzMDc5_89a2684f-476c-43ec-aaa1-f0c78f10e836">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY1LTUtMS0xLTEzMDc5_59f78e26-abc7-4e58-bec7-d5782727d1d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY2LTEtMS0xLTEzMDc5_37f086d9-e66e-4c4f-bcd4-64bb16ca7e0b">179,584,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY2LTMtMS0xLTEzMDc5_4f9c60d2-a460-4822-937e-c97381fdfd97">228,532,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY2LTUtMS0xLTEzMDc5_fbb2932e-0870-4b20-af6b-99b454899bd2">1,497,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY3LTEtMS0xLTEzMDc5_4b6cf276-169d-4635-95ed-ef00c2cd6d11">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY3LTMtMS0xLTEzMDc5_59092a30-6bb2-4a83-afcc-0db0aad1bb10">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0209f8c94d740adaa36dd67c48d6a20_I20181231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY3LTUtMS0xLTEzMDc5_3590cba2-6f34-49cc-9a45-ee908dc0e8d9">23,693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY4LTEtMS0xLTEzMDc5_9dce8e8b-d0d8-4345-98e1-9d844e46af15">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY4LTMtMS0xLTEzMDc5_3eb3407a-b675-4ed4-8235-f7dec63db2d6">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY4LTUtMS0xLTEzMDc5_0e8edd1c-d9a5-4673-91db-4c841cd5b67d">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzcyLTEtMS0xLTEzMDc5_958621e9-9207-49cd-9c7b-d65c97156582">204,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzcyLTMtMS0xLTEzMDc5_4b6ef9a3-122e-462e-8430-3a1a0a718592">136,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzcyLTUtMS0xLTEzMDc5_5ba7a519-bed4-49e3-8217-377e0abc5f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzczLTEtMS0xLTEzMDc5_6fd82d34-4344-4c6e-a8f3-d392ac1362e6">1,077,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzczLTMtMS0xLTEzMDc5_6059172e-4988-4e8e-ae44-1f908d3fb796">4,624,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzczLTUtMS0xLTEzMDc5_2e53b644-0315-4f15-88ab-49389e7982fb">2,717,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in prepaid expenses and other current assets included in fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTEtMS0xLTIzNzEx_8aecd647-6516-4d54-89bf-4bfc0b23dd74">7,709,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTMtMS0xLTIzNzEx_91d46590-fa3b-4d6d-93a5-f319c867368c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTUtMS0xLTIzNzEx_fc93f19b-1a4c-4c6f-8b68-5a1e94dfb3db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of issuance of convertible notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="ino:EquityComponentOfConvertibleDebtIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTEtMS0xLTEzMDc5_496e920b-0f13-4523-befe-ae12721092fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="ino:EquityComponentOfConvertibleDebtIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTMtMS0xLTEzMDc5_69a2b6e0-e091-4c10-9d1f-8157b5efe712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="ino:EquityComponentOfConvertibleDebtIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTUtMS0xLTEzMDc5_f7b567c0-e434-438c-94d9-efcebf0ffb7d">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc1LTEtMS0xLTEzMDc5_cd1afe78-5f53-4cec-8b4d-e1c2edc8457c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc1LTMtMS0xLTEzMDc5_67c19633-da95-41e5-9dbf-ce226a609158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc1LTUtMS0xLTEzMDc5_3becf4fe-0dea-411f-b1cb-a15307434a1f">14,634,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_133"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzMvZnJhZzo1YjE0YWM5YjFjMjc0YzMzODQ4OTA2M2ExMzczODZkNC90ZXh0cmVnaW9uOjViMTRhYzliMWMyNzRjMzM4NDg5MDYzYTEzNzM4NmQ0XzM2NDc_e6370eda-5c2c-479d-95b5-524290ec3607" continuedAt="idc110352ae284684b66bc44ad09b6182" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="idc110352ae284684b66bc44ad09b6182"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus ("HPV"). INOVIO has shown in clinical trials that its DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of INOVIO's integrated platform, SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and CELLECTRA&#174;.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">smart delivery devices facilitate uptake of its DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA&#174; smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's corporate strategy is to develop, seek regulatory approval for and commercialize its novel DNA medicines to address unmet global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include ApolloBio Corporation, AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, conducting or planning clinical studies of DNA medicines for COVID-19, which includes both homologous and heterologous boosting approaches; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzIx_a2a89be4-928f-41ea-ae70-b521bfe75c91" continuedAt="i8d1a2ccd9c4148c5a9bea2272146c564" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8d1a2ccd9c4148c5a9bea2272146c564" continuedAt="i3927c53b936d40afb564ceaaf0aa2dbc"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzcz_9cb31150-3c71-47c7-a274-42f6b7020f5a" continuedAt="i4270b351890140719daf0f33f855abd5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM1MTc_fa6289c7-81cf-4747-b711-c9c84dd98e76">303.7</ix:nonFraction> million for the year ended December&#160;31, 2021. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="ino:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM1ODY_923a3fa6-cef7-409e-a3e7-c820a63cb1b9">382.7</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM2MTk_c9bcbb16-c288-48c3-9444-69cfa4fc1b37">1.2</ix:nonFraction> billion as of December&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM5ODc_2020c4bc-d371-4162-a094-757f428b4b08">401.3</ix:nonFraction> million as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i61571339f1d34229a32dd11283124d8d_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMyOTc0OTc_51afcb71-7a73-474a-ac2c-7f74a5cdbdc2">162.1</ix:nonFraction>&#160;million from a January 2021 underwritten public offering, net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMzMDIyMzk_99811b74-0bb9-4922-a27a-d8bd9f8ebca1">47.7</ix:nonFraction>&#160;million under a Sales Agreement during the year ended December 31, 2021, </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3927c53b936d40afb564ceaaf0aa2dbc" continuedAt="i17982139fcd7480b81c9e39b7fcb1415"><ix:continuation id="i4270b351890140719daf0f33f855abd5" continuedAt="i50af6c1e07e3450badb4a2ebc9e5068a"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib2f6172e00ae438dba3e872301590376_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQ4MDQ_04c7a924-58bc-4b4a-893c-d50d29fb38e8">454.5</ix:nonFraction>&#160;million under Sales Agreements during the year ended December 31, 2020, and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5e3b5941f67f4dd7839d1d0ee8b932e6_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQ4Njg_e1802458-1de1-455a-a009-99ba2b1a200b">9.1</ix:nonFraction>&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3185052214d241188760405d062c3a93_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQ5Nzg_dd919013-9797-4a95-aa46-42a24aed15fe">75.7</ix:nonFraction>&#160;million from a private placement of <ix:nonFraction unitRef="number" contextRef="i9cb066154a0b4e63a1b45dee6f783336_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUwMDk_3cc0ff52-b5b6-485a-9002-6711c1fd8f0a">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iec094623890140ecbe43e62d969a9e6e_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUwNzc_279a9fe5-dedb-416a-b9a3-a00f14ea773d">14.5</ix:nonFraction>&#160;million from the private placement of <ix:nonFraction unitRef="krw" contextRef="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUxMTA_1c1429b2-9bc2-4d7e-aaf1-c3ad930305ab">18</ix:nonFraction>&#160;billion Korean Won (KRW) (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUxNDk_d77e4eaf-eef1-476d-a93b-e7933aafff2d">15.0</ix:nonFraction>&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUyMzg_7bc59ca6-f40c-4f5d-af9e-f8f05de3d9e6">1.0</ix:nonFraction>% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia4b54e7447e843b785376b2edd00a1df_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUzMjE_96c55388-5e82-447b-8c13-d97451610d95">4.0</ix:nonFraction>&#160;million from the private placement of <ix:nonFraction unitRef="krw" contextRef="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUzNTQ_989fc321-aea3-4afc-81d3-18a112d751a7">4.7</ix:nonFraction>&#160;billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUzODA_143bd92c-0120-449d-a751-117fb76406aa">4.1</ix:nonFraction>&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzU0Njk_18663929-0dce-4e6b-bd1c-1489e5779321">1.0</ix:nonFraction>% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i50af6c1e07e3450badb4a2ebc9e5068a">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements. </span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzky_f830482a-4ea5-4e35-aec7-1c94c3d7fbd6" continuedAt="i52352b86b27844a581ed589e94b7b8e7" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><ix:continuation id="i52352b86b27844a581ed589e94b7b8e7" continuedAt="i733f8fd90a2345d4b9f32d3755bc0bfd"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i733f8fd90a2345d4b9f32d3755bc0bfd"> the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.</ix:continuation>  Refer to Footnote 16 for further discussion of Geneos.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzI3_ef0c2f8a-a829-4de7-ad27-9236ffad4214" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4Xzk0NjI_f46a567b-e1a2-4d43-9865-0f995b0628d4">one</ix:nonFraction> segment operating primarily within the United States.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNjgz_e9695300-dc10-44ab-a138-5e5cb4bcd771" continuedAt="i6481a571e25c4183b727f6300680443b" escape="true">Use of Estimates</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i17982139fcd7480b81c9e39b7fcb1415" continuedAt="i02deafbb84cf4c188c137358793d08f9"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6481a571e25c4183b727f6300680443b">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</ix:continuation></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzE2_d06f1aa0-3747-40eb-bbdd-38738bf6f49f" continuedAt="i69f77836d9604c7780786384f36ddb7a" escape="true">Concentration of Credit Risk</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i69f77836d9604c7780786384f36ddb7a">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzU0_f20331bd-ba24-4258-b820-9cb6ff31f529" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNjk1_af4b8dc5-80ae-447d-8836-95fed9c5cea6" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2021 and 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzYz_47807245-c34f-450e-a999-f1bf5ae9ec40" continuedAt="i95db7fcd59934834a5baefcca4bc8a87" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2021 and 2020. </span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="i95db7fcd59934834a5baefcca4bc8a87" continuedAt="i0a2a5bd42fb54d8687b90bf9e1af2fe5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a2a5bd42fb54d8687b90bf9e1af2fe5">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzMz_9130d149-5e2d-45f6-b154-ae79e80d5e47" continuedAt="i237af026840e4452b8b480ae880b1018" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i237af026840e4452b8b480ae880b1018">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNTE3_b30eb0b6-11e2-4921-9331-e14b0c14c06c"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNTE3_fdd39d0a-bc0b-4f7c-a0c9-28a6e546da06">No</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts was deemed necessary at December&#160;31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzU1_5f218442-55c6-4c39-9be3-675629b2398b" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1">three</span> to <ix:nonNumeric contextRef="i1ef43783aafd41bcbd015396830a6453_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODI5_ac552237-bd0b-4cf9-823b-d46710f73b8d">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODM0_d445bb8e-9990-4a4b-bfb0-9c6799c44348" continuedAt="i94cd972c583044399cf77eac1b275858" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i02deafbb84cf4c188c137358793d08f9" continuedAt="icb9229af9f2e487a881bd4e8097fa591"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i94cd972c583044399cf77eac1b275858">analyses or comparable fair values of similar assets.</ix:continuation> The Company has not recognized any losses on long-lived assets through December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzQz_f03f18da-62e0-4d33-bcd4-cbe5e423bd9a" continuedAt="iac7ba0489f994cf2819558570003e386" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957">two</span> to <ix:nonNumeric contextRef="i1ef43783aafd41bcbd015396830a6453_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjMx_eb70156c-92b5-48b8-bb07-86599dc2f6d1">18</ix:nonNumeric> years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2021 and 2020, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMyOTgzMTI_6b8c68d2-4a92-478e-a7c9-b5458168dbbb">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMyOTgzMTk_425bf49a-5b3f-4f21-8069-f5a9d0e7e602">3.1</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2021, identifying no impairment.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iac7ba0489f994cf2819558570003e386">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODI2_368e3eb8-0010-4c7d-969f-74c8adec5c83" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzE5MjI0_3cc1fc2c-7b7f-417d-90e4-fae6e9546d31">237.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzE5MjMx_a1bbfa10-3646-4acf-bff7-d4c78777df1a">159.7</ix:nonFraction> million at December&#160;31, 2021 and 2020, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzAz_70544345-4ac5-48cd-84c1-c7da28135f62" continuedAt="i0cc39613e83e4623b976656959e02c34" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icb9229af9f2e487a881bd4e8097fa591" continuedAt="i1f25c496997548f8b29ff39f29d8f665"><div style="margin-top:5pt"><ix:continuation id="i0cc39613e83e4623b976656959e02c34" continuedAt="i5ca273e206c2450caa9e0f0d782e198f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ca273e206c2450caa9e0f0d782e198f"> (&#8220;Topic 606&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODQ1_3fc99511-6581-4626-a1c7-a1dbefeb54a4" continuedAt="i03883f7188034101984175e47083b5d5" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1f25c496997548f8b29ff39f29d8f665" continuedAt="i4aa1acb5c11e4e259153b5e89867b989"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03883f7188034101984175e47083b5d5">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</ix:continuation></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="ino:GrantRevenuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODM3_b2b1c629-6138-4359-b695-1ef1344d4a03" continuedAt="ie56b363e2ad44ef381f41319d3ea061d" escape="true">Grants</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ie56b363e2ad44ef381f41319d3ea061d" continuedAt="i4228790f083a4a2590e21f966c8e92f2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4228790f083a4a2590e21f966c8e92f2">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzU3_5ce51a83-fb6b-4ae3-8267-3e67e7444ae7" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODI3_81cb2bfc-55a5-47b8-bab8-93a4a780ea66" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQzOTgwNDY1NzQ0NTE_c122e9a0-2bcc-459b-814b-735db66737bd" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQzOTgwNDY1NzQ0NTI_1eeb1439-26b3-452f-907a-aa98215b16de" continuedAt="ia1d23a90f3a5409786075958e468717a" escape="true">Equity Investments</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ia1d23a90f3a5409786075958e468717a" continuedAt="i80611ee95b1346d5846ed96725561153"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i80611ee95b1346d5846ed96725561153"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzI4_86e643f5-adf7-44c4-ba45-cb821ce49baa" continuedAt="ib08a52532a2646498687c6189f9d9d30" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4aa1acb5c11e4e259153b5e89867b989" continuedAt="ib31091852dbd4819b035823f8eccc064"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ib08a52532a2646498687c6189f9d9d30" continuedAt="ib4e34c3d41f34159946a7ecb6d0170ca">accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ib4e34c3d41f34159946a7ecb6d0170ca">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNjk4_decce677-2d00-438b-8b7b-c20ab86acae3" continuedAt="ic8c91a4cef4a4945af18e8f1b35ac979" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-indent:27pt"><ix:continuation id="ic8c91a4cef4a4945af18e8f1b35ac979" continuedAt="i159db92270f04940b6473979a07c43d5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i159db92270f04940b6473979a07c43d5">For the years ended December 31, 2021, 2020 and 2019, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzQ1_39b0d8d3-2288-4936-861c-c031c831de3e" escape="true"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if22218578fe146a690414073c1055f9f_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzItMS0xLTEtMTMwNzk_fec48c65-a44a-44d2-8950-3aa1a6410ef1">10,488,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie75672a5cd7f4ee7b50fd63d1effb9b3_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzItMy0xLTEtMTMwNzk_17c8a45a-ae7c-4fa2-ad56-563947ee61f9">8,906,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib858b60634554cfeb353213f382d8701_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzItNS0xLTEtMTMwNzk_1b7e7ee1-0b49-402a-a9e6-8aa13c0f8d80">9,265,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1619b504fabd4b03803cf6d1bd43cdf7_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzQtMS0xLTEtMTMwNzk_8fc66ad7-aa8c-4fe7-bff6-68c4c894aa90">2,448,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf57bbc765a648e88af4e001faf909bf_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzQtMy0xLTEtMTMwNzk_274e0328-10ed-4bc4-831c-135a2c2fc657">2,558,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1d7d0e03523439aa100b18e4b73ea8f_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzQtNS0xLTEtMTMwNzk_9edbe7ed-9ac6-4f6f-b10b-0ec79f3b4557">2,069,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfd184b5e79415896cd4f9f6baac7f3_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzUtMS0xLTEtMTMwNzk_ce786221-503c-4d8d-a5df-91eeb336638d">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bf52c18686740578bf1f8f9c8cbaa61_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzUtMy0xLTEtMTMwNzk_a2f21cab-1fe0-49b6-9ea9-987419ba8585">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5417c1b5a9294d67b2ece5b90e913521_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzUtNS0xLTEtMTMwNzk_2c7d9733-39d0-4532-bd9c-c4b9e6f2dbd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153bb9c9446b45eb8aa80f75f7399f3a_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzYtMS0xLTEtMTMwNzk_65c070b5-13f1-4276-8fbf-74fe475dd54e">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie80d43743e6a4d668eea6d7bee8e1496_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzYtMy0xLTEtMTMwNzk_29f5ad0c-1128-4306-b30a-d9ace39e0f86">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ef6a305f4c7456382cbb6d2f1e80f0e_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzYtNS0xLTEtMTMwNzk_d6759e38-4f8d-4d45-8f72-339a945528f2">8,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib58bb2dd8a4143a19908c58b705c40c0_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzctMS0xLTEtMTMwNzk_0a82e47d-da87-4a6e-b95e-6edac1f19877">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f0ab257a6974dcdaba93f9ed07ea5f3_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzctMy0xLTEtMTMwNzk_8aab2e76-5cfc-4221-adfc-7be497c1eddf">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i818c9cc8d85740b2bf619cb778985673_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzctNS0xLTEtMTMwNzk_fbf6a524-78a9-4348-82bc-c21f16d35586">14,585,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f8eca20d5f34697abb3f086dc268f34_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzgtMS0xLTEtMTMwNzk_b2a6f917-5690-45be-9c0f-33ba679f3cb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14c7a36858de4d50ad50b6fa093cd1a5_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzgtMy0xLTEtMTMwNzk_69d14598-2f21-41a6-a93f-a21dbb025368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia57b862418ed4691a1094727113e9132_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzgtNS0xLTEtMTMwNzk_e90a9a3d-03a0-4a02-9107-ec9c951bbc15">3,799,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d211e27d9de438bae12df540aefb132_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzktMS0xLTEtMTMwNzk_2eb4adbd-2572-4e8a-9ff5-50194b004897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c100e0e5d064a128da83ec7e1d7bdb0_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzktMy0xLTEtMTMwNzk_a249d50c-2c86-4a88-b1a3-8820c8deb84c">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6c4d94d9b204b7b9bfcdd26fabbc2c7_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzktNS0xLTEtMTMwNzk_0a242b81-2d1b-4f76-b995-392c31685d1f">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzEwLTEtMS0xLTEzMDc5_c943bdaf-5740-4576-afc7-1acb5bb94cb9">16,654,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzEwLTMtMS0xLTEzMDc5_ab426d72-9a66-4712-84fe-1eeea734161c">16,190,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzEwLTUtMS0xLTEzMDc5_4cf5132c-2b19-4d4d-bf52-9afbe0debf93">30,737,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODM4_9a08c52f-cb9a-46a4-8bd9-8cbbf48669e6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzA0_9fb4cb04-78d1-4cb6-adda-7d8b79dd9008" continuedAt="i97e2d7e23f834efb8bcaeba57a2dc9c1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib31091852dbd4819b035823f8eccc064" continuedAt="ie3c0d39ffeb140e08ba296f32c0aa76a"><div style="margin-top:5pt"><ix:continuation id="i97e2d7e23f834efb8bcaeba57a2dc9c1" continuedAt="iaac1ca0cba9f42e2b7a240967f59e27f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></ix:continuation></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODE2_02b6baca-eb3d-4498-9a0e-d816724f6f70" continuedAt="ic4654fd2c45c4735871a2b83818905b7" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzItMS0xLTEtMTMwNzk_7debc3e2-e92c-4507-94ab-7b321c892664">0.91</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzItMy0xLTEtMTMwNzk_fcf9603b-8b02-45d8-8e65-88ac0673b7c8">0.63</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzItNS0xLTEtMTMwNzk_1634a7c5-2049-45cf-b1c9-311a855e4358">2.42</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzMtMS0xLTEtMTMwNzk_970163b8-62dc-4e14-9ce6-29148e1ade04">93</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzMtMy0xLTEtMTMwNzk_ead2f713-21bc-4ab6-bee8-6adfdacb70fe">78</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzMtNS0xLTEtMTMwNzk_27ff0d49-864a-4b6d-9599-1cc7f8d87296">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzQtMS0xLTEtMTMwNzk_24f02edf-7728-459b-bf88-badd7693bc82">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzQtMy0xLTEtMTMwNzk_e97c683b-1818-41a1-a0e2-4a48d5673848">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzQtNS0xLTEtMTMwNzk_d2ba7bd1-f90c-4187-95fc-2ef4d9f1435d">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzUtMS0xLTEtMTMwNzk_12994a02-48e2-4812-8cc6-cf7860e5ee15">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzUtMy0xLTEtMTMwNzk_afcf78bb-133c-4c9b-9b22-6d149dcec040">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzUtNS0xLTEtMTMwNzk_463abfc5-0254-4e03-8e07-643c67a7ee78">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaac1ca0cba9f42e2b7a240967f59e27f">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</ix:continuation></span></div><ix:continuation id="ic4654fd2c45c4735871a2b83818905b7"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzItMS0xLTEtMTMwNzk_6fe99fa4-4525-44e0-98de-bedf0dc7b127">1.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzItMy0xLTEtMTMwNzk_e39d6721-e020-41d4-a399-0c0077779a13">0.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzItNS0xLTEtMTMwNzk_174cd9fc-dd56-4b40-a1ff-20882ee85fd6">2.45</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzMtMS0xLTEtMTMwNzk_e204b8cc-0f2b-42ae-9a65-0c5f0da6e7bb">87</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzMtMy0xLTEtMTMwNzk_9f3651cb-b160-4180-a950-2f85d22cd6bf">76</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzMtNS0xLTEtMTMwNzk_a8164488-534d-4041-a0ad-0edb25c7a209">88</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzQtMS0xLTEtMTMwNzk_3c1eef56-a9b4-40f1-937c-a99ec96faac8">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzQtMy0xLTEtMTMwNzk_96ac1e07-3b55-4fbc-82db-4a1e67d0ddad">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzQtNS0xLTEtMTMwNzk_0f6d746d-21c3-4e5c-8fc1-2b36692fad76">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzUtMS0xLTEtMTMwNzk_078e4eed-20c9-4de9-a414-25614fe358cf">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzUtMy0xLTEtMTMwNzk_5708e4f2-d2a5-4b2c-8324-ad22e6b936fc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzUtNS0xLTEtMTMwNzk_c3f8a976-ad45-4598-9fee-dc3b8a419b47">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODAz_b8684d59-6343-45ca-b212-4650afbba407" continuedAt="i720d718672474008b125163b0f59c0ac" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Pending Adoption </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><ix:continuation id="ie3c0d39ffeb140e08ba296f32c0aa76a" continuedAt="ied1a857f8ca24794b722a2fe4bb0d34f"><ix:continuation id="i720d718672474008b125163b0f59c0ac" continuedAt="i30559bd3e3d54f329dd476e689c42771"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied1a857f8ca24794b722a2fe4bb0d34f"><ix:continuation id="i30559bd3e3d54f329dd476e689c42771"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company will adopt ASU 2020-06. The Company is finalizing its analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. The Company expects that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_139"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzU5Mw_b63f1c39-e561-4f71-8553-e09fe171d62f" continuedAt="i016a48bbea744957bbc4cf340efb21ba" escape="true">Revenue Recognition and Concentration of Credit Risk</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i016a48bbea744957bbc4cf340efb21ba" continuedAt="i4eeb183b844642058f1d56728461d8bb">During the years ended December&#160;31, 2021, 2020 and 2019, the Company recognized revenue from various license and other agreements. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzQzOTgwNDY1MTg3Njc_eb5a840b-2696-4c81-bcdd-aa86538f4e78" continuedAt="ibfe2bc37327f46eb95f94698b34afbe2" escape="true">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</ix:nonNumeric></ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4eeb183b844642058f1d56728461d8bb"><div><ix:continuation id="ibfe2bc37327f46eb95f94698b34afbe2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ebf37c07fc64f66897dbd181366f4f5_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItMS0xLTEtMjgwMjU_0fc217d2-e122-4d33-bf60-2ebc5ef1f0f6">41,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i161b5c6c81dd4f91ba0ee787fa80afde_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItMy0xLTEtMjgwNDI_a8abb916-8bc6-4d12-b818-90051e563762">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfdf8c8894d47eaa3893a5f0fb45ab8_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItNS0xLTEtMjgwNDQ_82f683b1-195f-48d3-a8fc-dbaf69a7e75f">170,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93761468f4d2413c9fbddde17352101f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItNy0xLTEtMjgwNDY_33d7f08a-018a-4048-8d65-986045bc06e2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656c17b4e38a4ee491d602bf63aa7c19_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItOS0xLTEtMjgwNDg_08593798-bb6c-4525-bc5c-fce60ccc9037">3,194,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i919eacd755534f7f903fe6245b2c707c_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItMTEtMS0xLTI4MDUw_09e751de-98af-4bb7-bd29-16334b539566">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e0b5e7a72c42b1895acaf229856efe_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtMS0xLTEtMjgwMjU_74075068-db5c-439e-8106-45b4378cba69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40e1d2d136dc4c518979cf57c6a1b20b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtMy0xLTEtMjgwNDI_ce56a706-93a3-47bc-8b46-758cb4bedfe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b4a0ade4f3147fc8b24dc411f419712_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtNS0xLTEtMjgwNDQ_f5f3d466-bfc9-40f4-a58d-3639eebf5c6f">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i873c90e08f654501a8ad20a07c60193f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtNy0xLTEtMjgwNDY_833aa7b9-9e88-44de-a80e-0bfe1d6da76a">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a1ac7d82334e4baf6955ef04815ce4_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtOS0xLTEtMjgwNDg_2f9c8a8e-8947-4c8b-9692-7d3332e099a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id57fe04684f046938af512e85a6ba191_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtMTEtMS0xLTI4MDUw_46a49948-88a3-4597-9387-1a85cd547fe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ec58bb67dc470a99951e5275067d10_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtMS0xLTEtMjgwMjU_197f9611-1c11-4c58-ba54-377adb9d27a3">245,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i206cac58be234c169495b0e1f07f3b28_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtMy0xLTEtMjgwNDI_4569d5dd-b1d2-4ff1-bab8-11e44ac65dd3">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if59018c846e149458509f9c8cd25b24c_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtNS0xLTEtMjgwNDQ_bcf81b47-c7eb-4ffd-97f9-db33c5d4e1c8">1,370,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib99bde567bfb41acbc76d3e0b885ec12_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtNy0xLTEtMjgwNDY_630962b1-eef0-4e45-b122-7ad964244e35">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb847a1857fb4bf8b3cbe776dd9e29ab_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtOS0xLTEtMjgwNDg_7e7c1d51-b0ca-412e-b171-3bb3e1366609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82e0404405254e2e98e726f09230deb6_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtMTEtMS0xLTI4MDUw_ed4a5ff7-b20b-4162-96d0-61067e37c5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department of Defense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i567cdce8ec3f4d2eab6aec7e81bd94f1_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtMS0xLTEtMjgwMjU_7e7c85c0-6ee9-4806-b4d6-1f11baa7dace">754,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b628859583d45a886cbba8bc22a2f8c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtMy0xLTEtMjgwNDI_990b00b1-6ed0-4d10-ba70-383f83324069">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01b088cd46a48608cf5867ab6b78956_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtNS0xLTEtMjgwNDQ_cbc555d4-7bbd-4c4f-8e8d-b5e28b8fc871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08cf4a688e1e4557bbe98d00332e150f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtNy0xLTEtMjgwNDY_ebdcd2d2-b42e-4095-82fe-0448af927095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e4662477174747a0d272e1d8792a76_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtOS0xLTEtMjgwNDg_ce861448-8e07-47d4-8b7d-d87ce4bbe35e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib8f9c1676db542ada5764c97da93a468_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtMTEtMS0xLTI4MDUw_2acbb274-ad99-40ed-8eff-38ad02203640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee4ca6918ae4fa796d41036cae115ee_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtMS0xLTEtMjgwMjU_51b1eca1-8a53-4e54-850b-ad7522603e4a">732,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia77dac3a01a74815904a03fe7971a7d2_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtMy0xLTEtMjgwNDI_cf6c2558-59f6-411c-a39e-72f7834e9d40">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b35ca32ad6b49038d3962c931ab0301_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtNS0xLTEtMjgwNDQ_260bfd4c-aae5-4b1e-aa53-cb3d33a1817f">870,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icad521f20e6d42869f7f73948ebbd477_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtNy0xLTEtMjgwNDY_20966de8-bb90-4da1-a6b4-497aa44ad870">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14838e9bc6fc4c4487a1c7f9172258a4_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtOS0xLTEtMjgwNDg_58f5db66-323c-419e-8288-ae7821f0cf40">917,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42c6acd539524f568bd5b29f3c45c3ef_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtMTEtMS0xLTI4MDUw_836bd00f-ee12-4d52-85fa-a11c1294f4cd">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctMS0xLTEtMjgwMjU_486fd6c7-f61e-438c-8d5b-830383cc77a0">1,774,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb2df8412c044c118cdb9553e4cf95ad_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctMy0xLTEtMjgwNDI_367145f6-4144-46e5-81df-c4c341f0fcec">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctNS0xLTEtMjgwNDQ_20fd326d-c4e8-4523-a36c-89117994c7fd">7,411,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52aca042d6ff42d1ba348dd26d66cffd_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctNy0xLTEtMjgwNDY_b693486a-f93e-46ec-a952-bdb509f27784">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctOS0xLTEtMjgwNDg_c2d3d1e7-27c0-4091-95fc-6fbcaf1cca07">4,111,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59968761470a4f2d802618f91010f7b6_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctMTEtMS0xLTI4MDUw_4aab8bbd-8706-4529-a69e-f9b827707df4">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the total revenue recognized during the year ended December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzUxNTE_e26b7a61-2537-4cf3-83a4-2fa624057cbe">46,000</ix:nonFraction> was in deferred revenue as of December 31, 2020. During the year ended December 31, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzUyNzc_fc2ab72f-2e9a-4a1b-b152-6ffe3e767be0">127,000</ix:nonFraction> that was included in deferred revenue at December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i6262eab5b3c948d69de6a49741df2b15_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEwNzc_54efc310-4594-4c19-a948-8afa845a642d">3.6</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="if71d5ef52a394d6797808af8b5299731_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEwODU_4cd69d56-0f57-404a-8257-d7915c1420ed">65</ix:nonFraction>%, and $<ix:nonFraction unitRef="usd" contextRef="i43ec222c4b76432ca9ce78c095a00f5b_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEwOTQ_6e333877-3e46-4454-b641-3bf5d9c5c704">1.9</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="i06bbd4127d1e42a6b45c7cdf18fc01b5_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzExMDI_e38a38ff-e1e0-47e7-93ea-6f8c68eff53b">34</ix:nonFraction>%, of the Company's accounts receivable was attributable to the DoD and the CEPI MERS grant, respectively. As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ia0f4b2524a6745389ebfd4167248f100_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyMzU_3d900928-be01-45d7-949b-2f69cef01267">11.4</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="i5e2613d428a449579acc6b28ca21928c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyNDM_aa16eab3-1d86-4834-92b6-b59c6b9713f1">62</ix:nonFraction>%, and $<ix:nonFraction unitRef="usd" contextRef="i6ded10e0f0e44a2bb4ece994cc771846_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyNTI_b18db613-f254-457f-982a-f9bbfbaed0ca">7.1</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="iaef8fd46f8504fc48eaafd248555647c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyNjA_5dee544f-476f-4cd8-aede-1147df4d4ef6">38</ix:nonFraction>%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</span></div></ix:continuation><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5Njc4_2194217d-b48a-4708-8be4-aa740adbd2ec" continuedAt="i09f0f11d519e42b3a4c48ff6445db8bd" escape="true">Collaborative Agreements </ix:nonNumeric></span></div><ix:continuation id="i09f0f11d519e42b3a4c48ff6445db8bd" continuedAt="i9fa3b1a17f65435ebb2a492709317810"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzOTY_7af59672-e21c-46ce-8071-f2ecd2e93a6d">3.0</ix:nonFraction>&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1MjU_046e2d17-4e12-4a4a-8685-7352564a6bd1">206.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. As of December 31, 2020 the Company had earned a $<ix:nonFraction unitRef="usd" contextRef="if4ec0f7d61a247a29e6f8b976b92fdd7_D20200101-20201231" decimals="-5" name="ino:CollaborationAgreementPaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE4MDk_46187adf-a8ee-4d3e-ba09-c7ba2c4defbe">2.0</ix:nonFraction>&#160;million milestone payment based on the enrollment of the first participant in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIzNzE_b7096154-439e-4ddd-9834-3c3a78c3c546">ten years</ix:nonNumeric> after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9fa3b1a17f65435ebb2a492709317810" continuedAt="i013987615ced4acc8125b5734d708b46"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" decimals="-5" name="us-gaap:CostMaintenance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyODIxMDE_1f6494c2-8f97-4876-ba7d-fd13d65abd78">1.5</ix:nonFraction>&#160;million for a period of <ix:nonNumeric contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" name="ino:AnnualMaintenancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyODIxMTQ_dfb1a7a1-9613-441c-a8a4-4340535227f6">five years</ix:nonNumeric>, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyODYwNDM_b5d67aee-6af8-4258-ab15-8fc06c6569a3">18</ix:nonNumeric> months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzQ0NDQ_f9c2d070-f7b0-4a0f-ad85-48711a8d8825">3.0</ix:nonFraction>&#160;million upfront payment received in January 2021 plus the initial $<ix:nonFraction unitRef="usd" contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" decimals="-5" name="ino:CollaborationAgreementPaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzQ0ODA_a5f373e4-02b4-4e8a-bd11-0766646891cd">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzY1MTk_ccbe7204-ba3c-40a2-87ef-c1b47d06cccb">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $<ix:nonFraction unitRef="usd" contextRef="i3e94d242541e4769b9580dca20dd055f_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzY4MTI_b3699691-f69c-47d8-998f-30636cd42d0c">5.0</ix:nonFraction>&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i6ded10e0f0e44a2bb4ece994cc771846_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMzMDcwMzQ_4c0f1340-6d7f-47bb-a490-c6912488a1f6">7.1</ix:nonFraction>&#160;million from Advaccine. There has been no additional revenue earned under this collaboration agreement with Advaccine for the year ended December 31, 2021. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the Global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore concluded to account for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMzMDc0MTU_3d200845-6505-4124-83d9-7b6b1bfdcd91">4.5</ix:nonFraction> million from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2c6068a0d87f4fa585046b88cd0c29e1_D20180301-20180331" decimals="-5" name="ino:ProceedsFromCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc3OTk_31b07f0f-e440-4488-a326-3f32e30258ec">19.4</ix:nonFraction> million in March 2018, which comprised the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2c6068a0d87f4fa585046b88cd0c29e1_D20180301-20180331" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc4NTY_d37a7750-b193-454f-b115-bb4301aed03d">23.0</ix:nonFraction> million less $<ix:nonFraction unitRef="usd" contextRef="i345933f791f148b9ab11262a4e3fabc8_D20180301-20180331" decimals="-5" name="ino:CollaborativeAgreementCorporateIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc4NjQ_a6dd943c-3df3-452b-a83b-610f7812637b">2.2</ix:nonFraction> million in foreign income taxes and $<ix:nonFraction unitRef="usd" contextRef="i345933f791f148b9ab11262a4e3fabc8_D20180301-20180331" decimals="-5" name="ino:CollaborativeAgreementForeignNonIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc4OTU_4ea80a11-8074-4dc1-a172-8f8ee838cbe9">1.4</ix:nonFraction> million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations. The Company also incurred advisory fees of $<ix:nonFraction unitRef="usd" contextRef="i2ae7a6139749478dae2789fde984a73d_I20190331" decimals="-3" name="ino:CollaborativeAgreementAdvisoryFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzgxODI_2e0ad775-e897-4123-9a57-cce907ce34e0">960,000</ix:nonFraction> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i013987615ced4acc8125b5734d708b46" continuedAt="i5cdf0aef3e854f3b9ba6c6bc7a981259"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzg3NzA_80e95468-3494-47a7-bea5-4507b41602ac">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzkzMTE_0a4567aa-3ca6-4763-9ad0-758e7a950bc7">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTQ3Nzc_e94b9d85-84db-4427-8c87-27c655b7a0d5">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTQ4MjY_ca321535-6fdc-454b-9758-1189c7d163bc">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzk5NDk_892307dd-b9aa-47ec-a2f5-afec561287ce">23.0</ix:nonFraction> million upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="ib423f4e3e0a948d1a2df6de8efddc903_D20180401-20180630" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzExNDI5_f64fcf9a-83c6-4145-8f85-0e995bae961e">23.0</ix:nonFraction> million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i38a9f6f4af6b431f8ca5510726bbceba_D20150901-20150930" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEyMzIw_f6019ad8-4d46-48cb-89d4-a4401a55d8e8">27.5</ix:nonFraction> million to the Company in September 2015. AstraZeneca was obligated to make potential future development and regulatory event-based payments to the Company and potential future commercial event-based payments, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca was funding all development costs associated with MEDI0457 immunotherapy. The Company was entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca could also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $<ix:nonFraction unitRef="usd" contextRef="iecc3a56b04444e0ea7504b1ecbc37e79_D20171231-20171231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzMTkx_c1aeca58-d048-4ba3-a915-12137aa518e4">27.5</ix:nonFraction> million upfront payment as revenue, as all identified materia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="i9e3823ff3500456ebdf2aa61528c8e05_D20181201-20181231" decimals="-5" name="ino:CollaborativeAgreementMilestonePaymentRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzMzg4_c4e9bb63-3556-4361-98bd-ad12bc48fed1"><ix:nonFraction unitRef="usd" contextRef="i4218b3818f30409db7b03360c59d6a05_D20190301-20190331" decimals="-5" name="ino:CollaborativeAgreementMilestonePaymentRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzMzg4_d4421412-e468-4870-b56a-c649bec0bcc1">2.0</ix:nonFraction></ix:nonFraction> million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, AstraZeneca provided notice to the Company to terminate the INO-3112 / MEDI0457 development program under the agreement. As a result of the termination, the agreement has been terminated in its entirety and the Company has no further obligations under the collaboration.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5cdf0aef3e854f3b9ba6c6bc7a981259" continuedAt="i48373c1ae74041ca93b302867e11dafb"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ie60c9823b100427ba62081e1ce28130e_D20180411-20180411" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0MjU5_1dfd83b2-3c8c-423b-9e6f-4b83b982d854">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="ie60c9823b100427ba62081e1ce28130e_D20180411-20180411" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5Njc3_4d1b59a6-9525-490e-81c6-229dfd9324de">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2021 and 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="ied6f8e470b114624a1428d5fe05d2883_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0NTY0_b8158c74-c32e-4995-9be2-787817f4d6c1">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibeaaf2a45e274b08822dc97c5f1d6548_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0NTcx_3c8105f2-0d4a-4fa2-8f64-2e66d13192a0">6.4</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2021, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i627a7ce3c55f4c9bac1b8724c31a2b9a_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMzMDc2MjU_36724f9e-eaf8-4b8b-979e-a67ea2cd4af6">1.9</ix:nonFraction>&#160;million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded $<ix:nonFraction unitRef="usd" contextRef="i48b9f355c6d44067b5c91a145b75b3d8_I20211231" decimals="-3" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0Nzc0_3753e7df-e308-44ad-8d0a-788e924d0c0f">23,000</ix:nonFraction> as deferred grant funding on the consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="ia3fab37e71394ac2af69e86ac41d336a_D20200101-20200131" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0OTQy_5d4a4b22-68f7-4e55-b5a0-8ff104e72de1">9.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="icad38c575aa2469a960d1b3021807208_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1MjQ0_f8c35673-f6f3-40ea-b5b4-75cd305734d1">6.9</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i5b1057c5132f4610b04adc365c092be4_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1NDIy_bb8a76fd-1334-4f55-b6eb-4bf8a5404722">5.0</ix:nonFraction>&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="i02735771448f4559ad8ad7eb771f42a0_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1NjA0_dee53dc6-c263-4830-83c7-e202fb96e807">1.3</ix:nonFraction>&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i33e5d35d7de44a078dff01c3cfa43227_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1NzE1_ae10e39c-e30e-4d64-b925-81ed49bd09f0">6.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia081c81a473a4f3399c27e4703bbc7ed_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTYxNzk_ae06ecec-2fcb-4773-b216-cf87d67f0f3f">10.0</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2021 the Company had $<ix:nonFraction unitRef="usd" contextRef="ibd977534e815463fb781c4067853b53b_I20211231" decimals="-5" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1ODYw_37fbeb9f-70dd-464a-9ab8-093e169d7b5b">1.8</ix:nonFraction>&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i781f7721feee4c4ca2ff6d186fcffbf3_D20181001-20181031" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2MTE3_37d61536-3715-4654-8a83-9d69be559d3a">2.2</ix:nonFraction>&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="i5fde4b781ebe4327bf969f8140d88ecf_D20190801-20190830" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2NDgw_36f9e910-d297-491a-8d14-de40db009e75">1.1</ix:nonFraction>&#160;million for the project. During the years ended December&#160;31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="iac1e6c89e8ca49e9b134471c2d4cd4c3_D20210101-20211231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2NTU1_14488677-7359-4dfd-a162-9ae2bedf0f78">182,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie34b4d8f0d4e4a1d973ed63d51a51649_D20200101-20201231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2NTYy_71e075f6-8b6c-4590-9f18-e8eac549e7eb">463,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i3bbf0edc36f446378983dc8302caa4d9_I20211231" decimals="-3" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2Njgy_44fcb3cb-c613-467a-964d-5cd067899f3c">384,000</ix:nonFraction> recorded as deferred grant funding on the consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="ibd0b58a07e594872a449c2f8a64d1f50_D20200301-20200331" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2ODM5_f9283892-4b2e-4909-af70-28f986c5933d">5.0</ix:nonFraction>&#160;million to accelerate the development of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the years ended December&#160;31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="iabd3cbd20ab142cca107c1f4cf711e83_D20210101-20211231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2OTkx_2aa71a90-c53d-40a9-9d0a-4f8dc1f5d142">893,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i00eb7864be0441e898f5a5f77d203ff1_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTYxOTg_0686e9ec-fb99-4088-b83e-d7fd3dd245d0">4.1</ix:nonFraction> million, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is $<ix:nonFraction unitRef="usd" contextRef="i8f4af1a162cd4deda134bce933897a10_D20200601-20200630" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE4MDc2_3d662c5e-6bec-47f6-a178-932b001daef6">54.5</ix:nonFraction>&#160;million. The Company has determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company will record contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s later-stage clinical trials. The total purchase price under the Procurement Contract is expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="i67b7af31bd224297994ebe728b26c780_D20210101-20211231" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE4OTI5_5f4fa659-5006-46a4-9e75-a3eb852dbb60">10.7</ix:nonFraction>&#160;million. As of December 31, 2021, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company determined that the Procurement Contract falls under the scope of ASC Topic 606 as the contract is with a customer and the Company is able to satisfy its obligations under the arrangement as the Phase 3 clinical trials of INO-4800 are underway. Performance obligations under the Procurement Contract consist of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. The Company will recognize revenue on the consolidated statement of operations upon shipment of the purchased devices and accessories. During the year ended December 31, 2021, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i5575e68486ee4cd5b43dde605b161a50_I20211231" decimals="-3" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEwOTk1MTE2NzMyNDE_a63c53e3-e7bb-4f49-b467-a45fd9a2dfda">755,000</ix:nonFraction> from the Procurement Contract. This revenue was recognized at a 100% margin as the sale was for products whose related inventory had previously been written down to zero. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i48373c1ae74041ca93b302867e11dafb"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i128585ac13474b3091b72cd864723b37_D20210101-20211231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5MjMy_9e14a040-a7c0-4f31-82a2-ee92abd06db2">27.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i00e2d517b98c4e12bb4ac8e2131fe365_D20200101-20201231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTYyNTk_f155ab69-dedb-4d6e-bbe2-00148171fbdc">21.2</ix:nonFraction> million, respectively, as contra-research and development expense related to the OTA agreement. As of December&#160;31, 2021, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i5575e68486ee4cd5b43dde605b161a50_I20211231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5Mzgw_bc22231a-a111-437f-912e-5625478329a6">3.6</ix:nonFraction>&#160;million on the consolidated balance sheet from the DoD. As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i5575e68486ee4cd5b43dde605b161a50_I20211231" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTY5ODk_f8b901de-5d87-40e3-8f49-636aa5dafab6">2.3</ix:nonFraction>&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the Procurement Contract.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing funding under the OTA Agreement and Procurement Contract.</span></div></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzMyMzk_49a482e0-a9e3-421a-baed-b7d5204124fc" continuedAt="i2eb8cfc5061e4990b9ef4f63d81fd64b" escape="true"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzMyMzk_ada5e68a-5374-4ff7-b712-17ed43bfc6bc" continuedAt="if88e3496bfca4238bda258cced9716c8" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i2eb8cfc5061e4990b9ef4f63d81fd64b" continuedAt="ie24894cc50454e51a08e43cb2763bc1f"><ix:continuation id="if88e3496bfca4238bda258cced9716c8" continuedAt="i8b5a7d8f7e3e4fa4ada0c86d59a67ef3"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzMyNDA_e9805e06-8c84-497d-9e04-c749a07871e9" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItMy0xLTEtMTMwNzk_22c096fb-c27d-4a37-8a60-376d367b5fd5">192,966,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItNS0xLTEtMTMwNzk_c6b8172e-4944-4b55-8453-bc2b5329064a">87,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItNy0xLTEtMTMwNzk_ea639ddc-f190-4501-93e7-b8a59f07f669">1,614,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItOS0xLTEtMTMwNzk_99d98af1-d335-4301-b153-1e8ba94190f8">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i1cf6fb5f859b42d78d7c7a430a42ff42_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtMS0xLTEtMTQ0MjEvdGV4dHJlZ2lvbjoxNzUzZGVjNTZiMTM0OWU5YjViMDA2MTk0MzQ5ZjA0ZV8yMTk5MDIzMjU1NTY5_4f05100b-30db-45bd-a568-e7de6fd22bd6">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtMy0xLTEtMTMwNzk_5eef9dd4-9ac9-413d-8c20-4147b938bf37">94,193,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtNS0xLTEtMTMwNzk_0c297190-a186-405a-91e5-e480befc7041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtNy0xLTEtMTMwNzk_9ccf5b12-0154-4e95-b0f3-be87d68aebb8">9,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtOS0xLTEtMTMwNzk_db5beef1-12a9-44c3-a41b-e072029bd8db">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="ib71562a57439406ab96e0f74edd9d947_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMS0xLTEtMjEwMzgvdGV4dHJlZ2lvbjpiMWI2YTZlMTdhNWQ0ZGRhODllMDg1YzNiNjJiNzVmNl8yMTk5MDIzMjU1NTY4_d3d7a7da-b0f5-4b02-9925-c7b173a8d610">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMy0xLTEtMjEwNTY_8aefa954-22db-4c26-8c28-037cb3e7f8ba">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNS0xLTEtMjEwNTY_b57ed0a6-b09f-48da-b74c-d10170f80f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNy0xLTEtMjEwNTY_6a3e1edc-490d-45ed-92a3-643e75ec0d4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtOS0xLTEtMjEwNTY_1214ab3c-3bfe-4cd4-919c-84d1529491fb">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i9327b185da7843ef8a8df8e03d20d44f_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMS0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpmY2RhOWYxOTYxNGY0OGNiYWYxYjg5ZmIzZGEzYTViMV8xNA_8e9abac0-f6b3-4e83-8887-19f57a94ecf4">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMy0xLTEtMTMwNzk_f0fbb64b-ab43-42fb-b303-48cbd6e3ee86">2,976,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNS0xLTEtMTMwNzk_403abf6e-f2d7-4df0-84aa-a23aba237b83">15,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNy0xLTEtMTMwNzk_8e394e1b-2ef1-4124-b578-bb690a217541">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtOS0xLTEtMTMwNzk_9b04321a-b376-49c9-9355-cdd5c451a79d">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtMy0xLTEtMTMwNzk_8e94a22d-c443-4a5f-b04e-d1151422b030">1,608,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtNS0xLTEtMTMwNzk_02f456ae-8f70-4d47-b721-f19dcb49961d">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtNy0xLTEtMTMwNzk_9227c655-6e1c-4cfa-a8c6-22c2584d3d5e">23,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtOS0xLTEtMTMwNzk_0c8c2d60-444f-4818-80fd-f987bf5bfb79">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctMy0xLTEtMTMwNzk_5b7f4baf-c725-4408-8da7-5f37d8ffce22">331,712,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctNS0xLTEtMTMwNzk_4be614f5-d7a0-4efc-a061-d8f3b4bea3ad">107,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctNy0xLTEtMTMwNzk_ed09db07-b51d-4e59-882c-425e8391dd11">1,648,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctOS0xLTEtMTMwNzk_0a282cfc-5a03-43a5-ae6d-7313e3c0599e">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b0d42be39843d9b1022921606edc04_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItMy0xLTEtMTMwNzk_1d4ecdce-6c52-48ef-9792-8c8ec28053b3">153,177,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b0d42be39843d9b1022921606edc04_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItNS0xLTEtMTMwNzk_69d1735a-60ad-463b-899c-f96440f2816a">2,339,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26b0d42be39843d9b1022921606edc04_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItNy0xLTEtMTMwNzk_d3008646-e34a-421e-8ff3-641b0864e078">644,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b0d42be39843d9b1022921606edc04_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItOS0xLTEtMTMwNzk_887bf890-965b-4e35-81d2-ad5282e5e8d5">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="ia7ac4c61823a437d8c9b6aee26cf229b_D20200101-20201231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtMS0xLTEtMTQ0NTYvdGV4dHJlZ2lvbjpmODRiODk5YmE5YzE0NzBiYjU4YTE1MjBhYmFhMDI1Y18yMTk5MDIzMjU1NTY4_278b5694-bf0d-46a1-95e7-98179733a5cd">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtMy0xLTEtMTMwNzk_c0aec5f3-0581-430e-9660-aa6abd652f67">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtNS0xLTEtMTMwNzk_b119a676-f5aa-4a91-88bb-09b297c7f50d">26,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtNy0xLTEtMTMwNzk_0647a403-b8b6-499d-b113-ebfb2570c4a3">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtOS0xLTEtMTMwNzk_622eb6da-52b8-4f2e-80b4-d18ac891405b">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtMy0xLTEtMTMwNzk_00dae82f-dceb-4b67-afad-991759e816b2">3,062,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtNS0xLTEtMTMwNzk_8fd46d23-7663-4cac-ae40-dea864b50f99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtNy0xLTEtMTMwNzk_2ed77ae1-7f3f-4635-88fb-6ab95c5921ea">36,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtOS0xLTEtMTMwNzk_b9fc197d-bc5d-4263-a1e0-47e39ccaffc2">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtMy0xLTEtMTMwNzk_d81fc691-feea-4199-a85c-c09576709098">159,239,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtNS0xLTEtMTMwNzk_e0a8b1e3-3fce-4ef7-af88-e56f1a5c0565">2,365,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtNy0xLTEtMTMwNzk_0e0ac4d7-5e2d-408d-aaf7-f554c54956d3">690,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtOS0xLTEtMTMwNzk_66327fbc-7c4f-4433-82b6-19d2c3a3d2ed">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4MDM_3a60c75b-58da-4ba9-a4f5-a4e1e64970df">394,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4MTE_a90a1715-b99b-4c1e-ab02-75e9659233f0">744,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4NzI_6d207f66-aed8-46d4-b042-4a993a41ece3">399,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4ODA_16996408-9b87-43aa-8001-70eb283a67c1">1.3</ix:nonFraction> million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzUwMjY_2de8dc3a-3d90-4ff7-afe8-2db95f0ac1b8">3.2</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzUwMzQ_fd41f0fc-6ae2-4f85-ae3e-0aa211ea1874">1.7</ix:nonFraction>&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2021,&#160;2020&#160;and&#160;2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2021, the Company had&#160;<ix:nonFraction unitRef="investment" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzUzNTk_3e3fbb8f-f042-4aca-ab74-bed6826ab83a">24</ix:nonFraction>&#160;available-for-sale securities in a gross unrealized loss position, of which <ix:nonFraction unitRef="investment" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzU0Mzk_160f0a11-4867-4445-85be-f89807355310">six</ix:nonFraction> with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzU0ODY_5cbabea5-605c-4ceb-9b5d-0c78e1daa50e">766,000</ix:nonFraction> were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2021&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie24894cc50454e51a08e43cb2763bc1f" continuedAt="i54795ab047c9458a87b83ded7680c0dd"><ix:continuation id="i8b5a7d8f7e3e4fa4ada0c86d59a67ef3" continuedAt="i02c152e113a44726b24f537a8fed6097"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzQzOTgwNDY1MjI0NzE_69150305-2cb8-4649-85a3-6137550039d9" escape="true"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7071211447db4c3e8f228036ebc64654_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtMS0xLTEtMjY0NDM_ed57dcf4-653d-4577-9dcf-43dc27e3d560">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26fd2f2ca1804cf8b78f9f97fc906ec9_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtMy0xLTEtMjY0NDM_9e48ed02-36ad-4519-af46-6778ad8c4256">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6f0020516c4a6497376d5f1359cbd7_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtNS0xLTEtMjY0NDM_7320099f-591c-43a9-bcf6-ed6f224f2b03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39b5179785c4f0d952c95c50da89619_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtNy0xLTEtMjY0NDM_1a9bf46c-4d67-4a50-833b-9488755df9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3f9b2236a74d2da2c502071722bc13_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktMS0xLTEtMjY0NDM_97dbde06-c403-4493-88e1-a479d64e0fcb">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15cdf0125f0d414b83d3aa528c069939_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktMy0xLTEtMjY0NDM_10f78a58-eb94-44cf-a40d-bb87ae6000bc">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c910afcfe76477c8adf69b6afc36738_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktNS0xLTEtMjY0NDM_773b416c-9374-4005-b7f9-df179c7abfab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb11ec937978481798d9a2fa621b2545_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktNy0xLTEtMjY0NDM_01f5acef-4564-4000-b00a-5136a066d18b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674ddfb5b1174eab854007ba42538368_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTEtMS0xLTI2NDQz_ea4702d2-35aa-459a-bd76-fa7af7761ac4">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b606f8ce6104231abbb11b014a54bb0_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTMtMS0xLTI2NDQz_24a75e21-564a-4b8e-89d5-094e1e42c6e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7104e94d6b6402b8ad5ba5ea9a6dcf3_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTUtMS0xLTI2NDQz_73650aaa-a23e-42bf-adfb-bd31e349aa7e">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78b7886eb8f4368bd3e159d7be11563_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTctMS0xLTI2NDQz_2e0716af-79b4-425b-8649-313f08edb41b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c4fc55ad384a2d90e87c0e989d38c7_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTEtMS0xLTI2NDQz_19b68bc9-4d95-45f4-b1df-d81100f7f6cd">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1effe86d89143f3aded22e7fd8fd339_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTMtMS0xLTI2NDQz_9fd04ce0-e8f3-44e8-80db-419db3ac0f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4c0a4f24f64339938c89d15957c736_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTUtMS0xLTI2NDQz_05f24d07-72d8-43ed-932f-5c2e92592517">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1245efc94094f599b7d7d3c818aa250_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTctMS0xLTI2NDQz_cb179263-e049-4e90-bc15-a19b56ada8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0a0b420ecc4a6b936201d1941936bc_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTEtMS0xLTI2NDQz_cf23ac42-f340-4704-816e-f904ff0fa66e">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d04338821da4044877e4bf707d5526b_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTMtMS0xLTI2NDQz_d5744f74-7ae7-4a31-ab5a-b7b527ef66c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2231094e244b4b8f8d798ed1d5a673_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTUtMS0xLTI2NDQz_0838b938-eb71-44ac-bb5c-5678ac44e564">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b914f5f74342a2862d941121e5a48f_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTctMS0xLTI2NDQz_f5b6077c-a1aa-422b-ba14-12926ae40124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395742f3d6cc49d3b3f55b2c752865d7_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTEtMS0xLTI4MzY3_6ddb7d63-5c98-4213-874e-47978d4f0f27">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d61d6b3e5354708ac4bab1f051af74a_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTMtMS0xLTI4MzY3_962e0f84-2639-4dad-bb69-25bee9a5f421">285,622,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTUtMS0xLTI4MzY3_426c58ba-71fb-4fe5-b54b-78aef4700e0f">44,547,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6d60d841db49b884995b9d409a2699_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTctMS0xLTI4MzY3_d73091e9-57a7-4f0d-a986-92ac0b445483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395742f3d6cc49d3b3f55b2c752865d7_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTEtMS0xLTI2NDQz_a10e1b28-17b7-4483-98f7-f4da3cdcf59a">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d61d6b3e5354708ac4bab1f051af74a_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTMtMS0xLTI2NDQz_9900077a-8a15-45af-baaa-bcab4f1c77df">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTUtMS0xLTI2NDQz_87251b66-70b3-41ed-aa41-e4b55ae5870f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6d60d841db49b884995b9d409a2699_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTctMS0xLTI2NDQz_0b3b78c0-4930-4a7c-854c-977b3b1e73ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395742f3d6cc49d3b3f55b2c752865d7_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTEtMS0xLTI4Mzcw_0c68aa39-0d35-4fec-b2a0-b48c6a1dd7ee">334,077,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d61d6b3e5354708ac4bab1f051af74a_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTMtMS0xLTI4Mzcw_639bada9-be77-45b5-ba84-692180b674ec">289,529,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTUtMS0xLTI4Mzcw_b49213ec-370c-4e25-80a2-c1dea5c02f12">44,547,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6d60d841db49b884995b9d409a2699_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTctMS0xLTI4Mzcw_a1facdf3-4594-4540-9be0-529eacfe75d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fcbe29e328435f900b5cf60bf4ffb7_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtMS0xLTEtMjY0NDM_4a6ba160-ffc9-41a0-a306-2319a97fe45d">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9693506cef01463bb3c7d6635695bba9_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtMy0xLTEtMjY0NDM_33811db0-6aeb-4622-ae07-d5c74c067deb">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32393fe851fd43879b59a162035f2f85_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtNS0xLTEtMjY0NDM_2b7122ba-c9b5-416c-8bc7-d56d74fc45c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56064b8e76fe40919fd24d219d24a453_I20201231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtNy0xLTEtMjY0NDM_73c53bbc-cd18-4a03-ad23-17fe4fa2e83b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8277afd2efb5453b93534cade2d9ce8f_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktMS0xLTEtMjY0NDM_981e5dde-d75f-4ddc-8b7c-3fe7a77dbf1c">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c766e601044c378ac2db7f87cde480_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktMy0xLTEtMjY0NDM_8bae5836-0adb-4498-b565-cd7f3148b702">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922af379e03e4956a28c8f5c205b7dc3_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktNS0xLTEtMjY0NDM_4f4b34a7-5426-435e-8b95-27e598a90985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ca8c127c9f48b3b63c86430c68e46d_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktNy0xLTEtMjY0NDM_15716418-dbec-4d84-80ce-9fc93eb4b2c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c565cc3c44415ead62595cf93e70f8_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTEtMS0xLTI2NDQz_85786d8f-e77b-4a48-b409-86f675efb3f2">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32dc71cb0364baaaed730794f9f6ac8_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTMtMS0xLTI2NDQz_a12855e8-cd52-4dfd-a818-01317c321b1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1784296ad78e4c20af0d84835cef9888_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTUtMS0xLTI2NDQz_e9d028b4-07e2-4cde-8c40-2310f2f26cc8">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7877ab15bcd4dac8a499d3c7b9e7072_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTctMS0xLTI2NDQz_de3409af-6c84-48a2-a727-a796a0c794b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a0e2b2399a434d9a99f30233dc02a7_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTEtMS0xLTI2NDQz_db0773ab-444b-4831-b8cf-e9d6f0a6bb03">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b384928838488791c262caec9215b6_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTMtMS0xLTI2NDQz_c540cd82-7f21-477c-9f8e-19e6c4c73561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab11fde10c2c4d87b33e70d030ae1653_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTUtMS0xLTI2NDQz_905487c0-a91b-444f-b75a-889d4ed578c1">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4fbe1fd8cc41b6947d447b6a6c741d_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTctMS0xLTI2NDQz_889949d8-5cbb-4c18-8128-f6720a294773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d84e84f3c84c92a7c4176575b1dc22_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTEtMS0xLTI4Mzcy_ac5094bd-6d11-42bf-998b-16647f465ae3">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd535af4c12849f0934bcc1b955d369d_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTMtMS0xLTI4Mzcy_e0124925-a86c-419b-be3f-6b5b6e5f3f45">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTUtMS0xLTI4Mzcy_2872024b-da6f-48e0-984b-a4104fe9d3d6">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTctMS0xLTI4Mzcy_013148d9-b5cd-4555-aaf6-54ffe43825c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d84e84f3c84c92a7c4176575b1dc22_I20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTEtMS0xLTI2NDQz_c9cd05ee-7b29-4f47-aa08-95d658d4d975">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd535af4c12849f0934bcc1b955d369d_I20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTMtMS0xLTI2NDQz_f2c0244c-a7e1-4170-ac18-b3c8641dca49">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTUtMS0xLTI2NDQz_a3eb107d-d612-40bc-8fcb-d27583a3e0c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTctMS0xLTI2NDQz_d8e567ba-6b7d-4822-8d47-c6a035b32b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d84e84f3c84c92a7c4176575b1dc22_I20201231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTEtMS0xLTI2NDQz_ae5e45b0-67a1-4bd8-ac9b-8cd07b431f81">225,372,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd535af4c12849f0934bcc1b955d369d_I20201231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTMtMS0xLTI2NDQz_d85fbb55-4400-4780-b97d-bf2755dc06d6">219,330,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTUtMS0xLTI2NDQz_5f3261dc-e0d4-4bb0-969f-087e478f5e82">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTctMS0xLTI2NDQz_15073870-3502-4acd-92bb-f13abc3a6105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2021 and 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="i28c32f98e31846aaa2d17068ee0b3b77_I20211231" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzI3NDg3NzkwODA2NzQ_9de0807b-2625-4f8b-b587-883db5749fc1">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain (loss) on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i54795ab047c9458a87b83ded7680c0dd" continuedAt="i5a0cfbd6cbb04850a262ad094b30d62b"><ix:continuation id="i02c152e113a44726b24f537a8fed6097" continuedAt="ic331f09fc54542f59d3e94a9c14ffa4f">professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</ix:continuation></ix:continuation></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5a0cfbd6cbb04850a262ad094b30d62b"><ix:continuation id="ic331f09fc54542f59d3e94a9c14ffa4f">There were no Level 3 assets held as of December&#160;31, 2021 and 2020.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzM3MQ_9cb739d5-b1ac-4132-85cb-011bf8ecafbf" continuedAt="i204f523cc3b44e02bae9b1e753404a86" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="i204f523cc3b44e02bae9b1e753404a86"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzM3Mg_4c35695b-ac2f-4344-ae9c-93fa6ddd1104" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzEtMS0xLTEtMTMwNzk_55010250-253b-49ed-979c-bf35fbe4cf5f">27,474,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzEtMy0xLTEtMTMwNzk_0f72db92-8d3c-4d0f-b9e3-a0b9e9092be7">35,661,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzItMS0xLTEtMTMwNzk_73846afc-0488-4152-8faf-d77396f869a1">11,362,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzItMy0xLTEtMTMwNzk_99f1cf6b-5575-4d0c-86e8-10b0b9ba7b18">4,695,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzQtMS0xLTEtMTMwNzk_2f82ac6a-0191-4ee6-b3b8-0b07bc4be1f3">38,836,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzQtMy0xLTEtMTMwNzk_646c35fe-73e9-45ff-8c00-848388c809b7">40,357,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.08pt">Includes prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacture of INO-4800. The Company deposited a total of $<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-5" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzEwOTk1MTE2MzExMjQ_5e1b13d4-4c28-4fc3-acce-2ce405dae279">50.0</ix:nonFraction>&#160;million to reserve manufacturing capacity, of which $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzEwOTk1MTE2Mjk5MzQ_6c076d54-a091-4ad4-8f99-e5d9d65ac180">30.0</ix:nonFraction>&#160;million was paid in 2020 and the remainder paid in the first quarter of 2021. Of these deposits, $<ix:nonFraction unitRef="usd" contextRef="i94ab88df768e4ba68e5d2e3d4e747e2b_D20211201-20211231" decimals="-5" name="ino:DepositAssetsForfeited" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzQ5NDc4MDIzMjc1MzM_48d27062-8b13-48b9-af31-0bab286633b6">35.0</ix:nonFraction>&#160;million was included in research and development expenses in December 2021.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:-18pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQ1Nw_fe316870-fbd6-4102-bb8b-79b41636f1fc" continuedAt="i9614488905c8470094a5bd06cf8463cd" escape="true">Fixed Assets</ix:nonNumeric></span></div><ix:continuation id="i9614488905c8470094a5bd06cf8463cd"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQ2Mw_5b57664c-f5a6-437d-81bd-e41206451d38" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d4ecd562014440beb00576acad3efd_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzItMS0xLTEtMTMwNzk_95e3c386-5e9b-47e3-b64e-7da1c0dba5a5">15,803,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69d4ecd562014440beb00576acad3efd_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzItMy0xLTEtMTMwNzk_de700004-1690-4328-bc30-3369130ca5b7">8,258,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d4ecd562014440beb00576acad3efd_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzItNS0xLTEtMTMwNzk_5ed03fc8-716e-485c-ade3-d7474579966e">7,544,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzQtMS0xLTEtMTMwNzk_5b759a0e-98ea-423f-857b-65240679cce7">12,392,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzQtMy0xLTEtMTMwNzk_7f486515-cd31-4e94-972b-78457f824668">4,279,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzQtNS0xLTEtMTMwNzk_087c1995-e50b-4acc-91c8-78e00f90a706">8,113,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb6a32bee874e46833ded3ae075b6b5_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzUtMS0xLTEtMTMwNzk_8a77f056-f21a-4e4e-a0fd-067e340cb2d1">2,827,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eb6a32bee874e46833ded3ae075b6b5_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzUtMy0xLTEtMTMwNzk_fee39e7a-9d5c-456f-a8da-b2c38a502a35">2,599,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb6a32bee874e46833ded3ae075b6b5_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzUtNS0xLTEtMTMwNzk_ec2e46f2-6536-44db-81d9-ff51effe0bef">227,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea32134d65f94c16977562bd8ec30416_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzYtMS0xLTEtMTMwNzk_039500b2-8bec-42e1-ba52-1a34c06affc6">5,374,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea32134d65f94c16977562bd8ec30416_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzYtMy0xLTEtMTMwNzk_3bf8bf49-d681-4800-8869-d15c6c5c9c50">3,806,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea32134d65f94c16977562bd8ec30416_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzYtNS0xLTEtMTMwNzk_ad026efe-114f-4d84-bb06-8a64e018812c">1,567,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzctMS0xLTEtMTMwNzk_5f346ebe-e68f-4552-abbb-e19ba9358b03">36,397,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzctMy0xLTEtMTMwNzk_0523d4d3-5014-4ab8-9c30-c09b0744a9f2">18,944,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzctNS0xLTEtMTMwNzk_b6ab3559-0ac0-4446-8c6b-d70dc17060b8">17,453,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5e0d4976d341d89e231839c5c36c4d_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzktMS0xLTEtMTMwNzk_50e4dc82-17d5-4a2f-918d-fe7cf643777d">15,179,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f5e0d4976d341d89e231839c5c36c4d_I20201231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzktMy0xLTEtMTMwNzk_cc433ed1-8a1f-4ae3-a8c2-b43784e9745a">6,549,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5e0d4976d341d89e231839c5c36c4d_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzktNS0xLTEtMTMwNzk_ba20efac-3787-4dcd-8950-3bdc96495292">8,630,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEwLTEtMS0xLTEzMDc5_28afdd82-0bc5-416a-8925-ac4bd31186e3">4,788,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEwLTMtMS0xLTEzMDc5_fe230eee-3167-4c19-952c-c07603259b47">3,727,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEwLTUtMS0xLTEzMDc5_e39735b4-3bfa-4ad3-823a-404c50ecd5ad">1,061,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzExLTEtMS0xLTEzMDc5_6d202e65-b6ec-431a-9d51-cecb36b027d4">2,828,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzExLTMtMS0xLTEzMDc5_155b32aa-a355-46c0-a8d9-cc319c49ef8c">2,296,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzExLTUtMS0xLTEzMDc5_b11c15bc-45b1-4c6b-b783-87f7cf3bff79">531,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb3ced61044408997e1d8f8a05e001_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEyLTEtMS0xLTEzMDc5_6d5065de-87a6-4462-ab1a-a8ca73d85a28">4,544,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eeb3ced61044408997e1d8f8a05e001_I20201231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEyLTMtMS0xLTEzMDc5_9ff8a44e-33ef-491a-9a77-64ad75fc7b7d">3,419,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb3ced61044408997e1d8f8a05e001_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEyLTUtMS0xLTEzMDc5_1f675b98-031c-416a-9124-1b89fff26835">1,125,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEzLTEtMS0xLTEzMDc5_b3ad0d8c-4331-4f70-b5f3-c107c9264518">27,341,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEzLTMtMS0xLTEzMDc5_94c6e109-bda7-4ad3-a426-6b8b08ce31e7">15,993,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEzLTUtMS0xLTEzMDc5_89384e92-da37-4d88-8cc2-e88faa04cf3d">11,348,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzE2Ng_b30de149-4090-4cdf-b67a-9189c69dd342">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzE3MA_346819e6-34b2-4673-838d-1743a8c09caa">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzE3Nw_36d5f0dd-6053-4b59-bb54-0ef359412384">3.6</ix:nonFraction> million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2021 the Company disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQxNw_5b823165-2585-4e43-b487-12a8d9d638ce">89,000</ix:nonFraction> and accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQ1Mg_cb536194-44c3-4f5b-8b8b-e0449b9fca63">89,000</ix:nonFraction>.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzgyNA_b88493a5-52ef-48e5-b0ce-75749f88cb44" continuedAt="id63a5cbb1e734e8eb9f66b99afd44180" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="id63a5cbb1e734e8eb9f66b99afd44180" continuedAt="i92bb40a30ac4458294fc61fb887bc957"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzgxMg_b472547b-5920-4c5d-99b6-0e26636291da" continuedAt="i8c31e1c64c4f4a45a6ddcdc3a518e8ca" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i92bb40a30ac4458294fc61fb887bc957"><ix:continuation id="i8c31e1c64c4f4a45a6ddcdc3a518e8ca"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtMy0xLTEtMTMwNzk_30aa7e60-3047-4a78-8c76-affeb19bfe0c">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtNy0xLTEtMTMwNzk_e2ebc632-103c-433b-bee9-905f96b4765e">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtOS0xLTEtMTMwNzk_0ed70626-51ad-4dc6-8a10-03a241a09004">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtMTMtMS0xLTEzMDc5_a7c9ea14-fcbf-44ca-81a2-3c96296acaf9">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a39711823f44fd6ac0aae903ff997dd_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMS0xLTEtMTMwNzk_ca8450e4-7937-4af8-92eb-68ca8bfdc797">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45f7a28571f47f4bd640ad228eaafca_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMy0xLTEtMTMwNzk_76066c32-ca0a-49e3-b9c8-53a96488990e">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id45f7a28571f47f4bd640ad228eaafca_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtNS0xLTEtMTMwNzk_df5b72b3-a059-42a2-9faa-daa495a37a68">1,305,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id45f7a28571f47f4bd640ad228eaafca_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtNy0xLTEtMTMwNzk_fc813871-dec3-4b4c-b5ce-f1a6b6980e01">18,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0adccf4f6d64811a0e0d98da2637677_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtOS0xLTEtMTMwNzk_09ab2bf7-b3e2-4331-ae9a-d88f0652712b">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0adccf4f6d64811a0e0d98da2637677_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMTEtMS0xLTEzMDc5_a675d4c8-648d-4a1a-bd14-63faaf9ecb43">1,276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0adccf4f6d64811a0e0d98da2637677_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMTMtMS0xLTEzMDc5_73448bc4-f443-4040-9629-e412dcce7711">46,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8bfadc7f8c124e2897d43453679cc488_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMS0xLTEtMTMwNzk_6c6fd9f8-11d7-4e1b-9410-579a3f71a263">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147d28db95ca40d8a9e71dd47520fcf3_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMy0xLTEtMTMwNzk_a32b16d2-8b67-4759-96b4-a5bf955f4316">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i147d28db95ca40d8a9e71dd47520fcf3_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktNS0xLTEtMTMwNzk_b6cca15e-1ab9-44f4-9596-65559c2c71d2">2,735,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147d28db95ca40d8a9e71dd47520fcf3_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktNy0xLTEtMTMwNzk_fd48613e-91b7-4a5e-a849-3390845d4927">2,364,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e398f1b0e24f15973a8336cc567723_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktOS0xLTEtMTMwNzk_49bfb9cb-ab07-4b16-9f59-2639d6cb4c6e">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1e398f1b0e24f15973a8336cc567723_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMTEtMS0xLTEzMDc5_5377efb2-3cc9-4c3e-90fa-2bbe7d3454e5">2,468,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e398f1b0e24f15973a8336cc567723_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMTMtMS0xLTEzMDc5_0c7550e7-cee1-468a-91c3-660bd37931e5">2,631,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0e15729cf93490bab53bb5b3743cc9c_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTEtMS0xLTEzMDc5_89d0a1b3-3094-40ff-80af-bfef326ac63a">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9792ca724094babb1ceaaaf9e7f9699_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTMtMS0xLTEzMDc5_997bf197-faae-494f-b115-edbc466a5b69">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9792ca724094babb1ceaaaf9e7f9699_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTUtMS0xLTEzMDc5_a6ac15f9-e05d-443a-988b-4ca3ad4ef64e">3,806,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9792ca724094babb1ceaaaf9e7f9699_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTctMS0xLTEzMDc5_a963246e-5e18-425f-9901-81765a327d91">243,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb405ddb59694654918b5c478e9d869e_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTktMS0xLTEzMDc5_420b7264-b5e9-41e5-b84f-36e4e64ce24c">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb405ddb59694654918b5c478e9d869e_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTExLTEtMS0xMzA3OQ_b9741829-082a-459d-9ec1-13cb547f1eb2">3,581,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb405ddb59694654918b5c478e9d869e_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTEzLTEtMS0xMzA3OQ_2bc563a4-94f9-4094-bd83-430a3ebed044">468,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7eef2a859d2a4a548cea3f9cc63a809a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTEtMS0xLTEzMDc5_28bffa47-15e6-49cc-8a53-3d90261bcb62">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTMtMS0xLTEzMDc5_e2cab8bb-fe32-43e8-87cc-df625451aa37">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTUtMS0xLTEzMDc5_622c2676-f76b-4df9-9c78-ea568b1a9eb8">7,847,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTctMS0xLTEzMDc5_16367834-03a0-498c-8913-b7045770ac27">2,626,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTktMS0xLTEzMDc5_5c7760c2-2c1c-4af8-aa66-ddedb2804145">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTExLTEtMS0xMzA3OQ_78e38041-573c-4082-8981-6f9810695418">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTEzLTEtMS0xMzA3OQ_42e0b1f5-0fae-40c8-8cf0-3c850aaa4b2d">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTMtMS0xLTEzMDc5_d69eade4-ec09-408c-804f-cf9739f7e3df">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTUtMS0xLTEzMDc5_74b76669-e70c-472f-857f-a74f097ef5b6">7,847,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTctMS0xLTEzMDc5_e5220564-0c07-4233-bc15-cce160e96c99">13,139,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTktMS0xLTEzMDc5_3e40abd7-ff84-4587-b59b-4fb8b1db6491">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTExLTEtMS0xMzA3OQ_859dab71-1ea2-4549-a422-d8051d1facbf">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTEzLTEtMS0xMzA3OQ_332a3ce9-c886-4e45-8be5-566387d8ed09">13,660,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzUwNw_0161cccf-1c66-4eb0-bd3d-4c00bec19744">520,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzUxMQ_1fecc8d8-cff9-493a-bb9c-f831c96c471e">547,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzUxOA_dbb5b499-0a6e-4c14-95ab-1091bc5a9a1f">1.1</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzgxNQ_91b21d59-3779-4804-ae8a-e26f6b1e559c" continuedAt="ia4104512ebd54315b0fe9bbfeafa5ad7" escape="true">Amortization expense related to intangible assets at December&#160;31, 2021 is expected to be incurred as follows: </ix:nonNumeric></span></div><ix:continuation id="ia4104512ebd54315b0fe9bbfeafa5ad7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzEtMS0xLTEtMTMwNzk_203a9854-f411-4401-b7b4-18cddce4ec1d">493,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzItMS0xLTEtMTMwNzk_63485340-f4dd-4136-bbe3-64e7ea711e3e">276,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzMtMS0xLTEtMTMwNzk_6993ce11-0f65-40d2-9d5b-ac844ff569b8">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzQtMS0xLTEtMTMwNzk_8d1b5cb6-f314-4feb-8f7a-c286780b0d8a">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzUtMS0xLTEtMTMwNzk_6e5684a4-0a56-4c99-afb3-1c7b33f9b48a">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzYtMS0xLTEtMTMwNzk_45d9a49c-bee9-411b-ab65-33e3559d972b">1,098,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzctMS0xLTEtMTMwNzk_fc0848bf-8f10-46b7-93f7-024168bfeda7">2,626,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzY4Mw_325ab6ea-04f6-48b2-9149-d5c77857fd9d"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzY4Mw_86b97708-9b29-4343-a9c4-64589c22bea8"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzY4Mw_b6dbaff1-ef31-4514-bea0-d24d93f2fee9">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment or impairment indicators present and <ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzczNA_051bb0c8-c948-4af3-94e8-7519b9000f21"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzczNA_2a36b0b1-4ca8-484a-a126-413ca44d3863"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzczNA_4cad2d8c-add9-4f3a-b2f8-39c006c7f1a4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> losses were recorded during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_163"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0ODgy_4b500148-d6a2-4dc3-b41e-f57b745494a7" continuedAt="i1212c8c1e5164cb395c04a2f47c9b548" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="i1212c8c1e5164cb395c04a2f47c9b548" continuedAt="i7542c955c06e45a7ba06cebbf5cdb417"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzEzOA_984e1351-3dff-4813-b298-b4c73e874446">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE3NQ_a273bccd-46cc-4f3e-8c87-b8632dbd878c">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i4c6e93100cda41698c2d90ac7b3add33_D20190219-20190228" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQyMQ_e489c0c7-dd78-461c-91f5-99528e282f43">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of <ix:nonFraction unitRef="number" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzYzMA_b8c9be79-4b74-404c-84ee-b39df687c73f">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0MzI_09da20cd-ac0d-4bcf-92b3-f0dcec02794c">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7542c955c06e45a7ba06cebbf5cdb417" continuedAt="i0d62fef60f9945419a6be13fca155f5b"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE3NDQ_8d2e6ed3-9eee-4469-97a6-65f81c9281f7">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE3OTU_742113df-a013-4ba7-91b3-4a6442cbe002">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE4NTE_7c2e0454-ca45-4b91-a9fe-27d7ed721144">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxMjI_23da3a48-592d-4e7b-b294-60bd84a27093">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $<ix:nonFraction unitRef="usd" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzI2NTE_860885b2-afb9-4030-8d66-cea9c58e23b6">78.5</ix:nonFraction> million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $<ix:nonFraction unitRef="usd" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzI5Njc_9b4df5ac-7c29-48a8-b2c1-90cd5ae80c8a">62.2</ix:nonFraction> million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $<ix:nonFraction unitRef="usd" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzMxNzk_5394fc86-f497-4e32-93d2-1008fe04d753">2.8</ix:nonFraction> million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzM4MzM_25844317-e21d-47ce-80a6-408bf3ceb10a">18.6</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is <ix:nonFraction unitRef="number" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQwNjM_3dd33c60-f41d-4165-aa04-5632b0d660b7">13.1</ix:nonFraction>%.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $<ix:nonFraction unitRef="usd" contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQxNTk_67192cf0-127d-4b31-8d22-8b4d9edee4c6">62.1</ix:nonFraction>&#160;million of principal amount of the Notes, which were settled into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQyMzY_d9539da7-3b9e-4174-a7fd-0f7db3811d33">11,535,660</ix:nonFraction> shares of the Company's common stock. The fair value of the Notes at the date of conversion was $<ix:nonFraction unitRef="usd" contextRef="ic34a66f65e034d328e08870d700f693e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzMzU_20f2876e-f0cc-4701-9c47-3b90a940b26a">43.7</ix:nonFraction>&#160;million compared to the carrying value of $<ix:nonFraction unitRef="usd" contextRef="ic34a66f65e034d328e08870d700f693e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzNzI_d6d4d647-bde7-4305-9633-c48ef4de10d8">52.5</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzOTE_9089f170-b431-4671-ae9d-8c7a513750f9">8.8</ix:nonFraction>&#160;million gain on extinguishment of debt. Thi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s gain was recorded in the consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0ODgw_3090278f-3217-4216-bc6d-dada7219899a" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzAtMS0xLTEtMTMwNzk_99b4c9fc-b56e-420b-9378-476c5937857e">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="0" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzEtMS0xLTEtMTMwNzk_fd6556de-8791-4753-bf52-9363b284f57f">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="0" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzItMS0xLTEtMTMwNzk_5579ed18-5b0b-4179-91d2-cf6e24cfe557">1,591,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="0" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzMtMS0xLTEtMTMwNzk_b471df06-c212-4c64-b518-b35cd2dcfd03">219,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="0" name="ino:DebtinstrumentAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzQtMS0xLTEtMTMwNzk_e556ec79-c9f3-4e35-9a2c-cdac6c020cce">355,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzUtMS0xLTEtMTMwNzk_0445704a-90e5-47d5-9315-8843ecace88e">14,959,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ3NjU_ac91f295-f0ca-4a4a-8c8e-78f42b84dd97">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ3NzI_bf4e0ad7-502e-4102-833d-2408ff56bcb9">6.9</ix:nonFraction>&#160;million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ4NDE_c1ff4c8b-d3e3-4095-916e-07ccdb0ec0de">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ4NDg_09bcaa69-8230-4fe0-a2b1-27c8b51fc662">4.1</ix:nonFraction>&#160;million, respectively, related to the contractual interest coupon. </span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzOTgwNDY1MzY1NTU_9dbbfab3-c3f7-44a4-b686-93cbc61a5712" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyODA5MzQ_cfc02137-82e3-402a-8d54-f8db60227456">6.5</ix:nonFraction>% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzMtMi0xLTEtMTQ5ODM_3b11bea6-6f8f-4c5a-910e-50ff5f39104b">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzQtMi0xLTEtMTQ5ODM_6eecb386-15b3-433e-8b36-dfdcde8c5697">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzUtMi0xLTEtMTQ5ODM_3b37cd25-9d03-403c-9f46-a5b9fedb5fce">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzctMi0xLTEtMTY5OTU_267cc760-6bdd-4ece-8e42-48755f5f1941">19,082,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzUwNjQ_80058217-6b02-4392-99ed-d8c8a04d2555">18</ix:nonFraction> billion Korean Won (KRW) (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzUwOTA_728cb357-630b-4df4-897b-52913502cc7f">15.0</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i51416fb82fda4188a3a2a2e3f710d077_D20190801-20190801" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzUzNDE_ccebdddd-d761-492e-ad97-61eb87c2a1e2">14.5</ix:nonFraction> million. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0d62fef60f9945419a6be13fca155f5b" continuedAt="i39ad98a8bde341f79a9f3b62b9082fee"><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzU0ODg_45916475-a32f-4995-996a-1c823c3a20a6">1.00</ix:nonFraction>% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020, the August 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i3478042f83d6449ead46d859f7d60ffe_D20200803-20200803" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzU3MTE_f86269a9-5543-4b2d-8463-10b5b44a2e4a">4,962,364</ix:nonFraction> shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="icd20ef4b33f94e01bf76d24ff90685b4_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzU5Mzg_c13e711d-032a-4b76-8193-afe6d87fe5c1">4.00</ix:nonFraction> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.69 shares per KRW1,000,000 in principal amount (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="iac8579f0882d4dc59ef160f7c64b5672_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzY0MDQ_2c177ca3-2ea7-4d6a-8281-738e6d52eca5">3.14</ix:nonFraction> per share). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzY4MzY_9b5cc53c-a72b-4b74-b5b1-24d6d8a0e7c2">7.1</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzc4NzM_af627c39-aa88-4cf9-bb4e-2f23e10deca0">7.3</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022. For the year ended December 31, 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i7ba0ea858d9c46c78c2859dc92d5033e_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzgwOTg_9639682a-c88d-4632-9390-ff7f5e68cd76">1.6</ix:nonFraction> million of interest expense related to the August 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i7ba0ea858d9c46c78c2859dc92d5033e_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzgxODY_11d344cc-d804-47ca-aa02-d02030dfaf11">87,000</ix:nonFraction> related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the August 2020 conversion in full of the August 2019 Bonds, the derivative liability associated with the August 2019 Bonds was revalued at $<ix:nonFraction unitRef="usd" contextRef="i0c5bcadd2c7245faa4cb1ac2870fd0ab_I20200831" decimals="-5" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzg0MTg_59fc2ced-15fa-4563-8eaa-da95c5a08b36">84.5</ix:nonFraction>&#160;million. The change in fair value of the derivative liability was an increase of $<ix:nonFraction unitRef="usd" contextRef="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831" decimals="-5" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzg0OTQ_5ba2c12a-c7da-4fcf-8890-f343db66a34c">75.7</ix:nonFraction>&#160;million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzg3NDA_95fcbd3e-4941-45a4-96d7-be2763b97ca5">8.2</ix:nonFraction>&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the <ix:nonFraction unitRef="shares" contextRef="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzkwNzg_898dfb82-3076-40ee-bb08-bc1c0229b501">4,692,364</ix:nonFraction> shares of the Company's common stock issued upon conversion.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i353adf10991e4196a4b209b6a5267e9c_I20191226" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzkzMzQ_4dff8101-5dfc-461f-ac4b-e22b31c8ebf2">4.7</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i353adf10991e4196a4b209b6a5267e9c_I20191226" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzkzNjA_d95a3820-1d70-44d5-af4d-9e5e7be529f8">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i6039cba34e8c4be6a904174d99de85a8_D20191226-20191226" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzk1MTM_b48fef62-98df-4f0f-b75f-094767985160">4.0</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrue interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i353adf10991e4196a4b209b6a5267e9c_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzk2NzA_0255f044-e0af-4eb9-b312-7b919c9f41bf">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzEwODQ_31847b40-4f81-4010-b9a3-1e3faa99fa41">1,009,450</ix:nonFraction> shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i5fceb3f6f682487baf3242c63275edbd_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzEwMzkx_c3bd2838-c7a2-4fd0-8332-a2d9969fd942">4.00</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature did not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature met the definition of a derivative, it qualified for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i39ad98a8bde341f79a9f3b62b9082fee"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the December 2019 Bonds was through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is <ix:nonFraction unitRef="number" contextRef="i23bc4609abe8422ca6b1d83a291a407a_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0MTYx_2b09c60c-9591-4022-a9a1-d9ecd9acd6d1">6.2</ix:nonFraction>%. For the years ended December&#160;31, 2021 and 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzg5OTU_2f1c59be-017e-4bb6-bc31-fa6fbe83921c">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic2fc5c2b195e47d38f45dbda9f77eb42_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0MjEx_8394f568-eaf5-433c-a69e-d605dd4c24aa">253,000</ix:nonFraction>, respectively, of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzkwMDQ_a9ab300b-2e5b-43f7-8a3c-0bad610eaf18">9,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic2fc5c2b195e47d38f45dbda9f77eb42_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0Mjc5_f0b0a0f1-c047-42ae-9523-4d66e05d5c8e">40,000</ix:nonFraction>, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all outstanding December 2019 Bonds were converted into <ix:nonFraction unitRef="shares" contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzkzMTc_83c826e6-1f68-43a9-b300-0276d179f706">1,009,450</ix:nonFraction> shares of the Company's common stock. Upon conversion, the $<ix:nonFraction unitRef="usd" contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzkzNDE_a4b83011-076f-49c5-9558-3c2c8ff1944f">4.4</ix:nonFraction>&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</span></div></ix:continuation><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90ZXh0cmVnaW9uOjQ5Y2M3MGM2MGMzZDRhMzVhNGNjYzQzNmZiOTQzZWM2XzE0Nw_b34ada42-6c10-4ee3-8ce4-8bff81a8b9fe" continuedAt="ic42884ae464f4773aac15ecdeb2f9e4c" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ic42884ae464f4773aac15ecdeb2f9e4c"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90ZXh0cmVnaW9uOjQ5Y2M3MGM2MGMzZDRhMzVhNGNjYzQzNmZiOTQzZWM2XzE0NA_a2c87691-f75c-49cf-9859-e6e5c5a59acc" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEtMS0xLTEtMTMwNzk_7aa6f055-fd21-475c-99d4-5b3600e45c2e">24,213,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEtMy0xLTEtMTMwNzk_b0643455-3fb9-4b83-964e-726d588e05b2">825,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzItMS0xLTEtMTMwNzk_54592c4a-4fae-4865-b1b6-edb6d6d134d0">16,112,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzItMy0xLTEtMTMwNzk_2c1e23d4-751e-42ce-896f-8b515464efd1">13,127,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued subcontract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="ino:AccruedSubcontractExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzMtMS0xLTEtMTMwNzk_e23a9522-9681-4104-a2ef-53dc73cd576f">11,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="ino:AccruedSubcontractExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzMtMy0xLTEtMTMwNzk_56e71735-f9f0-4427-b20a-cee8cd38bb68">247,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzUtMS0xLTEtMTMwNzk_5b0d359f-880b-40c6-b4c9-06f7a9ffd479">7,306,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzUtMy0xLTEtMTMwNzk_2753384b-a35f-48cd-a541-2b4d6929c592">7,003,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEwLTEtMS0xLTEzMDc5_213c7436-8bc4-4862-8156-260fd6b5694f">47,644,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEwLTMtMS0xLTEzMDc5_8aec0665-5e16-4b93-bf9b-ccbef07a121b">21,203,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwOTk_8545c000-5b5c-4bcc-bf3d-9992965378ac" continuedAt="i01c865825b9d4c4bb72bbffafc62561d" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="i01c865825b9d4c4bb72bbffafc62561d" continuedAt="i8bb8315a746d43b1aa2f98bb0543ab82"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwNzg_112a049e-9317-4346-a8db-eded11857066" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $<ix:nonFraction unitRef="usdPerShare" contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpkZjY4OWQyOTAyNzc0NDRjYTgwZWY1ODFkZjZjM2RjN18zNA_349ce023-c258-4ae8-820c-225e782d7749">0.001</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtMS0xLTEtMTMwNzk_6b46d908-f850-4dd9-b190-a8967f7e7be0">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtMy0xLTEtMTMwNzk_d577cae9-bc4a-480e-9b38-9369d62e6256">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtNS0xLTEtMTMwNzk_72967407-c7c9-4a64-a3ec-3cf237afb01e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98fcd21abb664100b8f5b38c37fe8294_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtNy0xLTEtMTMwNzk_e6abd370-b5fd-41bf-8433-5a70ff4ffd32">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, <ix:nonFraction unitRef="shares" contextRef="i40a8e6a6790645be83c7f3d6ff04f333_D20200601-20200630" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY1_6bff6e73-5cb1-4f86-8009-5b0bbb2a70f7">14</ix:nonFraction> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i25d15f4eda32428fa3a38009bc9b503f_D20200601-20200630" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzE1Mw_d364dc93-8676-4af6-86a4-e01b0fce42b4">5,147</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $<ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" name="ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUwMQ_bf19af12-86a0-4a52-bdf8-4c1130b76a6e">27.20</ix:nonFraction> per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzYxNA_af9e2058-aa9c-4651-8884-7cd35891ae05">3,309</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i0beb8343704b4e66bf518dc68c5d9e59_D20211109-20211109" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyNzk3OTA_fca781c3-93f5-4286-a5d3-98c710b1a943">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="i0beb8343704b4e66bf518dc68c5d9e59_D20211109-20211109" decimals="INF" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyNzk3OTM_9bd79599-adbd-4f40-9b21-d218edd3b194">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. For the year ended December 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyODAxMzk_a26311b8-c4c3-447b-8b1c-36cbf33ab40f">6,955,341</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyODAxMDE_198e866f-b473-4f73-8615-7eaacd299da1">6.96</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyODAxMjM_0ce2eb09-5d59-438a-b53b-d95f7de37ce0">47.7</ix:nonFraction>&#160;million. As of December 31, 2021 there was $<ix:nonFraction unitRef="usd" contextRef="i23b51ec2c12f42e7a12b929edad6ac3c_I20211231" decimals="INF" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NTU4ODA_3e01cd84-59de-4504-a082-02f06ca3f76b">251.6</ix:nonFraction>&#160;million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i49f555fa92724b73a79e6f05d158c07e_D20210125-20210125" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjM1MzQ_28bb06a8-6a01-496e-90a2-1ac4425100be">20,355,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b4c0934496e4fd69eff228d86ee8f98_I20210125" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjM1OTE_8bfd5319-5d7c-480c-862f-7ab4a1ae5aeb">8.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i49f555fa92724b73a79e6f05d158c07e_D20210125-20210125" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjM3MzM_a027823d-e801-420c-b6b2-550f49c0154f">162.1</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8bb8315a746d43b1aa2f98bb0543ab82" continuedAt="ie4203bd6fa7f465e9a13931a854fa643"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "2020 Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the 2020 Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i753fd66a6adf4a97a3cb8ca8d0b01238_D20200512-20200512" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAyNjk_82867da2-e5ae-4754-8a3f-3a152f534085">250.0</ix:nonFraction>&#160;million. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzMjE_48cd85d1-77c9-476f-8bcb-c4c95278322a">22,919,934</ix:nonFraction> shares of its common stock under the 2020 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzMzM_09fddd4d-d5be-4cac-95ca-6753c67ca941">10.91</ix:nonFraction> per share resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzNDI_173123a9-b0b5-4e21-a7eb-36e085845078">246.2</ix:nonFraction>&#160;million. As of December 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i6e3ea451d4a04b0abec238235c56f2be_I20201231" decimals="0" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzNDA_67cf027f-4894-4854-815d-1652550aacb6">no</ix:nonFraction> remaining capacity under the 2020 Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i43a1d23049ec4dc7a76ba1a881242cad_D20180501-20180531" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjQ4MjI_7faf6d34-da7d-433a-b68e-34a7586e9283">100.0</ix:nonFraction> million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into amendments to the Sales Agreement (as so amended, the "2018 Sales Agreement") to increase the amount of common stock that could be sold under the 2018 Sales Agreement from $<ix:nonFraction unitRef="usd" contextRef="i43a1d23049ec4dc7a76ba1a881242cad_D20180501-20180531" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUyMDk_01af127d-3df8-4285-bc28-3f73b93f6cbb">100.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ie5029be83e87418db970ef84ed1a4011_D20210101-20210331" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUyMTY_f1d92813-09bd-4f7a-b755-837305418610">250.0</ix:nonFraction>&#160;million. During the three months ended March 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i7880a35a7d84470b865daeee2cd2fc5c_D20200101-20200331" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUyODQ_27fefb41-f82c-43bf-b845-9f7cd2d97f9e">43,148,952</ix:nonFraction> shares of its common stock under the 2018 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b2929e55be54db5a11cf6c1aae0b709_I20210331" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUzOTg_3c11a3ee-8c58-4fab-b2d4-b25207b55638">4.92</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7880a35a7d84470b865daeee2cd2fc5c_D20200101-20200331" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjU0NTI_29abd6a3-e818-4a92-98ff-00a6bc0878c1">208.2</ix:nonFraction>&#160;million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i6b2929e55be54db5a11cf6c1aae0b709_I20210331" decimals="INF" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjU0ODk_d1585958-1d5c-4d6c-86d9-dc9de2ad21c7">no</ix:nonFraction> remaining capacity under the 2018 Sales Agreement. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December&#160;31, 2021, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i13e80425e56b494380b3ac92a6bad40b_I20160513" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzM3ODg_f1ddbae9-6791-4cb6-80c5-ea7ccb86d3b7">20,000,000</ix:nonFraction> shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i13e80425e56b494380b3ac92a6bad40b_I20160513" decimals="INF" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzM5NTM_e05780f5-0986-4d5d-93ec-7e6608b95d59">2,000,000</ix:nonFraction> shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2022, the maximum number of shares increased by <ix:nonFraction unitRef="shares" contextRef="ic3a43045796d477a93feae3365556de6_I20220101" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQyNTA_073e1bd6-bfac-4a73-9288-09d71917dd8e">2,000,000</ix:nonFraction>. At December&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="i368a7f5ff9214108a0ffca3a870b9948_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ0NTA_9274bc7c-27cb-41d7-9219-655b24bea839">4,481,745</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231" decimals="INF" name="ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ1MzQ_844a0d16-39bc-4f2e-9c1b-0f11cd447d6b">2,448,868</ix:nonFraction> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i368a7f5ff9214108a0ffca3a870b9948_I20211231" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ2Mzk_3a39cf21-3c8b-48bb-86f1-8c2c4f151cae">8,060,957</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ3OTY_2ec5cd68-92b7-4f74-acc0-45900be54e7f">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ4Mzg_52909d61-7e76-47b3-a361-9586e3ca2458">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2021, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i631230ffee974729a0560f9e16c5f441_I20211231" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUxMjE_cf89c96f-8e5b-40d3-9dc0-c4a216b9d718">2,428,036</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="i6791f3241d2d4b26860e5a3f33455b90_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUyNDc_d8695456-e1f3-4df3-851d-f3ecfb5e364b">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i6791f3241d2d4b26860e5a3f33455b90_D20210101-20211231" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUyODk_f9915a24-1dc4-4999-982d-342ff54b9c14">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i407c6b8fb0da42379265bd134df26349_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU0NjI_00acd5eb-497d-4ee6-b052-32cc194a522a">25.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i768073d462a746ae9a55cb59ee67fdff_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU0NjY_a9042a0a-ca0f-48ba-a9b7-46099bfcb76d">14.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2c52650eb05d4d77a1dc769d4513b048_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU0NzM_94470745-80f4-45e4-82ef-52e883a6bc56">9.8</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i36b6f9125f4245038f3ccc1233da0d79_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1MDA_4517d634-89b6-4691-adad-ecaa7beb415d">13.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i55226aff8520430581c928fb4cdbc54f_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1MDQ_be66ead6-4f69-4143-ae51-7d9955d83a7c">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i11d51be8fd474946a4d6832b362af324_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1MTE_5b1e034a-9d17-4454-a867-34b6323e008e">5.9</ix:nonFraction> million was included in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="i8c8d2335ada94a8d968b2b3a1caa5fdf_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1NzY_04e915ab-a9db-4f69-9d41-6ac4de4c439e">11.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibf8a9cd7d8fa44d79020983a83a16598_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1ODA_7b22631a-429c-48f8-b394-480103f0cb7e">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f5b1cda2b6d4b0b901a301aea31851b_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1ODc_f885ccee-9194-49f3-8f8f-87fcd0dff8b8">3.9</ix:nonFraction> million was included in general and administrative expenses, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU2OTQ_6f648eaa-6a9b-4e8a-950e-9a72c0a1411d">16.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU3MDk_815a27ea-5f3c-4df0-b241-5743fac71fc5">4.4</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU4NzQ_38b570a4-4225-4244-9d73-b2c3fe9d7be0">2.0</ix:nonNumeric> years and <ix:nonNumeric contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU4ODc_4b00e6e4-7328-444b-b0a4-1fc93db34063">1.4</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU5NDI_39122b5e-538b-4630-b835-5a9deb7957aa">13.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib54d8bf639154cb89c4ba6de26467b78_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU5NTc_ae7a2207-44b1-4e78-960e-8fef30b3409c">10.9</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzYxMzE_ec665c4e-b000-4cc4-b3d5-a65a08719b91">1.8</ix:nonNumeric> years and <ix:nonNumeric contextRef="ie18a5ae792de49a48808b18a814cd872_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzYxNDQ_fa7a423f-e42f-423d-9977-aec292f18a09">1.9</ix:nonNumeric> years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i3954ccf6ef6747ef8feb9744b59bb557_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY0NDA_0eadfa50-b84a-42e6-869d-0a7defd7ef10">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iaccbaf36a42a44229ce94ccb6af44093_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY0NDQ_288f5a28-ba46-4785-a105-483fb441f6cf">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i99beda0a9bac415092a4c08da1889be8_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY0NTE_9c1cf0ca-b3aa-4993-abef-f75ec29d690e">970,000</ix:nonFraction>, respectively. As of December&#160;31, 2021, options to purchase <ix:nonFraction unitRef="shares" contextRef="ifd750ff594294f0c811ec9edaa677c38_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY1MTI_1c620f5f-1b5b-465a-ba85-545ed7e22447">632,375</ix:nonFraction> shares of common stock granted to non-employees remained outstanding.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkxMDk_3c3e4686-a755-4c1c-81d6-ab142a721518" continuedAt="i9993c6f3805741a59baa37696d8e7eb6" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie4203bd6fa7f465e9a13931a854fa643" continuedAt="ie5ab6051f75346d2bb1d60f6ad0fd785"><div style="margin-top:5pt"><ix:continuation id="i9993c6f3805741a59baa37696d8e7eb6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjozMDQ2NGJlM2EyYmI0NGU1OTgyYmE3YjBjMTBhZjFkYV80_6a5e93f3-f138-487a-ba91-3cd56895d09b">1.60</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjozMDQ2NGJlM2EyYmI0NGU1OTgyYmE3YjBjMTBhZjFkYV83_3133c71d-168e-4db2-96ab-5e8e2ffefebf">3.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMi0xLTEtMTMwNzk_532ab2df-f75c-48d1-b282-f5a3022f43bf">272,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItNC0xLTEtMTMwNzk_4f8fba3f-459d-4e56-a1b6-d4c1b0178cdf">1.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItNi0xLTEtMTMwNzk_4fff39c9-036c-4d6e-9187-fd713b61019a">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItOC0xLTEtMTMwNzk_1df1348d-8558-432d-87df-97c53cf1f0f3">262,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMTAtMS0xLTEzMDc5_93185799-c5db-4d60-b52b-cca63668437a">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjowYjY4M2U4N2QxNjY0M2E5OThmNzVmZTcwNWRiMzg2Ml80_b7b2614c-95d7-4ca3-b3df-93507a38c1da">3.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjowYjY4M2U4N2QxNjY0M2E5OThmNzVmZTcwNWRiMzg2Ml83_c2ec5507-71a8-4326-b88d-24e63fec0a57">6.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMi0xLTEtMTMwNzk_21fd6d62-e291-4b27-ad29-fbefc7684638">2,583,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtNC0xLTEtMTMwNzk_a0ac2d9b-de19-488b-860f-6288cf49c7a1">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtNi0xLTEtMTMwNzk_ac097b40-4fea-492a-a4da-7756abec3bc2">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtOC0xLTEtMTMwNzk_8ad2318a-4105-4465-a843-325fce07bc62">2,137,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMTAtMS0xLTEzMDc5_1496d38e-e523-469d-9d7b-9841d65b75bd">3.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjo0MWMyYTNlZDUyZTQ0MGY0YjZkNzNmZDI0MzBmMTdhMV80_93780ac5-3970-4989-b2da-d5a09e80906e">6.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjo0MWMyYTNlZDUyZTQ0MGY0YjZkNzNmZDI0MzBmMTdhMV83_014eb591-a3f4-402d-a4e7-1b993021c84a">9.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMi0xLTEtMTMwNzk_6e28ece4-e34f-462d-b74b-a138db10c4c6">4,148,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtNC0xLTEtMTMwNzk_62c5cf60-6615-4bb2-a747-54b8aa8db6cb">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtNi0xLTEtMTMwNzk_f6bfdeba-f73b-4de2-8625-c8d368b0fbcb">7.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtOC0xLTEtMTMwNzk_4d8bf4c4-3217-4afa-bac7-d7c20648f43c">2,848,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMTAtMS0xLTEzMDc5_b179d1bd-54ed-4066-b92c-b99bdc79ecbd">7.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if9f81ea99dba400ca4654757465a0324_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpmY2VlNjliODJiZDA0ZjU1YTlhYTM3MTM5NTU4NWMxZV80_e4397f70-6d4e-4c07-bda9-3f49c09e5362">9.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="if9f81ea99dba400ca4654757465a0324_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpmY2VlNjliODJiZDA0ZjU1YTlhYTM3MTM5NTU4NWMxZV83_1c91c4c5-8314-4039-b230-515a75361487">12.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMi0xLTEtMTMwNzk_3430d5ad-d8d8-4510-a8be-59dbd01239d1">2,562,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if9f81ea99dba400ca4654757465a0324_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtNC0xLTEtMTMwNzk_a32c17fa-ed68-444d-bad5-abaafd1f9c6e">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtNi0xLTEtMTMwNzk_9b7cc448-d249-4384-a860-dbb18a25155c">10.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtOC0xLTEtMTMwNzk_bccae2b2-e9f0-4630-a3be-15f8a89d5770">827,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMTAtMS0xLTEzMDc5_ad702978-b9fb-4e09-9032-83d5a4a0f322">10.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i607dff749d1b494aa307f2fde9568207_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpjNDMyZjA3NTYxYTE0MDcyOWQ3ZTIxZDAwYzI5NDZlOV80_b3c17699-09e6-48ab-b3bd-e08e3d53237c">12.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i607dff749d1b494aa307f2fde9568207_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpjNDMyZjA3NTYxYTE0MDcyOWQ3ZTIxZDAwYzI5NDZlOV83_eddcc553-ce3f-4a70-8e84-6892fbdb6b72">15.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMi0xLTEtMTMwNzk_0fa6daf4-2c53-4b27-826b-6bb9cb81569d">824,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i607dff749d1b494aa307f2fde9568207_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtNC0xLTEtMTMwNzk_86cc474b-b0f7-404f-8f8e-f607a439089d">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtNi0xLTEtMTMwNzk_d6e1111f-1fd6-485f-8cb0-1ff920cc7c16">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtOC0xLTEtMTMwNzk_4f1b5631-324c-4c3f-a0f4-d2ba0e968213">663,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMTAtMS0xLTEzMDc5_1f9b8449-6a63-4f56-b12b-e04ade24c722">13.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpiYmJkMzJkZTJiMDA0ZGU3OWY4MjQyZTlkNzE3ZTNiYV80_63df19f4-cf20-4a9d-a65b-65016ea34d14">15.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpiYmJkMzJkZTJiMDA0ZGU3OWY4MjQyZTlkNzE3ZTNiYV83_24c97fb7-ecec-4dea-97ef-7d8086b50582">25.62</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMi0xLTEtMTMwNzk_3605e561-ea2b-4f42-a3b3-187bcb76c96c">98,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctNC0xLTEtMTMwNzk_05d01fbc-281e-4ee9-8d92-ad5d7d2c8e82">8.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctNi0xLTEtMTMwNzk_5befcc73-d84c-48c8-a960-522e24dded5f">20.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctOC0xLTEtMTMwNzk_2f8f53e4-77bd-42b2-9b64-bfd2e119fedd">52,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMTAtMS0xLTEzMDc5_533be647-6162-431f-adc7-5abf04b6badd">20.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtMi0xLTEtMTMwNzk_6cef3329-fe06-4218-be99-5f06f0425dc6">10,488,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtNC0xLTEtMTMwNzk_e4a7e12e-0ab9-4fef-84d4-23076c301f42">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtNi0xLTEtMTMwNzk_edb9f43e-f22d-49f5-a497-a72d631a564b">7.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtOC0xLTEtMTMwNzk_28529f31-6215-45cd-acd1-f9818f21a793">6,790,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtMTAtMS0xLTEzMDc5_3c227c96-0b0f-40d9-a48a-23db3f4bb6f3">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY3NTE_9a0dd8dd-2ce5-4794-b97e-df7d84822199">3.8</ix:nonFraction> million, the aggregate intrinsic value of options exercisable was $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY4MTI_786a9878-1dd1-456b-8d6c-2cd0ca91282c">3.1</ix:nonFraction> million, and the weighted average remaining contractual term of options exercisable was <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY4OTU_c0dc534e-045e-47a8-aa2f-0796241e010a">5.9</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the aggregate intrinsic value of unvested restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY5OTQ_a7d05d44-1180-437d-a46b-ef61f066b97f">12.2</ix:nonFraction> million and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzcxMTI_b65758c4-254c-4c32-8d34-2b6002ec8b80">12.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, options to purchase <ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzcxNjQ_a8bcbd15-0849-4066-84c2-f5ed37c92c87">10,488,993</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzcxOTQ_611a60e4-4060-4fe5-a3b8-aa8d37c2d6b4">2,448,868</ix:nonFraction> restricted stock units were expected to vest.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwODU_dd6a1c8d-f5da-41d9-96c9-2243d39c1692" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2021 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzktMS0xLTEtMTMwNzk_7509a12d-bb65-4b2a-b06f-20e7223ac2db">8,906,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzktMy0xLTEtMTMwNzk_3af9ee99-43a9-4164-b0d9-ce9f25c76578">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEwLTEtMS0xLTEzMDc5_2b6318a7-24cc-4577-9b65-6a6c6c49cc38">3,483,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEwLTMtMS0xLTEzMDc5_f7c2fa1a-faca-4330-9952-5b0689cd8bce">10.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzExLTEtMS0xLTEzMDc5_793ef0af-b1cc-4b69-9003-0e73ddf06da8">1,310,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzExLTMtMS0xLTEzMDc5_30af680c-367e-4a90-b3f3-91b5c71e185b">5.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEyLTEtMS0xLTEzMDc5_236f2244-96a6-40a0-a953-491da7db779b">590,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEyLTMtMS0xLTEzMDc5_1512336e-b64c-43e3-8cd5-4ac00cbdd5cb">10.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEzLTEtMS0xLTEzMDc5_48630ebe-24ed-4c19-bf6e-d1fdc77d4c43">10,488,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEzLTMtMS0xLTEzMDc5_4c4779f9-bf08-44bf-82ae-97dfb5fb9f94">7.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkxMTA_64d8b854-3a58-49a5-9248-3601864bb4cf" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2021 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib54d8bf639154cb89c4ba6de26467b78_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzktMS0xLTEtMTMwNzk_182ce814-69b6-47b5-bb13-75ed6fba885a">2,558,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzEwLTEtMS0xLTEzMDc5_0ba76155-f90c-4f8d-9fea-a793f71d1659">1,392,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzExLTEtMS0xLTEzMDc5_fde5092e-2aef-45ae-9443-4504fd8efdc7">1,387,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzEyLTEtMS0xLTEzMDc5_90745692-9fe4-4ea3-b65c-da8d15b4d91b">113,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzEzLTEtMS0xLTEzMDc5_a8046a30-2657-4a08-8c5e-b4aadf9bacb0">2,448,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc1MjM_a8dfdd86-3108-4a10-905e-894a773a7ec6">4.56</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc1MzQ_90985da6-92c2-473c-94b0-f049d0f1e8d5">7,000</ix:nonFraction> options which expired during the year ended December&#160;31, 2021, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc1OTg_c88c3e8b-9ba7-48cd-8d13-146eed31de3e">4.44</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc2MDk_4f4a9e23-b198-40de-9211-d227a32c111b">78,750</ix:nonFraction> options which expired during the year ended December&#160;31, 2020 and $<ix:nonFraction unitRef="usdPerShare" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc2NzY_2112a017-fd93-47ca-bcc9-11bc29c6ab60">6.27</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc2ODc_4be6f1f7-25d9-49bd-a885-42fdc2c37d63">324,502</ix:nonFraction> options which expired during the year ended December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc4MDg_260c8adc-42bd-4d09-9d66-3ce853714e1c">7.61</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc4MTI_fe144283-c6dc-4ee9-88e6-67e8fdc3a205">6.87</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc4MTk_26c4905c-efc2-442f-bdcf-20defbcc1578">2.19</ix:nonFraction> for options granted during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc5NTQ_0d1c57d4-7604-4494-8cc5-5b08fba9149c">10.37</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie18a5ae792de49a48808b18a814cd872_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc5NTg_1a4e103c-941b-4d94-afd1-4ee111f3cf4c">9.12</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id7b6cf865ace43d59c4d9b8cd23d0762_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc5NjU_d41d64fe-8dcb-432c-87e8-9d17027b81a0">3.09</ix:nonFraction> per share for restricted stock units granted during the years ended December&#160;31, 2021, 2020 and 2019, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie5ab6051f75346d2bb1d60f6ad0fd785"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgxMDA_bcc8c3f1-57b9-4781-a74e-fa10037e5756">6.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgxMDQ_0c2460da-4393-4430-87ae-32fd82c90706">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgxMTE_5ab448a3-7597-43ab-9981-b47879e4d6c8">113,000</ix:nonFraction> in proceeds from the exercise of stock options during the years ended December&#160;31, 2021, 2020 and 2019, respectively. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgyODE_c145c73b-b5e0-4231-afaf-1b2669c7ad77">7.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgyODU_388e2bdd-ccc9-41a0-a4db-b02e7a1d77a5">14.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgyOTI_cec6ed52-4570-42cd-adbe-607849ecf85e">25,000</ix:nonFraction> during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i99399af4f2764839b791a9aff6806132_D20200828-20200828" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg0MDA_ff1113c5-f00b-4493-8e7b-27e61076d675">663,353</ix:nonFraction> performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: <ix:nonFraction unitRef="number" contextRef="i768661574b0047a8978ccb5a91644538_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg1MjE_ccabfa25-374c-44ca-8b75-c442dc891c48">50</ix:nonFraction>% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining <ix:nonFraction unitRef="number" contextRef="ie684f486c3914e20a06a7b5a84e49ca3_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg2NDM_2db581ec-e3d3-440b-9e1e-e9c21ed8c5fe">50</ix:nonFraction>% of the shares in each tranche will vest upon subsequent completion of a <ix:nonNumeric contextRef="ie684f486c3914e20a06a7b5a84e49ca3_D20200828-20200828" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwODM_ae624046-4cba-43fe-8de2-cd3d554aa76f">one-year</ix:nonNumeric> service period. The grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i99399af4f2764839b791a9aff6806132_D20200828-20200828" decimals="-5" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg4MDM_dca55ac1-d01d-4582-9c09-da5551984b47">8.0</ix:nonFraction>&#160;million based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i99399af4f2764839b791a9aff6806132_D20200828-20200828" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg4NTc_81c502e8-1025-41f6-8f75-3c82b42f034f">12.06</ix:nonFraction>. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the year then ended.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzMwMTA_5af29707-1047-49ae-8d4d-97ce527afa05" continuedAt="i583966ee1c75409689426a9b8c51410a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i583966ee1c75409689426a9b8c51410a" continuedAt="i23bf256fec0142d9bfcb4628cfb39c78"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i72efe8598cfb48c48cb1d6f2d4c6fdd6_D20210101-20211231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzUw_fda0219d-15a6-408e-b3f0-a934809791bf">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="i940ff9e4c5b74f5581133846dcd72463_D20210101-20211231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE0MQ_927d0e47-102b-4c0d-a47b-103c83f53a34">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2021 of <ix:nonNumeric contextRef="i764e102832c147288be14730f1429377_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzI5Mw_7060780d-8745-47f5-9e1a-65014117235a">1.9</ix:nonNumeric> years to <ix:nonNumeric contextRef="ic5174769188e48278fd87c450cdc20d9_I20211231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzI5OQ_85f00cf9-7805-4df3-9ede-b1c568a31027">8.0</ix:nonNumeric> years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzMwMDc_460b8783-2309-4f8d-bf07-530503f8505d" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzEtMS0xLTEtMTMwNzk_fac06d54-89dd-4b80-ba93-af5f96e3693d">4,085,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzItMS0xLTEtMTMwNzk_3716a4cc-ad66-4311-930e-29e2fba4b8bd">4,089,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzMtMS0xLTEtMTMwNzk_5f053d3d-3d34-4717-8861-0e334db1158c">3,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzQtMS0xLTEtMTMwNzk_a137c72a-fb27-4a90-894b-6b96d6b4816b">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzUtMS0xLTEtMTMwNzk_6d388154-6288-45ee-a0e9-84850d8840a2">3,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzYtMS0xLTEtMTMwNzk_b1cc342c-3965-481b-bc2a-00e9c0ff9096">6,749,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzctMS0xLTEtMTMwNzk_c982a42a-ba3f-4b42-a4ec-7350475e6bed">24,175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzgtMS0xLTEtMTMwNzk_77ea7b0b-455c-4812-900a-ef3a91e275ba">6,111,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzktMS0xLTEtMTMwNzk_8df557e0-010f-4fcb-af61-3e0ada34e8b7">18,064,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzEwLTEtMS0xLTEzMDc5_d847292c-2f69-4dbf-be36-75415f6105e9">2,604,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzExLTEtMS0xLTEzMDc5_614d9fe0-4177-4d94-aa60-a317c0199676">15,460,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzEzLTEtMS0xLTEzMDc5_02a3d338-1090-4ea1-9244-db64cf05135e">6.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzE0LTEtMS0xLTEzMDc5_574b1c0e-2e24-44dc-b348-2b1095bbd6b3">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE5NjI_bc1b7a39-8f42-434a-ba43-4f55d41a18bc">3.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE5NjY_c38bf802-996e-47f6-95da-6d754cf8db75">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE5NzM_a49d7735-5e6a-45b9-8c57-458abf9da884">3.2</ix:nonFraction> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i23bf256fec0142d9bfcb4628cfb39c78" continuedAt="ie2b48135ab6e4a5698259da1ce0e745e"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="lease" contextRef="i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231" decimals="INF" name="ino:LesseeNumberOfLeaseAgreementsEnteredInto" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzIyNTU_a56c5b11-d269-4375-b3ca-0e1628137939">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzIzMDY_8e5e2bc5-41b9-48e3-aa61-e77bfd67c880">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing supply agreements with contract manufacturers to manufacture INO-4800 drug substance. Under the terms of the agreements, the Company is committed to certain minimum purchases in 2022. At December 31, 2021, the Company had a $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzEwOTk1MTE2MzMyNjA_355196c4-53ad-4535-a624-38b335856c4b">47.4</ix:nonFraction>&#160;million minimum purchase obligation in connection with these agreements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and J. Joseph Kim, the Company&#8217;s Chief Executive Officer, as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On August 3, 2020, the lead plaintiff filed a consolidated complaint, naming the Company and three of its officers as defendants. On September 21, 2020, the lead plaintiff and another purported stockholder filed a first amended complaint, naming the Company and three of its officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, the defendants&#8217; motion to dismiss. The court granted the defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on certain of the Company&#8217;s statements. The court denied defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, the defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, the plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#8217; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. Defendants intend to move to dismiss the new allegations in the amended complaint.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend these actions vigorously.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie2b48135ab6e4a5698259da1ce0e745e"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3Mjc_138d3417-9ad6-4444-8b9b-fe5f5bb147b1" continuedAt="i3749770684cf4aa7980cc218f99cb8b6" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i3749770684cf4aa7980cc218f99cb8b6" continuedAt="id336e8d3f30c4e049f133417590aa81a"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the accounting guidance for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3Mzk_0e39eace-e05f-460f-89a6-c69ae6878b92" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations before equity method investment are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzItMS0xLTEtMTMwNzk_188f6ae1-3ef5-4b9d-84b7-a98c20655c22">302,614,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzItMy0xLTEtMTMwNzk_b6c472cb-ad03-4fe7-bfa9-54727feee4ea">162,664,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzItNS0xLTEtMTMwNzk_f039d061-3d90-45d4-8faf-cee934402c6f">120,809,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzMtMS0xLTEtMTMwNzk_4921b9d7-a845-47b9-9f9a-f640ecc885be">610,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzMtMy0xLTEtMTMwNzk_4b13a46e-fac1-422f-bd32-db37e8a959ab">225,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzMtNS0xLTEtMTMwNzk_56f6985a-2c95-4f6c-8eda-f46806267e74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations before equity method investment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzQtMS0xLTEtMTMwNzk_89f5aea9-a492-4d6b-9d17-34390595e464">303,224,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzQtMy0xLTEtMTMwNzk_134c9881-fce8-4412-b5d2-9f3105d22a92">162,890,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzQtNS0xLTEtMTMwNzk_e330dbda-eb48-4ef8-a8a5-4aa33f0b9fec">120,809,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzM4NDgyOTA3MDUyMTE_07c2829e-31c0-4eac-b51f-d76b6a47036b"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzM4NDgyOTA3MDUyMTE_d4a043b8-23d2-4d23-ae26-7d89d1cc7c44">no</ix:nonFraction></ix:nonFraction> provision for (benefit from) income taxes for the years ended December 31, 2021 and 2020. There was an income tax benefit of $(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzEwOTk1MTE2MzU3NTI_a23b7ab6-2e80-425d-9e44-04936de90062">257,000</ix:nonFraction>) for the year ended December 31, 2019. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id336e8d3f30c4e049f133417590aa81a" continuedAt="ide96b08b8e874e4a843bc39aefd729ce"><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MTc_bb4c632f-dcd1-47e1-96f3-eee0dbea582e" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2021, 2020 and 2019, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (benefit) taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzItMS0xLTEtMTMwNzk_42fd6ba1-45de-4656-a9fd-e9e1ac9eb0e1">63,677,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzItMy0xLTEtMTMwNzk_3be929b2-a6b0-4b60-9e35-e8e4e2815990">34,207,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzItNS0xLTEtMTMwNzk_679c15d8-682e-403d-96f3-d9b859ccaefc">25,370,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzMtMS0xLTEtMTMwNzk_4cd25073-a5ab-4246-b0a8-73b66a22aa1e">3,447,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzMtMy0xLTEtMTMwNzk_b51effe4-9c28-4c96-af9b-65e494cf7168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzMtNS0xLTEtMTMwNzk_152fb528-bff8-43f7-9c08-411e332f2a5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzUtMS0xLTEtMTMwNzk_ca243c89-91be-4dca-bad4-ec8db784b59e">77,424,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzUtMy0xLTEtMTMwNzk_9d0a14fa-eccb-43be-acdf-f09fdc5aea1b">21,428,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzUtNS0xLTEtMTMwNzk_e8c3a33d-5ed5-4e00-bf77-4ef1b7ddd17d">25,457,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzYtMS0xLTEtMTMwNzk_dc806298-8b83-4a80-9c87-ae335a5d0f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzYtMy0xLTEtMTMwNzk_23e3df8a-ba96-4b9e-965b-5b7617fc037e">14,450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzYtNS0xLTEtMTMwNzk_d9dc5acd-f03f-4ac0-b380-fff8a342d7ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzctMS0xLTEtMTMwNzk_2dbc31e8-c679-4f07-8f99-87c7195dcbb5">16,523,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzctMy0xLTEtMTMwNzk_40510e50-4277-4ed0-aacc-53d408f05246">2,650,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzctNS0xLTEtMTMwNzk_9432deec-c4d7-4645-8971-fb94243c76fa">3,838,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzktMS0xLTEtMTMwNzk_653144da-8872-41f0-a90e-c9fbea415d54">483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzktMy0xLTEtMTMwNzk_5e3cda0a-abf5-4a76-88a2-2a91af2c5781">1,953,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzktNS0xLTEtMTMwNzk_ac16e1ff-adf5-4163-847e-c446c1c61f1e">1,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEwLTEtMS0xLTEzMDc5_757d48c7-c25a-4721-91f9-67441e7becf1">6,509,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEwLTMtMS0xLTEzMDc5_e3fdca31-f3ab-4763-a7f1-b86270fbd676">1,068,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEwLTUtMS0xLTEzMDc5_1ac7bafb-e612-40b7-bcae-3695ad960959">1,537,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzExLTEtMS0xLTEzMDc5_6d0b5466-883b-4830-b5a7-1efd6c928fd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzExLTMtMS0xLTEzMDc5_4ecedd4e-9c46-41d0-a349-11fe47f03e3f">853,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzExLTUtMS0xLTEzMDc5_822e37d3-4cb8-4672-90a6-12c623cdd9b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEyLTEtMS0xLTEzMDc5_520feef0-5f37-44dd-bdac-e544dc109d44">616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEyLTMtMS0xLTEzMDc5_5d8e67c9-236f-419f-981c-b51e7b76f594">468,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEyLTUtMS0xLTEzMDc5_b8cc6524-a144-49a3-8d3b-dcf55bc4f5ea">616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEzLTEtMS0xLTEzMDc5_203513c1-f22b-4747-939a-c0d9592790b0">542,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEzLTMtMS0xLTEzMDc5_0ae65dff-06e7-4c84-b6a4-672990185b64">368,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEzLTUtMS0xLTEzMDc5_d0d160fa-e769-4bc0-a588-3d7c078f75f8">616,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE0LTEtMS0xLTEzMDc5_edb8448e-900e-4699-9e1d-dccfdf2631d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE0LTMtMS0xLTEzMDc5_a979ea20-d1bc-4aa3-975d-a1fefd2e4795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE0LTUtMS0xLTEzMDc5_12b3d9f7-0ec3-4e8a-b3f6-83cdb5e89c94">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE1LTEtMS0xLTEzMDc5_3dab4a5b-813c-40cf-bbc5-1165face4d0e">24,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE1LTMtMS0xLTEzMDc5_9ef50208-687f-4143-8132-5c718504c921">9,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE1LTUtMS0xLTEzMDc5_dd73dfc9-0c77-41ac-92c2-04bb8b84fa03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE2LTEtMS0xLTEzMDc5_75118e6b-5734-46a2-86aa-d83aa0060ddc">819,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE2LTMtMS0xLTEzMDc5_7af551df-b6eb-4a38-b036-7820dc6090ac">920,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE2LTUtMS0xLTEzMDc5_7f1802c7-906c-4d8f-b83b-a18a042196a2">831,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE3LTEtMS0xLTEzMDc5_93326131-b2e0-47a0-b017-3c90c4ba0025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE3LTMtMS0xLTEzMDc5_4f3048ba-718c-4c98-a0f5-6a9cae94c01f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" sign="-" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE3LTUtMS0xLTEzMDc5_c2fd0c38-c1cf-409e-abe5-e8bef6c7b586">257,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit recorded during the year ended December 31, 2019 of $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzk5OA_a06c1855-7442-46d1-99eb-90e297a8fb01">257,000</ix:nonFraction> was principally due to a requirement under ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MzE_680c9a4e-ef8c-4f5b-a349-632f05bd576f" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzMtMS0xLTEtMTMwNzk_2a2a191e-6ebb-4f63-95f4-669967f7d0c8">4,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzMtMy0xLTEtMTMwNzk_a2d6ed6d-50d8-4f55-a387-e94f2e304a79">5,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzQtMS0xLTEtMTMwNzk_bd8263d2-e4e6-41ae-8225-dc8ef87cfe93">197,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzQtMy0xLTEtMTMwNzk_1184e55c-1cc4-4c78-b9cd-a27c23f47cb5">127,835,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzUtMS0xLTEtMTMwNzk_85dfb67f-dcc3-4464-8307-f43b1b68e0f6">23,005,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzUtMy0xLTEtMTMwNzk_61055ceb-25bf-4407-9f1a-1e6f4cce98af">13,242,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzYtMS0xLTEtMTMwNzk_aee6fb09-de17-4064-8ab8-907ca03f7e5c">987,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzYtMy0xLTEtMTMwNzk_46f89be6-2c0d-4d91-b800-baffd1880aed">1,628,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzgtMS0xLTEtMTMwNzk_c797f6a1-7ca6-4915-b311-1db7c783ba3b">3,599,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzgtMy0xLTEtMTMwNzk_b86842e2-f3ed-42bf-b66d-e55338c13295">3,256,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzktMS0xLTEtMTMwNzk_5b6cc9c8-c266-4fb1-bc23-f359bf9af8ba">637,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzktMy0xLTEtMTMwNzk_776b0b89-60d4-4cc7-a9cc-98b49a2576ba">757,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="ino:DeferredTaxAssetInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzExLTEtMS0xLTEzMDc5_313a094d-8a53-4e1b-9de5-e4a49fac6439">83,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="ino:DeferredTaxAssetInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzExLTMtMS0xLTEzMDc5_14776b61-9fe5-429f-a903-f1993a0bc605">564,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEyLTEtMS0xLTEzMDc5_5482d4be-56a4-42fd-804d-ccc423ef5af9">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEyLTMtMS0xLTEzMDc5_dffb0b9b-c8c6-4f52-94b6-ea246bc35ae0">542,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEzLTEtMS0xLTEzMDc5_f4035094-0f53-4220-bfb1-816cdd330c11">3,793,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEzLTMtMS0xLTEzMDc5_9d70e5b5-0c9d-4556-8dd1-6caeb0b29acc">4,283,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE1LTEtMS0xLTEzMDc5_f1849d34-d6b8-4f23-8f76-8ab6cbc2e159">5,973,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE1LTMtMS0xLTEzMDc5_8d58daa2-046f-4fa8-a977-c75aa8d876be">6,127,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE2LTEtMS0xLTEzMDc5_13b12832-f662-4884-b4e5-9ad3552dd433">240,171,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE2LTMtMS0xLTEzMDc5_94ab4a38-c8e3-47d7-bd88-3bd371db9680">163,484,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE3LTEtMS0xLTEzMDc5_26d9f65a-ffbf-4caf-8969-ac6b1396de2d">237,205,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE3LTMtMS0xLTEzMDc5_804515ac-a626-4d6e-af5f-097d22b36c38">159,705,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE4LTEtMS0xLTEzMDc5_a5c75785-4583-48c0-8b18-1c3701d677a5">2,966,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE4LTMtMS0xLTEzMDc5_10d55155-7fd8-4fcb-98fc-c721c4442007">3,779,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIwLTEtMS0xLTEzMDc5_fda0647a-dd36-42b1-af08-ab3e29a41fba">194,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIwLTMtMS0xLTEzMDc5_8bc524fd-1280-4374-9082-da7d08d7cb9a">179,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIyLTEtMS0xLTEzMDc5_fa3e6308-199d-4b14-af63-65003f3a418e">2,430,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIyLTMtMS0xLTEzMDc5_82c7294e-85f8-4894-b0ec-521bb52b8c94">2,676,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="ino:DeferredTaxLiabilitiesFinancingArrangementDiscount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIzLTEtMS0xLTEzMDc5_9c61d4fd-a6e9-4bb5-b2dc-050325dc4f2c">321,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="ino:DeferredTaxLiabilitiesFinancingArrangementDiscount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIzLTMtMS0xLTEzMDc5_575cd414-8f40-4d6f-914a-0bb05c39245b">469,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI1LTEtMS0xLTEzMDc5_ed0d6d1f-758e-4963-8752-fc467282d6b8">53,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI1LTMtMS0xLTEzMDc5_df6cc3e9-c6da-48e7-b184-3e74b6c5a715">487,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI2LTEtMS0xLTEzMDc5_ee462393-2040-4905-8aba-b36ce631bce5">32,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI2LTMtMS0xLTEzMDc5_ab31d08a-70a5-4c49-a4aa-a3c0b38eb679">32,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span><br/></span></div><ix:continuation id="ide96b08b8e874e4a843bc39aefd729ce" continuedAt="i08f8bb4ae8734b80acf9c49e9c34db83"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i553b47824270463b81580d012b8326f1_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIwMjI_aed40e1b-ce31-4080-8971-ac9738f72aee">864.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2a2629ea83a447d48947801594c4a4f4_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIwMjY_1613a051-e0c0-4602-9311-eb6904a4c804">146.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i28ea7f8947e74ae483e59fef6fba3c42_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIwMzM_e749eb60-cd3b-4a9e-a823-19361b856748">89.0</ix:nonFraction> million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $<ix:nonFraction unitRef="usd" contextRef="i170db3d65ef54746a1f01e2eeb793898_I20181231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIyMjU_8b7923eb-4524-4104-b849-b67c983bc15f">568.9</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2021, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2021, respectively, unless previously utilized. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also has Korean NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ifb481c2e100c4b24ab6801fa143fc5a8_I20211231" decimals="-3" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIxOTkwMjMyNjI2MzI_c79bf37a-dc6a-4db7-8b4a-d64677977ce0">806,000</ix:nonFraction> as of December 31, 2021. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2021, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i8600df4b8cfa4198a900a673aaa25e5e_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzI3ODY_e0eba5fa-110c-40be-8529-60340f22b4c5">35.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzI3OTM_475d09a7-929f-4ef9-a697-948bf743e6ff">4.4</ix:nonFraction> million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MTI_df7b9f0b-5683-434e-996c-5b92784ee55d" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtMS0xLTEtMTMwNzk_eea35715-0515-42e2-b9cb-37abe8696010">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtMy0xLTEtMTMwNzk_a1cde288-5cfe-4b9b-ac79-c000b277a2ed">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtNS0xLTEtMjYyMjg_deb6fece-1744-4984-b451-0a64e287b8fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtNS0xLTEtMTMwNzk_cfefbcb7-029d-481c-9dcb-794b27dd3cd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtNy0xLTEtMTMwNzk_7bd22cb8-08eb-4900-b759-2f9010a947a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtMS0xLTEtMTMwNzk_a7e97f74-e143-41e0-a4f5-6ae0751ac0c3">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtMy0xLTEtMTMwNzk_52a4de95-a7ac-47fd-81a3-45573052aa00">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtNS0xLTEtMjYyMjg_c4ab58cf-951d-4b24-b0ac-ec94dd97a2e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinThreeMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtNS0xLTEtMTMwNzk_566ed114-ea69-41aa-97f4-2c12af54babd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinThreeMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtNy0xLTEtMTMwNzk_a891005f-2081-4699-8f08-5cf8e1ed7483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtMS0xLTEtMTMwNzk_7d49d81e-8c14-4640-a61d-74f980b2fd21">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtMy0xLTEtMTMwNzk_a297990c-9c8e-4863-9a22-4d9f6990adab">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtNS0xLTEtMjYyMjg_2c733a46-50cb-488b-ae74-046728c6adc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFourMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtNS0xLTEtMTMwNzk_b2c2abfc-165e-4b8d-9e10-8b2d99ad4d43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFourMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtNy0xLTEtMTMwNzk_3506a260-c00a-4ff8-95b3-aa4f8bdb5c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtMS0xLTEtMTMwNzk_a92051ae-e7a8-413d-b8bb-0fe28cc59a21">267.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtMy0xLTEtMTMwNzk_41d11015-7fbe-4288-992d-0e88ece532c9">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtNS0xLTEtMjYyMjg_1a8d6cbb-4565-461d-890e-5a3a32d85121">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtNS0xLTEtMTMwNzk_ce74d379-ab74-4205-951b-dd6d7ff0d9b4">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFiveYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtNy0xLTEtMTMwNzk_92f1931b-3c41-4e7c-9452-e6f9e72523d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctMS0xLTEtMTMwNzk_7b0fb5c2-1f00-4502-acc3-531c2148ab39">568.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctMy0xLTEtMTMwNzk_a54be10b-b859-415a-ad7d-c9283c1423d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctNS0xLTEtMjYyMjg_eb6adafb-9e74-40e9-9de6-991e6c513c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctNS0xLTEtMTMwNzk_571cd0be-97ff-4e13-840c-741aa4c32c46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctNy0xLTEtMTMwNzk_b60cb5c9-d31f-4b90-bab3-ebc840eb2c8a">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtMS0xLTEtMTMwNzk_bcf623e0-fcda-4b3a-b6a6-ec7d1f4d120b">864.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtMy0xLTEtMTMwNzk_f7f0f119-53ab-4465-a9de-39ffdb892bf0">235.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtNS0xLTEtMjYyMjg_435818bb-6c7f-4651-963a-4183e03b85d5">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtNS0xLTEtMTMwNzk_a9af273f-1675-471a-b9e7-89366da2d413">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtNy0xLTEtMTMwNzk_5835ef24-2bfe-4d0d-a3ad-63af8b14e07b">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2021. As a result of the analysis, the Company estimates that approximately $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="ino:TaxBenefitsExpired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzM0OTI_42082b94-b038-40e5-a981-70e8173bdc6b">9.7</ix:nonFraction> million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2021, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.</span></div><ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MzI_48fca4ba-1656-449e-a2c2-c9e21c51ff3d" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzItMS0xLTEtMTMwNzk_2791cf21-dc46-4f94-b40f-d686f4ea9eca">12,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzItMy0xLTEtMTMwNzk_b936b1b4-46aa-47be-bee7-bcf41d97ac59">11,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0209f8c94d740adaa36dd67c48d6a20_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzItNS0xLTEtMTMwNzk_2069beb7-73b0-4a2c-b514-6a20b45fdcf9">9,632,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzMtMS0xLTEtMTMwNzk_96792703-7746-4b3d-9954-42b1fca071a3">6,602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzMtMy0xLTEtMTMwNzk_5729a30a-11d8-4ac4-ab10-259639d00726">1,043,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzMtNS0xLTEtMTMwNzk_9eb9db17-14fa-41a5-af48-969fc8b3b807">1,575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzQtMS0xLTEtMTMwNzk_dd8db929-796a-4ded-83cc-b24ae4652d18">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzQtMy0xLTEtMTMwNzk_35b64b1a-604a-4c4b-b390-3599557499c2">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzQtNS0xLTEtMTMwNzk_838e36db-ae6b-462a-9277-da52cfe1233f">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-3" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzUtMS0xLTEtMTMwNzk_3c6fd555-e354-405e-87ef-c24b116c8dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-3" sign="-" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzUtMy0xLTEtMTMwNzk_2cb51aed-e550-486f-ba6b-01a56709f731">64,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-3" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzUtNS0xLTEtMTMwNzk_a42660ef-46bd-43ac-bc48-60ceea625dac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzYtMS0xLTEtMTMwNzk_6bdc8ced-0fda-4287-98f1-0b35230db704">18,819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzYtMy0xLTEtMTMwNzk_8fa57a12-fe10-49e4-a706-4bc273c9a44b">12,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzYtNS0xLTEtMTMwNzk_ac8129b8-6752-4b53-bebc-ad543401a284">11,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i08f8bb4ae8734b80acf9c49e9c34db83"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzU2MDE_f557ec72-7197-427c-baf8-fa8e8af020e2">17.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5b698702e82d457c8216eac55fae002d_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzU2MDU_59dbb60f-d882-4643-b673-b4ea81acfd20">10.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzU2MTI_7aa994a9-72c5-4b02-9bdd-d67cad9775f3">9.9</ix:nonFraction> million as of December&#160;31, 2021, 2020 and 2019, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2018 and state and local income tax examinations before 2017. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is subject to examinations for tax years beginning in 2020 in Korea. The Company is not currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div></ix:continuation><div><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzU0NQ_167060bd-b9ab-4c30-a5ba-33b100efd3af" continuedAt="iecc7392283ca4dc0aa060eb446d17401" escape="true">401(k) Plan</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iecc7392283ca4dc0aa060eb446d17401">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches <ix:nonFraction unitRef="number" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzI2MA_08f7853e-abbf-4803-a1ad-40a24b0f6f80">50</ix:nonFraction>% of its employees&#8217; contributions, up to <ix:nonFraction unitRef="number" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzMwMg_c28c4690-b768-447a-a466-86bf0b9dc635">6</ix:nonFraction>% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzQ1Nw_4d60d90c-ed33-42a7-8210-e68f225ef7ea">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzQ2MQ_24d4b712-30c2-442d-bb51-5fd7d0ad712b">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzQ3Ng_a5de587b-5143-4cd6-b25c-74d3fe9838db">1.2</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_190"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ1NzU_a963a3c0-f0ce-4b0f-b5f4-9ce5bb10c715" continuedAt="i98cfff637b114bb187bcd9d440f071e9" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i98cfff637b114bb187bcd9d440f071e9" continuedAt="i5454a988e37341c6bba0c60c3f77ca6b"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned <ix:nonFraction unitRef="shares" contextRef="i016abb4ce4ae41eb96f478d01ecb4c74_I20211231" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzEzOTU_d8a2d737-829e-4757-97f2-a6fc3c4739ea">597,808</ix:nonFraction> shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, 2021 and 2020, representing a <ix:nonFraction unitRef="number" contextRef="i1ecadc9f1fe848b199e3eebeee7aec5f_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjAyMTQ_a35fa1f3-9c68-4fed-9b86-b88e33630aae">18.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i662f61a3c3334b0e9a41c8358963d412_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzOTgwNDY1MTk2MDE_8f40dda1-fb46-44c9-9c44-a68f826c026d">19.7</ix:nonFraction>% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2021 and 2020, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="i882b0a38e1f2460195c1411955ee5cbb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIwOTY_6068c0e3-a10a-4698-aa98-9982474cd26b">245,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i32a55572cadc4c63ad76c5efc89aa4aa_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxMDM_3ed0ef84-cc02-495a-992d-81b8cbbee72e">1.4</ix:nonFraction> million, respectively. At December 31, 2021 and 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i016abb4ce4ae41eb96f478d01ecb4c74_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTg_1edbfdaa-073e-47a7-97cd-d66d38c09e4e">25,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie83fbb635f5946a4b9deeceae49cb099_I20201231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIyMDU_d650b471-a8cc-4f5a-b143-6d7a0f5cfb47">67,000</ix:nonFraction>, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i7373234a664045788a5b334e1076415e_D20160301-20160331" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzI4NjI_f889048a-fbe2-4515-a1ba-60a1b7e9e897">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="i7373234a664045788a5b334e1076415e_D20160301-20160331" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ1Nzc_4b264591-9dde-4cac-b13e-d52a0e34dc58">five-year</ix:nonNumeric> term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will have the exclusive right to in-license new intellectual property developed in this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i87fa3d23bcb34cf791cf9f42fd01a6fc_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjExNjk_b6785921-4669-4118-9615-9d196cf78617">1.9</ix:nonFraction>&#160;million during the <ix:nonNumeric contextRef="i87fa3d23bcb34cf791cf9f42fd01a6fc_D20210101-20211231" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzOTgwNDY1MTg1NzA_785aa480-26ad-419a-a466-4b68690ca2a3">two-year</ix:nonNumeric> term of the agreements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a&#160;$<ix:nonFraction unitRef="usd" contextRef="i3814c1b2e66949a0bd31251687136440_D20161101-20161130" decimals="-5" name="ino:ProceedsFromSubGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzMwNjE_88c9bbac-94ff-487b-8ff8-1e18986ea850">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infectio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n, with funding through December 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="iba7798242f3b4c25b6738d30fa118ce1_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzMzNzI_52d9ec47-7027-4f96-a832-9f7a1ddea5db">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to $<ix:nonFraction unitRef="usd" contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzEwOTk1MTE2MzU3NDM_e99d9f6b-059c-4a85-9372-dfec2bd46cd0">13.5</ix:nonFraction>&#160;million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzM1OTM_b84db14a-773a-4135-9167-2787c1901f7b">6.0</ix:nonFraction>&#160;million in funding through September 2024, of which $<ix:nonFraction unitRef="usd" contextRef="ia60088662e644556a450fd3a05824f9f_I20211231" decimals="-5" name="ino:CollaborativeAgreementAwardedExercisedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzEwOTk1MTE2MzU5OTg_285fa677-cf0c-4ab2-83c4-8e5b7b2019fe">3.3</ix:nonFraction>&#160;million has been exercised as of December 31, 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5454a988e37341c6bba0c60c3f77ca6b"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ia7365de7ee2a44bdbaf064109d873902_D20210101-20211231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjMyNTA_41a6e2c6-7fe4-48db-93b4-a0e402060121">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i852044bbe3424614962d40fb0b43db9e_D20200101-20201231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjMyNDM_4c82f2b2-5e8e-453f-b50d-7ddfc4ab4b75">1.9</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i41b9a94f7b494158a6d83627c08f021c_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQyMjQ_1fc9d554-942b-46c6-a1d4-34809bd74dc6">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iba7798242f3b4c25b6738d30fa118ce1_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQyMzk_87bfe131-da40-475b-9896-591738b64c96">2.3</ix:nonFraction> million, respectively. At December&#160;31, 2021 and 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzMjk_c880fa53-ede5-4729-9853-8b8373c1c8a0">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9609157af4444ad383c75696d8f21624_I20201231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzMzY_459b9c30-f7c3-4866-a423-7dabeb9e2781">425,000</ix:nonFraction>, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ0MTE_9887303e-6f86-4910-b7f8-4e91cbc962e3">548,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9609157af4444ad383c75696d8f21624_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ0MTg_ab6f0a76-578b-4b59-9084-f00fbfa60bf9">643,000</ix:nonFraction>, respectively, related to Wistar. As of December&#160;31, 2021, the Company had a prepaid expense balance of $<ix:nonFraction unitRef="usd" contextRef="i9609157af4444ad383c75696d8f21624_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjM0MzY_a61452b2-84f7-4d85-81fc-db6d69fc8d5c">261,000</ix:nonFraction> and recorded $<ix:nonFraction unitRef="usd" contextRef="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ0ODE_25f81703-a3ec-48c1-8a40-52517036a711">37,000</ix:nonFraction> as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="ie30ae5fecfcc4388997084d44bc65ac3_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzkyNzc_be6ea71e-c9e6-4a85-a145-f7114c46833a" continuedAt="i3ca9bb6e976b4e098720f356d58ea9cb" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="i3ca9bb6e976b4e098720f356d58ea9cb" continuedAt="i4fa07156630d4f07b7cd7757e046808f"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="ib4b9648133c14f64986de131ff9b55c1_D20190201-20190228" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzM3OA_31d28730-40d2-44e0-bbdb-0bc072ee99af">1.2</ix:nonFraction>&#160;million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i2c28778c30d04e92b3843a48a585dbb4_I20190228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzUwNw_016422f2-d6e2-4df9-848f-04058864adcc">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i6d0ce816abac42bdabeaed537ab884e8_I20200101" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzgwMA_8f89e759-80e6-4296-8c82-4ab062aab63a">800,000</ix:nonFraction>. Following this transaction, as of March 31, 2020, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i14abd64fd4ca460b8acf05ac1d77a2c2_I20200331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg3MQ_fbaf7405-c8ba-41d4-a62f-076873d55d03">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i3ffdc36023f54e9fa96891a1aedfccaa_I20210630" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzExMjI_a7d15550-16ab-4650-929c-90efb40ff37c">800,000</ix:nonFraction>. Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="ic1a5d5fed4e84bfaaaa1da165905d43b_I20200630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzExNzM_04ee0ed9-bdb4-442a-9426-49dcd1e2b55a">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzE4NDM_1942cc2c-cd0f-4459-be94-bcc70ac03699">4.1</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzE4NTY_6f20f3ac-2255-489f-8674-27c9718f0109">2.4</ix:nonFraction>&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value. The gain has been recorded separately on the Company's consolidated statement of operations. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzkyNzg_ed966edd-1cc9-4c4f-b295-e66328f796cc" continuedAt="i7f237c07ad9a457d8e04a8a99aa91ad3" escape="true">The following table shows the amounts related to the deconsolidation accounting: </ix:nonNumeric></span></div><ix:continuation id="i7f237c07ad9a457d8e04a8a99aa91ad3" continuedAt="i3dba0345df8e4cc589375e7e9b29e739"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="ino:WorkingCapitalExcludingCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzAtMS0xLTEtMTMwNzk_173c2c40-0e13-456d-a5ed-8c7b9c76a856">59,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzEtMS0xLTEtMTMwNzk_00f14cba-8ef0-47c2-b6d0-6406b66cfcfa">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzItMS0xLTEtMTMwNzk_a61f8294-8d61-4fb8-8150-a60b83698e51">16,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzMtMS0xLTEtMTMwNzk_be0c82c9-1bb9-464d-9410-bf225eff04b7">3,181,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="us-gaap:RetainedInterestFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzQtMS0xLTEtMTMwNzk_41e10431-f325-4e02-8cab-b35729bfb8ac">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzUtMS0xLTEtMTMwNzk_966e6c4c-6ee0-4e96-bec4-be466b33c1f0">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzYtMS0xLTEtMTMwNzk_556b51b3-6cbf-4222-8bdc-e12b70ce70c6">2,774,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="i6afcb9b96a3643e394e9339a35bf52eb_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzIxNjQ_e4ddee5c-b44e-43db-a709-351d1b05d473">47</ix:nonFraction>% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzEtMS0xLTEtMTMwNzk_f9c4d4fa-a364-4410-a19b-464cfa7cf4af">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzEtMy0xLTEtMTMwNzk_c2f2612c-646e-4353-8678-bd58388794ab">0.273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzEtNS0xLTEtMTMwNzk_b9c3d6a5-a423-45f5-b76e-fd3de86f49f6">819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i923c4d838e73472daff6f5c2a0b66af9_I20200601" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzItMS0xLTEtMTMwNzk_97d1848d-ae01-4277-9639-4e99449a2920">2,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i923c4d838e73472daff6f5c2a0b66af9_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzItMy0xLTEtMTMwNzk_e226f8db-6b99-4e5a-b8d0-6fb21d897088">1.325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923c4d838e73472daff6f5c2a0b66af9_I20200601" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzItNS0xLTEtMTMwNzk_9585c5ed-3a78-463f-a6ba-4d36171a105b">2,799,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzMtMS0xLTEtMTMwNzk_4e98eaeb-fdc2-4f33-9c7c-59b666265208">5,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzMtNS0xLTEtMTMwNzk_4d52d0dc-ea6e-460b-b2ac-cfbaa1543cec">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217;s enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4fa07156630d4f07b7cd7757e046808f" continuedAt="ib573e1faab8043058d95c5660992844c"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption. The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. <ix:nonNumeric contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzkyNzk_6ff10805-96bb-49ec-b1a1-f9e1f0b1d6cd" continuedAt="i14a265a620ee495bb1abf9d46a5a6741" escape="true">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i14a265a620ee495bb1abf9d46a5a6741"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic982a0927e6846e8873518def396e93c_D20200601-20200601" name="ino:AlternativeInvestmentMeasurementInputTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzAtMS0xLTEtMTMwNzk_5efa1a98-934f-45ac-82b6-94c3fcfcd165">2.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic828dfae01914c5dadca776a2dbad2ad_I20200601" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzEtMS0xLTEtMTMwNzk_176b65e0-2788-4d0f-8bf1-9d1b0476baa0">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70c92f1527c04f16bf9084ab8878ced9_I20200601" decimals="4" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzItMS0xLTEtMTMwNzk_a28cdeba-93d0-4273-ab5c-65dd9403180a">2.46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="ino:EquityMethodInvestmentEnterpriseValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzMtMS0xLTEtMTMwNzk_4bbb985e-cb3e-41e9-96d9-9862cd34e0a2">4,966,531</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the Series A preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i48f7e5188b3845c9ab32ff4a6346e973_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzY4ODE_c85277ad-7c33-4af5-8183-aa1bfb44d86b">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="ie564892056a949fe9b105cc382205542_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzc1MDg_b2fad034-6a51-49cc-ab6b-93387e787c3b">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $<ix:nonFraction unitRef="usd" contextRef="i05ba584f59334065a632c11588572f53_D20200601-20201231" decimals="-5" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg0Nzg_992f9780-a8a0-4615-948e-982da260e747">4.6</ix:nonFraction>&#160;million and for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331" decimals="-5" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODAyMzQ_c6b1662d-ecb4-40e8-840a-dc56d6f20db8">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODAyNDg_e82f8a67-30cc-420b-8603-77fee067e9e4">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="i3ffdc36023f54e9fa96891a1aedfccaa_I20210630" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODAyNTg_3df9d02a-c04a-4d89-8123-69e1873fe509">0</ix:nonFraction>. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f this amount, $<ix:nonFraction unitRef="usd" contextRef="i30ef1cfdaf874c749abaf0297c07f342_D20200601-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg0OTg_66d6fc57-644c-4bf7-828c-34868ce61793">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i3aaedc813254497f95ad1fb1461a99b8_I20210331" decimals="0" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg1ODU_991086b4-2c19-4913-9067-d73392334662">0</ix:nonFraction> as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:continuation id="i3dba0345df8e4cc589375e7e9b29e739" continuedAt="i4de0083c9b1a48359acfb3b5a24a958f">The remaining </ix:continuation></span><ix:continuation id="i4de0083c9b1a48359acfb3b5a24a958f" continuedAt="i6304db0dc4624b008417487798ac7b55"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie01459eec92d4ada9c407fd1befdf459_D20200601-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg2MTI_74c22fbf-a226-4471-94e3-947ded170da3">4.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss has been allocated to the Company&#8217;s </span></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib573e1faab8043058d95c5660992844c"><ix:continuation id="i6304db0dc4624b008417487798ac7b55"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $<ix:nonFraction unitRef="usd" contextRef="i657942a14f6441a2bd23b51205eae9a3_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg3ODI_e4a0ea0f-d46e-4b31-97d8-34c31cf1d649">0</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzEtMi0xLTEtMTMwNzk_90be9744-838f-4028-8bc0-ae90a30324ff">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa18a071c4404f868cef43212fce1e2c_I20200601" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzItMi0xLTEtMTMwNzk_ceb79402-836e-4189-9f37-df89ad84fb99">1,399,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05ba584f59334065a632c11588572f53_D20200601-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzMtMi0xLTEtMTMwNzk_75ff363b-fc82-4f1b-8039-50d71cd7b7e7">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzQtMi0xLTEtMTcwMDc_1bbc8f5e-5214-44c8-a09c-c21648eb8953">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a42fdc8de284579bf2e8654f3f26a01_I20210331" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzQtMi0xLTEtMTMwNzk_d6e84d89-4327-47c2-a3ce-f45768a3ef2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="i1f23c07d6cfb47f2a060dfee7b1f5455_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODA3MDE_38d7b6c8-6144-4a2b-a359-2798d67775a6">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i377ac441325e467a8c00a33146b64c62_I20210228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODA3MDk_62abb40c-d53c-4d1f-9108-a80db2a46439">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ino-12312021x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i26014566c0af4ba99efeea5604cf9437_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subsidiary Name(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Asia, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ino-12312021x10kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie7a7422c9bf1443a8db01de285d3a07f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 236202) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 237172) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 252256) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No.333-161559) pertaining to Inovio Biomedical Corporation 2007 Omnibus Incentive Plan,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to Inovio Pharmaceuticals, Inc&#8217;s 2007 Omnibus Incentive Plan, </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, and 333-231872) Inovio Pharmaceutical, Inc.&#8217;s 2016 Omnibus Incentive Plan, and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-236201) Inovio Pharmaceutical, Inc.&#8217;s 2016 Omnibus Incentive Plan, as amended</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our reports dated March&#160;1, 2022, with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">March&#160;1, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ino-12312021x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i23f4eaeb0eb04dc4859cfe256fc748fc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, J. Joseph Kim, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ino-12312021x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i57229c1f767b49b68ac9d68652e2db6d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ino-12312021x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2f6448712b50492f931ba1e8d97b2cb1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ending December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>ino-12312021x10kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8e582575e2f3442d95392e335f3a56f1_33"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Inovio Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Resolutions of the Board of Directors </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Ratification of Equity Awards Made By CEO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Approved and adopted&#58; February 24, 2022</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Ratification of the Grant of Certain Stock Options and Restricted Stock Units </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, pursuant to Section 157(c) of the General Corporation Law of the State of Delaware (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;), a board of directors may, by a resolution, authorize an officer of a corporation to do one or both of the following&#58; (i) designate officers and employees of the corporation or of any of its subsidiaries to be recipients of equity incentive awards created by the corporation, and (ii) determine the number of such equity incentive awards to be received by such officers and employees&#59; provided, however, that the resolution so authorizing such officer shall specify the total number of equity incentive awards such officer may so award&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, from January 1, 2004 through February 11, 2022, Inovio Pharmaceuticals, Inc., a Delaware Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), acting via the President and Chief Executive Officer of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), awarded stock option grants and restricted stock unit awards to various employees and consultants on the dates and in the amounts of (i) shares of Company common stock, par value $0.001 or (ii) restricted stock units, as the case may be, listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> attached hereto (such awards, the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;), pursuant to the terms and conditions of each awardee's respective stock option grant agreement, stock option grant notice, and&#47;or restricted stock unit agreement (collectively, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">&#34;Grant Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;) and one of the following&#58; the Amended 2000 Stock Option Plan, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the 2007 Amended and Restated Omnibus Incentive Plan or the 2016 Omnibus Incentive Plan, as amended (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; and together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;)&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Section 204 of the DGCL defines a &#34;defective corporate act&#34; as any act or transaction purportedly taken on behalf of a corporation that is, and at the time such act was purportedly taken would have been, within the power of a corporation, but is void or voidable due to a failure of authorization&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, pursuant to Section 204 of the DGCL, no defective corporate act shall be void or voidable solely as a result of a failure of authorization, if ratified pursuant to Section 204 of the DGCL&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) has determined that the Grants were defective corporate acts because they did not fully comply with the requirements of Section 157(c) of the DGCL&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, the Board has determined that it is advisable and in the best interests of the Company and its stockholders to approve and ratify the Grants, in all respects&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, pursuant to Section 204(c) of the DGCL, the Company is not required to submit the ratification to the stockholders for approval&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, pursuant to Section 204(g) of the DGCL, the Company is required to give prompt notice of the ratification to all holders of valid stock, as of a date within 60 days of the adoption of these resolutions, which notice will be deemed to have been given if disclosed in a document publicly filed by the Company with the Securities and Exchange Commission (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;) pursuant to &#167;13, &#167;14, or &#167;15(d) of the Securities Exchange Act of 1934 (such notice, the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NOW, THEREFORE BE IT RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that, each of the Grants is a defective corporate act to be ratified hereby&#59; and be it</font></div><div><font><br></font></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FURTHER RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that the nature of the failure of proper authorization is that the Grants were not properly authorized in accordance with Section 157 of the DGCL&#59; and be it</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FURTHER RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that pursuant to Section 204 of the DGCL, the Board hereby authorizes, ratifies and approves the Grants, and the stock options and restricted stock units of the Company granted thereunder are authorized, ratified and approved in all respects, subject to the terms and conditions of each award's respective Grant Agreement and the applicable Plan&#59; and be it </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FURTHER RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that the appropriate officers of the Company are hereby authorized to file pursuant to &#167;13, &#167;14, or &#167;15(d) of the Securities Exchange Act of 1934 a Notice disclosing the ratification&#59; and be it </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FURTHER RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that the officers of the Company (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Authorized Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;), be, and each of them hereby is, authorized, empowered and directed, in the name and on behalf of the Company, to take or cause to be taken any and all such further actions, to execute and deliver or cause to be executed and delivered all such other documents, certificates, instruments and agreements, and to make such filings, with the SEC or otherwise, in the name and on behalf of the Company, to incur and pay all such fees and expenses and to engage in such acts as they shall in their judgment determine to be necessary, desirable or advisable in order to carry out fully the intent and purposes of the foregoing resolutions and the execution by the Authorized Officers of any such documents, certificates, instruments or agreements or the payment of any such fees and expenses or the doing by them of any act in connection with the foregoing matters shall conclusively establish their authority therefor and the approval of the documents, certificates, instruments and agreements so executed, the expenses so paid, the filings so made and the actions so taken&#59; and be it </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FURTHER RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, that any and all actions heretofore taken by any officer, representative or director of the Company in connection with any matter referred to or contemplated in any of the foregoing resolutions are hereby approved, ratified and confirmed in all respects as the act and deed of the Company. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:360pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit A</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#333333;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Date</font></td><td colspan="3" style="background-color:#333333;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Award Type</font></td><td colspan="3" style="background-color:#333333;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Equity</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Feb-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Mar-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Mar-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Apr-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Apr-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Jun-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Aug-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Aug-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Oct-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Nov-2004</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Jan-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Feb-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Feb-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Feb-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Apr-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-May-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-May-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Aug-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Aug-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Sep-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Oct-2005</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Feb-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Mar-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Mar-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Aug-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Aug-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Aug-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Sep-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Oct-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Nov-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Dec-2006</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Jan-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Jan-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,032</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Jan-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Feb-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Apr-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Apr-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Apr-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-May-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-May-2007</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-May-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-May-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-May-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-May-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Jul-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Aug-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Sep-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Oct-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Oct-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Oct-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Dec-2007</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Feb-2008</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Mar-2008</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Apr-2008</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Oct-2008</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jan-2009</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Apr-2009</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Oct-2009</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Dec-2009</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Feb-2010</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Mar-2010</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jul-2010</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Sep-2010</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Nov-2010</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2010</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Jan-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Jan-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Feb-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Apr-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-May-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-May-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jun-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Jul-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Jul-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Jul-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Sep-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Sep-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Oct-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Oct-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Nov-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Nov-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Dec-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Dec-2011</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Jan-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Feb-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Mar-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Mar-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Mar-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Apr-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Apr-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Apr-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-May-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jun-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jun-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Jul-2012</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jul-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Sep-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Oct-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Dec-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Dec-2012</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Feb-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Feb-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Apr-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-May-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Jul-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jul-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Aug-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Sep-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Sep-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Sep-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Oct-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Nov-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Nov-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Dec-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Dec-2013</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Jan-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jan-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Jan-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Feb-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Feb-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Feb-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Apr-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Apr-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Apr-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-May-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-May-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-May-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-May-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Jun-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Jun-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Jul-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Jul-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Jul-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Sep-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Sep-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Sep-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Sep-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Oct-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Oct-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Oct-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Nov-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Dec-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Dec-2014</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Jan-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Jan-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jan-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jan-2015</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jan-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Feb-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Mar-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Apr-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Apr-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Apr-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Apr-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Apr-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-May-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-May-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-May-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-May-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jun-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jul-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Jul-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jul-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Aug-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Sep-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Sep-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Sep-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Sep-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Sep-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Oct-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Oct-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Oct-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Oct-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Oct-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Oct-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Dec-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Dec-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Dec-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Dec-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Dec-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Dec-2015</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Jan-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Feb-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Feb-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Feb-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Mar-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Mar-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Mar-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Mar-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-May-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jun-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jul-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Aug-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Sep-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Oct-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Dec-2016</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Jan-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Jan-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Jan-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jan-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Feb-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Feb-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Feb-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Feb-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Feb-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Feb-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Mar-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Mar-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Mar-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Apr-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Apr-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Apr-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-May-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Jun-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Jun-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Jun-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jul-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Aug-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Sep-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Oct-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Oct-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Oct-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Oct-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Oct-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Oct-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Nov-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Nov-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Nov-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Nov-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Nov-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Nov-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Dec-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Dec-2017</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Jan-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Jan-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Jan-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jan-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Feb-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Feb-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Mar-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Apr-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-May-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-May-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Jun-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Jun-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jun-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Jun-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jun-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jun-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Jul-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Jul-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Jul-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Jul-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jul-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jul-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Aug-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Aug-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Aug-2018</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Sep-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Oct-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Oct-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Nov-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Nov-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Nov-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Nov-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Dec-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Dec-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Dec-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Dec-2018</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jan-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Feb-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Feb-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Feb-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Mar-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Mar-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Mar-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Mar-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Mar-2019</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Apr-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-May-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-May-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-May-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-May-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jun-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jun-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Jul-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jul-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Aug-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Sep-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Sep-2019</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Oct-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Oct-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Oct-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Oct-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Nov-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Nov-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Dec-2019</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jan-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Feb-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03-Feb-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Feb-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Feb-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Mar-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Apr-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Apr-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Apr-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-May-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Jun-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Jun-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-Jun-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Jun-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Jun-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jul-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Aug-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Sep-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Oct-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Nov-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Nov-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Dec-2020</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jan-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Feb-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Feb-2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Feb-2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Mar-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Mar-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Mar-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Mar-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Apr-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-May-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17-May-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-May-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-May-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28-Jun-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Jul-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-Aug-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07-Sep-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Sep-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Sep-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Sep-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23-Sep-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27-Sep-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Oct-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29-Nov-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-Dec-2021</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (NQ)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,668</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,375</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,332</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.814%"><tr><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31-Jan-2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Units (RSU)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7-Feb-2022</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options (ISO)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250</font></td></tr></table></div><div style="height:42.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ino-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:91a42a7e-9c16-46a4-89e4-78ae514a2e8d,g:17ea50c5-1e55-4356-a463-d0e13f29ef69-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.inovio.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.inovio.com/role/TheCompany">
        <link:definition>2101101 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRisk" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk">
        <link:definition>2108103 - Disclosure - Revenue Recognition and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskTables" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables">
        <link:definition>2309302 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails">
        <link:definition>2410404 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails">
        <link:definition>2411405 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2112104 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2413406 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>2114105 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>2315303 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>2416407 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>2119106 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>2320304 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2421410 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails">
        <link:definition>2422411 - Disclosure - Prepaid Expenses and Other Current Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.inovio.com/role/FixedAssets">
        <link:definition>2123107 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.inovio.com/role/FixedAssetsTables">
        <link:definition>2324305 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.inovio.com/role/FixedAssetsDetails">
        <link:definition>2425412 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>2126108 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2327306 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails">
        <link:definition>2428413 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1">
        <link:definition>2428413 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2429414 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
        <link:definition>2430415 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2131109 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2332307 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2433416 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceOfConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails">
        <link:definition>2434417 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>2435418 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpenses">
        <link:definition>2136110 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2337308 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails">
        <link:definition>2438419 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2139111 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2340309 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails">
        <link:definition>2441420 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2442421 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionsOutstandingDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails">
        <link:definition>2443422 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails">
        <link:definition>2444423 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails">
        <link:definition>2445424 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>2146112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2347310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2448425 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails">
        <link:definition>2449426 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1">
        <link:definition>2449426 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2150113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.inovio.com/role/IncomeTaxesTables">
        <link:definition>2351311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofPretaxLossfromOperationsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails">
        <link:definition>2452427 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails">
        <link:definition>2453428 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2454429 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2455430 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
        <link:definition>2456431 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
        <link:definition>2457432 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.inovio.com/role/A401kPlan">
        <link:definition>2158114 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.inovio.com/role/A401kPlanDetails">
        <link:definition>2459433 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2160115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2461434 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2162116 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2363312 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2464435 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDeconsolidationAccountingDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails">
        <link:definition>2465436 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncInvestmentinGeneosDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails">
        <link:definition>2466437 - Disclosure - Geneos Therapeutics, Inc. - Investment in Geneos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncFairValueAssumptionsDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails">
        <link:definition>2467438 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredStockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails">
        <link:definition>2468439 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EquityComponentOfConvertibleDebtIssued" abstract="false" name="EquityComponentOfConvertibleDebtIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFiveMember" abstract="true" name="RangeOfExercisePricesFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesIncMember" abstract="true" name="PlumblineLifeSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CEPIMERSMember" abstract="true" name="CEPIMERSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_TaxBenefitsExpired" abstract="false" name="TaxBenefitsExpired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ProceedsFromCollaborativeAgreement" abstract="false" name="ProceedsFromCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ProceedsFromSubGrant" abstract="false" name="ProceedsFromSubGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AfterJanuary22020ConversionPriceMember" abstract="true" name="AfterJanuary22020ConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DebtinstrumentAccruedInterest" abstract="false" name="DebtinstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFourMember" abstract="true" name="RangeOfExercisePricesFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_AllOtherCustomersMember" abstract="true" name="AllOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AnnualMaintenancePeriod" abstract="false" name="AnnualMaintenancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinTwoYears" abstract="false" name="TaxCreditCarryforwardExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_InitialConversionPriceMember" abstract="true" name="InitialConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_CommonStockEquivalentsAbstract" abstract="true" name="CommonStockEquivalentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PLSaffiliatedentityMember" abstract="true" name="PLSaffiliatedentityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementCorporateIncomeTax" abstract="false" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" abstract="false" name="DeferredTaxLiabilitiesFinancingArrangementDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" abstract="false" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeTaxReconciliationStatuteLimitations" abstract="false" name="IncomeTaxReconciliationStatuteLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AlternativeInvestmentMeasurementInputTerm" abstract="false" name="AlternativeInvestmentMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_AfterJuly22020ConversionPriceMember" abstract="true" name="AfterJuly22020ConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementRevenueFromTheProcurementContract" abstract="false" name="CollaborativeArrangementRevenueFromTheProcurementContract" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_August2019ConvertibleBondsMember" abstract="true" name="August2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" abstract="false" name="ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_PennsylvaniaStateIncomeTaxAuthorityMember" abstract="true" name="PennsylvaniaStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" abstract="false" name="CollaborativeAgreementMilestonePaymentRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ComprehensiveIncomeLossTaxExpenseBenefit" abstract="false" name="ComprehensiveIncomeLossTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" abstract="false" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PrepaidManufacturingExpensesCurrent" abstract="false" name="PrepaidManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedExercisedAmount" abstract="false" name="CollaborativeAgreementAwardedExercisedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardCarryforwardIndefinitely" abstract="false" name="TaxCreditCarryforwardCarryforwardIndefinitely" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DoDMember" abstract="true" name="DoDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WorkingCapitalExcludingCash" abstract="false" name="WorkingCapitalExcludingCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" abstract="false" name="OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_LesseeNumberOfLeaseAgreementsEnteredInto" abstract="false" name="LesseeNumberOfLeaseAgreementsEnteredInto" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinTwoYears" abstract="false" name="OperatingLossCarryforwardsExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OtherRevenueMember" abstract="true" name="OtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" abstract="false" name="ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" abstract="false" name="ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesSixMember" abstract="true" name="RangeOfExercisePricesSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccruedSubcontractExpenses" abstract="false" name="AccruedSubcontractExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_KoreanStateIncomeTaxAuthorityMember" abstract="true" name="KoreanStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PriorSalesAgreementMember" abstract="true" name="PriorSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DepositAssetsForfeited" abstract="false" name="DepositAssetsForfeited" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFiveYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsfromStockOptionandWarrantExercises" abstract="false" name="ProceedsfromStockOptionandWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OtherRevenueAffiliatedEntityMember" abstract="true" name="OtherRevenueAffiliatedEntityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NewSalesAgreementMember" abstract="true" name="NewSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesOneMember" abstract="true" name="RangeOfExercisePricesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsIndefinitelyCarryforward" abstract="false" name="OperatingLossCarryforwardsIndefinitelyCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetInterestExpense" abstract="false" name="DeferredTaxAssetInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinFourMonths" abstract="false" name="TaxCreditCarryforwardExpiringinFourMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_EquityMethodInvestmentEnterpriseValue" abstract="false" name="EquityMethodInvestmentEnterpriseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFourYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AmortizationOfOperatingLeaseRightOfUseAssets" abstract="false" name="AmortizationOfOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CaliforniaIncomeTaxAuthorityMember" abstract="true" name="CaliforniaIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinFiveYears" abstract="false" name="TaxCreditCarryforwardExpiringinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantRevenuePolicyTextBlock" abstract="false" name="GrantRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" abstract="false" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinThreeYears" abstract="false" name="OperatingLossCarryforwardsExpiringinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinThreeMonths" abstract="false" name="TaxCreditCarryforwardExpiringinThreeMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" abstract="false" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetsIntangibleAssets" abstract="false" name="DeferredTaxAssetsIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseInOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesThreeMember" abstract="true" name="RangeOfExercisePricesThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesTwoMember" abstract="true" name="RangeOfExercisePricesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ConvertibleBondsMember" abstract="true" name="ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" abstract="true" name="AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAdvisoryFees" abstract="false" name="CollaborativeAgreementAdvisoryFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" abstract="false" name="NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ino-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:91a42a7e-9c16-46a4-89e4-78ae514a2e8d,g:17ea50c5-1e55-4356-a463-d0e13f29ef69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cb79a39-6219-4524-851f-9e04c407efed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cb79a39-6219-4524-851f-9e04c407efed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9534947b-e8cf-47ed-8759-33d9f9a3fe93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9534947b-e8cf-47ed-8759-33d9f9a3fe93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_771638f1-819a-4a12-bb08-4f5ec7fbafcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_771638f1-819a-4a12-bb08-4f5ec7fbafcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_17b3aba6-6104-42e8-a03b-20a04c6f8f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_17b3aba6-6104-42e8-a03b-20a04c6f8f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_0de27c3c-ec16-4047-a78d-16c2231e7462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:to="loc_us-gaap_ShortTermInvestments_0de27c3c-ec16-4047-a78d-16c2231e7462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_49f616e3-2e1d-4c7f-a206-6e779f912638" xlink:href="ino-20211231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd1797f9-7917-4e1e-bdcb-cbcadf662b9c" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_49f616e3-2e1d-4c7f-a206-6e779f912638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_591d17ba-6dbb-4dbe-b36c-255cb8855b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_591d17ba-6dbb-4dbe-b36c-255cb8855b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_12afbd26-7264-46cf-a9b1-5c72f3d359fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_AssetsCurrent_12afbd26-7264-46cf-a9b1-5c72f3d359fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c8ed21b4-cace-4cd2-9f69-d453fcea389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_EquityMethodInvestments_c8ed21b4-cace-4cd2-9f69-d453fcea389e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c2d4d5e-43bd-4d79-8c88-f6039a924b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c2d4d5e-43bd-4d79-8c88-f6039a924b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3f501d19-d1b5-49b1-8a1b-f9ebcf84d967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_Goodwill_3f501d19-d1b5-49b1-8a1b-f9ebcf84d967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_262092bd-911b-4bf3-bba7-09048955a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_262092bd-911b-4bf3-bba7-09048955a674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_146727bc-3325-4133-bbc3-da63fbe63ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_146727bc-3325-4133-bbc3-da63fbe63ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5baeff87-5e42-414b-8611-efefb0c1c0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b161314-4689-4e4a-a064-ff41d474b6c3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5baeff87-5e42-414b-8611-efefb0c1c0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70721c2f-aa32-4696-b189-ea049cca684a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4803d2aa-81cd-4c97-9eb3-148e64306fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70721c2f-aa32-4696-b189-ea049cca684a" xlink:to="loc_us-gaap_PreferredStockValue_4803d2aa-81cd-4c97-9eb3-148e64306fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e43f15f4-23d1-4ad0-bb7c-31be4e562685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70721c2f-aa32-4696-b189-ea049cca684a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e43f15f4-23d1-4ad0-bb7c-31be4e562685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71bd7f92-1bd0-4781-8ee9-2aae8dbf5cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70721c2f-aa32-4696-b189-ea049cca684a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71bd7f92-1bd0-4781-8ee9-2aae8dbf5cfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_18a90262-e677-47ce-89af-dece57676bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70721c2f-aa32-4696-b189-ea049cca684a" xlink:to="loc_us-gaap_CommonStockValue_18a90262-e677-47ce-89af-dece57676bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_de8038be-306f-40fb-8602-3d5709d9b9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70721c2f-aa32-4696-b189-ea049cca684a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_de8038be-306f-40fb-8602-3d5709d9b9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f172897-a8cd-44f7-b2cb-4708767aaa02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_20c31b7e-b89c-4ff7-b15c-68b3ddf57082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f172897-a8cd-44f7-b2cb-4708767aaa02" xlink:to="loc_us-gaap_Liabilities_20c31b7e-b89c-4ff7-b15c-68b3ddf57082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_27f25bda-dc6a-4ced-a4df-c3e660393c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f172897-a8cd-44f7-b2cb-4708767aaa02" xlink:to="loc_us-gaap_CommitmentsAndContingencies_27f25bda-dc6a-4ced-a4df-c3e660393c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fe5a3ce-dbaf-4aeb-a81c-b347774f3dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f172897-a8cd-44f7-b2cb-4708767aaa02" xlink:to="loc_us-gaap_StockholdersEquity_7fe5a3ce-dbaf-4aeb-a81c-b347774f3dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8c64afcd-4db6-46ea-849a-72f90d6e9eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8c64afcd-4db6-46ea-849a-72f90d6e9eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f28f596d-15f3-4c05-8a52-c5072ed3fc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f28f596d-15f3-4c05-8a52-c5072ed3fc7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_1daa58c9-9b5b-44b5-ac38-d7469e9d7a17" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_ino_DeferredGrantFundingCurrent_1daa58c9-9b5b-44b5-ac38-d7469e9d7a17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_c4908097-a3e1-463a-af80-4db31aca6015" xlink:href="ino-20211231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_c4908097-a3e1-463a-af80-4db31aca6015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ff9f95c-9aff-452b-a1be-d254fd7650a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ff9f95c-9aff-452b-a1be-d254fd7650a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_3eaef8f2-a2f7-4801-a707-3feeae01b459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_3eaef8f2-a2f7-4801-a707-3feeae01b459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_2c0a2000-1694-4520-b785-d2ecc10d65f3" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2de876d3-dfc1-4dfb-a538-3109e0476260" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_2c0a2000-1694-4520-b785-d2ecc10d65f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_664a570c-97bf-485a-9187-4aeed7807ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_us-gaap_ConvertibleDebt_664a570c-97bf-485a-9187-4aeed7807ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1061a54-cbba-4d39-bf41-bd829eca8fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1061a54-cbba-4d39-bf41-bd829eca8fac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_42150623-e6e7-4771-82d5-a93bedac9ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_42150623-e6e7-4771-82d5-a93bedac9ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_44c4c22d-ebba-46ab-b4a7-52e3cec763bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_44c4c22d-ebba-46ab-b4a7-52e3cec763bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_df7db51f-598a-4ef0-af6f-0cce3a41323c" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_df7db51f-598a-4ef0-af6f-0cce3a41323c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7188f81f-cdd8-4443-818d-7ba241ed8a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7188f81f-cdd8-4443-818d-7ba241ed8a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_523332c1-0273-4555-99e2-5e362a6af29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_14c8ca64-08df-4124-b688-5e87e6b8b54e" xlink:to="loc_us-gaap_LiabilitiesCurrent_523332c1-0273-4555-99e2-5e362a6af29a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d2a00a96-a8a3-4963-86eb-7e0ad0dd03da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a9e377ae-ac4f-463b-ad97-1f78900cddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d2a00a96-a8a3-4963-86eb-7e0ad0dd03da" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a9e377ae-ac4f-463b-ad97-1f78900cddd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_07f6e438-d5a7-4528-97bd-097ea11f0e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d2a00a96-a8a3-4963-86eb-7e0ad0dd03da" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_07f6e438-d5a7-4528-97bd-097ea11f0e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b45a183d-a71c-4f44-8b93-546773690f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d2a00a96-a8a3-4963-86eb-7e0ad0dd03da" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b45a183d-a71c-4f44-8b93-546773690f7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f6a3809e-3088-4f6f-b4a3-bbf5db9dbdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_OperatingIncomeLoss_f6a3809e-3088-4f6f-b4a3-bbf5db9dbdf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d378caf8-9b66-4216-a11e-b2fb8263465b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_d378caf8-9b66-4216-a11e-b2fb8263465b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5ec1fd35-30a2-45dd-bb04-12be742e4b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_InterestExpense_5ec1fd35-30a2-45dd-bb04-12be742e4b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_883e7bf1-26ca-4736-8cf0-e3156126500b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_883e7bf1-26ca-4736-8cf0-e3156126500b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_540166f3-d9c6-4f22-b3c1-8862d2359b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_540166f3-d9c6-4f22-b3c1-8862d2359b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_06314b4b-23b1-40ab-91f7-04051e5d60cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_06314b4b-23b1-40ab-91f7-04051e5d60cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_109bf032-b51a-4069-9047-118b43147684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_109bf032-b51a-4069-9047-118b43147684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cddcc870-a68b-4bae-b57d-70504ef82be5" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cddcc870-a68b-4bae-b57d-70504ef82be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_3e55a2fa-9ad0-4404-bacb-c4d1d51802ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6a749459-7b32-40dc-9926-634cedf08a80" xlink:to="loc_us-gaap_InterestIncomeOperating_3e55a2fa-9ad0-4404-bacb-c4d1d51802ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f0637d5c-d3d1-4fb8-8055-fa8c541134a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5efc786a-bcd3-4cb4-a363-021c86eb0a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0637d5c-d3d1-4fb8-8055-fa8c541134a9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5efc786a-bcd3-4cb4-a363-021c86eb0a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f1924727-bd36-4934-8e38-0d562112c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0637d5c-d3d1-4fb8-8055-fa8c541134a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f1924727-bd36-4934-8e38-0d562112c13a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_469a8e27-ecad-4ad7-8295-993e3e565135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fc9a1025-6cce-4e93-b07d-afa9c1bf2e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_469a8e27-ecad-4ad7-8295-993e3e565135" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fc9a1025-6cce-4e93-b07d-afa9c1bf2e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_214c6a82-a759-4c2e-9824-80bfabaaed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_469a8e27-ecad-4ad7-8295-993e3e565135" xlink:to="loc_us-gaap_ProfitLoss_214c6a82-a759-4c2e-9824-80bfabaaed7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1bd8bbd7-c453-4ec4-a0e1-bb665eadcdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aae6a672-73b1-4889-886e-4ea99429eaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1bd8bbd7-c453-4ec4-a0e1-bb665eadcdc2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aae6a672-73b1-4889-886e-4ea99429eaa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_665ccb2c-a5dc-479b-b8c4-e4a8a49747ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1bd8bbd7-c453-4ec4-a0e1-bb665eadcdc2" xlink:to="loc_us-gaap_OperatingExpenses_665ccb2c-a5dc-479b-b8c4-e4a8a49747ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_782fcb51-06a5-4085-ba76-afe9d6dcd60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_79c2c28c-9a8b-4c8d-9d94-9f3d890e2f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_782fcb51-06a5-4085-ba76-afe9d6dcd60d" xlink:to="loc_us-gaap_ProfitLoss_79c2c28c-9a8b-4c8d-9d94-9f3d890e2f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c13cdb52-eb94-42a1-976b-778c37015dde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_782fcb51-06a5-4085-ba76-afe9d6dcd60d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c13cdb52-eb94-42a1-976b-778c37015dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ea125284-857e-4aac-ba5a-f2fa2c63713a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_782fcb51-06a5-4085-ba76-afe9d6dcd60d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ea125284-857e-4aac-ba5a-f2fa2c63713a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_240b60ab-de56-4f76-a429-1e894301f57c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ad0ff0b5-b1be-47cc-9f8e-a2643dc1c588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_240b60ab-de56-4f76-a429-1e894301f57c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ad0ff0b5-b1be-47cc-9f8e-a2643dc1c588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4f507211-72d3-4549-8f53-edf8fefe0b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_240b60ab-de56-4f76-a429-1e894301f57c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4f507211-72d3-4549-8f53-edf8fefe0b02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0664de26-fd6f-4252-a2a0-203216ef15ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_361e591f-3ce4-42fe-9150-0dc43118da6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0664de26-fd6f-4252-a2a0-203216ef15ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_361e591f-3ce4-42fe-9150-0dc43118da6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_635d17fc-3ae2-4f65-b00e-b74649374424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0664de26-fd6f-4252-a2a0-203216ef15ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_635d17fc-3ae2-4f65-b00e-b74649374424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c8e7927-eb31-4416-95fc-9f660762c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0664de26-fd6f-4252-a2a0-203216ef15ed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c8e7927-eb31-4416-95fc-9f660762c2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7895c39f-5724-4f68-8d0a-9b9bf54e617f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0664de26-fd6f-4252-a2a0-203216ef15ed" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7895c39f-5724-4f68-8d0a-9b9bf54e617f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7aa849e0-7fa0-4b51-b460-61bc320842b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7aa849e0-7fa0-4b51-b460-61bc320842b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_5f4d3fd4-9edf-4ba8-9300-3e3847df18df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_5f4d3fd4-9edf-4ba8-9300-3e3847df18df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2f0c3f41-0493-45b2-8558-77562d76b610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2f0c3f41-0493-45b2-8558-77562d76b610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_78b20891-dd52-49d2-ae0d-c183deca7a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_78b20891-dd52-49d2-ae0d-c183deca7a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_39076b8a-9c73-4e0f-b6bd-97bbd0755ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_39076b8a-9c73-4e0f-b6bd-97bbd0755ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_31323a75-2353-4e9a-a1e7-0ebdd97bb7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f7cfd39-d729-4b7a-875d-cd6755fe4794" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_31323a75-2353-4e9a-a1e7-0ebdd97bb7c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_184f4e1a-fb82-4a37-a92e-2d2b21c4467f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_184f4e1a-fb82-4a37-a92e-2d2b21c4467f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7724f9a3-cf0f-4d5c-a269-71387af6a59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7724f9a3-cf0f-4d5c-a269-71387af6a59b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_b1404484-83e6-4aaf-9441-65f737e861b2" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_b1404484-83e6-4aaf-9441-65f737e861b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_813b9326-00f1-46e2-94b9-3c9db77215e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_813b9326-00f1-46e2-94b9-3c9db77215e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_8dfc31b4-aa93-4b38-9d37-de6eabc1ecdf" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_8dfc31b4-aa93-4b38-9d37-de6eabc1ecdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_055f7f7e-5f8e-40de-a833-dc25bad2f84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_055f7f7e-5f8e-40de-a833-dc25bad2f84e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_f9cf8068-989d-48ca-86e9-6862a091af81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_f9cf8068-989d-48ca-86e9-6862a091af81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c03c4e24-d030-4477-9afd-87777ce8f2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c03c4e24-d030-4477-9afd-87777ce8f2d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_50671b56-393f-4890-9db2-6d034a8162f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_50671b56-393f-4890-9db2-6d034a8162f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_37caa552-1e8c-43ef-b89a-1ca515c3082c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_37caa552-1e8c-43ef-b89a-1ca515c3082c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_bebcd6aa-acde-4609-82cd-807542318a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_bebcd6aa-acde-4609-82cd-807542318a3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8e1fa8b3-53cb-4463-b4c8-7a38acf01b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8e1fa8b3-53cb-4463-b4c8-7a38acf01b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_40147b17-561e-4673-ad09-988a15367c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_40147b17-561e-4673-ad09-988a15367c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6bc14f67-c8bc-4a04-aed4-2e388ff1416c" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6bc14f67-c8bc-4a04-aed4-2e388ff1416c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_10a5e860-2136-472f-adaa-6506807a04a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_10a5e860-2136-472f-adaa-6506807a04a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_4ad88a98-7342-418b-8f03-2d63393793d2" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_4ad88a98-7342-418b-8f03-2d63393793d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0db7288f-6884-440c-9e08-469539c537d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0db7288f-6884-440c-9e08-469539c537d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_a8a36b34-b668-42f0-9b72-e14e6aeb657a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_a8a36b34-b668-42f0-9b72-e14e6aeb657a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2eeaff15-8388-46be-9e48-74c716639f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2eeaff15-8388-46be-9e48-74c716639f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_6073c93c-ccd8-468b-b86f-e9d76198b159" xlink:href="ino-20211231.xsd#ino_NonCashInterestExpense"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_NonCashInterestExpense_6073c93c-ccd8-468b-b86f-e9d76198b159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_ca461c7e-6861-4010-a88f-a0794716b9c3" xlink:href="ino-20211231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_ca461c7e-6861-4010-a88f-a0794716b9c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6a2ccd3f-3f73-4816-9225-eec7111b2cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_Depreciation_6a2ccd3f-3f73-4816-9225-eec7111b2cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a428054e-13be-479d-a4a1-e65af3b66b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a428054e-13be-479d-a4a1-e65af3b66b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_53909fcf-26ba-44e1-9404-721d4b9f10e9" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_53909fcf-26ba-44e1-9404-721d4b9f10e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_2dc851cd-1ae2-4e1e-9259-29facb2404e3" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_2dc851cd-1ae2-4e1e-9259-29facb2404e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cc6fb243-f163-4fb7-a7a1-7ee5140d8d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="26" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cc6fb243-f163-4fb7-a7a1-7ee5140d8d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ec9a8fa8-dea0-4332-89f2-705872d08d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_ShareBasedCompensation_ec9a8fa8-dea0-4332-89f2-705872d08d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_dce6ee10-b50c-4d7f-a730-a8a20a69fa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="28" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_dce6ee10-b50c-4d7f-a730-a8a20a69fa5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_662d7807-ec75-4e76-988f-f4480e4020e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="29" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_ProfitLoss_662d7807-ec75-4e76-988f-f4480e4020e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b977c19b-130c-406e-ac23-988b3f3ba43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="30" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b977c19b-130c-406e-ac23-988b3f3ba43e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_0bbc18c4-107f-4b82-a8f3-13f0c5e843d2" xlink:href="ino-20211231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:calculationArc order="31" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_0bbc18c4-107f-4b82-a8f3-13f0c5e843d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_3767267e-5791-4d0b-ae0c-da24fb1a8ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:calculationArc order="32" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_3767267e-5791-4d0b-ae0c-da24fb1a8ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_4d39c53a-494c-4637-9610-41460f5e3f37" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="33" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_807776d4-6347-4625-b49a-64abe824e733" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_4d39c53a-494c-4637-9610-41460f5e3f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_38e7dd30-4d54-468b-b8a1-c6c2c3d586e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_38e7dd30-4d54-468b-b8a1-c6c2c3d586e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_968b4fcb-ee4d-4457-916f-3945f83c26c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_968b4fcb-ee4d-4457-916f-3945f83c26c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2fd68d3e-7fe9-4176-b231-803f90214def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2fd68d3e-7fe9-4176-b231-803f90214def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_1fbca96f-0907-4877-8c19-e179c7104c2e" xlink:href="ino-20211231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_1fbca96f-0907-4877-8c19-e179c7104c2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_ed77fcb8-0f2c-4fd0-93da-22c44afff2c7" xlink:href="ino-20211231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_ed77fcb8-0f2c-4fd0-93da-22c44afff2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_9f422f73-39b0-4cbd-b827-2e2c1e58bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_9f422f73-39b0-4cbd-b827-2e2c1e58bd81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_8504420c-8442-4294-bc1d-b5e767ee59c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a98cfc56-dffc-4b82-825e-5ab0787dccfa" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_8504420c-8442-4294-bc1d-b5e767ee59c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fcc78f0-6adf-446c-9ba8-e72704ac3ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e801b4a-c5a1-4f66-a2ed-dfe178916003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fcc78f0-6adf-446c-9ba8-e72704ac3ac0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e801b4a-c5a1-4f66-a2ed-dfe178916003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9e729b8-354b-4c7f-bdc9-a27330af0640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fcc78f0-6adf-446c-9ba8-e72704ac3ac0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9e729b8-354b-4c7f-bdc9-a27330af0640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_41bd9a01-09fe-447e-9db5-8d61c8c7c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fcc78f0-6adf-446c-9ba8-e72704ac3ac0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_41bd9a01-09fe-447e-9db5-8d61c8c7c02f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8ac7a423-073e-4a1f-b148-ed54dc6c28d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3628a9e6-62a2-4409-96d4-d37a4a892716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac7a423-073e-4a1f-b148-ed54dc6c28d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3628a9e6-62a2-4409-96d4-d37a4a892716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9b1651cc-a304-4280-884a-03323daa5dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac7a423-073e-4a1f-b148-ed54dc6c28d8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9b1651cc-a304-4280-884a-03323daa5dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aa20396f-4c7d-4a4b-a7be-3c926c8b8287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ac7a423-073e-4a1f-b148-ed54dc6c28d8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aa20396f-4c7d-4a4b-a7be-3c926c8b8287" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_953abbb3-ff3c-4c48-b598-18cb7dc684dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_43ec3d85-fe14-4871-8ced-5505f38dec28" xlink:href="ino-20211231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_953abbb3-ff3c-4c48-b598-18cb7dc684dc" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_43ec3d85-fe14-4871-8ced-5505f38dec28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_0faad789-2cd1-464a-a05a-ca85f0bd15c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_953abbb3-ff3c-4c48-b598-18cb7dc684dc" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_0faad789-2cd1-464a-a05a-ca85f0bd15c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#FixedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_05492f5c-1c2a-4e79-acbb-1cd5b2bfd289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2aae1309-217a-4ba4-94b3-f522105189fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_05492f5c-1c2a-4e79-acbb-1cd5b2bfd289" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2aae1309-217a-4ba4-94b3-f522105189fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c6132c4e-2d4c-43e8-b650-f46fdf1190bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_05492f5c-1c2a-4e79-acbb-1cd5b2bfd289" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c6132c4e-2d4c-43e8-b650-f46fdf1190bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_7447a9b5-a646-491f-9949-cb905adbc972" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_41517402-bee2-490a-9469-d8a07ca9f74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_7447a9b5-a646-491f-9949-cb905adbc972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_41517402-bee2-490a-9469-d8a07ca9f74d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3ad3ee75-a5b5-44d2-b2bc-51d70c5a1e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_7447a9b5-a646-491f-9949-cb905adbc972" xlink:to="loc_us-gaap_Goodwill_3ad3ee75-a5b5-44d2-b2bc-51d70c5a1e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_57395c05-3378-4351-8603-a5d4feb971bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f97980b2-145f-481e-be66-a9d66d7da8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_57395c05-3378-4351-8603-a5d4feb971bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f97980b2-145f-481e-be66-a9d66d7da8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_69351baa-ff51-4d01-bbe2-f89cd19240f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_57395c05-3378-4351-8603-a5d4feb971bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_69351baa-ff51-4d01-bbe2-f89cd19240f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_ae423797-7dbf-4ef6-a20e-3d5295118f1a" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f74ebb1b-82f7-4c6f-955a-d6a8ed6d03c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_ae423797-7dbf-4ef6-a20e-3d5295118f1a" xlink:to="loc_us-gaap_Goodwill_f74ebb1b-82f7-4c6f-955a-d6a8ed6d03c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a749bee2-9452-494c-aab2-7a9156257267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_ae423797-7dbf-4ef6-a20e-3d5295118f1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a749bee2-9452-494c-aab2-7a9156257267" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_319ef611-f983-40e4-8cfc-07875557ffc6" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_0180d41a-52aa-4ba9-83c1-cabacae5da96" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_319ef611-f983-40e4-8cfc-07875557ffc6" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_0180d41a-52aa-4ba9-83c1-cabacae5da96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2ed22ff9-4221-49d8-b8a7-1acc4569f611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_319ef611-f983-40e4-8cfc-07875557ffc6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2ed22ff9-4221-49d8-b8a7-1acc4569f611" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ce3f6e9b-8d50-452f-a763-9454ab7719c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ce3f6e9b-8d50-452f-a763-9454ab7719c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e70a1dcc-2585-420b-b37c-267ad1905d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e70a1dcc-2585-420b-b37c-267ad1905d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7197ddc7-d16b-4971-b87a-2f1aade4492d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7197ddc7-d16b-4971-b87a-2f1aade4492d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_08097e4e-ee3f-4e0e-b1c6-b272e6fa8c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_08097e4e-ee3f-4e0e-b1c6-b272e6fa8c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_72662f20-c1c5-48c1-9e01-8fea4398a698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_72662f20-c1c5-48c1-9e01-8fea4398a698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ec67b430-9ee6-4d7a-81ea-8925db708879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e23ae4c8-295d-4720-96ce-d815639c56e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ec67b430-9ee6-4d7a-81ea-8925db708879" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9ec78068-a6d9-4475-9891-3415c5c7e624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22eeb7d5-69af-4fbf-8557-7b345cf7f887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9ec78068-a6d9-4475-9891-3415c5c7e624" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22eeb7d5-69af-4fbf-8557-7b345cf7f887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_3ac4a2aa-f094-4d54-8324-992381a6bd10" xlink:href="ino-20211231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9ec78068-a6d9-4475-9891-3415c5c7e624" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_3ac4a2aa-f094-4d54-8324-992381a6bd10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_69c4b9f7-969c-491a-9b0a-362a36a9931d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9ec78068-a6d9-4475-9891-3415c5c7e624" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_69c4b9f7-969c-491a-9b0a-362a36a9931d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e56966c4-6094-4cb5-b5b9-b3d168a79d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9ec78068-a6d9-4475-9891-3415c5c7e624" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e56966c4-6094-4cb5-b5b9-b3d168a79d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_72aa6909-648a-42af-b93b-1093951e38bd" xlink:href="ino-20211231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9ec78068-a6d9-4475-9891-3415c5c7e624" xlink:to="loc_ino_DebtinstrumentAccruedInterest_72aa6909-648a-42af-b93b-1093951e38bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_62fc7ae9-04f5-4750-aac4-7b4c62e774f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1c3c893f-778c-49e5-9717-eb60fb769372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_62fc7ae9-04f5-4750-aac4-7b4c62e774f3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1c3c893f-778c-49e5-9717-eb60fb769372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_aad43c44-ef98-420f-a355-676e08215e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_62fc7ae9-04f5-4750-aac4-7b4c62e774f3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_aad43c44-ef98-420f-a355-676e08215e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1b87dfc2-9210-4a69-b3d8-b4e6c7a40d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_62fc7ae9-04f5-4750-aac4-7b4c62e774f3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1b87dfc2-9210-4a69-b3d8-b4e6c7a40d2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9325a4fb-cbf4-419d-9439-3a894cc4cd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_fbab48b6-a340-45de-ab18-dd41f36ab4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9325a4fb-cbf4-419d-9439-3a894cc4cd29" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_fbab48b6-a340-45de-ab18-dd41f36ab4c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_43ce197a-04cc-4d90-b756-9907e5887dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9325a4fb-cbf4-419d-9439-3a894cc4cd29" xlink:to="loc_us-gaap_AccruedSalariesCurrent_43ce197a-04cc-4d90-b756-9907e5887dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_4a9ea5dd-4014-433d-9c33-e9bd10a291b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9325a4fb-cbf4-419d-9439-3a894cc4cd29" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_4a9ea5dd-4014-433d-9c33-e9bd10a291b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedSubcontractExpenses_adb56fd7-e284-4c90-9eef-14087ccbad41" xlink:href="ino-20211231.xsd#ino_AccruedSubcontractExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9325a4fb-cbf4-419d-9439-3a894cc4cd29" xlink:to="loc_ino_AccruedSubcontractExpenses_adb56fd7-e284-4c90-9eef-14087ccbad41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b1321b1e-f04a-400e-9b5e-0f7071574e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b1321b1e-f04a-400e-9b5e-0f7071574e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fdbe0544-8d9b-49b0-82ec-83ec71d1ec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fdbe0544-8d9b-49b0-82ec-83ec71d1ec85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8328ca62-e828-4f40-ba90-e9b6a3a93aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8328ca62-e828-4f40-ba90-e9b6a3a93aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_90b9725c-6112-4abb-b669-836c45f58423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_90b9725c-6112-4abb-b669-836c45f58423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_afc08b7a-6611-45eb-bbca-a014cd166da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_afc08b7a-6611-45eb-bbca-a014cd166da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_0351fb82-f72a-4909-9fb4-31013d5ac4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17816a1e-6ad6-40a7-a0ea-abb5537f4616" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_0351fb82-f72a-4909-9fb4-31013d5ac4c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_042107f9-7e02-4f78-a54e-b2e4810f5648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2cff4182-f2bc-4465-a1eb-3683b4bbc4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_042107f9-7e02-4f78-a54e-b2e4810f5648" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2cff4182-f2bc-4465-a1eb-3683b4bbc4f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff5c79bf-940e-4d4d-8690-cdd02d6adc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_042107f9-7e02-4f78-a54e-b2e4810f5648" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff5c79bf-940e-4d4d-8690-cdd02d6adc11" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a4e9619-f578-4c16-a2aa-a8a881902cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_006599a0-7125-48e8-8e63-89fc9f9427bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a4e9619-f578-4c16-a2aa-a8a881902cf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_006599a0-7125-48e8-8e63-89fc9f9427bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1503dd0f-3936-4911-ab27-70ac2cb1677a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a4e9619-f578-4c16-a2aa-a8a881902cf7" xlink:to="loc_us-gaap_OperatingLeaseLiability_1503dd0f-3936-4911-ab27-70ac2cb1677a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a6ee332-d7b1-4699-af8e-ce834e79e99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8a8743a5-04e3-42b4-93d3-728489f55fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a6ee332-d7b1-4699-af8e-ce834e79e99d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8a8743a5-04e3-42b4-93d3-728489f55fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9cbae4c4-6bd3-4d6c-b7ef-967f30687a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a6ee332-d7b1-4699-af8e-ce834e79e99d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9cbae4c4-6bd3-4d6c-b7ef-967f30687a9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:href="ino-20211231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_a85f44ce-acce-407f-b118-95c39253c6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_a85f44ce-acce-407f-b118-95c39253c6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_75203f03-005c-417b-9b07-5ee6203f5f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_75203f03-005c-417b-9b07-5ee6203f5f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_720d2610-19ea-4e4d-bfa2-cbdd2cc433af" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_720d2610-19ea-4e4d-bfa2-cbdd2cc433af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_a62e7bdd-7814-4def-a858-374b905c9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_a62e7bdd-7814-4def-a858-374b905c9b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_eaf5e7d8-8dd0-416a-9da8-f88b95276c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_eaf5e7d8-8dd0-416a-9da8-f88b95276c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_1eead4ce-58da-46a5-bd39-85b39f2222ec" xlink:href="ino-20211231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_1eead4ce-58da-46a5-bd39-85b39f2222ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b2833fef-9a82-41e7-8d99-79f5e4c71113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b2833fef-9a82-41e7-8d99-79f5e4c71113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_a49fbe79-7a2d-4dec-9d5c-47a5e5166c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_a49fbe79-7a2d-4dec-9d5c-47a5e5166c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a915ec01-9ced-4987-9226-2684db6ebe38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a915ec01-9ced-4987-9226-2684db6ebe38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_d0b40168-b95f-4e33-a615-e111971e00ff" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_d0b40168-b95f-4e33-a615-e111971e00ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_73625f37-5d32-439e-87aa-dfafd26ad60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_73625f37-5d32-439e-87aa-dfafd26ad60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_5a7f682b-695c-47f1-8936-fb0e90a9b3d4" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_5a7f682b-695c-47f1-8936-fb0e90a9b3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_fcb51753-701d-49f1-b03e-4e89487f1cd2" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_26cf8885-c384-47fb-9382-6d1d18073dd7" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_fcb51753-701d-49f1-b03e-4e89487f1cd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_062fda12-f420-4c9d-a206-b05cc23d21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ca62002c-c3ae-4055-8a6f-7b1bdc355329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_062fda12-f420-4c9d-a206-b05cc23d21ce" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ca62002c-c3ae-4055-8a6f-7b1bdc355329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5fc6e579-5126-4268-8832-5ee834337005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_062fda12-f420-4c9d-a206-b05cc23d21ce" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5fc6e579-5126-4268-8832-5ee834337005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_86e2000b-056e-488d-a35b-792ccff4ffe7" xlink:href="ino-20211231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_062fda12-f420-4c9d-a206-b05cc23d21ce" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_86e2000b-056e-488d-a35b-792ccff4ffe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_71e08b57-9e83-43e0-8509-9a92de92a8fc" xlink:href="ino-20211231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_062fda12-f420-4c9d-a206-b05cc23d21ce" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_71e08b57-9e83-43e0-8509-9a92de92a8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_93ee4e87-69ce-4593-b91c-6c477e1f80a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_062fda12-f420-4c9d-a206-b05cc23d21ce" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_93ee4e87-69ce-4593-b91c-6c477e1f80a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bd6adc7d-880c-43e5-af63-76d60071d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_bd6adc7d-880c-43e5-af63-76d60071d06f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f0d5cbb9-83c3-404e-9731-cd0902f622b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f0d5cbb9-83c3-404e-9731-cd0902f622b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_be0b003a-d32f-4be6-b4bc-e5d7a6092db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_be0b003a-d32f-4be6-b4bc-e5d7a6092db5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_bfbccd1e-b34f-4e6d-b7a2-2edd6b0a1068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_bfbccd1e-b34f-4e6d-b7a2-2edd6b0a1068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_365e443f-3154-4e01-9829-6cc3c49b02e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_365e443f-3154-4e01-9829-6cc3c49b02e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_7c141bd9-71b8-48ec-923a-dcbb56f2774d" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_7c141bd9-71b8-48ec-923a-dcbb56f2774d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_6e3c56db-b389-4528-81c0-dc9d753dffc4" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_6e3c56db-b389-4528-81c0-dc9d753dffc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_3d42a817-db9e-4f10-89d5-c21f56487097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_3d42a817-db9e-4f10-89d5-c21f56487097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_8ec17f7c-ae47-403d-a8a8-fa822bcc10fe" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_8ec17f7c-ae47-403d-a8a8-fa822bcc10fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_074ed5b7-c518-419f-9074-f3c0b36f4b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1991185b-0e8f-45a5-94f1-b192600fc86a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_074ed5b7-c518-419f-9074-f3c0b36f4b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4bda3c6f-6d27-40f7-8ddd-6f2f8fc503c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6d7dcfab-6c13-4cda-8d52-abe26d3c7989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4bda3c6f-6d27-40f7-8ddd-6f2f8fc503c4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6d7dcfab-6c13-4cda-8d52-abe26d3c7989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7777702f-a0fb-4885-9df7-1293cc19fc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4bda3c6f-6d27-40f7-8ddd-6f2f8fc503c4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7777702f-a0fb-4885-9df7-1293cc19fc69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ad0848c6-4b5b-4c61-a212-ad6aef40f333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_081a550c-73a3-4f11-8191-2288e5a10373" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_ad0848c6-4b5b-4c61-a212-ad6aef40f333" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_081a550c-73a3-4f11-8191-2288e5a10373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_a7ac178a-9bde-4a01-b47a-8527b26ab1bc" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_ad0848c6-4b5b-4c61-a212-ad6aef40f333" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_a7ac178a-9bde-4a01-b47a-8527b26ab1bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_0eb5d302-f473-489d-a3d6-1fb59dfd062a" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_ad0848c6-4b5b-4c61-a212-ad6aef40f333" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_0eb5d302-f473-489d-a3d6-1fb59dfd062a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_9f4610e1-f439-4a1d-a64c-5559735860ec" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_ad0848c6-4b5b-4c61-a212-ad6aef40f333" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_9f4610e1-f439-4a1d-a64c-5559735860ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_75a465f4-6510-4213-88e5-215dddf63d44" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_ad0848c6-4b5b-4c61-a212-ad6aef40f333" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_75a465f4-6510-4213-88e5-215dddf63d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c506e5d6-f8db-4015-b8b1-50a8e4f0e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_1d23f29c-df6b-4a68-812c-391e693144a1" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c506e5d6-f8db-4015-b8b1-50a8e4f0e3cc" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_1d23f29c-df6b-4a68-812c-391e693144a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_d79575d9-25e9-4c7c-a6f7-30ebd2fb3cad" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c506e5d6-f8db-4015-b8b1-50a8e4f0e3cc" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_d79575d9-25e9-4c7c-a6f7-30ebd2fb3cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_0d212cc6-2407-4a07-909c-5ba8e03ca273" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c506e5d6-f8db-4015-b8b1-50a8e4f0e3cc" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_0d212cc6-2407-4a07-909c-5ba8e03ca273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_9b73b32e-0a57-4599-8918-6fa08d9829ad" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c506e5d6-f8db-4015-b8b1-50a8e4f0e3cc" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_9b73b32e-0a57-4599-8918-6fa08d9829ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_3d34b66d-ebc1-42a0-bc40-d1877e6db460" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_c506e5d6-f8db-4015-b8b1-50a8e4f0e3cc" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_3d34b66d-ebc1-42a0-bc40-d1877e6db460" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ino-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:91a42a7e-9c16-46a4-89e4-78ae514a2e8d,g:17ea50c5-1e55-4356-a463-d0e13f29ef69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i843482c3f2054a8198789dcf6ef93a3f_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:to="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f309d6-e092-48cb-8745-48d7eb1dbd45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f309d6-e092-48cb-8745-48d7eb1dbd45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_06bf2758-fd10-4d1e-a472-019d6e74f34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_ShortTermInvestments_06bf2758-fd10-4d1e-a472-019d6e74f34e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d7bf724-0711-4ef5-9c44-635a09a69414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d7bf724-0711-4ef5-9c44-635a09a69414" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b894e59e-15b3-4530-a656-c7d6bc71a9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b894e59e-15b3-4530-a656-c7d6bc71a9c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acbe6925-90ec-4e20-bcf5-09c7c7d421c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acbe6925-90ec-4e20-bcf5-09c7c7d421c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f3a6c896-0141-4389-b0ab-e24b32b47fde" xlink:href="ino-20211231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f3a6c896-0141-4389-b0ab-e24b32b47fde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7708db14-e0f2-490a-b9f2-d42d7c1738a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_AssetsCurrent_7708db14-e0f2-490a-b9f2-d42d7c1738a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45fb0445-354a-4437-adb0-df78ff6f6288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_45fb0445-354a-4437-adb0-df78ff6f6288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_69c199db-a73a-4561-a964-ab8c2f00f746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_69c199db-a73a-4561-a964-ab8c2f00f746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_23fdd2eb-2d2e-471a-83db-68da053a6ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_EquityMethodInvestments_23fdd2eb-2d2e-471a-83db-68da053a6ce0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b043b21-1718-41b7-ad17-849b699569fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b043b21-1718-41b7-ad17-849b699569fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_85c99a2b-5e33-4537-94cf-4623ddac2125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_Goodwill_85c99a2b-5e33-4537-94cf-4623ddac2125" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06d87003-edd8-45a4-999b-21e3bafc96b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06d87003-edd8-45a4-999b-21e3bafc96b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6294eb69-72a3-4c7f-8c67-8304b62d4603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6294eb69-72a3-4c7f-8c67-8304b62d4603" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cfed2b30-ddbc-47c2-99b2-65e251c951dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_Assets_cfed2b30-ddbc-47c2-99b2-65e251c951dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_20393005-dd06-4b41-b167-4eb9860382c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_20393005-dd06-4b41-b167-4eb9860382c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_79879821-43e5-4ed1-888c-451430e3b9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_79879821-43e5-4ed1-888c-451430e3b9d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_6db4c17d-e248-4da6-bc47-1b6c9ef331e3" xlink:href="ino-20211231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_6db4c17d-e248-4da6-bc47-1b6c9ef331e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07a7f96f-7515-409e-840d-8e57eb0efaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07a7f96f-7515-409e-840d-8e57eb0efaf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f273409b-4330-4031-b318-c30d54d549e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f273409b-4330-4031-b318-c30d54d549e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_51f0968c-c0cf-4653-851a-d025507c8657" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_ino_DeferredGrantFundingCurrent_51f0968c-c0cf-4653-851a-d025507c8657" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_82abef5b-43a1-4c56-ac0d-3f67554c87b2" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_82abef5b-43a1-4c56-ac0d-3f67554c87b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d129cb0-f7d7-4fd6-8154-8dc57d200fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_LiabilitiesCurrent_4d129cb0-f7d7-4fd6-8154-8dc57d200fda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ac3c1476-3aea-4d67-b6b8-28d845b2404f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ac3c1476-3aea-4d67-b6b8-28d845b2404f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_3e774c28-a162-49a6-bd1d-f8ce80a4bc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_ConvertibleDebt_3e774c28-a162-49a6-bd1d-f8ce80a4bc36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69d63b3-de51-437c-b649-eec99591c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69d63b3-de51-437c-b649-eec99591c9c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_102323df-185a-4c3e-bcb9-0948f2ddbf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_102323df-185a-4c3e-bcb9-0948f2ddbf3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ce40f03a-73ea-4b56-a530-ab13823e5ab3" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ce40f03a-73ea-4b56-a530-ab13823e5ab3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2900572b-975b-403d-8286-7473c074308f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2900572b-975b-403d-8286-7473c074308f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_701e27ad-dbd8-4e1a-b2b3-f9aba32e708d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_Liabilities_701e27ad-dbd8-4e1a-b2b3-f9aba32e708d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21569e74-6bac-4e46-9e3a-3e8843e3fd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21569e74-6bac-4e46-9e3a-3e8843e3fd15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ee7313d9-01ba-4c48-936f-026fd90de42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_PreferredStockValue_ee7313d9-01ba-4c48-936f-026fd90de42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_58772484-8162-4fad-b8cb-faecfa25607a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_CommonStockValue_58772484-8162-4fad-b8cb-faecfa25607a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fee83169-7867-4600-89e5-4a06b2c818a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fee83169-7867-4600-89e5-4a06b2c818a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_818b639f-abc2-4b64-b84a-d614beece708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_818b639f-abc2-4b64-b84a-d614beece708" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d781508f-7878-4d1e-90ba-6d321a592db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d781508f-7878-4d1e-90ba-6d321a592db5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fbd5c83e-ed28-4065-a0dd-2f36a103c86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_StockholdersEquity_fbd5c83e-ed28-4065-a0dd-2f36a103c86d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_60006000-30e9-45e6-be25-3a8f61ad45da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_60006000-30e9-45e6-be25-3a8f61ad45da" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:to="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:to="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1279c796-f7f0-43c4-a370-2e7aa847c64c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1279c796-f7f0-43c4-a370-2e7aa847c64c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80339745-00c3-467a-a2e8-eebc8ca555f5" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80339745-00c3-467a-a2e8-eebc8ca555f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_958632bd-392b-4794-ad24-4305f9b3a8b5" xlink:href="ino-20211231.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:to="loc_ino_ConvertibleBondsMember_958632bd-392b-4794-ad24-4305f9b3a8b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i411c7d67810240baa7cf37705d2874d2_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bc58e366-a195-4890-899c-53572ea11dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_RevenuesAbstract_bc58e366-a195-4890-899c-53572ea11dd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38cad031-634b-4ec2-bad1-879353ac7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_bc58e366-a195-4890-899c-53572ea11dd2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38cad031-634b-4ec2-bad1-879353ac7af8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c1b0691-3d14-4c10-9d3f-49c6f124c3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c1b0691-3d14-4c10-9d3f-49c6f124c3e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2dc3c820-fb46-4c78-aac3-0d3164b4130d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2dc3c820-fb46-4c78-aac3-0d3164b4130d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3979bedb-e329-4c2f-8981-7951ecb49d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:to="loc_us-gaap_OperatingExpenses_3979bedb-e329-4c2f-8981-7951ecb49d97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2037ba85-dad3-4175-ab69-8b4413514246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_OperatingIncomeLoss_2037ba85-dad3-4175-ab69-8b4413514246" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_13112565-ebf1-48f3-a43d-989e4cee988f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_InterestIncomeOperating_13112565-ebf1-48f3-a43d-989e4cee988f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a849dc50-6cd2-4ec1-9e39-f070f62a597c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_InterestExpense_a849dc50-6cd2-4ec1-9e39-f070f62a597c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ae1cc6bf-e707-46f8-9c2c-7468adbe88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ae1cc6bf-e707-46f8-9c2c-7468adbe88b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_8353d7de-51d5-4bb1-ba6c-2a893259d1de" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_8353d7de-51d5-4bb1-ba6c-2a893259d1de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e8443381-0290-41a7-b755-ae04d4dca13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e8443381-0290-41a7-b755-ae04d4dca13b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af72b5c7-3202-41b6-9442-e40b60999d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af72b5c7-3202-41b6-9442-e40b60999d93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_373e8ce2-15e7-4ac1-b5d1-a62933ab3bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_373e8ce2-15e7-4ac1-b5d1-a62933ab3bba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60ceef89-e107-46e2-8217-43658a037229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60ceef89-e107-46e2-8217-43658a037229" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68a6597f-eb16-418a-be20-c1744cadc16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68a6597f-eb16-418a-be20-c1744cadc16e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_23d1d2bb-b960-423f-82a5-d71497869c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_23d1d2bb-b960-423f-82a5-d71497869c79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc9056c0-5a2d-4b4a-a420-544a5b91bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc9056c0-5a2d-4b4a-a420-544a5b91bde7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a8fdbb9-02cb-41cc-8e38-15239c7e6dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_ProfitLoss_6a8fdbb9-02cb-41cc-8e38-15239c7e6dc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cba4e83e-55f5-41c0-bf49-b8cfab577388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cba4e83e-55f5-41c0-bf49-b8cfab577388" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f28183e7-4813-4f4c-ac91-7d6f999af62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_NetIncomeLoss_f28183e7-4813-4f4c-ac91-7d6f999af62f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1a2cb219-ff1e-4a11-b4d3-d0f300a80a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:to="loc_us-gaap_EarningsPerShareBasic_1a2cb219-ff1e-4a11-b4d3-d0f300a80a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7a79c2f6-a3d7-4376-9d16-9b27d3f9923f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7a79c2f6-a3d7-4376-9d16-9b27d3f9923f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a34e8a55-4c5f-4749-8313-a3cbb3132d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a34e8a55-4c5f-4749-8313-a3cbb3132d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebf462ac-5014-4628-bd68-feb2b594c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebf462ac-5014-4628-bd68-feb2b594c045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:to="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3dc0fda-bdba-4e49-963b-0658b62acf2d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:to="loc_srt_ProductsAndServicesDomain_e3dc0fda-bdba-4e49-963b-0658b62acf2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:to="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6bd3c356-cc0d-4aa4-bcd0-b809927daee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_us-gaap_LicenseMember_6bd3c356-cc0d-4aa4-bcd0-b809927daee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_0925fbb6-9db3-422d-b0e4-7dee7e26e297" xlink:href="ino-20211231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_0925fbb6-9db3-422d-b0e4-7dee7e26e297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueMember_59d3f57a-0cb8-4849-a7e7-2cb16b0251d4" xlink:href="ino-20211231.xsd#ino_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_ino_OtherRevenueMember_59d3f57a-0cb8-4849-a7e7-2cb16b0251d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember_569ff32d-51d0-46e6-b6df-c4c1aeb09179" xlink:href="ino-20211231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_ino_OtherRevenueAffiliatedEntityMember_569ff32d-51d0-46e6-b6df-c4c1aeb09179" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:to="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_63b623d3-3f61-438d-b5d9-57a78b3eae84" xlink:href="ino-20211231.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:to="loc_ino_ConvertibleBondsMember_63b623d3-3f61-438d-b5d9-57a78b3eae84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67092635-df8c-4c97-b7e3-6ee308d76f7f" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67092635-df8c-4c97-b7e3-6ee308d76f7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i9771e7c0b18c46faa2eaf94f40511cf5_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78585134-8c8c-4f64-84b6-9916f207253e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_78585134-8c8c-4f64-84b6-9916f207253e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ce46a08c-444c-424f-8768-522ad6ad2100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_SharesIssued_ce46a08c-444c-424f-8768-522ad6ad2100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80dbb751-89af-4a0b-92f9-19f252201e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80dbb751-89af-4a0b-92f9-19f252201e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a2cf770-06a0-4da6-8796-b03fa5c5d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a2cf770-06a0-4da6-8796-b03fa5c5d00b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dc067530-b819-483e-9104-f4520b32d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dc067530-b819-483e-9104-f4520b32d4bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bf6fecd0-7701-4990-a6de-7f18d8c1fc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bf6fecd0-7701-4990-a6de-7f18d8c1fc93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0469e810-3fbd-4fe3-b783-7be01aa79026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0469e810-3fbd-4fe3-b783-7be01aa79026" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_209abb3a-efaf-4e63-827e-4ad904bda361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_209abb3a-efaf-4e63-827e-4ad904bda361" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5133239d-c0c6-4424-a5f0-9f2d4546fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5133239d-c0c6-4424-a5f0-9f2d4546fe70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_94a6c2e4-98e9-4003-ab02-02094af752be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_94a6c2e4-98e9-4003-ab02-02094af752be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eff37dd3-07cd-4316-b75b-0de112d71b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eff37dd3-07cd-4316-b75b-0de112d71b64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_eff6b2ff-3b76-4dcc-b38c-70d89bc8d534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_eff6b2ff-3b76-4dcc-b38c-70d89bc8d534" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_5dfa6658-f3e4-410f-b197-56842ff19a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_5dfa6658-f3e4-410f-b197-56842ff19a45" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b74d329-f225-49ea-b7f8-b533cc162efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_ProfitLoss_4b74d329-f225-49ea-b7f8-b533cc162efc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47187a93-9436-41f0-92cf-2d7b6daba1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47187a93-9436-41f0-92cf-2d7b6daba1a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3990994c-eefc-449f-ae1f-d00a39a937ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3990994c-eefc-449f-ae1f-d00a39a937ea" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5a014e84-6244-48b9-9409-4bc519d3df09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5a014e84-6244-48b9-9409-4bc519d3df09" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_109ddf3c-097f-468a-9c38-61495403c25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b06af5d6-71d2-483b-adcd-e66ab32fb9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_78585134-8c8c-4f64-84b6-9916f207253e" xlink:to="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0640a93f-fd11-4e72-aec5-523f726c048e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:to="loc_us-gaap_EquityComponentDomain_0640a93f-fd11-4e72-aec5-523f726c048e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:to="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c2b0a622-f78c-43a1-a79f-65a37f7b82a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_PreferredStockMember_c2b0a622-f78c-43a1-a79f-65a37f7b82a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a186251-755b-4d32-9715-9f1e995859f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_CommonStockMember_6a186251-755b-4d32-9715-9f1e995859f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b014c918-2b58-4c21-9cc4-240940479b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b014c918-2b58-4c21-9cc4-240940479b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_24cd0a14-3a9a-467c-ba0a-c84817405cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_RetainedEarningsMember_24cd0a14-3a9a-467c-ba0a-c84817405cb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67491071-eb03-41fc-bfd4-ac26a9290472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67491071-eb03-41fc-bfd4-ac26a9290472" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_db28eb60-35dd-493f-ac07-530225021a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_NoncontrollingInterestMember_db28eb60-35dd-493f-ac07-530225021a4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_21166d5d-14f3-4d9d-924e-9a4989858e03" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_21166d5d-14f3-4d9d-924e-9a4989858e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_dc6baa5b-8d4a-44e0-bfb3-3c337a06c4d6" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:to="loc_ino_August2019ConvertibleBondsMember_dc6baa5b-8d4a-44e0-bfb3-3c337a06c4d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i5f24b7233927452994da59bf03a6b95c_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1adebfb3-5dee-4586-b38c-06fa814677dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_ProfitLoss_1adebfb3-5dee-4586-b38c-06fa814677dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2bcd86c1-5819-44b3-a765-0aceb59046b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_Depreciation_2bcd86c1-5819-44b3-a765-0aceb59046b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b1765063-a783-45f3-8995-876f7eab4772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b1765063-a783-45f3-8995-876f7eab4772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_83039226-4bb3-4a18-90ac-d3c0811861e9" xlink:href="ino-20211231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_83039226-4bb3-4a18-90ac-d3c0811861e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_76e92951-5a37-4ab2-b0ac-3ca5842beac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_76e92951-5a37-4ab2-b0ac-3ca5842beac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_69c00df5-dae3-4fa2-b9ed-2acd8ce4c8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_ShareBasedCompensation_69c00df5-dae3-4fa2-b9ed-2acd8ce4c8c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_59270d15-0423-4295-bca2-59f617e93479" xlink:href="ino-20211231.xsd#ino_NonCashInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_NonCashInterestExpense_59270d15-0423-4295-bca2-59f617e93479" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_0e1981b4-7496-484a-a44d-294f2c9a9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_0e1981b4-7496-484a-a44d-294f2c9a9d77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_dff8ef5c-7f65-455a-a0cd-c75cd5f9584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_dff8ef5c-7f65-455a-a0cd-c75cd5f9584b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8ce54fc2-cb3a-49f9-a082-f527d68e751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8ce54fc2-cb3a-49f9-a082-f527d68e751f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_59e53005-f6c7-43a9-8c05-9b3bdc768cfa" xlink:href="ino-20211231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_59e53005-f6c7-43a9-8c05-9b3bdc768cfa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_01987495-7588-47e9-99fe-c0640046718f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_01987495-7588-47e9-99fe-c0640046718f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_873896a6-ac69-4848-8494-bebd785d30fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_873896a6-ac69-4848-8494-bebd785d30fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f9c18594-0e9f-49d4-800f-36ec48606494" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f9c18594-0e9f-49d4-800f-36ec48606494" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_cdf8b705-bbd1-4d97-9cf8-c55d88d7a284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_cdf8b705-bbd1-4d97-9cf8-c55d88d7a284" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_400c5792-4826-4d7e-95f3-17384e05c758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_400c5792-4826-4d7e-95f3-17384e05c758" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_24ad36ed-d4c0-44ac-a50e-15f47310966d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_24ad36ed-d4c0-44ac-a50e-15f47310966d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_06651084-9bc4-4091-83cd-175e1dcce92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_06651084-9bc4-4091-83cd-175e1dcce92d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_64adb744-b660-451c-bd1a-f647e0e8f339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_64adb744-b660-451c-bd1a-f647e0e8f339" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_383394aa-6833-4282-b7f8-49f96a37be5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_383394aa-6833-4282-b7f8-49f96a37be5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_c9f44ba8-387e-4fb8-97f7-79c4e81b7ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_c9f44ba8-387e-4fb8-97f7-79c4e81b7ad0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06311e7e-6d6a-4ea9-b5a7-e2956f421220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06311e7e-6d6a-4ea9-b5a7-e2956f421220" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_053ceba0-5c7b-47fc-8a85-ebd395715fe9" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_053ceba0-5c7b-47fc-8a85-ebd395715fe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_993f6386-e362-4d18-8a56-56ff669690d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_993f6386-e362-4d18-8a56-56ff669690d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b692e016-9998-45b9-a53a-1601d6042d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b692e016-9998-45b9-a53a-1601d6042d8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_f8e1be45-0e4d-45de-8420-f1fc693f1a90" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_f8e1be45-0e4d-45de-8420-f1fc693f1a90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_d8502c2a-bd04-49e5-9d2a-400c870c0040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_d8502c2a-bd04-49e5-9d2a-400c870c0040" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_520bf8a2-b4f4-4e41-bc93-aa7f380e56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_520bf8a2-b4f4-4e41-bc93-aa7f380e56ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_039b90de-8401-4be1-bc70-f29e0f209c85" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_039b90de-8401-4be1-bc70-f29e0f209c85" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_b014fcb2-6e29-46b9-b69f-619351c0a13e" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_b014fcb2-6e29-46b9-b69f-619351c0a13e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_7fcb36f1-502a-4642-892f-8fe8247e5370" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_7fcb36f1-502a-4642-892f-8fe8247e5370" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_aec3d363-97b5-43cb-b41a-2d24a6cbf0a7" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_aec3d363-97b5-43cb-b41a-2d24a6cbf0a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bd0a1123-645f-47c1-bd32-4eff835ed9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bd0a1123-645f-47c1-bd32-4eff835ed9b1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_519132e6-6f19-40e6-8b21-7edeb68303f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_519132e6-6f19-40e6-8b21-7edeb68303f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c5c54c42-e67d-4f61-90fa-860a82b7ccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c5c54c42-e67d-4f61-90fa-860a82b7ccd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ca06d286-1670-4cdd-bd94-d5a72a1c1a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ca06d286-1670-4cdd-bd94-d5a72a1c1a5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e414089-9c23-4224-b6a0-4759912874e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e414089-9c23-4224-b6a0-4759912874e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_f9bc2167-5e46-4d03-879f-bd309039c7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_f9bc2167-5e46-4d03-879f-bd309039c7de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_f17708d4-4b89-4a30-82cc-4d599d882181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_f17708d4-4b89-4a30-82cc-4d599d882181" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_64e22c42-329d-4e00-97e1-46b42789ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_64e22c42-329d-4e00-97e1-46b42789ae5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7673d46e-c2fa-4e21-8246-0dbddbeae3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7673d46e-c2fa-4e21-8246-0dbddbeae3d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a46ab55-dcd2-4702-9a57-4496cabeae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a46ab55-dcd2-4702-9a57-4496cabeae4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ba51c5d-83d9-46fd-bee8-0ac8bffd103e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ba51c5d-83d9-46fd-bee8-0ac8bffd103e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aaca6683-cfc9-450f-9fd0-ab4496876690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aaca6683-cfc9-450f-9fd0-ab4496876690" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_a9ad52e6-9b58-45b5-985c-6b2b5e6c434f" xlink:href="ino-20211231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_a9ad52e6-9b58-45b5-985c-6b2b5e6c434f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_a9d8eabd-99ac-414f-8c86-6cd15e81935b" xlink:href="ino-20211231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_a9d8eabd-99ac-414f-8c86-6cd15e81935b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_c11b45a0-e39c-49c3-aea2-ef3a941e9a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_c11b45a0-e39c-49c3-aea2-ef3a941e9a4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_ce17f426-fb93-4bbb-b9b6-94bd44247623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_ce17f426-fb93-4bbb-b9b6-94bd44247623" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e36043af-ff9a-4dc0-a2ce-c45198427554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e36043af-ff9a-4dc0-a2ce-c45198427554" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92230f80-9b34-463e-8b5c-6ace87e04d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92230f80-9b34-463e-8b5c-6ace87e04d3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_415551e0-67e8-4e9d-8e65-577feab526dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_415551e0-67e8-4e9d-8e65-577feab526dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd70bd7d-6edf-4ecd-8499-324cdc6f9149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd70bd7d-6edf-4ecd-8499-324cdc6f9149" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd821b97-6668-48fc-b5df-643ed71090dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a6213fdb-2664-4000-a0a9-8598247be469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a6213fdb-2664-4000-a0a9-8598247be469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_10530846-5839-430a-9ac9-c840c0d0d4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_us-gaap_InterestPaidNet_10530846-5839-430a-9ac9-c840c0d0d4be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_21f14caf-806f-46d9-9eef-69837c93743c" xlink:href="ino-20211231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_21f14caf-806f-46d9-9eef-69837c93743c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued_86cb3ec3-1510-4602-b1b0-0369de3f9aa0" xlink:href="ino-20211231.xsd#ino_EquityComponentOfConvertibleDebtIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_ino_EquityComponentOfConvertibleDebtIssued_86cb3ec3-1510-4602-b1b0-0369de3f9aa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9e47e895-190c-4e64-9876-8e4b60b3f7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9e47e895-190c-4e64-9876-8e4b60b3f7a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:to="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_40092741-8520-43bf-8995-a10ffa67e6a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_40092741-8520-43bf-8995-a10ffa67e6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_ef6a34cf-f147-410b-b581-c78f86f1b252" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:to="loc_ino_August2019ConvertibleBondsMember_ef6a34cf-f147-410b-b581-c78f86f1b252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c4ed8a90-fd7b-4325-bd52-a8fce47c008a" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c4ed8a90-fd7b-4325-bd52-a8fce47c008a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ie089a6f0b2064a6eb25cabf27e360914_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61f2bfc7-a73d-4b85-b74c-bea54a40abab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_NetIncomeLoss_61f2bfc7-a73d-4b85-b74c-bea54a40abab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_9c938bab-400e-42c9-aece-ed1b0bce1ae8" xlink:href="ino-20211231.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_ino_WorkingCapital_9c938bab-400e-42c9-aece-ed1b0bce1ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4251222b-a6d7-49a5-9b11-26164d2f10cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4251222b-a6d7-49a5-9b11-26164d2f10cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ff17c15-4ad3-49e3-8ee0-f8487edb7128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ff17c15-4ad3-49e3-8ee0-f8487edb7128" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09feb80b-1c44-4cb9-8475-3b2214862af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09feb80b-1c44-4cb9-8475-3b2214862af0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb89da2d-e6b4-410d-a7fb-4af40d9937c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb89da2d-e6b4-410d-a7fb-4af40d9937c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffd50db5-bc70-4070-99d9-a1357c291234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffd50db5-bc70-4070-99d9-a1357c291234" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ad9386b2-b120-4184-8c08-44e0fb76bf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ad9386b2-b120-4184-8c08-44e0fb76bf9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1312c784-ea4a-4bdc-b082-7a471cc65be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1312c784-ea4a-4bdc-b082-7a471cc65be7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_da3d8dd0-e9db-41c3-800c-9d5bdbbf18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_da3d8dd0-e9db-41c3-800c-9d5bdbbf18d1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3a77d1e9-8999-490a-9eee-3d8aa31d57d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3a77d1e9-8999-490a-9eee-3d8aa31d57d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6322da6d-1939-4770-9bd3-7b4441c08410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6322da6d-1939-4770-9bd3-7b4441c08410" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee6d760f-8a08-488c-80f3-966f42c00c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee6d760f-8a08-488c-80f3-966f42c00c85" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c026916-6fe6-40e4-bb9a-a49673b7a111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c026916-6fe6-40e4-bb9a-a49673b7a111" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_25994f99-af84-4b4e-9598-bccbf173047b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:to="loc_us-gaap_ClassOfStockDomain_25994f99-af84-4b4e-9598-bccbf173047b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eea1cef0-4d17-4813-8b67-a8ea0c23ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:to="loc_us-gaap_ClassOfStockDomain_eea1cef0-4d17-4813-8b67-a8ea0c23ccac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_993faeb4-9752-4b5d-8be5-0ccdf17121c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eea1cef0-4d17-4813-8b67-a8ea0c23ccac" xlink:to="loc_us-gaap_CommonStockMember_993faeb4-9752-4b5d-8be5-0ccdf17121c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06afccdc-b6e9-4881-9415-1382b98b4d7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06afccdc-b6e9-4881-9415-1382b98b4d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_7d5339a1-4563-40e6-a6af-e2e26acfffbe" xlink:href="ino-20211231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_7d5339a1-4563-40e6-a6af-e2e26acfffbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_bb7fd9e6-c4fa-468e-a61f-1c8d3a4fcebb" xlink:href="ino-20211231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:to="loc_ino_SalesAgreementMember_bb7fd9e6-c4fa-468e-a61f-1c8d3a4fcebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2527f49a-9a38-4044-8000-5f88e06d00e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2527f49a-9a38-4044-8000-5f88e06d00e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7b7a188-a03e-43ff-ad63-47ff350b8108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7b7a188-a03e-43ff-ad63-47ff350b8108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_390954fc-768b-4303-a9f9-3d0cc5215387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b7b7a188-a03e-43ff-ad63-47ff350b8108" xlink:to="loc_us-gaap_ConvertibleDebtMember_390954fc-768b-4303-a9f9-3d0cc5215387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8aac70f5-850a-4e58-ba41-89e1fbc2b44a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8aac70f5-850a-4e58-ba41-89e1fbc2b44a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b1793ac1-130a-4ebc-9292-e1b3a5ef1c55" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b1793ac1-130a-4ebc-9292-e1b3a5ef1c55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_5f57bdac-aae4-4dba-8a97-33bb68f0ec3c" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:to="loc_ino_August2019ConvertibleBondsMember_5f57bdac-aae4-4dba-8a97-33bb68f0ec3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_2a83fd63-5692-44a1-a787-db6a0c11a799" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:to="loc_ino_December2019ConvertibleBondsMember_2a83fd63-5692-44a1-a787-db6a0c11a799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_340c38b3-6536-4ff4-b8c8-b84c811f9ac5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:to="loc_srt_RangeMember_340c38b3-6536-4ff4-b8c8-b84c811f9ac5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:to="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bdb7d949-c9c8-4ad6-88e3-597d2538265f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:to="loc_srt_MinimumMember_bdb7d949-c9c8-4ad6-88e3-597d2538265f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e565a04d-5885-4945-96bb-26d5633be0cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:to="loc_srt_MaximumMember_e565a04d-5885-4945-96bb-26d5633be0cd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended" id="i7cbd893ea3ff448daf88755d95b5f9a1_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7fee406-1710-4fca-ae22-9087e4512411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockEquivalentsAbstract_905eb02a-41e3-468a-a53e-a766f6ab947d" xlink:href="ino-20211231.xsd#ino_CommonStockEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7fee406-1710-4fca-ae22-9087e4512411" xlink:to="loc_ino_CommonStockEquivalentsAbstract_905eb02a-41e3-468a-a53e-a766f6ab947d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bd9b48b-5374-4660-823e-1ddaf1d223fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_CommonStockEquivalentsAbstract_905eb02a-41e3-468a-a53e-a766f6ab947d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bd9b48b-5374-4660-823e-1ddaf1d223fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7fee406-1710-4fca-ae22-9087e4512411" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1886586a-32e4-4af4-93ed-c5d23e423e9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1886586a-32e4-4af4-93ed-c5d23e423e9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b674a551-7db0-4911-9f93-e2d78790a350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b674a551-7db0-4911-9f93-e2d78790a350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_82cb47a9-96ba-4af1-aca9-a09573ef6090" xlink:href="ino-20211231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_82cb47a9-96ba-4af1-aca9-a09573ef6090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_04b2dbaa-3ee5-467d-bd08-75e08622f724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_04b2dbaa-3ee5-467d-bd08-75e08622f724" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_c2805d2a-37d7-4d52-b567-d3166b1df3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_c2805d2a-37d7-4d52-b567-d3166b1df3ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_c5c3200f-ca23-4c06-9a3f-73e90d2deda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_c5c3200f-ca23-4c06-9a3f-73e90d2deda8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:to="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4aa94f6b-ca95-48c3-a682-8dd3183b10ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4aa94f6b-ca95-48c3-a682-8dd3183b10ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_59d25e52-d917-43d9-bae6-7bd5d8e2e03f" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_59d25e52-d917-43d9-bae6-7bd5d8e2e03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_d99e2d6e-0af8-40a5-8fc9-82cbcbadb9a0" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:to="loc_ino_August2019ConvertibleBondsMember_d99e2d6e-0af8-40a5-8fc9-82cbcbadb9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_ca51e63b-b0c0-42f2-9da0-31a7dc15030e" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:to="loc_ino_December2019ConvertibleBondsMember_ca51e63b-b0c0-42f2-9da0-31a7dc15030e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended" id="iefb4147fe7e74a4b9c1e72626a3f12ba_SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75716cad-bd6a-45d9-8020-bf2b70439be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:href="ino-20211231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75716cad-bd6a-45d9-8020-bf2b70439be3" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f0aeaed0-3353-4d96-a2de-330f607c2b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f0aeaed0-3353-4d96-a2de-330f607c2b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e8e7606d-80cb-4ecd-bd88-b8efffb31705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e8e7606d-80cb-4ecd-bd88-b8efffb31705" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fb5e96b0-a29c-4283-91d9-723f80d48131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fb5e96b0-a29c-4283-91d9-723f80d48131" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9064ee50-7525-4f6a-b20f-76ad4e5e2484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9064ee50-7525-4f6a-b20f-76ad4e5e2484" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75716cad-bd6a-45d9-8020-bf2b70439be3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:to="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_9529ad32-24e6-45fe-b839-dffe623bfaf6" xlink:href="ino-20211231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:to="loc_ino_EmployeesAndDirectorsMember_9529ad32-24e6-45fe-b839-dffe623bfaf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_3251041d-1b75-4828-9f78-b02efc3caf9b" xlink:href="ino-20211231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:to="loc_ino_NonEmployeeMember_3251041d-1b75-4828-9f78-b02efc3caf9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:to="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_080227f8-0bf7-45c8-8005-45e3f635840f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_080227f8-0bf7-45c8-8005-45e3f635840f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949ccd2-13a3-445e-b330-38d1a91a6f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949ccd2-13a3-445e-b330-38d1a91a6f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae3a7dce-9b69-431c-8bc2-32c5834134f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949ccd2-13a3-445e-b330-38d1a91a6f13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae3a7dce-9b69-431c-8bc2-32c5834134f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended" id="iac5ac6a397f942c5886e2f33578b3096_RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4aa7f054-289e-4f53-a121-50c6f42abe28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4aa7f054-289e-4f53-a121-50c6f42abe28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1239170e-5abf-4f8e-82d5-c19b9d4c338a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1239170e-5abf-4f8e-82d5-c19b9d4c338a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_72577c62-ec52-444f-b1d0-cf2d449ace93_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:to="loc_srt_NameOfMajorCustomerDomain_72577c62-ec52-444f-b1d0-cf2d449ace93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:to="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_a3d5049e-b9c9-4b97-a6f7-1148e3abcdc4" xlink:href="ino-20211231.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_AstraZenecaMember_a3d5049e-b9c9-4b97-a6f7-1148e3abcdc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_68b28c96-fe17-48fd-a728-f99c1a15b53e" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_AdvaccineMember_68b28c96-fe17-48fd-a728-f99c1a15b53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_855add82-7190-4f73-ad33-649b2bfe532c" xlink:href="ino-20211231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_855add82-7190-4f73-ad33-649b2bfe532c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_8af7c3ab-232a-4461-b6ab-9d2a089ff2a9" xlink:href="ino-20211231.xsd#ino_DoDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_DoDMember_8af7c3ab-232a-4461-b6ab-9d2a089ff2a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_ca642239-7862-4e79-a92b-b868ec82eda2" xlink:href="ino-20211231.xsd#ino_AllOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_AllOtherCustomersMember_ca642239-7862-4e79-a92b-b868ec82eda2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_560f1699-bebe-426a-b096-4a762d6d8818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_560f1699-bebe-426a-b096-4a762d6d8818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea7c813-77f0-4812-a506-ab412ec83d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea7c813-77f0-4812-a506-ab412ec83d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8d64d86c-b10d-4c31-afcd-b54c72c82cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea7c813-77f0-4812-a506-ab412ec83d47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8d64d86c-b10d-4c31-afcd-b54c72c82cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a0866282-188b-437c-b40d-0c2a1a5f55cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a0866282-188b-437c-b40d-0c2a1a5f55cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a62ca4df-d972-4474-8999-d68623f49d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a62ca4df-d972-4474-8999-d68623f49d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ceb35e5f-8d90-4761-8ed4-3ca505c2d35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a62ca4df-d972-4474-8999-d68623f49d5e" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ceb35e5f-8d90-4761-8ed4-3ca505c2d35b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="extended" id="i23504ced667d489db54b3435a238c6be_RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_34072ee4-1544-472c-8777-3015eb5d9530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_34072ee4-1544-472c-8777-3015eb5d9530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b3a6bd56-5c91-4b5b-ae20-bce015833b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_AccountsReceivableNet_b3a6bd56-5c91-4b5b-ae20-bce015833b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_649c6346-f644-4f98-ba13-6fa52f4364f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_649c6346-f644-4f98-ba13-6fa52f4364f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_56971a6f-5bc1-4367-a14e-818c9af9fe04_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:to="loc_srt_NameOfMajorCustomerDomain_56971a6f-5bc1-4367-a14e-818c9af9fe04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:to="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_6d187893-113b-4718-8f68-40df3d9e9693" xlink:href="ino-20211231.xsd#ino_DoDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:to="loc_ino_DoDMember_6d187893-113b-4718-8f68-40df3d9e9693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CEPIMERSMember_0d515ee3-d82c-4f7a-ac63-4d659021ad00" xlink:href="ino-20211231.xsd#ino_CEPIMERSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:to="loc_ino_CEPIMERSMember_0d515ee3-d82c-4f7a-ac63-4d659021ad00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_359d1119-d4a5-4586-8641-e788ba9c5c9a" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:to="loc_ino_AdvaccineMember_359d1119-d4a5-4586-8641-e788ba9c5c9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_836bdd49-6fc3-41a6-99f9-b07eefc48fff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_836bdd49-6fc3-41a6-99f9-b07eefc48fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_76067331-36ed-4288-893a-dd79bd1773df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_76067331-36ed-4288-893a-dd79bd1773df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_53d2a5c7-6e5f-4b37-9c8b-b1dbf90f5403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_76067331-36ed-4288-893a-dd79bd1773df" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_53d2a5c7-6e5f-4b37-9c8b-b1dbf90f5403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af3522a8-a9e2-41e8-8df4-1c4e52a14e55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_af3522a8-a9e2-41e8-8df4-1c4e52a14e55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00662923-bd04-49f3-a92f-fdcb7a0862a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00662923-bd04-49f3-a92f-fdcb7a0862a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_15b2d11f-be51-449b-94d2-5a87b811430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00662923-bd04-49f3-a92f-fdcb7a0862a9" xlink:to="loc_us-gaap_AccountsReceivableMember_15b2d11f-be51-449b-94d2-5a87b811430f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="id6658a1c217f4c8da39a9befb1e317ce_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1367b4df-9f25-4b0a-9b86-bcd42a1b1e80" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1367b4df-9f25-4b0a-9b86-bcd42a1b1e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_8be6cc43-e452-47a7-89e1-249a8e7b05cb" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_8be6cc43-e452-47a7-89e1-249a8e7b05cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_5b64e1e4-65ff-4b2f-b1b1-ef7b22ed1c43" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_5b64e1e4-65ff-4b2f-b1b1-ef7b22ed1c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_bd020f91-68d3-47cc-8d1a-966f4dd25dfc" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_bd020f91-68d3-47cc-8d1a-966f4dd25dfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_071c4fcc-be94-437d-80b8-11b09a8b6b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_CostMaintenance_071c4fcc-be94-437d-80b8-11b09a8b6b25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_6390c979-1c3c-488d-868a-d399c24160b0" xlink:href="ino-20211231.xsd#ino_AnnualMaintenancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_AnnualMaintenancePeriod_6390c979-1c3c-488d-868a-d399c24160b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3e89eef-680a-490b-a9e9-3922b9c9847b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3e89eef-680a-490b-a9e9-3922b9c9847b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_35482c78-f303-4910-b62d-36f144287de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_AccountsReceivableNet_35482c78-f303-4910-b62d-36f144287de3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_77ebd468-f607-4a1a-bbe8-4f114bef2fce" xlink:href="ino-20211231.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_77ebd468-f607-4a1a-bbe8-4f114bef2fce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_cf5842d3-4fd8-45bc-9640-75d19ee8aeef" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_cf5842d3-4fd8-45bc-9640-75d19ee8aeef" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_97c051e5-4686-4bc2-923f-aad0982622f7" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_97c051e5-4686-4bc2-923f-aad0982622f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_90c49d4f-7779-411b-8090-5439dd37f2d8" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_90c49d4f-7779-411b-8090-5439dd37f2d8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_ef76e6a0-b5f3-4a68-ad37-bf64b78881c1" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_ef76e6a0-b5f3-4a68-ad37-bf64b78881c1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_3ad075fa-8709-4d31-b343-f4dd58488ff6" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_3ad075fa-8709-4d31-b343-f4dd58488ff6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_9fec2eb4-d809-48f8-adb8-dfef6948103d" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_9fec2eb4-d809-48f8-adb8-dfef6948103d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_1517a6e5-65fc-44c8-83d3-e2e3fbbdd792" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_1517a6e5-65fc-44c8-83d3-e2e3fbbdd792" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_ccb1eed5-caeb-4643-8782-f28629591c7e" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_ccb1eed5-caeb-4643-8782-f28629591c7e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_009b7c88-3232-4434-9b70-dc43326fd860" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_DeferredGrantFundingCurrent_009b7c88-3232-4434-9b70-dc43326fd860" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_4771a708-26b4-4800-ba48-6b47e397bfc5" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_4771a708-26b4-4800-ba48-6b47e397bfc5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_3d0242e7-9b4a-42c6-81b8-eab7a991af87" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_3d0242e7-9b4a-42c6-81b8-eab7a991af87" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_9b4397fe-9d6e-4e67-a33c-5605e8fde516" xlink:href="ino-20211231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_GrantProceedsReceived_9b4397fe-9d6e-4e67-a33c-5605e8fde516" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_2386d5dd-8ed7-4a4d-ad34-2647a4d3a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_2386d5dd-8ed7-4a4d-ad34-2647a4d3a0c0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_b94ca4ec-bab4-4bd1-8494-48bc57067c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_GrantsReceivable_b94ca4ec-bab4-4bd1-8494-48bc57067c8b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9e11c08-d3ca-4949-b160-a44140578311_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9e11c08-d3ca-4949-b160-a44140578311_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_5f7f75f7-da14-4a9e-9b40-7e9b3ad1df89" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_AdvaccineMember_5f7f75f7-da14-4a9e-9b40-7e9b3ad1df89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_b9b63d43-abb5-4b32-96a6-5c07f284d584" xlink:href="ino-20211231.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_ApolloBioMember_b9b63d43-abb5-4b32-96a6-5c07f284d584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_8f9993f2-04f1-4ab2-abbf-0a9395220715" xlink:href="ino-20211231.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_AstraZenecaMember_8f9993f2-04f1-4ab2-abbf-0a9395220715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_f270ba01-5f29-4809-9f72-aa132327d2d5" xlink:href="ino-20211231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_f270ba01-5f29-4809-9f72-aa132327d2d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_193ccffb-e36b-405e-b5ec-2b2ea3792b8c" xlink:href="ino-20211231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_193ccffb-e36b-405e-b5ec-2b2ea3792b8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_f187d36a-42d8-43d4-9910-73d09b268afa" xlink:href="ino-20211231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_DepartmentOfDefenceMember_f187d36a-42d8-43d4-9910-73d09b268afa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f61c0284-8c74-47a2-90ac-cb05b462ddc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f61c0284-8c74-47a2-90ac-cb05b462ddc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b633a468-919f-4385-a908-62c71250cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b633a468-919f-4385-a908-62c71250cc9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b7e480c1-c533-49fa-8f61-941ca7e8cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b633a468-919f-4385-a908-62c71250cc9f" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b7e480c1-c533-49fa-8f61-941ca7e8cb14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_453450c4-cfaa-4a42-b568-84963e421e23_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:to="loc_srt_NameOfMajorCustomerDomain_453450c4-cfaa-4a42-b568-84963e421e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb67f603-754c-471e-8ad0-bc78a0f371a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb67f603-754c-471e-8ad0-bc78a0f371a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_58f3f8fd-65bd-4a78-adbe-3e96acc34980" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb67f603-754c-471e-8ad0-bc78a0f371a0" xlink:to="loc_ino_AdvaccineMember_58f3f8fd-65bd-4a78-adbe-3e96acc34980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:to="loc_srt_ProductsAndServicesDomain_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:to="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_84f21b48-2c9b-4a2d-aadb-a7101eaebf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_us-gaap_LicenseMember_84f21b48-2c9b-4a2d-aadb-a7101eaebf83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_07adc548-6f4a-4cad-ba2c-b3c4062f0906" xlink:href="ino-20211231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_07adc548-6f4a-4cad-ba2c-b3c4062f0906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_dff6f44c-4297-4e49-b2a8-1310b940448e" xlink:href="ino-20211231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_dff6f44c-4297-4e49-b2a8-1310b940448e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_2a7c0e3f-abf3-47d7-8d3c-8cda5e51994d" xlink:href="ino-20211231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_2a7c0e3f-abf3-47d7-8d3c-8cda5e51994d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_e2a6cf40-8c60-445d-a7b8-c60b355365fb" xlink:href="ino-20211231.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_INO4800Member_e2a6cf40-8c60-445d-a7b8-c60b355365fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_4574f165-3a26-45a1-8133-f0780e477518" xlink:href="ino-20211231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_4574f165-3a26-45a1-8133-f0780e477518" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_25ee53f4-2c01-4a1b-9b67-c84e92af780d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_25ee53f4-2c01-4a1b-9b67-c84e92af780d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ab4e92b-3996-4f44-a0ba-324bdd5a8bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ab4e92b-3996-4f44-a0ba-324bdd5a8bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_279a905d-c2c5-4a18-97f8-a86ad032d237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ab4e92b-3996-4f44-a0ba-324bdd5a8bba" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_279a905d-c2c5-4a18-97f8-a86ad032d237" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c981b35d-7ef1-4b07-a087-6a76f1bd884e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c981b35d-7ef1-4b07-a087-6a76f1bd884e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_98d70a7c-f876-490c-9b65-dce6d438f1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_98d70a7c-f876-490c-9b65-dce6d438f1e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_47534a1f-5891-4fac-bef2-d56f6f4ef170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_98d70a7c-f876-490c-9b65-dce6d438f1e5" xlink:to="loc_us-gaap_ForeignCountryMember_47534a1f-5891-4fac-bef2-d56f6f4ef170" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i26f5d36f036c40c99a37b35cbeb127fa_ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_abd8388f-dff8-41c7-94aa-c16e0f607154" xlink:href="ino-20211231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_abd8388f-dff8-41c7-94aa-c16e0f607154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a017cc9e-dca4-4d80-94ab-8031435b3932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a017cc9e-dca4-4d80-94ab-8031435b3932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51e47933-6c14-4535-b8f2-2b347a3bd52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51e47933-6c14-4535-b8f2-2b347a3bd52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58c82b9a-42d2-42f0-8a0c-9411d7a6ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58c82b9a-42d2-42f0-8a0c-9411d7a6ffb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8789ae58-f462-4810-b643-c9ce0afead49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8789ae58-f462-4810-b643-c9ce0afead49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d69408a4-6edd-4d24-b3cc-52b155642771_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d69408a4-6edd-4d24-b3cc-52b155642771_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_6efb547b-dc0f-4fdb-905d-162de5f6f59b" xlink:href="ino-20211231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_ino_MutualFundsMember_6efb547b-dc0f-4fdb-905d-162de5f6f59b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_4ba8c6f7-c876-488d-9ab5-8a8c157db1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_4ba8c6f7-c876-488d-9ab5-8a8c157db1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_025f081b-d5ef-47e1-a32f-75812932dc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_CommercialPaperMember_025f081b-d5ef-47e1-a32f-75812932dc46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_36755bfc-4bd5-4949-8772-b07b96b6e17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_CertificatesOfDepositMember_36755bfc-4bd5-4949-8772-b07b96b6e17f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_87038867-fefa-45c9-afd2-551cdd0904c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_87038867-fefa-45c9-afd2-551cdd0904c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:to="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0eb1b084-1916-4f72-98b1-bade0c99ab50_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:to="loc_srt_RangeMember_0eb1b084-1916-4f72-98b1-bade0c99ab50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0aac6af6-a37f-4da2-9f0c-79cc72cc9ea2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:to="loc_srt_RangeMember_0aac6af6-a37f-4da2-9f0c-79cc72cc9ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ebee8f1-27e9-49be-92ac-d1b01e264fc7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0aac6af6-a37f-4da2-9f0c-79cc72cc9ea2" xlink:to="loc_srt_MaximumMember_3ebee8f1-27e9-49be-92ac-d1b01e264fc7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i4bd203df34014d6b856a4c1081254e0d_ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1ba2715-08eb-48a8-9f89-cb187f8b1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1ba2715-08eb-48a8-9f89-cb187f8b1fde" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03f34869-8caf-4057-8092-b0bc48a02031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03f34869-8caf-4057-8092-b0bc48a02031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_660e88b3-ced0-4231-98a9-8e4f5218da2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_660e88b3-ced0-4231-98a9-8e4f5218da2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6651c0c3-15ff-4190-bfd1-448b6b0ab65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6651c0c3-15ff-4190-bfd1-448b6b0ab65b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_abee50dd-3b0b-45fe-afcd-c3461251689b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_abee50dd-3b0b-45fe-afcd-c3461251689b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1ba2715-08eb-48a8-9f89-cb187f8b1fde" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4bcba31-47f9-4216-a3e2-dde7ceba244a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d4bcba31-47f9-4216-a3e2-dde7ceba244a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c6d6b7b-76aa-49ad-a5c0-fb1a19e036cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c6d6b7b-76aa-49ad-a5c0-fb1a19e036cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dd61458e-9b24-4bbb-8a84-7a07788472bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c6d6b7b-76aa-49ad-a5c0-fb1a19e036cb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dd61458e-9b24-4bbb-8a84-7a07788472bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d26207b-1721-46e8-bd35-89192937104d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d26207b-1721-46e8-bd35-89192937104d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_a93a6ef1-d94c-491e-aee3-f2e306a2fd3d" xlink:href="ino-20211231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_ino_MutualFundsMember_a93a6ef1-d94c-491e-aee3-f2e306a2fd3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1cf31b4e-9a1e-456d-9571-f0506ebbebb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1cf31b4e-9a1e-456d-9571-f0506ebbebb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8db14f0e-f3a8-4731-95f0-f2b278232bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_CommercialPaperMember_8db14f0e-f3a8-4731-95f0-f2b278232bed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_02d81744-df76-4801-9ba9-7656931e0ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_02d81744-df76-4801-9ba9-7656931e0ccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_1ae0b0aa-da6e-4f3f-b77a-057df44c1952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_1ae0b0aa-da6e-4f3f-b77a-057df44c1952" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61e12654-d887-4822-bd0d-0034ca0a0422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61e12654-d887-4822-bd0d-0034ca0a0422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_253ebb2f-8c21-4467-809c-8236b5eec5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_253ebb2f-8c21-4467-809c-8236b5eec5fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac5fe620-e625-4172-b46d-229959201a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac5fe620-e625-4172-b46d-229959201a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2e1fdb5f-ea6e-46da-a55a-8663bb44c3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2e1fdb5f-ea6e-46da-a55a-8663bb44c3ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i6975b33ec0f9434bbc40b9b9b0deb6ac_ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_608023c0-3082-4486-8275-ce1fa1053c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_608023c0-3082-4486-8275-ce1fa1053c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_5e5bc586-4309-4fab-9ed9-ff8517a9cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_5e5bc586-4309-4fab-9ed9-ff8517a9cf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3be0ff5f-602b-4a13-8e79-a17a02c48630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3be0ff5f-602b-4a13-8e79-a17a02c48630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_201c992a-a94a-43fb-85a1-9c5a4c305cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_201c992a-a94a-43fb-85a1-9c5a4c305cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e4fb29b1-96f3-4094-a7fa-40e0901fed4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e4fb29b1-96f3-4094-a7fa-40e0901fed4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5cb30fc6-ac9a-49ad-8f21-e3168881e892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_5cb30fc6-ac9a-49ad-8f21-e3168881e892" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_87c29a75-ab8b-44dc-9107-7776956ff0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_87c29a75-ab8b-44dc-9107-7776956ff0ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_da2fc53f-5e0e-448d-aaa3-1b95ed4e9c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_da2fc53f-5e0e-448d-aaa3-1b95ed4e9c4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe14f7ad-adbe-4a8c-9402-aea315565b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fe14f7ad-adbe-4a8c-9402-aea315565b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b43fb66b-de25-48ce-938a-ba950a4cd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b43fb66b-de25-48ce-938a-ba950a4cd9fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_47089e78-acb1-4b1b-a815-7a444471c384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_47089e78-acb1-4b1b-a815-7a444471c384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:to="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a3b78509-da9b-423d-8b59-117fb4840791_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a3b78509-da9b-423d-8b59-117fb4840791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a227eeeb-3c08-4c65-aae1-a5fe6f5c5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a227eeeb-3c08-4c65-aae1-a5fe6f5c5f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_da075a6c-d4b1-4471-8a6e-5206bde804bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a227eeeb-3c08-4c65-aae1-a5fe6f5c5f76" xlink:to="loc_us-gaap_CommonStockMember_da075a6c-d4b1-4471-8a6e-5206bde804bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#FixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended" id="i7bf81d8c6a7740c5bf8e64f99ad3dc41_FixedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_07d317f4-1c65-4777-886d-5ed7236d89ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_07d317f4-1c65-4777-886d-5ed7236d89ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21255f2d-888d-4ec9-bb20-3e1b25a8246c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21255f2d-888d-4ec9-bb20-3e1b25a8246c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_81016fc4-a687-4734-b76c-f4fd5772fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_81016fc4-a687-4734-b76c-f4fd5772fbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0c750654-1c35-4f0b-bb4a-a387cf0ac7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_Depreciation_0c750654-1c35-4f0b-bb4a-a387cf0ac7e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_dac708c8-4d78-4b1d-9587-ee1b579a1d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_dac708c8-4d78-4b1d-9587-ee1b579a1d9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_8e4258f7-d22a-4697-ab68-3bcfee45fb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_8e4258f7-d22a-4697-ab68-3bcfee45fb01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecd359ba-8a53-4ac7-9b81-77199e35bacc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ecd359ba-8a53-4ac7-9b81-77199e35bacc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8229cef7-2b16-4dc1-bdb9-fad49ecc494e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8229cef7-2b16-4dc1-bdb9-fad49ecc494e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_136ccafa-0213-44d4-ab42-75226f70652e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_OfficeEquipmentMember_136ccafa-0213-44d4-ab42-75226f70652e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7f965999-01d9-431d-ae55-269d5e715751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7f965999-01d9-431d-ae55-269d5e715751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9b74da76-5691-426c-be1e-dffb07807c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9b74da76-5691-426c-be1e-dffb07807c43" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="i512e8f910c804e968a23cfaf3a8282c3_GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3cead8cb-7a62-4524-82fd-c18bb5e7e04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3cead8cb-7a62-4524-82fd-c18bb5e7e04f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9bd7d4a6-3559-4905-8f24-4984ef397262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9bd7d4a6-3559-4905-8f24-4984ef397262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_25c8b233-1b3c-45a7-8ae4-d2b742508641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_25c8b233-1b3c-45a7-8ae4-d2b742508641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_371587a6-dd80-4c36-b4c9-8c0cf06dd466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_25c8b233-1b3c-45a7-8ae4-d2b742508641" xlink:to="loc_us-gaap_Goodwill_371587a6-dd80-4c36-b4c9-8c0cf06dd466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab85bfc0-bc02-4635-82db-cb48e0280305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab85bfc0-bc02-4635-82db-cb48e0280305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2c65667-bf43-4086-816f-543231f49943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2c65667-bf43-4086-816f-543231f49943" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3b548d0e-ee59-42fe-965e-2367c394552e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3b548d0e-ee59-42fe-965e-2367c394552e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_e42fd693-db34-4d51-9022-1f77809a2fa1" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_e42fd693-db34-4d51-9022-1f77809a2fa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_ef3a5982-45df-4a2f-a3f8-0b43dcea767f" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_ef3a5982-45df-4a2f-a3f8-0b43dcea767f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3cead8cb-7a62-4524-82fd-c18bb5e7e04f" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_036766ad-671d-4331-bac2-96a61a3c3e2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_036766ad-671d-4331-bac2-96a61a3c3e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_63ff35e3-5f4f-4bf0-b117-282ea845681e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:to="loc_us-gaap_LicensingAgreementsMember_63ff35e3-5f4f-4bf0-b117-282ea845681e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_2f0e090e-cbbe-4bfa-a515-515a3652a335" xlink:href="ino-20211231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:to="loc_ino_BiojectMember_2f0e090e-cbbe-4bfa-a515-515a3652a335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_d0e6b4b0-c993-4b10-908c-012b5babd076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_d0e6b4b0-c993-4b10-908c-012b5babd076" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:to="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_188a6e72-5373-4cd3-ab94-362e17a7bb32_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:to="loc_srt_RangeMember_188a6e72-5373-4cd3-ab94-362e17a7bb32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09ebc836-e3d5-4292-9431-5567473c2169" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:to="loc_srt_RangeMember_09ebc836-e3d5-4292-9431-5567473c2169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_83fcf87b-4f66-4535-9b31-1a4c568464fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09ebc836-e3d5-4292-9431-5567473c2169" xlink:to="loc_srt_WeightedAverageMember_83fcf87b-4f66-4535-9b31-1a4c568464fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="ifb81baa4783d45f9b04768679b7f566c_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4cc2440a-97e7-4fbc-8c0b-8f3426bdfb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4cc2440a-97e7-4fbc-8c0b-8f3426bdfb1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d94f9dfe-33b3-4e6f-90ed-ab69086a8f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d94f9dfe-33b3-4e6f-90ed-ab69086a8f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_d75e515b-87be-4abe-b158-1930b6d42893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_d75e515b-87be-4abe-b158-1930b6d42893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5130146e-5ac0-456f-a55b-d124a09415fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5130146e-5ac0-456f-a55b-d124a09415fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_65358b35-cbf1-4ee1-a622-8bc602f07f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_65358b35-cbf1-4ee1-a622-8bc602f07f4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4cec8316-f060-4b11-9985-50cf82ddf879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4cec8316-f060-4b11-9985-50cf82ddf879" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0dded764-964d-4588-a75b-ff7b1756a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0dded764-964d-4588-a75b-ff7b1756a93a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3b26260-25f0-43e6-b0cf-5880a90cdd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3b26260-25f0-43e6-b0cf-5880a90cdd8f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_26f4ed34-0082-466e-96ff-630fcef030a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_LongTermDebtFairValue_26f4ed34-0082-466e-96ff-630fcef030a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9e7c7dae-4d5f-4e1d-bf09-461794620a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9e7c7dae-4d5f-4e1d-bf09-461794620a2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1094c659-3f2f-40fe-8d51-d954beade981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1094c659-3f2f-40fe-8d51-d954beade981" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0b90b6c7-b790-476e-b7d9-8b577f34f003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0b90b6c7-b790-476e-b7d9-8b577f34f003" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fbe826b1-b04b-4a98-a2b7-4623d830ed69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fbe826b1-b04b-4a98-a2b7-4623d830ed69" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_97877ea0-3df8-4d09-b865-c51d9e033367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_97877ea0-3df8-4d09-b865-c51d9e033367" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8476adb-fbd2-4917-9b74-8cd434fbe34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8476adb-fbd2-4917-9b74-8cd434fbe34a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ca98c2fd-9408-4850-934d-64754b261ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ca98c2fd-9408-4850-934d-64754b261ded" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_72c08db9-9ce8-418d-933f-14fa36372478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_72c08db9-9ce8-418d-933f-14fa36372478" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43a4ac4c-d8d1-4f4a-a04d-9aabd03df251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43a4ac4c-d8d1-4f4a-a04d-9aabd03df251" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_95867706-b75c-4bd6-98a2-7740d3b56af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_InterestExpense_95867706-b75c-4bd6-98a2-7740d3b56af2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7e3cebe3-b9f8-4b8d-93d0-fd87398fe727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_InterestExpenseDebt_7e3cebe3-b9f8-4b8d-93d0-fd87398fe727" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_5cc940b4-ad9d-4272-970d-59a2115fb10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_5cc940b4-ad9d-4272-970d-59a2115fb10c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_cf28482d-06bf-4f26-b920-b6e57878c678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_cf28482d-06bf-4f26-b920-b6e57878c678" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_3782f7a6-793f-4c52-9ada-61a0eefd0fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_3782f7a6-793f-4c52-9ada-61a0eefd0fec" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8facf0d7-e5a4-413c-83c7-4ebabc368d56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8facf0d7-e5a4-413c-83c7-4ebabc368d56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d084d81-c4db-4ae2-b7e4-b13a56b900e6" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d084d81-c4db-4ae2-b7e4-b13a56b900e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_6e594730-2dea-4479-a1ed-1977cf46faca" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:to="loc_ino_August2019ConvertibleBondsMember_6e594730-2dea-4479-a1ed-1977cf46faca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_49b75cec-633c-4a6b-aad0-766579126bbb" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:to="loc_ino_December2019ConvertibleBondsMember_49b75cec-633c-4a6b-aad0-766579126bbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe8eee29-a993-4657-bdde-d08bfc3127ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe8eee29-a993-4657-bdde-d08bfc3127ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fedb67b2-ec02-4f2a-affd-8aadbc8fadc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fedb67b2-ec02-4f2a-affd-8aadbc8fadc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0285d130-2a00-4099-9561-5afd14594d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fedb67b2-ec02-4f2a-affd-8aadbc8fadc1" xlink:to="loc_us-gaap_ConvertibleDebtMember_0285d130-2a00-4099-9561-5afd14594d46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_b09ae632-4522-45e7-a05a-a8d167a09b05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:to="loc_us-gaap_DebtConversionNameDomain_b09ae632-4522-45e7-a05a-a8d167a09b05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:to="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_66b5995e-b2c4-4fec-94e3-76311357d026" xlink:href="ino-20211231.xsd#ino_InitialConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:to="loc_ino_InitialConversionPriceMember_66b5995e-b2c4-4fec-94e3-76311357d026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_fd984643-d77c-45c2-b5c6-90cb96c87c19" xlink:href="ino-20211231.xsd#ino_AfterJanuary22020ConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_fd984643-d77c-45c2-b5c6-90cb96c87c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_4750686c-5149-4490-b9c2-a176b16088f0" xlink:href="ino-20211231.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_4750686c-5149-4490-b9c2-a176b16088f0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended" id="ife7fd50e7f3b4939bebce05388c4bc5e_ConvertibleDebtBalanceOfConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_79e778b9-ed6a-4b7f-a431-8ad991d2e46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_79e778b9-ed6a-4b7f-a431-8ad991d2e46f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_c7391f96-a635-4aa1-aa96-3ebc872ab79e" xlink:href="ino-20211231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_c7391f96-a635-4aa1-aa96-3ebc872ab79e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_25501362-63aa-44fc-a602-645fd3112c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_25501362-63aa-44fc-a602-645fd3112c4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3c04ecf7-0d31-4739-8bd3-1dea6ab09ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3c04ecf7-0d31-4739-8bd3-1dea6ab09ed5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_f9b2d97f-6dd7-4088-9b14-3f25cfeb7b08" xlink:href="ino-20211231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_ino_DebtinstrumentAccruedInterest_f9b2d97f-6dd7-4088-9b14-3f25cfeb7b08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a68360bc-9d3b-46a9-93fc-39fee739b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_LongTermDebt_a68360bc-9d3b-46a9-93fc-39fee739b99c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_92e89b86-9f73-49ae-b3ef-168d3fb78828_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_92e89b86-9f73-49ae-b3ef-168d3fb78828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d7ca5a53-e05b-46ca-8263-a27998165229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d7ca5a53-e05b-46ca-8263-a27998165229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6941cdb9-bbb8-4036-8ceb-3482319630ce" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7ca5a53-e05b-46ca-8263-a27998165229" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6941cdb9-bbb8-4036-8ceb-3482319630ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="ia68654340ef748ba9a0fbe1204c5ef76_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3602dab-eafc-4cce-920f-381ae20f98ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3602dab-eafc-4cce-920f-381ae20f98ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7dae1649-ea8f-491a-b17a-7be5a30eec38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7dae1649-ea8f-491a-b17a-7be5a30eec38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d9f29644-6d0c-430b-abdf-d2c1d9a6bb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d9f29644-6d0c-430b-abdf-d2c1d9a6bb80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20207958-2989-4fa0-8978-b1e2f1366d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20207958-2989-4fa0-8978-b1e2f1366d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_85b617ee-02d7-4cca-b6d4-cf4e89a82fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebt_85b617ee-02d7-4cca-b6d4-cf4e89a82fa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9b5b7ece-00dd-47ea-a218-1d5210e4a82f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9b5b7ece-00dd-47ea-a218-1d5210e4a82f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_888f2d50-67d9-4da8-9233-1340797b62b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_888f2d50-67d9-4da8-9233-1340797b62b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0dda437f-155f-448c-a0b0-64ad81024159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_888f2d50-67d9-4da8-9233-1340797b62b9" xlink:to="loc_us-gaap_ConvertibleDebtMember_0dda437f-155f-448c-a0b0-64ad81024159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:to="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18a184ca-29ce-4440-b0e8-3396515212d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18a184ca-29ce-4440-b0e8-3396515212d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e829172d-ec79-456d-8151-b203abe5d4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e829172d-ec79-456d-8151-b203abe5d4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e87cfaf4-8858-4c18-ab97-8916f31cfb10" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e829172d-ec79-456d-8151-b203abe5d4e5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e87cfaf4-8858-4c18-ab97-8916f31cfb10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended" id="ib0c33e87a1bd40ff8a7c0c7ccdf69003_StockholdersEquitySummaryofPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_06d69789-5a91-40e7-b0a9-e881ea32c396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_06d69789-5a91-40e7-b0a9-e881ea32c396" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec844e2e-0892-41f7-b440-c6421c1fd8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec844e2e-0892-41f7-b440-c6421c1fd8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_954b16f7-d1e4-4078-a16c-2b9a0e284b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_954b16f7-d1e4-4078-a16c-2b9a0e284b7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_614e2ac6-fa32-42f0-b3ce-ffc4217654ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_614e2ac6-fa32-42f0-b3ce-ffc4217654ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6472726b-2e10-4bbd-8071-49e5e5fa67f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6472726b-2e10-4bbd-8071-49e5e5fa67f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_06d69789-5a91-40e7-b0a9-e881ea32c396" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9aea0a82-06c2-499e-929a-6bcd4c80bf7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:to="loc_us-gaap_ClassOfStockDomain_9aea0a82-06c2-499e-929a-6bcd4c80bf7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_29e63a9b-e9d4-452d-90b2-3092b6cd255a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:to="loc_us-gaap_ClassOfStockDomain_29e63a9b-e9d4-452d-90b2-3092b6cd255a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_50d9bcf6-1bed-4dde-b874-42d552303e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_29e63a9b-e9d4-452d-90b2-3092b6cd255a" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_50d9bcf6-1bed-4dde-b874-42d552303e33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ie1fe1d9f12ba47fdb12146397f787c6e_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_d6da4dc2-7346-48d3-8646-c952c4d95cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_d6da4dc2-7346-48d3-8646-c952c4d95cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_beebe92d-d81a-40f2-80fe-1e5d031749ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_beebe92d-d81a-40f2-80fe-1e5d031749ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_9789dc53-88f8-422d-8c56-c03bdbeb0c20" xlink:href="ino-20211231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_9789dc53-88f8-422d-8c56-c03bdbeb0c20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b238670d-56d0-4af1-9fe7-ea7ba30f2fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b238670d-56d0-4af1-9fe7-ea7ba30f2fbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641aef96-f96a-4b48-a5ba-428f37f7acde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641aef96-f96a-4b48-a5ba-428f37f7acde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_16454bc3-d73d-42d6-b168-a3c80b5b26a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_16454bc3-d73d-42d6-b168-a3c80b5b26a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_08c699f5-47ea-472b-baa3-2bab60aa69a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_08c699f5-47ea-472b-baa3-2bab60aa69a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_fdd2330f-3df8-4b07-91b2-122a60089b76" xlink:href="ino-20211231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_fdd2330f-3df8-4b07-91b2-122a60089b76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_fc1ff23d-cef1-43f9-9022-80ceae1de5b0" xlink:href="ino-20211231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_fc1ff23d-cef1-43f9-9022-80ceae1de5b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_af65d057-0dcc-4527-8590-05d56795498c" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_af65d057-0dcc-4527-8590-05d56795498c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4430288f-fe75-4925-81f2-acfed07b7ddc" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4430288f-fe75-4925-81f2-acfed07b7ddc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_8ceaba97-b211-4bda-b0a5-7b8ba83c7c4e" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_8ceaba97-b211-4bda-b0a5-7b8ba83c7c4e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_378b8fe8-5b3d-4646-8a28-be98f2239e9e" xlink:href="ino-20211231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_378b8fe8-5b3d-4646-8a28-be98f2239e9e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5024c138-faf2-432e-b5df-e46241c59a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5024c138-faf2-432e-b5df-e46241c59a59" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fd306f03-5dbd-4471-b5a6-a3a18d107331" xlink:href="ino-20211231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fd306f03-5dbd-4471-b5a6-a3a18d107331" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7c97a477-8617-49a5-b3d2-b71565ebb66a" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7c97a477-8617-49a5-b3d2-b71565ebb66a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f0d8a1d0-7f58-4355-8819-bb36635d8dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f0d8a1d0-7f58-4355-8819-bb36635d8dad" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_1ae8a694-b9ad-4ad7-b5db-94c93f6d8a5c" xlink:href="ino-20211231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_1ae8a694-b9ad-4ad7-b5db-94c93f6d8a5c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_4849a844-8774-4519-b06e-9889e9beab28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_4849a844-8774-4519-b06e-9889e9beab28" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffbb27cf-a7d6-428d-a20b-327ed1544f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffbb27cf-a7d6-428d-a20b-327ed1544f8e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_bb858bca-5fb3-4660-8e34-82773b7db87b" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_bb858bca-5fb3-4660-8e34-82773b7db87b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d84a1954-e2f9-4d63-81e9-0256fd80effc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensation_d84a1954-e2f9-4d63-81e9-0256fd80effc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0ec46dc3-fa3a-4fae-a8eb-61b482cf061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0ec46dc3-fa3a-4fae-a8eb-61b482cf061c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8eeda121-cb3a-4727-b01a-9e7e094d8301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8eeda121-cb3a-4727-b01a-9e7e094d8301" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4971deff-771d-4517-821c-035b99137631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4971deff-771d-4517-821c-035b99137631" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2994b24-44f9-4b5d-9518-3b93814ccce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2994b24-44f9-4b5d-9518-3b93814ccce2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_be994c94-dfb1-4d06-b788-d7bb336c754f" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_be994c94-dfb1-4d06-b788-d7bb336c754f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_763b0900-3db0-46d7-83a7-a9753f3b668f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_763b0900-3db0-46d7-83a7-a9753f3b668f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_6eb65245-b7e7-4bfe-a3bc-158b5d4c0c37" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_6eb65245-b7e7-4bfe-a3bc-158b5d4c0c37" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_71f9647a-c4a2-4148-80b5-d280845c6c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_71f9647a-c4a2-4148-80b5-d280845c6c56" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2f9b38d9-9d24-41f6-9ca3-a91d766b514e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2f9b38d9-9d24-41f6-9ca3-a91d766b514e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_9ff314e6-0a7f-4e20-874b-951b45bb5357" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_9ff314e6-0a7f-4e20-874b-951b45bb5357" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cc7e4083-958e-4227-a057-2dc4d37cc0b5" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cc7e4083-958e-4227-a057-2dc4d37cc0b5" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6f319461-be9a-4924-bda0-9e25ceb4bbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6f319461-be9a-4924-bda0-9e25ceb4bbbc" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6ff3a2e9-74b6-4943-a242-c31f0d101710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6ff3a2e9-74b6-4943-a242-c31f0d101710" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51ee45f7-ef7a-4a06-a351-59a281cea0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51ee45f7-ef7a-4a06-a351-59a281cea0e9" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d4d2b53-19d5-40fa-be9e-fe15d2996cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d4d2b53-19d5-40fa-be9e-fe15d2996cef" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6a6a1b97-3b6b-4390-bed1-878dad6616cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6a6a1b97-3b6b-4390-bed1-878dad6616cc" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4ea8dab4-6c1a-4147-aa3b-5a2cefb44bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4ea8dab4-6c1a-4147-aa3b-5a2cefb44bab" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5bd9e5b3-345d-4b7f-bdfa-103425517981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5bd9e5b3-345d-4b7f-bdfa-103425517981" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d59d8d8a-0dfb-485d-b020-7bf454598843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d59d8d8a-0dfb-485d-b020-7bf454598843" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28c8e7bb-04c5-49fa-9aca-94c05cf0f9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_80ea6d68-1ed4-4cea-a021-927f74a20bb8" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_80ea6d68-1ed4-4cea-a021-927f74a20bb8" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ad88000-1b85-4dea-ac17-cfed63a88b2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:to="loc_us-gaap_ClassOfStockDomain_7ad88000-1b85-4dea-ac17-cfed63a88b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:to="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8976a1cd-f2ac-49c7-a30c-e4c86ea95fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8976a1cd-f2ac-49c7-a30c-e4c86ea95fec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_997d5d39-4046-4985-a8dc-0c93ee8d7d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:to="loc_us-gaap_CommonStockMember_997d5d39-4046-4985-a8dc-0c93ee8d7d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eeddc475-e93f-4176-8961-3c373cc31432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:to="loc_us-gaap_EquityComponentDomain_eeddc475-e93f-4176-8961-3c373cc31432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b86d71c-5962-4c52-911f-968432eac42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:to="loc_us-gaap_EquityComponentDomain_3b86d71c-5962-4c52-911f-968432eac42d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_08a6559d-06ea-40fc-80d3-0eec89d42e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b86d71c-5962-4c52-911f-968432eac42d" xlink:to="loc_us-gaap_CommonStockMember_08a6559d-06ea-40fc-80d3-0eec89d42e5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_897f7832-ad76-4d59-89e7-1258b5c11da1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_897f7832-ad76-4d59-89e7-1258b5c11da1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_6b059dd0-f70c-4371-9f36-1e3c8885d35d" xlink:href="ino-20211231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_6b059dd0-f70c-4371-9f36-1e3c8885d35d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_a03a9705-917c-4daa-91c5-a47528f5b892" xlink:href="ino-20211231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_SalesAgreementMember_a03a9705-917c-4daa-91c5-a47528f5b892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_cd026ad7-76ff-4679-a2e6-4eff4280c55a" xlink:href="ino-20211231.xsd#ino_PriorSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_PriorSalesAgreementMember_cd026ad7-76ff-4679-a2e6-4eff4280c55a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_58976061-d2be-4faa-b7ac-540345a1c9c8" xlink:href="ino-20211231.xsd#ino_NewSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_NewSalesAgreementMember_58976061-d2be-4faa-b7ac-540345a1c9c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_77faa062-4a77-43c0-be86-0dea5827cb9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:to="loc_us-gaap_PlanNameDomain_77faa062-4a77-43c0-be86-0dea5827cb9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:to="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_443bdad5-74d4-4003-90f3-d41454c874b9" xlink:href="ino-20211231.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:to="loc_ino_A2016IncentivePlanMember_443bdad5-74d4-4003-90f3-d41454c874b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_33c63359-4527-4530-91f6-9239ee9d4016" xlink:href="ino-20211231.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:to="loc_ino_A2007IncentivePlanMember_33c63359-4527-4530-91f6-9239ee9d4016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7bf664a5-4471-4bcc-a53d-590c0e24bad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7bf664a5-4471-4bcc-a53d-590c0e24bad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeeMember_0b9df592-0218-498e-8335-1dd7cc02d018" xlink:href="ino-20211231.xsd#ino_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_ino_EmployeeMember_0b9df592-0218-498e-8335-1dd7cc02d018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aaa9f285-4c35-4c47-8bdf-bacc16244770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aaa9f285-4c35-4c47-8bdf-bacc16244770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aec6150-0d11-4de8-b881-261654f4227d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aec6150-0d11-4de8-b881-261654f4227d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_b03ce00a-9178-4ad7-a79a-fa03358693dc" xlink:href="ino-20211231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_ino_NonEmployeeMember_b03ce00a-9178-4ad7-a79a-fa03358693dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f99c571b-19f3-4f38-be7b-6963c112bd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f99c571b-19f3-4f38-be7b-6963c112bd75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d2c8ae66-7a5f-478e-b9d2-bdd504d4556e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f99c571b-19f3-4f38-be7b-6963c112bd75" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d2c8ae66-7a5f-478e-b9d2-bdd504d4556e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_36863b34-ed2a-4722-b06f-8fb5a49ed98c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:to="loc_us-gaap_VestingDomain_36863b34-ed2a-4722-b06f-8fb5a49ed98c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:to="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fe54d291-dca1-40de-a3c1-cedb554f6cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fe54d291-dca1-40de-a3c1-cedb554f6cbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_36ab6998-203f-4240-815c-59c497f2ea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_36ab6998-203f-4240-815c-59c497f2ea6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_96b0e12a-1243-4e6b-899c-008050d52ab7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_96b0e12a-1243-4e6b-899c-008050d52ab7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a0cd876-7afc-4371-8f5b-2bdffbdeb932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a0cd876-7afc-4371-8f5b-2bdffbdeb932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bf06194f-7c65-4fbd-8e04-294e58239d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2a0cd876-7afc-4371-8f5b-2bdffbdeb932" xlink:to="loc_us-gaap_SubsequentEventMember_bf06194f-7c65-4fbd-8e04-294e58239d8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended" id="ib5d66776ce8444ca8ae96302f5f1603e_StockholdersEquitySummaryofStockOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ab3af928-9431-41a0-b6de-38bc27b5af91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ab3af928-9431-41a0-b6de-38bc27b5af91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ff0885fc-4b4b-494f-adc4-b27efec50e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ff0885fc-4b4b-494f-adc4-b27efec50e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_02e27cef-b143-4d6e-98e4-cdda2a3fa38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_02e27cef-b143-4d6e-98e4-cdda2a3fa38e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_38bee63f-90d2-4ba4-9077-05adb73717fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_38bee63f-90d2-4ba4-9077-05adb73717fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_75f778e1-c3a6-4b62-8579-fd05b82c16a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_75f778e1-c3a6-4b62-8579-fd05b82c16a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2a672965-8aaf-4429-9f35-3a8fa03a8edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2a672965-8aaf-4429-9f35-3a8fa03a8edd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9a94c8aa-a11c-4f61-be2e-13025ae6b893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9a94c8aa-a11c-4f61-be2e-13025ae6b893" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_34d8b463-2bbb-43fa-aa74-655f7838381d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_34d8b463-2bbb-43fa-aa74-655f7838381d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0fa10ded-1d8a-4825-8a72-ebe190dea10a" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesOneMember_0fa10ded-1d8a-4825-8a72-ebe190dea10a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_3d5d6ad7-dce3-46ef-9c27-a687c596823b" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_3d5d6ad7-dce3-46ef-9c27-a687c596823b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_2c074abb-7744-42f3-ba81-6c9e4a2ffd6f" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_2c074abb-7744-42f3-ba81-6c9e4a2ffd6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_d86d2568-ed52-420a-9d7b-f9498afd102b" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesFourMember_d86d2568-ed52-420a-9d7b-f9498afd102b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_c09dc0ed-ce99-4ec5-a1ca-06475c9c92da" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_c09dc0ed-ce99-4ec5-a1ca-06475c9c92da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_c73c94bf-622e-433a-8e77-b6284bedb266" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesSixMember_c73c94bf-622e-433a-8e77-b6284bedb266" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended" id="i137fee71ba7f4f8f997f747cb8123bfd_StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72952c29-cc28-4254-9fdf-a34da04ddc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72952c29-cc28-4254-9fdf-a34da04ddc57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505b4aae-462b-42fa-9914-1d1cd283bdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505b4aae-462b-42fa-9914-1d1cd283bdd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6997e6f3-ee39-45ff-aab2-d19c78e9211c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6997e6f3-ee39-45ff-aab2-d19c78e9211c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7e3b9eaf-4375-4133-a9f6-b1b0bfb8c96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7e3b9eaf-4375-4133-a9f6-b1b0bfb8c96d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c4ec315-ffd9-47f6-a58b-c35d972c5d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c4ec315-ffd9-47f6-a58b-c35d972c5d7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ac9fc46-cafc-41c8-9458-e424aea59fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72952c29-cc28-4254-9fdf-a34da04ddc57" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:to="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91159ce0-ac76-47b0-bb34-5962782b553e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91159ce0-ac76-47b0-bb34-5962782b553e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_527dc4d8-af5c-4a5e-bc36-b44838b7adcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_527dc4d8-af5c-4a5e-bc36-b44838b7adcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6288013f-07cf-4835-8a4f-f82864111049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_527dc4d8-af5c-4a5e-bc36-b44838b7adcf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6288013f-07cf-4835-8a4f-f82864111049" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i0e4a0ab442ee47169d8f28ced414dc39_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_8803c724-a01c-4867-8a81-dbebc6e789a6" xlink:href="ino-20211231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_8803c724-a01c-4867-8a81-dbebc6e789a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_36b4ecf4-57d4-492e-be79-c50fc2eb5496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_36b4ecf4-57d4-492e-be79-c50fc2eb5496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a1ec1e5d-b47c-40b2-a704-67a9a9a88d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_LeaseCost_a1ec1e5d-b47c-40b2-a704-67a9a9a88d16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_c5385a26-ca41-4b51-9fca-fb1ed3cf628e" xlink:href="ino-20211231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_c5385a26-ca41-4b51-9fca-fb1ed3cf628e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_5d2a68d0-6ba6-4970-b957-c9283f52d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_PurchaseObligation_5d2a68d0-6ba6-4970-b957-c9283f52d97e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9d5a9980-3247-4c3e-9e0b-de50d481d4cb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9d5a9980-3247-4c3e-9e0b-de50d481d4cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_de8a48ff-dd5e-4aff-ab77-74841b5b6ccd" xlink:href="ino-20211231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:to="loc_ino_SanDiegoCaliforniaMember_de8a48ff-dd5e-4aff-ab77-74841b5b6ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_b2438091-470e-4ff4-a266-b80e4b7e81ea" xlink:href="ino-20211231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_b2438091-470e-4ff4-a266-b80e4b7e81ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:to="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28e460e3-9e67-4c04-9d95-9c5c12ec99a4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:to="loc_srt_RangeMember_28e460e3-9e67-4c04-9d95-9c5c12ec99a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:to="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8816f714-5c4d-434e-8d89-870dde5d38c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:to="loc_srt_MinimumMember_8816f714-5c4d-434e-8d89-870dde5d38c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d10b9b53-057a-40b8-93e7-0cd01fa03a36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:to="loc_srt_MaximumMember_d10b9b53-057a-40b8-93e7-0cd01fa03a36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i31df2589f06f445387998b929d073722_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_31e670e1-3884-4895-a680-e99a6bbe2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_31e670e1-3884-4895-a680-e99a6bbe2d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_94e78c54-ac70-4ec3-8e32-708c669bc6b0" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_94e78c54-ac70-4ec3-8e32-708c669bc6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9817a71c-fb91-499e-a7e6-29a2744b3a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9817a71c-fb91-499e-a7e6-29a2744b3a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_56b5b8ed-65a4-4ead-b8a0-b84c3d77600f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_56b5b8ed-65a4-4ead-b8a0-b84c3d77600f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_b0a5ca69-e180-436b-ba30-0ceb12e3450a" xlink:href="ino-20211231.xsd#ino_TaxBenefitsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_ino_TaxBenefitsExpired_b0a5ca69-e180-436b-ba30-0ceb12e3450a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a583a847-2013-4db1-8e98-26aa8d3488d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a583a847-2013-4db1-8e98-26aa8d3488d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_41344b81-5d46-4170-9052-e85118b3343a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_41344b81-5d46-4170-9052-e85118b3343a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_ca2caf05-728b-46fb-a772-ce2c63ccc2ec" xlink:href="ino-20211231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_ca2caf05-728b-46fb-a772-ce2c63ccc2ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_dae43b95-8f42-4db1-b6d9-bc996be0a104" xlink:href="ino-20211231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_dae43b95-8f42-4db1-b6d9-bc996be0a104" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_b8cdde0d-0efe-40eb-beb2-2140258c04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_b8cdde0d-0efe-40eb-beb2-2140258c04c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember_f936349b-4a05-4880-aa54-37897c559442" xlink:href="ino-20211231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_ino_KoreanStateIncomeTaxAuthorityMember_f936349b-4a05-4880-aa54-37897c559442" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_db7a0780-5f03-4964-8258-88a77dad49c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_db7a0780-5f03-4964-8258-88a77dad49c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_153892d8-84d5-45a7-93f0-42eb3d182f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_153892d8-84d5-45a7-93f0-42eb3d182f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fd5c2de3-22ad-41fe-a6f9-c2b505327c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_153892d8-84d5-45a7-93f0-42eb3d182f48" xlink:to="loc_us-gaap_ResearchMember_fd5c2de3-22ad-41fe-a6f9-c2b505327c59" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended" id="icac2e714d14147018a9bef5e5e57e30a_IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_b005aef7-5cf7-430c-ae48-fab455c68261" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_b005aef7-5cf7-430c-ae48-fab455c68261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_0ca06486-2c80-4a1b-9629-3744a2916569" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_0ca06486-2c80-4a1b-9629-3744a2916569" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_93187f78-6683-43ee-a12d-8e4a22ffc753" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_93187f78-6683-43ee-a12d-8e4a22ffc753" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_e18e4dd4-180b-48a6-b35c-93efe24e5a79" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_e18e4dd4-180b-48a6-b35c-93efe24e5a79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d16df74f-f79c-4c0e-bbcc-9379da9ba975" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d16df74f-f79c-4c0e-bbcc-9379da9ba975" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1d3d65ff-b926-4781-9186-b8959fcfc952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1d3d65ff-b926-4781-9186-b8959fcfc952" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_0bd990dd-fb45-4862-886a-f7a5d6d82f94" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_0bd990dd-fb45-4862-886a-f7a5d6d82f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_b0b0fef5-cc81-4b2e-8e69-80a6691aee5f" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_b0b0fef5-cc81-4b2e-8e69-80a6691aee5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_e75191fc-e0d2-467b-8072-711cd2b403c0" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_e75191fc-e0d2-467b-8072-711cd2b403c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_68378e51-5354-43f6-b3bc-fe8fd724ccff" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_68378e51-5354-43f6-b3bc-fe8fd724ccff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_55d6dbe8-144b-4f2b-b0a4-4ae952f348fa" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_55d6dbe8-144b-4f2b-b0a4-4ae952f348fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_261a18cc-a309-48d0-87ad-27c006660375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_261a18cc-a309-48d0-87ad-27c006660375" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_14316283-2316-4174-bb09-b99bbb842ed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_14316283-2316-4174-bb09-b99bbb842ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7a822c72-eba2-49b5-8094-2f9a5d327077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7a822c72-eba2-49b5-8094-2f9a5d327077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_90f8fcc7-3bf3-49b9-add0-f84533e67bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7a822c72-eba2-49b5-8094-2f9a5d327077" xlink:to="loc_us-gaap_ResearchMember_90f8fcc7-3bf3-49b9-add0-f84533e67bc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f25e2e97-af8a-49b7-8e04-b0abdded5c46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f25e2e97-af8a-49b7-8e04-b0abdded5c46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_54b84a37-2e4d-4ef0-a0d7-245374c2fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:to="loc_us-gaap_DomesticCountryMember_54b84a37-2e4d-4ef0-a0d7-245374c2fff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_15ec1e32-6907-4c21-bfb1-fccc4c249542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_15ec1e32-6907-4c21-bfb1-fccc4c249542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d7e60042-3c6e-41d8-a0b8-c70de5d9c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:to="loc_us-gaap_ForeignCountryMember_d7e60042-3c6e-41d8-a0b8-c70de5d9c31d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i9c8fdb346fa74c4186d58527f8c2525a_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_af58f954-dc0c-42ec-8a61-f3e01f465f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_af58f954-dc0c-42ec-8a61-f3e01f465f08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4661f4fe-fff8-432c-b5b7-52cde7b2c96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4661f4fe-fff8-432c-b5b7-52cde7b2c96a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_3813c071-ce99-4846-ae7a-0f79d7326313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_RevenueFromRelatedParties_3813c071-ce99-4846-ae7a-0f79d7326313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_1127339b-3520-4b5b-bb72-e8bc3b601083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_1127339b-3520-4b5b-bb72-e8bc3b601083" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_e2e0aaad-ab5f-4783-9f5e-4f1dc09a22cd" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_e2e0aaad-ab5f-4783-9f5e-4f1dc09a22cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_52c85465-c503-43ff-8bc0-5bb1d031921e" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeArrangementTerm_52c85465-c503-43ff-8bc0-5bb1d031921e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSubGrant_6991632e-28e8-44e1-9ec5-2765a6aed740" xlink:href="ino-20211231.xsd#ino_ProceedsFromSubGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_ProceedsFromSubGrant_6991632e-28e8-44e1-9ec5-2765a6aed740" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_340e5b76-ad2b-4cca-81fc-60886d48fcc0" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_340e5b76-ad2b-4cca-81fc-60886d48fcc0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_cc4a5147-ba38-4000-8927-d090789340e6" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_cc4a5147-ba38-4000-8927-d090789340e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_fe8a719c-2ce3-4b0f-97e5-0f037cbb435e" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_fe8a719c-2ce3-4b0f-97e5-0f037cbb435e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_81330181-441c-4d05-bd3a-0ee12a8e07cd" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_81330181-441c-4d05-bd3a-0ee12a8e07cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_c6aed076-eaf4-43b4-ae0b-e6ba2f1f49bb" xlink:href="ino-20211231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_GrantProceedsReceived_c6aed076-eaf4-43b4-ae0b-e6ba2f1f49bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7fa5075e-31bb-4ec9-9f9d-7783d0675bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7fa5075e-31bb-4ec9-9f9d-7783d0675bdf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_dd209e26-8e26-4624-bfe3-03b1742eaa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_dd209e26-8e26-4624-bfe3-03b1742eaa13" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1a97d160-08e6-464d-b788-df403f4ae2be" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_1a97d160-08e6-464d-b788-df403f4ae2be" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_cf861597-8a1f-4777-a199-464f9766e471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_cf861597-8a1f-4777-a199-464f9766e471" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f03d2dda-dabc-42c5-b255-88853502f250_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:to="loc_us-gaap_RelatedPartyDomain_f03d2dda-dabc-42c5-b255-88853502f250_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:to="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember_668b6785-bf05-4da3-b2fb-5fb0e7f04961" xlink:href="ino-20211231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:to="loc_ino_PLSaffiliatedentityMember_668b6785-bf05-4da3-b2fb-5fb0e7f04961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_651ecb93-7ca3-434c-afe8-68a5b2c7a652" xlink:href="ino-20211231.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:to="loc_ino_TheWistarInstituteMember_651ecb93-7ca3-434c-afe8-68a5b2c7a652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_476d2d02-a895-43b0-a897-d5ebd914a140" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:to="loc_srt_DirectorMember_476d2d02-a895-43b0-a897-d5ebd914a140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_084d2ec0-d3aa-42e1-8c56-46803a36ff44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_084d2ec0-d3aa-42e1-8c56-46803a36ff44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c1c4df6d-21c5-4c3c-b7cd-a460e660264a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c1c4df6d-21c5-4c3c-b7cd-a460e660264a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_d3a787ce-c649-4918-a2c8-ca70eac67135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c1c4df6d-21c5-4c3c-b7cd-a460e660264a" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_d3a787ce-c649-4918-a2c8-ca70eac67135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c312e11f-a7b6-4e24-86e7-644d8f3ec397_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c312e11f-a7b6-4e24-86e7-644d8f3ec397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_730dbeaf-6420-4ea6-9f64-7d18a0935bde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_730dbeaf-6420-4ea6-9f64-7d18a0935bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_31e036d0-fd18-4769-ad67-ffdb2789e69f" xlink:href="ino-20211231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_730dbeaf-6420-4ea6-9f64-7d18a0935bde" xlink:to="loc_ino_PlumblineLifeSciencesMember_31e036d0-fd18-4769-ad67-ffdb2789e69f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3f907f73-4643-49c4-b6ca-3753b0628b8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3f907f73-4643-49c4-b6ca-3753b0628b8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0ccdc1da-246b-407b-9693-48786c09eaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0ccdc1da-246b-407b-9693-48786c09eaec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3d3bb3ab-1ff7-42e7-a075-fe09c3f5e9dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0ccdc1da-246b-407b-9693-48786c09eaec" xlink:to="loc_srt_DirectorMember_3d3bb3ab-1ff7-42e7-a075-fe09c3f5e9dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="id2ad87d515db4d3d87f7923227f60701_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ba209c62-8526-4874-a1d2-94c28fb52e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ba209c62-8526-4874-a1d2-94c28fb52e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d647a8b6-3d0f-483b-9420-ad90fc011258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d647a8b6-3d0f-483b-9420-ad90fc011258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0030ad31-b462-4595-bd04-82e846235183" xlink:href="ino-20211231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0030ad31-b462-4595-bd04-82e846235183" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c2380358-eb77-49a9-920f-ada7d8434423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c2380358-eb77-49a9-920f-ada7d8434423" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_bd341e4c-8d5a-485a-8979-7ee669bf5dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_bd341e4c-8d5a-485a-8979-7ee669bf5dbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424537a2-1db0-425f-93c9-6a215f80370c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424537a2-1db0-425f-93c9-6a215f80370c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_3115216b-5d47-4f1c-87d0-53fb88ab20ef" xlink:href="ino-20211231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_3115216b-5d47-4f1c-87d0-53fb88ab20ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bae863bc-04a9-4cf2-87e3-4b2621ad931e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bae863bc-04a9-4cf2-87e3-4b2621ad931e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1ede6167-7989-49f7-ba7f-c7ab7c4668ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_EquityMethodInvestments_1ede6167-7989-49f7-ba7f-c7ab7c4668ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d953fd9-f454-4fe2-9279-8d211a88ed79_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d953fd9-f454-4fe2-9279-8d211a88ed79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61788697-dcc4-46a5-9662-b755c2f17c91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61788697-dcc4-46a5-9662-b755c2f17c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_c1c99548-9398-4cb7-b747-8abc64a14188" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61788697-dcc4-46a5-9662-b755c2f17c91" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_c1c99548-9398-4cb7-b747-8abc64a14188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6d6f3165-39f0-499c-acac-29a37c8a6a20_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:to="loc_srt_OwnershipDomain_6d6f3165-39f0-499c-acac-29a37c8a6a20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6016eba0-674a-4638-ab1a-a8349d22c806" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:to="loc_srt_OwnershipDomain_6016eba0-674a-4638-ab1a-a8349d22c806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_ed70db03-b605-4bb4-9338-acac1a91b378" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6016eba0-674a-4638-ab1a-a8349d22c806" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_ed70db03-b605-4bb4-9338-acac1a91b378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:to="loc_us-gaap_ClassOfStockDomain_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:to="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1a72f166-18a5-4f5d-9ca0-357a5bee4163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:to="loc_us-gaap_CommonStockMember_1a72f166-18a5-4f5d-9ca0-357a5bee4163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_b1485532-dbca-4c5e-9204-4f9a724b3b7a" xlink:href="ino-20211231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:to="loc_ino_SeriesAOnePreferredStockMember_b1485532-dbca-4c5e-9204-4f9a724b3b7a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended" id="i61a00bfd93484d1890dfcf6b461e36b8_GeneosTherapeuticsIncDeconsolidationAccountingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_02069f10-33cc-48bc-b70f-a63941868b31" xlink:href="ino-20211231.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_ino_WorkingCapitalExcludingCash_02069f10-33cc-48bc-b70f-a63941868b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f56ec773-ddf4-42c8-9d97-f9d03435b3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_NotesPayable_f56ec773-ddf4-42c8-9d97-f9d03435b3fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a80a38ce-ff22-4c31-98ea-2dfc2a6feeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a80a38ce-ff22-4c31-98ea-2dfc2a6feeb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_95cd62c1-0b2d-484a-9302-834003952715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_MinorityInterest_95cd62c1-0b2d-484a-9302-834003952715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_f5346af7-b7af-4137-9721-82e25b5f0fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_f5346af7-b7af-4137-9721-82e25b5f0fb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_120ae703-98bc-4f9d-b99f-43c953397e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_120ae703-98bc-4f9d-b99f-43c953397e93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_47b5ab55-440d-49b4-82bb-502974ed1d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_47b5ab55-440d-49b4-82bb-502974ed1d8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:to="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7988aef2-50e7-4d5b-b117-8d9fb2e9a34d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7988aef2-50e7-4d5b-b117-8d9fb2e9a34d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_af649411-f73e-4e28-8284-a6e4d2e29a58" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7988aef2-50e7-4d5b-b117-8d9fb2e9a34d" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_af649411-f73e-4e28-8284-a6e4d2e29a58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncInvestmentinGeneosDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="extended" id="i25b19a0ae1894e35ac0634279a1e5c08_GeneosTherapeuticsIncInvestmentinGeneosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_393b3c96-0251-46b1-bfa1-37ef0cde2acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_393b3c96-0251-46b1-bfa1-37ef0cde2acb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_10c22e5e-00e2-4f9f-b4c1-a26450e5ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_SharePrice_10c22e5e-00e2-4f9f-b4c1-a26450e5ecb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9606751d-d37b-4862-9dcf-a60648b959bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_EquityMethodInvestments_9606751d-d37b-4862-9dcf-a60648b959bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:to="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12a7498c-4239-4949-8d17-b98bf9622a6a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12a7498c-4239-4949-8d17-b98bf9622a6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9397323-83d6-4e4a-84ba-3eb5b6a01aa1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9397323-83d6-4e4a-84ba-3eb5b6a01aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_20e3ac1c-ac56-43cc-bc81-0e19e8576eb5" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9397323-83d6-4e4a-84ba-3eb5b6a01aa1" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_20e3ac1c-ac56-43cc-bc81-0e19e8576eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3afb279-a5dd-413a-8942-2b62009bebb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:to="loc_us-gaap_ClassOfStockDomain_a3afb279-a5dd-413a-8942-2b62009bebb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:to="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_81640626-3d04-4cff-abe5-dbd4ad523433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:to="loc_us-gaap_CommonStockMember_81640626-3d04-4cff-abe5-dbd4ad523433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_090670fc-7718-41d5-9345-8401b691177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:to="loc_us-gaap_PreferredClassAMember_090670fc-7718-41d5-9345-8401b691177e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended" id="i871e92b8f79c402db0ba0a0e90af1600_GeneosTherapeuticsIncFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_63429f27-8896-4737-8ff6-b622ab0f9651" xlink:href="ino-20211231.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_63429f27-8896-4737-8ff6-b622ab0f9651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_841d2708-64e0-481e-9ac4-110bc88199a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_841d2708-64e0-481e-9ac4-110bc88199a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_120a3118-b3e9-4e33-a378-7b30171e0d3a" xlink:href="ino-20211231.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_120a3118-b3e9-4e33-a378-7b30171e0d3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:to="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3fd9546-e990-4755-a90d-4dc415ed3fe9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3fd9546-e990-4755-a90d-4dc415ed3fe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7a45903-19c2-4808-955e-ad655b8464e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7a45903-19c2-4808-955e-ad655b8464e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_18912171-c14b-4964-b3ae-c226dbd9296e" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7a45903-19c2-4808-955e-ad655b8464e2" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_18912171-c14b-4964-b3ae-c226dbd9296e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_986d7d3f-badc-4c42-9c31-271b7b4a049a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_986d7d3f-badc-4c42-9c31-271b7b4a049a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_746bc468-ab2c-46f7-bfae-483c127d94bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_746bc468-ab2c-46f7-bfae-483c127d94bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_941f3f70-e5e2-4119-a5d7-af3e9f1548ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_941f3f70-e5e2-4119-a5d7-af3e9f1548ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8fb88211-fe4a-48aa-8538-25251dd9d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8fb88211-fe4a-48aa-8538-25251dd9d76a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended" id="i4678761ab27e4983a10bdc640303fa11_GeneosTherapeuticsIncPreferredStockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fc1b670a-7b68-427f-8eca-6749d17f6586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:to="loc_us-gaap_EquityMethodInvestments_fc1b670a-7b68-427f-8eca-6749d17f6586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_641fd63c-ed2b-426c-98ab-dbe60d4b3131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_641fd63c-ed2b-426c-98ab-dbe60d4b3131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b7d47ab7-c1eb-4c12-9980-9db33e353cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:to="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:to="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_642d324b-421a-4d55-8a59-1ab25a812174_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_642d324b-421a-4d55-8a59-1ab25a812174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9554bd6-5cc3-4a27-b7fb-87eb7e80069c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9554bd6-5cc3-4a27-b7fb-87eb7e80069c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_5dd062af-8a0f-4228-9548-52d886f3a337" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9554bd6-5cc3-4a27-b7fb-87eb7e80069c" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_5dd062af-8a0f-4228-9548-52d886f3a337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_29e09154-7314-4ab9-bee0-106c694f23fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:to="loc_us-gaap_ClassOfStockDomain_29e09154-7314-4ab9-bee0-106c694f23fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5aee28d5-488a-4803-80a8-dafac52898e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:to="loc_us-gaap_ClassOfStockDomain_5aee28d5-488a-4803-80a8-dafac52898e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_4f754435-90de-4c54-9fc7-8bbd087c1dfb" xlink:href="ino-20211231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5aee28d5-488a-4803-80a8-dafac52898e2" xlink:to="loc_ino_SeriesAOnePreferredStockMember_4f754435-90de-4c54-9fc7-8bbd087c1dfb" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ino-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:91a42a7e-9c16-46a4-89e4-78ae514a2e8d,g:17ea50c5-1e55-4356-a463-d0e13f29ef69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4049d348-eba3-4fd5-9f7b-ea8867970561_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_262540d5-bdd5-4b13-a777-e991486074f3_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_41f6f786-7547-44a0-b10b-a5b4c24e991e_terseLabel_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue from affiliated entities</link:label>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_label_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue Affiliated Entity [Member]</link:label>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_documentation_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember" xlink:href="ino-20211231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherRevenueAffiliatedEntityMember" xlink:to="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ef595b20-cc12-4aae-97f4-6d5425e98b19_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_426c5d49-8bc4-4035-80fb-1e335465a77b_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b7c19370-9f12-4b40-a99a-6d4842d8b236_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_f42a6b8b-f67d-4625-94ba-bbafb988cbb9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d3045c8-f488-4aee-b1da-95dc8e180fe7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4dc822ae-cfe6-4f41-a434-35e9f675b2d3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ff0838eb-5f84-4e0e-af8a-368b97ec321d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9126eb82-31fe-419a-ae6e-88922d2705dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_526b19d3-251c-4f1c-869a-ae8cb9d49eee_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_ea6be97c-e337-4189-a0b8-a1a5c93afbc1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7138b8c4-2b83-4664-8e34-7297596cdd73_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ea994a9d-bc3d-4ca3-bd6a-580727142c73_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_912175c7-d5d4-48be-8483-166a198a8b48_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember" xlink:href="ino-20211231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenPublicOfferingMember" xlink:to="lab_ino_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b76c2a02-a832-4bc7-9a8f-2823c11c9445_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_e48ef6e2-d851-4646-96a9-4b1eb91769b0_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$9.01-$12.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFourMember" xlink:to="lab_ino_RangeOfExercisePricesFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5b3ae0cf-c263-49e2-9dc5-201deecad30f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d7112a9-2c78-4bdb-92b4-ddd812486622_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dcf34906-a895-40f3-8848-35bdafd571b1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_a7b61dd5-ad39-4c21-8475-68c4dffadd0a_verboseLabel_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_label_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares of Vested Restricted Stock Outstanding Under Plan</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_documentation_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:href="ino-20211231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:to="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_af1cc0d6-82c6-4cc0-9621-001751aa8311_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMaintenance_1aa05f55-420a-4c73-b106-946a8a0f52f3_terseLabel_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:label id="lab_us-gaap_CostMaintenance_label_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMaintenance" xlink:to="lab_us-gaap_CostMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9d03bf75-2b28-491a-83bd-06a06344b838_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_ba4c2171-7fdf-442d-a10a-c4b9ea329a70_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_011390f4-6299-4695-855e-4922094fabb8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_362a71ed-5794-419f-a795-6d760393d400_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.60-$3.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesTwoMember" xlink:to="lab_ino_RangeOfExercisePricesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5341ccab-dc3b-47f9-9cd5-861ece1159a9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_56aae353-92fd-4905-8550-1102aa3e0886_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_eddfb768-13c7-4fb3-ad30-0b842062831e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f8e8c12a-4fb7-4887-822e-25bfc6ee308c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_e3e1a626-7f9e-4ce5-9351-cfca6dd2cfe0_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU's expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_6696e3d2-3284-4656-80eb-230cac71575f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_5dd4bb72-143f-4c89-924d-fde7f0a66b87_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_70c0b216-5622-4e75-a1bc-143112983edb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_92bad5f1-c70d-4ce3-bfdf-5e7d94cc03e2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1c1e770d-1dff-49de-b1d8-a05012412d25_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_70bb0452-02e4-44d3-8e24-f6243765dfcb_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_1e31e53b-db3f-4727-a98e-187b033e3244_terseLabel_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_label_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component Of Convertible Debt Issued</link:label>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_documentation_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component Of Convertible Debt Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued" xlink:href="ino-20211231.xsd#ino_EquityComponentOfConvertibleDebtIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityComponentOfConvertibleDebtIssued" xlink:to="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1d733461-16da-422c-a960-ebc0e72ab4d1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3beabebb-d1b2-40fa-8ff5-024030ff26a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_578b2215-df51-4eda-98bc-a2fee13d3343_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_f776510f-b3a4-4306-9485-a33c3a8fb096_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5de2dbfd-9b50-46a1-8fb7-4632c772c90d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grants under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_95ff7380-e916-40bd-bfdc-9629631118d1_verboseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20211231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_88c4b787-45df-43b7-b069-3db142ba1df6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_2bfba92e-fbe0-4c05-ae58-97aebb410ea0_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_d6d80ed4-1c1a-4755-a277-debfcbd27f4f_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20211231.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48fea2d1-e38f-4426-a4c7-d416ccc61ce2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_4fb54aed-d8df-4b66-a543-2110bbfe026c_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_a966a942-5c7f-4b2f-ad0b-bc31ed1e270d_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_4720556c-8340-44e3-bcf7-389ad63a8f20_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, payment earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3f1e2497-ee49-4063-b6bc-1db49bb7eb3d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_e2cf4bd5-d6b3-4ad4-b72f-6c7aec28b304_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cebe037e-ebec-4a02-a9f9-f7c1fa4d6ac2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_90fd8bfe-a698-463c-a25f-d5a51003739d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, corporate income tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cdf4d070-bd18-4c7e-aa7a-965d5fdc94ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6b7ee1cc-b796-4800-a06e-8d5f1e800677_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f311599d-272e-4530-8774-fd2dfbcbff44_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_69d85066-3d41-48da-9e01-aff8412a5f25_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_35060121-bed4-4fc8-b694-5bfd4e0287b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_340799e4-665e-4181-8218-8d022a7eabd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercises in period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_f5668d47-6abe-4f9c-a285-e22ceab9904f_terseLabel_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:href="ino-20211231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:to="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cdd5ff68-0476-4f61-a8d3-14f3cb6a9da7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_a173ed30-b506-40e5-be9d-e492a2bfb7bd_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_9c027e17-9185-4890-b1bb-435eede43b6a_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant proceeds received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20211231.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_d5251524-7f90-4804-87c6-90bbf9553f52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, lower range limit (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b11bf2bf-918c-459d-a85c-76471f6f5d22_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_3dc270e8-f479-46a7-97cf-e21ca6c169fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_d07adef5-1126-4cba-bec2-8f7b9c43c983_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Net Book Value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b31406d4-6f76-4bf6-8da9-e35dbebc3442_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_fbd785c4-f026-405f-a3ad-6dfff4a0d97b_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_38d8ee12-3c2a-4b12-9745-52226ba66199_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_550382c9-1135-4050-a46b-c0ca90dd6204_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_a3e07f50-27e6-44d2-8921-372809732beb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c6419ef6-37b6-4b37-b309-2f6bb01c9bd3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and other estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_94aa1c1c-01e0-4f14-9727-af1c14b01b3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_04600af8-069f-42d0-af5e-a8d37544814c_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total antidilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c493b6a7-a1c8-471a-8708-d39dda324cd4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_986f9fc8-df7a-4f61-886b-eaa7a6ab3843_terseLabel_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease agreements entered into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_label_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_documentation_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:href="ino-20211231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:to="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e9ff99d0-0d56-4d63-8efe-a91297311963_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_23e1b5ec-153b-4e96-bf69-b34ecd6ab181_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_d74b17e1-5c3e-4889-af52-1f4cca938ed4_terseLabel_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input, expected term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_label_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_documentation_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:href="ino-20211231.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:to="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9d47de0a-a8bd-4071-a6cd-604b2de8e867_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e41d96b8-4376-4236-98ab-923852d616ee_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_1c043a5f-b582-475e-bd91-460cec5a1828_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_4646d0a4-c944-4b72-87b1-fc469330def6_verboseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_5247678f-691d-443d-967b-1109461c5163_verboseLabel_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises, net of tax payments</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_label_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_documentation_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:href="ino-20211231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:to="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a9b39402-ccbe-4da6-a81b-20b70098d4c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_58922dd0-e0e5-4f3d-a00f-c8f157479b93_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain/loss on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_08f2a8aa-1c6b-484e-bab5-b41b2ded277a_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_c61a092e-2b77-4cc0-afc9-fd422a7b7c17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_981d8ffe-0511-4758-b551-3e8e403e60e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from other unrealized gains on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c7df3341-a22f-4578-8355-bfbb0373bb58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_a474be93-2dd3-4fac-b0dd-20ad6f3d537a_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20211231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ad8fd27-7353-4e7f-acb1-980ccea4f6e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06ab7566-0972-4429-9469-edb5ddb1fcd8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_c9609759-b30b-42dc-a2dc-e818b679a00e_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_8e250356-aed1-4f26-af45-055ebfea6c90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_da96877d-e8ea-4e3a-b2b3-1c62aadb8dd3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6582cffb-927b-4024-8cbd-aea766424749_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ebae4eed-a314-4010-a917-b146630a77c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8bd2b192-a70f-4f5c-b01a-c53264057f32_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3258cde7-7002-45bd-93a6-d9afaf6782a8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_54e24343-c644-4492-bc5d-9c38d7bbf87a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7f154f82-e738-446d-9334-cfae4ec7d047_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff5558e4-8b7e-4226-ad0c-611b811c8bf6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c2d94df9-5d1d-426a-8849-da4541f979ff_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_432c75ac-4d89-45b0-8702-f0f0c7193d94_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">%&#160;of&#160;Total Revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0a3f02ae-01d3-429f-b2e1-60f675600a50_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_9ebe1c05-41b4-4b28-a7d2-2032dca234df_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:to="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0d49f5a8-2dce-4a48-9bca-48850e3aca71_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_c17dbf62-1ead-4360-9792-235bdb8df3f2_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_0fb84709-3e84-4f66-b321-ce10c24b9f1a_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20211231.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0557fbb7-b1fc-48a7-b9cd-e843c8a1ce3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5ce01c5d-c442-4301-a559-943d50200a8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_486f6622-8e79-454c-9e99-b1a187ef301e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_8025572a-59a2-405d-a1e4-14e42d112d26_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IN O4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I N O4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I N O4800</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20211231.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_5d25b3e4-1f89-44ee-b639-e503e7047dc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d7afe0a8-a4e4-45c7-b03c-8b2a1786c053_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8c6c7fb9-72aa-4575-a5aa-fa37c1152256_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_89ddd300-a569-42ba-a525-6f598a61e5f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_c531b522-fe4d-4e65-b949-57a928c44702_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of date conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_28b60e3a-9339-42c4-bc3d-4536ac1dadfb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_08961f8d-9282-40ce-8b45-e0a5f9832c46_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_42178c93-cc3a-440b-af0b-e5b7cdc5e187_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bf9b9db0-caeb-48ed-a9bf-4a31b99941d1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9775dc15-fedb-4a56-b1be-51a53df7484e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_da8c93d8-1376-4abc-a77e-f74006a46584_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20211231.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_c85d11f1-e187-4d23-b72d-40e84e3c1609_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations of Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0cb9c74b-210d-4050-8d1d-10ffe218c5e5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2918e02e-8427-4182-8bcd-550a27980317_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c455b301-f6aa-45aa-b493-2b5d91749b56_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_ebc55cd2-88f2-487c-b7e3-f29b54d71694_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_19430ed6-08a9-40fd-a3f3-895e57aded88_negatedLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_fd881dce-632a-45c7-861b-915cc7fae7c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_d0ffdf15-854f-47c4-8544-e0fd5d690052_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_148ac69f-2700-4ee7-a457-9451fc278774_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_c02dd11b-0153-48ec-bce9-9a97f80d7d77_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cff45d1e-8ab0-488b-bb85-748a80bbfaa2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_15bc94a4-6ed2-48f5-b778-572234a8f891_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborative agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement" xlink:href="ino-20211231.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_63531d51-f9ee-4a11-a7d9-0f39ad483a4f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a65b0959-96eb-460a-ba41-b0cf581b94e7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6c71b9f3-f6a7-461e-9f23-989febcd0db7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_692c3452-f7ad-4214-b563-8484970cc681_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_24932624-87e7-40ff-b875-2c9dee106b8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_d022beda-dc4c-4a85-b677-8e1f9241d418_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_fdcbd80b-1e59-427a-964d-e7177fbdd015_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_f346b8d1-7685-421c-9da6-d6fb022be7ae_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20211231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c7870163-c91b-4b3a-b657-e915a07b9807_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_2471f8bf-e94e-4833-a0e2-f642425f96b4_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_a6756237-1b1b-4af8-a488-577688f39348_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20211231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6e004a10-3ed9-428b-a224-702253290ca6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_033b3daa-cd6a-41ab-8924-28d1a4e401ae_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20211231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_a249cd75-390c-459f-8c68-a532d030ba3d_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20211231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55a67f64-349d-4dc5-ba2c-f93337a13e3a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_794282be-c38a-407a-85d9-159cbc6f8e76_terseLabel_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock" xlink:href="ino-20211231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantRevenuePolicyTextBlock" xlink:to="lab_ino_GrantRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_e8b43f3f-3cf6-4252-bde9-4eb1724141c6_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:href="ino-20211231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:to="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e0df489c-9e67-457b-a232-700837a7f772_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_36c0993c-1af0-40c6-be39-23610c994e01_negatedTerseLabel_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital (excluding cash)</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_label_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_documentation_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash" xlink:href="ino-20211231.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapitalExcludingCash" xlink:to="lab_ino_WorkingCapitalExcludingCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_90eedc97-162d-45d6-a937-908f8cd45e6a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6703fc00-a83a-44e4-b2ee-3096bc3a05c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_268b7572-295c-457c-a97a-a34186f1fcde_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_117db666-ec2d-4cde-b063-b8454d467584_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_05feaa14-968b-46d7-91f6-898a8387a9ea_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_0e66624d-c55c-4c44-b845-c9355b561849_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20211231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_d5d8d705-d4d7-4a44-a934-e03d7643506f_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of subsidiary</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:to="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_161ebc18-9cd9-4e77-8e4f-7c812fd5e125_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_1e2afeb7-2b21-4386-aa3b-629f6c5c5df1_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$15.01-$25.62</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Six [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesSixMember" xlink:to="lab_ino_RangeOfExercisePricesSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e850b453-2550-4c5a-b0f3-767f13e10349_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_85b10bc9-09e5-4e4f-82ab-b16fcd810887_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares outstanding under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_18bc98f9-1dcb-4eef-95ec-e659f6585a1b_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20211231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_3a8412b2-276b-4450-9bb1-27519c92a28a_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3ae65533-b44e-4029-aaff-da60968eccb6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7ff0c98f-e058-4778-833a-e60435099161_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_708d59a5-acc9-4aad-a5a6-ec0bb80d91e8_terseLabel_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Korean State Income Tax Authority</link:label>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Korean State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Korean State Income Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember" xlink:href="ino-20211231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_KoreanStateIncomeTaxAuthorityMember" xlink:to="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f090e71e-cf02-484d-b70b-af50c56653ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserved number of shares under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_a0896b1e-caeb-4dee-8402-5c1d26718b97_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e8752d9a-aaad-4d83-9e33-490b21773669_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_37f8f7c6-1d44-435c-a21d-b7463416d9a1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_a537e021-955c-4fba-93b6-72575a20d067_negatedTerseLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:href="ino-20211231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_227159fd-e626-4797-9056-87702caccb8b_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_09863157-12d0-419b-a28d-04ea1d470548_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c543c116-ac03-4f39-99bd-d4d8906121ce_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_dd8d1d39-4dc3-4255-abd3-9c8a6366e7e1_verboseLabel_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_label_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_documentation_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used in estimation of fair value of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:href="ino-20211231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:to="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_8250c570-6d33-4f75-ac98-ee3a1fcb821b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_33649137-98b0-4ad7-8735-d15df9897b4b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_acea8f58-f47a-45bc-8e08-741c5f8fa526_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held-in-trust</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6c80f526-2f85-4349-a894-2f77896e34d5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_298d9610-1285-488c-9edd-89fac75afd4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d606c91f-c06c-44cc-8000-4e929e2eda09_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ec845b04-67e3-48d0-97b4-1850b00a0166_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_62461183-c7dc-42fc-87ae-ad84002c2011_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_a141da9f-45d6-4e64-afda-5941982dd458_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20211231.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_0dce177c-b401-43be-8945-fcaa00948e63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0aed71c5-f17c-4024-9835-debe93bb8db9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f8316a0b-69a3-4653-81d3-83bea11ad41a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a050ceab-0c3c-4d0c-a576-f2707e4e29fb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_402e3f6d-af74-44c0-bc1d-5844344946d3_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_85d4c354-b419-4b93-8778-398aabb44361_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AllOtherCustomersMember_cb65f067-e0f2-4ddf-b4c8-6c3af4d68e79_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other, including affiliated entities</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember" xlink:href="ino-20211231.xsd#ino_AllOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember" xlink:to="lab_ino_AllOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0fac7594-a2c1-4ce5-9c90-8acaf1da5447_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e8b8fa13-4315-41d3-b791-dd74e907ef25_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_85b2ecf6-fa06-4878-b90a-83d388edd241_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_d8364470-ea67-4d4b-8996-132d32d2d6d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8ae75d16-0f74-4b0c-b58a-d2e147d1f9f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1332bcf8-e9ba-4498-8915-30ac0c354987_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_368966d4-e46d-41f1-8c2a-d57f55d30544_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_2064779f-e5ba-4fea-bf02-f0d3449d9f97_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a773ea2e-3ace-4ffc-bd7e-87fa3371eeb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_90550ecd-ebfd-43d7-8107-e8542d5f4107_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c8dcf98-1964-47cf-a52d-cf1d21ec871b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_91002520-a86f-4621-af8a-25bf342ee93f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_19ea70fb-c662-4906-9cb1-a0b793f94be7_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20211231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0686f3f4-dab6-4e04-934b-5cf0d9a0f78d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f0460be6-a830-428a-9f74-e39cf2c03937_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2b7de307-093a-4906-ad29-c985ac0e3839_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepositAssetsForfeited_ae5f57bf-793a-4fd4-aa0f-a4b32a703232_terseLabel_en-US" xlink:label="lab_ino_DepositAssetsForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits forfeited</link:label>
    <link:label id="lab_ino_DepositAssetsForfeited_label_en-US" xlink:label="lab_ino_DepositAssetsForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets, Forfeited</link:label>
    <link:label id="lab_ino_DepositAssetsForfeited_documentation_en-US" xlink:label="lab_ino_DepositAssetsForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit Assets, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepositAssetsForfeited" xlink:href="ino-20211231.xsd#ino_DepositAssetsForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepositAssetsForfeited" xlink:to="lab_ino_DepositAssetsForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_bfe68077-73d9-4373-9b80-a6571d9a3ba5_verboseLabel_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</link:label>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_label_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Equivalents [Abstract]</link:label>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_documentation_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockEquivalentsAbstract" xlink:href="ino-20211231.xsd#ino_CommonStockEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CommonStockEquivalentsAbstract" xlink:to="lab_ino_CommonStockEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_32831249-56de-4531-94d6-e739c1be729a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_a1138bea-a125-4ede-a8d2-b5029128d976_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_5799e9a7-054b-4fab-b32f-e4fa1ac31aad_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_428c9fc8-c5f3-4dc1-ab03-e6b0c37e13bd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0def51e2-c701-49cd-8b84-8a25d46c22da_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDeposits_ccd47d1d-9412-4d46-89f3-436527d9437d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForDeposits_label_en-US" xlink:label="lab_us-gaap_PaymentsForDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDeposits" xlink:to="lab_us-gaap_PaymentsForDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b42a16cc-5418-42f7-9ed1-8dced0ce4bf3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_536ec07f-671e-4c22-afa1-6a71bac36c12_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7151cfce-77e6-473e-854a-37250f7aabe1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, carrying amount of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_a8cf5def-0ecc-43f5-a975-61d52572fb96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_54ab9a75-1a48-480a-842d-2748eaeb6cc3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa2c0fad-3ef6-4886-850a-87b24e9da4f7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_4bf1baf1-5459-4f9b-a7ed-6d47398e3cca_terseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos enterprise value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:href="ino-20211231.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:to="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_5bf05954-c453-403c-b35a-9fd2eca968b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_daa9d280-b06d-4002-a43f-4c055464ac01_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_ca9004c1-cea5-47e3-b41b-55e0fe4a5e5e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_57feee5e-53de-4f90-a1b0-12958f78a189_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_60c02752-14a9-43ff-804f-2f4478c393c9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_5c7e6369-1c93-4a18-8f68-dd38c97b0c16_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_496417e5-1682-4b25-8187-f371a7d3dd12_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Geneos issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_483d5c30-71d5-485d-8353-7f935a4520c6_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_06cbf6f7-c1e9-429c-812e-6260975e512c_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_da3a438b-b6b1-4ed1-92b1-7338c4c51816_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_993d26fc-023f-475f-9d96-27febbdcc4c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d182041a-0f11-4450-969d-d41dc0d65ebe_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4b44ae32-ca1a-4e30-8e84-e9ee9a190e58_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_ae432207-fedd-48f8-93b5-1bfe94dd5065_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6ec2add8-db36-4d8d-992b-ea41ba6f2638_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_24114f25-f545-4309-9ac6-e91573be2085_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_12dc0337-a9e3-4c38-b29c-3bb2fd475639_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_b3633fbe-42d4-44ef-a792-39b8448ec8d4_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement, aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_bfa7e1bb-374b-470f-a81d-1c28d8df97bf_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, milestone payment, revenue recognized</link:label>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_label_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Milestone Payment, Revenue Recognized</link:label>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Milestone Payment, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:to="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_3173db75-cd09-4268-b4d9-94dd23ec25f4_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. (affiliated entity)</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember" xlink:href="ino-20211231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesIncMember" xlink:to="lab_ino_PlumblineLifeSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a9d21eac-e56f-4801-84e3-f361ca9fe6c7_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_ebf0eeac-fc10-47bf-8c62-2a7aad9769f2_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agents will be entitled to compensation</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20211231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_65b41e1a-5f2b-4a70-89b5-0c5b1c17c972_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_7a3728db-9033-467f-926d-5ba45a165b94_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3c9469a1-cf2c-4718-ba32-f69ef5fcdf73_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of capital raising related expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_d5342794-511c-4dbd-9b55-e9c5a609f271_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_862c2ab0-0618-40d5-b6a2-6ed47e034a01_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a6c0002f-6745-46bf-99cb-c5161b5a6bff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_4ce61d16-a5aa-49f9-bd7f-4e167d7705fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fc12647a-e03b-40bb-adf0-6b2c3a0b6433_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b20e4644-67eb-47cd-aedf-e526afa5644b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_c2c24b87-b727-4aea-b1da-17610bba014a_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_34fbda21-0cfd-4d2f-ae18-e69049e0ee99_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_8c318771-2b5c-4d17-b703-09315825558b_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c2587ea8-3f4e-47f4-81b5-45fd434f13da_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3aa19097-9b64-49da-a171-4c84987e6449_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of capital raising related expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_c491eb62-2cb2-449f-927c-32763406bd29_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20211231.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0f9cc226-bb32-4314-9016-9a7ba73152bb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_bc9f4c17-f529-40bb-bca4-07ccfca0cbc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ef92732e-5073-4f9d-b2cb-d424f161e3d3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_36697f34-70bb-4b83-a663-201b64e2a38d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction (gain) loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_b5b3d6d9-523c-4d04-9a3e-b09b303c8605_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20211231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2d3a3e67-babc-4671-b5f2-b3227658eaaa_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2021 and 2020, issued and outstanding: 217,382,887 at December&#160;31, 2021 and 186,851,493 at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_fbeea2c4-0bfa-4dd4-8c64-12a9a98d3c75_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_7f694c12-068d-4f90-b8ea-781b6b3686e8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_654305a2-132c-4a8c-a575-af5a1daeb87b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_7884f908-3d84-4c40-83f1-70d0474c8dba_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_c2f41bc8-d7a7-4375-8afc-30f9e7b58d18_terseLabel_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_label_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_documentation_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember" xlink:href="ino-20211231.xsd#ino_AfterJanuary22020ConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJanuary22020ConversionPriceMember" xlink:to="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_107c3fe1-6bdf-479e-aa43-fb14af34aec3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e103096a-7aa7-4e4e-8205-a98b8bc8e27d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_306d8db6-bd57-4737-87fa-a9890fff845a_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_305c0542-55c7-4bfa-aca7-5fa6b7f97e38_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_00a86804-0ede-4f25-ad50-6e7eef50a376_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8140e938-8171-4eae-add9-e4a4dc80e7e3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_fbd1a479-680b-4d88-9b46-facae9fb10b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to issuances of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4e3ff311-2fb3-4ffe-9a8b-48ef6cda24f0_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_d76409b4-fb1e-4674-9257-289e955defb7_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$6.01-$9.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesThreeMember" xlink:to="lab_ino_RangeOfExercisePricesThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_286a9e43-12ae-4cc1-bc49-f275a693d164_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_12ca96cc-de84-43cd-93c4-4f50cd91a2a0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest in Geneos, net</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_5ee5208f-b095-4f69-8274-cf78d65ccbc0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_0a09ae28-b129-429f-abfb-8991e84c37b8_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8c2cf510-17ad-47ee-b9ee-2513a9a240b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_febef7e7-8f07-48ac-b7cb-6d5db16da4ce_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c81c7528-94d5-4e3b-aeac-da654d9bb681_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertibleBondsMember_50ebc022-defa-4866-ba78-2add9bac6f51_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember" xlink:href="ino-20211231.xsd#ino_ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember" xlink:to="lab_ino_ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_04077157-8bd5-434b-9c49-ae0d4436af41_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3c0ec58a-152e-4b1d-8d7b-a8051209361a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_63f147d6-d702-4392-92cb-fcfa9e808a57_terseLabel_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_label_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_documentation_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember" xlink:href="ino-20211231.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJuly22020ConversionPriceMember" xlink:to="lab_ino_AfterJuly22020ConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_fb23dd3b-63e6-4f97-a543-280872dd4239_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20211231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ff11d62b-6318-4cfe-b041-994163037371_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1345b9d8-ee81-4cbb-8586-d6dfd2f125c6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6d7ecee-6d6d-4f38-aeeb-3ca212f3842e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_31c0d630-10ba-4ebf-a958-3ad4a80b0d9b_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3b5ca417-fb7f-4939-8e60-0f6e30f47e38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_21904dfc-fcc9-41ac-b137-e9a533ef8679_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20211231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_ec659829-c80b-452c-8507-681b5311f3dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_b7fa9e1d-17a5-4df3-96b9-3b7c5adb4795_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_a39263e2-d352-4cca-b1b9-29d0b55f0840_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00197ebe-6b0d-46b9-b9c8-d3b3e67c201b_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c986e54b-8285-40a5-991c-246e111dfbd8_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_eddadd3c-f72e-4e4d-b7b4-ac9772ac7bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_0dc851b5-61fd-4024-b1d1-75540c819470_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_06ff613f-5e08-4c4f-b3e0-eaaa737614c6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_72fbb82b-2cac-4132-8925-fe1323755393_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Item or Group for Fair Value Option [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3693f1c0-8046-49b2-96f0-38b2af179206_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_331ebf00-a169-469d-ab29-ff0b42a3c914_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_bc22fc4a-fcaa-4c4d-ab28-f0eaa40806f2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_4e5e4501-edd3-4c85-87a5-90533bd63bb2_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_a26b5b48-818e-415b-9413-c9faf08ded2f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_e161a14a-c786-44ab-a880-16bb883c053b_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20211231.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3562d878-4ae7-4c65-a401-127fdecf2bdd_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6e133403-9d53-4e60-ba2c-70ba5320bc91_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_b1838777-2022-42ee-95f1-89e482748338_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations of Tax Credit Carryforwards [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef60d32c-ca47-49c5-a5fa-84b85b239117_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_b7f5cfa9-b2a7-4759-b4f6-fafdb535ba8a_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible loss on extinguishment of debt</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:to="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_a93bb124-8195-479e-b547-075a7e67f9c9_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20211231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c40d9984-bb41-4a0c-aa0c-6da06ad420bd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a11d499e-cfe7-4100-8e12-1df1f054ac56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_3a694fba-0340-427c-82fa-c6f6b80c84f1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_10ecc4ea-f080-428c-a29a-03cc4c707fb8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_2b6bcddd-a24e-40ce-948e-245dad58d1a7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CEPIMERSMember_5ab899a2-df66-4ef2-8a39-d73ac5cfa6fc_terseLabel_en-US" xlink:label="lab_ino_CEPIMERSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI MERS</link:label>
    <link:label id="lab_ino_CEPIMERSMember_label_en-US" xlink:label="lab_ino_CEPIMERSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI MERS [Member]</link:label>
    <link:label id="lab_ino_CEPIMERSMember_documentation_en-US" xlink:label="lab_ino_CEPIMERSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI MERS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CEPIMERSMember" xlink:href="ino-20211231.xsd#ino_CEPIMERSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CEPIMERSMember" xlink:to="lab_ino_CEPIMERSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2ab3d303-ced3-4d65-96cf-20bba29dd473_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_45a62a17-906d-420a-be00-1aebc9b20bd8_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ae7083c7-8e70-4318-bbec-6c3289f32132_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_9f4dbd8f-da20-4839-8247-41bd3c06fecb_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_68e8300d-d26c-4e91-8370-deda1f797857_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2c7420e-eb2b-458f-8b0e-937f80458bdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5d42db23-6e7d-4cb1-9fe4-72c8bbd34644_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_be68a20a-2a2c-4de7-a4a1-af636b56e5fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6536cb3b-bb6b-4b89-bc5a-e8aec0dbb19a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5b9a2fc7-7f34-49fd-ab2e-2ccd3fdc53d8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_82381503-a803-44b3-bfcc-2d8cf66cfefc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d85d0185-2aa4-4d15-b82b-4f9f663d7754_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_534d4d01-fac3-4b38-8b36-dfeab770bf0a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_67e660c6-cec0-4877-b88b-dcc25f855a73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d35da6fd-fd2c-4a42-9d6f-d8fdaa9233f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_03611748-3652-4278-98f7-33931be00f08_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedSubcontractExpenses_f1c021bf-24c3-40cc-a6a7-3507bf4772d3_terseLabel_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued subcontract costs</link:label>
    <link:label id="lab_ino_AccruedSubcontractExpenses_label_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontract Expenses</link:label>
    <link:label id="lab_ino_AccruedSubcontractExpenses_documentation_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontract Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedSubcontractExpenses" xlink:href="ino-20211231.xsd#ino_AccruedSubcontractExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedSubcontractExpenses" xlink:to="lab_ino_AccruedSubcontractExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cef2d232-ea0f-443f-acbe-5877d36b5d3f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e38d52e-0f01-4f45-8f06-555366c32ddb_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a9e0ae32-6028-418d-8a41-7617fb66c3ca_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_79187d2b-fcf6-422b-89e8-dd647ed5fb6b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_b23a321e-47aa-4aac-aac1-b9b0335575c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3c78ee47-057e-4a7f-9761-6830850ab05e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_567c988e-b302-4bf3-b0ac-18bc6b8d452e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_ce321ccf-4ef4-465c-a012-954e0c47c751_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_23a13d68-61e2-4e69-8e32-94c382f11054_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a44f8052-e876-42a8-9cf7-848dbb027a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_6d53792c-ca9d-4a88-9c75-5a8d57376a89_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_926414b1-97d6-4943-b80d-78588570c16b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeeMember_4b4524c1-980b-42a7-959a-2d9b4261fdce_terseLabel_en-US" xlink:label="lab_ino_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_ino_EmployeeMember_label_en-US" xlink:label="lab_ino_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_ino_EmployeeMember_documentation_en-US" xlink:label="lab_ino_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeeMember" xlink:href="ino-20211231.xsd#ino_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeeMember" xlink:to="lab_ino_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_531cfe8c-fa9e-43fd-ac83-730ea587523b_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_6110a943-1297-41ef-b24e-e08e6102df14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7e23340b-7d77-48e0-96b3-8d0670ea46aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7da5d0d9-0ae7-44c2-b180-ce85be6f2d31_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_9241ef86-741e-4420-b469-7cbc695046a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7cf1c9d9-d180-4821-8953-f5efe225e228_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestExpense_ec1b5bbd-d586-4527-964d-674cef6c5192_terseLabel_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_label_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense" xlink:href="ino-20211231.xsd#ino_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestExpense" xlink:to="lab_ino_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0ea9249f-966a-4aa8-9090-935b41904208_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_b73b4fa8-88e4-4ab0-8e9c-8b910abdf100_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5e881958-6090-4e17-a055-febe23384697_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_c798ef17-1f75-499c-bc10-0ff920079bca_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7df8cf30-3ace-46bd-a858-165bfcc47485_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a5002041-d1ec-45e0-bc18-821db58aead0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_7a8e95d0-42d3-4fff-89df-fba2ede51ebf_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_e35f138a-864e-4382-9521-06b67567355c_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_bd725776-3d26-4555-8283-d653d1a49e2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cfa60365-a8fd-4cf6-a925-ffae34cc83eb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f5878c01-3133-4699-ad71-0439cea68a39_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_17219f11-dad8-4499-9c59-668b7cf8dc38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29706f84-0514-489d-a0e4-dff8b1db9609_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_fe5361eb-cb00-47c6-8300-1e7c3b35a5fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expirations in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3de06758-858b-4284-9076-68e5faae4896_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_71d9017c-cf31-46f9-aac0-4be5496bdeed_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bce6a5d8-ba35-40e4-aafc-eec790d0da24_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_9e5b239a-4d56-4d23-bec5-d6e96f681bf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_fa9d55c8-479c-4154-8dc0-e033a28f4f23_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_13379915-0abe-4cc5-b991-30591313c7d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_73136a2b-82ae-4213-bc44-3ff7653d8f31_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d4f774ec-9089-46ef-bbfb-731f8f9bf56e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_7d421386-6a32-47c6-bf4d-d2768587a56b_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20211231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_59512d8a-67e8-4be5-a60d-c05e6e75e75e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_43f223f5-3273-462d-b796-259827629b33_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_86fba519-7136-4361-9050-316376bddf6e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f128f239-5a94-4eaf-8394-4dd499f98e06_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6a4c1eb-7b25-4d3b-8f4c-4918a4ed6902_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_213384f5-6cae-40a6-b82a-83ff2a968743_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_bc64eb6f-a6ff-4cf2-8d1c-84317ab0da07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument principal amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a2b9c22a-944d-4115-8c86-3951be3e1b03_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of convertible bonds and senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3e69be74-443e-4d05-84e0-9b8aa7a3bec0_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_836fd763-74f2-4ed3-9ece-63fd1979be66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_6afb5d55-fe65-4ffa-94d8-ee82fb14c3e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b684f521-22bf-47e4-8597-37849b198905_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_26ef2967-9a6a-4c09-9005-7bc1e40bd9ce_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_393ecbd8-a92d-43ce-95ae-8f1436e6754f_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20211231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_74c1887a-83f7-4c50-b758-ffe5cd7f5171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized tax benefits rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2ffd4a21-2ec0-482f-b351-85677047754f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_76857e68-7e43-404a-9fa2-bf7cf87d9ab7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4ae2d409-e047-4ead-a0ba-306074b269e8_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ab4b0ab8-bcfc-427e-90c3-110cd26a3656_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e79f4d52-1559-451b-83f8-5a0eb0556bb2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_35cf008c-4cef-4093-a99b-f4091b796b28_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a4b0edca-1042-40c0-9a03-5824a63c209d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_60463a16-855e-4dda-b6c0-3a02fcf5b71a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_db4f908a-1fc2-4102-bd3a-1fec64d4f2c8_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20211231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_5d3921ec-a019-4fec-a748-b15b18872249_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ecc22f60-773b-4b5a-92d4-5bda80978c7a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_241025b9-5921-410b-be80-c1b6272ea496_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment disposed of</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_3d70c3bd-bc5f-4d42-bd75-503014f3f672_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, remaining contractual term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_f236ec6d-83a9-4772-9d1e-89437654d72a_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion, conversion price (in USD per share)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:href="ino-20211231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:to="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_cd415f45-463d-4ece-a5b4-c6d27f2c5a9d_verboseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount of current assets and current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20211231.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c9be763c-76db-4f00-abc0-c14bcd8a758e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_253288d7-d998-4da9-b8b6-6e6bca345fb4_terseLabel_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:href="ino-20211231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:to="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9281e8d9-8af4-4ffb-99bc-913d98effd12_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per Share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d62e774c-bc36-4727-bfcb-47dfca762482_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9fd5e2e5-1aad-4f88-b15a-c5e2121f4262_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_f3b25346-9dc4-4d1c-b479-1245ad633e71_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_ecb80e45-d467-4f63-813a-c4e67d6d1268_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_75bf6aa5-877c-42c1-8911-848a351cd287_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0515751d-1e19-41e8-afa7-8a12dc67aadf_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9ac14674-bd08-4f55-a923-579fc3461985_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_1bb3fb57-23af-4019-9636-9b0c5a24efff_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b88a1928-68a2-48a0-a615-e718aabe5a9f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c1c2635c-2fed-40fe-9719-ceaad2f09000_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_43eea7bc-a936-4e06-8883-b990fea01243_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f178c0b1-b067-46aa-8273-0fcdf3769921_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1cfb3a81-53e1-420d-90a3-98e1c8adfb59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredClassAMember_5b5e92d2-9c13-4a9c-8f3f-16e9c2132515_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred</link:label>
    <link:label id="lab_us-gaap_PreferredClassAMember_label_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember" xlink:to="lab_us-gaap_PreferredClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_9f419c15-1a30-4f4e-8e6f-49c07fe225ad_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded exercised amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_2a44420c-b1ae-4330-9871-de25889d4908_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_339f27c3-4c8a-467c-8e7d-697eb2a4285e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8a45871e-821e-49b2-81ac-a22ee5f3d670_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_40848f6a-bc80-472e-9d96-68dd2c17e500_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_7ecaf86e-c22f-4b08-bb07-fc24b918c4b2_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_1301c14c-40bc-4e91-a230-ef54d37bc261_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos upon deconsolidation</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_94c24db3-d607-4927-a30e-c616ee368112_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos as of March 31, 2021</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_4d136dae-3f35-4855-84e0-44c326526677_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:href="ino-20211231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:to="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_70b57e6e-18e0-4de1-bb50-2a35167658c0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_5bf8009b-30c3-4ce1-8fd9-8c92f1bcdec3_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$12.01-$15.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFiveMember" xlink:to="lab_ino_RangeOfExercisePricesFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5d1d5a5b-b1fc-4c87-b6d5-4d8063648e36_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_f2997c51-5a80-4cf9-aa34-05579f44e9da_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_05dcffe7-68ac-45d2-b610-38e11cfd29a4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_e9c832b0-17a6-4dd8-837e-93f108ed6191_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_9edfb968-b565-4936-8ee4-a1ee069987e2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise&#160;price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_d8850397-d649-4c5f-aeb1-9fa8b28ce755_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_647a5259-5697-40be-be2c-a401b6634ff5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea79aaaf-839a-4652-abdf-00b6bd1eb977_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10da9b81-48a0-4436-8dc7-d61491e880c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a4e0ec06-81f2-4caa-808d-3e8d6559cd47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8bcc0ea8-5908-41ef-836f-60f2625eb186_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromSubGrant_4df3a99e-5d94-49bd-9392-1d422962c9be_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromSubGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sub-grant</link:label>
    <link:label id="lab_ino_ProceedsFromSubGrant_label_en-US" xlink:label="lab_ino_ProceedsFromSubGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sub-Grant</link:label>
    <link:label id="lab_ino_ProceedsFromSubGrant_documentation_en-US" xlink:label="lab_ino_ProceedsFromSubGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sub-Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSubGrant" xlink:href="ino-20211231.xsd#ino_ProceedsFromSubGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromSubGrant" xlink:to="lab_ino_ProceedsFromSubGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_fc84846b-92dc-4952-9659-2f12241bbaf3_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, area of land under lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20211231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PriorSalesAgreementMember_b423e62c-fb3b-4128-8b22-f02cc62a843d_terseLabel_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_label_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember" xlink:href="ino-20211231.xsd#ino_PriorSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorSalesAgreementMember" xlink:to="lab_ino_PriorSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8cd86c02-9d28-4716-85cf-89cb3635ae12_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_43bd91ae-4e1e-462c-a81f-53f1da23c3bd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_6bbb0302-9344-4024-ba52-7af458560a41_totalLabel_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_label_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_documentation_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:href="ino-20211231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:to="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_215efbb8-270e-420d-9087-8030144d354b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1ffc01b6-3794-4fe5-9c88-988f3d45bc29_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_014987cd-54ac-43f1-9264-5a9e0fe5cc7e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_15a7e47f-9388-4e4d-b18c-bed69f0c8166_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7c3d192f-5458-42f0-8b80-9b3ba7704f8a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2afb3003-2cc0-4d70-926b-fa1d3bd867ab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_85e4a780-4ebd-4620-95af-384b32d74448_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_7bd10c31-6119-448f-992d-b6d78ad04616_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_64a51a73-b63d-410d-b929-bd0c405b958e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of shares authorized under stock option plans, by exercise price range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_52dc167c-2703-4b15-823b-cd326036f22c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_43555967-7de5-4dda-bc12-c378452e887e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_7487a4ae-7bb1-4b8f-8f86-9731590a0020_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_11299fc6-e90c-4269-9d00-966197895125_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AstraZenecaMember_a70eb825-5998-4131-a504-ae3c9f2a5b6c_terseLabel_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_AstraZenecaMember_label_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ino_AstraZenecaMember_documentation_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember" xlink:href="ino-20211231.xsd#ino_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AstraZenecaMember" xlink:to="lab_ino_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_84c2940e-d9f4-4908-b1e3-c9c7bd8423a9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_77914cb1-716d-473e-a8e5-55299fbe7eb6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_791ed73e-b411-4f1e-bf5a-1441b08d5fbe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e7c1f41c-69d9-4563-9794-a3ddccb46fd1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1db6615b-820d-490a-ad67-7d3258fd5148_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_87d8d2c9-3a83-4063-9f84-853299519330_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_ae424378-536e-469e-a811-37f494eff6b0_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_label_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:to="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d34411c3-e390-4ca2-ae50-577222c14295_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_613dce4e-967d-4df2-8bba-a8ccb8b391b3_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:to="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c8dcfdab-0853-46ff-bfc7-e5631309f884_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expirations in period, weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4a467fec-fc6e-4cf4-9df7-9befecdb1b3e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_c8a31677-a373-4454-ba1e-b055232dcf7e_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ino-20211231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_2f158dfe-e70d-4a0d-812c-e163951afbf0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_505b4f9d-3cbc-4992-b6d0-7972fcd1b748_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5bfa6665-67e9-4f54-983d-a41eef79a2c8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bba68c61-6893-4977-a090-41100bcb36be_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_ad533d79-94fb-4ec9-ba77-aa1752e03cda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_9ae41a31-a642-4351-94ea-0353577c07f5_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember" xlink:to="lab_ino_August2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c8ee3a71-e692-4fdd-8fac-b4d30358a5d7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2a81a3fb-fcba-46e3-b355-2ce42a711996_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c986470a-74c7-45b2-bb63-05459767eff7_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_8ef79f09-1817-48a3-aebe-a1bb23b4b539_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_89ae5a90-0e27-4daa-b676-8e33b018f731_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_e0815b10-23b0-4ff5-b70f-32e40595b05c_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73ce2120-9094-4c33-8f5c-6ecd9172678f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4b151669-ec70-454a-a0bb-b4fb719a6cab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c802f44b-eeb3-47eb-abdb-12b76257d3fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59e4ba06-aec0-44d4-ad51-61bda0538564_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6950a599-38d0-45e0-8c6a-655782d43cd1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_2904db70-a929-498e-9cbd-fd0b9ce45d4a_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_dca2bdaf-f64c-41b3-8504-05f130e6e320_terseLabel_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:href="ino-20211231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:to="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_acaa15f5-e8f2-41be-ba17-0c03b8c147c2_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6697fc73-03d6-422c-9b8c-6ad315c8c339_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_23002e81-ff79-4411-a69e-ddc8c98cff3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_42232266-b02e-4447-9b8a-cf26c962b620_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_af806514-d4f9-469a-a7c4-6e5c62adca99_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.60-$3.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesOneMember" xlink:to="lab_ino_RangeOfExercisePricesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cca4ee08-d9f7-4fa0-a454-6619e45a7f5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_29df1e5a-77ce-4455-b840-554422b96114_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_3ac608b2-12e8-433e-b79b-76be21539650_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c091020-1576-485f-8a1c-5505c0cff848_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67ba6b71-8e69-4fdc-aae1-d694aa4e06a5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_34c5c4b0-db2a-4856-a413-b5ee215366cf_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement, aggregate proceeds from issuance of stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_937a7ebd-4fc9-4465-91a5-d9c72d9085cd_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_363169eb-b710-4679-8e8e-d9d897d07f2d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxBenefitsExpired_c65eda64-566b-4323-8243-07c654575a8b_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_label_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_documentation_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired" xlink:href="ino-20211231.xsd#ino_TaxBenefitsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitsExpired" xlink:to="lab_ino_TaxBenefitsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a76456fc-dc67-4746-ad2d-ab42ad0a266a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_81192031-16e3-403d-b22e-ae562ae5b6f1_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (Yrs)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_7349fe05-801f-44ae-ab5e-8942a2527187_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20211231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32946a5b-cf68-4653-bc62-e2c7007bdba8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f05c6c62-a506-47e5-bff8-44058276d32d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PLSaffiliatedentityMember_15b80a90-9848-4e74-b8c0-d20d45b2eccc_terseLabel_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity)</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_label_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_documentation_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember" xlink:href="ino-20211231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PLSaffiliatedentityMember" xlink:to="lab_ino_PLSaffiliatedentityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b6dd68ab-a71f-43c8-a054-6b6bde608453_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d163294e-7bd1-4e2e-baf4-89b8a8ffb9b2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2791cd7d-28ac-4e55-b12d-9ccac36bfaa4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4b44e167-87e3-41bc-be72-2b93e2a77afc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4cc3243e-a1e4-4e66-9ff5-4fc3316458d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_7049f5ab-e8cf-4efd-9f35-d86fcefc4251_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bed7a226-c9f5-4061-a44b-f34145395acd_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9d390b51-ba36-4ad0-8836-3038eeeb215e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_44a2d6eb-d3e7-47da-8b54-9d8b0c48aba6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_650a58eb-73c5-4184-b872-a56989db273e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b7219585-0b83-407e-8e0a-07a57ab488b6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_aa35e634-f9f1-4a76-afd1-621a11716330_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fc2f9c48-838b-4a25-b915-87256b697207_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_286ed997-80dc-4c6e-a4e3-def912a8b5ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_455415f5-a54b-48ee-88bd-a0fb7eb86dc8_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:to="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d078366f-d666-47f7-9166-8c0a7c0a3d8d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_695c91d5-1693-4eb7-9a45-788f2234d909_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_9bfd89a4-70c3-4fa9-9b0a-69e94463688b_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_60d90827-c02d-4dc3-a120-b08e1a965c8e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_65b6047c-36be-46dc-8a6b-e36ea6202729_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5391e721-a0e5-40da-b8ab-1095d7011bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cba7cbdd-b7a3-4de6-a6e4-0503056babfa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_7df42d6b-7794-4d3f-9a19-337a8aeb4863_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5991c3ee-c5e4-4ebc-b94b-5a6bfd444963_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_dc17757b-2909-4cea-8b9e-d8df1b2419b4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_dc800371-82cf-4a08-8c71-6048925a136a_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_eea21fe6-5cb2-45a0-a0dd-d18ea01e6de9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7763e4df-ba5b-4079-bb01-b2ae1864ec74_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_8f1dd852-2d72-4f73-bf09-4a99f178dbed_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_8065c3a4-35eb-4cb8-829d-dc6949caab23_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c271abc8-a331-4425-b4e7-83bb7548aa12_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_0345794d-8e0b-4133-b85c-244c6a8098cb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3ec5b69b-1017-4632-a04d-2d8c9c303a94_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a50f4cbb-aa35-431d-831d-adbb9bb4a803_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8952ef16-ea69-4dd6-9cc7-104f3895884f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest based on the fixed rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83f0b38c-42c4-4802-bfcb-cfd4f1163a52_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b59fd55-af0c-454d-9250-1a571e5e55ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_6810660c-2f90-4cc2-9209-d79c6d80b1b0_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d9e85a95-d1bc-45f1-87ac-ec17dd6a3814_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e261f8a1-1e39-4633-a2d8-ddfdf3f3a588_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_934d4070-994e-4801-bac4-c11863878ac6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_c1a38b06-a992-40ee-b980-958e9ca80540_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_718a73f6-62c6-43d6-8abf-a2adcfbc9e81_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_bbc20d10-d50b-42f4-b02e-563b5493b4bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_61e0c807-14d8-4968-8609-96fd7ff30b3e_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_94e8f134-7e66-42df-9242-1dc8f3cf6ab7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_e4c3ebfd-dc9e-4957-af0f-3073ff82279c_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_07d732bd-b4e6-4150-b162-53dcf1675f79_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_e3528e09-28d3-413b-897a-402afbd0917f_terseLabel_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_label_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) In Other</link:label>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_documentation_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) In Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:href="ino-20211231.xsd#ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:to="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6813fa9-0211-42c0-918f-cc23f9981eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_51767380-e06f-4d2a-b682-ee1f582005b4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_18e01fd1-14fc-428b-8ad0-51136c3a5007_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_d11147ef-fb17-4d07-8894-cef295fff599_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a4ee3f4c-01b0-4052-989e-dd33783976e3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dbd5bb65-ca66-43fc-90d4-22bdc02a0550_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_d926dcdd-063f-492b-8843-e01583330c67_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_0cebec4e-bfad-4b1f-b4a4-36b955e40597_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20211231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NewSalesAgreementMember_a426d6de-4ed2-43da-aaf8-e06e1b2c6758_terseLabel_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_label_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember" xlink:href="ino-20211231.xsd#ino_NewSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NewSalesAgreementMember" xlink:to="lab_ino_NewSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_c40ab41e-10fc-4c5e-a536-f9de6364f93f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b29070a1-1d15-48b2-b5af-f00aed4db3b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_50c7f37b-9c5f-4533-97d2-3697bbeae6ea_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f272228d-b90c-4313-a531-c40c1c97d4c2_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_1e74b272-f38a-4507-98e0-acc483ee7aad_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:href="ino-20211231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:to="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_bfffcdbb-892d-4cfa-9946-a9b41da7bd24_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_67cef320-45fb-4893-a0ef-4c6620b0fe33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_75e26446-6557-466d-9e63-9e43c3354141_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a4c3868a-6b08-4f7f-bd32-73db32c9a733_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_477a3ee7-963c-4f17-b778-e9e4106c48dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5ad506c6-c7bf-4956-8b5b-a32f837461e6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_36e781d4-956f-4bb4-b057-868eaccde69b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cf7a962e-744b-4472-af34-0570df6dccd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bd495905-4ad1-48f1-af32-874231b74b8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_ee6ced15-dfea-4d4f-985f-adfca7d21500_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_62139173-0c06-4d18-ae87-ea8cf91aabf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8ac70119-a928-4046-a227-6cd8fa74353c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1c859e11-71bb-407a-815c-95727328cc6f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_26e42312-56eb-48f8-b5dd-62406ae83ed1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_cb35bb10-dc84-44de-a9d1-05dd8c9cafb0_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_14b9bfc9-3502-4cad-812b-707ea5f3b27e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, foreign non-income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d5dc5e05-5dc6-46e4-b22e-a0f72efa3c71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5cd6ea8b-2a80-4d60-bd74-0c5d08d5c55c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0b14fb5a-7c46-4f53-b813-a4a42e2dda10_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_78bb220c-abc4-488f-a6cd-abdfed311156_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_20dcf5e1-24f3-4d8b-9fee-d90a140fbd2d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_885754e4-e98e-4488-83d4-ae4c12298d89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_c99c14bb-5847-40ed-93d5-132e41193f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_ce84316e-2639-402a-b89c-db310a02fad2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c34948d-32ec-474f-8ec8-9ac44305d3f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_8680f8c7-391e-4cfe-905d-e00bbad9e594_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1c80b354-8159-4849-a00d-67fbdac51229_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d0415810-ee3b-4a5a-8bd7-19a3b6b9671c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3488ea8b-e2b9-489e-abe5-8b2b4be5ae39_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e63815ac-43a7-45b3-9c79-89c8d1251941_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_712386b3-6394-4eb6-9654-b8e1d82c6c12_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_57afcb0c-3ed8-4ddc-910e-c0d68d35badb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_0458b558-19a9-4549-9935-be9ca7b13a4e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d135bac4-45ec-439e-b770-f8925ab2fbfb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_eebacf00-a1e2-456c-bdcc-f8f6b0f8e3d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ccc3eac9-5474-46c5-be6e-6cc36a568d2b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f0e9c565-5629-4c22-9176-ee103593bee3_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20211231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b9680ad3-6340-437f-aac2-8a2999217e13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_686521c4-0d82-4841-b015-6822e4b01cd7_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_a8c38fea-9839-457b-a36a-ff2c53dc691a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation written off due to disposal of property plant and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_e462bad8-2f20-4436-861c-57657a640acb_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_e1271959-c1f3-44a7-8a7f-7a3d326ba2b8_verboseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_3f8b11b5-609b-4e8b-a599-5efcd562d72b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6cbb2585-9b05-48b6-bda3-1fa1433ca453_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_457a7d63-1a75-4784-ba4e-3d4ded8d2408_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_60111b62-8f30-4814-a37c-f94f9492a97d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, upper range limit (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a72f81a1-642b-4f32-9bbf-4e59217288a2_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_f10b4064-1a3e-4a94-a242-c372ffc9dd84_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a128f139-51b2-41db-8540-d0023848d128_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_938254bf-867d-4fb1-9333-ceaefa777686_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20211231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_e63a0fa2-a07e-4fe2-bbb2-ddb98d3f4ff6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investment in Geneos retained</link:label>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Interest, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:to="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c82dcfab-8529-4134-8573-e97739f2e355_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dce36568-281e-40e5-9b5f-a9988e4efce5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d387c1e4-b243-4d0b-a0cf-3dde23ac8dfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_93d6e5e5-c229-4a5d-82a1-e6d7a8dd4d5a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_de7e2e82-0a3c-4d59-b713-c368e8d0e99f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_00b31fc0-8e04-48ae-8fac-d2c2fdba2ff1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3131b3d9-56a0-4831-a434-7bb5e0a87725_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_bf48b8c1-3234-409c-8a3c-3ca436da46c6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_d4d0a3ed-0c39-46a9-89a2-f3ee000925b9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5edf43ce-47ae-4bb0-a58f-ac8a6be16f96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets, future amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2d65d61f-940a-4027-9fd5-f34eb7f6bcdc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8ae95466-fd98-40ca-b503-5dfaf4eb3778_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_274047e5-0fb9-4939-bc69-073b46d6ff16_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_db3eb148-eef5-417b-b507-16d64d139b0d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_3317aa01-b5a0-4f57-b1f2-5d1348d7bd6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_512b938a-3b80-4c6c-b67b-bace84a8b2a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_e3814a74-7e93-4a62-a93c-1a57791465f4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_55a5bf48-91e1-4fe0-b1e6-d3cd1dde62aa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_efc244df-1a4a-4871-9262-a6970a5ee5bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_3afa11f9-2c1a-4b5b-9a71-6d6f8e49ddf2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_241320e5-0562-48c6-82c8-c60fb9aa9030_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5288cc1c-ec65-4dbd-8338-f682d439cca4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9615936b-44b9-44e8-9614-48a83d372eea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss (gain) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bd65723e-1862-4ec0-9003-0c841287c761_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7f96be69-c773-43dc-b246-82a0adb4373b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AuditInformationAbstract_label_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ino_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract" xlink:href="ino-20211231.xsd#ino_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AuditInformationAbstract" xlink:to="lab_ino_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_dca9a34d-0b20-46c7-896b-9e383d43b846_terseLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20211231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48150e11-b1fc-4c43-955d-27b6faddf07c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b668cdde-1ff1-4f48-9ba5-d33d39781315_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_fac2f0a7-6f65-4768-9340-87c36bbfa928_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_7800e0f0-6809-48e8-84bb-ec97fe34e35d_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e0a8862d-a670-407a-bb7d-842d9e79323b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6dfc53c6-3d8d-4a12-8e9b-b8d5a4d04e66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e88103ea-f126-4a26-bcde-990c53d1638c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_e6dab1b0-d407-4d36-8ad4-66dce3a35f0a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_e54fb409-b0b4-49fe-95d4-f9ef74c012eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_1cedce61-1d8e-4f1d-9ad4-138e998daab0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_417680d0-f685-4165-846b-c077edce5567_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_d615389b-b68a-41ac-a335-849bf2a7041e_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_f59449ed-0e50-4491-a5f7-334a47895983_verboseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual year term of incentive plan</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2f715529-1723-4fa6-b446-f16afdca4d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_56e992dc-e9da-4fe7-a1e5-b54e753be426_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d153e0ab-6b20-44f5-9416-d13a0ad45154_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3b7522cf-a2f3-474a-b47c-03aaa50f97ee_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_96c694f4-4b6a-4120-a72a-f73b01b82816_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_e5ad0aeb-3021-46a6-810f-d38caca0631b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_14560488-6f0e-440b-bcc7-4bf4fbb085f7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_c3e95246-cf24-4740-af3c-d3673ac996d2_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_71053477-9d64-4b39-9f55-c6e37eadd828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of pretax loss from operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef92405d-d655-4ea7-9ede-5da5ad6a0663_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2e7454c-0525-4723-a6e3-e74148ec505c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fe04a0d-e363-4288-a3de-bbee11349389_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_c8a7775d-dbee-415c-a8a3-6994febf6b72_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_335e8d61-910c-4e98-9bea-842ee4509d8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_2fb9b894-474e-468f-ae2c-63245e8b9276_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20211231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_bb54f168-9c60-4b4e-af98-45bb2d7b26fd_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f5849b25-011c-4391-a68e-78a838445ce6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d3287421-2639-4014-a812-a3ab9d07369c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_3a318518-af0e-48f6-9cc6-0c2e0f644ecf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_bb25721b-fbff-4413-be3d-d17b44b8cdec_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_21325193-4ca0-4bf7-8efc-8fc4ac87c11b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8552616e-3e6f-4625-8d41-483de9bf05e9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_56942ac8-05c4-4bd4-b9cb-95ead521ede3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2383bd16-989d-4a2a-b144-687a54de68b0_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_6a6fc49b-dc7a-4b2f-9474-c0bdb6ac0e94_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9edc2ff8-e291-452d-b069-e5471d440acc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_133e3d75-c5df-4306-b8d2-d561adf5e674_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_6e958a9f-ffeb-4814-b69d-6e0fcb22f2db_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements from affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20211231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_a71abb8f-c618-4727-850a-4920cf2d0556_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6474ea82-1cf8-4874-8941-2672f591ffed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_343de739-3b8b-44cb-98b6-a50d1bc85749_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_566b1c52-0da8-4c05-aada-039acaad8d16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9ab98ab-9a37-48ec-aa4b-e46e7ba4b964_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b2da05df-9d03-45c1-9ff7-001a4e6414ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AnnualMaintenancePeriod_b535f912-9e67-4826-a064-a98130047952_terseLabel_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_label_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_documentation_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod" xlink:href="ino-20211231.xsd#ino_AnnualMaintenancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AnnualMaintenancePeriod" xlink:to="lab_ino_AnnualMaintenancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_4f9c5887-c337-4d95-a4bc-7ece380889e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_5544fba7-9121-4775-a010-b98941a9d6bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9eec1b49-209b-4754-955e-d90dce93934b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f21e6557-c5fc-4fcd-9c84-57bf5f9d50fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_952aef9d-9ae0-4c63-ae94-646afe6beabf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f504c59e-9a98-404e-a9eb-f314d9bcc730_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_ad8a8b0f-dcc8-4a21-a835-9ed569082235_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_12660a5c-48f7-4cfd-9061-29fbb3e9cd02_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_70c4ef1a-c0db-4dc5-b739-b8e49a8a0905_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_963f60df-1726-4911-8e9a-5b2537d5048a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ee7520ba-91cd-4eeb-8cfe-949c042a896a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0151f02d-287d-4e97-bf04-33f499329ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options, activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_a2f318b4-0aff-4097-b605-f6e306e970f4_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3a56c345-6253-4f32-9cf9-12219220bbc4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_478deef1-9148-4df1-944b-b6171714ba71_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2a7f2bd3-440d-442b-9f2c-fc9dd912ede2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_949e247a-5dd4-41c3-98c3-4870e4459c41_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_7b45e5cf-2e70-45bb-9160-a21e00619d22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_78ed78de-18f0-41f7-9c70-d60172c8432d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b8b13161-18f1-4110-8d00-874abaa36d9e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_345ff3f6-b8e4-4fd4-9ca9-ca9a3f0142ee_terseLabel_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in prepaid expenses and other current assets included in fixed assets</link:label>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_label_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Prepaid Expenses And Other Current Assets, Fixed Assets</link:label>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_documentation_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Prepaid Expenses And Other Current Assets, Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:href="ino-20211231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:to="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_57fe6daa-6c1b-48b9-844b-2e581b28d5db_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_cd83485b-5a62-40d6-b3d3-864eb04a14b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_cf294357-17d5-4b45-bf76-ab9ff3ea530e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e7df5199-fda7-456d-be3e-989870342f91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5d52dee8-c5cb-45ed-9f53-ca272a6ac5cd_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_7ab7e713-3c36-4e38-b190-2cf00179335f_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_fa4dd517-04fa-42f8-ad56-841e87abaf11_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_c033243f-0b57-44d3-a06d-e635f39bdccd_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:to="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_40daccc1-38be-43b9-b235-a0feeca8a238_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_63f16698-f80c-493e-82a0-932f56237acd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_cd95125e-28ea-4302-b5ed-4ce8c18c0e5e_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbf949a2-315b-44e3-aa46-f87a12e8ad70_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7c02f31d-80ee-44e4-86c0-b59a2df1fb99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a6c00bf3-b6fd-4024-9d82-0aea432559a8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0cceef58-54af-4f51-b833-2dc5a72d9aa3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dfeb6ff-82e7-411b-b531-7357e37a546a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dad427aa-2906-4dee-8cf5-c1dbe1187ef5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_de4166a8-1407-4a39-86c3-8d1cc3a70bf5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d9783bcb-f1d0-4e09-b94f-98fa49692393_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_babc87b8-9709-435e-9fab-ce72e7b524aa_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d45e4e67-3c6e-4890-ad81-a122de4190d0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8117eb26-e683-4bbf-992e-2c8b978abb34_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fa519cf7-2e2c-4ddf-9a31-0bbcf39483d6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_578370fe-144f-45ed-b069-65809cc8ed5b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_75dfb847-a06f-48ca-ab7f-5a1b3550ec2d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_2d42dad2-5944-47d7-8f44-506e506474b6_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20211231.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_742ffb3b-9dc2-4656-ad0e-e25a420983a6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_ec8b8c03-bb16-4b27-bc82-653aeefd03a7_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation period to pay royalties</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_19acbc8c-edc8-482e-9868-f1e9113c839d_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20211231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2075eb80-689a-4608-ae24-c46e96ab6a99_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_1f1dfefc-4b70-4dca-8d6e-3705ae91bb80_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_922f99a6-d7ad-4ba8-8e7e-b1a330406684_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investment of GeneOne</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e0b0e287-ce50-4070-b2bc-0e3f9eb921ee_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DoDMember_a9a3427a-db5f-4263-bbcf-f7722069f800_terseLabel_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defense</link:label>
    <link:label id="lab_ino_DoDMember_label_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD [Member]</link:label>
    <link:label id="lab_ino_DoDMember_documentation_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember" xlink:href="ino-20211231.xsd#ino_DoDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DoDMember" xlink:to="lab_ino_DoDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_3e7a4088-9ec1-4558-a53a-f231daa8cc31_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales made at a weighted average price (in USD per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_0166a6ed-58f4-4618-917b-40e49fc663f0_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20211231.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InitialConversionPriceMember_54b911bf-d82b-4de3-b11d-aec8e10b16e7_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember" xlink:href="ino-20211231.xsd#ino_InitialConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember" xlink:to="lab_ino_InitialConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_235f0dcf-9cc6-46fe-b18a-c5ee3f3a437a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_037de85f-189d-4182-8f5c-3e62e21439a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d81e844e-bd4c-4f88-8c01-264796d12c17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d5492589-4257-47ec-bb57-3af8fc6c20a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_093d3f0b-c91c-46ac-b725-397604fbc786_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements - Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_2acbba90-7579-4446-bfe8-32f57af9262c_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d694c487-9df7-4bfe-9bae-ba2abd06d6e4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_dad159d7-6f9e-4fa3-a4e3-ab63cb13b18a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77507a1a-3de7-431d-b938-e535dde92573_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_80a07497-b189-4f6a-90eb-8ef70eaaa1d0_terseLabel_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating loss and tax credit carryforward expirations</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:href="ino-20211231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:to="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_443dfe4d-9007-494e-82ab-95ecc8844da6_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_59ac8082-0eca-4fdd-80cd-601c66088506_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_090ef37f-fc45-4a6a-9617-8c353e5e8ed4_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1adebc0c-3266-4f77-a029-bbc27f12d412_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (benefit) taxes at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_83851049-6c2e-4b7e-91dc-9ba36dc6497e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_7967b0c5-5b45-47c0-bf46-c3222867d544_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_f6b2ef47-183d-4bec-a296-bcd5d5be4d5c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d6b4d788-f405-46e5-a3c5-7bf9fda1b9f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2bf00a89-b32d-4cbc-9703-3575bdb4566b_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2a0ea1c4-92b8-48b4-a94e-8fc3378d21f7_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_13adcee1-efd3-494e-abab-7128b2581932_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_31429c8c-e7f3-4228-87e6-c53eb21bcd3d_terseLabel_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest" xlink:href="ino-20211231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtinstrumentAccruedInterest" xlink:to="lab_ino_DebtinstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_1fb2e7e1-0907-475b-9a2a-df1012f505cc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_46fae7e4-03e8-4ab4-9673-14b7c486b620_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_6947158c-f141-4911-b3a8-0b2eb84193b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_fbc8421c-e26d-4989-8f82-6600e553e1cd_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0fc9263c-7e2b-4b76-bb43-44c9f50657ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value measurement inputs and valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherRevenueMember_dc135e9e-5845-4db0-b9e8-512276005f0e_terseLabel_en-US" xlink:label="lab_ino_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_ino_OtherRevenueMember_label_en-US" xlink:label="lab_ino_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:label id="lab_ino_OtherRevenueMember_documentation_en-US" xlink:label="lab_ino_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueMember" xlink:href="ino-20211231.xsd#ino_OtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherRevenueMember" xlink:to="lab_ino_OtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_31ca0fb5-2598-43c1-8d56-203854b03eb4_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a29efa32-cd66-4f9a-9683-0c6365154e2d_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3f622ad6-b93c-41f1-823b-92dbf6c98e33_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7523840b-1f00-4679-8934-f0454bfb1baf_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6a434e39-bae1-4228-9bd7-727674b66e16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_9557d5c4-025f-4568-9c2d-4079066bff2e_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_label_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetInterestExpense" xlink:to="lab_ino_DeferredTaxAssetInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_df4406ab-36fd-4a30-816a-c211123e14ca_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_eb5c7e2c-532d-4104-8c73-f9ad4b5f1e29_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1710214e-bc10-46a3-9ebb-80b0268b552a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_fef180c2-1fef-4d62-a44f-e4c7e458140b_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount on the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_8f9c4add-a793-44d1-bb73-9d8df7173c5d_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20211231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_6e73b5c3-6f39-4a46-8891-f0be317d832c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d3c1fac-d304-49f6-9047-9f3b535c7557_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ino-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:91a42a7e-9c16-46a4-89e4-78ae514a2e8d,g:17ea50c5-1e55-4356-a463-d0e13f29ef69-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_faceb9eb-75c2-4655-95ea-e15fbf09b2e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentType_faceb9eb-75c2-4655-95ea-e15fbf09b2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_60320d22-1669-4b43-9eb7-e2ef565c2e17" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentAnnualReport_60320d22-1669-4b43-9eb7-e2ef565c2e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dc316cae-7f21-4fe3-a7b9-3efdd7d601f1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentPeriodEndDate_dc316cae-7f21-4fe3-a7b9-3efdd7d601f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9550184a-f455-445a-b857-205ea3808f5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_CurrentFiscalYearEndDate_9550184a-f455-445a-b857-205ea3808f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f600cd81-16e2-4a52-a65e-06a50ec80c6b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentTransitionReport_f600cd81-16e2-4a52-a65e-06a50ec80c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8721a741-ae2b-4da1-ae55-32c244b29ae0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityFileNumber_8721a741-ae2b-4da1-ae55-32c244b29ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_84c22f14-dfbb-4e87-baad-6d752beed535" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityRegistrantName_84c22f14-dfbb-4e87-baad-6d752beed535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9901c822-7a48-4297-88e8-5fdf29c138dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9901c822-7a48-4297-88e8-5fdf29c138dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8f7a930f-980a-4af4-a075-16ab421e7914" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityTaxIdentificationNumber_8f7a930f-980a-4af4-a075-16ab421e7914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1d18e236-3837-4baa-bbb2-b1691fcf5aa4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityAddressAddressLine1_1d18e236-3837-4baa-bbb2-b1691fcf5aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_829e2d18-bc03-490f-98ca-7a1296f37860" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityAddressAddressLine2_829e2d18-bc03-490f-98ca-7a1296f37860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_13f7c1bf-04bf-4b79-a793-7cab4fa41d21" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityAddressCityOrTown_13f7c1bf-04bf-4b79-a793-7cab4fa41d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_28b2e07d-ea13-424f-a1b8-617c441cb904" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityAddressStateOrProvince_28b2e07d-ea13-424f-a1b8-617c441cb904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_85f2b07d-e1ce-422e-ab09-4143fc81c3b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityAddressPostalZipCode_85f2b07d-e1ce-422e-ab09-4143fc81c3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_cd6156a4-4933-466a-b356-19d1b49e81d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_CityAreaCode_cd6156a4-4933-466a-b356-19d1b49e81d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_56dcc7ad-2062-4766-82ec-7b0277eea505" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_LocalPhoneNumber_56dcc7ad-2062-4766-82ec-7b0277eea505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8b0b9d95-5fe4-4dc0-b806-e93578111631" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_Security12bTitle_8b0b9d95-5fe4-4dc0-b806-e93578111631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_74f51ab0-8697-494f-856e-ea21bfc02263" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_TradingSymbol_74f51ab0-8697-494f-856e-ea21bfc02263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e3e9761-dc9b-442c-9872-5e0c04e272b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_SecurityExchangeName_8e3e9761-dc9b-442c-9872-5e0c04e272b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4215da16-fb9f-4e79-8447-cf6779c47dc8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_4215da16-fb9f-4e79-8447-cf6779c47dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4c8d55fa-5177-4cd2-ac83-dd05d6ba23de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityVoluntaryFilers_4c8d55fa-5177-4cd2-ac83-dd05d6ba23de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7ace51ea-dce1-47ef-8880-b0c685b944b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityCurrentReportingStatus_7ace51ea-dce1-47ef-8880-b0c685b944b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_90e3447b-7a6f-4276-a0c0-4109ce485bda" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityInteractiveDataCurrent_90e3447b-7a6f-4276-a0c0-4109ce485bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_536fd4be-790a-46ed-92ed-79b1c70e274c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityFilerCategory_536fd4be-790a-46ed-92ed-79b1c70e274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c1a0ff82-1300-42d0-ad28-3652ae9036ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntitySmallBusiness_c1a0ff82-1300-42d0-ad28-3652ae9036ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_24a81c4a-a53b-42df-9b4b-2f9c04e91ef6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityEmergingGrowthCompany_24a81c4a-a53b-42df-9b4b-2f9c04e91ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9e1dc842-d170-454b-961e-d3af73f9e6a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9e1dc842-d170-454b-961e-d3af73f9e6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2c034f44-3d7f-4cab-b282-c17ef7cba5b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityShellCompany_2c034f44-3d7f-4cab-b282-c17ef7cba5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_00507965-215f-40cf-b1d9-252f8fb980a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityPublicFloat_00507965-215f-40cf-b1d9-252f8fb980a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2b79363b-9551-4ab0-b8ce-2f30addb6671" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2b79363b-9551-4ab0-b8ce-2f30addb6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f7557ec9-d654-4346-9c56-5463939b1909" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f7557ec9-d654-4346-9c56-5463939b1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c2f7ff9c-366c-487f-9629-54246e8efcdc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_AmendmentFlag_c2f7ff9c-366c-487f-9629-54246e8efcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_490bbbcf-27aa-4ebd-90e1-70426cbc6626" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentFiscalYearFocus_490bbbcf-27aa-4ebd-90e1-70426cbc6626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5e745b0c-b3e4-4a42-bf89-8fa45bc00c7a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5e745b0c-b3e4-4a42-bf89-8fa45bc00c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a7e8640c-e9f8-4174-9100-1c9ec1104cea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8edbf2e6-6f1d-4749-92d9-61fa85e0b4db" xlink:to="loc_dei_EntityCentralIndexKey_a7e8640c-e9f8-4174-9100-1c9ec1104cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AuditInformation" xlink:type="simple" xlink:href="ino-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract_6bb9fd74-1f01-4df1-aa67-e6d14b44faf6" xlink:href="ino-20211231.xsd#ino_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_137f69a6-c7ac-42c0-8116-6a91af29dd7a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_6bb9fd74-1f01-4df1-aa67-e6d14b44faf6" xlink:to="loc_dei_AuditorLocation_137f69a6-c7ac-42c0-8116-6a91af29dd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_2288cc81-5757-4cf3-98fe-335dd42bfcd4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_6bb9fd74-1f01-4df1-aa67-e6d14b44faf6" xlink:to="loc_dei_AuditorName_2288cc81-5757-4cf3-98fe-335dd42bfcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_fea1971a-9820-46ea-a13e-4423ddb313e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_6bb9fd74-1f01-4df1-aa67-e6d14b44faf6" xlink:to="loc_dei_AuditorFirmId_fea1971a-9820-46ea-a13e-4423ddb313e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0fe9b060-6ecb-4d1d-ba19-c593e20bf9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0fe9b060-6ecb-4d1d-ba19-c593e20bf9bd" xlink:to="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:to="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1279c796-f7f0-43c4-a370-2e7aa847c64c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80339745-00c3-467a-a2e8-eebc8ca555f5" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80339745-00c3-467a-a2e8-eebc8ca555f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_958632bd-392b-4794-ad24-4305f9b3a8b5" xlink:href="ino-20211231.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8b3579e-93ae-4a65-96f6-05ab8c53b882" xlink:to="loc_ino_ConvertibleBondsMember_958632bd-392b-4794-ad24-4305f9b3a8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1d110123-1375-43e8-a6a9-36f0f8fc07d7" xlink:to="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:to="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f309d6-e092-48cb-8745-48d7eb1dbd45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4f309d6-e092-48cb-8745-48d7eb1dbd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_06bf2758-fd10-4d1e-a472-019d6e74f34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_ShortTermInvestments_06bf2758-fd10-4d1e-a472-019d6e74f34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3d7bf724-0711-4ef5-9c44-635a09a69414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3d7bf724-0711-4ef5-9c44-635a09a69414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b894e59e-15b3-4530-a656-c7d6bc71a9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b894e59e-15b3-4530-a656-c7d6bc71a9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acbe6925-90ec-4e20-bcf5-09c7c7d421c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acbe6925-90ec-4e20-bcf5-09c7c7d421c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f3a6c896-0141-4389-b0ab-e24b32b47fde" xlink:href="ino-20211231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f3a6c896-0141-4389-b0ab-e24b32b47fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7708db14-e0f2-490a-b9f2-d42d7c1738a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f389b2f3-121a-4fe1-a84b-0f3eacf887be" xlink:to="loc_us-gaap_AssetsCurrent_7708db14-e0f2-490a-b9f2-d42d7c1738a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45fb0445-354a-4437-adb0-df78ff6f6288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_45fb0445-354a-4437-adb0-df78ff6f6288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_69c199db-a73a-4561-a964-ab8c2f00f746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_69c199db-a73a-4561-a964-ab8c2f00f746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_23fdd2eb-2d2e-471a-83db-68da053a6ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_EquityMethodInvestments_23fdd2eb-2d2e-471a-83db-68da053a6ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b043b21-1718-41b7-ad17-849b699569fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b043b21-1718-41b7-ad17-849b699569fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_85c99a2b-5e33-4537-94cf-4623ddac2125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_Goodwill_85c99a2b-5e33-4537-94cf-4623ddac2125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06d87003-edd8-45a4-999b-21e3bafc96b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06d87003-edd8-45a4-999b-21e3bafc96b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6294eb69-72a3-4c7f-8c67-8304b62d4603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6294eb69-72a3-4c7f-8c67-8304b62d4603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cfed2b30-ddbc-47c2-99b2-65e251c951dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_688e0b8f-0bd5-455a-8e67-56cf8fb52c1c" xlink:to="loc_us-gaap_Assets_cfed2b30-ddbc-47c2-99b2-65e251c951dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_068c557e-4588-493a-aa8c-5564ffb9ea66" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_20393005-dd06-4b41-b167-4eb9860382c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_20393005-dd06-4b41-b167-4eb9860382c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_79879821-43e5-4ed1-888c-451430e3b9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_79879821-43e5-4ed1-888c-451430e3b9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_6db4c17d-e248-4da6-bc47-1b6c9ef331e3" xlink:href="ino-20211231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_6db4c17d-e248-4da6-bc47-1b6c9ef331e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07a7f96f-7515-409e-840d-8e57eb0efaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07a7f96f-7515-409e-840d-8e57eb0efaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f273409b-4330-4031-b318-c30d54d549e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f273409b-4330-4031-b318-c30d54d549e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_51f0968c-c0cf-4653-851a-d025507c8657" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_ino_DeferredGrantFundingCurrent_51f0968c-c0cf-4653-851a-d025507c8657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_82abef5b-43a1-4c56-ac0d-3f67554c87b2" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_82abef5b-43a1-4c56-ac0d-3f67554c87b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d129cb0-f7d7-4fd6-8154-8dc57d200fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2e413a3c-c5a5-4b18-a965-f965f0731ccf" xlink:to="loc_us-gaap_LiabilitiesCurrent_4d129cb0-f7d7-4fd6-8154-8dc57d200fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ac3c1476-3aea-4d67-b6b8-28d845b2404f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ac3c1476-3aea-4d67-b6b8-28d845b2404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_3e774c28-a162-49a6-bd1d-f8ce80a4bc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_ConvertibleDebt_3e774c28-a162-49a6-bd1d-f8ce80a4bc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69d63b3-de51-437c-b649-eec99591c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69d63b3-de51-437c-b649-eec99591c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_102323df-185a-4c3e-bcb9-0948f2ddbf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_102323df-185a-4c3e-bcb9-0948f2ddbf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ce40f03a-73ea-4b56-a530-ab13823e5ab3" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_ce40f03a-73ea-4b56-a530-ab13823e5ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2900572b-975b-403d-8286-7473c074308f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2900572b-975b-403d-8286-7473c074308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_701e27ad-dbd8-4e1a-b2b3-f9aba32e708d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_Liabilities_701e27ad-dbd8-4e1a-b2b3-f9aba32e708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21569e74-6bac-4e46-9e3a-3e8843e3fd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21569e74-6bac-4e46-9e3a-3e8843e3fd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ee7313d9-01ba-4c48-936f-026fd90de42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_PreferredStockValue_ee7313d9-01ba-4c48-936f-026fd90de42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_58772484-8162-4fad-b8cb-faecfa25607a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_CommonStockValue_58772484-8162-4fad-b8cb-faecfa25607a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fee83169-7867-4600-89e5-4a06b2c818a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fee83169-7867-4600-89e5-4a06b2c818a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_818b639f-abc2-4b64-b84a-d614beece708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_818b639f-abc2-4b64-b84a-d614beece708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d781508f-7878-4d1e-90ba-6d321a592db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d781508f-7878-4d1e-90ba-6d321a592db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fbd5c83e-ed28-4065-a0dd-2f36a103c86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_856b702f-bd56-4aab-88a3-b88019e6ccc1" xlink:to="loc_us-gaap_StockholdersEquity_fbd5c83e-ed28-4065-a0dd-2f36a103c86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_60006000-30e9-45e6-be25-3a8f61ad45da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_86dd95c6-f1fd-4568-8283-e54e9f8f1ad5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_60006000-30e9-45e6-be25-3a8f61ad45da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0d389433-d146-4e06-8f8d-506e38c6a0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0d389433-d146-4e06-8f8d-506e38c6a0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3a083e7f-0e01-4619-97f4-0e783b121ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3a083e7f-0e01-4619-97f4-0e783b121ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_698822e1-1853-4144-b7bd-90f1cd4afe94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_698822e1-1853-4144-b7bd-90f1cd4afe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f02f4b19-bdca-4543-b098-52888a67bdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f02f4b19-bdca-4543-b098-52888a67bdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75a8a346-e751-499d-8262-dd6e769143dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75a8a346-e751-499d-8262-dd6e769143dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_865937c8-2a2b-4ed0-ae9f-a70765780607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_865937c8-2a2b-4ed0-ae9f-a70765780607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f8542a3a-0707-4be4-ac69-1ca556cf4bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_CommonStockSharesIssued_f8542a3a-0707-4be4-ac69-1ca556cf4bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_583b0aa3-1f90-4e7e-a27f-5fb9579805a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6df520a-2b27-4f32-9f43-6a8aaa685cb8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_583b0aa3-1f90-4e7e-a27f-5fb9579805a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_00d46ba9-a946-4714-b0da-1302b3bf5c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_00d46ba9-a946-4714-b0da-1302b3bf5c20" xlink:to="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:to="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e3dc0fda-bdba-4e49-963b-0658b62acf2d" xlink:to="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6bd3c356-cc0d-4aa4-bcd0-b809927daee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_us-gaap_LicenseMember_6bd3c356-cc0d-4aa4-bcd0-b809927daee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_0925fbb6-9db3-422d-b0e4-7dee7e26e297" xlink:href="ino-20211231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_0925fbb6-9db3-422d-b0e4-7dee7e26e297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueMember_59d3f57a-0cb8-4849-a7e7-2cb16b0251d4" xlink:href="ino-20211231.xsd#ino_OtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_ino_OtherRevenueMember_59d3f57a-0cb8-4849-a7e7-2cb16b0251d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember_569ff32d-51d0-46e6-b6df-c4c1aeb09179" xlink:href="ino-20211231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4767eaab-79bd-4654-b7df-a5847430a4d4" xlink:to="loc_ino_OtherRevenueAffiliatedEntityMember_569ff32d-51d0-46e6-b6df-c4c1aeb09179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:to="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0c5b9a6f-1dc6-423b-9c83-2a69c7c26673" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_63b623d3-3f61-438d-b5d9-57a78b3eae84" xlink:href="ino-20211231.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:to="loc_ino_ConvertibleBondsMember_63b623d3-3f61-438d-b5d9-57a78b3eae84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67092635-df8c-4c97-b7e3-6ee308d76f7f" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f2c173fb-6c33-4d1a-a837-895932c0948c" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_67092635-df8c-4c97-b7e3-6ee308d76f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aad87d0a-b837-41a5-869f-62f13aac096d" xlink:to="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bc58e366-a195-4890-899c-53572ea11dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_RevenuesAbstract_bc58e366-a195-4890-899c-53572ea11dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38cad031-634b-4ec2-bad1-879353ac7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bc58e366-a195-4890-899c-53572ea11dd2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38cad031-634b-4ec2-bad1-879353ac7af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c1b0691-3d14-4c10-9d3f-49c6f124c3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c1b0691-3d14-4c10-9d3f-49c6f124c3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2dc3c820-fb46-4c78-aac3-0d3164b4130d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2dc3c820-fb46-4c78-aac3-0d3164b4130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3979bedb-e329-4c2f-8981-7951ecb49d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_dbc6d334-94aa-4bd2-ada9-41dd64abf16f" xlink:to="loc_us-gaap_OperatingExpenses_3979bedb-e329-4c2f-8981-7951ecb49d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2037ba85-dad3-4175-ab69-8b4413514246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_OperatingIncomeLoss_2037ba85-dad3-4175-ab69-8b4413514246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_13112565-ebf1-48f3-a43d-989e4cee988f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_InterestIncomeOperating_13112565-ebf1-48f3-a43d-989e4cee988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a849dc50-6cd2-4ec1-9e39-f070f62a597c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_InterestExpense_a849dc50-6cd2-4ec1-9e39-f070f62a597c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ae1cc6bf-e707-46f8-9c2c-7468adbe88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ae1cc6bf-e707-46f8-9c2c-7468adbe88b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_8353d7de-51d5-4bb1-ba6c-2a893259d1de" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_8353d7de-51d5-4bb1-ba6c-2a893259d1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e8443381-0290-41a7-b755-ae04d4dca13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e8443381-0290-41a7-b755-ae04d4dca13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af72b5c7-3202-41b6-9442-e40b60999d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af72b5c7-3202-41b6-9442-e40b60999d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_373e8ce2-15e7-4ac1-b5d1-a62933ab3bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_373e8ce2-15e7-4ac1-b5d1-a62933ab3bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60ceef89-e107-46e2-8217-43658a037229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2df4c174-8e46-48d4-ae25-fedbf77e7091" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60ceef89-e107-46e2-8217-43658a037229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68a6597f-eb16-418a-be20-c1744cadc16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68a6597f-eb16-418a-be20-c1744cadc16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_23d1d2bb-b960-423f-82a5-d71497869c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_23d1d2bb-b960-423f-82a5-d71497869c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc9056c0-5a2d-4b4a-a420-544a5b91bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dc9056c0-5a2d-4b4a-a420-544a5b91bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a8fdbb9-02cb-41cc-8e38-15239c7e6dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_ProfitLoss_6a8fdbb9-02cb-41cc-8e38-15239c7e6dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cba4e83e-55f5-41c0-bf49-b8cfab577388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cba4e83e-55f5-41c0-bf49-b8cfab577388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f28183e7-4813-4f4c-ac91-7d6f999af62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_NetIncomeLoss_f28183e7-4813-4f4c-ac91-7d6f999af62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1a2cb219-ff1e-4a11-b4d3-d0f300a80a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:to="loc_us-gaap_EarningsPerShareBasic_1a2cb219-ff1e-4a11-b4d3-d0f300a80a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7a79c2f6-a3d7-4376-9d16-9b27d3f9923f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48b652b3-bfb7-4627-ad36-e88b4a2dbc74" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7a79c2f6-a3d7-4376-9d16-9b27d3f9923f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_317429dc-5b3d-4fd7-aa01-8560b02b63d8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a34e8a55-4c5f-4749-8313-a3cbb3132d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a34e8a55-4c5f-4749-8313-a3cbb3132d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebf462ac-5014-4628-bd68-feb2b594c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_d7f9cd1c-8817-491e-9b19-291ba02cb076" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebf462ac-5014-4628-bd68-feb2b594c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfb48b6c-5e9f-41f2-b7e4-e8f7095c82c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e64c812-e6f9-4ef8-a244-d7ce50fb7440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfb48b6c-5e9f-41f2-b7e4-e8f7095c82c0" xlink:to="loc_us-gaap_ProfitLoss_5e64c812-e6f9-4ef8-a244-d7ce50fb7440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_acf06319-b54a-491d-a894-0d477277d2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfb48b6c-5e9f-41f2-b7e4-e8f7095c82c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_acf06319-b54a-491d-a894-0d477277d2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5f820a6c-f2e2-43b1-8069-62973e07ef0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_acf06319-b54a-491d-a894-0d477277d2cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5f820a6c-f2e2-43b1-8069-62973e07ef0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dcebbf75-0ddc-4d33-baa3-aafdd2f55535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_acf06319-b54a-491d-a894-0d477277d2cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_dcebbf75-0ddc-4d33-baa3-aafdd2f55535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94a3d397-ecaa-4018-9e6c-cd82f02b3f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfb48b6c-5e9f-41f2-b7e4-e8f7095c82c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94a3d397-ecaa-4018-9e6c-cd82f02b3f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bdcb0446-c201-4db3-a9e5-98b043e2ad49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfb48b6c-5e9f-41f2-b7e4-e8f7095c82c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bdcb0446-c201-4db3-a9e5-98b043e2ad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe1d536f-669e-44b8-95dc-3db9ae8ae3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cfb48b6c-5e9f-41f2-b7e4-e8f7095c82c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe1d536f-669e-44b8-95dc-3db9ae8ae3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_483b936d-bfd7-405e-9ddf-09edc2eaa192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_483b936d-bfd7-405e-9ddf-09edc2eaa192" xlink:to="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0640a93f-fd11-4e72-aec5-523f726c048e" xlink:to="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c2b0a622-f78c-43a1-a79f-65a37f7b82a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_PreferredStockMember_c2b0a622-f78c-43a1-a79f-65a37f7b82a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a186251-755b-4d32-9715-9f1e995859f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_CommonStockMember_6a186251-755b-4d32-9715-9f1e995859f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b014c918-2b58-4c21-9cc4-240940479b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b014c918-2b58-4c21-9cc4-240940479b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_24cd0a14-3a9a-467c-ba0a-c84817405cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_RetainedEarningsMember_24cd0a14-3a9a-467c-ba0a-c84817405cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67491071-eb03-41fc-bfd4-ac26a9290472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67491071-eb03-41fc-bfd4-ac26a9290472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_db28eb60-35dd-493f-ac07-530225021a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_335ab096-01c7-4070-8614-74c16604bd80" xlink:to="loc_us-gaap_NoncontrollingInterestMember_db28eb60-35dd-493f-ac07-530225021a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e7d1127-cf78-4b0c-9bd9-5a5e8dab003e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_21166d5d-14f3-4d9d-924e-9a4989858e03" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_21166d5d-14f3-4d9d-924e-9a4989858e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_dc6baa5b-8d4a-44e0-bfb3-3c337a06c4d6" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c453117a-4408-4bbf-af03-496c84faed17" xlink:to="loc_ino_August2019ConvertibleBondsMember_dc6baa5b-8d4a-44e0-bfb3-3c337a06c4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_78585134-8c8c-4f64-84b6-9916f207253e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8a34d735-0cec-47e6-9d8c-2f846685e4e0" xlink:to="loc_us-gaap_StatementLineItems_78585134-8c8c-4f64-84b6-9916f207253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_78585134-8c8c-4f64-84b6-9916f207253e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ce46a08c-444c-424f-8768-522ad6ad2100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_SharesIssued_ce46a08c-444c-424f-8768-522ad6ad2100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80dbb751-89af-4a0b-92f9-19f252201e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80dbb751-89af-4a0b-92f9-19f252201e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a2cf770-06a0-4da6-8796-b03fa5c5d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3a2cf770-06a0-4da6-8796-b03fa5c5d00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dc067530-b819-483e-9104-f4520b32d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dc067530-b819-483e-9104-f4520b32d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bf6fecd0-7701-4990-a6de-7f18d8c1fc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bf6fecd0-7701-4990-a6de-7f18d8c1fc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0469e810-3fbd-4fe3-b783-7be01aa79026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0469e810-3fbd-4fe3-b783-7be01aa79026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_209abb3a-efaf-4e63-827e-4ad904bda361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_209abb3a-efaf-4e63-827e-4ad904bda361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5133239d-c0c6-4424-a5f0-9f2d4546fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5133239d-c0c6-4424-a5f0-9f2d4546fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_94a6c2e4-98e9-4003-ab02-02094af752be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_94a6c2e4-98e9-4003-ab02-02094af752be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eff37dd3-07cd-4316-b75b-0de112d71b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eff37dd3-07cd-4316-b75b-0de112d71b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_eff6b2ff-3b76-4dcc-b38c-70d89bc8d534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_eff6b2ff-3b76-4dcc-b38c-70d89bc8d534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_5dfa6658-f3e4-410f-b197-56842ff19a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_5dfa6658-f3e4-410f-b197-56842ff19a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b74d329-f225-49ea-b7f8-b533cc162efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_ProfitLoss_4b74d329-f225-49ea-b7f8-b533cc162efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47187a93-9436-41f0-92cf-2d7b6daba1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47187a93-9436-41f0-92cf-2d7b6daba1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3990994c-eefc-449f-ae1f-d00a39a937ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3990994c-eefc-449f-ae1f-d00a39a937ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5a014e84-6244-48b9-9409-4bc519d3df09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5a014e84-6244-48b9-9409-4bc519d3df09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_109ddf3c-097f-468a-9c38-61495403c25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_SharesIssued_109ddf3c-097f-468a-9c38-61495403c25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b06af5d6-71d2-483b-adcd-e66ab32fb9de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_32552206-6e09-4672-b230-d9e2785e6ba8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b06af5d6-71d2-483b-adcd-e66ab32fb9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_16f044db-2d59-4f83-bade-ecc838a8d3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_16f044db-2d59-4f83-bade-ecc838a8d3b7" xlink:to="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:to="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_40092741-8520-43bf-8995-a10ffa67e6a9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_ef6a34cf-f147-410b-b581-c78f86f1b252" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:to="loc_ino_August2019ConvertibleBondsMember_ef6a34cf-f147-410b-b581-c78f86f1b252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c4ed8a90-fd7b-4325-bd52-a8fce47c008a" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2d8dd84d-a672-4633-b349-a32c7e6c1233" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c4ed8a90-fd7b-4325-bd52-a8fce47c008a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_166932b5-a93f-49a9-a083-7e2a3ee44376" xlink:to="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1adebfb3-5dee-4586-b38c-06fa814677dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_ProfitLoss_1adebfb3-5dee-4586-b38c-06fa814677dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2bcd86c1-5819-44b3-a765-0aceb59046b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_Depreciation_2bcd86c1-5819-44b3-a765-0aceb59046b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b1765063-a783-45f3-8995-876f7eab4772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b1765063-a783-45f3-8995-876f7eab4772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_83039226-4bb3-4a18-90ac-d3c0811861e9" xlink:href="ino-20211231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_83039226-4bb3-4a18-90ac-d3c0811861e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_76e92951-5a37-4ab2-b0ac-3ca5842beac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_76e92951-5a37-4ab2-b0ac-3ca5842beac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_69c00df5-dae3-4fa2-b9ed-2acd8ce4c8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_ShareBasedCompensation_69c00df5-dae3-4fa2-b9ed-2acd8ce4c8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_59270d15-0423-4295-bca2-59f617e93479" xlink:href="ino-20211231.xsd#ino_NonCashInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_NonCashInterestExpense_59270d15-0423-4295-bca2-59f617e93479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_0e1981b4-7496-484a-a44d-294f2c9a9d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_0e1981b4-7496-484a-a44d-294f2c9a9d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_dff8ef5c-7f65-455a-a0cd-c75cd5f9584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_dff8ef5c-7f65-455a-a0cd-c75cd5f9584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8ce54fc2-cb3a-49f9-a082-f527d68e751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8ce54fc2-cb3a-49f9-a082-f527d68e751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_59e53005-f6c7-43a9-8c05-9b3bdc768cfa" xlink:href="ino-20211231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_59e53005-f6c7-43a9-8c05-9b3bdc768cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_01987495-7588-47e9-99fe-c0640046718f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_01987495-7588-47e9-99fe-c0640046718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_873896a6-ac69-4848-8494-bebd785d30fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_873896a6-ac69-4848-8494-bebd785d30fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f9c18594-0e9f-49d4-800f-36ec48606494" xlink:href="ino-20211231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f9c18594-0e9f-49d4-800f-36ec48606494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_cdf8b705-bbd1-4d97-9cf8-c55d88d7a284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_cdf8b705-bbd1-4d97-9cf8-c55d88d7a284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_400c5792-4826-4d7e-95f3-17384e05c758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_400c5792-4826-4d7e-95f3-17384e05c758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_24ad36ed-d4c0-44ac-a50e-15f47310966d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_24ad36ed-d4c0-44ac-a50e-15f47310966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_06651084-9bc4-4091-83cd-175e1dcce92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_06651084-9bc4-4091-83cd-175e1dcce92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_64adb744-b660-451c-bd1a-f647e0e8f339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8af1fbbb-0407-4872-89e5-c0eca4f873c2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_64adb744-b660-451c-bd1a-f647e0e8f339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_383394aa-6833-4282-b7f8-49f96a37be5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_383394aa-6833-4282-b7f8-49f96a37be5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_c9f44ba8-387e-4fb8-97f7-79c4e81b7ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_c9f44ba8-387e-4fb8-97f7-79c4e81b7ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06311e7e-6d6a-4ea9-b5a7-e2956f421220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06311e7e-6d6a-4ea9-b5a7-e2956f421220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_053ceba0-5c7b-47fc-8a85-ebd395715fe9" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_053ceba0-5c7b-47fc-8a85-ebd395715fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_993f6386-e362-4d18-8a56-56ff669690d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_993f6386-e362-4d18-8a56-56ff669690d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b692e016-9998-45b9-a53a-1601d6042d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b692e016-9998-45b9-a53a-1601d6042d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_f8e1be45-0e4d-45de-8420-f1fc693f1a90" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_f8e1be45-0e4d-45de-8420-f1fc693f1a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_d8502c2a-bd04-49e5-9d2a-400c870c0040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_d8502c2a-bd04-49e5-9d2a-400c870c0040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_520bf8a2-b4f4-4e41-bc93-aa7f380e56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_520bf8a2-b4f4-4e41-bc93-aa7f380e56ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_039b90de-8401-4be1-bc70-f29e0f209c85" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_039b90de-8401-4be1-bc70-f29e0f209c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_b014fcb2-6e29-46b9-b69f-619351c0a13e" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_b014fcb2-6e29-46b9-b69f-619351c0a13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_7fcb36f1-502a-4642-892f-8fe8247e5370" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_7fcb36f1-502a-4642-892f-8fe8247e5370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_aec3d363-97b5-43cb-b41a-2d24a6cbf0a7" xlink:href="ino-20211231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_aec3d363-97b5-43cb-b41a-2d24a6cbf0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bd0a1123-645f-47c1-bd32-4eff835ed9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c8c0203-46a1-41f6-a640-1fb7e1d1f166" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bd0a1123-645f-47c1-bd32-4eff835ed9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_519132e6-6f19-40e6-8b21-7edeb68303f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8961864b-91b0-4a7e-9154-7d3233f66c0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_519132e6-6f19-40e6-8b21-7edeb68303f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c5c54c42-e67d-4f61-90fa-860a82b7ccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c5c54c42-e67d-4f61-90fa-860a82b7ccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ca06d286-1670-4cdd-bd94-d5a72a1c1a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ca06d286-1670-4cdd-bd94-d5a72a1c1a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e414089-9c23-4224-b6a0-4759912874e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e414089-9c23-4224-b6a0-4759912874e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_f9bc2167-5e46-4d03-879f-bd309039c7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_f9bc2167-5e46-4d03-879f-bd309039c7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_f17708d4-4b89-4a30-82cc-4d599d882181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_f17708d4-4b89-4a30-82cc-4d599d882181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_64e22c42-329d-4e00-97e1-46b42789ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_64e22c42-329d-4e00-97e1-46b42789ae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7673d46e-c2fa-4e21-8246-0dbddbeae3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b764b575-11fb-4416-ac52-383f35ce1104" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7673d46e-c2fa-4e21-8246-0dbddbeae3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a46ab55-dcd2-4702-9a57-4496cabeae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a46ab55-dcd2-4702-9a57-4496cabeae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ba51c5d-83d9-46fd-bee8-0ac8bffd103e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ba51c5d-83d9-46fd-bee8-0ac8bffd103e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aaca6683-cfc9-450f-9fd0-ab4496876690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aaca6683-cfc9-450f-9fd0-ab4496876690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_a9ad52e6-9b58-45b5-985c-6b2b5e6c434f" xlink:href="ino-20211231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_a9ad52e6-9b58-45b5-985c-6b2b5e6c434f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_a9d8eabd-99ac-414f-8c86-6cd15e81935b" xlink:href="ino-20211231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_a9d8eabd-99ac-414f-8c86-6cd15e81935b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_c11b45a0-e39c-49c3-aea2-ef3a941e9a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_c11b45a0-e39c-49c3-aea2-ef3a941e9a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_ce17f426-fb93-4bbb-b9b6-94bd44247623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_ce17f426-fb93-4bbb-b9b6-94bd44247623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e36043af-ff9a-4dc0-a2ce-c45198427554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7102b0b-b054-435b-a212-6c7d35418e5b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e36043af-ff9a-4dc0-a2ce-c45198427554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92230f80-9b34-463e-8b5c-6ace87e04d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92230f80-9b34-463e-8b5c-6ace87e04d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_415551e0-67e8-4e9d-8e65-577feab526dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_415551e0-67e8-4e9d-8e65-577feab526dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd70bd7d-6edf-4ecd-8499-324cdc6f9149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd70bd7d-6edf-4ecd-8499-324cdc6f9149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd821b97-6668-48fc-b5df-643ed71090dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd821b97-6668-48fc-b5df-643ed71090dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19fef279-c12d-48c2-8240-9c2b4b3944b4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a6213fdb-2664-4000-a0a9-8598247be469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a6213fdb-2664-4000-a0a9-8598247be469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_10530846-5839-430a-9ac9-c840c0d0d4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_us-gaap_InterestPaidNet_10530846-5839-430a-9ac9-c840c0d0d4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_21f14caf-806f-46d9-9eef-69837c93743c" xlink:href="ino-20211231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_21f14caf-806f-46d9-9eef-69837c93743c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued_86cb3ec3-1510-4602-b1b0-0369de3f9aa0" xlink:href="ino-20211231.xsd#ino_EquityComponentOfConvertibleDebtIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_ino_EquityComponentOfConvertibleDebtIssued_86cb3ec3-1510-4602-b1b0-0369de3f9aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9e47e895-190c-4e64-9876-8e4b60b3f7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f7d39031-2cff-44b7-9163-66a4348f005c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9e47e895-190c-4e64-9876-8e4b60b3f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20211231.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c07331d6-5f32-4b54-a152-d1ed1348626d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_44945dcd-9fa5-4bdd-be1b-2cfdd511232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c07331d6-5f32-4b54-a152-d1ed1348626d" xlink:to="loc_us-gaap_NatureOfOperations_44945dcd-9fa5-4bdd-be1b-2cfdd511232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cee4778e-5e3b-408a-82ab-d8040992b5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8a9802b1-773a-4bfd-b11e-c766457584c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cee4778e-5e3b-408a-82ab-d8040992b5e7" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8a9802b1-773a-4bfd-b11e-c766457584c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fcfff149-fdb4-48ce-b4cb-c8a08868953d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fcfff149-fdb4-48ce-b4cb-c8a08868953d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_77aeedab-7866-40bc-9bab-4338f0fa0720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_77aeedab-7866-40bc-9bab-4338f0fa0720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2cc96b7b-d7bc-42a8-85a9-7d4c2de6b9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2cc96b7b-d7bc-42a8-85a9-7d4c2de6b9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_62dd8782-cc62-4b41-9835-7da71d39173f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_UseOfEstimates_62dd8782-cc62-4b41-9835-7da71d39173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a7986d57-d06e-4348-855e-0e14820fdd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a7986d57-d06e-4348-855e-0e14820fdd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_10598fe6-47ae-460a-bdc2-b12b99d62ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_10598fe6-47ae-460a-bdc2-b12b99d62ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cd06f36e-80e3-4f7d-a68a-6c92ad460318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cd06f36e-80e3-4f7d-a68a-6c92ad460318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_519c19e9-6b5d-4a01-abe9-c16b3aa8166f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_519c19e9-6b5d-4a01-abe9-c16b3aa8166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_ab07cea9-e96d-47f9-bd2d-ad925958e8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_ab07cea9-e96d-47f9-bd2d-ad925958e8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4b1bcbd6-0df1-4d5b-80fd-4798804800ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4b1bcbd6-0df1-4d5b-80fd-4798804800ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8ae73267-239c-498e-bba3-497113d1e2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8ae73267-239c-498e-bba3-497113d1e2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_816d9106-2560-484f-ba76-bc3bd4a88baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_816d9106-2560-484f-ba76-bc3bd4a88baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_132522e9-3896-4c24-9d76-4c60e8645c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_132522e9-3896-4c24-9d76-4c60e8645c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_13d51ab9-12cc-4ccd-a2d9-4ddc2a846840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_13d51ab9-12cc-4ccd-a2d9-4ddc2a846840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c4d7569e-5247-45c2-9f30-8e0d6ce8daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c4d7569e-5247-45c2-9f30-8e0d6ce8daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_2b2820bc-0363-4365-8ddf-94d7fe93c1ed" xlink:href="ino-20211231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_ino_GrantRevenuePolicyTextBlock_2b2820bc-0363-4365-8ddf-94d7fe93c1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_e9853b54-de1f-4457-abf5-2f9542bad0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_e9853b54-de1f-4457-abf5-2f9542bad0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_00417a95-1fa8-44dc-a84f-afa1494fb55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_00417a95-1fa8-44dc-a84f-afa1494fb55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_7d767425-14e3-4a3f-b8aa-cb1e967518ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_7d767425-14e3-4a3f-b8aa-cb1e967518ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_7eaef4de-0332-4d79-bc50-0aa540c2e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_7eaef4de-0332-4d79-bc50-0aa540c2e7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fcae4a9d-77b7-41fa-950d-9c1027a39a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fcae4a9d-77b7-41fa-950d-9c1027a39a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_710e1472-075e-43dc-841d-03f6ab3740fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_710e1472-075e-43dc-841d-03f6ab3740fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_38275d05-17eb-4685-ac0a-b96b34c9de82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_38275d05-17eb-4685-ac0a-b96b34c9de82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_fe450730-aa1f-4ffb-b189-39d580c2bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_fe450730-aa1f-4ffb-b189-39d580c2bd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d093a283-de43-486d-b9c7-baa3d16b32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4db8b55e-3653-488d-a695-62975f40e07c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d093a283-de43-486d-b9c7-baa3d16b32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b2d98903-7f5e-4645-b419-17e3594a7b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c2a0252a-73b7-468b-99a3-64745ab66532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2d98903-7f5e-4645-b419-17e3594a7b9d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c2a0252a-73b7-468b-99a3-64745ab66532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a7c93177-de1b-413e-8e09-8d40a36c24dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2d98903-7f5e-4645-b419-17e3594a7b9d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a7c93177-de1b-413e-8e09-8d40a36c24dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6cbc9236-83a1-4892-83b0-352b3a981403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6cbc9236-83a1-4892-83b0-352b3a981403" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eea1cef0-4d17-4813-8b67-a8ea0c23ccac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25994f99-af84-4b4e-9598-bccbf173047b" xlink:to="loc_us-gaap_ClassOfStockDomain_eea1cef0-4d17-4813-8b67-a8ea0c23ccac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_993faeb4-9752-4b5d-8be5-0ccdf17121c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eea1cef0-4d17-4813-8b67-a8ea0c23ccac" xlink:to="loc_us-gaap_CommonStockMember_993faeb4-9752-4b5d-8be5-0ccdf17121c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06afccdc-b6e9-4881-9415-1382b98b4d7d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_7d5339a1-4563-40e6-a6af-e2e26acfffbe" xlink:href="ino-20211231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_7d5339a1-4563-40e6-a6af-e2e26acfffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_bb7fd9e6-c4fa-468e-a61f-1c8d3a4fcebb" xlink:href="ino-20211231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_56da4c47-0704-4af6-9971-48ea352bd7a7" xlink:to="loc_ino_SalesAgreementMember_bb7fd9e6-c4fa-468e-a61f-1c8d3a4fcebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7b7a188-a03e-43ff-ad63-47ff350b8108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2527f49a-9a38-4044-8000-5f88e06d00e4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7b7a188-a03e-43ff-ad63-47ff350b8108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_390954fc-768b-4303-a9f9-3d0cc5215387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b7b7a188-a03e-43ff-ad63-47ff350b8108" xlink:to="loc_us-gaap_ConvertibleDebtMember_390954fc-768b-4303-a9f9-3d0cc5215387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8aac70f5-850a-4e58-ba41-89e1fbc2b44a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b1793ac1-130a-4ebc-9292-e1b3a5ef1c55" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b1793ac1-130a-4ebc-9292-e1b3a5ef1c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_5f57bdac-aae4-4dba-8a97-33bb68f0ec3c" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:to="loc_ino_August2019ConvertibleBondsMember_5f57bdac-aae4-4dba-8a97-33bb68f0ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_2a83fd63-5692-44a1-a787-db6a0c11a799" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bb81a6f-7c60-45c8-bfeb-b076bbbe4d87" xlink:to="loc_ino_December2019ConvertibleBondsMember_2a83fd63-5692-44a1-a787-db6a0c11a799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_340c38b3-6536-4ff4-b8c8-b84c811f9ac5" xlink:to="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bdb7d949-c9c8-4ad6-88e3-597d2538265f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:to="loc_srt_MinimumMember_bdb7d949-c9c8-4ad6-88e3-597d2538265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e565a04d-5885-4945-96bb-26d5633be0cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b7c4678-8b7d-48ac-a6f3-906ed9a1d856" xlink:to="loc_srt_MaximumMember_e565a04d-5885-4945-96bb-26d5633be0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2937a122-36d6-4959-8af6-a30c7e5eb737" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61f2bfc7-a73d-4b85-b74c-bea54a40abab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_NetIncomeLoss_61f2bfc7-a73d-4b85-b74c-bea54a40abab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_9c938bab-400e-42c9-aece-ed1b0bce1ae8" xlink:href="ino-20211231.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_ino_WorkingCapital_9c938bab-400e-42c9-aece-ed1b0bce1ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4251222b-a6d7-49a5-9b11-26164d2f10cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4251222b-a6d7-49a5-9b11-26164d2f10cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ff17c15-4ad3-49e3-8ee0-f8487edb7128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0ff17c15-4ad3-49e3-8ee0-f8487edb7128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09feb80b-1c44-4cb9-8475-3b2214862af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09feb80b-1c44-4cb9-8475-3b2214862af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb89da2d-e6b4-410d-a7fb-4af40d9937c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb89da2d-e6b4-410d-a7fb-4af40d9937c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffd50db5-bc70-4070-99d9-a1357c291234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ffd50db5-bc70-4070-99d9-a1357c291234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ad9386b2-b120-4184-8c08-44e0fb76bf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ad9386b2-b120-4184-8c08-44e0fb76bf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1312c784-ea4a-4bdc-b082-7a471cc65be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1312c784-ea4a-4bdc-b082-7a471cc65be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_da3d8dd0-e9db-41c3-800c-9d5bdbbf18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_da3d8dd0-e9db-41c3-800c-9d5bdbbf18d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3a77d1e9-8999-490a-9eee-3d8aa31d57d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3a77d1e9-8999-490a-9eee-3d8aa31d57d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6322da6d-1939-4770-9bd3-7b4441c08410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6322da6d-1939-4770-9bd3-7b4441c08410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee6d760f-8a08-488c-80f3-966f42c00c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ee6d760f-8a08-488c-80f3-966f42c00c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c026916-6fe6-40e4-bb9a-a49673b7a111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_de7a6616-66cf-4d04-a582-6c8b22a4bf60" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c026916-6fe6-40e4-bb9a-a49673b7a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04c8245b-7a08-4cef-992f-0ab5abc1dabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04c8245b-7a08-4cef-992f-0ab5abc1dabd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1886586a-32e4-4af4-93ed-c5d23e423e9c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b674a551-7db0-4911-9f93-e2d78790a350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b674a551-7db0-4911-9f93-e2d78790a350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_82cb47a9-96ba-4af1-aca9-a09573ef6090" xlink:href="ino-20211231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_82cb47a9-96ba-4af1-aca9-a09573ef6090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_04b2dbaa-3ee5-467d-bd08-75e08622f724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_04b2dbaa-3ee5-467d-bd08-75e08622f724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_c2805d2a-37d7-4d52-b567-d3166b1df3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_c2805d2a-37d7-4d52-b567-d3166b1df3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_c5c3200f-ca23-4c06-9a3f-73e90d2deda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dfe60f6-9b3d-445e-88ea-6d851f61b43a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_c5c3200f-ca23-4c06-9a3f-73e90d2deda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:to="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4aa94f6b-ca95-48c3-a682-8dd3183b10ac" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_59d25e52-d917-43d9-bae6-7bd5d8e2e03f" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_59d25e52-d917-43d9-bae6-7bd5d8e2e03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_d99e2d6e-0af8-40a5-8fc9-82cbcbadb9a0" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:to="loc_ino_August2019ConvertibleBondsMember_d99e2d6e-0af8-40a5-8fc9-82cbcbadb9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_ca51e63b-b0c0-42f2-9da0-31a7dc15030e" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_315e2f5a-6dca-47ab-afe7-03b84e7babed" xlink:to="loc_ino_December2019ConvertibleBondsMember_ca51e63b-b0c0-42f2-9da0-31a7dc15030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7fee406-1710-4fca-ae22-9087e4512411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1d69ee71-2b15-454a-969d-4e9b98e96773" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7fee406-1710-4fca-ae22-9087e4512411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockEquivalentsAbstract_905eb02a-41e3-468a-a53e-a766f6ab947d" xlink:href="ino-20211231.xsd#ino_CommonStockEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7fee406-1710-4fca-ae22-9087e4512411" xlink:to="loc_ino_CommonStockEquivalentsAbstract_905eb02a-41e3-468a-a53e-a766f6ab947d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bd9b48b-5374-4660-823e-1ddaf1d223fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CommonStockEquivalentsAbstract_905eb02a-41e3-468a-a53e-a766f6ab947d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bd9b48b-5374-4660-823e-1ddaf1d223fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b797ed69-ae25-4b72-8f29-da88f1fbc574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b797ed69-ae25-4b72-8f29-da88f1fbc574" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:to="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5a51f3fc-c6e9-4d31-a8bd-1016a4332dd6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_9529ad32-24e6-45fe-b839-dffe623bfaf6" xlink:href="ino-20211231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:to="loc_ino_EmployeesAndDirectorsMember_9529ad32-24e6-45fe-b839-dffe623bfaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_3251041d-1b75-4828-9f78-b02efc3caf9b" xlink:href="ino-20211231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_965ebadc-f1fd-496c-8ac8-b0abd98f5470" xlink:to="loc_ino_NonEmployeeMember_3251041d-1b75-4828-9f78-b02efc3caf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:to="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949ccd2-13a3-445e-b330-38d1a91a6f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_080227f8-0bf7-45c8-8005-45e3f635840f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949ccd2-13a3-445e-b330-38d1a91a6f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ae3a7dce-9b69-431c-8bc2-32c5834134f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949ccd2-13a3-445e-b330-38d1a91a6f13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ae3a7dce-9b69-431c-8bc2-32c5834134f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75716cad-bd6a-45d9-8020-bf2b70439be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec8eae6d-5b4d-43de-8bc9-a71404f821f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75716cad-bd6a-45d9-8020-bf2b70439be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:href="ino-20211231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75716cad-bd6a-45d9-8020-bf2b70439be3" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f0aeaed0-3353-4d96-a2de-330f607c2b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f0aeaed0-3353-4d96-a2de-330f607c2b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e8e7606d-80cb-4ecd-bd88-b8efffb31705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e8e7606d-80cb-4ecd-bd88-b8efffb31705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fb5e96b0-a29c-4283-91d9-723f80d48131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fb5e96b0-a29c-4283-91d9-723f80d48131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9064ee50-7525-4f6a-b20f-76ad4e5e2484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_275f041a-24bb-406d-98c4-c2d625f8da90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9064ee50-7525-4f6a-b20f-76ad4e5e2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20211231.xsd#RevenueRecognitionandConcentrationofCreditRisk"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_913787a6-7a94-450e-bc6c-a378ddc47845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1fe2b949-0805-4eb8-8511-ad75b1c28bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_913787a6-7a94-450e-bc6c-a378ddc47845" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1fe2b949-0805-4eb8-8511-ad75b1c28bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20211231.xsd#RevenueRecognitionandConcentrationofCreditRiskTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fcb50c39-9ad9-4eca-87d4-fa7be312bdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e867773e-08d7-4e95-b331-1750e37f208c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fcb50c39-9ad9-4eca-87d4-fa7be312bdeb" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e867773e-08d7-4e95-b331-1750e37f208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4356a087-ba42-4048-9bec-0e0f81550434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4356a087-ba42-4048-9bec-0e0f81550434" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_72577c62-ec52-444f-b1d0-cf2d449ace93" xlink:to="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_a3d5049e-b9c9-4b97-a6f7-1148e3abcdc4" xlink:href="ino-20211231.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_AstraZenecaMember_a3d5049e-b9c9-4b97-a6f7-1148e3abcdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_68b28c96-fe17-48fd-a728-f99c1a15b53e" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_AdvaccineMember_68b28c96-fe17-48fd-a728-f99c1a15b53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_855add82-7190-4f73-ad33-649b2bfe532c" xlink:href="ino-20211231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_855add82-7190-4f73-ad33-649b2bfe532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_8af7c3ab-232a-4461-b6ab-9d2a089ff2a9" xlink:href="ino-20211231.xsd#ino_DoDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_DoDMember_8af7c3ab-232a-4461-b6ab-9d2a089ff2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_ca642239-7862-4e79-a92b-b868ec82eda2" xlink:href="ino-20211231.xsd#ino_AllOtherCustomersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_47378088-073f-4442-934a-706d75bd786f" xlink:to="loc_ino_AllOtherCustomersMember_ca642239-7862-4e79-a92b-b868ec82eda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea7c813-77f0-4812-a506-ab412ec83d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560f1699-bebe-426a-b096-4a762d6d8818" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea7c813-77f0-4812-a506-ab412ec83d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8d64d86c-b10d-4c31-afcd-b54c72c82cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aea7c813-77f0-4812-a506-ab412ec83d47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8d64d86c-b10d-4c31-afcd-b54c72c82cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a62ca4df-d972-4474-8999-d68623f49d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a0866282-188b-437c-b40d-0c2a1a5f55cc" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a62ca4df-d972-4474-8999-d68623f49d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ceb35e5f-8d90-4761-8ed4-3ca505c2d35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a62ca4df-d972-4474-8999-d68623f49d5e" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ceb35e5f-8d90-4761-8ed4-3ca505c2d35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0b0e5274-3068-4690-bd4d-61c0ae6dbe5a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4aa7f054-289e-4f53-a121-50c6f42abe28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4aa7f054-289e-4f53-a121-50c6f42abe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1239170e-5abf-4f8e-82d5-c19b9d4c338a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e052ff0d-4f3a-42ca-9358-0090051b58b8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1239170e-5abf-4f8e-82d5-c19b9d4c338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50d211ce-d208-4dec-ac25-c3f557f1dd74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50d211ce-d208-4dec-ac25-c3f557f1dd74" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_56971a6f-5bc1-4367-a14e-818c9af9fe04" xlink:to="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_6d187893-113b-4718-8f68-40df3d9e9693" xlink:href="ino-20211231.xsd#ino_DoDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:to="loc_ino_DoDMember_6d187893-113b-4718-8f68-40df3d9e9693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CEPIMERSMember_0d515ee3-d82c-4f7a-ac63-4d659021ad00" xlink:href="ino-20211231.xsd#ino_CEPIMERSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:to="loc_ino_CEPIMERSMember_0d515ee3-d82c-4f7a-ac63-4d659021ad00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_359d1119-d4a5-4586-8641-e788ba9c5c9a" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bbd60cbd-ec75-4f79-bdb2-242d200248c4" xlink:to="loc_ino_AdvaccineMember_359d1119-d4a5-4586-8641-e788ba9c5c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_76067331-36ed-4288-893a-dd79bd1773df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_836bdd49-6fc3-41a6-99f9-b07eefc48fff" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_76067331-36ed-4288-893a-dd79bd1773df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_53d2a5c7-6e5f-4b37-9c8b-b1dbf90f5403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_76067331-36ed-4288-893a-dd79bd1773df" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_53d2a5c7-6e5f-4b37-9c8b-b1dbf90f5403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00662923-bd04-49f3-a92f-fdcb7a0862a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_af3522a8-a9e2-41e8-8df4-1c4e52a14e55" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00662923-bd04-49f3-a92f-fdcb7a0862a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_15b2d11f-be51-449b-94d2-5a87b811430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_00662923-bd04-49f3-a92f-fdcb7a0862a9" xlink:to="loc_us-gaap_AccountsReceivableMember_15b2d11f-be51-449b-94d2-5a87b811430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e8abadf4-c072-49d2-9ff0-fa4778e36b77" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_34072ee4-1544-472c-8777-3015eb5d9530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_34072ee4-1544-472c-8777-3015eb5d9530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b3a6bd56-5c91-4b5b-ae20-bce015833b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_AccountsReceivableNet_b3a6bd56-5c91-4b5b-ae20-bce015833b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_649c6346-f644-4f98-ba13-6fa52f4364f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d4ffb335-15b0-41fa-906f-13c0a6b64ce9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_649c6346-f644-4f98-ba13-6fa52f4364f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20211231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f41b4018-9a66-474c-81a6-2aa45548ef48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c3c4a83-8ad4-4b7a-b97b-756b45cda3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f41b4018-9a66-474c-81a6-2aa45548ef48" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c3c4a83-8ad4-4b7a-b97b-756b45cda3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9de52df-db14-414e-9ca2-b13065c7f3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9de52df-db14-414e-9ca2-b13065c7f3bd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f9e11c08-d3ca-4949-b160-a44140578311" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_5f7f75f7-da14-4a9e-9b40-7e9b3ad1df89" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_AdvaccineMember_5f7f75f7-da14-4a9e-9b40-7e9b3ad1df89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_b9b63d43-abb5-4b32-96a6-5c07f284d584" xlink:href="ino-20211231.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_ApolloBioMember_b9b63d43-abb5-4b32-96a6-5c07f284d584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_8f9993f2-04f1-4ab2-abbf-0a9395220715" xlink:href="ino-20211231.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_AstraZenecaMember_8f9993f2-04f1-4ab2-abbf-0a9395220715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_f270ba01-5f29-4809-9f72-aa132327d2d5" xlink:href="ino-20211231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_f270ba01-5f29-4809-9f72-aa132327d2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_193ccffb-e36b-405e-b5ec-2b2ea3792b8c" xlink:href="ino-20211231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_193ccffb-e36b-405e-b5ec-2b2ea3792b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_f187d36a-42d8-43d4-9910-73d09b268afa" xlink:href="ino-20211231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bff9121a-97f5-4d6e-bc76-8a4ef278df97" xlink:to="loc_ino_DepartmentOfDefenceMember_f187d36a-42d8-43d4-9910-73d09b268afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b633a468-919f-4385-a908-62c71250cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f61c0284-8c74-47a2-90ac-cb05b462ddc4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b633a468-919f-4385-a908-62c71250cc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b7e480c1-c533-49fa-8f61-941ca7e8cb14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b633a468-919f-4385-a908-62c71250cc9f" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b7e480c1-c533-49fa-8f61-941ca7e8cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb67f603-754c-471e-8ad0-bc78a0f371a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_453450c4-cfaa-4a42-b568-84963e421e23" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb67f603-754c-471e-8ad0-bc78a0f371a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_58f3f8fd-65bd-4a78-adbe-3e96acc34980" xlink:href="ino-20211231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb67f603-754c-471e-8ad0-bc78a0f371a0" xlink:to="loc_ino_AdvaccineMember_58f3f8fd-65bd-4a78-adbe-3e96acc34980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a2f09eeb-08f0-45ab-ad0c-fde5c3eff819" xlink:to="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_84f21b48-2c9b-4a2d-aadb-a7101eaebf83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_us-gaap_LicenseMember_84f21b48-2c9b-4a2d-aadb-a7101eaebf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_07adc548-6f4a-4cad-ba2c-b3c4062f0906" xlink:href="ino-20211231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_07adc548-6f4a-4cad-ba2c-b3c4062f0906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_dff6f44c-4297-4e49-b2a8-1310b940448e" xlink:href="ino-20211231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_dff6f44c-4297-4e49-b2a8-1310b940448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_2a7c0e3f-abf3-47d7-8d3c-8cda5e51994d" xlink:href="ino-20211231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_2a7c0e3f-abf3-47d7-8d3c-8cda5e51994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_e2a6cf40-8c60-445d-a7b8-c60b355365fb" xlink:href="ino-20211231.xsd#ino_INO4800Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_INO4800Member_e2a6cf40-8c60-445d-a7b8-c60b355365fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_4574f165-3a26-45a1-8133-f0780e477518" xlink:href="ino-20211231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_585c53c0-662f-45e3-a968-7ed4cb66ad4b" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_4574f165-3a26-45a1-8133-f0780e477518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ab4e92b-3996-4f44-a0ba-324bdd5a8bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25ee53f4-2c01-4a1b-9b67-c84e92af780d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ab4e92b-3996-4f44-a0ba-324bdd5a8bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_279a905d-c2c5-4a18-97f8-a86ad032d237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ab4e92b-3996-4f44-a0ba-324bdd5a8bba" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_279a905d-c2c5-4a18-97f8-a86ad032d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_98d70a7c-f876-490c-9b65-dce6d438f1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c981b35d-7ef1-4b07-a087-6a76f1bd884e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_98d70a7c-f876-490c-9b65-dce6d438f1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_47534a1f-5891-4fac-bef2-d56f6f4ef170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_98d70a7c-f876-490c-9b65-dce6d438f1e5" xlink:to="loc_us-gaap_ForeignCountryMember_47534a1f-5891-4fac-bef2-d56f6f4ef170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_58c9d16c-5440-4df4-9427-cc6f622c19c2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1367b4df-9f25-4b0a-9b86-bcd42a1b1e80" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1367b4df-9f25-4b0a-9b86-bcd42a1b1e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_8be6cc43-e452-47a7-89e1-249a8e7b05cb" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_8be6cc43-e452-47a7-89e1-249a8e7b05cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_5b64e1e4-65ff-4b2f-b1b1-ef7b22ed1c43" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_5b64e1e4-65ff-4b2f-b1b1-ef7b22ed1c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_bd020f91-68d3-47cc-8d1a-966f4dd25dfc" xlink:href="ino-20211231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_bd020f91-68d3-47cc-8d1a-966f4dd25dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_071c4fcc-be94-437d-80b8-11b09a8b6b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_CostMaintenance_071c4fcc-be94-437d-80b8-11b09a8b6b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_6390c979-1c3c-488d-868a-d399c24160b0" xlink:href="ino-20211231.xsd#ino_AnnualMaintenancePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_AnnualMaintenancePeriod_6390c979-1c3c-488d-868a-d399c24160b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3e89eef-680a-490b-a9e9-3922b9c9847b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3e89eef-680a-490b-a9e9-3922b9c9847b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_35482c78-f303-4910-b62d-36f144287de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_AccountsReceivableNet_35482c78-f303-4910-b62d-36f144287de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_77ebd468-f607-4a1a-bbe8-4f114bef2fce" xlink:href="ino-20211231.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_77ebd468-f607-4a1a-bbe8-4f114bef2fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_cf5842d3-4fd8-45bc-9640-75d19ee8aeef" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_cf5842d3-4fd8-45bc-9640-75d19ee8aeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_97c051e5-4686-4bc2-923f-aad0982622f7" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_97c051e5-4686-4bc2-923f-aad0982622f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_90c49d4f-7779-411b-8090-5439dd37f2d8" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_90c49d4f-7779-411b-8090-5439dd37f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_ef76e6a0-b5f3-4a68-ad37-bf64b78881c1" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_ef76e6a0-b5f3-4a68-ad37-bf64b78881c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_3ad075fa-8709-4d31-b343-f4dd58488ff6" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_3ad075fa-8709-4d31-b343-f4dd58488ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_9fec2eb4-d809-48f8-adb8-dfef6948103d" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_9fec2eb4-d809-48f8-adb8-dfef6948103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_1517a6e5-65fc-44c8-83d3-e2e3fbbdd792" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_1517a6e5-65fc-44c8-83d3-e2e3fbbdd792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_ccb1eed5-caeb-4643-8782-f28629591c7e" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_ccb1eed5-caeb-4643-8782-f28629591c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_009b7c88-3232-4434-9b70-dc43326fd860" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_DeferredGrantFundingCurrent_009b7c88-3232-4434-9b70-dc43326fd860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_4771a708-26b4-4800-ba48-6b47e397bfc5" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_4771a708-26b4-4800-ba48-6b47e397bfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_3d0242e7-9b4a-42c6-81b8-eab7a991af87" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_3d0242e7-9b4a-42c6-81b8-eab7a991af87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_9b4397fe-9d6e-4e67-a33c-5605e8fde516" xlink:href="ino-20211231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_ino_GrantProceedsReceived_9b4397fe-9d6e-4e67-a33c-5605e8fde516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_2386d5dd-8ed7-4a4d-ad34-2647a4d3a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_2386d5dd-8ed7-4a4d-ad34-2647a4d3a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_b94ca4ec-bab4-4bd1-8494-48bc57067c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53490295-3bf2-4fc5-a22d-1f093979bc7c" xlink:to="loc_us-gaap_GrantsReceivable_b94ca4ec-bab4-4bd1-8494-48bc57067c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2d44eb58-3313-455d-9e7b-1bc89b165412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0dc48cde-5c6c-48e7-adfa-ed002d40c560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2d44eb58-3313-455d-9e7b-1bc89b165412" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0dc48cde-5c6c-48e7-adfa-ed002d40c560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2b7106da-ae5c-40bc-a4d0-931e4339b0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2d44eb58-3313-455d-9e7b-1bc89b165412" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2b7106da-ae5c-40bc-a4d0-931e4339b0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64ddf3e6-bd1d-49ed-ac81-22354f3a7eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1911a608-66f7-4f52-9aaf-ae202bcaf94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64ddf3e6-bd1d-49ed-ac81-22354f3a7eef" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1911a608-66f7-4f52-9aaf-ae202bcaf94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bb99f5c6-a1c6-4fa8-a44d-9a94dc4357fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_64ddf3e6-bd1d-49ed-ac81-22354f3a7eef" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bb99f5c6-a1c6-4fa8-a44d-9a94dc4357fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_95879d0b-7744-419e-aa36-2c463d3f27ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_95879d0b-7744-419e-aa36-2c463d3f27ba" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d69408a4-6edd-4d24-b3cc-52b155642771" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_6efb547b-dc0f-4fdb-905d-162de5f6f59b" xlink:href="ino-20211231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_ino_MutualFundsMember_6efb547b-dc0f-4fdb-905d-162de5f6f59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_4ba8c6f7-c876-488d-9ab5-8a8c157db1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_4ba8c6f7-c876-488d-9ab5-8a8c157db1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_025f081b-d5ef-47e1-a32f-75812932dc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_CommercialPaperMember_025f081b-d5ef-47e1-a32f-75812932dc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_36755bfc-4bd5-4949-8772-b07b96b6e17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_CertificatesOfDepositMember_36755bfc-4bd5-4949-8772-b07b96b6e17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_87038867-fefa-45c9-afd2-551cdd0904c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82b142a3-bfae-4c56-9a14-9b64b394d5a8" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_87038867-fefa-45c9-afd2-551cdd0904c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:to="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0aac6af6-a37f-4da2-9f0c-79cc72cc9ea2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0eb1b084-1916-4f72-98b1-bade0c99ab50" xlink:to="loc_srt_RangeMember_0aac6af6-a37f-4da2-9f0c-79cc72cc9ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3ebee8f1-27e9-49be-92ac-d1b01e264fc7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0aac6af6-a37f-4da2-9f0c-79cc72cc9ea2" xlink:to="loc_srt_MaximumMember_3ebee8f1-27e9-49be-92ac-d1b01e264fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0553741f-63d2-4d03-8424-a70df0db9ece" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_abd8388f-dff8-41c7-94aa-c16e0f607154" xlink:href="ino-20211231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_abd8388f-dff8-41c7-94aa-c16e0f607154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc444996-e735-4e1f-a603-ba27d7d23666" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a017cc9e-dca4-4d80-94ab-8031435b3932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a017cc9e-dca4-4d80-94ab-8031435b3932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51e47933-6c14-4535-b8f2-2b347a3bd52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51e47933-6c14-4535-b8f2-2b347a3bd52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58c82b9a-42d2-42f0-8a0c-9411d7a6ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58c82b9a-42d2-42f0-8a0c-9411d7a6ffb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8789ae58-f462-4810-b643-c9ce0afead49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ddf58e7e-6abd-40ec-96d8-52c9838aa40b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8789ae58-f462-4810-b643-c9ce0afead49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bf2fc94c-40cf-4e31-83c3-568b09e81c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bf2fc94c-40cf-4e31-83c3-568b09e81c62" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c6d6b7b-76aa-49ad-a5c0-fb1a19e036cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d4bcba31-47f9-4216-a3e2-dde7ceba244a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c6d6b7b-76aa-49ad-a5c0-fb1a19e036cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dd61458e-9b24-4bbb-8a84-7a07788472bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c6d6b7b-76aa-49ad-a5c0-fb1a19e036cb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dd61458e-9b24-4bbb-8a84-7a07788472bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d26207b-1721-46e8-bd35-89192937104d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_a93a6ef1-d94c-491e-aee3-f2e306a2fd3d" xlink:href="ino-20211231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_ino_MutualFundsMember_a93a6ef1-d94c-491e-aee3-f2e306a2fd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1cf31b4e-9a1e-456d-9571-f0506ebbebb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1cf31b4e-9a1e-456d-9571-f0506ebbebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8db14f0e-f3a8-4731-95f0-f2b278232bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_CommercialPaperMember_8db14f0e-f3a8-4731-95f0-f2b278232bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_02d81744-df76-4801-9ba9-7656931e0ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_02d81744-df76-4801-9ba9-7656931e0ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_1ae0b0aa-da6e-4f3f-b77a-057df44c1952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57f48854-0bd6-4ced-a4fa-8deba647650a" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_1ae0b0aa-da6e-4f3f-b77a-057df44c1952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61e12654-d887-4822-bd0d-0034ca0a0422" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_253ebb2f-8c21-4467-809c-8236b5eec5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_253ebb2f-8c21-4467-809c-8236b5eec5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac5fe620-e625-4172-b46d-229959201a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac5fe620-e625-4172-b46d-229959201a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2e1fdb5f-ea6e-46da-a55a-8663bb44c3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0de6e47b-076d-4e04-92f0-86e71ce968b5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2e1fdb5f-ea6e-46da-a55a-8663bb44c3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1ba2715-08eb-48a8-9f89-cb187f8b1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be1fcf44-9374-43d2-9614-fc5dddc9a4f7" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1ba2715-08eb-48a8-9f89-cb187f8b1fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1ba2715-08eb-48a8-9f89-cb187f8b1fde" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03f34869-8caf-4057-8092-b0bc48a02031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03f34869-8caf-4057-8092-b0bc48a02031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_660e88b3-ced0-4231-98a9-8e4f5218da2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_660e88b3-ced0-4231-98a9-8e4f5218da2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6651c0c3-15ff-4190-bfd1-448b6b0ab65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6651c0c3-15ff-4190-bfd1-448b6b0ab65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_abee50dd-3b0b-45fe-afcd-c3461251689b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_29f90a3b-57a1-4782-be54-76fd40575ca2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_abee50dd-3b0b-45fe-afcd-c3461251689b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe14f7ad-adbe-4a8c-9402-aea315565b96" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b43fb66b-de25-48ce-938a-ba950a4cd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b43fb66b-de25-48ce-938a-ba950a4cd9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_47089e78-acb1-4b1b-a815-7a444471c384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_209504df-f349-4d86-9123-9373f05dbe15" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_47089e78-acb1-4b1b-a815-7a444471c384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:to="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a227eeeb-3c08-4c65-aae1-a5fe6f5c5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a3b78509-da9b-423d-8b59-117fb4840791" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a227eeeb-3c08-4c65-aae1-a5fe6f5c5f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_da075a6c-d4b1-4471-8a6e-5206bde804bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a227eeeb-3c08-4c65-aae1-a5fe6f5c5f76" xlink:to="loc_us-gaap_CommonStockMember_da075a6c-d4b1-4471-8a6e-5206bde804bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_88ea5c09-8f5e-456b-a1fc-f185c1a64055" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_608023c0-3082-4486-8275-ce1fa1053c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_608023c0-3082-4486-8275-ce1fa1053c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_5e5bc586-4309-4fab-9ed9-ff8517a9cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_5e5bc586-4309-4fab-9ed9-ff8517a9cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3be0ff5f-602b-4a13-8e79-a17a02c48630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3be0ff5f-602b-4a13-8e79-a17a02c48630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_201c992a-a94a-43fb-85a1-9c5a4c305cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_201c992a-a94a-43fb-85a1-9c5a4c305cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e4fb29b1-96f3-4094-a7fa-40e0901fed4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_e4fb29b1-96f3-4094-a7fa-40e0901fed4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5cb30fc6-ac9a-49ad-8f21-e3168881e892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_5cb30fc6-ac9a-49ad-8f21-e3168881e892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_87c29a75-ab8b-44dc-9107-7776956ff0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_87c29a75-ab8b-44dc-9107-7776956ff0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_da2fc53f-5e0e-448d-aaa3-1b95ed4e9c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e69ae3f2-4546-46ad-88be-903dc1a8faf9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_da2fc53f-5e0e-448d-aaa3-1b95ed4e9c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="ino-20211231.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_35ffbcf9-8fa4-443b-a46b-ead38bfe305f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_9524683a-dd4d-4961-aeb5-e74320840205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_35ffbcf9-8fa4-443b-a46b-ead38bfe305f" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_9524683a-dd4d-4961-aeb5-e74320840205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="ino-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0cd4aedd-6c8a-4d7c-a9a1-dd51c00c404c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_ebcf33b6-eac0-469f-ad92-84c84433de8b" xlink:href="ino-20211231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0cd4aedd-6c8a-4d7c-a9a1-dd51c00c404c" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_ebcf33b6-eac0-469f-ad92-84c84433de8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ce967b01-f1f5-4a14-a0a5-667354bc98b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_3c3fbae3-60c6-457f-8f50-44db3e593b7b" xlink:href="ino-20211231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ce967b01-f1f5-4a14-a0a5-667354bc98b2" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_3c3fbae3-60c6-457f-8f50-44db3e593b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_5eb44316-94a7-483f-b27c-41b1fa09007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ce967b01-f1f5-4a14-a0a5-667354bc98b2" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_5eb44316-94a7-483f-b27c-41b1fa09007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3839c1f4-3379-41f1-8899-1588795f8bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_ce967b01-f1f5-4a14-a0a5-667354bc98b2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3839c1f4-3379-41f1-8899-1588795f8bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#PrepaidExpensesandOtherCurrentAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5c48a874-9d14-4131-a3c6-94b38c220f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_2deafa47-03cc-4f42-bac3-3b57d6b06f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5c48a874-9d14-4131-a3c6-94b38c220f35" xlink:to="loc_us-gaap_DepositsAssetsCurrent_2deafa47-03cc-4f42-bac3-3b57d6b06f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDeposits_9a92319f-16f5-48c2-826e-68c724bcd9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5c48a874-9d14-4131-a3c6-94b38c220f35" xlink:to="loc_us-gaap_PaymentsForDeposits_9a92319f-16f5-48c2-826e-68c724bcd9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepositAssetsForfeited_a792d4a1-183a-475a-99ef-54cc561cf7ea" xlink:href="ino-20211231.xsd#ino_DepositAssetsForfeited"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5c48a874-9d14-4131-a3c6-94b38c220f35" xlink:to="loc_ino_DepositAssetsForfeited_a792d4a1-183a-475a-99ef-54cc561cf7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20211231.xsd#FixedAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3554387b-759e-43c8-a051-e197d64bc1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_eab3cde9-7c1e-41fd-9ac0-fb271b2ca73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3554387b-759e-43c8-a051-e197d64bc1a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_eab3cde9-7c1e-41fd-9ac0-fb271b2ca73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20211231.xsd#FixedAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_baf10ddd-6606-41f2-8721-0805abf86558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_89ae6688-faa5-4360-98ee-962499eaaa25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_baf10ddd-6606-41f2-8721-0805abf86558" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_89ae6688-faa5-4360-98ee-962499eaaa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#FixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec8b19db-7e5f-41e6-8c95-587269672c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec8b19db-7e5f-41e6-8c95-587269672c45" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ecd359ba-8a53-4ac7-9b81-77199e35bacc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8229cef7-2b16-4dc1-bdb9-fad49ecc494e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8229cef7-2b16-4dc1-bdb9-fad49ecc494e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_136ccafa-0213-44d4-ab42-75226f70652e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_OfficeEquipmentMember_136ccafa-0213-44d4-ab42-75226f70652e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7f965999-01d9-431d-ae55-269d5e715751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7f965999-01d9-431d-ae55-269d5e715751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9b74da76-5691-426c-be1e-dffb07807c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d247e79b-8133-4c9e-baa3-fb9e807e9ac0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_9b74da76-5691-426c-be1e-dffb07807c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1577f5b3-3469-43f2-b0fe-2f44b2116def" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_07d317f4-1c65-4777-886d-5ed7236d89ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_07d317f4-1c65-4777-886d-5ed7236d89ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21255f2d-888d-4ec9-bb20-3e1b25a8246c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_21255f2d-888d-4ec9-bb20-3e1b25a8246c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_81016fc4-a687-4734-b76c-f4fd5772fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_81016fc4-a687-4734-b76c-f4fd5772fbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0c750654-1c35-4f0b-bb4a-a387cf0ac7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_Depreciation_0c750654-1c35-4f0b-bb4a-a387cf0ac7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_dac708c8-4d78-4b1d-9587-ee1b579a1d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_dac708c8-4d78-4b1d-9587-ee1b579a1d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_8e4258f7-d22a-4697-ab68-3bcfee45fb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9c40ed92-5dc1-4b01-8e8b-c9c46776cddf" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_8e4258f7-d22a-4697-ab68-3bcfee45fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6051cd6-7173-45fd-a7fa-8ad8c9956093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_20f05563-7254-4c53-b5de-08acbcbd637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f6051cd6-7173-45fd-a7fa-8ad8c9956093" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_20f05563-7254-4c53-b5de-08acbcbd637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c905e0b6-963a-4632-b003-69c1b19f3ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_f554b054-7b4b-4d70-a40c-687544bc81b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c905e0b6-963a-4632-b003-69c1b19f3ead" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_f554b054-7b4b-4d70-a40c-687544bc81b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_960622cc-bbcb-4a35-b623-7f1af52c91ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c905e0b6-963a-4632-b003-69c1b19f3ead" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_960622cc-bbcb-4a35-b623-7f1af52c91ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eb0abb7d-093c-452d-b26c-1b4da9273d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eb0abb7d-093c-452d-b26c-1b4da9273d1c" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_036766ad-671d-4331-bac2-96a61a3c3e2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_63ff35e3-5f4f-4bf0-b117-282ea845681e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:to="loc_us-gaap_LicensingAgreementsMember_63ff35e3-5f4f-4bf0-b117-282ea845681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_2f0e090e-cbbe-4bfa-a515-515a3652a335" xlink:href="ino-20211231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:to="loc_ino_BiojectMember_2f0e090e-cbbe-4bfa-a515-515a3652a335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_d0e6b4b0-c993-4b10-908c-012b5babd076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41acf533-7106-4bcb-900b-99a72750548b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_d0e6b4b0-c993-4b10-908c-012b5babd076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:to="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09ebc836-e3d5-4292-9431-5567473c2169" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_188a6e72-5373-4cd3-ab94-362e17a7bb32" xlink:to="loc_srt_RangeMember_09ebc836-e3d5-4292-9431-5567473c2169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_83fcf87b-4f66-4535-9b31-1a4c568464fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09ebc836-e3d5-4292-9431-5567473c2169" xlink:to="loc_srt_WeightedAverageMember_83fcf87b-4f66-4535-9b31-1a4c568464fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3cead8cb-7a62-4524-82fd-c18bb5e7e04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_072b9366-46d6-48ec-b904-fd70a71fde85" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3cead8cb-7a62-4524-82fd-c18bb5e7e04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3cead8cb-7a62-4524-82fd-c18bb5e7e04f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9bd7d4a6-3559-4905-8f24-4984ef397262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9bd7d4a6-3559-4905-8f24-4984ef397262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_25c8b233-1b3c-45a7-8ae4-d2b742508641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_25c8b233-1b3c-45a7-8ae4-d2b742508641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_371587a6-dd80-4c36-b4c9-8c0cf06dd466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_25c8b233-1b3c-45a7-8ae4-d2b742508641" xlink:to="loc_us-gaap_Goodwill_371587a6-dd80-4c36-b4c9-8c0cf06dd466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab85bfc0-bc02-4635-82db-cb48e0280305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab85bfc0-bc02-4635-82db-cb48e0280305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2c65667-bf43-4086-816f-543231f49943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2c65667-bf43-4086-816f-543231f49943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3b548d0e-ee59-42fe-965e-2367c394552e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b874a450-9d7a-4f3f-95d2-75602351246d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3b548d0e-ee59-42fe-965e-2367c394552e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_e42fd693-db34-4d51-9022-1f77809a2fa1" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_e42fd693-db34-4d51-9022-1f77809a2fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_ef3a5982-45df-4a2f-a3f8-0b43dcea767f" xlink:href="ino-20211231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_8398f957-889d-4e9c-95b1-cf49b157d7e6" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_ef3a5982-45df-4a2f-a3f8-0b43dcea767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c356894a-fc54-46f5-9ca7-3c8805b06ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_00011200-5db4-4f71-b390-76c08b4919ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c356894a-fc54-46f5-9ca7-3c8805b06ecb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_00011200-5db4-4f71-b390-76c08b4919ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7633257c-3092-4624-811f-da108dee857f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c356894a-fc54-46f5-9ca7-3c8805b06ecb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7633257c-3092-4624-811f-da108dee857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c4eac939-790d-449a-a020-7caf36d05b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c356894a-fc54-46f5-9ca7-3c8805b06ecb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c4eac939-790d-449a-a020-7caf36d05b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc985e7a-3a07-4f79-8649-1fce2d590f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc985e7a-3a07-4f79-8649-1fce2d590f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9ffa1a56-3e9f-4c5b-99e4-ec952ab4294c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9ffa1a56-3e9f-4c5b-99e4-ec952ab4294c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fafe1bd1-57b4-4feb-b8ac-bfbf07998f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fafe1bd1-57b4-4feb-b8ac-bfbf07998f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_be500f0d-6026-4626-9ea8-79b7c2e7e731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_be500f0d-6026-4626-9ea8-79b7c2e7e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3006eab9-a91d-4875-b9ee-4aed79292f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3006eab9-a91d-4875-b9ee-4aed79292f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9b6b32aa-80f7-4127-82f6-bad97c22229c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9b6b32aa-80f7-4127-82f6-bad97c22229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_544e7eae-5f82-4ce2-b27c-2009cf70a21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b78233d3-f72b-4c50-bd9d-8fbb547ae127" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_544e7eae-5f82-4ce2-b27c-2009cf70a21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67c1e673-c26f-42e9-afa7-0395d0205960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cbecd39e-0417-4ee9-a32d-2a00d6eb03dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67c1e673-c26f-42e9-afa7-0395d0205960" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cbecd39e-0417-4ee9-a32d-2a00d6eb03dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_104edfe8-4fcf-4577-a813-2100387126e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_8af6befe-a6eb-4118-a025-e4bbace34894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_104edfe8-4fcf-4577-a813-2100387126e9" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_8af6befe-a6eb-4118-a025-e4bbace34894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_11b7e7cc-535f-4290-97db-02cdc28f37a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_104edfe8-4fcf-4577-a813-2100387126e9" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_11b7e7cc-535f-4290-97db-02cdc28f37a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6495c33a-89d0-4833-9b62-806b744612e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6495c33a-89d0-4833-9b62-806b744612e8" xlink:to="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8facf0d7-e5a4-413c-83c7-4ebabc368d56" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d084d81-c4db-4ae2-b7e4-b13a56b900e6" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d084d81-c4db-4ae2-b7e4-b13a56b900e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_6e594730-2dea-4479-a1ed-1977cf46faca" xlink:href="ino-20211231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:to="loc_ino_August2019ConvertibleBondsMember_6e594730-2dea-4479-a1ed-1977cf46faca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_49b75cec-633c-4a6b-aad0-766579126bbb" xlink:href="ino-20211231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef45040-a1cd-4bc0-8114-b3c9b3d680cb" xlink:to="loc_ino_December2019ConvertibleBondsMember_49b75cec-633c-4a6b-aad0-766579126bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fedb67b2-ec02-4f2a-affd-8aadbc8fadc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe8eee29-a993-4657-bdde-d08bfc3127ae" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fedb67b2-ec02-4f2a-affd-8aadbc8fadc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0285d130-2a00-4099-9561-5afd14594d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fedb67b2-ec02-4f2a-affd-8aadbc8fadc1" xlink:to="loc_us-gaap_ConvertibleDebtMember_0285d130-2a00-4099-9561-5afd14594d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b09ae632-4522-45e7-a05a-a8d167a09b05" xlink:to="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_66b5995e-b2c4-4fec-94e3-76311357d026" xlink:href="ino-20211231.xsd#ino_InitialConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:to="loc_ino_InitialConversionPriceMember_66b5995e-b2c4-4fec-94e3-76311357d026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_fd984643-d77c-45c2-b5c6-90cb96c87c19" xlink:href="ino-20211231.xsd#ino_AfterJanuary22020ConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_fd984643-d77c-45c2-b5c6-90cb96c87c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_4750686c-5149-4490-b9c2-a176b16088f0" xlink:href="ino-20211231.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_c6c613f5-6525-4337-99d8-777b0a0611a0" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_4750686c-5149-4490-b9c2-a176b16088f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d52f15f-d08c-4c39-aadc-46fff98db8cd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4cc2440a-97e7-4fbc-8c0b-8f3426bdfb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4cc2440a-97e7-4fbc-8c0b-8f3426bdfb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d94f9dfe-33b3-4e6f-90ed-ab69086a8f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d94f9dfe-33b3-4e6f-90ed-ab69086a8f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_d75e515b-87be-4abe-b158-1930b6d42893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_d75e515b-87be-4abe-b158-1930b6d42893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5130146e-5ac0-456f-a55b-d124a09415fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5130146e-5ac0-456f-a55b-d124a09415fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_65358b35-cbf1-4ee1-a622-8bc602f07f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_65358b35-cbf1-4ee1-a622-8bc602f07f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4cec8316-f060-4b11-9985-50cf82ddf879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4cec8316-f060-4b11-9985-50cf82ddf879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0dded764-964d-4588-a75b-ff7b1756a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0dded764-964d-4588-a75b-ff7b1756a93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3b26260-25f0-43e6-b0cf-5880a90cdd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3b26260-25f0-43e6-b0cf-5880a90cdd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_26f4ed34-0082-466e-96ff-630fcef030a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_LongTermDebtFairValue_26f4ed34-0082-466e-96ff-630fcef030a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9e7c7dae-4d5f-4e1d-bf09-461794620a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9e7c7dae-4d5f-4e1d-bf09-461794620a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1094c659-3f2f-40fe-8d51-d954beade981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1094c659-3f2f-40fe-8d51-d954beade981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0b90b6c7-b790-476e-b7d9-8b577f34f003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0b90b6c7-b790-476e-b7d9-8b577f34f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fbe826b1-b04b-4a98-a2b7-4623d830ed69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_fbe826b1-b04b-4a98-a2b7-4623d830ed69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_97877ea0-3df8-4d09-b865-c51d9e033367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_97877ea0-3df8-4d09-b865-c51d9e033367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8476adb-fbd2-4917-9b74-8cd434fbe34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c8476adb-fbd2-4917-9b74-8cd434fbe34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ca98c2fd-9408-4850-934d-64754b261ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ca98c2fd-9408-4850-934d-64754b261ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_72c08db9-9ce8-418d-933f-14fa36372478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_72c08db9-9ce8-418d-933f-14fa36372478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43a4ac4c-d8d1-4f4a-a04d-9aabd03df251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43a4ac4c-d8d1-4f4a-a04d-9aabd03df251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_95867706-b75c-4bd6-98a2-7740d3b56af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_InterestExpense_95867706-b75c-4bd6-98a2-7740d3b56af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7e3cebe3-b9f8-4b8d-93d0-fd87398fe727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_InterestExpenseDebt_7e3cebe3-b9f8-4b8d-93d0-fd87398fe727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_5cc940b4-ad9d-4272-970d-59a2115fb10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_5cc940b4-ad9d-4272-970d-59a2115fb10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_cf28482d-06bf-4f26-b920-b6e57878c678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_cf28482d-06bf-4f26-b920-b6e57878c678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_3782f7a6-793f-4c52-9ada-61a0eefd0fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3c2a148-bf5f-4683-9e3a-09e8da199b61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_3782f7a6-793f-4c52-9ada-61a0eefd0fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_df869cbe-5a93-489a-958f-20e733536fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_df869cbe-5a93-489a-958f-20e733536fa5" xlink:to="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d7ca5a53-e05b-46ca-8263-a27998165229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_92e89b86-9f73-49ae-b3ef-168d3fb78828" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d7ca5a53-e05b-46ca-8263-a27998165229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6941cdb9-bbb8-4036-8ceb-3482319630ce" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d7ca5a53-e05b-46ca-8263-a27998165229" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_6941cdb9-bbb8-4036-8ceb-3482319630ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a766d6ad-b968-4c88-bd74-5b032f4a32e2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_79e778b9-ed6a-4b7f-a431-8ad991d2e46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_79e778b9-ed6a-4b7f-a431-8ad991d2e46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_c7391f96-a635-4aa1-aa96-3ebc872ab79e" xlink:href="ino-20211231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_c7391f96-a635-4aa1-aa96-3ebc872ab79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_25501362-63aa-44fc-a602-645fd3112c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_25501362-63aa-44fc-a602-645fd3112c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3c04ecf7-0d31-4739-8bd3-1dea6ab09ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3c04ecf7-0d31-4739-8bd3-1dea6ab09ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_f9b2d97f-6dd7-4088-9b14-3f25cfeb7b08" xlink:href="ino-20211231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_ino_DebtinstrumentAccruedInterest_f9b2d97f-6dd7-4088-9b14-3f25cfeb7b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a68360bc-9d3b-46a9-93fc-39fee739b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_97fb30c4-e186-40f9-8ff9-afc2a708884d" xlink:to="loc_us-gaap_LongTermDebt_a68360bc-9d3b-46a9-93fc-39fee739b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fda83a78-ed99-442f-9e64-c9f9ce775c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fda83a78-ed99-442f-9e64-c9f9ce775c08" xlink:to="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_888f2d50-67d9-4da8-9233-1340797b62b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9b5b7ece-00dd-47ea-a218-1d5210e4a82f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_888f2d50-67d9-4da8-9233-1340797b62b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0dda437f-155f-448c-a0b0-64ad81024159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_888f2d50-67d9-4da8-9233-1340797b62b9" xlink:to="loc_us-gaap_ConvertibleDebtMember_0dda437f-155f-448c-a0b0-64ad81024159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:to="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e829172d-ec79-456d-8151-b203abe5d4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_18a184ca-29ce-4440-b0e8-3396515212d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e829172d-ec79-456d-8151-b203abe5d4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e87cfaf4-8858-4c18-ab97-8916f31cfb10" xlink:href="ino-20211231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e829172d-ec79-456d-8151-b203abe5d4e5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_e87cfaf4-8858-4c18-ab97-8916f31cfb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3abbd29a-8eda-4565-8b31-7ccf9545b801" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3602dab-eafc-4cce-920f-381ae20f98ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3602dab-eafc-4cce-920f-381ae20f98ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7dae1649-ea8f-491a-b17a-7be5a30eec38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7dae1649-ea8f-491a-b17a-7be5a30eec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d9f29644-6d0c-430b-abdf-d2c1d9a6bb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d9f29644-6d0c-430b-abdf-d2c1d9a6bb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20207958-2989-4fa0-8978-b1e2f1366d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_20207958-2989-4fa0-8978-b1e2f1366d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_85b617ee-02d7-4cca-b6d4-cf4e89a82fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b8f0e2a9-e2fc-4688-a906-07423cf1b86d" xlink:to="loc_us-gaap_LongTermDebt_85b617ee-02d7-4cca-b6d4-cf4e89a82fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ino-20211231.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_edd31aff-d672-4770-bd15-b620083ad399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e2e957dd-1cda-44af-a06a-e7f17272b0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_edd31aff-d672-4770-bd15-b620083ad399" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e2e957dd-1cda-44af-a06a-e7f17272b0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ino-20211231.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c4a6c559-211c-40b8-a764-c34a33ab950d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bcaa917f-abd9-410d-9e70-75ebac94c8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c4a6c559-211c-40b8-a764-c34a33ab950d" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bcaa917f-abd9-410d-9e70-75ebac94c8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5c98729d-7361-4527-be8a-33c20b1e1a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1ee78ae8-9cc0-4cd2-8985-3d582f7593e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5c98729d-7361-4527-be8a-33c20b1e1a90" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_1ee78ae8-9cc0-4cd2-8985-3d582f7593e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_0f37b604-20a8-482f-972c-075c3c60d88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5c98729d-7361-4527-be8a-33c20b1e1a90" xlink:to="loc_us-gaap_AccruedSalariesCurrent_0f37b604-20a8-482f-972c-075c3c60d88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedSubcontractExpenses_aa9824da-25ce-4a79-bb59-78701848668f" xlink:href="ino-20211231.xsd#ino_AccruedSubcontractExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5c98729d-7361-4527-be8a-33c20b1e1a90" xlink:to="loc_ino_AccruedSubcontractExpenses_aa9824da-25ce-4a79-bb59-78701848668f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bd4b33b9-c0d3-47fb-a92d-c0a15f119499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5c98729d-7361-4527-be8a-33c20b1e1a90" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bd4b33b9-c0d3-47fb-a92d-c0a15f119499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_99b9080b-8904-4c58-8424-77fc08c3ead4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5c98729d-7361-4527-be8a-33c20b1e1a90" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_99b9080b-8904-4c58-8424-77fc08c3ead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5b215559-5d0d-433d-8b5c-bea9f4fc2f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_adba1c6d-7539-4ba4-9f87-598d04ac5bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5b215559-5d0d-433d-8b5c-bea9f4fc2f81" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_adba1c6d-7539-4ba4-9f87-598d04ac5bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_68d0cebf-c6e0-4cd7-88a7-8f6b2899f8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_267da60e-6431-4ce6-b1ac-f989309322ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_68d0cebf-c6e0-4cd7-88a7-8f6b2899f8a1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_267da60e-6431-4ce6-b1ac-f989309322ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_296bef24-45e6-4543-a494-3d852531182e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_68d0cebf-c6e0-4cd7-88a7-8f6b2899f8a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_296bef24-45e6-4543-a494-3d852531182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7a1c9163-c365-4115-80a0-b8de6596bec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_68d0cebf-c6e0-4cd7-88a7-8f6b2899f8a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7a1c9163-c365-4115-80a0-b8de6596bec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_36e04bcd-92c6-4610-bd28-d83f82ba87b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_68d0cebf-c6e0-4cd7-88a7-8f6b2899f8a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_36e04bcd-92c6-4610-bd28-d83f82ba87b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e6867fc9-00e5-4620-9a7c-0ae25ae1225b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e6867fc9-00e5-4620-9a7c-0ae25ae1225b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_29e63a9b-e9d4-452d-90b2-3092b6cd255a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9aea0a82-06c2-499e-929a-6bcd4c80bf7f" xlink:to="loc_us-gaap_ClassOfStockDomain_29e63a9b-e9d4-452d-90b2-3092b6cd255a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_50d9bcf6-1bed-4dde-b874-42d552303e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_29e63a9b-e9d4-452d-90b2-3092b6cd255a" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_50d9bcf6-1bed-4dde-b874-42d552303e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_06d69789-5a91-40e7-b0a9-e881ea32c396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43ef2a4d-11d1-4241-bf35-6e5baaf580dc" xlink:to="loc_us-gaap_ClassOfStockLineItems_06d69789-5a91-40e7-b0a9-e881ea32c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_06d69789-5a91-40e7-b0a9-e881ea32c396" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec844e2e-0892-41f7-b440-c6421c1fd8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec844e2e-0892-41f7-b440-c6421c1fd8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_954b16f7-d1e4-4078-a16c-2b9a0e284b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_954b16f7-d1e4-4078-a16c-2b9a0e284b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_614e2ac6-fa32-42f0-b3ce-ffc4217654ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_614e2ac6-fa32-42f0-b3ce-ffc4217654ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6472726b-2e10-4bbd-8071-49e5e5fa67f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_555c5b07-c178-4029-9cfe-5658915463f5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6472726b-2e10-4bbd-8071-49e5e5fa67f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f15561fe-dd80-4168-a98d-210824f4ee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f15561fe-dd80-4168-a98d-210824f4ee2e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ad88000-1b85-4dea-ac17-cfed63a88b2f" xlink:to="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8976a1cd-f2ac-49c7-a30c-e4c86ea95fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8976a1cd-f2ac-49c7-a30c-e4c86ea95fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_997d5d39-4046-4985-a8dc-0c93ee8d7d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_51c4c290-ca49-4c6e-8e13-9e2e0a450a70" xlink:to="loc_us-gaap_CommonStockMember_997d5d39-4046-4985-a8dc-0c93ee8d7d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b86d71c-5962-4c52-911f-968432eac42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eeddc475-e93f-4176-8961-3c373cc31432" xlink:to="loc_us-gaap_EquityComponentDomain_3b86d71c-5962-4c52-911f-968432eac42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_08a6559d-06ea-40fc-80d3-0eec89d42e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b86d71c-5962-4c52-911f-968432eac42d" xlink:to="loc_us-gaap_CommonStockMember_08a6559d-06ea-40fc-80d3-0eec89d42e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_897f7832-ad76-4d59-89e7-1258b5c11da1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_6b059dd0-f70c-4371-9f36-1e3c8885d35d" xlink:href="ino-20211231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_6b059dd0-f70c-4371-9f36-1e3c8885d35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_a03a9705-917c-4daa-91c5-a47528f5b892" xlink:href="ino-20211231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_SalesAgreementMember_a03a9705-917c-4daa-91c5-a47528f5b892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_cd026ad7-76ff-4679-a2e6-4eff4280c55a" xlink:href="ino-20211231.xsd#ino_PriorSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_PriorSalesAgreementMember_cd026ad7-76ff-4679-a2e6-4eff4280c55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_58976061-d2be-4faa-b7ac-540345a1c9c8" xlink:href="ino-20211231.xsd#ino_NewSalesAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9515dd3e-caf6-461f-abf3-62676d1ac51d" xlink:to="loc_ino_NewSalesAgreementMember_58976061-d2be-4faa-b7ac-540345a1c9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_77faa062-4a77-43c0-be86-0dea5827cb9d" xlink:to="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_443bdad5-74d4-4003-90f3-d41454c874b9" xlink:href="ino-20211231.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:to="loc_ino_A2016IncentivePlanMember_443bdad5-74d4-4003-90f3-d41454c874b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_33c63359-4527-4530-91f6-9239ee9d4016" xlink:href="ino-20211231.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_274018f6-eef6-47cc-be10-8328b31ffcd9" xlink:to="loc_ino_A2007IncentivePlanMember_33c63359-4527-4530-91f6-9239ee9d4016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7bf664a5-4471-4bcc-a53d-590c0e24bad3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeeMember_0b9df592-0218-498e-8335-1dd7cc02d018" xlink:href="ino-20211231.xsd#ino_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_ino_EmployeeMember_0b9df592-0218-498e-8335-1dd7cc02d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aaa9f285-4c35-4c47-8bdf-bacc16244770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aaa9f285-4c35-4c47-8bdf-bacc16244770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aec6150-0d11-4de8-b881-261654f4227d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3aec6150-0d11-4de8-b881-261654f4227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_b03ce00a-9178-4ad7-a79a-fa03358693dc" xlink:href="ino-20211231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_af9be59a-5d23-4f54-a30f-c5dae1ab7586" xlink:to="loc_ino_NonEmployeeMember_b03ce00a-9178-4ad7-a79a-fa03358693dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f99c571b-19f3-4f38-be7b-6963c112bd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8e8bdbf5-74d6-4fbc-9e7f-a39d509fefa8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f99c571b-19f3-4f38-be7b-6963c112bd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d2c8ae66-7a5f-478e-b9d2-bdd504d4556e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f99c571b-19f3-4f38-be7b-6963c112bd75" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d2c8ae66-7a5f-478e-b9d2-bdd504d4556e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_36863b34-ed2a-4722-b06f-8fb5a49ed98c" xlink:to="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fe54d291-dca1-40de-a3c1-cedb554f6cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fe54d291-dca1-40de-a3c1-cedb554f6cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_36ab6998-203f-4240-815c-59c497f2ea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_281e92bb-095a-4190-bedc-1e59d50a319d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_36ab6998-203f-4240-815c-59c497f2ea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a0cd876-7afc-4371-8f5b-2bdffbdeb932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_96b0e12a-1243-4e6b-899c-008050d52ab7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a0cd876-7afc-4371-8f5b-2bdffbdeb932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bf06194f-7c65-4fbd-8e04-294e58239d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2a0cd876-7afc-4371-8f5b-2bdffbdeb932" xlink:to="loc_us-gaap_SubsequentEventMember_bf06194f-7c65-4fbd-8e04-294e58239d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4dad9255-3e88-4e68-ad57-d04489d7014e" xlink:to="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_d6da4dc2-7346-48d3-8646-c952c4d95cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_d6da4dc2-7346-48d3-8646-c952c4d95cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_beebe92d-d81a-40f2-80fe-1e5d031749ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_beebe92d-d81a-40f2-80fe-1e5d031749ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_9789dc53-88f8-422d-8c56-c03bdbeb0c20" xlink:href="ino-20211231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_9789dc53-88f8-422d-8c56-c03bdbeb0c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b238670d-56d0-4af1-9fe7-ea7ba30f2fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b238670d-56d0-4af1-9fe7-ea7ba30f2fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641aef96-f96a-4b48-a5ba-428f37f7acde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641aef96-f96a-4b48-a5ba-428f37f7acde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_16454bc3-d73d-42d6-b168-a3c80b5b26a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_16454bc3-d73d-42d6-b168-a3c80b5b26a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_08c699f5-47ea-472b-baa3-2bab60aa69a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_08c699f5-47ea-472b-baa3-2bab60aa69a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_fdd2330f-3df8-4b07-91b2-122a60089b76" xlink:href="ino-20211231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_fdd2330f-3df8-4b07-91b2-122a60089b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_fc1ff23d-cef1-43f9-9022-80ceae1de5b0" xlink:href="ino-20211231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_fc1ff23d-cef1-43f9-9022-80ceae1de5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_af65d057-0dcc-4527-8590-05d56795498c" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_af65d057-0dcc-4527-8590-05d56795498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4430288f-fe75-4925-81f2-acfed07b7ddc" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4430288f-fe75-4925-81f2-acfed07b7ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_8ceaba97-b211-4bda-b0a5-7b8ba83c7c4e" xlink:href="ino-20211231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_8ceaba97-b211-4bda-b0a5-7b8ba83c7c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_378b8fe8-5b3d-4646-8a28-be98f2239e9e" xlink:href="ino-20211231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_378b8fe8-5b3d-4646-8a28-be98f2239e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5024c138-faf2-432e-b5df-e46241c59a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5024c138-faf2-432e-b5df-e46241c59a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fd306f03-5dbd-4471-b5a6-a3a18d107331" xlink:href="ino-20211231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fd306f03-5dbd-4471-b5a6-a3a18d107331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7c97a477-8617-49a5-b3d2-b71565ebb66a" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7c97a477-8617-49a5-b3d2-b71565ebb66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f0d8a1d0-7f58-4355-8819-bb36635d8dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f0d8a1d0-7f58-4355-8819-bb36635d8dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_1ae8a694-b9ad-4ad7-b5db-94c93f6d8a5c" xlink:href="ino-20211231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_1ae8a694-b9ad-4ad7-b5db-94c93f6d8a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_4849a844-8774-4519-b06e-9889e9beab28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_4849a844-8774-4519-b06e-9889e9beab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffbb27cf-a7d6-428d-a20b-327ed1544f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ffbb27cf-a7d6-428d-a20b-327ed1544f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_bb858bca-5fb3-4660-8e34-82773b7db87b" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_bb858bca-5fb3-4660-8e34-82773b7db87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d84a1954-e2f9-4d63-81e9-0256fd80effc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensation_d84a1954-e2f9-4d63-81e9-0256fd80effc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0ec46dc3-fa3a-4fae-a8eb-61b482cf061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0ec46dc3-fa3a-4fae-a8eb-61b482cf061c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8eeda121-cb3a-4727-b01a-9e7e094d8301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8eeda121-cb3a-4727-b01a-9e7e094d8301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4971deff-771d-4517-821c-035b99137631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4971deff-771d-4517-821c-035b99137631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2994b24-44f9-4b5d-9518-3b93814ccce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2994b24-44f9-4b5d-9518-3b93814ccce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_be994c94-dfb1-4d06-b788-d7bb336c754f" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_be994c94-dfb1-4d06-b788-d7bb336c754f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_763b0900-3db0-46d7-83a7-a9753f3b668f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_763b0900-3db0-46d7-83a7-a9753f3b668f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_6eb65245-b7e7-4bfe-a3bc-158b5d4c0c37" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_6eb65245-b7e7-4bfe-a3bc-158b5d4c0c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_71f9647a-c4a2-4148-80b5-d280845c6c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_71f9647a-c4a2-4148-80b5-d280845c6c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2f9b38d9-9d24-41f6-9ca3-a91d766b514e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2f9b38d9-9d24-41f6-9ca3-a91d766b514e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_9ff314e6-0a7f-4e20-874b-951b45bb5357" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_9ff314e6-0a7f-4e20-874b-951b45bb5357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cc7e4083-958e-4227-a057-2dc4d37cc0b5" xlink:href="ino-20211231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cc7e4083-958e-4227-a057-2dc4d37cc0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6f319461-be9a-4924-bda0-9e25ceb4bbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6f319461-be9a-4924-bda0-9e25ceb4bbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6ff3a2e9-74b6-4943-a242-c31f0d101710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_6ff3a2e9-74b6-4943-a242-c31f0d101710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51ee45f7-ef7a-4a06-a351-59a281cea0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51ee45f7-ef7a-4a06-a351-59a281cea0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d4d2b53-19d5-40fa-be9e-fe15d2996cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d4d2b53-19d5-40fa-be9e-fe15d2996cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6a6a1b97-3b6b-4390-bed1-878dad6616cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6a6a1b97-3b6b-4390-bed1-878dad6616cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4ea8dab4-6c1a-4147-aa3b-5a2cefb44bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4ea8dab4-6c1a-4147-aa3b-5a2cefb44bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5bd9e5b3-345d-4b7f-bdfa-103425517981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5bd9e5b3-345d-4b7f-bdfa-103425517981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d59d8d8a-0dfb-485d-b020-7bf454598843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d59d8d8a-0dfb-485d-b020-7bf454598843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28c8e7bb-04c5-49fa-9aca-94c05cf0f9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_28c8e7bb-04c5-49fa-9aca-94c05cf0f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_80ea6d68-1ed4-4cea-a021-927f74a20bb8" xlink:href="ino-20211231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8cefb615-77cb-4fe5-a3f3-261a21828461" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_80ea6d68-1ed4-4cea-a021-927f74a20bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_70000c47-2cd0-4ee8-893f-a0707f5d0ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_70000c47-2cd0-4ee8-893f-a0707f5d0ebd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_34d8b463-2bbb-43fa-aa74-655f7838381d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0fa10ded-1d8a-4825-8a72-ebe190dea10a" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesOneMember_0fa10ded-1d8a-4825-8a72-ebe190dea10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_3d5d6ad7-dce3-46ef-9c27-a687c596823b" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_3d5d6ad7-dce3-46ef-9c27-a687c596823b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_2c074abb-7744-42f3-ba81-6c9e4a2ffd6f" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_2c074abb-7744-42f3-ba81-6c9e4a2ffd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_d86d2568-ed52-420a-9d7b-f9498afd102b" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesFourMember_d86d2568-ed52-420a-9d7b-f9498afd102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_c09dc0ed-ce99-4ec5-a1ca-06475c9c92da" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_c09dc0ed-ce99-4ec5-a1ca-06475c9c92da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_c73c94bf-622e-433a-8e77-b6284bedb266" xlink:href="ino-20211231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_c9d1c1f0-5591-419a-9424-42e3db6458f1" xlink:to="loc_ino_RangeOfExercisePricesSixMember_c73c94bf-622e-433a-8e77-b6284bedb266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c060df3-1fbb-4249-b21b-6f214466d785" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ab3af928-9431-41a0-b6de-38bc27b5af91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ab3af928-9431-41a0-b6de-38bc27b5af91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ff0885fc-4b4b-494f-adc4-b27efec50e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ff0885fc-4b4b-494f-adc4-b27efec50e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_02e27cef-b143-4d6e-98e4-cdda2a3fa38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_02e27cef-b143-4d6e-98e4-cdda2a3fa38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_38bee63f-90d2-4ba4-9077-05adb73717fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_38bee63f-90d2-4ba4-9077-05adb73717fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_75f778e1-c3a6-4b62-8579-fd05b82c16a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_75f778e1-c3a6-4b62-8579-fd05b82c16a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2a672965-8aaf-4429-9f35-3a8fa03a8edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2a672965-8aaf-4429-9f35-3a8fa03a8edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9a94c8aa-a11c-4f61-be2e-13025ae6b893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_a3ac9c03-aea0-4281-a98d-bd379889ecb3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9a94c8aa-a11c-4f61-be2e-13025ae6b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_31078184-4de0-46ca-bc0a-dca5e2128b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_31078184-4de0-46ca-bc0a-dca5e2128b51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c47d22e6-ffdb-4b44-8c46-0b61f682dc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c47d22e6-ffdb-4b44-8c46-0b61f682dc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6570041-4c90-4077-8eb8-10159d689b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6570041-4c90-4077-8eb8-10159d689b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e7dec9b-42f7-4768-8e30-2be1d9f179cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e7dec9b-42f7-4768-8e30-2be1d9f179cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9d42d698-faf1-415d-b351-d4c861dc1f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9d42d698-faf1-415d-b351-d4c861dc1f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8ad75c83-f6e7-4646-a2b8-8a2d1ff20480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_154bd16e-422d-4b86-ad25-05e608329154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8ad75c83-f6e7-4646-a2b8-8a2d1ff20480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_31078184-4de0-46ca-bc0a-dca5e2128b51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_562b0efe-bb30-4113-a225-86ca37dfde03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_562b0efe-bb30-4113-a225-86ca37dfde03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2ddb78a5-97ce-400a-9721-a67c6f491fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2ddb78a5-97ce-400a-9721-a67c6f491fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4238add2-e957-4239-9e87-c7cd44d40015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4238add2-e957-4239-9e87-c7cd44d40015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1e5abf45-e0c8-4dd8-84a8-f6c7eabe1b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1e5abf45-e0c8-4dd8-84a8-f6c7eabe1b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2ad16231-d48e-471a-a31a-c3812862fe40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0e62fa0c-cba2-431c-a09b-cba0a47d5b85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2ad16231-d48e-471a-a31a-c3812862fe40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ccd17b53-9613-42d3-897a-cc3f876d9f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ccd17b53-9613-42d3-897a-cc3f876d9f87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:to="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_527dc4d8-af5c-4a5e-bc36-b44838b7adcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_91159ce0-ac76-47b0-bb34-5962782b553e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_527dc4d8-af5c-4a5e-bc36-b44838b7adcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6288013f-07cf-4835-8a4f-f82864111049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_527dc4d8-af5c-4a5e-bc36-b44838b7adcf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6288013f-07cf-4835-8a4f-f82864111049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72952c29-cc28-4254-9fdf-a34da04ddc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ef67bd8-93d2-413c-bee4-f9cd79dbc360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72952c29-cc28-4254-9fdf-a34da04ddc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72952c29-cc28-4254-9fdf-a34da04ddc57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505b4aae-462b-42fa-9914-1d1cd283bdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_505b4aae-462b-42fa-9914-1d1cd283bdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6997e6f3-ee39-45ff-aab2-d19c78e9211c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6997e6f3-ee39-45ff-aab2-d19c78e9211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7e3b9eaf-4375-4133-a9f6-b1b0bfb8c96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7e3b9eaf-4375-4133-a9f6-b1b0bfb8c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c4ec315-ffd9-47f6-a58b-c35d972c5d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7c4ec315-ffd9-47f6-a58b-c35d972c5d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ac9fc46-cafc-41c8-9458-e424aea59fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b20a5245-5e29-48b9-b1ef-3615c8be0cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ac9fc46-cafc-41c8-9458-e424aea59fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2b5ef73f-8f86-4d8b-8f86-470054392729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ee18da47-ebeb-495b-9118-376c5bc3d29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b5ef73f-8f86-4d8b-8f86-470054392729" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ee18da47-ebeb-495b-9118-376c5bc3d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_252f19e3-4a96-4278-9779-4bf16269e70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe88232b-4fac-428d-8db5-1ad1644d7fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_252f19e3-4a96-4278-9779-4bf16269e70a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fe88232b-4fac-428d-8db5-1ad1644d7fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0264640e-8938-4539-863b-b906b85f8427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0264640e-8938-4539-863b-b906b85f8427" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_9d5a9980-3247-4c3e-9e0b-de50d481d4cb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_de8a48ff-dd5e-4aff-ab77-74841b5b6ccd" xlink:href="ino-20211231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:to="loc_ino_SanDiegoCaliforniaMember_de8a48ff-dd5e-4aff-ab77-74841b5b6ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_b2438091-470e-4ff4-a266-b80e4b7e81ea" xlink:href="ino-20211231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_de39b724-29f4-4f42-975b-c878b8383f69" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_b2438091-470e-4ff4-a266-b80e4b7e81ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:to="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28e460e3-9e67-4c04-9d95-9c5c12ec99a4" xlink:to="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8816f714-5c4d-434e-8d89-870dde5d38c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:to="loc_srt_MinimumMember_8816f714-5c4d-434e-8d89-870dde5d38c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d10b9b53-057a-40b8-93e7-0cd01fa03a36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0c449ff8-e709-4fda-a7f0-561a59ba74e0" xlink:to="loc_srt_MaximumMember_d10b9b53-057a-40b8-93e7-0cd01fa03a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ac8bb244-a5ee-440d-9909-eeb2c2324e64" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_8803c724-a01c-4867-8a81-dbebc6e789a6" xlink:href="ino-20211231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_8803c724-a01c-4867-8a81-dbebc6e789a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_36b4ecf4-57d4-492e-be79-c50fc2eb5496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_36b4ecf4-57d4-492e-be79-c50fc2eb5496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a1ec1e5d-b47c-40b2-a704-67a9a9a88d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_LeaseCost_a1ec1e5d-b47c-40b2-a704-67a9a9a88d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_c5385a26-ca41-4b51-9fca-fb1ed3cf628e" xlink:href="ino-20211231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_c5385a26-ca41-4b51-9fca-fb1ed3cf628e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_5d2a68d0-6ba6-4970-b957-c9283f52d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_91504eef-14f7-4228-a31c-5bcb46e20a59" xlink:to="loc_us-gaap_PurchaseObligation_5d2a68d0-6ba6-4970-b957-c9283f52d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_3453f1da-3999-407c-92f9-601fb4d03fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_3453f1da-3999-407c-92f9-601fb4d03fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5dba55b2-657f-4ae7-b90d-3deb2e53d35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5dba55b2-657f-4ae7-b90d-3deb2e53d35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0d10f443-7eac-487f-88c3-f39ae1dd782c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0d10f443-7eac-487f-88c3-f39ae1dd782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4799c2ba-e583-4fee-a93a-ed623150838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4799c2ba-e583-4fee-a93a-ed623150838c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_23827cc8-8bfa-4d69-b8c5-58208529e925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_23827cc8-8bfa-4d69-b8c5-58208529e925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ae0f82f2-b1ab-4252-995e-060ec5b0214a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ae0f82f2-b1ab-4252-995e-060ec5b0214a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44eadac4-f625-4600-aa19-6c69a736feb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44eadac4-f625-4600-aa19-6c69a736feb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5523070-29d9-46e2-adf1-0482c5f62761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5523070-29d9-46e2-adf1-0482c5f62761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4d4017d7-c106-4270-b020-76a38e4b2de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_OperatingLeaseLiability_4d4017d7-c106-4270-b020-76a38e4b2de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d397213-649e-4551-b61e-478f10de701c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d397213-649e-4551-b61e-478f10de701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ef2508c9-bdc4-4469-aed6-d428428219fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ef2508c9-bdc4-4469-aed6-d428428219fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dbd950f4-0b12-4289-8cc4-1eff336b23e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_dbd950f4-0b12-4289-8cc4-1eff336b23e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dbcfe473-b49f-405f-b74b-7ea7cfa885be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d97a4bc7-f536-469f-b841-4e62c2cdc026" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dbcfe473-b49f-405f-b74b-7ea7cfa885be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20211231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_65e98047-1392-427f-a431-e618c742c23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ae1028a5-94aa-4adb-9054-d51c4c26d654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_65e98047-1392-427f-a431-e618c742c23d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ae1028a5-94aa-4adb-9054-d51c4c26d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9ec9ed-56b4-4624-8d7c-6a88f7ebb05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d1f8e0bb-bb6c-4e17-81a9-46bff63cbb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9ec9ed-56b4-4624-8d7c-6a88f7ebb05e" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d1f8e0bb-bb6c-4e17-81a9-46bff63cbb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7f6f70f8-3e71-4b4a-b93e-91cb252c4395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9ec9ed-56b4-4624-8d7c-6a88f7ebb05e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7f6f70f8-3e71-4b4a-b93e-91cb252c4395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5221b8cb-e6b6-42a4-9b96-c2ba654c872e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9ec9ed-56b4-4624-8d7c-6a88f7ebb05e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5221b8cb-e6b6-42a4-9b96-c2ba654c872e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_ebb317e5-05f7-4b96-adac-c973775af67d" xlink:href="ino-20211231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9ec9ed-56b4-4624-8d7c-6a88f7ebb05e" xlink:to="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_ebb317e5-05f7-4b96-adac-c973775af67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2e7d2966-a201-41da-82c8-10c05c5cfd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac9ec9ed-56b4-4624-8d7c-6a88f7ebb05e" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2e7d2966-a201-41da-82c8-10c05c5cfd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46331147-293a-4667-98a1-07bc4b0ef2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d13cecc8-86c0-451a-93f6-0c966f610966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46331147-293a-4667-98a1-07bc4b0ef2ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d13cecc8-86c0-451a-93f6-0c966f610966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_55121c91-1ded-40c0-b78a-2950dcd40057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46331147-293a-4667-98a1-07bc4b0ef2ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_55121c91-1ded-40c0-b78a-2950dcd40057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3418082c-c6ba-4fd3-b195-df2048903515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46331147-293a-4667-98a1-07bc4b0ef2ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3418082c-c6ba-4fd3-b195-df2048903515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_30361c8e-dac3-4ff0-b909-98ae4745a17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30361c8e-dac3-4ff0-b909-98ae4745a17f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b4e2057b-53e4-4b2b-b98d-b4c9b44272d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b4e2057b-53e4-4b2b-b98d-b4c9b44272d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_454b0f97-f7fa-477e-8820-e60883c09000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_454b0f97-f7fa-477e-8820-e60883c09000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_fcfb24f2-1ead-4574-9d73-9f12ad4dab93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_fcfb24f2-1ead-4574-9d73-9f12ad4dab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_a6f47f2f-83a9-4f59-b863-16f9a644b948" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_a6f47f2f-83a9-4f59-b863-16f9a644b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_236941e4-e877-4f31-b5ad-976299a80c55" xlink:href="ino-20211231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_236941e4-e877-4f31-b5ad-976299a80c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_63237f5b-e393-40f4-8c03-8bde8757012c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_63237f5b-e393-40f4-8c03-8bde8757012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_194425f0-3211-4bb7-bb76-a140773e4292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_194425f0-3211-4bb7-bb76-a140773e4292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_80cb20f7-bcbb-4eec-ac5c-f0ac14e3f4df" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_80cb20f7-bcbb-4eec-ac5c-f0ac14e3f4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5637e2b7-699d-48ea-bc74-13b3376e4d85" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5637e2b7-699d-48ea-bc74-13b3376e4d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_dc9ffb7d-a023-4dac-84d0-67c6f68e480e" xlink:href="ino-20211231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_dc9ffb7d-a023-4dac-84d0-67c6f68e480e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_bd7876bf-a35b-4aa6-aa9b-649ab0ab804f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_bd7876bf-a35b-4aa6-aa9b-649ab0ab804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5404f56a-d593-4c06-ac9f-e9c594eb6db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_5404f56a-d593-4c06-ac9f-e9c594eb6db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_d7b89d9f-3d2f-4207-8138-31f1acf3ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_d7b89d9f-3d2f-4207-8138-31f1acf3ee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_f9d2dd1b-886c-4255-820e-a348e08eac1f" xlink:href="ino-20211231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3ece1a2d-2410-4bbd-b0b1-50f56a44d30c" xlink:to="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_f9d2dd1b-886c-4255-820e-a348e08eac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_98780838-f731-41e6-bd0d-641a0e0e2545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_98780838-f731-41e6-bd0d-641a0e0e2545" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35dcbb06-5e0b-4bf5-9abb-f1d40ba04c6d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_41344b81-5d46-4170-9052-e85118b3343a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_41344b81-5d46-4170-9052-e85118b3343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_ca2caf05-728b-46fb-a772-ce2c63ccc2ec" xlink:href="ino-20211231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_ca2caf05-728b-46fb-a772-ce2c63ccc2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_dae43b95-8f42-4db1-b6d9-bc996be0a104" xlink:href="ino-20211231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_dae43b95-8f42-4db1-b6d9-bc996be0a104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_b8cdde0d-0efe-40eb-beb2-2140258c04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_b8cdde0d-0efe-40eb-beb2-2140258c04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember_f936349b-4a05-4880-aa54-37897c559442" xlink:href="ino-20211231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d6bcce2e-20f6-4b55-bce8-b832f616bc09" xlink:to="loc_ino_KoreanStateIncomeTaxAuthorityMember_f936349b-4a05-4880-aa54-37897c559442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_153892d8-84d5-45a7-93f0-42eb3d182f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_db7a0780-5f03-4964-8258-88a77dad49c2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_153892d8-84d5-45a7-93f0-42eb3d182f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fd5c2de3-22ad-41fe-a6f9-c2b505327c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_153892d8-84d5-45a7-93f0-42eb3d182f48" xlink:to="loc_us-gaap_ResearchMember_fd5c2de3-22ad-41fe-a6f9-c2b505327c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c1be2d22-6f54-41bd-a8df-ee5c1b3428c2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_31e670e1-3884-4895-a680-e99a6bbe2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_31e670e1-3884-4895-a680-e99a6bbe2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_94e78c54-ac70-4ec3-8e32-708c669bc6b0" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_94e78c54-ac70-4ec3-8e32-708c669bc6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9817a71c-fb91-499e-a7e6-29a2744b3a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9817a71c-fb91-499e-a7e6-29a2744b3a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_56b5b8ed-65a4-4ead-b8a0-b84c3d77600f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_56b5b8ed-65a4-4ead-b8a0-b84c3d77600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_b0a5ca69-e180-436b-ba30-0ceb12e3450a" xlink:href="ino-20211231.xsd#ino_TaxBenefitsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_ino_TaxBenefitsExpired_b0a5ca69-e180-436b-ba30-0ceb12e3450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a583a847-2013-4db1-8e98-26aa8d3488d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_432e28f4-2ef1-48ee-affa-ad58f41bb6a0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a583a847-2013-4db1-8e98-26aa8d3488d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21b046b7-908d-482b-a2a3-d6ffcb6097fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21b046b7-908d-482b-a2a3-d6ffcb6097fe" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa31b960-f190-4c0d-b335-bc09f4dd5c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa31b960-f190-4c0d-b335-bc09f4dd5c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6f10773d-51f9-4f1c-9ea4-11259d8ec2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6f10773d-51f9-4f1c-9ea4-11259d8ec2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_cea6c0a4-c925-467b-8004-b1185f42ce5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_cea6c0a4-c925-467b-8004-b1185f42ce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1b655546-847e-42a3-9225-c1350781b026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1b655546-847e-42a3-9225-c1350781b026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c6b37fb3-8ed3-401e-bf7a-83edaaddc7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c6b37fb3-8ed3-401e-bf7a-83edaaddc7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_9b3eca98-2b7b-425e-b418-5c60e80e35f5" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_9b3eca98-2b7b-425e-b418-5c60e80e35f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_400abade-b78c-4c8f-862f-7696a06c22d3" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_400abade-b78c-4c8f-862f-7696a06c22d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_5cb99374-8e3c-4997-8d9a-d8cfb0e02a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_5cb99374-8e3c-4997-8d9a-d8cfb0e02a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_fe1fb231-3082-45b5-ae55-fe3a3babfa3e" xlink:href="ino-20211231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_fe1fb231-3082-45b5-ae55-fe3a3babfa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9af5dc88-bbf2-4d3c-971b-1c242664b014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9af5dc88-bbf2-4d3c-971b-1c242664b014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bd96bfda-904f-430a-84cb-6c176ce2d287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bd96bfda-904f-430a-84cb-6c176ce2d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_43be047c-d5a1-4d17-94ed-341759832eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_43be047c-d5a1-4d17-94ed-341759832eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_97236134-fc1d-4544-afdd-a5b813180b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_24830d04-9575-45a0-adea-33609d8282d7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_97236134-fc1d-4544-afdd-a5b813180b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ca49409c-966a-40de-8376-3857fea48886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21b046b7-908d-482b-a2a3-d6ffcb6097fe" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ca49409c-966a-40de-8376-3857fea48886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2892ed57-aaae-491b-86de-2655dd0f9974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ca49409c-966a-40de-8376-3857fea48886" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2892ed57-aaae-491b-86de-2655dd0f9974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_0533bef6-df81-458d-962b-125d33d56fcc" xlink:href="ino-20211231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ca49409c-966a-40de-8376-3857fea48886" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_0533bef6-df81-458d-962b-125d33d56fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_3a5a783b-a422-4c60-8ed5-9e69a902ce55" xlink:href="ino-20211231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ca49409c-966a-40de-8376-3857fea48886" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_3a5a783b-a422-4c60-8ed5-9e69a902ce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3fe0f1a8-4240-4752-869c-9e9daf0e3d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ca49409c-966a-40de-8376-3857fea48886" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3fe0f1a8-4240-4752-869c-9e9daf0e3d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_18c614e5-ea82-4f78-b379-d3ff06d50666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21b046b7-908d-482b-a2a3-d6ffcb6097fe" xlink:to="loc_us-gaap_DeferredTaxLiabilities_18c614e5-ea82-4f78-b379-d3ff06d50666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d7a24796-8f75-4ed8-9132-ca15c8dc72fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d7a24796-8f75-4ed8-9132-ca15c8dc72fd" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7a822c72-eba2-49b5-8094-2f9a5d327077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_14316283-2316-4174-bb09-b99bbb842ed5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7a822c72-eba2-49b5-8094-2f9a5d327077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_90f8fcc7-3bf3-49b9-add0-f84533e67bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7a822c72-eba2-49b5-8094-2f9a5d327077" xlink:to="loc_us-gaap_ResearchMember_90f8fcc7-3bf3-49b9-add0-f84533e67bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f25e2e97-af8a-49b7-8e04-b0abdded5c46" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_54b84a37-2e4d-4ef0-a0d7-245374c2fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:to="loc_us-gaap_DomesticCountryMember_54b84a37-2e4d-4ef0-a0d7-245374c2fff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_15ec1e32-6907-4c21-bfb1-fccc4c249542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_15ec1e32-6907-4c21-bfb1-fccc4c249542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d7e60042-3c6e-41d8-a0b8-c70de5d9c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7af6733d-400f-45b7-827f-e7e79f1e78d2" xlink:to="loc_us-gaap_ForeignCountryMember_d7e60042-3c6e-41d8-a0b8-c70de5d9c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_778cff94-7f60-4660-b92d-f4b669ca88c6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_b005aef7-5cf7-430c-ae48-fab455c68261" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_b005aef7-5cf7-430c-ae48-fab455c68261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_0ca06486-2c80-4a1b-9629-3744a2916569" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_0ca06486-2c80-4a1b-9629-3744a2916569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_93187f78-6683-43ee-a12d-8e4a22ffc753" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_93187f78-6683-43ee-a12d-8e4a22ffc753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_e18e4dd4-180b-48a6-b35c-93efe24e5a79" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_e18e4dd4-180b-48a6-b35c-93efe24e5a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d16df74f-f79c-4c0e-bbcc-9379da9ba975" xlink:href="ino-20211231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_d16df74f-f79c-4c0e-bbcc-9379da9ba975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1d3d65ff-b926-4781-9186-b8959fcfc952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_237b8119-b591-4321-9124-9c5e8c1f4925" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1d3d65ff-b926-4781-9186-b8959fcfc952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8b5c55cf-6ce3-4d84-9876-1b55bd846a3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_0bd990dd-fb45-4862-886a-f7a5d6d82f94" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_0bd990dd-fb45-4862-886a-f7a5d6d82f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_b0b0fef5-cc81-4b2e-8e69-80a6691aee5f" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_b0b0fef5-cc81-4b2e-8e69-80a6691aee5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_e75191fc-e0d2-467b-8072-711cd2b403c0" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_e75191fc-e0d2-467b-8072-711cd2b403c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_68378e51-5354-43f6-b3bc-fe8fd724ccff" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_68378e51-5354-43f6-b3bc-fe8fd724ccff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_55d6dbe8-144b-4f2b-b0a4-4ae952f348fa" xlink:href="ino-20211231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_55d6dbe8-144b-4f2b-b0a4-4ae952f348fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_261a18cc-a309-48d0-87ad-27c006660375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_fef2e69f-3556-400e-8a64-40bfd1a0bbbb" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_261a18cc-a309-48d0-87ad-27c006660375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d72031e7-dccb-4e5c-9205-965a11d06fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d72031e7-dccb-4e5c-9205-965a11d06fd2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_41f24cba-fc78-4b6f-ae75-3703826f5a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_41f24cba-fc78-4b6f-ae75-3703826f5a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_fff135c2-98b0-488b-9b2e-e2742e180059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_fff135c2-98b0-488b-9b2e-e2742e180059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e2191466-66c4-468d-927c-8747de03646e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e2191466-66c4-468d-927c-8747de03646e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bf28a55c-f84f-4c38-b04c-59646f4a1db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_bf28a55c-f84f-4c38-b04c-59646f4a1db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_a81884ee-902f-4105-afb6-19ddaa4d0e1f" xlink:href="ino-20211231.xsd#ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:to="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_a81884ee-902f-4105-afb6-19ddaa4d0e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7169b7ed-bf68-445b-a108-e4b90c7ad2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_09729664-19f2-4e02-9c65-403d04ed5daa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7169b7ed-bf68-445b-a108-e4b90c7ad2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20211231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c5893c8d-f433-429c-af8d-320f6e9d3494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_88c44dc9-b3ff-4aaa-82e7-ffad96f7bcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c5893c8d-f433-429c-af8d-320f6e9d3494" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_88c44dc9-b3ff-4aaa-82e7-ffad96f7bcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9b503bb7-3030-47a6-94df-4078653cd539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_342569a6-bd91-4be4-8575-ffeb65101850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9b503bb7-3030-47a6-94df-4078653cd539" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_342569a6-bd91-4be4-8575-ffeb65101850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_dcd3110b-f7b6-44f6-81b1-0bee0aef048b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9b503bb7-3030-47a6-94df-4078653cd539" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_dcd3110b-f7b6-44f6-81b1-0bee0aef048b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_02538bf2-6372-4d33-a1e6-2a3315a4f848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9b503bb7-3030-47a6-94df-4078653cd539" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_02538bf2-6372-4d33-a1e6-2a3315a4f848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_f0f96628-80f9-444a-a3a2-c93799eef791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_255b4e67-55c6-4ca0-8277-336305c20c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_f0f96628-80f9-444a-a3a2-c93799eef791" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_255b4e67-55c6-4ca0-8277-336305c20c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_ec1c143e-eb5a-4311-92c7-602671c62825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_ec1c143e-eb5a-4311-92c7-602671c62825" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f03d2dda-dabc-42c5-b255-88853502f250" xlink:to="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember_668b6785-bf05-4da3-b2fb-5fb0e7f04961" xlink:href="ino-20211231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:to="loc_ino_PLSaffiliatedentityMember_668b6785-bf05-4da3-b2fb-5fb0e7f04961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_651ecb93-7ca3-434c-afe8-68a5b2c7a652" xlink:href="ino-20211231.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:to="loc_ino_TheWistarInstituteMember_651ecb93-7ca3-434c-afe8-68a5b2c7a652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_476d2d02-a895-43b0-a897-d5ebd914a140" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_eaaa71d3-bcc2-46e5-acfc-2b33fe194a2e" xlink:to="loc_srt_DirectorMember_476d2d02-a895-43b0-a897-d5ebd914a140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c1c4df6d-21c5-4c3c-b7cd-a460e660264a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_084d2ec0-d3aa-42e1-8c56-46803a36ff44" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c1c4df6d-21c5-4c3c-b7cd-a460e660264a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_d3a787ce-c649-4918-a2c8-ca70eac67135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_c1c4df6d-21c5-4c3c-b7cd-a460e660264a" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_d3a787ce-c649-4918-a2c8-ca70eac67135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_730dbeaf-6420-4ea6-9f64-7d18a0935bde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c312e11f-a7b6-4e24-86e7-644d8f3ec397" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_730dbeaf-6420-4ea6-9f64-7d18a0935bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_31e036d0-fd18-4769-ad67-ffdb2789e69f" xlink:href="ino-20211231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_730dbeaf-6420-4ea6-9f64-7d18a0935bde" xlink:to="loc_ino_PlumblineLifeSciencesMember_31e036d0-fd18-4769-ad67-ffdb2789e69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0ccdc1da-246b-407b-9693-48786c09eaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3f907f73-4643-49c4-b6ca-3753b0628b8b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0ccdc1da-246b-407b-9693-48786c09eaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3d3bb3ab-1ff7-42e7-a075-fe09c3f5e9dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0ccdc1da-246b-407b-9693-48786c09eaec" xlink:to="loc_srt_DirectorMember_3d3bb3ab-1ff7-42e7-a075-fe09c3f5e9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ee662d85-16b0-4b4c-80cc-a8f9c705000f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_af58f954-dc0c-42ec-8a61-f3e01f465f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_af58f954-dc0c-42ec-8a61-f3e01f465f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4661f4fe-fff8-432c-b5b7-52cde7b2c96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4661f4fe-fff8-432c-b5b7-52cde7b2c96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_3813c071-ce99-4846-ae7a-0f79d7326313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_RevenueFromRelatedParties_3813c071-ce99-4846-ae7a-0f79d7326313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_1127339b-3520-4b5b-bb72-e8bc3b601083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_1127339b-3520-4b5b-bb72-e8bc3b601083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_e2e0aaad-ab5f-4783-9f5e-4f1dc09a22cd" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_e2e0aaad-ab5f-4783-9f5e-4f1dc09a22cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_52c85465-c503-43ff-8bc0-5bb1d031921e" xlink:href="ino-20211231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeArrangementTerm_52c85465-c503-43ff-8bc0-5bb1d031921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSubGrant_6991632e-28e8-44e1-9ec5-2765a6aed740" xlink:href="ino-20211231.xsd#ino_ProceedsFromSubGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_ProceedsFromSubGrant_6991632e-28e8-44e1-9ec5-2765a6aed740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_340e5b76-ad2b-4cca-81fc-60886d48fcc0" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_340e5b76-ad2b-4cca-81fc-60886d48fcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_cc4a5147-ba38-4000-8927-d090789340e6" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_cc4a5147-ba38-4000-8927-d090789340e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_fe8a719c-2ce3-4b0f-97e5-0f037cbb435e" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_fe8a719c-2ce3-4b0f-97e5-0f037cbb435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_81330181-441c-4d05-bd3a-0ee12a8e07cd" xlink:href="ino-20211231.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_81330181-441c-4d05-bd3a-0ee12a8e07cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_c6aed076-eaf4-43b4-ae0b-e6ba2f1f49bb" xlink:href="ino-20211231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_GrantProceedsReceived_c6aed076-eaf4-43b4-ae0b-e6ba2f1f49bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7fa5075e-31bb-4ec9-9f9d-7783d0675bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7fa5075e-31bb-4ec9-9f9d-7783d0675bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_dd209e26-8e26-4624-bfe3-03b1742eaa13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_dd209e26-8e26-4624-bfe3-03b1742eaa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1a97d160-08e6-464d-b788-df403f4ae2be" xlink:href="ino-20211231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_1a97d160-08e6-464d-b788-df403f4ae2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_cf861597-8a1f-4777-a199-464f9766e471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_af17d991-af8c-4c12-9d2d-cf4d1cd64047" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_cf861597-8a1f-4777-a199-464f9766e471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_40e094a7-9536-4bfb-a8b5-0598e61a24ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e659a756-c158-4ec0-9ae9-f71b25b95f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_40e094a7-9536-4bfb-a8b5-0598e61a24ac" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e659a756-c158-4ec0-9ae9-f71b25b95f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_a4baf08b-8aa9-42dd-a5f2-83598b8e7810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_0f835b01-d45d-44a9-a28e-eeb54e1408af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_a4baf08b-8aa9-42dd-a5f2-83598b8e7810" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_0f835b01-d45d-44a9-a28e-eeb54e1408af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cb1ce0fb-ece1-4ae3-8fe6-adbc519dcda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_a4baf08b-8aa9-42dd-a5f2-83598b8e7810" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cb1ce0fb-ece1-4ae3-8fe6-adbc519dcda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_8a626e3b-f8cb-4a37-b991-175be7a0dc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_8a626e3b-f8cb-4a37-b991-175be7a0dc4d" xlink:to="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61788697-dcc4-46a5-9662-b755c2f17c91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9d953fd9-f454-4fe2-9279-8d211a88ed79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61788697-dcc4-46a5-9662-b755c2f17c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_c1c99548-9398-4cb7-b747-8abc64a14188" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_61788697-dcc4-46a5-9662-b755c2f17c91" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_c1c99548-9398-4cb7-b747-8abc64a14188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6016eba0-674a-4638-ab1a-a8349d22c806" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6d6f3165-39f0-499c-acac-29a37c8a6a20" xlink:to="loc_srt_OwnershipDomain_6016eba0-674a-4638-ab1a-a8349d22c806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_ed70db03-b605-4bb4-9338-acac1a91b378" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6016eba0-674a-4638-ab1a-a8349d22c806" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_ed70db03-b605-4bb4-9338-acac1a91b378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f2dd4cb5-82e6-4cf7-89e0-8b03782a6a69" xlink:to="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1a72f166-18a5-4f5d-9ca0-357a5bee4163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:to="loc_us-gaap_CommonStockMember_1a72f166-18a5-4f5d-9ca0-357a5bee4163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_b1485532-dbca-4c5e-9204-4f9a724b3b7a" xlink:href="ino-20211231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec3d38d3-4579-4da0-8d33-b0f850cac150" xlink:to="loc_ino_SeriesAOnePreferredStockMember_b1485532-dbca-4c5e-9204-4f9a724b3b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_44f5a9b1-9455-4a00-90ca-d578e961e042" xlink:to="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ba209c62-8526-4874-a1d2-94c28fb52e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ba209c62-8526-4874-a1d2-94c28fb52e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d647a8b6-3d0f-483b-9420-ad90fc011258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d647a8b6-3d0f-483b-9420-ad90fc011258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0030ad31-b462-4595-bd04-82e846235183" xlink:href="ino-20211231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0030ad31-b462-4595-bd04-82e846235183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c2380358-eb77-49a9-920f-ada7d8434423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c2380358-eb77-49a9-920f-ada7d8434423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_bd341e4c-8d5a-485a-8979-7ee669bf5dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_bd341e4c-8d5a-485a-8979-7ee669bf5dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424537a2-1db0-425f-93c9-6a215f80370c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_424537a2-1db0-425f-93c9-6a215f80370c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_3115216b-5d47-4f1c-87d0-53fb88ab20ef" xlink:href="ino-20211231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_3115216b-5d47-4f1c-87d0-53fb88ab20ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bae863bc-04a9-4cf2-87e3-4b2621ad931e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bae863bc-04a9-4cf2-87e3-4b2621ad931e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1ede6167-7989-49f7-ba7f-c7ab7c4668ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5caea958-92f3-47a7-af70-40e87a370153" xlink:to="loc_us-gaap_EquityMethodInvestments_1ede6167-7989-49f7-ba7f-c7ab7c4668ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_42814b9e-6d65-47d8-8fe4-00035fc26d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_42814b9e-6d65-47d8-8fe4-00035fc26d87" xlink:to="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:to="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7988aef2-50e7-4d5b-b117-8d9fb2e9a34d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e2fc2d5f-f7c2-4cd3-8b49-da9bbe5877c5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7988aef2-50e7-4d5b-b117-8d9fb2e9a34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_af649411-f73e-4e28-8284-a6e4d2e29a58" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7988aef2-50e7-4d5b-b117-8d9fb2e9a34d" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_af649411-f73e-4e28-8284-a6e4d2e29a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_a4d72fed-e740-462c-939f-23cd190faaef" xlink:to="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_02069f10-33cc-48bc-b70f-a63941868b31" xlink:href="ino-20211231.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_ino_WorkingCapitalExcludingCash_02069f10-33cc-48bc-b70f-a63941868b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f56ec773-ddf4-42c8-9d97-f9d03435b3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_NotesPayable_f56ec773-ddf4-42c8-9d97-f9d03435b3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a80a38ce-ff22-4c31-98ea-2dfc2a6feeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a80a38ce-ff22-4c31-98ea-2dfc2a6feeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_95cd62c1-0b2d-484a-9302-834003952715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_MinorityInterest_95cd62c1-0b2d-484a-9302-834003952715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_f5346af7-b7af-4137-9721-82e25b5f0fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_f5346af7-b7af-4137-9721-82e25b5f0fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_120ae703-98bc-4f9d-b99f-43c953397e93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_120ae703-98bc-4f9d-b99f-43c953397e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_47b5ab55-440d-49b4-82bb-502974ed1d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_05048784-4c2a-4642-a66f-a50f080a86ea" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_47b5ab55-440d-49b4-82bb-502974ed1d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncInvestmentinGeneosDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_792cb110-c90a-46fb-859d-8ad82a91614f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_792cb110-c90a-46fb-859d-8ad82a91614f" xlink:to="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:to="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9397323-83d6-4e4a-84ba-3eb5b6a01aa1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_12a7498c-4239-4949-8d17-b98bf9622a6a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9397323-83d6-4e4a-84ba-3eb5b6a01aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_20e3ac1c-ac56-43cc-bc81-0e19e8576eb5" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9397323-83d6-4e4a-84ba-3eb5b6a01aa1" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_20e3ac1c-ac56-43cc-bc81-0e19e8576eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3afb279-a5dd-413a-8942-2b62009bebb6" xlink:to="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_81640626-3d04-4cff-abe5-dbd4ad523433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:to="loc_us-gaap_CommonStockMember_81640626-3d04-4cff-abe5-dbd4ad523433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_090670fc-7718-41d5-9345-8401b691177e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_368ae36e-1513-4b30-8756-e0b9e70f2bfd" xlink:to="loc_us-gaap_PreferredClassAMember_090670fc-7718-41d5-9345-8401b691177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_0054f288-000a-427c-aa6a-036a880849b5" xlink:to="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_393b3c96-0251-46b1-bfa1-37ef0cde2acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_393b3c96-0251-46b1-bfa1-37ef0cde2acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_10c22e5e-00e2-4f9f-b4c1-a26450e5ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_SharePrice_10c22e5e-00e2-4f9f-b4c1-a26450e5ecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9606751d-d37b-4862-9dcf-a60648b959bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_2d99d477-2707-4ea5-95b3-52fea1e6fe0b" xlink:to="loc_us-gaap_EquityMethodInvestments_9606751d-d37b-4862-9dcf-a60648b959bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_cd88cb43-3707-4066-8388-214d86c346f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_cd88cb43-3707-4066-8388-214d86c346f2" xlink:to="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:to="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7a45903-19c2-4808-955e-ad655b8464e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3fd9546-e990-4755-a90d-4dc415ed3fe9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7a45903-19c2-4808-955e-ad655b8464e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_18912171-c14b-4964-b3ae-c226dbd9296e" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c7a45903-19c2-4808-955e-ad655b8464e2" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_18912171-c14b-4964-b3ae-c226dbd9296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_986d7d3f-badc-4c42-9c31-271b7b4a049a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_746bc468-ab2c-46f7-bfae-483c127d94bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_746bc468-ab2c-46f7-bfae-483c127d94bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_941f3f70-e5e2-4119-a5d7-af3e9f1548ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_941f3f70-e5e2-4119-a5d7-af3e9f1548ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8fb88211-fe4a-48aa-8538-25251dd9d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a3dee69-9ddd-46a0-9581-e24e9371be31" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8fb88211-fe4a-48aa-8538-25251dd9d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_beb47dfd-9f07-4e49-a108-fb0080cc3e07" xlink:to="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_63429f27-8896-4737-8ff6-b622ab0f9651" xlink:href="ino-20211231.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_63429f27-8896-4737-8ff6-b622ab0f9651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_841d2708-64e0-481e-9ac4-110bc88199a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_841d2708-64e0-481e-9ac4-110bc88199a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_120a3118-b3e9-4e33-a378-7b30171e0d3a" xlink:href="ino-20211231.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_198df5a2-eff8-448c-9015-003ebdfdcf34" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_120a3118-b3e9-4e33-a378-7b30171e0d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20211231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_241158ff-94d5-4a78-9bf1-de29f48446ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_241158ff-94d5-4a78-9bf1-de29f48446ed" xlink:to="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:to="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9554bd6-5cc3-4a27-b7fb-87eb7e80069c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_642d324b-421a-4d55-8a59-1ab25a812174" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9554bd6-5cc3-4a27-b7fb-87eb7e80069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_5dd062af-8a0f-4228-9548-52d886f3a337" xlink:href="ino-20211231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9554bd6-5cc3-4a27-b7fb-87eb7e80069c" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_5dd062af-8a0f-4228-9548-52d886f3a337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5aee28d5-488a-4803-80a8-dafac52898e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_29e09154-7314-4ab9-bee0-106c694f23fc" xlink:to="loc_us-gaap_ClassOfStockDomain_5aee28d5-488a-4803-80a8-dafac52898e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_4f754435-90de-4c54-9fc7-8bbd087c1dfb" xlink:href="ino-20211231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5aee28d5-488a-4803-80a8-dafac52898e2" xlink:to="loc_ino_SeriesAOnePreferredStockMember_4f754435-90de-4c54-9fc7-8bbd087c1dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_70b85d9d-24dd-4127-bc69-2983489ddf0c" xlink:to="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fc1b670a-7b68-427f-8eca-6749d17f6586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:to="loc_us-gaap_EquityMethodInvestments_fc1b670a-7b68-427f-8eca-6749d17f6586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_641fd63c-ed2b-426c-98ab-dbe60d4b3131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_641fd63c-ed2b-426c-98ab-dbe60d4b3131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b7d47ab7-c1eb-4c12-9980-9db33e353cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f6d5863f-35a1-4260-8bf0-207430675ce6" xlink:to="loc_us-gaap_EquityMethodInvestments_b7d47ab7-c1eb-4c12-9980-9db33e353cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ino-20211231_g1.jpg
<TEXT>
begin 644 ino-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
MN]HB( B(@"(B (B( B(@"(B (B( B(@(J.^B^('4GV9TE^,F.5,97.>^B^('
M4GV9TE^,F.5,9 $1$ 1$0!$1 $1$!G3V!>VQEMEM7AD1>:YI7,G5JZLPX.Y>
M/3C,FCR5*/EA'*XL9I9*S^SZS$4M*4F&4)(KO>A=<XG4V'QV?P5Z#)8?+5(K
MN/O5BZX;%>8>1,?)B$F?D)(S$9(I1.*0!D A;7-J93NHN\-?;3,!HC5UWIT%
MG;3O6NV92:+2F8LF/%SJ-WCAPUXW)LH/SL*U@PR?6(#=:8"WXB_.*43$3 A,
M#%B Q=B$A)N1(2;EB$F=G9V=V=GY;R7Z( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ
M:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^VX^Q^7_&3,JCRKPW=3_2_
M;<?8_+_C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (OX,V$7(G81%G=R)V869FY=W=_)F9O-W?W,L)M]^\>V0
MVW.6OJS<G3-7)0B[R86A>#-9P'9F<0EQ.':[=JO+SQ$5N*O')YN)\"7'CSM1
MQ\:#LR;Z<>M=YW60JA_2FXK?Y;GAU#5,;$K=N5D48U2[V7VPIA^'-9**W^6^
MYFXBKE;I>DF;5XUY8]):.UAJR0>/"GM>HZ:QTC>?/,ULKN0#SXX_Y*-G%W=W
M%VZ7P2UEZ2SN+;,_F>VVT=AH2YZ&RN5S.H)P;R_ZZM'IV$B;S?EZC"[.S=/E
MR\<:GXT\-XK<9:C"V2],>JZ]=-UTLA7Y3[>EGP?9ID7ZKX[<+8C:EJ<;I+TQ
M:,C(3_"VNITOMZ6?PZER%W1G5&#(>D!]H>R;E!-HJB#NSM'%IDIN&XXZ>JSD
M97=G?SYXY;R\^.>?AAWZW:.>;QOFAT\S=?7X#:6H>"WG_0^.MS\/Y/Z)U<?H
MN?-:K9[2'#D?3/EU],:'[^MR_P#,TV_VI>&8?=U*77;=8M27X^]DQ_JW^1>\
M14?L1W^':#B,2GGT;<#EW>.733PL_LNW'77R$1,S$[']7EN.>EW99$Z.](LW
M)@(&S>@-&Y6-OHO@^[F<-/)Y\_T6:3,0B_R>57CW>3OR[_IC^T?PQ-[3ORZ?
MVK,2QK_L7:_X#']JKA&3VLOSL=;_ &K<&R2_^'=[Z?AOT[=M[?"*O+MCZ0_H
M/(/%'JO0FI]-R&?$DV,NT-248@\O:>1X\->-_?[(8U_+WDWR2/[2=Z!L5K,H
M8<;N'A<?<G< CH:CD/3=DI#?ICB!\P-2M/-(3L(0U[$TA.["P\NS/O6C>*?#
MN>TL76,&4Y?9KMM6-:^W14Y*IM;Z]N3<D/0?&;A74W&.'KNG2G/[-5URQ+I?
M)49:HN;^2AOOT[F?:+U*-^"S&,U>:*Q";<A+!($L1M]49(R(2;]9U[:WY--;
MKJGV:[$F)IK==4^S79A$1?)\A?,S.9J8ZG;OW[$52C1K3W+EJP8QP5JE:(IK
M%B:0G88X880.20R=A$!<G?AG7TU7V](/[7MG1NV=#;73\Q/J?=*T>.LA7(O6
MZVDJG'PJ401L\A39>[)1PL(^RTE>SDB FD@$#P7$VO4Z7@96?>UY>-5*S9M+
MFEVA!-]$YS<8KX;[OH?AE9$:JY62[16_P_!;^F[V165[:_:/S':DWMR&=IG8
MBTO28L/I2*<9 CQ&D:,\IC>EKGQX60S4YG?L"3-.<UBK2D?PJ40PY/:/T+2P
MN/K8S'Q-%6JQB -[SD+CVYIBX;KFF+DY#?R(W?AF%F%N%[%[1U=%:?8;3QM?
MFC]<S%KV> , Y:L)_P#P*8,X#P_2<GB2_H_+U-4;DW)JSS8T_5(F<VB)@CDE
M,69NDS\0"$')O:81'V>7;J+CE<N^!_!7C?Q[XAU2'#CQ:-(TNSGSM9U.Z['T
MV.1?S^5%>33D9&1?;&$UC8]%%BHQHJRZ5$;H\](?$;C?](Y:A&>^+"WDJV^S
M;:]][I?+;=5I_9KZI)S:.\HL?_)_Y<?Z5R73NE[63O4\;CZ\EN_?LP4Z56%N
MJ6Q9L2#%#$#<LW)F0MR_ C[R=F9W77NWNH9<GAJ%V=V>:6.09G%F9BE@FEKR
M%TMPS.11.3LS,S._ERS,I[NZC[,C2%/N9F:WE&<^/TI'-&S\OT/!D<S&Q>YO
M;DQU23I8WXO&/ /$1UKX2]GS6-2XXR>"KVJLG2M6U#3M9R*.:=6)7I&79B:C
MD0E.$.9>93*K%YX0\RZVB,E#G>VM\)Z3/5=5JTNA;2YY?2+.ZHHJ?UUK6VW3
MI&">RE;.$&US$C_8\[,%#;#2D&-$8Y<[D!AN:BR <%ZQ?Z/*M"?#/ZCCV,H*
MHO\ 1_/+!,TDYLU77OB<-ZCVCLY,X]+973>D\DS\<=;!0/$]7O?J\\2X>3"W
ML<<<LY%<Z%5'._;PGJ^]VE\B+,+9#;G&5GX8&8Y,=J/4Y$9=+=92/'?AC<CY
MY (A'R!V7])GLH:%A:'J6%I.G4QQL+'TN[#QZ8^D*W5;O)]YV3=<K+;);RLL
M<[)MRDV6@\6M&IQ^&7C8]:A3C2I4(KTBE.&[?K*3GO*3ZRDW)[MF '9JRKT-
MY]I[C/TL.Y&BXS?V_*&UJ''U+#\![;_.)Y'Z69^M_9)G%R97XV6O.P&2]0U9
MI#(>7YBU-IRXWES^=LM2G\VY;GZ#ZK?KLMADI*]IVG;,TJS];'R8?]'97+_]
MJ:[[.%_-I>5#]2ZI_P!*$E_X B(JO%BS KO0OI?]T_M8G_?-94EL7_S6?_=#
M_0ZNT]Z%]+_NG]K$_P"^:RI+8O\ YK/_ +H?Z'5U/9E_P5G_ /X@_P#]-05)
M]I#_ )5IO^CC_OYELWN+?B-?[=-3?Z:*F14-W<6_$:_VZ:F_TT5,BJR^)W_M
M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
M0W=PL[B=!5).DCQ=5X=2:@$']XRO2LCA*Q_*+1Y*^WR&,9,[*O'"W >KZNTM
M/P+[X;[.Y1\O'BUW4LBSEIBU^KS\S](LD;3M(R<E[44SFM_M*.T%L_6R6T$_
MDY;_ "*\\=9Y#8!'DB+@?+RY_P#+ZOUEE;M=HJ* 6D<&9V9BD/CI)^.7=W?W
M_K-SPW/#>2SF[?G90VIVEU3B]NM!S9S4.H\;7#):SU/GLC#.]:S>B_,.G*%#
M'T\=C*[Q5V^%+LKUK5J,+M&IZ_)(-R*+&2],&-I,'Z,@9RX\W;R\F;CSY?ZC
M<NZ[7^PY[,$>&=-OU_7L;%NUG4]HX490C>L#3%%-.N5D$H7YUCE.V4-U]'KQ
ME&?UEL7%7B;J=E-BTNJ:=SER6^7+F49?>3:75PWVEMNE/INS],7M9KG6V6+#
M[98K.Y?4458[Q8_!2L/-&"6&"Q9MC8GAI1P1R6(0>><XV>66.+J,I!!\PM"=
MWAVNRZ7L:!KSQMYN&9RFG:,W2)<=+2T[PMU%[V<PD)V\W=6+^Z)[&Y[9[?CG
M\Y5:'6>NA@RN5 V%Y<7B68SPF&<F9W:2.M+Z[?!B<1O6Y8&<AK!(<LZKO[2G
M@+P1Q7Q3EZA7I>/BU0KCB7?HZC$QJL[(IG8[<^3ACN2NL<U3YM4X^;717;+>
M<G(F'A+P7Q9Z;C/497.^=:G*"\M.N,NL(.4ZYV<ZCMSK=*+?+M[N[J#8+N\=
M^2A,LKMT5*6,'-_4]18#(Q2.+>8QB%Z*PTA?H(WA(?Z:5EU3)#K3;G.O$?P_
MH[/U^#Z6*UB[11\D(R 0$ 6ZQ$QL$@//6D=C82?@E=/7!-PML=/ZLQYXK4>(
MHYB@?GX%V )?#/\ ^+!(_$M>9N&XE@..1O<Q<>2IGQC[!FDRBLGAC5]0T?4:
M6YT_2+'D8[FDW%*VI4Y>-)RV^NA9?R+M1)GTUCV?\5Q5FF9N1BY,'S0\]JRM
MR7;:=4:K:GO]^+LY?2ML@G[/?>T9[%O!C]P:7S0TF<(WS>-BK5,Q"'DSR6*8
MM7H9#I;Z)XO4)79G)_&E?VIR-JMX--ZUQ<>8TSE:V4I'PQO"73/6D=N? N5C
M89ZDX^?,4\8$_#D/(\.\+/:;[I^U0CL9C;6Q/D8 \6:33&1GC*]&'/7X>(OR
M-$-L8VY:.K?+ULQ9A:Y:G=A.+;;W<75FW>?*]A[=[ 9NC(=6Y!)&4;FT4GSV
MCDZ,XL$\32#[=>S&_2;,0]$C,;1IHWC]Q[X;9U.D\?8.1J^DS:A1J2DKLAUK
MO9B:DU&O4'&.\IXV=*&6MX\]M"V4M7P_$3B#AC(AA\046YF(WRPR')3M<5WG
M1E=(Y.RZRJR&KEO%2G5T3N=(H]NR'V_M/[BA!B,N]; :QX$/@TI"&EER:/J.
M?"S3$3N74Q]6-GF.[$+<QG;C8YFD(9UT;X+XWTOB'3Z-4T?,JS<*]>[96_>A
M-)<U-U;VLIOKW2LIMC&<>FZV:;LMH6OXFI8T,K"NA?3/[T>\9+O"R#VE79'?
MWH32DNCVV:;\HB+:S,!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'AU3N[YWL
MVOHS=!]44(&CP>OJ[Y07 .F.OJ"KTP9JL_'+,]AGJ90"9VZSN6@$&:NY%<24
M>G>>]FK^:9M+G:5.#Q<_IYFU-IYQ8.L[F, RMT6<FYZ<CC"N5!$2%O63JREU
M>"P$!1Z1.?Y/Y/\ MM\G'RLB (B( B(@)/\ ND.TE_,_W;QU*[8>+!:X"'2^
M28BZ8 OSV!+ 79&Y9F.#($]$9'9VCAREGR9C<@NHK6X,3MPXDXDSLXD+NQ"3
M>;$+MP[$+\.+L_+.W*OB]@7M)!NIM=IW4\DPR9>.$L-J,&\BAS^+&.&ZYCR_
M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
M:5]9H:BVLR4[>+C7?4NFF,FYDHVI6AS=(.79^:MPZMV(!Y<PO6BZ1&N1%8I6
MOI[,&^EW;77NF-:4G,FPV3ADOU@-P]>P\[^KY:B3MRW-FA).,1$)#'8:&5P+
MP^'O^:<U#3RV/I93'3A:H9&I7O4K,;\QSU;40302@_\ 2G&8DS/YMSP[,_D@
M/M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"K]]^WVE&QNG<)M=0L<7-2209_/Q@_!#@\9;=\9!*[/Y!
M>S-5YP'CDO@@V=V!W&2?;)Y*O3K6+EN>*M4J02V;5F>08H*]>",I9IYI3<0C
MBBB$I))"=A !<B=F9U01[7O:"GW0W%U-K.1Y6JY*Z\.'@E=^JM@Z+>JXF'H)
MF\(BJ@-F:)F;ILV)^>HR,R QK1$0!$1 $1$!W)V?-E<CN+K33NB\8Y!8S^2A
MJ2V1#K]1HMS+D<@0O[+M1HQV++"3B,AQA$Y#U\ML"M(:4H8+%8W"XNN-7&XF
MC5QU"N'+C#4IPA7@CY?S)QCC%B,G<C+DB=R=W5=?N'NS5YZBW6R,'T02Z5TT
M\@-PP^)#8SN0B<N7\1SBJ8V*4&$@ <C#UD,T@#9)0'E$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!8%=Z!\0>YGV#A_"N/6>JP*[T#X@]S/L'#
M^%<>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!
M$1 $1$ 1$0!$1 $1$ 5,_OI]5_"._&6IL74V!T[IK$]/E[!S4CSK^3?HB'-1
MN[OYNW2WN85<P5$OO)=1/E=^-T+;DY.&I&QW+N[OQA<9CL((^UP_ #CF!F]S
M,+,/(LSH#"-$1 $1$ 687=]Z8^&-[-LJ+CUB^JJ5N0>.>8L8$V4EY^LT5,W=
M_D9N5AZI/NYSTYZ_V@-)3<=0X?'ZHRIMT]3<?,_?Q0.7LDS,,V5B(2=QXD$.
M"ZN!("ZDB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"J*=
M^UI?U/>+#Y$ 88LQH+$2&?GS)=H9G4-2?GR9O9J?!PL[.[_(["S#U6ZU6<](
M'TZS9';'+"/#O3U/C92X\RXFP]JNSOU?]7^:79NE^?$=W)N.' KI(B( B(@"
M[V[+>I7PVYNW65ZG$<?KK25F5V?CF"//4'L@[_TLE?Q8R_[).NB5]/"W_5;M
M*TWD]6Y5LL_U'KSQRL_[70@-CXR\KXVG,GZ[CZ%SR_-=.K9\N./S1!'+Y<>7
MZ-?90!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!46N\V^/O<W[.5?P'B5>E5
M%KO-OC[W-^SE7\!XE 8*(B( B(@"D5[I7Z8O;/\ M^KOX/=7*.I2*]TK],7M
MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQ
MRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3W1WQ"
M:*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 %TSO_ +#:=W*TKD](:HJ-:QF1C9Q,>!LT+D7)5,C1E=G>"[3EXDAD;R=N
MJ*1CADDC+N9$!K]^U)V:-0[3:POZ/U$ G- S6L9D81,:F9Q$TDH4\I4ZV9V&
M5XI(K$/M/5N0V*KF?A-(>.ZO8=O'L78C>G1TF(G>.CJ/%^-=TMFG 2*C?(!Z
MZEA^GK/&9)HHX+\0.Q#TPV8^9JT;/1_W T!F-*YO*:<S]&7&YK#7):&1I3<.
M<%B)VYZ3%R"6&4'":O/&10V*\D4\)%%(!.!P]$1 $1$ 1$0&5'8\[6&?V>UE
M3U/ASDGHR%'5U%A>MAKYS$.?,M8^KD([4#N]C'6O(Z]H69R>M+9AEO,;,;Q8
M#7VF<3JS3-T;V'S%8;%>3R&:$_H9Z=N+EWKW:<S'7M5R]J*:,AY<>"?7?J3O
MNT.WY:V<U*^-S4TL^W^H+$8YNLPR3EAK;],4>H:,4;%)S"#,&3K0A(5RH+/'
M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'&]7:1QF>Q=_"YFC7R6*RE6:E?HV@:2
M"U6G!PEBD%_/S%_9(7$XRZ9(R$Q$FIG=Y+W9.4VJN2YK#M-DM W+,<>+RQD\
MMO"6+)],6&SI,//21N,5#).[QW'...3P[GSJ6ZJOA:FTSC\S0MXK+4JV1QN0
MKR5;M&Y$$]:S7E;@XIH9&(#%V^JW+/P3.Q,SMOO 7'^5H62YU_6XESBLK%;V
MC9%??K?:%T%OR3VV:]V:<>VL<3\+TZG3RS]RZ"?DW);N+?W9+[U<GMO'=-/K
M%I]]9Y-!)"9@8D$D;\.WN)G9_)V=OVG$F\O<[+Z$FO[X P')XS-QP1OP?UNH
MF;VN/JNW4_RN[\NIT.\H[I[(:"*YJS1<5O+:(=[%B<7<;&0TD)%XGJ^0Z1&6
MY@HW(PJY-@DGHPQC'E9#-O7K< 6:I2UI3BF!XY!XY9_<[?(0O[B%_>Q,[MQ^
MLZN_PYQ)CY^/'+P+U959LFETG7-?:JNK[PLCOUC+NFI1;A*,G5W6>&I8][HS
M<>+G#K!RBI)Q?:=<]NL9?&+7;:24DTO6R^N+Q\]),'O;GCJ?_/Y?YEQ/ [E:
MAP.6H9["YG(8K,XNQ'=QV2HV"@M4K4)=4<T!#[(D#M]"XN!-R!B0.XO^=WY?
MUUPZ]YN_ZSM^WRMC<W8G&SWXR7+*,DG&2ET<7%[Q::Z----=&932\6NK9UPC
M6ULTXI)IKJFFNJ:^3]"VYW?7I"&+RKT-);ZM%ALL7%:KN#2K1Q8&\?DP?-'0
MK]+X2U+RS/>H5Y,09L1318J/I8K$>Z':%T5HW3#ZRU'J3$T--O7CM5<H]N&:
M#)1SP^/5'$^ <I92:Y%Q)4BH-.=@'8XF<.2;6)XG;Z>W\\M=5:!_/CAO'D;Z
M@B7/AC_VC;GZ@.R[H"26*CC\6UBU)CL2-D<92GM6)ZN.&Y*T]UJ$$LAQ4_6Y
MQ&>TU8(FL3,,DK&;,Z@?B3P*TO*RX78ET\&N4]\G&J@K*FN_][N4E]'DWT<=
MK*DGO"$5'DE(57B=9CU.IQCE7);0LE)I0?;ZUI/S-N_NM2>VTI[O=3.]X3WR
MFJ-SFMZ7T'\(:-T)(4D-F;KC@U)J:OTN'1D9ZYR_!6.EY<_@ZA8\:<.D+]N2
M(I:;0>&+"S,S,S-Y,S-PS,WDS,S>YF9F9F7TI?E_:7SI?Y?WW4O\.<.X>F8\
M<;"HC34NLMNL[);[.=MC]ZR;_6DWLMHQ48I14>YNK9&;=YV38[)OMOTC!;_9
MKBO=A'Y175]7O)MOY\OR?R_0NOF2?(OIR_H?Y?H77SG%R<1$2(B)A$ %R,B)
MV$1 19R(B)V$19G<B=F9G=^%M-/_ !^X_2G^W^P^38 BZ1$2(S)@ !%S,S-V
M$  !9R,S)V$!%G(B=A9G=U<Z[ESNK_YF>.AW1U]0%MP<W1<<+B9VZRT;A;@B
M1-,!"PAJ+)1,+72'K/&TW?'QRC)/D!+IWN=NZ,DPAXW=K=/%]&99HKNB])WH
MP)\0),,D&H<S ;%T98F<9,70/B3&"_K-H&OO'%3LWLJH^-?BVLA6:-I=N]*?
M)G95<NES71XM,EWJ3_EII[6M>7%^4I^;-'!G"[K4<O)CM/;>FJ2^PO2R:_6?
MW(M>ZNK][;E,R\HBJ\22$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 766
M\^U>-UQI3/Z2RX,6/S^,M8Z=^GJ*%YXW:&S&W+?/:L[168GY'B2(7Y;CE=FH
M@-=%N-H'):5U!FM,YB+P,I@,G=Q-^-N7'UBE.<)21.["YP3L(SUY.&:6"6.1
MFX)EPQ3W=^GV;"Q&JL)N7CH.,?JB!L/G7!F88,[C8F>C8/I9O+)8MGBY?GB7
M%DY$Y6 %H$4 1$0!$1 %;K[DKM(EJK;BQHO(V'ER^@K+5:WB%S++IO(%)/BG
M?SY)J$S6\:+\,P5J],?:+J)ZBBSE[N?M'OMANOIW-V+'@83)F6G=1]7/A?!.
M6DB#UB1F?AO@^]'2O^*_T 5Y1=VBDD8@+U:+P),[,[.SL[,[.WFSL_N=G^5G
M^1UY0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$7AW0$07?.=I5]%;7OIK'SO'G-?V),*# 3-)!@(8_&SUI_E8
M98RK8H69V(GR12#U#!*RIVJ0OO/NTF^Y6[>>M5)_%P&FB?3&G^ERZ)*^.D(<
MA>%G=V_Y0RKVYHB$8^:04A,&E W*/1 $1$ 1$0!<DT=I.]G\OBL%BXGGR6:R
M5'$X^%F=WENY&U%3JAPWGP4\P,_'R<KC:G$[CKLV_-%KO);@WZY%C-#P-6QA
MF+/#+J3+02QMT.[>U)C<64TQL/G"=^D;MR8.P%F3L[[,8_;S1&FM%XP1:M@,
M7#3*06X]:N$Y6,E>/R9WEOY":U=E?@>9)R?I'W-W0B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>YGV#
MA_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
M B(@"(B (B( B(@"(B +7Q=I_._">Y.O\@Y=3V]9:DEZN6?GG+6AYY;R_0_(
MM@G>G\*":7_X<4DG_P @$7O?R;W>]:Z+761>YG,W;=^I[>9RMIWY8N7L7[$S
MOU,S,7+GSU-Y/[V\D!Q9$1 $1$ 4U_<08+Q]W<[?<6=J&A<C$SO^A.]F,(S$
MWLNS%T59!ZNH782(68F)^(4%8&]'_P 9U:JW&N.W]"T_@ZP/U<</-D;LI\C\
MO+0!P7R>;-[T!:*1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 5=#OX.S6\]+3FZ>-KL\E OF:U,X#[15+)^-@KQ\-Y!5M>
MMT)R)R)_7Z3"PA";JQ>NJ=\MI,=KS1^H]'Y5OS%J'$W,;)(S<G6EGB?U6[#S
MY>/1M-#<@ZF<?&@#J$AY%P->*BY?N#H3):7SN8TYF(? RF"R5O%WXO/AK-.8
MX3(.>'>*7I:6)W9G*(P=V9WX7$$ 1$0!$1 9&=DK?NSMEN+I;6D!R-!BL@(9
M2&-_SWA+P%2RU4A]TG53FDEA$F)@MPUYQ9I(8W:_CA<Q6R%.I?IS!8IWJT%R
MI8C)CCGK68@F@EC(7<2"6(Q,"9W8A=G9W9:X)7 >Y7[2;:OVR?2-VQXF9V]D
M@Q; ;_/3T[;:8\#*W/T4588+6+#A_G<=&$2$1*)S F/1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 >K=NQ5H9K$\@0P5XI)II9'88XHH@<Y)#)_(0 !(B=_)A9W=4
M(NVMVAI]T=R]4:M*0RQT]^6AI^(W_.^GL<9U<4W2SNP26H!^$+(,1B-NY.(2
M'&(.K/\ WQO:2?0^U%K!8^SX.>UY,^ J.!<308ANB;4%H6;VFZZ'_)@2-TO%
M+D@F _$B$2IKL@"(B (B( B+[FF-,Y#-Y+'X;$UCNY3+7:V-QU2/Z.Q=NS!7
MK0L[^0L<T@"1O[(#R9.PB[L!8?[ASLW#+)J/=3(5V=H#DTIILY1=R:1XZ]K.
MWH&?AF'HEJ8V.<6)W)LC78@Z)1.RJND^SELI0VZT1IO1F.Z2@P.,AJRSB+#Z
MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0&-_:X[0-/:_;S4NM+?0<N+HD&+JD0L][-7":IB:8L
M7T32W98BG<1-XJH6)W%PB-4%M09ZYE;][*9"<[-_)W+60O63?D[%R[.=FS.;
M^;N4L\AF_G[R4X'?@=JKYH=6X_;7$V6/$:/9KV=>-WXL:GMQDP53X?@@Q&.,
M/_\ ;R%D"9BJB[P4( B(@"(B +,[N_>SNVY^Z^F--V(&L8B"<L]J$"%RB?!X
M8X9;44_ NS0WK,E/&%U<"17PC<A<V=L,5:_[C3LW_ .ALEN)?KO'D=;6"JXL
MI!'K#3F(L2P1R!^C ,ADPMS-U=+3UZU*<6*(H3<"= 19O)F9F9F9F9N&9F]S
M,O*(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*O
MX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[
MI7Z8O;/^WZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F
M=)?C)CE3&5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265V
MGNCOB$T5_=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B Z$[2O9T
MT[NGI'):0U) QU;@>)3N@ %;Q&3C VIY6@1M[%JJ1EY<L$\)S59N8)Y!*B[V
MCNSSJ+:[5N2T?J6#HNT2:2K<CBDCIY?&RN;5,KCRD;YY4LL!B[,1O7L16*<I
M>/7E%M@ZL >\([#N,WHTB=6(:]/6.&"6SI;,R\@,<Y<%-B[Y@)$>,R(@T<C.
M)%4L-%<A;JCDCF HVHN1ZPTCD]/Y;)8+,TYL=EL1=L8_)4; N$U6W6-XY8C;
MW.W+,<<@\QS1%'-$1Q2 9<<0!$1 $1$ 68/8F[8.;V9UG5U#0\:[AK733U-@
M6F*.#+8PG=G(6\XX\C0(GLXVRXNX2B=>3FM9L 6'R(#8G[5[HX/6FGL3JC3E
MZ+(X;,U(KE*S&[<]$C>W!/'SU5[=:3KKVZLK#-5LQRP3",D9"W8*IF=UYW@<
M^TNH6T[J.U-+M]J*W"%P2?Q!TUDYC:$,]6!W9PIFQ"&;ACZG.M%';AC.Q6\*
MQ<JIW(;$,5BO)'-!/$$T$T1C)%+#*+''+&8NXG'(!,8&+N)"[.SNSL@/91$0
M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
M]//5'1?JQ%4G?CF&[-'S%;$B B<SV>NY6]=RF3M2WLEDK=F_D+LY=<]N[<F.
MQ:L2D_T1S32'(7N;DN&9F9F7R41 $1$ 1$0'<G9ZV7R.X>MM-:,Q@GZQGLK6
MJ33@!&U#'=;293)2L+C\ZQ^/"Q:)NH7D>,80?Q98Q?8"Z)T?C]/8?%X+%0#6
MQN'H5<;1K@S,,56G"$$(>3,W+ #=3LS<ER_RJO\ =Q1V6RJ4<UNQE8&:7)L>
MG]*B;.Q!0KRN^;R+,[<.URV%>A7)O, HW/-QLLPV*$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY
M5_ >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%W
MM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD
M^S.DOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!"GWL_=Y?S0\5)N!I"FY:WP
M-(_A#'UQ'JU3AJP^)X(APSR9G'1B98WH)I+D!2X\AGE]0:&HZ0N+N),XD)$)
M"3.)"0NXD)"3,XD+L[$+LSB[.SLSL[+9'*L!WP7=W? \]W=O1-%_@NY.TNM,
M/4A=QQMJ;R+4=6*-N(Z-J3ALN BPUK<K7^&AFM%"!7N1$0!$1 $1$ 5B3N>^
M\0;'R4-H=:W6&C*3PZ'S%J0W]6L2R<CIFW*9$PUI2,WPLA.P5S_Y,\HBI!'7
M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
M %N&$1%F$19F9F9F7[(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>Y
MGV#A_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=
M3)( B(@"(B (B( B(@"(B (B( B(@"(B (B("F9WN79$;;;<23.XFL\6E=>2
MW<O1:,>*^/S?B#-F\4W2S#"!2V!R-*'R#U>U+#79XZ1A%%$K\?;2[,5#=O;[
M-Z1L^%#D)(2NZ?R$H,7P;GZD<A8ZR[\=30'([U;H@[')2L6 %V)Q=J'FK-*Y
M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
MB(@"DL[L7MLR;0ZXCKY6<FT1JF6"CJ.-W)PQ]AN8\?GX@;R8J,AM%>X;F3&R
M3%[4E> 5&FB V1%2W%/%%/!($T,T82PS1$)Q2Q2"QQR1F+N)@8.Q 8NXD+L[
M.[/RO85?#N8>W@V6H1;0ZKNBV2Q%9OF)O69G<\CB8!+Q=/D4GOLX>(1/&BQD
M\V,ZJT81CC0\:P>@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B *KUWU7;@;,7WV@TU:ZL9BIZ]K6=J
M%_8N9: QL4L&)L_SR#%DT-R]Q[!9#U>!_GE"5FE6[S7MR0;/Z->MBIHCUSJ:
M*Q3T[6ZA(\="P]%O4-F/@F:&AUB-,)68;>0**-F.&&V\5*:W;FL2RV+$TMBQ
M/+)//8GD.:>>>8WDFFGED<I)9I9"*260R<S,B(G<G=T!ZZ(B (B( B([_P#N
M@,ENR)V;<CNQK[!Z,H/)#!;E>YFKT3#U8S 4RC?)WF<V(&E8)(ZM3K$@*]:J
M@0D)NSWVM*:5Q^#QF/PV)JQ4<9BZ=?'T*D+.T=>I4B&&"(.7=W8(P%NHG(S?
MDC(B=W>*SNANQP^W&A&U/FZ;P:OUQ#7O6XYH^+&*P8]4F)Q3\^U%+-'(V2OQ
M^P36)XJTPN=$7:7- $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^
MF+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[
M3W1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!8G]L?LE8#>+1UO3.8$:]V+KMZ?S(QL=C"Y<8R"&T
M'#B4E:7GP;]3K$;59R'D91BDBRP1 :[G>#://:#U+EM):FI^I9K"V?5[<3.1
MPR"0#+7MU)2"-YZ5RN<=FI/T#XL$@$XB74 ]:JZ;WFO8#K[PZ;'*X2.&#7^G
M:TCX6P3A$&8I,YS2Z?O2EPPQS&<DN.G,F&I=-^MVKV;+JF!D\99HV;-*[7FJ
M7*=B:K;J6(RBL5K->0H9Z\\1LQ1S0R@4<@$S.)B[.WD@/11$0!$1 $1$!(#W
M>O;ER>R^K1GG.Q<T9FI(X-48>-^MV!FZ(<S1C?Z')8[GJ<0<?7:?BU).3]6D
M@NV:1U=C<]B\?FL/=@R.*RE2"_C[U8VD@M5+,8RPS1FWZ$@)N6=F(7Y$V$Q(
M6UR2FQ[I?O#WT!E8=O-8WN-%9RX 8?(62,@TOF;<O0+')YM%A,G/( VR-F@Q
MMEQOG)!4*\; 6WT7\@;$S.SL[.S.SL[.SL_FSL[>]G;S9V\N%_2 (B( B(@"
M(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^
MVX^Q^7_&3,JCRKPW=3_2_;<?8_+_ (R9E 2%(B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B J6]]O3]4WKQTK#TC?V^T_9Z_:Z3DCS>J:9MR3]/6
M$=6'J$/98"C)VZI"=XPL/D/=YO\ )]3^7R*9OO\ O2[P:CVVU (^S;P^>PT\
MG''M4;M&]3#JX\^6R%XF9W;IZ7=F?J+B"O#W_=Y_471CPBRU?PWI4UZ8[I?R
M=%ME#7R_D]U\FBA'B]H[AK6I;K[5_FI[=U=7"U?]_;\3M[(1-+$4C?1,+N_E
MY\LS_P";R;]OA?5[GQV#M*;6.Y,#>NZL%W=V%G<]OM7 (N_+,_6;B+#^B-Q9
MF=W9<:Q]YBC)G]S@3?YEZ'=F9@<=O]M39)^EBU9#2;EF?SRM*]B1;AR%O,KS
M"SL_(N[$(D3,#YKC2CFTG5H+O9I>H0_.6)<E_6?7P43KS)J7:&7ILEO\%=8_
MX;&P)1.5U=O/O)IS;_365U=JO(QXO!X>N\]NS(SF9$1#'!5K0@SR6KEN<HZ]
M2K")2SSR!& \OY<TJ*)VSA55"5EEDHPKKA%RG.<FHQC&*W<I2;222W;>R+[6
MVQA&4YR480BY2E)I1C&*W<I-]$DENV^B1U_VK.U#IK:'1N2UCJ:8GAJB\.-Q
ME<XVR&<RTD9E3Q./"4@ K%D@=RD,AAK0#+9L&,,)NJ/6^.]^J=X-99#6VK;#
MG9MEX6/H 9?!^"Q41/ZIBL;&["T=> .2FEZ1FNVCGNV2.Q.9+GG:_P"UCJ+?
MG6QZCRT94<'C3M4](X!C<H\/B9IA=Y+#]1!+E\B$%:;+6(^F,I(HZ\(M6K1.
M_4."TYE<QDL=I?2^-L9C/9:R%/'8VF(//<M&SN,8%(44,48BQ'+8L2PUZ\0G
M/8EBA S&^7A+X8TZ!B/-S?+_ $A;4Y7V3<5##IVYG1&;?*MDE+(MW47)<J;K
M@I2IOXJ^(]VK9,=+TWG=/.HQ4$W*V>_+YDHI<W=\M5??KNTI2:CRC:S:O/[@
MZGQ6A-&U&M9?+2.(D76-6E6B;JMY3(S )^KX^E%S)/*XNY.X00C)8GBB.Z]V
M-^R-IS9K1]736#C&>]-X=O46<./IN9[+O&PS7)_,GC@B;F"A3%_#IU1 &8I2
MFEEZI[O3L'8G9/2YPR'#D]9YP8;&J,Z+=0%* #X6(Q9%'')%AJ!=3PB8M+:L
MR37+'!21PUY"%7GQC\59:U>\+#G*.EX\^C6\7F6Q?\M-=&JH]J:VO\[/:4HQ
MJFSPI\,Z]$QE=?%3U"^.]DGLW3&75UQEUWF_\9-?*$6XQ;F1$4'$OCE0Q][M
MW@3[8Z=;0^D[O1N%JRF_1/ X'+IG 32'7L9@Q?GP[UUHK%/#,0NX3C/>X<:;
M!+GAVRNUA@=F]#9+5^;()IQ=J.!Q+&XV,YG9XY#I8V!A8B$7\*2Q<G87"K2@
ML6#X:/SHU:MUEG=<ZFR^LM57GR.:S5I[M^WTO'"). C'6JPD1^KTJ<0A4IUV
M,O"@AC#J,F<RGOP0\-/TKE+4,RO?3\2Q<D)1]W+R8[25?5;2IJZ2N3W4VXU;
M23LY8@\6O$&&D8<J:II9=\&ELUS4UOIS?%3GUC7\.LMTU#?C&G,2-2$K,[N1
M/R;D9.9R2/[1$9%R1$1/U&1.[N[\N[N[NID>Z4["3[D9\=S-6U!ET1IRZ8X2
MA8C=XM1ZCI2C\](2;HEQ&#E$O&;VQM94 JN[!2N1281=D+LK9C>[7-72N->:
MII_'/7NZMS,3-_R5A7E(7CA)V<'RF4>&:KC )B%I6FMF!UZDPO>$T!H+$Z6P
MF+T[@:4..P^&I08_'4H!88X*U<& !^J1EYG+(7)RRF<LCD9D3S#XZ>)BTW'>
MDX-FV;DU_P!\3@_>Q<::[;K[-UZZ0^]75O9T<ZI$1^"WA]//R'K>HPWJA/?&
MKFNEED7T?7O"I]9>DK-H[M0G$Y@B(J1ENPJW_?A]I["RW=+;4TH(+V8K6OFF
MS=UW8GP@'5GJ8JA%TO\ GS)C/8L61-F:"G%5?@RN"\,T?;![3F(VAT!G-;99
MPE*C$%;$8]W?Q<OG;K^#B\;"(NQDTUA_%M&#MZM0AMVY""&O(8T2[>HLMJG/
MYG5VHK1W,SG<C9S&4MF[^W:M2O*0QB_/AUX6Z*]2 7Z(*L4,$8C'&(M8CP!X
M#GFYDM6N4HXV"Y0H[I79<H;=UMO"B$U.:[.<JXO>/.B%_&3C:K3L+Z*FI79*
MBYKHW"A37I^M9)<L?@E)K9\K.IM]<>SQT+3,WLR2UB?_ +PM+&WU/^KD_P#=
M8X/']99A;JTVGPLI-Y^%+!8'Y?<3QD_Z_ARG[O\ 1RL3WB5PL6W:*7P;1%F!
M=O6OAOT^:?5?UGQ#@9V=G;EG;S_]V5Y7N+>U9+K_ &ABTSEK96=1;<V!P$\D
MI,\UK3\K%/IRT;O[9E7J-)ASD+J*1\6,\DA2SGQ1]>+]92O]RYVBCV^WSP56
MQ8:'":Z@ET=EA-V:+Q[9-9P-I^786FKYB""J$A._36R-P!%RE9VCKQAX;6J:
M'DJ,=\C#3S<=[>]O3%NV":ZOS*'9%1[2L5;:WBC>>#]8>-FU<SVKN:IL6_3W
MVE"7^S/E>[[1YMNY?01>&7E<^BP01$0!$7AW0'E%^-BQ'%&<LIC'%&)'))(0
MA'& ,Y&9F;L(@(LY$3NS,S.[NS,H]=]N]4V-V^EFIY36M7+9:%W$\/I:"?45
MT)&\WCGFQXGC*,C,[.T>0R-,B9V<&)EDM+T;+S;/*P\6_*L]8453M:7QER1?
M+%>LI;)>K/+E9M-$>>ZVNJ/ZUDXP3^2YFMW\EU)$$59W=#TB"L+RQ:)VXGL>
M1C%>U/EPJ S^?1*^/Q<-J24/<Y0O?K$_FS2M[UA%JGOU=^,D1>IGHO  [OT#
MBM-SSF _(Q'G,MF!,_<Y$T48D3<M&(^PI/T[P*XAO2E/'HQ4^WTG(@G^<:?.
MG'\)13^1JF5X@:;6]E99:UW\JJ6W[Y\B?XIM%S]%1@O][;V@K1$9:^FAZAZ.
MFKA\%7%N7=^H6#'<"3=7D3>?#"WR+@MOO'=^+0D,FZ6JF$V9G:&:E![GY]DH
M*0&/U^DFY;R?RY6PU>SIJS^WF:='\)Y,OQ_]V7]FYBY^)^$NU&4_]FI?_M2^
MRBU_5WMJ[QVS\27=/73&PL',>?M1-TL[NWL1],?5R[^UT\NW#._#,S>E_/@;
MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
M?0,X$1%2XML0S=^QAO6-BSM=/46.U?IFPWT7(M/9EI$7L^7##:\W-NGCGW%P
MJG0OUXIV]_'_ ).KC??(X3UWL^:U-AZO4)<!D/<;]+09['@Y>Q[N&E\W/D&;
MWM[E3BQ#]>,D;W\,S\?W_P#S_E\MY/9OOYM!OAW=>H9"_!2IQI)+\VW^93WV
MBJN74<*S;O51^]76QW_=LBZMW5&8]<[/^VQ>_P!6P\]%_+CSI9&[7^J_/'0S
M<MPS\>3-[E(4HGNY2RCV.S_IR,F=CI9K5E,VZ>EN!U!>GBZ?-^IO L1<EY<G
MU-QPW+RPJH_'E'E:WJ]?I'4\Y+\/I-FW\"TG"UWF:9I\_P!;"Q7^^F!\C4&'
MBR-"[CY_Z#>J6:<WES\ZM0G!)Y<MS[)OY<MS[N6]ZUV.GL7)C<CD\3./1-CK
M]_&3 [_02TK4U24'][>P<1#^U\JV,CJA+VPM(?,WOMNKBF#PXWUSFLK$/GTM
M#J&Q\T,;!S^@$,JP"S>R+#T#Y!PT[^S%G\N7JN+O_*48]Z7^ALG5)_\ Q$/X
M$,>T3I_F:9CW)?R=EL-_G.$9Q_W4B3?N$]8O3W(W#TVY/QF-)4,W&/+]#'IW
M,A1D=AYX8S'4T?4[-R81#R_3&*[(])L[20:>VET]MO7L,-_<34$5N[7&1AD/
M3^D)JF6F(X_)S@?.'@A?Y.L!Y\N5@[W3.JVPO:)TV)&X19S%:AP9LW_6//0]
M?@!_K/:QL!/]3I43'?I=K*+=/M$ZJEQ]I[."T-!#M[AN@V*N3X"W?FS=J)@9
MA([&H+V2B*<F>66"G5B<RAKP<;IJ7!GTKQ AE2B_)HPL?4[);='=3S8F-'?L
MI*VFNQ+UC3+\3W>%NK>;PO3!-<RMMQU\HRVNE^35C7^TB//2N\5R@T=:VY7*
M0.PBTC\V*\?/T,,CO[48>;C!([BWT,91LZR6Q&?JWX!L5)@FB+Y1XY$OE"0?
M>!M\HDS.W/+>3L[QUG8+]9?:TYJN]BI_'IS/&[\,<9-U12CS]#)&_D7U&)N#
M'WB3.I]MQ$^L>C_@S\]4X6KNWG7M7;W?3:$W^TDNC?ZR7QW3[J0DI5^3RKB&
MV&=M:J@NR8_&7YI<76>WDQJUIK4=6J '));,X0-PK11QR2S2RB(UX@DEE<8A
M*1ON>*SLSL_+/\OR.WU>?E7B4-FUTYEMNM^JW[;_  W]#0[<&=4Y0LCRRB]F
MGL_3?OV?1I[K=--'O/+_ "_ERO3G 3;S;ZS/_+W_ *WU/J+\7E_DR_(I?Y<^
M:_6$'W6Z?R/M"O;KV/OX35%[&2,=>9^EGYZ";JC?]<'?V?UQ=OUW7=6FM^;.
M/RN+SV/.7#Y["WJN2QN0JDYC#>IRC-!,S-T2 W6##)'R8G&Y@1=)N*QP>5?D
M\GRM_F7K:4HRA9%2A*+C*+2<91:V:::V::;33Z-/9GER-%QKK89$J_+R*VG"
M^INNU-/=-N+2EL]MN=2V]-F;&WL3]LS3&\>BL+J#%Y+%CG9<?!\T>G(<A7FR
M.#RT?SB[#/48AM#4DL@<F-M2UXAMTI()A$"(HQS*Y6K;PV?M8ZU#>H6[./O5
MRZJ]VE8FJ6X"_IH+58XYX2\F]J.07;C]921[-=[QO_HQH8:>O)\Y1BZ>,=JR
ME4U!7,0^A K<XQ9F.-OE&KEJ[E\KN[#Q4[B;V;KO-MMTK-I\J<Y3AC94;*W5
M%MM51O@KO,Y5[L7.%;Z+FDWO)S?IGB)!0A#*IL<HQC&5U?++G:23G*#Y.5ON
MU%M;]DET-@$JJG?:]C+YF,_#O'INHX8C4ER"CK.O6BXAH9\X^BGG#"-F&"#-
M!"U:],[,!9AH992*UE2*3UMJ_2.\K&,46M=MZ-MV86EN:7R\U-Y"_1&&.RL=
ML8F9^':-\E+U>;/(S^:S O=]7V;]R-.Y72FN*NK<%BL]CYL;DX,MIZ7(5BBL
MBX$]>SIJ?-6@D@)QF@LE3@."8 E!F(&=:QPEPEQ1PSJE.:M,R,BA/RLJO#E7
MD^?C3:YU&%,YSYH[*RO>":LA'FZ<R/VXER=)UK MQ+,FJ$I+FJE<G7Y5J3Y)
M-S2CL]W&6SZQD]NNS*R^1A'(U&EC=QFC9G8P)QD$A=B"0#!V(3$F9V(79Q=F
M(79V97#.ZA[:G\U?0(8K-VVEUUHJ*GBM1>*8^LY6KX918O4?2S#U/DHZ\D=\
M@%@')U[+\1QS0"].7)7</@L]E,3C-05-18:K=FBQ>=A">M%E<:[\U+9U[4-:
M>K8. @:U7EA!X+0S1CU (&7??9C[35S:'<+"ZZPM@+-.*4:FH<;#-&_PMIVW
M+%\)4NGEV]9CC$;= WX:._6KN3^$\HG9+Q2X*KXATEJJ/]^4Q^DX,I1<)\SB
MG*B:FE*"R()0E&2CR6JN4]O+:*U>&NO9'#FK2Q<B,_H5\G78TG*M+F>TXR6\
M7Y4O>BXM\U;E&._,MK]Z+JO1V]VDL]B<;F\7J'#V,=E:5;(4IOA&F+G7M1#+
M&Y \W5&;"3#)&7!QR,49LQ"[+[MG<O3D(]<V?PD0<LW7)E:$8<O[FZCL,W+_
M "-RN>\\.Z,G"55BE%N+BX234D]FFMMTT^C1=J-\&DU.+32::DMFGU33WZIK
ML<W6'7;B[(.'WGT)?TM?>*IE87?(:9S91,<V&S< OX$S.W!O2MCS3R=<"9IZ
M<INS-/'!)'V1J/M5[9X@'/):_P!'5!'GGQ=1XGEN.KGD0M$3<=)?)\CLL4]?
M][MV?L !]6OJV9F%N0KZ<QV5SA2OS]"%FC3/'@[-R[E8N0Q^7'7U.(OL/#^E
M:Q#)HR=.P\Z6119&RJRC&NGRSB^C]V#CR^DE+W7'=2WBVC&:IE8,J;*<N['5
M5D'"R%EL(J49+9KK)/?X;=4]FNNQ3BR6GLKIK,YC2>I:4N/S.$OV,7DZ5@2$
MX;58W!S#K$?%KS#T6*=D.8;=2:&S <D$T9EEUV"NV'>V+U\&1LG:L:(S[14-
M6XR'KE$(.L7JY^I6;GKR.(?K=F#@[5">W5=CE*J4/T^\U[7^VN\&I,1J71&G
M=0X?-TX),?F,ME@Q]6'/8Z-F*@\N/J6KT@VZ$GB!7MG8CDDI6'@LQ.4%0:\;
M-S/V+(B$I\QC]"(LS-^V_'47[;NS/SPS+H#1MK.C1IU;"G1/+H\O*Q)[;US3
MV<H23ER[3BKJ)?;A[G,E.+13A<.9&DZX\K2LJN6/"SF5F\MIQVWVY%'WGLW7
M8FXPFN;:336_;W>2=NW7G:KU+7KC5OZ'VDT_;F^ M/W)">_E[ 2''\T6;JAX
M<<^3E@X"C4=SHX6(YA@LW;$DUB3'C0VA,7I^KZMCJXQ]3,\]DN"LVB']'/+Q
MR_'GT@W$<;<L(MR_/:^V&VVH-9YRCIO2^*MYK.9 G:KCZ0,<K@) ,EB8R<8:
MM.!Y \>[9DBJP=8-+,#F'-F#L5]R)C,,534.[TU7.Y(/"LU](8^:0\'3E;ID
M <S<88BS,L;\--2A8,4YL44AY.L_5)K6K\3Z+PM@U8N\**ZH?WO@T^_D7;M[
MS<6^9N<MW.^Z48.6ZYM]HDLJ&IZY:^6+56_O2>\*(;?K2V?/)=-H1YFNC4(]
M61@]@+NTM2[P7*^:RK6M/;?03<VLS+"06\YX1<24-/1RL+2=3L\5C+.Q4Z;M
M(,;6K43UAN([8[88+1N"QVF]-8VOBL-BX!KU*=8.D1%OHY93\SGLSGS+9LS$
M<]B8SEF,C)W?F-#'5ZD$-6K!%6K5XPA@KP1A#!!#&+!'%#%&PA'& LP@ "PB
MS,S,S+W53GCSQ$S=>N4K?J<6MMX^)"3<*_3GLELG;<UT<VDDMU",$VG+_#7"
MV/IM;4/?NFOK;Y+:4OV8KKR5I]HIO?O)R>VQ$11^;.$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 %7)[^'LV/+5TYNGC:[.=0FTSJ<HX^2>M.138*_*
M8^Z."SZUCY2/GDKM$1<6 NJQLNI=]MHL=KW1VH]'Y1OS'J#%6\>4G')59Y8W
M>I=B;R^?4K30VXN>1>2$6-B!R%P->2BY9KS1&2TSF\MIW,0^KY7"9"WB\A#Y
M\#:IS%#*X._OB-Q\2$O+KB(#X]I<30!$1 $1$!DSV.^T!8VPW(TMK*(S:IC[
MXU\U"!$PV\#D&>IEH)!;R/HK2/<KL3$(7:M6?H(HA97Z<7DX+M:O<JRA/5MP
M16:T\;L4<U>>,9890)O(@DC,3%V]XNSK6^JXGW,?:3^;/:V/3%ZP\V:V\D@P
MDG6[/+)@9QFDT[,_M<O'!6@GQ0%TB_3C!ZNH^J0P)=K5J."*2:8PBAAC.666
M0F"...,7,Y#(N!$ %G(B=V9A9W?R94+>W-VBYMT=SM3ZI8S?%O</%Z>B,G=H
ML!C))*V.-A]T9WA8\E. \]$UPX^N3H8WM!=[_P!I0M![47<5C['@Y_7$KZ=H
M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
M&O(J5GO >P?H?M&[8YW;'7=1BHY(&M8?,P002972VH:T<C8O4>%DF$FAOT#E
M,2%B +E&:YCK!/5N3BX&ED7T,1E[F.N4\CC;EK'9+'6ZN0QV1HSR5;V/R%&>
M.U2OTK,3C+6N4[,45BM8C(9(9HPD!V(6=90=MSL7ZW[/^Y.?VOU_3]7S.%-I
MZ60ACD'&ZCP5F28,7J/$&?+GC\D$$OSMR*6E;AM49W\6L1%B>@-JGW '?0T>
MTYH8],:OLU:6]&AZ<,>IJ0L,,6JL./AP5-:8B'E^ M2.U;-TAY+'95B(6>E<
MIF5AU:/_ +-?:/UEM#KK3FY&W^7DPFK=+7FNXRX+&=>>,Q>&]BLE6"2/U[#Y
M>F<U#*T2D ;5.:01.*88I8]N]W6?>5:.[46U>*U_IMX<=FH0KX[7&D7MC:O:
M0U0, G<QDQ=$,L^/G/KL8/*'7KAE<:\5D8H96GKP 21(B( B(@"(B (B( B(
M@->CZ:1\9NP_VBZU_#^#5+U70O32/C-V'^T76OX?P:I>H";'T<GZ=G87[*ZX
M_@JUXMM^M2!Z.3].SL+]E=<?P5:\6V_0!$1 %JT/2NOIQ]0?<\V^_>V46TO6
MK0]*Z^G'U!]SS;[][91 5OE:\]#O^F<UC]QC/_C?HI50U:\]#O\ IG-8_<8S
M_P"-^BD!LM$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1W=[1VC3VF[-F\VOH)1A
MO830V6AQ)&SNQ9O,B&"P<7#,[L\V6R=.$79G<2-B9GX9E(BJTWI9>LI\7V/,
M]1B(VCU'K[;O#66#CI*"#4$>H1&7VFY!K&"KDS,Q?/!C?I\G(0-7)"#B "Y$
M;B+,YF_49NS>9F[^;F3\D3_*[NZ_1$0%_7T.OL*TZNE];]HC-X]BRV;RUS;_
M $-8L1@15].X<*4^ILI1=P)XFRNH)#PDLHR!(?S-SQE$T)1RSW>U#;Z/MHNG
M@NQOL)7I>#T7]%QYV?P..DKVH,A>S.0(^&;Y^5V[.5GRY]8>3EW?S>9) $1$
M 1$0!$1 $1$ 1$0&,_;#[*6E=[MMM6[8:SJM9P.K,5-0ED8!*SC;C<2XW,8\
MB_H.1Q-Z.O?I2BXN,\ \ETN3/IBNT1L-J':S7FK]M]61!%J/1&?R&GLJ\3.T
M%F6E+^9\C5ZA$O4\K2.KE*?4+&U6Y",@A(Q@.\-6M,]+[[-<>E.T3I7<"E7"
M''[I:!A>X0=#>+JC1.0DQF4F< 8>EI<%EM*^T3$<LT5HR,OH0 JA*Y)Z''VL
MYL)NGN'LO>LNV+USIGYML#"9-X8:FTG8IT,K!$# Y>+E-/Y..T3D;1!'IL^&
M:2?YY3;4LW<3[LRZ,[76Q65">2O#>U>>FKIQ<]1TM38G(X>2!^';V)I[%8#9
MWX<?9X]R W!2(B +%[MO_$MN_P#<NU_^*>664*ZOWOVV^;/1>K]'^N_!OS5Z
M7S^F_A'U?UOU#X=Q-O%^N^J>/6]:]5]:\?U?UFOXWA^'X\75X@@0V]P7\7NL
M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
M1$0!$1 %1:],D[%L)8_;7M 8FDWK-6\6VNL[$(^T=&_%<R^D;MOI%^8J=^KE
M\6,QF QS9FI S&5@>B]*HTN^([-8;M=F;>3130-8NVM%Y/+X<'%Y"'.::!M1
M88X@9GZK Y'&5WKMY?/O#X('9C8#3>+^H[$T)A-6F*O9@DCGK6 _HE>S 8RU
M[$?N^>03 $H/RW20,_++UJTS2QQRMRS21A(S/\C&+$W^9_Y?)^Z W./=9=K&
M/?#L][4[G,_YLU%I6M%FP<G)X-2X*>QIW4]?J)W.08=08K(A',?25B)HY_#C
M:5A'/]4\_0WM^RS&RFX>W=B82ET+KX\G0A=S>0,5K#'PWR+E_9&%\O3R?0 M
MPTCRD[D1NPW#$ 1$0%13TR7Z7G;S[L.+_%'5RUO2V0OIDOTO.WGW8<7^*.KE
MK>D!WYV3_C7VJ^Z?MY^..%6[T6D+[)_QK[5?=/V\_''"K=Z( B(@"HG>F.]N
M8XH] =G7#VC%[L5?<S7(Q%Q&5&"Y>QFC,7,0B_6<V3H9C,SU_$ H&QN*FEBD
MCO5S"]BM-'WM7:N;>SM&[L;AP6&M8F_J>UA=-S"_5')IC2_& PLT!](N5>[7
MH/DH'(1/P[S,3,3<,!'6N=;7;8YS6VI].Z,TS5:[J/5N<QFG,%5?J:.7*9BW
M%2J/.8B;Q5(9)FL7;'00UJ<4]DVZ(B7!5:.]$I[)[:Z[2>0U[D*?CX3:#2%O
M+P3%X3@&L=4SM@M.Q]!?/'<,.&K;WBP\>!-4J!([C9Z7 V(78N[*VGMDMK=%
M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
M?2W"R(#3FY/N4>US3&4Y^SON6P0MU2%#BZ5D6;AGY%ZV1E\3CGS\/JX\V?W/
MQB]N/V)-Y]'C*>J-H]RL'%!U>/8O:*U#ZG XD0%XU^"A/1CZ2$O,K#,[-U,[
MC[2W::_B2(3%Q,1,7]XDS$+_ *[/RSH#1%06XI6=XI(Y&;R?PS$^'^H_2[\/
M]9U[#K<X]J;NL>SUO.,Y[B[2:*SN2G P^:(,+4QNJ(NL.ABBU)C(ZF99X_(H
MP.X<0F('X;D+.U*CO4_1/]4;?8W,:\[/.4RVX&G*+'=N;:Y2 +&N<;28W*P>
MF\I7*&+5L%.)^L,38I5M0E7A(:UK4&0.."0"H=MYKG-Z0S%746D\SE=,9^B?
MB5,UI_(6L/E*Y<L[L%W'RP6/#-Q'Q(2,H9F9AFC,/95LCNQ_2P-RM"WJ.F>T
M,$VY6B#<(&UACZ-:#<# "Y</9NQUSJ8[5="-G(I(7JT\W&WG%<OMT50J)SP2
M1220S1R030RR03P3QG#/!/"91303PRB$L,\,H'%-#( R12B4<@B8NR_) ;Q_
M9?>O2FXNE\+K70^=Q^I=*ZAI19##9K&2O+4NU96?@AZA"6&6,F**Q6LQ0VJL
MX25[,,4\9QCVBM7_ .C.]['>V1W4H[3:JR;MM/NKF(:/3<LN-31^N[P#5Q&>
MJ#(7@UJFH; 4\%GA%X@.0\9DI'=Z$WB[/]OY?R_E_P"0'E$1 %67]+7^E R?
MW1MO?PM*K-"K+^EK_2@9/[HVWOX6E0&KW7SLQ^=+7['G_<B7T5\[,?G2U^QY
M_P!R) ;WNO\ T./_ +@_ZK+]E^-?^AQ_]P?]5E^R (B(#7Q>FF?&%L%]INOO
MPWIA4K%=3]-,^,+8+[3=??AO3"I6(";#T=#Z<_9#[)ZH_$?4JVX"U'_HZ'TY
M^R'V3U1^(^I5MP$ 1$0!$1 %Q/7FA,-JC"9;3FHL;3S.!SN/MXK,8G(0C8I9
M''7H3KVZEF$V<9(9X9#C-O?P_(NQ,SMRQ$!J3>_([G[,=E3<=WQ,-R_M!K*W
M:GV^STY-/)CY!%[5K1>9G9F=\IB(G(L?9D$2R^(B:U[5JK?Z805NSNV5V0-$
M[[;=:CVRU_CAOX#4-0HO& 8FR&'R,;.6.SN&L2QRM3S&)L]%JC:$"Z) >.09
M())8CU!_>%]@'7/9JW-R^V6N8GL351:_IW4D-4ZN,UEIN:0XZ6H,6!23C&TA
M@=;)4&L3R8G)PV*,TDC!%-,!ACB,O;Q]RGD<?:L4,ACK=6_C[U24H;=&_2GC
MM4[M68?:ALU;,45BO*/M1RQ@8^;+:5^CY=]/3[2^AVT9K>_5@WPT/C@^:. 8
MFIQZRP44S5:>M,3#UG&4A"=6KJ>G 0^H9HWLQUJN,RF-C;5B+NOLY=HG6.TN
MMM/;B: S$N#U9IBZ-W&W8^2AE'R&UC<E78@&]B,E!U5,E0E)H[%8R9BCF"*:
M,#>"HHT^ZJ[S#1_:DVLQVN].G!0SU-XL7KK23S^+=TIJ88 EL4Y!-@EFQEP2
M>WA<DP/!?I$[!(]FM<B@DL0!$1 8[=K[XI=T?N=ZV_%K)K2#X?\ .E7]CP?N
M0K=\=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"@/HK;!^C$_2/[+?LC=/\ AFW#
M6I\6V#]&)^D?V6_9&Z?\,VX: GM1$0$-GI!VDGS78RW_ *@Q^(5;1D6:%G*4
M.E].9[#Z@:7F%G)_ ^#/&8";P9'C\.P[0%([:B);J;O$ML7UKL+O+I-N>=0[
M9:UQ3=).)/ZWI^_'PQ-YB3\\"[>;.[<+2GT)WE@AD=N'DBC-V;Y'(!)V_:=T
M![2V=WHBVKAR/9(]19XW/3NZ>O,1*( 8D!67Q&HP&4B(ADD*#/0R,<3 #121
M1D/BQRD6L16PS]"\W%:QM1O3I%Y ZL1N=CM2!$Y"QN.H]'X;%R2L//6X=6E8
MP<NGH8F9N>IW9 7/41$ 1$0!$1 $1$ 53/TQ/Z6O2'W7-/\ X U,K9BQJ[47
M8]VSWJP-72^ZFC\7K73]+)19BKB\N]KU6+)P06*T-QFJV:QE+'!;L1BQD0,T
MI/T\LSL!I)$6WD_*_'8R_4^:&_\ ER_^]$_*_'8R_4^:&_\ ER_^]$!J&T6W
MD_*_'8R_4^:&_P#ER_\ O1/ROQV,OU/FAO\ Y<O_ +T0&H;1;>3\K\=C+]3Y
MH;_Y<O\ [T3\K\=C+]3YH;_Y<O\ [T0&H;1;>3\K\=C+]3YH;_Y<O_O113=]
MYW5/9+V3[+F[6X&F=C=&XK55/#8_!Z6R-0LE'=Q^H-6Y[%:6QV3I/-E'![&&
MDR[YEFZ)':+'RFT4O0\9 :W1?.S'YTM?L>?]R)?17SLQ^=+7['G_ '(D!O@4
M1$ 1$0!$1 $1$ 1$0!$1 8W=LGXH-U?N;ZY_%C*+2'X?\Z5?V/!^Y"MWAVR?
MB@W5^YOKG\6,HM(?A_SI5_8\'[D* ^BMLQZ-)])-LG^Q]<?PD:P6IG6V8]&D
M^DFV3_8^N/X2-8("=A$1 $1$ 1$0!$1 $1$ 1$0!$1 >'6G3[[/4T>7[7':#
MO1=/0^XENJW1U./..Q6*QQ^9B+]774+K\N&/J8>19G6XL6D8[7VY46L]W-UM
M75Y?&J:FW+UWG*,OB-,)X[(ZIRMG&]$S"#2Q#CSK!#*PBTD0@3,S.R QW5C'
MT5'3Y7>V7I2R(=38G0FX>0,NHF\,9,74Q3'P/D7)Y,(^D^!^>=3>V(*N<K<'
MH;NW,U_M$;C:H>-BIZ9V>MXHC=G^=Y'5>L-,S4B$F-N']1TOF(W$@)B:7J9Q
M(&Y V2"(B +5R>EE?3A9+[F6@/W34"VC:U<GI97TX62^YEH#]TU @*U2M6>A
M]?30ZF^X[J/\9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@.@NU!V9=
M&;Q:$U'MQK_$QYG2VIZ$E'(52=H[$!/[=;(8^STD=+*8ZP,=S'W8V<ZUJ&,^
M"%B M0YWGW=P:R[+VZ62V]U2TM[%V!ERNB-5^"T535FF"L%#!>'HZHH<I2-A
MIYS'B773N=$K"-2[2.3<P*,_O6>[-TEVI=JLIH+//%B\_68\IH;5XU([5W2F
MI80_,ML!)PDGQ=[AJ&>QT<\'PABYIHHYJ]H*MJN!IOUV3LYO#J?;W5>G]<Z+
MR]C :LTMDX<O@LQ68#EI786(.2BD$HK%:Q!)-4NU9A*&W3GGK2BX2DRY+VD>
MSIK#:376I-N->XB;"ZKTKD)*&2IRL3PS!SU4\ICIW$1NXC+57COXN_%S%:J3
M ;=)M( =(H#< =SGWKFE^U9M?6U)3]6Q6O=/!3Q6Y&DHW,7PV>.NQ^OXT)CD
MEL::SG1+<P=OQ9W")IL;;F^$L?=C"7!:6[N\^WWKCLV[G87<K1%@I"JR14]2
MZ>EF./&:OTS),)Y' Y(&)@8SCZIL5>=GEQ63&"Y'U1-9KV-O?V-.U_HG?;;K
M3NYN@,F&1T_J"KUO&[L-[$9*!_"R>"R]9^)*>5Q5L3K6J\HBY=(687DJ6*\T
MH&42(B *&+TAOZ2[M ?:?6_&+"*9U0Q>D-_27=H#[3ZWXQ81 :BQ>']SKRO#
M^YT!N<NZ=^E8[-/W -F_X.M.+/\ 6 '=._2L=FG[@&S?\'6G%G^@"(B (B^7
MG,W4QM*YD;]B*I1H5;%V[:G,8X*U2K"<]BQ-(;L$<4,,9R2&3L(@+D3LS.@*
M>_I?';V+2FV>F=AL#?>'-[G76S6K1@D(9HM!:>F\1J!E&8E$VH-1?!T,HR.X
M6L5CLK2.*2*W(4>NK4A/>J=MFUVA=_-P]T"GGDPV3R@XC1U:660X\?HO3\;8
MS 05@,G&".]'%/GK,<0Q!)D\S?LE$$L\C*/9 <[VLVQS6MM4::T7INJ=W4.K
ML_A],X.J L1397.7X,;2%V(@%HPGL#).9& 10!)+(81@1-NF.Q?V7<'LKM5H
M7:S3D8AB]%Z?IXD9!9N;E[VK67R<KL$;G8RN6L7LE9E(!.6Q:DDD]LB=:MON
M%>TWL9LOO<6ZF^&1R]2#2>G[0Z&JXK361U&\^I\PYX^WDIAQT,ST3Q&'>U'6
MEEZ'F/*FT75X,O3=U_+8/8X_3/KC_)SJC_TB LF(JV?Y;![''Z9]<?Y.=4?^
MC3\M@]CC],^N/\G.J/\ T: LF(JV?Y;![''Z9]<?Y.=4?^C3\M@]CC],^N/\
MG.J/_1H"R8BK9_EL'L<?IGUQ_DYU1_Z-/RV#V./TSZX_R<ZH_P#1H"R8H^N]
M+[$U#M"[$;@;76HX_A#,XE[VF+9](EC=7X64,KIJ]'(3CT"&4JP5[8]<86<?
M8N4YC:O9EYBX_+8/8X_3/KC_ "<ZH_\ 1I^6P>QQ^F?7'^3G5'_HT!JZ\MA[
MF.N7,=DJTE+)8VW:QV1I3,XS4\A0L25+U2479G:6M:AE@D9V;@XW7SU*+WQN
M[FS&X>_>K=Q-C+N0L:4UT\.I<Q4R.GKNFY*&L[QS?-(\-2[%"4\66L@&<GLQ
MQLTF1R-\Y#DF.0E%T@-@!Z'AV\_A/3&M>SOGL@\E_2UN;7>@HK!!UOI?,25Z
M^I,13]MCD@P^HC'+.#Q$4'S4&/K!5VK5ZMW!:5ON\^V!D=A-ZMO=V<>\Y1Z4
MS@'FJE=RZLEI?)PRXK4N.*,?SQXV'N69:\!>3WZ].4'CFABECW.^@==8C5&"
MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
MB(@"(B (B( B(@,;NV3\4&ZOW-]<_BQE%I#\/^=*O['@_<A6[P[9/Q0;J_<W
MUS^+&46D/P_YTJ_L>#]R% ?16V8]&D^DFV3_ &/KC^$C6"U,ZVS'HTGTDVR?
M['UQ_"1K! 3L(B( B(@"(B (B( B(@"(B (B(#%_ML[WQ[:[/[FZ^DL>JOI+
M0VILY!8]GYU=I8FU)0+VG86;UWU=G=WX;GGSXX?21XZ)XZ\$9?1!#$!?KB L
M_P#G9;._TM7M4CH?LS1:&IV&CS.[VK<;IEHQ<FE'3.&"34FIK(\?.RBD:AB\
M'.!\N\>=ZXQ8H_%BUCB +8,>AA;)O2V_WEW#EA(2U)K#"Z6IV/T$]+2N).[+
M&S^YWKY#4-IG;S=O$?E^'9FU\DD@@)&3L(BSD1/[A86Y=W^LS-RMNAZ/AV8)
MMJ.R5M/A;\'J^;U#C;VO<\#@\<@7];9&SGJU6<"Y=K&,PMK$XB8N>)),>4@\
M";,P$T:(B +5R>EE?3A9+[F6@/W34"VC:U<GI97TX62^YEH#]TU @*U2M6>A
M]?30ZF^X[J/\9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@"(B KK^D
M"=RQ2[3>B8M6:.K5Z>].A:-HM-V2-J\&KL,_YIN:-RY]+@YV)(FFT_D)>'QF
M3=XC,:%^\+ZL3)XNW0M6Z%^I9H9"A:LT,A0NPG7NT+].8ZURC<KR,TE>W4LQ
M2U[,$C,<4T9@3,XNM[&J3?I/'<?GJFME>TMM-B))M3XZK%-NII;&P 1ZAP]&
M'POFTQE2&)II]08BJ,09V&,SDR>%JA9A@._0(;H&OS4X'<;]\)F>RKN.WPS9
MR.1V=U=)'5U[IRN/K3XR?JA"IKC"5>/&^%L-$!PWZ560!S.(GL1'7M9&GB'@
M@] V)F(78A)F<29V=G9VY9V=O)V=O-G;R=E_2 WI6C-9XG46(QF>P.1IY?"Y
MFC5R6*RF/GCLTLA0NPC/5MU9XG*.6">$QDC,7X<7^3S7)EKA?1F^^X+:W.X[
ML^;I94(]M=3Y%XM!:AR,SM%H74M\WZ<#<LR&XPZ6U%<((Z3F(PX3-V'(Y8L=
M?E>EL>6?EF=O-G\V=O-G_6= >5#%Z0W])=V@/M/K?C%A%,ZH8O2&_I+NT!]I
M];\8L(@-18O#^YUY7A_<Z W.7=._2L=FG[@&S?\ !UIQ9_K #NG?I6.S3]P#
M9O\ @ZTXL_T 1$0!5D?2H.WK%M5V>+6WF+M^%JW?![^CJT41#XT&C(88"UU>
MD;Q!,*T^-N5].N;!*QS9^*/HZ/$EALVN_'F_DS>]_J+4:]_QV^&[0':1U=E\
M7;]:T7H62?;S1) 3O7M8_ WK$>8S==NHF\/.YWUVS7D;I\?&08R4XXI'*, (
M66;CR7E%DKV<>QMNQO!8RM7:S;W4^O9\%#5GS(:<I!:^#8KIRQTRMG+-  /9
M.O.T0"1&[1&3BPLSN!C4BE _(3NUW^IUW.__  34_P!X)^0G=KO]3KN=_P#@
MFI_O! 1?HI0/R$[M=_J==SO_ ,$U/]X)^0G=KO\ 4Z[G?_@FI_O! 1?HI0/R
M$[M=_J==SO\ \$U/]X)^0G=KO]3KN=_^":G^\$!%^BE _(3NUW^IUW.__!-3
M_>"?D)W:[_4Z[G?_ ()J?[P0$7Z*4#\A.[7?ZG7<[_\ !-3_ '@GY"=VN_U.
MNYW_ .":G^\$!%^BE _(3NUW^IUW._\ P34_W@L.>T-V6=R-I,O4P&Y^B-0Z
M$S5^@V4HXW45-JEBYCGFDK>N5G"2:*:$;$4D,G1(YQ2"S2 #'&Y ="K9:>B9
M]OP=Q=DK^SV9M$>J=E)*5''C,0]5W;_-G<DTW+ 3OXDWP+:IY'!6@X/U.O!A
MR.00OUH@UI:E:[E3MX3=GCM$Z&UI8G./2F:N0Z)U[$Q2^&^E-27*M:;)E#&_
M$TFG;XTLX#&$A/7IW((1&6R,@@;A9%^-:S'-''-%($L4H#)%+&0G')&8L021
MF+N)@8NQ"0NXD+L[.[.OV0!$1 $1$ 1$0!$1 $1$ 5?STH?Z23=G[)[7_P +
M&B58#5?STH?Z23=G[)[7_P +&B4!JDE\W,_G2U^QYOW,E])?-S/YTM?L>;]S
M) ;QKLW_ !=Z"^TO2WX#HKNA=+]F_P"+O07VEZ6_ =%=T( B(@"BC[Z/N]ZW
M:3V"U;H2"&+YK<> :JV_NR.0%3UA@@EFHP.8!(_JN;JG=T_?!P,7IY260&CL
MPU[$,KB(#1*6*TT$DL%F&2M9KRRU[-:8>B:M9@D*&Q7F!_,)H)@.*4'\PD A
M?W+\E9X]*=[O =H]]8MRM/XTJ^BMZVOYN4Z\ C1QVX-(XSU32)X0&*M)G(K-
M74=>.1@DO69<]/"\Y5+A15AT!L#_ $03O$?AK2NI>SAJ7)%)E='26-6[=#:D
MC8I='9&6$<Y@*9.32SMI[.RR9*.)P,J]'4 01R-3I0P5KL*TD_8R[4><V3W6
MT%NQIP7DRNAL_#E6JL71\(XRQ7L8K/X@C8@Z1R^ R&3QCNY,#/:8I&*-C MS
MUL#OCIS<S1&E-P=(WAR6F=98#&:BPEP1.,I*&4JQVH0GAD$)JUN!I'KW*EB.
M.S4MQ35;$4<\,D8@=O(B( H)_2&^\5?L^=GG/RX.\U7<+<-ST/H;PWA>Q1L9
M*$_AS4;1S,8N&GL&URW [QR">6DQ<$@>#-+)'.N[LS.[^3-YN[^3,S?*ZU*O
MI!W>)!VA^T/F[F$R W=OMNH9M":%> C>G<"I9>34^HHG?I"8L[G **&T$8A-
MA\3A_"*:,6L3 0<BW#>\B?Y2,B,R?Y2,R=R(B?S(B=R)W<G=W=W7\32C&!&3
M\" D1/\ 4$6=W?CW^3,OT4W/H_?=X!VB.T1@,=F\>5W0&W\,>O-=-+"TE"Y!
MC[D4>GM-W'D%X#;4.:Z'EI'UE=P^+S0/"< 3E&!>I]&V[N@]A>S[CLGGZ;U]
MP-UIJVN=4C,/%C%4;5&"+3&F7]D>@<3BF:W;!^LWS.5RK^*5=JL4%@Y$0!$1
M $1$!HY]_OC W ^WW6OXSY5=3KMC?[XP-P/M]UK^,^574Z V2OH:OTM&XWW?
M]2?P9[3*VVJDGH:OTM&XWW?]2?P9[3*VV@"(B Q?[;WQ+;O?<OU_^*F66D>P
M_P"=*O['@_<A6[A[;WQ+;O?<OU_^*F66D>P_YTJ_L>#]R% ?16VA]&K^DEV.
M_8>M_P"$S6:U+RVT/HU?TDNQW[#UO_"9K- 3GHB( B(@"(B (B( B(@"(B (
MB( B(@"(B T/F%_.=7^T1?Z@KZ:^9A?SG5_M$7^H*^F@-G'Z(7]*5-]UC7O^
MKA%:-57+T0OZ4J;[K&O?]7"*T:@"(B (B( B(@"(B (B( B(@"XMKC6-#3N%
MS&H,I+X&,P6+R&8R,W#/X-#&5)KMN5NHA%_#KP2'YD+>7F3-YKE*@F](_P"U
M9%M5V3=PI(K0ULWK\:NVFG19S:::_JH; Y$H&!V]JCIRGG,F?B?.GBI&!]3F
M($!JD==;@W]79[.ZMRA=63U7G,QJC)$S\L^0U#DK.8N\/P/+>LW9&%^EN69G
MX9<67\B+"S"S<,S,S-]1F]R_I 78O0OMC'LZVWLW-FKET8C3.G]O\;:X?I\7
M.9/YI<]79^..?#P6F9?>_//Z'H]K8'*M3Z*7V;3T/V4,+J6Y6]7R>Z>I=0ZU
MDZ@<)BQ$5T].Z=.5G;VAM8K"QY2L;._52R-?GI=G +*R (B("HIZ9+]+SMY]
MV'%_BCJY:WI;(7TR7Z7G;S[L.+_%'5RUO2 [\[)_QK[5?=/V\_''"K=Z+2%]
MD_XU]JONG[>?CCA5N]$ 1$0$<_>Y[%ON3V9][=(1Q#-:R&WFHK- '$B+X0Q%
M&3+TO"$!(GG>Q1C"!NEV>4@8O9=W;30UIVECCD;GB2,#;GW\&+$W^E;W*6(3
M$@,1,#%Q,"9B$A)N"$A?EB$F=V=G9V=GX?R6E?[Q#LLR[)[X[G[7E#+#2TKJ
MS)08)I>IW/3%^1LIIHQD,0>=APMVE7.=A899X)B9F]S 89K82>AF]HR/([=;
ML;4V)W>WI+5E#6&.K./ MA]847JV) -R?Q";,8*WXP@S-",M=S87G$I->VIU
M/1Q>U_!L_P!JW1$^3MC3T_N)4O[7YN20NBN):DL4+>GYIR=B$7CU/BL37B/H
M<_S;)")Q!8E)P-LXB(@"(B (B( B(@"(B (B( B(@"(B \.3-YN[,S-R_/R-
M]7]9:@WO-.\8W.U1VAMZ,SIO=#</$:=FW#U!0P6-Q.LM0XO'4\7@;#8"K%5H
M8_)0TX <,7XI/!&(S22E.[D<I&6SZ[T;M4P[*]GW=G<@CB&]I_1N7; 12NW3
M:U1DZQ8K357HY8I0ES=VCXXQ,4C51GD87:-UIAQ<W;F662>4N2EGE)SEFE)W
M*6:4R=R.64W*20R=R,R(B=W=W0&3?\^QO1_9AW4_RA:M_P![JZ-Z'CK7<#6F
M6W[U+K'6>L=4X_#T=O=/X@-2ZDS&>JPW\E-JS)YAZ<>4OVAK6(:M'">.<<8/
M+';A'K/PR$:#ZV@7HG'9ZDT;V5:FI;-<H;FY^L=0:QZC87>;&UWKZ9PTH$SD
M7@R4<$,P1OTL,DLTC Q2F1 6;D1$ 6H%[^_Z<?M ?;E4_%C +;]+4"]_?]./
MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
MB(@"IB=^+Z._OCVE-^;>Z.@-2;4XS3]C1^F=/#3UAJ#5^,S W,*63*S*5?"Z
M"U%2]6D]>!H";(O*70;R0Q^3/<[1 :TC\IS]J?\ 3GL!]^.XO_"138]PMW F
M]?9>WGS&X>X>H-K<K@LAH',:6AKZ,U!JS)Y8,E>S.G\A7EDK9S0FFJ;4F@Q=
MH9I1R!SA*5<0JRA)))#<&1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!Z&4Q=:]6L4K
ME>"W3MP2UK56S$$]:S6G HIZ]B&02CFAFB(HY8I!() (A(7%W94#>W%Z'[K_
M "6Y6?RNP.I=L\-MIEI&R.*TYKK4&K\?EM-6[4DTE[!T'P^B-40V]/TR>+X&
MGMY'X0BKR/2LA(U2.U8V *(#6D?E.?M3_ISV ^_'<7_A(O#^AS=J=_\ ]L]@
M/OQW%_X2+9<(@,8.Q%LIE=M=E]H=N<[8Q]O-Z VOT!HK,6L3+9GQ5G*Z5TIB
M<%D+&,GN5*%N;'S6Z$TE*6U1IV9*Q1G/4KRN4(9/HB U\?;.]&,[8N]FZFN-
MU-2ZUV!')ZRSMK)!2^;7<6:+#XH7:OA<%6D;:"$3KX;%15:(S-#"]N2*6[+$
M$]J5EC)^4Y^U/^G/8#[\=Q?^$BV6Z("FCW('HU6O=@=YX]V=X\YMUGWTU@\A
M!H?&Z)RVILN]?4N8#X.LYO*?#^D=+0QCC\'+D:F.BA:^Y6\F]UVJS8^K(=RY
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!0A[QOT3[=O7N]NX>NMHM1[1X?0NL
M<Y\TE##:KSVL,5F,9D\I4K6-1P'6PV@M14"JV-0ED[].0,B\CU[D<<T(2QD1
MX3?E.?M3_ISV ^_'<7_A(MENB UW/9F]%G[8VU&XFBMRM+:Z[/\ !G]$:BQV
M?Q_5K'<9HK+59>F]C;/&T;N]/+XV6YB;K,SEZI=F<.)&!VV']9Y'CC>8 "5P
M%Y0CD*6,)'%G,(Y2BA*0!+E@D*&(C%F)XP=^EOW1 $1$ 1$0!$1 $1$ 477?
M,=BC5G:'[.NN=I-$7]/8S4NI;>CK&/N:JN9*A@HAT[K;3VI;@W+>(Q&=OQ%-
M2Q%B&MX.+LL5HX0E\&(CFCE%1 :TC\IS]J?].>P'WX[B_P#"1>M<]#?[4\T,
ML7S:]G\?$C./J^;#<5^GK%QYX_F2MSQSSQRW/U5LP$0'7NT>E+.!TIIC!W3@
MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ino-20211231_g2.jpg
<TEXT>
begin 644 ino-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 Z17AI9@  34T *@    @  U$0  $
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M5QX.\#^,/%EO8N([F71M&N+]+=B,A7,2,%) R >M<?7Z]_\ !M1_R1[XH?\
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M*21N-VTD<JRED<95L_.HSJT(5(.%SN7"^78SFH8#%*51+9JR?H_U5S\"ZD'
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M.WM86FED/7A5!)_ 5TVM_LX?$3PSI<E]J7@/QII]E"ADDN+G1+F&)% R269
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M.Q3DY&*7_!1;]KGXL>&Y_'_@]? ;6_P\N(%TQ/$$FEW8WB5$W,+@GR"&+,@
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MO? W@+PSH>I1^&9DMM2O=2,C1R2 ?O(8(XG39LR%WL3\RL-F "?6]*M/ _\
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M4(X_'UL-!Q7*G9JVMFWIYO7YD936HK'XVMAXN*Y4[-6ULV]/-Z_,^._VN?\
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MY2#GIVG[8OQ:\<?!CX9V^O\ @G1M/UQX;D+J$5Q;2W!A@*G$JK'(AP& !/.
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M:#P_=ZA!#J,T4RPO# T@5W#,"!M4EN1V[=1]Y?M7?\$I?#Z_"&.X^%>DR?\
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M+Q7M_P"Q/^WQX[_87\6W5YX6FM;[2=4*?VEH]\K-:W@7HPVD-'( 2 ZGOR&
MQ7B5.3K7CXK,N32COW.*CCJN'J*K0DXR6S1^GC_\'(=V=/VK\'[=;K;_ *P^
M)R8\_P"Y]ESCVW5\2_MB?MO^.OVW?'-OK'C"ZM8[;3E:/3=,LHS'9Z>C8W;
M269FV@LS,2< < !1X_3E7->;7Q^(JQY*DKKY+\CNS#B/,L=3]CBJKE'M9)?.
MR5_F?3G["W_!4WQ]^P_I\FB6<-KXG\'S2M.='OI&3[-(WWF@E&3'N/)4AD)R
M=H8DGZ6\2_\ !QSJUUH<R:1\)]/L-09"(I[SQ ]U"C=B8UMXRP]@X^M?F?3G
M'1:VP&,Q+:I0EI\MC? <39IAZ2P]"LU%=+)V]&TVODSM?CK\?/%7[3GQ3U#Q
MAXPU)M2UC46 R!MAMHE^Y#$G1(U!X ]222Q)/US^UU_P61_X:R_9HU3X=?\
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M">?+7\*]2_9L_:D\4_LP:A</X?FAFTV^=7NM.NP7MYF'&X $%'QQN4C/&<@
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MWK:_XG33XDS.%)48U7R_*]O6U_Q.D\'_ !.N_#GQATCQA?\ FZO?:?K$&L7
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M>,/^"G'Q$^!^FVUKX[^#\UCJ<B[!=F^DM;6Y<=2@,4@/T$AKXC^#7QEU_P"
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M88AX98-R_=IWM9;^MK]>YYM3-,5+"+ N7[M.Z5EOKUM?J^I]7?L^_P#!3O\
MX41^SMI_@'_A"/[4^P0W4/V_^V?(W^?-++GR_(;&WS<?>.=N>,X'R;FG.>:8
MYPM&(Q^(Q$(4ZTKJ"M'1*RT[+79;DXS-,5BJ=.E7E>--6CHE9:*VB5]EO<83
MDU]0?LZ?\%5O''P-\,V^AZK96GC#2;*/R[474S0W<"C 5!, VY0.@921TS@
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M9/V/-/C\8>$[V^UCP/=7 MYTN@&NM'D;[@=U #QL<J'P"#M4Y)!/IG_!'_\
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M4;BQ. .<XJ<5)>RHI/\ K0QSK$0>799&,EI:^NWP[]C]/?\ @Y _Y-"\&?\
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M.33G.!3*J)F-<YIM!.315"8CG IE.=LTVMXZ(4@J,G)I[GY:95Q)"FN<TXG
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M5!Q35&34J=:R! @YJ8#FF1KM%2H.:S-!RC-3)R:C0<5*G(J9;%1'QU(@IJC
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MS_&[4RW^SI;?_'JY)^%N'7PX^+_[AR#_ %*QWE]Z_P SYB"\^U3(.:^I(?\
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M#P3EZZ_G([Z? \%O&/XL_!Y_%]VJ_>A7_@-1_P#"67+YW72J/^ BOZ'/#_\
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MJ+J^6W79'][IQT6J+-N;-=$8]3CG4MH@)R:,\445H<_6Y\OT445^@'0%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:5P*=10!&5)J*ZTVWO
M4VS0PS+Z/&&'ZU9QBC%%K[BY4]SE=<^"7@_Q)G^T/"GAN^W=?/TR&3/YK7'Z
M[^PM\'_$0;[5\.?"N6ZF*R6$_FF*]:ZT5C+#TI?%%/Y(YJF"P]3XZ<7ZI,^<
M]>_X)5?!'6PVWPG)I['O::A/'CZ#<17&:Q_P1:^%-^#]EU+QAIY/39?1R ?]
M]QFOKXKFEVXKEGE>$G\5-?<OT//K<.975^.A'[DOR/@[7/\ @AIX?FW?V9X_
MUNW_ +HNK&&;'XJ4KC-<_P""&GB2#=_9OC[1+A>PN;"2,_FK-7Z1[0*4#%<E
M3AW+Y?\ +O\ %_YGFU>!\EG_ ,N4O1M?J?E3X@_X(Q_%O2@39WGA'5!V$=_)
M$Q_!XP/UKBM?_P""77QPT ,6\'+>*O>TU"WES^&\']*_8K:*38,UQRX3P+VN
MOG_P#S:OAOE,O@YH^DK_ )IGX@Z[^QE\6?#1;[9\._%BA>IBL&F'YIFN,UKX
M=>(O#;[=2\/ZY8,O47%A-'C_ +Z45^^6WW--D@65<,H8'J",YKDGP;0?PU&C
MRZWA=A7_  ZTEZI/_(_GUD81-M;Y6]#Q0'5AP:_>W6/A1X7\2(RZAX;T&]#=
M?/L(I/YK7#^(_P!AGX0^*-WVSX=^%V9NK168A;\TP:XY\&U/L5%\U_PYYE;P
MMK+^%77SC;\FS\2Z*_7SQ'_P2C^".O!O+\+7.FL>]IJ5PF/P+$?I7#:__P $
M4?AEJ.YM/UKQ=IOH/M$4P'_?2?UKCJ<(XQ?"T_G_ , \RMX:YI'X)0E\VOS1
M^7E%?H7XB_X(86K!FTGXBW2^BWFEJ_ZHX_E7!>(_^")7Q"L"W]F>*/"NI+V$
M@FMV_P#06'ZUQU.&\PC]B_HT>36X%SJG_P N;^C3_4^,:DAN6B^GI7TEK_\
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M? FFZA(N,2:E))>$_@[%?TKLI_ZGX3^%AY57WE_P7^A]'A?#G'2UJN,?G?\
M(_#/2/@_HQF6."PEOINR[FE8_P# 1_A7J7@+]C#XA>,0O_"/_#/Q+<(V-LL>
MDO'&1_OL /QS7[J>%/A3X8\"0K'H?AW0](1>@L[&*'_T%16]MXKI7&U"@N7
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MJGA_2/%'AW5->T0D:CIMGJ4,]Y8$':?.B5B\>&X^8#GBJ6D?M!^ ?$'@^_\
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M4/BKX7TGX@V/A*Z\2:#:^*M4@-S9Z-+J$2:A=Q .3)' 6\QU BD.Y5(_=O\
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M:3=X^ZM[820$_BK,/TKBJ<+X^"TBGZ-?\ \.OP!G5/54U+TDCX4HKZF\4?\
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M\#Z3)HN@I<272VK7MQ=A)'QN(:9W8 X!P#C.3C).78#X2^/_ ,+_  _\8/\
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MAA:^$;&3P)-(\K:3=337:;W?>6#RNT@;=R"&RIZ8K._9]_8 ^#_[+/B:;6O
MO@FQT75IXVA-X]U<7DR(V-RHT\CE <#(7&:=@/AG]G3_ )R4_P#<8_\ <]7
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M%/C)XD^*G@*UU;X:^*+56T:[EU&-6DN%:VPR""87$3;4E&2%R,CN ?LKX*?
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M \(V?B"XTD,MI.9Y[6:)6()3S(71F7(SM8E<D\<FH?@=^P[\*_V;/'NH>)O
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MK/7O#?VZV^&QC/AQ/[0NHO[.\L1!.4E4R8$,?^LW9V\]3E6%8^,/#_PR\/\
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M0!67R0&QPP'%,H^1O@MXCUGPU_P2#^-[^&[F]%K=>-+*TO[B,'S#8NL8.YL
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MXF\5PW'Q#^Q)+:07WEVFE,ZV;FXLX\'R9V,^2^6SY<?'R\KF%<_1CQ!\>?\
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M5B 7"Y^I]%?EA^VO\9?B'X#_ &S_ !E%\4O%/QX\#_#8@)X4U+P)/]FT^ ;
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MXM>(?%GPA\;6>L_\(['J]QX5>36-4CVI*C06\KP#S7C+IYVX >1(P._D>/\
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MC%XA^)$GB'6OA_X=DT.\C?0DMVUMW6_7[072;;#_ ,?H^18V'[KJ-WR_3=%
M'R1XQ_X)AZSX?^,'BSQ9\(?B]KOPE7QXYFU[3K;28M1MKB4EBTD6^1#"Y9W8
M,,E"[;2H.*NW7_!*OPWI7[!/B+X(>'M>NM,D\57$%]J7B*[M!>7%U<QW,$[2
M/$'0$$0*@4. H.?F.=WU510!\M_M0_\ !-;_ (:2_8I^'?P>_P"$T_L7_A ?
M[-_XF_\ 9'VC[=]CL);3_4>>GE[_ #-_^L;;C'.<B/\ :!_X)NZI\1?VJ_\
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M&@?;-*BL8=/0AAO95>0RR@.Q#D@[FW'+ $=-^S)^PI_PSE^TY\5OB-_PE/\
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M'1TC?4)'&T/$Z2A8(T5(56/8X C(# , OUE10!\R_LH_\$Z/^&8? 'Q7T/\
MX3'^W/\ A9\\\WG_ -D_9O[-\R.5,;?.?S<>9GJF=O;/&'\/_P#@DMX;T?\
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M$#_@DGX'\6?L.Z7\$].U34M(M='U!=9M]8\I9IY;_$BO/-'E0X9)77:"N!L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/!_^M6-2O&$XPE]K1/I?>WSZ$RDDTGU.JHHHK8H**** "BBB@ HHHH ****
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M$?X+Z3X7U#P]KV@W\WP'L=.M+B_L)+9;#6[?4Y;JVC<R* LL<R02&-L,% /
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MD%%0IX:M67M.5)I6Z*&RW_Y=[VUUT222^;-$^ UW9_'C0[@>#;I-/TWX ?\
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M0ZU8VFB7-QJ,5N-:NG>X-K%&T\G[MXV^5&;800-HS7T5^V5IMGJWP[T>/5O
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M][ZZK2W-_JS:I^[G:*32TU7-S7OM=6F[;6TT>M_S_P#^%,ZWX?UKQU8>,O\
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M;S_FLDK?WOF1#(J5-QK5*ONT[]DE\/,V[Z6Y/EKJ?%_[(?P;N;'_ (4KX?\
M$1^/D?BKX92.9M,D\,Z98Z!H=Q'!+:W,AU,6$'VNUN/,<@07=Q+,)4>0,RNZ
M^S?M2:O+X%_:]^"WBJYT7Q9J6@Z/IOB.VOKG1/#M_K1LY)TL!")$LX977>4?
M!*X.T^E?1%%<];-'4K^VE'I)66GQ<U[:?WG;1^;9UT,E5'"_5X3UO!W:;^!Q
MM?77X4G9I=DE9'PS^TYX-\2_M(^'_C=X\T7PCXOM=.O/"6E>$-!L;S1KBVU/
M7VM]2FNI[E;.15N(XU,X1!)&K-MD< *038^-_P"S]XK^"/[4WPYL_"7A^^U3
MX1ZYX_C\9W,6FV4EQ_PA^H1VEQ'=#9&I*VMUYPF4#A)EE "^8@/V]16M/.YP
M2A&*Y;-6]8J*^:M>_=M;.QC4X=IS;J2F^=M.Z[J4I-6[/FM;LD[\RN? ?B#]
MF[XS_$/X ^)/BE8SZ+I?BS5/$_\ PM#3?#.H^%;IO$5O-9#98::UU]L"AC90
MI"8VM.&GE7 +%J]V_;HTB]_:#_8+NHK+PSK5Y-XFDT"[DT.73I6O4B;4[&::
M*:W*[U9(]_F*R@J$?<!@X^AJKZOJMOH6E75]=2>5:V<3SS/M+;$4%F.!DG !
MX'-1+-JDZM.HXJ\)7C;332T=-TK*SW-(9%2IT:M)3=JD.65];O6\M=$WS.Z6
MFW8^(/VI?@9KGB!_VSKS3_!VK7U]XI\,:);Z+/;Z3))-J\D5G(&2W94)F9'6
M/(3)5@O0@54^+OP8U0_$_P".NA>-)_C=)IOQ-U&"?3[?P7X6T_5K/Q%826D-
MM';M>3:?-]BFMWB<?Z1<V\<>Y)4*EGD/VYX!\<Z7\3_ NB^)=#NOMVB>(K"#
M4]/N?*>+[1;S1K)$^UP&7<C*<, 1G! /%:U;1SJK3]R4-K+S5E!=4[? NG5V
ML[-<\^'J-7]Y";]YMZ;-2=1O9J_\1VUZ*]TVG^=W[37P\UGPM^S]^T!X#U3X
M>_$#QIXP^(&L6NM:#J-IH$^L'4K1;>S2W,][#&T44]H;696B=U/"F(.LJYZS
MQ#\+?$FA?M+^(_&FH>%/$>J>#_#_ ,88-?O;6WTN>YEO+8^&H;."_MX$0O=+
M;7CHQ$*NP,;$ E#CZ=L/VM_A[J<&FRP:^SQ:QH]_X@L7_L^Z5;K3[)U2XN4)
MCY0%T*G_ ):JZM'O4AJTO#W[1W@?Q5\"T^)ECXBL9O LEB^H_P!K,'CB6%-P
M<LK .K*RLI0J'#*5*[N*W_M+$QARND];Q>^[48V6FCM#3>SOVLN59/@YU.:-
M=.UI+X=%%RDF]=5>I=O2ZMWN_F7XV>&W^*GCGPWX@\&_#?Q=H>EW6F^.#=/<
M>'9+"74+J?3[>)+J2#'FQ-<2(RH+A(II6C+;"&5FX_XM_LR>.-:^$7P/\.^!
MO#M]HFL-\%O$7AV\E6Q:VCL;J>PTOR[6YD*@0223+.%\PJP?S&ZAB/L[P;^T
M#X1\?W/AF'2M6\]_&>AKXDT/S+6:!=3L6$;>9&9$4%E66)FCSYB"12RJ"#79
M5A'-ZU!P7);EO9._7F6M][<S^[H=,LAP^)4Y>TOSVNXV5K<CTMM?E7R?4^1_
MV3_!-GK7QG\$ZX)/C]+JGA?PM-I9A\2^%M/T'2M!MY5@SITDD>GV;7A5X4V?
M9S/"K0[MRAE+_7%%%>9C,5[>?-:R2M;YM]$NK[?CJ>SE^"6&I\E[MN[>O9+J
MV]DNOI962**P=9^)VA^'_B'H7A2\OO)U_P 2VUW>:;:^3(WVF*U\D3MO"E%V
M?:(>&8$[^ <'%\>)+<^*&T?R[_[4MJ+PR?89_LNPN4P+C9Y)DR,^6'W@8;;M
M(-<WLY)7:WU^6U_OT.KVL&VDU=.S];7MZV:=NQ?HHKD_'_QR\+_##49+36]3
M-K<P:1=Z]-'':S7!@L;4 S3R>6C;%&0!NP7;*H&8$44Z<IOE@KOR"I5A3CS5
M&DN[T.LHKRWQ+^V9X!\,>(=-TEKGQ/JFI:MHT'B&WM]%\):OK$AL)V9(IW%I
M;2^6&9&&'VMD<@<5I:)^U)X#\1?#[2_%5GX@BFT#5M3CT:.[^S3JMM>R2>2M
MO<J4#6LGFE8B)Q'MD=$.&=5.SP>(24G!V?DS".885MQ52-UOJM/Q\T>@4445
MSG6%%9^N>)+?P]+IZ7$>H2-J5TMG#]FL9[H([*S R&)&$4>$.9)-J E06!90
M="G9[BYDW9!1112&%%%% !1110 4444 %%%% !1110 4444 %?G]\4+KPA\-
MOVVYM:@N? ?Q&\2WGCZS\S1+^"\TGXC:!+(EE O]GSJ=U[I<<333F)HHK9HC
M(IFD^:OT!JAI?BK2];U?4M/LM2L+R_T65(-0MH+A))K"1XUE1)4!S&S1NC@,
M 2KJ1P0:]#+\8\/*4K-IJSL[:>;LW;T:?GT/+S3+UBXPCS*+C*Z;5]4GLKI7
M]4UY=5^<7ASX0_#W4+K1O!\?A_PI''_PTOJ-OK&CV]I!'NLUM-::TAN(5',!
MB!"(XV-&6 !4D5S_ .W!KWA"SU#XAKI&A_"SP'XB\$^)-/M[ 74=QJ'CJ?[+
M-8O%=6'S1MH^FQVZ*T9C\V H'P(BY+?J917K4^(FJRJRBW;IS=;W?2SOMJGZ
MW1X=7A.,L.Z$9I7Z\BVY6E;5--;W35W>ZLVC\[->\":3\3/C[9Z'KMC!J>D7
MW[1VJ"ZLYU#PW2+X8#^7(IX>-MH#(P*LI*D$$BLW6?"GAFV\!Z]H]_XD^'OA
M'0_!/Q9\46?AK0?'.B27G@6Z8V8DBL[D!XX+0(\TLD!+?*3+Y<4A!4?I+5#3
M_%6EZMKFH:7:ZE876I:1Y?VZTBN$>>R\Q=T?FH#N3>H)7<!D#(S6<<^GI:+M
M%+KZZZQ:UO;;YFDN&:=VW-7DWNGMH[:23=N6^]NZMO\ '7[-R:3^UCI/PW\)
MMX7E\/\ @GPKX4U>]GTN/5I]2LY(KN6ZT:P:":=5E:TFM%U-X"ZKB(HJ#8!G
MS7X8^.-4UWP5XQN?&7A_7O$T/[+/@34/!=Q865U-9W&KZI)++#)-%<0?O5SI
MUG:,TRY9!>RE5)!S^CU4- \5:7XK2\;2]2L-273[J2QNC:W"3"VN(SB2%]I.
MV13PRG!!Z@5G'.;.35/3I[SNKMM^]O[RDU??9]#67#]U!.K[R3O[JM*RBH^[
MLN5QC)+5;JR3/R@\8R>&](O_ (U0>%;CX06^DZC\#]<5[3X;6SKHR2PWD!BA
MEO-_EZC>103#?.L43@2_-&H89]X^,_AKPK^S3\0;?^Q_!;7>B6?P.UR[OM)T
M2:32Y]49M0T99I9+BV'FJ[+\TLXW/M5F.[&#][45M4XA<I1O!V5[^]O=);I+
M:VCW\S"EPJH1FE45W:SY-K-MZ-O=O5;>5M#\B_B%)H.GVGQT@\,7'PCCTR_^
M"U[)<6OPTLGAT-9H=1BV(]SO,>H7,45PH>X6.)@)@K1ID ^J?MT? /PS\,[W
MXT>#_"_A?3;;1YO@BNN3V=O9*PNK^TU&<)J$J@8DNE1G)N&!D/4MQ7Z045?^
MLDN>,E!Z:_%O\-KZ+;ET]?OS7"$/9S@YJ\E9/EV7OWM[SWYM=EIYZ?G)^TU/
M\+? 7Q<D\3>%;CX3^/5CMM#;0?!$D,VDZW';()?L1\(ZE;$[O,N_+)BM(61G
M$Z--&V5KZ9_X*/>7_P *=\-?VM]H_P"$&_X2[3?^$SV;_)_L;<_G?:-G/V;?
MY/FY^7R]V[Y=U?05%<%3-N:=*;B[P[RU>BVLDDU;>S>UV['I4\CY(5H*22J=
M%'1.[;O>3;3O9QNDE>R5V?F%\:/ O@3QCHGC%?!^C>'M4^#J_$WP7'X=%M:1
M3Z&+R6Y6+5EL.#%Y+J84D$/[MF,J\Y85]9_\%%/$'A_X=?L_^'=-U+PQX5U3
M0]1UZSTF*'Q#J<FE>%](*Q326\^I>4C(]DDD,:^1(OEN[P@[3M8?15%76SCV
MDZ<I1=H._P 3N](K=):^[=OJV31X?]E3JQC)7J*U^567O2=K-O3WK)=$EJ?'
M/_!)F6QL=?\ CII6CZAX;O=!L?%T$VG#PYICZ5HICET^W8RV5JTLHC@D8,RL
MDC)+C>C%66OL:BBN#'XKZS7=:UKV\]DE?9;VOL>GEF!^IX:.'O>U^EMVW:S;
MVO;=[!1117&=X5Q/Q.MI/"NL6/BRU5F^P_Z/J"*.9;9CU]RIP?\ ]5=M4=W:
MQW]K)!,BR0S(8W0]&4C!!^HKGQ6']M3<$[/=/LUJG_730BI'F5A;:YCO+>.:
M)EDCE4.C#HP(R"*?7%?"Z\D\-ZE?>%+MV:33?WUB[=9K9CQ^*G@_EVKM:,+B
M/;4U-Z/9KLUHU]XZ<N97"N>^+G]L?\*H\3_\([N_X2#^R;K^S-N-WVKR7\K&
M>,[]O6NAHKJC+EDI!4CS1<=KGYR_"#P[\-/%6M_"+3_ -CIFI:]>>%]8@^+M
MLD/G7$\;:;)YJ:\C@LUR=4\O:+H>83YNWY=U>V?L$>$-+T#_ ()(^&(]/>X\
M)+JO@J6\O-2T&P9KZ&>2V8/>1QP*9)KD8##:&D9D4#)P*^H/$OB;3?!GA^\U
M;6-0L=)TK3H6N+N\O)U@M[6)1EGDD8A54#DDD "KD$Z74"21NLD<BAD=3E6!
MY!![@U[6+SB5:GR\KM=.[=]G)]K/XNVB2W/G<#D,,/5Y^9-\K5E&UDU!77O-
MKX&WKJVW='Y?>&]230/@=\4_#7PDM?A[X@N$\&Z?<-XR^%BWEK%<:>EW;QO#
MJ.EPRE8]5:!]0D#I/]H>.-E_=XQ5KQYX9\'V?[/WQ9U+P'\0OAEKFC3^#+**
M\T/X=>#Y]'T6.3^T86ANKJ07ES +[898S&VRX:,@L"L8Q^G-%=7^L3YN90>Z
M;U3O;EWO'^[IR\J5]$<?^J:<>5S7PN*]UKEOS;6FOYM>;F<K*[/S8^*OABV\
M5_''XL0^-/B'X#\!_$7_ (2Q/^$8GU'P7>:OXS@L-\7]FOHDL5_'(\+$,#%:
MV[#>;@2!MS5Z3X:T[X/WGQP^(;?& V/_  MA?'['PZ+@S/XC.G[HETW^SHX\
MW$EIM<[U@5H3BX\X%1)C[>HKGGGDI14+-:6T:5MMFHWL[;-OIKO?HI\-QA-S
MO%W=_>BY)_%NG.W,N;=)==-5;\K]"\*>'/"WP\\/:(C?#GPGX+L?BCXIMO'
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M20>5+(P-\8WN21YFP+\^P5E_"3X4:+\6/B7\$-#U[11K?POEUWQM<^#M-U>
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M&NHKA_'H;P'XQLO$\8Q9W&VRU0#^X3A)3_NG SZ8'>O.QG[F:Q2V6DO\/?\
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M@N(3>RP?:55R\C$J'*$\9\'OA9I/Q9^+/P*T7Q)HO]O?#C[9X\E\'Z;KMO\
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M'[MN5WU22O;5W-*?#ZA.[G'>32<+K7E;:O*_,N723;M?1)'YA:#IFFZUX-\
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M32VT\]SNX?R^KA*,X54E=IZ*VT(1ULVKMQ;WUWT>B****\@]X**** "BBB@
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M<WB/5? ?@O4_$-R(A-JEWHEM->RB)D:+=,R%SL:*,KD_*8T(QM&)M-_9_P#
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MDK<MMN6_O?XEMU.D@A6W@2-=Q6-0H+,68@>I/)/N>:=117BGT04444 %%%%
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M-"T_Q[J,UW#=Z_/;WK9L-/67%FME*D\4<9$C*)U=U6150MM#_:O_  BNE_\
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M110 5S'Q4\-W&LZ''?:?QJVCR?:[0XSN(^\GT8#&.YQ73T5CB*,:U-TY;/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*V5*]!AL 8K[=_;F^.W_  S]^SMKVN6NHPV.L)$%L ^&:20L!A5/7K7X7?M
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MO!_QEUQ]-\+^'/&VM7T<9F:&"TMMRH.IYN!ZUWG_  T%?_\ 1-?B1_X"6?\
M\DUC/"58.TE9^=CBJ8ZE";ISNI+=.,DUI?56TT:?H>D45YO_ ,-!7_\ T37X
MD?\ @)9__)-'_#05_P#]$U^)'_@)9_\ R34_5Y_TU_F1_:%#N_\ P&7^1Z11
M7F__  T%?_\ 1-?B1_X"6?\ \DT?\-!7_P#T37XD?^ EG_\ )-'U>?\ 37^8
M?VA0[O\ \!E_D>D45YO_ ,-!7_\ T37XD?\ @)9__)-'_#05_P#]$U^)'_@)
M9_\ R31]7G_37^8?VA0[O_P&7^1Z117F_P#PT%?_ /1-?B1_X"6?_P DT?\
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MG_?"_P#Q5.46MPC.+V.CHKFF^*6GKUAO?^^%_P#BJ8WQ;TU?^6-]_P!\+_\
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M\T\F[(4G^ZI(P">6(PH8\5Y!JUU\4/C?8?VAXQ\26WPM\*S,%2U@F\NZE4]
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MTL_M-C-/,TCR7EO V)HA$NZ>(*6()9P%,_7Z7]>E_P"NW4PEQ!A%NW]WE?\
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M9=/-GT^%X9E4IRK5?=A'?2[?DEW_ "/JZ+XN:$]YY<4UU,N<>9';2-'_ -]
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M_P $%E_\36OLX_SK\?\ (^7^M5?^?,OOA_\ )GI%%>;_ /"K?'W_ $5*\_\
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MV[ #N:ZB\G6*!F8_*@)8YZ <U\IZ#K&N?M?>+M>UK1=12QT'PW?&QLXG4_\
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M2^+^M3N=$;A6QTKIM,/S1_45S>C1$ 5TFEC#I]17WV$DS\OS"UV;%8_P^O\
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M*^+SKA_$Y?5<9J\5U7F?29-F%/-<-/&X.,O91DXW:ML[7.^_:&US6O#GP/\
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MO9*^VOR?X(\M_9UU"/PS_P %A+VUM5E5;BVUBUN=\F[EYH+E=H[#*OQ]*_3
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M (JC_A=_C3_H;_%'_@UG_P#BJO\ XDVI?]#-_P#@M?\ R1'_ !.I7_Z%:_\
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M?\*7\'?]"GX9_P#!7!_\31^Z\_P#_;/[OXDG_"X/"7_0T>'?_!E#_P#%4?\
M"X/"7_0T>'?_  90_P#Q51_\*7\'?]"GX9_\%<'_ ,31_P *7\'?]"GX9_\
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MU)5A9=P^7KDUX'\5?CM-X:A,.B0S7VIQ,0D$7)/U]!75>/=4UCQ[?KHVD?\
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M-J?C[]IKQU\2-0@;[#';?V;:S,<YN)IC<72+P#A2L';DMU)! _0H2<8KQ?\
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M)!(Y8%]OI\H )XR/45PFH^'_  _I/C":.UN[/P_)]^!XU$<329R P!*]SE2
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M1$4L!DA%&< 5W?\ PJ3X?_\ 16=+_P#!!J'_ ,;KS.BOU^&7RA\%62]%#_Y
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M?C_F'U6K_P _I?=#_P"0/-_^%J^._P#HE>I?^#VP_P#CE'_"U?'?_1*]2_\
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M%>SI>R6\OP75_BDO-HUHT)5ZL:$=Y?@NK.#U37'NKB:9AY;3/NV_W!T5?P
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/6EI&H
M\L_; _9]L?VC_@W=:'>:A)I7V65;^*Z3I$T8).X=U*E@1[U^'_QF\(6-WXLF
MU*'5!<:;IZ210W ;;9RJ&(#GW!'UK^@^Z@2[ADBD57CD4JRD<,#U%?%?[?\
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M#V,ERR.7X.&%B^;E6K>[;U;?JPHHHKS#U HHHH **** "BBB@ HHHH ****
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MM*X^O]-/HI_\D-'_ *^U/T/\N?I:?\E[+_KU3_)A1117]*'\RGTI_P $L/\
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MW_X9TD_Z*!\2/_!NG_QJC_AG23_HH'Q(_P#!NG_QJO2**/K%3O\ D']G8?\
ME_%_YGF__#.DG_10/B1_X-T_^-4?\,Z2?]% ^)'_ (-T_P#C5>D44?6*G?\
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MP['-Q_#_ ,L?\?G_ )"_^RJ8>"<?\O7_ )#_ /KUO44O;3[A[*)A_P#"&?\
M3S_Y#_\ KTC^"M__ "\_^0__ *];M%+VT^X_9Q,$>!\?\O7_ )#_ /KTY?!F
MW_EX_P#(?_UZW**/;3?47LXF./">!_Q\?^0__KTY/"^S_EO_ ..?_7K6HH]K
M(KD1F+X<VG_7?^.?_7J6/1=@_P!9G_@/_P!>KU%3[20<J*,FC>8N/,_\=_\
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M7P_8,1J&O/Y.Y>L$/_+1S_P'(_/TKL*Y_1O!\UOXYU/6KR:.:2X1;>S50?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8X$T-H[1?]]XV_K7,CK7Y=B_$S/M*BA&$9;>Z[/YMZV\CQ:F<8G>R2]#[O\
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M_P"@5XL_\!;?_P"/4#_@I#X'(_Y!7BO_ ,!K?_X]7Q+3T^[1_P 10SS^:/\
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M^ \/_P =KY+3I3J3\4,\_FC_ . H/[8Q'=?<?6?_  W5X1_Z!WB/_P !X?\
MX[2C]NGPB3_R#O$?_@/#_P#':^3Z5/O5/_$4<]_FC_X"@_MC$=U]Q]7G]NGP
MB#_R#O$?_@/#_P#':!^W1X2/_,.\1?\ @/#_ /':^4'^]2ITJO\ B*&>?S1_
M\!1/]LXGNON/J[_AN?PE_P! [Q%_X#P__':=_P -R>$_^@?XB_[\0_\ QVOE
M&I*?_$4,\_FC_P" H/[9Q/=?<?50_;C\)D_\@_Q%_P!^(?\ X[3O^&X?"?\
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M?M*Z$W_+IJW_ 'ZC_P#BZ\-IT='_ !$[//YH_P#@*#^V,1W7W'N'_#2>A_\
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M[_\ [X3_ .*I1\8M,(_U%]_WPG_Q5>9C[WX4]/NUJN-LS[Q^XK^T*WD>D_\
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M *"GA7_P)N/_ (S7VI11_P 0OR/^67_@3#^QL-V?WGQ8O_!.3QP/^8IX5_\
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MS7V!11_Q"_(_Y9?^!,/[&PW9_>?(/_# /C+_ *"7AG_P(G_^,TJ_L!>,@?\
MD)>&?_ B?_XS7U[11_Q"_(_Y9?\ @3#^QL-V?WGR'_PP)XQ_Z"7AG_P(G_\
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M_P#&Z%_8W\3@_P#']H/_ '^E_P#C=?2U%'_$+\C_ )9?^!,/['PWG]Y\U_\
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M['P_G]Y\]_\ #)WB+_G]T7_O]+_\;IP_90\1 ?\ 'YHO_?Z7_P"-U]!44?\
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M13A\ =8S_P ?.F?]_'_^(KUZBG_Q#G)OY9?^!!_95#S^\\A7X ZP/^7G3?\
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M>F44_P#4?*^TO_ A_P!G4?,\T'P;U0'_ (^+#_OM_P#XFG+\'=3 _P!?8_\
M?;__ !->DT57^I.6=I?>']GT?,\W_P"%/:G_ ,]['_OM_P#XFG#X1:D/^6]C
M_P!]M_\ $UZ-15?ZEY8NDOO'_9]$\[_X5)J6?]=8_P#?;?\ Q-"_"74A_P M
MK'_OMO\ XFO1**K_ %-RWL_O']0I'GJ_"?40/]=9?]]M_P#$T[_A5&H_\]K+
M_OMO_B:] HJO]3\N71_>'U&D<!_PJO4/^>UG_P!]M_\ $TX?"W4,?ZZS_P"^
MV_\ B:[VBJ_U2R_L_O#ZC2.#7X7:@&_UUG_WVW_Q-._X5C?Y_P!=9_\ ?;?_
M !-=U15?ZJ8!=']X_J5(X=?AI?C_ );6G_?3?_$TJ_#6^'_+:T_[Z;_XFNWH
MJO\ 5; =G]X_J=,XG_A6]]_SVM/^^F_^)IP^'-\#_K;7_OIO_B:[2BJ7#.!7
M1_>'U.F<;_PKR]S_ *VU_P"^F_PH'P\O0?\ 6VO_ 'TW^%=E13_U;P2Z/[Q_
M5*9QZ_#^\4_ZRU_[Z;_"E'@"\'_+2U_[Z;_"NOHJO]7<'V?WC^JTSDAX#O /
M]9;?]]-_A3O^$%O/^>EO_P!]'_"NKHJO]7\(NC^\/JL#E5\#W8_Y:6__ 'T?
M\*<O@JZ!_P!9;_\ ?1_PKJ**?]@X3L_O#ZM Y@>"[H _O+?_ +Z/^%._X0VZ
M_P">EO\ ]]'_  KI:*M9'A5T?WC^KP.;_P"$.NO^>D'_ 'T?\*</"-R/^6D'
MYG_"NBHI_P!BX;S^\?U>!SP\)W 'WX?S/^%*OA6X!^_#^9_PKH**K^Q\.N_W
MA["!@_\ ",7&/OP_F?\ "G#PS<9^_#^9_P *W**K^R</Y_>'L8G,Z_\ #V/Q
M-I4EG?1P302]02<J?4''!'K70V%FNGV,-NA8I BQJ6ZD 8&:EHK3#Y=AZ%1U
MJ<?>DDF^K2O97\KO[RHTHQ?,MPHHHKN- HHHH **** "BBB@ HHHH **** "
MBBB@"OJNI0Z-IEQ>7#;+>UB::1O[JJ"2?R%?,/[!'P_E\=>+?$GQ4UB)FNM6
MO)X]/W\[ S$RN/ID1@]@KBO9OVJ-6DT;]G;Q?)#N\V;3GM4"]29L1 #W^>MS
MX0^ X_AA\,-"\/QA?^)79QPR%>CR8S(W_ G+'\:^9QN#^N9S1]I\%"+G;^])
M\L?N49->9QU*?M,1&^T5?YO1?DSI****^F.P**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW\5Z*+*WUAU )BBD2211)M.=DFP]!C)4'SCU#WBBOGVT_P""B_AO7/C9X@\
MZ)X)^)GB/6O"NKKI.K2:7H\4]KI^XJJ7$DGG +"Q9L'&_$4A*!5S7T%0 444
M4 %%%% 'DWB+]N3X6^$_VE-/^$&H>*/L_P 1-4"&VTG^S;MO-#QF1?WRQ&$9
M12>7'3'7BO6:_)O]HC_E91\ _P#7.Q_]():[[XN?\%A?C%X3_;]\??!7P?\
M#;P]XXN[%OL/ABVM8YX;N2YVP2F6[E:?R_)2$W!;:L?(3+* Q/UU;A><U1^I
MN[E2527,TDKNSL]$DO/[SXFAQ?"FZ_UY64:SI1Y8MMV5U=:MM^2[:'Z35R<W
MQW\'0_%Z'P!_PD>ER>-)[5[X:-',)+N.!0I,DB+GRUPRX+XW9XS7Q;^PA_P5
M7^*'Q/\ VU=2^!/QL^'^A^$?&$,$SP'2?,58)(HO/V2*\TRNKP_.LL<FTX&
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M?%R02:3IG]G7<WVM9YI((CYL<31)NDB=?G=<;<G ()]6K\0_BQ\</B!\</\
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MY2;;W4H\K5K::=;_ "-LVX1IX_$5:\ZG+SPC%)+X7&7,I7OKKTMMU/S.MO\
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MWQ=J'C+0;'6=&AU77]0U<ZI]OU(WSERMS]R11$]NN8_EW ]\D^K^,_B-9_\
M!-7_ (+L>*O''Q)M]3M?!OCBWN)K+5H+5YH_*N8XFWA0"SB*5#&ZIEAUP1C/
MZ@3?LD?"FYMM)AD^&/P]DAT"0S:7&WARS*Z:Y*$M"/+Q&Q,:$E<$[%]!6_\
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M\*?#SP-X9U-@0;O2=!M;*<@@@_/'&K<@D=>YK9^(OPG\+?%_15TWQ;X9\/\
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M:/Q,\)_&;]I#]F_2_ NM:/XD\9V?C:#5VFTB[CO&M-%2)S>M(T;';'(NS&2
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M$>J?!#1O&]KK]K?V$OB%+T^(8K>Q\Z-I;>.1Q"T<@0Y8DN6_V,GLOV9?V*?
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M\/\ XC?!+Q=KFB>:?!^I7'G>']02&0%KRU;G=.,E2P*KM#8!.XU]M4 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>_M'?LU
MZ%^T]X;T+2]?NM6L[?P_KMIXAMVT^6.-WN+8L45RZ.#&=QR  3Q@BO0J** /
M/=5_9KT+6/VG-+^*\EUJR^(M(T*3P]#;K+']B:W>4REF79O\S<2 0X&.W>N9
M^,W[#_AWXM?%$>-[#Q%XV\ ^+Y+,6%WJOA34UL9M1MU^['.KQR1R!>,$KD87
MGY5Q[110!Y_^SG^S1X8_9?\ !]WI/AQ=0N)=4O)-2U34M2N3=:AJUT_WIYY3
MC<QP.@ '8#)SUOC/P;I7Q$\)ZCH6N6%MJFCZM;O:WEI<)NCN(V&&5A[C\16G
M10!\SC_@E]X;M_"\GAJU^)7QHL?!4B-#_P (U#XG']G+ V<VX+1&81$'&P2X
MQD=SGM/BC^PEX!^)/PI\*^$;6WU3PC9^!;A+OPY>>'KLV=[HLJ@C?%(0W)R2
M2X;<>3D\U[)10!X#X3_X)W^&?#?QE\*?$*\\8?$CQ)XR\(R3FUU/6]8CO'GA
MEA>%K=T,0C6+;)(<1+&VYR2Q.,>C_!7X":/\"9_&4FD7.I7#>-_$MUXIOOMD
MB/Y5U<)$CI%M1<1 1+@-N;).6/&.WHH \/M_^"?O@$_LLZ?\([S^V]0\.Z1>
M2ZC87DUVL>I65T]S-<B>.:)$"R(\[A2%^[P=W.9OA-^PSX=^&OQ.3QEJWB3Q
MQ\0O$UK8R:;8WWBS4TOFTVWD_P!8D*)'&B[QPS%2Q!(S@G/M5% 'S'=_\$J/
M DFF7VA6?BSXG:3X#U*Y:YN?!ECK_E:$^Y][QB/RS*L3-R464"O3M2_9-\+7
MOQK\ ^.(6U'3[[X;Z9<:1H]A:O&E@+>:+RBKH4+G:@ 7:Z@8Y!KTZB@#QKXR
M?L2Z#\6/BDOC;3_$WCCP#XLDLETZ[U+PMJ:6<FHVZG*).LD<D;[3T.W(]>!C
MJ/V=_P!G#PW^S'X*N=%\.C49_P"TKZ75-1O]1NFNK[5+N7&^>>4_><A5'  P
MHXZUWM% 'DW[2_[&OA7]J#4-!U34[SQ%X=\3>%Y7DTGQ!X>OOL.J60<8=%DV
ML"C<'#*>^,9;/!>'_P#@E5\.-!UJQ\0-J_C[4?'5CJL6K#Q?>Z\\VN3-&-OD
MO+M"&%ERC((QE3C/ Q]+44 %>!^*O^">GAF]^(&M>)?"GB[XB_#+4/$LWVK5
MT\):PEI:ZE.<YFDAEBEC\PY)+*JDDD]2<^^44 >/_#/]A?X>_#/X<^+?#:V.
MH:Y'X^25/$NHZS>O>:CK?F*RL9ISAL@.V-NW!.1@\UYSK/\ P2;\&^*_AF?!
MNN_$#XP:_P"%H+<6^GZ7?^(T>UTH*-L9B180&,0P$$WF*@ P.*^IJ* /-;']
MES0;+XS^%?'7]H:U-K7A'PZ_AFU1Y8OL\]NQ4F251&"9<H.5*KR?EJ;3OV9/
M#=C\;?&7CJ1K^^U#QUI5MHVIV5RT;V)MX%90%38&RP<AMS,#Z"O1** /F>T_
MX)7> X;&ST6?Q-\2+_P'I]XMY;^"KK7?,T&-ED\Q4\OR_-:,/D[&E*Y/0UUG
MQ?\ V%?#OQ1^*UQXXTSQ-X\^'WBS4+5++4=1\*:JMD^JQ(,1K.LD<B.4  5M
MH8  9X&/;** /!=4_P""<WP]U#]E'Q!\((9/$%GH/BJ[34=6U*.]635K^Z%S
M%<&>2:5'5I&>% 24QMR !U'=?M$_LU^&_P!IKPG8Z9KS:I97&CWT>IZ5JNE7
M9L]1TBZC^[-!,,[6P2.00<],@$>@44 >._!;]BS0?A!\3IO&MYXD\;>.O%S6
M!TN#5?%&I)>36-J7WM%"J1QQQAF&20N3SSR<^Q444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %>/_MJ?LGK^UU\*[/1;;Q!+X1U[1M4
M@U;2-<AM/M4FG3QY5B$WIN#1NZD;@.03G&#[!10!POPM^ &A_"S]GC2?AM9J
MSZ'INC#1G9?W;W"F,I+(<$X9RSN<'JQKY_T;_@FKXUTKX%W?PI_X7EJB_#.2
MTGL;?3;?PS:PWZ6\FYA#)>;R9(]S?,%1&=<KN4&OKJB@#YMUS_@G[<2^ _A.
M=#\=7'AOXA?"'1XM$TSQ-:Z4LD-[;) L+17%F\A#HZH"5\SABQ!&<"7P_P#\
M$\[/Q1!\0;KXI>++[XC>(/B-I46AWU\MDFE0V%E$2\<5M C.L9$F)-S%B74'
MNV[Z-HH ^7=-_P""?7BSQ&OA'1/'WQBU3QIX#\%WMO?66BKH,-A<7KV__'N+
MN[61FF5,#(")NQDG/-:/BG_@GQ_PDOPS^.OAW_A+O)_X75JQU3[1_96[^QLK
M$-FWSAYW^KZYCZ]..?I&B@#R#]H;]E/_ (7U\'O"?A/^WO[)_P"$7U?2]5^U
M?8?/^T_8F#>7L\Q=N_'WMQV^C5A?%']C37KOX\ZI\2/AI\1;CX<^)/$EG#9:
M_'+HT6L6&L+ NR&1H7>,I*B@*'5N@QCEMWOE% 'S39?\$U=%NO@+XM\+ZUXL
M\0:MXK\:ZNOB+4O%@"V]VNI1L&@EBB7Y(XXR,"+D;689&05N>'?V)_%GB;XQ
M>#?%WQ1^*3?$ _#^::[T2QMO#<&C1)<R($\^8QR.9&  ( V*& .,9!^BJ* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .!^-/P0M_B5:_:K7R[76(5PLA
M&%G _A?^A[?3I\XZEI>I^!]<\FXCNM-U"W.1R4=?=2.WN#@U]F5F>*/!VE^-
M+'[/JEE#>1+RN\89/]UA@K^!%?D_&_A;A\XJO'X&2HXC=O[,GW=M4_[ROYIO
M4\3,<FAB'[6D^67X/^NY\L^%/BCJWA;QFNMBXDNKE\+<"5C_ *2F -K'Z 8/
M8@&OJ7P;XPL_'7AZ#4K%]T,PY4_>C8=58=B/_K]*\9L/V8FU;XB:A'_I%GX=
MM)0$D<YEG^4$JGL"2-Q_4YKV_0]"L_#6EQ6=C;QVMK",*B# ^I]2?4\FO/\
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M=$TWQ#HEGJD\6G7P6ZDN(O.MU<1OYB+<1LSCD>6,],>]?\%@?VJO%OQ*\=?
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M*#CN;PJ1EL6****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNA'X5TU>*_LJZ[YL]W:-GYD9QZ#:PX^OS&O:J "BBB@ HHHH **** "BBB@
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M*_ '6/B9IK:A+>:-J^D07-Q:122! 7+V\4@>)MH;8_E.I9LD=![E_P $FO\
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M (2#PU97G\4T0+?[PX;]0:^</MC0HHHH **** "BBB@ HHHH **** "BBB@
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MRB,9B,CE'1B?(8 \Y7Z\M+N+4+2*XMY(YH)D$D<D;!DD4C(8$<$$<Y%? O\
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MCEK'B/\ 9K_93_;&NXU;7/!^H#1?%\T*F,WFGS32V5Q(5'RC+QRD # :ZXR
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M_;Y^(?PR_P""'6B7S^*+RU\67?C%_  \2O))/=V-L#-,9U?[^](8FB5@"X4
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M@DYXYS5:FZ<8\[][6Z[?\./#Q<KWMZHTO#?C2/7]1FNM<:WCO(4C6WCF8;$
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M44 %%%% !1110 4444 %%%% !7GG[2WP$M?VA?AV^D37!L[FW?[1:S[-XC<
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M/]<\,ZLCR:7XBT^XTR\1" S0S1M'( 2",E6/8U^6_P (OV2OVV_^"<MGXJ\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"O<_B=INRXFX]2*\5\26QCD<>] '5_LT>+/^$>^(EO;NVV&\W6K9/][YE_\
M'E _X%7T]7Q#IFHR:7JMO<PMMFC8%3_=92"OZ@5]G>%->C\4>&['4(>8[R%9
M1[9% &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS03/&BN64HCJ***#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMM*DNZ\)-Q,H(. G49_VMOXUV8.5CR\5"[N?5U%%%=AF%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >2?M#_L2^ ?VF]5MM1\26%U'JEK%Y"WME/Y,SIG
M(5^"& ).,@D9->?:)_P26^$ND7T<TD?B*]6,Y,4VH!8W^NQ%;\B*^G**B5.+
M=VC15)I63.2^&WP(\'_"&';X;\/:;I;, &ECBW3-]9&RQ_$UUM%%4DEHC.[>
MX4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR0*8O*&V-"T952TC'GG 'UKT#5OAUH&OQ[;[1-)O%\XW)$UI&^92 "_(^\0
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MZ</^"UWP@(_X]?%W_@N7_P"+I?ZK9M_T#R^X7^LV5?\ /^/WGU]1G%?(:_\
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MHKY-/_!9'X3K_P NWBS_ ,%Z_P#Q=-;_ (+*?"8?\NWBW\-/7_XNC_5C-?\
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MKX1#_EU\7?\ @M7_ .+H_P!6LT_Y\2^X/]:,I_Y_Q^\^O,T5\@_\/K?A"/\
MEU\7?^"U?_BZ#_P6O^$"C_CU\7?^"U?_ (NC_5K-/^?$ON#_ %HRK_G_ !^\
M^OJ*^0/^'V/P?_Y]?%__ (+E_P#BZ/\ A]C\(/\ GU\7_P#@N7_XNE_JWFG_
M #XE]P_]9LJ_Y_Q^\^OZ*^/_ /A]E\'\_P#'KXP_\%R__%TC?\%M/@^/^77Q
MA_X+5_\ BZ/]6\S_ .?$ON'_ *S95_S_ (_>?8.:-U?'O_#[7X/C_EU\8?\
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MWP:_Y]?&7_@L7_XY1_P_&^#/_/KXR_\ !8O_ ,<H_P!7<R_Y\R^X?^LF6?\
M/^/WGV117QL/^"Y/P9/_ "Z^,O\ P6+_ /'*0_\ !<KX,@_\>OC+_P %B_\
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MB_\ \%J__%U/*T+_ %DRS_G_ !^\^O*,U\A_\/JOA#_SZ^+O_!<O_P 70O\
MP6G^$)_Y=O%W_@N7_P"+J7H'^LF6?\_X_>?7E%?(O_#Z7X1Y_P"/7Q=_X+E_
M^+IP_P""T7PC(_X]?%W_ (+E_P#BZGGCW%_K)E?_ #_C]Y]<9HS7R/\ \/HO
MA'_SZ^+O_!<O_P 72G_@L]\)/^?7Q9_X+E_^+J'6@MV'^LN5_P#/^/WGUOFC
M-?)*_P#!9SX2D?\ 'KXM_P#!<O\ \72C_@LU\)6/_'KXL_\ !<O_ ,74?6J*
M^T@_UERO_G_'[SZUS17R7_P^8^$O_/KXL_\ !>O_ ,70/^"RGPG/_+MXL_\
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M^)__  !'_P 54OBC*EO7C]X?ZS95_P _X_>?4E&:^7!_P5N^%[?\NOB;_P
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M5?\ @ O_ ,73_P!>,A_Z"H?>/_6;*O\ G_'[SZNHKY-/_!9#X4#_ )=?%?\
MX +_ /%TT_\ !9;X3C_EU\6?^"]?_BZ/]=\A_P"@J'WA_K-E7_/^/WGUI17R
M0W_!9WX2IUM?%G_@O'_Q=,;_ (+1?"-3_P >GBS_ ,%R_P#Q=/\ UVR+_H*A
M]X?ZS95_S_C]Y]=49S7R$?\ @M5\(U_Y<_%W_@O7_P"+IC_\%L/A"H_X\_%W
M_@N7_P"+I_ZZ9%_T%0^\?^LV5?\ /^/WGV!1FOCL_P#!;?X/C_ES\7?^"Y?_
M (ND/_!;WX/C_ET\8?\ @N7_ .+I_P"NF1_]!4/O#_6;*_\ G_'[S[%S1FOC
M=_\ @N'\'4_Y<_&'_@N7_P"+J,_\%S/@VO\ RY^,?_!:O_Q=/_7+)/\ H)A]
MX?ZS95_S_C]Y]F9HS7QBW_!='X-*/^/3QC_X+5_^+IK?\%U_@PH_X]?&7_@L
M7_XNG_KADO\ T$Q^\/\ 6;*_^?\ '[S[0S17Q6?^"[_P5!_X]/&?_@L7_P"+
MIK?\%X_@JO\ RY^-/_!8O_QRG_KADW_03'[P_P!9LK_Y_P ?O/M;-%?$W_#^
MKX)_\^?C3_P6+_\ '*8W_!>_X)J?^//QM_X*U_\ CE'^MV3?]!$?O#_6;*_^
M?\?O/MS-&:^(&_X+[?!%3_QY^-S_ -PM?_CE-;_@OY\#P>;/QO\ ^"M?_CE5
M_K;D_P#T$1^\/]9,K_Y_Q^\^X<T5\-M_P<!? Y!_QY^./_!6O_QRHV_X."O@
M8.MEXX_\%2__ !RC_6S)_P#H(C]X?ZR97_S_ (_>?=&:*^%6_P"#A#X%C_ES
M\=?^"I?_ (Y3#_P<+_ D?\N?COK_ - I?_CE5_K5E'_01'[Q_P"LF6?\_P"/
MWGW;FC-?!Y_X.'/@0O\ RY^//_!2G_QRFG_@XA^ P_Y<_'G_ (*4_P#CE'^M
M64/_ )B(_>/_ %CRS_G_ !^\^\LT5\%'_@XI^ :_\N?CW_P4)_\ '*0_\'%_
MP#4?\>?CW_P4+_\ '*K_ %HRK_G_ !^\/]8\L_Y_Q^\^]J*^!3_P<:_ $?\
M+EX]_P#!0G_QRF'_ (./O@ O_+EX^_\ !0G_ ,=I_P"LV5?\_P"/WA_K%EG_
M #_C]Y\4C_@B%\9 /^/SP3_X,IO_ (S3T_X(C?&1?^7SP5_X,IO_ (S117ZK
M_P 1"S?^:/\ X"3_ *NX/L_O)1_P1,^,0'_'YX+_ /!E+_\ &:>G_!%'XQ+_
M ,O?@O\ \&4O_P 9HHJ?^(@9OWC_ . D_P"K>"[/[R1?^"*OQ@'_ "]>"_\
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M .(HHH_XB%F_>/\ X"1_Q#O)^TO_  (D7_@F5\2E/WO#O_@<W_Q%/3_@F?\
M$I1][P]_X'-_\1111_Q$+./YH_\ @(O^(=9.^DO_  )CE_X)I?$@#[WA_P#\
M#F_^(H/_  30^)!/WO#W_@<W_P 1111_Q$+./YH_^ D_\0XR;^67_@3&M_P3
M.^))_B\._P#@<W_Q%-;_ ()E_$H_Q>'?_ YO_B***/\ B(6<?S1_\!#_ (AS
MDW:7_@3&_P##LKXE?WO#O_@<W_Q%-;_@F1\2F/WO#O\ X'-_\1114_\ $0,W
M_FC_ . E?\0[R?M+_P "8U_^"8GQ+;^+P[_X'-_\133_ ,$POB8?X_#G_@<W
M_P 1112_U^S;O'_P$?\ Q#O)^TO_  (:?^"7_P 3"?O>&_\ P.;_ .(H;_@E
M]\3"/O>&_P#P.;_XW112_P!?LV[Q_P# 1_\ $/<H[2_\"&_\.O/B9_?\-_\
M@<W_ ,13?^'7/Q._YZ>&_P#P.;_XW112_P!?,V[Q_P# 0_XA[E':7_@0T_\
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M_P"N&8OJON#_ %-RWM+[QW_#H#XL?\_'A/\ \&$G_P :IW_#H/XL?\_'A/\
M\&$G_P :HHK-\5X]]5]PO]3<M[2^\5?^"0OQ8 _X^/"?_@PD_P#C5*/^"1'Q
M8'_+QX3_ /!A)_\ &J**S?$V.>[7W!_J9EO:7WC_ /AT7\5_^?CPI_X,)/\
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M?\$M/B<O_+3PU_X'O_\ &Z**R>'@P_U'ROM+_P "'#_@EM\3L_ZSPW_X'O\
M_&Z4?\$N/B<!_K/#?_@<W_QNBBLW@Z;%_J/E?:7_ ($/_P"'7?Q-V_ZSPW_X
M'-_\;H7_ ()>_$P'[_AO_P #F_\ B***S>7T7W#_ %'ROM+_ ,"'?\.O_B9_
M?\-_^!S?_$4X?\$POB8!][PY_P"!S?\ Q%%%9RRG#O>_WB_U&ROM+_P(<O\
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M?_B:**B7A=D3WC+_ ,"8?Z@Y3VE_X$._X=_?$#CY=%X_Z?#_ /$TX_L!>/\
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M;?\ !,'XF-_%X<_\#F_^(HHI_P#$*\A_EE_X$Q?ZAY3VE_X$12?\$N_B:_\
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:D_\ \8HHJO\ 4'*>TO\ P(/]2<L[2^\__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ino-20211231_g3.jpg
<TEXT>
begin 644 ino-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .D!TL# 2(  A$! Q$!_\0
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M?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\
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M\357^VM/_P"?^U_[_+_C0!=HJE_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\
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M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
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M/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__
M )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*
MI?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
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MQA2C;.CGQ'^S[\>O!WA&?QCKGC3PCXUBNEB'B2Y^U7EE=01JQ99L E&RHVX
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M+=N++[*(C%/=&/.UAO96#8^\PYX^7U7]M'Q)XD\+^&_"]Y8W7B+3O!RW[?\
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M\Y7RA+#'@MSG&?NCI67^TAX8\37%YK'B?6/B3?>!/AYHVCNUI%X>OY+6\FU
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MBI_C0!BT5M?\(?J__/I_Y%3_ !H_X0_5_P#GT_\ (J?XT 8M%;7_  A^K_\
M/I_Y%3_&C_A#]7_Y]/\ R*G^- &+16U_PA^K_P#/I_Y%3_&C_A#]7_Y]/_(J
M?XT 8M%;7_"'ZO\ \^G_ )%3_&C_ (0_5_\ GT_\BI_C0!BT5M?\(?J__/I_
MY%3_ !H_X0_5_P#GT_\ (J?XT 8M%;7_  A^K_\ /I_Y%3_&C_A#]7_Y]/\
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M7X'UO2=-\?>'= MM O8=221].U*!%4,K,HWJ P8A@N3\H^7%?4G_  A^K_\
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M]7_Y]/\ R*G^-6=+\*ZI;ZE:2R6NV..9&9O,0X 8$]Z .I\8?\BY=_\  /\
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M421].U&!$4$,R 2+M8,P8#)PH.W%?47_  A^K_\ /I_Y%3_&C_A#]7_Y]/\
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MG5_!7Q?^*OBJ^N+*73O%4]A)916[N98Q!'(K^:"H )+C&TMWSBO</^$/U?\
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M!G# ]_85PW_"'ZO_ ,^G_D5/\: ,6BMK_A#]7_Y]/_(J?XT?\(?J_P#SZ?\
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M44T;:A=:'%<#4M4CC8%4EW@1IN(!)3H0#AL8KZU_X0_5_P#GT_\ (J?XT?\
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M+-%K=I>7]S)]JMI$"_N]_F?.H+$ E03MYXKZF_X0_5_^?3_R*G^-'_"'ZO\
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MX?\ _(&F_P"OAO\ T%:Z:L+P?IMSI>FRQ74?E2-,6"[@>-JCL?8UNT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1"I?] S_ / E_D?K%_PG&E_WY?\ OW1_PG&E_P!^7_OW7Y._\)5K7_07O_\
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M7_07O_\ P)?_ !H_X2K6O^@O?_\ @2_^-'^I=3_G^O\ P'_@A_Q$*E_T#/\
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M H QO^$XTO\ OR_]^Z/^$XTO^_+_ -^ZV?L5O_SPB_[X%'V*W_YX1?\ ? H
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M -^Z/^$XTO\ OR_]^ZV?L5O_ ,\(O^^!1]BM_P#GA%_WP* ,;_A.-+_OR_\
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M ,\(O^^!1]BM_P#GA%_WP* ,;_A.-+_OR_\ ?NC_ (3C2_[\O_?NMG[%;_\
M/"+_ +X%'V*W_P">$7_? H Q1XZTPYYF'_ .OZTO_"<:7_?E_P"_=5?"MO%)
MJFMAHD8+/@ J#CYGZ5T?V*W_ .>$7_? H QO^$XTO^_+_P!^Z/\ A.-+_OR_
M]^ZV?L5O_P \(O\ O@4?8K?_ )X1?]\"@#&_X3C2_P"_+_W[H_X3C2_[\O\
MW[K9^Q6__/"+_O@4?8K?_GA%_P!\"@#&_P"$XTO^_+_W[H_X3C2_[\O_ '[K
M9^Q6_P#SPB_[X%'V*W_YX1?]\"@#&_X3C2_[\O\ W[H_X3C2_P"_+_W[K9^Q
M6_\ SPB_[X%'V*W_ .>$7_? H QO^$XTO^_+_P!^Z/\ A.-+_OR_]^ZV?L5O
M_P \(O\ O@4?8K?_ )X1?]\"@#&_X3C2_P"_+_W[H_X3C2_[\O\ W[K9^Q6_
M_/"+_O@4?8K?_GA%_P!\"@#&_P"$XTO^_+_W[H_X3C2_[\O_ '[K9^Q6_P#S
MPB_[X%'V*W_YX1?]\"@#&_X3C2_[\O\ W[H_X3C2_P"_+_W[K9^Q6_\ SPB_
M[X%'V*W_ .>$7_? H QO^$XTO^_+_P!^Z/\ A.-+_OR_]^ZV?L5O_P \(O\
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M[X%'V*W_ .>$7_? H QO^$XTO^_+_P!^Z/\ A.-+_OR_]^ZV?L5O_P \(O\
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M\"@#&_X3C2_[\O\ W[H_X3C2_P"_+_W[K9^Q6_\ SPB_[X%'V*W_ .>$7_?
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MX3C2_P"_+_W[H_X3C2_[\O\ W[K9^Q6__/"+_O@4?8K?_GA%_P!\"N(LQO\
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M/^$XTO\ OR_]^ZV?L5O_ ,\(O^^!1]CMO^>$7_? H QO^$XTO^_+_P!^Z/\
MA.-+_OR_]^ZV?L=O_P \(O\ O@4?8[;_ )X1?]\"@#&_X3C2_P"_+_W[H_X3
MC2_[\O\ W[K9^QVW_/"+_O@4?8K?_GA%_P!\"@"CI?B2SUBZ:"W\PNJ;R67
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M_AKKQA_T#=#_ ._$W_QVE'[7'C#_ *!NA_\ ?B;_ ..UX?3EZ5X;S_-/^?\
M(]O_ %<RG_H'B>WC]KCQ@?\ F&Z)_P!^)O\ X[3A^UKXO_Z!NB?]^)O_ ([7
MB"T]>E1_K!FG_/\ D3_JYE/_ $#Q/;A^UIXO_P"@=HG_ 'XF_P#CM*/VL_%_
M_0.T3_OQ-_\ ':\26G+UK-\0YK_T$2)_U=RG_H'B>V?\-9>+O^@=HO\ WXF_
M^.TX?M8>+C_S#M%_[\3?_':\3IZ]JE\0YK_T$2)?#N5?] \3VK_AJ[Q;_P!
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MSYZ;_P!^I/\ XY7F=.7I2?%N>_\ 07+^OD3_ &/@/^?*/2O^%^>(/^?/3?\
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M_ J7_"OCUJC;O3_LO!?\^_S_ ,P_MK,/^?K^Y?Y'V(W_  4R\6#_ )DO1O\
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M/;7T729+<0/HUB8,8\OR@,?Y_P :\X\5> 8O!*Q:SX8W:?#'<K.&@ 62SG)
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M3>F#TVG(PPYKZ<_9KM?VB;;Q%JY^,]]H%WI!M5%@NCB,.)]_S%MJCC;7A'[
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MGAI^I>+_ !/\8OBW-IL^DZ)XUUKS=+M[@8,D2-(QD]Q^\"Y[D-6G_P %3O\
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M4?ZCYC_S\A]\O_D2?]>LM_Y]S^Z/_P D?%=/7M7VC_PSO\/O^A?_ /)VX_\
MCE+_ ,,\_#[_ * '_D[<?_'*7^H^9?\ /R'WR_\ D1?Z\Y;_ ,^Y_='_ .2/
MB^GU]F_\,\_#_P#Z '_D[<?_ !RE_P"&>_ '_0 _\G+C_P".5'^HN9?\_(??
M+_Y$C_7C+O\ GW/[H_\ R1\9KTIRU]E_\,^> /\ H ?^3EQ_\<H_X9]\ ?\
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MJ?\ B'^:?\_*?WR_^0)_USR_^2?W1_\ DCYCIR]*^N/^%$>!O^@'_P"3<_\
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M:?WR_P#D!?ZW8#^2?W+_ .2/E=>U/KZF_P"%)^"_^@-_Y-3?_%T?\*5\&?\
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M1_Y,S?\ Q=3_ ,0TSC_G[3^^7_R O]:L%_)+[E_\D?,Z]*?7TM_PIWPA_P!
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M_P! O_R8E_\ BJ7_ !"W.O\ G[2_\"G_ /($_P"LF$_EE]R_S/GNOAGXC?\
M)0/$_P#V%+K_ -&M7ZI>*OAUX>TW26FMM/\ +EWJ-WG2'^;5RUQ^Q]\)M<GD
MU&\\+F6[NV-Q-)]ON1N=SN8X$F!DD]*_8?#7AW%<'8O$8C'RC)5(I+D;;NG?
M7F43\^XPFN(*%*EA='%MOFTZ>5S\LFZU$U?J;_PQ3\'/^A3;_P &-U_\<I/^
M&)_@W_T*3?\ @QNO_CE?OW]O8;^67W+_ #/RS_5G&?S1^]_Y'Y8-435^J?\
MPQ+\&O\ H4C_ .#&Z_\ CE)_PQ%\&C_S*3?^#&Z_^.4?V]A?Y9?<O\P_U9QG
M\T?O?^1^5#5&W>OU:_X8?^#/_0HM_P"#&Z_^.4G_  P[\&/^A1;_ ,&5U_\
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MQ*A:%WF\UBI*'^+( ;< "1CFIU\"0+HMWIJW5P1?S&:_N'5#+=;L!PV% &5
M7Y0, #%(ARBSC_#OQ G\-R6MIJEO/<ZE=60U#4)&NBT=M^ZDE 56 VJ FT\
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MH%%%%<IV'AG[67_),M=_Z\&_]"%?FY7Z1_M9?\DRUW_KP;_T(5^;E?KG!O\
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M_P#"77?_ $!+K]?_ (FC_A+KO_H"77Z__$UTU%?*'VYS/_"77?\ T!+K]?\
MXFC_ (2Z[_Z EU^O_P 37344 <S_ ,)==_\ 0$NOU_\ B:/^$NN_^@)=?K_\
M37344 <S_P )==_] 2Z_7_XFC_A+KO\ Z EU^O\ \37344 <S_PEUW_T!+K]
M?_B:/^$NN_\ H"77Z_\ Q-=-10!S/_"77?\ T!+K]?\ XFC_ (2Z[_Z EU^O
M_P 37344 <S_ ,)==_\ 0$NOU_\ B:/^$NN_^@)=?K_\37344 <S_P )==_]
M 2Z_7_XFC_A+KO\ Z EU^O\ \37344 <S_PEUW_T!+K]?_B:/^$NN_\ H"77
MZ_\ Q-=-10!S/_"77?\ T!+K]?\ XFC_ (2Z[_Z EU^O_P 37344 <S_ ,)=
M=_\ 0$NOU_\ B:/^$NN_^@)=?K_\37344 <S_P )==_] 2Z_7_XFC_A+KO\
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MHTVUZ,/^$NN_^@)=?K_\31_PEUW_ - 2Z_7_ .)I?^%F^#_^AKT/_P &,/\
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M2Z[_ .@)=?K_ /$T?\)==_\ 0$NOU_\ B:?_ ,+(\)?]#3HO_@PA_P#BJ/\
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M6)X5_P"AFT?_ ,#XO_BJ/KN%_P"?L?O0?5,1_P ^Y?<R+_A+KO\ Z EU^O\
M\31_PEUW_P! 2Z_7_P")J7_A8?A7_H9M'_\  ^+_ .*I?^%A>%?^AFT?_P #
MXO\ XJCZ[A?^?L?O0OJF(_Y]R^YD/_"77?\ T!+K]?\ XFL?POKD^F:?)%%I
MTUVK2EM\><#@#'0^GZUO?\+"\+?]#+H__@?%_P#%5SW@?QQX<M-)E2?7]+A<
MSDA9+V-3C:O/+4OKN%_Y^Q^]!]5Q'_/N7W,V_P#A+KO_ * EU^O_ ,31_P )
M==_] 2Z_7_XFI_\ A8'A?_H9-(_\#XO_ (JC_A8'A?\ Z&32/_ Z+_XJCZ]A
M?^?L?O7^8?5<1_S[?W,@_P"$NN_^@)=?K_\ $T?\)==_] 2Z_7_XFI_^%@>%
M_P#H9-(_\#HO_BJ7_A/O#'_0QZ3_ .!T7_Q5'U["_P#/V/\ X$O\P^JXC_GV
M_N97_P"$NN_^@)=?K_\ $T?\)==_] 2Z_7_XFK'_  GWAC_H8])_\#HO_BJ/
M^$^\,?\ 0QZ3_P"!T7_Q5'U["?\ /V/_ ($O\P^JXC_GV_N97_X2Z[_Z EU^
MO_Q-'_"77?\ T!+K]?\ XFK'_">^&?\ H8M)_P# Z+_XJE_X3SPS_P!#%I/_
M ('1?_%4OKV$_P"?L?\ P)?YB^JU_P#GV_N96_X2Z[_Z EU^O_Q-'_"77?\
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M?_ N/_&C_A,-!_Z#>F_^!<?^-']H8/\ Y_1_\"7^8?5ZW\C^YE'_ (2Z[_Z
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MX2Z[_P"@)=?K_P#$T?\ "77?_0$NOU_^)K67Q%I3N$74[-G/11.F3^M7U8,
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M)=?K_P#$UTU% ',_\)==_P#0$NOU_P#B:/\ A+KO_H"77Z__ !-=-10!S/\
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MF6N_]>#?^A"OS<K]<X-_W2I_B_1'X5Q__OU'_!^K"BBBOOS\O"BBB@ HHHH
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M) *_-_>R.F.?1X_'>B3:Y=R7'AJTT 6>OKH\E[<:<DOVB,6S,5W#'EG8#SR
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M****XCT3PS]K+_DF6N_]>#?^A"OS<K],/VF='O/$7@?5-,TZ$W-]<63)%""
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MV1F7_0-/_P  E_D>=45Z+_PSS\0O^A;E_P# B'_XNC_AGGXA?]"W+_X$0_\
MQ=']I8'_ )_P_P# E_F']D9E_P! T_\ P"7^1YU17HO_  SS\0O^A;E_\"(?
M_BZ/^&>?B%_T+<O_ ($0_P#Q=']I8'_G_#_P)?YA_9&9?] T_P#P"7^1YU17
MHO\ PSS\0O\ H6Y?_ B'_P"+H_X9Y^(7_0MR_P#@1#_\71_:6!_Y_P /_ E_
MF']D9E_T#3_\ E_D>=45Z+_PSS\0O^A;E_\  B'_ .+H_P"&>?B%_P!"W+_X
M$0__ !=']I8'_G_#_P "7^8?V1F7_0-/_P  E_D>=45Z+_PSS\0O^A;E_P#
MB'_XNC_AGGXA?]"W+_X$0_\ Q=']I8'_ )_P_P# E_F']D9E_P! T_\ P"7^
M1YU17HO_  SS\0O^A;E_\"(?_BZ/^&>?B%_T+<O_ ($0_P#Q=']I8'_G_#_P
M)?YA_9&9?] T_P#P"7^1YU17HO\ PSS\0O\ H6Y?_ B'_P"+H_X9Y^(7_0MR
M_P#@1#_\71_:6!_Y_P /_ E_F']D9E_T#3_\ E_D>C?L5_\ (YZS_P!>\7_H
MROT+KX:_9;^&_B3P#XHU2ZU_2WTZ":&-4=I$?)#Y(^5CVK[._P"$LTG_ )_%
M_P"^&_PK\=XDJTZV93G2DI*RU3NMD?OW"5&KA\IITZT7&5Y:-6>[Z,UZ*R/^
M$LTG_G\7_OAO\*/^$LTG_G\7_OAO\*^8/L37HK(_X2S2?^?Q?^^&_P */^$L
MTG_G\7_OAO\ "@#7HK(_X2S2?^?Q?^^&_P */^$LTG_G\7_OAO\ "@#7HK(_
MX2S2?^?Q?^^&_P */^$LTG_G\7_OAO\ "@#7HK(_X2S2?^?Q?^^&_P */^$L
MTG_G\7_OAO\ "@#7IKHLB,CJ&5A@JPR"/2LK_A+-)_Y_%_[X;_"C_A+-)_Y_
M%_[X;_"@#RW_ (8U^#OVQ9?^$-3[&MQ]K&C?VA=_V3YH;<'_ +/\W[+G=S_J
MNM>A>/\ X9^%OBEX?&B>*]"L]<TQ9%GCAN4YAE7[LD3C#1NN3AT(89.#6A_P
MEFD_\_B_]\-_A1_PEFD_\_B_]\-_A0!QWP__ &=_A_\ #'7I-=T+0I#KSP?9
MO[7U74+K4[U(<Y,23W4DDB(3U56 .!Q6I\4/@SX,^-%CH]GXST.+7+;2-1BU
M:R2262/RKF,,$?,;*6&&8%&RK9Y!K=_X2S2?^?Q?^^&_PH_X2S2?^?Q?^^&_
MPH H_$;X<^'?BSX/O/"_BO3_ .U="O)(99[3SY(=[0S)-&=\;*PQ)&C<'G&#
MD$BN*^(W[*WPT^*_C!_%/B31M0FUY[2.Q>\L->U#3R\,;.R(RV\\:G!D<Y(S
M\U>A_P#"6:3_ ,_B_P#?#?X4?\)9I/\ S^+_ -\-_A0!@?"SX+^"O@KI-UIW
M@O0(-%AO)?/NY5>2:XNI,8WS32,TDK8[NQZFNVK(_P"$LTG_ )_%_P"^&_PH
M_P"$LTG_ )_%_P"^&_PH H>#?AOX<^'\GB-] T[["WB+59M;U/,TDOVB\E5$
MDE^=CMRL:#:N%&. ,FN0\&?LM_"_X?>*+;Q!H/A6.SU&S:1K%9+RXGM]/,F?
M,-K;R2-%;;LD'R43()%=]_PEFD_\_B_]\-_A1_PEFD_\_B_]\-_A0!7\?^"]
M.^)'@7Q!X4U="^EZW83Z=<A<;O+EC*,5]" V0>Q KSOPW\'X?B7\"=!\%_&3
MPW9ZY>Z8BVEP9F5EN)+<F*.^A>-MT32HHD&"KIYA4XP:],_X2S2?^?Q?^^&_
MPH_X2S2?^?Q?^^&_PH X7X9?LR?#7X/Z[+K?ACPXT&MR0FV_M/4=0NM1NDB.
M"8TEN99&1"0,JI ..152Z_9-^$]YXKF\0S>$(7O)[T:E-:?;+D:?-=@[OM#V
M0D^S-+NYWF,MGG.:]%_X2S2?^?Q?^^&_PH_X2S2?^?Q?^^&_PH YCQ3\!_ W
MC7_A-?[9T/[9_P )E8VVFZ[_ *7/']LM[?S/)3Y7'E[?.DYCVD[N2<#%;XC_
M +._P^^+&M0ZOXFT%KO5([?[&UW:7US923V^XMY$S02)YT623Y<FY.3QR:[#
M_A+-)_Y_%_[X;_"C_A+-)_Y_%_[X;_"@#SF;]DWX4R>#?#OA:+PK]AT?P[/<
MW.CC3M1N[2XT][B1I)_)N(I5F179VRJN%QA<;0 $MOV2_A/9Z+XLTFW\))!8
M>++*+3]=CCOKI3J,4;2,AE82[FDW2R$RY\P[N6/%>C_\)9I/_/XO_?#?X4?\
M)9I/_/XO_?#?X4 5]=\!Z%XF\2>&M?U*Q^TZOX;GFN=*N/.D3[/)- \$C;58
M*^8Y'7#@@9R,$ UYMXJ^'<?P=\,^,M2^%OP[D\3Z_P"*[HR7VB_VT;>S>602
ME[@QW$ODQ*6D)D$*JS[LD,0,>H_\)9I/_/XO_?#?X4?\)9I/_/XO_?#?X4 >
M:?"/X77_ .S9^S%H_@_POIL?B+Q#H.CMY5JDJPIJ&HL&DD)=V 17G=B23PI[
MX KI/@/\+A\&_A1H'A1[H:A?VL;S:A?@8^UWLTC37,WT>621@#T! [5T_P#P
MEFD_\_B_]\-_A1_PEFD_\_B_]\-_A0!KT5D?\)9I/_/XO_?#?X4?\)9I/_/X
MO_?#?X4 :]%9'_"6:3_S^+_WPW^%'_"6:3_S^+_WPW^% &O161_PEFD_\_B_
M]\-_A1_PEFD_\_B_]\-_A0!KT5D?\)9I/_/XO_?#?X4?\)9I/_/XO_?#?X4
M:]%9'_"6:3_S^+_WPW^%'_"6:3_S^+_WPW^% &O161_PEFD_\_B_]\-_A1_P
MEFD_\_B_]\-_A0!\U_&;X5>*?'WCNXN]!TO[?;PQ^5(_VB*/#>;(<8=@>A%<
M2O[-_P 1?^A=_P#)ZV_^.5]6>'=<L;+4-7DFN!&DTVZ,[2=PRW/3W%;W_"6:
M3_S^+_WPW^%?&XSA7!8VO/$5)R3D[NS5O_23[O!<8X_ 8>&&I0@XQ5E=2O\
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MQ?\ OAO\*/\ A+-)_P"?Q?\ OAO\*7^H^7?\_)_?'_Y$7^O69?\ /N'W2_\
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M?'_Y 7^N68?R0^Z7_P D?,:_ WQO_P! 3_R;@_\ BZ4? WQO_P! 3_R;@_\
MBZ^F_P#A+-)_Y_%_[X;_  H_X2S2?^?Q?^^&_P *G_B'>5?\_*GWQ_\ D!?Z
MX8_^2'W2_P#DCYF_X4=XV_Z O_DW!_\ %TY?@?XVX_XDO_DU!_\ %U]+_P#"
M6:3_ ,_B_P#?#?X4?\)9I/\ S^+_ -\-_A2_XAWE7_/RI]\?_D!?ZWX_^2'W
M2_\ DCYJ_P"%(^-?^@+_ .34'_Q=._X4EXT_Z W_ )-0?_%U])_\)9I/_/XO
M_?#?X4?\)9I/_/XO_?#?X4O^(<Y3_P _:GWQ_P#D!?ZW8_\ DA]S_P#DCYM7
MX)^-./\ B3?^34/_ ,73_P#A2OC/_H#?^34/_P 77T?_ ,)9I/\ S^+_ -\-
M_A1_PEFD_P#/XO\ WPW^%3_Q#C*?^?M3[X__ " O];L=_)#[G_\ )'SB/@KX
MS_Z W_DU#_\ %TY?@OXR_P"@/_Y-0_\ Q=?1G_"6:3_S^+_WPW^%'_"6:3_S
M^+_WPW^%+_B&^4?\_:GWQ_\ D!?ZVX[^2'W/_P"2/G3_ (4OXR_Z _\ Y-0_
M_%TJ_!CQE_T!_P#R:A_^+KZ*_P"$LTG_ )_%_P"^&_PH_P"$LTG_ )_%_P"^
M&_PI?\0VRC_G[4^^/_R!/^MF._DA]S_^2/G=?@SXQ_Z _P#Y-0__ !=+_P *
M:\8_] ?_ ,F8?_BZ^A_^$LTG_G\7_OAO\*/^$LTG_G\7_OAO\*7_ !#7*/\
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M^%3_ ,0QR?\ Y^U?OC_\@'^M&,_DC]S_ /DCP3_A4/BW_H$_^3,/_P 72_\
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MI:^*M*CM84:[4,J*"-K>GTI?\0LR7_G[5_\  H?_ " O]8\7_+'[G_F>,_\
M"K/%'_0,_P#)B+_XJG?\*M\3_P#0,_\ )B+_ .*KVG_A+-)_Y_%_[X;_  H_
MX2S2?^?Q?^^&_P */^(69+_S]J_^!0_^0%_K%B_Y8_<_\SQ;_A5OB?\ Z!G_
M ),1?_%4[_A5WB?_ *!G_DQ%_P#%5[/_ ,)9I/\ S^+_ -\-_A1_PEFD_P#/
MXO\ WPW^%+_B%>2_\_:O_@4/_D!?ZQ8K^6/W/_,\8_X5?XG_ .@9_P"3$7_Q
M5._X5?XF_P"@9_Y'B_\ BJ]E_P"$LTG_ )_%_P"^&_PH_P"$LTG_ )_%_P"^
M&_PI?\0JR7_G[5_\"A_\@'^L.*_EC]S_ ,SQS_A6/B;_ *!O_D>+_P"*H'PQ
M\2_] W_R/%_\57L?_"6:3_S^+_WPW^%'_"6:3_S^+_WPW^%+_B%.2?\ /ZK_
M .!0_P#D"?\ 6#%?RQ^Y_P"9Y OPO\1LX4V*J#_$9X\#_P >KL/"OPE2QN([
MK5I4N70[EMX^4S_M$]?I_.NO_P"$LTG_ )_%_P"^&_PH_P"$LTG_ )_%_P"^
M&_PKU<M\.,BRZNJ_+*HUJE-II?)**?SN<];.L76CR74?3^F:]%9'_"6:3_S^
M+_WPW^%'_"6:3_S^+_WPW^%?J)X)KT5D?\)9I/\ S^+_ -\-_A1_PEFD_P#/
MXO\ WPW^% &O161_PEFD_P#/XO\ WPW^%'_"6:3_ ,_B_P#?#?X4 :]%9'_"
M6:3_ ,_B_P#?#?X4?\)9I/\ S^+_ -\-_A0!9US_ ) M_P#]<'_]!-5?"/\
MR+MG]&_]"-5=6\3:9<:7=Q1W2M(\3*J[6Y)!]JK^&_$6G6.BVT$]R(Y5#;EV
ML<?,3Z4 =5161_PEFD_\_B_]\-_A1_PEFD_\_B_]\-_A0!KT5D?\)9I/_/XO
M_?#?X4?\)9I/_/XO_?#?X4 :]%9'_"6:3_S^+_WPW^%'_"6:3_S^+_WPW^%
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MY+!%21=@57$;C9@LS'))(7G&:]W_ .$GT8*R_:8]K9++Y;8.>N>*<OBO2%4
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M^^&_PH_X2S2?^?Q?^^&_PH UZ*R/^$LTG_G\7_OAO\*/^$LTG_G\7_OAO\*
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M_P#?L5?HH H?V#IO_/C;_P#?L4?V#IO_ #XV_P#W[%7Z* *']@Z;_P ^-O\
M]^Q1_8.F_P#/C;_]^Q5^B@"A_8.F_P#/C;_]^Q1_8.F_\^-O_P!^Q5^B@"A_
M8.F_\^-O_P!^Q1_8.F_\^-O_ -^Q5^B@"A_8.F_\^-O_ -^Q1_8.F_\ /C;_
M /?L5?HH H?V#IO_ #XV_P#W[%']@Z;_ ,^-O_W[%7Z* *']@Z;_ ,^-O_W[
M%']@Z;_SXV__ '[%7Z* *']@Z;_SXV__ '[%']@Z;_SXV_\ W[%7Z* *']@Z
M;_SXV_\ W[%']@Z;_P ^-O\ ]^Q5^B@"A_8.F_\ /C;_ /?L4?V#IO\ SXV_
M_?L5?HH H?V#IO\ SXV__?L4?V#IO_/C;_\ ?L5?HH H?V#IO_/C;_\ ?L4?
MV#IO_/C;_P#?L5?HH H?V#IO_/C;_P#?L4?V#IO_ #XV_P#W[%7Z* *']@Z;
M_P ^-O\ ]^Q1_8.F_P#/C;_]^Q5^B@#/_P"$?TT_\N,'_?L4O]@Z;_SXV_\
MW[%7Z* *']@Z;_SXV_\ W[%']@Z;_P ^-O\ ]^Q5^B@"A_8.F_\ /C;_ /?L
M4?V#IO\ SXV__?L5?HH H?V#IO\ SXV__?L4?V#IO_/C;_\ ?L5?HH H?V#I
MO_/C;_\ ?L4?V#IO_/C;_P#?L5?HH H?V#IO_/C;_P#?L4?V#IO_ #XV_P#W
M[%7Z* *']@Z;_P ^-O\ ]^Q1_8.F_P#/C;_]^Q5^B@"A_8.F_P#/C;_]^Q1_
M8.F_\^-O_P!^Q5^B@"A_8.F_\^-O_P!^Q1_8.F_\^-O_ -^Q5^B@"A_8.F_\
M^-O_ -^Q1_8.F_\ /C;_ /?L5?HH H?V#IO_ #XV_P#W[%']@Z;_ ,^-O_W[
M%7Z* *']@Z;_ ,^-O_W[%']@Z;_SXV__ '[%7Z* *']@Z;_SXV__ '[%']@Z
M;_SXV_\ W[%7Z* *']@Z;_SXV_\ W[%']@Z;_P ^-O\ ]^Q5^B@"A_8.F_\
M/C;_ /?L4?V#IO\ SXV__?L5?HH H?V#IO\ SXV__?L4?V#IO_/C;_\ ?L5?
MHH H?V#IO_/C;_\ ?L4?V#IO_/C;_P#?L5?HH H?V#IO_/C;_P#?L4?V#IO_
M #XV_P#W[%7Z* *']@Z;_P ^-O\ ]^Q1_8.F_P#/C;_]^Q5^B@"A_8.F_P#/
MC;_]^Q1_8.F_\^-O_P!^Q5^B@"A_8.F_\^-O_P!^Q1_8.F_\^-O_ -^Q5^B@
M"A_8.F_\^-O_ -^Q1_8.F_\ /C;_ /?L5?HH H?V#IO_ #XV_P#W[%']@Z;_
M ,^-O_W[%7Z* *']@Z;_ ,^-O_W[%']@Z;_SXV__ '[%7Z* ,\>']-&?]!@_
M[X%+_8.F_P#/C;_]^Q5^B@"A_8.F_P#/C;_]^Q1_8.F_\^-O_P!^Q5^B@"A_
M8.F_\^-O_P!^Q1_8.F_\^-O_ -^Q5^B@"A_8.F_\^-O_ -^Q1_8.F_\ /C;_
M /?L5?HH H?V#IO_ #XV_P#W[%']@Z;_ ,^-O_W[%7Z* *']@Z;_ ,^-O_W[
M%']@Z;_SXV__ '[%7Z* *']@Z;_SXV__ '[%']@Z;_SXV_\ W[%7Z* *']@Z
M;_SXV_\ W[%']@Z;_P ^-O\ ]^Q5^B@"A_8.F_\ /C;_ /?L4?V#IO\ SXV_
M_?L5?HH H?V#IO\ SXV__?L4?V#IO_/C;_\ ?L5?HH H?V#IO_/C;_\ ?L4B
M^']-7_EQ@_% :T** *']@Z;_ ,^-O_W[%']@Z;_SXV__ '[%7Z* *']@Z;_S
MXV__ '[%']@Z;_SXV_\ W[%7Z* *']@Z;_SXV_\ W[%']@Z;_P ^-O\ ]^Q5
M^B@"A_8.F_\ /C;_ /?L4?V#IO\ SXV__?L5?HH H?V#IO\ SXV__?L4?V#I
MO_/C;_\ ?L5?HH H?V#IO_/C;_\ ?L4?V#IO_/C;_P#?L5?HH H?V#IO_/C;
M_P#?L4?V#IO_ #XV_P#W[%7Z* *']@Z;_P ^-O\ ]^Q1_8.F_P#/C;_]^Q5^
MB@"A_8.F_P#/C;_]^Q1_8.F_\^-O_P!^Q5^B@"A_8.F_\^-O_P!^Q2?V!IO_
M #XV_P#W[%:%% &>/#^FCC[#!_W[%+_8.F_\^-O_ -^Q5^B@"A_8.F_\^-O_
M -^Q1_8.F_\ /C;_ /?L5?HH H?V#IO_ #XV_P#W[%']@Z;_ ,^-O_W[%7Z*
M *']@Z;_ ,^-O_W[%']@Z;_SXV__ '[%7Z* *']@Z;_SXV__ '[%']@Z;_SX
MV_\ W[%7Z* *']@Z;_SXV_\ W[%']@Z;_P ^-O\ ]^Q5^B@"A_8.F_\ /C;_
M /?L4?V#IO\ SXV__?L5?HH H?V#IO\ SXV__?L4?V#IO_/C;_\ ?L5?HH H
M?V#IO_/C;_\ ?L4?V#IO_/C;_P#?L5?HH H?V#IO_/C;_P#?L4?V#IO_ #XV
M_P#W[%7Z* ,\^']-/'V&#_OV*7^P=-_Y\;?_ +]BK]% %#^P=-_Y\;?_ +]B
MC^P=-_Y\;?\ []BK]% %#^P=-_Y\;?\ []BC^P=-_P"?&W_[]BK]% %#^P=-
M_P"?&W_[]BC^P=-_Y\;?_OV*OT4 4/[!TW_GQM_^_8H_L'3?^?&W_P"_8J_1
M0!0_L'3?^?&W_P"_8H_L'3?^?&W_ ._8J_10!0_L'3?^?&W_ ._8H_L'3?\
MGQM_^_8J_10!0_L'3?\ GQM_^_8H_L'3?^?&W_[]BK]% %#^P=-_Y\;?_OV*
M/[!TW_GQM_\ OV*OT4 4/[!TW_GQM_\ OV*/[!TW_GQM_P#OV*OT4 9_]@:;
M_P ^-O\ ]^Q1_8&FC_EQM_\ OV*T** *']@Z;_SXV_\ W[%']@Z;_P ^-O\
M]^Q5^B@"A_8.F_\ /C;_ /?L4?V#IO\ SXV__?L5?HH H?V#IO\ SXV__?L4
M?V#IO_/C;_\ ?L5?HH H?V#IO_/C;_\ ?L4?V#IO_/C;_P#?L5?HH H?V#IO
M_/C;_P#?L4?V#IO_ #XV_P#W[%7Z* *']@Z;_P ^-O\ ]^Q1_8.F_P#/C;_]
M^Q5^B@"A_8.F_P#/C;_]^Q1_8.F_\^-O_P!^Q5^B@"A_8.F_\^-O_P!^Q1_8
M.F_\^-O_ -^Q5^B@"A_8.F_\^-O_ -^Q1_8.F_\ /C;_ /?L5?HH H?V#IO_
M #XV_P#W[%']@Z;_ ,^-O_W[%7Z* *']@Z;_ ,^-O_W[%']@Z;_SXV__ '[%
M7Z* *']@Z;_SXV__ '[%']@Z;_SXV_\ W[%7Z* *']@Z;_SXV_\ W[%']@Z;
M_P ^-O\ ]^Q5^B@"A_8.F_\ /C;_ /?L4?V#IO\ SXV__?L5?HH H?V#IO\
MSXV__?L4?V#IO_/C;_\ ?L5?HH H?V#IO_/C;_\ ?L4?V#IO_/C;_P#?L5?H
MH H?V#IO_/C;_P#?L4?V#IO_ #XV_P#W[%7Z* *']@Z;_P ^-O\ ]^Q1_8.F
M_P#/C;_]^Q5^B@"A_8.F_P#/C;_]^Q1_8.F_\^-O_P!^Q5^B@"A_8.F_\^-O
M_P!^Q1_8.F_\^-O_ -^Q5^B@"A_8.F_\^-O_ -^Q1_8.F_\ /C;_ /?L5?HH
M H?V#IO_ #XV_P#W[%']@Z;_ ,^-O_W[%7Z* *']@Z;_ ,^-O_W[%']@Z;_S
MXV__ '[%7Z* *']@Z;_SXV__ '[%']@Z;_SXV_\ W[%7Z* *']@Z;_SXV_\
MW[%']@Z;_P ^-O\ ]^Q5^B@"K:Z7:64ADM[:.%R-I9%QQZ?I5JBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW2/_  ,%'_#4W@S_ *#ND?\ @8*/J6*_Y]2^YA_:."_Y_1_\"7^9[117B_\
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M!G_0=TC_ ,#!1]2Q7_/J7W,/[1P7_/Z/_@2_S/:**\7_ .&IO!G_ $'=(_\
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M9].E '745S/_  D6L?\ 0$D_,_X4?\)%K'_0$D_,_P"% '345S/_  D6L?\
M0$D_,_X4?\)%K'_0$D_,_P"% '345S/_  D6L?\ 0$D_,_X4?\)%K'_0$D_,
M_P"% '345S/_  D6L?\ 0$D_,_X4?\)%K'_0$D_,_P"% '345S/_  D6L?\
M0$D_,_X4?\)%K'_0$D_,_P"% '345S/_  D6L?\ 0$D_,_X4?\)%K'_0$D_,
M_P"% '345S/_  D6L?\ 0$D_,_X4?\)%K'_0$D_,_P"% '345S/_  D6L?\
M0$D_,_X4?\)%K'_0$D_,_P"% '345S/_  D6L?\ 0$D_,_X4?\)%K'_0$D_,
M_P"% '345S/_  D6L?\ 0$D_,_X4R7Q-JT,;N^C,BJ"Q9B< #OTH ZFBN4M?
M%6J74*RQ:0TJ-T="<'G'I4O_  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X
M4?\ "1:Q_P! 23\S_A0!TU%<S_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '3
M45S/_"1:Q_T!)/S/^%'_  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\
M"1:Q_P! 23\S_A0!TU%<S_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/
M_"1:Q_T!)/S/^%'_  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\ "1:Q
M_P! 23\S_A0!TU%<S_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/_"1:
MQ_T!)/S/^%'_  D6L?\ 0$D_,_X4 =-17*7/BK5+6%I9=(:)%ZNQ.!^E.A\3
M:M-$DB:,SHP!#*3@CUZ4 =317,_\)%K'_0$D_,_X4?\ "1:Q_P! 23\S_A0!
MTU%<S_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/_"1:Q_T!)/S/^%'_
M  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\ "1:Q_P! 23\S_A0!TU%<
MS_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/_"1:Q_T!)/S/^%'_  D6
ML?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\ "1:Q_P! 23\S_A0!TU%<S_PD
M6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/_"1:Q_T!)/S/^%'_  D6L?\
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M45S/_"1:Q_T!)/S/^%'_  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\
M"1:Q_P! 23\S_A0!TU%<S_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/
M_"1:Q_T!)/S/^%'_  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\ "1:Q
M_P! 23\S_A0!TU%<S_PD6L?] 23\S_A1_P )%K'_ $!)/S/^% '345S/_"1:
MQ_T!)/S/^%'_  D6L?\ 0$D_,_X4 =-17,_\)%K'_0$D_,_X4?\ "1:Q_P!
M23\S_A0!TU%8&B>(KG4M4FL[BT%JT<>\C)W#D<?K6_0 4444 %%%% !1110
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M=Z?XB/AR3Q;J5_>?9H-)CO/LI\M8VDEF:3RWPJ!0#\IR74=Z9X\_:&\=Z?\
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M:M2U#XRS;^:/_@)'^IN5?RR_\"/J[_AJSPE_T#M:_P"_$/\ \=I?^&JO"?\
MT#]:_P"_$/\ \=KY37K3UK-\:9M_-'_P$S?!^5=I?>?5?_#5'A/_ *!^L_\
M?B+_ ..TO_#4WA3_ *!^L_\ ?F+_ ..U\KT^L_\ 7;-_YH_^ D_ZGY7VE]Y]
M3?\ #4?A7_H'ZQ_WYB_^.TO_  U#X5_Z!^L?]^8O_CM?+B]*>O2LWQOG'\T?
M_ 2/]4<K[2^\^HO^&H/"W_/AK'_?F+_X[2_\-.>%O^?#6/\ OS%_\<KY?J1:
MC_7C./YH_P#@)G_JEEG9_>?3O_#3?A<_\N&K_P#?F+_XY3A^TQX7/_+AJ_\
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MX_X7KH/_ #Z:E_WZC_\ BZ/^%Z:#_P ^FH_]^H__ (NO"J<M3_Q$;/OYH_\
M@*)_U>P/9_>>Z?\ "\]!_P"?34?^_4?_ ,74&H?&K1+O3[F!+74 \L3("T:8
MR01S\]>)KUIU3_Q$C/\ ^:/_ ("B?]7\#V?WGL>@?&#1M+TF"UEMKYI$W9*1
MH1RQ/]_WK1_X7=H7_/IJ'_?N/_XNO#E[4^H_XB1G_P#-'_P%$_ZOX+L_O/;_
M /A=NA_\^FH?]^X__BZ/^%V:'_SZZA_W[C_^+KQ*G+4_\1)S_P#FC_X"B?[
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M"V'_ %P3_P!!%5/%_P#R+MY]%_\ 0Q5O0_\ D"V'_7!/_010!>HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CKG_(%O_\ K@__ *":J^$?
M^1=L_HW_ *$:M:Y_R!;_ /ZX/_Z":J^$?^1=L_HW_H1H V**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***1ONT 9'BKQ=HW@?1+G6/$&J
MVFC:5;KNFO+V58HT'N3W]N]>#6__  41^ %SK TY?'\*N7V"XDLKA8,^OF&/
M&/?I7B6I>%Y/V[/VMO%6C>(+FX/PF^&LRVO]EV\K(FH7I)#%R/\ :5\D<A4
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MNI?"6>_] DOZ^9/]L8#_ )_(\W6EKT@? 3Q /^7S3?\ O[)_\;I?^%"^(/\
MG\TW_O[)_P#&ZC_5'/?^@27]?,C^U\!_S]1YTM*O2O1Q\!]?'_+YIO\ W]D_
M^(H'P'U__G\TW_O[)_\ $5#X1S[_ *!)?A_F3_:^ _Y^H\[IRUZ)_P **U__
M )^]-_[^R?\ Q%*/@7KW_/WIW_?V3_XBI_U0S[_H$E_7S(_M; _\_4>=KUIU
M>ACX&:]_S]Z=_P!_)/\ XBF77P5URTM9IWNM/*1(7(61\X SQ\E9_P"I^?\
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MN1<VW*GT7FC\KXTQ&"HXRDL3AW4?+OSN/5Z629[E_P ,GZU_T,FA_P#?U_\
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M\-HH^JYC_P!!2_\  %_F'U[*?^@)_P#@Q_\ R)[E_P ,GZU_T,FA_P#?U_\
MXFC_ (9/UK_H9-#_ ._K_P#Q->&T4?5<Q_Z"E_X O\P^O93_ - 3_P#!C_\
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M_P"&3]:_Z&30_P#OZ_\ \31_PR?K7_0R:'_W]?\ ^)KPVBCZKF/_ $%+_P
M7^8?7LI_Z G_ .#'_P#(GN7_  R?K7_0R:'_ -_7_P#B:/\ AD_6O^ADT/\
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M\)U;?\^=U_WR/\:R=+\7:%X=US6H=5UK3],FDFWI'>74<3,NYQD!B,C-:_\
MPLWP?_T->A_^#&'_ .*KGEB:$'RRFD_5'5'"XB:4HTVUZ,3_ (3JV_Y\[K_O
MD?XT?\)U;?\ /G=?]\C_ !I?^%F>$/\ H:]$_P#!C#_\52_\+*\(_P#0U:+_
M .#&'_XJH^N8;_GY'[T5]3Q/_/J7W,;_ ,)U;?\ /G=?]\C_ !H_X3JV_P"?
M.Z_[Y'^-/_X61X2_Z&G1?_!A#_\ %4O_  L?PE_T-&B_^#"'_P"*I?7,-_S]
MC]Z%]3Q/_/N7W,C_ .$ZMO\ GSNO^^1_C1_PG5M_SYW7_?(_QJ3_ (6-X3_Z
M&?1O_!A%_P#%4O\ PL3PI_T,VC_^!\7_ ,51]=PW_/V/WH/JF(_Y]R^YD7_"
M=6W_ #YW7_?(_P :/^$ZMO\ GSNO^^1_C4W_  L+PK_T,NC_ /@?%_\ %4?\
M+!\+?]#+H_\ X'Q?_%4OKN%_Y^Q^]"^JXC_GW+[F0_\ "=6W_/G=?]\C_&C_
M (3JV_Y\[K_OD?XU/_PL#PO_ -#)I'_@=%_\52_\)]X8_P"ACTG_ ,#HO_BJ
M/KV%_P"?L?\ P)?YA]5Q'_/M_<RO_P )U;?\^=U_WR/\:/\ A.K;_GSNO^^1
M_C5G_A//#/\ T,6D_P#@=%_\51_PG?AK_H8=*_\  V+_ .*I?7L)_P _8_\
M@2_S%]5K_P#/M_<RM_PG5M_SYW7_ 'R/\:/^$ZMO^?.Z_P"^1_C5K_A.O#?_
M $,&E?\ @;%_\52_\)QX<_Z&#2__  -C_P#BJ/K^$_Y_1_\  E_F'U:O_(_N
M94_X3JV_Y\[K_OD?XT?\)U;?\^=U_P!\C_&K?_";^'?^@_I?_@9'_P#%4O\
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M +Y'^-=-10!S/_"=6W_/G=?]\C_&C_A.K;_GSNO^^1_C7344 <S_ ,)U;?\
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M^?.Z_P"^1_C6_P#;K?\ Y[Q?]]BI58,,@@CU!H YK_A.K;_GSN?^^1_C2_\
M"=6W_/G=?]\C_&NADNH8FVO+&C>C, :<DRR*&1@R^JG(H YS_A.K;_GSNO\
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MX6LK6T:!L;KI9I5=5.>'#LN?<BN6CC,5-QHU)6FTFWHTDXMZ6\T_DO.YVXC
M8*G&>(I0<H1;BE[R;:E%.]]=$UMU>NUCD?#?P<US7;KQ#'=SV'AVV\/R>3J5
M]K,YB@@E+E!%E58LY(; 4'I],Y/CWP!J7P[U:"RU"2UNH[JVCO+2]L9?-M[J
M!\[9(VP"1D$<@'CI7T9^TI<6^J>#?B1_9A$OV7QU;/>>2V=B?V?Y>6QV\X,/
M]ZO+/BYOM_@_\';2[W#4ETZ^G99'RX@DNF,!]E*@X]OI6^#QU;$.G4EHINW+
MV]SFO]^GHU\^;'Y;A\+&K2A=N"YN:^_[SDM;;;7U3^7D-%%%?1GR84444 %%
M%% !1110 4444 ?1?[%?_(YZS_U[Q?\ HROT+K\]/V*_^1SUG_KWB_\ 1E?H
M77XAQ1_R-)^D?R1_1O!G_(FI^LO_ $IA1117R9]P%%%% !1110 4444 %%%%
M !1110 4444 %%%% '$>*/BYH_A+XH^!O =Y;7TFL>,(M0FL)H(T-O$MG'')
M+YK%PP)$J[=JMD@YQW[>OFSXV?\ )['[,_\ UX^+/_26TKL_VK]8T#2_@OJ%
MOXCG\1+8ZI>6>F1V?A241:AJ,TMPBQV<;G 43-B-CN7Y&8;AF@#V"BO@WP3H
M8^'7[6'A+3]'\ 0? FSU[PIK4FH65KJ]O<"X\H6[17-Q!#F%'B9I,2;V+?,"
M0!\V+\+_  B/@CXG^$VJ>+?!MLWV_6+2PL_C#\/_ !$MTGB:6[5HH%U.&1?,
MEBG9T<LK.JL%*LJCY@#]#**_.7Q=X1'PL;7/B+XK\-VOCOPW;^)9=6_X71X$
M\11C7M-A6_.8)H9%(>*+!MGAB=E"JPV!LE?0OBCX=\&_%;XG?$^6+X6:K\6[
MG2I([#4M<\1ZQ;V&E>'Y8[9&-O8L^98BJ.)7DCB8[W)W'Y10!]L5\]?\-C6^
MH>)O%>C^'OA-\2/%J^&M8GT.^U#1;"Q>V^U1!2ZHTEXC$8=#RHX85L?L3Z_J
M7BC]DWX6ZGJ]]/J6HSZ'#YUW=.7ED*Y4%F/+' ')Y/>O#/V?;/XS7'C+X_M\
M.]6\"V&B?\+.U431^)]+O;JY-QY%KN*M#<QJ$V^7@%2<AN<$  'V#X#\53>-
MO"ECK5QX?U?PM-=>9NTG7HHH[R#;(R#S%CDD0;@NX8<_*RYP<@;]?&7[2%OX
MV\=?&[X0?#G5+#POXGANO#=]JVHZ'J]_=Z9HNKZE"8$? 2*=Y5C#R2)!(& 5
MBS$E5SRMQ\$_&>B_"_XOZ=:W'@^WOO".HZ7XQ\)>#O"VN3ZH?#]]:H9Y8")H
M8F@CN4C^2, +^^EQ@'D ^]Z*^"?B%\4K[XD:;\;OCSX*N)/L?@_P)%HGA:_A
M4MY=Q=6\=_?7*CL\:2VB[L<&)O0YD\&?!'Q1X)\0?"3Q7HMG\+_ 'GZM8K=^
M(K/QE?SWOBFSF0^;;2+-9QB\FE0F1-[E@Z @@9H ^\J*^5?V/OA5X8N->^)7
MCJ[TN*^\5V_Q&\46]GJESEY;* W\RF&$G[D9+2,5'5I&)KZJH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#XI_:4_Y*2?^O?\ ]K2UY:M>I?M*
M?\E)/_7O_P"UI:\M6OYWX@_Y&=?U/Z<X=_Y%&'_PDT=3+4,=3+7R\CW9$R]J
ME6HE[5*M<TCGD3+VJ9.E0KVJ9.E<TC&1*M3)TJ%:F3I7-(YV3+]ZIEJ%?O5,
MM<TC&1*E3+TJ%*F7I7-(YY$RU(O2HUJ1>E<TC"1*O2GTQ>E/K%[F,B2I%Z5'
M4B]*R9FQZ]JD7K4:]JD7K6#,6/\ \*DJ/_"I*R9DQZ]:D6HUZU(M8LR9(O6G
MK3%ZT]:R9DR1:D2HUJ1*QD9,NZ;J=WI-PMQ9W$EO,O1D./P/J/8U[QX)\4#Q
M5HJW#JJ7,;>7,J]-V.H]C_C7S\M>L?!>UECL=3N&!$4KHB\=2H;/_H0K]<\-
M,SQE'.8X&$FZ512YET5DVI>3NK>=_0^7SRA3EAG5:]Y6M_D>DT445_61^>A1
M110 4444 %%%% !5+6O^0-?_ /7O)_Z":NU2UK_D#7__ %[R?^@F@"EX/_Y%
MRT_X'_Z&U;58O@__ )%RT_X'_P"AM6U0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!C>+_P#D7;SZ+_Z&*MZ'_P @6P_ZX)_Z"*J>+_\
MD7;SZ+_Z&*MZ'_R!;#_K@G_H(H O4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!1US_ ) M_P#]<'_]!-5?"/\ R+MG]&_]"-6M<_Y M_\
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M2",<G/%4OC1\(]7_ ."?-SX9^(_P[\9Z[?\ AB75H=.UGPYK5UY\<T;Y.5P
M,X5AG&02"#U%2_'KQ5X\\'_\%'/[0^'/A2#QEXD'A&.,:9<3B%#$2V]]Q9>1
M@<9[UTNL_"7X_P#[8/B7PU9_%K0M*^'7P[T>^34+C2[&Y$]Q?R+T4X=NQ(R2
M  Q."<5[B<HJ#E)*%M5]_0\%KFYTD^:[U/NJTNEO+.&=/N2HLBY]",BOCO\
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MF?/DD\^]E5$DE^=CMRL2#:N%&. ,FK/_  FFD_\ /PW_ '[;_"C_ (332?\
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M?_\ A--)_P"?AO\ OVW^%8?A'Q!8Z3ILD-S*4D:8N $)XVJ.P]C4?\0QR?\
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M'_PFFD_\_#?]^V_PH_X332?^?AO^_;?X5]<><;E%8?\ PFFD_P#/PW_?MO\
M"C_A--)_Y^&_[]M_A0!N45A_\)II/_/PW_?MO\*/^$TTG_GX;_OVW^% &Y16
M'_PFFD_\_#?]^V_PH_X332?^?AO^_;?X4 ;E4M:_Y U__P!>\G_H)JA_PFFD
M_P#/PW_?MO\ "JVI^+=,N=-NX8YV,DD+HH\MADE2!VH M^#_ /D7+3_@?_H;
M5M5R/AOQ-IVGZ+;V\\Q25-V5V,>K$^GO6E_PFFD_\_#?]^V_PH W**P_^$TT
MG_GX;_OVW^%'_"::3_S\-_W[;_"@#<HK#_X332?^?AO^_;?X4?\ "::3_P _
M#?\ ?MO\* -RBL/_ (332?\ GX;_ +]M_A1_PFFD_P#/PW_?MO\ "@#<HK#_
M .$TTG_GX;_OVW^%'_"::3_S\-_W[;_"@#<HK#_X332?^?AO^_;?X4?\)II/
M_/PW_?MO\* -RBL/_A--)_Y^&_[]M_A1_P )II/_ #\-_P!^V_PH W**P_\
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M_OVW^% &Y16'_P )II/_ #\-_P!^V_PH_P"$TTG_ )^&_P"_;?X4 ;E%8?\
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MNFKDM"O8M0\97]Q V^)X/E.".FP?TKK: "BBB@ HHHH **** "BBB@ HHHH
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MRZQ_X'R__%5S]%'U>C_(ON0?6\1_S\E][.@_X6%XI_Z&76/_  /E_P#BJ/\
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M%/\ T,NL?^!\O_Q5<_11]7H_R+[D'UO$?\_)?>SH/^%A>*?^AEUC_P #Y?\
MXJC_ (6%XI_Z&76/_ ^7_P"*KGZ*/J]'^1?<@^MXC_GY+[V?3G[(/B35M>\7
M:O%J>J7NHQ)!$52[N'E4$R8) 8FON_\ LFR_Y\[?_OTO^%?G_P#L5_\ (YZS
M_P!>\7_HROT+K\5XFC&&9S45967Y(_H;@^<JF3TY3=W>6_JRI_9-E_SYV_\
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MRD\ZSNX4N(9-I7>CJ&4X(!&01P1F@!/[)LO^?.W_ ._2_P"%']DV7_/G;_\
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M ._2_P"%']DV7_/G;_\ ?I?\*^#E^)?B_C_BJM;_ /!C-_\ %5(OQ*\7<?\
M%4ZU_P"#&;_XJN=\=89?\N9?>BWP'B5_R_C]S/NW^R;+_GSM_P#OTO\ A1_9
M-E_SYV__ 'Z7_"OAA?B1XM_Z&G6O_!A-_P#%5(OQ&\6<?\51K7_@PF_^*K-\
M>X9?\N)?>C-\"XE?\OH_<S[C_LFR_P"?.W_[]+_A1_9-E_SYV_\ WZ7_  KX
MA7XB^*_^AGUG_P &$O\ \54J_$3Q7C_D9M8_\#Y?_BJS?B!A5_RXE]Z(? ^(
M7_+Z/W,^V?[)LO\ GSM_^_2_X4?V39?\^=O_ -^E_P *^*U^(7BK_H9=8_\
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MZ7_"ODE?'/B3_H8-4_\  V7_ .*J0>./$>?^1@U3_P #9/\ XJL_^(EX1?\
M,/+[T0^$:_\ S]7W,^LO[)LO^?.W_P"_2_X4?V39?\^=O_WZ7_"OE'_A-_$?
M_0?U3_P,D_\ BJ?_ ,)MXB_Z#VJ?^!DG_P 54?\ $3<'_P! TOO1/^J=?_GZ
MON9]5_V39?\ /G;_ /?I?\*/[)LO^?.W_P"_2_X5\KKXU\0_]![4_P#P,D_^
M*J3_ (33Q#_T'=3_ / R3_XJI_XB?@_^@:7WHC_52M_S]7W,^I/[)LO^?.W_
M ._2_P"%<[X&L;>YTF9IK>*5A.1N= 3C:O'-> #QGX@S_P AW4O_  ,D_P :
M9:^*-9M5*0:O?0H3DK'<NHSZ\&I_XBC@_P#H&E]Z)?"U9?\ +U?<SZD_LFR_
MY\[?_OTO^%']DV7_ #YV_P#WZ7_"OF0>,M?W?\AS4O\ P+D_QIZ^,->_Z#>I
M?^!<G^-1_P 13P?_ $#2^]$OA>LO^7B^YGTQ_9-E_P ^=O\ ]^E_PH_LFR_Y
M\[?_ +]+_A7S4OC#7O\ H-ZC_P"!<G^-/7Q=KO\ T&M1_P# N3_&I_XBK@O^
M@:7WHG_5FM_S\7W,^DO[)LO^?.W_ ._2_P"%']DV7_/G;_\ ?I?\*^<5\7:[
M_P!!K4/_  *D_P :<OBW7/\ H,ZA_P"!4G^-1_Q%;!?] LOO1'^K=7_GXON9
M]&?V39?\^=O_ -^E_P */[)LO^?.W_[]+_A7SL/%FN8_Y#.H?^!3_P"-2KXL
MUL?\QB__ !N7_P :G_B+&"_Z!9_>B?\ 5VK_ ,_%^)]"?V39?\^=O_WZ7_"C
M^R;+_GSM_P#OTO\ A7CWAWXJ:KIDR+?.=0M2?F#X\P#U#=_Q_2O9+"^AU*SA
MNK9Q)!*H9&'<5^B\.\59?Q)"7U1M3CO&6C7GU37FOG8\/&9?6P+7M-4^J&?V
M39?\^=O_ -^E_P */[)LO^?.W_[]+_A5NBOL3S2I_9-E_P ^=O\ ]^E_PH_L
MFR_Y\[?_ +]+_A5NB@"I_9-E_P ^=O\ ]^E_PH_LFR_Y\[?_ +]+_A5NB@"I
M_9-E_P ^=O\ ]^E_PH_LFR_Y\[?_ +]+_A5NB@"I_9-E_P ^=O\ ]^E_PJIK
M&FV<>DWK+:0*RP.0PC4$':>>E:U4M:_Y U__ ->\G_H)H R_">GVL_A^U>2V
MAD<[\LT8)/SGOBM;^R;+_GSM_P#OTO\ A5#P?_R+EI_P/_T-JVJ *G]DV7_/
MG;_]^E_PH_LFR_Y\[?\ []+_ (5;HH J?V39?\^=O_WZ7_"C^R;+_GSM_P#O
MTO\ A5NB@"I_9-E_SYV__?I?\*/[)LO^?.W_ ._2_P"%6Z* *G]DV7_/G;_]
M^E_PH_LFR_Y\[?\ []+_ (5;HH J?V39?\^=O_WZ7_"C^R;+_GSM_P#OTO\
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M_9-E_P ^=O\ ]^E_PJW10!4_LFR_Y\[?_OTO^%']DV7_ #YV_P#WZ7_"K=%
M&1K6FV<>CWK):0*RPN0RQ@$'!]JK>%=/M9M!M'DMH9'(;+-&"3\Q]JTM<_Y
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M(0J;AP3G.#CC!KURKA-5%S(Y,5AI82JZ4VFUO;6WEZ]UT]2I_9-E_P ^=O\
M]^E_PH_LFR_Y\[?_ +]+_A5NBM#D.6TN%(/'&HI&BQH(!A5& .$KJ:YG3_\
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M110 4444 %%%% !1110 4444 %%%% !1110!1US_ ) M_P#]<'_]!-5?"/\
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MJ>VJ2J6M=W/2P]+V%*-*]^5)'BG[4>GW.K?#_5[.RMY+N[EL66."%"[N=PX
M')K\_P#_ (53XT_Z%/6?_ &7_P")K]7-0T.QU219+J#S74;0=S#C\#5;_A$=
M(_Y\Q_WVW^-?195GU7*:4J5."E=WU/E<[X9HYY6C6JU'%Q5M+=[GY6?\*I\:
M?]"GK/\ X R__$T?\*I\:?\ 0IZS_P" ,O\ \37ZI_\ "(Z1_P ^8_[[;_&C
M_A$=(_Y\Q_WVW^->W_KEB/\ GU'[V?.?\0_PG_/^7W(_*S_A5/C3_H4]9_\
M &7_ .)H_P"%4^-/^A3UG_P!E_\ B:_5/_A$=(_Y\Q_WVW^-'_"(Z1_SYC_O
MMO\ &C_7+$?\^H_>P_XA_A/^?\ON1^5G_"J?&G_0IZS_ . ,O_Q-'_"J?&G_
M $*>L_\ @#+_ /$U^J?_  B.D?\ /F/^^V_QH_X1'2/^?,?]]M_C1_KEB/\
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MGA?Q9JTVL:/?:7#)!&J27ENT2L1)D@%@.U?<W]N:=_S_ -O_ -_5_P :J?\
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M'_/F/^^V_P :/^$1TC_GS'_?;?XT 6O[<T[_ )_[?_OZO^-']N:=_P _]O\
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M_P#?U?\ &JO_  B.D?\ /F/^^V_QH_X1'2/^?,?]]M_C0!:_MS3O^?\ M_\
MOZO^-']N:=_S_P!O_P!_5_QJK_PB.D?\^8_[[;_&C_A$=(_Y\Q_WVW^- %K^
MW-._Y_[?_OZO^-']N:=_S_V__?U?\:J_\(CI'_/F/^^V_P :/^$1TC_GS'_?
M;?XT 6O[<T[_ )_[?_OZO^-']N:=_P _]O\ ]_5_QJK_ ,(CI'_/F/\ OMO\
M:/\ A$=(_P"?,?\ ?;?XT 6O[<T[_G_M_P#OZO\ C1_;FG?\_P#;_P#?U?\
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M]N:=_P _]O\ ]_5_QH_MS3O^?^W_ ._J_P"-5?\ A$=(_P"?,?\ ?;?XT?\
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M1TC_ )\Q_P!]M_C0!:_MS3O^?^W_ ._J_P"-']N:=_S_ -O_ -_5_P :J_\
M"(Z1_P ^8_[[;_&C_A$=(_Y\Q_WVW^- %K^W-._Y_P"W_P"_J_XT?VYIW_/_
M &__ ']7_&JO_"(Z1_SYC_OMO\:/^$1TC_GS'_?;?XT 6O[<T[_G_M_^_J_X
MT?VYIW_/_;_]_5_QJK_PB.D?\^8_[[;_ !H_X1'2/^?,?]]M_C0!:_MS3O\
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MU5_X1'2/^?,?]]M_C1_PB.D?\^8_[[;_ !H M?VYIW_/_;_]_5_QH_MS3O\
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M#HQVD GW.:BL=!\*V+QOYT-RT7^K^TW)E5.<\*3M'/H*UO\ A$=(_P"?,?\
M?;?XT?\ "(Z1_P ^8_[[;_&@!VH7VE:E:O;RZBL:/C+6]V87X.>&1@P_ UC_
M -B^'_\ H-:A_P"#ZZ_^.UK?\(CI'_/F/^^V_P :/^$1TC_GS'_?;?XT 9/]
MB^'_ /H-:A_X/KK_ ..T?V+X?_Z#6H?^#ZZ_^.UK?\(CI'_/F/\ OMO\:/\
MA$=(_P"?,?\ ?;?XT 9/]B^'_P#H-:A_X/KK_P".T?V+X?\ ^@UJ'_@^NO\
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M_P"_J_XT?VYIW_/_ &__ ']7_&JO_"(Z1_SYC_OMO\:/^$1TC_GS'_?;?XT
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MRCRMWTWV=CF?^$T?_H%W7Y?_ %J/^$T?_H%W7Y?_ %JZ:BO(/>.9_P"$T?\
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M^$T?_H%W7Y?_ %JZ:B@#F?\ A-'_ .@7=?E_]:C_ (31_P#H%W7Y?_6KIJ*
M.9_X31_^@7=?E_\ 6H_X31_^@7=?E_\ 6KIJ* .9_P"$T?\ Z!=U^7_UJ/\
MA-'_ .@7=?E_]:NFHH YG_A-'_Z!=U^7_P!:C_A-'_Z!=U^7_P!:NFHH YG_
M (31_P#H%W7Y?_6H_P"$T?\ Z!=U^7_UJZ:B@#F?^$T?_H%W7Y?_ %J/^$T?
M_H%W7Y?_ %JZ:B@#E8_'1D9U&FS,5."%.2/KQQ4G_":/_P! NZ_+_P"M1X5_
MY#.O_P#7Q_[,]=-0!S/_  FC_P#0+NOR_P#K4?\ ":/_ - NZ_+_ .M7344
M<S_PFC_] NZ_+_ZU'_":/_T"[K\O_K5TU% ',_\ ":/_ - NZ_+_ .M1_P )
MH_\ T"[K\O\ ZU=-10!S/_":/_T"[K\O_K4?\)H__0+NOR_^M7344 <S_P )
MH_\ T"[K\O\ ZU'_  FC_P#0+NOR_P#K5TU% ',_\)H__0+NOR_^M1_PFC_]
M NZ_+_ZU=-10!S/_  FC_P#0+NOR_P#K4?\ ":/_ - NZ_+_ .M7344 <S_P
MFC_] NZ_+_ZU'_":/_T"[K\O_K5TU% ',_\ ":/_ - NZ_+_ .M1_P )H_\
MT"[K\O\ ZU=-10!S/_":/_T"[K\O_K5'#XZ,RDKILS ''R'</Y5U5<SX!_Y!
M5Q_U\'_T%: #_A-'_P"@7=?E_P#6H_X31_\ H%W7Y?\ UJZ:B@#F?^$T?_H%
MW7Y?_6H_X31_^@7=?E_]:NFHH YG_A-'_P"@7=?E_P#6H_X31_\ H%W7Y?\
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MFC_] NZ_+_ZU=-10!S/_  FC_P#0+NOR_P#K4?\ ":/_ - NZ_+_ .M7344
M<S_PFC_] NZ_+_ZU'_":/_T"[K\O_K5TU% ',_\ ":/_ - NZ_+_ .M1_P )
MH_\ T"[K\O\ ZU=-10!S/_":/_T"[K\O_K4?\)H__0+NOR_^M7344 <S_P )
MH_\ T"[K\O\ ZU'_  FC_P#0+NOR_P#K5TU% ',_\)H__0+NOR_^M1_PFC_]
M NZ_+_ZU=-10!S/_  FC_P#0+NOR_P#K4?\ ":/_ - NZ_+_ .M7344 <S_P
MFC_] NZ_+_ZU'_":/_T"[K\O_K5TU% ',_\ ":/_ - NZ_+_ .M1_P )H_\
MT"[K\O\ ZU=-10!S/_":/_T"[K\O_K4?\)H__0+NOR_^M7344 <S_P )H_\
MT"[K\O\ ZU'_  FC_P#0+NOR_P#K5TU% ',_\)H__0+NOR_^M1_PFC_] NZ_
M+_ZU=-10!S/_  FC_P#0+NOR_P#K4?\ ":/_ - NZ_+_ .M7344 <S_PFC_]
M NZ_+_ZU'_":/_T"[K\O_K5TU% ',_\ ":/_ - NZ_+_ .M1_P )H_\ T"[K
M\O\ ZU=-10!S/_":/_T"[K\O_K4?\)H__0+NOR_^M7344 <S_P )H_\ T"[K
M\O\ ZU'_  FC_P#0+NOR_P#K5TU% ',_\)H__0+NOR_^M1_PFC_] NZ_+_ZU
M=-10!S/_  FC_P#0+NOR_P#K4?\ ":/_ - NZ_+_ .M7344 <S_PFC_] NZ_
M+_ZU'_":/_T"[K\O_K5TU% ',_\ ":/_ - NZ_+_ .M1_P )H_\ T"[K\O\
MZU=-10!AZ+XF_M?4)+4VCV[)'OR[<]0,8Q[UN5S.G_\ (]ZE_P!<!_*.NFH
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MWQX\7>$_$^J6/A+P1\,;F'3I-,OI(8;C5KNQ>^^U#80#)!!]DVMU0SL0<G@
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MEK6L? 7XX^&M0O/%%SI/ASQQX5BTJ'QI*)M6M8)[[2YFBFDWNS@.S%=[%PK
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MNH[R O\ ZG)C:-HTVQ_O4P@Q7C7PG\0Z7;_LP_LXZ+J?C7Q=IT5UH,TQ\(^
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'T7^Q7_ ,CGK/\
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M[/10!Y!XF_9HT36=4T76-(\2>)/!GB/2])CT+^V_#]S#'<7=BA!6&=989(G
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M%CIO_"2^/_%'B[5M _MC4;YS<ZE>P0:G:@*!;QHJ1Q1><V(T4*"['N:^N:*
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M/[P';W%=G7XW4IRI2<);H_>J=2-6"G'9A11169J%%%% !1110 4444 %%%%
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MR;_XJNFHH YG_A%]2_Z#UQ^3?_%4?\(OJ7_0>N/R;_XJNFHH YG_ (1?4O\
MH/7'Y-_\51_PB^I?]!ZX_)O_ (JNFHH YG_A%]2_Z#UQ^3?_ !5'_"+ZE_T'
MKC\F_P#BJZ:B@#F?^$7U+_H/7'Y-_P#%4?\ "+ZE_P!!ZX_)O_BJZ:B@#F?^
M$7U+_H/7'Y-_\51_PB^I?]!ZX_)O_BJZ:B@#F?\ A%]2_P"@]<?DW_Q5'_"+
MZE_T'KC\F_\ BJZ:B@#F?^$7U+_H/7'Y-_\ %4?\(OJ7_0>N/R;_ .*KIJ*
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M_P!!ZX_)O_BJZ:B@#F?^$7U+_H/7'Y-_\51_PB^I?]!ZX_)O_BJZ:B@#F?\
MA%]2_P"@]<?DW_Q5'_"+ZE_T'KC\F_\ BJZ:B@#F?^$7U+_H/7'Y-_\ %4?\
M(OJ7_0>N/R;_ .*KIJ* .9_X1?4O^@]<?DW_ ,51_P (OJ7_ $'KC\F_^*KI
MJ* .!T71KN\U#4XXM3EMWAEVO(N<RG+<GGV/YUL?\(OJ7_0>N/R;_P"*K%L_
M&6C^%]>UJ/4[S[,\LVY!Y3OD!W'\(-:'_"W/"?\ T%?_ "6F_P#B*VC0JR5X
MP;7H<DL9AJ<G&=2*:\T6O^$7U+_H/7'Y-_\ %4?\(OJ7_0>N/R;_ .*JI_PM
M[PE_T%O_ "6F_P#B*3_A<'A$?\Q?_P EIO\ XBJ^KUOY']S(^O83_G['_P "
M7^9<_P"$7U+_ *#UQ^3?_%4?\(OJ7_0>N/R;_P"*JE_PN+PA_P!!?_R6F_\
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MPX_Z&+_R1N?_ (W3^J8C_GW+[F']H8/_ )_1_P# E_F=/_PB^I?]!ZX_)O\
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ML2O]GW1ZL3VBK3_X:Z^$W_0U_P#E.N__ (U3^IXG_GU+[F']H8/_ )_1_P#
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M?DW_ ,57G?\ PV7\'?\ H</_ "F7G_QFD_X;.^#G_0X?^4R\_P#C-'U/$_\
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M9?\ 7/\ K0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU\P?M1>!X/B)^T%\ M#N=6UO1(IGUYS>>']2ET^[7;9QMA9HB&4'&" >1D4
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MW^TA\._AMXC'A_7M?>+76L8=2CTRQT^ZO;F:VE>5$DBC@B=I!F"7.P$J%!;
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M:T\KP?X?GOI-.N(VG07*W]C/F.WB6(R$L1'M*@CFNV^-'_)1_P!L[_LDMO\
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MW7L'_"::3_SW;_OVW^%'_"::3_SW;_OVW^%:?VEB.Z^XP_L#!=G]YXX?V?\
MQ#_S^:9_W]D_^-TP_L^>(O\ G]TO_O[)_P#&Z]F_X332?^>[?]^V_P */^$T
MTG_GNW_?MO\ "G_:6([K[@_L#!=G]YXN?V>?$9_Y?=+_ ._LG_QNF']G?Q)_
MS^Z7_P!_9/\ XW7M?_"::3_SW;_OVW^%'_"::3_SW;_OVW^%']IXCNON%_J_
M@NS^\\1/[.?B3_G^TK_O[+_\;IA_9Q\2G_E^TK_O]+_\;KW'_A--)_Y[M_W[
M;_"C_A--)_Y[M_W[;_"G_:>([K[@_P!7\#V?WGAA_9N\3'_E^TG_ +_2_P#Q
MNHS^S7XG_P"?[2?^_P!+_P#&Z]W_ .$TTG_GNW_?MO\ "C_A--)_Y[M_W[;_
M  H_M3$=U]P?ZOX'L_O/!C^S3XG/_+_I/_?Z7_XW3#^S-XH/_+_I'_?Z7_XW
M7OG_  FFD_\ /=O^_;?X4?\ "::3_P ]V_[]M_A3_M3$]U]PO]7\#V?WG@!_
M9C\4G_E_TC_O]+_\;II_9@\4G_E_T?\ [_2__&J^@?\ A--)_P">[?\ ?MO\
M*/\ A--)_P">[?\ ?MO\*/[4Q/=?<'^K^![/[SY[/[+OBK_H(:/_ -_I?_C5
M,/[+?BL_\Q#1_P#O]+_\:KZ'_P"$TTG_ )[M_P!^V_PH_P"$TTG_ )[M_P!^
MV_PI_P!JXGNON#_5[ ]G]Y\[']ECQ7_T$-&_[_2__&J8?V5?%G_00T;_ +_S
M?_&J^C/^$TTG_GNW_?MO\*/^$TTG_GNW_?MO\*/[6Q/=?<'^KV![/[SYP/[*
M?BT_\Q'1?^_\W_QJL[2?V9_$^M6[S07^DHJOL(DFE!S@'M&?6OJ#_A--)_Y[
MM_W[;_"L3PGX@L=)L)HKF5D=IBX 0GC ';Z4_P"UL3W7W"_U>P/9_>>"G]DW
MQ=_T$=%_[_S?_&J8?V2O%Y_YB6B?]_YO_C5?3'_"::3_ ,]V_P"_;?X4?\)I
MI/\ SW;_ +]M_A1_:V*[K[@_U=P/9_>?,I_9'\8?]!+0_P#O_-_\:IA_9%\8
M_P#02T/_ +_S?_&J^G?^$TTG_GNW_?MO\*/^$TTG_GNW_?MO\*?]KXKNON#_
M %=P'9_>?,!_9"\8G_F):'_W_F_^-4P_L?\ C+_H)Z%_W_F_^-5]1?\ "::3
M_P ]V_[]M_A1_P )II/_ #W;_OVW^%']L8KNON#_ %=P'9_>?+1_8]\9_P#0
M3T+_ ,")O_C--/['7C/_ *">@_\ @1-_\9KZG_X332?^>[?]^V_PH_X332?^
M>[?]^V_PI_VQBNZ^X7^KN [/[SY5/[&_C3_H)Z#_ .!$_P#\9IC?L:^-3_S%
M-!_\")__ (S7U;_PFFD_\]V_[]M_A1_PFFD_\]V_[]M_A1_;&*[K[@_U=P'9
M_>?)[?L8^-C_ ,Q30/\ P(G_ /C-1M^Q;XV/_,4T#_P(G_\ C-?6G_"::3_S
MW;_OVW^%'_"::3_SW;_OVW^%/^V,5W7W!_JY@.S^\^2&_8K\;G_F*^'_ /P(
MG_\ C-1M^Q/XX/\ S%?#_P#X$3__ !FOKO\ X332?^>[?]^V_P */^$TTG_G
MNW_?MO\ "C^V,5W7W!_JY@.S^\^06_8C\<G_ )BOA[_P)G_^,TQOV(?'1_YB
MWA[_ ,"9_P#XS7V#_P )II/_ #W;_OVW^%'_  FFD_\ /=O^_;?X4?VSB^Z^
MX/\ 5S =G]Y\=M^P[X[/_,6\._\ @3/_ /&:C;]AGQX?^8MX=_\  F?_ .,5
M]D?\)II/_/=O^_;?X4?\)II/_/=O^_;?X4?VSB^Z^X/]7,!V?WGQHW["WCT_
M\Q?PY_X$W'_QBH+K]AGQY;V\LS:MX=*QJ7.+F?. ,_\ /"OM+_A--)_Y[M_W
M[;_"H-0\7Z7<6-S$D[%WC95'EMU((]*/[9Q?=?<'^KF [/[SXJTW]B'QUJUF
MES#JOAY8WR 'N9P>#CM#5@_L&^/S_P Q?PW_ .!-Q_\ &*^P/#7B;3]-T>&W
MGE9)5+9 0GJ2:U/^$TTG_GNW_?MO\*?]M8ONON#_ %=P'9_>?%!_8*^(!_YC
M'AO_ ,"KC_XQ49_8'^(/_08\-?\ @5<?_&*^V_\ A--)_P">[?\ ?MO\*/\
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MI''-<6,<ZM/"CYV,Z [E#;6P2,':<=* +U%<KH/Q6\$^*M>GT31?&&@:QK4
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M_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\
M/I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y
M](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]
M^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_O
MTO\ A1_9=E_SZ0?]^E_PJU6.WC+0%\6+X6.N::/$S6GV\:*;N/[:;;=L\_R<
M[_+W#;OQC/&<T 7O[+LO^?2#_OTO^%']EV7_ #Z0?]^E_P *M44 5?[+LO\
MGT@_[]+_ (4?V79?\^D'_?I?\*ENKJ&QM9KFYFCM[>%&DEFE8*B*!DLQ/
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M^R[+_GT@_P"_2_X5\_']HSQ)_P ^.E?]^I?_ (Y3#^T=XE'_ "XZ5_WYE_\
MCE/^S,1V7WA_K!@>[^X^A/[+LO\ GT@_[]+_ (4?V79?\^D'_?I?\*^>3^TC
MXF'_ "XZ3_WYE_\ CE1G]I3Q/_SXZ3_WYE_^.4?V7B.R^\/]8,#W?W'T5_9=
ME_SZ0?\ ?I?\*/[+LO\ GT@_[]+_ (5\YG]I;Q./^7#2?^_,O_QRF']IGQ0/
M^7#2/^_,O_QRG_9>)[+[Q?ZP8'N_N/H_^R[+_GT@_P"_2_X4?V79?\^D'_?I
M?\*^;3^TYXI'_+AI'_?F7_XY33^T_P"*1_RX:/\ ]^9?_CM']EXGLOO#_6#
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MP'=_<?6O]EV7_/I!_P!^E_PH_LNR_P"?2#_OTO\ A7R.?VPO&?\ T#-"_P#
M>;_X]33^V+XS_P"@9H/_ (#S?_'J?]CXKLOO%_K%@.[^X^NO[+LO^?2#_OTO
M^%']EV7_ #Z0?]^E_P *^0C^V1XT_P"@9H/_ (#S_P#QZF-^V5XU'_,+T'_P
M'G_^/4?V/BNR^\/]8L!W?W'V!_9=E_SZ0?\ ?I?\*/[+LO\ GT@_[]+_ (5\
M>-^V=XV'_,+T#_P'G_\ CU1M^VEXV'_,+T#_ ,!Y_P#X]3_L?%=E]X?ZQX#N
M_N/L?^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\ "OC5OVU/&X_YA7A__P !Y_\
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M7^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\ "OSG;_@I'\3!_P P/PG_ . ES_\
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MPH_LNR_Y](/^_2_X5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J*
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MR/6-3U',U[K-]>(_G,0B_--+R%4 8PH'2@##^)7QD^)FH>)/C3+\-()-8L_
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MX=\=P6'BKP1?Z[=V.I7V@K=VDT>J73SS1O;&=6#(&55D253\I.,,5':_!KX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAGN/"_F2L6!;^T+H=&([2UI_\,B_";_H5/\ RHW?_P =KJ?#ZZ[_ &5%]B,
MMLMMWXSU.?UK2V^*/[UK^E/ZYB?^?DOO8?V?@_\ GS'_ ,!7^1P?_#(?PE_Z
M%/\ \J5W_P#':3_AD'X2?]"E_P"5*[_^.UWNWQ1_>M?THV^*/[UK^E'US$_\
M_9?>Q_V?@_\ GS'_ ,!7^1P'_#'WPB_Z%+_RI7G_ ,>I/^&//A#_ -"C_P"5
M*\_^/5Z!M\4?WK7]*-OBC^]:_I1]<Q/_ #]E][#^S\'_ ,^8_P#@*_R//O\
MACGX0?\ 0H_^5.\_^/4W_AC?X/\ _0H?^5.\_P#CU>A[?%']ZU_2C;XH_O6O
MZ4?7,3_S]E][#^S\'_SYC_X"O\CSO_AC3X._]"?_ .5.\_\ CU)_PQC\'/\
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MXH_O6OZ4 &G_ /(]ZE_UP'\HZZ:N/\._:O\ A+KW[;M-SY'S[.G\&/TQ784
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M."I'4&KOA/XE>$/'MQ?V_AGQ5HGB*?3W\N\BTG48;IK9_P"[((V)0\'@XZ4
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MG[0GQ>\._#U_'6I_!C1Y_#5OIXU:[71_&AN;Y+01^:[QPR6$2R.J9.SS!G&
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MKPW_ -##I7_@;%_\57R"U0M3_LF'\[#_ %FK?\^U][/L/_A//#7_ $,6D_\
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MT:+_ .#"'_XJOA1JA:G_ &+3_G8O]9ZW_/M?>S[Q_P"%D^$?^AIT7_P80_\
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MOB\_\PC_ ,F8?_BZ[%B*/\Z^]'F_4<7_ ,^9?^ O_(X=N]1-WKN6^#?C _\
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M8?\ $/L-_P!!$ON1^4W_  KGQ9_T*^M?^"^;_P")H_X5SXL_Z%?6O_!?-_\
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M_P#?QO\ &C_A#=(_Y]3_ -_&_P : +_]L6'_ #^V_P#W]7_&C^V+#_G]M_\
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M/_?QO\: +_\ ;%A_S^V__?U?\:/[8L/^?VW_ ._J_P"-4/\ A#=(_P"?4_\
M?QO\:/\ A#=(_P"?4_\ ?QO\: +_ /;%A_S^V_\ W]7_ !H_MBP_Y_;?_OZO
M^-4/^$-TC_GU/_?QO\:/^$-TC_GU/_?QO\: +_\ ;%A_S^V__?U?\:/[8L/^
M?VW_ ._J_P"-4/\ A#=(_P"?4_\ ?QO\:/\ A#=(_P"?4_\ ?QO\: +_ /;%
MA_S^V_\ W]7_ !H_MBP_Y_;?_OZO^-4/^$-TC_GU/_?QO\:/^$-TC_GU/_?Q
MO\: +_\ ;%A_S^V__?U?\:/[8L/^?VW_ ._J_P"-4/\ A#=(_P"?4_\ ?QO\
M:/\ A#=(_P"?4_\ ?QO\: +_ /;%A_S^V_\ W]7_ !H_MBP_Y_;?_OZO^-4/
M^$-TC_GU/_?QO\:/^$-TC_GU/_?QO\: +_\ ;%A_S^V__?U?\:/[8L/^?VW_
M ._J_P"-4/\ A#=(_P"?4_\ ?QO\:/\ A#=(_P"?4_\ ?QO\: +_ /;%A_S^
MV_\ W]7_ !H_MBP_Y_;?_OZO^-4/^$-TC_GU/_?QO\:/^$-TC_GU/_?QO\:
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M_/J?^_C?XT 7_P"V+#_G]M_^_J_XT?VQ8?\ /[;_ /?U?\:H?\(;I'_/J?\
MOXW^-'_"&Z1_SZG_ +^-_C0!?_MBP_Y_;?\ [^K_ (T?VQ8?\_MO_P!_5_QJ
MA_PAND?\^I_[^-_C1_PAND?\^I_[^-_C0!?_ +8L/^?VW_[^K_C1_;%A_P _
MMO\ ]_5_QJA_PAND?\^I_P"_C?XT?\(;I'_/J?\ OXW^- #?$6IV<VB7B1W<
M#NR8"K(I)Y^M'AW4[.'1+-)+N!'5,%6D4$<_6G?\(;I'_/L?^_C?XT?\(;I'
M_/L?^_C?XT 7_P"V+#_G]M_^_J_XT?VQ8?\ /[;_ /?U?\:H?\(;I'_/J?\
MOXW^-'_"&Z1_SZG_ +^-_C0!?_MBP_Y_;?\ [^K_ (T?VQ8?\_MO_P!_5_QJ
MA_PAND?\^I_[^-_C1_PAND?\^I_[^-_C0!?_ +8L/^?VW_[^K_C1_;%A_P _
MMO\ ]_5_QJA_PAND?\^I_P"_C?XT?\(;I'_/J?\ OXW^- %_^V+#_G]M_P#O
MZO\ C1_;%A_S^V__ ']7_&J'_"&Z1_SZG_OXW^-'_"&Z1_SZG_OXW^- %_\
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M:H?\(;I'_/J?^_C?XT?\(;I'_/J?^_C?XT 7_P"V+#_G]M_^_J_XT?VQ8?\
M/[;_ /?U?\:H?\(;I'_/J?\ OXW^-'_"&Z1_SZG_ +^-_C0!?_MBP_Y_;?\
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M.X\;ZC)$ZR(8!AD.0>$[UU-9VG>'['2IVFMHC&[+L)WD\9![GV%:- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117Q7XSL_
MC)^Q[K6M^+-&OX_B%\*Y[R2^O-'O9/*GTY9)"S",DG: 6P"F5.<F,=:Z:-'V
MS<5))]+]?F<F(Q'U=*;BW'JUT\[=C[4HKY:TG_@I%\&K_3;:XN[_ %73+F1
MTEI-ITCM$W=2R94_4&OI;0-;M?$VA:=J]@[26.H6T=W S*5)CD4,I(/0X(XJ
M:E"K1_B1:*HXJCB/X4U+T+]%%%8'2%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>6S:M:_1>:[GY[Q!Q5+),6L,J//>*=[VW;79]C]7/^%P:%_SWB_\"(_\:/\
MA<&A?\]XO_ B/_&ORCHKW?\ 4N'_ #_?_@/_  3YK_B(53_H&7_@7_VI^KG_
M  N#0O\ GO%_X$1_XT?\+@T+_GO%_P"!$?\ C7Y1T4?ZEP_Y_O\ \!_X(?\
M$0JG_0,O_ O_ +4_5S_A<&A?\]XO_ B/_&C_ (7!H7_/>+_P(C_QK\HZ*/\
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M@?=?E7344 <S_P )NG_0/NORH_X3=/\ H'W7Y5TU% ',_P#";I_T#[K\J/\
MA-T_Z!]U^5=-10!S/_";I_T#[K\J/^$W3_H'W7Y5TU% ',_\)NG_ $#[K\J/
M^$W3_H'W7Y5TU% ',_\ ";I_T#[K\J3_ (3B,<G3[D#Z"NGJ"^_X\KC_ *YM
M_(T <['X[BD7<+"X/^[@BG_\)NG_ $#[K\JF\#_\@%?^NC5T% ',_P#";I_T
M#[K\J/\ A-T_Z!]U^5=-10!S/_";I_T#[K\J/^$W3_H'W7Y5TU% ',_\)NG_
M $#[K\J/^$W3_H'W7Y5TU% ',_\ ";I_T#[K\J/^$W3_ *!]U^5=-10!S/\
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MNWG_  '_ -#6@"BOCF-E!%A<G(SP 12_\)NG_0/NORK8T/\ Y MA_P!<$_\
M015Z@#F?^$W3_H'W7Y4?\)NG_0/NORKIJ* .9_X3=/\ H'W7Y4?\)NG_ $#[
MK\JZ:B@#F?\ A-T_Z!]U^5'_  FZ?] ^Z_*NFHH YG_A-T_Z!]U^5'_";I_T
M#[K\JZ:B@#F?^$W3_H'W7Y4?\)NG_0/NORKIJ* .9_X3=/\ H'W7Y4?\)NG_
M $#[K\JZ:B@#F?\ A-T_Z!]U^5'_  FZ?] ^Z_*NFHH YG_A-T_Z!]U^5'_"
M;I_T#[K\JZ:B@#F?^$W3_H'W7Y4?\)NG_0/NORKIJ* .6D\=Q1KDV%PO^]@"
MG?\ "<1_] ^Y_(5+XZ_Y ?\ VU7^M;MM_P >\7^X/Y4 <]_PFZ?] ^Z_*C_A
M-T_Z!]U^5=-10!S/_";I_P! ^Z_*C_A-T_Z!]U^5=-10!S/_  FZ?] ^Z_*C
M_A-T_P"@?=?E7344 <S_ ,)NG_0/NORH_P"$W3_H'W7Y5TU% ',_\)NG_0/N
MORH_X3=/^@?=?E7344 <S_PFZ?\ 0/NORH_X3=/^@?=?E7344 <S_P )NG_0
M/NORH_X3=/\ H'W7Y5TU% ',_P#";I_T#[K\J/\ A-T_Z!]U^5=-10!S/_";
MI_T#[K\J/^$W3_H'W7Y5TU% '+R>.HXU+&PN !_>P!2KXYC90187)!'8 BK_
M (N_Y%V\^B_^A"K.@_\ (%L?^N"?R% &1_PFZ?\ 0/NORH_X3=/^@?=?E734
M4 <S_P )NG_0/NORH_X3=/\ H'W7Y5TU% ',_P#";I_T#[K\J/\ A-T_Z!]U
M^5=-10!S/_";I_T#[K\J/^$W3_H'W7Y5TU% ',_\)NG_ $#[K\J/^$W3_H'W
M7Y5TU% ',_\ ";I_T#[K\J/^$W3_ *!]U^5=-10!S/\ PFZ?] ^Z_*C_ (3=
M/^@?=?E7344 <S_PFZ?] ^Z_*C_A-T_Z!]U^5=-10!S/_";I_P! ^Z_*C_A-
MT_Z!]U^5=-10!S/_  FZ?] ^Z_*C_A-T_P"@?=?E7344 <S_ ,)NG_0/NORH
M_P"$W3_H'W7Y5TU% ',_\)NG_0/NORH_X3=/^@?=?E7344 <S_PFZ?\ 0/NO
MRH_X3=/^@?=?E7344 <S_P )NG_0/NORH_X3=/\ H'W7Y5TU% ',_P#";I_T
M#[K\J/\ A-T_Z!]U^5=-10!S/_";I_T#[K\J/^$W3_H'W7Y5TU% ',_\)NG_
M $#[K\J/^$W3_H'W7Y5TU% ',_\ ";I_T#[K\J/^$W3_ *!]U^5=-10!S/\
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MA'PO\4[CQUX*F\.>(OA^MA)>Z99:DE[;7<=\Q2TDANFCB&UG5E8NB[-I)X%
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M-NA^OY5BY8W"1JSWV?R):***\T]8**** "BBB@ HHHH **** "BBB@ HHHH
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M-0Q!P6)4#@\D<5B?L\_&.7X[?#F/Q9)HO]A1S74L$-O]H,Y94P-^[8O5MPP
M?N]>P^*[GXX-K7_!/>;0Y;C_ (FUGJ4'AYQO&XPAO/C)![>7&4X_N5]G?LN^
M%_\ A#_V?? FF[=C?V9'=.N3PTV9F'/(.9#QVKQ\7@88/#2YU[_.XI^27ZZ'
MLX3'SQF*CR/W/9J37]YO]-3U*BBBOGSZ(**** "BBB@ HHHH **** "BBB@
MHHHH YGPW_R,&N?]=/ZM735S/AO_ )&#7/\ KI_5JZ:@ HHHH **** "BBB@
M HHHH *\_P#CIX4\8^-/AW>:7X$\0IX7\1R31/#J4CLH1%<%QE58\KD=*] K
MS+]HU?B')\)]4B^%J;_&$CQQP8>%&6,N!(RM,0@(7."3GTYK:C?VD;-+7KM\
MS#$6]E*Z;TZ;_+S/B?XS6OQM^ ^F?:?%?[15C#=NF^#2[6XGEO+C_<C\K@?[
M3$+[UV7[$-U^T#X\\<:=XH\7ZQK$OP_2"8M_:\NQ;QFC98S$A&YP&(;=PO'!
M)XKR#PE^R_\ M'>&?&4_BJ]^&NF^+=>E?S?M?B;4[.^(D[OM:Z 9O=@2,#&*
M^M/@?XF_:>U+XCZ?!\2_">CZ5X0:.8W5U9RVS2*PC8Q@!+AVY?:.%-?28B4(
MT7&#A)VU>B^Y(^1PD9RQ$9SC4BKZ+WFO^WF^GR/IZO@[4%^('[$_QP\<>(=,
M\&WGC7X<>,+LWS?V:"9+60L[@'"L4*&21?F&UUV\Y&!]XT5\_0K^QNFKQ>Z/
MJ<3AO;\LHRY91U3/SW^*'Q/^)/[<4.G_  _\*?#S4?"GAE[N*;5=8U96VH%.
M0&8JJJ!][:-S,0,8P<_>_AW0[?PSX?TS1[3/V33[6*TAW==D:!%S^ %>'?MV
M>,-;\"_LZ:QJ_A[5;O1=4BN[1$O+&4Q2J&F4, PYP1Q7J_PEU"YU;X5^#+Z\
MGDNKRYT6RFFGE8L\CM A9F)ZDDDD^]=&(E[2A"4(J,;M6\]+MLX\+#V>)G&<
MG*;2;>B5M;))'5T445YI[!\S_ML_\DYU3_MU_P#1PKX!K[^_;9_Y)SJG_;K_
M .CA7P#7['PA_P B^7^-_DC\!X\_Y&D/\"_.04445]P?G 4444 %%%% !111
M0 5M^"-1M]'\::!?W<GDVEKJ%O/-)M+;46168X R< 'I6)142BIQ<7U+IS=.
M:FMUJ>^^-OBAX9U>R^.<=IJ?FOXEU#39]*'V>5?M*13.TAY7Y, @_/C/;-6O
M#_QPT#5O@3XBT3Q%*T/C*'2QI&GW?DLQOK7S%>.-F53@Q%6 +8&&ZDDU\\45
MY/\ 95#D4+O1Q:?6\5&/;9J*O_PUO<_MO$JHZB2UC*+5G:TI2EWW3D[/\];^
MTZ[K_@[XR:)X>NM>\3/X1\4:3I\6EW#75C+=6U[%'GRY5,(+*^#\P(P>,4W5
MOBMX?\#Z'X<\+>$K&S\5Z7I=]+JM]=:_8DV^I7;Q&(?Z.6R(T0X&2"6 .!CY
MO&**U67T](N3<%>T=+*_ROU=KMV^2MB\TJZSC&*F[)RUN[6[MQULKM)7^;O[
M%8_$3P;\1M:NX?&?AC0?"-O+ITEM9:EX:TZ2%+.XSN6:6%'/FCJIX)'&,<FM
M%?BMIGP@\&Z'H?@C68_$>JV^L2:Y/JDEB\=M&[6SVRQ)'* S?([,6(&#C&>W
MAE%$LNHR]UM\G\M[Q_'7Y7MY!'-J\+RBDJG\Z5I;I]&ETWM==SWYOCW8ZE\!
M?$FB75EX?M/$%]J*^586>AQQ1M 8MK3#:FP2J3P^=PP,5;;QQX"\8>+O!_Q
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M>?!O]E;Q=\(;?]G;3)8-/OX_"NN:]JNN3:2XCM;!;VRO%CCB65A)(BR3I&"
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M_<'^KV.[+[SY7:HFKZK_ .&6/"G_ $$-9_[_ $7_ ,:IO_#*OA/_ *"&L_\
M?^'_ .-4_P"UL-W?W"_U>QW9?>?*3=ZC:OJ;5/V7?"MGIUS<)J&L%XXRP#31
M8R!_URJ'1?V7O"NIZ7;W,NH:PLD@)(2:(#J1_P \J?\ :V&[O[A?ZO8[LOO/
MEIJC;O7UK_PR;X1_Z".M?]_X?_C5)_PR7X0/_,1UO_O_  __ !JG_:V%[O[@
M_P!7<=V7WGR.U1-7UW_PR/X//_,2US_O_#_\:IO_  R+X/\ ^@EKG_?^'_XU
M5?VOA>[^X7^KN/[+[SY";O435]@_\,A>#C_S$M<_[_P__&J;_P ,?^#3_P Q
M/7?^_P##_P#&J?\ :^%[O[@_U=Q_9?>?'C=ZC:OL;_ACWP;_ -!/7?\ P(A_
M^,TW_ACKP9_T$]>_\"(?_C-/^V,+W?W"_P!7<?V7WGQLU1MWK[+_ .&-_!?_
M $$]>_\  B#_ .,TG_#&O@H_\Q37O_ B#_XS1_;&%[O[A?ZNX_LOO/C!JB>O
MM(_L8^"C_P Q37__  (@_P#C--/[%W@D_P#,4U__ ,"(/_C-5_;&%[O[@_U<
MQ_9?>?%+=ZB;O7VR?V*_!!_YBOB#_P "(/\ XS33^Q/X'/\ S%?$'_@1!_\
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M110 4444 %%%% &/XN_Y%V\^B_\ H0JSH/\ R!;'_K@G\A5;Q=_R+MY]%_\
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M_"@_B!_T+-S_ -]Q_P#Q5'_"@_B!_P!"S<_]]Q__ !54O^%S>./^AIU/_O\
MFC_A<WCC_H:=3_[_ )HMF_>G]TO\POD7:M]\/\B[_P *#^('_0LW/_?<?_Q5
M'_"@_B!_T+-S_P!]Q_\ Q54O^%S>./\ H:=3_P"_YH_X7-XX_P"AIU/_ +_F
MBV;]Z?W2_P POD7:M]\/\B[_ ,*#^('_ $+-S_WW'_\ %4?\*#^('_0LW/\
MWW'_ /%52_X7-XX_Z&G4_P#O^:/^%S>./^AIU/\ [_FBV;]Z?W2_S"^1=JWW
MP_R+O_"@_B!_T+-S_P!]Q_\ Q5'_  H/X@?]"S<_]]Q__%52_P"%S>./^AIU
M/_O^:/\ A<WCC_H:=3_[_FBV;]Z?W2_S"^1=JWWP_P B[_PH/X@?]"S<_P#?
M<?\ \51_PH/X@?\ 0LW/_?<?_P 55+_A<WCC_H:=3_[_ )H_X7-XX_Z&G4_^
M_P":+9OWI_=+_,+Y%VK??#_(N_\ "@_B!_T+-S_WW'_\51_PH/X@?]"S<_\
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M-XX_Z&G4_P#O^:+9OWI_=+_,+Y%VK??#_(N_\*#^('_0LW/_ 'W'_P#%4?\
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MK_G]3\C_ (4?\)3I7_/ZGY'_  J3_A'=,_Y\8?\ OFC_ (1W3/\ GQA_[YH
MC_X2G2O^?U/R/^%'_"4Z5_S^I^1_PJ3_ (1W3/\ GQA_[YH_X1W3/^?&'_OF
M@"/_ (2G2O\ G]3\C_A1_P )3I7_ #^I^1_PJ3_A'=,_Y\8?^^:/^$=TS_GQ
MA_[YH C_ .$ITK_G]3\C_A1_PE.E?\_J?D?\*D_X1W3/^?&'_OFC_A'=,_Y\
M8?\ OF@"/_A*=*_Y_4_(_P"%'_"4Z5_S^I^1_P *D_X1W3/^?&'_ +YH_P"$
M=TS_ )\8?^^: (_^$ITK_G]3\C_A1_PE.E?\_J?D?\*D_P"$=TS_ )\8?^^:
M/^$=TS_GQA_[YH C_P"$ITK_ )_4_(_X4?\ "4Z5_P _J?D?\*D_X1W3/^?&
M'_OFC_A'=,_Y\8?^^: (_P#A*=*_Y_4_(_X4?\)3I7_/ZGY'_"I/^$=TS_GQ
MA_[YH_X1W3/^?&'_ +YH C_X2G2O^?U/R/\ A1_PE.E?\_J?D?\ "I/^$=TS
M_GQA_P"^:/\ A'=,_P"?&'_OF@"/_A*=*_Y_4_(_X4?\)3I7_/ZGY'_"I/\
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M.E?\_J?D?\*/^$ITK_G]3\C_ (5)_P ([IG_ #XP_P#?-'_".Z9_SXP_]\T
M1_\ "4Z5_P _J?D?\*/^$ITK_G]3\C_A4G_".Z9_SXP_]\T?\([IG_/C#_WS
M0!'_ ,)3I7_/ZGY'_"C_ (2G2O\ G]3\C_A4G_".Z9_SXP_]\T?\([IG_/C#
M_P!\T 1_\)3I7_/ZGY'_  H_X2G2O^?U/R/^%2?\([IG_/C#_P!\T?\ ".Z9
M_P ^,/\ WS0!G:SXBTVXTF[BCNT>1XF55 /)Q]*B\.^(-/L]%M89KI8Y5!W*
M0>.3[59UK0]/@TF\DCLXD=8F*L%Y!Q4/AO1;"ZT2UEEM(I)&!RS+R>30!?\
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M_J?D?\*D_P"$=TS_ )\8?^^:/^$=TS_GQA_[YH C_P"$ITK_ )_4_(_X4?\
M"4Z5_P _J?D?\*D_X1W3/^?&'_OFC_A'=,_Y\8?^^: (_P#A*=*_Y_4_(_X4
M?\)3I7_/ZGY'_"I/^$=TS_GQA_[YH_X1W3/^?&'_ +YH C_X2G2O^?U/R/\
MA1_PE.E?\_J?D?\ "I/^$=TS_GQA_P"^:/\ A'=,_P"?&'_OF@"/_A*=*_Y_
M4_(_X4?\)3I7_/ZGY'_"I/\ A'=,_P"?&'_OFC_A'=,_Y\8?^^: (_\ A*=*
M_P"?U/R/^%'_  E.E?\ /ZGY'_"I/^$=TS_GQA_[YH_X1W3/^?&'_OF@"/\
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MC_A*=*_Y_4_(_P"%2?\ ".Z9_P ^,/\ WS1_PCNF?\^,/_?- $?_  E.E?\
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MADAEU7=&ZE67[/$,C_OBBS^*GBBQMT@AU39$G"K]GB.._=:Y%:>M9/B#./\
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M'3 <C:^005C^.&KV/BCX'Q:Q:R+?>'[FZTJ_GDV[D>Q^V6\DK.N.4\K<6![
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M]6KIJYGPW_R,&N?]=/ZM734 %%%% !1110 4444 %%%% !7BO[8'Q(O/A/\
M W5?$ECI&DZW<6]S;1BTUNV-Q;$/*JDL@93D9XYZU[57$?&3XJ>'_@UX!O\
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MXD_Y&M;Y?^DH_I?A+_D2X?\ [>_]*D%%%%?-'UP4444 %%%% !1110 4444
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MFOQCH?QR7QOJ=IX'\,:!-X/O/#(\->#XI(XK!Y;F"99E8PH)RWE.&)6+:!&
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MWQQAW_RYE]Z/A]:E3K7VY_PKWPK_ -"SH_\ X 1?_$T?\*]\+?\ 0M:/_P"
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M9M(O=3\"3W.EP-=:MI-S;ZO:6Z]9I+>59?+'NZHR#_>KN::PS33L[B>IXO\
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M#=(0@9R 6P#Q[5^AW[<WBK1O&W["?Q&UK0-4M=9TB\TL/;WUE*LL,J^<@RK
MX(R#7EFJ?\$<?A!J^J7E_-K_ (F$MU,\[A;B+ 9F+''R=.:^B5_90\++^S&?
M@=]OU'_A%S9FR^U;U^T[/,\S.<8SGVH ^6O^"0>G?VM^R/XULO,\K[3K5W#Y
MFTMMW6L:YP.3UZ5]&:;H?@Q?V?[?2M'\1V/]D6=Y:P2ZAJ5IY5M=W4<L:^3,
MH1-ZNX6,\$\@$DBNB_9F_9?\.?LK^ ]0\*^%+_4+JRO+Q[YI=0=7=9&14XP
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M_P"9\;_\,(Z;_P _FL_]_8/_ (FC_AA'3?\ G\UG_O[!_P#$U]D44?V]F?\
MS_?X?Y!_JQD__0.OQ_S/C?\ X81TW_G\UG_O[!_\31_PPCIO_/YK/_?V#_XF
MOLBBC^WLS_Y_O\/\@_U8R?\ Z!U^/^9\;_\ #".F_P#/YK/_ ']@_P#B:/\
MAA'3?^?S6?\ O[!_\37V111_;V9_\_W^'^0?ZL9/_P! Z_'_ #/C?_AA'3?^
M?S6?^_L'_P 31_PPCIO_ #^:S_W]@_\ B:^R**/[>S/_ )_O\/\ (/\ 5C)_
M^@=?C_F?&_\ PPCIO_/YK/\ W]@_^)H_X81TW_G\UG_O[!_\37V111_;V9_\
M_P!_A_D'^K&3_P#0.OQ_S/C?_AA'3?\ G\UG_O[!_P#$T?\ #".F_P#/YK/_
M ']@_P#B:^R**/[>S/\ Y_O\/\@_U8R?_H'7X_YGQO\ \,(Z;_S^:S_W]@_^
M)H_X81TW_G\UG_O[!_\ $U]D44?V]F?_ #_?X?Y!_JQD_P#T#K\?\SXW_P"&
M$=-_Y_-9_P"_L'_Q-'_#".F_\_FL_P#?V#_XFOLBBC^WLS_Y_O\ #_(/]6,G
M_P"@=?C_ )GQO_PPCIO_ #^:S_W]@_\ B:/^&$=-_P"?S6?^_L'_ ,37V111
M_;V9_P#/]_A_D'^K&3_] Z_'_,^-_P#AA'3?^?S6?^_L'_Q-'_#".F_\_FL_
M]_8/_B:^R**/[>S/_G^_P_R#_5C)_P#H'7X_YGQO_P ,(Z;_ ,_FL_\ ?V#_
M .)H_P"&$=-_Y_-9_P"_L'_Q-?9%%']O9G_S_?X?Y!_JQD__ $#K\?\ ,^-_
M^&$=-_Y_-9_[^P?_ !-'_#".F_\ /YK/_?V#_P")K[(HH_M[,_\ G^_P_P @
M_P!6,G_Z!U^/^9\;_P##".F_\_FL_P#?V#_XFC_AA'3?^?S6?^_L'_Q-?9%%
M']O9G_S_ '^'^0?ZL9/_ - Z_'_,^??A#\ Y?@W)=-I:WEZ;F2.5OMCQG!3.
M -H']ZO7/[4\1_\ 0+A_[Z_^RKIJ*\>O7JXFHZM:5Y/=GO8;#4<'2C0H1Y8K
M9?B<S_:GB/\ Z!</_?7_ -E1_:GB/_H%P_\ ?7_V5=-16!TG,_VIXC_Z!</_
M 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_^@7#_P!]?_94?VIXC_Z!</\
MWU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^@7#_ -]?_95TU% ',_VIXC_Z
M!</_ 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_^@7#_P!]?_94?VIXC_Z!
M</\ WU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^@7#_ -]?_95TU% ',_VI
MXC_Z!</_ 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_^@7#_P!]?_94?VIX
MC_Z!</\ WU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^@7#_ -]?_95TU% '
M,_VIXC_Z!</_ 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_^@7#_P!]?_94
M?VIXC_Z!</\ WU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^@7#_ -]?_95T
MU% ',_VIXC_Z!</_ 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_^@7#_P!]
M?_94?VIXC_Z!</\ WU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^@7#_ -]?
M_95TU% ',_VIXC_Z!</_ 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_^@7#
M_P!]?_94?VIXC_Z!</\ WU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^@7#_
M -]?_95TU% ',_VIXC_Z!</_ 'U_]E1_:GB/_H%P_P#?7_V5=-10!S/]J>(_
M^@7#_P!]?_94?VIXC_Z!</\ WU_]E7344 <S_:GB/_H%P_\ ?7_V5']J>(_^
M@7#_ -]?_95TU% ',_VIXC_Z!</_ 'U_]E3)M0\130O&=+B 92IPWK_P*NIH
MH XO1SK^D68MXM-1TW%LN1GG_@57O[4\1_\ 0+A_[Z_^RKIJ* .9_M3Q'_T"
MX?\ OK_[*C^U/$?_ $"X?^^O_LJZ:B@#F?[4\1_] N'_ +Z_^RH_M3Q'_P!
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M?_0+A_[Z_P#LJZ:B@#F?[4\1_P#0+A_[Z_\ LJ/[4\1_] N'_OK_ .RKIJ*
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M]J>(_P#H%P_]]?\ V5=-10!S/]J>(_\ H%P_]]?_ &5']J>(_P#H%P_]]?\
MV5=-10!S/]J>(_\ H%P_]]?_ &5']J>(_P#H%P_]]?\ V5=-10!S/]J>(_\
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M/_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\
MZ!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344
M<S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7
M_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</
M_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:
MGB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E
M1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_
M -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_
M *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:G
MB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7
M344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!<
M/_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\
MZ!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344
M<S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7
M_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</
M_?7_ -E7344 <S_:GB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:
MGB/_ *!</_?7_P!E1_:GB/\ Z!</_?7_ -E7344 <S_:GB/_ *!</_?7_P!E
M1_:GB/\ Z!</_?7_ -E7344 <WX7L[Z'4-1N+RW\@SD-U&,Y)P.?>NDHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^'/$'@[XK_LE_&[QAXP\ >$7^('@
MCQ=<&\N]*L58S6\I=I-H1 64JSR!6"LI5L$9 Q]QT5TT*[HW5KI[IG'B,,L0
MHM2<91U370^ OB)J'QR_;5DT[P;)\-;[X8>"UNH[C4KK6%D5V"]#NECC+XR2
M$1.3C)P,C[PT31[;P]HMAI5DGEV=C;QVL"?W8T4*H_("KM%56Q'M4H1BHQ71
M$X?"^QE*I*3E*6[?ET5M@HHHKD.X**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-?-%%'^KF5?\^?QE_F'^MF=?]!#^Z/\ D?2__#;NM?\ 0"'_ (,'_P#B:/\
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M#%U^O^-=-10!S/\ PA\__08NOU_QH_X0^?\ Z#%U^O\ C7344 <S_P (?/\
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M0,$CUK0_X0^?_H,77Z_XU:\%_P#(O6_U?_T(UN4 <S_PA\__ $&+K]?\:/\
MA#Y_^@Q=?K_C7344 <S_ ,(?/_T&+K]?\:/^$/G_ .@Q=?K_ (UTU% ',_\
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M:Z:B@#F?^$/G_P"@Q=?K_C1_PA\__08NOU_QKIJ* .9_X0^?_H,77Z_XT?\
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MUE_R3+7?^O!O_0A7YN5^N<&_[I4_Q?HC\*X__P!^H_X/U84445]^?EX4444
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MY_UQ?_T$U;JIJW_(+O/^N+_^@F@#.\%_\B];_5__ $(UN5A^"_\ D7K?ZO\
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M  9#_,\-HKW+_A6_P>_Z*%=?]^O_ +71_P *W^#W_10KK_OU_P#:Z/[8H?\
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MKF?[8\0_] F/_OK_ .O1_;'B'_H$Q_\ ?7_UZ .FHKF?[8\0_P#0)C_[Z_\
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M7_UZ\VIEN!K2<ZM"$F^KBF_R/3IYICZ,%3IUYJ*V2E))?*Y@K^S[X!7IH/\
MY.7'_P <J1?@)X$7IH7_ ).3_P#QRMK^V/$/_0)C_P"^O_KT?VQXA_Z!,?\
MWU_]>L7DV6/?"T__  "/^17]K9B]\1/_ ,"E_F9*_ OP.O31,?\ ;W/_ /%T
M]?@GX+7IHV/^WJ?_ .+K3_MCQ#_T"8_^^O\ Z]']L>(?^@3'_P!]?_7J/[#R
MI[X2G_X!'_(G^U,>]Z\__ I?YF>/@SX.7IH__DU-_P#%T\?!WP@O32/_ "9F
M_P#BZN_VQXA_Z!,?_?7_ ->C^V/$/_0)C_[Z_P#KU']@91_T!T__  "/^1/]
MI8W_ )_S_P# G_F5!\(?"0Z:3_Y,S?\ Q=/'PG\*#II7_DQ+_P#%U8_MCQ#_
M - F/_OK_P"O1_;'B'_H$Q_]]?\ UZG_ %>R;_H#I?\ @N'^1/\ :&,_Y_2_
M\"?^9"OPK\+KTTO_ ,F)?_BJW=+T'3M%4BQLH;7=P6C0 GZGJ:R/[8\0_P#0
M)C_[Z_\ KT?VQXA_Z!,?_?7_ ->NK#91EV#G[3#8:$)=XPBG]Z1C4Q5>JN6I
M4;7FVSIJ*YG^V/$/_0)C_P"^O_KT?VQXA_Z!,?\ WU_]>O6.8Z:BN9_MCQ#_
M - F/_OK_P"O1_;'B'_H$Q_]]?\ UZ .FHKF?[8\0_\ 0)C_ .^O_KT?VQXA
M_P"@3'_WU_\ 7H Z:BN9_MCQ#_T"8_\ OK_Z]']L>(?^@3'_ -]?_7H Z:N9
M\ _\@JX_Z^#_ .@K1_;'B'_H$Q_]]?\ UZQ_#-_JEK92K96*W,9E)9F/1L#C
MK]* .^HKF?[8\0_] F/_ +Z_^O1_;'B'_H$Q_P#?7_UZ .FHKF?[8\0_] F/
M_OK_ .O1_;'B'_H$Q_\ ?7_UZ .FHKF?[8\0_P#0)C_[Z_\ KT?VQXA_Z!,?
M_?7_ ->@#IJ*YG^V/$/_ $"8_P#OK_Z]']L>(?\ H$Q_]]?_ %Z .FHKF?[8
M\0_] F/_ +Z_^O1_;'B'_H$Q_P#?7_UZ .FHKF?[8\0_] F/_OK_ .O1_;'B
M'_H$Q_\ ?7_UZ .FHKF?[8\0_P#0)C_[Z_\ KT?VQXA_Z!,?_?7_ ->@#IJ*
MYG^V/$/_ $"8_P#OK_Z]']L>(?\ H$Q_]]?_ %Z .FHKF?[8\0_] F/_ +Z_
M^O1_;'B'_H$Q_P#?7_UZ .FJIJW_ ""[S_KB_P#Z":Q/[8\0_P#0)C_[Z_\
MKU!?:KKLEG<++I:)&T;!FST&.3UH T?!?_(O6_U?_P!"-;E</X?U'6+?2HDM
M-/6> %MLA/7DY[UI?VQXA_Z!,?\ WU_]>@#IJ*YG^V/$/_0)C_[Z_P#KT?VQ
MXA_Z!,?_ 'U_]>@#IJ*YG^V/$/\ T"8_^^O_ *]']L>(?^@3'_WU_P#7H Z:
MBN9_MCQ#_P! F/\ [Z_^O1_;'B'_ *!,?_?7_P!>@#IJ*YG^V/$/_0)C_P"^
MO_KT?VQXA_Z!,?\ WU_]>@#IJ*YG^V/$/_0)C_[Z_P#KT?VQXA_Z!,?_ 'U_
M]>@#IJ*YG^V/$/\ T"8_^^O_ *]']L>(?^@3'_WU_P#7H Z:BN9_MCQ#_P!
MF/\ [Z_^O1_;'B'_ *!,?_?7_P!>@#IJ*YG^V/$/_0)C_P"^O_KT?VQXA_Z!
M,?\ WU_]>@#IJ*YG^V/$/_0)C_[Z_P#KT?VQXA_Z!,?_ 'U_]>@#0\5_\B_>
M?[H_]"%3>'_^0'8_]<5_E7-ZWJ6M3:7<)<Z<D,# ;I >G(]ZDTO5-;BTZV2#
M34EA5 $<GJ,=>M '845S/]L>(?\ H$Q_]]?_ %Z/[8\0_P#0)C_[Z_\ KT =
M-17,_P!L>(?^@3'_ -]?_7H_MCQ#_P! F/\ [Z_^O0!TU%<S_;'B'_H$Q_\
M?7_UZ/[8\0_] F/_ +Z_^O0!TU%<S_;'B'_H$Q_]]?\ UZ/[8\0_] F/_OK_
M .O0!TU%<S_;'B'_ *!,?_?7_P!>C^V/$/\ T"8_^^O_ *] '345S/\ ;'B'
M_H$Q_P#?7_UZ/[8\0_\ 0)C_ .^O_KT =-17,_VQXA_Z!,?_ 'U_]>C^V/$/
M_0)C_P"^O_KT =-17,_VQXA_Z!,?_?7_ ->C^V/$/_0)C_[Z_P#KT =-17,_
MVQXA_P"@3'_WU_\ 7H_MCQ#_ - F/_OK_P"O0!KZ]_R!;[_K@_\ (U6\(_\
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M>(?^@3'_ -]?_7KPJ^)K8F7/5E=GL4,-2PT>6E&QTU%<S_;'B'_H$Q_]]?\
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M_H0K\W*_7.#?]TJ?XOT1^%<?_P"_4?\ !^K"BBBOOS\O"BBB@ HHHH ****
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M#.44CJ*L?\-'?#O_ *&'_P DKG_XW7SI^TM_R4IO^N!_]'2UY8M?E6:<5XW
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MA&MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\5_\
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MKQO*UIE2P80R'SV92P ^7C*@GG'%6]0\8:9I>N:?H]S<F/4=0#FUA\MSYFP
MMA@,<9&>>]>47D\:^%_@NWFKL?4K':S,,-_H4W3GKTKHO%]U"?C!\/1YL99H
MM41<..6$<60#W/!X]C18GV:YK'I?G'/3(JK9ZQ!J%J+BVE6>'+C>K<94D$9]
MB"#7GOQ'\47,.J:7IMOK2Z'IMY;SR?VI"GF;Y$95$ (R 2&8^IVD+TI/#%KJ
MWAOP'J5]JFI.UE'932P6MS L;0($9MSMC=DCGYAD \\TB(TURWN=1X!^(6G_
M !%\+V^NZ4VZTD>2)E9LE'1V1U./1E/X56\/_%71/$&BZ_J\4S1Z=HMY<6=U
M<,I(!A \QQC)*CGGVKQ#PG<7_P +KBTT#3HL0^-]*MI]-$2GR;?4O*1;D\=
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M(_'GGWK7I'-U"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9+9K_@GS!^S)HGQ)\8?%SQ=\5O'WAQ/!4>J:;!I5EHG(E98VW>;(I^;(Y&6
M)W'   S]/T45%:K[:7-:WEZ&E"BJ$.2]^MWU;"BBBL3H/&OVE=%O/$W@O4]*
MTZ+[1?7-DR11;@NXEAQDD =#U-?#O_#-/Q%_Z *_^!MO_P#%U^H%Q8VUVP:>
MWBF8# ,B!B/SJ+^Q[#_GQMO^_*_X5]%EN>XG*Z<J5",6F[ZI_HT?*9QPW@\Z
MJQK8B4DXJVC2ZWZIGYB?\,T_$7_H K_X&V__ ,71_P ,T_$7_H K_P"!MO\
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M/]0<K_Y^5/OC_P#(GYB?\,T_$7_H K_X&V__ ,71_P ,T_$7_H K_P"!MO\
M_%U^G?\ 8]A_SXVW_?E?\*/['L/^?&V_[\K_ (4?ZX8_^2'W/_Y(/]0<K_Y^
M5/OC_P#(GYB?\,T_$7_H K_X&V__ ,71_P ,T_$7_H K_P"!MO\ _%U^G?\
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MA_PF6D?\_1_[]O\ X4?\)EI'_/T?^_;_ .%7_P"Q[#_GQMO^_*_X4?V/8?\
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M/^?&V_[\K_A1_8]A_P ^-M_WY7_"@"A_PF6D?\_1_P"_;_X4?\)EI'_/T?\
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MO^_*_P"%']CV'_/C;?\ ?E?\* *'_"9:1_S]'_OV_P#A1_PF6D?\_1_[]O\
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M<:JP\MC@X^E;7]CV'_/C;?\ ?E?\*/['L/\ GQMO^_*_X4 4/^$RTC_GZ/\
MW[?_  H_X3+2/^?H_P#?M_\ "K_]CV'_ #XVW_?E?\*/['L/^?&V_P"_*_X4
M 4/^$RTC_GZ/_?M_\*/^$RTC_GZ/_?M_\*O_ -CV'_/C;?\ ?E?\*/['L/\
MGQMO^_*_X4 4/^$RTC_GZ/\ W[?_  H_X3+2/^?H_P#?M_\ "K_]CV'_ #XV
MW_?E?\*/['L/^?&V_P"_*_X4 4/^$RTC_GZ/_?M_\*/^$RTC_GZ/_?M_\*O_
M -CV'_/C;?\ ?E?\*/['L/\ GQMO^_*_X4 4/^$RTC_GZ/\ W[?_  H_X3+2
M/^?H_P#?M_\ "K_]CV'_ #XVW_?E?\*/['L/^?&V_P"_*_X4 4/^$RTC_GZ/
M_?M_\*/^$RTC_GZ/_?M_\*O_ -CV'_/C;?\ ?E?\*/['L/\ GQMO^_*_X4 4
M/^$RTC_GZ/\ W[?_  H_X3+2/^?H_P#?M_\ "K_]CV'_ #XVW_?E?\*/['L/
M^?&V_P"_*_X4 4/^$RTC_GZ/_?M_\*/^$RTC_GZ/_?M_\*O_ -CV'_/C;?\
M?E?\*/['L/\ GQMO^_*_X4 4/^$RTC_GZ/\ W[?_  H_X3+2/^?H_P#?M_\
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M )^C_P!^V_PK1_L>P_Y\;;_ORO\ A1_8]A_SXVW_ 'Y7_"@5D9__  E^C_\
M/T?^_;?X4?\ "8:/_P _1_[]M_A6A_8]A_SXVW_?E?\ "C^Q[#_GQMO^_*_X
M4#,__A,-(_Y^C_W[;_"E_P"$RTC_ )^C_P!^W_PJ_P#V/8?\^-M_WY7_  H_
ML>P_Y\;;_ORO^% %#_A,M(_Y^C_W[?\ PH_X3+2/^?H_]^W_ ,*O_P!CV'_/
MC;?]^5_PH_L>P_Y\;;_ORO\ A0!0_P"$RTC_ )^C_P!^W_PH_P"$RTC_ )^C
M_P!^W_PJ_P#V/8?\^-M_WY7_  H_L>P_Y\;;_ORO^% %#_A,M(_Y^C_W[?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW/(FU5PJ$')KZ=\6>-/#_@+1WU;Q-KNF^'-*1@C7VK7D=K K'H"\A"@G![T
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MXN?&+X]_##3_ (4^'2/AS=?$#QEX@GTJ6Y%G?G2H8EB,D;*OG"4-\I!)+#T
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M?RYEM=/N)@C8!P62,C.".]$GCK0HM'MM4?4$6PN)A;QS%&_UA)&UAC*G@YW
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MYDLMUI]Q$ N0.-T8R<D<#)H W:*IZMJ]IH=@][?2^1;(RJS[2V"S!5X )Y+
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M;8>$S[TSQ1:+\8/VA;;PY=CS_#/A"V2_N[8\I/>2?ZH,.X4<X/H?6O>(U"#
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MRK^P'XC\0?#SQM\2_@AXR\.KX-U"QO'\6>']#%^EZD&F7DI+P13( KI%*>N
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M^&O@S+X5U+1KG4]3\8ZUJM^^KQW1WM+=S.ED[?:8Y,D*CL0RA5SQG] /A?\
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M7_FXW_LLWB/_ -MZ]'\-?L@_"/PCKFC:WI?A%8==TB\%]::O-J%W/>B41O&
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MOQ785G:3H-CH?GM:1,);A@TTTTKRRR$# W.Y+' X&3QVK1H \&^/G_(V6?\
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M'P_\4'_N#7/_ ,17I'PK_8-\>^.-:@?Q1:'PEH2L&FEN&5KF1>ZQQ@G!/JV
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M]-GP84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_\?O\
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M?1[:#RNC*CAUS+?4YSX<>-+7XA>"='\0VC*8[ZW61E7^!^CK^#9KR?X\R/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ino-20211231_g4.jpg
<TEXT>
begin 644 ino-20211231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*=[J3V%OI_BC0H([-[@0-.B+=07$L;^8J[4*%@SLJ9W'%?GM^TQK?BGX<?\
M!YS\,I_@R\B7GBOPG86WC.WL\XO+5M)NTG$X'W@EO;02C=T,$;?PBJ7_  <.
M?LE>,+_X:^,_^"G7P'\VR\??L^?M)I=3ZG9I^^33)=-T)HI^.6-M>I;NHZ*L
M\['@&@#]<?V_/^"@?[.__!-CX$_\-#?M+7^K1:$^KPZ;;P:%IOVNZGN)%=P%
MCW+\JI'([,2  OJ0#PNC_P#!6OX':[^P?-_P4CTSX.?$B3X4PZ?+J)U8Z7IX
MNFL(Y7BDO!:F^\WRUDC8$;=Y&&"%/FK\]_\ @J7^T[X?_P""G_\ P1&^*_[?
M/A^P:#PWH?PO\-Z+H5DRG;!XAO\ 6=&N]=VYXD%OLL;))1T=+Y <,U=K\*/^
M5-ZZ_P"S?-:_]*KJ@#Z8\,?\'"7_  3ZU+X2^!?VAO'H^('@?X<?$C5KC3/"
M'Q#\6^"Y4T:ZNX9I8'ADN+9IA;,)+><?O@@Q"[_<4M7V]8WUEJ=E#J6FWD5Q
M;W$2RV]Q!('25&&596'# @@@C@@U_/S^Q[_P3[_;+_X*R_\ !O3^SA^QA\+-
M$\&>#_ -GXZUC7O$'Q)\2>())[MXH=<UJ,PVFG00$LX:Y?F2:,-Y0&0'+#]9
M?VMO'7PZ_82_8<\&?LYV_P <M/\ !G]L6VD?#7PMXT\4Z[!8_P!FPBU\F?4G
MN)V6-9K>PM[FY3<0'GCBCZR 4 >Q_LS_ +5'P0_:]\!:A\2_@%XSAUS1]+\5
M:KX>O+J'HE[I]U);3+U.58H)$;^.*6-QPPKQ/]MK_@L)^S?^P#\;_!GP!^/W
MPY^(0UOXC7BVG@.;0]&M+NVUN<RPPF.-Q=AHV$MQ$A$RQ\N",K\U?F#_ ,&[
M/[0'P_\ V!O^"MGQN_X))^&OC-HGB[X:^-]6GUOX0^(M$\00:C9W-Q!%Y\:)
M/"[1O++IQ"S$,2)M."8SFNP_X.H+G4++_@HW^P1>:1IGVV[A^(-P]K9><(_M
M$@U?0BL>]N$W' W'@9S0!^DF@_\ !67]D\_M4:+^Q1\6%\6?#3XF^)K1+CPM
MX<^(?AJ2Q76E;<%6UNT,EK,Q9'0*)<LZE%RW%8O[;W_!8[]FG_@GY\;O!_P#
M_:"^'7Q"76_B#<BW\#2Z'HMI>6^M2F6*$I&RW0:-A+-$A$JQG+@_=YK\T?$G
MCBZ_X+@?\'"?@'X7?&+0U^ MY^RI>+J2>"?$-Z;G7?%EY9ZA'>2K;21(L"Q?
MN;9^)&8P,TT?F!F,71_\'2/_ "DV_8'_ .R@-_Z>M%H _53XP?MR?#SX.^.O
M!7P3O/A[XKUWXF^/K*XO=!^&/AV*QFU5;.W -Q=7$DEW'96T$9*J99+E5=SL
MC+MD"Y\"OVT?AG\=_BWXE^ %GX0\7^&?'7@W2;/4?%/A?Q=H!M9;&"ZDF2W=
M)T:2VO$<P2XEM99HOD(+A@5'PG_P7(_X)[_MZ?$O]JSP/_P4C_X)1_%^VM_C
M5\*_!BZ3K'@=[^W2;4=&EN;N6%XTN/W$@=VO$:&?:LHC&QM\04^<?L:_\%O/
MB[^UO\)?VE/A=\<OV8KGX7_MB?"C]GSQ#=VQM+.YM1J<=E;2R0A;:<^9;3Q7
M=Q"XB8ON$Y>-PI90 ?H);?\ !3OX"^.OC_XI_9C_ &:_"/B[XP>+_ @ \=V_
MP\L[-K+P]*Q=5M[F_O[JUM!<%D=?(29Y 8W!4%'V[_[+7_!0C]FW]L#4_%_@
MKX1Z[J,7C;X?WCVGC?X<^(M-;3M=T:<$@)+;3E0R,1A9D=X6R,25^=__  9<
M:5H)_P""9WC_ ,60E9M9U+XWZ@FKW;MNF<1Z7I;1JS=2!YLC#/>5O6O*_C'K
M?BGX=?\ !Z;X.7X./(DWB[PG:VWC>UM"0MW:G0)_-\\#J$CM;:89_B@C/84
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M\3M!F\)2:=J.C!H+BY=#!J#6YG:."W,I,)=9$EB,+2[N/$?^#7[PSX(\/?\
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MI\/_  UXQNO#%YXU/@R%;"YU"WO);-Q;E[I9)X_/AD02(A7*D$@@@=G\)/\
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M7X;7=Q%9^*_"NG>(;/2=6C6#4;2ROH?.MS<0!F,19<X.2K;3M9@,UWE?)/\
MP2^_8!O_ -C74/B;XA^(?PP\%6WB76?%TNGZ#XW\/ZE?7>I>(/"EJJKI7]IM
M>.WEW<<;-$Z0D1$1(0. :^MJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7UM>ZUITWPR?2Y8)X1<@>7+_ &G<(8V^TMN1HR<* &&37WW10 5\IW7[*O\
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M#':6UI;V"L^I78DMXHK?*C:I,D\TA)+MGVRB@#\\/@S_ ,$/?BM^S]_P5O\
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MK''*V5RTFW*G]*?VOO&O@_X?_LN?$'Q/X[\5:=HVFP>#-3$M_JEZEO"A-I*
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MQGXZ@U'POI-]:R+/J-E]MU*X-U&H4DP+#<0RM*<(J2!BP'-?$'P-^)GPS?\
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MC]K_ /8L^-GC+XE3?%5]*G\<^/-8F1M,U.]MUG6** );6Z"XBCD/FJD>$\U
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MJ,FA:L+J/SA%JD<GV^<20D;3/-++;/#,OF()%2N*_P""@OQ&_8%^.W[2S_\
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M'&G:3\&_&/P=GTGP;\2-3OT70[2<V>H?NC=L?*CW/.C[MP7;>HV=I) !V_\
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MNUNOV?-,(O\ 3?$/A^3Q&+O7]3BEBGECM[35;%T>RLE:W\W?(N[5KN)E5XN
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MX\-ZW+X?\<6&FAEMI+R.**5+J!6)9(I8ID;:2=KB102%!/A/[3G_  6M\7?
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M\M_+:3:<?.W[*7[5?@?2/^"B7[67C+5/^"COCGXG:7X2TF&\O?@(OPKUU)O
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MNVEQYMO=0K(CX.1E6!!Y /X5+;V\%I EK:P)%%$@2..-0JHH&  !T ':GT4
M,C@@A>22*%%:5]TK*H!=L!<GU. !GT ]*?110!5BT+1(-6EU^#1[5+^>,1S7
MJ6ZB:1!C"L^-Q' X)["K5%% !1110 4T00B1I1"NYP [;1E@,X!]>I_.G44
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MAEX>^#OPQT"+2O#GA71+72-!TR$DI:V=O$L,,0+$D[411DDDXR237S=^V/\
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MFO%@42N@Z*7QD@>A-3>1!O>3R4W2 "1MHRP'0'UZG\Z\)_X*%_\ !1+X%?\
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MWP]%:+_Q-;VRN8KJQ6:8DD6\5S#%.8E4&22&(,_EB2*3G?VYOVV_AI_P3[^
MVH_M+_&SP=XHO_!NB-%_;^J>&;.WN6TQ99XK>)I(I)XY'5Y9D4&)7V\EMHYJ
MU^Q5^V+\/_V[O@-I'[2GPA\&^)M.\(^(8VE\/7_B:TM[>348EEDB:1(HYY'1
M0\;#]Z$)X*AE.: /6J;'###N\F)4W,6;:N,D]2?>G5F^,?$-QX3\*ZAXFM/#
M6H:S)86KSKI>D^3]IN=HSLC\Z2.,L1T#.H/K0!I55U71-&UR%+?6](M;R.*4
M2Q)=6ZR!''1@&!P1DX/6O#O^"=?_  4?_9Q_X*A? _4?V@OV8'UUO#^E^*)]
M NCXATL6D_VN&WM[A\('?*;+J+#9ZY&.*][H **** &2V]O,\<DT".T+[XF9
M02C;2N1Z'#$9]"1WI]%% !6?JWA/PKK]BNF:[X9T^]MEN#.MO=V22()2Q;S
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MI*)K*6>8DDPP3+'<+$BJ3-!"S.54QMZ%10 =>M1BSM D40M8PL!!@4(,1X!
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MIC=3S2S3RS7=Q(L\L2G]U'''(X$;,QDH _*C_@L5^V3\3OVQ+3P/_P %O_\
M@FQHUS+X-_92^)U_X4N_%)O5>[U=9TM&GOTLF@=8-/'F)!YDKM)*+[<T$:1[
MF^UOV ?CQX0\2Z%\)/#W_!(#6_!NL^%_B[=:WX]^/.N_$#3[G4-?TN_DDC^U
MWVH-:75O$+^XNV^RI;^7'&1"\D.8("HX_P#9$_X-X/VFOV!/'GC_ ,#_ +*'
M_!1RPM?@?\2&E3Q!\-_''PI@UTM;NC1>63+=)"\ODL8C-L59%VB2&0(HJ?\
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MKS2O%#V, B@N;RSN'A-PB#A/-18Y&4857=E4!0*_//\ X. KGQ;9_P#!P/\
ML-7?@+1=.U'6X[[3&TJPU?4Y+*UN+@:[\B2W$<,[PH6P"ZQ2%1R$;I7ZM?\
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M1\2++_@J;^TO_P %#?VDOB7^R9\'?V9/C;X<\&_$5?#5I?\ QY\.Q-J'A/\
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M:2RQ020PM(JR2(<X /JZBFQ2Q7$2SP2JZ.H9'1LA@>A![BG4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@
M#NOA=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\
MDT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I
M6[6%\+O^29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/V
MY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_H
ME*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5]V]6>9BL9BL;4]IB*CG+NVW^84445WG.%%%% !1110 4444 %%%% !1110
M4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M
M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
M&944N[  #))/2N \4_M'^ =(U(^&_":7?BC6>BZ9X>A\\J?]N0?(@!Z\DCTK
MS,SSG*LEHJIC:T::>BN]9/M&.\GY13?D=>$P&,Q\W##P<FM[;)=V]DO-M(]
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MN?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V
MK3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=AFNAK"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 45C^-/'W@WX=Z2=;\:>(;
M;3[<9VM,_P TA'9%&6<^R@FN"_X3WXT?&']S\+/#I\,:+)P?$NOP9N)5_O06
M_P"H9^"#V-?/YIQ+EN68A857JXAJZI4US5&N[5TH1_OU'"']X]+"95BL73]M
MI"FMYR=H^B>\G_=BG+R.Y\<_$KP-\-M._M3QKXDMK&,@^5'(V9)3Z(@RSGZ
MUP__  G/QP^+G[KX:>&/^$4T:3_F8/$,&ZYD7^]#;=O4%^"#U!K<\"_ #P-X
M.U'_ (2;4A<:]KSD-+KFMR>?-N_V,\1@=MHR!QDUW%>=_9_$N>:X^K]6I/\
MY=T97J-?WZUER^:I*+3VJR1U_6<JR_3#0]K/^>:]U?X:?7UFVG_(C@O!_P"S
MMX%\/:F/$_B1[GQ+KAP7U?7Y?/=3_L(?E0#M@9'K7>T45[^69/EF34'1P5*-
M.+U=EK)]Y/>4GUE)MOJSS,7CL7CZG/B)N36U]DNR6R7DK(****](Y0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_
M -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBD9E52S,  ,DD]*\W\2?M #4]7E\&?!+P\WBK6(SMN+B)]MA9'UEFZ'_ '5/
M.",@\5Y6;9WEF2THSQ<[.3M&*3E.;[0A%.4GY13MN]#LP>7XO'S<:,;I:MNR
MC%=Y2=DEZL[[6]=T7PUIDNM>(=5M[*T@7,MQ<RA$4?4_RKS67XQ?$'XK2MIO
MP"\+[+ L5D\7:[$T=LO8F"(C=*?0D8!'(QS5G0_@!=>)-3B\6_'GQ(?$VHQM
MOM],52FFV9]$B_Y:'MN?KW&>:]*BBB@B6"")41%"HB+@*!T '85X7LN)>(=:
MK>#P[^S%IUY+^])7A23[0YY]IP>AZ//E66? E7J=W=4UZ+24_67+'^[)'!^"
M_P!GWPSH6KCQAXUU&X\4^(3@MJVL881'TABY6(#MC)'8BN^HHKZ#*\GRW)L.
MZ."I*";N^KD_YI2=Y2D^LI-M]6>;B\=B\?4YZ\W)[+LEV26B7DDD%%%%>D<@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +
M_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_)
M,_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"5T& S>0F2!V&:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_@GPQIW@SPGI,-AI6D6$-EIEC;KB.WMXD$<<:CLJJH ]A5^BB@ KRC]N?\
MY-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T
M2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK-\4^+_
M  QX(TE]=\6Z[;:?:1]9KF4*"?0#JQ]ADFLJ]>AA:,JM:2C"*NVVDDN[;T2+
MITZE6:A!-M[):M^B-*N?^('Q1\#?#'3AJ/C+7HK;S/\ CWMA\\TY]$C'S-SQ
MG&!GDBN);XG_ !5^,!^R?!7PZ='TA^&\6Z];D;U_O6\!Y?V9N.Q K?\ A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK)\7^.O!_@'3#K'C+Q':Z=;\[6N)<%SZ*OWG/LH)K'$8G#X.A*
MM7FH0CJY2:22[MO1&E*E5KU%3IQ<I/9)7;]$C6JCXC\3^'?".ER:WXHUNVL+
M2/[\]U,$7/H,]3Z <FO.!\8/BC\43]G^"'@$VU@_ \3^)E:& C^]%"/GD]CT
MSU%7_#G[.>A/JD?BOXK:[=>,-97E9M5 %M ?2*W'R*/KGU&*^4_UEQF;>[D6
M']K%_P#+ZI>%%><7;GJ^7LX\CV]I$]G^R:&"US&IR/\ DC:53YZ\L/\ MY\R
M_E91D^-/C[XG.UA\!/!3/:,=K>*M?C:&T4?WHH_OS?EP>HQ6AX6_9XT*'5D\
M8?$_6KCQ=KJ\K=:JH^SVYZXA@^X@S]>>1BO0T1(D$<:!54855& !Z4M:T.%:
M>)K1Q&<57BJB=TI+EI0?>%)-QNNDINI-=)HBIG$J4'2P,/8Q>C:=YR7]Z>C]
M5%1B^L0  & , =!1117UAXH4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
M)H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME.6*JK5.K9QB^\*22IPMTDHN?>;W(JYUB%3=+"15&#T:A>[7]Z;O*7I?E[)
M  , 4445]4>,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6C17+B,9B\4_WU1R]6W]W8YZV*Q.)?[V;EZNX4445S'.%%%% !1110 4444
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M *Z+Q?\ $BY>)O50D BVK[9XH^J8"'QXA/\ PQD__2N0/JV"A\==/_#&3_\
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M?%%SH9\9>$=2T,:U9)NFT_[7:R6_VB,9&73S-X&1DJ.17PM\=/\ @D+^U/\
MMO\ BS6OAC^W+^T9X/UWX?:QX1\%Z=XGU[PEX%ET[5O$W]B:KK%[Y*I)?S1Z
M9)(;V(S3QB175V2)(?F- 'B__!Z'<V.I_P#!*/P#J=C-'/#+\=M(DMYXR&5T
M;1=:(92.H(P<U]C?\%0OV7/VQ/VQ?V"]&^!O[$_Q3\)^#O%-QK.@ZG>:SXP\
MTVXMK%TO$C58[>X#,;J"T)5XRA19%8,&P>?_ ."S7_!(SQ;_ ,%;?V?_  S^
MS'IG[2ND?#3PIX;\46VNQK%\/)-6NI;BWM+JUCC$G]I6Z)$$NG.WRR<JOS
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSK^%%8*D^LN6I7:\HINE3\G)U7W@F=?)DN ^-NO/LKQIKU;M.7HE#RDSS?\
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MM/\ P)7_ !K7EEV,G&2Z%NBH;;4M.O7,=G?P3,!DK%*&('X&IJ5FA;!1110
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MX]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0
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M<W?/_+2Y;-?3M%>A#,\QI1Y:=:45V4FE]RLCEGF^:U'>5>?_ ($_\SYZMO\
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M4DV_-W"BBBF9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445!JFJ:9HFG3:OK.HP6EI
M;1F2XNKF98XXD'5F9B H'J:F4HPBY2=DA-I*[)ZK:OK.D>'].EUC7M5MK&T@
M7=/=7DZQ1QCU9F( 'UKY=^./_!3#P_INHGP/^SEX<?Q1K$TGDQ:A)!(;;>>
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MMQ,*RZ\LDVO5;KT:1[.%QV#QL.:A44EY/\^Q/1117LG4%%%% !1110 4444
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MOZV5Y5++N>4Z]2M.=KRJ2OM>W+"*C"&[ORQ5]+WLK%%%%>4>L%%%% !1110
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ME5O=56O9K:VMK*W2TL[=(HHE"QQ1(%5%'0 #@"G[;A' _P .E5Q,N\VJ4/\
MP"#G-K_N+%^78]AQCC_XE6EAH]H)UI_^!S4()_\ <*2\^_SC_9__  4Q^-/_
M !_ZSX(^#>E2_P#+*RB_MW5XP>H+-BVZ=UP0?PJSHW_!-GX-:OJ47B3]H+QG
MXN^*>K1MO6;QEKTKVL3_ /3*VB*HB_[#;AS7T112EQ=FU*+A@5##1_Z<Q4)>
MCJ:U6O6;''@_**LE/'N>*E_T^DYQOW5/2DG_ (::,GP;X#\$?#O1D\.^ /!^
MEZ)81_<LM)L([>(>^V, 9K6HHKYJI4J5IN=1MR>[>K?JSZ>G2IT::A3BE%;)
M*R7H@HHHJ"PHHHH **** "BBB@"MK.LZ1X<T>[\0^(-5MK&PL+:2XOKV\G6*
M&WA12SR.[$!%5026)  !)KY6MO\ @M)^Q'-JSW5S>>-[;P?_ &/I.IV_Q,G\
M!7__  C\UMJ5Y>65G-YZQF6*"2>QF1;J6*.V?=&4E8.#7OG[2WP.T#]IS]G7
MQY^SAXJU:[L-,\?>#M2\/7]]8$":VAO+62W>2//!91(2 >"1@\9K\"_A/^T9
M^TK_ ,&_?[4.K?L._P#!5_P5'\7?@5XJ\ :)X/LO'6CJ95TCPO\ ;-:-@"@7
M<5+SZH&M9F$RI;MY#ND"!P#]GOV^O^"K?[#7_!-3PD/$?[5/QE@TZ^G0G3?"
M^DV[7NJWS8RJI;QY*!@#AY3''P?G%>E?M!?M3_ []E?]GG6/VI?CYXVB\.>"
M]!TN.^U+4[N-F9$D*K'&L:!FDE=W2-8U!9G< 9S7YA?\'H=S8ZG_ ,$H_ .I
MV,T<\,OQVTB2WGC(971M%UHAE(Z@C!S6;_P>&>(/%>E?\$A?AEI&BR2QZ=JG
MQ4T:'66BSB1$T?498XW_ -DR(K\_Q1K0!^C?[//_  4(^"O[0/QHU+]FR3P]
MXE\$_$;3?"MGXG_X0CQO9VT%]=:)<X$6H0FVGGBDBWD(Z^9YL3D+(B$@'A_B
M!_P67_8P^'/B'Q9_;6I:_/X-\ >.K7P9\0/BC9:?"_A[PYKTY55L;F4S"<E'
M>-)98H)(86D59)$.<?"'[6/B#QIX7_X.[?V<X?AW$\DMU^SS<6UY:1YV7$ L
MO$LFQ\?PAXXF'^TBU\)?LVZKJOB'_@TE_:Q\3>)[N6YU74/VD]/GU"YN>9)9
MVN/#+NS9YW%F<GW)H _J(BEBN(EG@E5T=0R.C9# ]"#W%.KP/_@E9KOBOQ/_
M ,$R?V>O$/CF6635KWX*^&)KZ:<GS)7;2[<^8^>=S##'W)KWR@ KRC]N?_DT
M?Q[_ -@%_P#T-:Z3XS:)\<M;TRRB^!WC?1=#NTG8WTNM:8URLL>WA5 (VG/.
M:^?/VK?!O[:=A^SKXNO/B!\9_!^H:+'I+'4;*Q\./%--'N7*HY;Y3G'- 'T'
MH?CSP/\ #?X*Z%XJ^(GC+2M!TN#0[,3:EK.HQ6L"$P+C,DK*H_.O!/%__!7O
M]G:\UR;P/^S)X+\9_&?Q%&I'V#X?^'IIK:)LX_>W,BJJIW\Q!(H%?$WQJ_X)
MN_'C3I[+XM_%Z]\1^.=/DMH[FTU:XOFU.*TMG4,L)CE#>0BJ0!NCV#H":]A_
M9J'P/O\ 0K3P!/\ MG?%_P"'$<?$.EV>MVUKIRL?^><L%NJ1CUWH@]S7FX'C
M3PP6.^HYGFGU;$=(5:-:DGZ2E349)]+25^C/GL7QCEV QOU:G@JM6:ZSE3H0
M?I>3E)>O)Y)GL_VW_@L+^T@^;+3/ 7[/V@3/Q)=.OB'75C8=0H_T;..S>6P-
M6=!_X)!?!?Q3J<'BK]K;XO\ C[XSZQ'S_P 5?XCFBL(GSG,-K R^6O\ L%W7
MVKI=/_8%37;*+5;?]OGX_7<,R!H+BP^)*B*1.Q!6 AOKFIO^'<?AR3B]_:V^
M/%RI_P!8L_Q(<A_KB(5^B1H\.Q2E1S!171PHSO\ *4I<UO\ MZQU_P"MO&/+
M;#9;&DG_ "U8)_\ @24I/[SV7X8_!CX1?!71O^$>^$/PQT#PQ9$#?;:%I,-J
MLA'0OY:C>?=LD^M=-7SI_P .U/A?+_Q_?'GXP70'W1<?$*<[?IA11_P[(^ [
M_-=_$'XE7$AZRS>/;HL?K@BN:6 X7E+FGF$VW_TXO^=5'G2S7B^K+F> @V^^
M(_\ N3/HNBOG3_AUQ^RR_P MR?&,Z'[T<OC:^(;ZXD%'_#JO]C&7B^\$ZY=*
M/NI<>,=1(!]1B<5/U'A!;XZM\L/']<0B?KW&3VP-'YXF7Z89GT74,NI:=!(8
MI[^!''57E (_#-?/7_#I_P#8+DYO?@G/<MV>?Q9JA('IQ<BIHO\ @E5^P+#&
M(D_9^A('0OXAU)C^9N<T?5.#%_S&8A_]RU/_ .:@^M\;/_F"PZ_[F:G_ ,R?
MJ>Z/XO\ "<;%'\4:<I4X(-[&,?K55OB5\.44N_C_ $0 #))U6' '_?5>0)_P
M3"_80C4(O[/.G848&[4[TG\S-S5I?^";7[#:,&'[.>B9!R,RSD?^C*/8<&+_
M )B,0_\ N#37_N=A]8XV?_,-AU_W'J/_ -UT>F2?&3X0Q(99?BIX;55&69M<
MMP /^^ZK/\?/@5&ADD^-/A)5499F\1VH 'K_ *RN%3_@GA^Q+&XD7]F[PWD'
M(W6S$?D6YJRG[ ?[%T;AU_9I\)94Y&[2U(_(]:/9<&+_ )>XA_\ <.FO_<K#
MVO&S_P"7.'7_ '$J/_W$CJ6_:3_9U12[_'SP4 !DD^*K3 '_ '\JO_PU3^S!
M_P!'(> O_"PLO_CM8R_L+_L;HP<?LR^"L@Y&= A(_(K5C_ABK]D#_HV#P%_X
M2EI_\;HY>#%]K$/_ +=IK_VYBYN-G]G#_P#@51_^VHLM^U_^R6K%6_:B^'0(
M."#XVL./_(M03?MG_LAP2&-_VH/ !([IXNLV'YB0BIE_8]_9)50H_9<^'7 [
M^"; _P#M*I;?]DK]E6T!%K^S-\/H]WWO+\&6*Y_**C_C#%_T$?\ E/\ X(?\
M9N_^@=?^#7_D9\_[;G['MNGF2?M.^!2,X_=^)[9C^2N34/\ PW5^QM_T<UX+
M_P#!]#_\56U_PRM^S!_T;?X"_P#"/LO_ (U3X/V7_P!FBU?S+7]G?P+&V,;H
M_"5D#C\(JKFX*M\.(_\  J?_ ,B+EXXO\6&_\!J__)'.3?M\?L802>6_[2_A
M$D=TU9&'YC(IO_#?W[%O_1ROA/\ \&8KJ_\ AF_]G?\ Z(+X+_\ "6M/_C=.
MC_9S_9[A<2P_ CP:C*>&7PO: C_R'1S\$V_AXC_P.G_\@'L^.;_Q,-_X!5_^
M6'&W'_!0C]BFV ,G[2?A@YZ>7>E__00<5'_P\2_8D_Z.0\.?]_W_ /B:[W_A
M0WP-_P"B,^$__"=MO_B*!\!_@<#D?!GPI_X3MM_\10JO!5M:6(_\&4__ )4#
MI<<7TK8;_P %U?\ Y:<%_P /$OV)/^CD/#G_ '_?_P")H'_!1+]B0G'_  TC
MX<_[_O\ _$UZ-_PI_P"$O_1+O#G_ ()(/_B*0_!_X2$8/PM\.?\ @DM__B*G
MVO!G_/G$?^#:?_RHKV/&W_/[#_\ @JI_\N.&@_;V_8QN6*1_M+^$ 0,_O-71
M!^;8K4L?VQOV2=2(%I^T[X 9CT1O%]FK'\&D!K9G_9]^ ETH2Z^"/A"0 Y D
M\-6I /XQUEWW[(W[*>I _;_V9_ $I/\ $W@ZRW?GY611S<&2^SB%_P!O4W_[
M;$7+QM'[6'E_V[5C_P"W2-K2_CE\$]<(&B_&'PM>$]!:^(+:3/\ WRYKI+._
ML=1A^T:?>Q3QGH\,@8?F*\BU3_@GW^Q7K *W?[-?A9,]?LMAY'_HLK7-WG_!
M*[]AN:;[7I?P?GTNX_AN=*\3:C"R_0"?;^E'U?@VIMB*\/\ N#3E_P"YX_D'
MUCC:GOAL//TK5(?^X)_F?0U%?.3_ /!-GP+I?/P__:1^,OA<K_JX]&^($HC'
ML5D1LCVS0/V0?VKO#8S\//\ @HIXMA"_<3Q-X8LM6S[$R%3^-/\ LCAZK_"S
M*,?^OE*K'_TVJH?VSQ'2_BY9*7_7NK2E_P"G'2/HVBOG/_A&/^"I7A#_ )!'
MQ0^$?C")/O?V]HM[I\T@]OLQ* _7BC_AH/\ ;^\&\>._V&+#78%_UM_X-\>6
M_'^[;SKYC?G1_JM6J_[MBJ%3TK1@_NJ^S?RM</\ 6NA2_P!ZPF(I>M&4U]]'
MVB^=['T917SE_P /'_"?AOY/C#^S;\6_!@7_ %MYJO@MY;0>I66%FW >H6NH
M\$?\%"?V+/B RQZ#^T7X=@=S@1:S<-IS9],72QG/M6-?A+B:A3]H\)-P_FC%
MSC_X%#FC^)M0XPX7Q%14UC*<9O[,I*$O_ 9\LOP/9:*I:#XF\.>*K$:GX7\0
M6.I6S?=N+"[29#_P)"15VOGYPE"3C)6:[GT4)PJ14HNZ?5!1114E!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 45F^(/&/A'PG%Y_BGQ5INF)C._4+Z.$8^KD5P?B+]M/]D;PMN76?VE/!*N
MGWHH/$=O.X^JQLS?I7=A<LS+&_[O1G/_  Q<OR3.'%9IEF!_WFO"'^*48_FT
M>G45\^:E_P %3/V%["?[%:_&LZA<?PP:7X>U"X+?0I!M_6J__#R_X3:C_P B
M9\$_BWXCS]P:'\/IY-Q]!YC)7L1X,XL:O+ U8KO*$H+[Y)(\67&W""=HX^E)
M]HSC-_=%MGT717SI_P -X?$35.?"_P"P+\9I@?N_VMH,-C^>^4XH_P"&M/VO
M[_YM!_X)Q^))!U']H>-]/M#CZ,#[?KZ4_P#4_/5\:IQ_Q5Z$?_2JB%_KGD+^
M!U)?X:%>7_I--GT717SI_P -!_\ !0V\XMO^">5A99X!O/BUI\FWW/EQ\BC_
M (7#_P %)9OWD?[''@^$'I'-\0HV8?4JF*/]4\P7Q5L.O^YG#O\ *HQ?ZWY<
M_AH8A_\ <KB%^=)'T717SI_PLO\ X*:GD?LS?#H9['QG)D?^.TO_  LK_@IK
M_P!&T?#G_P +.3_XFC_57%_]!.'_ /"BE_\ )#_UMPG_ $#8C_PGJ_\ R)]%
M45\Z_P#"RO\ @IK_ -&T?#G_ ,+.3_XFD/Q5_P""EUO\LO[*/@2X)Y#0>.B@
M'L0RYH_U5Q?3$8?_ ,**7_R8?ZVX/KAL1_X3UO\ Y ^BZ*^=/^%N?\%*?^C0
MO!?_ (7Z_P#Q%'_"ZO\ @H_#^[D_8F\,3,.LD7Q)@53] R9H_P!4\<]J^'_\
M*:'ZU _UNP'7#XC_ ,)J_P"E,^BZ*^=/^%\?\%%;;F;]@K1;G/06_P 4K--O
MUW)S^%'_  T5_P %"+?F;_@G);7&>@M_B]IJ;?KNCYH_U2S)[5<._P#N:PR_
M.J@_UPRQ;T<0O^Y3$O\ *DSZ+HKYT_X:=_;N@^6]_P"":UTK'D"#XL:7*,?4
M)P?:C_AK#]L:'Y+S_@G#X@5Q]\0^/-/D ^A YH_U0SA[3H/TQ6&?Y5@_UQR;
MK"NO7"XI?G1/HNBOG3_ALC]I:'Y[W_@G?XZ5.F8-;LY&S] 1^='_  V[\:8#
MLOO^"??Q25NI$$=M*,?4/U]J/]3\]Z*F_2O0?Y5 _P!<\AZNHO6A77YTSZ+H
MKYT_X;W\:0#???L%?&]5/ -OX6CE.?H)1@>]'_#PZ2#Y=0_8;_:%B*_ZQT^'
M&]%'KN$_(QUH_P!3>(^E%/TG3?Y2%_KKPTMZS7K3J+\X'T73+FYM[.WDO+RX
M2**)"\LLCA510,EB3P !SFOG'4?^"F/P_P!#L)=4\2_LT?&O2[6!"\ESJ'P]
M>.-5'4EO-P .Y.*^9_VG_P#@HMKW[4=XWPU^$GA+Q7IGA-=IU-_[$E>XN1D9
M:=8-Y2)3T09W$9.>%7YWB3*N*LBP#J8?+JF(K/2%*G9RD^FS=H]Y/;I=V1Q8
M_P 0^%<'1<EB(RGTCJF_O6B[L]9_:-_;%\>_M >+3^SI^R3;75REX[07^MV9
M*O=+T<1MQY4 _BE)&X=,+][V#]DS]B?P3^SGIT?B+61#J_BV:+%QJC)F.TR.
M8[<$?*.Q<_,W/0';7CG[-G[4G[%_[,OA :'I'ASQW_:ETBG5-9OO 5VLUZX[
M#"G9&#T0'C.3DDD^D?\ #T_]D&/B\\0>)+<C_6";P9J ,?KG$1Z5\EPQX*\=
MU\Q7$'$N#J5\<_@@H2=/#KI&FE=.2ZSUUV;=Y2\W <1\*2KK&YCF%%U>B<XJ
M,%V2;W[O_AW]%T5\Z?\ #UW]A6/YKOXNWD"=Y9O"6IA1^5L:?!_P5<_8"N6*
M1_'] 0,_O/#6IH/S:V%?I[X*XR7_ #+:_P#X)J?_ ")] N.>"F[?VGA__!U/
M_P"2/HBBO +?_@J1^P7<N4C_ &A+,$#/[S1K]!^;0"IT_P""G/["3N$7]H?3
M,DX&=/O /S,/%9O@_BZ.^7U__!53_P"1-%QGP?+;,:'_ (.I_P#R1[Q17AW_
M  \G_8:_Z.,T7_OS<?\ QNGP_P#!2']AV>01)^T;H0)[NLRC\S&!6?\ JGQ2
MO^8"M_X*G_\ (FG^MW"C_P"9A0_\&T__ )(]NHKQ?_AXE^Q)_P!'(>'/^_[_
M /Q-'_#Q+]B3_HY#PY_W_?\ ^)J?]5N)O^@&M_X*G_\ (E?ZU\+?]!]'_P &
MP_\ DCVBBO$[C_@HY^P_:@&3]H[0#GIY9E?_ -!0XK-U#_@J-^P9IF?M/[0E
MDV,Y^SZ/?S=/]R UI#A'BNH_<R^N_2E4_P#D3.?&/"-)7GF%!>M:FO\ VX]^
MHKYT_P"'I7[)]_\ \BE>^+-?S]S^QO!5^^[TQOC7K_2D_P"'A<VL';X$_8O^
M-^K@_<N6\$_9K=O^VDDO]*V_U+XIC_$PDX?X[0_]+<3#_7?A.7\/&0G_ (&Z
MG_I"D?1E%?.?_#3O[</B;Y? W_!/:[M8F^[>>)_']E:[/K"%+G\#1O\ ^"I_
MC'E8?@YX-MG_ +[7^H7<?Y8B-'^JF+I_[QB*%/UKTY/[J<IR_"X?ZVX.I_NV
M&Q%3TH5(K_P*K&G'\;'T9399HK>)IYY51$&7=VP%'J3VKYT_X9/_ &OO&?S?
M%;_@H'K\<3_>LO!/A>TTKRQZ+.-SGZD9IT/_  3 _9OU>5;GXL:[XZ\?S*0Q
ME\9^-KN<LWJ1$T8//MBG_9/#F'_WC,5+_KS2G/\ ].^Q7Z!_:_$N(_W?+7'_
M *_580_]->W?X7/0?'_[8O[*_P +PZ^./C_X5M)8\[[2/5XY[@?]L8BTG_CM
M>>-_P4N^%'B@F'X%_"+XD_$5F.(KGPQX-G%MGU:6?R]B^^TUZ3X _9(_9B^%
MQ23P)\!?"MA-']R[71HI+@?]MI TG_CU>AJJJH50  , #M1]9X0PO\/#U:S[
MSJ1IQ^<(1E+_ ,JA]5XRQ7\3$T:*[0IRJ2^4YRC'[Z1\Y?\ "X_^"C'Q*_=_
M#O\ 93\+>![=^(M1^(/BO[4Q7^\;>R&]#[-GFC_AEG]L;XC_ #_&O]NK5--M
MI/\ 6:1\-]"ATSR_4+=MNE/XKQ7T=11_K15P_P#N.%HT?-4U4E_X%6=22?G%
MKRL'^JE+$:X_%UZ_DZCIQ_\  :*I1:\I)^=SP/PK_P $T?V2]%U1?$7B_P &
MZAXUU8?>U3QSK4^I2/\ [R.PB;\4JW\6/^">G[-7Q*L"NA^"K?PG?*F(;OPQ
M;1VT8QTW0*/+8>N%#'^\*]QHKYCB=SXTP3PF>R>)I?RU&Y)=N5-^ZUT<;-=#
MMP_#'#N$I.G1PE.*>]H)-^;:5V_-NY\-7'P>_;H_8HF?4_A1X@D\6>%X6+O9
M6\37$07J=]HQWQ$]2T)/ Y:O3O@=_P %,OA/X\DBT#XKV+^$M5)V-/,QDLG;
MI_K,;HN>SC:/[YKZ7KRWXY?L>? SX^)+>>*O"ZV6K./EUS2L0W.?5S@K+_P,
M-[$5^0O@?BCA-^TX3QMZ2_YAL0W.G;M3G\</)7LWN['-_9&89;[V6U?=_P"?
M<]8_)[K^KL],T_4=/U>QBU/2KZ&ZMIT#P7%O*'213T96&01[BIJ^&M1_9]_;
M0_8JOY?$7P*\43>)_#:N9)["WA,@*]_-LR2<^KQ$M@=5KT_X#_\ !2WX6?$"
M2+PW\6K/_A$M8+;&GF<M8ROT_P!8>83GLXP/[YKOROQ-P"QD<NX@HRP&*>T:
MG\.?G3JKW)+UMKHKF^'S^C[54,;!T:G:7POTELSZ6HJ.TO+34+6.^L+J.>"9
M \4T+AD=2,@@C@@^HJ2OTU-25UL>^FF@HHHI@%%%% !1110 4444 %%%% '(
M_M ?"L_'7X#^-O@BOBBYT,^,O".I:&-:LDW3:?\ :[62W^T1C(RZ>9O R,E1
MR*^%OCI_P2%_:G_;?\6:U\,?VY?VC/!^N_#[6/"/@O3O$^O>$O LNG:MXF_L
M35=8O?)5)+^:/3))#>Q&:>,2*ZNR1)#\QK]%Z* /B;_@LU_P2,\6_P#!6W]G
M_P ,_LQZ9^TKI'PT\*>&_%%MKL:Q?#R35KJ6XM[2ZM8XQ)_:5NB1!+ISM\LG
M*K\P (/HG[9G_!./PQ_P4$_8&O?V)OVI?&UO>75U8VIMO&'AG0FL38ZC;8,%
M[#;37$Y7!!#1F4[TDD3<N[(^E:* /DC]GW_@F5JWAS]N8_\ !1;]J#XJ:5XS
M^).G?#6S\#^%4\/^')--T_2["(NT]T4EN)WDNIWDE^;<JQQR-& ^=]>,^.O^
M#?;PSK7PY^*G[)'@7X[0Z!\!?C+\6K3Q]XN\)1>&VDU>PN(Y();C3["]^T"*
M*WFDM;<JSP.\*(R#S-P9?T=HH H>%O#'A_P3X8T[P9X3TF&PTK2+"&RTRQMU
MQ';V\2"..-1V554 >PJ_110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)
MH_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2N ^,_[$?[/OQK\V_UCPBNE:I+D
MG5]#Q;REO5U *2'U+*3[BN_^%W_),_#O_8"M/_1*5NUYF:Y-E.>85X;,*$:L
M'TDD_FK[/S5FCGQ.%PV+I^SKP4EV:N?$6H?L@_MD_LM7LNO_ +-GQ)FUK3 Y
M>33K=Q'(X[[[64M%(<<94ESV K=^'7_!3[4?#NJ?\(?^TO\ "N\TF_@8)<7F
MG6[HR'UDMIB&7U)5C[+7V!7._$7X1_#/XM:7_8_Q(\$Z?J\(4B,W< ,D6>I2
M08>,^ZD&OS=^'.;</2=3A/,9X=;^PJWJT'Y*]Y0OU:<F>&\CQ."?-EM=P7\D
MO>A^.J]5=D'PS^-OPG^,=A_:'PU\=Z?JH"[I(()ML\0_VXFPZ?\  E%=37R/
M\3/^"6^FV^H?\)1^SU\2;S0K^%O,MK/4I79$;MY=Q'B2/'N'/O7+I^T#^WS^
MR:PM/C/X*D\3Z% <'4+M?.&SVO(<[2?^FP9O:C_B(6?<.^YQ5ELZ45O7H7JT
M?627OP7D[OR%_;6,P.F8T'%?SP]Z/J^J^=S[@HKP#X2?\%(?V=_B/Y5AXDU.
M?PKJ#X!AUE1]G+?[,ZY4#W?9]*]XTS5-,UJPBU31M1@N[69=T-S:S+)'(/56
M4D$?2OT#).)<@XCH>VRS$PJKKRM77^*/Q1]&D>UA,?@\=#FP]127D_S6Z^9/
M1117MG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<QXV^"GP<^)08?$/X4>&]=+CYFU?1(+AOKF1"0?>NGHK:AB*
M^&J<]&;C+NFT_O1C7P]#$TW3K04HOHTFON9X#X@_X)D?L;ZK?'6?#_PUN?#.
MH_P:AX5URZL73_=5)/+'_?-4/^&(?C5X-._X+?M]?$G3-O\ JH/%HM]?B3_9
M"SJGR^U?1M%>_#C'B514:F)=5+I54:J]+55-6^1\[/@SAAR<J6&5*3ZTG*B_
M6])P=_.Y\Z#2/^"HG@+_ (\O%WPH\?6J?>_M.PN]*O9/]WR<P@_6@_M:_M8>
M"N/BU_P3\\3M$GWKSP/XBM-8\P>JPKL<?0G-?1=%5_K%A*_^]Y?1GYQ4Z3^7
MLIQA]\&O(7^K>,H?[IF->'E)PJKYNK"<_NFGYGSK!_P5"_9@TR=;/XH0>,O
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M#Z+HKYT_X9R_;[UT9\1_\%"8K"-OOVVA?#*Q7\I7?</RI/\ A@KQUKWS>/\
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M/[*T&RML8Q]GM43&.G05=HK.>)Q%16G-OU;-(8;#TW>$$O1(****Q-@HHHH
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M37+*>!]U ?0DO]J?##X8>"O@]X,M/ ?@'1DLM/M%X4<O*Y^])(W5W;N3].
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MGS76E* UT(QSL>+&R[3Z#>,\+D;J_/G/CKP\_B<V99>NO_,32CY]*J7?XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444=.M !7E_[2_[5OPZ_9I\._:=?N!?:U<Q$Z9H-O(/-F/0.YY\N//5S
MUP0H8C%>;?M2_P#!0?P_\/9Y/AO\#$B\0^*97\AKJ!?.MK*0G&T!?]?+G@(O
MR@]22"IYO]F[]@[Q+XQ\2?\ "]/VN;J;4]4O)1<0Z#>R;V9OX6NNV ,8A'
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M<_C:FOM*BC_4_P 28_#Q(_GA*+_4/[,SU;8__P IQ_S/C.W_ ."O.G-M^U?
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MOV/4XI<_]\L:^EPN=9-CO]VQ-.?^&<9?DV=U/%X6M_#J1?HTS9HHZ]**],Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\
MH_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:
M?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6
M@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?_D>N:^,6@_\%E/@_P##'6OB9K7[7?PVGM=&LS<3PV7@]?-=00,+OMPN>>]
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M?]'C?"S_ ,) _P#R/0!]AT5\>?\ "F/^"U'_ $>-\+/_  D#_P#(]'_"F/\
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M_P CU[3^Q=\4/B'\6?@W)X@^*.I6EYK%GKU[I]Q<V5J(8Y!!)L#!1TS@G\:
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M8B.*$V\O[T$,AK^GC1SJATFU.N+"+W[,GVP6Y)C$NT;]N>=N[.,]J +%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E'^T/^V%^WA\/?\
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MW_\ !'OX'?M<_&OX=?\ !.C_ ()M^*?B!JO[./A/XBS>,_C#XAU#Q9-?^#]
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M&MG!)8QPW<TJ,CB0D(N;B1U\%_X(H_M[?MO_  9\%?ML_#?]N_XN7WQ8T/\
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M/&'1U/4%3P1[&I(XXX8UBB0*J@!548  Z "EHH **** "BBB@ HHHH ****
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M6W1/^_K?_$UQ7_#LG]EG_H$ZU_X.&_PH_P"'9/[+/_0)UK_P<-_A4?6_&?\
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M;1H%*,2%5=DC@APQ((*CY^_8Q_;,_;G^,'_!8;]I[X'_ !!^#GA]?#_PXL_
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M.?\ ?A__ (JC_AW;^Q)_T;?X<_[\/_\ %4>RX,_Y_8C_ ,%4_P#Y:'MN-O\
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M_%,MG<QZ7;+);R",GRI48%6C;#*000#0!\7_ /!5'X\_&_\ X)>_\%8?"/\
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MI9_%[PU+)-^QY#X?A$>N0'S-6_X2:*?[ I#_ #7/E$2>2/GV\XQ0!Z;\!O\
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M)XVLM3\0>/;?P'8_#;4[807P\3S7GV1;-YV'EK ),L;C'" C9Y@\JNY^&?\
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MA/Q3\+=2M-+\1>%/'2VEG=F_G@^T>7&\$T\+P^48W2=9&202 K\N"0#W77-
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MP[E\VXFD8*JEE4<LS*JLP /3::L,*RM.L2B1U =PO+ 9P">^,G\S7R5\7_\
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M]D;]JCX(>//@WXP\?.T7@"Y\9PZ?<:/XFN%*AK6TU#3KNYB$^64>3/Y+DO&
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MYGF?_#5GPY_Z 7B;_P )Z;_"C_AJSX<_] +Q-_X3TW^%>F44O[-XQ_Z&%/\
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M"+GQK\6_#>^GM-1O],T_1);VW8JT%IJ&IVME=<CD;H)Y8\]C(#6__P $Y_\
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MS2=.MFD@O;B^OV0ZE>6[-NFG*0J%/R!=Q7&* /1_VLOV@_\ @J)^Q?\ MY_
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M?6=/C\RZTZ[_ +/@M[:Y@>,QF.58(Y%>=$;< 7K-_;S_ &4OVH-<_;+^ /\
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M4>@444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508789927848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,403,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791766680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793680248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 71,143,778<span></span>
</td>
<td class="nump">$ 250,728,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">330,170,940<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,466,850<span></span>
</td>
<td class="nump">18,559,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">2,565,194<span></span>
</td>
<td class="nump">503,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">38,836,991<span></span>
</td>
<td class="nump">40,357,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">261,192<span></span>
</td>
<td class="nump">106,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">448,444,945<span></span>
</td>
<td class="nump">471,170,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">17,453,206<span></span>
</td>
<td class="nump">11,348,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investments in affiliated entity</a></td>
<td class="nump">3,906,796<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,626,355<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">11,571,026<span></span>
</td>
<td class="nump">12,741,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,425,794<span></span>
</td>
<td class="nump">25,957,448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">495,941,493<span></span>
</td>
<td class="nump">539,772,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">47,644,530<span></span>
</td>
<td class="nump">21,203,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">548,032<span></span>
</td>
<td class="nump">642,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">10,326,266<span></span>
</td>
<td class="nump">9,950,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">21,628<span></span>
</td>
<td class="nump">46,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,603,956<span></span>
</td>
<td class="nump">2,329,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">4,559,721<span></span>
</td>
<td class="nump">7,474,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,741,633<span></span>
</td>
<td class="nump">41,705,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">64,361<span></span>
</td>
<td class="nump">79,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">15,459,559<span></span>
</td>
<td class="nump">18,063,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">14,826<span></span>
</td>
<td class="nump">57,663<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">96,272,072<span></span>
</td>
<td class="nump">78,631,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2021 and 2020, issued and outstanding: 217,382,887 at December&#160;31, 2021 and 186,851,493 at December&#160;31, 2020</a></td>
<td class="nump">217,382<span></span>
</td>
<td class="nump">186,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,609,589,797<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,209,855,522)<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(282,236)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">399,669,421<span></span>
</td>
<td class="nump">461,140,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">495,941,493<span></span>
</td>
<td class="nump">539,772,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">14,959,647<span></span>
</td>
<td class="nump">14,139,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,515,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793502344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">217,382,887<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">217,382,887<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793488984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,774,758<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">249,240,324<span></span>
</td>
<td class="nump">94,245,436<span></span>
</td>
<td class="nump">88,017,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">53,752,353<span></span>
</td>
<td class="nump">37,247,828<span></span>
</td>
<td class="nump">27,203,156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">302,992,677<span></span>
</td>
<td class="nump">131,493,264<span></span>
</td>
<td class="nump">115,220,475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(301,217,919)<span></span>
</td>
<td class="num">(124,082,044)<span></span>
</td>
<td class="num">(111,108,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">3,363,080<span></span>
</td>
<td class="nump">3,311,846<span></span>
</td>
<td class="nump">2,605,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,936,447)<span></span>
</td>
<td class="num">(8,702,450)<span></span>
</td>
<td class="num">(7,948,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,670,977)<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="num">(553,570)<span></span>
</td>
<td class="nump">36,556,658<span></span>
</td>
<td class="num">(3,090,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="num">(3,222,838)<span></span>
</td>
<td class="nump">1,695,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">343,371<span></span>
</td>
<td class="num">(704,896)<span></span>
</td>
<td class="nump">496,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit</a></td>
<td class="num">(303,224,323)<span></span>
</td>
<td class="num">(162,890,304)<span></span>
</td>
<td class="num">(120,809,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">257,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(434,387)<span></span>
</td>
<td class="num">(4,584,610)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="num">(167,474,914)<span></span>
</td>
<td class="num">(120,551,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">1,192,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (303,658,710)<span></span>
</td>
<td class="num">$ (166,411,157)<span></span>
</td>
<td class="num">$ (119,359,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (1.45)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (1.45)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">208,829,801<span></span>
</td>
<td class="nump">155,126,857<span></span>
</td>
<td class="nump">98,717,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">208,829,801<span></span>
</td>
<td class="nump">155,126,857<span></span>
</td>
<td class="nump">98,717,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,177,043)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,762,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">902,260<span></span>
</td>
<td class="nump">5,170,586<span></span>
</td>
<td class="nump">3,636,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">245,310<span></span>
</td>
<td class="nump">1,453,730<span></span>
</td>
<td class="nump">235,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_OtherRevenueMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">627,188<span></span>
</td>
<td class="nump">786,904<span></span>
</td>
<td class="nump">237,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember', window );">Other revenue from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793907224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (303,658,710)<span></span>
</td>
<td class="num">$ (167,474,914)<span></span>
</td>
<td class="num">$ (120,551,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(30,134)<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="num">(755,963)<span></span>
</td>
<td class="nump">1,001,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(303,684,796)<span></span>
</td>
<td class="num">(168,203,672)<span></span>
</td>
<td class="num">(119,550,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">1,192,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (303,684,796)<span></span>
</td>
<td class="num">$ (167,139,915)<span></span>
</td>
<td class="num">$ (118,357,744)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508786108632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>6.50% Convertible Senior Notes Due 2024</div></th>
<th class="th"><div>August 2019 Bonds</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Common stock </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 87,032,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,794,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (620,426,436)<span></span>
</td>
<td class="num">$ (528,867)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of capital raising related expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of capital raising related expenses</a></td>
<td class="nump">9,089,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,085,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(780,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(781,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,901,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,795,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos, net</a></td>
<td class="nump">2,960,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,960,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,359,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,192,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/loss on short-term investments, net of tax</a></td>
<td class="nump">1,001,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of capital raising related expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,064,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of capital raising related expenses</a></td>
<td class="nump">454,486,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,420,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 43,694,386<span></span>
</td>
<td class="nump">$ 102,671,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 11,536<span></span>
</td>
<td class="nump">$ 4,961<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">$ 43,682,850<span></span>
</td>
<td class="nump">$ 102,666,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">8,241,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,238,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,647,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,655,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos, net</a></td>
<td class="nump">2,379,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Geneos</a></td>
<td class="num">(3,181,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,181,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(167,474,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166,411,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,063,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/loss on short-term investments, net of tax</a></td>
<td class="num">(755,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">27,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of capital raising related expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,310,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of capital raising related expenses</a></td>
<td class="nump">209,441,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,414,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,377,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,376,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,211,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">2,057,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,055,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">26,336,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,336,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/loss on short-term investments, net of tax</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(30,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 399,669,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 217,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,609,589,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,209,855,522)<span></span>
</td>
<td class="num">$ (282,236)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508787066296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (303,658,710)<span></span>
</td>
<td class="num">$ (167,474,914)<span></span>
</td>
<td class="num">$ (120,551,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,040,096<span></span>
</td>
<td class="nump">3,038,996<span></span>
</td>
<td class="nump">3,598,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">520,415<span></span>
</td>
<td class="nump">547,081<span></span>
</td>
<td class="nump">1,066,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">1,170,270<span></span>
</td>
<td class="nump">1,041,713<span></span>
</td>
<td class="nump">851,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,670,977<span></span>
</td>
<td class="nump">1,763,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">26,336,764<span></span>
</td>
<td class="nump">15,647,523<span></span>
</td>
<td class="nump">10,901,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">858,644<span></span>
</td>
<td class="nump">4,077,686<span></span>
</td>
<td class="nump">5,230,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premiums on investments</a></td>
<td class="nump">1,633,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Loss (gain) on short-term investments</a></td>
<td class="nump">5,397<span></span>
</td>
<td class="nump">588,270<span></span>
</td>
<td class="num">(476,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,713,770)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,913<span></span>
</td>
<td class="nump">5,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss (gain) on equity investment in affiliated entities</a></td>
<td class="nump">553,570<span></span>
</td>
<td class="num">(36,556,658)<span></span>
</td>
<td class="nump">3,090,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Share of net loss in Geneos</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized loss (gain) on available-for-sale equity securities</a></td>
<td class="nump">3,222,838<span></span>
</td>
<td class="num">(1,695,497)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Tax benefit from other unrealized gains on short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(266,215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction (gain) loss on foreign-currency denominated debt</a></td>
<td class="num">(176,927)<span></span>
</td>
<td class="nump">15,902<span></span>
</td>
<td class="nump">471,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">13,093,117<span></span>
</td>
<td class="num">(17,859,894)<span></span>
</td>
<td class="nump">2,616,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="num">(2,061,412)<span></span>
</td>
<td class="nump">844,423<span></span>
</td>
<td class="num">(593,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,188,872)<span></span>
</td>
<td class="num">(38,849,572)<span></span>
</td>
<td class="num">(178,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="num">(154,760)<span></span>
</td>
<td class="nump">374,107<span></span>
</td>
<td class="nump">70,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">24,531,654<span></span>
</td>
<td class="num">(23,285,424)<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">26,235,907<span></span>
</td>
<td class="nump">3,115,828<span></span>
</td>
<td class="num">(4,337,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="nump">375,921<span></span>
</td>
<td class="nump">5,962,381<span></span>
</td>
<td class="num">(1,622,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="num">(94,937)<span></span>
</td>
<td class="nump">135,650<span></span>
</td>
<td class="num">(248,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(39,853)<span></span>
</td>
<td class="num">(68,078)<span></span>
</td>
<td class="num">(180,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(2,329,394)<span></span>
</td>
<td class="num">(2,091,855)<span></span>
</td>
<td class="num">(1,733,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="num">(2,914,589)<span></span>
</td>
<td class="nump">1,409,098<span></span>
</td>
<td class="nump">1,899,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="num">(58,500)<span></span>
</td>
<td class="num">(784,925)<span></span>
</td>
<td class="nump">816,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(42,837)<span></span>
</td>
<td class="nump">20,720<span></span>
</td>
<td class="num">(48,507)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(215,708,525)<span></span>
</td>
<td class="num">(177,979,046)<span></span>
</td>
<td class="num">(97,850,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(348,953,236)<span></span>
</td>
<td class="num">(156,216,677)<span></span>
</td>
<td class="num">(100,950,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of or maturity of investments</a></td>
<td class="nump">174,839,758<span></span>
</td>
<td class="nump">62,991,023<span></span>
</td>
<td class="nump">92,893,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(1,231,006)<span></span>
</td>
<td class="num">(1,520,665)<span></span>
</td>
<td class="num">(987,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi', window );">Proceeds from sale of investment of GeneOne</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,125,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,774,851)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,399,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(175,344,484)<span></span>
</td>
<td class="num">(58,795,751)<span></span>
</td>
<td class="num">(9,044,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuances of convertible senior notes and convertible bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,443,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Costs related to issuances of convertible senior notes and convertible bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,314,757)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">209,441,410<span></span>
</td>
<td class="nump">454,486,400<span></span>
</td>
<td class="nump">9,089,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsfromStockOptionandWarrantExercises', window );">Proceeds from stock option exercises, net of tax payments</a></td>
<td class="nump">6,668,741<span></span>
</td>
<td class="nump">12,269,801<span></span>
</td>
<td class="nump">112,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</a></td>
<td class="num">(4,611,348)<span></span>
</td>
<td class="num">(4,028,177)<span></span>
</td>
<td class="num">(892,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
<td class="nump">2,960,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Geneos issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">171,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">211,498,803<span></span>
</td>
<td class="nump">465,279,613<span></span>
</td>
<td class="nump">105,397,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(30,134)<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(179,584,340)<span></span>
</td>
<td class="nump">228,532,021<span></span>
</td>
<td class="num">(1,497,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">23,693,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">71,143,778<span></span>
</td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">204,815<span></span>
</td>
<td class="nump">136,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,077,803<span></span>
</td>
<td class="nump">4,624,764<span></span>
</td>
<td class="nump">2,717,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets', window );">Change in prepaid expenses and other current assets included in fixed assets</a></td>
<td class="nump">7,709,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityComponentOfConvertibleDebtIssued', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,634,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,177,043<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,762,030)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AmortizationOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Prepaid Expenses And Other Current Assets, Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityComponentOfConvertibleDebtIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Debt Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityComponentOfConvertibleDebtIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsfromStockOptionandWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Option and Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsfromStockOptionandWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791529672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus ("HPV"). INOVIO has shown in clinical trials that its DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of INOVIO's integrated platform, SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and CELLECTRA&#174;.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">smart delivery devices facilitate uptake of its DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA&#174; smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's corporate strategy is to develop, seek regulatory approval for and commercialize its novel DNA medicines to address unmet global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include ApolloBio Corporation, AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, conducting or planning clinical studies of DNA medicines for COVID-19, which includes both homologous and heterologous boosting approaches; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791997464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $303.7 million for the year ended December&#160;31, 2021. The Company had working capital of $382.7 million and an accumulated deficit of $1.2 billion as of December&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $401.3 million as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering, net proceeds of $47.7&#160;million under a Sales Agreement during the year ended December 31, 2021, </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net proceeds of $454.5&#160;million under Sales Agreements during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  Refer to Footnote 16 for further discussion of Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2021 and 2020. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December&#160;31, 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2021 and 2020, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.6&#160;million and $3.1&#160;million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2021, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $237.2 million and $159.7 million at December&#160;31, 2021 and 2020, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020 and 2019, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,654,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Pending Adoption </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company will adopt ASU 2020-06. The Company is finalizing its analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. The Company expects that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508795329624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition and Concentration of Credit Risk</a></td>
<td class="text">Revenue Recognition and Concentration of Credit RiskDuring the years ended December&#160;31, 2021, 2020 and 2019, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department of Defense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the total revenue recognized during the year ended December&#160;31, 2021, $46,000 was in deferred revenue as of December 31, 2020. During the year ended December 31, 2020, the Company recognized revenue of $127,000 that was included in deferred revenue at December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and the CEPI MERS grant, respectively. As of December&#160;31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791983480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements <div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first participant in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an accounts receivable balance of $7.1&#160;million from Advaccine. There has been no additional revenue earned under this collaboration agreement with Advaccine for the year ended December 31, 2021. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the Global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore concluded to account for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company received funding of $4.5 million from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018, which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca was obligated to make potential future development and regulatory event-based payments to the Company and potential future commercial event-based payments, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca was funding all development costs associated with MEDI0457 immunotherapy. The Company was entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca could also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified materia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue $2.0 million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2021, AstraZeneca provided notice to the Company to terminate the INO-3112 / MEDI0457 development program under the agreement. As a result of the termination, the agreement has been terminated in its entirety and the Company has no further obligations under the collaboration.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2021 and 2020, the Company received funding of $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2021, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $1.9&#160;million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded $23,000 as deferred grant funding on the consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $6.9&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.0&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2021 the Company had $1.8&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2021 and 2020, the Company recorded $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2021, the Company had $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0&#160;million to accelerate the development of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the years ended December&#160;31, 2021 and 2020, the Company recorded $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is $54.5&#160;million. The Company has determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company will record contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s later-stage clinical trials. The total purchase price under the Procurement Contract is expected to be approximately $10.7&#160;million. As of December 31, 2021, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company determined that the Procurement Contract falls under the scope of ASC Topic 606 as the contract is with a customer and the Company is able to satisfy its obligations under the arrangement as the Phase 3 clinical trials of INO-4800 are underway. Performance obligations under the Procurement Contract consist of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. The Company will recognize revenue on the consolidated statement of operations upon shipment of the purchased devices and accessories. During the year ended December 31, 2021, the Company recorded revenue of $755,000 from the Procurement Contract. This revenue was recognized at a 100% margin as the sale was for products whose related inventory had previously been written down to zero. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement. As of December&#160;31, 2021, the Company had an accounts receivable balance of $3.6&#160;million on the consolidated balance sheet from the DoD. As of December&#160;31, 2021, the Company had $2.3&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the Procurement Contract.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing funding under the OTA Agreement and Procurement Contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508795948440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $394,000 and $744,000, respectively, and gross realized loss on investments of $399,000 and $1.3 million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(3.2)&#160;million and $1.7&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2021,&#160;2020&#160;and&#160;2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2021, the Company had&#160;24&#160;available-for-sale securities in a gross unrealized loss position, of which six with an aggregate total unrealized loss of $766,000 were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2021&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2021 and 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain (loss) on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a </span></div>professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2021 and 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $394,000 and $744,000, respectively, and gross realized loss on investments of $399,000 and $1.3 million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(3.2)&#160;million and $1.7&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2021,&#160;2020&#160;and&#160;2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2021, the Company had&#160;24&#160;available-for-sale securities in a gross unrealized loss position, of which six with an aggregate total unrealized loss of $766,000 were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2021&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2021 and 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain (loss) on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a </span></div>professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793914760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,474,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,661,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,357,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.08pt">Includes prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacture of INO-4800. The Company deposited a total of $50.0&#160;million to reserve manufacturing capacity, of which $30.0&#160;million was paid in 2020 and the remainder paid in the first quarter of 2021. Of these deposits, $35.0&#160;million was included in research and development expenses in December 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791559128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text">Fixed Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,258,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,397,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,944,378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,453,206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,179,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,549,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,727,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,419,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,341,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,993,571)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,348,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $3.0 million, $3.0 million and $3.6 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2021 the Company disposed of fixed assets with a net book value of $89,000 and accumulated depreciation of $89,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791592168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $520,000, $547,000 and $1.1 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Amortization expense related to intangible assets at December&#160;31, 2021 is expected to be incurred as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791612536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled into an aggregate of 11,535,660 shares of the Company's common stock. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8&#160;million gain on extinguishment of debt. Thi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s gain was recorded in the consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020,&#160;the Company recognized $1.9 million and $6.9&#160;million, respectively, of interest expense related to the Notes, of which $1.1 million and $4.1&#160;million, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,082,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were $14.5 million. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020, the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.69 shares per KRW1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022. For the year ended December 31, 2020,&#160;the Company recognized $1.6 million of interest expense related to the August 2019 Bonds, of which $87,000 related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the August 2020 conversion in full of the August 2019 Bonds, the derivative liability associated with the August 2019 Bonds was revalued at $84.5&#160;million. The change in fair value of the derivative liability was an increase of $75.7&#160;million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature did not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature met the definition of a derivative, it qualified for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the December 2019 Bonds was through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is 6.2%. For the years ended December&#160;31, 2021 and 2020,&#160;the Company recognized $50,000 and $253,000, respectively, of interest expense related to the December 2019 Bonds, of which $9,000 and $40,000, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock. Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791731016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,213,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,112,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,127,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued subcontract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,644,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,203,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791647368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, 14 shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#8217;s common stock.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $27.20 per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. For the year ended December 31, 2021, the Company sold 6,955,341 shares of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $6.96 per share, resulting in aggregate net proceeds of $47.7&#160;million. As of December 31, 2021 there was $251.6&#160;million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1&#160;million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "2020 Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the 2020 Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0&#160;million. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company sold a total of 22,919,934 shares of its common stock under the 2020 Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2&#160;million. As of December 31, 2020, there was no remaining capacity under the 2020 Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into amendments to the Sales Agreement (as so amended, the "2018 Sales Agreement") to increase the amount of common stock that could be sold under the 2018 Sales Agreement from $100.0&#160;million to $250.0&#160;million. During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the 2018 Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2&#160;million. As of March 31, 2020, there was no remaining capacity under the 2018 Sales Agreement. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December&#160;31, 2021, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was 20,000,000 shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2022, the maximum number of shares increased by 2,000,000. At December&#160;31, 2021, the Company had 4,481,745 shares of common stock available for future grant under the 2016 Incentive Plan, 2,448,868 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 8,060,957 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2021, the Company had options outstanding to purchase 2,428,036 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 was $25.0 million, $14.5 million and $9.8 million, respectively, of which $13.4 million, $8.0 million and $5.9 million was included in research and development expenses and $11.6 million, $6.5 million and $3.9 million was included in general and administrative expenses, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021 and 2020, there was $16.5 million and $4.4 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.0 years and 1.4 years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021 and 2020, there was $13.4 million and $10.9 million, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.8 years and 1.9 years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, 2021, 2020 and 2019 was $1.4 million, $1.2 million and $970,000, respectively. As of December&#160;31, 2021, options to purchase 632,375 shares of common stock granted to non-employees remained outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.60-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,148,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the aggregate intrinsic value of options outstanding was $3.8 million, the aggregate intrinsic value of options exercisable was $3.1 million, and the weighted average remaining contractual term of options exercisable was 5.9 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the aggregate intrinsic value of unvested restricted stock units was $12.2 million and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, 2021 was $12.7 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, options to purchase 10,488,993 shares of common stock and 2,448,868 restricted stock units were expected to vest.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2021 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2021 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,387,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $4.56 for the 7,000 options which expired during the year ended December&#160;31, 2021, $4.44 for the 78,750 options which expired during the year ended December&#160;31, 2020 and $6.27 for the 324,502 options which expired during the year ended December&#160;31, 2019.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $7.61, $6.87 and $2.19 for options granted during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $10.37, $9.12 and $3.09 per share for restricted stock units granted during the years ended December&#160;31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $6.7 million, $12.3 million and $113,000 in proceeds from the exercise of stock options during the years ended December&#160;31, 2021, 2020 and 2019, respectively. The aggregate intrinsic value of options exercised was $7.0 million, $14.2 million and $25,000 during the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the year then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791622088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2021 of 1.9 years to 8.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,175,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,111,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,064,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,460,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 were $3.4 million, $3.4 million and $3.2 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has existing supply agreements with contract manufacturers to manufacture INO-4800 drug substance. Under the terms of the agreements, the Company is committed to certain minimum purchases in 2022. At December 31, 2021, the Company had a $47.4&#160;million minimum purchase obligation in connection with these agreements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and J. Joseph Kim, the Company&#8217;s Chief Executive Officer, as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On August 3, 2020, the lead plaintiff filed a consolidated complaint, naming the Company and three of its officers as defendants. On September 21, 2020, the lead plaintiff and another purported stockholder filed a first amended complaint, naming the Company and three of its officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, the defendants&#8217; motion to dismiss. The court granted the defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on certain of the Company&#8217;s statements. The court denied defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, the defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, the plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#8217; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. Defendants intend to move to dismiss the new allegations in the amended complaint.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend these actions vigorously.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791585736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the accounting guidance for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations before equity method investment are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations before equity method investment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for (benefit from) income taxes for the years ended December 31, 2021 and 2020. There was an income tax benefit of $(257,000) for the year ended December 31, 2019. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2021, 2020 and 2019, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (benefit) taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,370,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit recorded during the year ended December 31, 2019 of $257,000 was principally due to a requirement under ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,835,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,005,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,242,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,171,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,484,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,205,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,705,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,676,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $864.5 million, $146.5 million and $89.0 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $568.9 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2021, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2021, respectively, unless previously utilized. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also has Korean NOL carryforwards of $806,000 as of December 31, 2021. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2021, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $35.1 million and $4.4 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2021. As a result of the analysis, the Company estimates that approximately $9.7 million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2021, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $17.4 million, $10.9 million and $9.9 million as of December&#160;31, 2021, 2020 and 2019, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2018 and state and local income tax examinations before 2017. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is subject to examinations for tax years beginning in 2020 in Korea. The Company is not currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791557688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#8217; contributions, up to 6% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.5 million, $1.1 million and $1.2 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791546344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned 597,808 shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, 2021 and 2020, representing a 18.9% and 19.7% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2021 and 2020, the Company recognized revenue from PLS of $245,000 and $1.4 million, respectively. At December 31, 2021 and 2020, the Company had an accounts receivable balance of $25,000 and $67,000, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will have the exclusive right to in-license new intellectual property developed in this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $1.9&#160;million during the two-year term of the agreements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a&#160;$6.1 million&#160;sub-grant through Wistar to develop a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infectio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n, with funding through December 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.5&#160;million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024, of which $3.3&#160;million has been exercised as of December 31, 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2021 and 2020, the Company recorded $3.0 million and $1.9 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2021 and 2020 were $2.9 million and $2.3 million, respectively. At December&#160;31, 2021 and 2020, the Company had an accounts receivable balance of $2.6 million and $425,000, respectively, and an accounts payable and accrued liability balance of $548,000 and $643,000, respectively, related to Wistar. As of December&#160;31, 2021, the Company had a prepaid expense balance of $261,000 and recorded $37,000 as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791588536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested $1.2&#160;million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1&#160;million, of which $2.4&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value. The gain has been recorded separately on the Company's consolidated statement of operations. The following table shows the amounts related to the deconsolidation accounting: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217;s enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption. The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the Series A preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $4.6&#160;million and for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f this amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remaining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss has been allocated to the Company&#8217;s </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $0 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793514856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $303.7 million for the year ended December&#160;31, 2021. The Company had working capital of $382.7 million and an accumulated deficit of $1.2 billion as of December&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $401.3 million as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering, net proceeds of $47.7&#160;million under a Sales Agreement during the year ended December 31, 2021, </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net proceeds of $454.5&#160;million under Sales Agreements during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div>The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span> the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short Term Investments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2021 and 2020. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow </span></div>analyses or comparable fair values of similar assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2021 and 2020, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.6&#160;million and $3.1&#160;million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2021, identifying no impairment.</span></div>Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $237.2 million and $159.7 million at December&#160;31, 2021 and 2020, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span> (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div>For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantRevenuePolicyTextBlock', window );">Grants</a></td>
<td class="text">Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text">Equity Investments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and </span></div>accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span>For the years ended December 31, 2021, 2020 and 2019, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span>The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Recently Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Pending Adoption </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company will adopt ASU 2020-06. The Company is finalizing its analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. The Company expects that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793926328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,654,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used to estimate the fair value of stock options</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508876110136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue from External Customers</a></td>
<td class="text">The following table indicates the percentage of total revenues in excess of 10% with any single customer:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department of Defense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791582504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508876109304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,474,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,661,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,357,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.08pt">Includes prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacture of INO-4800. The Company deposited a total of $50.0&#160;million to reserve manufacturing capacity, of which $30.0&#160;million was paid in 2020 and the remainder paid in the first quarter of 2021. Of these deposits, $35.0&#160;million was included in research and development expenses in December 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791587976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,258,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,397,584&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,944,378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,453,206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,179,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,549,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,727,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,419,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,341,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,993,571)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,348,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508792737592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of intangible assets by major asset class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of finite-lived intangible assets, future amortization expense</a></td>
<td class="text">Amortization expense related to intangible assets at December&#160;31, 2021 is expected to be incurred as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508792750120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities of long-term debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,082,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791525064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2021 and 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,213,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,112,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,127,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued subcontract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,644,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,203,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793280152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of preferred stock authorized, issued and outstanding</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of shares authorized under stock option plans, by exercise price range</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.60-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,148,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options, activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2021 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock unit activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2021 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,387,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791998712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,175,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,111,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,064,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,460,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508792716152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of pretax loss from operations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations before equity method investment are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations before equity method investment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2021, 2020 and 2019, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (benefit) taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,370,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,835,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,005,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,242,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,171,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,484,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,205,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,705,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,676,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock', window );">Schedule of operating loss and tax credit carryforward expirations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits rollforward</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508792747336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of equity method investments</a></td>
<td class="text">The following table shows the amounts related to the deconsolidation accounting: <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The remaining <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss has been allocated to the Company&#8217;s </span><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $0 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value measurement inputs and valuation techniques</a></td>
<td class="text">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785875416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,658,710<span></span>
</td>
<td class="nump">$ 166,411,157<span></span>
</td>
<td class="nump">$ 119,359,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209,855,522<span></span>
</td>
<td class="nump">906,196,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209,441,410<span></span>
</td>
<td class="nump">454,486,400<span></span>
</td>
<td class="nump">9,089,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,626,355<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,205,000<span></span>
</td>
<td class="nump">159,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,700,000<span></span>
</td>
<td class="nump">$ 454,500,000<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of current assets and current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785774392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">16,654,503<span></span>
</td>
<td class="nump">16,190,768<span></span>
</td>
<td class="nump">30,737,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">10,488,993<span></span>
</td>
<td class="nump">8,906,624<span></span>
</td>
<td class="nump">9,265,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">2,448,868<span></span>
</td>
<td class="nump">2,558,052<span></span>
</td>
<td class="nump">2,069,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,799,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CommonStockEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CommonStockEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793289352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.91%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in estimation of fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508786018104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,774,758<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 41,659<span></span>
</td>
<td class="nump">$ 170,587<span></span>
</td>
<td class="nump">$ 3,194,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AstraZenecaMember', window );">AstraZeneca | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 245,310<span></span>
</td>
<td class="nump">$ 1,370,396<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. (affiliated entity) | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">Department of Defense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 754,853<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">Department of Defense | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 732,936<span></span>
</td>
<td class="nump">$ 870,237<span></span>
</td>
<td class="nump">$ 917,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785979848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">Department of Defense | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">Department of Defense | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_CEPIMERSMember', window );">CEPI MERS | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_CEPIMERSMember', window );">CEPI MERS | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_CEPIMERSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_CEPIMERSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508781678760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,559,721<span></span>
</td>
<td class="nump">7,474,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">902,260<span></span>
</td>
<td class="nump">5,170,586<span></span>
</td>
<td class="nump">3,636,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration agreement, payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Cost, Maintenance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AnnualMaintenancePeriod', window );">Annual Maintenance Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement | Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Agreement period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Collaborative agreement, corporate income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Collaborative agreement, foreign non-income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized', window );">Agreement, milestone payment, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | Lassa Fever And MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | COVID19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | IN O4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | D N A Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract', window );">Collaborative Arrangement , Revenue from the Procurement Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,100,000<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AnnualMaintenancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AnnualMaintenancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Milestone Payment, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementMilestonePaymentRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement , Revenue from the Procurement Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementRevenueFromTheProcurementContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785893400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 331,712,413<span></span>
</td>
<td class="nump">$ 159,239,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">107,195<span></span>
</td>
<td class="nump">2,365,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,648,668)<span></span>
</td>
<td class="num">(690,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">330,170,940<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">192,966,772<span></span>
</td>
<td class="nump">153,177,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">87,069<span></span>
</td>
<td class="nump">2,339,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,614,411)<span></span>
</td>
<td class="num">(644,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 191,439,430<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 94,193,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(9,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 94,183,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 39,967,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">39,967,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">2,976,210<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">15,618<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 2,991,490<span></span>
</td>
<td class="nump">$ 3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 1,608,137<span></span>
</td>
<td class="nump">$ 3,062,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">4,508<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(23,998)<span></span>
</td>
<td class="num">(36,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 1,588,647<span></span>
</td>
<td class="nump">$ 3,025,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785447816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 330,170,940<span></span>
</td>
<td class="nump">$ 160,914,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">191,439,430<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">39,967,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,991,490<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,588,647<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">330,170,940<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">3,906,796<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">334,077,736<span></span>
</td>
<td class="nump">225,372,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">285,622,950<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">3,906,796<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">289,529,746<span></span>
</td>
<td class="nump">219,330,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">44,547,990<span></span>
</td>
<td class="nump">6,041,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">44,547,990<span></span>
</td>
<td class="nump">6,041,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">191,439,430<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">191,439,430<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,996,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">94,183,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,996,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">94,183,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">39,967,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">39,967,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,991,490<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,991,490<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,588,647<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,588,647<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793565864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>investment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">$ 394,000<span></span>
</td>
<td class="nump">$ 744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">399,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="num">$ (3,222,838)<span></span>
</td>
<td class="nump">$ 1,695,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | investment</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | investment</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">$ 766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508796122232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidManufacturingExpensesCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 27,474,159<span></span>
</td>
<td class="nump">$ 35,661,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">11,362,832<span></span>
</td>
<td class="nump">4,695,509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 38,836,991<span></span>
</td>
<td class="nump">$ 40,357,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508789925272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDeposits', window );">Deposit payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DepositAssetsForfeited', window );">Deposits forfeited</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DepositAssetsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposit Assets, Forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DepositAssetsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785828504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 36,397,584<span></span>
</td>
<td class="nump">$ 27,341,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(18,944,378)<span></span>
</td>
<td class="num">(15,993,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">17,453,206<span></span>
</td>
<td class="nump">11,348,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,040,096<span></span>
</td>
<td class="nump">3,038,996<span></span>
</td>
<td class="nump">$ 3,598,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposed of</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated depreciation written off due to disposal of property plant and equipment</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">15,803,108<span></span>
</td>
<td class="nump">15,179,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(8,258,608)<span></span>
</td>
<td class="num">(6,549,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">7,544,500<span></span>
</td>
<td class="nump">8,630,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">12,392,916<span></span>
</td>
<td class="nump">4,788,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(4,279,816)<span></span>
</td>
<td class="num">(3,727,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">8,113,100<span></span>
</td>
<td class="nump">1,061,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,827,476<span></span>
</td>
<td class="nump">2,828,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,599,643)<span></span>
</td>
<td class="num">(2,296,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">227,833<span></span>
</td>
<td class="nump">531,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">5,374,084<span></span>
</td>
<td class="nump">4,544,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,806,311)<span></span>
</td>
<td class="num">(3,419,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 1,567,773<span></span>
</td>
<td class="nump">$ 1,125,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785853224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(7,847,406)<span></span>
</td>
<td class="num">(7,326,991)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">2,626,355<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, Gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, Net Book Value</a></td>
<td class="nump">$ 13,139,726<span></span>
</td>
<td class="nump">13,660,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(1,305,600)<span></span>
</td>
<td class="num">(1,276,852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 18,161<span></span>
</td>
<td class="nump">46,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(2,735,556)<span></span>
</td>
<td class="num">(2,468,889)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 2,364,444<span></span>
</td>
<td class="nump">2,631,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(3,806,250)<span></span>
</td>
<td class="num">(3,581,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 243,750<span></span>
</td>
<td class="nump">$ 468,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508796142584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 520,415<span></span>
</td>
<td class="nump">$ 547,081<span></span>
</td>
<td class="nump">$ 1,066,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508790127064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,098,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 2,626,355<span></span>
</td>
<td class="nump">$ 3,146,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508783703496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,936,447<span></span>
</td>
<td class="nump">$ 8,702,450<span></span>
</td>
<td class="nump">$ 7,948,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,670,977)<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,591,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,762,030<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of date conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(8,177,043)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt | After January 2, 2020 Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock Issued During Period, Value, Conversion of Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt | After July 2, 2020 Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0003579611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785845128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance Of Convertible Debt (Details) - 6.50% Convertible Senior Notes Due 2024<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">(1,591,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(219,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">355,657<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 14,959,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtinstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtinstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793895512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - 6.50% Convertible Senior Notes Due 2024 - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 14,959,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 19,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508795751752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 24,213,673<span></span>
</td>
<td class="nump">$ 825,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">16,112,912<span></span>
</td>
<td class="nump">13,127,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedSubcontractExpenses', window );">Accrued subcontract costs</a></td>
<td class="nump">11,602<span></span>
</td>
<td class="nump">247,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">7,306,343<span></span>
</td>
<td class="nump">7,003,239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 47,644,530<span></span>
</td>
<td class="nump">$ 21,203,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedSubcontractExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontract Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedSubcontractExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508781657400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series&#160;C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508780551432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare', window );">Convertible preferred stock, shares issued upon conversion, conversion price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,336,764<span></span>
</td>
<td class="nump">$ 15,647,523<span></span>
</td>
<td class="nump">$ 10,901,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,488,993<span></span>
</td>
<td class="nump">8,906,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value for options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm', window );">Options exercisable, remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber', window );">Number of options expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,488,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expirations in period, weighted average exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expirations in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">78,750<span></span>
</td>
<td class="nump">324,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.61<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value of unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber', window );">RSU's expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,448,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.37<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,392,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under a share-based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,481,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan', window );">Number of shares of vested restricted stock outstanding under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,448,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,060,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs) | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs) | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Commissions and other estimated offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sales Agents will be entitled to compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,955,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Sales made at a weighted average price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Prior Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | New Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,919,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Sales made at a weighted average price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of vested restricted stock outstanding under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508781629608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">10,488,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 7.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">6,790,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 7.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember', window );">$1.60-$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">272,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">262,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember', window );">$1.60-$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">2,583,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,137,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember', window );">$6.01-$9.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">4,148,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 7.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,848,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 7.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember', window );">$9.01-$12.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">9.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">2,562,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 10.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">827,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 10.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember', window );">$12.01-$15.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">12.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">824,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 13.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">663,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 13.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember', window );">$15.01-$25.62</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 25.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">98,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 20.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">52,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 20.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508791826472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">8,906,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,483,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(1,310,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(590,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">10,488,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 6.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">10.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share) | $ / shares</a></td>
<td class="nump">5.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in USD per share) | $ / shares</a></td>
<td class="nump">10.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 7.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793850840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) - Performance-based restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,558,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,392,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,387,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(113,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,448,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785413384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto', window );">Number of lease agreements entered into | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Minimum purchase obligation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Number Of Lease Agreements Entered Into</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeNumberOfLeaseAgreementsEnteredInto</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785808744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">$ 4,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">4,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">3,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">3,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">6,749,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">24,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(6,111,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">18,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,603,956)<span></span>
</td>
<td class="num">$ (2,329,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 15,459,559<span></span>
</td>
<td class="nump">$ 18,063,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508796325848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Pretax Loss from Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Domestic</a></td>
<td class="num">$ (302,614,003)<span></span>
</td>
<td class="num">$ (162,664,355)<span></span>
</td>
<td class="num">$ (120,809,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(610,320)<span></span>
</td>
<td class="num">(225,949)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit</a></td>
<td class="num">$ (303,224,323)<span></span>
</td>
<td class="num">$ (162,890,304)<span></span>
</td>
<td class="num">$ (120,809,112)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785826072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income (benefit) taxes at statutory rates</a></td>
<td class="num">$ (63,677)<span></span>
</td>
<td class="num">$ (34,207)<span></span>
</td>
<td class="num">$ (25,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(3,447)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">77,424<span></span>
</td>
<td class="nump">21,428<span></span>
</td>
<td class="nump">25,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt', window );">Nondeductible loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeTaxReconciliationStatuteLimitations', window );">Research and development tax credits</a></td>
<td class="num">(16,523)<span></span>
</td>
<td class="num">(2,650)<span></span>
</td>
<td class="num">(3,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">483<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits', window );">Expired NOLs and credits</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits', window );">Limited NOLs and credits</a></td>
<td class="num">(542)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
<td class="num">(616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(819)<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (257)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ComprehensiveIncomeLossTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationStatuteLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Statute Limitations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationStatuteLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785786632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (257,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxBenefitsExpired', window );">Tax benefits expired</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">17,400,000<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">864,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">35,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">146,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">89,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">235,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember', window );">Korean State Income Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">$ 806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefits Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793271768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">197,144<span></span>
</td>
<td class="nump">127,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Research and development and other tax credits</a></td>
<td class="nump">23,005<span></span>
</td>
<td class="nump">13,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">987<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,599<span></span>
</td>
<td class="nump">3,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetInterestExpense', window );">Interest expense</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in affiliated entity</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">3,793<span></span>
</td>
<td class="nump">4,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,973<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">240,171<span></span>
</td>
<td class="nump">163,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(237,205)<span></span>
</td>
<td class="num">(159,705)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">2,966<span></span>
</td>
<td class="nump">3,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(2,430)<span></span>
</td>
<td class="num">(2,676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount', window );">Note discount</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Financing Arrangement, Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesFinancingArrangementDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508793534104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2022</a></td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2023</a></td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2024</a></td>
<td class="nump">16.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">267.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">568.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">864.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2023</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2024</a></td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">235.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinThreeMonths', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFourMonths', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">35.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">35.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinThreeMonths', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFourMonths', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Indefinitely Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsIndefinitelyCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Carryforward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardCarryforwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Four Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Three Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508795588008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 12,210<span></span>
</td>
<td class="nump">$ 11,204<span></span>
</td>
<td class="nump">$ 9,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">6,602<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 18,819<span></span>
</td>
<td class="nump">$ 12,210<span></span>
</td>
<td class="nump">$ 11,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) In Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508787025672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution to 401(k) plan</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508787210296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Agreement amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedExercisedAmount', window );">Awarded exercised amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.90%<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember', window );">PLS (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromSubGrant', window );">Proceeds from sub-grant</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedExercisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Exercised Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedExercisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromSubGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sub-Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromSubGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785578328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508783628808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,453,206)<span></span>
</td>
<td class="num">$ (11,348,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapitalExcludingCash', window );">Working capital (excluding cash)</a></td>
<td class="num">$ (59,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="num">(16,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="nump">3,181,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedInterestFairValueDisclosure', window );">Fair value of investment in Geneos retained</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapitalExcludingCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital, Excluding Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapitalExcludingCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInterestFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInterestFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508785789256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Investment in Geneos (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,113,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508795729800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details) - Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityMethodInvestmentEnterpriseValue', window );">Geneos enterprise value</a></td>
<td class="nump">$ 4,966,531,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AlternativeInvestmentMeasurementInputTerm', window );">Equity method investment, measurement input, expected term</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.0246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AlternativeInvestmentMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AlternativeInvestmentMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentEnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentEnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140508783632872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos upon deconsolidation</a></td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">$ 4,584,610<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos from June 30, 2020 - December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>ino-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ino="http://www.inovio.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20211231.xsd" xlink:type="simple"/>
    <context id="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id38a5c1786aa4218ab4b1daf6b02098d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i463a7ab03b6446db9e60c8b7ad87def3_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="ia60088662e644556a450fd3a05824f9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b698702e82d457c8216eac55fae002d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i347d60d556c2498fb9d80645b9a706b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04336b766df84aa2a42f4abf68368421_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib64eac47556245f8b42cc012f2ffe0ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ecae667f48745ad9fd43b801e35b9c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92ed9e2d8d23416fa2216a18597af29a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c6ed30dc86a4b31b83a17f1a97066df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idea5902416e14a1a8963131a95b4e349_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic28851dd7ca34c3cb482d22189f39e47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a3f177a526c4d6e9937328cb2042e27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i402a2216be6243d79489c5e44b694136_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib87e8afe51e242b296534833ed309ce2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44dd97a11a2748a98bed361bca96dcc5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1adaf3d29db647be821417221977869b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib54e996352a04ec28cb7e31c037d184e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4990fae62ff441f4acf38817077260d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cbcf710c43f435cb1efd59b9274f753_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iafe285a056e84e7690752bb6bae44144_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i411612102a3e4c9e911d58c817263069_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40d1df5b1c5b4cc3b96a485c772c8fc7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib319c6f186cc48f394c757bf041fbc05_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id00acd8f0e9248db874b93cb6b3eb23a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36c6f4ee12934a40a1ea728d479c1b02_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i02a77f36ff44452d920fe5904cb46826_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iac56a7bfee5749ab9ef8c4fb331f0dd3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1d85a8106cf746239de37759928ef0f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if4ef69988114421e91fd39d86626a033_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic92f9fbbfaa2469dbe870606abca1b9d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id0209f8c94d740adaa36dd67c48d6a20_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0a501ec111d47fbb2c02a92d18044b8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i934d7a839de6474e9b47fe4f2dde4862_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba84c3ae05e74f7b95113a5d797a1b3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38bba6f63c734bfb8d21fd427b61fbe7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c45e9e8670742aabe1a2097889e1003_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a9737ecdffd44d1b2551cce0509fa59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12b5dcddd0d942b9afa00d1eb75fd3fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cada50c939e412c9ab1db2da9a0465e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59302a922e4f4aca836ef50c844fef86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b91df562f874655a19dab108f20fb24_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee3c8a7e151648fa9963ae445b27955e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98ad737a11be4f09bde8169850c3ab12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bd975f309a74bc9830110950e77a982_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i636993c134064180ad2590c08fa52072_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d08995f70474651a10b743f24c3decc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6a0eee5ee74422dbf15e46a3b2632fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01da3ab01f954252bc6510f0dbd029c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iceb449b556844657b6e6671a8579fde4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c72b6e9e8eb4b8ea4fdb38d60151ad5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib722279b8997488c897a37f118e63061_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if11f8a3ab55d49a8bb586876044a035e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i019963c050f847419c1846c58634267e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f5e9f8d356d417887e0a2ce250b61f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c5137421a60479cb080a26e2eb6d08c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f35c89987a74786896285ad7ae13979_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13876df5a7d44b1a938e8ee19872763d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie453dc0fe621472f991c3336fea7f4cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2aed4a0d2c3496d81638d7203fff95f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idcee4832a056439890bc22cca53ebf0a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i755387a3bd2040869919d38bac155975_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5f38759d4c94c9c9f578011dc9fc2d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if64e7bfdf2294cae86cf31ff7714dac5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d91dffb8ff14276905969cb9451fbd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i416413e6f44e49bf9af9f5ca9c4a9d19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i386a00e8a13746fa9abf8ea15747827d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3348c69519f04942adeb29a5daf412ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic404b3bf911d46e48fef168a1506f7d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cbb09860a3f4b019d6e6f2db9a0996b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61571339f1d34229a32dd11283124d8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2f6172e00ae438dba3e872301590376_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e3b5941f67f4dd7839d1d0ee8b932e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3185052214d241188760405d062c3a93_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cb066154a0b4e63a1b45dee6f783336_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec094623890140ecbe43e62d969a9e6e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4b54e7447e843b785376b2edd00a1df_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6fbf1d83933c4796bd3e5b9f8257c137_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ef43783aafd41bcbd015396830a6453_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if22218578fe146a690414073c1055f9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie75672a5cd7f4ee7b50fd63d1effb9b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib858b60634554cfeb353213f382d8701_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1619b504fabd4b03803cf6d1bd43cdf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idf57bbc765a648e88af4e001faf909bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1d7d0e03523439aa100b18e4b73ea8f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5cfd184b5e79415896cd4f9f6baac7f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bf52c18686740578bf1f8f9c8cbaa61_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5417c1b5a9294d67b2ece5b90e913521_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i153bb9c9446b45eb8aa80f75f7399f3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie80d43743e6a4d668eea6d7bee8e1496_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ef6a305f4c7456382cbb6d2f1e80f0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib58bb2dd8a4143a19908c58b705c40c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f0ab257a6974dcdaba93f9ed07ea5f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i818c9cc8d85740b2bf619cb778985673_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f8eca20d5f34697abb3f086dc268f34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14c7a36858de4d50ad50b6fa093cd1a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia57b862418ed4691a1094727113e9132_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d211e27d9de438bae12df540aefb132_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c100e0e5d064a128da83ec7e1d7bdb0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6c4d94d9b204b7b9bfcdd26fabbc2c7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i985caa6fe2204c79885e3f347c621473_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9ebf37c07fc64f66897dbd181366f4f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i161b5c6c81dd4f91ba0ee787fa80afde_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8cfdf8c8894d47eaa3893a5f0fb45ab8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93761468f4d2413c9fbddde17352101f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i656c17b4e38a4ee491d602bf63aa7c19_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i919eacd755534f7f903fe6245b2c707c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36e0b5e7a72c42b1895acaf229856efe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40e1d2d136dc4c518979cf57c6a1b20b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b4a0ade4f3147fc8b24dc411f419712_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i873c90e08f654501a8ad20a07c60193f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47a1ac7d82334e4baf6955ef04815ce4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id57fe04684f046938af512e85a6ba191_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9ec58bb67dc470a99951e5275067d10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i206cac58be234c169495b0e1f07f3b28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if59018c846e149458509f9c8cd25b24c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib99bde567bfb41acbc76d3e0b885ec12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb847a1857fb4bf8b3cbe776dd9e29ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82e0404405254e2e98e726f09230deb6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i567cdce8ec3f4d2eab6aec7e81bd94f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b628859583d45a886cbba8bc22a2f8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie01b088cd46a48608cf5867ab6b78956_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08cf4a688e1e4557bbe98d00332e150f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67e4662477174747a0d272e1d8792a76_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib8f9c1676db542ada5764c97da93a468_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ee4ca6918ae4fa796d41036cae115ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia77dac3a01a74815904a03fe7971a7d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b35ca32ad6b49038d3962c931ab0301_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icad521f20e6d42869f7f73948ebbd477_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14838e9bc6fc4c4487a1c7f9172258a4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42c6acd539524f568bd5b29f3c45c3ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idb2df8412c044c118cdb9553e4cf95ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52aca042d6ff42d1ba348dd26d66cffd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59968761470a4f2d802618f91010f7b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6262eab5b3c948d69de6a49741df2b15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if71d5ef52a394d6797808af8b5299731_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43ec222c4b76432ca9ce78c095a00f5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06bbd4127d1e42a6b45c7cdf18fc01b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0f4b2524a6745389ebfd4167248f100_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e2613d428a449579acc6b28ca21928c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ded10e0f0e44a2bb4ece994cc771846_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaef8fd46f8504fc48eaafd248555647c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4ec0f7d61a247a29e6f8b976b92fdd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e94d242541e4769b9580dca20dd055f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c6068a0d87f4fa585046b88cd0c29e1_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i345933f791f148b9ab11262a4e3fabc8_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i2ae7a6139749478dae2789fde984a73d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib423f4e3e0a948d1a2df6de8efddc903_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i38a9f6f4af6b431f8ca5510726bbceba_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="iecc3a56b04444e0ea7504b1ecbc37e79_D20171231-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9e3823ff3500456ebdf2aa61528c8e05_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4218b3818f30409db7b03360c59d6a05_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie60c9823b100427ba62081e1ce28130e_D20180411-20180411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-11</startDate>
            <endDate>2018-04-11</endDate>
        </period>
    </context>
    <context id="ied6f8e470b114624a1428d5fe05d2883_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibeaaf2a45e274b08822dc97c5f1d6548_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i627a7ce3c55f4c9bac1b8724c31a2b9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48b9f355c6d44067b5c91a145b75b3d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3fab37e71394ac2af69e86ac41d336a_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="icad38c575aa2469a960d1b3021807208_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i5b1057c5132f4610b04adc365c092be4_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i02735771448f4559ad8ad7eb771f42a0_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i33e5d35d7de44a078dff01c3cfa43227_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia081c81a473a4f3399c27e4703bbc7ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd977534e815463fb781c4067853b53b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i781f7721feee4c4ca2ff6d186fcffbf3_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i5fde4b781ebe4327bf969f8140d88ecf_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="iac1e6c89e8ca49e9b134471c2d4cd4c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie34b4d8f0d4e4a1d973ed63d51a51649_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bbf0edc36f446378983dc8302caa4d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd0b58a07e594872a449c2f8a64d1f50_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iabd3cbd20ab142cca107c1f4cf711e83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00eb7864be0441e898f5a5f77d203ff1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f4af1a162cd4deda134bce933897a10_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67b7af31bd224297994ebe728b26c780_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5575e68486ee4cd5b43dde605b161a50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i128585ac13474b3091b72cd864723b37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00e2d517b98c4e12bb4ac8e2131fe365_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4422f4760ee74f3ba71d8253cc93cf53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cf6fb5f859b42d78d7c7a430a42ff42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0732cac3e67f42b28ba168e6b4b35a13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib71562a57439406ab96e0f74edd9d947_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9327b185da7843ef8a8df8e03d20d44f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib292d78a61bd4623a795a93607e5c9ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i003f22a5fb7445d89be30a83788b0272_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26b0d42be39843d9b1022921606edc04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7ac4c61823a437d8c9b6aee26cf229b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i156d5ef8518844db95ef4f40d37d1035_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id939b4ea33cc496d933ef0fa32e5168b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7071211447db4c3e8f228036ebc64654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26fd2f2ca1804cf8b78f9f97fc906ec9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea6f0020516c4a6497376d5f1359cbd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie39b5179785c4f0d952c95c50da89619_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b3f9b2236a74d2da2c502071722bc13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15cdf0125f0d414b83d3aa528c069939_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c910afcfe76477c8adf69b6afc36738_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb11ec937978481798d9a2fa621b2545_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i674ddfb5b1174eab854007ba42538368_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b606f8ce6104231abbb11b014a54bb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7104e94d6b6402b8ad5ba5ea9a6dcf3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if78b7886eb8f4368bd3e159d7be11563_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66c4fc55ad384a2d90e87c0e989d38c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1effe86d89143f3aded22e7fd8fd339_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd4c0a4f24f64339938c89d15957c736_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1245efc94094f599b7d7d3c818aa250_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f0a0b420ecc4a6b936201d1941936bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d04338821da4044877e4bf707d5526b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b2231094e244b4b8f8d798ed1d5a673_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5b914f5f74342a2862d941121e5a48f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i395742f3d6cc49d3b3f55b2c752865d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d61d6b3e5354708ac4bab1f051af74a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief6d60d841db49b884995b9d409a2699_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1fcbe29e328435f900b5cf60bf4ffb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9693506cef01463bb3c7d6635695bba9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32393fe851fd43879b59a162035f2f85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56064b8e76fe40919fd24d219d24a453_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8277afd2efb5453b93534cade2d9ce8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73c766e601044c378ac2db7f87cde480_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i922af379e03e4956a28c8f5c205b7dc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69ca8c127c9f48b3b63c86430c68e46d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9c565cc3c44415ead62595cf93e70f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id32dc71cb0364baaaed730794f9f6ac8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1784296ad78e4c20af0d84835cef9888_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7877ab15bcd4dac8a499d3c7b9e7072_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43a0e2b2399a434d9a99f30233dc02a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45b384928838488791c262caec9215b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab11fde10c2c4d87b33e70d030ae1653_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff4fbe1fd8cc41b6947d447b6a6c741d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18d84e84f3c84c92a7c4176575b1dc22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd535af4c12849f0934bcc1b955d369d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28c32f98e31846aaa2d17068ee0b3b77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94ab88df768e4ba68e5d2e3d4e747e2b_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69d4ecd562014440beb00576acad3efd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0eb6a32bee874e46833ded3ae075b6b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea32134d65f94c16977562bd8ec30416_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f5e0d4976d341d89e231839c5c36c4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eeb3ced61044408997e1d8f8a05e001_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a39711823f44fd6ac0aae903ff997dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id45f7a28571f47f4bd640ad228eaafca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0adccf4f6d64811a0e0d98da2637677_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bfadc7f8c124e2897d43453679cc488_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i147d28db95ca40d8a9e71dd47520fcf3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1e398f1b0e24f15973a8336cc567723_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0e15729cf93490bab53bb5b3743cc9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9792ca724094babb1ceaaaf9e7f9699_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb405ddb59694654918b5c478e9d869e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7eef2a859d2a4a548cea3f9cc63a809a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12c81efc53744ccbba4e8d22c10d48c8_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="i4c6e93100cda41698c2d90ac7b3add33_D20190219-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i916cd8866e36499abf272f07df39ec4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64bb83c1af53463db93165f16058040b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic34a66f65e034d328e08870d700f693e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90a45ddead5f4816a5c59b73845dad0e_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i51416fb82fda4188a3a2a2e3f710d077_D20190801-20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="i3478042f83d6449ead46d859f7d60ffe_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="icd20ef4b33f94e01bf76d24ff90685b4_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="iac8579f0882d4dc59ef160f7c64b5672_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i7ba0ea858d9c46c78c2859dc92d5033e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c5bcadd2c7245faa4cb1ac2870fd0ab_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i353adf10991e4196a4b209b6a5267e9c_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i6039cba34e8c4be6a904174d99de85a8_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i85915c3d427b495197df94d39dff08ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fceb3f6f682487baf3242c63275edbd_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i23bc4609abe8422ca6b1d83a291a407a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2fc5c2b195e47d38f45dbda9f77eb42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i064aac05f8624a0389f91fa023f36ad6_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i338ace46836e41128cd3590125bfb51c_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="id595b8847ae94191b14b7d82020a700e_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i2b7d314600cf45488694aa3608c2b239_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98fcd21abb664100b8f5b38c37fe8294_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40a8e6a6790645be83c7f3d6ff04f333_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25d15f4eda32428fa3a38009bc9b503f_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0beb8343704b4e66bf518dc68c5d9e59_D20211109-20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="i23b51ec2c12f42e7a12b929edad6ac3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49f555fa92724b73a79e6f05d158c07e_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i1b4c0934496e4fd69eff228d86ee8f98_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i753fd66a6adf4a97a3cb8ca8d0b01238_D20200512-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-12</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e3ea451d4a04b0abec238235c56f2be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43a1d23049ec4dc7a76ba1a881242cad_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ie5029be83e87418db970ef84ed1a4011_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7880a35a7d84470b865daeee2cd2fc5c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6b2929e55be54db5a11cf6c1aae0b709_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i13e80425e56b494380b3ac92a6bad40b_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="ic3a43045796d477a93feae3365556de6_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i368a7f5ff9214108a0ffca3a870b9948_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i631230ffee974729a0560f9e16c5f441_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6791f3241d2d4b26860e5a3f33455b90_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i407c6b8fb0da42379265bd134df26349_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i768073d462a746ae9a55cb59ee67fdff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c52650eb05d4d77a1dc769d4513b048_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36b6f9125f4245038f3ccc1233da0d79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55226aff8520430581c928fb4cdbc54f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11d51be8fd474946a4d6832b362af324_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8c8d2335ada94a8d968b2b3a1caa5fdf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf8a9cd7d8fa44d79020983a83a16598_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f5b1cda2b6d4b0b901a301aea31851b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib54d8bf639154cb89c4ba6de26467b78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie18a5ae792de49a48808b18a814cd872_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3954ccf6ef6747ef8feb9744b59bb557_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaccbaf36a42a44229ce94ccb6af44093_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99beda0a9bac415092a4c08da1889be8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd750ff594294f0c811ec9edaa677c38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59bd8fb3a94a4250b276d32d4de3f266_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia38954b11aa549609db2fb805ac849ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9f81ea99dba400ca4654757465a0324_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04c01a40e2f44c378fc95b4edf730f2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i607dff749d1b494aa307f2fde9568207_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7b6cf865ace43d59c4d9b8cd23d0762_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99399af4f2764839b791a9aff6806132_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i768661574b0047a8978ccb5a91644538_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ie684f486c3914e20a06a7b5a84e49ca3_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i72efe8598cfb48c48cb1d6f2d4c6fdd6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i940ff9e4c5b74f5581133846dcd72463_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i764e102832c147288be14730f1429377_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5174769188e48278fd87c450cdc20d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i553b47824270463b81580d012b8326f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a2629ea83a447d48947801594c4a4f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28ea7f8947e74ae483e59fef6fba3c42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i170db3d65ef54746a1f01e2eeb793898_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifb481c2e100c4b24ab6801fa143fc5a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:KoreanStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8600df4b8cfa4198a900a673aaa25e5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46f662a8f3a3462b9e7192ba6281596b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2469103cd1da4e7d8121957ac4b2cd24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i648b48da56f54bfab41cbc5eae47c6a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc560e22c9154ac688112e684c7e03ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i016abb4ce4ae41eb96f478d01ecb4c74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ecadc9f1fe848b199e3eebeee7aec5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i662f61a3c3334b0e9a41c8358963d412_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i882b0a38e1f2460195c1411955ee5cbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32a55572cadc4c63ad76c5efc89aa4aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie83fbb635f5946a4b9deeceae49cb099_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7373234a664045788a5b334e1076415e_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i87fa3d23bcb34cf791cf9f42fd01a6fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3814c1b2e66949a0bd31251687136440_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="iba7798242f3b4c25b6738d30fa118ce1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7365de7ee2a44bdbaf064109d873902_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i852044bbe3424614962d40fb0b43db9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41b9a94f7b494158a6d83627c08f021c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9609157af4444ad383c75696d8f21624_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4b9648133c14f64986de131ff9b55c1_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i2c28778c30d04e92b3843a48a585dbb4_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i6d0ce816abac42bdabeaed537ab884e8_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i14abd64fd4ca460b8acf05ac1d77a2c2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3ffdc36023f54e9fa96891a1aedfccaa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic1a5d5fed4e84bfaaaa1da165905d43b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i6afcb9b96a3643e394e9339a35bf52eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i923c4d838e73472daff6f5c2a0b66af9_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="ic982a0927e6846e8873518def396e93c_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="ic828dfae01914c5dadca776a2dbad2ad_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i70c92f1527c04f16bf9084ab8878ced9_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i48f7e5188b3845c9ab32ff4a6346e973_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ie564892056a949fe9b105cc382205542_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i05ba584f59334065a632c11588572f53_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30ef1cfdaf874c749abaf0297c07f342_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3aaedc813254497f95ad1fb1461a99b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie01459eec92d4ada9c407fd1befdf459_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i657942a14f6441a2bd23b51205eae9a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa18a071c4404f868cef43212fce1e2c_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i0a42fdc8de284579bf2e8654f3f26a01_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1f23c07d6cfb47f2a060dfee7b1f5455_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i377ac441325e467a8c00a33146b64c62_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="segment">
        <measure>ino:segment</measure>
    </unit>
    <unit id="investment">
        <measure>ino:investment</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lease">
        <measure>ino:lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl80LTEtMS0xLTEzMDc5_8755cd1d-91d1-41b9-abbe-2c7dcd95375a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl82LTEtMS0xLTEzMDc5_3c2d0efc-7cbd-4670-9985-b27825f9e973">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl83LTEtMS0xLTEzMDc5_4bcde891-53ea-43e2-a319-ae32be777286">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM180L2ZyYWc6NWVkY2Q4OGZmYmFiNDNiYWIzODM3YTJmYWVlMDNiZDMvdGFibGU6ODUxYmFiYWI2ZmNiNDFkZThhNDg3OGU1MzFmNzY1N2YvdGFibGVyYW5nZTo4NTFiYWJhYjZmY2I0MWRlOGE0ODc4ZTUzMWY3NjU3Zl85LTEtMS0xLTEzMDc5_e9c89ecb-12ca-4003-996e-8b503292b952">0001055726</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6fbf1d83933c4796bd3e5b9f8257c137_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6fbf1d83933c4796bd3e5b9f8257c137_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i4c6e93100cda41698c2d90ac7b3add33_D20190219-20190228"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzItMS0xLTEtMTMwNzk_4423523c-0ff7-4e62-b292-9db84deb65f4"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i064aac05f8624a0389f91fa023f36ad6_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzUtMi0xLTEtMTMwNzk_2f8efbb9-e559-4a7b-b12a-9f582b3a1bc3"
      unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i338ace46836e41128cd3590125bfb51c_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzYtMi0xLTEtMTMwNzk_664055f3-c0b4-4d80-b686-ce098cb9815e"
      unitRef="number">0.0002756873</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="id595b8847ae94191b14b7d82020a700e_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzktMi0xLTEtMTMwNzk_2cc082c1-a41a-4200-844a-a4ec8f0df4e6"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i2b7d314600cf45488694aa3608c2b239_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjYvZnJhZzpiODlmMzRiNjhjODg0ZjIxOTIwMGJhZDk2ODMzZDlhNi90YWJsZTo3YmY3NzQyZTEzNzc0ZjdiYWZiODhmOGFjOTdkNmZmMC90YWJsZXJhbmdlOjdiZjc3NDJlMTM3NzRmN2JhZmI4OGY4YWM5N2Q2ZmYwXzEwLTItMS0xLTEzMDc5_af3f5804-0a5a-4fe4-9efb-f66657e69664"
      unitRef="number">0.0003579611</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI0_6863daf9-0139-4de0-a905-a6d4bd1f1e4c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6ZWU0MmM2NjU3YTUyNGE2Mzg0ZTVlZWY3NDk0MTY0MjkvdGFibGVyYW5nZTplZTQyYzY2NTdhNTI0YTYzODRlNWVlZjc0OTQxNjQyOV8wLTAtMS0xLTEzMDc5_dce53dcd-fc38-4836-9c07-8268f3b5e3bf">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8xMjQ_f457bb89-8a96-47a7-a2cb-baf00510802c">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8xMjQ_6b645f4d-2f65-46a9-8ae0-920ad43db61c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6ZTI5ZTliOThiOTlkNDhhZDg3ZDk5YWQxODk4YTI1NmUvdGFibGVyYW5nZTplMjllOWI5OGI5OWQ0OGFkODdkOTlhZDE4OThhMjU2ZV8wLTAtMS0xLTEzMDc5_26530c64-2106-49c0-afa3-530b51c00274">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDMy_73de356a-7c80-4a12-af08-be1c4d6a9ec7">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDIx_2e6435c1-6a09-4fb4-9246-0ccd7a9f673d">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8wLTAtMS0xLTEzMDc5_fb064926-ab91-4c78-b3a4-6a60caf1c7a7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8wLTItMS0xLTEzMDc5_777d8d1c-e0b3-4aaa-bae0-72702932199b">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfNA_6a05842b-90e9-492d-8be2-82c1d4a77fe1">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfOA_102b23d4-0fc0-4f63-90cc-53898117ef95">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfMTE_7b249baf-600f-4c1d-afe6-8cb7a4a09766">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTAtMS0xLTEzMDc5L3RleHRyZWdpb246MDU1NGZmZDAxMjI1NGYwMmFmODA0YWZiN2FmYjZmMDlfMTU_91c56e0c-0991-4e15-afa1-7b55a30d9f8e">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6YzU5OGY1YzI3OTU2NDE5NzhjYTA3YzBmMmJiYzFlYmEvdGFibGVyYW5nZTpjNTk4ZjVjMjc5NTY0MTk3OGNhMDdjMGYyYmJjMWViYV8zLTItMS0xLTEzMDc5_7e0a9b2e-30e7-4b2f-85f8-c53d1cd6eb78">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI4_fe1ce93a-5bf6-4bd3-9380-06138860c2c4">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI5_7c4ebbf6-3f4e-4a15-bee2-21ad6ba74ac9">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6M2MyY2JhOTZjYTQyNGU5YTg0ZWQzYThjMDViMDBkYTkvdGFibGVyYW5nZTozYzJjYmE5NmNhNDI0ZTlhODRlZDNhOGMwNWIwMGRhOV8xLTAtMS0xLTEzMDc5_9304f695-8932-410b-bb29-61386a5cab3d">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6M2MyY2JhOTZjYTQyNGU5YTg0ZWQzYThjMDViMDBkYTkvdGFibGVyYW5nZTozYzJjYmE5NmNhNDI0ZTlhODRlZDNhOGMwNWIwMGRhOV8xLTEtMS0xLTEzMDc5_30ba976c-a7e1-4fbe-a000-2922e7c876c0">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6M2MyY2JhOTZjYTQyNGU5YTg0ZWQzYThjMDViMDBkYTkvdGFibGVyYW5nZTozYzJjYmE5NmNhNDI0ZTlhODRlZDNhOGMwNWIwMGRhOV8xLTItMS0xLTEzMDc5_f507c043-fc4a-4a2b-8dd7-082aa328611a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDIy_e6253f52-9f73-48c1-8f76-5f7b1356722a">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI2_814f0741-8b1e-48e0-8eda-02d48cf4f9b7">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDMw_6757a2b0-0b91-4670-a71e-2e199a772796">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDMx_fb814bb6-216c-4658-8079-8bd0717c8feb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6MzkyNTM5YWUxMjAxNDllOWEyMWI4OWVlZmFjODk2ZGEvdGFibGVyYW5nZTozOTI1MzlhZTEyMDE0OWU5YTIxYjg5ZWVmYWM4OTZkYV8wLTAtMS0xLTEzMDc5_ba6bc444-acd6-408e-875b-629fcd027114">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6MzkyNTM5YWUxMjAxNDllOWEyMWI4OWVlZmFjODk2ZGEvdGFibGVyYW5nZTozOTI1MzlhZTEyMDE0OWU5YTIxYjg5ZWVmYWM4OTZkYV8yLTQtMS0xLTEzMDc5_ed07a27b-dc5c-41e1-a5a0-3f285b0ec392">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGFibGU6MzkyNTM5YWUxMjAxNDllOWEyMWI4OWVlZmFjODk2ZGEvdGFibGVyYW5nZTozOTI1MzlhZTEyMDE0OWU5YTIxYjg5ZWVmYWM4OTZkYV8zLTQtMS0xLTEzMDc5_6270cffb-f10c-4d31-b222-2acf2b323760">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDIz_16d12cce-38ae-4157-a21f-1ff7ef7b2844">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI1_cb800a51-d772-49cd-93b8-7b4ad99f3243">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="id38a5c1786aa4218ab4b1daf6b02098d_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8yNzQ2_9f258804-352d-4652-b1f8-7db0b394f270"
      unitRef="usd">1900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i463a7ab03b6446db9e60c8b7ad87def3_I20220225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8yOTYx_d6d50bd9-b767-4770-9d9b-e93109fa8fa2"
      unitRef="shares">217403287</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xL2ZyYWc6YTc5N2Y3MWQ5NGUyNGE0MGI0ZmE3YWI4NmU5ZTYyZmUvdGV4dHJlZ2lvbjphNzk3ZjcxZDk0ZTI0YTQwYjRmYTdhYjg2ZTllNjJmZV8zNDI3_b26fc995-338a-404a-b9f9-7fd48d436e50">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#x2019;s 2022 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x2019;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#x2019;s fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMDkvZnJhZzoyNGZmYjA0ZDFhOWM0ZmRhOGNiNzU5YmVjMmNmOTZiMy90YWJsZTowNDRkNzU1YjIwNzA0YzMzYjI3ZWJjZWY4NDZmNjNkNi90YWJsZXJhbmdlOjA0NGQ3NTViMjA3MDRjMzNiMjdlYmNlZjg0NmY2M2Q2XzEtMC0xLTEtMjg4NzEvdGV4dHJlZ2lvbjozYTJmNDJjMDNlZGY0YzVmODJhMmY2NWE2ODMwNjE1OF8zODQ4MjkwNjk3MzA0_286d6b76-2307-4acf-91e5-982d93bf0804">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTIvZnJhZzo5OTZiMzRmZWVkMWE0NTQ3YjMyYjgxNTQ2NGMxOTc3Yi90YWJsZTozMDkwOTFhNDMwMzM0YTc3YWY1NjE0NDMyNjU1YTJkMC90YWJsZXJhbmdlOjMwOTA5MWE0MzAzMzRhNzdhZjU2MTQ0MzI2NTVhMmQwXzAtMC0xLTEtMjg0NDIvdGV4dHJlZ2lvbjozZTYzZmRiNWY4Yzg0YWJlYmM5ZjZmZmUwNGU4MWMxMV84MjQ2MzM3MjA4MzYy_a228d8e0-c756-4b43-8023-87efcf72bb8b">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTIvZnJhZzo5OTZiMzRmZWVkMWE0NTQ3YjMyYjgxNTQ2NGMxOTc3Yi90YWJsZTozMDkwOTFhNDMwMzM0YTc3YWY1NjE0NDMyNjU1YTJkMC90YWJsZXJhbmdlOjMwOTA5MWE0MzAzMzRhNzdhZjU2MTQ0MzI2NTVhMmQwXzMtMC0xLTEtMjg0MzI_23657c10-dbfd-4d31-9795-f2bbf405e7e9">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQtMS0xLTEtMTMwNzk_0e57253f-11cb-4047-b241-521c0eae63b9"
      unitRef="usd">71143778</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQtMy0xLTEtMTMwNzk_1c8ba4f8-f401-4ade-8e22-f632e64edddf"
      unitRef="usd">250728118</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUtMS0xLTEtMTMwNzk_5b023ccd-3044-43f5-b1e3-099b6be62186"
      unitRef="usd">330170940</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUtMy0xLTEtMTMwNzk_b933ddc4-dd54-48c3-b991-c5ad1560a8de"
      unitRef="usd">160914935</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzYtMS0xLTEtMTMwNzk_af974c7f-1815-4e56-9f6d-ac9bb5dd1987"
      unitRef="usd">5466850</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzYtMy0xLTEtMTMwNzk_f83c45fd-f1c6-479e-b0c5-89e87aff427c"
      unitRef="usd">18559967</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzctMS0xLTEtMTMwNzk_180ab256-209c-4937-b3be-f7cfdec2d8fe"
      unitRef="usd">2565194</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzctMy0xLTEtMTMwNzk_a425dd53-14f0-4dc1-95f9-44d5270d4442"
      unitRef="usd">503782</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzgtMS0xLTEtMTMwNzk_3270a8da-2b5f-4dec-ae10-069f90900566"
      unitRef="usd">38836991</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzgtMy0xLTEtMTMwNzk_99646a74-770b-49b5-ac2d-50c3d61d7399"
      unitRef="usd">40357456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzktMS0xLTEtMTMwNzk_1e1eb32d-2a65-4e08-8814-813cf59981d0"
      unitRef="usd">261192</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzktMy0xLTEtMTMwNzk_7a06f0d8-7f92-46b1-91c7-58df88e59746"
      unitRef="usd">106432</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzExLTEtMS0xLTEzMDc5_524a9c27-8b1a-46e0-a09c-0478aa3fad7e"
      unitRef="usd">448444945</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzExLTMtMS0xLTEzMDc5_edb34346-c628-4fe1-ab5d-d674b7564bed"
      unitRef="usd">471170690</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzEzLTEtMS0xLTEzMDc5_0a08bf59-d18c-4e3b-acbf-6a62549e219a"
      unitRef="usd">17453206</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzEzLTMtMS0xLTEzMDc5_d439d933-6ca8-4f19-924f-b0400251502e"
      unitRef="usd">11348144</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE0LTEtMS0xLTEzMDc5_092b5617-21ff-4e68-b925-df199674cb8c"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE0LTMtMS0xLTEzMDc5_8f7b1698-8824-4586-bf80-d50cd9682cda"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE1LTEtMS0xLTEzMDc5_c977c1eb-62dc-4333-b5b0-b1fceced086e"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE1LTMtMS0xLTEzMDc5_c8239d6d-7068-46d8-b44c-61217cf98e1c"
      unitRef="usd">434387</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE2LTEtMS0xLTEzMDc5_4a15d924-5dbe-44c6-a83c-5769013cb117"
      unitRef="usd">2626355</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE2LTMtMS0xLTEzMDc5_6ec05d9c-5e62-4183-9300-8ce72d38ccf9"
      unitRef="usd">3146770</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE3LTEtMS0xLTEzMDc5_71375df8-37db-4bba-bf7a-a72b563f5d55"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE3LTMtMS0xLTEzMDc5_40b765fd-d1b0-40d3-87d1-d8d23b4414b7"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE4LTEtMS0xLTEzMDc5_88f53c0c-6afb-4ba0-b235-a628d466ae62"
      unitRef="usd">11571026</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE4LTMtMS0xLTEzMDc5_1540dc56-0861-43a5-97cd-c52eced479bb"
      unitRef="usd">12741296</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE5LTEtMS0xLTEzMDc5_f8d87c53-4a8f-42f9-8d11-9679de0d52c8"
      unitRef="usd">1425794</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzE5LTMtMS0xLTEzMDc5_fff8d83a-7555-4b42-b1dc-086d06523f64"
      unitRef="usd">25957448</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIwLTEtMS0xLTEzMDc5_742645ea-1d54-4e31-a28d-4cf8a9205bd7"
      unitRef="usd">495941493</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIwLTMtMS0xLTEzMDc5_7118ef1b-223b-4d70-b05d-a6db8bcb6f31"
      unitRef="usd">539772472</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIzLTEtMS0xLTEzMDc5_1dcf4d7d-7844-4f33-8d69-0ce205fcdc1c"
      unitRef="usd">47644530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzIzLTMtMS0xLTEzMDc5_7c68c2cc-c1da-466b-b662-0f7ac2423297"
      unitRef="usd">21203808</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI0LTEtMS0xLTEzMDc5_8ac24c35-d7d0-4b95-bdfc-8460e8549f04"
      unitRef="usd">548032</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI0LTMtMS0xLTEzMDc5_b1fb56d3-103a-4477-829c-42cdc7b348a3"
      unitRef="usd">642969</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI1LTEtMS0xLTEzMDc5_ab037b34-fd37-40bb-bfd5-e6f02b60a1fd"
      unitRef="usd">10326266</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI1LTMtMS0xLTEzMDc5_10ad3662-991f-41fd-8450-dbad7ce9d2e0"
      unitRef="usd">9950345</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI2LTEtMS0xLTEzMDc5_2eb37e5c-32f9-4ddb-845c-c34d44a82fda"
      unitRef="usd">21628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI2LTMtMS0xLTEzMDc5_ade49475-ad65-4df8-9337-9345ba8b9c95"
      unitRef="usd">46628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI5LTEtMS0xLTEzMDc5_c0e8da5b-3bc4-4848-b0df-94c69457bb57"
      unitRef="usd">2603956</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzI5LTMtMS0xLTEzMDc5_fa46d9cf-6bda-48a7-b6eb-6caad6d6f974"
      unitRef="usd">2329394</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMwLTEtMS0xLTEzMDc5_897def91-a838-4f82-994a-7905d6c649b8"
      unitRef="usd">4559721</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMwLTMtMS0xLTEzMDc5_92d0b999-ccea-4023-bdac-be787f357efc"
      unitRef="usd">7474310</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMxLTEtMS0xLTEzMDc5_c60c4e7c-e1b7-45be-9bca-229b72e67055"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMxLTMtMS0xLTEzMDc5_ef9fa9e3-6ce5-4b8c-9ea9-8a194f8ad55c"
      unitRef="usd">58500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMyLTEtMS0xLTEzMDc5_3516df00-af5d-4fed-bc68-ab02299d6eef"
      unitRef="usd">65741633</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMyLTMtMS0xLTEzMDc5_ef5b5115-068a-400d-82a0-fdc520be988e"
      unitRef="usd">41705954</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMzLTEtMS0xLTEzMDc5_0d857260-3bff-4742-80a5-25139fa56cd8"
      unitRef="usd">64361</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzMzLTMtMS0xLTEzMDc5_4f43e89b-3a7b-40a7-9e4c-4ebec0436c27"
      unitRef="usd">79214</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM1LTEtMS0xLTEzMDc5_8004978e-3098-4871-a877-3a3af0c11f52"
      unitRef="usd">14959647</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i04336b766df84aa2a42f4abf68368421_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM1LTMtMS0xLTEzMDc5_f5625ca3-d7e1-4ccb-bf3c-b752b4268650"
      unitRef="usd">14139988</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ib64eac47556245f8b42cc012f2ffe0ff_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM2LTEtMS0xLTEzMDc5_dad645be-7060-4992-ae35-af5023f6b0eb"
      unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i7ecae667f48745ad9fd43b801e35b9c4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzM2LTMtMS0xLTEzMDc5_1d122093-60a9-40c9-bfca-db7fd97c9f73"
      unitRef="usd">4515834</us-gaap:ConvertibleDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQwLTEtMS0xLTEzMDc5_54fd8535-752d-4176-9ffe-8d90299b80b0"
      unitRef="usd">15459559</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQwLTMtMS0xLTEzMDc5_07e689eb-ac66-4acf-b67a-2acdf6417f23"
      unitRef="usd">18063515</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQxLTEtMS0xLTEzMDc5_bfe38dfd-b183-448b-861f-04c408ca5d9b"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQxLTMtMS0xLTEzMDc5_aa55e4da-5861-4a71-8234-4227d8b0c953"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQyLTEtMS0xLTEzMDc5_db31ca23-8b12-4286-bf59-e13499a485e3"
      unitRef="usd">0</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQyLTMtMS0xLTEzMDc5_771e3cf7-8971-4f17-b149-797c652c4ba1"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQzLTEtMS0xLTEzMDc5_97b737c6-7b11-4c06-b251-9976e7f333f4"
      unitRef="usd">14826</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQzLTMtMS0xLTEzMDc5_f5da52c8-6140-44c4-97d1-b9428f4b89a4"
      unitRef="usd">57663</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ0LTEtMS0xLTEzMDc5_67e1788f-bbdf-4977-ae98-06f922f8196c"
      unitRef="usd">96272072</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ0LTMtMS0xLTEzMDc5_c451fdac-5486-4d1f-bd58-a92ab9bb1215"
      unitRef="usd">78631714</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ1LTEtMS0xLTEzMDc5_3a1d1497-ddf7-45e5-bf30-dd469a38a2b5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ1LTMtMS0xLTEzMDc5_55f421fb-6c8a-4426-a11b-09faa3a3ebf7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfMzA_567c02d2-af95-4412-9d6f-e1a75986e046"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfMzA_f77625d6-187c-4b77-992a-5818eacb0d5f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfNTM_a15b3bb1-a137-484d-a9a0-b5c665bd49c2"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfNTM_e6be87c6-dd36-4a4a-a6bb-6a80210cf7ee"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_023a1652-d22a-48ab-b5a3-043c382457af"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_440f6976-ad42-419d-9bc4-8e5e52a8877d"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_7f8158c6-bfac-4658-9888-3a9a2fea6948"
      unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ZjJiYzRiYmUxZDUzNGRhZTg4YTU1NWNjNTgxN2RkY2NfODg_ce63adce-88be-4dd5-982a-f323b7582681"
      unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTEtMS0xLTEzMDc5_775bf9d6-b673-408f-9422-623563e61c31"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ3LTMtMS0xLTEzMDc5_2918d987-70a0-4fc5-9e27-166eed4f1456"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMjc_86528556-127d-48b8-99b9-cf5732ebff12"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMjc_c19573c1-40f9-4be6-bcbf-f9a83e661431"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfNTA_4258b446-6c40-4730-a55c-d0f72ba4521e"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfNTA_9200e9c3-8224-4e30-8182-3a3ff47ae3d8"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTIx_1a626fd3-238d-4486-8673-132bb64d8221"
      unitRef="shares">217382887</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTIx_5e1b45ea-ab21-4b2b-a831-b35145244053"
      unitRef="shares">217382887</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTQ5_1df94c8a-844f-4ac9-baef-59e95e9bec84"
      unitRef="shares">186851493</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTAtMS0xLTEzMDc5L3RleHRyZWdpb246ODM4YWE4NjA0MTcxNGNkYTgxZTdlNDViZjQxNGZmYjlfMTQ5_7ce6e63b-904b-45a6-839c-09d596cf903d"
      unitRef="shares">186851493</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTEtMS0xLTEzMDc5_e360496a-b1d6-4767-a25a-c94092b26702"
      unitRef="usd">217382</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ4LTMtMS0xLTEzMDc5_b154c3de-49bc-480b-9520-2ca5aa8a8ca4"
      unitRef="usd">186851</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ5LTEtMS0xLTEzMDc5_0f37b658-1411-4977-a2bc-437139e56d02"
      unitRef="usd">1609589797</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzQ5LTMtMS0xLTEzMDc5_60233695-002a-40a9-8fb1-2978ef12ba5f"
      unitRef="usd">1367406869</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUwLTEtMS0xLTEzMDc5_dc07fd03-85ae-4f6e-9665-76542ae7daca"
      unitRef="usd">-1209855522</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUwLTMtMS0xLTEzMDc5_32ba93d1-9077-4782-b994-c929f1b446a5"
      unitRef="usd">-906196812</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUxLTEtMS0xLTEzMDc5_4c5c1c2c-bbd5-48f7-8ffb-2b4c295039c4"
      unitRef="usd">-282236</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUxLTMtMS0xLTEzMDc5_8df758b3-c4fe-4e11-9f46-7ec156315047"
      unitRef="usd">-256150</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUyLTEtMS0xLTEzMDc5_c711a586-cd92-4e63-a08d-f155adc80de8"
      unitRef="usd">399669421</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzUyLTMtMS0xLTEzMDc5_a26bad17-417c-4e38-a232-7b116d8f2671"
      unitRef="usd">461140758</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzU1LTEtMS0xLTEzMDc5_ae35feef-f829-4f05-b49f-c7bd72549191"
      unitRef="usd">495941493</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTUvZnJhZzo4YjdkMmZmYTYyYzM0ZDcwYmJjOWRiOWVlOWY3NDEzOS90YWJsZToyOGE5YzY4MmE1NTM0OWQzODgyZmU1OWRjMzNiYWVjOS90YWJsZXJhbmdlOjI4YTljNjgyYTU1MzQ5ZDM4ODJmZTU5ZGMzM2JhZWM5XzU1LTMtMS0xLTEzMDc5_21bbddee-cfae-43a8-b248-4d872426563b"
      unitRef="usd">539772472</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92ed9e2d8d23416fa2216a18597af29a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzUtMS0xLTEtMTMwNzk_62d750d7-ba6a-4390-90c3-5218a30c1441"
      unitRef="usd">902260</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c6ed30dc86a4b31b83a17f1a97066df_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzUtMy0xLTEtMTMwNzk_1b292e2d-28de-404f-b8d1-6255bdd65c34"
      unitRef="usd">5170586</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idea5902416e14a1a8963131a95b4e349_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzUtNS0xLTEtMTMwNzk_14a13c71-f5c8-4f69-9362-5b7bb73b315b"
      unitRef="usd">3636945</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic28851dd7ca34c3cb482d22189f39e47_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzYtMS0xLTEtMTMwNzk_647de6ed-0173-4bd4-99fa-10990e5077e4"
      unitRef="usd">245310</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a3f177a526c4d6e9937328cb2042e27_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzYtMy0xLTEtMTMwNzk_765b3b78-f020-4a2a-9c17-d1e2ca0b4190"
      unitRef="usd">1453730</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i402a2216be6243d79489c5e44b694136_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzYtNS0xLTEtMTMwNzk_41b3521b-4d1a-4d4d-b1cf-d875082fe714"
      unitRef="usd">235649</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib87e8afe51e242b296534833ed309ce2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzctMS0xLTEtMTMwNzk_49eeba6a-458d-4164-8fd0-1897410dddb1"
      unitRef="usd">627188</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44dd97a11a2748a98bed361bca96dcc5_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzctMy0xLTEtMTMwNzk_2ee55f0e-6b82-43d0-bdbf-543893878753"
      unitRef="usd">786904</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1adaf3d29db647be821417221977869b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzctNS0xLTEtMTMwNzk_3d521754-d89e-4999-9e71-f0991f276cc2"
      unitRef="usd">237536</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54e996352a04ec28cb7e31c037d184e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzgtMS0xLTEtMTMwNzk_30565b8f-c3e3-4bda-ba65-2ed95a1179d1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4990fae62ff441f4acf38817077260d8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzgtMy0xLTEtMTMwNzk_21ffcb64-50f6-4ece-bb00-823c8bce4406"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cbcf710c43f435cb1efd59b9274f753_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzgtNS0xLTEtMTMwNzk_2147afe4-efd5-4a82-836b-505d5e1b178d"
      unitRef="usd">1800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzktMS0xLTEtMTMwNzk_f81b6d8a-015b-4900-9edf-f6ddc46db3ad"
      unitRef="usd">1774758</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzktMy0xLTEtMTMwNzk_b1a1d7ef-52ec-4876-989d-9b29de605d9d"
      unitRef="usd">7411220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzktNS0xLTEtMTMwNzk_3c039756-fe26-41e4-b53d-83c882968dd3"
      unitRef="usd">4111930</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzExLTEtMS0xLTEzMDc5_e8bee94c-073c-4464-bf1d-3063704292f5"
      unitRef="usd">249240324</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzExLTMtMS0xLTEzMDc5_ffa13d5f-3456-49ea-8963-6f9604c263c8"
      unitRef="usd">94245436</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzExLTUtMS0xLTEzMDc5_7081c732-262b-4726-abea-df8ce1cacdb3"
      unitRef="usd">88017319</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzEyLTEtMS0xLTEzMDc5_21d60819-1991-4b13-ad28-e59a5da85b42"
      unitRef="usd">53752353</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzEyLTMtMS0xLTEzMDc5_69d89fc3-44c5-4f10-bd2b-a9ee6be26392"
      unitRef="usd">37247828</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzEyLTUtMS0xLTEzMDc5_7186b9a3-976e-4aa2-8e26-d250bec82545"
      unitRef="usd">27203156</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE1LTEtMS0xLTEzMDc5_158b96af-ed1e-4525-bd5a-9aa1c7125e1c"
      unitRef="usd">302992677</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE1LTMtMS0xLTEzMDc5_f633836e-e70c-4538-9b60-af7f60d81903"
      unitRef="usd">131493264</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE1LTUtMS0xLTEzMDc5_451f172e-b7de-4f12-857d-2828ec48f6be"
      unitRef="usd">115220475</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE2LTEtMS0xLTEzMDc5_56c1d656-e6d0-4ffd-b629-efbef9fa6061"
      unitRef="usd">-301217919</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE2LTMtMS0xLTEzMDc5_65b22f89-01fc-4421-8612-c660691f398a"
      unitRef="usd">-124082044</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE2LTUtMS0xLTEzMDc5_80132179-1bf3-48c7-81a1-242fdc1ce51a"
      unitRef="usd">-111108545</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE4LTEtMS0xLTEzMDc5_39d36f0d-6851-433b-96ff-739b851731b2"
      unitRef="usd">3363080</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE4LTMtMS0xLTEzMDc5_cc3cf863-8eb1-494b-8aba-3ef1f51e9779"
      unitRef="usd">3311846</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE4LTUtMS0xLTEzMDc5_2f36c3c4-cc03-41f5-ab2b-c0ca3612457d"
      unitRef="usd">2605981</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE5LTEtMS0xLTEzMDc5_45a60334-2472-4044-8571-4807d3aeccca"
      unitRef="usd">1936447</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE5LTMtMS0xLTEzMDc5_e9bfdb9c-f1cc-401a-8e14-b5277892d04d"
      unitRef="usd">8702450</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzE5LTUtMS0xLTEzMDc5_38076ee7-f990-4e1a-bcef-552a89f160fc"
      unitRef="usd">7948539</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIxLTEtMS0xLTEzMDc5_f4524e3a-08a1-4131-a11e-09fdb6274b1d"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIxLTMtMS0xLTEzMDc5_36e88b32-7550-4247-87f4-e6a4ad7b8fe8"
      unitRef="usd">-75670977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIxLTUtMS0xLTEzMDc5_5124fe33-5d44-4de7-9b9f-31f08c5cc440"
      unitRef="usd">-1763652</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIyLTEtMS0xLTEzMDc5_05c2176b-1c45-4f13-9e57-4da45785ea07"
      unitRef="usd">-553570</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIyLTMtMS0xLTEzMDc5_48b65a14-47bd-414a-b31a-e7f254af7c6c"
      unitRef="usd">36556658</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIyLTUtMS0xLTEzMDc5_5a41cef4-98b0-4a9b-a2bb-b409a79e9d0f"
      unitRef="usd">-3090557</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIzLTEtMS0xLTEzMDc5_7386d331-f1c5-4b57-bdf8-bf601710062d"
      unitRef="usd">-3222838</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIzLTMtMS0xLTEzMDc5_a8eb97cf-997d-4854-95ee-5133dea73a3f"
      unitRef="usd">1695497</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzIzLTUtMS0xLTEzMDc5_92dca74d-e09b-472d-b806-0b86e7365272"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI0LTEtMS0xLTEzMDc5_61906a26-f5f9-4e21-b1c8-ce213372a480"
      unitRef="usd">343371</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI0LTMtMS0xLTEzMDc5_0dc6b938-d0e3-4026-91f2-10003cdd46bc"
      unitRef="usd">-704896</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI0LTUtMS0xLTEzMDc5_066e2d36-3947-441a-a527-2408523c6962"
      unitRef="usd">496200</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI1LTEtMS0xLTEzMDc5_702bff14-f2a3-4cee-963d-9af3efdc3285"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI1LTMtMS0xLTEzMDc5_04211f76-af9e-411d-9196-a99af564c9b0"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI1LTUtMS0xLTEzMDc5_d8fa3c97-5b48-4a99-95e6-cdae23b47876"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iafe285a056e84e7690752bb6bae44144_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI2LTEtMS0xLTEzMDc5_41d73eae-b168-448a-bad9-9f5010bd7e25"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i411612102a3e4c9e911d58c817263069_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI2LTMtMS0xLTEzMDc5_652d93cc-4c71-4682-80dc-46009fdb6b8d"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i40d1df5b1c5b4cc3b96a485c772c8fc7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI2LTUtMS0xLTEzMDc5_83779823-cb57-4bb5-b8ed-2ca5dbf1b00d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib319c6f186cc48f394c757bf041fbc05_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI3LTEtMS0xLTEzMDc5_fc892cc0-6f64-44ef-adf5-46551cb6e999"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI3LTMtMS0xLTEzMDc5_78504ff7-3c24-47f1-9856-09357476738b"
      unitRef="usd">8762030</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id00acd8f0e9248db874b93cb6b3eb23a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI3LTUtMS0xLTEzMDc5_8c965b26-0278-4b74-b6d4-27633f7053cb"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI4LTEtMS0xLTEzMDc5_36f66860-81ee-45bc-81b7-720dfd3509ab"
      unitRef="usd">-303224323</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI4LTMtMS0xLTEzMDc5_f71558f9-6bd3-4e84-b13c-1cddf6318792"
      unitRef="usd">-162890304</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI4LTUtMS0xLTEzMDc5_21a34a1f-f983-4234-b0b0-a9d2cad78e01"
      unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI5LTEtMS0xLTEzMDc5_334c485e-2aa1-498c-98f0-c0ee79eebf05"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI5LTMtMS0xLTEzMDc5_f3dbacca-74d4-479a-87b6-2889da38a5f5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzI5LTUtMS0xLTEzMDc5_54e10ba2-4a5e-40ee-9189-5353070b5c40"
      unitRef="usd">-257335</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMwLTEtMS0xLTEzMDc5_470e614f-2832-40c9-b806-7b99d7d88fa8"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMwLTMtMS0xLTEzMDc5_5f4da069-21e3-4ab5-a828-b5ae430e14cc"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMwLTUtMS0xLTEzMDc5_90390f9f-e3ba-4ae0-a891-02b8fb12fc82"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMxLTEtMS0xLTEzMDc5_968f648a-088f-4ff2-a513-dce5e864cf0c"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMxLTMtMS0xLTEzMDc5_c99f6566-0229-4530-96f4-177519e4b07c"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMxLTUtMS0xLTEzMDc5_4fff3d64-c4c6-4278-a9f9-bce7fa2e459d"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMyLTEtMS0xLTEzMDc5_7de85d60-1bae-4ccd-a52d-56f1a47806bd"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMyLTMtMS0xLTEzMDc5_a5460dd8-c13b-4e99-a702-57e4be06eb89"
      unitRef="usd">-1063757</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMyLTUtMS0xLTEzMDc5_25020c43-f2fb-4cf7-b9df-c98cdc00247f"
      unitRef="usd">-1192558</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMzLTEtMS0xLTEzMDc5_457ccdf4-5e04-4c96-9a1d-aa513df791d7"
      unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMzLTMtMS0xLTEzMDc5_2ac17756-8249-4721-a011-a6ca348246b9"
      unitRef="usd">-166411157</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzMzLTUtMS0xLTEzMDc5_0d76f51f-fed7-427f-8f2a-b127bbf78843"
      unitRef="usd">-119359219</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTEtMS0xLTEzMDc5_58bc7676-2a5d-446c-9966-a65d6affe243"
      unitRef="usdPerShare">-1.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTEtMS0xLTEzMDc5_e9b1d62e-b6c3-4e0a-ae5d-859622023ce9"
      unitRef="usdPerShare">-1.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTMtMS0xLTEzMDc5_0460868f-30cc-4d1c-a746-d378ce994a99"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTMtMS0xLTEzMDc5_a766b946-257a-48e4-9e58-cdf9cb9fab64"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTUtMS0xLTEzMDc5_5d72c847-77d6-451d-b87a-4f4b3e0b6752"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM1LTUtMS0xLTEzMDc5_f65541e8-e252-4fdb-8282-efc198818062"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTEtMS0xLTEzMDc5_b4881f4b-c928-4acf-b1ea-59fba2d3e1d1"
      unitRef="shares">208829801</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTEtMS0xLTEzMDc5_b4a21adb-74cf-46f2-9380-02f1021fa434"
      unitRef="shares">208829801</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTMtMS0xLTEzMDc5_3dca35c6-770d-4b9a-9e24-7b1d463308a4"
      unitRef="shares">155126857</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTMtMS0xLTEzMDc5_91bf1802-8156-4ec0-bf62-d5e476e38f01"
      unitRef="shares">155126857</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTUtMS0xLTEzMDc5_591c67fb-ad93-401e-b2ee-7dd3f9767bbc"
      unitRef="shares">98717999</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMTgvZnJhZzo0ZjZmMjc5MTdkYWY0NDY3YTg1ZTkzNWQ3ZmI4ZDBmMS90YWJsZTpmODliMTRhY2IwYTI0MmNjOGE1ZWU4MWM5YjIyZTNkMi90YWJsZXJhbmdlOmY4OWIxNGFjYjBhMjQyY2M4YTVlZTgxYzliMjJlM2QyXzM4LTUtMS0xLTEzMDc5_910ea4fd-699f-45aa-9e4a-77679ce8f77f"
      unitRef="shares">98717999</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzItMS0xLTEtMTMwNzk_18300cfa-81d6-4f3a-b26a-9e10bff7e2f2"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzItMy0xLTEtMTMwNzk_c2b55eeb-a642-40bf-b032-473a0bfdb248"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzItNS0xLTEtMTMwNzk_413b70bf-5d48-4172-8f71-f3f94b7b9a69"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzUtMS0xLTEtMTMwNzk_b7c044b1-2f50-4392-aa6b-92223ac04dd5"
      unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzUtMy0xLTEtMTMwNzk_515536e1-ba28-4053-af57-5e4d3519322f"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzUtNS0xLTEtMTMwNzk_05f0c623-0cb3-430f-b82f-e2805fc87e71"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzYtMS0xLTEtMTMwNzk_2aa1994f-ebac-4116-812d-99b7a99be5ce"
      unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzYtMy0xLTEtMTMwNzk_d28a0ee2-4cc0-49c3-949f-205950917b1d"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzYtNS0xLTEtMTMwNzk_23de3233-d0bd-489c-96f4-66deab1af767"
      unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzctMS0xLTEtMTMwNzk_e59e1b22-7c17-4f65-84a8-5c47aceb4d59"
      unitRef="usd">-303684796</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzctMy0xLTEtMTMwNzk_5c5ecbda-c448-4ee7-a838-f8832f38eaf7"
      unitRef="usd">-168203672</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzctNS0xLTEtMTMwNzk_07726299-2d55-4521-8925-be72afc48733"
      unitRef="usd">-119550302</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzgtMS0xLTEtMTMwNzk_4dc0cbd6-197d-4f0a-a1b0-5e9fb2739f39"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzgtMy0xLTEtMTMwNzk_6685e19e-2565-44eb-9137-e3e0fa4323f6"
      unitRef="usd">-1063757</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzgtNS0xLTEtMTMwNzk_8b4d3fb9-cc02-4479-9ff1-4403d9f402b7"
      unitRef="usd">-1192558</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzktMS0xLTEtMTMwNzk_e46831c7-9c5c-4fc6-8280-a1ad95653cdf"
      unitRef="usd">-303684796</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzktMy0xLTEtMTMwNzk_c9390cbb-b324-47c4-8393-75159ee5978d"
      unitRef="usd">-167139915</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjEvZnJhZzowNjI4YTczNmZjN2E0NzM1YmE1MjliMjBkYmVkYjA1Ny90YWJsZTo3Y2JlNDE0YjlkNjY0NTc0OGJjOWU4MWU0Y2VmNGVmNS90YWJsZXJhbmdlOjdjYmU0MTRiOWQ2NjQ1NzQ4YmM5ZTgxZTRjZWY0ZWY1XzktNS0xLTEtMTMwNzk_274be3d7-9236-440c-a0b8-1b49abf94cde"
      unitRef="usd">-118357744</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i36c6f4ee12934a40a1ea728d479c1b02_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTEtMS0xLTEzMDc5_94e384e9-62a9-4c32-bb9d-bf3fc86c6b6d"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36c6f4ee12934a40a1ea728d479c1b02_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTMtMS0xLTEzMDc5_ff57598c-90db-4964-8c09-541323c1e1a6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i02a77f36ff44452d920fe5904cb46826_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTUtMS0xLTEzMDc5_cef3ab44-fe17-42c1-aabd-d1964d802e9d"
      unitRef="shares">97225810</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02a77f36ff44452d920fe5904cb46826_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTctMS0xLTEzMDc5_caedd1e0-a121-4ead-bc4c-213236d31eb9"
      unitRef="usd">97226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac56a7bfee5749ab9ef8c4fb331f0dd3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTktMS0xLTEzMDc5_191c9563-e090-402c-a4ce-c31b48708311"
      unitRef="usd">707794215</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d85a8106cf746239de37759928ef0f3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTExLTEtMS0xMzA3OQ_62bb87dd-f1b3-4111-b114-54b37732a47d"
      unitRef="usd">-620426436</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4ef69988114421e91fd39d86626a033_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTEzLTEtMS0xMzA3OQ_6c020b5d-5876-4ca3-9f91-212706c0b96a"
      unitRef="usd">-528867</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic92f9fbbfaa2469dbe870606abca1b9d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTE1LTEtMS0xMzA3OQ_c3db4bcc-f566-4c28-9051-db16322f442e"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0209f8c94d740adaa36dd67c48d6a20_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzgzLTE3LTEtMS0xMzA3OQ_6a746abf-ffd5-4d16-9fae-9d9807126506"
      unitRef="usd">87032407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTUtMS0xLTEzMDc5_6f034c1c-9841-441a-b406-ce7ee25d7050"
      unitRef="shares">3340678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTctMS0xLTEzMDc5_69c35c3c-796d-4846-afc1-4d029ddf13d0"
      unitRef="usd">3340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTktMS0xLTEzMDc5_cceaebd8-b53c-43ae-b800-6155f590573b"
      unitRef="usd">9085669</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg0LTE3LTEtMS0xMzA3OQ_d3408998-92ee-4cc5-b4ac-9cccd05818cd"
      unitRef="usd">9089009</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTUtMS0xLTEzMDc5_59067d9d-1795-472d-9767-6f6b856ea7b4"
      unitRef="shares">794546</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i30c6a383f0a5437b87c02ae0a8eeeb21_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTctMS0xLTEzMDc5_c5a02126-23c1-4218-ad4a-99498a3cd608"
      unitRef="usd">795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTktMS0xLTEzMDc5_e6a57da7-a533-4199-a385-bfffea965bab"
      unitRef="usd">-781200</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg1LTE3LTEtMS0xMzA3OQ_acf34a84-a991-4dd8-a719-bac45ee5be98"
      unitRef="usd">-780405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg2LTktMS0xLTEzMDc5_79744570-798d-4563-a496-fac6126f09d6"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg2LTE3LTEtMS0xMzA3OQ_ed0a9fbf-3dc6-4803-adda-3851ae927e7e"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic1d38fadbd1548f3b005b34d8c667ccb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg3LTktMS0xLTEzMDc5_02c81920-b852-4f2a-bd27-ab9708c3ba92"
      unitRef="usd">10795403</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg3LTE1LTEtMS0xMzA3OQ_8d47f526-ad83-4e16-9dbf-b7ea4e2f2372"
      unitRef="usd">105917</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg3LTE3LTEtMS0xMzA3OQ_4c7013d7-56ba-400a-af65-c29425e97539"
      unitRef="usd">10901320</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg4LTE1LTEtMS0xMzA3OQ_420d873c-5803-4d92-9307-2aa01c3971a9"
      unitRef="usd">2960131</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg4LTE3LTEtMS0xMzA3OQ_272d7387-5ebf-4c2b-aea3-a86ed6bc1044"
      unitRef="usd">2960131</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="if0a501ec111d47fbb2c02a92d18044b8_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg5LTExLTEtMS0xMzA3OQ_2828838e-2144-4bd2-814d-f0f7e9474382"
      unitRef="usd">-119359219</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idfc077c51e814e9f93f4baf6e4813811_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg5LTE1LTEtMS0xMzA3OQ_03c8cde0-807b-4c30-9348-dc8bcd663cf2"
      unitRef="usd">-1192558</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzg5LTE3LTEtMS0xMzA3OQ_8320f7b9-ab68-4d49-bc50-65eb029496ef"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i934d7a839de6474e9b47fe4f2dde4862_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkwLTEzLTEtMS0xMzA3OQ_17829c3f-d2a5-4b6a-8ddb-b06e4d1d1b28"
      unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkwLTE3LTEtMS0xMzA3OQ_5224f4f8-5449-4b70-b207-60cf6905d56c"
      unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="iba84c3ae05e74f7b95113a5d797a1b3e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTEtMS0xLTEzMDc5_222e65de-187d-481b-b170-06069f6f0e8b"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba84c3ae05e74f7b95113a5d797a1b3e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTMtMS0xLTEzMDc5_5f939573-4c67-48e0-921e-3ce435eaa794"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i38bba6f63c734bfb8d21fd427b61fbe7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTUtMS0xLTEzMDc5_8cd3fbf5-e980-4125-b901-ee18ad00bc64"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38bba6f63c734bfb8d21fd427b61fbe7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTctMS0xLTEzMDc5_56bf3c13-4651-40d9-97f0-ba978d4da506"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c45e9e8670742aabe1a2097889e1003_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTktMS0xLTEzMDc5_eceb4ca3-61c1-422c-b8dc-a385b97ea276"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a9737ecdffd44d1b2551cce0509fa59_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTExLTEtMS0xMzA3OQ_be38b762-3fe5-4ccb-b02a-36d76e0ad678"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12b5dcddd0d942b9afa00d1eb75fd3fc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTEzLTEtMS0xMzA3OQ_45841a98-7edd-49f6-98c8-58386a73b73a"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cada50c939e412c9ab1db2da9a0465e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTE1LTEtMS0xMzA3OQ_61e71b54-09af-460e-9701-d1a420713e5f"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkxLTE3LTEtMS0xMzA3OQ_14ac31b3-7b88-447a-8ba2-6235224cb393"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTUtMS0xLTEzMDc5_7af8defd-9b0e-458d-ba59-6f6c91fac661"
      unitRef="shares">66064886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTctMS0xLTEzMDc5_8badaf6c-a552-4426-a73d-dc6685e65f93"
      unitRef="usd">66065</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTktMS0xLTEzMDc5_5061400a-e918-4f7f-a0ef-e749cffc62de"
      unitRef="usd">454420335</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkyLTE3LTEtMS0xMzA3OQ_2e25d209-c3f7-4822-a2ad-31039058a1ea"
      unitRef="usd">454486400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iee3c8a7e151648fa9963ae445b27955e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTEtMS0xLTEzMDc5_38174794-66a2-41bb-9f97-ed9d07c3cc59"
      unitRef="shares">-14</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTUtMS0xLTEzMDc5_b71b08c1-25e9-4ea5-ba62-fe02a40e9ac6"
      unitRef="shares">5147</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTctMS0xLTEzMDc5_00222deb-8e6d-4e30-9ba2-68c88ed37de9"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTktMS0xLTEzMDc5_881273e2-acc9-469f-ba93-e8291786a084"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzkzLTE3LTEtMS0xMzA3OQ_8e4d727c-701e-46e4-a9a8-4f535a441371"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i98ad737a11be4f09bde8169850c3ab12_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTUtMS0xLTEzMDc5_4c6d6565-b809-4a3c-9cfd-ea69ba7254d6"
      unitRef="shares">11535660</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i98ad737a11be4f09bde8169850c3ab12_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTctMS0xLTEzMDc5_0514ef75-6e43-4bef-aefb-63b80a3ebf1a"
      unitRef="usd">11536</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4bd975f309a74bc9830110950e77a982_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTktMS0xLTEzMDc5_7e5a8431-1f43-4ee1-b0e6-89f5c1fe00c7"
      unitRef="usd">43682850</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk0LTE3LTEtMS0xMzA3OQ_db5c7712-58fd-4bcc-b201-aa8b7398c9ab"
      unitRef="usd">43694386</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i636993c134064180ad2590c08fa52072_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTUtMS0xLTEzMDc5_01ff68df-9f61-4914-87a8-a5655606898e"
      unitRef="shares">4962364</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i636993c134064180ad2590c08fa52072_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTctMS0xLTEzMDc5_f0ad43c0-d197-443e-883e-93a3e29a9245"
      unitRef="usd">4961</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7d08995f70474651a10b743f24c3decc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTktMS0xLTEzMDc5_e5b13658-5051-425e-9776-597e3624d7d6"
      unitRef="usd">102666349</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib6a0eee5ee74422dbf15e46a3b2632fc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk1LTE3LTEtMS0xMzA3OQ_abd351ce-9660-47bf-b687-b770c3a09962"
      unitRef="usd">102671310</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTUtMS0xLTEzMDc5_7664d697-1678-4ed3-82e1-dc8dccfba6a0"
      unitRef="shares">2922402</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1b7614fe803744729ee8a968340f18e6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTctMS0xLTEzMDc5_42b0414d-f337-48ed-8ab4-17d1fb87b7ea"
      unitRef="usd">2923</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTktMS0xLTEzMDc5_f461b43c-8cdc-4b46-9383-aadd5f672b26"
      unitRef="usd">8238701</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk2LTE3LTEtMS0xMzA3OQ_bc97f397-92e2-4417-abf4-a500f4152017"
      unitRef="usd">8241624</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk3LTktMS0xLTEzMDc5_1e76f6b2-3041-4415-b4b1-0bda196cb24c"
      unitRef="usd">15655585</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk3LTE1LTEtMS0xMzA3OQ_09559b45-171f-4484-afd5-ccff318812d2"
      unitRef="usd">-8062</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk3LTE3LTEtMS0xMzA3OQ_e9a99872-2f92-48d5-8de8-689c3e05d9cc"
      unitRef="usd">15647523</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk4LTE1LTEtMS0xMzA3OQ_ad91289d-a5fc-4762-913b-593459c29bc2"
      unitRef="usd">2379969</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk4LTE3LTEtMS0xMzA3OQ_dca4c51d-8d80-42ea-83f7-f8142df17d10"
      unitRef="usd">2379969</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk5LTE1LTEtMS0xMzA3OQ_3ded8841-0467-4d3a-8aa2-050f89d2c52b"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzk5LTE3LTEtMS0xMzA3OQ_fc29bee1-02c3-480b-b729-3eb7d1e95f4f"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="i01da3ab01f954252bc6510f0dbd029c0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMC0xMS0xLTEtMTMwNzk_ab981bec-38de-4f26-98e9-51fcee5a4ca2"
      unitRef="usd">-166411157</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMC0xNS0xLTEtMTMwNzk_86c9df0d-ff85-42ba-9eb0-c8494f41a1d2"
      unitRef="usd">-1063757</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMC0xNy0xLTEtMTMwNzk_d9a06dc8-8892-4599-8721-da53cb65d14e"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i6b91df562f874655a19dab108f20fb24_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMS05LTEtMS0xMzA3OQ_6212b1c6-2f37-43da-866e-ed62859d3fbd"
      unitRef="usd">-96269</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i39311e62d54b459ba3b0a98dd130c818_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMS0xNS0xLTEtMTMwNzk_c685ffc9-e692-4067-ae43-fcc3e35c1560"
      unitRef="usd">96269</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMS0xNy0xLTEtMTMwNzk_5d303c60-68a0-46f9-9007-ab29155453d0"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iceb449b556844657b6e6671a8579fde4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMi0xMy0xLTEtMTMwNzk_98321154-076a-4de1-aafe-85fc78ed0d14"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMi0xNy0xLTEtMTMwNzk_998b17b0-c264-40ef-89d4-47c42d3074d9"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iceb449b556844657b6e6671a8579fde4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMy0xMy0xLTEtMTMwNzk_21e4e689-07b6-452c-bbe4-f26c3e5ba84f"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwMy0xNy0xLTEtMTMwNzk_5c7b1ddd-18ab-4014-9555-74ae4e681833"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i2c72b6e9e8eb4b8ea4fdb38d60151ad5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xLTEtMS0xMzA3OQ_9a7818e7-9d80-416d-9606-cae144525a29"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c72b6e9e8eb4b8ea4fdb38d60151ad5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0zLTEtMS0xMzA3OQ_033aa943-82b2-4d5f-b1ae-13b382cf40e8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ib722279b8997488c897a37f118e63061_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC01LTEtMS0xMzA3OQ_9ed6bc27-cb11-4834-ac26-ef0c9402a37c"
      unitRef="shares">186851493</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib722279b8997488c897a37f118e63061_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC03LTEtMS0xMzA3OQ_a489d9bd-cd68-4c66-ad34-00125eadf73b"
      unitRef="usd">186851</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if11f8a3ab55d49a8bb586876044a035e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC05LTEtMS0xMzA3OQ_ae02a2b8-1234-48fc-8faa-68e22c28dcf5"
      unitRef="usd">1367406869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i019963c050f847419c1846c58634267e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xMS0xLTEtMTMwNzk_2028754f-1f48-4274-b3d9-242b42cdac4f"
      unitRef="usd">-906196812</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f5e9f8d356d417887e0a2ce250b61f5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xMy0xLTEtMTMwNzk_f588d13b-cda6-4baf-b5ce-b22692ee0f92"
      unitRef="usd">-256150</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c5137421a60479cb080a26e2eb6d08c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xNS0xLTEtMTMwNzk_76c214fb-db0a-48d6-bb6c-a785a1384a5c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNC0xNy0xLTEtMTMwNzk_696cf5a0-d99b-4bcf-9e1f-5ccb8adfa1e7"
      unitRef="usd">461140758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS01LTEtMS0xMzY4MA_463b58d5-1ca6-4b7d-96a9-907324038b29"
      unitRef="shares">27310341</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS03LTEtMS0xMzY4MA_4a65c3bb-5adf-4786-8562-8b10b6042b7e"
      unitRef="usd">27310</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3f35c89987a74786896285ad7ae13979_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS05LTEtMS0xMzY4MA_4e58ddca-4f2c-419a-8325-2edaefa49ab6"
      unitRef="usd">209414100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNS0xNy0xLTEtMTM2ODA_40c6129b-e78c-4658-9671-2730e0c93eb0"
      unitRef="usd">209441410</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i13876df5a7d44b1a938e8ee19872763d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi01LTEtMS0xMzY4MA_0c8d3307-6d7b-4909-b532-268914b21862"
      unitRef="shares">1009450</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i13876df5a7d44b1a938e8ee19872763d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi03LTEtMS0xMzY4MA_f37b03c4-1e09-425a-b673-92295ef7b364"
      unitRef="usd">1009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie453dc0fe621472f991c3336fea7f4cb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi05LTEtMS0xMzY4MA_6f68b860-bc3e-483e-a25c-008d5b93b361"
      unitRef="usd">4376883</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic2aed4a0d2c3496d81638d7203fff95f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNi0xNy0xLTEtMTM2ODA_68dd05c5-7f8a-420c-8eb1-401ad8934061"
      unitRef="usd">4377892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy01LTEtMS0xMzY4MA_8b329dd4-f62a-4f2d-9d1f-f70f543da61c"
      unitRef="shares">2211603</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i069d23b4b11149cb973e52cbba2dd7f3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy03LTEtMS0xMzY4MA_0de21051-aa29-447b-8a4a-a73dae440fab"
      unitRef="usd">2212</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3f35c89987a74786896285ad7ae13979_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy05LTEtMS0xMzY4MA_786de3bc-72c7-490c-a854-2fdf1c8c055e"
      unitRef="usd">2055181</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwNy0xNy0xLTEtMTM2ODA_3fd07372-2a76-4c45-96f8-ee4a6586d461"
      unitRef="usd">2057393</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3f35c89987a74786896285ad7ae13979_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOC05LTEtMS0xMzY4MA_d6c97d5b-c11b-4866-9fbd-a69d6e8ca6b2"
      unitRef="usd">26336764</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idcee4832a056439890bc22cca53ebf0a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOC0xNS0xLTEtMTM2ODA_9c643418-35fe-4af3-a300-99380ef369d7"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOC0xNy0xLTEtMTM2ODA_073d3e85-059e-4619-b728-352d014bb3cd"
      unitRef="usd">26336764</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i755387a3bd2040869919d38bac155975_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOS0xMS0xLTEtMTM2ODA_cb7bb454-e693-4318-bdba-9748182e7c3b"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idcee4832a056439890bc22cca53ebf0a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOS0xNS0xLTEtMTM2ODA_890b773c-c703-43ef-83f7-17613dffaadc"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzEwOS0xNy0xLTEtMTM2ODA_4f9ace36-abc4-4ae7-b26d-b65628d56ad9"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id5f38759d4c94c9c9f578011dc9fc2d9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMC0xMy0xLTEtMTM2ODA_0649d123-97e7-4e71-acba-066455f20084"
      unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMC0xNy0xLTEtMTM2ODA_038d901c-4e10-4034-9c21-45ccab12fe9a"
      unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id5f38759d4c94c9c9f578011dc9fc2d9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMS0xMy0xLTEtMTM2ODA_71d53824-0cf6-4cdc-91a4-b71543cb4c24"
      unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMS0xNy0xLTEtMTM2ODA_b000bcf5-a4b4-4515-ab1d-4b5002c5f9a7"
      unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="if64e7bfdf2294cae86cf31ff7714dac5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xLTEtMS0xMzY4MA_30beb8bb-244c-43b0-b4b2-6f828a245709"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if64e7bfdf2294cae86cf31ff7714dac5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0zLTEtMS0xMzY4MA_6c4f11ac-174c-4ddb-8bf3-9eb7c351993b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i1d91dffb8ff14276905969cb9451fbd4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi01LTEtMS0xMzY4MA_9923f90d-3492-4444-a519-9f4cfa528eb8"
      unitRef="shares">217382887</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d91dffb8ff14276905969cb9451fbd4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi03LTEtMS0xMzY4MA_53c012ce-37ec-42c7-9b43-c6e1385a5ba2"
      unitRef="usd">217382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i416413e6f44e49bf9af9f5ca9c4a9d19_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi05LTEtMS0xMzY4MA_0a130e80-4591-4b3a-a9ae-aca2ee6db192"
      unitRef="usd">1609589797</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i386a00e8a13746fa9abf8ea15747827d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xMS0xLTEtMTM2ODA_d69beacd-b54e-492b-b3c7-b700a73864d8"
      unitRef="usd">-1209855522</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3348c69519f04942adeb29a5daf412ac_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xMy0xLTEtMTM2ODA_6d927326-9f85-4bbe-a5a1-524777a2ab31"
      unitRef="usd">-282236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic404b3bf911d46e48fef168a1506f7d1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xNS0xLTEtMTM2ODA_4042e617-76e5-4d65-80ca-e544f739f138"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjQvZnJhZzo3MmUwMmZmNDA4NWQ0MGE4OTJiYjkwMWQ0YmY1ZmJlMi90YWJsZTo2NGM2ZWUyYzBhNmM0NmIxYmFlNzI0NDhlYTE2YmI2My90YWJsZXJhbmdlOjY0YzZlZTJjMGE2YzQ2YjFiYWU3MjQ0OGVhMTZiYjYzXzExMi0xNy0xLTEtMTM2ODA_11acfeca-4e7f-4577-abf6-7f41c653c1ed"
      unitRef="usd">399669421</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMtMS0xLTEtMTMwNzk_9c793b06-62b3-4f23-a3da-e9331ebd1ce7"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMtMy0xLTEtMTMwNzk_8e80ba74-1cc3-4452-965e-4af6743026f0"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMtNS0xLTEtMTMwNzk_6e824d16-7feb-4fe3-a45d-b04a54a68495"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUtMS0xLTEtMTMwNzk_fab2decd-536d-465c-a869-13428ca3298b"
      unitRef="usd">3040096</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUtMy0xLTEtMTMwNzk_6f510c7c-aa3e-41ea-9801-d4bc898a783c"
      unitRef="usd">3038996</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUtNS0xLTEtMTMwNzk_1b27fa0a-8756-4163-a183-ee0a4d7494d8"
      unitRef="usd">3598388</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYtMS0xLTEtMTMwNzk_3bd9f2dc-b872-4008-9141-82494b95e044"
      unitRef="usd">520415</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYtMy0xLTEtMTMwNzk_d082fe67-2c2a-430c-af9a-d55926ccd376"
      unitRef="usd">547081</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYtNS0xLTEtMTMwNzk_aeecc233-130f-4299-9d51-c866c783acff"
      unitRef="usd">1066294</us-gaap:AmortizationOfIntangibleAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzctMS0xLTEtMTMwNzk_c835c1dd-f8ff-4fcd-9c07-02b873142c82"
      unitRef="usd">1170270</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzctMy0xLTEtMTMwNzk_1013137a-8954-491f-b302-4bc460248641"
      unitRef="usd">1041713</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzctNS0xLTEtMTMwNzk_d9946a4e-5b6e-496c-81b0-f84792e2aadd"
      unitRef="usd">851760</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzktMS0xLTEtMTMwNzk_b37c4053-92cf-4b1a-9377-37024b9ad973"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzktMy0xLTEtMTMwNzk_2cac3514-86d8-4142-b173-71bdbb518856"
      unitRef="usd">75670977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzktNS0xLTEtMTMwNzk_e09b4121-010a-451c-a3fe-54ca50bfe427"
      unitRef="usd">1763652</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzExLTEtMS0xLTEzMDc5_20d29bc8-2965-4124-87ef-439bfafeaf1d"
      unitRef="usd">26336764</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzExLTMtMS0xLTEzMDc5_ec9f5a2d-0204-4277-8b2b-3f394efe7bc2"
      unitRef="usd">15647523</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzExLTUtMS0xLTEzMDc5_9f7110a9-fcb2-40fc-9f1b-7bcd0d305577"
      unitRef="usd">10901320</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestExpense
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEyLTEtMS0xLTEzMDc5_28dbc904-fe56-4b06-a5a2-48be37c71537"
      unitRef="usd">858644</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEyLTMtMS0xLTEzMDc5_37a68eba-a60d-4701-bd12-010a00db1161"
      unitRef="usd">4077686</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEyLTUtMS0xLTEzMDc5_06e61952-8bef-47a0-bab1-100bf94c2eaa"
      unitRef="usd">5230954</ino:NonCashInterestExpense>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEzLTEtMS0xLTEzMDc5_b51a8215-05a7-47e1-845e-1074add96da4"
      unitRef="usd">1633286</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEzLTMtMS0xLTEzMDc5_98a2dfc5-465a-4bec-89ce-df78815f2367"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzEzLTUtMS0xLTEzMDc5_42e597ea-22c4-457d-8370-289d677bf1eb"
      unitRef="usd">1962</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE1LTEtMS0xLTEzMDc5_6011391d-7475-4a5a-b43e-d910d050facd"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE1LTMtMS0xLTEzMDc5_de466f6e-8dc1-4f67-8ada-a9912e7e6557"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE1LTUtMS0xLTEzMDc5_52971d60-a22f-4a6b-ae62-104c2face96f"
      unitRef="usd">-5397</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE4LTEtMS0xLTEzMDc5_f862feb0-8feb-448c-b9e6-54f8e2a80fea"
      unitRef="usd">-5397</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE4LTMtMS0xLTEzMDc5_c6cfb47b-0be6-46fe-9f80-4d065fee9ab6"
      unitRef="usd">-588270</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE4LTUtMS0xLTEzMDc5_3190f4a9-be0b-4730-af63-7c116441408d"
      unitRef="usd">476368</us-gaap:GainLossOnSaleOfOtherInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE5LTEtMS0xLTEzMDc5_78abfc15-a5ac-4246-87f2-427275d08e3c"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE5LTMtMS0xLTEzMDc5_acde1310-cfed-441b-b042-5cf4c47ababd"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzE5LTUtMS0xLTEzMDc5_635a1841-338c-42f8-8b69-aeee36d749d3"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIwLTEtMS0xLTEzMDc5_f483ecfa-6f02-4a98-9e2f-6ad8e51c6964"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIwLTMtMS0xLTEzMDc5_56336769-684e-46fb-8ab1-a27645f96a60"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIwLTUtMS0xLTEzMDc5_88d5639d-7793-4d7c-9ffc-c527568a39c8"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIxLTEtMS0xLTEzMDc5_836ce064-d337-4f70-acf5-c73162431958"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIxLTMtMS0xLTEzMDc5_245e3bfe-d67c-4a49-b702-b932c0be8ea4"
      unitRef="usd">-26913</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIxLTUtMS0xLTEzMDc5_cb69c731-a6ec-4976-8fb7-2aa2f87147bf"
      unitRef="usd">-5889</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIyLTEtMS0xLTEzMDc5_a1cab045-4352-4f5b-be27-80eee6d6a950"
      unitRef="usd">-553570</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIyLTMtMS0xLTEzMDc5_88b44acd-be76-4f06-a8f7-46aee3c7a34a"
      unitRef="usd">36556658</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIyLTUtMS0xLTEzMDc5_fb011310-da22-4f9b-b086-3fe21fb4c5a4"
      unitRef="usd">-3090557</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIzLTEtMS0xLTEzMDc5_da4e9da7-ff10-46f4-82bf-71fc82289458"
      unitRef="usd">-434387</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIzLTMtMS0xLTEzMDc5_31d04ac0-5616-41dc-be8c-89e4e078ce02"
      unitRef="usd">-4584610</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzIzLTUtMS0xLTEzMDc5_101d1df4-be62-4634-9ac7-3d78c69f3331"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic2aed4a0d2c3496d81638d7203fff95f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI0LTEtMS0xLTEzMDc5_41cd9362-1785-4a51-9858-a447a80b3711"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib6a0eee5ee74422dbf15e46a3b2632fc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI0LTMtMS0xLTEzMDc5_0387913a-b4b6-4464-ba3d-3db860d1a077"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3cbb09860a3f4b019d6e6f2db9a0996b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI0LTUtMS0xLTEzMDc5_bc0cb04e-0211-49dd-b7a6-f5d05cbbf45f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib319c6f186cc48f394c757bf041fbc05_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI1LTEtMS0xLTEzMDc5_ba6909de-7e66-4ec4-ac1c-10cb9f541522"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i549364b8c5334f4894b5f42ad3c81222_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI1LTMtMS0xLTEzMDc5_5e0055e6-4710-46ca-9af9-471264fddbed"
      unitRef="usd">8762030</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id00acd8f0e9248db874b93cb6b3eb23a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI1LTUtMS0xLTEzMDc5_36ea4104-cb64-4467-a9d2-f1c6fc367fb2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI2LTEtMS0xLTEzMDc5_e452529c-1c12-4008-b5f1-23ffbc102aa7"
      unitRef="usd">-3222838</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI2LTMtMS0xLTEzMDc5_ac87d7a9-dd14-4d34-9b3b-7571fe24c655"
      unitRef="usd">1695497</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI2LTUtMS0xLTEzMDc5_f2030ccb-f848-4c4d-8870-76c882a33d5e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI3LTEtMS0xLTEzMDc5_0eb26d45-bad5-4938-88ac-3659b916e485"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI3LTMtMS0xLTEzMDc5_6321484f-7e68-4b9f-91ab-1f16e0092bbd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI3LTUtMS0xLTEzMDc5_43be4500-b5cf-42ed-b5bf-5019041d3c2f"
      unitRef="usd">-266215</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI4LTEtMS0xLTEzMDc5_a8748968-0182-4431-b477-7099ba2f9e35"
      unitRef="usd">176927</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI4LTMtMS0xLTEzMDc5_50725b1c-1998-47a6-abae-55369e3cbc8f"
      unitRef="usd">-15902</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzI4LTUtMS0xLTEzMDc5_ee318d3d-8a1a-4e92-adb3-23c415368e7f"
      unitRef="usd">-471172</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMwLTEtMS0xLTEzMDc5_12208846-7178-426a-b42a-006a03abc73d"
      unitRef="usd">-13093117</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMwLTMtMS0xLTEzMDc5_41122633-6020-44a5-8a5a-bf2b53267f0e"
      unitRef="usd">17859894</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMwLTUtMS0xLTEzMDc5_d5b7e338-7504-4a1a-8aea-c9a2efd85175"
      unitRef="usd">-2616288</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMxLTEtMS0xLTEzMDc5_25761609-f21a-4aca-9bce-f44c1dec59e8"
      unitRef="usd">2061412</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMxLTMtMS0xLTEzMDc5_eb03c9f2-ca20-47d6-95d4-9bdb647f81a8"
      unitRef="usd">-844423</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMxLTUtMS0xLTEzMDc5_42534321-b072-4a13-8de3-b161767c7d55"
      unitRef="usd">593461</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMyLTEtMS0xLTEzMDc5_7dedf7d8-60a6-49cd-947f-86fff1a81dec"
      unitRef="usd">6188872</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMyLTMtMS0xLTEzMDc5_912910a6-e19f-4ee5-ace3-5a10a5d4fadd"
      unitRef="usd">38849572</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMyLTUtMS0xLTEzMDc5_4093b412-1a31-49c7-aad7-6f3aca9b9c89"
      unitRef="usd">178008</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMzLTEtMS0xLTEzMDc5_a77dad24-64a2-43d2-b4e0-1ab4e4ee70d4"
      unitRef="usd">154760</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMzLTMtMS0xLTEzMDc5_78067fb6-9cf1-4263-8aac-4dc0a6858977"
      unitRef="usd">-374107</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzMzLTUtMS0xLTEzMDc5_b168dad9-246b-4081-9a13-b3678e7f8249"
      unitRef="usd">-70665</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM1LTEtMS0xLTEzMDc5_686ae1a6-2655-4a8f-96df-bacc994c96bd"
      unitRef="usd">-24531654</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM1LTMtMS0xLTEzMDc5_e509d62a-fffc-4f1f-8799-1c1cb6724e95"
      unitRef="usd">23285424</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM1LTUtMS0xLTEzMDc5_b7c53faf-a8df-47a8-85a8-1c6a3a5c5df9"
      unitRef="usd">2026</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM2LTEtMS0xLTEzMDc5_196afeb8-214e-49f7-aee7-a006302f61de"
      unitRef="usd">26235907</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM2LTMtMS0xLTEzMDc5_692d21b6-5d4e-4ec4-a6dd-365379a08f7e"
      unitRef="usd">3115828</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM2LTUtMS0xLTEzMDc5_0ea74c1a-9c86-46a2-a275-846b63b96a13"
      unitRef="usd">-4337829</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM3LTEtMS0xLTEzMDc5_bff4de95-6f14-4e79-8a73-88f06806e623"
      unitRef="usd">375921</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM3LTMtMS0xLTEzMDc5_abf25c70-ce57-439b-ac34-4a6978d21c2b"
      unitRef="usd">5962381</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM3LTUtMS0xLTEzMDc5_62514984-1260-4328-8233-46a74b1aa2f6"
      unitRef="usd">-1622037</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM4LTEtMS0xLTEzMDc5_12367082-31d4-4ea0-93ea-dfd757932f89"
      unitRef="usd">-94937</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM4LTMtMS0xLTEzMDc5_8d33424b-5c0c-4ad1-867d-45628b69c9cc"
      unitRef="usd">135650</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM4LTUtMS0xLTEzMDc5_91e1393d-6570-43cb-8255-0d8e36e05acb"
      unitRef="usd">-248063</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM5LTEtMS0xLTEzMDc5_659c3d9b-376a-4a96-9ff7-53be76a8cb38"
      unitRef="usd">-39853</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM5LTMtMS0xLTEzMDc5_cf6e0a26-2b48-4559-bb89-a6dc3aa2b806"
      unitRef="usd">-68078</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzM5LTUtMS0xLTEzMDc5_c5b01ca7-5cca-45c4-8f61-5bb12850823b"
      unitRef="usd">-180450</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQwLTEtMS0xLTEzMDc5_3b053406-0eec-4706-9bf5-e9ab5453e302"
      unitRef="usd">0</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQwLTMtMS0xLTEzMDc5_28edd639-edb8-4ebf-9d6c-37037c947a2c"
      unitRef="usd">5725</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQwLTUtMS0xLTEzMDc5_ed7b1f94-c8b9-4927-bfdc-db2cb2cb3c94"
      unitRef="usd">-1800</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQyLTEtMS0xLTEzMDc5_aea4d04f-d855-41dd-b6dc-ba48686de627"
      unitRef="usd">-2329394</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQyLTMtMS0xLTEzMDc5_84e15327-cd84-4f69-ae88-dd0f8440657d"
      unitRef="usd">-2091855</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQyLTUtMS0xLTEzMDc5_f56335da-4753-47bb-b968-3bd07a666842"
      unitRef="usd">-1733599</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQzLTEtMS0xLTEzMDc5_f4253e26-7075-42fd-8e21-1ff74a8bb9c1"
      unitRef="usd">-2914589</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQzLTMtMS0xLTEzMDc5_759a9069-b1b5-4fcb-a9ae-d4abce89532c"
      unitRef="usd">1409098</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQzLTUtMS0xLTEzMDc5_a674bbb7-6ea1-414f-972e-16c3b5dd914a"
      unitRef="usd">1899364</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ0LTEtMS0xLTEzMDc5_dcb736c0-4f95-47c5-b227-01104615f25b"
      unitRef="usd">-58500</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ0LTMtMS0xLTEzMDc5_4667bd6b-a880-4374-a9d8-18ced0954ed5"
      unitRef="usd">-784925</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ0LTUtMS0xLTEzMDc5_2f5fdac5-cbd2-4ebe-ab01-11e99bd87014"
      unitRef="usd">816342</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ1LTEtMS0xLTEzMDc5_7ae6790c-7bbc-4a98-9ed2-72350b9e9adc"
      unitRef="usd">-42837</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ1LTMtMS0xLTEzMDc5_1302f98c-040e-4b23-bb45-b05ff2a136b0"
      unitRef="usd">20720</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ1LTUtMS0xLTEzMDc5_57c3d169-4a92-4eeb-a4ba-d76a123ecd26"
      unitRef="usd">-48507</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ2LTEtMS0xLTEzMDc5_eea1f715-ce12-42aa-a02b-8ff7eaae931f"
      unitRef="usd">-215708525</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ2LTMtMS0xLTEzMDc5_616b69a8-1998-427e-b518-ff7f6323997b"
      unitRef="usd">-177979046</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ2LTUtMS0xLTEzMDc5_f188878a-dd46-4f18-94e9-c708b08ba065"
      unitRef="usd">-97850136</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ4LTEtMS0xLTEzMDc5_72bb8c52-9033-40de-a46a-01cb8e92c7f3"
      unitRef="usd">348953236</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ4LTMtMS0xLTEzMDc5_656adc18-62de-4573-a215-609456a4d95b"
      unitRef="usd">156216677</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ4LTUtMS0xLTEzMDc5_4f55c30c-6e26-434e-b262-00db7944b6eb"
      unitRef="usd">100950301</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ5LTEtMS0xLTEzMDc5_463c5d1e-259c-4007-95f3-19f2d451b9b1"
      unitRef="usd">174839758</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ5LTMtMS0xLTEzMDc5_105d075a-51aa-433f-9f9d-044bc5a0a8e3"
      unitRef="usd">62991023</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzQ5LTUtMS0xLTEzMDc5_f5567ace-644d-4f23-8b6d-89858d6e3aee"
      unitRef="usd">92893232</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUwLTEtMS0xLTEzMDc5_ec452f9f-4d70-470c-bd5a-9bfe97c7e590"
      unitRef="usd">1231006</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUwLTMtMS0xLTEzMDc5_2e3496db-8631-4354-9f3b-96118964a6f5"
      unitRef="usd">1520665</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUwLTUtMS0xLTEzMDc5_8d014997-a17b-4338-a144-75087c36249b"
      unitRef="usd">987926</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUxLTEtMS0xLTEzMDc5_8f746e7a-9bc3-4ff0-b706-406f3eb6c1c3"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUxLTMtMS0xLTEzMDc5_1dfe871d-e44d-4dd1-9997-4f4df9768f17"
      unitRef="usd">40125418</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUxLTUtMS0xLTEzMDc5_77a6a8f8-d34a-434f-8a88-cf6bddaaaa64"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUyLTEtMS0xLTEzMDc5_663855cb-42c7-4e74-ba7c-fb983be0dbab"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUyLTMtMS0xLTEzMDc5_b1845fd6-a1a4-4ac8-9fda-9a0634520e08"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUyLTUtMS0xLTEzMDc5_688b9b52-135c-4044-bda3-ad3649395c2c"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUzLTEtMS0xLTEzMDc5_1d1496d1-fd8c-408a-9649-086ba05b7c5a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUzLTMtMS0xLTEzMDc5_cd1bd62e-2614-4fb5-a58c-fdc72dad4672"
      unitRef="usd">1399999</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzUzLTUtMS0xLTEzMDc5_82c156d8-b9ec-4f52-b516-ffe88d764b46"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU1LTEtMS0xLTEzMDc5_81e572be-0328-4917-8003-1a803adf7e58"
      unitRef="usd">-175344484</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU1LTMtMS0xLTEzMDc5_fa636975-2757-406c-bcf1-cc607ec3be2f"
      unitRef="usd">-58795751</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU1LTUtMS0xLTEzMDc5_144b3de5-e591-433e-a658-0a1a0c608b3e"
      unitRef="usd">-9044995</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU3LTEtMS0xLTEzMDc5_f3504f33-ea41-4eff-8384-ed7c39e31652"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU3LTMtMS0xLTEzMDc5_a6404b99-2c0a-4ff7-89f8-8769b3327af4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU3LTUtMS0xLTEzMDc5_245ecec5-bf4b-4b69-8c20-97f571d14a9a"
      unitRef="usd">97443617</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU4LTEtMS0xLTEzMDc5_9fa07ac7-1cd4-4fbe-8a10-786a804f9c1f"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU4LTMtMS0xLTEzMDc5_e0f5013a-af5b-4526-a417-2373a4c4d023"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU4LTUtMS0xLTEzMDc5_3dca36f9-da7b-4eca-a95f-f013e2001832"
      unitRef="usd">3314757</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU5LTEtMS0xLTEzMDc5_9b7e9692-ced4-47a2-ba8e-df97ce12cc44"
      unitRef="usd">209441410</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU5LTMtMS0xLTEzMDc5_016188c3-a292-4805-886c-0fc672f16ace"
      unitRef="usd">454486400</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzU5LTUtMS0xLTEzMDc5_ae15a57e-9431-40ca-8edf-d0d58ab224ad"
      unitRef="usd">9089010</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYwLTEtMS0xLTEzMDc5_34808601-bb3f-4e0c-89cb-6df23e37648c"
      unitRef="usd">6668741</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYwLTMtMS0xLTEzMDc5_f5c8176c-6e28-4734-a518-1e4d490e7ce2"
      unitRef="usd">12269801</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYwLTUtMS0xLTEzMDc5_00fbbacb-68ff-4ab6-8250-f1958e2f9c55"
      unitRef="usd">112522</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYxLTEtMS0xLTEzMDc5_7b4b05ef-a47f-4fcb-92b5-81fce0c32f83"
      unitRef="usd">-4611348</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYxLTMtMS0xLTEzMDc5_2e65332c-d37b-43c4-b353-3ace20584559"
      unitRef="usd">-4028177</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYxLTUtMS0xLTEzMDc5_b3be5d89-5163-4da5-8cd1-9814a50301c3"
      unitRef="usd">-892928</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYyLTEtMS0xLTEzMDc5_8a96dc1a-07c6-4dc0-8fb0-e678577f5a00"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYyLTMtMS0xLTEzMDc5_595d8892-16d5-4b9e-8cf6-456fb8ecf2c9"
      unitRef="usd">2379969</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYyLTUtMS0xLTEzMDc5_c95b976b-6d5f-43f4-afcc-7f6e79bc1c64"
      unitRef="usd">2960131</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYzLTEtMS0xLTEzMDc5_1d0c4c6f-f09d-4249-a877-25a51e2ea432"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYzLTMtMS0xLTEzMDc5_98d216e9-a0bc-4cbd-9e72-5b252929eb64"
      unitRef="usd">171620</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzYzLTUtMS0xLTEzMDc5_1bfd7876-e428-402c-bbd6-2a2f376ad5cb"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY0LTEtMS0xLTEzMDc5_8b330cb5-9964-4ea1-b44e-dbac4edfb98c"
      unitRef="usd">211498803</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY0LTMtMS0xLTEzMDc5_e0b994c3-28da-4019-baa5-15ebac4c5002"
      unitRef="usd">465279613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY0LTUtMS0xLTEzMDc5_c72c63e9-fc2f-4e08-9b7f-f53a01a4789a"
      unitRef="usd">105397595</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY1LTEtMS0xLTEzMDc5_76813332-d436-4359-a268-d191265a62bc"
      unitRef="usd">-30134</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY1LTMtMS0xLTEzMDc5_89a2684f-476c-43ec-aaa1-f0c78f10e836"
      unitRef="usd">27205</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY1LTUtMS0xLTEzMDc5_59f78e26-abc7-4e58-bec7-d5782727d1d4"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY2LTEtMS0xLTEzMDc5_37f086d9-e66e-4c4f-bcd4-64bb16ca7e0b"
      unitRef="usd">-179584340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY2LTMtMS0xLTEzMDc5_4f9c60d2-a460-4822-937e-c97381fdfd97"
      unitRef="usd">228532021</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY2LTUtMS0xLTEzMDc5_fbb2932e-0870-4b20-af6b-99b454899bd2"
      unitRef="usd">-1497536</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY3LTEtMS0xLTEzMDc5_4b6cf276-169d-4635-95ed-ef00c2cd6d11"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY3LTMtMS0xLTEzMDc5_59092a30-6bb2-4a83-afcc-0db0aad1bb10"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id0209f8c94d740adaa36dd67c48d6a20_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY3LTUtMS0xLTEzMDc5_3590cba2-6f34-49cc-9a45-ee908dc0e8d9"
      unitRef="usd">23693633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY4LTEtMS0xLTEzMDc5_9dce8e8b-d0d8-4345-98e1-9d844e46af15"
      unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY4LTMtMS0xLTEzMDc5_3eb3407a-b675-4ed4-8235-f7dec63db2d6"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzY4LTUtMS0xLTEzMDc5_0e8edd1c-d9a5-4673-91db-4c841cd5b67d"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzcyLTEtMS0xLTEzMDc5_958621e9-9207-49cd-9c7b-d65c97156582"
      unitRef="usd">204815</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzcyLTMtMS0xLTEzMDc5_4b6ef9a3-122e-462e-8430-3a1a0a718592"
      unitRef="usd">136711</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzcyLTUtMS0xLTEzMDc5_5ba7a519-bed4-49e3-8217-377e0abc5f6b"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzczLTEtMS0xLTEzMDc5_6fd82d34-4344-4c6e-a8f3-d392ac1362e6"
      unitRef="usd">1077803</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzczLTMtMS0xLTEzMDc5_6059172e-4988-4e8e-ae44-1f908d3fb796"
      unitRef="usd">4624764</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzczLTUtMS0xLTEzMDc5_2e53b644-0315-4f15-88ab-49389e7982fb"
      unitRef="usd">2717585</us-gaap:InterestPaidNet>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTEtMS0xLTIzNzEx_8aecd647-6516-4d54-89bf-4bfc0b23dd74"
      unitRef="usd">7709337</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTMtMS0xLTIzNzEx_91d46590-fa3b-4d6d-93a5-f319c867368c"
      unitRef="usd">0</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTUtMS0xLTIzNzEx_fc93f19b-1a4c-4c6f-8b68-5a1e94dfb3db"
      unitRef="usd">0</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:EquityComponentOfConvertibleDebtIssued
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTEtMS0xLTEzMDc5_496e920b-0f13-4523-befe-ae12721092fa"
      unitRef="usd">0</ino:EquityComponentOfConvertibleDebtIssued>
    <ino:EquityComponentOfConvertibleDebtIssued
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTMtMS0xLTEzMDc5_69a2b6e0-e091-4c10-9d1f-8157b5efe712"
      unitRef="usd">0</ino:EquityComponentOfConvertibleDebtIssued>
    <ino:EquityComponentOfConvertibleDebtIssued
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc0LTUtMS0xLTEzMDc5_f7b567c0-e434-438c-94d9-efcebf0ffb7d"
      unitRef="usd">15752698</ino:EquityComponentOfConvertibleDebtIssued>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc1LTEtMS0xLTEzMDc5_cd1afe78-5f53-4cec-8b4d-e1c2edc8457c"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc1LTMtMS0xLTEzMDc5_67c19633-da95-41e5-9dbf-ce226a609158"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMjcvZnJhZzo3NDQ5ZGM4MzdiZDQ0Yjg0YjQ0MDJkMDEwM2Y4YTJjYy90YWJsZTo5MmM4MWE2ZjY2Njg0MmVhYmQ3MmM4NmEyMzMzOGRjYS90YWJsZXJhbmdlOjkyYzgxYTZmNjY2ODQyZWFiZDcyYzg2YTIzMzM4ZGNhXzc1LTUtMS0xLTEzMDc5_3becf4fe-0dea-411f-b1cb-a15307434a1f"
      unitRef="usd">14634769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzMvZnJhZzo1YjE0YWM5YjFjMjc0YzMzODQ4OTA2M2ExMzczODZkNC90ZXh0cmVnaW9uOjViMTRhYzliMWMyNzRjMzM4NDg5MDYzYTEzNzM4NmQ0XzM2NDc_e6370eda-5c2c-479d-95b5-524290ec3607">The Company&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;), is a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus ("HPV"). INOVIO has shown in clinical trials that its DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#x201c;dBTAs&#x201d;), all of which utilize the two components of INOVIO's integrated platform, SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and CELLECTRA&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's proprietary SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#x2019;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's patented CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;smart delivery devices facilitate uptake of its DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA&#xae; smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's corporate strategy is to develop, seek regulatory approval for and commercialize its novel DNA medicines to address unmet global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include ApolloBio Corporation, AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently evaluating the feasibility of, conducting or planning clinical studies of DNA medicines for COVID-19, which includes both homologous and heterologous boosting approaches; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzIx_a2a89be4-928f-41ea-ae70-b521bfe75c91">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $303.7 million for the year ended December&#160;31, 2021. The Company had working capital of $382.7 million and an accumulated deficit of $1.2 billion as of December&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $401.3 million as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering, net proceeds of $47.7&#160;million under a Sales Agreement during the year ended December 31, 2021, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net proceeds of $454.5&#160;million under Sales Agreements during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  Refer to Footnote 16 for further discussion of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957"&gt;two&lt;/span&gt; to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2021 and 2020, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.6&#160;million and $3.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2021, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;8 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $237.2 million and $159.7 million at December&#160;31, 2021 and 2020, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021, 2020 and 2019, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,265,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,654,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,190,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Pending Adoption &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company will adopt ASU 2020-06. The Company is finalizing its analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. The Company expects that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzcz_9cb31150-3c71-47c7-a274-42f6b7020f5a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $303.7 million for the year ended December&#160;31, 2021. The Company had working capital of $382.7 million and an accumulated deficit of $1.2 billion as of December&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $401.3 million as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering, net proceeds of $47.7&#160;million under a Sales Agreement during the year ended December 31, 2021, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net proceeds of $454.5&#160;million under Sales Agreements during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM1MTc_fa6289c7-81cf-4747-b711-c9c84dd98e76"
      unitRef="usd">-303700000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM1ODY_923a3fa6-cef7-409e-a3e7-c820a63cb1b9"
      unitRef="usd">382700000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM2MTk_c9bcbb16-c288-48c3-9444-69cfa4fc1b37"
      unitRef="usd">-1200000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzM5ODc_2020c4bc-d371-4162-a094-757f428b4b08"
      unitRef="usd">401300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i61571339f1d34229a32dd11283124d8d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMyOTc0OTc_51afcb71-7a73-474a-ac2c-7f74a5cdbdc2"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMzMDIyMzk_99811b74-0bb9-4922-a27a-d8bd9f8ebca1"
      unitRef="usd">47700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib2f6172e00ae438dba3e872301590376_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQ4MDQ_04c7a924-58bc-4b4a-893c-d50d29fb38e8"
      unitRef="usd">454500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5e3b5941f67f4dd7839d1d0ee8b932e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQ4Njg_e1802458-1de1-455a-a009-99ba2b1a200b"
      unitRef="usd">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i3185052214d241188760405d062c3a93_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQ5Nzg_dd919013-9797-4a95-aa46-42a24aed15fe"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9cb066154a0b4e63a1b45dee6f783336_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUwMDk_3cc0ff52-b5b6-485a-9002-6711c1fd8f0a"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="iec094623890140ecbe43e62d969a9e6e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUwNzc_279a9fe5-dedb-416a-b9a3-a00f14ea773d"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUxMTA_1c1429b2-9bc2-4d7e-aaf1-c3ad930305ab"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUxNDk_d77e4eaf-eef1-476d-a93b-e7933aafff2d"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i163c9e373d8e4dc380aafb0a12e6ddc1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUyMzg_7bc59ca6-f40c-4f5d-af9e-f8f05de3d9e6"
      unitRef="number">1</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ia4b54e7447e843b785376b2edd00a1df_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUzMjE_96c55388-5e82-447b-8c13-d97451610d95"
      unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUzNTQ_989fc321-aea3-4afc-81d3-18a112d751a7"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzUzODA_143bd92c-0120-449d-a751-117fb76406aa"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabcf8dc100a14d9ba7f6c8323f32eadf_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzU0Njk_18663929-0dce-4e6b-bd1c-1489e5779321"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzky_f830482a-4ea5-4e35-aec7-1c94c3d7fbd6">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt; the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzI3_ef0c2f8a-a829-4de7-ad27-9236ffad4214">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4Xzk0NjI_f46a567b-e1a2-4d43-9865-0f995b0628d4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNjgz_e9695300-dc10-44ab-a138-5e5cb4bcd771">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzE2_d06f1aa0-3747-40eb-bbdd-38738bf6f49f">Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzU0_f20331bd-ba24-4258-b820-9cb6ff31f529">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNjk1_af4b8dc5-80ae-447d-8836-95fed9c5cea6">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzYz_47807245-c34f-450e-a999-f1bf5ae9ec40">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzMz_9130d149-5e2d-45f6-b154-ae79e80d5e47">Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNTE3_b30eb0b6-11e2-4921-9331-e14b0c14c06c"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNTE3_fdd39d0a-bc0b-4f7c-a0c9-28a6e546da06"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzU1_5f218442-55c6-4c39-9be3-675629b2398b">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEyNzU4_07859a6e-1f97-45db-a7e9-815a4e8423c1"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1ef43783aafd41bcbd015396830a6453_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODI5_ac552237-bd0b-4cf9-823b-d46710f73b8d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODM0_d445bb8e-9990-4a4b-bfb0-9c6799c44348">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow &lt;/span&gt;&lt;/div&gt;analyses or comparable fair values of similar assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzQz_f03f18da-62e0-4d33-bcd4-cbe5e423bd9a">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjI1_ba10c8d3-9d5b-4ba3-bd40-a6d90e0b7957"&gt;two&lt;/span&gt; to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2021 and 2020, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.6&#160;million and $3.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2021, identifying no impairment.&lt;/span&gt;&lt;/div&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1ef43783aafd41bcbd015396830a6453_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzEzNjMx_eb70156c-92b5-48b8-bb07-86599dc2f6d1">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMyOTgzMTI_6b8c68d2-4a92-478e-a7c9-b5458168dbbb"
      unitRef="usd">2600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzIxOTkwMjMyOTgzMTk_425bf49a-5b3f-4f21-8069-f5a9d0e7e602"
      unitRef="usd">3100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODI2_368e3eb8-0010-4c7d-969f-74c8adec5c83">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $237.2 million and $159.7 million at December&#160;31, 2021 and 2020, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzE5MjI0_3cc1fc2c-7b7f-417d-90e4-fae6e9546d31"
      unitRef="usd">237200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzE5MjMx_a1bbfa10-3646-4acf-bff7-d4c78777df1a"
      unitRef="usd">159700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzAz_70544345-4ac5-48cd-84c1-c7da28135f62">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt; (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODQ1_3fc99511-6581-4626-a1c7-a1dbefeb54a4">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantRevenuePolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODM3_b2b1c629-6138-4359-b695-1ef1344d4a03">Grants&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.</ino:GrantRevenuePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzU3_5ce51a83-fb6b-4ae3-8267-3e67e7444ae7">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODI3_81cb2bfc-55a5-47b8-bab8-93a4a780ea66">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQzOTgwNDY1NzQ0NTE_c122e9a0-2bcc-459b-814b-735db66737bd">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQzOTgwNDY1NzQ0NTI_1eeb1439-26b3-452f-907a-aa98215b16de">Equity Investments&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzI4_86e643f5-adf7-44c4-ba45-cb821ce49baa">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and &lt;/span&gt;&lt;/div&gt;accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNjk4_decce677-2d00-438b-8b7b-c20ab86acae3">Net Loss Per Share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;For the years ended December 31, 2021, 2020 and 2019, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzQ1_39b0d8d3-2288-4936-861c-c031c831de3e">&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,265,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,654,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,190,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if22218578fe146a690414073c1055f9f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzItMS0xLTEtMTMwNzk_fec48c65-a44a-44d2-8950-3aa1a6410ef1"
      unitRef="shares">10488993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie75672a5cd7f4ee7b50fd63d1effb9b3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzItMy0xLTEtMTMwNzk_17c8a45a-ae7c-4fa2-ad56-563947ee61f9"
      unitRef="shares">8906624</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib858b60634554cfeb353213f382d8701_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzItNS0xLTEtMTMwNzk_1b7e7ee1-0b49-402a-a9e6-8aa13c0f8d80"
      unitRef="shares">9265390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1619b504fabd4b03803cf6d1bd43cdf7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzQtMS0xLTEtMTMwNzk_8fc66ad7-aa8c-4fe7-bff6-68c4c894aa90"
      unitRef="shares">2448868</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf57bbc765a648e88af4e001faf909bf_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzQtMy0xLTEtMTMwNzk_274e0328-10ed-4bc4-831c-135a2c2fc657"
      unitRef="shares">2558052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1d7d0e03523439aa100b18e4b73ea8f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzQtNS0xLTEtMTMwNzk_9edbe7ed-9ac6-4f6f-b10b-0ec79f3b4557"
      unitRef="shares">2069936</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5cfd184b5e79415896cd4f9f6baac7f3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzUtMS0xLTEtMTMwNzk_ce786221-503c-4d8d-a5df-91eeb336638d"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8bf52c18686740578bf1f8f9c8cbaa61_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzUtMy0xLTEtMTMwNzk_a2f21cab-1fe0-49b6-9ea9-987419ba8585"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5417c1b5a9294d67b2ece5b90e913521_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzUtNS0xLTEtMTMwNzk_2c7d9733-39d0-4532-bd9c-c4b9e6f2dbd5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i153bb9c9446b45eb8aa80f75f7399f3a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzYtMS0xLTEtMTMwNzk_65c070b5-13f1-4276-8fbf-74fe475dd54e"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie80d43743e6a4d668eea6d7bee8e1496_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzYtMy0xLTEtMTMwNzk_29f5ad0c-1128-4306-b30a-d9ace39e0f86"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7ef6a305f4c7456382cbb6d2f1e80f0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzYtNS0xLTEtMTMwNzk_d6759e38-4f8d-4d45-8f72-339a945528f2"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib58bb2dd8a4143a19908c58b705c40c0_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzctMS0xLTEtMTMwNzk_0a82e47d-da87-4a6e-b95e-6edac1f19877"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7f0ab257a6974dcdaba93f9ed07ea5f3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzctMy0xLTEtMTMwNzk_8aab2e76-5cfc-4221-adfc-7be497c1eddf"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i818c9cc8d85740b2bf619cb778985673_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzctNS0xLTEtMTMwNzk_fbf6a524-78a9-4348-82bc-c21f16d35586"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1f8eca20d5f34697abb3f086dc268f34_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzgtMS0xLTEtMTMwNzk_b2a6f917-5690-45be-9c0f-33ba679f3cb5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i14c7a36858de4d50ad50b6fa093cd1a5_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzgtMy0xLTEtMTMwNzk_69d14598-2f21-41a6-a93f-a21dbb025368"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia57b862418ed4691a1094727113e9132_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzgtNS0xLTEtMTMwNzk_e90a9a3d-03a0-4a02-9107-ec9c951bbc15"
      unitRef="shares">3799071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0d211e27d9de438bae12df540aefb132_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzktMS0xLTEtMTMwNzk_2eb4adbd-2572-4e8a-9ff5-50194b004897"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c100e0e5d064a128da83ec7e1d7bdb0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzktMy0xLTEtMTMwNzk_a249d50c-2c86-4a88-b1a3-8820c8deb84c"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6c4d94d9b204b7b9bfcdd26fabbc2c7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzktNS0xLTEtMTMwNzk_0a242b81-2d1b-4f76-b995-392c31685d1f"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzEwLTEtMS0xLTEzMDc5_c943bdaf-5740-4576-afc7-1acb5bb94cb9"
      unitRef="shares">16654503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzEwLTMtMS0xLTEzMDc5_ab426d72-9a66-4712-84fe-1eeea734161c"
      unitRef="shares">16190768</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo3NmNmOWM0ZmU4YTk0ZTVlOWIwYTMxYmE4M2FhYWYzOC90YWJsZXJhbmdlOjc2Y2Y5YzRmZThhOTRlNWU5YjBhMzFiYTgzYWFhZjM4XzEwLTUtMS0xLTEzMDc5_4cf5132c-2b19-4d4d-bf52-9afbe0debf93"
      unitRef="shares">30737956</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODM4_9a08c52f-cb9a-46a4-8bd9-8cbbf48669e6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxNzA0_9fb4cb04-78d1-4cb6-adda-7d8b79dd9008">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures as they occur. &lt;/span&gt;The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODE2_02b6baca-eb3d-4498-9a0e-d816724f6f70">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzItMS0xLTEtMTMwNzk_7debc3e2-e92c-4507-94ab-7b321c892664"
      unitRef="number">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzItMy0xLTEtMTMwNzk_fcf9603b-8b02-45d8-8e65-88ac0673b7c8"
      unitRef="number">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzItNS0xLTEtMTMwNzk_1634a7c5-2049-45cf-b1c9-311a855e4358"
      unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzMtMS0xLTEtMTMwNzk_970163b8-62dc-4e14-9ce6-29148e1ade04"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzMtMy0xLTEtMTMwNzk_ead2f713-21bc-4ab6-bee8-6adfdacb70fe"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzMtNS0xLTEtMTMwNzk_27ff0d49-864a-4b6d-9599-1cc7f8d87296"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzQtMS0xLTEtMTMwNzk_24f02edf-7728-459b-bf88-badd7693bc82">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzQtMy0xLTEtMTMwNzk_e97c683b-1818-41a1-a0e2-4a48d5673848">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzQtNS0xLTEtMTMwNzk_d2ba7bd1-f90c-4187-95fc-2ef4d9f1435d">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzUtMS0xLTEtMTMwNzk_12994a02-48e2-4812-8cc6-cf7860e5ee15"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icbef4b1b2d354828a9405379e0762ffd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzUtMy0xLTEtMTMwNzk_afcf78bb-133c-4c9b-9b22-6d149dcec040"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4aade99396514278bd95fe1d1a8e13ac_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTpjMjBlNzYzMjQ5M2Y0OTJlODhmYTg4Mzg2NGZlZDZmZi90YWJsZXJhbmdlOmMyMGU3NjMyNDkzZjQ5MmU4OGZhODgzODY0ZmVkNmZmXzUtNS0xLTEtMTMwNzk_463abfc5-0254-4e03-8e07-643c67a7ee78"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzItMS0xLTEtMTMwNzk_6fe99fa4-4525-44e0-98de-bedf0dc7b127"
      unitRef="number">0.0145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzItMy0xLTEtMTMwNzk_e39d6721-e020-41d4-a399-0c0077779a13"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzItNS0xLTEtMTMwNzk_174cd9fc-dd56-4b40-a1ff-20882ee85fd6"
      unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzMtMS0xLTEtMTMwNzk_e204b8cc-0f2b-42ae-9a65-0c5f0da6e7bb"
      unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzMtMy0xLTEtMTMwNzk_9f3651cb-b160-4180-a950-2f85d22cd6bf"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzMtNS0xLTEtMTMwNzk_a8164488-534d-4041-a0ad-0edb25c7a209"
      unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzQtMS0xLTEtMTMwNzk_3c1eef56-a9b4-40f1-937c-a99ec96faac8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzQtMy0xLTEtMTMwNzk_96ac1e07-3b55-4fbc-82db-4a1e67d0ddad">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzQtNS0xLTEtMTMwNzk_0f6d746d-21c3-4e5c-8fc1-2b36692fad76">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i985caa6fe2204c79885e3f347c621473_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzUtMS0xLTEtMTMwNzk_078e4eed-20c9-4de9-a414-25614fe358cf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic27c07569e4f4166b7879ffda9141b75_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzUtMy0xLTEtMTMwNzk_5708e4f2-d2a5-4b2c-8324-ad22e6b936fc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i43199a7247b8448c8d5dea09aa6c0296_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90YWJsZTo2YmM4ZTU5ZWI2YjQ0NTE0YTY2Nzg3ZWNjYWMyOGZlMi90YWJsZXJhbmdlOjZiYzhlNTllYjZiNDQ1MTRhNjY3ODdlY2NhYzI4ZmUyXzUtNS0xLTEtMTMwNzk_c3f8a976-ad45-4598-9fee-dc3b8a419b47"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzYvZnJhZzowNWFkMDllMGUxMjQ0NmM0YWI2Nzg2NmNlNDUwNmE4OC90ZXh0cmVnaW9uOjA1YWQwOWUwZTEyNDQ2YzRhYjY3ODY2Y2U0NTA2YTg4XzQxODAz_b8684d59-6343-45ca-b212-4650afbba407">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Pending Adoption &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Effective January 1, 2022, the Company will adopt ASU 2020-06. The Company is finalizing its analysis of certain assumptions that will be utilized at the transition and expects the effect of adopting ASU 2020-06 will result in an increase to retained earnings, a decrease to additional paid-in capital, and an increase to the convertible senior notes. The Company expects that interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzU5Mw_b63f1c39-e561-4f71-8553-e09fe171d62f">Revenue Recognition and Concentration of Credit RiskDuring the years ended December&#160;31, 2021, 2020 and 2019, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advaccine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc. (affiliated entity)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Department of Defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,411,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,111,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Of the total revenue recognized during the year ended December&#160;31, 2021, $46,000 was in deferred revenue as of December 31, 2020. During the year ended December 31, 2020, the Company recognized revenue of $127,000 that was included in deferred revenue at December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and the CEPI MERS grant, respectively. As of December&#160;31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzQzOTgwNDY1MTg3Njc_eb5a840b-2696-4c81-bcdd-aa86538f4e78">The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advaccine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc. (affiliated entity)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Department of Defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,411,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,111,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ebf37c07fc64f66897dbd181366f4f5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItMS0xLTEtMjgwMjU_0fc217d2-e122-4d33-bf60-2ebc5ef1f0f6"
      unitRef="usd">41659</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i161b5c6c81dd4f91ba0ee787fa80afde_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItMy0xLTEtMjgwNDI_a8abb916-8bc6-4d12-b818-90051e563762"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cfdf8c8894d47eaa3893a5f0fb45ab8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItNS0xLTEtMjgwNDQ_82f683b1-195f-48d3-a8fc-dbaf69a7e75f"
      unitRef="usd">170587</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93761468f4d2413c9fbddde17352101f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItNy0xLTEtMjgwNDY_33d7f08a-018a-4048-8d65-986045bc06e2"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i656c17b4e38a4ee491d602bf63aa7c19_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItOS0xLTEtMjgwNDg_08593798-bb6c-4525-bc5c-fce60ccc9037"
      unitRef="usd">3194877</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i919eacd755534f7f903fe6245b2c707c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzItMTEtMS0xLTI4MDUw_09e751de-98af-4bb7-bd29-16334b539566"
      unitRef="number">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36e0b5e7a72c42b1895acaf229856efe_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtMS0xLTEtMjgwMjU_74075068-db5c-439e-8106-45b4378cba69"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i40e1d2d136dc4c518979cf57c6a1b20b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtMy0xLTEtMjgwNDI_ce56a706-93a3-47bc-8b46-758cb4bedfe6"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b4a0ade4f3147fc8b24dc411f419712_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtNS0xLTEtMjgwNDQ_f5f3d466-bfc9-40f4-a58d-3639eebf5c6f"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i873c90e08f654501a8ad20a07c60193f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtNy0xLTEtMjgwNDY_833aa7b9-9e88-44de-a80e-0bfe1d6da76a"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a1ac7d82334e4baf6955ef04815ce4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtOS0xLTEtMjgwNDg_2f9c8a8e-8947-4c8b-9692-7d3332e099a2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id57fe04684f046938af512e85a6ba191_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzMtMTEtMS0xLTI4MDUw_46a49948-88a3-4597-9387-1a85cd547fe2"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9ec58bb67dc470a99951e5275067d10_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtMS0xLTEtMjgwMjU_197f9611-1c11-4c58-ba54-377adb9d27a3"
      unitRef="usd">245310</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i206cac58be234c169495b0e1f07f3b28_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtMy0xLTEtMjgwNDI_4569d5dd-b1d2-4ff1-bab8-11e44ac65dd3"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if59018c846e149458509f9c8cd25b24c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtNS0xLTEtMjgwNDQ_bcf81b47-c7eb-4ffd-97f9-db33c5d4e1c8"
      unitRef="usd">1370396</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib99bde567bfb41acbc76d3e0b885ec12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtNy0xLTEtMjgwNDY_630962b1-eef0-4e45-b122-7ad964244e35"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb847a1857fb4bf8b3cbe776dd9e29ab_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtOS0xLTEtMjgwNDg_7e7c1d51-b0ca-412e-b171-3bb3e1366609"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i82e0404405254e2e98e726f09230deb6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzQtMTEtMS0xLTI4MDUw_ed4a5ff7-b20b-4162-96d0-61067e37c5ea"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i567cdce8ec3f4d2eab6aec7e81bd94f1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtMS0xLTEtMjgwMjU_7e7c85c0-6ee9-4806-b4d6-1f11baa7dace"
      unitRef="usd">754853</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b628859583d45a886cbba8bc22a2f8c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtMy0xLTEtMjgwNDI_990b00b1-6ed0-4d10-ba70-383f83324069"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie01b088cd46a48608cf5867ab6b78956_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtNS0xLTEtMjgwNDQ_cbc555d4-7bbd-4c4f-8e8d-b5e28b8fc871"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i08cf4a688e1e4557bbe98d00332e150f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtNy0xLTEtMjgwNDY_ebdcd2d2-b42e-4095-82fe-0448af927095"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67e4662477174747a0d272e1d8792a76_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtOS0xLTEtMjgwNDg_ce861448-8e07-47d4-8b7d-d87ce4bbe35e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib8f9c1676db542ada5764c97da93a468_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzUtMTEtMS0xLTI4MDUw_2acbb274-ad99-40ed-8eff-38ad02203640"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ee4ca6918ae4fa796d41036cae115ee_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtMS0xLTEtMjgwMjU_51b1eca1-8a53-4e54-850b-ad7522603e4a"
      unitRef="usd">732936</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia77dac3a01a74815904a03fe7971a7d2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtMy0xLTEtMjgwNDI_cf6c2558-59f6-411c-a39e-72f7834e9d40"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b35ca32ad6b49038d3962c931ab0301_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtNS0xLTEtMjgwNDQ_260bfd4c-aae5-4b1e-aa53-cb3d33a1817f"
      unitRef="usd">870237</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icad521f20e6d42869f7f73948ebbd477_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtNy0xLTEtMjgwNDY_20966de8-bb90-4da1-a6b4-497aa44ad870"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14838e9bc6fc4c4487a1c7f9172258a4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtOS0xLTEtMjgwNDg_58f5db66-323c-419e-8288-ae7821f0cf40"
      unitRef="usd">917053</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i42c6acd539524f568bd5b29f3c45c3ef_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzYtMTEtMS0xLTI4MDUw_836bd00f-ee12-4d52-85fa-a11c1294f4cd"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctMS0xLTEtMjgwMjU_486fd6c7-f61e-438c-8d5b-830383cc77a0"
      unitRef="usd">1774758</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb2df8412c044c118cdb9553e4cf95ad_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctMy0xLTEtMjgwNDI_367145f6-4144-46e5-81df-c4c341f0fcec"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctNS0xLTEtMjgwNDQ_20fd326d-c4e8-4523-a36c-89117994c7fd"
      unitRef="usd">7411220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i52aca042d6ff42d1ba348dd26d66cffd_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctNy0xLTEtMjgwNDY_b693486a-f93e-46ec-a952-bdb509f27784"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctOS0xLTEtMjgwNDg_c2d3d1e7-27c0-4091-95fc-6fbcaf1cca07"
      unitRef="usd">4111930</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i59968761470a4f2d802618f91010f7b6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90YWJsZTo1NThkOTRlMDMyNjE0ZWFmOTBiZTRjMDEwNmRkOGVjOS90YWJsZXJhbmdlOjU1OGQ5NGUwMzI2MTRlYWY5MGJlNGMwMTA2ZGQ4ZWM5XzctMTEtMS0xLTI4MDUw_4aab8bbd-8706-4529-a69e-f9b827707df4"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzUxNTE_e26b7a61-2537-4cf3-83a4-2fa624057cbe"
      unitRef="usd">46000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzUyNzc_fc2ab72f-2e9a-4a1b-b152-6ffe3e767be0"
      unitRef="usd">127000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AccountsReceivableNet
      contextRef="i6262eab5b3c948d69de6a49741df2b15_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEwNzc_54efc310-4594-4c19-a948-8afa845a642d"
      unitRef="usd">3600000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if71d5ef52a394d6797808af8b5299731_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEwODU_4cd69d56-0f57-404a-8257-d7915c1420ed"
      unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i43ec222c4b76432ca9ce78c095a00f5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEwOTQ_6e333877-3e46-4454-b641-3bf5d9c5c704"
      unitRef="usd">1900000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i06bbd4127d1e42a6b45c7cdf18fc01b5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzExMDI_e38a38ff-e1e0-47e7-93ea-6f8c68eff53b"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="ia0f4b2524a6745389ebfd4167248f100_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyMzU_3d900928-be01-45d7-949b-2f69cef01267"
      unitRef="usd">11400000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5e2613d428a449579acc6b28ca21928c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyNDM_aa16eab3-1d86-4834-92b6-b59c6b9713f1"
      unitRef="number">0.62</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i6ded10e0f0e44a2bb4ece994cc771846_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyNTI_b18db613-f254-457f-982a-f9bbfbaed0ca"
      unitRef="usd">7100000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaef8fd46f8504fc48eaafd248555647c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xMzkvZnJhZzo2NTRiZjMwMTdlZWU0NWM2YjAyYTc4MzI1MGJlMDY0MS90ZXh0cmVnaW9uOjY1NGJmMzAxN2VlZTQ1YzZiMDJhNzgzMjUwYmUwNjQxXzEwOTk1MTE2MzEyNjA_5dee544f-476f-4cd8-aede-1147df4d4ef6"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5Njc4_2194217d-b48a-4708-8be4-aa740adbd2ec">Collaborative Agreements &lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#x2019;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#x2019; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first participant in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company had an accounts receivable balance of $7.1&#160;million from Advaccine. There has been no additional revenue earned under this collaboration agreement with Advaccine for the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the June 2021 amendment, the Company determined that the Global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore concluded to account for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company received funding of $4.5 million from Advaccine that was recorded as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contra-research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018, which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca was obligated to make potential future development and regulatory event-based payments to the Company and potential future commercial event-based payments, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca was funding all development costs associated with MEDI0457 immunotherapy. The Company was entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca could also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified materia&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;l performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue $2.0 million in milestone payments from AstraZeneca triggered by AstraZeneca&#x2019;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 28, 2021, AstraZeneca provided notice to the Company to terminate the INO-3112 / MEDI0457 development program under the agreement. As a result of the termination, the agreement has been terminated in its entirety and the Company has no further obligations under the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2021 and 2020, the Company received funding of $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2021, the Company had &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an accounts receivable balance of $1.9&#160;million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded $23,000 as deferred grant funding on the consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $6.9&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.0&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received funding of $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2021 the Company had $1.8&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Bill &amp;amp; Melinda Gates Foundation (&#x201c;Gates&#x201d;) awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2021 and 2020, the Company recorded $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2021, the Company had $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0&#160;million to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the years ended December&#160;31, 2021 and 2020, the Company recorded $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is $54.5&#160;million. The Company has determined that the OTA Agreement should be considered under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company will record contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s later-stage clinical trials. The total purchase price under the Procurement Contract is expected to be approximately $10.7&#160;million. As of December 31, 2021, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;he Company determined that the Procurement Contract falls under the scope of ASC Topic 606 as the contract is with a customer and the Company is able to satisfy its obligations under the arrangement as the Phase 3 clinical trials of INO-4800 are underway. Performance obligations under the Procurement Contract consist of the delivery of a specified number of CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. The Company will recognize revenue on the consolidated statement of operations upon shipment of the purchased devices and accessories. During the year ended December 31, 2021, the Company recorded revenue of $755,000 from the Procurement Contract. This revenue was recognized at a 100% margin as the sale was for products whose related inventory had previously been written down to zero. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recorded $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement. As of December&#160;31, 2021, the Company had an accounts receivable balance of $3.6&#160;million on the consolidated balance sheet from the DoD. As of December&#160;31, 2021, the Company had $2.3&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the Procurement Contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing funding under the OTA Agreement and Procurement Contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzOTY_7af59672-e21c-46ce-8071-f2ecd2e93a6d"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1MjU_046e2d17-4e12-4a4a-8685-7352564a6bd1"
      unitRef="usd">206000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="if4ec0f7d61a247a29e6f8b976b92fdd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE4MDk_46187adf-a8ee-4d3e-ba09-c7ba2c4defbe"
      unitRef="usd">2000000</ino:CollaborationAgreementPaymentEarned>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIzNzE_b7096154-439e-4ddd-9834-3c3a78c3c546">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:CostMaintenance
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyODIxMDE_1f6494c2-8f97-4876-ba7d-fd13d65abd78"
      unitRef="usd">1500000</us-gaap:CostMaintenance>
    <ino:AnnualMaintenancePeriod
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyODIxMTQ_dfb1a7a1-9613-441c-a8a4-4340535227f6">P5Y</ino:AnnualMaintenancePeriod>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyODYwNDM_b5d67aee-6af8-4258-ab15-8fc06c6569a3">P18M</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzQ0NDQ_f9c2d070-f7b0-4a0f-ad85-48711a8d8825"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzQ0ODA_a5f373e4-02b4-4e8a-bd11-0766646891cd"
      unitRef="usd">2000000</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzY1MTk_ccbe7204-ba3c-40a2-87ef-c1b47d06cccb"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e94d242541e4769b9580dca20dd055f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzY4MTI_b3699691-f69c-47d8-998f-30636cd42d0c"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i6ded10e0f0e44a2bb4ece994cc771846_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMzMDcwMzQ_4c0f1340-6d7f-47bb-a490-c6912488a1f6"
      unitRef="usd">7100000</us-gaap:AccountsReceivableNet>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i64f31efa1c9a4f148e260320e63fa0f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMzMDc0MTU_3d200845-6505-4124-83d9-7b6b1bfdcd91"
      unitRef="usd">4500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:ProceedsFromCollaborativeAgreement
      contextRef="i2c6068a0d87f4fa585046b88cd0c29e1_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc3OTk_31b07f0f-e440-4488-a326-3f32e30258ec"
      unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i2c6068a0d87f4fa585046b88cd0c29e1_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc4NTY_d37a7750-b193-454f-b115-bb4301aed03d"
      unitRef="usd">23000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementCorporateIncomeTax
      contextRef="i345933f791f148b9ab11262a4e3fabc8_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc4NjQ_a6dd943c-3df3-452b-a83b-610f7812637b"
      unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
    <ino:CollaborativeAgreementForeignNonIncomeTaxes
      contextRef="i345933f791f148b9ab11262a4e3fabc8_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzc4OTU_4ea80a11-8074-4dc1-a172-8f8ee838cbe9"
      unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
    <ino:CollaborativeAgreementAdvisoryFees
      contextRef="i2ae7a6139749478dae2789fde984a73d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzgxODI_2e0ad775-e897-4123-9a57-cce907ce34e0"
      unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzg3NzA_80e95468-3494-47a7-bea5-4507b41602ac"
      unitRef="usd">20000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzkzMTE_0a4567aa-3ca6-4763-9ad0-758e7a950bc7">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTQ3Nzc_e94b9d85-84db-4427-8c87-27c655b7a0d5">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTQ4MjY_ca321535-6fdc-454b-9758-1189c7d163bc">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="if6abdd04d76a4f1aa25bf47d2c6dcc67_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzk5NDk_892307dd-b9aa-47ec-a2f5-afec561287ce"
      unitRef="usd">23000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ib423f4e3e0a948d1a2df6de8efddc903_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzExNDI5_f64fcf9a-83c6-4145-8f85-0e995bae961e"
      unitRef="usd">23000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i38a9f6f4af6b431f8ca5510726bbceba_D20150901-20150930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEyMzIw_f6019ad8-4d46-48cb-89d4-a4401a55d8e8"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="iecc3a56b04444e0ea7504b1ecbc37e79_D20171231-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzMTkx_c1aeca58-d048-4ba3-a915-12137aa518e4"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementMilestonePaymentRevenueRecognized
      contextRef="i9e3823ff3500456ebdf2aa61528c8e05_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzMzg4_c4e9bb63-3556-4361-98bd-ad12bc48fed1"
      unitRef="usd">2000000</ino:CollaborativeAgreementMilestonePaymentRevenueRecognized>
    <ino:CollaborativeAgreementMilestonePaymentRevenueRecognized
      contextRef="i4218b3818f30409db7b03360c59d6a05_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEzMzg4_d4421412-e468-4870-b56a-c649bec0bcc1"
      unitRef="usd">2000000</ino:CollaborativeAgreementMilestonePaymentRevenueRecognized>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ie60c9823b100427ba62081e1ce28130e_D20180411-20180411"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0MjU5_1dfd83b2-3c8c-423b-9e6f-4b83b982d854"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="ie60c9823b100427ba62081e1ce28130e_D20180411-20180411"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5Njc3_4d1b59a6-9525-490e-81c6-229dfd9324de">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ied6f8e470b114624a1428d5fe05d2883_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0NTY0_b8158c74-c32e-4995-9be2-787817f4d6c1"
      unitRef="usd">10000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ibeaaf2a45e274b08822dc97c5f1d6548_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0NTcx_3c8105f2-0d4a-4fa2-8f64-2e66d13192a0"
      unitRef="usd">6400000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:AccountsReceivableNet
      contextRef="i627a7ce3c55f4c9bac1b8724c31a2b9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMzMDc2MjU_36724f9e-eaf8-4b8b-979e-a67ea2cd4af6"
      unitRef="usd">1900000</us-gaap:AccountsReceivableNet>
    <ino:DeferredGrantFundingCurrent
      contextRef="i48b9f355c6d44067b5c91a145b75b3d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0Nzc0_3753e7df-e308-44ad-8d0a-788e924d0c0f"
      unitRef="usd">23000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ia3fab37e71394ac2af69e86ac41d336a_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE0OTQy_5d4a4b22-68f7-4e55-b5a0-8ff104e72de1"
      unitRef="usd">9000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="icad38c575aa2469a960d1b3021807208_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1MjQ0_f8c35673-f6f3-40ea-b5b4-75cd305734d1"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i5b1057c5132f4610b04adc365c092be4_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1NDIy_bb8a76fd-1334-4f55-b6eb-4bf8a5404722"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i02735771448f4559ad8ad7eb771f42a0_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1NjA0_dee53dc6-c263-4830-83c7-e202fb96e807"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i33e5d35d7de44a078dff01c3cfa43227_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1NzE1_ae10e39c-e30e-4d64-b925-81ed49bd09f0"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ia081c81a473a4f3399c27e4703bbc7ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTYxNzk_ae06ecec-2fcb-4773-b216-cf87d67f0f3f"
      unitRef="usd">10000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="ibd977534e815463fb781c4067853b53b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE1ODYw_37fbeb9f-70dd-464a-9ab8-093e169d7b5b"
      unitRef="usd">1800000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i781f7721feee4c4ca2ff6d186fcffbf3_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2MTE3_37d61536-3715-4654-8a83-9d69be559d3a"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i5fde4b781ebe4327bf969f8140d88ecf_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2NDgw_36f9e910-d297-491a-8d14-de40db009e75"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="iac1e6c89e8ca49e9b134471c2d4cd4c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2NTU1_14488677-7359-4dfd-a162-9ae2bedf0f78"
      unitRef="usd">182000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ie34b4d8f0d4e4a1d973ed63d51a51649_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2NTYy_71e075f6-8b6c-4590-9f18-e8eac549e7eb"
      unitRef="usd">463000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i3bbf0edc36f446378983dc8302caa4d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2Njgy_44fcb3cb-c613-467a-964d-5cd067899f3c"
      unitRef="usd">384000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ibd0b58a07e594872a449c2f8a64d1f50_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2ODM5_f9283892-4b2e-4909-af70-28f986c5933d"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="iabd3cbd20ab142cca107c1f4cf711e83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE2OTkx_2aa71a90-c53d-40a9-9d0a-4f8dc1f5d142"
      unitRef="usd">893000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i00eb7864be0441e898f5a5f77d203ff1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTYxOTg_0686e9ec-fb99-4088-b83e-d7fd3dd245d0"
      unitRef="usd">4100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i8f4af1a162cd4deda134bce933897a10_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE4MDc2_3d662c5e-6bec-47f6-a178-932b001daef6"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i67b7af31bd224297994ebe728b26c780_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE4OTI5_5f4fa659-5006-46a4-9e75-a3eb852dbb60"
      unitRef="usd">10700000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="i5575e68486ee4cd5b43dde605b161a50_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzEwOTk1MTE2NzMyNDE_a63c53e3-e7bb-4f49-b467-a45fd9a2dfda"
      unitRef="usd">755000000</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:GrantProceedsReceived
      contextRef="i128585ac13474b3091b72cd864723b37_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5MjMy_9e14a040-a7c0-4f31-82a2-ee92abd06db2"
      unitRef="usd">27100000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i00e2d517b98c4e12bb4ac8e2131fe365_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTYyNTk_f155ab69-dedb-4d6e-bbe2-00148171fbdc"
      unitRef="usd">21200000</ino:GrantProceedsReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i5575e68486ee4cd5b43dde605b161a50_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzE5Mzgw_bc22231a-a111-437f-912e-5625478329a6"
      unitRef="usd">3600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:GrantsReceivable
      contextRef="i5575e68486ee4cd5b43dde605b161a50_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDIvZnJhZzphNTA2Y2ZmNWJhN2E0YjU0YWViYzRmMDM4NWI4ZmJmMS90ZXh0cmVnaW9uOmE1MDZjZmY1YmE3YTRiNTRhZWJjNGYwMzg1YjhmYmYxXzIxOTkwMjMyOTY5ODk_f8b901de-5d87-40e3-8f49-636aa5dafab6"
      unitRef="usd">2300000</us-gaap:GrantsReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzMyMzk_49a482e0-a9e3-421a-baed-b7d5204124fc">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $394,000 and $744,000, respectively, and gross realized loss on investments of $399,000 and $1.3 million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(3.2)&#160;million and $1.7&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2021,&#160;2020&#160;and&#160;2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2021, the Company had&#160;24&#160;available-for-sale securities in a gross unrealized loss position, of which six with an aggregate total unrealized loss of $766,000 were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2021&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2021 and 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain (loss) on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain (loss) on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a &lt;/span&gt;&lt;/div&gt;professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2021 and 2020.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzMyMzk_ada5e68a-5374-4ff7-b712-17ed43bfc6bc">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $394,000 and $744,000, respectively, and gross realized loss on investments of $399,000 and $1.3 million, respectively. During the years ended December&#160;31, 2021 and 2020, the Company recorded net unrealized (loss) gain on available-for-sale equity securities of $(3.2)&#160;million and $1.7&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2021,&#160;2020&#160;and&#160;2019. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2021, the Company had&#160;24&#160;available-for-sale securities in a gross unrealized loss position, of which six with an aggregate total unrealized loss of $766,000 were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2021&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2021 and 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain (loss) on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain (loss) on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a &lt;/span&gt;&lt;/div&gt;professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2021 and 2020.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzMyNDA_e9805e06-8c84-497d-9e04-c749a07871e9">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItMy0xLTEtMTMwNzk_22c096fb-c27d-4a37-8a60-376d367b5fd5"
      unitRef="usd">192966772</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItNS0xLTEtMTMwNzk_c6b8172e-4944-4b55-8453-bc2b5329064a"
      unitRef="usd">87069</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItNy0xLTEtMTMwNzk_ea639ddc-f190-4501-93e7-b8a59f07f669"
      unitRef="usd">1614411</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4422f4760ee74f3ba71d8253cc93cf53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzItOS0xLTEtMTMwNzk_99d98af1-d335-4301-b153-1e8ba94190f8"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i1cf6fb5f859b42d78d7c7a430a42ff42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtMS0xLTEtMTQ0MjEvdGV4dHJlZ2lvbjoxNzUzZGVjNTZiMTM0OWU5YjViMDA2MTk0MzQ5ZjA0ZV8yMTk5MDIzMjU1NTY5_4f05100b-30db-45bd-a568-e7de6fd22bd6">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtMy0xLTEtMTMwNzk_5eef9dd4-9ac9-413d-8c20-4147b938bf37"
      unitRef="usd">94193441</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtNS0xLTEtMTMwNzk_0c297190-a186-405a-91e5-e480befc7041"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtNy0xLTEtMTMwNzk_9ccf5b12-0154-4e95-b0f3-be87d68aebb8"
      unitRef="usd">9921</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0732cac3e67f42b28ba168e6b4b35a13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzMtOS0xLTEtMTMwNzk_db5beef1-12a9-44c3-a41b-e072029bd8db"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="ib71562a57439406ab96e0f74edd9d947_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMS0xLTEtMjEwMzgvdGV4dHJlZ2lvbjpiMWI2YTZlMTdhNWQ0ZGRhODllMDg1YzNiNjJiNzVmNl8yMTk5MDIzMjU1NTY4_d3d7a7da-b0f5-4b02-9925-c7b173a8d610">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMy0xLTEtMjEwNTY_8aefa954-22db-4c26-8c28-037cb3e7f8ba"
      unitRef="usd">39967853</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNS0xLTEtMjEwNTY_b57ed0a6-b09f-48da-b74c-d10170f80f13"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNy0xLTEtMjEwNTY_6a3e1edc-490d-45ed-92a3-643e75ec0d4f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f3ee0206f344588a0ca5fc6a3fb4f05_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtOS0xLTEtMjEwNTY_1214ab3c-3bfe-4cd4-919c-84d1529491fb"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i9327b185da7843ef8a8df8e03d20d44f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMS0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpmY2RhOWYxOTYxNGY0OGNiYWYxYjg5ZmIzZGEzYTViMV8xNA_8e9abac0-f6b3-4e83-8887-19f57a94ecf4">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtMy0xLTEtMTMwNzk_f0fbb64b-ab43-42fb-b303-48cbd6e3ee86"
      unitRef="usd">2976210</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNS0xLTEtMTMwNzk_403abf6e-f2d7-4df0-84aa-a23aba237b83"
      unitRef="usd">15618</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtNy0xLTEtMTMwNzk_8e394e1b-2ef1-4124-b578-bb690a217541"
      unitRef="usd">338</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib292d78a61bd4623a795a93607e5c9ce_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzQtOS0xLTEtMTMwNzk_9b04321a-b376-49c9-9355-cdd5c451a79d"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtMy0xLTEtMTMwNzk_8e94a22d-c443-4a5f-b04e-d1151422b030"
      unitRef="usd">1608137</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtNS0xLTEtMTMwNzk_02f456ae-8f70-4d47-b721-f19dcb49961d"
      unitRef="usd">4508</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtNy0xLTEtMTMwNzk_9227c655-6e1c-4cfa-a8c6-22c2584d3d5e"
      unitRef="usd">23998</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i003f22a5fb7445d89be30a83788b0272_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzUtOS0xLTEtMTMwNzk_0c8c2d60-444f-4818-80fd-f987bf5bfb79"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctMy0xLTEtMTMwNzk_5b7f4baf-c725-4408-8da7-5f37d8ffce22"
      unitRef="usd">331712413</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctNS0xLTEtMTMwNzk_4be614f5-d7a0-4efc-a061-d8f3b4bea3ad"
      unitRef="usd">107195</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctNy0xLTEtMTMwNzk_ed09db07-b51d-4e59-882c-425e8391dd11"
      unitRef="usd">1648668</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTpmZDQxZTllYjZlMDI0ODBkYTlmYzA0OTBkOWViZjMyZi90YWJsZXJhbmdlOmZkNDFlOWViNmUwMjQ4MGRhOWZjMDQ5MGQ5ZWJmMzJmXzctOS0xLTEtMTMwNzk_0a282cfc-5a03-43a5-ae6d-7313e3c0599e"
      unitRef="usd">330170940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i26b0d42be39843d9b1022921606edc04_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItMy0xLTEtMTMwNzk_1d4ecdce-6c52-48ef-9792-8c8ec28053b3"
      unitRef="usd">153177675</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i26b0d42be39843d9b1022921606edc04_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItNS0xLTEtMTMwNzk_69d1735a-60ad-463b-899c-f96440f2816a"
      unitRef="usd">2339639</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i26b0d42be39843d9b1022921606edc04_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItNy0xLTEtMTMwNzk_d3008646-e34a-421e-8ff3-641b0864e078"
      unitRef="usd">644140</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26b0d42be39843d9b1022921606edc04_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzItOS0xLTEtMTMwNzk_887bf890-965b-4e35-81d2-ad5282e5e8d5"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="ia7ac4c61823a437d8c9b6aee26cf229b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtMS0xLTEtMTQ0NTYvdGV4dHJlZ2lvbjpmODRiODk5YmE5YzE0NzBiYjU4YTE1MjBhYmFhMDI1Y18yMTk5MDIzMjU1NTY4_278b5694-bf0d-46a1-95e7-98179733a5cd">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtMy0xLTEtMTMwNzk_c0aec5f3-0581-430e-9660-aa6abd652f67"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtNS0xLTEtMTMwNzk_b119a676-f5aa-4a91-88bb-09b297c7f50d"
      unitRef="usd">26260</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtNy0xLTEtMTMwNzk_0647a403-b8b6-499d-b113-ebfb2570c4a3"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i156d5ef8518844db95ef4f40d37d1035_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzMtOS0xLTEtMTMwNzk_622eb6da-52b8-4f2e-80b4-d18ac891405b"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtMy0xLTEtMTMwNzk_00dae82f-dceb-4b67-afad-991759e816b2"
      unitRef="usd">3062256</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtNS0xLTEtMTMwNzk_8fd46d23-7663-4cac-ae40-dea864b50f99"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtNy0xLTEtMTMwNzk_2ed77ae1-7f3f-4635-88fb-6ab95c5921ea"
      unitRef="usd">36755</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id939b4ea33cc496d933ef0fa32e5168b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzQtOS0xLTEtMTMwNzk_b9fc197d-bc5d-4263-a1e0-47e39ccaffc2"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtMy0xLTEtMTMwNzk_d81fc691-feea-4199-a85c-c09576709098"
      unitRef="usd">159239931</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtNS0xLTEtMTMwNzk_e0a8b1e3-3fce-4ef7-af88-e56f1a5c0565"
      unitRef="usd">2365899</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtNy0xLTEtMTMwNzk_0e0ac4d7-5e2d-408d-aaf7-f554c54956d3"
      unitRef="usd">690895</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphM2ZkYjQwY2I5YzI0MDYxYmEyMWJjN2NhZTE2ZTg4Ny90YWJsZXJhbmdlOmEzZmRiNDBjYjljMjQwNjFiYTIxYmM3Y2FlMTZlODg3XzYtOS0xLTEtMTMwNzk_66327fbc-7c4f-4433-82b6-19d2c3a3d2ed"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4MDM_3a60c75b-58da-4ba9-a4f5-a4e1e64970df"
      unitRef="usd">394000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4MTE_a90a1715-b99b-4c1e-ab02-75e9659233f0"
      unitRef="usd">744000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4NzI_6d207f66-aed8-46d4-b042-4a993a41ece3"
      unitRef="usd">399000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzQ4ODA_16996408-9b87-43aa-8001-70eb283a67c1"
      unitRef="usd">1300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzUwMjY_2de8dc3a-3d90-4ff7-afe8-2db95f0ac1b8"
      unitRef="usd">-3200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzUwMzQ_fd41f0fc-6ae2-4f85-ae3e-0aa211ea1874"
      unitRef="usd">1700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzUzNTk_3e3fbb8f-f042-4aca-ab74-bed6826ab83a"
      unitRef="investment">24</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzU0Mzk_160f0a11-4867-4445-85be-f89807355310"
      unitRef="investment">6</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzEwOTk1MTE2MzU0ODY_5cbabea5-605c-4ceb-9b5d-0c78e1daa50e"
      unitRef="usd">-766000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzQzOTgwNDY1MjI0NzE_69150305-2cb8-4649-85a3-6137550039d9">&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7071211447db4c3e8f228036ebc64654_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtMS0xLTEtMjY0NDM_ed57dcf4-653d-4577-9dcf-43dc27e3d560"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26fd2f2ca1804cf8b78f9f97fc906ec9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtMy0xLTEtMjY0NDM_9e48ed02-36ad-4519-af46-6778ad8c4256"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea6f0020516c4a6497376d5f1359cbd7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtNS0xLTEtMjY0NDM_7320099f-591c-43a9-bcf6-ed6f224f2b03"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie39b5179785c4f0d952c95c50da89619_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzgtNy0xLTEtMjY0NDM_1a9bf46c-4d67-4a50-833b-9488755df9e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b3f9b2236a74d2da2c502071722bc13_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktMS0xLTEtMjY0NDM_97dbde06-c403-4493-88e1-a479d64e0fcb"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15cdf0125f0d414b83d3aa528c069939_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktMy0xLTEtMjY0NDM_10f78a58-eb94-44cf-a40d-bb87ae6000bc"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c910afcfe76477c8adf69b6afc36738_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktNS0xLTEtMjY0NDM_773b416c-9374-4005-b7f9-df179c7abfab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idb11ec937978481798d9a2fa621b2545_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzktNy0xLTEtMjY0NDM_01f5acef-4564-4000-b00a-5136a066d18b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i674ddfb5b1174eab854007ba42538368_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTEtMS0xLTI2NDQz_ea4702d2-35aa-459a-bd76-fa7af7761ac4"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b606f8ce6104231abbb11b014a54bb0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTMtMS0xLTI2NDQz_24a75e21-564a-4b8e-89d5-094e1e42c6e6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7104e94d6b6402b8ad5ba5ea9a6dcf3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTUtMS0xLTI2NDQz_73650aaa-a23e-42bf-adfb-bd31e349aa7e"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if78b7886eb8f4368bd3e159d7be11563_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEwLTctMS0xLTI2NDQz_2e0716af-79b4-425b-8649-313f08edb41b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66c4fc55ad384a2d90e87c0e989d38c7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTEtMS0xLTI2NDQz_19b68bc9-4d95-45f4-b1df-d81100f7f6cd"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1effe86d89143f3aded22e7fd8fd339_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTMtMS0xLTI2NDQz_9fd04ce0-e8f3-44e8-80db-419db3ac0f25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd4c0a4f24f64339938c89d15957c736_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTUtMS0xLTI2NDQz_05f24d07-72d8-43ed-932f-5c2e92592517"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1245efc94094f599b7d7d3c818aa250_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzExLTctMS0xLTI2NDQz_cb179263-e049-4e90-bc15-a19b56ada8e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f0a0b420ecc4a6b936201d1941936bc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTEtMS0xLTI2NDQz_cf23ac42-f340-4704-816e-f904ff0fa66e"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d04338821da4044877e4bf707d5526b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTMtMS0xLTI2NDQz_d5744f74-7ae7-4a31-ab5a-b7b527ef66c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b2231094e244b4b8f8d798ed1d5a673_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTUtMS0xLTI2NDQz_0838b938-eb71-44ac-bb5c-5678ac44e564"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5b914f5f74342a2862d941121e5a48f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzEyLTctMS0xLTI2NDQz_f5b6077c-a1aa-422b-ba14-12926ae40124"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i395742f3d6cc49d3b3f55b2c752865d7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTEtMS0xLTI4MzY3_6ddb7d63-5c98-4213-874e-47978d4f0f27"
      unitRef="usd">330170940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d61d6b3e5354708ac4bab1f051af74a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTMtMS0xLTI4MzY3_962e0f84-2639-4dad-bb69-25bee9a5f421"
      unitRef="usd">285622950</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTUtMS0xLTI4MzY3_426c58ba-71fb-4fe5-b54b-78aef4700e0f"
      unitRef="usd">44547990</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief6d60d841db49b884995b9d409a2699_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE0LTctMS0xLTI4MzY3_d73091e9-57a7-4f0d-a986-92ac0b445483"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i395742f3d6cc49d3b3f55b2c752865d7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTEtMS0xLTI2NDQz_a10e1b28-17b7-4483-98f7-f4da3cdcf59a"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d61d6b3e5354708ac4bab1f051af74a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTMtMS0xLTI2NDQz_9900077a-8a15-45af-baaa-bcab4f1c77df"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTUtMS0xLTI2NDQz_87251b66-70b3-41ed-aa41-e4b55ae5870f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ief6d60d841db49b884995b9d409a2699_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE2LTctMS0xLTI2NDQz_0b3b78c0-4930-4a7c-854c-977b3b1e73ea"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i395742f3d6cc49d3b3f55b2c752865d7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTEtMS0xLTI4Mzcw_0c68aa39-0d35-4fec-b2a0-b48c6a1dd7ee"
      unitRef="usd">334077736</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d61d6b3e5354708ac4bab1f051af74a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTMtMS0xLTI4Mzcw_639bada9-be77-45b5-ba84-692180b674ec"
      unitRef="usd">289529746</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i960e6301836842ef9fbf82a8e1e3c3b7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTUtMS0xLTI4Mzcw_b49213ec-370c-4e25-80a2-c1dea5c02f12"
      unitRef="usd">44547990</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief6d60d841db49b884995b9d409a2699_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTozMmM5YjQyN2IwMTA0MDYwYTU4ZDhiNjYwYTY0MDJhYS90YWJsZXJhbmdlOjMyYzliNDI3YjAxMDQwNjBhNThkOGI2NjBhNjQwMmFhXzE3LTctMS0xLTI4Mzcw_a1facdf3-4594-4540-9be0-529eacfe75d5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie1fcbe29e328435f900b5cf60bf4ffb7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtMS0xLTEtMjY0NDM_4a6ba160-ffc9-41a0-a306-2319a97fe45d"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9693506cef01463bb3c7d6635695bba9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtMy0xLTEtMjY0NDM_33811db0-6aeb-4622-ae07-d5c74c067deb"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i32393fe851fd43879b59a162035f2f85_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtNS0xLTEtMjY0NDM_2b7122ba-c9b5-416c-8bc7-d56d74fc45c0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i56064b8e76fe40919fd24d219d24a453_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzUtNy0xLTEtMjY0NDM_73c53bbc-cd18-4a03-ad23-17fe4fa2e83b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8277afd2efb5453b93534cade2d9ce8f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktMS0xLTEtMjY0NDM_981e5dde-d75f-4ddc-8b7c-3fe7a77dbf1c"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73c766e601044c378ac2db7f87cde480_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktMy0xLTEtMjY0NDM_8bae5836-0adb-4498-b565-cd7f3148b702"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i922af379e03e4956a28c8f5c205b7dc3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktNS0xLTEtMjY0NDM_4f4b34a7-5426-435e-8b95-27e598a90985"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69ca8c127c9f48b3b63c86430c68e46d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzktNy0xLTEtMjY0NDM_15716418-dbec-4d84-80ce-9fc93eb4b2c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9c565cc3c44415ead62595cf93e70f8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTEtMS0xLTI2NDQz_85786d8f-e77b-4a48-b409-86f675efb3f2"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id32dc71cb0364baaaed730794f9f6ac8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTMtMS0xLTI2NDQz_a12855e8-cd52-4dfd-a818-01317c321b1a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1784296ad78e4c20af0d84835cef9888_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTUtMS0xLTI2NDQz_e9d028b4-07e2-4cde-8c40-2310f2f26cc8"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7877ab15bcd4dac8a499d3c7b9e7072_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEwLTctMS0xLTI2NDQz_de3409af-6c84-48a2-a727-a796a0c794b4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43a0e2b2399a434d9a99f30233dc02a7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTEtMS0xLTI2NDQz_db0773ab-444b-4831-b8cf-e9d6f0a6bb03"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45b384928838488791c262caec9215b6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTMtMS0xLTI2NDQz_c540cd82-7f21-477c-9f8e-19e6c4c73561"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab11fde10c2c4d87b33e70d030ae1653_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTUtMS0xLTI2NDQz_905487c0-a91b-444f-b75a-889d4ed578c1"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff4fbe1fd8cc41b6947d447b6a6c741d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzExLTctMS0xLTI2NDQz_889949d8-5cbb-4c18-8128-f6720a294773"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18d84e84f3c84c92a7c4176575b1dc22_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTEtMS0xLTI4Mzcy_ac5094bd-6d11-42bf-998b-16647f465ae3"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd535af4c12849f0934bcc1b955d369d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTMtMS0xLTI4Mzcy_e0124925-a86c-419b-be3f-6b5b6e5f3f45"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTUtMS0xLTI4Mzcy_2872024b-da6f-48e0-984b-a4104fe9d3d6"
      unitRef="usd">6041761</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzEyLTctMS0xLTI4Mzcy_013148d9-b5cd-4555-aaf6-54ffe43825c0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i18d84e84f3c84c92a7c4176575b1dc22_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTEtMS0xLTI2NDQz_c9cd05ee-7b29-4f47-aa08-95d658d4d975"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icd535af4c12849f0934bcc1b955d369d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTMtMS0xLTI2NDQz_f2c0244c-a7e1-4170-ac18-b3c8641dca49"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTUtMS0xLTI2NDQz_a3eb107d-d612-40bc-8fcb-d27583a3e0c5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE0LTctMS0xLTI2NDQz_d8e567ba-6b7d-4822-8d47-c6a035b32b77"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18d84e84f3c84c92a7c4176575b1dc22_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTEtMS0xLTI2NDQz_ae5e45b0-67a1-4bd8-ac9b-8cd07b431f81"
      unitRef="usd">225372101</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd535af4c12849f0934bcc1b955d369d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTMtMS0xLTI2NDQz_d85fbb55-4400-4780-b97d-bf2755dc06d6"
      unitRef="usd">219330340</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fbc8a92b21340f4a9f9dd87139c73b8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTUtMS0xLTI2NDQz_5f3261dc-e0d4-4bb0-969f-087e478f5e82"
      unitRef="usd">6041761</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9ff9e828ab24a868e3715a0d9d1a3cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90YWJsZTphMTg5MTk5OGY1ZDY0ODcyYWQyZWYyZjI1ZmE4M2E4MS90YWJsZXJhbmdlOmExODkxOTk4ZjVkNjQ4NzJhZDJlZjJmMjVmYTgzYTgxXzE2LTctMS0xLTI2NDQz_15073870-3502-4acd-92bb-f13abc3a6105"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i28c32f98e31846aaa2d17068ee0b3b77_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNDUvZnJhZzo0Nzg5MmE0ZmEzMjk0MDdhYWUyZmE2MGJmZDYwZTA4MS90ZXh0cmVnaW9uOjQ3ODkyYTRmYTMyOTQwN2FhZTJmYTYwYmZkNjBlMDgxXzI3NDg3NzkwODA2NzQ_9de0807b-2625-4f8b-b587-883db5749fc1"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzM3MQ_9cb739d5-b1ac-4132-85cb-011bf8ecafbf">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at December&#160;31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,474,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,661,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,357,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.08pt"&gt;Includes prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacture of INO-4800. The Company deposited a total of $50.0&#160;million to reserve manufacturing capacity, of which $30.0&#160;million was paid in 2020 and the remainder paid in the first quarter of 2021. Of these deposits, $35.0&#160;million was included in research and development expenses in December 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzM3Mg_4c35695b-ac2f-4344-ae9c-93fa6ddd1104">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at December&#160;31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,474,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,661,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,357,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.08pt"&gt;Includes prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacture of INO-4800. The Company deposited a total of $50.0&#160;million to reserve manufacturing capacity, of which $30.0&#160;million was paid in 2020 and the remainder paid in the first quarter of 2021. Of these deposits, $35.0&#160;million was included in research and development expenses in December 2021.&lt;/span&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzEtMS0xLTEtMTMwNzk_55010250-253b-49ed-979c-bf35fbe4cf5f"
      unitRef="usd">27474159</ino:PrepaidManufacturingExpensesCurrent>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzEtMy0xLTEtMTMwNzk_0f72db92-8d3c-4d0f-b9e3-a0b9e9092be7"
      unitRef="usd">35661947</ino:PrepaidManufacturingExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzItMS0xLTEtMTMwNzk_73846afc-0488-4152-8faf-d77396f869a1"
      unitRef="usd">11362832</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzItMy0xLTEtMTMwNzk_99f1cf6b-5575-4d0c-86e8-10b0b9ba7b18"
      unitRef="usd">4695509</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzQtMS0xLTEtMTMwNzk_2f82ac6a-0191-4ee6-b3b8-0b07bc4be1f3"
      unitRef="usd">38836991</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90YWJsZTo2Zjg0MGQwZmE2MWE0M2MxOWFlYjhmMjFlYTE5Y2JlZC90YWJsZXJhbmdlOjZmODQwZDBmYTYxYTQzYzE5YWViOGYyMWVhMTljYmVkXzQtMy0xLTEtMTMwNzk_646c35fe-73e9-45ff-8c00-848388c809b7"
      unitRef="usd">40357456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzEwOTk1MTE2MzExMjQ_5e1b13d4-4c28-4fc3-acce-2ce405dae279"
      unitRef="usd">50000000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PaymentsForDeposits
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzEwOTk1MTE2Mjk5MzQ_6c076d54-a091-4ad4-8f99-e5d9d65ac180"
      unitRef="usd">30000000</us-gaap:PaymentsForDeposits>
    <ino:DepositAssetsForfeited
      contextRef="i94ab88df768e4ba68e5d2e3d4e747e2b_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTQvZnJhZzphNTMwNWU2Mjg0MDI0ZDMxYTIxMWEzY2FlZTZhMzg5Mi90ZXh0cmVnaW9uOmE1MzA1ZTYyODQwMjRkMzFhMjExYTNjYWVlNmEzODkyXzQ5NDc4MDIzMjc1MzM_48d27062-8b13-48b9-af31-0bab286633b6"
      unitRef="usd">35000000</ino:DepositAssetsForfeited>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQ1Nw_fe316870-fbd6-4102-bb8b-79b41636f1fc">Fixed Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,258,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,544,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,392,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,113,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,397,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,944,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,453,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,179,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,549,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,788,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,727,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,296,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,419,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,341,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,993,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,348,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2021, 2020 and 2019 was $3.0 million, $3.0 million and $3.6 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2021 the Company disposed of fixed assets with a net book value of $89,000 and accumulated depreciation of $89,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQ2Mw_5b57664c-f5a6-437d-81bd-e41206451d38">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,258,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,544,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,392,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,113,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,397,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,944,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,453,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,179,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,549,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,788,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,727,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,296,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,419,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,341,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,993,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,348,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i69d4ecd562014440beb00576acad3efd_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzItMS0xLTEtMTMwNzk_95e3c386-5e9b-47e3-b64e-7da1c0dba5a5"
      unitRef="usd">15803108</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i69d4ecd562014440beb00576acad3efd_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzItMy0xLTEtMTMwNzk_de700004-1690-4328-bc30-3369130ca5b7"
      unitRef="usd">8258608</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i69d4ecd562014440beb00576acad3efd_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzItNS0xLTEtMTMwNzk_5ed03fc8-716e-485c-ade3-d7474579966e"
      unitRef="usd">7544500</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzQtMS0xLTEtMTMwNzk_5b759a0e-98ea-423f-857b-65240679cce7"
      unitRef="usd">12392916</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzQtMy0xLTEtMTMwNzk_7f486515-cd31-4e94-972b-78457f824668"
      unitRef="usd">4279816</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6424d4d5328d4d82a3e41a0f3e633e68_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzQtNS0xLTEtMTMwNzk_087c1995-e50b-4acc-91c8-78e00f90a706"
      unitRef="usd">8113100</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0eb6a32bee874e46833ded3ae075b6b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzUtMS0xLTEtMTMwNzk_8a77f056-f21a-4e4e-a0fd-067e340cb2d1"
      unitRef="usd">2827476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0eb6a32bee874e46833ded3ae075b6b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzUtMy0xLTEtMTMwNzk_fee39e7a-9d5c-456f-a8da-b2c38a502a35"
      unitRef="usd">2599643</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0eb6a32bee874e46833ded3ae075b6b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzUtNS0xLTEtMTMwNzk_ec2e46f2-6536-44db-81d9-ff51effe0bef"
      unitRef="usd">227833</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea32134d65f94c16977562bd8ec30416_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzYtMS0xLTEtMTMwNzk_039500b2-8bec-42e1-ba52-1a34c06affc6"
      unitRef="usd">5374084</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iea32134d65f94c16977562bd8ec30416_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzYtMy0xLTEtMTMwNzk_3bf8bf49-d681-4800-8869-d15c6c5c9c50"
      unitRef="usd">3806311</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iea32134d65f94c16977562bd8ec30416_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzYtNS0xLTEtMTMwNzk_ad026efe-114f-4d84-bb06-8a64e018812c"
      unitRef="usd">1567773</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzctMS0xLTEtMTMwNzk_5f346ebe-e68f-4552-abbb-e19ba9358b03"
      unitRef="usd">36397584</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzctMy0xLTEtMTMwNzk_0523d4d3-5014-4ab8-9c30-c09b0744a9f2"
      unitRef="usd">18944378</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzctNS0xLTEtMTMwNzk_b6ab3559-0ac0-4446-8c6b-d70dc17060b8"
      unitRef="usd">17453206</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1f5e0d4976d341d89e231839c5c36c4d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzktMS0xLTEtMTMwNzk_50e4dc82-17d5-4a2f-918d-fe7cf643777d"
      unitRef="usd">15179447</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1f5e0d4976d341d89e231839c5c36c4d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzktMy0xLTEtMTMwNzk_cc433ed1-8a1f-4ae3-a8c2-b43784e9745a"
      unitRef="usd">6549418</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1f5e0d4976d341d89e231839c5c36c4d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzktNS0xLTEtMTMwNzk_ba20efac-3787-4dcd-8950-3bdc96495292"
      unitRef="usd">8630029</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEwLTEtMS0xLTEzMDc5_28afdd82-0bc5-416a-8925-ac4bd31186e3"
      unitRef="usd">4788678</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEwLTMtMS0xLTEzMDc5_fe230eee-3167-4c19-952c-c07603259b47"
      unitRef="usd">3727508</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2ce9bccd8b5f418b9449eca740fbc69f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEwLTUtMS0xLTEzMDc5_e39735b4-3bfa-4ad3-823a-404c50ecd5ad"
      unitRef="usd">1061170</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzExLTEtMS0xLTEzMDc5_6d202e65-b6ec-431a-9d51-cecb36b027d4"
      unitRef="usd">2828675</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzExLTMtMS0xLTEzMDc5_155b32aa-a355-46c0-a8d9-cc319c49ef8c"
      unitRef="usd">2296942</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib348f7b2b7e54e0a8a4aaa4c92526c2a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzExLTUtMS0xLTEzMDc5_b11c15bc-45b1-4c6b-b783-87f7cf3bff79"
      unitRef="usd">531733</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9eeb3ced61044408997e1d8f8a05e001_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEyLTEtMS0xLTEzMDc5_6d5065de-87a6-4462-ab1a-a8ca73d85a28"
      unitRef="usd">4544915</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9eeb3ced61044408997e1d8f8a05e001_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEyLTMtMS0xLTEzMDc5_9ff8a44e-33ef-491a-9a77-64ad75fc7b7d"
      unitRef="usd">3419703</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9eeb3ced61044408997e1d8f8a05e001_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEyLTUtMS0xLTEzMDc5_1f675b98-031c-416a-9124-1b89fff26835"
      unitRef="usd">1125212</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEzLTEtMS0xLTEzMDc5_b3ad0d8c-4331-4f70-b5f3-c107c9264518"
      unitRef="usd">27341715</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEzLTMtMS0xLTEzMDc5_94c6e109-bda7-4ad3-a426-6b8b08ce31e7"
      unitRef="usd">15993571</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90YWJsZTo5Zjk5OTIxMTg2MDI0N2FiYTIyOWIxMzc2NWE0YWM2MC90YWJsZXJhbmdlOjlmOTk5MjExODYwMjQ3YWJhMjI5YjEzNzY1YTRhYzYwXzEzLTUtMS0xLTEzMDc5_89384e92-da37-4d88-8cc2-e88faa04cf3d"
      unitRef="usd">11348144</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzE2Ng_b30de149-4090-4cdf-b67a-9189c69dd342"
      unitRef="usd">3000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzE3MA_346819e6-34b2-4673-838d-1743a8c09caa"
      unitRef="usd">3000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzE3Nw_36d5f0dd-6053-4b59-bb54-0ef359412384"
      unitRef="usd">3600000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQxNw_5b823165-2585-4e43-b487-12a8d9d638ce"
      unitRef="usd">89000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNTcvZnJhZzo0ZGNkMGMwOTg5ZTk0NWZlYTFkOGEzY2ZlODBkZGU1Yi90ZXh0cmVnaW9uOjRkY2QwYzA5ODllOTQ1ZmVhMWQ4YTNjZmU4MGRkZTViXzQ1Mg_cb536194-44c3-4f5b-8b8b-e0449b9fca63"
      unitRef="usd">89000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzgyNA_b88493a5-52ef-48e5-b0ce-75749f88cb44">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:53pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,735,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense on intangible assets was $520,000, $547,000 and $1.1 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Amortization expense related to intangible assets at December&#160;31, 2021 is expected to be incurred as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzgxMg_b472547b-5920-4c5d-99b6-0e26636291da">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:53pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,735,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtMy0xLTEtMTMwNzk_30aa7e60-3047-4a78-8c76-affeb19bfe0c"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtNy0xLTEtMTMwNzk_e2ebc632-103c-433b-bee9-905f96b4765e"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtOS0xLTEtMTMwNzk_0ed70626-51ad-4dc6-8a10-03a241a09004"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzMtMTMtMS0xLTEzMDc5_a7c9ea14-fcbf-44ca-81a2-3c96296acaf9"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3a39711823f44fd6ac0aae903ff997dd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMS0xLTEtMTMwNzk_ca8450e4-7937-4af8-92eb-68ca8bfdc797">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id45f7a28571f47f4bd640ad228eaafca_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMy0xLTEtMTMwNzk_76066c32-ca0a-49e3-b9c8-53a96488990e"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id45f7a28571f47f4bd640ad228eaafca_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtNS0xLTEtMTMwNzk_df5b72b3-a059-42a2-9faa-daa495a37a68"
      unitRef="usd">1305600</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id45f7a28571f47f4bd640ad228eaafca_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtNy0xLTEtMTMwNzk_fc813871-dec3-4b4c-b5ce-f1a6b6980e01"
      unitRef="usd">18161</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib0adccf4f6d64811a0e0d98da2637677_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtOS0xLTEtMTMwNzk_09ab2bf7-b3e2-4331-ae9a-d88f0652712b"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib0adccf4f6d64811a0e0d98da2637677_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMTEtMS0xLTEzMDc5_a675d4c8-648d-4a1a-bd14-63faaf9ecb43"
      unitRef="usd">1276852</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib0adccf4f6d64811a0e0d98da2637677_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzYtMTMtMS0xLTEzMDc5_73448bc4-f443-4040-9629-e412dcce7711"
      unitRef="usd">46909</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8bfadc7f8c124e2897d43453679cc488_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMS0xLTEtMTMwNzk_6c6fd9f8-11d7-4e1b-9410-579a3f71a263">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i147d28db95ca40d8a9e71dd47520fcf3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMy0xLTEtMTMwNzk_a32b16d2-8b67-4759-96b4-a5bf955f4316"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i147d28db95ca40d8a9e71dd47520fcf3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktNS0xLTEtMTMwNzk_b6cca15e-1ab9-44f4-9596-65559c2c71d2"
      unitRef="usd">2735556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i147d28db95ca40d8a9e71dd47520fcf3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktNy0xLTEtMTMwNzk_fd48613e-91b7-4a5e-a849-3390845d4927"
      unitRef="usd">2364444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id1e398f1b0e24f15973a8336cc567723_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktOS0xLTEtMTMwNzk_49bfb9cb-ab07-4b16-9f59-2639d6cb4c6e"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1e398f1b0e24f15973a8336cc567723_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMTEtMS0xLTEzMDc5_5377efb2-3cc9-4c3e-90fa-2bbe7d3454e5"
      unitRef="usd">2468889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id1e398f1b0e24f15973a8336cc567723_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzktMTMtMS0xLTEzMDc5_0c7550e7-cee1-468a-91c3-660bd37931e5"
      unitRef="usd">2631111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if0e15729cf93490bab53bb5b3743cc9c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTEtMS0xLTEzMDc5_89d0a1b3-3094-40ff-80af-bfef326ac63a">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if9792ca724094babb1ceaaaf9e7f9699_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTMtMS0xLTEzMDc5_997bf197-faae-494f-b115-edbc466a5b69"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if9792ca724094babb1ceaaaf9e7f9699_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTUtMS0xLTEzMDc5_a6ac15f9-e05d-443a-988b-4ca3ad4ef64e"
      unitRef="usd">3806250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if9792ca724094babb1ceaaaf9e7f9699_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTctMS0xLTEzMDc5_a963246e-5e18-425f-9901-81765a327d91"
      unitRef="usd">243750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb405ddb59694654918b5c478e9d869e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTktMS0xLTEzMDc5_420b7264-b5e9-41e5-b84f-36e4e64ce24c"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb405ddb59694654918b5c478e9d869e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTExLTEtMS0xMzA3OQ_b9741829-082a-459d-9ec1-13cb547f1eb2"
      unitRef="usd">3581250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb405ddb59694654918b5c478e9d869e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEwLTEzLTEtMS0xMzA3OQ_2bc563a4-94f9-4094-bd83-430a3ebed044"
      unitRef="usd">468750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7eef2a859d2a4a548cea3f9cc63a809a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTEtMS0xLTEzMDc5_28bffa47-15e6-49cc-8a53-3d90261bcb62">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTMtMS0xLTEzMDc5_e2cab8bb-fe32-43e8-87cc-df625451aa37"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTUtMS0xLTEzMDc5_622c2676-f76b-4df9-9c78-ea568b1a9eb8"
      unitRef="usd">7847406</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTctMS0xLTEzMDc5_16367834-03a0-498c-8913-b7045770ac27"
      unitRef="usd">2626355</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTktMS0xLTEzMDc5_5c7760c2-2c1c-4af8-aa66-ddedb2804145"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTExLTEtMS0xMzA3OQ_78e38041-573c-4082-8981-6f9810695418"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzExLTEzLTEtMS0xMzA3OQ_42e0b1f5-0fae-40c8-8cf0-3c850aaa4b2d"
      unitRef="usd">3146770</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTMtMS0xLTEzMDc5_d69eade4-ec09-408c-804f-cf9739f7e3df"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTUtMS0xLTEzMDc5_74b76669-e70c-472f-857f-a74f097ef5b6"
      unitRef="usd">7847406</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTctMS0xLTEzMDc5_e5220564-0c07-4233-bc15-cce160e96c99"
      unitRef="usd">13139726</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTktMS0xLTEzMDc5_3e40abd7-ff84-4587-b59b-4fb8b1db6491"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTExLTEtMS0xMzA3OQ_859dab71-1ea2-4549-a422-d8051d1facbf"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTpmZjdlMzM3ODBiNzY0NGM4YjFmMzhmNWQxOWJjZDgxYy90YWJsZXJhbmdlOmZmN2UzMzc4MGI3NjQ0YzhiMWYzOGY1ZDE5YmNkODFjXzEyLTEzLTEtMS0xMzA3OQ_332a3ce9-c886-4e45-8be5-566387d8ed09"
      unitRef="usd">13660141</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzUwNw_0161cccf-1c66-4eb0-bd3d-4c00bec19744"
      unitRef="usd">520000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzUxMQ_1fecc8d8-cff9-493a-bb9c-f831c96c471e"
      unitRef="usd">547000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzUxOA_dbb5b499-0a6e-4c14-95ab-1091bc5a9a1f"
      unitRef="usd">1100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzgxNQ_91b21d59-3779-4804-ae8a-e26f6b1e559c">Amortization expense related to intangible assets at December&#160;31, 2021 is expected to be incurred as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzEtMS0xLTEtMTMwNzk_203a9854-f411-4401-b7b4-18cddce4ec1d"
      unitRef="usd">493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzItMS0xLTEtMTMwNzk_63485340-f4dd-4136-bbe3-64e7ea711e3e"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzMtMS0xLTEtMTMwNzk_6993ce11-0f65-40d2-9d5b-ac844ff569b8"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzQtMS0xLTEtMTMwNzk_8d1b5cb6-f314-4feb-8f7a-c286780b0d8a"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzUtMS0xLTEtMTMwNzk_6e5684a4-0a56-4c99-afb3-1c7b33f9b48a"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzYtMS0xLTEtMTMwNzk_45d9a49c-bee9-411b-ab65-33e3559d972b"
      unitRef="usd">1098000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90YWJsZTozNzI5ZTkxNTUxY2U0ZjNhODgzMjNiNjYwOGRmMmJkOC90YWJsZXJhbmdlOjM3MjllOTE1NTFjZTRmM2E4ODMyM2I2NjA4ZGYyYmQ4XzctMS0xLTEtMTMwNzk_fc0848bf-8f10-46b7-93f7-024168bfeda7"
      unitRef="usd">2626000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzY4Mw_325ab6ea-04f6-48b2-9149-d5c77857fd9d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzY4Mw_86b97708-9b29-4343-a9c4-64589c22bea8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzY4Mw_b6dbaff1-ef31-4514-bea0-d24d93f2fee9"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzczNA_051bb0c8-c948-4af3-94e8-7519b9000f21"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzczNA_2a36b0b1-4ca8-484a-a126-413ca44d3863"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjAvZnJhZzpjYWYyNTA1ZGJhYWY0OTM4OThiNzE5MDZmZjRmMjY4MS90ZXh0cmVnaW9uOmNhZjI1MDVkYmFhZjQ5Mzg5OGI3MTkwNmZmNGYyNjgxXzczNA_4cad2d8c-add9-4f3a-b2f8-39c006c7f1a4"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0ODgy_4b500148-d6a2-4dc3-b41e-f57b745494a7">Convertible Debt&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled into an aggregate of 11,535,660 shares of the Company's common stock. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8&#160;million gain on extinguishment of debt. Thi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;s gain was recorded in the consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,959,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021 and 2020,&#160;the Company recognized $1.9 million and $6.9&#160;million, respectively, of interest expense related to the Notes, of which $1.1 million and $4.1&#160;million, respectively, related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,082,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;August 2019 Convertible Bonds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were $14.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020, the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.69 shares per KRW1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the August 2019 Bonds was through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022. For the year ended December 31, 2020,&#160;the Company recognized $1.6 million of interest expense related to the August 2019 Bonds, of which $87,000 related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the August 2020 conversion in full of the August 2019 Bonds, the derivative liability associated with the August 2019 Bonds was revalued at $84.5&#160;million. The change in fair value of the derivative liability was an increase of $75.7&#160;million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature did not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature met the definition of a derivative, it qualified for the equity scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#x2019;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#x2019;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the December 2019 Bonds was through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is 6.2%. For the years ended December&#160;31, 2021 and 2020,&#160;the Company recognized $50,000 and $253,000, respectively, of interest expense related to the December 2019 Bonds, of which $9,000 and $40,000, respectively, related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock. Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzEzOA_984e1351-3dff-4813-b298-b4c73e874446"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE3NQ_a273bccd-46cc-4f3e-8c87-b8632dbd878c"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i4c6e93100cda41698c2d90ac7b3add33_D20190219-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQyMQ_e489c0c7-dd78-461c-91f5-99528e282f43"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzYzMA_b8c9be79-4b74-404c-84ee-b39df687c73f"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0MzI_09da20cd-ac0d-4bcf-92b3-f0dcec02794c"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE3NDQ_8d2e6ed3-9eee-4469-97a6-65f81c9281f7"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE3OTU_742113df-a013-4ba7-91b3-4a6442cbe002"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE4NTE_7c2e0454-ca45-4b91-a9fe-27d7ed721144"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxMjI_23da3a48-592d-4e7b-b294-60bd84a27093"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzI2NTE_860885b2-afb9-4030-8d66-cea9c58e23b6"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzI5Njc_9b4df5ac-7c29-48a8-b2c1-90cd5ae80c8a"
      unitRef="usd">62200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzMxNzk_5394fc86-f497-4e32-93d2-1008fe04d753"
      unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i12c81efc53744ccbba4e8d22c10d48c8_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzM4MzM_25844317-e21d-47ce-80a6-408bf3ceb10a"
      unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQwNjM_3dd33c60-f41d-4165-aa04-5632b0d660b7"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQxNTk_67192cf0-127d-4b31-8d22-8b4d9edee4c6"
      unitRef="usd">62100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQyMzY_d9539da7-3b9e-4174-a7fd-0f7db3811d33"
      unitRef="shares">11535660</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic34a66f65e034d328e08870d700f693e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzMzU_20f2876e-f0cc-4701-9c47-3b90a940b26a"
      unitRef="usd">43700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ic34a66f65e034d328e08870d700f693e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzNzI_d6d4d647-bde7-4305-9633-c48ef4de10d8"
      unitRef="usd">52500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzOTE_9089f170-b431-4671-ae9d-8c7a513750f9"
      unitRef="usd">8800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0ODgw_3090278f-3217-4216-bc6d-dada7219899a">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(219,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,959,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzAtMS0xLTEtMTMwNzk_99b4c9fc-b56e-420b-9378-476c5937857e"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzEtMS0xLTEtMTMwNzk_fd6556de-8791-4753-bf52-9363b284f57f"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzItMS0xLTEtMTMwNzk_5579ed18-5b0b-4179-91d2-cf6e24cfe557"
      unitRef="usd">1591909</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzMtMS0xLTEtMTMwNzk_b471df06-c212-4c64-b518-b35cd2dcfd03"
      unitRef="usd">219101</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtinstrumentAccruedInterest
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzQtMS0xLTEtMTMwNzk_e556ec79-c9f3-4e35-9a2c-cdac6c020cce"
      unitRef="usd">355657</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="i347d60d556c2498fb9d80645b9a706b2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZTo2MGRiMDgzM2M5MWY0ZmM1OWY0ZTFiZGQzMTdhZWZiMC90YWJsZXJhbmdlOjYwZGIwODMzYzkxZjRmYzU5ZjRlMWJkZDMxN2FlZmIwXzUtMS0xLTEtMTMwNzk_0445704a-90e5-47d5-9315-8843ecace88e"
      unitRef="usd">14959647</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ3NjU_ac91f295-f0ca-4a4a-8c8e-78f42b84dd97"
      unitRef="usd">1900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ3NzI_bf4e0ad7-502e-4102-833d-2408ff56bcb9"
      unitRef="usd">6900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i6e1b7219b2774b0b8cd6172df54c441c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ4NDE_c1ff4c8b-d3e3-4095-916e-07ccdb0ec0de"
      unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i64bb83c1af53463db93165f16058040b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQ4NDg_09bcaa69-8230-4fe0-a2b1-27c8b51fc662"
      unitRef="usd">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzQzOTgwNDY1MzY1NTU_9dbbfab3-c3f7-44a4-b686-93cbc61a5712">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,082,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyODA5MzQ_cfc02137-82e3-402a-8d54-f8db60227456"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzMtMi0xLTEtMTQ5ODM_3b11bea6-6f8f-4c5a-910e-50ff5f39104b"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzQtMi0xLTEtMTQ5ODM_6eecb386-15b3-433e-8b36-dfdcde8c5697"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzUtMi0xLTEtMTQ5ODM_3b37cd25-9d03-403c-9f46-a5b9fedb5fce"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="i916cd8866e36499abf272f07df39ec4d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90YWJsZToyMjVjYjVkNWRhNGI0MjZlOTc1NTYwNDk5YWJlOTBjYS90YWJsZXJhbmdlOjIyNWNiNWQ1ZGE0YjQyNmU5NzU1NjA0OTlhYmU5MGNhXzctMi0xLTEtMTY5OTU_267cc760-6bdd-4ece-8e42-48755f5f1941"
      unitRef="usd">19082000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzUwNjQ_80058217-6b02-4392-99ed-d8c8a04d2555"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzUwOTA_728cb357-630b-4df4-897b-52913502cc7f"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i51416fb82fda4188a3a2a2e3f710d077_D20190801-20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzUzNDE_ccebdddd-d761-492e-ad97-61eb87c2a1e2"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzU0ODg_45916475-a32f-4995-996a-1c823c3a20a6"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i3478042f83d6449ead46d859f7d60ffe_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzU3MTE_f86269a9-5543-4b2d-8463-10b5b44a2e4a"
      unitRef="shares">4962364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="icd20ef4b33f94e01bf76d24ff90685b4_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzU5Mzg_c13e711d-032a-4b76-8193-afe6d87fe5c1"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="iac8579f0882d4dc59ef160f7c64b5672_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzY0MDQ_2c177ca3-2ea7-4d6a-8281-738e6d52eca5"
      unitRef="usdPerShare">3.14</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzY4MzY_9b5cc53c-a72b-4b74-b5b1-24d6d8a0e7c2"
      unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i90a45ddead5f4816a5c59b73845dad0e_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzc4NzM_af627c39-aa88-4cf9-bb4e-2f23e10deca0"
      unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpense
      contextRef="i7ba0ea858d9c46c78c2859dc92d5033e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzgwOTg_9639682a-c88d-4632-9390-ff7f5e68cd76"
      unitRef="usd">1600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i7ba0ea858d9c46c78c2859dc92d5033e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzgxODY_11d344cc-d804-47ca-aa02-d02030dfaf11"
      unitRef="usd">87000</us-gaap:InterestExpenseDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i0c5bcadd2c7245faa4cb1ac2870fd0ab_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzg0MTg_59fc2ced-15fa-4563-8eaa-da95c5a08b36"
      unitRef="usd">84500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzg0OTQ_5ba2c12a-c7da-4fcf-8890-f343db66a34c"
      unitRef="usd">75700000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzg3NDA_95fcbd3e-4941-45a4-96d7-be2763b97ca5"
      unitRef="usd">-8200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i20202f34a17e4484a5db9dee4a908204_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzkwNzg_898dfb82-3076-40ee-bb08-bc1c0229b501"
      unitRef="shares">4692364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i353adf10991e4196a4b209b6a5267e9c_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzkzMzQ_4dff8101-5dfc-461f-ac4b-e22b31c8ebf2"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i353adf10991e4196a4b209b6a5267e9c_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzkzNjA_d95a3820-1d70-44d5-af4d-9e5e7be529f8"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i6039cba34e8c4be6a904174d99de85a8_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzk1MTM_b48fef62-98df-4f0f-b75f-094767985160"
      unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i353adf10991e4196a4b209b6a5267e9c_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4Xzk2NzA_0255f044-e0af-4eb9-b312-7b919c9f41bf"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzEwODQ_31847b40-4f81-4010-b9a3-1e3faa99fa41"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i5fceb3f6f682487baf3242c63275edbd_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzEwMzkx_c3bd2838-c7a2-4fd0-8332-a2d9969fd942"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i23bc4609abe8422ca6b1d83a291a407a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0MTYx_2b09c60c-9591-4022-a9a1-d9ecd9acd6d1"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzg5OTU_2f1c59be-017e-4bb6-bc31-fa6fbe83921c"
      unitRef="usd">50000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic2fc5c2b195e47d38f45dbda9f77eb42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0MjEx_8394f568-eaf5-433c-a69e-d605dd4c24aa"
      unitRef="usd">253000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzkwMDQ_a9ab300b-2e5b-43f7-8a3c-0bad610eaf18"
      unitRef="usd">9000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic2fc5c2b195e47d38f45dbda9f77eb42_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzE0Mjc5_f0b0a0f1-c047-42ae-9523-4d66e05d5c8e"
      unitRef="usd">40000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzkzMTc_83c826e6-1f68-43a9-b300-0276d179f706"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i85915c3d427b495197df94d39dff08ba_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjMvZnJhZzoyOGRmNjViYmZlN2I0ZDI3OGNhMjIxZjI2NDgwMWM5OC90ZXh0cmVnaW9uOjI4ZGY2NWJiZmU3YjRkMjc4Y2EyMjFmMjY0ODAxYzk4XzIxOTkwMjMyNzkzNDE_a4b83011-076f-49c5-9558-3c2c8ff1944f"
      unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90ZXh0cmVnaW9uOjQ5Y2M3MGM2MGMzZDRhMzVhNGNjYzQzNmZiOTQzZWM2XzE0Nw_b34ada42-6c10-4ee3-8ce4-8bff81a8b9fe">Accounts Payable and Accrued Expenses&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,213,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,112,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,127,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued subcontract costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,003,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,644,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,203,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90ZXh0cmVnaW9uOjQ5Y2M3MGM2MGMzZDRhMzVhNGNjYzQzNmZiOTQzZWM2XzE0NA_a2c87691-f75c-49cf-9859-e6e5c5a59acc">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2021 and 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,213,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,112,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,127,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued subcontract costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,003,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,644,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,203,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEtMS0xLTEtMTMwNzk_7aa6f055-fd21-475c-99d4-5b3600e45c2e"
      unitRef="usd">24213673</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEtMy0xLTEtMTMwNzk_b0643455-3fb9-4b83-964e-726d588e05b2"
      unitRef="usd">825516</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzItMS0xLTEtMTMwNzk_54592c4a-4fae-4865-b1b6-edb6d6d134d0"
      unitRef="usd">16112912</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzItMy0xLTEtMTMwNzk_2c1e23d4-751e-42ce-896f-8b515464efd1"
      unitRef="usd">13127257</us-gaap:AccruedSalariesCurrent>
    <ino:AccruedSubcontractExpenses
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzMtMS0xLTEtMTMwNzk_e23a9522-9681-4104-a2ef-53dc73cd576f"
      unitRef="usd">11602</ino:AccruedSubcontractExpenses>
    <ino:AccruedSubcontractExpenses
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzMtMy0xLTEtMTMwNzk_56e71735-f9f0-4427-b20a-cee8cd38bb68"
      unitRef="usd">247796</ino:AccruedSubcontractExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzUtMS0xLTEtMTMwNzk_5b0d359f-880b-40c6-b4c9-06f7a9ffd479"
      unitRef="usd">7306343</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzUtMy0xLTEtMTMwNzk_2753384b-a35f-48cd-a541-2b4d6929c592"
      unitRef="usd">7003239</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEwLTEtMS0xLTEzMDc5_213c7436-8bc4-4862-8156-260fd6b5694f"
      unitRef="usd">47644530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNjkvZnJhZzo0OWNjNzBjNjBjM2Q0YTM1YTRjY2M0MzZmYjk0M2VjNi90YWJsZTowNDA3MWMwOTM1MjQ0MjY4YjgwMzBkNTRmMTYwZDY1YS90YWJsZXJhbmdlOjA0MDcxYzA5MzUyNDQyNjhiODAzMGQ1NGYxNjBkNjVhXzEwLTMtMS0xLTEzMDc5_8aec0665-5e16-4b93-bf9b-ccbef07a121b"
      unitRef="usd">21203808</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwOTk_8545c000-5b5c-4bcc-bf3d-9992965378ac">Stockholders&#x2019; Equity&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, 14 shares of the Company&#x2019;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#x2019;s option, to convert all or any lesser portion of such holder&#x2019;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;as $27.20 per share, such&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. For the year ended December 31, 2021, the Company sold 6,955,341 shares of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $6.96 per share, resulting in aggregate net proceeds of $47.7&#160;million. As of December 31, 2021 there was $251.6&#160;million of remaining capacity under the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "2020 Sales Agreement") to sell shares of its common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the 2020 Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company sold a total of 22,919,934 shares of its common stock under the 2020 Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2&#160;million. As of December 31, 2020, there was no remaining capacity under the 2020 Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#x201c;Placement Agent&#x201d;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which the Placement Agent will act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into amendments to the Sales Agreement (as so amended, the "2018 Sales Agreement") to increase the amount of common stock that could be sold under the 2018 Sales Agreement from $100.0&#160;million to $250.0&#160;million. During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the 2018 Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2&#160;million. As of March 31, 2020, there was no remaining capacity under the 2018 Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December&#160;31, 2021, the maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan was 20,000,000 shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2022, the maximum number of shares increased by 2,000,000. At December&#160;31, 2021, the Company had 4,481,745 shares of common stock available for future grant under the 2016 Incentive Plan, 2,448,868 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 8,060,957 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2021, the Company had options outstanding to purchase 2,428,036 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 was $25.0 million, $14.5 million and $9.8 million, respectively, of which $13.4 million, $8.0 million and $5.9 million was included in research and development expenses and $11.6 million, $6.5 million and $3.9 million was included in general and administrative expenses, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021 and 2020, there was $16.5 million and $4.4 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.0 years and 1.4 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021 and 2020, there was $13.4 million and $10.9 million, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.8 years and 1.9 years, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, 2021, 2020 and 2019 was $1.4 million, $1.2 million and $970,000, respectively. As of December&#160;31, 2021, options to purchase 632,375 shares of common stock granted to non-employees remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.60-$3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.01-$6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,137,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01-$9.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,148,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.01-$12.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.01-$15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01-$25.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,790,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the aggregate intrinsic value of options outstanding was $3.8 million, the aggregate intrinsic value of options exercisable was $3.1 million, and the weighted average remaining contractual term of options exercisable was 5.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the aggregate intrinsic value of unvested restricted stock units was $12.2 million and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, 2021 was $12.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, options to purchase 10,488,993 shares of common stock and 2,448,868 restricted stock units were expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2021 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,310,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,387,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price per share was $4.56 for the 7,000 options which expired during the year ended December&#160;31, 2021, $4.44 for the 78,750 options which expired during the year ended December&#160;31, 2020 and $6.27 for the 324,502 options which expired during the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $7.61, $6.87 and $2.19 for options granted during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value was $10.37, $9.12 and $3.09 per share for restricted stock units granted during the years ended December&#160;31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received $6.7 million, $12.3 million and $113,000 in proceeds from the exercise of stock options during the years ended December&#160;31, 2021, 2020 and 2019, respectively. The aggregate intrinsic value of options exercised was $7.0 million, $14.2 million and $25,000 during the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the year then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwNzg_112a049e-9317-4346-a8db-eded11857066">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpkZjY4OWQyOTAyNzc0NDRjYTgwZWY1ODFkZjZjM2RjN18zNA_349ce023-c258-4ae8-820c-225e782d7749"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtMS0xLTEtMTMwNzk_6b46d908-f850-4dd9-b190-a8967f7e7be0"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtMy0xLTEtMTMwNzk_d577cae9-bc4a-480e-9b38-9369d62e6256"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtNS0xLTEtMTMwNzk_72967407-c7c9-4a64-a3ec-3cf237afb01e"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i98fcd21abb664100b8f5b38c37fe8294_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZToxYzRjMDJkODM2NzE0ZGRiYjI4MzkyMDEwMzQ3NmRhMy90YWJsZXJhbmdlOjFjNGMwMmQ4MzY3MTRkZGJiMjgzOTIwMTAzNDc2ZGEzXzQtNy0xLTEtMTMwNzk_e6abd370-b5fd-41bf-8433-5a70ff4ffd32"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i40a8e6a6790645be83c7f3d6ff04f333_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY1_6bff6e73-5cb1-4f86-8009-5b0bbb2a70f7"
      unitRef="shares">14</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i25d15f4eda32428fa3a38009bc9b503f_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzE1Mw_d364dc93-8676-4af6-86a4-e01b0fce42b4"
      unitRef="shares">5147</us-gaap:ConversionOfStockSharesIssued1>
    <ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUwMQ_bf19af12-86a0-4a52-bdf8-4c1130b76a6e"
      unitRef="usdPerShare">27.20</ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzYxNA_af9e2058-aa9c-4651-8884-7cd35891ae05"
      unitRef="shares">3309</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i0beb8343704b4e66bf518dc68c5d9e59_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyNzk3OTA_fca781c3-93f5-4286-a5d3-98c710b1a943"
      unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage
      contextRef="i0beb8343704b4e66bf518dc68c5d9e59_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyNzk3OTM_9bd79599-adbd-4f40-9b21-d218edd3b194"
      unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyODAxMzk_a26311b8-c4c3-447b-8b1c-36cbf33ab40f"
      unitRef="shares">6955341</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyODAxMDE_198e866f-b473-4f73-8615-7eaacd299da1"
      unitRef="usdPerShare">6.96</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i2cdafd8f6010493e97519bfc8976bac6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyODAxMjM_0ce2eb09-5d59-438a-b53b-d95f7de37ce0"
      unitRef="usd">47700000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i23b51ec2c12f42e7a12b929edad6ac3c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NTU4ODA_3e01cd84-59de-4504-a082-02f06ca3f76b"
      unitRef="usd">251600000</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i49f555fa92724b73a79e6f05d158c07e_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjM1MzQ_28bb06a8-6a01-496e-90a2-1ac4425100be"
      unitRef="shares">20355000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1b4c0934496e4fd69eff228d86ee8f98_I20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjM1OTE_8bfd5319-5d7c-480c-862f-7ab4a1ae5aeb"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i49f555fa92724b73a79e6f05d158c07e_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjM3MzM_a027823d-e801-420c-b6b2-550f49c0154f"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i753fd66a6adf4a97a3cb8ca8d0b01238_D20200512-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAyNjk_82867da2-e5ae-4754-8a3f-3a152f534085"
      unitRef="usd">250000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzMjE_48cd85d1-77c9-476f-8bcb-c4c95278322a"
      unitRef="shares">22919934</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzMzM_09fddd4d-d5be-4cac-95ca-6753c67ca941"
      unitRef="usdPerShare">10.91</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i12390b7136bf4f9281531bd1ed87fb34_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzNDI_173123a9-b0b5-4e21-a7eb-36e085845078"
      unitRef="usd">246200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i6e3ea451d4a04b0abec238235c56f2be_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzIxOTkwMjMyOTAzNDA_67cf027f-4894-4854-815d-1652550aacb6"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i43a1d23049ec4dc7a76ba1a881242cad_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjQ4MjI_7faf6d34-da7d-433a-b68e-34a7586e9283"
      unitRef="usd">100000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i43a1d23049ec4dc7a76ba1a881242cad_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUyMDk_01af127d-3df8-4285-bc28-3f73b93f6cbb"
      unitRef="usd">100000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="ie5029be83e87418db970ef84ed1a4011_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUyMTY_f1d92813-09bd-4f7a-b755-837305418610"
      unitRef="usd">250000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i7880a35a7d84470b865daeee2cd2fc5c_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUyODQ_27fefb41-f82c-43bf-b845-9f7cd2d97f9e"
      unitRef="shares">43148952</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6b2929e55be54db5a11cf6c1aae0b709_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjUzOTg_3c11a3ee-8c58-4fab-b2d4-b25207b55638"
      unitRef="usdPerShare">4.92</us-gaap:SaleOfStockPricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i7880a35a7d84470b865daeee2cd2fc5c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjU0NTI_29abd6a3-e818-4a92-98ff-00a6bc0878c1"
      unitRef="usd">208200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i6b2929e55be54db5a11cf6c1aae0b709_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzEwOTk1MTE2NjU0ODk_d1585958-1d5c-4d6c-86d9-dc9de2ad21c7"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i13e80425e56b494380b3ac92a6bad40b_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzM3ODg_f1ddbae9-6791-4cb6-80c5-ea7ccb86d3b7"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i13e80425e56b494380b3ac92a6bad40b_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzM5NTM_e05780f5-0986-4d5d-93ec-7e6608b95d59"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="ic3a43045796d477a93feae3365556de6_I20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQyNTA_073e1bd6-bfac-4a73-9288-09d71917dd8e"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i368a7f5ff9214108a0ffca3a870b9948_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ0NTA_9274bc7c-27cb-41d7-9219-655b24bea839"
      unitRef="shares">4481745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan
      contextRef="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ1MzQ_844a0d16-39bc-4f2e-9c1b-0f11cd447d6b"
      unitRef="shares">2448868</ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i368a7f5ff9214108a0ffca3a870b9948_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ2Mzk_3a39cf21-3c8b-48bb-86f1-8c2c4f151cae"
      unitRef="shares">8060957</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ3OTY_2ec5cd68-92b7-4f74-acc0-45900be54e7f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ie618544291f74d8e8f91fa01dda8697b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzQ4Mzg_52909d61-7e76-47b3-a361-9586e3ca2458">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i631230ffee974729a0560f9e16c5f441_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUxMjE_cf89c96f-8e5b-40d3-9dc0-c4a216b9d718"
      unitRef="shares">2428036</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6791f3241d2d4b26860e5a3f33455b90_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUyNDc_d8695456-e1f3-4df3-851d-f3ecfb5e364b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i6791f3241d2d4b26860e5a3f33455b90_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzUyODk_f9915a24-1dc4-4999-982d-342ff54b9c14">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensation
      contextRef="i407c6b8fb0da42379265bd134df26349_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU0NjI_00acd5eb-497d-4ee6-b052-32cc194a522a"
      unitRef="usd">25000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i768073d462a746ae9a55cb59ee67fdff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU0NjY_a9042a0a-ca0f-48ba-a9b7-46099bfcb76d"
      unitRef="usd">14500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2c52650eb05d4d77a1dc769d4513b048_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU0NzM_94470745-80f4-45e4-82ef-52e883a6bc56"
      unitRef="usd">9800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i36b6f9125f4245038f3ccc1233da0d79_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1MDA_4517d634-89b6-4691-adad-ecaa7beb415d"
      unitRef="usd">13400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i55226aff8520430581c928fb4cdbc54f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1MDQ_be66ead6-4f69-4143-ae51-7d9955d83a7c"
      unitRef="usd">8000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i11d51be8fd474946a4d6832b362af324_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1MTE_5b1e034a-9d17-4454-a867-34b6323e008e"
      unitRef="usd">5900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8c8d2335ada94a8d968b2b3a1caa5fdf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1NzY_04e915ab-a9db-4f69-9d41-6ac4de4c439e"
      unitRef="usd">11600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibf8a9cd7d8fa44d79020983a83a16598_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1ODA_7b22631a-429c-48f8-b394-480103f0cb7e"
      unitRef="usd">6500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1f5b1cda2b6d4b0b901a301aea31851b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU1ODc_f885ccee-9194-49f3-8f8f-87fcd0dff8b8"
      unitRef="usd">3900000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU2OTQ_6f648eaa-6a9b-4e8a-950e-9a72c0a1411d"
      unitRef="usd">16500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU3MDk_815a27ea-5f3c-4df0-b241-5743fac71fc5"
      unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU4NzQ_38b570a4-4225-4244-9d73-b2c3fe9d7be0">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU4ODc_4b00e6e4-7328-444b-b0a4-1fc93db34063">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU5NDI_39122b5e-538b-4630-b835-5a9deb7957aa"
      unitRef="usd">13400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib54d8bf639154cb89c4ba6de26467b78_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzU5NTc_ae7a2207-44b1-4e78-960e-8fef30b3409c"
      unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzYxMzE_ec665c4e-b000-4cc4-b3d5-a65a08719b91">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie18a5ae792de49a48808b18a814cd872_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzYxNDQ_fa7a423f-e42f-423d-9977-aec292f18a09">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3954ccf6ef6747ef8feb9744b59bb557_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY0NDA_0eadfa50-b84a-42e6-869d-0a7defd7ef10"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaccbaf36a42a44229ce94ccb6af44093_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY0NDQ_288f5a28-ba46-4785-a105-483fb441f6cf"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99beda0a9bac415092a4c08da1889be8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY0NTE_9c1cf0ca-b3aa-4993-abef-f75ec29d690e"
      unitRef="usd">970000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifd750ff594294f0c811ec9edaa677c38_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY1MTI_1c620f5f-1b5b-465a-ba85-545ed7e22447"
      unitRef="shares">632375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkxMDk_3c3e4686-a755-4c1c-81d6-ab142a721518">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.60-$3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.01-$6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,137,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01-$9.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,148,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.01-$12.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,562,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.01-$15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01-$25.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,790,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjozMDQ2NGJlM2EyYmI0NGU1OTgyYmE3YjBjMTBhZjFkYV80_6a5e93f3-f138-487a-ba91-3cd56895d09b"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjozMDQ2NGJlM2EyYmI0NGU1OTgyYmE3YjBjMTBhZjFkYV83_3133c71d-168e-4db2-96ab-5e8e2ffefebf"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMi0xLTEtMTMwNzk_532ab2df-f75c-48d1-b282-f5a3022f43bf"
      unitRef="shares">272063</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="id842db37cd6d4830ba4f482fb1397c95_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItNC0xLTEtMTMwNzk_4f8fba3f-459d-4e56-a1b6-d4c1b0178cdf">P1Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItNi0xLTEtMTMwNzk_4fff39c9-036c-4d6e-9187-fd713b61019a"
      unitRef="usdPerShare">2.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItOC0xLTEtMTMwNzk_1df1348d-8558-432d-87df-97c53cf1f0f3"
      unitRef="shares">262148</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i0f6e9f1fcfaa4313843f20644b3ea031_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzItMTAtMS0xLTEzMDc5_93185799-c5db-4d60-b52b-cca63668437a"
      unitRef="usdPerShare">2.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjowYjY4M2U4N2QxNjY0M2E5OThmNzVmZTcwNWRiMzg2Ml80_b7b2614c-95d7-4ca3-b3df-93507a38c1da"
      unitRef="usdPerShare">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjowYjY4M2U4N2QxNjY0M2E5OThmNzVmZTcwNWRiMzg2Ml83_c2ec5507-71a8-4326-b88d-24e63fec0a57"
      unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMi0xLTEtMTMwNzk_21fd6d62-e291-4b27-ad29-fbefc7684638"
      unitRef="shares">2583652</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic521f786ce7e495395e99fff73bf9578_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtNC0xLTEtMTMwNzk_a0ac2d9b-de19-488b-860f-6288cf49c7a1">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtNi0xLTEtMTMwNzk_ac097b40-4fea-492a-a4da-7756abec3bc2"
      unitRef="usdPerShare">3.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtOC0xLTEtMTMwNzk_8ad2318a-4105-4465-a843-325fce07bc62"
      unitRef="shares">2137202</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i59bd8fb3a94a4250b276d32d4de3f266_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzMtMTAtMS0xLTEzMDc5_1496d38e-e523-469d-9d7b-9841d65b75bd"
      unitRef="usdPerShare">3.88</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjo0MWMyYTNlZDUyZTQ0MGY0YjZkNzNmZDI0MzBmMTdhMV80_93780ac5-3970-4989-b2da-d5a09e80906e"
      unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjo0MWMyYTNlZDUyZTQ0MGY0YjZkNzNmZDI0MzBmMTdhMV83_014eb591-a3f4-402d-a4e7-1b993021c84a"
      unitRef="usdPerShare">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMi0xLTEtMTMwNzk_6e28ece4-e34f-462d-b74b-a138db10c4c6"
      unitRef="shares">4148238</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ieaec62e1e92443be91ddd62c111ac26c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtNC0xLTEtMTMwNzk_62c5cf60-6615-4bb2-a747-54b8aa8db6cb">P6Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtNi0xLTEtMTMwNzk_f6bfdeba-f73b-4de2-8625-c8d368b0fbcb"
      unitRef="usdPerShare">7.60</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtOC0xLTEtMTMwNzk_4d8bf4c4-3217-4afa-bac7-d7c20648f43c"
      unitRef="shares">2848150</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ia38954b11aa549609db2fb805ac849ef_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzQtMTAtMS0xLTEzMDc5_b179d1bd-54ed-4066-b92c-b99bdc79ecbd"
      unitRef="usdPerShare">7.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="if9f81ea99dba400ca4654757465a0324_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpmY2VlNjliODJiZDA0ZjU1YTlhYTM3MTM5NTU4NWMxZV80_e4397f70-6d4e-4c07-bda9-3f49c09e5362"
      unitRef="usdPerShare">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="if9f81ea99dba400ca4654757465a0324_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpmY2VlNjliODJiZDA0ZjU1YTlhYTM3MTM5NTU4NWMxZV83_1c91c4c5-8314-4039-b230-515a75361487"
      unitRef="usdPerShare">12.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMi0xLTEtMTMwNzk_3430d5ad-d8d8-4510-a8be-59dbd01239d1"
      unitRef="shares">2562668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="if9f81ea99dba400ca4654757465a0324_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtNC0xLTEtMTMwNzk_a32c17fa-ed68-444d-bad5-abaafd1f9c6e">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtNi0xLTEtMTMwNzk_9b7cc448-d249-4384-a860-dbb18a25155c"
      unitRef="usdPerShare">10.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtOC0xLTEtMTMwNzk_bccae2b2-e9f0-4630-a3be-15f8a89d5770"
      unitRef="shares">827259</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i04c01a40e2f44c378fc95b4edf730f2b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzUtMTAtMS0xLTEzMDc5_ad702978-b9fb-4e09-9032-83d5a4a0f322"
      unitRef="usdPerShare">10.77</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i607dff749d1b494aa307f2fde9568207_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpjNDMyZjA3NTYxYTE0MDcyOWQ3ZTIxZDAwYzI5NDZlOV80_b3c17699-09e6-48ab-b3bd-e08e3d53237c"
      unitRef="usdPerShare">12.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i607dff749d1b494aa307f2fde9568207_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpjNDMyZjA3NTYxYTE0MDcyOWQ3ZTIxZDAwYzI5NDZlOV83_eddcc553-ce3f-4a70-8e84-6892fbdb6b72"
      unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMi0xLTEtMTMwNzk_0fa6daf4-2c53-4b27-826b-6bb9cb81569d"
      unitRef="shares">824184</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i607dff749d1b494aa307f2fde9568207_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtNC0xLTEtMTMwNzk_86cc474b-b0f7-404f-8f8e-f607a439089d">P5Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtNi0xLTEtMTMwNzk_d6e1111f-1fd6-485f-8cb0-1ff920cc7c16"
      unitRef="usdPerShare">13.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtOC0xLTEtMTMwNzk_4f1b5631-324c-4c3f-a0f4-d2ba0e968213"
      unitRef="shares">663646</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i3e52516b45654a51bf00e5f9ae24f3fa_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzYtMTAtMS0xLTEzMDc5_1f9b8449-6a63-4f56-b12b-e04ade24c722"
      unitRef="usdPerShare">13.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpiYmJkMzJkZTJiMDA0ZGU3OWY4MjQyZTlkNzE3ZTNiYV80_63df19f4-cf20-4a9d-a65b-65016ea34d14"
      unitRef="usdPerShare">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMC0xLTEtMTMwNzkvdGV4dHJlZ2lvbjpiYmJkMzJkZTJiMDA0ZGU3OWY4MjQyZTlkNzE3ZTNiYV83_24c97fb7-ecec-4dea-97ef-7d8086b50582"
      unitRef="usdPerShare">25.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMi0xLTEtMTMwNzk_3605e561-ea2b-4f42-a3b3-187bcb76c96c"
      unitRef="shares">98188</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i54c532668ab84d78ae93e5902b39a8f3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctNC0xLTEtMTMwNzk_05d01fbc-281e-4ee9-8d92-ad5d7d2c8e82">P8Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctNi0xLTEtMTMwNzk_5befcc73-d84c-48c8-a960-522e24dded5f"
      unitRef="usdPerShare">20.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctOC0xLTEtMTMwNzk_2f8f53e4-77bd-42b2-9b64-bfd2e119fedd"
      unitRef="shares">52227</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="iab6ee4037eb5497aa0a8913a3b11d2d4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzctMTAtMS0xLTEzMDc5_533be647-6162-431f-adc7-5abf04b6badd"
      unitRef="usdPerShare">20.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtMi0xLTEtMTMwNzk_6cef3329-fe06-4218-be99-5f06f0425dc6"
      unitRef="shares">10488993</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtNC0xLTEtMTMwNzk_e4a7e12e-0ab9-4fef-84d4-23076c301f42">P6Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtNi0xLTEtMTMwNzk_edb9f43e-f22d-49f5-a497-a72d631a564b"
      unitRef="usdPerShare">7.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtOC0xLTEtMTMwNzk_28529f31-6215-45cd-acd1-f9818f21a793"
      unitRef="shares">6790632</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo1MjNjNDkzZDM3ZTg0ZTdkODIyOGI1MGJjY2JjNDQyNC90YWJsZXJhbmdlOjUyM2M0OTNkMzdlODRlN2Q4MjI4YjUwYmNjYmM0NDI0XzgtMTAtMS0xLTEzMDc5_3c227c96-0b0f-40d9-a48a-23db3f4bb6f3"
      unitRef="usdPerShare">7.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY3NTE_9a0dd8dd-2ce5-4794-b97e-df7d84822199"
      unitRef="usd">3800000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY4MTI_786a9878-1dd1-456b-8d6c-2cd0ca91282c"
      unitRef="usd">3100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY4OTU_c0dc534e-045e-47a8-aa2f-0796241e010a">P5Y10M24D</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzY5OTQ_a7d05d44-1180-437d-a46b-ef61f066b97f"
      unitRef="usd">12200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzcxMTI_b65758c4-254c-4c32-8d34-2b6002ec8b80"
      unitRef="usd">12700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzcxNjQ_a8bcbd15-0849-4066-84c2-f5ed37c92c87"
      unitRef="shares">10488993</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber
      contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzcxOTQ_611a60e4-4060-4fe5-a3b8-aa8d37c2d6b4"
      unitRef="shares">2448868</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwODU_dd6a1c8d-f5da-41d9-96c9-2243d39c1692">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2021 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,310,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzktMS0xLTEtMTMwNzk_7509a12d-bb65-4b2a-b06f-20e7223ac2db"
      unitRef="shares">8906624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzktMy0xLTEtMTMwNzk_3af9ee99-43a9-4164-b0d9-ce9f25c76578"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEwLTEtMS0xLTEzMDc5_2b6318a7-24cc-4577-9b65-6a6c6c49cc38"
      unitRef="shares">3483118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEwLTMtMS0xLTEzMDc5_f7c2fa1a-faca-4330-9952-5b0689cd8bce"
      unitRef="usdPerShare">10.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzExLTEtMS0xLTEzMDc5_793ef0af-b1cc-4b69-9003-0e73ddf06da8"
      unitRef="shares">1310263</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzExLTMtMS0xLTEzMDc5_30af680c-367e-4a90-b3f3-91b5c71e185b"
      unitRef="usdPerShare">5.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEyLTEtMS0xLTEzMDc5_236f2244-96a6-40a0-a953-491da7db779b"
      unitRef="shares">590486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEyLTMtMS0xLTEzMDc5_1512336e-b64c-43e3-8cd5-4ac00cbdd5cb"
      unitRef="usdPerShare">10.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEzLTEtMS0xLTEzMDc5_48630ebe-24ed-4c19-bf6e-d1fdc77d4c43"
      unitRef="shares">10488993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTozMWM5MjU5NjU0N2Q0MzdjODJjMzQ1N2RmMTc5YTZmNC90YWJsZXJhbmdlOjMxYzkyNTk2NTQ3ZDQzN2M4MmMzNDU3ZGYxNzlhNmY0XzEzLTMtMS0xLTEzMDc5_4c4779f9-bf08-44bf-82ae-97dfb5fb9f94"
      unitRef="usdPerShare">7.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkxMTA_64d8b854-3a58-49a5-9248-3601864bb4cf">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,387,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib54d8bf639154cb89c4ba6de26467b78_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzktMS0xLTEtMTMwNzk_182ce814-69b6-47b5-bb13-75ed6fba885a"
      unitRef="shares">2558052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzEwLTEtMS0xLTEzMDc5_0ba76155-f90c-4f8d-9fea-a793f71d1659"
      unitRef="shares">1392124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzExLTEtMS0xLTEzMDc5_fde5092e-2aef-45ae-9443-4504fd8efdc7"
      unitRef="shares">1387384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzEyLTEtMS0xLTEzMDc5_90745692-9fe4-4ea3-b65c-da8d15b4d91b"
      unitRef="shares">113924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibfc5a8cf7a374d108c9c4c30c4928d5b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90YWJsZTo2YTk2MWMxNjVlN2M0ODZhYmQyYjY5NmYyNTA4NDZlYi90YWJsZXJhbmdlOjZhOTYxYzE2NWU3YzQ4NmFiZDJiNjk2ZjI1MDg0NmViXzEzLTEtMS0xLTEzMDc5_a8046a30-2657-4a08-8c5e-b4aadf9bacb0"
      unitRef="shares">2448868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc1MjM_a8dfdd86-3108-4a10-905e-894a773a7ec6"
      unitRef="usdPerShare">4.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc1MzQ_90985da6-92c2-473c-94b0-f049d0f1e8d5"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc1OTg_c88c3e8b-9ba7-48cd-8d13-146eed31de3e"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc2MDk_4f4a9e23-b198-40de-9211-d227a32c111b"
      unitRef="shares">78750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc2NzY_2112a017-fd93-47ca-bcc9-11bc29c6ab60"
      unitRef="usdPerShare">6.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc2ODc_4be6f1f7-25d9-49bd-a885-42fdc2c37d63"
      unitRef="shares">324502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc4MDg_260c8adc-42bd-4d09-9d66-3ce853714e1c"
      unitRef="usdPerShare">7.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc4MTI_fe144283-c6dc-4ee9-88e6-67e8fdc3a205"
      unitRef="usdPerShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc4MTk_26c4905c-efc2-442f-bdcf-20defbcc1578"
      unitRef="usdPerShare">2.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia04bf6a44f2f4ac09462ec0cb4653510_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc5NTQ_0d1c57d4-7604-4494-8cc5-5b08fba9149c"
      unitRef="usdPerShare">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie18a5ae792de49a48808b18a814cd872_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc5NTg_1a4e103c-941b-4d94-afd1-4ee111f3cf4c"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id7b6cf865ace43d59c4d9b8cd23d0762_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzc5NjU_d41d64fe-8dcb-432c-87e8-9d17027b81a0"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgxMDA_bcc8c3f1-57b9-4781-a74e-fa10037e5756"
      unitRef="usd">6700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgxMDQ_0c2460da-4393-4430-87ae-32fd82c90706"
      unitRef="usd">12300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgxMTE_5ab448a3-7597-43ab-9981-b47879e4d6c8"
      unitRef="usd">113000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgyODE_c145c73b-b5e0-4231-afaf-1b2669c7ad77"
      unitRef="usd">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgyODU_388e2bdd-ccc9-41a0-a4db-b02e7a1d77a5"
      unitRef="usd">14200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzgyOTI_cec6ed52-4570-42cd-adbe-607849ecf85e"
      unitRef="usd">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i99399af4f2764839b791a9aff6806132_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg0MDA_ff1113c5-f00b-4493-8e7b-27e61076d675"
      unitRef="shares">663353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i768661574b0047a8978ccb5a91644538_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg1MjE_ccabfa25-374c-44ca-8b75-c442dc891c48"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie684f486c3914e20a06a7b5a84e49ca3_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg2NDM_2db581ec-e3d3-440b-9e1e-e9c21ed8c5fe"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie684f486c3914e20a06a7b5a84e49ca3_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzkwODM_ae624046-4cba-43fe-8de2-cd3d554aa76f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="i99399af4f2764839b791a9aff6806132_D20200828-20200828"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg4MDM_dca55ac1-d01d-4582-9c09-da5551984b47"
      unitRef="usd">8000000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i99399af4f2764839b791a9aff6806132_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzIvZnJhZzo5Y2Q5ZjhlOTZiNDc0YTMzOGJkNTIyMTk3NzEyMGM3ZC90ZXh0cmVnaW9uOjljZDlmOGU5NmI0NzRhMzM4YmQ1MjIxOTc3MTIwYzdkXzg4NTc_81c502e8-1025-41f6-8f75-3c82b42f034f"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzMwMTA_5af29707-1047-49ae-8d4d-97ce527afa05">Commitments and Contingencies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2021 of 1.9 years to 8.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of December&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,085,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,749,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,111,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,064,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,604,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,460,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2021, 2020 and 2019 were $3.4 million, $3.4 million and $3.2 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has existing supply agreements with contract manufacturers to manufacture INO-4800 drug substance. Under the terms of the agreements, the Company is committed to certain minimum purchases in 2022. At December 31, 2021, the Company had a $47.4&#160;million minimum purchase obligation in connection with these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and J. Joseph Kim, the Company&#x2019;s Chief Executive Officer, as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. On August 3, 2020, the lead plaintiff filed a consolidated complaint, naming the Company and three of its officers as defendants. On September 21, 2020, the lead plaintiff and another purported stockholder filed a first amended complaint, naming the Company and three of its officers as defendants. Defendants filed a motion to dismiss plaintiff&#x2019;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, the defendants&#x2019; motion to dismiss. The court granted the defendants&#x2019; motion to dismiss, and dismissed with prejudice, the claims premised on certain of the Company&#x2019;s statements. The court denied defendants&#x2019; motion to dismiss as to the remaining statements. On March 9, 2021, the defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, the plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#x2019; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. Defendants intend to move to dismiss the new allegations in the amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#x2019;s current directors as defendants. The Devarakonda complaint also names one of the Company&#x2019;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to defend these actions vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#x2019;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#x2019;s new matter. A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i72efe8598cfb48c48cb1d6f2d4c6fdd6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzUw_fda0219d-15a6-408e-b3f0-a934809791bf"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i940ff9e4c5b74f5581133846dcd72463_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE0MQ_927d0e47-102b-4c0d-a47b-103c83f53a34"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i764e102832c147288be14730f1429377_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzI5Mw_7060780d-8745-47f5-9e1a-65014117235a">P1Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ic5174769188e48278fd87c450cdc20d9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzI5OQ_85f00cf9-7805-4df3-9ede-b1c568a31027">P8Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzMwMDc_460b8783-2309-4f8d-bf07-530503f8505d">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of December&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,085,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,749,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,111,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,064,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,604,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,460,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzEtMS0xLTEtMTMwNzk_fac06d54-89dd-4b80-ba93-af5f96e3693d"
      unitRef="usd">4085000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzItMS0xLTEtMTMwNzk_3716a4cc-ad66-4311-930e-29e2fba4b8bd"
      unitRef="usd">4089000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzMtMS0xLTEtMTMwNzk_5f053d3d-3d34-4717-8861-0e334db1158c"
      unitRef="usd">3050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzQtMS0xLTEtMTMwNzk_a137c72a-fb27-4a90-894b-6b96d6b4816b"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzUtMS0xLTEtMTMwNzk_6d388154-6288-45ee-a0e9-84850d8840a2"
      unitRef="usd">3139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzYtMS0xLTEtMTMwNzk_b1cc342c-3965-481b-bc2a-00e9c0ff9096"
      unitRef="usd">6749000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzctMS0xLTEtMTMwNzk_c982a42a-ba3f-4b42-a4ec-7350475e6bed"
      unitRef="usd">24175000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzgtMS0xLTEtMTMwNzk_77ea7b0b-455c-4812-900a-ef3a91e275ba"
      unitRef="usd">6111000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzktMS0xLTEtMTMwNzk_8df557e0-010f-4fcb-af61-3e0ada34e8b7"
      unitRef="usd">18064000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzEwLTEtMS0xLTEzMDc5_d847292c-2f69-4dbf-be36-75415f6105e9"
      unitRef="usd">2604000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzExLTEtMS0xLTEzMDc5_614d9fe0-4177-4d94-aa60-a317c0199676"
      unitRef="usd">15460000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzEzLTEtMS0xLTEzMDc5_02a3d338-1090-4ea1-9244-db64cf05135e">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90YWJsZTozNmVjMGNlZDVhNGM0MWI0YTYyNzkxNzQ3NDE0MGI1Ni90YWJsZXJhbmdlOjM2ZWMwY2VkNWE0YzQxYjRhNjI3OTE3NDc0MTQwYjU2XzE0LTEtMS0xLTEzMDc5_574b1c0e-2e24-44dc-b348-2b1095bbd6b3"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE5NjI_bc1b7a39-8f42-434a-ba43-4f55d41a18bc"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE5NjY_c38bf802-996e-47f6-95da-6d754cf8db75"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzE5NzM_a49d7735-5e6a-45b9-8c57-458abf9da884"
      unitRef="usd">3200000</us-gaap:LeaseCost>
    <ino:LesseeNumberOfLeaseAgreementsEnteredInto
      contextRef="i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzIyNTU_a56c5b11-d269-4375-b3ca-0e1628137939"
      unitRef="lease">2</ino:LesseeNumberOfLeaseAgreementsEnteredInto>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzIzMDY_8e5e2bc5-41b9-48e3-aa61-e77bfd67c880"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:PurchaseObligation
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xNzgvZnJhZzowN2I1Nzg5ODJmMDQ0MTk2YTc0ODc2ZmVlNTFhMTY3Ny90ZXh0cmVnaW9uOjA3YjU3ODk4MmYwNDQxOTZhNzQ4NzZmZWU1MWExNjc3XzEwOTk1MTE2MzMyNjA_355196c4-53ad-4535-a624-38b335856c4b"
      unitRef="usd">47400000</us-gaap:PurchaseObligation>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3Mjc_138d3417-9ad6-4444-8b9b-fe5f5bb147b1">Income Taxes &lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the accounting guidance for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations before equity method investment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,614,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,664,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations before equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303,224,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,890,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no provision for (benefit from) income taxes for the years ended December 31, 2021 and 2020. There was an income tax benefit of $(257,000) for the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2021, 2020 and 2019, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (benefit) taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,677,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,207,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,370,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,650,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,838,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax benefit recorded during the year ended December 31, 2019 of $257,000 was principally due to a requirement under ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,835,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,242,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,793,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,283,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,171,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,484,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,205,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159,705,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,966,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,676,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(487,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $864.5 million, $146.5 million and $89.0 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $568.9 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2021, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2021, respectively, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also has Korean NOL carryforwards of $806,000 as of December 31, 2021. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of December 31, 2021, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of $35.1 million and $4.4 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;amp;D credit carryforwards as of December&#160;31, 2021. As a result of the analysis, the Company estimates that approximately $9.7 million of tax benefits related to NOL and R&amp;amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;amp;D carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2021, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $17.4 million, $10.9 million and $9.9 million as of December&#160;31, 2021, 2020 and 2019, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2018 and state and local income tax examinations before 2017. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is subject to examinations for tax years beginning in 2020 in Korea. The Company is not currently under Internal Revenue Service (&#x201c;IRS&#x201d;), state, local or foreign tax examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3Mzk_0e39eace-e05f-460f-89a6-c69ae6878b92">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations before equity method investment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,614,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,664,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations before equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303,224,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,890,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzItMS0xLTEtMTMwNzk_188f6ae1-3ef5-4b9d-84b7-a98c20655c22"
      unitRef="usd">-302614003</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzItMy0xLTEtMTMwNzk_b6c472cb-ad03-4fe7-bfa9-54727feee4ea"
      unitRef="usd">-162664355</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzItNS0xLTEtMTMwNzk_f039d061-3d90-45d4-8faf-cee934402c6f"
      unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzMtMS0xLTEtMTMwNzk_4921b9d7-a845-47b9-9f9a-f640ecc885be"
      unitRef="usd">-610320</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzMtMy0xLTEtMTMwNzk_4b13a46e-fac1-422f-bd32-db37e8a959ab"
      unitRef="usd">-225949</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzMtNS0xLTEtMTMwNzk_56f6985a-2c95-4f6c-8eda-f46806267e74"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzQtMS0xLTEtMTMwNzk_89f5aea9-a492-4d6b-9d17-34390595e464"
      unitRef="usd">-303224323</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzQtMy0xLTEtMTMwNzk_134c9881-fce8-4412-b5d2-9f3105d22a92"
      unitRef="usd">-162890304</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo5YWYzNTA5YTFjNDQ0MjQ2OGVlOGVmZmY5ODM0MDk2MC90YWJsZXJhbmdlOjlhZjM1MDlhMWM0NDQyNDY4ZWU4ZWZmZjk4MzQwOTYwXzQtNS0xLTEtMTMwNzk_e330dbda-eb48-4ef8-a8a5-4aa33f0b9fec"
      unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzM4NDgyOTA3MDUyMTE_07c2829e-31c0-4eac-b51f-d76b6a47036b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzM4NDgyOTA3MDUyMTE_d4a043b8-23d2-4d23-ae26-7d89d1cc7c44"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzEwOTk1MTE2MzU3NTI_a23b7ab6-2e80-425d-9e44-04936de90062"
      unitRef="usd">-257000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MTc_bb4c632f-dcd1-47e1-96f3-eee0dbea582e">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2021, 2020 and 2019, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (benefit) taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,677,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,207,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,370,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,650,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,838,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzItMS0xLTEtMTMwNzk_42fd6ba1-45de-4656-a9fd-e9e1ac9eb0e1"
      unitRef="usd">-63677000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzItMy0xLTEtMTMwNzk_3be929b2-a6b0-4b60-9e35-e8e4e2815990"
      unitRef="usd">-34207000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzItNS0xLTEtMTMwNzk_679c15d8-682e-403d-96f3-d9b859ccaefc"
      unitRef="usd">-25370000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzMtMS0xLTEtMTMwNzk_4cd25073-a5ab-4246-b0a8-73b66a22aa1e"
      unitRef="usd">-3447000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzMtMy0xLTEtMTMwNzk_b51effe4-9c28-4c96-af9b-65e494cf7168"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzMtNS0xLTEtMTMwNzk_152fb528-bff8-43f7-9c08-411e332f2a5b"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzUtMS0xLTEtMTMwNzk_ca243c89-91be-4dca-bad4-ec8db784b59e"
      unitRef="usd">77424000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzUtMy0xLTEtMTMwNzk_9d0a14fa-eccb-43be-acdf-f09fdc5aea1b"
      unitRef="usd">21428000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzUtNS0xLTEtMTMwNzk_e8c3a33d-5ed5-4e00-bf77-4ef1b7ddd17d"
      unitRef="usd">25457000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzYtMS0xLTEtMTMwNzk_dc806298-8b83-4a80-9c87-ae335a5d0f74"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzYtMy0xLTEtMTMwNzk_23e3df8a-ba96-4b9e-965b-5b7617fc037e"
      unitRef="usd">14450000</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzYtNS0xLTEtMTMwNzk_d9dc5acd-f03f-4ac0-b380-fff8a342d7ac"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzctMS0xLTEtMTMwNzk_2dbc31e8-c679-4f07-8f99-87c7195dcbb5"
      unitRef="usd">-16523000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzctMy0xLTEtMTMwNzk_40510e50-4277-4ed0-aacc-53d408f05246"
      unitRef="usd">-2650000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzctNS0xLTEtMTMwNzk_9432deec-c4d7-4645-8971-fb94243c76fa"
      unitRef="usd">-3838000</ino:IncomeTaxReconciliationStatuteLimitations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzktMS0xLTEtMTMwNzk_653144da-8872-41f0-a90e-c9fbea415d54"
      unitRef="usd">483000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzktMy0xLTEtMTMwNzk_5e3cda0a-abf5-4a76-88a2-2a91af2c5781"
      unitRef="usd">-1953000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzktNS0xLTEtMTMwNzk_ac16e1ff-adf5-4163-847e-c446c1c61f1e"
      unitRef="usd">1114000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEwLTEtMS0xLTEzMDc5_757d48c7-c25a-4721-91f9-67441e7becf1"
      unitRef="usd">6509000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEwLTMtMS0xLTEzMDc5_e3fdca31-f3ab-4763-a7f1-b86270fbd676"
      unitRef="usd">1068000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEwLTUtMS0xLTEzMDc5_1ac7bafb-e612-40b7-bcae-3695ad960959"
      unitRef="usd">1537000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzExLTEtMS0xLTEzMDc5_6d0b5466-883b-4830-b5a7-1efd6c928fd5"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzExLTMtMS0xLTEzMDc5_4ecedd4e-9c46-41d0-a349-11fe47f03e3f"
      unitRef="usd">853000</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzExLTUtMS0xLTEzMDc5_822e37d3-4cb8-4672-90a6-12c623cdd9b1"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEyLTEtMS0xLTEzMDc5_520feef0-5f37-44dd-bdac-e544dc109d44"
      unitRef="usd">616000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEyLTMtMS0xLTEzMDc5_5d8e67c9-236f-419f-981c-b51e7b76f594"
      unitRef="usd">468000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEyLTUtMS0xLTEzMDc5_b8cc6524-a144-49a3-8d3b-dcf55bc4f5ea"
      unitRef="usd">616000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEzLTEtMS0xLTEzMDc5_203513c1-f22b-4747-939a-c0d9592790b0"
      unitRef="usd">-542000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEzLTMtMS0xLTEzMDc5_0ae65dff-06e7-4c84-b6a4-672990185b64"
      unitRef="usd">-368000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzEzLTUtMS0xLTEzMDc5_d0d160fa-e769-4bc0-a588-3d7c078f75f8"
      unitRef="usd">-616000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE0LTEtMS0xLTEzMDc5_edb8448e-900e-4699-9e1d-dccfdf2631d9"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE0LTMtMS0xLTEzMDc5_a979ea20-d1bc-4aa3-975d-a1fefd2e4795"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE0LTUtMS0xLTEzMDc5_12b3d9f7-0ec3-4e8a-b3f6-83cdb5e89c94"
      unitRef="usd">12000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE1LTEtMS0xLTEzMDc5_3dab4a5b-813c-40cf-bbc5-1165face4d0e"
      unitRef="usd">-24000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE1LTMtMS0xLTEzMDc5_9ef50208-687f-4143-8132-5c718504c921"
      unitRef="usd">-9000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE1LTUtMS0xLTEzMDc5_dd73dfc9-0c77-41ac-92c2-04bb8b84fa03"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE2LTEtMS0xLTEzMDc5_75118e6b-5734-46a2-86aa-d83aa0060ddc"
      unitRef="usd">-819000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE2LTMtMS0xLTEzMDc5_7af551df-b6eb-4a38-b036-7820dc6090ac"
      unitRef="usd">920000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE2LTUtMS0xLTEzMDc5_7f1802c7-906c-4d8f-b83b-a18a042196a2"
      unitRef="usd">831000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE3LTEtMS0xLTEzMDc5_93326131-b2e0-47a0-b017-3c90c4ba0025"
      unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE3LTMtMS0xLTEzMDc5_4f3048ba-718c-4c98-a0f5-6a9cae94c01f"
      unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTpkZGM1ODJiZGQ1NzM0MzYyOTNiYjM4Y2YyYmE4NjRmMC90YWJsZXJhbmdlOmRkYzU4MmJkZDU3MzQzNjI5M2JiMzhjZjJiYTg2NGYwXzE3LTUtMS0xLTEzMDc5_c2fd0c38-c1cf-409e-abe5-e8bef6c7b586"
      unitRef="usd">-257000</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzk5OA_a06c1855-7442-46d1-99eb-90e297a8fb01"
      unitRef="usd">-257000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MzE_680c9a4e-ef8c-4f5b-a349-632f05bd576f">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,835,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,242,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,793,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,283,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,171,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,484,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,205,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159,705,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,966,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,676,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(487,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzMtMS0xLTEtMTMwNzk_2a2a191e-6ebb-4f63-95f4-669967f7d0c8"
      unitRef="usd">4200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzMtMy0xLTEtMTMwNzk_a2d6ed6d-50d8-4f55-a387-e94f2e304a79"
      unitRef="usd">5250000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzQtMS0xLTEtMTMwNzk_bd8263d2-e4e6-41ae-8225-dc8ef87cfe93"
      unitRef="usd">197144000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzQtMy0xLTEtMTMwNzk_1184e55c-1cc4-4c78-b9cd-a27c23f47cb5"
      unitRef="usd">127835000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzUtMS0xLTEtMTMwNzk_85dfb67f-dcc3-4464-8307-f43b1b68e0f6"
      unitRef="usd">23005000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzUtMy0xLTEtMTMwNzk_61055ceb-25bf-4407-9f1a-1e6f4cce98af"
      unitRef="usd">13242000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzYtMS0xLTEtMTMwNzk_aee6fb09-de17-4064-8ab8-907ca03f7e5c"
      unitRef="usd">987000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzYtMy0xLTEtMTMwNzk_46f89be6-2c0d-4d91-b800-baffd1880aed"
      unitRef="usd">1628000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzgtMS0xLTEtMTMwNzk_c797f6a1-7ca6-4915-b311-1db7c783ba3b"
      unitRef="usd">3599000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzgtMy0xLTEtMTMwNzk_b86842e2-f3ed-42bf-b66d-e55338c13295"
      unitRef="usd">3256000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ino:DeferredTaxAssetsIntangibleAssets
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzktMS0xLTEtMTMwNzk_5b6cc9c8-c266-4fb1-bc23-f359bf9af8ba"
      unitRef="usd">637000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetsIntangibleAssets
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzktMy0xLTEtMTMwNzk_776b0b89-60d4-4cc7-a9cc-98b49a2576ba"
      unitRef="usd">757000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetInterestExpense
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzExLTEtMS0xLTEzMDc5_313a094d-8a53-4e1b-9de5-e4a49fac6439"
      unitRef="usd">83000</ino:DeferredTaxAssetInterestExpense>
    <ino:DeferredTaxAssetInterestExpense
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzExLTMtMS0xLTEzMDc5_14776b61-9fe5-429f-a903-f1993a0bc605"
      unitRef="usd">564000</ino:DeferredTaxAssetInterestExpense>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEyLTEtMS0xLTEzMDc5_5482d4be-56a4-42fd-804d-ccc423ef5af9"
      unitRef="usd">750000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEyLTMtMS0xLTEzMDc5_dffb0b9b-c8c6-4f52-94b6-ea246bc35ae0"
      unitRef="usd">542000</us-gaap:DeferredTaxAssetsInvestments>
    <ino:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEzLTEtMS0xLTEzMDc5_f4035094-0f53-4220-bfb1-816cdd330c11"
      unitRef="usd">3793000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <ino:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzEzLTMtMS0xLTEzMDc5_9d70e5b5-0c9d-4556-8dd1-6caeb0b29acc"
      unitRef="usd">4283000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE1LTEtMS0xLTEzMDc5_f1849d34-d6b8-4f23-8f76-8ab6cbc2e159"
      unitRef="usd">5973000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE1LTMtMS0xLTEzMDc5_8d58daa2-046f-4fa8-a977-c75aa8d876be"
      unitRef="usd">6127000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE2LTEtMS0xLTEzMDc5_13b12832-f662-4884-b4e5-9ad3552dd433"
      unitRef="usd">240171000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE2LTMtMS0xLTEzMDc5_94ab4a38-c8e3-47d7-bd88-3bd371db9680"
      unitRef="usd">163484000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE3LTEtMS0xLTEzMDc5_26d9f65a-ffbf-4caf-8969-ac6b1396de2d"
      unitRef="usd">237205000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE3LTMtMS0xLTEzMDc5_804515ac-a626-4d6e-af5f-097d22b36c38"
      unitRef="usd">159705000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE4LTEtMS0xLTEzMDc5_a5c75785-4583-48c0-8b18-1c3701d677a5"
      unitRef="usd">2966000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzE4LTMtMS0xLTEzMDc5_10d55155-7fd8-4fcb-98fc-c721c4442007"
      unitRef="usd">3779000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIwLTEtMS0xLTEzMDc5_fda0647a-dd36-42b1-af08-ab3e29a41fba"
      unitRef="usd">194000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIwLTMtMS0xLTEzMDc5_8bc524fd-1280-4374-9082-da7d08d7cb9a"
      unitRef="usd">179000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIyLTEtMS0xLTEzMDc5_fa3e6308-199d-4b14-af63-65003f3a418e"
      unitRef="usd">2430000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIyLTMtMS0xLTEzMDc5_82c7294e-85f8-4894-b0ec-521bb52b8c94"
      unitRef="usd">2676000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesFinancingArrangementDiscount
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIzLTEtMS0xLTEzMDc5_9c61d4fd-a6e9-4bb5-b2dc-050325dc4f2c"
      unitRef="usd">321000</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
    <ino:DeferredTaxLiabilitiesFinancingArrangementDiscount
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzIzLTMtMS0xLTEzMDc5_575cd414-8f40-4d6f-914a-0bb05c39245b"
      unitRef="usd">469000</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI1LTEtMS0xLTEzMDc5_ed0d6d1f-758e-4963-8752-fc467282d6b8"
      unitRef="usd">53000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI1LTMtMS0xLTEzMDc5_df6cc3e9-c6da-48e7-b184-3e74b6c5a715"
      unitRef="usd">487000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI2LTEtMS0xLTEzMDc5_ee462393-2040-4905-8aba-b36ce631bce5"
      unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowOTgzODBjYjNlM2M0MzgzYWJjOWJkOWE1MGExYjlkYi90YWJsZXJhbmdlOjA5ODM4MGNiM2UzYzQzODNhYmM5YmQ5YTUwYTFiOWRiXzI2LTMtMS0xLTEzMDc5_ab31d08a-70a5-4c49-a4aa-a3c0b38eb679"
      unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="i553b47824270463b81580d012b8326f1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIwMjI_aed40e1b-ce31-4080-8971-ac9738f72aee"
      unitRef="usd">864500000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="i2a2629ea83a447d48947801594c4a4f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIwMjY_1613a051-e0c0-4602-9311-eb6904a4c804"
      unitRef="usd">146500000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="i28ea7f8947e74ae483e59fef6fba3c42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIwMzM_e749eb60-cd3b-4a9e-a823-19361b856748"
      unitRef="usd">89000000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i170db3d65ef54746a1f01e2eeb793898_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIyMjU_8b7923eb-4524-4104-b849-b67c983bc15f"
      unitRef="usd">568900000</us-gaap:OperatingLossCarryforwards>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="ifb481c2e100c4b24ab6801fa143fc5a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzIxOTkwMjMyNjI2MzI_c79bf37a-dc6a-4db7-8b4a-d64677977ce0"
      unitRef="usd">806000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8600df4b8cfa4198a900a673aaa25e5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzI3ODY_e0eba5fa-110c-40be-8529-60340f22b4c5"
      unitRef="usd">35100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzI3OTM_475d09a7-929f-4ef9-a697-948bf743e6ff"
      unitRef="usd">4400000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MTI_df7b9f0b-5683-434e-996c-5b92784ee55d">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtMS0xLTEtMTMwNzk_eea35715-0515-42e2-b9cb-37abe8696010"
      unitRef="usd">6100000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtMy0xLTEtMTMwNzk_a1cde288-5cfe-4b9b-ac79-c000b277a2ed"
      unitRef="usd">400000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtNS0xLTEtMjYyMjg_deb6fece-1744-4984-b451-0a64e287b8fa"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears
      contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtNS0xLTEtMTMwNzk_cfefbcb7-029d-481c-9dcb-794b27dd3cd5"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzMtNy0xLTEtMTMwNzk_7bd22cb8-08eb-4900-b759-2f9010a947a8"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtMS0xLTEtMTMwNzk_a7e97f74-e143-41e0-a4f5-6ae0751ac0c3"
      unitRef="usd">5300000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtMy0xLTEtMTMwNzk_52a4de95-a7ac-47fd-81a3-45573052aa00"
      unitRef="usd">1200000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtNS0xLTEtMjYyMjg_c4ab58cf-951d-4b24-b0ac-ec94dd97a2e4"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:TaxCreditCarryforwardExpiringinThreeMonths
      contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtNS0xLTEtMTMwNzk_566ed114-ea69-41aa-97f4-2c12af54babd"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinThreeMonths>
    <ino:TaxCreditCarryforwardExpiringinThreeMonths
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzQtNy0xLTEtMTMwNzk_a891005f-2081-4699-8f08-5cf8e1ed7483"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinThreeMonths>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtMS0xLTEtMTMwNzk_7d49d81e-8c14-4640-a61d-74f980b2fd21"
      unitRef="usd">16500000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtMy0xLTEtMTMwNzk_a297990c-9c8e-4863-9a22-4d9f6990adab"
      unitRef="usd">9100000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtNS0xLTEtMjYyMjg_2c733a46-50cb-488b-ae74-046728c6adc4"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:TaxCreditCarryforwardExpiringinFourMonths
      contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtNS0xLTEtMTMwNzk_b2c2abfc-165e-4b8d-9e10-8b2d99ad4d43"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFourMonths>
    <ino:TaxCreditCarryforwardExpiringinFourMonths
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzUtNy0xLTEtMTMwNzk_3506a260-c00a-4ff8-95b3-aa4f8bdb5c58"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFourMonths>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtMS0xLTEtMTMwNzk_a92051ae-e7a8-413d-b8bb-0fe28cc59a21"
      unitRef="usd">267700000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtMy0xLTEtMTMwNzk_41d11015-7fbe-4288-992d-0e88ece532c9"
      unitRef="usd">224900000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtNS0xLTEtMjYyMjg_1a8d6cbb-4565-461d-890e-5a3a32d85121"
      unitRef="usd">800000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:TaxCreditCarryforwardExpiringinFiveYears
      contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtNS0xLTEtMTMwNzk_ce74d379-ab74-4205-951b-dd6d7ff0d9b4"
      unitRef="usd">35100000</ino:TaxCreditCarryforwardExpiringinFiveYears>
    <ino:TaxCreditCarryforwardExpiringinFiveYears
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzYtNy0xLTEtMTMwNzk_92f1931b-3c41-4e7c-9452-e6f9e72523d9"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctMS0xLTEtMTMwNzk_7b0fb5c2-1f00-4502-acc3-531c2148ab39"
      unitRef="usd">568900000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctMy0xLTEtMTMwNzk_a54be10b-b859-415a-ad7d-c9283c1423d5"
      unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctNS0xLTEtMjYyMjg_eb6adafb-9e74-40e9-9de6-991e6c513c1c"
      unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely
      contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctNS0xLTEtMTMwNzk_571cd0be-97ff-4e13-840c-741aa4c32c46"
      unitRef="usd">0</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzctNy0xLTEtMTMwNzk_b60cb5c9-d31f-4b90-bab3-ebc840eb2c8a"
      unitRef="usd">4400000</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i46f662a8f3a3462b9e7192ba6281596b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtMS0xLTEtMTMwNzk_bcf623e0-fcda-4b3a-b6a6-ec7d1f4d120b"
      unitRef="usd">864500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2469103cd1da4e7d8121957ac4b2cd24_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtMy0xLTEtMTMwNzk_f7f0f119-53ab-4465-a9de-39ffdb892bf0"
      unitRef="usd">235600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i648b48da56f54bfab41cbc5eae47c6a0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtNS0xLTEtMjYyMjg_435818bb-6c7f-4651-963a-4183e03b85d5"
      unitRef="usd">800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="idc560e22c9154ac688112e684c7e03ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtNS0xLTEtMTMwNzk_a9af273f-1675-471a-b9e7-89366da2d413"
      unitRef="usd">35100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i18f99b5756ab4ed0a27d48c449ae0f94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTowMWViYjgzY2FkNmU0MTEyYTdkZDIwNzdmNjlhODVhOS90YWJsZXJhbmdlOjAxZWJiODNjYWQ2ZTQxMTJhN2RkMjA3N2Y2OWE4NWE5XzgtNy0xLTEtMTMwNzk_5835ef24-2bfe-4d0d-a3ad-63af8b14e07b"
      unitRef="usd">4400000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:TaxBenefitsExpired
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzM0OTI_42082b94-b038-40e5-a981-70e8173bdc6b"
      unitRef="usd">9700000</ino:TaxBenefitsExpired>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzY3MzI_48fca4ba-1656-449e-a2c2-c9e21c51ff3d">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzItMS0xLTEtMTMwNzk_2791cf21-dc46-4f94-b40f-d686f4ea9eca"
      unitRef="usd">12210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzItMy0xLTEtMTMwNzk_b936b1b4-46aa-47be-bee7-bcf41d97ac59"
      unitRef="usd">11204000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id0209f8c94d740adaa36dd67c48d6a20_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzItNS0xLTEtMTMwNzk_2069beb7-73b0-4a2c-b514-6a20b45fdcf9"
      unitRef="usd">9632000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzMtMS0xLTEtMTMwNzk_96792703-7746-4b3d-9954-42b1fca071a3"
      unitRef="usd">6602000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzMtMy0xLTEtMTMwNzk_5729a30a-11d8-4ac4-ab10-259639d00726"
      unitRef="usd">1043000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzMtNS0xLTEtMTMwNzk_9eb9db17-14fa-41a5-af48-969fc8b3b807"
      unitRef="usd">1575000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzQtMS0xLTEtMTMwNzk_dd8db929-796a-4ded-83cc-b24ae4652d18"
      unitRef="usd">7000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzQtMy0xLTEtMTMwNzk_35b64b1a-604a-4c4b-b390-3599557499c2"
      unitRef="usd">27000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzQtNS0xLTEtMTMwNzk_838e36db-ae6b-462a-9277-da52cfe1233f"
      unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzUtMS0xLTEtMTMwNzk_3c6fd555-e354-405e-87ef-c24b116c8dd1"
      unitRef="usd">0</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzUtMy0xLTEtMTMwNzk_2cb51aed-e550-486f-ba6b-01a56709f731"
      unitRef="usd">-64000</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzUtNS0xLTEtMTMwNzk_a42660ef-46bd-43ac-bc48-60ceea625dac"
      unitRef="usd">0</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzYtMS0xLTEtMTMwNzk_6bdc8ced-0fda-4287-98f1-0b35230db704"
      unitRef="usd">18819000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzYtMy0xLTEtMTMwNzk_8fa57a12-fe10-49e4-a706-4bc273c9a44b"
      unitRef="usd">12210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90YWJsZTo4ZWViZTFjYzFmZmI0OWJjYTA0ZGI1ZjliZTcwYzQ2OC90YWJsZXJhbmdlOjhlZWJlMWNjMWZmYjQ5YmNhMDRkYjVmOWJlNzBjNDY4XzYtNS0xLTEtMTMwNzk_ac8129b8-6752-4b53-bebc-ad543401a284"
      unitRef="usd">11204000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzU2MDE_f557ec72-7197-427c-baf8-fa8e8af020e2"
      unitRef="usd">17400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i5b698702e82d457c8216eac55fae002d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzU2MDU_59dbb60f-d882-4643-b673-b4ea81acfd20"
      unitRef="usd">10900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i59302a922e4f4aca836ef50c844fef86_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODQvZnJhZzo0OGY3MDJkODE3YzA0YmI0YmJmMmM5YWFkMWU3ZTEwYS90ZXh0cmVnaW9uOjQ4ZjcwMmQ4MTdjMDRiYjRiYmYyYzlhYWQxZTdlMTBhXzU2MTI_7aa994a9-72c5-4b02-9bdd-d67cad9775f3"
      unitRef="usd">9900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzU0NQ_167060bd-b9ab-4c30-a5ba-33b100efd3af">401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#x2019; contributions, up to 6% of their annual compensation. The Company&#x2019;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.5 million, $1.1 million and $1.2 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzI2MA_08f7853e-abbf-4803-a1ad-40a24b0f6f80"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzMwMg_c28c4690-b768-447a-a466-86bf0b9dc635"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzQ1Nw_4d60d90c-ed33-42a7-8210-e68f225ef7ea"
      unitRef="usd">1500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzQ2MQ_24d4b712-30c2-442d-bb51-5fd7d0ad712b"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2b768c7518ae4c2f861bff40ca4343ca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xODcvZnJhZzplMjc5ODYzODUyZjk0Yzc0YTZlZjJlZDEwMzA2Mzc5YS90ZXh0cmVnaW9uOmUyNzk4NjM4NTJmOTRjNzRhNmVmMmVkMTAzMDYzNzlhXzQ3Ng_a5de587b-5143-4cd6-b25c-74d3fe9838db"
      unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ1NzU_a963a3c0-f0ce-4b0f-b5f4-9ce5bb10c715">Related Party Transactions&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company owned 597,808 shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, 2021 and 2020, representing a 18.9% and 19.7% ownership interest, respectively. One &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2021 and 2020, the Company recognized revenue from PLS of $245,000 and $1.4 million, respectively. At December 31, 2021 and 2020, the Company had an accounts receivable balance of $25,000 and $67,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will have the exclusive right to in-license new intellectual property developed in this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $1.9&#160;million during the two-year term of the agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company rece&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ived a&#160;$6.1 million&#160;sub-grant through Wistar to develop a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMAb&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against the Zika infectio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n, with funding through December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.5&#160;million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024, of which $3.3&#160;million has been exercised as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2021 and 2020, the Company recorded $3.0 million and $1.9 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2021 and 2020 were $2.9 million and $2.3 million, respectively. At December&#160;31, 2021 and 2020, the Company had an accounts receivable balance of $2.6 million and $425,000, respectively, and an accounts payable and accrued liability balance of $548,000 and $643,000, respectively, related to Wistar. As of December&#160;31, 2021, the Company had a prepaid expense balance of $261,000 and recorded $37,000 as deferred grant funding on its consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i016abb4ce4ae41eb96f478d01ecb4c74_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzEzOTU_d8a2d737-829e-4757-97f2-a6fc3c4739ea"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1ecadc9f1fe848b199e3eebeee7aec5f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjAyMTQ_a35fa1f3-9c68-4fed-9b86-b88e33630aae"
      unitRef="number">0.189</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i662f61a3c3334b0e9a41c8358963d412_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzOTgwNDY1MTk2MDE_8f40dda1-fb46-44c9-9c44-a68f826c026d"
      unitRef="number">0.197</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i882b0a38e1f2460195c1411955ee5cbb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIwOTY_6068c0e3-a10a-4698-aa98-9982474cd26b"
      unitRef="usd">245000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i32a55572cadc4c63ad76c5efc89aa4aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxMDM_3ed0ef84-cc02-495a-992d-81b8cbbee72e"
      unitRef="usd">1400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i016abb4ce4ae41eb96f478d01ecb4c74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTg_1edbfdaa-073e-47a7-97cd-d66d38c09e4e"
      unitRef="usd">25000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ie83fbb635f5946a4b9deeceae49cb099_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIyMDU_d650b471-a8cc-4f5a-b143-6d7a0f5cfb47"
      unitRef="usd">67000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="i7373234a664045788a5b334e1076415e_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzI4NjI_f889048a-fbe2-4515-a1ba-60a1b7e9e897"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="i7373234a664045788a5b334e1076415e_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ1Nzc_4b264591-9dde-4cac-b13e-d52a0e34dc58">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="i87fa3d23bcb34cf791cf9f42fd01a6fc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjExNjk_b6785921-4669-4118-9615-9d196cf78617"
      unitRef="usd">1900000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="i87fa3d23bcb34cf791cf9f42fd01a6fc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzOTgwNDY1MTg1NzA_785aa480-26ad-419a-a466-4b68690ca2a3">P2Y</ino:CollaborativeArrangementTerm>
    <ino:ProceedsFromSubGrant
      contextRef="i3814c1b2e66949a0bd31251687136440_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzMwNjE_88c9bbac-94ff-487b-8ff8-1e18986ea850"
      unitRef="usd">6100000</ino:ProceedsFromSubGrant>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="iba7798242f3b4c25b6738d30fa118ce1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzMzNzI_52d9ec47-7027-4f96-a832-9f7a1ddea5db"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzEwOTk1MTE2MzU3NDM_e99d9f6b-059c-4a85-9372-dfec2bd46cd0"
      unitRef="usd">13500000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="i8713f36b6646400d8e92d9e1187ba464_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzM1OTM_b84db14a-773a-4135-9167-2787c1901f7b"
      unitRef="usd">6000000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:CollaborativeAgreementAwardedExercisedAmount
      contextRef="ia60088662e644556a450fd3a05824f9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzEwOTk1MTE2MzU5OTg_285fa677-cf0c-4ab2-83c4-8e5b7b2019fe"
      unitRef="usd">3300000</ino:CollaborativeAgreementAwardedExercisedAmount>
    <ino:GrantProceedsReceived
      contextRef="ia7365de7ee2a44bdbaf064109d873902_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjMyNTA_41a6e2c6-7fe4-48db-93b4-a0e402060121"
      unitRef="usd">3000000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i852044bbe3424614962d40fb0b43db9e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjMyNDM_4c82f2b2-5e8e-453f-b50d-7ddfc4ab4b75"
      unitRef="usd">1900000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i41b9a94f7b494158a6d83627c08f021c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQyMjQ_1fc9d554-942b-46c6-a1d4-34809bd74dc6"
      unitRef="usd">2900000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="iba7798242f3b4c25b6738d30fa118ce1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQyMzk_87bfe131-da40-475b-9896-591738b64c96"
      unitRef="usd">2300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzMjk_c880fa53-ede5-4729-9853-8b8373c1c8a0"
      unitRef="usd">2600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i9609157af4444ad383c75696d8f21624_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQzMzY_459b9c30-f7c3-4866-a423-7dabeb9e2781"
      unitRef="usd">425000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ0MTE_9887303e-6f86-4910-b7f8-4e91cbc962e3"
      unitRef="usd">548000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i9609157af4444ad383c75696d8f21624_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ0MTg_ab6f0a76-578b-4b59-9084-f00fbfa60bf9"
      unitRef="usd">643000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i9609157af4444ad383c75696d8f21624_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzIxOTkwMjMyNjM0MzY_a61452b2-84f7-4d85-81fc-db6d69fc8d5c"
      unitRef="usd">261000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="i319dcba0f77e40a7b288e510a6b6bc9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTAvZnJhZzphYTgwNjkyMTRlZWM0YzJmODQwNGM3M2IwYzgxOGJmNC90ZXh0cmVnaW9uOmFhODA2OTIxNGVlYzRjMmY4NDA0YzczYjBjODE4YmY0XzQ0ODE_25f81703-a3ec-48c1-8a40-52517036a711"
      unitRef="usd">37000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzkyNzc_be6ea71e-c9e6-4a85-a145-f7114c46833a">Geneos Therapeutics, Inc. &lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested $1.2&#160;million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1&#160;million, of which $2.4&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value. The gain has been recorded separately on the Company's consolidated statement of operations. The following table shows the amounts related to the deconsolidation accounting: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#x2019;s enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption. The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#x2019;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the Series A preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160;There have been no observable price changes or impairments identified since the deconsolidation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the period from June 1, 2020 through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as $4.6&#160;million and for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f this amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The remaining &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loss has been allocated to the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o $0 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos from June 30, 2020 - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos for the three months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ib4b9648133c14f64986de131ff9b55c1_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzM3OA_31d28730-40d2-44e0-bbdb-0bc072ee99af"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i2c28778c30d04e92b3843a48a585dbb4_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzUwNw_016422f2-d6e2-4df9-848f-04058864adcc"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i6d0ce816abac42bdabeaed537ab884e8_I20200101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzgwMA_8f89e759-80e6-4296-8c82-4ab062aab63a"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i14abd64fd4ca460b8acf05ac1d77a2c2_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg3MQ_fbaf7405-c8ba-41d4-a62f-076873d55d03"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i3ffdc36023f54e9fa96891a1aedfccaa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzExMjI_a7d15550-16ab-4650-929c-90efb40ff37c"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ic1a5d5fed4e84bfaaaa1da165905d43b_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzExNzM_04ee0ed9-bdb4-442a-9426-49dcd1e2b55a"
      unitRef="number">0.47</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzE4NDM_1942cc2c-cd0f-4459-be94-bcc70ac03699"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzE4NTY_6f20f3ac-2255-489f-8674-27c9718f0109"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzkyNzg_ed966edd-1cc9-4c4f-b295-e66328f796cc">The following table shows the amounts related to the deconsolidation accounting: &lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The remaining &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loss has been allocated to the Company&#x2019;s &lt;/span&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o $0 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos from June 30, 2020 - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos for the three months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <ino:WorkingCapitalExcludingCash
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzAtMS0xLTEtMTMwNzk_173c2c40-0e13-456d-a5ed-8c7b9c76a856"
      unitRef="usd">59992</ino:WorkingCapitalExcludingCash>
    <us-gaap:NotesPayable
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzEtMS0xLTEtMTMwNzk_00f14cba-8ef0-47c2-b6d0-6406b66cfcfa"
      unitRef="usd">171620</us-gaap:NotesPayable>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzItMS0xLTEtMTMwNzk_a61f8294-8d61-4fb8-8150-a60b83698e51"
      unitRef="usd">16340</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MinorityInterest
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzMtMS0xLTEtMTMwNzk_be0c82c9-1bb9-464d-9410-bf225eff04b7"
      unitRef="usd">3181640</us-gaap:MinorityInterest>
    <us-gaap:RetainedInterestFairValueDisclosure
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzQtMS0xLTEtMTMwNzk_41e10431-f325-4e02-8cab-b35729bfb8ac"
      unitRef="usd">3618998</us-gaap:RetainedInterestFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzUtMS0xLTEtMTMwNzk_966e6c4c-6ee0-4e96-bec4-be466b33c1f0"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ibc246805d54b41cab283d5d252cb5acd_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo0MWVlYjU5Mjg5MTg0ZTQ4OGFhYjA0M2VhM2VhZmNiOC90YWJsZXJhbmdlOjQxZWViNTkyODkxODRlNDg4YWFiMDQzZWEzZWFmY2I4XzYtMS0xLTEtMTMwNzk_556b51b3-6cbf-4222-8bdc-e12b70ce70c6"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6afcb9b96a3643e394e9339a35bf52eb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzIxNjQ_e4ddee5c-b44e-43db-a709-351d1b05d473"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzEtMS0xLTEtMTMwNzk_f9c4d4fa-a364-4410-a19b-464cfa7cf4af"
      unitRef="shares">3000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzEtMy0xLTEtMTMwNzk_c2f2612c-646e-4353-8678-bd58388794ab"
      unitRef="usdPerShare">0.273</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="ieba2248d0e5945f1ace5dfd8e9f6b75a_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzEtNS0xLTEtMTMwNzk_b9c3d6a5-a423-45f5-b76e-fd3de86f49f6"
      unitRef="usd">819000</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i923c4d838e73472daff6f5c2a0b66af9_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzItMS0xLTEtMTMwNzk_97d1848d-ae01-4277-9639-4e99449a2920"
      unitRef="shares">2113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i923c4d838e73472daff6f5c2a0b66af9_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzItMy0xLTEtMTMwNzk_e226f8db-6b99-4e5a-b8d0-6fb21d897088"
      unitRef="usdPerShare">1.325</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i923c4d838e73472daff6f5c2a0b66af9_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzItNS0xLTEtMTMwNzk_9585c5ed-3a78-463f-a6ba-4d36171a105b"
      unitRef="usd">2799998</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzMtMS0xLTEtMTMwNzk_4e98eaeb-fdc2-4f33-9c7c-59b666265208"
      unitRef="shares">5113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestments
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo2OGE2OWM2NjQxNDQ0ZjcxYTllNTMxMTQ1YjQzMGM1YS90YWJsZXJhbmdlOjY4YTY5YzY2NDE0NDRmNzFhOWU1MzExNDViNDMwYzVhXzMtNS0xLTEtMTMwNzk_4d52d0dc-ea6e-460b-b2ac-cfbaa1543cec"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzkyNzk_6ff10805-96bb-49ec-b1a1-f9e1f0b1d6cd">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:AlternativeInvestmentMeasurementInputTerm
      contextRef="ic982a0927e6846e8873518def396e93c_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzAtMS0xLTEtMTMwNzk_5efa1a98-934f-45ac-82b6-94c3fcfcd165">P2Y11M1D</ino:AlternativeInvestmentMeasurementInputTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="ic828dfae01914c5dadca776a2dbad2ad_I20200601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzEtMS0xLTEtMTMwNzk_176b65e0-2788-4d0f-8bf1-9d1b0476baa0"
      unitRef="number">0.70</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i70c92f1527c04f16bf9084ab8878ced9_I20200601"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzItMS0xLTEtMTMwNzk_a28cdeba-93d0-4273-ab5c-65dd9403180a"
      unitRef="number">0.0246</us-gaap:AlternativeInvestmentMeasurementInput>
    <ino:EquityMethodInvestmentEnterpriseValue
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTo4YjJhZWFlZjg1YWE0OGU1YTQ5MWJmMTk2MTlkMDgxMy90YWJsZXJhbmdlOjhiMmFlYWVmODVhYTQ4ZTVhNDkxYmYxOTYxOWQwODEzXzMtMS0xLTEtMTMwNzk_4bbb985e-cb3e-41e9-96d9-9862cd34e0a2"
      unitRef="usd">4966531000</ino:EquityMethodInvestmentEnterpriseValue>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i48f7e5188b3845c9ab32ff4a6346e973_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzY4ODE_c85277ad-7c33-4af5-8183-aa1bfb44d86b"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie564892056a949fe9b105cc382205542_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzc1MDg_b2fad034-6a51-49cc-ab6b-93387e787c3b"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="i05ba584f59334065a632c11588572f53_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg0Nzg_992f9780-a8a0-4615-948e-982da260e747"
      unitRef="usd">4600000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODAyMzQ_c6b1662d-ecb4-40e8-840a-dc56d6f20db8"
      unitRef="usd">1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODAyNDg_e82f8a67-30cc-420b-8603-77fee067e9e4"
      unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3ffdc36023f54e9fa96891a1aedfccaa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODAyNTg_3df9d02a-c04a-4d89-8123-69e1873fe509"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i30ef1cfdaf874c749abaf0297c07f342_D20200601-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg0OTg_66d6fc57-644c-4bf7-828c-34868ce61793"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3aaedc813254497f95ad1fb1461a99b8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg1ODU_991086b4-2c19-4913-9067-d73392334662"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie01459eec92d4ada9c407fd1befdf459_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg2MTI_74c22fbf-a226-4471-94e3-947ded170da3"
      unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i657942a14f6441a2bd23b51205eae9a3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzg3ODI_e4a0ea0f-d46e-4b31-97d8-34c31cf1d649"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzEtMi0xLTEtMTMwNzk_90be9744-838f-4028-8bc0-ae90a30324ff"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifa18a071c4404f868cef43212fce1e2c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzItMi0xLTEtMTMwNzk_ceb79402-836e-4189-9f37-df89ad84fb99"
      unitRef="usd">1399999</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i05ba584f59334065a632c11588572f53_D20200601-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzMtMi0xLTEtMTMwNzk_75ff363b-fc82-4f1b-8039-50d71cd7b7e7"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4562abf23e8b4059b8337d36ec9455d0_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzQtMi0xLTEtMTcwMDc_1bbc8f5e-5214-44c8-a09c-c21648eb8953"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0a42fdc8de284579bf2e8654f3f26a01_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90YWJsZTpiN2Y4N2FmZTJkYWM0ODYxYjI2YTk2NmEwNmY1NzU4ZS90YWJsZXJhbmdlOmI3Zjg3YWZlMmRhYzQ4NjFiMjZhOTY2YTA2ZjU3NThlXzQtMi0xLTEtMTMwNzk_d6e84d89-4327-47c2-a3ce-f45768a3ef2e"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1f23c07d6cfb47f2a060dfee7b1f5455_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODA3MDE_38d7b6c8-6144-4a2b-a359-2798d67775a6"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i377ac441325e467a8c00a33146b64c62_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUzMGFlNWZlY2ZjYzQzODg5OTcwODRkNDRiYzY1YWMzL3NlYzplMzBhZTVmZWNmY2M0Mzg4OTk3MDg0ZDQ0YmM2NWFjM18xOTMvZnJhZzowYjhhNjI1NjM5NTQ0ZTM1OWQyM2I3OWIzOGQzYjc1Zi90ZXh0cmVnaW9uOjBiOGE2MjU2Mzk1NDRlMzU5ZDIzYjc5YjM4ZDNiNzVmXzI3NDg3NzkwODA3MDk_62abb40c-d53c-4d1f-9108-a80db2a46439"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &!_850'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !@?V%4VA@*Z^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O315D=#E9<,G!<&!XEM(;EM8DX;DI-VWMZU;A^@'\#%W__SN
M=W"-B=)T"5]2%S&1PWPS^#9D:>**'8BB!,CF@%[G<DR$L;GKDM<T/M,>HC9'
MO4<0G-^#1])6DX8)6,2%R%1CC30)-77IC+=FP<?/U,XP:P!;]!@H0U56P-0T
M,9Z&MH$K8((1)I^_"V@7XES]$SMW@)V30W9+JN_[LJ_GW+A#!>_/3Z_SNH4+
MF70P./[*3M(IXHI=)K_5Z\WVD2G!A2AX7?!J*[B\>Y"W]<?D^L/O*NP[ZW;N
M'QM?!%4#O^Y"?0%02P,$%     @ 8']A5)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MEB@^XA0GBF_SSQHKKA1/\L,-H[#:]0-P?\VY.I[H%Y2?TN[^ E!+ P04
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M%#9@"X#OYQ96\?:B?;UA]SK+S=]02P,$%     @ 8']A5"'B&W73 @  N0D
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M?>PTA\8UYR_$S\D'C<O'_RM^L8UF'S\?D@G8M]%Q QJU=4K;:0Q][;"[?0H
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M EMW[UQT7XQ^;-]"6&IC]*[]N%422I\%P.\;#4K;?[$W&-Y\N?D34$L#!!0
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MHKUHO*CJ8M8JPPAF:;[\FSRT@5A3P"R@0%H%8BFPT!UHJT#M.\B  FL5F*W
M PIQJQ#;"C2@P%L%;BG$)* @6@5A*="0T[)5D)8"$0$%U2HH2X&'G,;H:>:0
M/1.AJ<.KR;9GFP33XVFZL3/?P8$]33BV9YP$59ZF'#=S/ERF;Y/[)TF='!Z4
MQ7U4&GFP9SXT"ZC1AY1/<[/6K^H2?DU!KSX\+O*JR-))4NM)=%7#'UC(=145
M-W!5C+]/BVRBR^H?T>GOB[1^C ;1MZN3Z*>_O3L8UG![8V0X;F]UM+P5"=SJ
MGT6=9!ZUXWXUOA^COT<PSCM=UNEUIJ,KG:=%&8V*6E?1R4)'!!'F,7S2;_C#
MXA8B#,I814=%/JD\)D[[37R!PJ3+$D)7F6!Y#'SL-W!<S&90\4+:GW;7?GF8
MSG:_R2XA.]\2]<DD-54^R:)YDDX&:1Z-DWGJ3XU?7VKKY='X_-);[A*;BRW&
MQ^/%;)$U:Q'VJW2<UAXCE[L;*>JI+J-Q,0,.F)H-^DY':0[7.OHI*ZK*MXI'
M_>9'13X BWE=%AG\=@OV:EWJRAKI$.K0JAB153$BC6T6L'VD;],\-T:ODRS)
MQS!*B&\U3<#^NRBIHQ,]WH\H_ME$6?J6Z](^;^P;S+D[)/1@>+>^(%T1)0B)
M)48KP8W!T]7@Z3,'O\. CY8VQ=IHI$"4,"0VAWWJ"B++,5?".,8WI<Y=*8&$
M4(S@>%/RPI4<<((8X8Q:1B\]HC&1DEM.C#Q#Y(0K?^#9*O"L4:.!P)_G8Z#<
M"I(%HMU\>@=)Z=^^_O,5LC8"2KQ/RLE_>U(V7MT\[IWU\ZI:-),-&^9XK5)&
M@.%0&:KISU$.Q&Y^79:)J$S2RF1)J9=K5#\ MU=0E-9RW;>1Q$[>4LH0%](?
M/;YR@+^1 [[TYNYB0U(AI*S<Y4YB&.>LU/4:BWDH?\0J J(W J</NARG51.!
MI>O%W)3X*DKR202)4B:&B)[BT7Q[!P7/Q !4OEY]JU8QJI,'V!<>EPRU94*%
MXPXLPYAQOS=RY8W\(=[X9E<Z'@R$1 Q9E>2C=&N.LF3.O;8PM*S^<*A5.%1_
M.);KWFR!10Y^&+?2C93O$"$W;.#S4SECP[&(H7!)RXD=!#>\P*C#=-3K1U/-
M!J:KG33.P(I+S+1Z,1RYPT *84KL%>65A+EAR-HU1U[)6&$1<&RM_\"]CGT8
MPPQ5#5.9^<@!+WQT82KZ)YWK8IF=7K>QN_DK#FYCVY?M@IO.=/R"^P%F!.O&
M<!5L_7697B_JQ.1576Q4UG9/\KK@PLD UD <8R&LO?3"*XL5C17!RO;8+TOB
M.)28'?7@?NSYEL.6FZ5_0%[>)FD^;-PWKDZ+LA[ Y,U@ZDR!::K(>FGQ!H!Z
MT@QA)JQR<;F#X*9#'4U@UNL0P(%.;P'K%]#8Y>/'J(:*667AU<:<D01J%NZ@
M O=3Q6D^V9&"E;=I=5G!P6"/#(8EP#&B+##\#BEP/U-8P]]AR$?8W=RA"C$9
M6R7V%+NH8(.P1V3IFEW]W'L*@[? 5#8+>T0'@BH0Y+&3FJXL$X0C:2]*5PXK
MKD0<X!G< 0T6;T_$N",0W(\@;\?$V*4&SA%GT'H$8MAQ ^X'A[^6B[%+"H!^
M3'*&G&Q63C8;'VU^"E@DB-) 220=?)!^^%B>HU3M%CW?//0:5LN3E8:>[+UN
MRP2>$A<K!IA9$? (Q5#I-Z4^>:0PCBGT!U9$SSR2#/I0R@.%CW0P0_IAYN6!
M\B4)<3G%<N6X%5E/#NC.%:/2:M%//)(8$2Z >NR,\XC&=K ]UB#8W(ZT9WC*
MJ<,>/P?6#7_U.RJ)C*W1?PXXRCEE@<)*ULZG^OGN1[6*Q'.NI0AAB 0\ZO"-
M]./;6[:+Q&4V21CFQ%GP[CD1N$OMM/&9HU*@ ,:3#@%)/P(^I]DB+O[AF .'
MNN/U2L; X%:RCSR2 XEX:+([K"3]6/EZO1;Q$:90BMN=QPZ"F\YTD$GZ(1/0
M9O7LJG5H.6CO>#W\1K'$W#YD&NTBN3GB#LM(_T'3G^T.B7MB-,!<,,&4O6=>
M^&4YPU"F[5-9KRSB5,2![IYT*$CZ4? DK6"*%D\3-$O^5Y1 G8/B/C?;XN*Z
M2B=I4CY&OWWZ=_0A3V? 46?03]: 5T"Q^]XPN-!GGVMX1#8/FEO'/8=./0?2
MI(-'T@^/K]L4$Q?M!B*.%;<JS.4.@IN/-CH"I/T$^-RFF+J(102Q#P8OMXIM
M#K?C,-K/83OWS^9$S*52Z@*)?6#M$<&22^!2%0IV1QET"V7TM<_>$1]1%Q 8
MQY@AX330K6CODR179.F<_2S)O2NTV8(A+NVU=N&1'2C$H>.5F-AIX9$E,<<V
MZXT\@J&G>&N/\>C;-\^T8P_:SQYOUSQ3ES*(H.;\)P!0M ,-^E9/Q;S)[F$*
MI!C#S&EE6E%A^V@GLM^B,1C*IXY3:#^G_&7-\QGU'" A&'8<&G-'*K2?5%ZU
MCSUI;[;9NPDAE;7NSSR"V'E6^-EOCDL9*KP=K= ?\^QLZTIT.800C#D*>=2!
M"-WR^.L-VSOJT@=LY8(J^^B9NB=:X"ZQUZ377 PH'GA=H(,9]GK/TIB'4#B%
M38Y;Q'V^L^3((QE8L:PC'M9//'^VMV">,QB**(^EL*OEQ3-D1Q[9D*\='[%^
M/GI=NF8>=$+,HJ;+;5*;KG2PP?J/7Y[+U<P]\X#08\KLX6Z5VQSPVKLV_7BR
M.UEC'UDSESELLO:($"RH)%(&VE'6<0E[UG.U'49\Q%R"H$IQ;MZ8LLC:(VKS
MB$=DZ9Q=3%PYV Y4+)50]H-@CZQY:*QD',?$1FN?,)&$V$>WHUYGEN$?KKUV
M;/YCP&52WJ:PM63Z!G30O@ 3Y?)=^^5%7<R;-Y&OB[HN9LW'J4Z@)!D!^/VF
M *1H+\S+S:O_\7#X?U!+ P04    " !@?V%4!Q81:'X-  !%/@  &    'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;+U;;6_C-A+^*T)P!VR!>L-W2HO= %F[
MUUN@+T'3WGU69#K1599<24ZR_?4WE!33)D=T<CAT/VP<YQ&E9X:<>69(?7QJ
MVM^[!V/ZY'E;U=VGBX>^WWVXO.R*![/-N_?-SM3PETW3;O,>?FWO+[M=:_+U
M<-&VNF2$J,MM7M875Q^'[V[:JX_-OJ_*VMRT2;??;O/VZV=3-4^?+NC%RQ>_
ME/</O?WB\NKC+K\WMZ;_;7?3PF^7AU'6Y=;47=G426LVGRZNZ8>5'BX8$/\J
MS5-W]#FQ5.Z:YG?[RY?UIPMBG\A4INCM$#G\>#1+4U5V)'B./Z9!+P[WM!<>
M?WX9_1\#>2!SEW=FV53_+M?]PZ>+]")9FTV^K_I?FJ=_FHF0M.,53=4-_R=/
M$Y9<),6^ZYOM=#$\P;:LQY_Y\V2(HPNHFKF 31<P_P(Q<P&?+N"OO4!,%XC!
M,B.5P0ZKO,^O/K;-4]):-(QF/PS&'*X&^F5M_7[;M_#7$J[KKY9-W355N<Y[
MLTYN>_@!3NV[I-DDR[Q[2/X!$Z-+%LEOMZODW=^^^7C9PTWMI9?%=(//XPW8
MS TH2WYLZOZA2[ZKUV9].L E/.WAD=G+(W]FT1%7IGB?</IMP@BCR ,M7W\Y
M02Y?O?IRFD78\(,#^# >GW. M?)FL/*F;;8)K.@V[\OZ?EP295^:[D/D/N)P
M'S'<1\S<YR>((573=9@'QROU<*4-%(]7"TZXDJFF8*''8]LB4*JTT"*CXA2Z
MPJ",2$FUU@?H"1=YX"*C-KM>_P=6QCA1^P;"3]'415F9I)Y(VF_MY\(:=]_!
MU"[K-UM6'9Y&12V[,A!QBS*W<0RS[GBU.K(#)X*03'FFQ7 \S7S<"L')+.5I
MBAM5'VCH*(WK;=/VY9\##;O\R[K/Z_OR#LR:=YWIT9FC@V>1C @J/6H(3&B2
M4H]9"*-$*98)G%EZ8):^B9F;")6!E)&T-C<LFLT"9DJ$:QH^'=6$:7^)(#@P
MB:;<8QOB4E@;BN!DLP/9+$IV^0!>,W:^;_*R31[S:F\LZ;5IR\?<)MFD*O.[
MLBK[KQC++'@JGU^(T%)IDAVMZI%@" 1Z$%88SI 2E[-(E.-MWQ2_+VRZ7R=%
MLP4-U,VNOFFHXZ=@BG.EE1>OE@B22B6T9+[G,"3)".5LQGGT*!W3>)ANZL40
MM6#YF=9T?6*>+3^#<J/(%$J5")B%.$&T5JD?6A @L">9G%F!E#E>[$UK$$+F
MMMQO06C40/713.$<9<E":X,'F?_T2P1(?(+(6)F:FY NAU-^)@5L3-O";.SS
M9X.3X&?7U7G("H%(GLUD4^JD 8UK@Q]LRGQW#U7"-]8?W0/X:@'3;WO6-2+^
M/!,Q!)6F0>!<(;B%L!%C)K-1IQ>HC <,T_?5H&SMW(-L;2 6VLSV5/8/P#>'
ME6;_ L%D:PU@X\LHQ_+-!D+EH([A:HB9R;N;'VYQ'2S/NSB$+&QFT*$M8H.=
M6L'I%!H7*M_G5@75D J*@^J?EN/WIC8-[N)0;@2L0LA"4$:)ECZKV&"GK)QL
MH7'=,DQ>RZKL=DV75Y;.IGP&A\VG<AHJC8!4"&$J"Y(X H.YG<V0<HJ%QB6+
MMR+-'WL[]=QJM/G=GYKE3.0)=8:47 :R!<$M(%E+!76 3SJ$0I( :3\7B9QX
MH7'U<FN7HO7@0<D#T<CD#"6&X(*G001"<#(5RB]O5@AP9H(RIU987*W8RFM?
MMR:ORC_!5]6I:_/'O*QL+%ILFG8!\]>\>+LSQ;Z==2L+-0AGC$$=X'%'@%"R
M04KWX_0*0<Z1=WJ&Q?7,K_ES<@?^VY3]5-_V#Z8]MH>U1/>VM,-"F>+/YO.0
M%0)9,"@WCJJ74]).[+"XV/G-L>O;',3IV..:G%Y- 0O\;<I[D'M[D YU\17B
M<MULRWI8T6MSUZ/40P$#&41ES)_R")#*C##?""%,:*AK9B01<Y*(G>EK#'5(
MYQ7>0T1.\GI]*$+.%.',B1@6%S'71='L;4? I7?4@*'(H!"\.'#V+8C($:I3
MJ+4SO]6!0)FBBLW5Y,PI%Q97+@@K7)C,A0E$<3"B*.1GGVZ(3(400?&#C2@S
M#L%TAJO3)RRN3VY:L\O+]4O%,\Z3,5Z,:Z2/I'2&B!!%TS35 5$$R=-49-*'
MKC H3 %"YOSJ5 N+JY97<WV;MT,ULJ!2'#<5)AN$0*X%*#;? "%.$U $,_2=
MOF%Q??/SP#3BS5!A,"$Y5=*O;1'D@D%Q* 4+5BD&)4S-D'&BA<5%RV&-[O*O
MPP*UOLR+HMT;YV"49:@VF&(<PG00BT(D1"R9,E^:(<"%X%RG;$:3<J=C>%S'
M7$^,"OA#68#0[ML2_H\1Y(A(T3)C7N-OB> DE.4\Z! B0! SC!$^(SVY4RH\
MKE1>Y<5DO3>VN?S*]<@1B9&)C/ON17"42R5]R8*-QT1*%)]A[R0+CTN60P>C
M-8^FWJ.IDR/:@V>IY#X;!*=2HOVYBN%H2H2<49W\:$_EE?V8B<V;@B@_WZI!
M() \_&H705E^<^R<TN%QI?/S^?ZU+[&^M0452A81.1 ^,^YKG"6*)!E-9< ;
M%4X<XMI<#')RB,?ET/<@IZ&0V-?K@7ZLD<TQY9-1J/LRGUF(I +JV2R8L @P
MS3*N9MJCW$D??J8U@_-ZV[Q%Q(I,)0DF+X+3('_"^1L"4ZJXF*D-N!,_/"Y^
MQNQ_-#U1.HB6$5#?!K$3:=00S8+0B0T'UIG+&T[*\+B4^>DU^XPH04R.4*E)
M*GU7+#$LU3K3&1%^$Q_#9E"W$,IGI YW4H=G\:K.VZT>"_4W[%8[M2'B:N-F
MWQ8/>3?V9<_T P2B"KA(,\D9]S<),"R54/4K%6Q@H5A",DDXF:EVA-,;(JXW
M;MJF,&8]&7)H_-B]R3;9YKWM^WQ]#7%$-VB1\DS[/;LE E4LRR@)"CP$F;$T
M UO.+'SA5(:(JXP3IQ;YKNQ!0,Y7 0(3"(R#"P*O8DC)3DJ5B1V"S%*=S94!
MPHD.$1<=N$./>K93G_WG&E57XKSL0"""4"8%]3-5=+!3?D<'2.*R8V6*=M ;
M$..&@->:;E\-BW]@#$'];5L+(M0) 6-,=&B8XM*O#**#G3)V:D/$U<:7DWY[
MA,CYG1\$LJ \L_]\(J_>^1%.7HBXO AR%!:W469H T1R(43J"T0,*V%E21TZ
M"X%")A-9-M-9$$Y;"/VF#+4IZ[PNWI"A7.(7\<1_NM[+KMO#C5[V$<&^;3\<
MGNE,74)4KYM^ZO(<__&NJ=>XX<,D'DRILY 5 LFT$%S1&=DCG!(09\Z9--W0
ME:P&70HE\?_; .</HIR'K!#(@G,J]-Q6E70"19X1**C[_5WDH? :\L +H+"&
MPQA+Y*0*R82@(CB%AT"%A"6IA*_V5P@T(VE&Z$Q0D4[ R#<)F&'/O-D-8=\\
MF[8HNZGNM/3[_-DV5F:5C$3DB5*I%GZK" %2QE26$C_(8$A(EFQ&Q4BG8F1<
MQ?QJ#WDD0_OV:/Y;HL-) ICPQZ<-IMV\_"EOU\X>NQ/C^69#+80(%Z$H!:'K
MFPA#$I;20.!BR#1C&9OI;TLGAF1<#%T70+LK7T1 ;8\U-77?-E5E8_'+Z2:4
MZ'DAA$ 8UUFF_&2* 3,%E=",?)=.#<FX&CJ=_:,V.(D"-MZ]]!)1FN?5#P*A
MFJJ@MHT.=<KOZ(AM7/L<) /,U,=R#7/\[BN:3%%NH89AE(HL38G?+$2@0DFF
M,Q6<M4"@E-CS1G).-DBGD&1<(7VWV9AB7*_/Q7B$$HIXB-;3-F8S:=XA?]D/
M=ED_@L:?BV?8)A/,.U\T(3BF&?&K%@0VYV&GE&2\"_.EGO3\N_6D[+\Y2/M7
MT\0VG$#RI8*+8#8CC1J60HU._/V %3JL $?/=3"D4VTRKMJ6<_2^3>[,?5G7
M=G;; &W:LEFCG)&]*4DTQ%>_#%MB4$8A  5G+S D5QE7?*:U+YU2DV>4VCQC
M8S<=HUR1P[ZPD+GVF_E+!#ECE14&]:UR>A+?B3)%HNK_=K_;C:DWK^R)L*)J
MNGUKHL?\G>!19W:(MN,&T<NFT 94[>ZXHP&A$DQIDSW8U1IZ9Y\$?2<@U":,
MB#0X.(_@*%?@ L^D"&XF/B@G<U1<YGQY.8%LE0Y* CEB0F!F!#$> 0K%1' $
M>X4 F89Z,YV)[\KI$177(^Y8_.[5.^]E753[]5@PGSM1J$*AH37)>-"N1H!^
M.H]"3OD[N:+B<N6[487:T_)-/2G3TYK%U61#I8:2/"]9SD-6"(1*+:V&GV'I
M1(N*BY9?D)VPYJ[/ 39X\9#;[=(=-\^:NZJ\'YI5..7SK9WSD!4"H4)Q6 $S
M.V+JZ.6CN'"YWM_O88W:M]&2SV$Q?3JJTP8JWD7YB]ZP<EE;Q;/V<'3YG;WQ
M>![VV=X%"HR'ERIK[KR<.M]'02"V5"+"UY_1L4Z)N>2LXLE9O9?D[\GR:/7=
MCNV2GX9VR6IO['N*(F)$[9*CCB?'O\:IVN53'<^G_[-3IW%UQ*D(9)%J*)VX
MOS:C@XW,+H_>K]V:]GYX3[E+AO,BXWNKAV\/[T)?#V\ >]]_IA]6XQO-;ICQ
M!>L?\_;>GH.MS :&).\U1(QV?&=Y_*5O=L-;O'=-WS?;X>.#R=>FM0#X^Z:!
M"3/]8F]P>'/\ZK]02P,$%     @ 8']A5#X<N#VJ"   G!(  !@   !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6R=6&UOVS@2_BN$#]AM 2=^:7K=:]( CI-N
M<I>DAI--@3O<!UJB+6XH4D=2=K6__IX92HZ2S1:+!8K&(CDOG'GFF9%.=LX_
MAD*I*+Z5QH9/@R+&ZN-H%+)"E3(<NDI9[*R=+V7$H]^,0N65S%FH-*/I>/SW
M42FU'9R>\-K"GYZX.AIMU<*+4)>E],V9,F[W:3 9= M+O2DB+8Q.3RJY47<J
M_E(M/)Y&>RVY+I4-VEGAU?K38#;Y>'9$Y_G @U:[T/LMZ"8KYQ[IX2K_-!B3
M0\JH+)(&B3];-5?&D"*X\;]6YV!OD@3[OSOMG_GNN,M*!C5WYJO.8_%I\--
MY&HM:Q.7;G>IVON\)WV9,X'_%[OV['@@LCI$5[;"\*#4-OV5W]HX_!F!:2LP
M9;^3(?;R7$9Y>N+=3G@Z#6WT@Z_*TG!.6TK*7?38U9"+I_>%$G-75M(V)Z,(
MA;0\REKALR0\_0/AR53<.!N+("YLKO+G"D;P9._.M'/G;/I=C><J.Q3O)D,Q
M'4\GW]'W;G^]=ZSOW1_H^^(WTNK?)"%@B(O:X(S.90*$S<7"JZ!L3 MN+3YK
M*VVFI1%W6%1 7PSB/[-5B![X^>]W/#K:>W3$'AW]M8#_:6%Q9=U6.[$H),"9
MJ3KJ3)HPQ#I"^";BY ]_^VDZ'1^W OPT.1;.=QM7MU\>KKZTZV^'0@<AQ4J[
MJ++".N,VC<A:8VL'+*I<($HKK^T&_T1T *)_!'& #C*-2FM0#T%O+ Z>W\Y$
MJ7*=X0:!0[V567J 7*%,!2FR!&GE*J/$VKM2:+OF<JV#R*$1Y88;:9N9.B>3
M<SA\?C#YQY U=HHBV&BO9J=C(3(D4?ET*G,VUY1?N!&"0W(C_.-C15U**RI9
M:6-<*;?:P^Z;P>7B8?#V4*3PB$(&$0JWL_!#9,@(Q1DV 1+<I8!E#8S0?=L;
MDO6<0(:[XJ=8*83%@'L\[&H+KS.04"!UE*65RQNQU1*Q1T0JKU4$.XJ V$8(
M;G6FA(1_.XXY!&R=&:6S YGIO*=YHV :&O(ZBQQD)CQX(=:U90J$V_=LF^,B
M;=1L&R50(3J4I@U8/$0!!S:*HE3)6#@H3AE,40V'H@?#'\.+5%>Z4@1;0A.A
MQVO&S1JN>Z5$;"H<PF/K:2]8'_G^16/(\:P?46  %_>R8I3SCB[+VKJTJND
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MHA<!F6)7KHB*Y 4W9$E(@P"LZD@"7)=@!DN5<V,E H,_8A]!5#%)@34L9_"
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MXB[_B-N8Q33)L;2V%3;2*44X%0A+HX4BE%/ 4@*; U=VTCB(=W.JAGK@%8A
MH9@23:@5ID]J;$OBY*)6WJQJ4[;"%<AM3;WC[DZT"=!@;FE>"O5F$]2YPMJ2
MW8OA@=#]Q>H,D(T]J *J">RW(.%1)ULVA=GA"TXA\6+*SX4$(OUR@V:%B+=]
M/Q7/B, HZ_Z;3&.#L!'SSMFM2M)L;?@@<KM?0(0YO\<0YG5+A.12\%YY2ABI
MC6EO$)_ L1U:O/I SDFK*S3-@EO&F:M8^ 8GP<Q/?H0.'!:P< L.,S)UJJ"X
MV<NM1>!0H"E8W^V1"9$X  &B0>G)A5D:$5Q38'&?//-A 4ZO+Y/&*N#,M)V_
M74R]![86-MI3H;W/R)/USECU'>U:4(@I3C=US#,5;IB-6NAUQD![+]*BJ^!6
M="G8<X234#?ZEFQQU&<X)0!9B5(/\ L-]-*@:TIS :AP(#9+B'S0"'&C#R:V
M+C@G28W,7#T1%%2G@ZJRR:N=N;S]6V1Y'*WB!![GYN#R+#><;+4$AF+#KFR"
MC26GP-Q>(COV:7K?LC5V-"83< ,#0*SLL00["D382(GIV=3E='^ ,ZFAV8P>
MM\X!<7] EI"1'QAGHYI;6]EE$6! 'IXE;[&<E7\)2N\7 '3IBF(96VSA#D1)
MWQ4EJ7(G'S 0PH8%14H,%]YH/])F01?S&!(._,@'7PREHR=G"JF.*9YH$:C4
M/<='"DN M'QC&71>T!0='0_BZY67[OZY88XH8!__XC[2-R&3+GA)XNMA.Y4#
MU*4Y4ADE,UXH0 M+%-;I$X;^#.O%R$2X81/A1HW&R+YA6TN'V.CM2Y"2[E0L
M#+01FG[E# ^2[=RY,3U-,;(:9!$3%:I8'POB]D>*7L"6OL0LJ/C&O,1$TX4W
MD0L-\,MCVG(/QW*#+6BRTR1K%3C (%#YHFLE8P.;N[K71YG GA;B]"4'D[2%
M"E=>!?7&@0 :3_T,!9Y/S<4+JO>B2?[PJ@<MM-(QJRM$YN2"^V%DA[%04I]N
MEOSL#,T/:J)=\R7[.: X1\M03YD/N81TUTZ9JX?36NE)+)?&:":.T>5&;0-N
M8@O.L;',R0":U/UY&REP4UBYA 7%TQ:*+Q';8)Y?0L"R" L:KOB8'!T3!;$<
M-V/& 6[UCA(1&$6BY([(,9_Q\.CC('71/@QO>'4.Z4XQX%Y!^":8-SH5<11G
M)ZQ20M)*G5T56#XD?F^IIC%F==SRWIL2CR67DG)V3-UR:J>3=\#,,VE%DF\:
M*>7[C"WIY2G9.=AOZ4J3#XJ*\32&B<B2(4PZ$^!AA\5[](V-/ 1F-IKU(6P6
M#*@:JIIT -=1K++"B4Q4@8(()Q._IREDGJLJ+I91_>-,0&T:FE1F806LF@I:
MZ#!!GYB<8P(*YJI%WAC=CE3Z\1BW+EL?]=MXP!ASCQ35B<Q/!Q3L',VX&5J[
M(.(T"*+&@31+/CH/&(TLLU>[DF-\Q/%SYS5'\TO&#!G5K9;4^H@5O;A2JN,C
M HH+3$DIG6#IQ9=K\QKS-JANP.N)9\]X-Y[O=$@I8PH656ZDW!7C%(Z>E2XD
M%L!""R"ET,4#5._A:FNQ[<K2%6<0F,%\+<_)[D_>0D37FS(*W#ZN?W_"8=+1
M*?=4A.F>7BQ'=:^&1U4-I.(@*#1+?L0)Q(-<3A@[U^%LHTG% QF ,\9)-KA.
M99F$VR\Z"GI?G5\>7<S/4\PW4YO,!QK F+R1EM&CJ4"X\@KF;67:XD0>Y&)^
MX29Q!./&C Y[(]A5"[JY-]%\3);0K'C!9&EJM!M9:RU=.49T4!Y=$I\]KAI4
M:V<\Y'D0NI$Q(>9(4B9L4[I$DE[PO;U P\S^:TM#8?'"WP?Y[&E;D/.U\?!F
M;<ML1^XU:S@?K$>+>[.P.?451A-&AD]2F==RQ^$JA4]KDKGE3XS9,#4P4O;[
M"XQE[IH.$@L"4S2A2>NW]A2+D<;2DW@ I:@1GZ(0!FFSB9&*&G#SU^H&[_D*
M.E^^$[9:[!]JP9O+HCB>H)OL$YL:$KBO3XS"+'%U]!T%0*/S<WLEUX!L]1Y,
MU%3K&Y(92E]O!+)]42S[1N)B?':IP**9TWR,261'K>EZJJD]G56X=V>6HP$D
M>_:9=*S0^*U6)>ED(.J^VO.ZM)M'PU,Y=#VU5ZA8U3<@:R*$1Z:H+F(Q$=:E
M,(C,JBEC7QS.7%5@:'N-1Z6\GH(N+GUI;-@Y*W<1TSV.T1 I1PW@U9'^.LK'
M<X,XAN*/J-HZ'IB*2T\BC'OTI%U%3?\[BTE];8A>3@"64^D"&#X6')CD%5>>
M[9+?PGE2>&TZ44Q"H=OPBS8R?2LN&5+OEGIY<U2MX&]&"^>VJG4^%3.-6ZES
M<RBZ>'?WR-"29)^UZ+BZR4M%O>5H4O?$$)[ @@651=6X$\NEU G>4>_?="74
MX%!+06T$-^U5:L_?0T3(&:N]>-A[/J/72WSGS6S=G;#C#.$IKS/LPYGJ$%;Q
MBD5>3Z)Z@5#=AK.WOQ5>G"5O%."P6&W8^RONI?028=<M?7$$[NV&1]PKTH<2
M_1><J/7 #4K +NC')%(+__S7*>JSAD/>2>>N,^B2P\_OWCRYQ^+ B7)-NRZV
MJ3,1>L&)*Z>D)?D[7739.!@0SKP;&RI45ZLOXCL $GLHJ4;6P@#-@,-Y-M-.
MPM=9(5_;@Q_!.J1&PZ[IO[Z2P76\>@R&O;C<H=Z][CK(PV^W)1TMJJ"GX(,A
M#PIYQ>>Q@I@?N258[G1X+!GI^HX+<'C$C?")*Y/RY^95*9@4MRX'TT#A,1=U
M<4T'PRCQX0GO'/M89M'6S<*U>BY3;3^4Z?>=^\(*32MPOB.-X>,BV7!,UR(>
MZ$JB!QZDFPR)-)QR"IY/N0NJ]J,*<?(YM.$, S8ZE)\#,W!W0-NDJB5D'4TS
MQ&R?'Q,<<[JX_N&<0C$J#,,K7^H2CJWX1.Z6+Z4[Q=KX\($C?>LFF%T1$A,E
MUC2J/S%&XQ#K_K>=1K@B>\E[@_(B1Q;3)*C3\*<='8N5'&XE86\WC4L$@8/B
MR6"J393E)J<W: $,GOM+TC0D!TQBTK?18;P^F#D5M;%.SQUA]N/I!C) C$>7
MN%K585MT, Y!?25MS-BB?*1T!FJ(O)#P?% [B36FP3RQGSVPU!ON0EP!5GQP
MV#5YR2=;M$O7*#(/);;JY\C$7PGT;?LO/_L(N E<T!WP$0?3T4QC1[HOY1Z@
MN+,.^&%;]L2Q &#OF7L06@FF>G&8-2 Y^CXJK+$.>9V*<R6MR\'CQK6_#[Z)
MBZP,L[$\C+_!^L"@OO)UD,EZHX9"<!>^G-U+;L)^B:T>FKBB0H)[2S=Y0'%8
MFR,?4WL&<D-3;S5(B3/^P#_;<5F!ZYQ^_<NU3#W6WXK-IJ^(H\U62V_SGZ]?
MMH-33E21MFY@(EJ3WD22*?8X )"%M(P-?>@KOP(OK 7'H5%P5*6DV(86?H,#
M"R(,+JV!D(-)9"[+V&$FK_6V3% .Y]^7():^_IB#DQ]&K3IT$>&\E];G!145
M.I;/O2Y2UZ7>/=<6E?]6E0=)(1AN[O\4][9$H6LU/Z>^]VS8&<&S6OT$M7:
M5#U,X%36S1??2:91PL:64O 5]%(M918C3U]P%..6<J7=>-@*9_6RQ$2/H+2J
MH-H.B"6Z2FXIHE$X-/1M +(?]A 4NN-16W=U1"\N"4^5P/II?.5Z_#C</^@7
MS%3HKE CT4A?5YXH/0(+2V[-EPK,Y5GRD^NR+NEK?W1SDA<<$_53\OU7,'A[
MYZ'*[^^Q;HJ_30E49YW[Z(CO7@ 7JBZEX"U&(";JT50LR\#X4=S&W[%@M)4M
M+A__=F_;T[4,'_=EZ=)T."J=IA!,Q:F_^#M,R.KA2WF,O.&Y3)*NYJ8I[PX^
M.'!09SWH^SH]J7&,GFL 7&4V'X>W)?EL<[6DO6#RE;,H.7X!!?L>^YH^8.">
ME#]^!6GFOTW46P72?]K3>#[LS+HM\M"6<-^1@G^@[^:1(3)W](V[""^FV.#2
MJIX:9FCD"7\W*6[  7],;-+0V/C[NV;):_K.K'P?9*;,Q+VG 9\83:$+=U\>
MY@>YH1,?SL$BCR38FA_0V@TV-_D["<B"Q ^Q\U4_"JKI?6<Z?<,7^3?(H)SX
MX^^-1"?4#]=RZ3X?,L=2,[0$'')H1VI(LE^QBJ7E>_73\ 9?\BJD0Q#<#K\[
M(CSH+VY$(GUWFGX;T&"BX>%XC.W5$Y_D"C+EWK8\*)9'#KX#5W1 X1NY*8V9
M[K]6-[@$<3@U[$CI25K8V3(;#[41ZM*K'@6EPN9FQ7"\F-*"NZW!Y#X6;2!Y
M,-'IEM"IE(.)<.YBX$ 3IW;6O^3)313:"M_16;W= *N#R#PX!/6MW9^*F #3
MF0[ J9:^0F0 %I9*?K'<_3X"D".[$CNLFS$\Q#&1Z'(XX;OR?>1O WG2[O^*
M3FRWD[X[_(*;!<DPDLW[R<M(_@-M;Y=,I'+DZ!*;0=PZD@[I?:(AD@CZK7_^
MD)QO0]] O]' 95^8ZH;L24##8KH.\Y/OA^&OMN-O;:<,N1='*F"7L5!AX61'
M0Q?OP5I(:&!=&)D0UE&Z%*$[<L?DUL+ODO]"7?!FS_>TT<W1-SK^ZK]K1P>;
MQM >S].SR\OTZNHT@?_/+]*+D[/D*CVY.$]/K^9:5JAU#=/W<I*>G5VFEQ>7
M\-/Y^64Z/S^!G^875^G5Z05J08U7W;_,Q<5I>GI^ZOXE+^SD>VP'<WDK$ BB
MO/E->')^)?^_3,_.+Z*G>5SM:3H_ U NY\%/QV?I^>5Y>@';C+X TVVL_YZF
MSZZNTOFSXV3BBS7=4\?I?'X%(,R#GWXCF_D8L'H.&\Y/\<?CJWGZ#'!U"O^<
M/DNO .;WV)S+!2:(")K*QF/"?*,T/;*G;H-&$@R>Y4#?4;T\HO)A<OMECL7P
M2?_%9@].#183:OA>7+!M6B>\D;^=1!23CU]V1J.,>@B_QZV1,+E&KGVFV447
M.2YI>#9PW> WT_O(BE0E< &1&RA)B))^=BEOL<H/F%]P,] E"3[&7S$LV7$(
M8&&M64]N_"1;E.*/KJ5D6/@9S6-1>.CF=;K6$#8T)-0Z"*/EL+:]HTE/WL**
M1IKIWYOHJ^A0-#<<QE#IK',IF\ '<9HJ*!4<D*9FV(4@"??Q-#T9'* 3DL(Y
M>'QP'F,=F?1^%V?4_Y59KD%B94!UP8PY[I(?;S2L+_&Q@1N4/4<OB100(_"\
M&76<TN,MRRD1?%GXK**V>?ZT>_'\:='"_S+X#T@9_D_<]MITYL5S^A*@5Q:;
MF"E6_,/!\4'P5]3]/QQ<'W]W?7+P%-[TC[]XO@5+[F?PZ7#6;FF7\.I\]NS\
M@&E;?^GJ+2Z)>8RNWM"/&)RQ#3X GR]K$*/R"VZ 40,"[\7_ E!+ P04
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M9KQL1J7GX\W ><?U4E"U2RQ(-1RDHQXQZ(>X9F'5V@]."V6)1O^ZHKD7M3M
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MJ\ID )^R^^(C[$FB3'),,DSJ5*D"$+;^V 1&,57UK5)E"A#P(Y) (WXWH+W
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MNDW5H*R 439K68!*4;C WG4!GEB@&A9JG.NYKE&9,TP4YR1*$+#@VI8WZ/*
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M$V*W3&)UYJ*9-Q!$T=6;R>G6>T-Q$7EK=?*-RJ^P%J%X.S?..M6("K9$MRC
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M.N-((Y7M,$LTF)C1GTF^&)S$0:M/L:[[T&00FHOTUI!/[]P@TJB37X0F88"
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MC&6>_5I&_#?$B;"![]<*7]2M;+:B\I=DVUKS20.JJMJ*JT6&R 3,>VF5*"G
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M,A3I[L:_Y!7NWPMW$#L! D^AYG,Q@F[[*_%PA=?'8C(<BWB8'+4(G9=2Y$6
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MW;'3TQ0G'%_I0C@XL@W$7/_PT^W-JW@AP%BF-GKIM1;61]1ZT(C&#1F0F!Z
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M+,TO>E>C[ZXG?#X<^*AHY3K7@CV9&?.9;VZSB]Z0 9&FU+,&B7\/=$-:LR+
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MA K@UIQ!Z'E=V..PQ/L@Z9_5 R'].H88UG#0/R'XGT ^G,?S]VL:P^AY"(6
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M<VAE970R-2YX;6R]/=F2VT:2OX+H]>YT1Y!4D[HM6Q&MPQ[-2+)"+=D/&_L
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MNORMR-O-CV=/SI+<K-*N;#_6^[\;V=!#G"^K2TO_3_;\[,,'9TG6V;;>RF"
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MX "L9\4.!?@630P5U_-9#R%+.">,B:MN#:9?@) S]\W\:?("GSN[.,$)#P+
MQW'R $CGD/+QMT$\/ CXZO\=#8XU T0$WSE4(") 0M=K X\T7I,>(8W%N' 7
M?:/<=??#\?=Z#RJBF81*#K4)CD9I#_R<+$&FWZ1%2=J^8-RPP)Z@:"Y6_N<)
M#5HR"D'O@L&Q ?T7&!A BKPH.\1LD]2XPWT!^B[- 0J+A$I!L&6L7AMT0H@/
MS%<0P A3:,>!/H2E<Q"^2!&$VI*^1I@#B$)=1UL259>;,CU,0!J .#?TE,U
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M?[SV3#>8CO^3<_$745JP84,0="\&1<0S"0R3I2%]7QY$.T;L WC(-L019!B
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M*7MSE6\#C*G/4,49<&0)$U4I!5_DK'3H+9Q(1CDK;#)HT!5'].*PM*< )<E
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M(;"!J+AO8+H)-?2VU!(V7$_4V]1*4!O!36N5VO)TV\'@S,=)/)S<7RHLQ[+
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MCQ^>L36N'V"+]&[Q9=VV]9;^Q."B:? !^'U5UZU^P 7<V^:?_R]02P,$%
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M\0A#[/3%;^@[%>]?UVMM%-+F[S,&DM% X@PD7\>YE$V#?-1;JM"*V5)#]J"
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M)XT&B\TB6K'SBSR<[P[\(?'DGLPA9+(UYC8LOM2+* V$4&'E X*@X0[7J%0
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MC,6<BM7;2/N8D666#9:7[GSRI /1)=AU?=9!98[:]\UHM(ZM?-5WL&_'^^_
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MM4[HGK!)EC(_#(C8-T7G0F#AA*5!<D!NL.CDDL0CP[[+\"[;SZTII!=*8V.
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M.T_I-%0WGW2$D1LW$RREH0G#+4L:Z5!9 >*OI#0[PAH8AL3Y?U!+ P04
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MBRG5Q_3CNQ><;L/(W&A' S@L&WKQT'@%.J\UI7<O> ?#&[KZ#U!+ P04
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M].B/@)T,8">O!IMP,=3Q9GB!M$UI1C$?U7T8\]M1(_\'^"-84_-'*?-HPNQ
M)B0S&C&$_E<*I,<V3>@_/-Z'U?<#EG&BC0#*64B#)Z71<@C(V=ZN5:-:N8U2
M0R[;QG1KUT =EM:+;E=[9N\VW@]"K4K*585+$J6!16\DU6V1W<'(C=O<%M+0
M'N@>U[1XH[(,=+^4M+?T!VM@6.7G_P)02P,$%     @ 8']A5*E "37J @
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MY@.TOU+T06M?V$%W0U[\"U!+ P04    " !@?V%4JA_8EK8&  #7(0  &0
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M60'XF^L)4>"HE]FVM[;M66W+%EAF94H$G2J.ECW05,WG7LL^1$X4>IZ'T%9
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MJB\QXPF6JLN7ML@XX,B $FI[CM.S$TQ2:S(R8PL^&;&-I"2%!4=BDR28[V9
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MZ:NW",]KG;PC669>_X],JEK"-%>J/@2N)ZCO,6-RW]$+E!7GY"]02P,$%
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MW@5^'Q-B%9S$9P8;M;-&-I1[(1[LYCH=>X'U"')(M(6@YK.&&/+<(AD__JU
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MN$I[8S#=N+(\+RT'9RS[ 3SR7*42_LX33(X!7$VCYA*\<ID'%Q$7&-]"Z-]
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M,RHFP<< ,LS91M"]VG[&)I^AXTN5,/X7MDUL/X!T8TB5#=@Z*+FLGVS7U.$
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MC0@CH4H#\_M:2OUX4R9HC@07_P)02P,$%     @ 8']A5#T9P0W3!   ;1<
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M9RI689*"B"U5*CSU5%^*<F^WO)!\4VR//G I>5R<KAD-F,@#U.]+SN7S1?Z
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MWGF"FTDV?;N9:+&QK6\I-#92.USC50?2&.#W0@C]/#'=M+L\TS]02P,$%
M  @ 8']A5#W0WC%;"0  5C8  !D   !X;"]W;W)K<VAE971S+W-H965T-3,N
M>&ULQ5M;<^*X$OXK*O92F2H&K*OMW215$SBY3;*5FM3L/FSM@P,"7&-LUA:Y
MG#H__LA&03:VA9P)-7D(&-2M3^I6?]UM<_R4I-^R!><"/"^C.#OI+818_38<
M9I,%7P;9(%GQ6'XS2])E(.1E.A]FJY0'TT)H&0V1X[#A,@CCWNEQ\=E=>GJ<
MK$44QOPN!=EZN0S2ES,>)4\G/=A[_>!+.%^(_(/AZ?$JF/-[+KZN[E)Y-=QJ
MF89+'F=A$H.4STYZG^!OMR[.!8H1?X;\*2N]!_E2'I+D6WYQ-3WI.3DB'O&)
MR%4$\N61CW@4Y9HDCG^5TMYVSERP_/Y5^WFQ>+F8AR#CHR3Z*YR*Q4G/ZX$I
MGP7K2'Q)GBZY6A#-]4V2*"O^@Z?-6-?O@<DZ$\E2"4L$RS#>O ;/:B-* MAI
M$4!* .T*P!8!K 3PC@!J$R!*@-@*4"5 =P7<%@&F!-B. &E;M*L$7-L9/"7@
MV:[!5P*^K0!T7BWG6(MLC;UK[7:15W/#77NWB[P:'!86'VY\L7#D<2""T^,T
M>0)I/E[JR]\4IZ&0E_X;QOG!O1>I_#:4<N)TE,2//!7A0\3!F#\(\!'\$:1I
MD!\G<#3F(@BC[,/Q4,BY<HGA1.D]V^A%+7H_K><#X. ^0 YR?@9#D"V"E&>;
M_PWJ1F9U8SX9 ,1R==#_>C\&1S]_T%H;](UMX,&*O@8M_S%K.></$I6W3\NY
M!18,-UNEM+2NZ\)BGY0NJ'1-@Q<+ US:*]X+\LI:EVG;KCMH^?SE+W#TZT\>
M9O#W)EV?.[C7/ETW'5QKGZY;LZ[;(-WCID-YWK>''FT//2K4XM;ERH-^%6<B
M74L.%N#O&SD 7 F^S/XQJ,=;];A03UK47\6"2\<0@#_+_"+C36Z\T> 6&O+D
MXO$4^I@1XAX/'\M>61_GN0XBU*F.NZJ/<WWB4>QOQU660K9+(<:EC!9!/.<@
MC,$L"%/P&$1K#I*93 W2\'$3)*,P> BC4+PT+7.CG95@[0"_K(_XZ%+F.KZ[
MLQ57#2.ARS"CJ'F-=+M&:EPC&U#G%U F@GL>ATD*_D@$S\!8KE@>>F)P#+:=
MB1W"[]RM>M>XD$)]N%7?ES:;<! LDW4LFHSCUC;4]:B3_S5OJ+?%X5G@R+)U
M$,OY)TDFLCZ(>2,&KX8!01\ZL!F!OT7@=]N)=2RW05KWOWP*IF$V:=L2OP8'
M4A_Z3LLQ@HY.,QPCH@M90X"C*,FR#T#FZ_Q9A/%\'6:+PA'DB9J4_.\AB:<9
M".(IR#:>&.>>V,B&3NW<[QXP-8150@A##MX-(49=U667LBOX'F<+_ _L)F*&
M\P!UG(<'"?101WIH#O4=C]PM;(C3QC,'=:2&YE"MH"CJR8NY:>YI8L'!+'R6
M%S*I;:2B/7H+$S8F.6^3NWZCW&UWN>I.:CZ 9D*X2Y,)Y_($SM)DJ0-907N[
MCJG29%HW*W6K9E6;9C&R"EN3"V3=?+$44EXOBG[#*@WE<HYD0,I3JA5/-[GQ
M!WD*C37%A0+@E\#3 ?9:@&O:@AUYJP)<+"2:11)-<Z03^7TP+VPAB\/)-[46
MD8;S.4\;,9OGAM@9.&:_T;0';7AO_SI$&DQE] >R,,GDGLN71N -U-CF(YH7
M84=B;($H/\[X9%TD>)9PZ]2)6^ BS9K(S)HUN"F?\N5*;+VX7W**)E1[]$-G
MG_61ICIDIKJ;))Y_E-%W642)?BEA;@IF2EDY#C"$#'$ E8H;]%[IUZU257$R
MSX1",R/JR(R6*=@M:BB-/&;"I"D265&DQK2ERYP;^X#/9KQHI.[S*O,T$ ^@
MV:DT%2$S%5G']+QCE311DYH PG):-X >]1Q"6S944PZRH!R-8@M/FEB#SD]J
M/ E70=2>&%VJB:KG 9JLKND%6=#+/I!]17O%P9'?Y.RX^22GQ?:N$:H741!2
M3!EKPZWI!)GIY+Q:<4L/+:VB$8M7VT."3;D%TKR!OH<W)D&:ON04L;%O#I?_
MNP[%BQRV7"4Q;[%YG3(H,B7#6!,'_A'EUB5NJ*5,X1)K]L!F]K#J&=4Y0Y:F
M]23S4@TLPV2^":;F%FSFEEV8_;:4^ +7F07"1K#U@<1T\'&I#6>FH$_K^5I"
MS7N'X"RWL:FWITD$DX,T#W7,Q^:8?Z!6 :Y7'C53T'J+S8.NZQ"\VVZLCVPS
MER83;":3FKFZ=06P)@3L'L2".G+CCH6 N2LPQO7 #3=QL-;FM1UYK4;F39U2
M'N6\_E5'W]B.KFZ(I@]L11^=>Q/C/7IA/7M7^[1'KBGO5_OV5LF;[EBK+7E-
M;L1,;IW[$V-2;^U!0IL<S&9D%;:F.&*FN(/W)\X4@')_0J;BI 6X)CUB4U!U
M+V7&I$YM+C;MI:8V8E%='2BG/5-S5QC99P@S4G66\Z:!S*\,K*ZO=-NI8Z7V
M#OGF6,U9Z;V9,@VB*9O\",H^)W7*_NB9F@1$DRTQDZU%OGFI5%12.%,A3C0#
M$W-)9IU&7I)Z?>6Y[0@T19-.Q97=[<QS4N_)>>;HJ"F2F.GA.^^TGBOU]HUE
MJOF&FOG&)C&3'UW%H0AED3_2D?PNC^0&SJ.:/"@\1,Y&=9"G'8/\N[.3 E I
MSUM,HWF =NRR=>T/G:D)(*KTAZ37(%FN4;^E141U)*?F2&[I/)]F,B* ZR!>
M!^D+0)OG;#JY4NEV/SV(*^G82M_I1DR[45B;45S*/!>W&$7'7[JO)3;ARP>Y
MX6\MMJ@.M-0[R&[KP$D[MJ;,Q=:(U@/E;K]ADPK;#KQ6 RO%$W&;*ZW/EH.K
MSY?H4,VL;IAT+K1&>_2V%EIOE+M^H]SG[G+5G=2$P\S52N<B:\3J[3G26,1;
M#*R"UB3&.I+8&V]P[)F&#9!YES5_L1]7QURP>GDBSZ]??GBN"EN3&C.3FDVW
MEM6K#=K0_F3UQ]H0Q>V^H&F.F6L2^U8MJS?S_ :@]6*$&'RV]$R<F2WOB_OX
M5QO3CM=I7M?=R:0WF?;!GWD6W"^G ?+\?95Y9K.]Z_>0"#&=*\V7[#WX\FTY
M,--4R@Y"I4Q3*?NNNSS?GP./6 .G-AO'U9SG=GQ(H&NZ-5(3-.7 Q'49:T&H
MN<3=U_FR=!^5!:^C-Z7 KN8)]R#/Q;DZKKL'KDM&;EM=@JGK,[C[@.BP]!.0
M_!=7MT$ZE_.#B,^DN#-P9?1*-S]BVER(9%7\*N0A$2)9%F\7/)#5=CY ?C]+
M$O%ZD?_09/M3LM/_ U!+ P04    " !@?V%4Y4^-\:D"  "O!@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U-"YX;6R5E5UOVC 4AO^*%6U2*ZWD Q*@ J12
M-*W2/E!9MXMI%R8Y$*N.G=D.M/OU.W;2B(Z 5"Z('9_SOL^)G9/)7JI'G0,8
M\E1PH:=>;DQY[?LZS:&@NB=+$+BRD:J@!J=JZ^M2 <U<4L']* @2OZ!,>+.)
MN[=4LXFL#&<"EHKHJBBH>IX#E_NI%WHO-^[9-C?VAC^;E'0+*S /Y5+AS&]5
M,E: T$P*HF S]6["Z_G(QKN 'PSV^F!,;"5K*1_MY"Z;>H$% @ZIL0H4+SNX
M!<ZM$&+\:32]UM(F'HY?U#^ZVK&6-=5P*_E/EIE\ZHT\DL&&5MS<R_TG:.J)
MK5XJN7;_9-_$!AY)*VUDT20C0<%$?:5/S7,X2(C"$PE1DQ Y[MK(42ZHH;.)
MDGNB;#2JV8$KU64C'!-V4U9&X2K#/#.[E6('RK U![* M2%79$XY%2F0;QMR
MM'JQ $,9UY<8E_3BX/VKD!4()A7Y*@UHLJB 1$$TF/@&.:V;GS9,\YHI.L&T
M@+1'^N$'FQX^K!;DXMWE:Q4?JVQ+C=I2(R?;/RF+!=P);52%I\J07Y\Q@-P9
M*/3O,_+]5K[OY <GY)>*B925E!-:R$J8KKIKA:%3L*_+;C8<Q8']3?Q=A_>@
M]1Z\R9ND]:Y 1I@P$J=%@:^ SJD"W056RR<'8%=)%#BV;K*X)8O/DCT(),+C
M\1=1,KL!&=.I0T0>DP/AC*X99^;90I920/>3BX\!PW@<CH-Q-U_2\B5OXV-:
M5^[XIU)WDB3')%$X#H.P&V38@@S/@MRDJ:KJ_0+<I$[KX9%U/XZ3>-CM/&J=
M1V>=OTM#>9?=Z.BTAH-Q/$X&_QOZ!_W'MO(O5&V9T(3#!E.#WA!W3]7ML9X8
M6;J6M)8&&YP;YOA% 64#<'TCL84T$]OEVF_4[!]02P,$%     @ 8']A5-,?
M7D"L @  5@@  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULM59A;]HP
M$/TK5K1)K;01)X1 )D!:B:956J>JK-N':1\,'& UB9E]@>[?[^RD&5T#997V
M!7S)O??N'O:9X4[I.[,&0':?9X49>6O$S3O?-_,UY,)TU 8*>K-4.A=(H5[Y
M9J-!+!PHS_R0\]C/A2R\\= ]N];CH2HQDP5<:V;*/!?ZUP5D:C?R N_AP8U<
MK=$^\,?#C5C!%/!V<ZTI\AN6A<RA,%(53,-RY+T/WJ4!MP"7\57"SNRMF6UE
MIM2=#2X7(X_;BB"#.5H*05];F$"662:JXV=-ZC6:%KB_?F#_X)JG9F;"P$1E
MW^0"UR-OX+$%+$69X8W:?82ZH9[EFZO,N$^VJW.YQ^:E09778*H@ET7U+>YK
M(_8 070 $-: \%1 MP9T3P5$-2!RSE2M.!]2@6(\U&K'M,TF-KMP9CHTM2\+
M^[M/4=-;23@<3U2Q!8URE@%+88;L+9O2WEJ4%*LENQ)8:HD2##M+ 87,S#FE
MQ)T>?\WVL5,HI-+LLT)*34M@(0\CRKR=INSLU?G01RK62OKSNK"+JK#P0&$I
MS#NL&[RQ1$$+?'(R/$A:X.EQ^)70'<9;X3XYW-@<-C:'CJ][L!RR]K(PJ$LZ
M-,B^?Z($=HF0FQ]'Z+L-?=?11P?HOR@469O'%:SO8'8$;,=!E/22..H/_6V+
M8-0(1D<%_]XV1WKH-92]_V%1W-#'1RMV]+) T&#0C8H%H[F#:V!+>4^!%@AM
M%AZG=2>A;7N^#);^,^R1&?W&C/Y1'CI385NO_:?;A<=]SGG[;ADT<H/GY+IM
M<A4J/E4N:>22Y^2B-KGDJ5R<1(.#>@'_,T3YR\Y?C7OD:,('X5--?V^&VQN7
M)M!*%H9EL"0H[_3I].CJ$JL"5!LWUF<*Z9)PRS5=_*!M KU?*IK%=6!OBN:O
MQ/@W4$L#!!0    ( &!_852Z#_0>IP(  "H'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;(V5WV^;,!#'_Q4+[:&5MH)M?J0506J33=O#M*A=MX=I
M#P:<8-5@9INF_>]G&\+2A'1] =O<]^YS=[9)MT(^J(I2#9YJWJBY5VG=7OF^
M*BI:$W4A6MJ8+VLA:Z+-5&Y\U4I*2B>JN8^"(/9KPAHO2]W:2F:IZ#1G#5U)
MH+JZ)O+YAG*QG7O0VRW<LDVE[8*?I2W9T#NJ[]N5-#-_]%*RFC:*B09(NIY[
MU_!JD5A[9_"#T:W:&P.;22[$@YU\*>=>8($HIX6V'HAY/=(%Y=PZ,AA_!I_>
M&-(*]\<[[Y]<[B:7G"BZ$/PG*W4U]V8>*.F:=%S?BNUG.N0367^%X,H]P;:W
MC8QQT2DMZD%L"&K6]&_R--1A3P##$P(T"-!;!7@08)=H3^;26A)-LE2*+9#6
MVGBS U<;IS;9L,9V\4Y+\Y49G<ZNBT)TC59@19Y)SBD@30G,HNQH"3X^F<VB
MJ )G2ZH)X^H<? #W=TMP]NX\];4);YWXQ1#JI@^%3H1:TN("8/@>H #!"?GB
M[?+@I=PW28^9HS%SY/SA$_Z&A-6_C E7X-=UKK0TF^OW*R'P& *[$.&)$-\E
M*4U%=R5N^XA3E>O]),Z//7B/&0H1Q'&"4_]QOT;'AC,413 >S5Z AB-H^"KH
MKN&%J&W'B3UA4YB]EW@O.HPA1)<0'6!.&&*($A0ETZ#1"!J]"51U>2$:UR@#
MK;2:HHV.(6 <'*(>6Z$P22Y/5#0>0>-70;_IBDK;>H=+AX,T11D?Q4]P$./P
ML/,3=D& $;Z<!DU&T.1_%7VQ.]UQV'%S1G+&F6;3Z,G19@R3. PC'!RP'QLB
MB (\"V8'\/[>36;_(E^)W+!& 4[71AI<)*9;LK^9^XD6K;O<<J'-5>F&E?F9
M46D-S/>U$'HWL??E^'O,_@)02P,$%     @ 8']A5!*34B#) @  4 H  !D
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M,%4M'W!MH/:7C,GGB6XJZB8R^@-02P,$%     @ 8']A5'4IZL@\#   548
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MR@;@_E)*LY]8@OJ-'/X!4$L#!!0    ( &!_851F%#*:O0,  , -   9
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MFWR6^7$A'VBQ=?WP4FC37;O'C3EB$6D7F/=K(?1Q8!V4A[;)/U!+ P04
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M+H#W.RG-\\!V.WUWN_X&4$L#!!0    ( &!_850(U>[]Q0(  &0'   9
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M0Z,R6<OHPIFJY%P29K8"1]&PFZH^/T=@HQ9LU OV3"4E(LT1[*T0_0;Z]-K
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MYTESF5," ZP6P/=+SM7'C?Z!]K\.T_\!4$L#!!0    ( &!_8533\D?9+@0
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MYBN_N%P!->]%=H&YOQ!"/PVL@?KP:/(-4$L#!!0    ( &!_851F.URQ8P0
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MN%OJH#!UPC$TXC']6O"@,'B\,40.U/@[M*!!8=#<4D$)7^^Z%!X7S&<! =_
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M0\1W"0BY86FGGILMX?'EQ/ZI:^&= DXN1\? M[-I1 \[YMD\/*$S&H8L8D4
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M41VT,\#O*X6GLUFX4:T=_N?_ E!+ P04    " !@?V%4<M C9S0#  "G#
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M$,ATLG(J+C>"KO44=T>%G GU,I'_)( I 7F_I%0\;-1@6/\W&?\#4$L#!!0
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M\BQAYB.X2]\E==M2FV_X?3\,PJ#3[KKWZ\OVI-E&Y*TZ\E9CY..423!!<SR
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" !@?V%4,YUZIZT%  !&,@  #P   'AL+W=O<FMB;V]K+GAM;,6;76_;-A2&
M_PKAFZ7 4MNR)+=%4R!UFBY T1AQUMN"D>B8B$1Z))VO7S]*KK?#S'VQFU-?
M)9)L^?$AQ><<DG[_8-W=C;5WXK%MC#\9K$)8OQL.?;52K?2O[5J9>&5I72M#
M/'2W0[]V2M9^I51HFV$V&I7#5FHS^/!^=Z^Y&](#&U05M#7Q9'?BFU8/_M_K
MW:&XUU[?Z$:'IY-!_W^C!J+51K?Z6=4G@]% ^)5]^,,Z_6Q-D,VB<K9I3@;C
M[85OR@5=_>?THH.\EC>^/Q/DS96,(">#<A1ON-3.A_X5_?UE9+Q7\<7;HTVP
MY[H)RIW)H#X[NUEK<]O=)GZ+(?D:?1QV?[=!?.?^3QCM<JDK=6:K3:M,V,;1
MJ:8#-'ZEUWX@C&S5R6!F[Y43<WFKNB\5/^6BWG[!$,E(N-P['2^XB[IGY.,Y
MW=0ZB NS?7.\2K R@)7Q8LWBL6UT'3^]%A]E(TVE1-^\G@!. .#D8(#B:"X)
M9 X@\U\(N>@@NC=X89?B<JT<@2P 9'$PR)EMUP2R!)#EP2 7P58$<@H@IX>+
MI/0K OD&0+[AA;Q>J;Y=I7DB0&\!T%M>H,6F;:5[ZIM2WQH=WR9-$*=593<F
M:#I,C] X/>+%O%+WRFR4N%*5C93==2%-'6,91QX3*";4";-/9M'8\L8ZV?E7
MG-XZM>V$E ]Y9<PLEL7*NG <,X$V2N]>^;!]1+I(GDM-A\0QLLN862]SI]92
MU^+38[R)5UO R["*N<-LXQ),Y)<QLV#.]6,<:DZ]3[T\1CH9,_ODL[7U@VZ:
M/F07,;TTMQW!'DKDDS&_4.Z[-+<C.U,WR?.+%#)F=LB/8<_'%/5)=G!=%.-)
MMU%=;Z282")C9HMTTKU;V:96SO\F/OVUB<4&94,^&3,+)=JMU61<B4T=8KFA
M3*45[7\9TDG&K),+4]E6B6OYF#(A=V3,[LA'XZ.[5V(>DVF*!,L09EU<=2=C
MSY]+%Y[$M9/&R[[\38*&3)$QF^*S,LIZ$=,J)]=J$PMG_WL<]JK7%! Y(F-V
M!,ROOF<4$VDC8]8&QIQ03.2-C-D;, U,HXDTDC%K!*99*2;22,:L$9AFI9C(
M*!FS46B:)8ZN.R_[5W0>!)EDPFP2G&\)BHGD,F$O3-*$:V\<D6HFS*J!F5?2
M%R=PWHO9-_LRK[VQ1,Z9L$]\@11,'%%,Y)P)LW-H$K8WAL@T$V;3_#2QV))2
M3&2:";=IH+=SBHE,,^$N6"!F03&1:2:'G S[7M)I;>2<_)"384FREB/GY,S.
MP9BT;^;(/#G[8LO^.3MQ=*:"I#.@.3)/SFT>F%,FC0[77+CK'8B9-#IR3\Y=
M[T!,.B#ER$(YLX5PAIXT.K)0SFPAC)DT.K)0SFRAM)#HG^XFR3AR))^<63ZP
MDD@RX +)ISADP9-TR0+)IV"6#\:D7;) \BGX5_K3NNQ8?)7NAXN.SB@FDD_!
MO][_$G.WZG^Y%#.*B>13\*_XO\1<Q-O6FW@<<SJ*"9?\F>6#:]WD$4+R*9CE
ML[?6C1']D2133"2?@KL$VH^Y>XPH)I)/<8 UFW^BF0[OR$(%=PD$,6G?+)&%
M2F8+84PZO)?(0B7[M!N:B3FFF,A");N% &;2-TMDH9+90LF$T7&_C\::W1Z?
M.=T64"(+E<P6>H'9E;\QD(WN7RDLQ406*G_E]%N:=KRH>TNX]8S90@DFG979
M-C_%1!8JF2V48'9U4!7Z+0-KW44U:71DH9+90@GFG\9MIV:>(VH\)3Y23&2A
MDME"9"U\;Z$V1>Z9LD^__6Q5O&>EF,@]4^X*Z*<SV/W#3C&1>Z;,[D&89RK9
M6XK<,SW41H.(>6%HECE%[IDRNP=AGB>#^A2Y9\J]2PU@SAW]<< 4N6?:NV?8
MO]A_>%^KI3:J_AH_PL?SE6RJN1/=GWY75)87W<ZHY:9I9O'<I?EB9;W[&<3N
M)QP?_@902P,$%     @ 8']A5'-\>"Q1 @  ^RP  !H   !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+""X[JN25IQ13S*-L@'DE!^*
M;1#02K+[MIR!?5 />A)Q1JA 7/X)GQ#P^%(.S;AO3\-NWPV+S^/A-*RJW3AV
MO^IZ6._*L1GNVJZ<SD<V;7]LQO.RW]9=LWYOMJ66Y3+J_G9&]?1X.W/Q^M65
M_YG8;C;[=?G=KO\<RVG\Q^#ZH^W?AUTI8[5X;?IM&5=5_7FX[A[JRR;=G2=7
MB^>W5=4_OZ6JGCM(($CF#U((TOF##()L_B"'()\_*" HY@_*$)3G#[J'H/OY
M@QX@Z&'^H+1$&9<$21.L";1.R'4B\#HAV(E [(1D)P*S$Z*="-1.R'8B<#LA
MW(E [H1T)P*[$^*="/06U%L(]!;46PCTELG#-H'>@GH+@=Z">@N!WH)Z"X'>
M@GH+@=Z">@N!WH)Z"X'>@GH+@=Z*>BN!WHIZ*X'>BGHK@=XZ>5E"H+>BWDJ@
MMZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>AWD:@MZ'>1J"WH=Y&H+>AWD:@
MMTU>=A/H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H[:BW$^CMJ+<3
MZ.VHMQ/H[:BW$^CMDX^5!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>@?J'01Z!^H=
M!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9Q,"O0/U#@*] _4. KT#]0X"O3/J
MG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSJAW)M [H][Y)_4>QJ]#&:X]WVN\
M_D]2/9[/+=?+7Y;?.R?W^ 7G^K9B>/H+4$L#!!0    ( &!_853.%<Q?#P(
M .HK   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:S6[B,!0%X%=!V5;$^#?3
M$;"9F6V'15_ 32XE(HDMVVWA[<<);:56'305(_5LB,#V/3>^TK=B>7OT%&>'
MOAOBJMBEY+\S%NL=]3:6SM.05[8N]#;EK^&>>5OO[3TQL5@85KLAT9#F::Q1
MK)<_:6L?NC3[=<@_Q]8-JR)0%XO9C]/&,6M56.^[MK8IK[/'H7F7,G].*//)
M:4_<M3Y>Y0T%^S!A7/E[P/.YWX\40MO0;&-#NK%]WL4.'8OIV%$LSY?XH$>W
MW;8U-:Y^Z/.1,OI MHD[HM1WY:GHU?GDE&^83I_\XORIS+G O',3G(]Y8H$^
M'_<RDO'TW.="%%)[_A5?$W/IB]^/QFDWU/QC=K[>)Q?VTSPBFQZ7W_';&;_6
M_V0? J0/"=*' NE#@_1A0/JH0/KX!M+'-4@??('2"(JH'(54CF(J1T&5HZC*
M45CE**YR%%@YBJP"15:!(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(
M*E%DE2BR2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56A
MR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%DU2BR:A19-8JL!D56@R*K09'5
MH,AJ4&0U*+(:%%D-BJP&15:#(FN%(FN%(FN%(FN%(FN%(FN%(FOUE;+>.;?_
MS_'3L^QM.[SDL^DOONL_4$L! A0#%     @ 8']A5 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !@
M?V%4VA@*Z^\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !@?V%4F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &!_850=%1B>
M_P8  %8;   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !@?V%4%?Q;H"4"  !Z!0  &
M@(%##P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 8']A
M5+MXY$H7"   VB(  !@              ("!GA$  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( &!_850AXAMUTP(  +D)   8
M      " @>L9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" !@?V%4AS<5T!0(   %(P  &               @('T'   >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 8']A5*HW\N^. P  J@H  !@
M             ("!/B4  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( &!_853A-1<+H@D  /TP   8              " @0(I  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !@?V%4!Q81:'X-  !%
M/@  &               @(':,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ 8']A5#X<N#VJ"   G!(  !@              ("!CD
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &!_851\42 6
MT"D  #^%   9              " @6Y)  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ 8']A5!UD_MO)!   50L  !D
M ("!=7,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !@
M?V%4]2=MNAL:  "770  &0              @(%U>   >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &!_853>EO(?+@H  &\U   9
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M970Q-RYX;6Q02P$"% ,4    " !@?V%4P?SU!Y8"  #8!0  &0
M    @(&(N0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M &!_851- OG(Y0T  *XN   9              " @56\  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ 8']A5)Z4%5K-$0  SS0  !D
M             ("!<<H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " !@?V%4S-FH6S8/   V*0  &0              @(%UW   >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &!_8514]3/2] (
M '8&   9              " @>+K  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ 8']A5,!+;.W@!@  AA,  !D              ("!
M#>\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !@?V%4
M;EKVV D/  !/+P  &0              @($D]@  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( &!_853TE)AWC"4  'E^   9
M      " @60% 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ 8']A5,$4K$$\!   @ H  !D              ("!)RL! 'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !@?V%4UPCRBT@#  #L!@
M&0              @(&:+P$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( &!_852V$<B#@@4  (@/   9              " @1DS 0!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 8']A5)OAY3U/
M P  ,P<  !D              ("!TC@! 'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " !@?V%4)@5KFF\#   H!P  &0
M@(%8/ $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &!_
M853CIH7B000  # *   9              " @?X_ 0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ 8']A5)H^TC!- P  3P<  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( &!_852%0P!3[00  "T+   9
M  " @:E: 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M8']A5*H?V):V!@  UR$  !D              ("!S5\! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " !@?V%4WU1 FV$$  #=%   &0
M            @(&Z9@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( &!_850C=@-P> ,  'T.   9              " @5)K 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 8']A5)B"O\?G!
M6AH  !D              ("! 6\! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " !@?V%4@C4(,XD#  !>#@  &0              @($?
M= $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &!_851>
M@!<]@0D  .,Y   9              " @=]W 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ 8']A5'?C@V&T!0  4AL  !D
M     ("!EX$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &!_85075,Y6Q@0  !X4   9              "
M@8>8 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 8']A
M5#T9P0W3!   ;1<  !D              ("!A)T! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " !@?V%4,(Z'!)L"  !&!P  &0
M        @(&.H@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( &!_853_%BG:BP(  $@'   9              " @6"E 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 8']A5#W0WC%;"0  5C8
M !D              ("!(J@! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " !@?V%4Y4^-\:D"  "O!@  &0              @(&TL0$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &!_8533'UY
MK (  %8(   9              " @92T 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ 8']A5+H/]!ZG @  *@<  !D
M ("!=[<! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !@
M?V%4$I-2(,D"  !0"@  &0              @(%5N@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( &!_851U*>K(/ P  %5&   9
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M970V,BYX;6Q02P$"% ,4    " !@?V%4%/^,\V0#  #I"@  &0
M    @('!V@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M &!_850(U>[]Q0(  &0'   9              " @5S> 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ 8']A5&L=7L&2!   @1   !D
M             ("!6.$! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " !@?V%4T_)'V2X$  !($@  &0              @($AY@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( &!_851F.URQ8P0
M .@/   9              " @8;J 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ 8']A5*/ [2Y&!   LQ0  !D              ("!
M(.\! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " !@?V%4
MV(R_8T(#  #;"0  &0              @(&=\P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &!_850">+V[F (  /$&   9
M      " @1;W 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ 8']A5'-(&AL$!0  :Q0  !D              ("!Y?D! 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !@?V%4KB350G$%  !-&@
M&0              @($@_P$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    ( &!_853CX+["D0,   @,   9              " @<@$ @!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ 8']A5'+0(V<T
M P  IPP  !D              ("!D @" 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    " !@?V%4SVGI;+H"   S"   &0
M@('["P( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( &!_
M852":DZY;0,  % -   9              " @>P. @!X;"]W;W)K<VAE971S
M+W-H965T-S8N>&UL4$L! A0#%     @ 8']A5+?QFK]H P  R!8   T
M         ( !D!(" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !@?V%4EXJ[
M',     3 @  "P              @ $C%@( 7W)E;',O+G)E;'-02P$"% ,4
M    " !@?V%4,YUZIZT%  !&,@  #P              @ $,%P( >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ 8']A5'-\>"Q1 @  ^RP  !H
M     ( !YAP" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ 8']A5,X5S%\/ @  ZBL  !,              ( !;Q\" %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     %0 5  #%P  KR$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>409</ContextCount>
  <ElementCount>583</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>113</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenue Recognition and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2146112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2160115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2340309 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2347310 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2351311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2363312 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Prepaid Expenses and Other Current Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssetsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt - Balance Of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails</Role>
      <ShortName>Income Taxes - Components of Pretax Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2453428 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2456431 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails</Role>
      <ShortName>Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/A401kPlan</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2464435 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2465436 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Geneos Therapeutics, Inc. - Investment in Geneos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Investment in Geneos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ino-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ino-20211231.htm">ino-20211231.htm</File>
    <File>ino-12312021x10kex211.htm</File>
    <File>ino-12312021x10kex231.htm</File>
    <File>ino-12312021x10kex311.htm</File>
    <File>ino-12312021x10kex312.htm</File>
    <File>ino-12312021x10kex321.htm</File>
    <File>ino-12312021x10kex991.htm</File>
    <File>ino-20211231.xsd</File>
    <File>ino-20211231_cal.xml</File>
    <File>ino-20211231_def.xml</File>
    <File>ino-20211231_lab.xml</File>
    <File>ino-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20211231_g1.jpg</File>
    <File>ino-20211231_g2.jpg</File>
    <File>ino-20211231_g3.jpg</File>
    <File>ino-20211231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1189">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 409,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 762,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 11
   },
   "keyCustom": 103,
   "keyStandard": 480,
   "memberCustom": 53,
   "memberStandard": 51,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenue Recognition and Concentration of Credit Risk",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk",
     "shortName": "Revenue Recognition and Concentration of Credit Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Short-term Investments and Fair Value Measurements",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Fixed Assets",
     "role": "http://www.inovio.com/role/FixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.inovio.com/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorLocation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.inovio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorLocation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - 401(k) Plan",
     "role": "http://www.inovio.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160115 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables",
     "shortName": "Revenue Recognition and Concentration of Credit Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Fixed Assets (Tables)",
     "role": "http://www.inovio.com/role/FixedAssetsTables",
     "shortName": "Fixed Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340309 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347310 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.inovio.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2363312 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i3369dbbb9721454ea81e4ab0e4dbc76a_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails",
     "shortName": "Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "idb2df8412c044c118cdb9553e4cf95ad_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
     "shortName": "Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "idfc31d4d5e344fef894e245cc1fded7d_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i395742f3d6cc49d3b3f55b2c752865d7_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:PrepaidManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:PrepaidManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5b698702e82d457c8216eac55fae002d_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositsAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Prepaid Expenses and Other Current Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5b698702e82d457c8216eac55fae002d_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepositsAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Fixed Assets (Details)",
     "role": "http://www.inovio.com/role/FixedAssetsDetails",
     "shortName": "Fixed Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i916cd8866e36499abf272f07df39ec4d_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i347d60d556c2498fb9d80645b9a706b2_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
     "shortName": "Convertible Debt - Balance Of Convertible Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i347d60d556c2498fb9d80645b9a706b2_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i347d60d556c2498fb9d80645b9a706b2_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i916cd8866e36499abf272f07df39ec4d_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia718bbbcb64c4cc489a6ee78063fe0ab_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5b698702e82d457c8216eac55fae002d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ib54d8bf639154cb89c4ba6de26467b78_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
     "shortName": "Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ib54d8bf639154cb89c4ba6de26467b78_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i64d5a8971eba4dd5b123f6d3af041845_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails",
     "shortName": "Income Taxes - Components of Pretax Loss from Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453428 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails",
     "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:TaxBenefitsExpired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i46f662a8f3a3462b9e7192ba6281596b_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:OperatingLossCarryforwardsExpiringinTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456431 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
     "shortName": "Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i46f662a8f3a3462b9e7192ba6281596b_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:OperatingLossCarryforwardsExpiringinTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5b698702e82d457c8216eac55fae002d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails",
     "shortName": "Income Taxes Unrecognized Tax Benefits Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "id0209f8c94d740adaa36dd67c48d6a20_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i36c6f4ee12934a40a1ea728d479c1b02_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i36c6f4ee12934a40a1ea728d479c1b02_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - 401(k) Plan (Details)",
     "role": "http://www.inovio.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464435 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ifa18a071c4404f868cef43212fce1e2c_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465436 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
     "shortName": "Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:WorkingCapitalExcludingCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "ia60088662e644556a450fd3a05824f9f_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Geneos Therapeutics, Inc. - Investment in Geneos (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
     "shortName": "Geneos Therapeutics, Inc. - Investment in Geneos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
     "shortName": "Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5f9c9e26a558402ca97a9fa6ee2e8274_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i5b698702e82d457c8216eac55fae002d_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:AmortizationOfOperatingLeaseRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Company",
     "role": "http://www.inovio.com/role/TheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20211231.htm",
      "contextRef": "i95a71c7984c14ab4bff4e1ca4cecf4e2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 113,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "6.50% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AccruedSubcontractExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Subcontract Expenses",
        "label": "Accrued Subcontract Expenses",
        "terseLabel": "Accrued subcontract costs"
       }
      }
     },
     "localname": "AccruedSubcontractExpenses",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AfterJanuary22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After January 2, 2020 Conversion Price [Member]",
        "label": "After January 2, 2020 Conversion Price [Member]",
        "terseLabel": "After January 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJanuary22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AfterJuly22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After July 2, 2020 Conversion Price [Member]",
        "label": "After July 2, 2020 Conversion Price [Member]",
        "terseLabel": "After July 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJuly22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AllOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Customers [Member]",
        "label": "All Other Customers [Member]",
        "terseLabel": "All other, including affiliated entities"
       }
      }
     },
     "localname": "AllOtherCustomersMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AlternativeInvestmentMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Measurement Input, Term",
        "label": "Alternative Investment, Measurement Input, Term",
        "terseLabel": "Equity method investment, measurement input, expected term"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInputTerm",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_AmortizationOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Operating Lease Right-Of-Use Assets",
        "label": "Amortization Of Operating Lease Right-Of-Use Assets",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AnnualMaintenancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Maintenance Period",
        "label": "Annual Maintenance Period",
        "terseLabel": "Annual Maintenance Period"
       }
      }
     },
     "localname": "AnnualMaintenancePeriod",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumptions used in estimation of fair value of stock options.",
        "label": "Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]",
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options"
       }
      }
     },
     "localname": "AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.inovio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C E L L E C T R A3 P S P Proprietary Smart Device",
        "label": "C E L L E C T R A3 P S P Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CEPIMERSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEPI MERS",
        "label": "CEPI MERS [Member]",
        "terseLabel": "CEPI MERS"
       }
      }
     },
     "localname": "CEPIMERSMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CaliforniaIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Income Tax Authority [Member]",
        "label": "California Income Tax Authority [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets",
        "label": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets",
        "terseLabel": "Change in prepaid expenses and other current assets included in fixed assets"
       }
      }
     },
     "localname": "ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "Loss (gain) on equity investment in affiliated entities",
        "verboseLabel": "Gain (loss) on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration agreement, payment earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Obligation period to pay royalties"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAdvisoryFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Advisory Fees",
        "label": "Collaborative Agreement, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "CollaborativeAgreementAdvisoryFees",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Amended Amount",
        "label": "Collaborative Agreement, Amended Amount",
        "terseLabel": "Agreement amended amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAmendedAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedExercisedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Exercised Amount",
        "label": "Collaborative Agreement, Awarded Exercised Amount",
        "terseLabel": "Awarded exercised amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedExercisedAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementCorporateIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Corporate Income Tax",
        "label": "Collaborative Agreement, Corporate Income Tax",
        "terseLabel": "Collaborative agreement, corporate income tax"
       }
      }
     },
     "localname": "CollaborativeAgreementCorporateIncomeTax",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementForeignNonIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Income Taxes",
        "label": "Collaborative Agreement, Foreign Non-Income Taxes",
        "terseLabel": "Collaborative agreement, foreign non-income Taxes"
       }
      }
     },
     "localname": "CollaborativeAgreementForeignNonIncomeTaxes",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementMilestonePaymentRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Milestone Payment, Revenue Recognized",
        "label": "Collaborative Agreement, Milestone Payment, Revenue Recognized",
        "terseLabel": "Agreement, milestone payment, revenue recognized"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePaymentRevenueRecognized",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Agreement, number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Agreement period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementRevenueFromTheProcurementContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "label": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "terseLabel": "Collaborative Arrangement , Revenue from the Procurement Contract"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromTheProcurementContract",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CommonStockEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock equivalents.",
        "label": "Common Stock Equivalents [Abstract]",
        "verboseLabel": "Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect"
       }
      }
     },
     "localname": "CommonStockEquivalentsAbstract",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_ComprehensiveIncomeLossTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "label": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossTaxExpenseBenefit",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible Bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion, conversion price (in USD per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "D N A Encoded Monoclonal Antibody Technology",
        "label": "D N A Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "D N A Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DebtinstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Accrued Interest",
        "label": "Debt instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtinstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability",
        "verboseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "label": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "terseLabel": "Grant funding liability from affiliated entity, net of current portion"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateNoncurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Interest Expense",
        "label": "Deferred Tax Asset, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestExpense",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetsIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Intangible Assets",
        "label": "Deferred Tax Assets, Intangible Assets",
        "terseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxLiabilitiesFinancingArrangementDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Financing Arrangement, Discount",
        "label": "Deferred Tax Liabilities, Financing Arrangement, Discount",
        "negatedTerseLabel": "Note discount"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangementDiscount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department Of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DepositAssetsForfeited": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit Assets, Forfeited",
        "label": "Deposit Assets, Forfeited",
        "terseLabel": "Deposits forfeited"
       }
      }
     },
     "localname": "DepositAssetsForfeited",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DoDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DoD [Member]",
        "label": "DoD [Member]",
        "terseLabel": "Department of Defense"
       }
      }
     },
     "localname": "DoDMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 12.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary",
        "terseLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt",
        "terseLabel": "Nondeductible loss on extinguishment of debt"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "label": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "terseLabel": "Expired NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 13.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "label": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "terseLabel": "Limited NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EquityComponentOfConvertibleDebtIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component Of Convertible Debt Issued",
        "label": "Equity Component Of Convertible Debt Issued",
        "terseLabel": "Equity component of issuance of convertible notes"
       }
      }
     },
     "localname": "EquityComponentOfConvertibleDebtIssued",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EquityMethodInvestmentEnterpriseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Enterprise Value",
        "label": "Equity Method Investment, Enterprise Value",
        "terseLabel": "Geneos enterprise value"
       }
      }
     },
     "localname": "EquityMethodInvestmentEnterpriseValue",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, Gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, Net Book Value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Grant proceeds received"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Revenue [Policy Text Block]",
        "label": "Grant Revenue [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I N O4800",
        "label": "I N O4800 [Member]",
        "terseLabel": "IN O4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "terseLabel": "Loss from equity method investment, recorded and allocated to investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncomeTaxReconciliationStatuteLimitations": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Statute Limitations",
        "label": "Income Tax Reconciliation, Statute Limitations",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStatuteLimitations",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.",
        "label": "Increase Decrease in Deferred Revenue From Related Parties",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParties",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.",
        "label": "Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "negatedLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_KoreanStateIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Korean State Income Tax Authority",
        "label": "Korean State Income Tax Authority [Member]",
        "terseLabel": "Korean State Income Tax Authority"
       }
      }
     },
     "localname": "KoreanStateIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever And MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeNumberOfLeaseAgreementsEnteredInto": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Number Of Lease Agreements Entered Into",
        "label": "Lessee, Number Of Lease Agreements Entered Into",
        "terseLabel": "Number of lease agreements entered into"
       }
      }
     },
     "localname": "LesseeNumberOfLeaseAgreementsEnteredInto",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Lessee, operating lease, area of land under lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements from affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Sales Agreement [Member]",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "verboseLabel": "Number of potential shares authorized for issuance under a share-based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of vested restricted stock outstanding under the plan.",
        "label": "Number of Shares of Vested Restricted Stock Outstanding Under Plan",
        "verboseLabel": "Number of shares of vested restricted stock outstanding under the plan (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "label": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "terseLabel": "Net operating loss carryforwards that will expire due to IRC Section 382 limitations"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Five Years",
        "label": "Operating Loss Carryforwards, Expiring in Five Years",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinFiveYears",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Four Years",
        "label": "Operating Loss Carryforwards, Expiring in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinFourYears",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Three Years",
        "label": "Operating Loss Carryforwards, Expiring in Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinThreeYears",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Two Years",
        "label": "Operating Loss Carryforwards, Expiring in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinTwoYears",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsIndefinitelyCarryforward": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "label": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinitelyCarryforward",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OtherRevenueAffiliatedEntityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenue Affiliated Entity [Member]",
        "label": "Other Revenue Affiliated Entity [Member]",
        "terseLabel": "Other revenue from affiliated entities"
       }
      }
     },
     "localname": "OtherRevenueAffiliatedEntityMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_OtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenue [Member]",
        "label": "Other Revenue [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PLSaffiliatedentityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PLS (affiliated entity) [Member]",
        "label": "PLS (affiliated entity) [Member]",
        "terseLabel": "PLS (affiliated entity)"
       }
      }
     },
     "localname": "PLSaffiliatedentityMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PennsylvaniaStateIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pennsylvania State Income Tax Authority [Member]",
        "label": "Pennsylvania State Income Tax Authority [Member]",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PennsylvaniaStateIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences, Inc. [Member]",
        "label": "Plumbline Life Sciences, Inc. [Member]",
        "terseLabel": "Plumbline Life Sciences, Inc. (affiliated entity)"
       }
      }
     },
     "localname": "PlumblineLifeSciencesIncMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PrepaidManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Manufacturing Expenses, Current",
        "label": "Prepaid Manufacturing Expenses, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpensesCurrent",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PriorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Sales Agreement [Member]",
        "label": "Prior Sales Agreement [Member]",
        "terseLabel": "Prior Sales Agreement"
       }
      }
     },
     "localname": "PriorSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ProceedsFromCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collaborative Agreement",
        "label": "Proceeds From Collaborative Agreement",
        "terseLabel": "Proceeds from collaborative agreement"
       }
      }
     },
     "localname": "ProceedsFromCollaborativeAgreement",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "terseLabel": "Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsFromSubGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sub-Grant",
        "label": "Proceeds From Sub-Grant",
        "terseLabel": "Proceeds from sub-grant"
       }
      }
     },
     "localname": "ProceedsFromSubGrant",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsfromStockOptionandWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Stock Option and Warrant Exercises",
        "label": "Proceeds from Stock Option and Warrant Exercises",
        "verboseLabel": "Proceeds from stock option exercises, net of tax payments"
       }
      }
     },
     "localname": "ProceedsfromStockOptionandWarrantExercises",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RangeOfExercisePricesFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Five [Member]",
        "label": "Range of Exercise Prices Five [Member]",
        "terseLabel": "$12.01-$15.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesFiveMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Four [Member]",
        "label": "Range of Exercise Prices Four [Member]",
        "terseLabel": "$9.01-$12.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesFourMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices One [Member]",
        "label": "Range of Exercise Prices One [Member]",
        "terseLabel": "$1.60-$3.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesOneMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Five [Member]",
        "label": "Range of Exercise Prices Six [Member]",
        "terseLabel": "$15.01-$25.62"
       }
      }
     },
     "localname": "RangeOfExercisePricesSixMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Three [Member]",
        "label": "Range of Exercise Prices Three [Member]",
        "terseLabel": "$6.01-$9.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesThreeMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Two [Member]",
        "label": "Range of Exercise Prices Two [Member]",
        "terseLabel": "$1.60-$3.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesTwoMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S A R S Co V2 C O V I D19 Vaccine",
        "label": "S A R S Co V2 C O V I D19 Vaccine [Member]",
        "terseLabel": "COVID19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "terseLabel": "Sales Agents will be entitled to compensation"
       }
      }
     },
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement [Member]",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego, California [Member]",
        "label": "San Diego, California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoCaliforniaMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "label": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "terseLabel": "Schedule of operating loss and tax credit carryforward expirations"
       }
      }
     },
     "localname": "ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based Restricted Stock Units",
        "label": "Service Based Restricted Stock Units [Member]",
        "terseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedTerseLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "verboseLabel": "Contractual year term of incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "RSU's expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Stock sale agreement, aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Stock sale agreement, aggregate proceeds from issuance of stock"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Sales made at a weighted average price (in USD per share)"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxBenefitsExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefits Expired",
        "label": "Tax Benefits Expired",
        "terseLabel": "Tax benefits expired"
       }
      }
     },
     "localname": "TaxBenefitsExpired",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardCarryforwardIndefinitely": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Carryforward Indefinitely",
        "label": "Tax Credit Carryforward, Carryforward Indefinitely",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "TaxCreditCarryforwardCarryforwardIndefinitely",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Five Years",
        "label": "Tax Credit Carryforward, Expiring in Five Years",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinFiveYears",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinFourMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Four Months",
        "label": "Tax Credit Carryforward, Expiring in Four Months",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinFourMonths",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinThreeMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Three Months",
        "label": "Tax Credit Carryforward, Expiring in Three Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinThreeMonths",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Two Years",
        "label": "Tax Credit Carryforward, Expiring in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinTwoYears",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) In Other",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) In Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseInOther",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of current assets and current liabilities.",
        "label": "Working Capital",
        "verboseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_WorkingCapitalExcludingCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital, Excluding Cash",
        "label": "Working Capital, Excluding Cash",
        "negatedTerseLabel": "Working capital (excluding cash)"
       }
      }
     },
     "localname": "WorkingCapitalExcludingCash",
     "nsuri": "http://www.inovio.com/20211231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r57",
      "r59",
      "r133",
      "r134",
      "r310",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r207",
      "r397",
      "r403",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r309",
      "r352",
      "r429",
      "r430",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r648",
      "r723",
      "r726",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r309",
      "r352",
      "r429",
      "r430",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r648",
      "r723",
      "r726",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r207",
      "r397",
      "r403",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r205",
      "r397",
      "r401",
      "r651",
      "r722",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r205",
      "r397",
      "r401",
      "r651",
      "r722",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r309",
      "r352",
      "r409",
      "r429",
      "r430",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r648",
      "r723",
      "r726",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r309",
      "r352",
      "r409",
      "r429",
      "r430",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r648",
      "r723",
      "r726",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r133",
      "r134",
      "r310",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r208",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "verboseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r624",
      "r626",
      "r629",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average Useful Life (Yrs)"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r679",
      "r710"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r23",
      "r698",
      "r753"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r23",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r22",
      "r131",
      "r608",
      "r611",
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r53",
      "r131",
      "r608",
      "r611"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r43"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r277"
     ],
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated Depreciation and Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment",
        "terseLabel": "Accumulated depreciation written off due to disposal of property plant and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r64",
      "r66",
      "r67",
      "r702",
      "r731",
      "r732"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r67",
      "r74",
      "r75",
      "r76",
      "r138",
      "r139",
      "r140",
      "r536",
      "r727",
      "r728",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r472",
      "r616"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r469",
      "r470",
      "r471",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of issuance of convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r432",
      "r434",
      "r475",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r434",
      "r465",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r30",
      "r215",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Equity method investment, measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r110",
      "r262",
      "r269"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total antidilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r187",
      "r197",
      "r203",
      "r239",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r529",
      "r541",
      "r575",
      "r614",
      "r616",
      "r669",
      "r700"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r56",
      "r126",
      "r239",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r529",
      "r541",
      "r575",
      "r614",
      "r616"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r560"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets held-in-trust",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r220",
      "r248"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r219",
      "r221",
      "r248",
      "r676"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r436",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Liquidity"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r112"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r112",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r580"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Decrease in cash resulting from the deconsolidation of Geneos",
        "terseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r123",
      "r126",
      "r153",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r167",
      "r239",
      "r291",
      "r296",
      "r297",
      "r298",
      "r302",
      "r303",
      "r350",
      "r351",
      "r355",
      "r359",
      "r575",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r517",
      "r518",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r286",
      "r680",
      "r708"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r287",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "verboseLabel": "Common"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "verboseLabel": "Number of common stock shares outstanding under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r616"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014par value $0.001; Authorized shares: 600,000,000 at December 31, 2021 and 2020, issued and outstanding: 217,382,887 at December\u00a031, 2021 and 186,851,493 at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r83",
      "r686",
      "r716"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r82",
      "r525",
      "r526",
      "r547",
      "r685",
      "r715"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r81",
      "r524",
      "r547",
      "r684",
      "r714"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r207",
      "r573",
      "r574",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r207",
      "r573",
      "r574",
      "r733",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r207",
      "r573",
      "r574",
      "r733",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r171",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r175",
      "r176",
      "r207",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "%\u00a0of\u00a0Total Revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r207",
      "r573",
      "r574",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r540",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities (VIE)"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r378",
      "r379",
      "r398"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r378",
      "r379",
      "r398"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r18",
      "r671",
      "r701"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r304",
      "r306",
      "r307",
      "r309",
      "r319",
      "r320",
      "r321",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r339",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r350",
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "verboseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r19",
      "r20",
      "r362",
      "r368",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Cost, Maintenance"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r174",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r115",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r115",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r115",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r115",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r323",
      "r330",
      "r331",
      "r333",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r125",
      "r136",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r339",
      "r340",
      "r341",
      "r342",
      "r593",
      "r670",
      "r671",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Debt instrument, convertible, carrying amount of equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r308",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r46",
      "r308",
      "r368",
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r306",
      "r339",
      "r340",
      "r591",
      "r593",
      "r594"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "netLabel": "Principal amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r321",
      "r339",
      "r340",
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of date conversion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r45",
      "r337",
      "r591",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest based on the fixed rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r125",
      "r136",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r339",
      "r340",
      "r341",
      "r342",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r125",
      "r136",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r339",
      "r340",
      "r341",
      "r342",
      "r368",
      "r372",
      "r373",
      "r374",
      "r590",
      "r591",
      "r593",
      "r594",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r319",
      "r590",
      "r594"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized debt discount on the liability component",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Debt securities, available-for-sale, realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Debt securities, available-for-sale, realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r226",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedLabel": "Gain on deconsolidation of Geneos",
        "negatedTerseLabel": "Gain on deconsolidation of Geneos",
        "terseLabel": "Gain on deconsolidation of Geneos"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r38",
      "r319",
      "r592"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance cost",
        "terseLabel": "Debt issuance costs, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r482",
      "r483"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]",
        "terseLabel": "Expirations of Operating Loss Carryforwards, Components [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "terseLabel": "Research and development and other tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]",
        "terseLabel": "Expirations of Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r483",
      "r497"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Company's contribution to 401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Maximum annual contribution per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r110",
      "r275"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r397",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r39",
      "r131",
      "r294",
      "r296",
      "r297",
      "r301",
      "r302",
      "r303",
      "r608"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r131",
      "r294",
      "r296",
      "r297",
      "r301",
      "r302",
      "r303",
      "r608",
      "r678",
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r151",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r558",
      "r559",
      "r687",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r153",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r558",
      "r559",
      "r687",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r580"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r164",
      "r241",
      "r367",
      "r375",
      "r469",
      "r470",
      "r471",
      "r506",
      "r507",
      "r557",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r727",
      "r728",
      "r729",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of ownership"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r34",
      "r188",
      "r236"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Investment in Geneos as of March 31, 2021",
        "periodStartLabel": "Investment in Geneos upon deconsolidation",
        "terseLabel": "Investment in Geneos",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r34",
      "r105",
      "r238",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Investments in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Investments in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r235",
      "r719"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Net unrealized loss (gain) on available-for-sale equity securities",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale equity securities",
        "verboseLabel": "Net unrealized gain on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value measurement inputs and valuation techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r560",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r321",
      "r339",
      "r340",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r425",
      "r561",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r560",
      "r561",
      "r563",
      "r564",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r321",
      "r410",
      "r412",
      "r417",
      "r425",
      "r561",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r321",
      "r339",
      "r340",
      "r410",
      "r412",
      "r417",
      "r425",
      "r561",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r321",
      "r339",
      "r340",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r425",
      "r561",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r321",
      "r339",
      "r340",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r425",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r232",
      "r233",
      "r234",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r253",
      "r332",
      "r365",
      "r556",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Eligible Item or Group for Fair Value Option [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r268",
      "r271",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r268",
      "r653"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r263",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r268",
      "r652"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite lived intangible assets, net",
        "totalLabel": "Intangible assets, Net Book Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction (gain) loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "negatedLabel": "Share of net loss in Geneos"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedTerseLabel": "Loss (gain) on short-term investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r343",
      "r344"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (loss) on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of convertible bonds and senior notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r255",
      "r257",
      "r616",
      "r668"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r259",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r110",
      "r256",
      "r258",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants Receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r274",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r128",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S. Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r187",
      "r196",
      "r199",
      "r202",
      "r204",
      "r666",
      "r682",
      "r689",
      "r720"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income tax benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r128",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r79",
      "r110",
      "r185",
      "r236",
      "r681",
      "r712"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Share in net loss of Geneos",
        "negatedTerseLabel": "Share in net loss of Geneos from June 30, 2020 - December 31, 2020",
        "terseLabel": "Share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r279",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r486",
      "r493",
      "r499",
      "r508",
      "r511",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r149",
      "r150",
      "r186",
      "r484",
      "r509",
      "r512",
      "r721"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r480",
      "r481",
      "r493",
      "r494",
      "r498",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r479",
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income (benefit) taxes at statutory rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r109",
      "r649"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r261",
      "r266"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r184",
      "r589",
      "r592",
      "r688"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r90",
      "r327",
      "r338",
      "r341",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r102",
      "r107",
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Amortization of premiums on investments"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r734",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned (in shares)",
        "verboseLabel": "Shares (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r238",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r667",
      "r691",
      "r752",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r602",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r126",
      "r198",
      "r239",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r530",
      "r541",
      "r542",
      "r575",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r126",
      "r239",
      "r575",
      "r616",
      "r673",
      "r705"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r126",
      "r239",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r530",
      "r541",
      "r542",
      "r575",
      "r614",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r320",
      "r335",
      "r339",
      "r340",
      "r671",
      "r701"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r136",
      "r289",
      "r325"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r136",
      "r289",
      "r325"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r136",
      "r289",
      "r325"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r54",
      "r126",
      "r239",
      "r291",
      "r296",
      "r297",
      "r298",
      "r302",
      "r303",
      "r575",
      "r672",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Carrying value of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r375",
      "r527",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Dissolution of majority-owned subsidiary VGX Animal Health, Inc."
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r54",
      "r88",
      "r523",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r168",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/TheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r68",
      "r70",
      "r76",
      "r80",
      "r111",
      "r126",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r156",
      "r187",
      "r196",
      "r199",
      "r202",
      "r204",
      "r239",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r559",
      "r575",
      "r683",
      "r713"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss from operations",
        "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r70",
      "r76",
      "r149",
      "r150",
      "r533",
      "r546"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements - Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r376",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Deconsolidation of Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r376",
      "r527",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos, net"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r375",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r18",
      "r671",
      "r701"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r187",
      "r196",
      "r199",
      "r202",
      "r204"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r595"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r601",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r600",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r679",
      "r710"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Tax benefit from other unrealized gains on short-term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax",
        "verboseLabel": "Unrealized gain/loss on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r254"
     ],
     "calculation": {
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForDeposits": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.",
        "label": "Payments for Deposits",
        "terseLabel": "Deposit payments"
       }
      }
     },
     "localname": "PaymentsForDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Costs related to issuances of convertible senior notes and convertible bonds"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Investment in Geneos",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r409",
      "r411",
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r436",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class A [Member]",
        "terseLabel": "Preferred"
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "verboseLabel": "Preferred Stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r616"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u2014par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December\u00a031, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r677",
      "r709"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expense"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuances of convertible senior notes and convertible bonds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Commissions and other estimated offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from Geneos issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
     "auth_ref": [
      "r103",
      "r231"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Proceeds from Sale of Equity Securities, FV-NI",
        "terseLabel": "Proceeds from sale of investment of GeneOne"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale of or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r96",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r68",
      "r70",
      "r76",
      "r104",
      "r126",
      "r141",
      "r149",
      "r150",
      "r187",
      "r196",
      "r199",
      "r202",
      "r204",
      "r239",
      "r291",
      "r292",
      "r293",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r524",
      "r532",
      "r534",
      "r546",
      "r547",
      "r559",
      "r575",
      "r689"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r281",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Property, plant and equipment disposed of"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r276"
     ],
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r278",
      "r616",
      "r692",
      "r707"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "negatedTerseLabel": "Fixed assets, net of accumulated depreciation",
        "totalLabel": "Net Book Value",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Computer equipment and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r278",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant, and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Minimum purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r419",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r419",
      "r607",
      "r608",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r419",
      "r607",
      "r611",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r605",
      "r606",
      "r608",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r477",
      "r650",
      "r770"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r375",
      "r472",
      "r616",
      "r703",
      "r730",
      "r732"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r241",
      "r469",
      "r470",
      "r471",
      "r506",
      "r507",
      "r557",
      "r727",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedInterestFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.",
        "label": "Retained Interest, Fair Value Disclosure",
        "terseLabel": "Fair value of investment in Geneos retained"
       }
      }
     },
     "localname": "RetainedInterestFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r182",
      "r183",
      "r195",
      "r200",
      "r201",
      "r205",
      "r206",
      "r207",
      "r396",
      "r397",
      "r651"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r175",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r400",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition and Concentration of Credit Risk"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r87",
      "r294",
      "r296",
      "r297",
      "r301",
      "r302",
      "r303",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "verboseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r599",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of pretax loss from operations"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "verboseLabel": "Summary of intangible assets by major asset class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r436",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of shares authorized under stock option plans, by exercise price range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r441",
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options, activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r123",
      "r165",
      "r166",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r359",
      "r365",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r347",
      "r348",
      "r349",
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Summary of preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r492",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits rollforward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets, future amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock",
        "verboseLabel": "Series\u00a0C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)",
        "verboseLabel": "Vesting period of incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Reserved number of shares under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for grants under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options, exercises in period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "terseLabel": "Options, expirations in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r443",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Number of options outstanding to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r433",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, expirations in period, weighted average exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price, lower range limit (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price, upper range limit (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per Share (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value of unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value of vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r460",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value for options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise\u00a0price (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r16",
      "r674",
      "r675",
      "r699"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r119",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r123",
      "r126",
      "r153",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r167",
      "r239",
      "r291",
      "r296",
      "r297",
      "r298",
      "r302",
      "r303",
      "r350",
      "r351",
      "r355",
      "r359",
      "r367",
      "r575",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r52",
      "r74",
      "r75",
      "r76",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r164",
      "r241",
      "r367",
      "r375",
      "r469",
      "r470",
      "r471",
      "r506",
      "r507",
      "r557",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r727",
      "r728",
      "r729",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r164",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r324",
      "r367",
      "r368",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock/senior notes to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r367",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of capital raising related expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r367",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r367",
      "r375",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r367",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock/senior notes to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r52",
      "r367",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Stock Issued During Period, Value, Conversion of Units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r367",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of capital raising related expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r375",
      "r435",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r27",
      "r28",
      "r126",
      "r217",
      "r239",
      "r575",
      "r616"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Inovio Pharmaceuticals, Inc. stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r75",
      "r126",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r239",
      "r241",
      "r375",
      "r469",
      "r470",
      "r471",
      "r506",
      "r507",
      "r522",
      "r523",
      "r545",
      "r557",
      "r575",
      "r581",
      "r582",
      "r586",
      "r728",
      "r729",
      "r789"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r587",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r587",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r587",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r232",
      "r233",
      "r234",
      "r332",
      "r365",
      "r556",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "verboseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r132",
      "r410",
      "r425",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r478",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r169",
      "r170",
      "r172",
      "r173",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r152",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r151",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r771": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r772": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r773": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r774": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r775": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r776": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r777": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r778": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r779": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r780": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r781": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r782": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r783": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r784": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r785": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r786": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r787": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r788": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001055726-22-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-22-000008-xbrl.zip
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MP/D<CH]?HY@E80%N0D,:?94/V*1:'#IK3JRQ;O"JS7\.J*61RDR;Z>#UI<[
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M5+?D]L9@M=?<[]!"G(#'+0$ZC1/;X["J4\Y-9.G7'T+);PB(CFJFF$YMZ5
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M9:3 .Y$!(C)2TJ9^A.^6(3-Z=O3/0MI8:5OB.,^91JN DL+H& 2^MNP 02$
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MFHN\REC7>H<2+HR.)<$"$1;K!CXF$<E#(JK^XC5UY_80EBBA&23.RC (RES
M7@(>P"Q&D\LHQ>R<0,O/<RJE!@'_>F8,^P-*B2!@_74#2TRU?4U$<)36H9U#
M2(2$S"-Q$]%23H0+'%UIO"X=(JC["=@7DHPOFD9=N$11V6H(^*>XEO'?+&.
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M>'(VF;[9TI9E#$#OMHC^^,.FL&QZWCKC>$ /<G4R-WZ9JK[ECLV@JEU1[Z*
M"4F>T1C5]OT,M=Z_ZQW;^$/7,9>D2-$[FF_O1&!EK!$84 7*HGN8/P7:1C5]
M;J)12DD"1!U(NZ(7!)TD"87W0$/NQL#\(\7%79RI8C5N>6;X9%'O304%#EL
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M7TZ)M8,ZJ.-4!J/T<1G=P1VC.[@S21RX8W0'=W!W1-)A[: .ZMBR8YI A%4
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M+14=B_!6K-.'CU\$2VLCZSV9]U<^=B,Q7:E%,QFX9;4&RZFLTG&W'V<RQ5S
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MGMVO/%EW].+<X@X^&(8YUI>K#'<0=Y!A&-P9(@[<F3,,>V--"^[@K@[I>.7
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M'R]&/;!^\2<$]QNPB<3P'Z[]<H\RAG\RB:9K^6.>+<+S_P]02P,$%     @
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M75*RJUFLQ51(#PW00T?1$5Q)$3D%BR3 KJ$*135RA@D\>*8!.L(H^*8!DL-
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M%U[.YNLCY&N:UX_7O%V1]0U<I$&QQ54? !U2!A-\RF)2=*W5$;C;'7F&<HE
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M@>^9,K,V4Q9$(S_?IY8(((>4B3D6ATS.9H=C6*6W,V6;H<J&R0*L4JT1TXP
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MP80?S$5;2IW*8G%[.IV]6DW6?VZ%Z,CIM9+6]KS2^OVF7T.O&AL*)%.LA>B
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M64CF]!!' OI_8AO[A(C^N[/K-U&P#%,G)N2#./G]V'3M?:?:F%;:#6#.DZH
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MC31AZ>-AB$1X"K5%MJHD"2>F(HJN))^TQ*5,TE4/;4IUCQ8(>K,,Z=W;Y[)
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M(%2UK(.'O9E@D3QL^W*"F[3-Q(A 45-8A]1,S"V<46T<%PY_DO5W(?)=9L!
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M9CQ89Y4K]4?MKMC&8&54_IMZ_0N5( R?+'.WO"6>SP"'<55[(F%KOY*)QLN
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MC9ITKEK,=>3<D O-::#Z;<7YDT:2,_^S;I^9WB*H624#96&V,1BY,SQ#6TB
M6=:4@E6 4SSUKY:JG:34-3?OC\5S,I.H<H_#7ZC%YE5P5L 505!H+1 R?"93
M;[*'6#__(UE.W"78[P(%+:GJZOFRQ)57!*/TND04OR3+DU?=0[U2WA?$/IY#
MV4;L)6*XG>3\%J<QI4HBYIS[\N3T0*-@3 3GJ+,F<4\41!UVKEB1*SAW,$6>
M?LLF;QT?]7@9E,-0PN#=OQ4/A%^VCBCSNNH:+YJ@'XA0?70VL@%?I;K Y7,I
M0:4B??3$7*ZBFZK@_&;8*Z/3%OF0F-N4L8-DH6<'R2XTX-2[)1J9RH*52&E
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M:]F_>N5G^!J;S^"K9#),)VA_:&L 8\U%Y2C,](Z]H4WC\O+9ZS/WXL.OC7I
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M(0I@X\PY-" Q\@SY: L )#+",G2:FGZDL7*0+$'+RYL/$<>H&D#V7S*Q@@O
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M/74)2,_UI'0=!F@T*M]5$FU[0V#S)<X$<(UE^5:MR83 &E!RQ?1XF&GCU%I
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MPUZ,LBQBL-#0.:)4YJ/@"R"_;-K6^)W$X#^$OU"T&U(',94+JXDR6W34P1B
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M1)YJLUFGKW45MDG;7A6787/HQY!]K14 G67XU? R=]#1.Y8E^SNR+]* J:1
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MT4[:A*(;4H]6BXNV8>OJVB9^Q2W^IP<']__]?QT^OO^C)<1 ]QE.->4I.MP
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MQ"H;N01'.?B4+Q2\='SR/#S'E'Q.E^%YZ?QHF/QM_L@FOVO9RLB/BPU'=(Q
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MM?J6^B7Q\(P81T+>WFRO?6JB-+*TYT^>ES'TH:4$=([U :DJ+4Z$+]T!6#R
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M UG<,CSG=-"6V;)DEDOW#\]0GA1=>%"!(\R*U-<_SNF]<_4-HI44-;1T]-1
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MXXW =+W0%(<-GP-QZ);M-HEET*J4'5!:[5$TML@_)>_H6'F40)^#&#[KPE]
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MX1X^,<?FM7#)EJ-?^%?V??2_8;4R=CT.=6UOCG_2UUE((N*\U_PJ 9Q]R&4
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ME<'&QX^AH"+#B^K]4C=] &<3K3 PS^J0Z>U6X.BE P*M$OTV:Q8_UZMP$G3
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M?/EDL>(6&N0%\3Q<^H1&.C%I0.@"+1X(2,HPF*7:UE9 .")J7^@WEXL0SU.
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M[8[@,]+";7$E")VRIJNT"C?)\1RS8-(@PG.7[ NP-C(YG.,N.$63]%.:]FM
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M7.R+*BRBV*@$<ML64 /V)NCY\B:[$V";@F267H>B5GA?6Y3_U3=JCB@O*?"
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M_'B97G ,5!F;]C'(*SU.QM=P:]?B$2Z4I6=-L @EG>>(!F/EWD&0I*XUL04
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MH!R53*NSF5-U0TF2SOQ&3)<<,_&0(9\_"O-R.@U2()JK8^BMDL<0-K!LAD&
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M[W2P+Q<O;PYM&:(D*G5*>PN/TPVZ7^B9]F$=K)MRY0BS8# WFPM<!P\X$'[
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M,SK%,NW:FE_-><V)A<O%JUFK!K>5)#_:O-1<:KH:!_7W,')L"9>2B.%!*K!
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MG-5F[1[FL7['P2LK9W2LG>W!@\XU\:,$ET\G"WUJO->80H,1#0Q+@1N:1Q(
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M'\/"0'F:R!ZN;U)9FMORNFY8MY W66PV%"^U-9NTE.!/M-[&08?V.ZJN^?;
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M)N2E#+:*.IMF:ERZBT7+C@VEY5$N%LY?+URC"(M_#3G-$&QU1>'W1=B[E,Z
MM'E1K6.PQAN+#FTQKYX-*#R.9M'=,F1)34IW;/IF2Q/?#I!M WG8IMCT+0V*
M./K!1+# -&M,I2O,"X!H%5J])SWBRU.-$L6SCSZ,2TBK0\CG#&AYA1QZT 69
M+,J)7/'2ZQ=-F*8AE:6$)"[SGA80)XZ"+CATHJ+&=>S9_E:5V.W#0L-*GP:
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M(\U/Q-5Q;K'S+[TZP+M4=G\20, !]LM><9XV[6.1!N09=MQ[;!KGWX2 [JX
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MK(5;MJX;(V+,"]X9S"ZE%!V,?F\H#F0)-[-;9B3?L3J )?+[;JE]5-3:!7Z
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MP%@EV"J[^NFYOV]2$4UT"Q!F7I!&M&9B;XUK0U[B'[Z5G/VR_/NKE2\:CHL
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MD9/9$+QAR=V?6_[;CI0^.Z4+_AF T_-*>4#*-S8*P6^Y5@H  @@2\ -3:DO
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ME)'7<*P6PK@MY7<GF@=D/2P0@*5%H5A<*[W04031;-&M_6,9<K87KA?T5N-
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M&X+6<\H^#*@YY,?49Q&IF7 $@R:P?*WN[,JY%36,1QRYA%$_)>N0*K[6AM(
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M>WGNUGX!E'.F3"T!R6T%E%=:2"4["66V)B:NZT*%VO B+QIMQF"A<ZK/9BS
MMG0?@2,^,3#ZM/18\C-;:F2D(T+&S>R%'NE2:H0BW?%Q?I6QAEM=,F;W1K,[
M%R(&WCM]HBLG@ JJ@CR?.Y 2]L 8C:2#+>4 Y1.=YS4O<CV/_"8.M1M VXG;
MKB=E4<TT ,> 1I6C1PXE*I%Z%6U)UUZ4IC0V( 5;80D?#,AB"KQOA.YC=F?A
M$1G]1^'C 4I8RW*\D*HK_7U59Z*^IO5<([E_Y3I^U8FQIUB_3P(D\!QMZ$85
M%T+:\\Q8L*Z[=#".DLRK!C:5"G5);-A3PL0"QX$O5U@/0=B(<A7\0_*EG)(M
M,5E F(#;:\^UN7!.[<;V6A8(EZ4 -8F2OIRX+Y#YCN%<SCCKYU5FBX/:OPN^
M1(41K<:&$*MQ*MV'FJ>!U$:]6KE^0#;OPOHTN5U;*FJ/#+<WHY4$8E!K+2%K
MR]MZI2!50BH JW5<K:;L<]*W7N<:?M (;S$$H>&5N>(EV\')JM?3X:$.4[B=
MZ"H1Q'A>U"X<PLO'IN7%K37SK,7@:VD$BP5?6?X=OGJI^^+MR@U/I+&UKLJ*
MB=MWD?JB5#'.4BZNA8/07[*?6Z.*95A=-M>H83Z#I?%*Z*3Q#"I7D307_+98
MZW6W <;M*\-KCOA5=H&=:KPG(;*%BL8LE,0>:VK0"_JY6/#!YL?Q!7*;UXVH
MQ42;6+5,$4N9N8VOU3J\P^G*%[^T0..LX70V5H%,%2T$$7]GJ?>\KV;RHJEE
M/(#^IFEUW",H0[4%](J-4M4L5-N1264-5;_(A4GX\7HGBEJ\SJT;[%$,S"&R
M/8VRL@X8HH,0)XB.XV:JM)?\ZI,-U-MH%5Y;NBLUF?^"5U9>]64UPW_?Z_7"
M'O_/J\=<JI#@+_?;OMLLU^2J)>HQ2C6:DGGPRC0M%M:6=,;*$K!<P[(=G#G4
M#.72$]I ]!HA?*#+O4I-"UA.Z^U9=[AF@,U)UL,BL TO<4D9\2F@C=KWB<$)
M>S*3@9U0EG)I]T9N_]:VK[][;[MYK['BODOPZ+ #CUZS/%A81F?0*MPFIT:M
M9QZJ1.DZ5P-D+E7=NMB<WDNWJB7;M*OJ3P*.XKGT'#X*CP@?"-[R)4?^/&*3
M!L#^W!#KBK;/TJJ_S;MBJ!"J/@MMW=H6B"*MN[Q^A"\(?8)"GSN]G-<()3)S
MH61A7L/)I:!MPU>G+!]AAZ,K&(9W$[!=CA6R5./!JI%K.AVBBTM^E<A:9XP\
M0^!;5X7QPUO^LULPUV<GQ_)*/ K@U&L%0XWWBB$79#':F7EWG-MQE*&BB@R/
MQ(?,6KQ[MK#ZO9I2\367^]XT?PPV>&C42S">.=L)2G*&17SV1Z&_JT.Q^WVB
MI02;:N.H1A*1(+".N!9X,<+OL2_/197$-*ND5)^*5LO/ZF 8F&2 @SG/8R(Z
MH\.H!89"G&/[EUJK8,%7KM$ZVQM60*.2Y,W:3K'<E%U5I LN:FR:XFH>9EY*
M=S*M)XFP?!!TI20 G&KX]U+6 K\TGTN9+QD1!9=X;?$[Y@VBIKK1XSX@]P9\
M.IRT+?PFW2W-&1OK@A*X<4FNF+7)_3:L24>X/1(I9K(.,^]BO[.Z!Q1J>O5J
M^V&OB_OVLWY29?A&>*T:"\PQ-[9"F9Z&BH&NJ7JO_*)V.MOSQ<Q(N@[4#4K<
MUSAJ$O.2,N+*%C4L_-]H?)"&<4YUI2-IJ3["]@D@522, @V7PS%>2%Q10O+J
M!1>JPFN]D;%7K]/7=OA4XQHQ^91FX?51'!U0/BXE9:'XN 9>;[=46*,5<:<B
M+33^9P4W^ABS<,R27G)#[ (5T*JJ^# @/B,,!<^-<<UO6GD$T%DQTW-3"'=D
MEN0^E]G&63;''@X&:V*PPDADT(Q(+75X]N\HR4QM%)V@"W/"S$&QT6-AOUC,
MJ7\KXJXC&(C]E-,T1K(-I9G/4V' $)7F=Z3V[49:<K)47IL1;:9@T.OOARP!
M&$>9*LD6FL\@@<]9?I5I1^Y/\*WC2L[G?^?G97 $+[F"3TT6<<*&QU@G!]1:
M8GS$_>J)^>"VOAX90'*\<;B <L(1&DL2MCS]LH&=C[YH!;UG42% 0ZY.O[97
M!(;_0C=F!,^:!;S!T!24J,=P5TN325D$F-ZT'P[Z^F'(ZB[RWX3/C^WKQZ3[
MI+NMW._XR*&M?>;PU5\5F<#*<!"\Q-S-C#66K6^F_NMZC$SY8]OKZZ]NK8*#
MUQ_47B]%?5M4$EVO3I5$<(VF9U75\WDT^DP:T4@T0P1#6G$\+B>YQ^& Z2R]
M.@I*.<,I JV92L;J:F)D/Y@%'9/"S"+$W=,F3:9(C8CRL/,M:VN%-DH=;P?K
M&[%.KO\B-HZ$P4K(6IS"@@KFXW@AR# 8B(E23FV \V+5FO=<NOTH$0V2;.Q*
M(7%TO\,-HS03W@Q<L8$IZ^R==)<6SF'2+Z DY<=Q45WP](J(;D#N?2SY"$$"
M_+@=O&M8?9Q_T1TDSW=GQZN +(B^@RKS+RFU6+^5->.H-P-:ZMC2E(>W9,BM
MN!*NSV'7W#6$_/NO( !8S"H94T=?* >!]558U%8RRH&"N/ V3"MK=KLQ<+$X
MVF/-GD6+][OS1JV#XE7[J/XEE>=1[GRCBMM:A"^T1$D-6 AGS6$4'E*8S[AR
MIEKI;IP]0H)B/PME((7$94Y[BO0%QD+G*&QB<2A),Z"F8$Y].K43I(M#N6R>
M.7+FSY2<45V+="$!I*K4RK/IM,HXR,])4\&14#XKK!4'.H2_QII;"&H=,L?I
MFJI8\1R/C[;E4:3M>;CR<SD_R!V"K)R^/"5:8,'8YTG>:'TH;0[KR!\)+#1"
M_+50#H4\B:=<L'P<[P6]#&N$6@%6&!_#T<X1$9MX"DBP0T3?@'=FGC43#C7G
MV24?)&[J,M<<1."0BL?VXWO3>NU85WD[>(.,T5\BU"=*?Y_ GI1L-<ZK=C!0
M&64F55^?28DU->L!0TAYPR>,;0(=PNS-M<(XLOMR26P2N"E%%LW8@9S07]L.
M_IR8C)?9A<5@VXQ X_D\&!X%AA=4 ),Q40?6]YV]E:R]3H9#]Z2G^N )'C,U
M7C0B@]B,3?.6$GN68WF6(@:M;FZ::BT]KS9@I!2R@0/"L9TO^7EX,,U;8C:L
M^&NR$>(/?'"1B*@Q+20K@H,O$09@S_%]3IW"L!K,(Q1 ((3TK&![RXI*G%C,
M]A#6CK!9>A-IS)5]_PAE2D1HN0 #9(^5#K*!V<7,SAQLS*N\^(SBNC+G\ Y#
M42K!=-?<_BO#$13:.")0EZ>M!Z&64WV-!!]?FQRML/&0D.6X?.)"%]J0]JH1
M&Q(UQK&EBV1U!@AOF23^SQ>)&?8BLPM7\G@TVAD>'!P>[O<.=N*=G?/1WFXT
M&OZ__N&+I2<^-K?$Z:>3MT'_E^U_^U_]O=ZKY7_^\>[CR=G[W_]Q\CHX^W3T
MYDUP_/[MVY-WG\XV+U+W+K\N];0^X^2%O^^F&@S69%,-5NZI#Q_??SCY^.GT
M9 ,WT9]$BH44B6 MU-N@"]UD+MEZ"J\272FIO/K7:TQ<ZXS(7&&FPB!>)^8B
M#WXG0W'C[&SP.X_@-DPQ\C:D6X/0"^204[0H96R6F MOD@)LLL:L0\9U4>0]
M@$FP:66_% ;'&(S.BRR)V -%=(M:$JU/E"L5XRFY%QWLAS1,<6,IS9+>XF%@
M!B 5-D:$A.T<#;D.-N+#1G8ZV,@URY//% 9"L9?84JVB?3M&TU VEQ_JGID1
MIV#\@ATX;_]=90;W\2Y3:@MC].KMZY5S\'MS+%A(.0/+QPV#L/UPT-L/2BSN
MPL"/$9 J&)(S#KZ@KX7>:)6DL:;$[4'3SBT$>I4AM0\' ^QPO/\[RBJ$EL)$
M]H@2%GYL#^J03NJ@CPX?4O)H7:DM(%UU4AE)RYUSZ*=Z6L&CJ\@!EH7 V!5:
M\E_(60%C>.CBV)R-MH$M\*[F$ZRY,QIMOY16*<+MZ$*-EAI7XY-^')[X%+G1
MH+V^B/PM=#E&<8<H+\]%;40H').C:3>14K&8:Y9B6>\=AB[G$B=<;6>^P*01
M!;>)%\_[T3R7I,]>R]63Z952OX+.L$0I;K^#(@0KYLSH8.V+ZRXB.DI\AMS>
M;'\#>9.U+;?;9\BG.W(D;LJ#E1J!MEO*W9%AL_]4YL'W&4?ET5E5!494R^6;
M<\4P:U<GZAJV-7D/[:^^.U?/>NGR9 1K?2?#R][!P<+]RB\<]D@'#&]6BANW
M=W$)G8KBA%<I_+L8%*$67D5>75!;E?FMY'8/';I*8L]/B38+SQQ%>Z3PY(76
M=>%0?CC<Q:.Y>?[$AW0QA3TS"=Y*BQ<6Z<:=$!#86U)GH'-V;G8KVJ<=>H56
MFK6;F"B6^G4R0YJ_#+&Y7%8NTLN(M#RZJ6@")6)B6?=$K;"=U1IQA3#0 .KW
MMW=7Z<2O-1'_--JA4D;K>5?V-MBX'?%U.K-=%/?0F2MD^A4Z<_!<=.;.(>M,
M<E'21;N+LF+];N>C#/;#W8-AW6#:N(WL>7#[;58K!\]IS;2KYU<OW.Y^.-SK
M+SEWGJ9)^0EX9.08+9V*0Q)MLQ:'H+YVM#0AVB3T4'@)+&K,1?VN*JUM]^SS
MC;N)XB0S/4>R%J5&(604>UP-^<ZO0,87A6'B(\ZMGO/B1R*\)0W1'X:[=3]!
M*5^6-D7M>E-!LI(L@W,SOT*2\*9@N5T&W[?RI]T-!!![-#5TYPM6A. TPA:3
M8F(W5FV9&(_N.3;_K*17.+;':S#J, 7+=?UDSIC"YLK0=VO;'4\A[00=GM8.
M>RE6.A-FZ6<!%6Z 0U:,&+G"!.^<KL-$YOWDM&^%]'6)M\'NFN1(ABMS)+^?
M_'KT>_#AX_OCDY/7I^]^O6VJY/$IZO=W,"'@BB5_3S0W?;M<V_[3E<JJM=X?
MD/8 SSUB4Y/H3;W^,TB#BA"WD>)RX4@F>&V\';W&4$ <7.(MDU\F>?"AAET!
M8^4T&VTS6G8[^&^P8F>3X._)-"2#>IRD*ZJFP+=EK$!PC#K:'N*3J$3PKOL8
M]*YO^X=!%DT9)]3V4NKR/4G,.#AA*CTXU^^Y>(" OXR90) ).PC*Q<OXC])B
M.*98C^]!T\8P5;'&DA(N!F94QIGPC<'(4*U*:?3-CFR_<9RE;4(NM\52W15Y
M0+#4J6-U5GM2@']>[2Y.0 @)2&;)&"$/YC-:Q\X1 9O5$&5 '$VC"Z9-.3>3
M*!U;Z$<U9S2$;(6,S8,KJ1)PM5EMIJRG_J+Y/"\RLR@%?$)F\G;P7LRK_H%N
M189MHNCA6L7&2@8ONZPR:? G:.$DFGK5#1%B6*+8S9&>>%1=8%/5H3[R;;'M
M?LM;+Z)6J7E*^)+8W]KU;<0-EQK\OLT- Z\\,[.Y8-K[K:_EA9-&2NZLN<K2
M,#C*X@).^/\U&;S(CG-,\6(URK]NH*_MO]O'3W,-4\-&@SU<NK6T,*$50_"#
M@,$NSYH6XXTY+RA;@(%>=M"<5*D&G2/D!:J8BR+*+$0,3"'M-9\M:G]T0]<-
MM#1R37'@6^BI)K[-S^2%_!_P$[*39X7Y"_;P2(#"0@<-?YU2-8$T?.%<ZK#'
M&@?WL81!>YX.\(<%TTIN-RHJ>\@%U8R>7EVQT#JS%C_4-5Z2KE0I9N65*2P#
MEDI/AB5!7[^+(:D<=%X7<C[1.[1O^:#; RLO+P632<0+"UTJ>V7@.Y! FR<'
MK^%> .<%*&+;-G7*#=5-QFFJVO[99XO7WS\J63>.QAJB+@6E<$F&&FU:RX%E
MSPY;F<37R-N05BN:UQ)B;J,G>(Q@X6,]-A2'\(99.UJN3!,7R)<I/AU!NW2K
MU)ME++WT:TW%)[ J%%IPDU4!_TLNY59Q,OG%3!#?AR8%7=GH]:;;#VXOT!SJ
M[D=>3'&4M@#N.ON 2.$%E<^_EKM85 8A%TN*-%FU026"BBS%C>'L!2EVNMD&
M:PQC-*H4N-Q6P3<F,*' @S6+6+N>*8M6X29">CGDY.;R78UAN6*_D.LE*4#5
MH2I\5,5NAZJX9GDLX#T4.*\4XPD+UU=;JQ6=GBL#GGI4^B0&A:&Z"6=L[B[;
MFG $%Q+S)#TT 44D1TYN)BJV3QT)-ZJ)^03.(Y53+5W?^"3K)?F<.OYIINK*
M>9(24HZI((43@%KG8 I ;R5$>0=IGEU0V7%6>K%&'+MG20^<-=)W,\5 EA>M
MN$$;"S3Y(=3N*")@!+9W+6%/H;K_Q2 @7C4^#?^UN8R*Z',..E?_?*G7PC;]
MYZ=);;RLB!MEVK8&6W1QV2I@?%]&5=M>'.I:[>^/SED)!#['!Y7,N";4QRVW
M2>2>Z)E8_>5M67-2*&!,9KXO,BI8<1D/65Z,_1;F>M_\M7N*"U[HPGKOE65*
M2CDE&VB9T +O.[M$XK\W&R5OS!Q61FR2]39)O(VH1LF-AR$O+=5P3>3>8J@E
M[_SJP;Z_466%9)/@RM2>I*P04F70W+D*<F(W0-4P%G5_H<G@?YR#*M^T/5=C
M:Y&"'"[]T(JGR^0BQRZ%MV_TN#;5BO_X]?^<WB;>N9ZBT8O2AH>NC!<4LBY?
M)@0 >(+AH!XSI]<'3/[@?[^%]USD<"@7^)T,*VW\LVP+VG"MO%@H]C1]GZ'"
M'9O@;$25:?PQH2/D8RE)S"^XD)S.D/<@;/[!%:^48A#>0?1V2_D:.1>,28MX
M# 1+] *7:(&.D!><$M1(*+UPF2Y[:J=-U<)&&1*:P05(]41_5?&%\$^*I39J
MTEV3?ZO/QOC@7U7&!;O4.V <4DC1EB"':M^%[5'#T!:KA5[\D?4+/Y )$G#:
MSBYJ$S?U>-*8P:P0LH!B88=(R71&89+&I>A-KBEA/^;%?]E;>HF8<9PE-)PO
MI%I3>);[+SL0JRYKF^FLHJ1@P=MQTW3ATOU+^U%DD$E\*J3 R!19H;0RLD(I
MZVUEZT.;F_N*$;=V/Y-%W-C/H>\9@'GNJ@*5?H)X=DODII7M5&4(60E,!C?U
MA#AN-(SGC0I/0]MV_C;[%VMAC\"F#'G'K5K!H,XD;XT 6;'W:7ZQ"'Y)<FFT
M5:JZB2PI? .@FA<7L.O^Q8OCK[')+J(+UC1*!ZT/M=8%^21Y:?2'MB#:)SOS
M3B8:OOO+1S/SPI;X;1N+K@D@1'=K5LT5?>O'U;2H6T151!2X!;5>>]R8HB(T
M%L4G]UL4A3O%%!NE:FQ+JL#G^E8G-SB2.N.8:%S$,$SM50K+7$HY+Q88FXT[
MZS6[)[JXP!IAOJ= _N@&"PK>'J Y^]&:]%K>O[35A0_#V4Q>D7-I4FR+Y'^_
M?;=LG)WEC(7--;4L>L4><IW5P]E<M[LDCD]^__WD^-/'(W3G\73_3DW43'#D
MK@TYH-Y?%)4C:3>9#,$X+3H^KO\(U;<JET,U&=H]-CD6J!AXK)QC934=MMI=
M(;' )ZYG)1DMUUYA=6/N#N88*#\X@!>V? C.])A;<=QTSZV^X=Y[Q44VR615
MKV^4Y82D383>KI',\MS3H9]TE,UT"39RE8JY>Y>'NL1N?[@TNMHU5?NM;\Z$
MR_8,2^*8263;M94D"'C_ZIFI;6!O5U)VF2-@UVXAR:TN[Z*5UHV5O9.ER_2K
MV-UU:C2\2X9-_5X]T/6K:P#F7-15Y$N@M@X8GK.+28^T6>>#)9'@[]W3Y$UV
M?/YS6J[BI.SN8O\N;K/ 57AWN)*]E\"CFS+QSMN&+7#0,N!;(O$.U@2)M[,2
MB??V]-U)<';TYN33_P2O3\^.?W]_]L?'3:0N>)?//=J4U8?XNTQ9[JU.6=Y^
M-P_[+]8CS_GXR]I^M#X<??P4G)ZN8,_Y9J,Y? 1>E>'.FFBJW=6:ZNCCWT\^
M!6_>?PP^GOQZ>@8F_;M/<KV<$7'/^W?!R?_WQ^FG_PGA&[\??2)6G_?'?__M
M_>^O3SX&;X\^?3KY>!8<O7L=G)Z=_0%_^O#'Q^/?CLY.SH+W;^2W2&;_Q\?3
M._"W/-'NDVZ-IX[6:N/*--XO-12;1=JI_(?>=J]'/+:<OT.?[ *&J*TX!&3S
M+BKCZ)_!K]RQ\XR;G,G2Y#6[GL*X_1TOB5HNIN=Y&KPX??<^?(&E5!S  C>1
M+1T*%UHXS[O_.3L)WO[]D^UOL(%E3D<-1%M?@7?B.3=*7'J]FGBT-PKU>1OE
MV#(4W0GI-YE5M,[(N>9_&8SM"Z(>Q#5'^:'Y[;[+#PK\MBM2ME?6GW,UR85W
M,3/CA"C8\BMJB'E>S?'3TFB[(_S:Q!!+&CRCP,(12OR?8SXD_ZSO84<5N\]F
MADOQ:R-;FBUG_N.<41NVNK Y2C<.)?^7H<P+]%NQ]Q.]&)D[J+G!QNTB\B'3
MO'0=<>PI;>V-DV?+6XXR+3\,MX<#BMHS]Z%WV%8?ZZ>/[UVKEE\G&/_.XENQ
M1NVME0E-P"RNKJ6(=[; #A\\&^TPT.R.B?%P">AAS+PP?C_PM@9G?TK1:F80
M<TA5B=1(]OHW:9B_!?5H#R2W/M9.3+@9EQ\LT1MO"EHIN%0\=DOY/97MZ>5>
M?RVBV>2FX8K[0H^_;@<^M6*YP,E@45Y^Q>V7"E-*\G2IN7)-DC8STY*6IKO[
M: JC&D4(FHK-%XX;GOU;-)V]^L )G.-HAAFTN1E-LISR:;@H7^SF$Z6$\3QT
M 0T_R!4@6CZ @$'>2Q7L?%_R#*.RK'#IHN 'O&>]OCSY4C%H?\]+G-0/!391
MCJC!)LW)+D)A_">.J0.D/0DADX_?#$FY:=/X3EC[-DJF%T%9C, 'R?(M7(/^
M8-C_?Q<[VW_-+E[ J.8K/FEXZ[W>[,NK^J#P2J2^A:,HE8'0"/AC\2]W=P]F
M7] 979KA#'&2V<56:L:P_7H'=]GT1QA17+'5#VZUT__#$SK?>OW!3\/^3RQI
MUP66I>J76M7%:D6Z38[S&U#!<%]2FX2E/=C%1&HQD?TUAW%[V_RFHP>OF-/5
M9<6"Q2Y;"""*9J7Y6?_E%>;1TVCQ<Y+1@M"/[G.L#@^W=_?Z.+5Y ?^+]<4R
MZVV:]4_S>/DSM'!V=E9^W-ONK_SLNL?V>]M[._OW>NSUG^T.N\%V@^T&BX/=
MO=V ?B*=P'H!- _JNO]\,;17NER\/_>"/MVY^KQKOCJ8?<$OM]@<#4W%2NI;
MWRC-*WW)(B<M#Q=XW\79;Y[4<YS__G<^_X/O?/Z'W_?\![WO?/[]VOQON BP
M&]M%D5=9O"5#'(V,&8]?73-M]-:6S--\]M S7G(A>LPRM;KLRL]<K=P4@YO7
M0DQY-/UA*0*JN ET9OY"]8*6Y2+ZPJ?9).U+!O_<[O7:E^6;+05^2DMR^Z6X
MYA#>N$U7'N3O3[R[X!?V.^D^5^GN@\/22?>92G=G?WMWMY/N,Y5N?P#B'73B
M?:;BW>]O'ZZK675G-V!,_V]CW(!:<O%>MG[+A#=CV]W+G&\7[X,JCL8K[Z4X
M-EA(_>V]NUKEG9 >5T@'>]M[W4%:;QD=[F\?WM6$ZF3TR#+:W3ZXJQ?3R>CQ
M?9'!\.F$]-SCTDV<VM?$GS=P=WU%B'E#G=D-%-+@\-ZQQ$Y(CR:DW>W#O4Y(
MZRVD_<%V?[\3TEH+:;!S_\18)Z1'$M*PMW-WW^$;"NFYQTEOJ+6@8HHN?-IY
MJ^LFI,'!]FXGI'47TO[VP5VMH$Y(CRRDG9WM?A= 77,A[?6W#SHAK;F0#@^>
M-!5!INI/5#[64L#VJ!7M],3;]V+_-!'&!L=<8(N%A=%!Z/Z)N (K=1,N+\_,
MR)1E5"34/0O;6Q.9(C;=X4:F*QXK#4^\]]C'CJLB2THD^BOS%!DWD,%M-&*^
M0!["&_A1T.]M_5U[5C-3 M7^EA.LZF7N.NU<!4\XIYEH<W5BXB7V<"0AQ_^8
M&EA1+?"_,!GW%-3F1-YOL>"T]N/&B*0W\D+H=3UF%:]AYA%W0.@?#H?$]" =
ML"SIIO?5$R%6\7ZS4_^-^3(R,]L1A3HESRWUI_*2$_&YMP)!65&!M.7)J4TJ
M;"PED7-<8=\DMZC,.<C3HX=%H_D:\,Q>2Q#PT6")0' 6I8:$_4=6F(NDY*['
MWJ)O(M-;=GONG2=:_0]5 7NYY*4_^6>%C;6]13_G)GJGV"21>="/QGB(Z+Q^
MB(KG*9G5 _VZAL?#_1?_M1;D97LKR<L^GIR=?/S'R>N'YHJ[I:!6#?-VHO,I
M0E9)[JY;=<5SUHI*[SH%<^WX;UBD[Y)^X:"^'/>CI-SIV9/_-)P-3ZAL]J]A
M2GQW].O)VQ./'A&I7?\X.SM]_X[H#^$+O__/V2G1'KXY?7?T[OCTZ/?@^/V[
MUZ>?]#N@LO[X_1-]Y?V'DX]'^,%Z\L+>V05(E'",&+.I,2T8A]CL>BO-\\_U
M'KS:.)RZ5"5(*4A$XKS4@_TCY1BZC<V+-WW]]_V3EM_?9 B32U&:H-:!/$53
M%RQC\4;,)?T]Y[Z>\D>8!'@@R)U7<U!.02KYU/;J6N15@#Q)R"Q##7]7+PY9
M,D2(ST%\MH[+ #?>H/=J&BU"^M?^*_W359*FS;^5D[Q*X^9?F<^K^==9&F7-
MOV'SLU$R@T$U/SE'&OK+I3]C!]IIR]=G8!PG+>_,T=& 9=._PZK*1](EQ#V)
MF_]>6.>05@27B&5!U'_,:T6,+=[BM4B5&/4RHO*F@2&!_3;N"O0$G80+4U;I
MG D'XV0,GHW7 ^I^_()K=F:/TCGLD8L)^GDB4]?)F3>*-(0!QP[) EW3OFLV
M+RZOUQW7=N_U.T36'L[]<W/M)4"\F7!2T&^\J")J6:W\<2J4,$AAL"D[W-A_
M(<&&%C6.,O  1A.<DO3\?IL7!EL98'>!A%N#@9N:X?<R98^$!Y34 8)HQ/!E
M,QA0<@Y.Q'QA*<FP87 1C1;"U3^=I09VLBE+53JK%X>8^G"!V.W-\B _3Y4S
M']1,-8NY%_+BYF<%= \+21J%"N@GH(:/.*CQD;4Q]AC/R4_G8^,]@2(C<PZ
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M'C?E+(B;/MSQ%4]\%!7% C]$+)7QYDWC]:;N["\,V"!Y"W((1#,\';#7F6^
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M]FJ"J#;(!:5-F(URYO!6=H*$J*!+O1MQCR-LJZ[L%_HO)_ZJSJS5@!BQXVE
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M2JX&[R77ZA]EW+ HC>1L;#$]=9Y%H@=O\6U_>-$,;5]:@MYR"1QV"F;O9#8
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M[;DAY@.@,(F7_$YQ4N3*3T6[7Y[,GR1%]]]9E&V1H /*3-9$;98R6J1T_7-
MR!%>8(/H&XKEO=>T8UIR@;=L:?"8:DDI)S@D#%S,":[=@!E@%C!U_N27R(%/
M5U>^M[F,8NS)G<94-_*=^3F6<<=2V3"NZB#8J$,T"Q75(W/]!:K*T';RL(66
ML3H9FQCW9@G9&T4(C$?SE[Q-WRKM)$JGRO_SQI/WRBEPG3/E\/#X1D@^%[#B
MC8KSV"+-7/:QH\0D9>^RO[Q'>AUY5^_"B+9%/WHO5A<!27S!_& O?!__6L39
M7+?NV":&VL18,?%B$86K4Q1NKH\__\X"HG16?ZW5]97?K5O6-NN&L=FR8AK:
M7 !7I(@LGT*Q:MC$IH]>,X#MAG/6'G5B0P\[I83L#-C*'GI<XR0*O?G)#2\0
M+KPING!.WPD>"],H7G2J@;N55 -S1U(-=L*&Y:7-'^O*JMKF;O_W]HERT/G4
M/3EJ]0^ZG2?6^+(;*9_8()FAH8#C1I D>5KALAR$()Z(CM]($J0D4>159!"?
M%)^+!.$WV/4D'%Z)UB5Y7_>>T)P-S<J4X7T@S4O4GCYS<T/9$YTM\+E#[[+Z
M)EP5"VGAR_Q5^/U9(M[ 0"6*KYCH]"?LO5A4\*%)E/7AKW8!)*]N.DU"G\<$
M\<-9A&KI:]0,N.J'-9*ES7S&=^8GYIE1''KG5 11S4[&'_)?\)JB@&4>RF+4
M!+5]R;3!*4Z "4)>T#:<H1U&"M]5H>Q59@E@3%Z 5[>;K_TWFT*8V^"3J^SY
MTG7F5R\R /CQL',1N>WC1&RD7 "]S!5?OK?"C<]+,6Z#$^@NF4X]G &CH-6
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M\BEP7Z*0IL%/J:GZ,8NB]&IT@5;HUD3O'[.(E?,%;RPZ;4V*3BDZ)1]Z9#/
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MJ)OIH491GV98NR)1'F\N@&[O.**LWV )4=+[PI3K,F)$'J1[@XBFY_\S8W@
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M%#@!_E.,%D9-MD0NF19RK34):K[W@T5(Z!Z.9QZ)>;277 F!]]20-Y3V)_C
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M]^BY.RHR I#.B?M5+"2CN0=&8RXH#TW=;-K!T%'-9C!0K<' 4P?#IJ=Z38R
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M#9M:)#?,E]9M2Q+_ X9<)/'?-_$OJ";VP-9U6]4:#CI&M$!U#$]3AX%O&]J
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M!8.M#L+&IC*=UM=NO4"AC4LVAZ&F,,MA9)PA)J*C!=+1_/1F;3(WUA8((15
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MBLRU%&>Z/T_8_6$T/'I</[,_.*X/\G2RT7 P_GXJR)-U>_Y='E>F&_DJB/[
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M94X6R&HR2)-C*M58Q):R5XK'F)EBKGCEOLJ.7SE00#2YC#0Y=Y SY.HO&"U
MEJP 8VQ5&\*#U,GHS'S2QE:BE*Z19*?5/%%>^C "<21QY/+<]R4HDHN@4DPI
M53\+17"^>,82S\&HDF2)9$"N,C/.%K6ALLB]LV!R2H"N:' V6E!66NV-#$;Z
MC4TTU81DUYZ$2]1(U+C*U&BC;\&FZ*3+R$5T/O 41/+.,]3J+K.P1(W7IL;9
ML^B:9\.#0F!U#P34+(,SC$/B'@4S7&;53K!V3E>S4<WW_B!R)')<(W)43DX;
M'(F,!7WT5NI<*EE:Q)*+U42.JTR.LS6UO(I8\B#!!&L!T7BPP0O00K9RVQBD
MDQN;;9@K=O:<1AU+2H[W_?C_Q^;([6#_V6:P#2Z]Z,<'GX[]QY.I;KV1GQ:N
M]T;YT$]RZN5W;;9;OEK?V-.G=4:,L@HJ#8];?]K5K<^YUM&1BS^,%3I80A(F
M":^6A"]78\>#T;S:-99)4S<_X7*VWFDKD15NLVYGBP0[/5M4[9X+%-LU&CZI
MM3M[2.BD!J_>XO0E:ENT2+OF_5P9GO'%IEP2N%"]/50V0?#*@2XZ.EY\U)IO
M;&K=,5W-&JL7=%2("&*5">*<$/KUV.%\GVB>&Z:C<XD:;H@:9HK0JG>3?*4!
M\$J)ZO"T(=M&)DB5$ZS*NI7NGU+#HDX0$BW<+UK0P?%4E!;%&M1*>>Z2#YS9
M(E@) HD65H 69DJP%*M,W\9I9\<M8#$%/,L%LD$72XE:I+RQB0H[%*R3DKAA
MC;B!O$:2,$F8)$P27F8)7Z8 P'!9I Y:HZYOEFQV(KG,N37!UU^1!;<"%MS\
M(,,L5!+,092EG;H6 KSP"21GTC%E/<_^U(:SNJMR7QD;[K[WCWD\'-1+&3?4
M#DOOS2B7/!KE=)K3FAEXN%Z3#K]>%7]N0#MG&:TWF2NNT1;OG)8^(ZH@C%,J
M7R2@_:T:^:]%MC]+<+><?#_I5Q1\;IQ%!'<Y@OLPUWA&6F[0. 2MO0#D(8 K
MSD!.+C$398S*;6SR^2/E-$QC6<%-PXM604I+G5*\ /&2V;E(5IY)-0;# [.Q
M"E-E!YB]@N"U@)*9\,BR\U&W BJ.\Y-1"/>KB?N[S122J;5X4,\D"1D30J0<
MH(HN55"W\673JD@;K<U)FI2KJ;6H8]@$Z#OWI6XBR7<Y-XJ@?4/0GDGT6<N%
MD5F C['NU]J5UG]&0K;"<6.U9Q;/@S8Y4<N*:G*B2$HD)9+2^DAI23-=EPQ%
M4,/AZ\2&Y^:T9DQ&F B&\5SMFHS@G6^E3$HJC\BEX8MN.4PGM2Z;VAKG07\X
MZ@V&D_H!B\AKK>P &!K30U(B*=U%@L)9GXPTGO.0L3 74K9<.ZM8E#YP00F*
M%38-V%R" J-.6FD%P3('Z&4$%TN"[+4+W@B%J77=Y5VU$SJM%U440^"_:_"?
M,P+S>LB_26> 8']=V,^F,!3'7(R"Z@E(P) +^%P":%EYP,L<"O>GL%_4\4>"
M_/)!'D-R1A7)G#<8HK.2<<Z<8MD8[RQ!?I4A/Y/:,%EYBY(#+PWR.7,(+&NP
MKJC(2V8LFHU-E)VVHJND3[!?+=B3,T92(BF1E-9'2I=I6X=.:@PV*BFQH'48
M5$'ADXR6"T&&SBH;.G/9CA14-(8+4+:DZMW$V$9!<_#>!B.=;2U=3TP=AYU<
M6(,7.LMSV83'H^.7Q^/)=!!T[_OA("TFZ[&RF5O*KY.42$IWD?704CO7IL\A
MT\@M\TDHQR*SQ2O!#&4]5ME$X'-9#\9+T385<$5S0,<1K/$6O-)*:::MLZV?
M2^>TZ*K=N$0%$83]!7=KNA[PR3%89M3/)#U*E2[*R"!Q9P!19K"V?G'2RRR<
M=P+5">H7-5^4$+]\B#>)6>=4,0S;T0WN.0L&91$8985:),2O,.)G1V>JP*56
M%A1K,X6%:L,]C ;E3)9:8#+3Z@8F.JUU)W%1XST(]^2+D91(2B0EDM+=63I!
M>Y9S5CD;1"%2*%QEU%X&H:4H9.FLLJ4SE_3P(4G%8[5PM&: )A0(VAH(QK0"
M/N:<%J>VCN&=Y-<N\*!C'A<&[=-W>13[X^E GI.N9<,W[9&//TWDZ?E!ZKW-
MXTF;PE-7/7O^Z_C3E)Z)?]=[X]\?Y<'D6A-Y5H_M*!%/4B(IK4&CJNG7[_TX
MI\?#HS9[S+=K)*-A@4:#F!^$HS4F[0QP;2Q@3A*LR!Q2M"G&$GPU(#<V1>>$
MZ)"))2J3(,"O;H<J@OIM0'TF]X$B,.28H$C9NA_G!-8'!&X2+\&:8%KWXP9U
M23"_MS"_S=DT!//;@/E,PJ.@Y@%E!!M3! RHP4DKP5>M5D4;$83>V+2=D+8S
M[-II3H(Z.5HD)9(228FD=.?&S6TVLR+CYC:,F[D<1XC.%.D,.)';>$YNP(>"
MX!5C!;FJ4C53\P9YI\6UZS;I7,>%<3H%"X2&B': XQ,DZ  'I=!)2B0EDA))
MB:2T E;THD.$C]*KX_%D6KJP-WQ4'UR[ '_XL^^GK<%C_Z8_\8=3:SK,6M//
M\O\>]\?]27Z>1V_[,9^8W\]R'+X<3-]E:HF3S;U FUO.!11Y-KKH($ RY,WB
M5A P<& A5<W0L6I$W-CDJJNJTBE+0R]6C!F(OTE*)*7;'R CG>0\:Y$4!E0N
M>!F8=S8E+EFTW%YY@ SMMZNUWS[E,S$NYE35!U3 #2]UQ[4(OB0%,98B>1M0
MDT2+<3$]7Y!#8VB6E1ON,(Y-C+!BC# ;]<[..V>- %&< +25#&S*%K1U46:F
MDHNG-CB:3EV_@(<*^R\,ZT?Q!"&G_8SJ0X>&Y='P\+ 5\O<KK$=Y/*G?]'[,
M@SP\J>FG&GY*M)*42$HD)9(228FD1%(B*9&42$I+%(2X?GSRRR#$SG!PQC':
M.O6+M@9QE/TX_S :'CT_#N-^ZOO1^Z?5IYJ\;Y5W?A IO+#(\ *>$W#TR7%A
M70*O2@0T6H#C,H!RLDH^"A>B:$>#I'&=T]=ND42@7UK0+SKR2*!?&M#/M4B/
M'J/B"6RR#%!D#U86 \5R%*FT8X%L.4%_WRMIG^2*F?'PL)_\Q[#B2>B02FDI
MK452(BF1E$A*)"62$DF)I$12(BG=K[+&BT00JHOT*8(PXRY1X&"!@0-U3K10
MIIRL10X,M0%,TH/U7@!3K%B71%0B;&S*CEO>:9QO,DHEBO<!Y[<3*22<WQ[.
M9P.$I07^VY!H)J($M"Q ,,*!S,$DGITJ6)8.Y_>]W' G3WJ'P_&XYR>343\<
M3WPXS+,S$P^&ARF/J%$PY:)(2B0EDA))B:1$4B(I+<CU83QYZ0/CQ2D4U=N-
M6G%66 J)"1?9E4]N_CP:EO[DIVK>D7.S..?FZ9_;CZM3<]+38+*]M_WGSH?7
M?_C@+ \Y@K0I Q:AP54?%A0O58>5Q^C;L!2M.^2\X\I<P[\A,!/EDI26\K \
M4>[-4>[.#.5:'5VJVR248A6@"!Y<#@RB18<%N>?M7#OOF):=(<*]IU"^?N"8
MH'S[4'[_)923\TRG:,':=B!=.0?6" [)*QF#5HEC;M:3Z=!@Y_A\(]8[ ?.]
MKQSMC\?#P^./5:-'_M5PU)^\A^&?@UR?\*=2Z]YO/_Y/[]&@P:'W[^P/)P==
M;VL0'U"!*24E24HD)9(228FDM +GM:[?J_4KQO1V?S U'<XKQ'B64SXZF5Y+
MEO9"+>WG3,T48>B*U\"C!E':U#:9/%BM,^2DA54NR1+2QJ;3G;C^$2W".;$Q
M28FDM(I2NLL29=HK[V:OG LP1VU5*=%!UBTJQ;0!GU%"B5%FJ2)7FGUULZ2R
MY&7%]AU6)5\)VJ7_+B?XD$=#0O554#T3:U9),ADU VT] ]3%@6.LS?T2CBN%
M2B;V:9M>(AOXOI<B_SJH4#BLZ]-)17*K/CX8CB90H7+4ZP_>YM.>P]..IRT>
M/?'OJ":9LI<D)9(228FD1%(B*9&42$JK+:7+1)YB#H@N**4MHE8FZ*RUX=XJ
MXTK*5T_7[$X.\J@-[ACE@SP8]]_FK4$<'N7/-OJ_AX?MP?[H^X-6(K4[>)[C
M<75M^WG\:-0?UY?.CKC>R9/=LN??4<QJH=YMG[W;GO%NG96"<X7 C/: *7/P
MOF2PJD1C<V*)X\:F4:IS>GZN!Y5$+BLM$'FO@I26HG"5R'M5R'LV-.F<#=RT
M$G:A$9#E M:E^IV)*))D!I-;,O*^[R6P/PQ']<=!K^)CE ?Q?6\RJF]V.&T9
M0N6ME-PB*9&42$HD)9(228FD1%):;2G=:NSQ8EYK<U!/C?#'IS;X7C/!3Z[P
MT2#M?3;(/P\F)I_U1GS6]_,!1\$S9FT=L*H"@$I$""$C%*&CS"IXV]KZ"=,)
MII:HFH;H@$C[GDCI#NL9B;17@[3G:B"C"3RE!-SZ ,@X@E-*@4$_97-NI5Q"
MTK[O)9#?^\,VJZSG)[TG.>:CD$<]R;M>P^)U*AW#<)3R".I]/6R/?MKTN-?N
MYCZQW?C C_)XAO!$-*):IB[;:JX&FSV6%*1-FG'%?5)_;)W'<UL[/\PRW?/I
MN[=I<CD1!5V2@G8>G]+/YX.(SIO*,MF FXZ+XSJ!TTQ#])ECM2*5%VYC<U%C
MXBX&@!5*C:X%HN?MEZO!><YL>7ZFJ_7IF,A!/#QNS^WGX6AJE)QIA[TW/+^9
M/)W26!P]?)BA!R:E]PXE6!$$8%(% O<9N*SB%K$@RW9AAS2()%:8),[=]H/Y
M_]E[T^8VCB5K^*]T\)UXGCL17;ZU+_8$(VA1\N4\)BE+LCVZ7QRUBFV#  <
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MM_,G\,^S5CT>7A4JW1LW$WCI^F[?HS@]3F_LQR)IURAI/QX^PQ\/NXE.DIL
M]D5&@9KE41%DO;,(2\F%2!1CS7,-4\QUCW*<"A\4UGXD5MI@FFIA[6UA[:7T
M5*:#P<0#81.,.&8<&4\)XL)[ZPA-T=C^L?9CSTQ],1K#G\,*(#*.0W]13<=P
ML,&W%V38VLA("3\7*Q4K%2L5*Q4K%2L5*Q4K/3XK?4WVR^KKC7=DO]PE8;-:
MG;OCS^;>^)OLC,].=6\8WERYYE>[-8N O1<!^WIYV5&1()BF'&&?<D7!X)$A
MEB.GB.#,.^XISYDT-6'+>RM+VG%?.:$P]S98J1=YBX6YMX.YNTN/#H:F\TD@
MRQU'7!!XY$A W F,J1?)6-4OYG[LZ8\_VH$=^EC9:;4??3QU<5PQ4E<9CZMD
M.;K1.,0QFMW,[QG<_3 ZSWOM\Q4M7H6K_CX;9C(:-&'VRO81XM=UZDJ21^52
M2)2",VNCECXQDI)2A ?KQ1\'7]J@JSWZK-9UX::OY:9FSDM7)?,8=M%IYQ#E
MW"/.'$8P85$DDZ;:4BX4-CN[9DT1D77 8XLBJX4-;O&.OHT*;J]Y/R]9\OQ_
MSYOI!?A"@_-\WUZ.QJVG<ZW6R9O1T6B83V,\&L#9OSN $P(>F9:-7.NCED\=
M:I&>)T*L1T1E:@G!(>T20R8ZY9D@QN2]LNNM%%8(YJD1S*WN!@F&A)2<3HEP
MJJ3!PLC<,!!\[^0"_T9WH^BDM1)&M]&G,90E@P-BW%#$X0=9H ED$O?)"JK!
M4]G9I4353--::U5(XR$O\5:BN$W5;9(G_F,3QO\*H_>).I=]LV_CS0?QS0K?
MKLRWW5ZK@GE,J(^(J0@.6N[#:!QGR,M(F!96.$LO^;9P;>':PK5KY%I.)"<L
MRL1YY,8E8Y-)PEOCN36!F,*UV\RUW=84V!*&H\:("T,0=\PB:VQ$UEL:HPR.
M&.#:W,#>U$*;6IGBW1;&+8R[UL LT])B0"%@47&9 ( NZ6B)R.V#J IW4NX=
M\=C"O;WDWJ6J?4$:%ZT/R D>$3?4(<? VW4*8ZM@5/"@,_E2(%\M1"WHLKO[
MY6'8PKN%=POOWN!=QK671A"3,#><VA =-58$FSBAUA?>?22\V\E[D<%0Q6CN
MPJ8%.+T._%UA"1*4*Z4LM8[E'LB:UI3)PKB%<0OCKF=MP7,,$M,E0TC@,G*=
M8B(2_%Z!95*!E!C[ME)LMU@J&)I&2112,@+%!BF0QMZB*#A/BIE$F"Y!]L*S
MA6?O@V>MQ%AK*0&"G LA+1<X!6:QT)0GD\H:[G:3;<>?S=E,*0*[\J@2XD(I
M9%V22(&,\5(P3V+8V67&U%*:FN=4XJTGW#83_)_MP(-_0_-^][_:7[,K<.-_
M[EY>S>+%Q?6<VO&[9MB>F+C)@C[F,;MN>!/\.7S3C.\W)[&RWH].X;LOX/94
MP]$4CF['\/2P:N#,WHWMH#JSXUG=VY,XB1GV[8VUTQBJU SMT#?PILD4GFCK
MY'YWYVV8?SDCW^6[<#::M$T)OQ_'O"'C??SA0Q.F)PONN?:YN;GQU4>L@W,X
MG][]D;[<XA=(W;P=UW_G\VTI*#)LHP! )>\YT]H8A34/G#L D_7L#T+5SN)3
M)^/%19S9=Q&Y<;1_(9O@&K^W@P_V8K+SSYN##T;>_)P$AY/NSRU3M]ZR@^'H
M?3.J7IY8X' ?SUM$3NH*9H*[A];&$7;[M3P[/GI]_//!_MZ;Y_O5ZS?PS^'S
MHS>OJ^,7U;.]U_^J7OQ\_/OKI8NZFU.6KONV"YWU-+S$3LN)<,$#>S:)WR\>
M_!":R=G 7GS?#-O3;C_TP_PVS@&7[V1WGTK^OMG+\X%DS'<*JSR6YKMDYE\\
M'V;?M<.LP^^SUR3Y3F-VY\OX.W+G:W]W6(*_4TI^TV'__C7!RLDJ9;[HL)_9
M-O65NZ,VNROU-D?E\IJ(^)*+FF%S,Y>UQ$R+<E-Y0J_>1CNNXC# 9+[8_S6[
M8D;J&Q?]9"QZ34S?Y4_>XE+VV]I_NYOO*R_XSC3]1WKC<+EQWW3CB/D:_MBB
MC;2W7_ S.SFITF#T85*E\>BT&IW%,<@:4%59\;YORUY^_R5#Z3/:=_4Q]LW[
M<)[N23[VXI.+MNBK[+!_9*N\MUUAKU=K>U&88_L:BOG+1=BC_5_$OW\ZY(>?
M0M.^[\]W\/\O^'#_O_\ZW'_^X9"^Y6_?_/>?;R\N%V'%X2F\__?G^<SH$;S_
M\/2WD[>GO[#\_-'I\XO#3X>?CG]Z]>?;U]U%V+\NWGYZ]_'MFW^?'L%GC_=_
MN?CW[R_@>WU^GKY]<P"?/.3__NGHY'\^'4ZO)7)]./KTUQ\&C,<<EDA2QQ!/
ME"'+@D71,$:B"\1'U<-F8FNJL%-HZ7'2DE:$)2:=E%S"T8*.A@83"='*67BJ
MI26\H"5<:&GCM'1QDY9TU-A9Q1'Q'FB)"XJ,%!%QFZ3B#%.9\,XND:KFBM>&
M]*3(3Z&E0DM_0TO4*:F]$D3;R#U-6I+L,&'PEQAGOFV?3,R<EH@IM+1I6CKJ
M>$LR:LH#R?'IZ,!;BN M<1&0P]P*;J7F1@ M45P+06JEEG<<E=IC]X#!JPI\
MDVHZJL814.>;06P;K68YFI_-CWU>6SF?Q%#E!JWK7ECIR[)$KX^QIA60V:QG
M>CPH]^,9#,3F"?;=V& SH>LWO4R%ZYL*?UU:.$C64;B7 0DF ^)2>&2U-(@P
M3K6WC!KM=G99C3FNL5G>BU"J\SX6#*\NM@N&'PC#'94MDR#8*T"N9:"M2;3(
M:#!3X,YKHZW2S+<89KHV!<./&,.K*]."X8?!<%>2$D=5LM@BK80$#$N0I$0S
M%".V/"ANVIW8K!9&UTROW(BO?ZJT_TI@[S1O.?C4@B'G/S?#J1V^:W)RI9U,
MXG0I6OI%M%1ZC7Z]/+ANB>-T<&F'O=8,A:C61U1OEP0#<\$D&CQR6E$$0T,C
M0SA!F@)'.2,BYGQG5U!<<R)ZU"^T] _NMUPHF'Y 3'<$1,":IB@5HIY:Q!D&
M*9&,14$(0Z7W@2D)F.:JQGI=6[<*ION'Z77+AX+IA\-T5U#8&+VGC"'"<$*<
M&H-,$ 1Y+:57FEF?4B[MA*6LJ5D.O&]]9^_M$Q17D:Q!M)-8M?<*C1(ZGZPD
M,9["RL>Z)$8S''5HZWAAE9^S45[ETSM.OTX*B:V=Q/R2V/":"4]"0$DG(+'D
M S(>*X0IJ ]&./6Z+0Y*%*ZI6DYJ+"N;CP7?ZY(;!=\;Q7='>("Y&&'*(FT$
M1]R0A!S#%''GN<24:\E)ZZ1P4L, */A^M/A>E_0H^-XDOKLB)!C#I>41"2=S
M?5GID28.PW3.E:&16AC2.[LZ)]G)/LW>GY$@BUH)<++Q[PEAF]_Y9 ([ST[L
M\%W,N83)-N/JO1V<QZS' ASM?5N*IAHTUC6#9GI18CP/%.,Y&/IQ)NS]./OW
M8+A_:8Z?Y]9HXF0+:BAN W7_M22]'%.>8\&0H1ZDER,6&:848@K\,F=L,(JM
MNWYB61/N'Z[7'>?Y)EP7OVQ%<'=T%_4V-QKE2,N@$2><(D<40XJXX!PXX5K(
MG5TE:JEP;6[9_U#P_5CPO>Z83\'W!O#=U5T1&\<))0CL9A$7Q"/+$L@P[JW
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MGRT7B+9@3(>Y0)P)"M)$..0B54CC&*,,TAJ!@<\$JT7)%M\VH&\JU:H ?(,
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MX+=.LA++&T>$\2P8AYB2N9"RD<BDI)!@+L(SVCNF=W:9J;58A:O*^FE_D?Z
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MN]+MFQZNTW#KDDXG'3YH7>?9?F.@X0@\?-Y&I=O[E6 D-+.X--R@NETARA"
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M<3RQJ08(@OD4Q=IY.^"]P1^KF]7-[D51<)0P88^F(.LG05+$RI&F*7E($I[
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M+"\,?? P'& DVD,K[#)!1YUG126P_X-E5!MM,\H+68HB4R7CQ><(NE=A@_^
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MK=#"U]@EN&7GZ;"]%FJM5]?IN8-4 EO7S<7M2\O.8J+P&Z;NEBUF<?#0T('
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M[W^G8%$SZBX*X726QC!O@F4WG,8P?!':I@;Y&IRX2-J+0-K1#IP81*$(H'K
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MV?I.G6A6M(NZ[;(V>RXM[LP)UKBF5.?TD*@C8XEV(-EF(-&,Z"=Q-(H(BTZ
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M1;(&\->(._#K= +6\!PI";L_/X,YS0:I(_G@AQ=+#20/"IU5&2CG'\,UCV!
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M7,NY$<H N4I'M;>4P&)NFHS7"IE/.N_]W;TC:XD$\,X0"1ITBF8<&>HD<L+
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MXX9URX+RW<LWX_],J\CI28ZD+CQQ+4/*T_KA&)!!1LNS*RPVD]ZT$\MT6%T
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M/(T9CH'6SM3P!7'#3B'!A=-NL<)-!WWP^B@D$+C*$F1R2B7G>8*<MAE&<"S
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MG8/A><^/.Q++HCLUUEGN]0:UH*\!:;6_BT<T0W<Y-;G.&VGJ:)HPV:@2:6,
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MJT[&+]NAP)2P5]7&_U)_898T-QNAERW167;&-'=G&\>5LK&%YLMS]VX+]Q[
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MO B^I2>'[Q6CN[#*9*-%NW+F&[((?(7 BQS;],Z"$JX?D-.2#_!30R _EF6
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MG1R0_T>WZ6.O4)&;[=H', "^ ]K9[A%HEL6O/_T>O\=625KDYVJJ[S'5?\$
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MJX6C9\I:+X]IN<J9O/(P7B57'KONMH2L,LEO==L;\B>NJ4+V7-D1:JXC;0>
M.N,T#/:"<VK -+?(B)CKQ5U05;MEF+#YGD< $_J0%EFOS?,\[Q5?C>_X?A%E
ML_;(=;MTL^K%)CQ_^S2VOL<&#.;@E=LKI8.Y<[YYOB%VMX]^;&Y__;%#O^+=
MP\T#&-]YXW"SN7FX<[KU&:XY_O?1UF]3#N;#!FL<MEI;VQ_)YO:GP]UM.(]^
MY%OKC;,&W: P+KX+NLO.\1?^S_E%K;Z+'K<4,VNTX"AQ0A#GH#4ZY3@BVH?@
M(P=;-ZRL@2&T9!UN%Y3!M]1(RZX40V^^>/'S0%-6%[9/.Q4B+0Z1-F8023*N
M!>,8$"D$Q F3R+G(D.1113!]261@'%$EEZP#P5O0_?B]$.E-M!!^1D0ZZ,98
M8=+B,*DQBTG&,!]!0<))"L1QH,@$X9#UFO.4A#2Y>"(5E9;T])@D*BUI^3#I
M4V?0K2!I<9#T90:2="!.>"=18H0CGJ)#.BF+/-52:>QPT'9AD%2I27>")%FI
M24L(27!N!4F+@Z2OLUI2%%)SRQ&V0B+NC4$V.8:(5XZQ9!Q?("156M(=BD =
MQ&ZTJ1^[E:ZT7,#T(2]*A4Z+1Z>=&73B(AC+C4<N%KTM"9AO#JPYQB(3P@2C
MJ%M9(W5L]"M3F6Z=:#)9?J]*-'F"":KPLRKX^4P0Z6<@,GFLN78)+$F"$9=.
M(<.20IAR(N'W&.Q%?X#%J7!+F6DR-TS]5KDGRQ.T7JA]96;%TX4C;VQ^FF;I
MC>,3V^P>PX3,AJ1^_.%;@[R HRRS20Y/S1\QH//8[;QXYKY_Q"%<?[K'J !U
M)5J$>0+C2CN*#.$&A5S)/]?="B;<"; ?&'M<K?/CK+.6SBB%-3*.@IH*2X&L
M\1Q)+K3QE+IH]9W6^8%I)=4Z/\XZ.QF<38F@F!A!7! .AHG%*% >0.C2!%;*
MREJ[,R-D;_ZAUKQ8H%JG._XO$$L@!/N=;J\V2NS*(>C/*AU&A'))5;_/5,6I
MR ;(QI]O?MC#@CB7R[![PW7NV\*0X5$CP''C#.@3B9)GAH=J0>^RH-0"-V$'
M$. M+*CF%EE"90Y\@47@@6G)GEFN5PMZEP6%=0PT:(_ , $!GG(*&:P"8L9C
M++U*Q/+[ GL+YAWL@\EDZ3#HYOCU120>W2%5]VHSYRK[J""&R+"-(@&V>,^9
MUL: KL,#Y\Y+83W+/>I6;I.L\<3I H5!91X],VL]NOYZL^=AH0?=)4JR:@PY
MJ7.6?0^;AW\W=XYW6YMT \[=8%N?-P\:AQL_@%/HYOK^:>-;0V3?Q 0G'6YD
MWP/<\]_-W>.O;.?PSZ/&H><[].-9(U?2. 2N7/_P8^?\* <JP_?]LSWN!.@2
M(.B"S,6$@F?(<1)1$LJI7%N(6S6=9D4HH5Y[$@61W#MFA,?<TL25-TYP/9UF
M]5NG73@'LL<A3_\]<J!N?N3D$)7@U!L!9\G(@6B<!6"(SB7A [S?,&?J-DGQ
MZC%YH;CCNV;?MIK^%NZ&\8G\*[:;H'IN=OKPQ-O6;'BZ-[OV/;;:M4_1=0>V
M>U;+")EQL@#,ANWZ@QJI#Y$S ^YO'9")[3-8W^.35LS9=18TZ^;W7"G@I&4!
M@0LE/-TI*S@3$XG)"Z8X]]Z!8AUUH-03'+CV.KM208(S?)/@SN2\T>X!G>=A
M?(+A?#CN#-JW]*(^?Q[PDZ/.^=:'/8#O2)@@B(640"'+_5&IT0 \7K&H84EX
M+FNN5V?[HUXD MN+<A% #&W?/+&M7#AB4-)"L]^[VN2"U0"A_304 <8[:!*]
M_I\PTK_Z.:_TC]CU<,#NQPLR0/3MT0';_+)GJ6+.^X"X]#[K<1'!3"OD0"&G
MP06MM%]9DZMBU@_^WWGU+K"P5V)AN\#",(A9 ^.UGS)\_,__TY3B]P5,%M_)
M^Y]7:]MPI$3.0M'K=5JYM,H8LG12BJ7.UZG]9P#PG)I%]95>O]D?Y!$ N;G!
M6<QF_J#;&]A<P*53^W, HR&<?P!J"[%,5?\K>E ?^TUXV =?4"<QC-5S5C 0
M3E8D5P%7^[F:BX\Q],K2//G*BT$4@[P+OG$OHV$$8Q\L)])H3X/!-D>)@,[,
MV-!"H<2@\@O5UU<]^&,XN$\PMHU>?E\?MU*F]0KIYE/XE[/&E[W(-=@D7J$0
M%)B>DGAD<J\W8P35D6I08$ 75V)578ETMZ['M"2R_9*U;/>",P?M7N8"8*&.
M:S7W"\6NEUEA7,)G!<!Z#RIC4>8HPV;MQ)X5*>/ G-[V#N!^QTUDVZ ;MEIG
M!<MVNX5%!OPP5!Z*^_P53_IEKC')CXD6CF33K5YS$2:MG;D*+AD[;:1SV#[
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M9T[C?&,/FV IJ'S(>@Q*M?,)&>H82CCXZ#%5AH,^+5:9GM4V,@45Q/0SD/C
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M: 1[$J9)C?->A^E;*XG>SH6">6NJI0V.<Y+1Y#SO9G&ET]/3A^WRD_EGOHB
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M5F,!@4/A:\!T=LK3#)Z>SQ8C+QY.[YYBMD-ZTJ4DHP+P\XX@GK1$&F.#A,-
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MB@EI'CBB#"OI&2:)TSSTR315)$WFY/V-K#M1F<;?_*H0:([0Q.!,XBRB1&E
MW"2!+!C@R"H:)"-62%X,?5H9E7F.9*2QDEZWE=0XJQ\65!:<U5I0DQA!DN99
MEL('9'T@*!E-=*+$*I-+4-K*X+9DBXEP;]Q(:HA80\0:;_<KP\@%;S?SE"IO
M),(.)\1Q,,"\M 7;+SB6N',RL<R\Z*KP<67.[G]-LI2\*Y:5Y;I_>&RK!.8B
M<QG^F"ZFN'H?)/!P\A/EZTH40%>NVXW^-9?R///! SL"JE]@M9B"6^UU'O&X
MTWS<-R:MS>AC)A;E-C#2;N7CVFY-]F++[NZ.XJZ=Q%;_<#+J'X[[OO7=#HYC
M:YA:P_)@M8871D_KQ(Y;5Q8EK*W F70!(DA,4:1_.%S"MC9&HXP(!_"P?SF]
M>,OO]C3_:N/$CD(%$3/6V\;TQC].[_NO?-LW(UKRA8+(U__=P_[@KT/[MSG>
MVA_L?]T<'&Q]^"*Z!Q]Q]^R/O<Y9A^\<? :0^?@#ULHZVQ]/=L["M_\]VV'=
M[?<]8W$(.@1$?02BI Q'SJB(0E)!<TTI,6;M'5M?S#QN@6@/X(=;2%V\0/A;
M2]W=--:%L%VMLA8%SBT1N!DM=5G.2"-H2P2-P\\]I:4U6FE$ O!P+J1#.D@/
M<A>PMX9037T6M,6*J0M!@W->"-M)Q0M:MB0&K='475S(3.4O;DWBZ. J\7L@
MC_D*8&U&R&[H&']M?O'[B-O6]I>>Q\$+QB/"7$3 -:N1M30AK(RDG$38.9N[
M(RWXM5OYH8W77S0M:-V"$1P??H_C?): LL.+/O\XSER] ./QK7':)2^L]DE9
MIG@@6'OCN6?8<T-U$$MZ7J\0I]__Y[@_.?UX"'=SG'\YWH)G,-K>LX<5@B_A
M"=UA]20:'%]RL&#MGWM6!2P"YX@0C1%G*H#1 & >DR0)2PGL(14M;1>-ABF0
MG^/XE8*Y3![W^GZO5<DL8%P&_7RM?&Q;$0YB6#P&MR<;&  ?* 9/-''KL>'
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M17.'/8^[$S6(6^R0YKE!,;I<LB"89GQC2^1-EEU7I"8R\Z9UT>X.!R>-/?@
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MMDF>-QL?QJ6^R^3S%48F3UD@#ILFMT+^*$MTS#Z?0#P$'M65.R^RZV9C>[#
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M[< _9[TX[,  B5G7\TPA;BQ&6DB)F,LMSF7(19!76R\/ OXG?\0R*1<3KY@
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M^;6%_!J:)#<#>NU]N 7&Y\\]7,Y<L IA&_.@$VV1HI8BS(V11O*@,:OOESP
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M24U=SE"S5X!<>98G*@\TT2)89GG.%.KXF<HW))'SLK^\5C0!P5 \ZR!E@A1
M\_%&]FO\]NK=/Q]?_7LF7MH8*@C#H<H$58-S>(,O(XMZ12\'$))V5H4T>,FE
M297RS'OCO<^UM]F"5)RY3,R=_PZ*_E73]T\Z;IK4NKV3XOS=R-OWC#P9CTY/
MN_#.;Q?-T^;5WND6O.O]D699T&E@( ;1K1&\2Y21H%BB'&$"M"[ML;JG)J#^
MKT@!JUVV$#2(%,0P8PQ$L%<:))5DF03A['A*ZU-MUI=])[4'P />LWV8-@^^
MQ<PJ"?:;<SI-@L'&Y=PJN';. 4ADD%180H6#RU:;>9T;:WBZHQR&&9N@L0]
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M^0C-)_B^ B?(-)"A(["'80G$1Q\'K&VA9EC)@+(C9B@1H7T\,R K-AA<444
M\%*"RY0Q@+(@N)+"H9<N!&6RS*95^W1:M4\GE,J;75GO]%7$J(/.EOWOH.CZ
MK5'RUVYUM+OMCQ,3Y%Z*;^NQ :[)]K>.6.HHVJ@))PX;ZGNP4(TS"3&6Y-1[
MI72H;Z4^EVZ%Q'8[24WFPK;*# %,YQOTD54J$NMT,0, 9Q>5Z5M%K\PY+-\\
M8]OXEJO&F*_4@)-:V'<N+< > 7.<&B8YTUSJ3&;.&%[.-ITE1SI+C4U08;O
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M='BC^]O '\N\@,D'M4"JQ1'3.+VF80:8+.-[);W&\<*FC/G G8VBAST08D4
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MJ(I\5,@<!MW8K[6VH+DL&I^JO(]%X\"$9<(8ME@!^AYV$?EY6&>WW7CK37>
M+5R0CFM:.VGL$='!KI;ULU1O[L53VW[4%66#EO%H0;_YI)DVC]85AN6YMIQC
M#8;G(M?2$J)!L>#""&X%K50-2N6Z*\S] \RW(W0/&$YLXC)F$^[2D&#91J(E
M<89J+CA3KUZS^7K5^^D0\[/T5*GM:^,O;6O0*[XC5[0*&[MUQDX>5^TW]2GD
M/[QD@>=PZYIKLK7QH!.V69,NABU?\ &H.:8Y_V-:3WR* R_.S@;MV,-5GU]%
M2?=FYY]_=MX<?-AZJ8?ZE,=97F@?9T["&X^O&N>P?#31QN-!JV9L4T,1A[,\
MSP%HL9,:-A#8 '6B@XW.CWT[*7L%#:\)/<(6$Z2K$;E#AM#'75]V P4A@KU[
M2^?Q>:?OVV7WY<Z5;O5A554CPIEJAN%Z8K^YLBO0Q QR["$=EU9V"(57@!+<
M[TVTWZ[6@</PA@<PTX:Q[!Q4*3\ED@UPX>W8Y"UVF"N[]0Z5HG@\@_X %:U1
MS^2)X=DKS,G^ 1B\Q:CY1>LWY.+ZC?^8CKN"?YWTSUJO_S]02P,$%     @
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M6UW64K#DRW0=):L[B!P2WH',93,Q$K5%+D#)UQI8HK>ZU@*!D<.P1TM^1?V
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M"!P6!J&8 BPEE$%Q*61JX4WOIBM.$&SO18&>J]VVW/XJ)R_Q6.Y<<80GY>Q
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M666()0A(,6>1DI(RE"V,0 ,H0R@YZ\Z\4XBMM[Y<'Z?)_W6V6.]/C$(]UTQ
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M,&B##>7GD_%RB/\<SK\\7\SFDV.<K@WQ8XV1V6!IJ 6LYC1\YA&<8IDB< K
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M<#&NFUKU-/>L0D!S&PQ%A$:7!$K5?LZ2D@L4*$N,M7"\BRQ_YP?^)%&/#ME
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M5J20%@*+ :10,6<=7(SA, BR??/9YOS8QO@M>'%+EW9A??",XJ4DDJ[#=K7
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MFN98+YJ=R[3.J,EG=8EKFR,O;2[@G\;U';*G@<*:I!E?7I(!2ZM^%\B2O2F
M%+HPQXGC&HGC%CD$*0I8[;CP4N2DVMRJ;H3S'9/G</4TB);^A+/%N(Q3[?%;
M>\!^F<['-TW.I+%:QSJX.F:]FMC@K!40F8W>1(/<MNE:^ 2H[YD_/:FJ063S
MC^EL\2E\PM<A_3?FNWWQS7Q^A?GUM[\^_#;]BK-)%<6'+]/)?#K#_,NRD_%L
M/+_=/YUETCECH9 _ $HG#Z&0YZPU3SDSSU2CD8G]X/^.N7D$ O3<9N=]30I?
M^B(,(X_,*>">UWH">HV\BQQBR+C,O(JZOPYIMX\]MSC6_C+M\92[!7%SV':
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MB4=G'+B:QZH%,S&C8RJV:7CW",KP-D??^MI0N+Z_L(>8VO/K^!_,JV#V_@G
M&S[DX+3>YX"M)>O:6!S/+IE@K6))T[=H5/$^9)F3XJ,-GW?8B_1N-B4+9O'M
MW468+%Y-<DT:^E*9=!<U]DDQS%Z SJG:DO0*.'01$OW"6&M2SFVN9)['=N@V
MLO4)O\UJ:A2S6=)VJ8#7]T59:\$YDT%CMD*:['P9>.5+7,-O,#VS9'V#Z5$-
M#7S>5RE=75Y=T*Z:?\8O,TSCY<9*7U_@4NR3_.IR.EM<;[A;%S,27&A=1+UT
M<;5P(WF(43"0R*/0P0EE4IN[S9Y6<';$.XIJ&YA#6X']B8N1XXR;DA0$4\M6
MK50022Q05,G:6E%B;E,F\!2JLZ-2;RIHDF-[Q^T12U:S6L7,DZ3=M+!(5%4!
M@G0V%1:2Q3:^TWT49Z?^O47<(%MUZU)_'L^_3.?A8DX&?++,)?($LG4U/E@[
ME1$UD?8K;7W@V;<)Z3^/[>RHT;,Z&N1Z[G@,UFCEV[)U67SD4 GMBH4L1 !E
MO(40C0,94T%4NI#\3L'0>6XA9T?%8RJZ0<+I7?;35HRKJ#JG0[;H*$$2QEH^
M4$?M%011E(J"<T.Z;4+(K@B'RA=KS*\F"CF53+&M2WK][3;JBBE+[6, %[0$
M1=LZ^.@X6,N]1ZEC2&U<O [@CG7MU88470_9/94SI)-6 5[?!W>!V/0VK /(
MXUR']:[@K@0Z4#M'(E(6RJ+U$1R7!#5YA%CSMTOTZ)A%'U*;NMNC$>B9*[)3
MX,\N2FG F]\QS/'S]"*_N?PRFWY=I:;<M"$6PB<D2TY$;L@-H:,_YNBAA*P\
MIJ1\HPK$)T"=D/F]KQ*G;330(,K]MI1QPML%WS1DE2:E4 *0\F2M$U)DX"L!
M5@MABF5&BS:TV CG_ AQN-1;Y()>S4BN5S.D!?\Z_J=^=4-26[S1WGO26*XF
M&L\04&L0QF>-EBPXW<:SWX[I_$C1D_P;!)*WKOSMXC/.EBVFKX'Z:%4.UH V
MGKQ(81)$Y.0OE!*9)0DD)8>U/]8AGA]OVFAG:X"ZQ_R-WZ;3_/?X@G#G-Y-%
MF'P:DS^X2G/X<'5Y&6;?IN6)O[-_SD=/#SXX3Z2% -9R2S07Z(KG+#FF:I?
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M\/9N&,^1*[WII$VOB(28Y[^27-[,YU=U!N3;4O&/LM6HN28BV^5L&_HC<NV
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MZ01\]+MZDY&*<,J)#,Q$$E,1M#UZP2 :U-99ETPCXW9GJ.=*K3XUM(%3!P>
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MM@[%C0QB[;&LO1'6B:BU;-,%XM2F_@S)A"=G!.VBD9<R7:7+FG[,".J4)'T
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MXH'GSX$#A?R8";X9$W[Y!V=I/+]E+'F@DO%:[*8X22(S#3%+<D$1N0@.F3W
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M #G$FCN2R.L36H-S3DO-1!&:#6EF;\!XK/J4 ?C2S=@^5&]-\C7N\-P44G1
MU+2&Y3&FXU2OM-+B$V0Y0 7#D(,,]6!YEA!3J@V*4$-()8&(4A;D7@6!+YH4
MS]2O'(\3NTB^[UF@OW\(-V9]IF/M;B"=,2X:2YMDK%-*50X$3Y0(ND2&MC#E
M.[7ZW_J XUK!^TA^VK?8>I[D\/$S_FL\7X39F\F<$%TM\ :3YIBBEV!3J.D
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MO$KMYF8+)!NB3<H8%X8\LLZ&%'W(N\>>>=L6N[K!5:KHX",'K[0&%1@#SU*
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M6H>XR)KZ7Y'J\#UYE]CUA_O>ZLJU=T)OB7N'(;N4>TT>E5QTE#NY,&=PRE!
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M2;-S53$475M>\/Y?P-[)(1LLWSLYHL#1:;E?_[C_DB6@^>M?_@=02P,$%
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M != !" 'T #> )@![  >@ #@/4 "( M0 J@#= "& !# $F '@ "@ $_ %T
M(!00!8@'I  R 3F 0D 9H!)0!V@&M -Z (. 7X IP )@%; %. "< JX!]T @
M$!&(#L0!$@$I@*^!C$!V("]0&"@!E >J G6 'X$60##0&>@)] 6& F. *<#O
MP$)@!; !V [L!XX!YX!KP#W@.? .!A8&#087A@R&#H85AA?F XP<C#J, 8P%
MC .,.XP?3 1,$DP63 E,+4P[S"#,%,PJS ',%2P %A46'Y8*EAF6%U8,5@E6
M%]8<%@+K#1L"FP";!5L&VPC;"SL!NPI["'L+AP"' T<)QPPG "<-IP$'@G.
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MT-O$N\.'QL?/9^NSU.>"+RA?;+X,?WWW->;KI:^6;Z,?F=]GOPU_*?_B (P
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M61;:\7]E5<F*MHOYYA\\Z=F K_?Y\EWIZRK#AAPG2Y5ICYB.,P5EIHK5ZI*
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M$"ZF*^9%7',O(%5?F8,SOD>XAC"^^\#IT[IJU_+($U<1W-<](0C?)TM]!%^
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M(]*%#0GD1\:'VK)D[6]N\!^6R:K$>'EP584NL^OUR'17V[Z?7=K["29/Z#Q
MY[ J7>?0@.EBD>\4LM*;JY+<M#U97<P5D-$=TH]%JXC]0@IFI[![ZP05=9D6
MJIVF8&LX,"0/G4[\%KR9=E/^=5(552L_ACS?.*!68A[-6_PQ"LPP'SW+2%(<
MRE%6=".QKB"HD#.3T&"<+*=NC2OUH"D:\7"J4+>Y0E%:6'N]K,$GZRQ_%/A%
MF!5T%A&HZ>G&.-IK0Z+>'?HD]99-:<A/#Z)]RW:W3V)ONB,75Y+7.4#-()T"
MPXI*P1-8X[U@"=C1/K 3^)K<W?=FOJ_#3<<_]%M(*WG5:'PEI:'DU5[?SV>
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MVJ_/J /X3>!K3L?VR@*_/7XM-6#-[9\R0['7(=,\;^1 L&S3E/*@=W=6B20
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MML'<I'*GM'#VP!&<6R_V8(=24MDP_GBU)VZ)S9Q.#FG>T_N.!%8TD$5R+('
ME/[?#?13+&;=2DFC<*_  M'CN;'>I>?M)>'LEM4$4C3>])$RO ]+_1X@Q6%9
MAQ:-+-B;TD0<T4VR^@T7T"'ADR/Z;@F%=-[U$5K?1JO4;&71)W3E:D+=Y^3H
MV4<6D.KZ2TE7?]]GRC][2P]EU#;?";+#\^C?2DL^<D>9%EE8D7]R<]'^$HE?
ML_@B<>+J#?CCI)$53NF;ZR$)*;YBLHPK7S-COJZ7:O9NI"M[ADF&1;?4H;L-
M(F::__6I[QI@GG_8^C6E!7%&1P;N5Y?D_SV\OF-=KBH!.1W6V^-___IXY(;:
M&0&1IJZ/5CO<-X6CM?C'OU8&R6Q86[&AIDX$6KI2Y[/-5+FVLB#O9_=0+]C9
MI-]=N QBB[\<SGK-OMHI.02N*^IS,'*I6[C'HB%C&H\$AO S4_DA?C17*?(P
M\HM*"-1[Q8"+"W<38$)12(UBOA85B)6[-RR-BM$DDK4?5;;0MQ3:/Q!NE,X0
M[HTP7^JE\H/?C@U;?=OA0LR;4M1^IN4WV*[2^U[V[AU70L5C2UP6%K=RD%1T
M0S$9Z^NLG$B6R(LD?B)"%FPS2PXQ4,P^38\Q%5E3FZ921-T@M5&0MHKE&=<-
M]#/'IF6<8['FU@#^AJC6[?.(S>/G3X%;-C1=BU12M=4>HWNJ"JQAN&H93JO5
MR6T_!!T;]=,R,T_;0EDY033MAQ (Y$'\O\Q?"4B;N+CXWZ/1D#:1A$Y.&?1F
MSU]01HB+\T..AP#7K[RZ[4>Q=WR#S-J1MD7!?>2U:A:;TQ>*%*$*/QLM!D\$
MZ0&KY689G/U4=P!8%[$G4[C .T=Q>#MZ<C$XM+:L(=P^#4ABD0FS3XI2T0.1
M,I;ZMK5IR.])-$?K3;NJ/E\SQ7_$9%K1>'+FA^:J.FL3I0V2![#TP=VB:G58
M[(Y\?(^2.RML/BN=5'Y,2/PRL$13@01R<0B66J0XC<[;PA85#IY_7.,\M6MW
MIY;4$\"4&\\<2[X8:?*XA8 P?XS_%)4SXER-CIOP_>*R?\<T^+^)/9H.L,7U
M _? ,=V;QU'ZQ3I&!T(7UXAE2&K0@[6/Y&S_5X+=?\^56UBN6.M1.T76%+2(
M\3KTJTP@\_L?=O^ A.;4_*58\MY8THUU_QLKCNSS"?]W.QH0,96C9.KRF/]\
M3MEJ'?L]_?N/;559VB9^&]#TX XMU^E4#S,[R>FE[J:.4[SP45HI]_D>BA_<
M,Q%S)CNSQ0VFY7SW?H%GH=>./DD1$+/Z#PYJF?),U#*-SR6)W4K(*DYQ1/'Y
MTXS0S)[,G)STM7\.E;2/=EYJ%@)J7Z7I*57]X9(#P RO<N2#'LVC\J,U/X:U
M@GNK'G4E?>6UZI1_"W"OT_H.^UR ;;5$(*K!JERB0 >@:N#1#T>*>Q91.,"K
M+7G3*%83:'K6D_A>/;1=A<,#='4[_J@?_3?JWC(H[N?;$X8(@4 @@>"6X GN
M#@D:/$!P"S:X#<$M"0[#X(-#<(? X)H@,P.#!->! #/HX.[[^]^]NWMOU;[8
M>NK9K;KOOEW576WGG/[V.9_^',8,IU216N.EK0D_ZD6A7./%GK&_0&_ ]@5-
M7Y+[V"I05^7U5$+15GZ"=WCA:4 QJYKV#ZG_>T_^'["W_\=L2D\QMZ<6SS-&
MH?.Z!Q@]C4?_CF7Y3ZF-*J0J>WUT;WD7/,YD>2\&,MY]T/D_Z(V0*L#"NV(B
M2S0?>+6@/3!%SG? GSX;9;SNQB])]K%?ES)D,QF!TAW$KNC_T'(T9PZ#J _S
M*3UF">.'/5 "V/3@/!A1L%'\%14KV$K6+B@HV7Y01KDTO##BLKL8O=*WD-!
M 89,,ZN]8[_,8^9#KJ!/^1^ZP_R,F/ W,UI]?2M.S?EC3$3F/[3WUS[/[YTW
MW8OD@@+%RW_7F!ED(/?-Q,Z]_F2FI"UEU30WR^P0UFQ74D2R-F=QKQF',!H)
M'T2&9,W+M*?GS#,WN):B7*Q3I^?KEZMLCH"2\N8"LCI]:X7,IU)*(LQ 7_OQ
MAQX@LZOUA.)&<?KH=<$KXX?OO?A,.DC@8_*F64M+9^(FVX$%)/M'GFY_:E@;
MC=FG3=WFB9U"#\T%W-X44:Z@O4/8P0*NM$M](8;2Y=U[P]AO-Q->929(_<,O
M$>D<M>OSA@,K \8\%O3A=JZ/YX<*SEP)VYO+9B#L@ #^9& RCW\:J5/*%I4
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MM"9$#,_$H09%8#,):X#,AP%/[ 2]^%-J;-Q&R.W_5%KM(@7:&_2VIZ)*ZZ3
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MPM_LS!CISC$W[E7.H=08?#0-_<H-Q:Q'_K*G1-+F%--VCS@3\@N)K)*)%B>
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MA_BK38%H#*_+AGA!PC3?U\GZW,('KTX)$W+_DS.2)#>?#5O.>KP(KUV1D\S
MX?JC18Y)+PH<U<.3(E*;O1M/M,V IXJIQ>Y@F>@^Q:E6*UOM5JQYPC)G6*2Z
MJ"X1T.5*N?N8_UN_@UEHL"D;S0-3(8R5_\P*5K\A6F871C6\-\+J*?2Z.D-#
MT\<;*Y61,?^%C;K=QR,;@7P1/@!BZR0%U+?I@#S^,@T!0Z(R!DW."=4OBQBR
MYBI8=?N.B $5H:HX0#0<>Z#,?6785&4R7L.PH/C['C49"W'".X?2%6D>?!J
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M\-;P]N.6W0@AN2#XU#M2+XM<]6Y&-P:4NHC*UG=O1TNH-&LY\66Y0OPGP"D
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M";C-]L1ZGP%S^/O0 -'TUX%'BVI4TT,;.,8BV#V68,T])E3"4IQ#/TAE2BC
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M#YFCKIVW<$'Q3C.USI+GWIC,]+?_)ZV.5M;B QY[<:]9YQZM.>\(\X,6?FO
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MM0IBV"0F<$D'T1N?:<6V3W-&IG^)*AR%L:VE)"K,K*.>3P+'JTU,+3<8J$K
MWQ=?6?NF_*7(&R,C=XU47(U$/NM("<,[QAL: B@PPH2.;(T.+95ZI@0KNT?Z
MB@1(F G@I[4\P5,HK&5 I4.?&LRT,IJ]P0' 4+HKWCQWM6Z_,9D4Z6_&C^BO
M%)VT9<C?3P<'Z#AYCN?/#+,;N-55>854CQW;L(3A>%ID1H]HF?XT6N&2(PQZ
M*(B.[&7&5K@!)K8:F3T_T,!_O1<C?L;RM\MS[?X'0QNU=__0]@=#W[S72N;Q
M"@OUZ*VSF/[Y/0P".4[M^F@0;W/76"+>QE,U2CO RN(48D_#+!5Y'MK'\#[,
ME,?#6XR;5'1Q.;K86,S@T32&W&^[%K<V6,+1*0"%_ :-*/1W.O@:49ZM1;!0
M$ND_JC&868#]8!.=Q.]0L$M]YG-WW:^]P%VV&320\C.P7)19W/DMB3QCTP#I
MEYX7HV= V>MYU'!.Z#^(O/B C:/.17,I#Z,N)4-#&Z7B3Z>U(OX_GLDF:$75
MO9DQ\Q$KGFN>[4[X9E9=O#MM))5,/3Z&'&N.A#.,Z_<;I&<>+)Z,C!MA#_>T
MK5N/8"X['XT@LQ=UUXY)3AK,W70F/?G^MJ@\7O]&7.XO[24>L_;L 7R3$EW:
MNL&ILP-]*BHJPND1#*$2OGH3([UP<NT4%54^A0&9&'A>&V1_?E:"[QY +-(W
MBM0>F>$I[77+Y6ZWLR?T2PG=.I9R.0/X7[8M,N#M)T*AAW9--,8!1Q^&Y3UH
MB/K9_ @!;:WT2MT<@1DW:4O[B=GV?([D7R[4(7@&>:?XD8U%S6>5C5,+JB%O
M!N4)7R(R;DY.>C3_8#QHWU')FF64[=% #AZA5V:_]Z+KK">[V[FMY\O?G_5%
MW*30A]G:=]776=V!GA307CY? 9+Q+N4-VXNZG"?UA.:#75+/(C,/HGY>"51J
MF-+G^!1FMKM(+QP5- M0=[?+XC:9FI=]#"F?;/CXNVC0BK5$\XKW-]$OR]JS
MM\Y]6&LKO51A<&$(_M[!P>:U?$DN+=:$A,D,6$?:[]7($-]H,"--)-Q'$+OC
M7<<,.^@.^:+6E_G0D..)DZ!8T_H=O\0CJ=8AX-%JWZUJ-,&?^BQ32/ )+820
M;XKU#>.CJ\)<QGYMFY3EP>6O;-[U\7)W$(5-KS[VX075=*GU;&M6:6LYUU)L
M\7LS-'N!A4)UEE/1>#**)CFO:E0WRVO>GS]+[Y9;6UNC<U!'$QQAJN;3 :=H
M0!W=)<3-1S8&6CI?)!MJOC])K+"$I\/B;@Q9K(T9*R?U*S"4Z"4IUWULL8(W
MN5B;&,W5Z0D3$BX,CJ]B9A;VK!-T]WANL>F6-A"8589$SSPE<.4C*]9TK>E]
M_7V8DP?"OJH)9SWK<;:Y3-:! Q6@]J @40XJB;/KCC"V;?3Q=:4"/7I+XKR&
MZA1]:/"Y[? /QOMG#XO<;NN(:_%6Z^DB7G5-H;7%BJ>)9=V3?*/3=;W4>:2)
M;KU]XZZ(_A0Q@&[_0(O#J!T;W<+4S1?J=@MAL$S&XZZ9#P_BG$/?#-Z0N&;N
M*"J]XB>Q<!$8HIP0]+/IL=)P]!O=V:M;67R&CM"-%%%T\[7'YK+:C\U%YY*@
MV;<RFLOZ&W>'HW6]V[_=RMN,/;,UM7(;7$8[\FT(+S&\'PM*;L"/2$*BNH,Y
M.[L],SIS<.5" >6>25M#@3.;::(-W7.#1=T5D.-*PW[ 5$#^B6*@J)V/Z;J*
M?,8B%$5^F[NQ9#/,EQ!$=^\_U#0+4+0FJONTQ"@=.-:A)M91%LM^=LOP!X-L
M8EY#194#>AJBM!%"V13WT-YT)KL"M9L4=5,3R)RD@OD\G,FQNU4.:74'SN*V
MB0;!Z#MF)S!VZ;A2A[ILF6=SRR]/Y:?4I962&O1/U[N.EMSV98&@S?E@$SZ6
M^]1TV2G;TUCR3=OU]1*7T((-[7R;/EV'8?-B>U262TT.MQ:RB,!407Q0(",@
M5F>51B2J]&"P 2G!O&' 3J8AG*&I:: V5#O+;U2X8>[ &J]RM&*Z.%4D($/Y
M$7"?V8J\7Y%;J1@0VS]I.\3]<;Y0QF5)6%1C3'MD,E[=J41GXN31(7"H[$+9
M-%N)/S!L#8IH%0Q7$Z[IP]20E,Z&QQZIK%HL+LG3?7B(.J&V5DIWS>$XJ=@J
M_T74I[4E%$R=@ WWW]H]GP'DP>ARZER7-TQ)\JI)W9,8BOHX,='-SCU&)FKS
MN!S2^Q,GP^=( W;V0&^H@58PV%_ZY"[<QMWB<S!M(Y9YVEC487OO7JV(<[-Y
ML>W,9F+2J_J-.T/N">7T&]E.0YW())%5_=JE^BWTL+]80D)$T#9[IN5-U3?!
MJS='H(IW92 O^P\0DA.ASKP/JEJ*S" 0:-@VEXFGMQLH_=*<S#A\P4DT-5M\
MNQ$_N"BFS")&IL!1V/'M*_TB5>S2J0H\EXE7LU48WU[WX&\2]3U].MP-$"A
MG#W:H95:-7IO[]J6H2Y'PQEGN[%P!:X[?9V=%N?,')'X>8\14W)"A;4'<YD.
M >H"NJOMFON9N=GR[:6'W(:HP ,=[+#Z!.$@8ESQI@1!7%@-H)%W_;?FR(HV
M:F4TY66>>6Z=H$.T3UFU)C^+O(3[#VOZ&$<+\( V._D9D:0A3RH "'L" )P,
M+A[]8&@+=0F0UW]_J<[4(W$ MJF@<1^ZKL$<I4D0RS%+/,2XE!W'!Y.#/BSI
M,+@1$/@L<D67SI(?CHN\W+:Q2#7>M3;_@]$;\$+C3E&(4^E:3DKB4;#+R*3
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M1QPV4-EV I-=KJ:HV\%>R;@3IJ._*'X!GF1[ ?P",]<(W$"ISQCD]&G:5IN
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M\&375%[S\.@LE]^>,E-_-;46(&F()MF#"-8JIK1P'V;*/6J@-,<%4*>3W1H
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M$N]OH[._XS>UFF_'L2$;/E$WR &5Y0\V@NKCS:,#BUA/RJY*=#M@5FS2C2=
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MDU(=[N[H*M8T=$E$U)+U52ML+4Y4.UHWE00X50_(-$B/R F1M),X??$HT #
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M\J- YA'K]S%US$NJLSHOJ'UI')3'DVA2S?>L,/]A'K/5';[?7SY3;@)=S$C
M:3@DM+&^NF&VNML9EBA2.^.@T^1.FE;J[9QPABBX+)#%X;HA1-D/\(X9" QV
M,SQR!/O-Y[N\N%@^"7.!0A\@"/DBGDM3<G=OX9$23UQOH1@=GD>690/*8VH6
M=FT.[@A"S&P-P>4"U*-LF_]7RA[]J_B5H\, [MPU;X#3K+M-<63KBQ\VVFHV
M./)Y2&ZIU') #_V -^2!Z;;XE@),1,@G07^VVT2P<S *UMEI/4Q!]J]:N%^5
MSV5^1HM:X,]O82*)$XF?' M%_92?.*(:#XI:C'S#/Y.W99#;J$=-5W*680"@
MIN 23VJ.:.X6C$K03,NW7;,^LZF0^6$.\+L3DLRA37%Z_D\FALYOHLN/?GT1
M8P?W.RV'.U1?+%V5I =),=\>2C]KS#R1Y")I=(-!;&I)S!^9A4\=E[V%61TA
M#RY/;46"SKQTL]"?)Z[;O;?MO-LS+BK(.@I+K0QH'<8*D=.K->0GJRVM+?^+
MJ6'_CP@R^WE9I-'F,JUOYJ5;]2\1!<RG_[8VY:H]JB?)&@(7+F#'ON5)GO^I
MS-'CH_]:H_3Y[9&KV.K^Z1,F46D;2E;N.?^"+_^39O(?$>1DIN1YW_QVNK<Z
MORV.1]:?)/[70/5?'U;;_;$HNCJ]VAWJ(8WEUR:8XV@;6HP]QEOW+3S]XJG-
MZIE(\+-\R* ,,!Y=L%2WR:<A4*^S&>"W,-*V_P=#J[T,12,Q.CHZO'_0_7=\
M[Q:%^LNI;<W6A+7E([JO<]8W%KEHE;](;CI^W  >X\7,6_ YR4)<G9Y9=&VP
M"+RN6J=3.(]^IY>7D_;]9=&_O]7Q_E]&_A"Z,IT/_HKH>:"I5+7C;Y<L!ZNP
M1,I:'2I),T."O7P>,.&<6:WI2GY .8\"(>&JGUA?BF?8/?7*\V[(L^K+2/>,
M\R$^,%O=B&FP9P%KA1;<L$^7\STK^)5;]QN\C^;[JQ*C'U$8$=R^M;[^VDO4
MO%<54]\(.B:U.+"@9.0K>"/&(N3U^.3=83<. P1"PL<?\7'[AH&RZM,L0A+_
MNWL"H>B_H,$ZW$=E5T&C_CD3N:'L93;_J*@:'ZUZWN'8/W?7L<9LI;;QKV#Q
M8XGX?QE7:_]H;&F&_&W,XDS\306AW5V/@\K(KW=0UR;!=9H8/*L&"D7,L[%L
M10EBUFM6Y0K&W4ATW>_>1EQW?F@I3H:2!XJ"S9S1^47^+T.YFQBQ#UX]TFLY
MST1=Y!<JY_MYP:F HEA,P< =G_Z)0NK=R3V87^LMJ"KXJKJB@7M"BU[XA$_G
M1BQWO?< 8GC7D9M,76A_)]9#.S2FLODV1.9"Z TB2B#B@H/_8#KKZ^>!;O.*
M'^84S]M*BLK!>/&XK0)F&3@4+<P1<HO!&\N6MY<PXL?'FK,W!F05I2_D%!-Z
M%6Y\!3$6^8:/101.=-8)K:_[0R-LE5HB%B70'*_K4Z%8M^8N<VA5216M*?+A
M(@[:9#MRSM#8G#Y9:!)T*4>'.*!=#-)F4)%?0\.KE,7PQN/)N@K]U:.D(7F9
M\ZN*)>$9;C;--"Z+4RU(_SH'\35<M]B&+H>%^5=H3Y1/Z&<:Z85,:U&&4*^8
M6,#R-SO>XFPA'3O86L-EPE:1:WMA2\Q./45=S@0'#:2Y)X- Z: L\^1D?WU=
MA6:C)F(91DF_5].VT;!T;GZY/>YV'WIDA>+RW+T(U?I1Z#9Y_G'5,S7T8U(1
M-_-GRDLK/]'T,'1^!"LO-N?F/D^?T_Z0;-E"A%>7#6.,30$IZT98G]PZV>^7
MY.!PW+L8P/Z>D=+5:[*G=[RTMKDH,?'6A\O TJT'JT5?V7E*3X&ICW5B#:,K
M''VK:S$4^8-F8=(/'[^C;)Q7;ZBS,E$ES**6:FFT3\:QB7S?:G%M%6PI-*+5
M,IKW]K:KB]A=%2]+Z^\LY0S!!V2:&=7J?>NIUL+^@\X/$?U(Y@=@+<>ZR0&)
M\26X8Q8<>VQW" V+Y2#V5DX?KY55.5+%/QO[Q#L3DC3A#4X+,4\C3J7O[!Q/
MFG# ]AH=<U+4B52UI_+W*SB@],/,#OQX]OYM%J@\6O&(W"#),A WRV^6+@ZU
MA%-(D,B*'2X"G'U;96MEJK\3^W B<2--&5!7K,-7*:XJP-\1+[3MYUJX^UQ<
M!EFFD7I5V@$8>7C.MY!>;2S+=,;WB2Q&)_EKIJF4%':H+G+^1<W,PF&T,[;^
MCJ&3^@!FOPF \";'+<W[F-^=7X0J2 W>H?/Q+-E-#&^%GA Z6&?<RGE[4A$]
M]]M ^J=OU[PU^W[LBB _TQGJ0APOR^XPJ+RER<"P18%4AB\H=91767Q1*[\.
MY HM[\R.RIFQ4\W0QYRQ*#KKQ0*+DH/!5/Q\&"?FM8:1<7T">ZMRLD4,*>YN
MV9($C3_L\#GB19CK)YO]P4EA$;S%F=_,@_K'U[=TMZ+,FPTS/T=,RW-J98 H
MS%+DHI0O7[NTC'E"+13LLPR;'$V*3_1#*5CCV@P+Y2KJG)3[(_75G6D*/YVR
M[D^G4+Y,BXJ7(\)(5+UC." I-7>;+IVFEDBN/<M'JAB:MP/8M*#HRR0S(='K
MJET)/[U?*JG9(Q#F*QU/6X#MU,8I^CKYZ);75;$^(*0]TP<:O;+)@@T[VP8(
MW5?'7UV+-1(LTR-5QJA;&R-M1EEY7B>,FCPB?"%LH4$=U4=E0;:QFK\V.NOZ
MYB&@#X#6I<HJ8"60W=4@G-=H<J<4CXV?IY;1Y1!I[B_RE(Y,/>X9/3S"-_PE
M"P-*9Z9L<\1!O,ULAK^4;L;@@A 6,%Q[QV#J'Q._C\>1#-TZ#&^"6[G6K*$[
MQ6EEZA,I$BL#;[SSOZ^.&N/B<E 6G(02N$J+RV[V#[@;N;C3/5LF:_2:MO";
MB-C;M!BR$TMA3G^R=5Q,[#+2[L_;X/'C#P:7T@:KV]&X4"]7XL&@AUD'I,'?
MP1N5W\'@Y"GY/G;V?&LA:O*[#-1QV%N42Z1#XE0V+:*5;ZUS,&V1-^E7")Q6
M<BF+GN,I5MN>YLGW(^WB0;.CR<%53RX1YL)O<?WSE=#D@5K!.8L4NQD[14YB
MB<MR%09&R*J#J-^M83LIB9+_R?5"&"&H^6KM#T9Z[G6@OTMK56@&\_7@RTCW
M"?J[+VXJJIW7D9Z$0N+XFX>J8X##LMRZ_AHN*J,"3G],X380;U039&TR=Q/]
M1:BKO,P#O*=M92%CMXF.H8@6+/C6Z$C;N\2$B#H7]HCJ5Q%P G@*S5V#)+1*
M%5K<6+.URZ;RDN/;.GA;[F>?'BK"&K$[[)>:'Q:)LSG#_7(X(@,0.F2P/QCB
M-P'2T\TMB3I.EC38.4).7AM_,$Q25Y:1P[DC]T>GT(;9:;Z>T9/(K!26K'>4
M2S*=XQB-L_2_#/8>YO-H!@+P[0W9UO!?BS5'4CD<<"A-N7.M-Y".0P1D:.-E
ME,FTK[F*!JW>LTRH)61#NQ#V60S87FI=>J\#7W9EA?7JQ<;&6ZPG9#'A3*Q0
M2+CNL [.M>.+KC$69!B\@JX]Q)H&=*W^P?#J;,ZXOLK 5*^T^S8YKM_*WUW@
M@UU$WB>P@P7;=L+^ZV]H<).37^I/;>;K4A4WHZR"V5\+UA:[,>,1 ?&*O[D^
MTW,/W/[GO/3_YR)VJ);X$=9P6^76+!.RJ=>94%/OKD6_*+M[EMG)>R5"KD"\
M9%U%:;AGN/+C?NGO!7/D'PS^^Q\;Z*LI;8/4LU.;KQ#G&<A*>KO,7]=OM.CG
M->W$$^Q&Q3TDNG\P7I\?2 #_8/C2XYZ<!M[ "5[L(\6XJF,! @H+#XC ^'%@
M;K-/<\64[HWVD=*=M$K=#.,9!&:3S[!#$RCE-(PQMC&EA#RM!G$=&>'/FZC?
MY.0^-S543*XCN6O-_O6IU7MY^1QP@"?=+SX>?)?N[HO:ZJ8XR:4\[L>55DS5
MG0$"W0Q!F]6J47?W"MMWVY,[@\V!?)/-TO4JSV*@$'X<?Z/?$KSV+>7^!X%1
M]AJ!\5/4V;_W=&PJ5=UU=O3*9J82QP?5(]D@27J8O>VFGRH7^Z6M8IX=^30A
MU2F*(LPBZC,?K9!I>-P;*0/<U=>M1G?O#G7$4[(7-P>V>$EK=7#"T7>"&XV<
MU20N-^3V[U=F0@3(OT8(=DJW+#@[U_N,2S[AU>L(6)#6;R4DB11@9"$WK39N
M-7<;$:F]>.LJ]90S2.G-Z.%PX2T\U /KX!!G9F 7&NG\=KV"**DY;*BO (XC
MKH'/B>=$4[%.(RU@C";^-(QGN^B:0/@P?G;V5I2@Q'*]581&GZ._M*E/X)XF
M[$";_V64T6152=LW9;6$F"/T[D*64_<LOV'XSKP5M!^7QJZIKSWY?4D?;^*R
M7?D>C19;_6$OT[A'9+K;N2W?$WH6!@2/-U\\\34N1B-@7;6;#P0X6A\9>_[.
M%_3;_(AT1X3,LC<G=-)=L*,[HZH^(W$,!SN,SX*'\>?ZD8S$K^,Q#K5"<=U6
M$)Z^!"[7I>GA\+QCQ7'5ZG>&S"E3*OG2"SH!'9:I.T]15BO:+S4,2)=EK,E*
MMA?X(F>)GJ6/UJX#N<_+;OMH)C12184!(/J#\^&F8NZ^"LM%G3[>%C=E_S*-
M;45#EOW;6(WH^<HQ^J7#C/7K0)S%B<3KOJ9N9\771Z1&J8@\@7RG-@.ZA&]G
MWJ6FQU9^?275QKW"EZN7&7[:3^<- \2+3')TA-H"]@F XM7RC([L24UKIJ2$
M$$+2OT\(Y!3R=[F-ORMN6-WG5>K/OH3L@L!GM55#]4=UE9EV;/=SD@4<L5TD
M?4#CL._"D/C(8/UBTHCM2L?#61+JRXO$6XW4 _EF<6U"0K/A,"E# ]T]/X'L
M_K&4,2O@E8.5V6Y-((O3<WYZ)VI4A"\VE;]T]W=L4<A!)XXX7OO/H$(F\MXA
M=5L9H/)@X]_D]0ZIV(J"O$Q'QI2#QEIYGX8;1K?DM60<ZF_@<X%N97DQL+3:
MD!.I-LC%7O,), /"  GP.2,+Y#?\E45E0A;5K"^S1X3 ^S1Q'-U!O76[T<S"
M[YSQ(FWXU;#D,7-<],FA*R(5WUTP . V>([HLW@Z_W8#BXQ=U&'S] \&[A5U
MM9TA/!OW<;C#W2)Z+S-VWZ)7X?)RMWG%D%;5GZ69RI4V8EX@JZ PKI8S9@_9
M;V<?F!U=-G%U.J0<4&I_^%.T6:#< 2-4UYY3F?.+C+KTYW*P9?V35<X[$2\[
M&M%?F% 7BGWII];B5EOFIQ]L.]H>]#)[1?'+Q^-_?AG&5+?;$86@.G3P/#TN
MB.R.7R2^5(:QF4;)]RGY/>%4Q>39D;-(4 19>3LHTRF+3 RXZ^:HGPE!DA8+
M4C0">1,D&5C.6& F=2V?DW6>?8M2D,=C"--K*4B0#(B+X7$R'!Z<DWHB%XX.
MTEL.-K\R01W)=&W ^5&EABT=0M>Z@W<6L0;HZHB6A:^W3=5RV"8GMVI(MW*E
M_($OOFP_W,><L^$&W'U-,HH3LI:'2T>'@ T#W_DSG<VS-6229N6B(,\T>?9R
M40YIXZ>(LCLPCCR)3(X:ANUF<F^X9X]@JR?S999<<.; _\7=6T"UU75KH]1+
MH:4X*5:<XI#BUE*D>('B5BQX\ 2G+5H<@@=IT>(2($!P"TYQ @1W=X?>]SO?
M>^[]WG.^<\[]Q_GECILQ,L;:&<G*VFON/?><SWK6,W63FYK6;@,S4 !L6"-E
MZ"],U#V:J#;EA<36NA[Y Y63_M1TA<F00KT^599WD@%$(_FX\L-\F%+ >98
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MU549:/V4BPLD3+&7 R&R$A48@;>>:XC;O) 54&)<Q4ND3:,#5W]3LMGRQI5
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MZ_9Z+$NW^0&Z70'&G[@BAUUYA,)!!.0&;$N.QVQFK%KA.F9?TR@8BO5>$H)
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M&5U*C]+NX3*0O,B<$T8H+(1?;1[=RI4'M3);#_$XQ?'I'8T=%PBYX(%%]1@
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M+CSV(C:B2GSSYONQ0^"=S:X3D 09H8T("J#-Q(!S==ZG]408$0WOSJZ-J6%
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M$L$?LY=8+BL/D1CI\ JAB= 3C,A!%JSKJC5)@5?^MI)5GO^HO %5;>)C2*N
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MQ_C$OCX/%P'"*K] #''&<RN0E2,>Z$SA(PZC!C9U2\^5S(SBU+Z%+QF&2Y\
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M*C^RNJ>=\4=)R1WPZ-=#\3[JMFS_W7<X].*(!!O.P1LM*ZXP**.V[+3 -?"
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M@V/])46D>Y.X2H,[AYZ.EZ]9<K7JWJ1UR%YBR&[AI3"8G%*THW(+9&DNRIW
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ME3I27:9UN9V'WP, N'KB[R*UDGM 3WK?Z/33]IMRE]A9N+?L"KXI>L'CER7
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M-)-K-[@E<^8V-Q=JWY.-F-_MC,BZO\1\U+_&Y_Z+ZC#4^$=F1[5D!5CGMOH
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MB3]J*SV?)#Y3<+R5-2$H47G''9Z0M<@(\3^ZD9LE94SH%,H3MHSI%5H->:K
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MO4KP6JN(WU2WA:TUAVNQO=A /%G1SYU& U0N6E>D]DTZ74XRVK4XUK!FR\]
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M)^Y1$S.Q(-#*5I#:EADXWO,:15Z_>^:[W"K3X%5%5G;2D_V (5J0[(,@E^;
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MD_8@@7HX*,Z[L%5B;?:<P@[PZJQP?'$@%T1^+K4>S! XV-/1J]3A3N+'B7G
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MCH7@:'R/@>!7."M4&EL#@CB"Y':?I;CE'S!:L)"%I) 2/B<EY'GR!!OZEUJ
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M$L8B^>)14?O.WE\+K)3P;F9FZJ(^![LY#?^Z+I).@$'IOJ2X%&=VQ;/B!\1
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MH=\"=194+Z1WS<TI5E*IG_S%=NJ5=)_9T,:2#,:+ $8CVL;*ZNE:I+U48$]
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M:L?/]");(Z\>;BDG]5R0^V57655(TB5/ZV&0\<Z3G">H2=13 ZB[AX[6MCU
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M-4UM^\,?M'I^GD;\65S$Z&Z@<#3"#0$ P#3Q>5>T9/VNOH"GEA%B6M\+ 4(
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M$,I.=ZL#)(FC3U,CCRQZ5>P63\P$Q=2=;1[/3[I65X..6=:1MU'EZP,J7C
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MS_>\\]34-V)J9.S1R\8C?C[5&$LZME6\N0G]>566KN]VVIYT\RL+/H]P_H@
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MJ69/5$WX;9,:6_>FKW2+&; C<2M:H 35/]+F'TP]>F\(NS-Z&'KPQC7W!T3
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MTV1]@G](CS\<$%EA +7*[#IL-'DM(YO+5FN^7RB*O=H-OAA YE4MANY]NU)
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M?DW*_]Z^L2&+T-S9&9(EA/"NH8+L:NU%V/]]X=8!5M\*)RZ3M#<:0\*/9BM
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M(X78#;+-M*'3H/+K7?1CCKR^)ZMG/D>= 89>9[?S1[>>@=I*43#TH,$XM@'
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M53Q,/?F.NVM@+98]\Z:7BW5(2NG,K.4H$"R5%%W@)1C=M&XPFD=C7]_A/G%
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M+^)9150W0_@&_?VZFXS9X7#Z(5-1NE[ O(Z:@^R"26UAE?OW_%&?ES;%I7Q
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M:/S:W_8^WNM,Q>-R61RO]E':O?'=O5&5+!1=UT .I>?8@&WE<7?VSS["?!E
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M!KQ^D%]O%!D(@R=.3#RMYBHBV280C:CC(AE@* 0,6'7/(<='T9-5RBX6$?G
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MV8MR\T]D8S[:FO7FLJY<= F$5%$[P/'D2:;B[=)-<6N@G%+&R>3PW6JK$E,
MAB[1V?!3#<<]$TA!9T;%G+>M41Z?S^7@?EG)+)Y96WI!G"[QT72X5IFV#]26
MJ/]Y]:O^<,<U&YSJS5EVK9-;*FV'M6[?N$5,!S(QVFBPZ6;!>D;%EJ7-IU9<
M9VE!.)K*)/WKF(.&/7O]+.7!WK/&,GDCOUF/!0G=*XEVL<;BY-QTA@FO(-ZR
MPS?+:?M-U[=>XZCC(MY;&\\@KPF3Y"^(%;Z+-MLM?=YI-*\=WU 3>4$\CR!1
M8IJ#WQ0U9\ZW1]?ZO[_ILVWL&R^['=SOGS&#1CN>F#ZC*6VH7MG"TX_I$ZE9
MX8DUUFD]M9OZO<)Z@?1Y&/*F,(G?>S5.\\6WAY\+]7?YEKD(Z-"7\GIHO(M4
MS^XL[K)!*3M"G7ZP@,H"QE94;H_>L7CH:K\$YYU>N:=M&T1G!VG4^KJ.;?K0
M:$%LMUD-.X%RG#BQJ%/VOHVCENXHDU==7/1<FASDOP-LZ<8ASPBG?N=10S6)
M\&^8@E13<HSYG)D](,3')U(JH@T*H_/@'Z8RK6):9Z2[-!Y"!$I_U3.ADA?%
MUU[/MUV?!^.E@7A$EG+51;W 32#,2640J;<GJJY\+*][QO75[$T9FNIV;?AD
MX=E6X\DEUXQ9Q2O0XC%7\AV@XIQB2L T/PF5.R$1>4+Y/\A[RZ@XNFY;F#@$
M"P[!@D-P=P@0(+AK(PG2N$/CD 2"T[A;<&VLL4:#TVAP&F@(#HV[DYOGG/<=
MXWWN=^XX9YPK?[Y=56/LJA\ENVKO6GNNM>8<,^W7FID;*)=*(PO '/D$T>_X
MUL*'-2;^KI'^%2%)[F,;JL*RI*)X*N!GAA!A>BQM]B>&'[W?--)A!BH_ME^N
MZE?ZC9;_&XVH?:=,6+N;CMAY(*]GD:/(Q((^P<5745PP*F^-88E'18&QP3 [
M@*ZK9CIQ)<;"4)5$08]^7L6Q>/"F*'VAV:8R5"NM2E/:>/\[Z(ED^<GQ+_<"
M\\P1%<+3_J@*1H'UK]5>"7!"M@F*)2QES6$\#-+WSSAQT!PIZ^,/-I:V&;VH
M'3WH*X='3V2E/2-#'?W [Z*7AQ[&)&FO!L;Z^G-2 F0)$8/%&PL.'F-)!XDP
M2_H+![[L!8%T.35<E>8YUK=%0V^6!CVZM(("<:P9F_T$N2)D3()#[]K+ULES
MBP^L%V=D5&U335]D]L()#;",3T@==817(GK8Z8U@@I$FUE8O'/7S8E5R0BUG
M-.W8]-IJB22[GP06_D:S27:C>NL2M3JU0E]()K\4E<_0:DG<J,KNH2*>CHJQ
M=W90L]()+X:JXJMY(/D;/5 Q'315<M)&COXN8=1Y<"VGWVC*G _?$+ZXN2>
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MQR&/+>T]3$0W *!?!A:SOO_8&G;O^\Z;T/WUM;#!RLO9+<]?K\4<W]G.)\N
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M."/#TG6T&;]%DL.!60MW@TG'+7FQKGO?0' &4>GM0&1$DWY,$E/K,=Q\-B+
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ME^?*/!=OXGW84,036P=Y3][X <L3K:0*L.9^1?3M\X,M\2$H921^0DO+K>N
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M?\KM8H<7"_]5]4@0FU6*OK[5^<2QA+US'-@:-3PAQ:<94ZN\^Q&_/-#?<5B
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M@6Q2'S<N?X6HX#O+FO8W>@.S)+]RNAK)O8C-=[8S<0J'=EK[6/5L !-KO*D
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MUE7]$'X'^P1?<X'E.CY;U/<>(%%30K^=,T# O#-T*LZ</%@4\CRH:(:V/(X
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M=,GX/4!/4_;1/2!=W.$>\'OO"+UP#R"XU;\HDD';:,9?I-T#GNRN[J_>M<-
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ME&[KE6)5V/K&'&(^1HA!7ZA]8S3WJUN%/-4&)P'VCB5M:D9GX-NM76Z-^9$
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M#II@RWS>F_0>070WFG0WGMNZJZKTI.2OBJPFNX+Y<(U1Y66_-!!+/E%<D?+
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M8$V$%DJ4PA9!0\9OC(S"P]^%/19[L.YA9$WS566XDGTE9-+6*Y?ZHL47)*#
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M/&'T?Z.'G%^1YZ^:^I@LIA9!30DQO^7K V-)S'7#<C?+<.&$6DE-T8XTGC"
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M7%D7U/!*:-;S6%'H="#]^4N#_]@>MR[XQRK#.V5KPZ5%W<S6MB.F_F!F+ H
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MD<C]\-?9Z!O B[T(\0?9E_TYCV%79#*9W!-YW+U6&/8L1XMY$3V87G#)I6%
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M'+UPOXXP"?FGZ'()(.1 '==QSFAU X #EYE=@L?7;P 5O+4Y8XJ+;;)7 3>
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M+RL+%);YY.['-?T^0/CF/,[E J4(*<2VI@I>*>Q4"5:5P[GNSND4*O7@_6\
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M!*R1*%ZEYPJOSJ$:/@R%'C -*SK&70ZHVM2?6/?GQ<+I8I%)DKBXWC+]_Y8
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ME)=BKEIWI-)SZ&)@)SZOF-Z]>Z0=2@R%PZ.@ET]81C63W)MO#Q,,=.:\<BJ
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M/>&NI#RL?L(34)6D1<Q9-6&%IQ']<552'-"GU=U.AGMJ\#CE/;:J]CQG@&L
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M']6@+_<\Y_>?,MA@7_]J;*KMF)JDSI+3!W5]&3DT&2,@I@P3SO!=BQI_.];
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MR'0*5(:(K/FR;]28=W[%EBUGZ73A:)Y=?FQ28MVCYF,?,:/FPY)4UY2ZKRJ
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MPE9C I@U-FQX8HQI^;XJJ7LYKA= CP8G7*C@0*5R(Z))#/>)EYN%?VHQJ$)
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M/- V;R0^GLK*T]?*5:/82J\@7+-*;MOY<\8I?OH7:Z. &>S%,D[-/\J.HX4
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MECU08*T$.6[ VLZ96]9=G_QN2Y)TI:O_H<OU(?#$W/>3JC*^.854+I_,06:
M9=*JAX?WT?J9!GS%ESMDG)*A<Z]#X'5*U-OR:I-R<0O"R]TXYX_Y%M[E$\%1
MA?/S5-0)11E-R=>L5U]UG*66?R=F^'\H#OE_:I9V@S#!UT]!"XHCG8Z%D3/
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M'U_S67#Q"^=OL@/K4?MP&!7L.0D=\W;TD>M#VZB /VO]^MMG?::O?YX/O&H
M,U/[)#QS79>=9#=D1_-JM$S^5\*KBP?H]O$Z<GHQ2JL,@,_YG#Y]R60!T"DO
M"#W\,/"A%(ONVEZ9MCK4OP&!>9:NEE<2FRP83K_[ZM:VARL=(&D(]<C/Z@O;
M1LD)0!'=3K(IX,&.?IN'RT?'80*'2P.RW+$]NPQJ.7$$1<W6<Z\[U7+TU"P!
MWS]7F-;M8C21W#.=4^0ULS<&IH&B FHH4@JHE0FJ4:#X>60_IP-B*87;3Z?0
M9C/SJ[8OD=858Z?T"%Z,(4ZZQ"?YN;RJ"& ;.G0GT2[]\>;MT<* C>%G:H^
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M/VO])@2BQ5&CU'VE_GZ^0*G.C, VD2H<:GN.];WO!7:H)+[IFAB.?X1W9'O
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MT!#2W'(K4(V+&]-7O21]*/-ZL0V4/0V.7KI%&O4 :E+R5+H2I-Z?IY%B<=D
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M3/3K^^?A:]5R_W(*PV0)Z#-Z&0S\GS'2IFEB=U-',71'B?,9 @BI7,%N6GK
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M*D26PEG==>K8&N$/?"*W'=9JHS4T7I]15V[P4\V2BY"5QUZ9_;CSP+BIB*]
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M8!])V;>RE(8GDC@2?!U!P8U\3[U&7B5ML9X)(UCPYJ.M#W>%-(1S$TH<-\_
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M<J1%P8&LHKR5D'[!WBC77%96UA3Q(KEF60.*G9'E%>R<,LDMBG_#(^])?!<
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M/B.,=4QBTYIDA\H,::(Z:PG,55=E6GEQZXC:2#[?#-VJ'9WIU6Y%M:,WLH=
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M*1"5P/4 $)A]H<-;^YJ.ZM/FE$X2#=B<+ZW7<MY,P705.=E#MX6F.@UIX#;
M2Q3=(UTB&0UL'C9;#Y3 C@4ZCO<Z KW581V?8#IAZSZ.%TULAQYH56-*$V.
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MO2RV0D8*V^/K]'L1N8NE1,HN;I<LYF5B>_8\,;!NL]^S!?!OI>6&2@% [K?
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M,]S4>B$(EY34B&KR"<@RN1#-@>3<9(I45F[_G C!O?(?:*3S<59L\\>*Z=B
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M!Y(\P2B>G!R<0K??F3IHP1167-1Z\E':B7N@3Q&T]&@9UF=6H(:?9@VUL1Z
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M@ 6JYW"/8]53]V I?.[HDY$1>,=0+N1?YE:W\D>)PZ1-DC [&54DN)WF?;=
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MEEUJ/28N'-H,0$!#" *#3IC%,>Y;[O>1K=;Y+7J#JDGQ:E;R^O+U*$R8!6<
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M/JV*35:<=3-V-U98CJ S>=FQ0<V*'+/Y,6=:"ZVZQ_M'7%JWFN%%)MMJ<)"
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M3XVQO#+P]&!MS5F(O^/DVGW]R2[:!4B5UR>K7KJ#\+.O,[]^!;/.J:8K*.X
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MYP A',C9WZ-<6(P)RW8QZ?**=%=O:9F5Z&==F?2SM_56K2^IQ0!GR"GZWP,
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M>#,_+*N188?I07CO(M!"M?BC3F/SJ*ZZL?Q*_B-\^N9.R$&=B-#*F,T9=3X
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M4*,X(T3H56B^,5!!CB>7PJG15N]_(MRJ5"4P<_9[0QIOLQ!BLG-KS5R5=F2
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M [,E<6L>7OFQDBMEK36N)'S*S+V6FZ9J(NT]W]3)CC6KVL9WLZ)-Z]CY426
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M[2?"&Z1 %T+H*]6!IU_$:3D[[4C'%8G8N]YQ8#TC'>^G8>9 K^JC1(NH0A>
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M7G<X]PF@<\@ -8W]CXP[I<_VC;D2U_# M.,*CQ5^G>AFSOR,:>1&+%R<T81
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MQ$Z-UR9_/+?<_6,A=P<KG[,UHUGY2J3TYASJD"$SBI3=_#^WGE:&723$?>O
M\B*$ +R7D&M:<$-"I \=,%LV7DKE2\P0H@GG8RN+X\! P#FD&0:JHV2AHMJ-
M[D*LT5.ID<])V8_?_'2,3_Z\/401V[MH^3DJV:R^"(+O5:] K=@5/C-K,(,:
M)(;D$.NQBH;K=C6!/1ISZ[U:=:$]I%]6N8BL6E #WADHH^E<@;**EGY4XLE3
M!E?V>"U*1)H+/'*J6.F@%'SRA[D9%U\\%Q_FT"E1B]2ZG]N*0%Y(-4>?4!K:
MZ'2Q 5?F9 I%-$VY 95 _I=+"\N5R*%Y6$I6HL;#O8L3.X"40XI:_T;%L>U&
M:-6M<B'DC'I-H/&-WV'%[ NK0^V!RE[A>1LBV8H/K-TJRJKKX6/<B$?X=L/P
MS=,0/]Q<[DP2NH)3-E^XZYLZ%B%MMK4CC34_QF*-J(9T4<]$SS7'4E74N*'"
M[^6D<2&];,LQ,D"*2L6(^:'5@#R@IWF)L\D;W"%=JORS&1: MSI#-&<,<W$_
M=CI\L(?EJU,VRXEC*8T@3+YJ>KX2?E@UGW3(CA_4SBNO 2_#L3C'?M^C<U;>
M7ROO,;G:]-/?^%"U?X1Y^6!9-2(IY.P!-+:+LC_@[[!;D)\G?]*$W)P/);C(
M+DZLS:TB^ >'KH>M (8;&Z3FO(B#"*ECL?N/,0*8R*JA=<OVM>?%:K!N\[^M
M8^KQ.8+.T8O?>"KR%%9R<]5ASC,=PCX**U6[<UP^TQ#KL#ZS&:1](6UR4\LZ
M\:C#:,6$%MZ'0PSUWA4B532L '$VAE:K<U[-F<^5K<]&*L=/IGDP,'W1[!-[
M:><@D,>,X?]AN/-59#"A5.![CA-\@R&#-FAPF'Z8; HT& :#S?VM)M0Y@!4)
M%G^!VD.)^:67%@V-1=1(8474Y!<O%-^#LOUACX+L*(SQFO[167M=;G)7,W/M
MT5PX#:(#>]/E9Y%+?>-1_)R\QFO-G>-_$JUDP[[2(O_J<8EKF7./PQ-G1;(=
M(QL3O6,;=V6U+3LQ"?6M9HF4,:\T?#MZ$:'\(WP.S[<W +RN71XESLR2)E=8
MMGE>KCT?H]UT)C6E[RW2>X;/_8R$CQX#Q$WN+CNP2LKM?#P)\#+D9=&G$L90
MF[!RA%$FI"L6!W_KG38EW%?)%_E $]:+805B.VET;Y5J5E#:VVYZCE@RB:1B
MZ:*Z_#JM\B:6+X*G@-Q'(!44IMA$Y$1HPZG@RPW3)FIBJ,H'9LDU5DF#PZMU
M8E1V%"O[E3@^CT]YZ7*P/MD4%H@Z14LMS>R4(N2Z!AWA.YTF)P?G^)F6:_13
M\NDAV1TR8J=C>3)(&M-<"HV=3':@-IA8O\B.?7PT8(3R'=LP Y%_']%GU+#8
M1EY5DV/7<O0(N7G=+P<C*^J5K_R7X2E9930<RW#9M)$A:-K"<+4"&>&[6?$0
MSB]UH"]M>C#8)1 /M ,$'MN3U?DY;YSPH:M\( _WBE<9?\Z_E9\U^.&Y@/OJ
MC^:9GA!W=XO5$'>&\\8CM!.>(^?Z*^Z'T&90+N/%9ME\F TZZ>'(AVZL'K:A
M$>%[%':OT;O;;WR/8;!S=$, P!%Q-??A;V;@'2W[)74A$H;6)';C+BK6S-][
ME*7@9P8SKL<CRE)I<3&DEX<]I)?7,-0&+E"CKZUO8.@43^*>W7!J1 B(I:6B
M_8/S9F&0*&U3MX4];3LA1DJ\JW]\(V>(_<^6A'*S4I)7R2=3WR;FLKX&61!N
M;]TRIQ3'Q$&5.R4O;U4T'X;',7E<3@Y^A!'GKMTQ8 ]83X='HB@98XH[C-!S
M!)(<W;32#DW<M*8=W=DWYSPN!UA?Z9'LE\TN,%B_21;*:E,8DQ;0Q)U\NV=$
MST&$3N-*,W[AONTH@E9&0&7"%!H[0&J_I&X_G;HO4 36QI(M/!90E"IP'O>X
M%-RP/XW,U+F99V$!E>O%::\9H1(N1XUT!% ],7JR@H*Z$G$1)X:_EA%<;[&6
MD5+/L)PVLNX.LG#P;@1S.2-[*681/M]A2,TZXB2\;%?AK'[K#/6,RIVZ='SR
M1EBSLX$ YW(O5:D.RAE2OY;E99'48$V)%(D;4\3>[(GW^7&U7H+SR.<LFYHS
M8+C,M,XJ5FR9]K,Q@(!BKBNT)ZIOA]?RT@/Y]:*)I8J_BUPO#&C)R^EN=RYK
MNV^.>+A:C89IMR,/68UX;W.SIFZW<W,=(TNJMB;^Y%:"8)5K (V F*>R J_2
M@U-N@?D3T6V7<$P>-MC':RZ^KDM9;=]"GAPW)G1)IPTY:<-!4+IR L_$(&L:
M7.::&-JAC@WH%>=QPIG(.3/OU2[\]Z]=_GMI#-GEZ:+*09!P=\J027E'>9U)
M7=Q'DXCI3,YP#X80:<;U$,NP[$2F1P&BU"^ !""#'4H>ZRL)LO[$1CX;"3C6
MXZCD,X"N68,3$N]BZ)N;4'><9W7N,*$2"^OJ4\2VO#0[Z?O(9*8-;QXFLBMX
MZ8KN><65LDNUKY_8;B2/PEWBQ,QE9<I'_3;3:.MCOJ]?",C4D5-? KH CG4C
MJA,J6OX=6M T%7=O9;>-8D1^ Z^KAMZ>!7>T'GV_W1XX%=R#_Z.M&HJMBJA\
MJ!:CMFS869Z1_11;R,VYHOTQ2X)E]@/V+[BHO,*_5XH[+7SX#_*_/VFBI9>F
MH9+PM^M,N_-]VQ^S!O^PXT%MO[KWM\;A/$16O6=45Z"T3!DV:[;#-@&T+YWE
MH>ATU85>>3FDO=N\22;J (E>?%57R;WGR]AD2_?JW7^7KS+_OQVZBL"YU@L9
M/4V,H6FC2TS.^D3'4*<O1X(,_R,$0__)R1F&P.ZZ626AGR8#2Y_&J46(A7$9
ME\?-X*%4P6=;LQ...VH^X-Z(Z2&Z)"4;85@8YI-]ZKWC4;(\4"M[S=48=9F:
M7S^QC8IZ) 93+@^KY5 EK,D["XM9TNQ@C?&=!)HR&6LJ%PYW)[=.',#E[!5<
M:?@Z,'ZNM!<J*T'W(;<R=$"<Q4-?,\ SC&D'$ZLBSC*OT%H$"S'.9'!&/IH(
M8,#$7Z'RF1QXZNWA[HUTL$02L87/8PGA:Q0(@I==>/2L=X0XOB0R1"PK"B41
M#GOA-W@0_5B1<S?%#;G5?1/Q$#4WUU=-_ 5&D#\]=@^U"92]\P@._J-B!,#'
M35A_2SB&[1SDG+G@0")^MH.,-'-&JQF;\1RA"BF#U_%6C/.8]^I#P=@//+W,
MW9^H<EV<.76QO%KSW[)X^CB:$P_]'*<1IQ6[\P"Y=O,+>R;\&$25V8U&WHU7
MEW5I]BR%BBB[<*L_3S8=NPZ;=M8H&C.A&)SQT308U$:X0,F,5<IE4[]KQV0O
MP8RC";,A/18."AC@LYR :D!*/D_9C#EV)P:75&2:KM42'^YA7OA>>HC"^-1#
M!LNKDPM8K.CGW< #[-(4')*X,^46DJJ]%0D#?8:6-#<O74H&<N$S7TPTRT=I
MB3;\9)(S)9-<#DXR]D$O4#E0PY+C>=V6SR44S?PV;B4"6O=O-I-Z9J_PU^]1
MOFF)N'BV3CCPZ;S9+"<M':<UIKR5P.6].^2JNO)(SRCQ!I@BX3W@QL8;"OM?
M@3PMX&:7Q5!R0>I4M^_2@1;MC-YMW7(JNVEVJM!-8VIVJM[UQ$VL&$(J-;J.
M."97,,SO:\YRC_?T9'>>NK;I:U_),M@MS&8C6TW2WK%"A>NGZ[<=1;.M((;A
M?UP;2CX?B]-H&L)A;98R/G*:?>;IH@F+(Y-CS_6H-!C(3^0+['8 IS:FJ16\
ML/@HN.0\V\[U4IKV[C'2,/BTCU0JJJ.9T&[ >6+^.?2G1H!V1M,,1>BJ DA7
M8X/S@=B7P0UG2C]I(M(6Z8NL)/*?<V N@J2D-)&DI'HG#R8) O:7'-+[^QZK
M*.ZK\P,1?((?LZZ_\7J#0DX@URQ6[Q!2V?13WKFQ475A;X@-Z?(/5=.<H>P)
M4^^-9*%/4YIT3FP[&5WH/,W)0U_7@S9/\J^E[*LU#[P8EDI3QD !.K=O]39[
M=W75<[=?G [I>_HS?NF&8O)C"K-Y$&OK+I-(_U3$ HZB(O1K>=+P[;53;339
M9E+7YQ+SXKH:DUA(!BSF!]1P1ZPG/[_+S80>R7*/X<K2!MGOW37<F<5*I?]1
M:VJ^-R-9.VUA;W]M<)&Y]1[EP_@Y\!S;(=_*V\V9<%!R]J%]M/*0]Y<2#LWO
M/4,83_%:$CKEM*X;6H @RVX=C=?& >*.63POO\CB?"(3BO>FW47N3_/[-,[9
MOHK<RQY4)!$1K5L]F+E'>4E3FS$\[TO58WS8YLM3S)E&&LFJDP-B&WKLR0L_
MUW"WM"(? *A'S\WS<:Q730$%N\&3B=]"2$,*)Q+3-L_6"4TCC7K>?\[N6MHZ
MD)+'TZAV&;#8GJL';KD[GNLA1<QO:8[Y:K7>7ZA182FG-EO%13\]-2BO?X\5
M\+%;DN8!L:,\3PK'C'7F<X97NUR0UY7IQWW<D?])+<>_;&+HH]UYT=SFN4DW
M3^MDD93POA8$Y4TU@%5-5YJ+>6[X3'(S)XA((5KV$H8VK.UD!=_J24$/2#2H
MB"1G!7*?Q_M$;/E/?;E4\IVX1\D7\K\^A!M>O"LMW;I'<3>QIS#W*9^<978Z
M2N5B31RQ&7B;^?6*@2F]?S60C!?]:21AJ6+&N)?)H+O.\-OVE^_'*]']WZ=I
M>V(NAWNH_"\J7>+BH@8)53;6\<KX.;6B[;4L&)W*2@M^&(C5ZMK1L^)3EEWE
MX27W(MH1Y'_X\KT96M.2\.-DBS(@KCH!9.1[=F3%U!')JP:7%5M 'YT^1WW"
M6N]*UORR.I9:0,&EETHM9-IZ&$^(O3&,8FAR Q>UX+B:(;MU]MS> )H$^C%5
M_%T_AZ_?[DPUI*C$$=7UHE/A6:)=PX7[$VP<WG0O_24">F#H?.=/@5LJGT.O
M5M2,,6U>($.W=3JOLM+:6^TKO=1$BU)F-A:#@7CIE:ZU_9&XA? 6-C\ETR.(
M>?;7[_)T<A;;J9GB)02O^W]QM;'IBA=2-(Y[<!P  %!;_Y.88;D1,^OG1M@]
MRMZ[QW>A;DCG6BF;!83O\&S&9W C%60Z_7*7/3G]L1567]3G83E7FUXS)-61
MI)+R2&M?W18)&?0V)M>%!G%8\S%+2(F0*F9QW\ER'1_]TI.<+&LH*XL;+8OG
M0M[BC;V2*-I5C@GK[3E(]Y.E.R8(4(XC+I19LR(=DVA:&<;\(HEV_;C//'WM
MR\T%D-,7_9,#O87^^/?KO&O.[2K33EOA*75Z9_K=T3K=J#Z @(CB;*+,$*Q%
MF3U^80N+^ZU70F17+T>=UY0+$;/,\F2/";-R?*]V?+07\V@V681:$N;>ZDMI
MQ. >8G!XYT,->MTN)&3M*UW^F;+&:I'RB+2\5I>AE J%R\V)&^F$,VXM]@!@
M=3XC&.ZY0][<Y,5L[WJ66G)RLH>!Y9^W-WSZIJZ!OV@8.?+\0"7@2<9<TO*5
M8+U?47WX0\,>LU8)98WYMY=8!_."PL]J69RM2FO*37D^?H(^,:TM/'V,:?=V
MC.NTR^09/W/'@HSA:ST^WBJ$$+P4U@E>EO$6M5LG<GOCCYDZ_F%$N' RCI^?
M@*<JQ;F2G!!S-5KV]?;53+BJ(JE+ADFZCOKKWG\U^5X';F.[X]HLC,^V.IS>
M3>B,3KB1$RB;<2>6D.DF]JU0]1HO]7YDS3,KY 5@I)IFD;C0%&0GFY<3R>-+
M8V>Y3CQ9:+A'2<!$ F]=8'ZM/HHWHKH"7U!+@$??,TKN4<J\V<_W"UN7K^H(
MLL_G93(0A1"="(S2$B,'^^>0R1JNV?"%]%K[.S9,\V>.)M4+]*5SU1P@EF"Y
M4;W>?M7W00%G)B?BJA*D;..]_QP] LA_\8-MVVD;K.IQ+7TB;P43GK.H2=3D
MMK53\Y($3/F5(Y[PZ!_=6LVA'< C#JQ>M(P"DP@R6E7]'C6F88ZHSQ_2CM)O
M"W_UX8UZOEK7>O#%ME82K3JFW^4L_U8 @;X8O7*/TB%E'"/36>>G?Z8Y"8@J
MY5-F_^:2,B05U+8]SWA%PY UT!79T^5.YZ<JZZLOELO=WFYRT^D?GE\H8Y[Y
M+$G:$S4GDGQ\ZS<;,E?]\MM7P^-7J^Y\AKI+50!I?D6;^E]#J&7<0U/"\TK/
MWP0B7#H(=%KVJGY+#7^C]RQI&8-#RAKJ-$A/Q1TPZ%#IAD/<[?>::';D:K/J
M'L7W*NW"/^M_-?YA3R_?#T_Y30LE79]/+$(?@U/^K^^DO'->&Q:H:ML*'"J;
MO35D>VTGF^VZYA%94B>O-M^5D8R )15E%'-O*7,KO0@\E5=]8++F];'>\_$?
MP1V';/O1N>X>A?50S<]9"7O.67;<A/&W%V[JVY :98&(GJ$8.Y[,CB8>^G:K
M9D6S/:]NC:?$ H7MZ(&DY;M8-"AD2GY,([-9)YL5%+Z B'N4I_@#KJ(V%8C%
MK010\AA)Q#<>>S5-A-[,$'-I=5E.;Z>$ALUE^9 $>D9V?/TK1EL[<[FCN;AF
M[0?5+K.E3P>7.+6"GN22?=[ZYQG .+MOC< BL-+_/ 70)$OEO]D093(_B=:E
M/0XFU2AIAV',V&@J06P23;]S?V(#T+H5S53,S$T3/U'2Q%>5"\.RHOBZB52^
M<IG!;B7KND<)^OQO$"H\\FL,_W[B4A0N[.:EJS#6Z#8[Z:-U;B47NA\E\&XK
MO>[/0\"J \7L8<W:\!YS"I'<ZJ;3O:5^ST,>'QV2V*'/I3%,=!A47*1EU)3/
MR!N/&ELAY591H?60*W2:W$.=D.[B,=@,<N<:9@LB*C+:D[48E %B!$[PZ4!_
MB+]YLAK.Y\X0IP5+*S)602VE^;>9ZI-U=^-.</>"W6#S>^MLII9YQ,8T^.*B
M,MW'D)<D_%;(9'6$8C"A?C738[W^W+G&\,?#XR ]4:E;!/5(3V.BA0.[^Q61
M[]^BWL VACOMWJ(-EEJ-P%#-,'**NBRBS=I60X/5*75BIG"S,K5WA4U#T&/)
M%500K64:0\8X?$9;8&N!1?A.2')RY29?Q-IO/+/-YV*/_896EW4452IS>U':
MH?IYUUG@7,;4%'$6D'V[F<:=RY1)3=':SL9;@-N3C"\9*K;SRCG-*?@[1U3Q
MP<ML4Z;WTHV*E$2]J)BU>?\BT?!P6\=Y&;/O>*+.\WS#/G>H$W&>-(=DB)XL
M=V J.6FI[M]A$19.+$C4"K?-2[ 3R7&3451834B#V?J4JX5D*O;;N@C9A.KD
MZ/FJ94%$MD>,A/\</M;$?Y$PE3^$K\_TJ(,^(E9KTR1*':QN$O/&G&T$.-U=
M(4U1-R];N;WN4=2M&Q2E%W3Q GL5EU:/$RBKSSC4O>QEC*BMOA$BY.E_ YBE
MN9@:'1<MX[UMI&8 U%H!7YHFX(Q"(*8XOD<W7)1QD*'0F>G;EW3,T*3GVI\O
M0.N3A@#3*QJ?K--V@SZDO=I[VPW[T2$CIM%4'_5LZ<%FR<&W?GQ.>S_S5W'?
MG3A>-KEIF6X5QH0$6ZY&LGJ$8>G<YC2_$IXBQI=7VX8;Q,T+*BB9&PQ'C5PE
MFFAY]9K8$/NI376F\PYJ*>F<.&OK_*SDXKGT8" 47MCK;2RO,6?<PY^U*24B
MY2)%=WF__;&95#."8C1(NZI(RX9,A$FSF=&S%GMC\+I!,]3^8Q;<?_01D1ST
MEL;D@=^7$*WY>Y0FZ%[S%+V?"_@.7#I[_6FF' C15J3/G6UN'!XR34P=5I.V
MVDU<6[_*6(#/'%4-K^WM(9D!C:W"YUII:7M2B"]?$C;J8?NVYE^S"@==URWU
M%W-#YQ]VPQV'UGO(%6Y<-OS':YH$N+SGTTYO$A>G]UXBW':Q@)<+9[NE/SR:
M1 )R3GU)&QH6:DL\V-E[Q_C=*BZ=Z]E(ZC&JA(554O.!S171*E0<G.,)&TO!
MGU-@>9[H<"6X4^?QQK#_^'=ZU0H162U__1;Q1%Z_?0&NDIP9@VZ2Y@89'&3W
MC$TI\.7&:)<W>MZ1VC+\*ME+7HCEC=&JKV&H%2?U79_CR,^/]L)SPUT 0$[X
MPW$2S5H/HN(WW/A.7GS*X[44$I4/(;U.JU:]LBG03" ]" A<-YM]J$U@SBZ9
M79U94ZFQL&0P1B*;/QA4\I'FXZET*>.[MRE%5C>4-:\%WMZY,:^=LC(QM[X(
ME@^8Q[9;:">/RK<8BH;$3' MV>U9U']K<[3V\>8RLQZM_L5R':]4Z2,4WV=$
M\_>3@$WWUE\?4D[UBI%%X X8O13]\WF[!]34U'\\:$?]"U;#:N,QN!P'ASJY
M'!?D3_[,Y<4R#[.D(OQJU7S.-9U/# IA13I _9W=U"0B915K?1L9'CWG5SO-
MWWK5NY!E.D%JKY8@C)"/434>.5%KR;DN;D'30EAW$T>=+(:\S5D]79&K.Y<5
M<,WM70)RCSNSTA'2XQ[6D<:$JG]^L@]U?/Y[M1!2^1M/=VJW(%;<A(Z(FE'E
MOK5X2+'!@+']SX(SBR<;_,759S2>.4_,*6,*0KA QC[V'VYQE*:<)%X:/K.M
M]U )^A4 9U,:&AZ'9@H;441[;$8;QK@S YTI>2+O/G!!LDY'S.]N3_D.445^
M1\D:%^J'6B/K$@#M>Q2],\/]134_'+S?L18#R/E?UXLV$ENB%?)A%#/.>BBD
M0&KDS4@)9+N?%%!;?5I3!L4>X%-[HV2@-+A'-\#[SJ[UNV?]F1Z&ED-(4"=V
MU9%$GFO-MPD+A3'T#RJS_?-CJR1?#6BB G.9'T5BGIH1^/(243_(;L3;<@?Y
MMJ=S[3:;UJ4%4@I:N/;0J,F:TO(:[X;UH.H(IDT+8_1R.@X+*2 !K@<E5##-
MQGS3&NEDM=FARK$&,2@*-HU2Q/S([,',#&VOM5YUTNES)9 IKS<19D9*W^>9
M')!VSF] G<?@RY[=VB*4R[>QL+6%)0OA'Q(QE=G.$.0^#?DV>3'8!N](5"CI
M5S]HP%!1/;42\B!^8!O1KX]V)$$1+S0\^A_8]^]9JF*,8ZTC_>F9P<+'[N4]
M\F^S\#(,JF\NQ#K$5USOK0<SM3@UP6_]J RTF8'<]*EY$ZF8^M]357I)EYDT
M<8H996ECX43_BM.B?__:-=6LT\6<L%2K!'\Q!=$8%!.RX<E_$.YU1A4K)_ ]
ME?H/D1=E[).@X*[YA(?>3EX4O])6NGKMF[*V'7UPIUV>CG3O2O5&PP1Q*T7B
MN 92ECNIPI4"^P>/)._)+:='"UKF@LSRD^+>DY*@*%6 !B_*CX<Z,NL"UVIW
MZ6</]WN<_):I#^Y"^:S=[U'._HY424_\NY]#=9D2YO239LGJAV=ZYH:VL,I_
M$C-SV."QIAQJ.#=HRIDX:F,0]NU]^&YO^W%J2Y&.R4XEWT*NBVA$M:GL?8CR
M#TJ>P[/A$U. R;[%CDW4Q$3#M)$,0PFXIDI,?F/:R2(".YS ^D+OE16))15>
M>4B7E$;8X,^.L[5PW2HHWFQ"(N<_HV=>C#-ZMGHY"-WS%^E;';:;\CF9PJ9"
M"^W>2J_)&VCVD4_&#BS9.,K"WB9CQ32-:1_X4A@=CM^R[D!_KE\T%%-,!:__
MS]84Q,D/6R6O0:=[9WOD#;.L,M4>/A@E+EG<7]_,E@N5<&A'6B@SJ4*B9%"G
M.BU9I42+9B;HXEN51'N;8@S6G(:>R!/A+O/]/JHP^S L=Z&49GS?F3F5NE1F
MY^J:!L0]"IJ?I#4+R(]BLL2=Z$?5I/EV<Q2X>[2Q6;"%5S<YK61P?2?)PG%%
M&MTN]#13)IHO&87.D> K36QN)*T3\$VT:OB+V$?U1K'?PR*U/Z^B^R;>CO[U
M'U)Q6^28R=8 A2)VRT#QDH;C,T/RA79;NX37J44;<B'/J,8;YI2M=0.=%VAP
M,UIQ%>5Q38@7GK,-O,H.HCLPH4D5D/H77&Q7[X3O6FT(L_+C[)D?Q0NNF.*-
M3B?#_!(]S]7+N%I!EQ'26A%UVS9)= ,D^5?PI[%44W37I;@-$F5C)]ZU(F=9
M+<1J):1PV&TMD9&._YF6XHH 98AX5-<P8Q^<I.++?UP*(W;/:>-(0\NA^&D2
M=5\Y"/O&82A0?AT9E/\<0W.UOC:?\Z@:4^V5-8QQF609AS1N=1WRTDB5\##K
MW3^G55F_Y]@1Y@V4U/GUM8V@YP.-5)_FYM1,CH@[)B-T0@TW#O9-%$"Z'];>
MZ?B]ST3*\6UVFVQ+*.-&)J[+U= 5OF.(*U5-V95Z_1L5QG+4S=T*/LL8LLY0
M2<LOJ2%DVCAE^S;T 4.GUM$$3&9;8[ A_00A@S^IC*-,JB%)1[B9*((C_T."
M/$Z/X)_I[R/"*Y%;V-4]2E7-R$XS:AU,D2)I:--=@KW4>F94FW1*[17^Z[LO
MH\2^S\Y8@*Y[J34"J+5YY?(L*C_C*J92"Q_7TPG\"'#Y<R1=RZV$4/TT[*9:
MQV;R2V"*\C\@&@^)S^GX7_/<##^[>YLVF\J?'T<\9#+H(/C]40^IOC3'.X6V
MJX7M*\J,DI40QI:7,.>#["=7+780+C=7#&S!CVTBI(=[ZQ=7Y?NZ@/_FY/1_
M5R>6/C@+4[:_YLI3V]8J(\.3137?H.2ZB]9+C]5='YESUO_1SGE&-8%E<5R*
M"C*AC,C0ZXC2I(2ZH8@CB,B048::@$(P$$J0!$/HC$ H RA%Z0F(!:0G$) (
MS! ( @&D2B $Z240I8X@X*JS'];9/?MQ]^PYO$__3_?<=]X[]_SN/??\<]Y+
M7G))41T(>G%_V0%GFQ4LVU#$U_UX(HX9&O<^&!Z,E&$T=;.__"L/T:9/@'&+
M^B=@!$;?#A_W@2\\<@J9F>=ZOY"*_?00E4V$+AR&=/!\I66R^<F!O$;^R^@1
MX%>)\^Z5>/F:L?'=^Q^6 Z:Y&?0$ ,SLJ[S!_X401_]8:XXG^#R?86?][&>A
MN!SXSH]M$H2Z16?*Z6Z3F2:G^S*P39'@(6XFFB0C++FZ_?;5[Q/LBWUEP4_]
MW_VPJS"8#0 _2R2,K9_LQ*=X+41OX_67V)HW]O37/#\>@>T#>M+:I.W8$VU,
M$S^;UHVK'9V_#CBM:P='\B[:DS*\$QM@<M=A&"3W^<C+G&\3^'97TB8<&6R8
MHM \K"X4!F8AI3=&Y&L(0QL9EV> ?:5;,LGD2$M^UUX^@OPK^P5JF:@(T'+@
MQ->S+]N/1S@K*:VKX#H7NQ]6:7:6TZCW)A'@GUUK*H@A+QP,UX:KC5;<VQW\
MQ/*&MA\U.A!O)W@\*, :<^$OU0[PWNJY9O:7VDJ<$):<QQCT2Z[J/=FB)0[E
MR,!J=&";K)J!,=QF4!W\S8\H%ZSQMIF:CVH:N.[VC71Z]<^&;_C+7R?.R2.4
MDXWT1^E?9?B&<I?\-[33U.K2OO,OU&7HJ7=8SM1&PW(.U+\P4#X0?W_T2952
M4)I0G11%^R1PI['LK5_51?0-/>I$YRH<;$;*H0@93]DF;^O9IH1=>VYEMGX,
M-<7J&$38)"Y.H9V6[[5/C10=55WC]?=M.^\SMJJV6(JI?!4/CS!*'H"4)L27
M%)**2<U%.;FFV&,$L(^WM@4@?5]4%Q7B= 2K"8E"X(0,J$1E]FI.%RB>G,NV
MY/U6% 4=DH1I7!&E\<JO2'QJI1",A-]""UO.;HD+4$0$3#EQ>PTD$FF'M ,R
MRP,%4DFDO=3H_N.RUVK,K$:C"_;I.K2W^_/G'!O;/EN)CT#JZH_7N/7YM&9N
MZ0^OLC"(73Q$XD>IIY4N!@;+.F%H6%>W" 68IEL^>X#DU!CH,>,9<DIJ?0$D
MUNAEE>^NBB]UO:*T6-UM/)[2L"2"-)SIQAMMG$<PKW>*US<Q6EP9+0/DCT?J
M;]7#R-4.9@5L9&B2\J_4<)N[KCF)W:5E37=Y/2.Q(4[B3.><R3AZT **X,FT
M*=83[*.X\Q9RI@.>/ -3L\"F#I(.F.U+G0Q&P[KGL?QON^V1SBNOO0+"C/O7
MF>'YM]%](\XSU2:,B2*#\X41 B1(7&Z9>[$A,7UIO &JTJYB6+L&1_^>3&/$
MAD(?J3[P,X91[]5#(R#QF'&2V+CW(']0ZN1B@;:N'_WDTKY&#+67"10R-3FA
M93,[K=YKB[3HJ.50.KDJJ,2LHIWFQER?/PRN.RZN$JDG;U])I8[FN2S/3#MX
M)4Y7 0!ZJ0B%Y720?RX]'Q5T21^XV$"6<P=?BB+IMS&>YA4]$G+UM?8[*E;-
ME!C_"5IJ6+T%CJ?F!R+HZI4VG!%OCQCY5B\!EJ%,,8)^\?@Z=RO]LT4D_<MA
M_KF9F $, 6HN_9.M#8#2NR]^[A6EKV6\J#$4;._7HP&J0+^[&6BO)_9D9)-D
MSVZ/I\%>ZIP*I 1D%XOVZ:D <&3K4:RG=.?0+$]XYGE?JZ^'1 [&FUA0E@&$
M"+?#5''<T &H-38],KXT'@#('LJ!E8?":>6Y:Y[-<@.24'>)>#/[9Z%E3#2V
M'-O#\TV !OX+7@7N.R>E;ZN=L?R.*W?>=-4IR5$AV;/&Q0H6PG?A@K"'/CJ0
M1UG6-9K0N<,MKU=H]QF7VK^Y&CZ&B=(\H?4%ER!EA4Z?<:E%>JU/ND66XUCS
M%V A0QYRGPG+_"#@*]@+X7JJ7^4Z.>AL<BF![I,<EQ=JO6VG%&L(#*&$J,8<
M+:=]!V89P>[<$N!1UI'G=\*IG#Z&..&4]J_]A1,/RVYBYB'%9A4#0^K%:O(2
M2;.ZY(>5B@P-M5)?RZCC\+-YI"T:[: JO5A)5$(Z:$356GU!NGIA75[O<><B
M"O/80QG@7ZTC *I^Z5(?J* D%BG>)3:6,W9&^5,QSH5_XL],1B/A_;\9R[&6
MHBQ]H[;5:FT9'!9Q6,HD[$=O2F-J[S5\]E#CR 'FM[E-M\>#MW%QT,J)&XM6
MYL% %\0^3,4>5X[.#%"OD-9Q2_QRE6O76X#][R:;^R,*B7F$^GKR-, HV!H!
ME;[J$W$EM_VF)$M,P-V[JP*@EOU+H1)1@S]TTED+E.G>K4.Y\/_6AO_/HD (
M_3.<3F9J=YA[91!NWGF C-K-N#4WK"MP>2Y@;A&GN]F<3^5SJKE'G;HIX%:7
M2 P0=DC73WBH*?$RP3+J'QV(7%M:8B+7K\(G#>]E://S&_!^K]D- H%(I'I!
MEFUA?;U7<04C+T+=K1<R@/*6\0WR5-&+G+0Q5!/S$Q:.2VX&W'$UR'F@@S'
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M[7]?GBJ$>(_ZK%*CGFQJ 9T(WOYI?;(1[]S9%&<V[Z2[W&WD:[Y;:.O/"*T
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M.BO0ZU^Z_%6L2H"/YHM6(Z+PYK#W=G?QO8GNR^=^#R6$=*HE-YKKJ\"&7QJ
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M=IVZ5V2/-,5BF&,$.IU?]P"-\ZQX[5,7*\?#=Y613=4NF/AM3[NM*7TJ-QG
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MDTU;XA!$84?3&%/IO)9(?4N174H(["@#Q?O/A#^5+>73/S[[- -YOU,XC7<
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M9.)@?G4U5/@+(LDB;@<R!\0_ 1,$T1$4@%/6!;T]>MR5N07\K)_LS-_UVM$
MH,L^(<$B'RC;S7U;+,G6,*'58[YO8? =YH=[)YJW9X'$Z*K@&AAPI4G5]YN-
M?/WGA2NQ3@(WM/NU ?P\F8!MFWZ/_6)]G:G KPO^!JS&&>*_\T1+LN@RRI;7
MR@;[[+OT.']UA=RA>H\0Z5,-\.\Y3CU339RJ$]B#23;-R!&KGWEC\KVWW):^
M2-'?F:5K&1XJ7KKJ[DEZ"UY(G.?9*VPCM @'0YL2)A\THU3"8C-2$/:?)-J3
MS_7[.ZZ8I:R8F3^7XJ@;0 4WV5BI::R53]J$F_K[<5JQ2S 8K\3NG G.D]!
M_@40)^AN!>Q(K@U1":3>F><SFUS@#JL5U$3-T+Q+PYO"0+<[=/=E)?S"DI]5
MF;IKB'D!7FB#\-!N"F"*OA-S">&413!7=.!N-CX^GI]YT@#H8<SF[0@+-\K8
MOISQWRI,G"'C%7%"3A09$9GN;.0V&=6 MI63XNUZ*=J-6E32F=)E2H76]IG\
MGDPTAFQH]!!O>1^[D^+@;%/.4 Z0*$JO]#U_PO'&_L:<4+J;Q>WW8Y_HHF^%
M-C<;.,>@%[+05;O;&OATP_$6SLWXM>MN=!7YC(6>=RWZZL2D;C>YMAD\YXW6
M]&AO@#+9POE>'U@2FZ9)&+Q+('3#!A04ZW.Z#7_J'K2#0G,'9*44*1??\(00
MK;#%:KRX 0.M--R??5>Q'2O%S#_N*O-O8GZSQ_0P1'":[UP#Z6C"5@6#IK)$
M16JV>F[C,IO2'K06WNYZ]3="6BC?*/&);CP-*S/'$56QL4[%U!" RZM:3EI1
M-U_?A*2LE'WA*#6?E+RVN@+5W=][9M7RVLW;@!'IGY*X#-9-@)FBGP"3&KG"
M.=DT?I]LKQN+O]BS<8'IIB\G=Q_F3(0^$9J_7D@(M&LVK.)L]B:-E_NFVEM7
M,3:97M(^EZON]KNZ/0NQX95R>YVNJ>#Z,50HSRA1G[YN<YY*B!N^,D6;?E0N
M*,+EK1O*"SQBMYLU=GY$__13Q[S4Z+?<JRG&SPNQ-AH&N!\(9CGFT^RZUY#H
M6AU6ZWHE* 5@;5DSO".]3)I^&50=,CT[*J_DTZ^-:4H\WU()N>)>/_,GQV@X
M6&Y%=L!WO]#PP]$9!1#FJJ= 9@_CL4T;.2T<,OPFUL!1KUA$F*0_*K;C*"C&
MY3V(-[Z4RRK&0&<;O6=<U%L<;\1W5>PQ2^?YN%C@A%S(564MD&QT6@P-ZUT&
MNM[*A-N%7#3TVCT7OU^]E?A B<7D^>AC;5>96'WEV"NR90_TW^"^/;%+M#2Q
MUE@1Y.<3=:H(*,^Y/RV29_?N\:?/$\KR7XQ,M6,]1+]4>#F)"#TPJNPMK&PM
M,'L<7^$AFK=@7-];H%SZ.$98*%)$^&)9?"SUHIQW,AP+)J)_ @HFAH=OL'0K
MR^][B*GDO&*)A5M:PC+28,::0T^OL,1ZB/6ZO%26GW09K:[-+8D48-*-S5AE
MF:YA$*T(*.1+XE0NMW5@N?5. S3(>E^!*I[5R/)9>)^"8O"IRYP*T%+?1#_.
MM.[U$G"G5MFRT+Q\Y^1M^>ED2F2;4M^TL6S2:(/RS#O?[">5E=10E3A<TLDU
M:QR7?N*Z.U);D1V[P\]=9.]NV3;6I'2\-4 K*WUB, ]<A$1TSUEJ/;:G109I
MVL3:QWN5E1^";EX-D+%(<ZUWJN-ME38:39M&1?59=R-OVFPFW10I:HRUO1/A
M7KAI81DSCW/^D^T;:L'.^ J.8EF?<E9AF<V2DW)Z,Z7N'<("7(487!JIAL])
M#2FZ]O#0Q>0[J1_(A>C[B0U'5FGH1B4V.B3.:7&<IN\7O1KSO\.^!S)EH!,3
MM#%X89H3H2/7CY%S^"RUH1NO*4XC="+]PFS@2=0[_1@QC59.-9$=V#V+=/L8
M)9P+$%=.UUO;8,'#07Y1N,O42 B<: ]>]"MWM&14J5Z5LPQ&*3>^EQ(]EVT:
MCO8MC$5%NWT;%)/S3$A8+TZ4U^2T0#3JEZ;E =\8M(ZKG& %16;/Q@5&$C98
MC#0,K[ 8W;\>6.^FT&$ZDU+:ZOH!$O<I!?1(*^\)27^MRCHY_CQZ+##7$:0B
M]6L<T0"HZ!<:2)*\_;G&2.,-1QBU[F4U _,*K5_.9<!-"H +Y?<[*Q"/Z7:Z
M%YWJWV1P4H(M\:-A_T0^.2K],%D<1J OKZ(3R6E@N!@ZP.+($O!^+-S/2 2*
MD[^,*Y[M6]$=F$%)6'[ZI/!C+C9I;<$[C+47LO2G2P>5?4!M"FHG@LJ5HU;/
MH]VR8NS8*^<..W"!24W5]J/*F09=-FV.H:JC"M$U3[K68$>[Y.M%%$#"O;U'
MY X%Q-F=S7TNHRI-OJ,S:K)R]90\E'F!((TOQ8'0T<&>"]1$;Q;J/%%EI5&V
MJ7#,Y)'#?N6S[L:SBQ[:?\2'8L^RW-M\[S!,9!2,F"<C#:K^R&$AQ#)77RHS
M>EI, 11L1AY""<JYIO41>@295]6_:_V8-TWZKKDGZ-QX)B;#^_L3SZ69H,#)
M*"*(T(7E9B)(A_1$.^X91-S!1_DG&F7 $IP-*]+L8+3#T.TK3<UEG2*J/W0N
M%5?,D!GY"+L+B!@$O@B,O;Z7$A9L34HE51\/;EE;SE/I1*;C7X6 3)/:@1D@
M=^6WF-CP)C_!(^<2*OT]TLI5TP!O\;33Z>Y45[64>S]RY]]P)RB2S1$$8=17
M!P=:)";L,FGXBQ+PD_ >\G=6./QVPR1ZH4B%L525.B*;8..ZQOBQK*.84G%F
M69V-$-@AC'PMZ-R0*$?0/V>P6N<3(WQ:@#)L]%78]+N@K ,G?B_PLTS//T\0
M=_V?Q17A#L%">U+I!62,.O>$%(B>.X2/Z2-;715&1Z6\QN.Z!L_OD5LUMXU^
M5BI=RL 5L@IN%>51 .4,WF6/^:R3-64M+<^V\;M_2?<H@-#/X*6A)DZJKC]
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M?*B&S7=B29R4DH4?OMDJ/=,=WXMK0_.MJ4"(K#CPK>>;:1KH")I.U<W1DKX
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M&Y?7:-#[!C-[+'Y]45,G]EH=0Q5-1PK'Y1Q7 4>UFI<,?%S5&:.KYN9^+13
M2L!7+I:JZ$9VL:-L,(SOF4@C1A/IGMF,4O])2IU>;,/@M<ME5]ME)"Q1=6_=
MI5TT?O0J=L\[><D0';QTJ.I.(SXV2H0BJ/H602\4JP-)F<3+Z.MP?AU/Q^^/
MO 6F-4MYKK[>,C>7%I"[>_&<(?H/Q]7;OUH7 %H_=,Z%R)TI6<P(K *?&C[Z
MC0L%X*QRD5 U+C_A-5-]''S:^HH"*&&X<2'F*ZZZRSA6)498T\FK5'ZN_(<#
MQS-'?S6)'R@[]J=J5='?RFM;TH+'XVP(O8*#T>B%SWZ3?-+FB:;U!.\K<ZO3
MB2[A>Z[\\9Q?XI(-E,3M+EU?CSR $FY?Z]E"XC#G7%3D']&SQ*,)8H5$5N''
MA*.%"8(['N<DI28C$-];ZES %N9.K&7X_#CZTK6.DDK;"[:1-'T)\Y^HIJ)&
M^JY&BR\]ANUIQ$4VN6*!UZ'/_=/T/I8?6=O._['@5ZC]S6NN90P1Z[AM=SMV
M?-VHE.[GVF_&C9NH\^JI[+27,,>Q).5BS6^*[.)K&"3TH![OOIU4-DN(.FXD
M9/OY223J"T>B!/ID7(OJC.^*#-J;F5WZ 8!L:A%9KP9((Q92YL43-.<$:BU5
MJP,3$0XZR%]9TU;&J#VF;>$]NK/NE?GC[O/.AJ2NYDYFVKN9B@WQ2</AC\0O
M7KN]\/XZ/!O1]@C\F@*(@%/!X;VG?]2C86+ P@#4,JU/5_OP7-)M&K>AJ=>G
MZ<&O):%;4JG$<T7@$%3+!3%SGR$.,O%W/C#JK\]K7FN$-=8<[_@#B;>8R'2N
M6/>I'FQP%A/\CM7<H^RH8C<)7]4@1(W61;W^>'WFF&6_5^&&G;NWWP) FR/D
M]JPJX+9W8)4_>Q<7/*X4$^]1.\U66]D_$V%0.7M5!#QE^L0'UP0ETS;NE1X[
M9;5&81&1-C?P+=]P7_-\K!TA-8IO&O)<+-[)*MG7^0"E54VQVJZ=[S;G&4FQ
M:#OW"""+!-$)M@?13#R76E$]UY>"<EG<RV/6_/WK8844-TQ$R8DQ:,G3\N6F
MJ"!]M]ZDZ1M[^$@M78S*GYC7DI+"?2)2D[#"0E=+=<-_*]E0[1ODB_S[T>FL
MT[)?_2X^N=)GXK/UU^"H*(L?.Y6ZJ;=70 (JF;KJ9AYR9W'G)DY\EZ*.Q<=J
M,%R;:85AP5>G?6/RY[/S<N6/ATY_E+U^9YNR_&:*DS3%_3Q6)2X4O%!!C<"&
M<=?((V=L<0O02_W3W4FY&]!IOX:ZY.$NB76>'WF>5P%58<D/H1Q@J=E8V#CX
M919!9+ #$44!5#\'T\'_FY]:]V.;]CL6'RQ2U7(LG?KP-XR:G24;EP!H'3C%
M.*V$Z4V7=5D=G]XS3_F+D>BT_^H"%Z<)^Q(@IB%2N\L'4^T^&5<]V3>PRR"E
MHM!_-X]-"75VB]+7@VWWQKOS[5B&2)GG!O5!L \)"@^KQ)S6.AG".5X>W,V\
MW[: 6"C$H';?DB6)?@3WQ;APRZZ*NA)_:\59?:$L;W<4]J=.^7CG<+>U'R<C
M2\:KPU_( #RPE>DO^MB[:;Q)PW.1BHY5RMB0VL!,%*P\/\VCZT7=)STY#X $
M[_FEWL'.+&"+'%%ZCWW;#(8#7B6J5=7A&5/D187B^7M=&D;X;PE$WT1[-_&(
MV #,) HE4 NKS-^X^'J5-'0*[8,P+=L^6P%37<Y_72ZVUQN]_Y)8HYQN#IN?
M.Y[4KQT[[YX\QI/2*0!W(.#9:^BM[+IAZ2^G6783:K^,)UQ_.H;OJXD5K]'+
MLEVZ$@21P0T2^*7;T=%I5[HK\<B>DQN?8M=D_!B1A=) #WG_>.\-ZU^#CT:0
M%,!+>!<%@'+OH%?U=U<3QY/]R2%]\BIL^:^7 R !FKV5NRM"@3R3)GA(-[2:
MB7@KKDUEO"><?'L*-FGY(WI.C:O)LOEH-_F5C";S[+5)/CN&;:/!_EF'!N4[
MUH4QQUXQ+?);% "R\?#>VFAAI+-%864Q/<Q(+]D*D94&C3_UW8-AS2OQCW!N
M*.P]. =VO$8\N?;GS=JUV6A6'Z7+N:+FQO<%_EOP*;O,"9J#CV9Q%Y!R6^[Y
MIW=76TK&'1]-IO(V?)M_HAW%XVSPYF;.TJ&P\*5\C\5\. (:;YI0B)^;&<T^
MU10U-BLH:FS?F4\9Q=,EI-_H,_THGM'JL6DLTE;PO?A6N8.I%B/J-B?U_PV_
M[]FMWL87!D!L>0\2T]KZBA@-DG[BRK6\LYI/(Y&\VN_K2XP^3#9%6B6;=9C&
MSW+$%>U<-W_0I1T:N9C,E#3/D+.O<WV*[N_<KH&*_^#OOT2QR)ZD8FS ':/:
M1W$/Y<PXQLX?"<.$+BT7S>BGV:1KAE@66-7._(YK'<LY 788KRN6\MAQ?UX_
MXY[IJU\RB1_6A-VWTD0'.?640\Y-_ENDUSSV3%8N/M913=YZ!@LS.X6[+S^1
M>*4V>M/;^/9*WJ,(5@&[-_H@+:!EO":8+I7]M[K,@&YHFFTT7=)5MCR[W.(;
M+TQ,/8V+^LR])!D-&HV_KS]YD%QLQUDF^//S,L]82;U\)^_&8PY69A%?T*!\
MF8=HTNU_#Y=7E5A^%Z7&>*>Y7EX:-A7BSZ"S5YZ1GYY7N:,M)NOEM .WM'^N
M0P?+&/W46M3;FQORI#UT)!*6Z?S6E<5H.E2F(J! N36_H'[@]25G66\#1..3
M\IM?39Z/EB@HRP,, XWTWW29FDW)<FNPW'IGQ4QM>)JV-R=4X?*"J<^J_'3-
M!7V' >6X/J-1.:[5-%=QGC185G+-A0\KD1<&6(V$'KU2,W%Z1AQ+JOK[N6C0
MTCN#SI7>_':>]SN]?X_<.3_-QZ=?3/ZZ*O3>0L#O22C-BB4B38#'+)#>E;7/
MBH8NK9PCXE?DP+?<6*?$WT^"X::8_\9<A6"1SRQ_B&N6]6_?URZ#FQ-+<AA\
M=ZV>.'.R/M^G689PQ3G$?AT;F9!SVOA/K*\UO65'-)S59HKH7!_5_*OH.RYQ
MQ;VA#/Z^V)EMYQ[<++O"+CIDBR1ZZVF:.W;ZWH:_S^M)AM5^M\7OY;D/FON7
MUGN\?J(3L+4=?+O>)FWY\EF@OH"(*J8&L:W7E07CW%H_<AIR=:GIKEGF\-#%
M,)[@W.F*]=T5K3I"2F2^\;3^TA-P@S]8-T-#W=^J>-5.-,C2O6%L5(T.D-O,
MBJT]5G?H=RE>R3:9KUHR$)TR,%,ZFZCD!$&,ZV9S-#;GFR6NZRMS'BK[/G4.
MCO,QRHD4'U)]'RGR_2IR0.1L?)WQ+E'L6\GN5[.^Q(^;'8G-#Y=1T4&#F1[W
MGHJM>)MI[4J/!:V4.X(V7M;$])4.7V$QLKYZY]_40PTR>J_43TW2[".<8-98
M88)',NN.<^;5RE!A8Q&+F&<-K-Z-&SPL9QQ??]G"9NWZV4B#=>0%*^M6BUDC
M M6E-U&-XHZ3-0:'^;-^L[ 4&GLY<)?&.?:]GPF]PT]<H-@O?&FZO?<^'O'-
MS$<4\JFW:$DC$8F%YKR4HQ>DFZX@&2T9=3KUF=A^8Q7XO$T!<+U\#BD64QM>
M+=Q]O+G<T 2Z'\&@CD*^.@7OTO642X(.EB<=K,05;W8XF*#UZR0-QP?L%0;3
M"FTZ44,[L95T(CDMYI[+B5IIAT-FG/)GS@QTOJ]:F>[6R"/2#[H<3\HEA7>0
M$\T92"R\4 /\+L%F3Z;$"U$&\CHG>98TJO6.(YH\3R=]$IWR7)D^V/)K_S5*
M7!,C92:A_'3Z @/-^JSO24*6-V<S"PKV?RBM_,3_Y1@]R2]5VH%,:P7&V[6/
M-F6&B+8I9%ENB2V]E/4OM'MQ3#9-'.3]>?KSWGU>?</ZQH0U"L WA":P&_7,
M)&;%B74\8=9FWURJF=[4B!BS$9CF?+WTZ8 _J'(D \G+S CO>BN;VZPMINHX
M!QR-S! ,'-OP;M/AO5D-X7PZ]91V@-O34M,R=/*AVDCA?'Z\ DHLFNZ4^#NN
MNF1Z:B/VV?9+I^%HE.+9V,3> D332BM9*G?#U\3\>5?4ZRKGN<XL^]H"BZ[0
M-&31P$I?;?.]N_6I,B?Y%9U&U_N?41/ZITHL?T=9ECE!^_XE?_*U[K[:%8\S
M:(3^0.#U!Z?ML.AWZ(74>:XA7_1'OFO#1WU!O-:"HTC4C%70SZE=MZE+CW=X
MV,R-+_"$_UM_\]R8,:F AEM"8A:']'7O(\;![OXI3(8D!7H:>T7%MKB"A[R\
MG#K*Z?X3'8Y<2%Z-5/GWZ7NHO.H;7J?A?+'JY4]&,7\=@X),AWHRQWF,CDN3
M\3N@PR_K18+7N!42JH2JZWH+K6<1="31_9^U$:22LK>KGALP'@=1P\*"K3_W
M_JZEL%@+$<CAF1F2XE)+_!,MWO36W4W.>D&1EJ4WIX+;(A;- ;TEQSQZ9'QI
M9(8G%&J%HQ)I/$#.Y,ZI,X@#=-<7"50H''B47OG]:+E$@U.^TS*>AG4_X<*&
MK--BY&,>D\1=<Z\+"R],QEZ80!+$-#A!&5^9+EW,N_3O%>3=:)2.$4_NQ7P;
MMK2FM'@:D%P@B[*_9;P62Q<G2,P+EGE?&<)Z-]K$T-O *-'8>#8PVC2T'$0#
MNBOI8+C,6V+&"=:U93RZRT#73R.V Z+B7N&E36.QE?<1FO7%HD7*A1?2VHW'
MLG_])V;*8V+Z:JQXHNKR->7BMRNI7-NL8HPPN0>_Y4R$A7(?=.EF1*:ZF&KU
M&-\N*&HMILFW5\R/Y N]F&?T[LDED"Q#VL![GO=Y/-1^I'FN5%VH<*KAJ[D5
M2?MY4AG$G>:I7"#39_[ATX.<M.X*L2VV$ZZGKW/"UZWX_\'%L(;)+:[52%=Q
MA46=A[?%Y"8R5R^F/DF] AI0R;WGG//IXK_I^$^]]>W>F3X)E^G-^YZ1)OY
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M^D6@01L%$!\H$U9L^,)X!MX.1+&>Q61=;W)![\YT 0]>6BJ@\4^9IDN(Q!;
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M=]Y@2,,K-!%>O^%O],[*P>B?&'&23@\"BE_]\YV' C@J>6RR#M69H9YH@0M
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M1K7?>^+DKVZ'0B2:V"O\2^XUP!/+G!DP/E86?5*(W230!K9)NM,D:1-WA_6
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MN#:@Z-ZL$@EPPP0:HF.H-5SS9J@5.')9C.Y?%548&;Y/6_N%P4@#P'*!BO6
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M=^\0)(T()^U$TT\S]8'"Q0]TFLT%N-_6VP'.\%M_OM>:=\6VW/)1 TE2-S#
M63!A9_IQCY0H84N0@K9@N<^GH?V3"S0GX[N#?FXJZBGYS]1 /KO?BY[SR)YS
M!K\-<>I'2^/@-<)((086*P&([0[AQ6&\*)69[A#&W8L^XK&+-B/E2<B%,[F#
MY^04:%DUEY9^L(:6@OJ!4F/D&013")U0_E\+ AM&%X"4\B?9MR=NYR$"B3\R
M$F9%:C\J6W)]=6/S0NE'"Y2?KLE%R3!GL8I3:&(Q3MB(?T.,*=U$0<<@(7*?
MQ(IDA,T1HQ(-JX]5&ZK .4939SHN7[[U)YT'+IK"/)9$W=M_2TUO6JC'=3)4
MNHT$1H(\Q^_/_+PG'A?Q)2L8+E7+Z6PF^?VHY$8RB''\'=:>$0,E%CDM-$QA
MD*:45<*\"/P(\@:E7++ZU^;'^'7Y6UIF,MN.'FM6F1T51X^;!6^@FVIZY]SV
M@QDY2']R&O^";>M$^Z6[&H'OL&E+S6%[@@_74U/-)'[=N2Q79(IZ@+!E'I.D
M^2)R29RYW6ZPIV"!WQB..;?&]1_?>:0BWGC,OKHKOG.N=W)#\.?HY]P>&.76
M&0,[EK!T3:'T ;#5&&DJQ"6PLOI"E=.3P<^OQSQGC=6"O/RF";D70^2K34XJ
ME ]S?;_EU >M.P311;[ 9Z#[;-2#;K_ D"AT(IC_E\V5O9MC8I>,NIM/S-H8
MML5!5B(TN0G2!_>\I5N.?K;?9V.\;T3/9.WK46JZ82(F13];2QJ::\)RN"G3
M71\]W2\?2Y*=-NM[D>F\E]5!!$4YB/Z9I6FB.WWH-M32_8$Q T@E HW_&XX7
M$-MPFH$DA/I5!0GM+CI_O"V@<,W+)Y!2P9EZI]0S%G?U ^C=)Z@P/9*B&XNT
M9/E_5OU$FM7" _:G'\!#HZ*B7E8=@E;KS;8ES)DC$@?E*OMO !\#Z4,0CSA=
MS99E2+N,?&CG)J#-5:C>>[U(G/[7Z38N_<=YH.T/E0QPSU_;1*2V7&/I>MZ3
M?<P%LT5]6M2+G!F+WD>+IDI6J7+&!-$$(@13P E4E/_X#L!Z"X2I2K]?*B\N
M6$]L[2A%LS_][!6F^I1P*EKOBVHN$$-MZT3S;%?)4YU2VB&D5XWL*<Z_/1QY
M=3Y=ZCUA\<6MX.(@<I6FRIQ#G6.\8<JCQJ349Q#BULV R0>;>R3:GZL45[TD
M;0[+FB7-C^=C H3US82/><N'='!-OG#*80Y"Q4-MQ>F<F.YY':IYU]S-Q3,J
MNJXU3T-5\HTM1OHD\GP4-=/!*J"55DP"3-9 F!IK_8R"246J+N;6KY!"TEQY
MR5RT>?NF^<]K[.7OVGV)N01UN#.UN0<#7#.X0_'9P!?P8N%UZ"[=\GZE_3B_
M3 \X<WH/YBU4&:P<W&AB;H2P2W^-9L%%7(U<#GG1*?K81O1K[83$P/,?[IJE
M_H&V,U84'6USH9H9XX*791FB661;.3\TWR\>;;A@@.OUI\5=ES/W[-K2)^<U
M(^\MG31?O ]EHUM15GL,A6G674SY$:1ER?:9_<\:?U7[=/F+D \&"A\,'YT0
M[3H$X6\@+[ TOXTI> @"G LXF?-[2,SFPM8&K"GB5>^0ZM>%-@,OR<'P6R [
M=Z//-!ND+J6IMMS_;VDWA/UG:WP\^WW'*=>M2BU_(I%=4^NI7#ADGGU'P,Y#
M]QGR7A' ^OW]OTU/RW^VSN>&\,3N=BUK!*Z B%L9/(Y+7D\O2]UR8G5L/B7*
M#E,8!I@=@DA&%!A=T=,WBY'-: [<G_O3NZ""8DR3)08#;*A.7?L+)^Y07A0H
M#GM1';K!]U/, J^<_& IQK,GQC=_YYJJ;&?P;J$5:/[=IP5^I >E,!7I48Y
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M>-9NB2ZZ/W^1@GI5Z>^XN+W?N^/2'+_R3;@AR3OM/\V3\X5:(*-[JQFN!6S
M*Q(NN55EOS".SG*%63;S7C3/[">B2]()#@O2FDN1/M&ZIZNAEHRW[6PUP!Q=
MRXM<R#4/9.J>;\H^6A^HM/MQ_?C9Y5W]U."; (&,BV'* CF&XMTL%2A)J+3Q
MFZ)^OR_5^+EJ8/;THS'N.;Q$1_)-=[XW9G1Z*4C60[3/$S6,8ANCL_LO#F!D
M$%<$>&&UUH%W;7SF0FCQG"^>_8?+Z1:Y?=GK2\;WD??,8<\C4W3A)XL!8&G@
MR@$^$D9'W?\8H+/K/!-R"')A*?^Z$576C[WF7;O6_K_# F(0XOL_,-U02LI<
M3T!PT7VAV=F?![EV&L5/_&7"EA:>O 2?E]>T78Z73_W0?SP,8_(_ZUEO^/^/
MBP3_7;%:++<KF'<M\N;(96Y.:7^_-T<WBWSX]))!Z197BP)  VNF=P-PO.VZ
MB]F]I22&@!WXU]X=$=Q?H;R%=R5VMB%7RWIA0M=V;06976 N^BV7&B,YA._C
M4#]UY-,_):K15!6ZD#ZQ&BN0]78]SUIN/_)]!^JZ,RK[UX3H@#VDZ]_C87I&
MIYMRAP-320)'"T5G4&V3T,1$3P[<CQ"<&*+"9IMCWJ;KZ2$(6<8(&$+^6_FJ
M.7GJQXQNM[H1;+MJ.X_*_+#ZQVFM1W1Y@H2L+OF5^:N5_FIIDO@UK^27T*]
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MC.=:-=^*(ZI#%@NW8FBG +A[H]L@V)/R^G7<DOHA2/U41MA'KMI.XF^NH]@
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MZ(@4WQ>M;H[8IXW3 GNF7NL<V?DZ>LD31+*0&W<.NP0&3A^"NM,@)-U-$ZJ
MVV2#BX%IB7EI\?N9^_,V/A"C$8.P]1HUM3JUJ&+.KH]*)L?W8"^@4DR9^W(<
M%,+F[T56H..<2-_I#D\"ROQFH,_4#*JN?)LN4';1J)[+6_&]>06U:SZS3@XS
MKIF%RP+"YD A<<L:SY0?"PP-%'>,J:I1V[8/>=P;&0N]82X?;<S![LGCRTK<
M),;K$(92)0D(\!4)#)==RPYUHSZ6^2"AT4\_!&F+KRB^^WCS2B:/@[R?P/N
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MA03(44#0RB_7.<3HEU'FXCDD_NZ&A'X^Z$/8[@1&DO\6I=OI<1%=F,KUE!Y
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ME 3 Q,($&/_BI.*8+VY4@VX1)'UEA)P7D(L@?TSK:6MK;"\5,E=>0;PXW:'
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M7ZP5-J-$"<>[W1O;"?_H*RZNEV_18[:@MKDKZ?#P4?&N=?+J[((HZM1WNCP
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M4&6-&DM!$UJ8^L@;6=W^B SE_V;J&4\WM\+50%:EZL$:R\<]'>\T;,Y&\X6
M*0X[QVVH]C#&2Z1_\")<%!],%=BT5'\O/N]1\N);4U"0&KESU]?+R'JY?IE
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MZWD.+K*1=Y *8<KK)CP(?7+WK\T5LDVR-:^+I=FKE_2W]V;T5"W<9!^/T-D
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M31Y^C;3W4EN<HW->F>P8M^B?(R[7=MEYP=52^*'KC/.U 2NCXQF@"]+'^B-
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M_?9M0'?]2E[6VK]=V/_[;+#2M:Z/:_;&,84!EI(V&J+&LRHA.5Z-9+OW82(
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M00B+:PHF];;L\?07P]QL9)4,>X65S@7?^YJXI5CZ2^/8'6D%MP7_?Q,AQHX
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M1N=3PSN^W+VTRWURAGY]\D3#@[WLP&PGU'F=OC?AID-UH4E#\-Z]L.-7!0[
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M4+&16A=5>]GH)8]BB1=*$3LW1@4X/..+T_)KP'&>=U@!M91"P(5%4U-PVS+
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M/]^8#:ZC\J,I EMZY8\8]N<=?G=Z-W!_O<S%C['3URB"C']2*]^R?.)@AFW
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M?L1[/XV9N8;H70S)=@.Y3LWMU^RCZDEXA^%M?OY&,[6%])N_:IOKJH+DBQ/
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M)#=M_)_MA2;WVQVS%&M4?]L(5-V0OY?F[TBI*QGTQUGBOQ)6"N=-_/@Q?*.
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MO">N=&?GI95L#^P4A%::CX=.N1L"W>>]6Y2QS(_4D<05"T4&);C[+;E>_@3
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M&V0L7\/>-EIRIBY/]%O-VQR#(-"9R<MI&.?2Z.(*7R["HX>0@J. Z6">5K2
M!=EI'7A%!O8G&:-%D(^6X?>2;<G3GN/!G\S%";>FUQEDZ820-PL_\NK);W]J
MCQK$S?C"+\L"W\FES3.LC*E46?K+WDY>W%SK.HP,--6'A/1Y0%@:.C\/M*7V
MO3D""):3[,D/@QZ11(MGYOSDOX=<Q,?-+KWFC=ZWN8)NU_K-%^$3?;5J-5-
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M('J0 A>A M9^93IX8+C,//NL=:^_'-(EUTH5)K/+>#:I9B-,W?=*'_>'-]%
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MU"LY.3,P,,R9WW-K'ET'GU+5%Z^9BU,9(%]K4*K+O+$GGT2N2QJW:@=5.G:
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M=Q #N::-3=K;N![C48.I_3'R19738PCY"QCP['R:Z8[CF]F4I*1JW8=NC4U
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M@U>_EXE!:3<L4N\G+([!)$YC%M97L^R0IE8J+@GBF.Z<?NY)95+I#L5L.M
MJ71MG!>D@,D/?;CNR]XN_X$IHW]S9X4211I1^0#Y#2N#[P*Q>E/]WSP[QW+_
M=K&0HSND;%_@81\-$'>F>Z*(:C$#HW-P(AIM28$%5KHXXH,@SBK+63TGNVU8
M766%&N#NX"KU"$3XZW0"-0_EBLNEL=-TJW=GNVTGD2K#)C"52*WXSQ3RM\N?
M8*?OP\9G_H7-69,"=A%=E%3Y2QWXT(>-/DL+1_:<<)WF(229CLYBEZ+U+5*W
M4+&<3#_Z<<(O]-[(&XK[>%TU9:(\JW3O] 7]"^P#O^.!MN64R;^X]*9ZO;AJ
M$CP]8GI!UZ;OT@!F[C1 4 *A*('#"G[DJ+*DTIV7DH!^-II;/=GY\1XY.425
M N[IO!1Z^.;ORK"^L<VM!G7)K?_[4OU6,G+3.&YHNT&58;@O4UQ^0+@J,?*0
M_E&6?_*#!$YP9G@P.(S.O>_/WU5LF"=9^"A6+MG"YIEI@"Y#^<[-J_2=X((?
MMM/-A_$R9]V%02F[O-R&0E)!$=(<"MN)H $P)7$$J"[HR"Z8#I3N=S@L&KK<
M!O+4/4@&=#>70^HHE*)4MM( K717%E.0@"%^N4$#& 62<NDL3030<$]HR235
MU-O8C"XLI\R?2=\4NJH'(>F,GG_ 4+](S4:2J2005:Q".K;6P2/'4.6*@@[Y
MFK<B-Z)"T.)&O2K?^X#[B6'BB22+8,EP[^!%JU[N"IGPUN'I<F)Y"-T&GUH+
M?L!?IBT5G1[4\[Z"!KA*Y]4 CQ:X'FL-IEX?S:DG^\0O_2QXO(<;FE<-GR[>
M7ZDGU"PSO_Z*BJ>Z!YY,(W6\'VR0Z0) ?^['B%5$ET^3HK3#B(-/9%O:=]3/
M%-, 2B:EN-AD,_7IB*L&S_\]HQZ\#<BMHEA@X[B^6P;,;J9WI^6BJUW90;,]
M4&ZH[N#C(=1K$1S# K?$A#VAYQT/YQK6H@X-XR>5+YM>]DG6')%QUK*]!UWR
MWC<3H %JY/\1_*=O[@$^H+O%>E-N6@/;6FE_4J/,^D-0G&).<HZ%^\E';X6"
MD#O@P #8K];=5H35$6AF2#NW:C^!=ZWU^@ABIUPV3O*XFZ#T4U)B.TFS"&1B
M+W3W\#P2!K9:I2K?6#VIM-Q^K:LF]W#$ON_^M_6/GB\& %<-,@W2 ;?S9/1/
MJ5W]?S@<2/VV&>USE\:]=0*9$:;!<H,NQ5L(,Z_#V/?FS\*;*GD?']QL+M(Y
M02Y0!R(Q&SVJ8YC&<5>O>D=\;:WWVA6=M)>F^A^%AA5N2D/N79I.5'43DDJ+
M'_SFIQ"3>BL(43@1/V&UD9(V0-Q.L#J5B*VLF;6^\S )_,ADFVCJMK/41'2L
M,8$XJE<3.%/<7Q5;6H',Y]1?9\]AA%-%/^)-4D(O7MBXT/56@UB)ER):SL/
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M3LZMT>="+X?N#%;FBG4O53XJ^^E% Y!$LY,#[2_.XV-P%OH/@/BD]8$?2QY
M!CS2Q&AD9_\6PER-/"!EM*'JG:#]9O*AY9''(97)_>N?<HADE",PH\FY+F9_
M8%X4L!ST*_:-]^D\>K*9M<:>]2%GJLS5]XAB5G@3]\S1+O4C*X?YR:E2XUG<
M<6YPL]P*R']_*>VS2,%3=,)(JQ6,CB*R1^7/76P1)1;M2P-PF4!5%@I;!6KN
M':7KQASUKGS]6X_CN5#%X?./0C^/L-ZK?#G[9;%2J-9]QX.88*'6_6"C6]^,
M7^?R[(G##C:7].B'\8<)1?$K>-16*M)^+ <5._0V54!X5*1>\U/<5N513CXZ
MO]*DMST99-P/3!$4I5Y15S.KUK))X<GL(SCDDM*<CJ(V36\0C%V;8U8]DY]^
MBUU%"0S>P'';V50F&V3EVWXZ$1C'W9B9ORV 6IGG5W%!LE N5.JX1/,:3DH"
MR,I?7/;T;FU%B)!+-;^+I HR72/8/BFS"=(GS=,3,"SPBE60!+[\%X?$RXS^
MQA2]Q[^TO]E11Z6:G]88+_?[YE)K%6XO%AB:AD&.@,](.\1P/*R#OQ]!BM*I
MS#*N2Q3:7+T+R!;DMOO^B,$9#^* _7A)85BLE$:O*<N,Y43:N;WA>5EM^FJ=
MF/:!!D#J_Z%(DMCP(;N#\\9.!_TG6JKY=2["NSK9\O=SC\0SL[5C]VQ:#KM@
M9RC2\=BM1H$TXK5#K94_EN6:5T55Y,](["9^WU 8ZS8VC9,[<0W\8\O;/>GS
MCN=@=*_RAY,*W@)V=K..JN.GU_VQ*B<Q1A7L&<&7?:/>AZZ*PW@X<97D37#1
MK<T>M8UZD;ZY;;E1V0IWA^M)OLP_)F3&!DRF; )1W1G%)(&>3E,5MAWO!-99
MG3N^E1EO)2%8C=LC9U^A/KW,=$S\G0["L4V-8DXR[UBUUR:!SJ*'@5M'U%<I
M%XW O6?^<2X-E%IR&9Y9ZWQ;H?S)N(!YWD:64A%L9^\ID,=38W@G9B:LJ#B_
M=60IJ][RR'F4Z$0P:]<T,R3I8#\D5'V=:U3/NYXZ\FJ2Z?$?E9U_>J@!K*B9
MH.LG#8+UA#LA'*2$_-Z%(?:WI7L$1^_D&@X/3>ODT+W[5QY?D7:WIB#]%*DP
M]X7Q]@=-6N9$C=_<9BV7G?(3>S&--\N\F:JJJNJ>BGX#M]U=J28V\NWFV<FQ
ML,>@.&/:<*8UIF*<S0S8!-Q!(>4RJ;_,3UF/:6X>]FH:/#KG[+')J1!<'+CH
M\[OC6OH3H82J/A](V3^ P_)97=XUU/CTGDP<)UK+^O!!S3O+JM1[7\FH/1VZ
MRNM3Y"^ZCCCYN.?&5JO$U(R;".1_N<O04#@'^V&L)%YD.V.E6P!VG['4QFO#
M\6GKS[K7NBRTKF!OA#+,F"ET/BDK05(885^&#RQ+IKI.?AV'3?3JG*I%:C#E
M'B!38(N;RAQ1S\EVX/2GTS)SCSVQ+.)?Y+:G$Q15?+,_EQ)A>%,IQHWT3YRU
MQVYIPEUC91<UE5X5L-V;"BN-[8_7.K/A[(^9[VP]H-H1I;4IR&W'B<],'K>O
MO/%"IBS0W='7M>K.*K7%G_EQD2;)G<>>XJR=EV]=..08#1F"UPW""9O8YR',
M"1WRZ=:3"B;;)="01D3*24T96"+?\]G<\UA"+S7C#&#CE.$+OQ7P6)$!ZH46
M:EAF?M:]+TY3$MQ5L#9DH7&OWG[QTQ)0F]1&9<HC*P0W/0_O#K!I&W#C7KG0
M?/1L16W!<<FNV0-@]G%RZ@".53D_35''>U.CO/D\F/-O7;[>%WU7G37PKK!>
M9=%[;]&^!^E ?GGOE<:>E8H6UV,>^R\1SUG%KC5:=<W-3IKL609LA(@,VZ3U
M#+T[!)Y7%MFP%!K^^:U[1<?4O?^95G?P6%C1K*X[ZIB5BUWOLKKLNF*WENS:
MT/H=2;'L6['N5VVP0NDASV_GQJPIG([9DT)O&F;HD$0]991O1M$3XG6B]F'U
MS(S%=!7OYT-5V?'Z^Y8]MW\Y>'</'/U$,N(G<7D8)-N3A4>\NB.+Z9.&=9+5
MF\<#B$[TA.Q#2*S<Y.B,):,[DWA^V<6=Z^E7^GM]E\MB(A[N]J-H %X!6W&Y
M@BC$5JE(58!+4VW_<;!D<)1:4 Z2.DV]5SV.>G^'_<=A&I'8*O39Z>:(SUB-
MS^@SN .7FN,1=>22YOF?T=;OYOO%E5[1?>W9\424EM*COX_'%.2CY]=-5<VC
M\])'AG!RTGK2FKNV5M__I-^XLIU]O>"]<.8YZ8-CT&0!#5 Q^URX\YI:$\PW
MA0:0(+MN!=NK!=6JN,+YCT9L]8I(+P9[=,+;JT%H=9YC'23.)3(2='-#/$'$
M.8*--^+CI<</!Y\%U.$Z,''R[:WB8W8)[;[ID2G$T)-PCF8: "W =WFCY(W
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MI'KOED]T0<,N9$K[U)UZ\<&0*@*T!PJTVE"^68^'QU0<2(4U,D0&\9>0&FF
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M/]8S1ZFCUU^;O5UU^:;$<:#_I%M<^]K1@*=L[GP>R'_+GL_F,R9W8SSG:M[
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M/WF$XI#*\LXHREX8U\\4U3(9&,R\;L*PZ!+LOH)C ";I(#7Y>7VS/<N]6+/
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MV@L&6C(?6&.]$;\Z)&7&RV1\E_G64T<6'M'Q5$=#4-?B'65Q,\*@T9\C,:8
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MRCL!B@[$4C[PB@G&Y/W%;-AQ6PB$%^Y;/O]::Y)4[FR_#J#4PTF*;ZS&D(Z
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M"6^KKQ;D;:HSN3/$+KJJ'*3Q[)&J8-E[;V5YB!Y2:B\^5SZQ9^'>*$FFGKZ
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M>19U6**I-AA+1J$LHN!%O@V4K\6OW: "+T@J+T@8PH*XNO:HMA9O D'.=E/
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M4^#]Z+N71M@MB#_]JL"FU0EB? K!C$D9BAFI-7^XT*1@Y/9BWPCAP7HX"1R
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MTI2^'4N4ALAA%S(8$W*6:*YLX-]JC/6!W?-1/0P>0S<EK[X"B(- 7AHK7QX
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M5+C$%73/D +;G,<2K5$/RS:*)N\32#^<'>-F'M<[FVN26P6=)/KV?'E]OJ(
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MP;Z8Q)8Y:7":O'!)ZIS'J]=TICR14<RY5% >8)JN:DR$U4N\-N]HDCCMQ++
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MTQ/XY5K7OQ?H. F\>3'$YBSN<W7-Q-FKD]]KT4E^[$.F@$G0I*8%@VIO0;;
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M.03L]_RY1')) 6PF;H9)QC.N^NU>;^[.6K(WC*8LY=&C-Q<MJZ '%LP9'VM
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M8$O/6.I+M$N%P+]H!O[TK,_R%E\YN EB8/NR!ZAS]69#=/_T'"?-NX+#9D#
M#&D$M2%*KE!.OET_F%-&;S9T1"&+A]D03N)3<,(KI/S;#/ZP\PSO=(FC+?UE
M\?Y1H;@QZLHI/IK1(F5=EA%)ZV9#ZDP1S!;\89;&0[U%Z:[2[\6*I;=:SP0V
M34[D=(I(K@&#/V+NT*.IW2<Q\3"H3;V@>=;L,>)@HK)T"GKUJAYF,7WT=:BB
M,GQPD&#>M3A>TEU4Y"L5?OESP]N#'R#\323 >)D->:+'V:LK4(@?$BF2^A1
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M2=9<O\&<^99/%T:^@=*V;I\M,? ,K]<@KAXD] 9X ?A] ??BGYI.%:)J4,Y
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MQLZSVMZ"2P&LB;E5K$%+O]@#_)&%[T%5!8/A2?QK#B\%?"]O=BF>?(CU;6N
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M7%7@Y[*KJA9C=QNT"><A]FAS^K;A(.K@D1G$DM%R\Z\KB<X>$L9A/?O%%@6
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M/]T$-BK!)<T#<O80==-\B-0Y!JL##B!5QM/.N^[Y-GJ(<OC!]>J$BZ@EO&[
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MWR19A&X+EF).P!VLS2-J=KQ%*J]8?>I:=9(S^M3_*Y5^);FC0UN2-8Y;[1&
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M"O(S(#!_8RJ]\$,9++'_X4'QI<,69O!GL5V%?MYC1W?9+^\;;QUS;">44D?
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M )5$XZXVP1$U;9)O&_>H_51-_]V*](MQ8-EGB25UYS7<.#V59V_UKV$,OE;
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MV<.5\NXMD;5$%]QH['K54G:M.D6O:$?51L3//0NZX8QOICD"@4F,HPD@M#+
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MY9L6J3N_,AW/,8@MFEN=;+YCO/X_VN_R?XSKP@.5,38L22XF"J:Q;JV_B.<
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MP:^AM.W+KN\GI7]VLBL4^C'S=W-3'?7MM\R8F$):*)3J[ITHJ+<.!OD12R=
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MN2N5W=RK,_4#QBE&'_+UF]D#,<CK$<L9*QGO:TW33]4_Z-SYBWA!0@93^5[
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MLS][2 %)S[(.((C@IZGM'U"5BU7BJ/D%1@W-!Z_02R%7^ [,\Z(_83HKG31
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MWFI\#>G^@$O84LJPGFSK%0_ ZP!IL6JT@5BR>6;IY-F-E.7O_P-02P,$%
M  @ 8']A5,*%7XM5V ( %"D$ !,   !I;F\M,C R,3$R,S%?9S,N:G!G[+P'
M6-/;LC[\HP@B7:27J* H51&D"$14F@A(D0Y1$2D1D!X@$ 3I( H""DJ0(DU
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MA^_DWTR#=5%&*M<H51%"Z*2@/5:O$A-=('W@31S4-T/S@I-23.B-ZU;*^8"
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MZ2.7I[;>XQ^0@6<ND;]N+,/L61!0I ?5HON$5#+P:#A"4L7/&/&&-X=(!IZ
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M-?-A%VO?;@>!^)/'*<6[$RXJZRE8O*I*0/IB9!IK7 =:T@LD$]^87$^@5:>
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MJR3_C\)T+U@KWVI$?GA<GJ/=/D_17Y3ZE#U4.R[^Y[2>[6Z-ZT;UOL+"+<8
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M3%)8W>(I5C^\7'9=6D3]S2<:+_HLO2CW;I\7/V\_5[TO :4Y(>VPZ[ CU?O
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MA&)DB("H6_9PDD@FZ>+>?^&@!CJ*KW_CX+5>ZT>6 A,QXPP<?PP^/P'$D"G
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M)JGNBP?_:2('LARGL0/&TZ],_Q(:L.S[KY9+7\#^"F$Q?)W#//SEE3_.O#
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M#O<4O9E6M%Z;7MDJFD3 FJYDA,W+1],1"U#S[VU1NS/3^#/%W1U$GG^_\#(
M/BD #]]119O 2415 CB?YDH&DD"H_?<O=?UW7_\??_GKZ)6WZIF:'9X]N2H7
M."@MS?*FKKEYJ/%UU/D^#8D2;N8;QV/=07IY&-'QD;M#9<4_MF<+L\.9!J;+
MH_H]7APSS5!5?0>2(ZU8S U(@L:+QP4;ATE@!^;B5P0/1\R!3J^2>+@*]+,/
M H+%7!(/SSRMY"!VP\"AN[^FF-O;&Q/LY\S 8//2=,(V>O9!_H<5/'V-V>1J
M\QLU^EKK_<3'=!:7+_G3BK454A-L9SJA <6S"95?X*#6C.1-F5/#W8\N3D:
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MNU!M,7=0"Y(-3.#F%B9 \ER"\['S" H3X**O!Q]2ZI8T+C.!X[!2O-L'_2<
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M7AGD.V0W?=X)DV7,E2"MJ/FIC(;S!*TK]LI%E8_/<'UPL]3TM44C[5R$QIF
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MQ0V\?B-K)%ZW5N<V6O>C\ZXE@?3P(HPZ;!%KS!N9P/!&:R9@ 1N^$SQG:YC
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M3^/M6J[6+@<S1QI$'#YC>BZR"<]CHT ;-$5)BI  51DS 2KW8OVZ QI."TQ
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M0*%50XV_6<JV70?<.G>3X%C_.VKN+Y?^;&DHXGOT9J:-+6TK\R53=9_H2+W
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MAFSY'LP5:)W5:ZCNAE093)07[R-,/'=E>6TW0N\NA_H<?HE7XFK+6MW>+=0
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MVPBL@S7_K%S@+SMJBB$7@&YL9(VSX>\$-@^&8L\>M6ZVL@DB/H$O$H(R^2&
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M!^VWA.)U#SIP'2Q@_]I?X-0?]D]"@P-Q#<"?F.6DQ[B5H[E^_P:!3M EU1_
MZM-W,/(YC[_ LULOOI+:B].5@;5%]M68J7;;;"5?@ L:GY._4)^--QO[>%RL
MJAV_/&G],5 S]0QUDIZ4\ICJBX68K;L;UR#[F+Z:O$XG?>97VFS'.;M^5OL*
M!:._L%^ K;HN])@#<_,O*#\@F?W35]O9?S9@> ZF['Y%M^UDQ L19?*T2,$
M90U22T#9Q%%#K2!P KK/K-WK(,>,OIZ2M5"ZL_E50W,T;J ECV9Q70_\WR"
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M]9Z2?7ZJLS/(Y(I2JQG0H$2]WIP?]H%7EUY$9OJXQ?Z+K+PZKO#1WJH6NJZ
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M-1&F* V=_BP>[M+HQ=,O:Y&F,CD*:AQJ&M&P)'N*_IQZGYE=UTAKT\!;UUO
MH2['&3AH=S>VL=-JGRV,D$<<*!<GJ](?;#$OG+74[JM[*?<\AK0AVX5H:F/
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MBWX/DW$9)!CGI+K8.R=KB8^(@U.^G/LOK#Q578"5NYS$G5'UFOSE+6CZS'%
M#+>[08(2=QCG)_)R;9^5]1EJWVFGS7'>5K5"25:[+C<I[KAB-[)[SQ1G8)%I
M"SQ?<:I4?8]E+=;)*]4S@W]YE\X]2LA>69V';,/[CZR]2-81AQF9-MS\G'Z-
M:IBA;SN9_^P8Y8GQQ3<DFQO#+0;I/AG3HU>2ANXI]7T5/'/R1O[61K#)] WA
MP/ L5W. D')PN;-<_/"M]OV'DE7']H-[CC:SO;LY&T%MG\*H^K34^H6&C':;
MSP:V274<DW(IN5EF/::B+36'EG%K'G+>-#+DW2OX+?D$M>+UI8F$7N</^XQ3
MR]UKGD0,I1_[%G-**%?-]?,;&Q_C/1J*RNX*K>?U);P3;\2;B\J6S-4.'S%C
M>R=S2=97S.1C;+KT@R(-&?JDH+_]ZZ*\ZS7FVK6V3:W=CW97V8U:+7Z[O*5?
M4@B^>_\NS9>)H[7OW-YE/#0\8_.N:;(S8JSRN#T3V"XOL_<,5! :\(<NEI7Q
M%B1^D2]ZJ]AS:SKLS:5AU(WBNQ@3@=RR*F6Q>>M*G(>@TU%+MX-1K66;B4J;
ML'L-?:O%*WQ#ZZ,$K1 1R<?B^ZJ*&5+YA/)#6]"W/F7#;UK>E:\^:!?=4+_Q
M%[$[ 25IPFTOFD5;PY&]2G+%A@;^J66=.0QK106ZT1 B*%FR>Q'.-N&]ZC^Q
MBIO.?;%Z'C'USOQE\2_!KT[?#FJ.\A'B%>_)IE^FA-8XB]<D?@P=CKK8=KY3
M53=3V,2CL@N5$#]RJT539P<PUR5<?@5C,52YG:Y*1=0B(CK,)J)]0OSY\CNF
MHQ;C*@H3G3NKT\0,Y3ITUD9K,S@*!*I:D?2SG72]H;;(Y*-4:TS0+,HFL>$N
M9PC:\RJ/4662.RSQ E+HX6O-J?'Z$*V6(-,>@OK#RP.JULH\>3&/;;=^E-*3
M;!EH5WR]+S_ ^B51X]/$)]3Q[LHC]MZ1Y,5.NC%G7#E?O+)+80\3L,=M:MLM
MIUVE(["I:.M^+,ZX'<5%R27JYW=[<.U:OZ=FT3M70S3L6 P2M'X9KYMQMBEG
M7L[YZUO1QX*A%R*&RX5)3&"?.>I*E[R4G2YA6C,OU<'I5*>SL^#%&-*Q\Q<*
M3M[4KFGZ+&(*,[ !A]!W!E4HEBB5_""M=[&G$VN&#;JDS!,"$S*>*_C[[L$.
M/"FW>T *\FA5\7UN4-UQR75UWNIMI.YSN?7FYL:TF@5=:V*O@T@%Q7"8Y/)R
M'9WIH)AW)K?1S?]*EEO.H2F"*?^AZT\3-;QVET>ZY&X[U5NQY8213T$MN%5.
MF+\V42$5ZE1IFITUMUMLK\I7EO8D\,VIGK_^H"E[;W'\>VUQI:N35J;!@3!:
M_MB2=V$>HY6ZG59;$Y7F:'$C&8=TVK[^IFOCI[Y"U5+9<-$/H=X?9?VZ]4Q)
MV,B%*'%2Y;O5F^6E(ZL/<W(F9TDTYUSI:;MR].CI@J^R/+<BGPV)"Z<7E<6/
M&\1+WS9KR#DJ5K*F:7AQ&B6ETVB7G4C ]BB[A1>N&2%/O MZCY"^&3!*8-MA
M6:EU:M9$HC+Y0V] @5*T6=WK\#L[=[(/LMT)<*LWRW6?%T!=D!PC]L7E$H:D
M"%^6?;4N%?$K?1L=&5;O6PJ,6^"]3L/6K'I'H4ZEV_M5O"OIQ+XZWBKBZNH?
M]#GH'M>US;8625GG+UD;C(_ZI ^Y=;D9F5Z*08Z\5^<OU46&6J@UQ#D2J&\2
MV'K[3K]_8\PMW6U8=Z2IT7"S+_Y^H)0#<5>EF-.@, *86%+N+N>PS1[4/U3J
MNPM5S_O\4,N.,NX"\:]BEQE;*(@Z\'ZIH8_W>8P&%1GJ?+MHMV."[)>!OL9D
MT=O13;DI>7OA(0">@B$IY)%@0C[XAGV,E!MNF;3H5[+FW]J5[O5K;@54GK=6
M"U_VR/7OBKUW?H Q.VG;,U)SZ>'AVXG/"3.]M\M<=#URG"3QOE*&_9 KWJS8
MWF=63,.2)E>D9^7*P-UZ#D+NUN^MKYT+-C@\37<6&E.]#!88(0906ZC9)YRP
M;ZP;,QUW56?9-%U?DQ8]G7_"MMUOSBF50JC!"]'5J(3(&55%\"4\M%PGT),_
M]I)Y5.NS;)V ])1;0<D;KG[R'^.J 0LP$7+X^PPYRN'4W&\=%DZ&S9[. ;=B
M?)M/R@II']]@-/I@R%O-*?GX,U]GX<?X(9$>4=Y@['12;LXI@YB!WO>=7KC<
MTMRB!=661OY$T_LHMJ$*IYK8B7T)8=F>ECXN]!M(GCQ+8@'?//?KZ+O/3@@'
M<3V>.QDTS@1P)I'%]?@=V"DLMK!E;3J0J)](_CA*.,&W"77_<?].5S?BLPY:
MY!"Z#A1 '6TOEPQ(I]E=3#CC9)=O*?>TX]M+P<OOZ[7B%<:"C6+[=TJ^I&51
M&ALQNS'5BI+PT%LN"X)-BSIG8KQUI+D+\@(OK/BPQ;:)OSG5]J4M1C<A$%'K
MGFKK.LE]-B6[@F"LZ/_MT SQE\2*J9C\*3<\OX<*]DM:M8@LE3U$OO6L+G:/
MC:5YWSE/R?/']H82]WO?/#:R906]?SA7 MY[<@@?6GYH37FB.)[:KXZ[&=^J
MD+XL*[?\L%,S]^:U0%?=/4%5^VWW8NUI<93N0!F47"EEL+S=?-#J(!YS\T(X
M4OE9UN$A#L!G3&#30\DV56L*GIQ6!P\N3M[>LZB_H^:-4@JC,ZC-UZ7.)3NU
M*YT[MG"WYE0R(-#J9/(P]H&M1T^RON6JD-F.9AW21%=VBM+EBRE?WDO&:=V8
M%8LUF<>;M.I'8>8<+?#K=Z:9P&-/<BDALER#"RH"0VRXJ3)?4"I#7-P.2T4%
MM$A]*3?9_5'GZ_>[9G'?.BK^=>_ @R'".UHGB?"0;DYQ0/&YE*L)CRRUV'GZ
MKE'NR7TI?#7TO-'AHX^0K;S=.9J*=Q:=%\:E:B_7E^3DKS25DUM('KT3=5I'
MVU6A]!&7D(B_D('ALPG]@<Z!8OJ6O<>\^-E#T3A'D\S1-]_D8I[Y6:L9>O?9
M?D+!2 &*U8'\G7)J(G 9O;R[5^_P]9]'D\5+Q,4P1@A)1J<%<LFN3I<)\-+4
M.;X(ZN=KJSJL/]\?=1T7_7AKI.?\CBLS5>_3-<D56E6!'+3Z(?A&;$BG&:4R
MNR?OR2U/P5JWKS7/>63OUTX+GQ(&3N5 >L!ST<\-S8:4/@S/J'\UD5C?TGJ,
MP'DL1^2EV.NG(D/Y+LT?CV_8"[@JY4AH$.ZEO1]>M4Q;_#1<W1-B&IX1N=2>
MY>UDO3:A;Z["!&HSS*=P4_1M.?:5!RDNZ'0?C\;U</E\08WPLYF:6S8Z3YD*
M:D^=X:VP8:?L&9I%,SA:W=/4<UXYBO"7EIQ,VC6_$O]4=>68:?*)6L_]0@_=
M9^,(FH:/]SR[U8;YD&[P,ORQZZ+::Y&,Q6(,QO55A*3MAU/?[XG9_>$;$YA3
MFT L5H%')M_\RZV&=V#X? )E^'U,S3^EQ0T%&>4GOM>Q;1@QYWX4G2S+9OHU
MM!'Y)78(7N4SV&E(NTN6LJV[OX$OZ(U4><*FY.2K7\(:UQK%W\JO&@]'"BSJ
M;_:Y]Y%P:9]>:P/&;8=%D+8MW\?VM^:Z.TT=#N0K7\,KR>E_#C6'?#WQZU-J
M9XV"Q0>7&[JT6>VG5G-6ZE,AJO.$Q&79+^GNIRZ/6I?1I]J>M7XK?98I]QCC
MM;1B;96V)LNH"92C>D?*@7N=7'6',)SF@QJ@,S*#2V&59-#=[@4DG6G@>(NX
M] 9OD$5";*,?H.78D9_O(\\N/7_;+76M(D0GV]0B.JJ&?7,*&Z@2HJDV.9/9
M<B)+HO.BH7[':L#7+WI;+Z4=:=@ID]/KO58$5X-"4[M;?0MC8/ 0];7-SBZZ
M@7WO!3XGX43EC1:#L"?J#4+.HGMG+2J5F,"].XZ5,A0;_$OQZK9=%D49:?UF
MX;W>5P5B%/0^SVUQ*U-J<USKB<#D=#BJ+N228RJ(9QDI-M*!'W&/D[Q&]=V_
MSM+$/R9YOV9\2#R$F\[N\>;P];F@R/W8[>F3!_=.(K3;-5Q-,J8SSZ?F>+MW
MU'8L\:2<7Q[5$3FZ9O!M6;FX=MWFX_M!W;*26^:V]WBD9[QW D*)="; !(*-
MAO57>18Q] T)K -.NUO/G<OK%C.7?C%OK?G)^_@P1=Z2P2TLRD UKB\1AQ$:
M<7;=MQ,-4R]N-_7N6K&:#;$?BTNQR-'BYW66&AP;M:-+8/:!G]*RF<#0#CSK
M/--,E /K?.L")G!'EG4TZ&H:$]CZ,)H)J-LRUI#4E.^(VQ!71UD_3#)8^S*/
MH7)1,/,,Q&VX))QTF=;)"%:S8P+ C=^.&_VST'#:+Q[HE7G8<A_K!)^P;[#Y
MK_#9(M:1+81C6O15]& MXP#K<+N6&:W_;R)J_2'A9[ .7@.VK00TT;/_+$\*
M@U<_"CYNU -2MB 8A_&7F0")NP,^]@$D.K/.$!)]#;8]80*5?:PS8ZSR8/,3
M<'\N6BA-?X4)R)3 XC!_E@@:DT%-6]_NU\8 6EAGV$Y@Z >5M>@KZ+5I? /Z
M>_"3\:*, *W9JTQ@%Q-@'1 XNBPZ5_"C0&B:L;H<$WBI;\X$J@1 6N*Z$1.X
MKZ4- 3O!! **62<H?8]__78=V):^/@4GPTCP,7KE2*#)GP2"!FQ/:\ L')V$
MT]ADF, >1";X@QF^QY]KAEY9A%6$TL_1Q2$73.A'OV_[LT1_MKG3HO[W5O@>
M_6(+-R1IRO);)A &WH<PS*U%KYC_62"M/UD],(,)_&B('Q3 *+D&'^L*7(+]
M[8;_>]P04NEUS%:G9'[JS1R%O!2B@VOS)L<8&\O"\W4Z,1NNJ)CV$_L2O:%G
M6<M^NB%ZD ]M#?E-0 :<UO&#1SD-SPMY%!S3K?NHX-+G*PGS?SSZ]KUK=(U1
M;(QI]TI9/+Y8;A92-&M92Q8DC8L#<9X)()D :$IWQ/Y$K;ZA;RT8_9WX,0:1
MP<#2VM=+TL"V=?SZ.H*:B?\9T U.:^X7(9VN@6NK^&&MI:_/(7,L,8'E1; A
M\Z^"X--F['2K"@-DK32:8)TG^2/XK)]ZYVF^_PPXX&]H?T/[&]K_/&A;M$(\
M)74#=,U]7:Y%7<<<^3"T13 I>K++]-SWC#&4,(=?&0^S3M#]3NX[4C]@LO].
M\F[$SR9< /<=[93O)3<&?S8);B3\  K]@T&,_VIJ>L&!^-%>\.]M(F_ZD]+E
M;V0_1Y;K7[TO+C4Y5D+?G4?:3NS8PPT-W5]Q/U0P/W@,8/EWL/XOA&8L[WRS
MQOKPXNZE@8$7KIGY&W4D?"9U_[64=,B=MP?R=F?G% J:?2T+.<KO93P"H)\M
MY2!_P S5R??/_:X2$$9W /\W*O9O:+]!T^=Q[#%5YNQRLZX5>\"_/7^C_@>)
MC^ALLW.OOX@.5CU\^T*B SA314Y@<'/^YF0@-?4[&J#@?\OL^S]W7OG_']F6
MR7WU]WOU)@Y-[9SFN).U7^R9B$1Q\**39,"6GE,NI(<:G'$.@.A7>>1W>>GU
MCRG'?B/Q?XEB$WM[GA'GUIU_"WG\ST+^.BWK'"4MZE94;F%B -UL^,.CC7A-
M=E&*_/Q8%!.X2@RI%'WG_USF,EH[KGKSN1 V]>#S;Y>;Y1?:?D(0>;'" EX;
MJZ5V04VB]')46Z@TZT2M1XVNG,41'DE/7,_,SPR>1%_D1D_VOHQD;%M2762O
M*SVVR[FQQ5\T_Y%2XTS7L^3RAY(SF)^I9HK14=_;/_65T59K0P]]+\*]'H3B
M3+724,@C[Y6YMWO0"KB!+M-N6]V ..,#([7=51<67A7B4U@6<W;*N+G[@Y8J
M\IJVT,)>WIZ_RDZ$0Q<T+'HOQ]I_2PM-U373K _N61AE @EK2)8-+OZ[;#BF
M_)]TF),X8<G:?8^G55HW*>ZH[K5TPAPIV/G Z]&VY5/IV1ZP[9_+D6/G;K>#
M66MZS7%&SRBOIX56M_?\I>NR._+WFJ0Z+LU-2.Y3E^U9OLD_-!:BN0/.9L8$
M/E?"F,"+GI=,(&@2RU"Q(/XTU\>N1Y*8P"JG(XRF7LH$A@O!:S20$601RN#*
MQ=.FG<"_:E7TEV1"F<"X?#HXM#K)!!ZV_XD8+N?GLYD _$]":OV)6$_QS_S;
ML-/90TUZW.I<EI7V$'?1F$GB];'UA$</&+S8O^?NOZ']6S]UB57U5E?H$HO0
MB%>X<_71"*S$VMCNL[V"LE6K?+;(Y0=E.OV-#X+ZU[9_^M?_TIOEMO>J/$)A
MI*4@V!4LHK*+8L/ZG'QO']"LGG+50T%QN9- .PDIIY?(V(%FO4B];&#966?\
M*C'M\$/'SQ9*(<_-CEJ6S$L',X%-%)H&:0"IWWUK>C':V]9-N.O0XD93O^,W
MFOJ:FG@7NGD,,RQ2G91C7&I30E-#]0PCHM8V\QB8/?_WK'?\^_K[^OOZ/W7Y
M\D\+KIWW\5Y"4EI3&=A-J\EIZ=KM#JO&&1MU0RYQG+"M>35ZV_6BV95]*]UX
M%R80N7K+.=L1!#S#5.7"#OL';1ZY:JND0O\:>O.XW[!0Q'1J4(Z%*M7"+Q4L
MG\^ZN1>ENOYL-'.PN<SO\UIRQ%#@5I3])W4UGRV$>AN1DX?*FGJ6^8JW;RKJ
M3-^<<LOUHH#V_J$0]MZRB=''-[8I-9NGE.Z)TLZH'CC^*D*"XQ24HGQJB#6C
MG.\W[&R=/=G$?=E.*-:*2)>!<3*!ML4$QI9ZAGQ3X(];V08\U'U4JY BD9_1
M8N>,[5AONT.6%D_6"@O>VV'TU71PP&(J, .LH5*(T+1A#@[=0D 5T \$5RPU
M OA7$_09(+Z,L6T.0]V5!7Z290)5F!58)H)2CE*$$GH/@B;(SRIU.!IKP?GU
M&TS@;AX8%6C2KO7'R*U@W5FHKCC=P@0V@B/_[SQA$];P%09CEG: "7!O+UYG
MDZ%O8P+1JZE_X@'[00+"J#,/F.'!!,;6UO!#H?1?)(@+._ 4<8;61,(/+.1^
MY(^(*S1@I'9"D\_L#!.X!_L;Y-\@_TM %MM2W76ZKQ^]\FFP=*YE\_M3; 0V
M>:@LVY;"!#Y)3\XQ@4G36D0>@O[0KVW=OYX)I$@N2%=R*51E%_,?D[O1ZN0T
MD1OX-/JK8>O;$_7O57.(>DM>IS T/1CCKC<B@0E8H+_[7.HHV:0V_!2JHR!H
MX_R>*^!B^O=?LMZ\NO,7@X^P_3WT[Z'_=4/CT(V:FI[[;GVX/!1\2G2RD5><
M?ABJLT^78:&HRM$*!D=.8ID H9'Q8;'S$OO)'X+"X,<0T=, W.&41/CZQAF\
M# ,'^^='CZ[_X4.UN!X^>'_^6\%Q=MB!?GB<I_$'&COCC"ELD0(N\+Y@8^S1
M@MIQ:\(H$^A)^?Y+;F($\!4DR8&KFP<"$>N.\']^_);^8J?=_\2!FM0LB1B/
MLD= FRK7J+7:Y6[\"+\O$[!",($S<AN"N![N: ^QEB7=G0D5G:^'?T\IRX8#
M2M=^1*B)7N7.>?_?50'_50,M] 6?#!_KO5%S=^ =+/FH44/K04E.V:%[)^-&
M0(D.*H(>N8R90:]OO3P(8P*/A-'K;HC1TP+_QV/E_XJA,N)1B7+'/%J"V<I<
MX7'<M"^O3]=>>'?%'RNZ8I(6CA]A\X<\$DJ (@*0ZC@3UMT9A1N2_KN!_'OH
MWT/_@T.OCE<>9A"ZQ' *:)=F$7J9>]<.6Y'%$JN//YX<]"_/"&)=-/VE :IF
MU! 3Z$T9*L*13>"?E:\)MMP=?7HV&*-R;V>:!/X1UA!).Y)6O<4P)]=QLW8U
M^_DD=B8@G$444?4?FD2@X3O+MY$1(7ZP![FJFB%*N "3(S?\>0?/&.L<N%TK
MJK0#]YPR'<A)_X76/ R&?D+MH^">$X/Q!)OF5U_DW.G5@<;<USUG;<9FQC1%
M>K@&K/?UKJV/?;3)4=70MS547RAR&*1GZ;\C@4-/O;T(%K"ZY;=*G4G6YE(I
M0&:F;%&_#/*QS(CDM-]*VY(R+>X5ZFQ0HZM],MLG.L=.=&:D./K<W8.6K]@V
MB-[7&&,CY@0(6"E].W5-K+>(&#T^FF=04ZTQX(1M#>8QL!)_[6,W#34M8BW6
M3 "[!=)R<*"+Z3?8O[TW^4R0\<V(CG@%WS[,!)8GX$/K9@8:O,MCHZ3_Y!L3
M]G;P3]T*7@U^#;\BM(A978YD IJFX]:!!^IA<W*8UZ 8J$FQHX=GK$(%W_FK
M&CRFS1A7-PQOY7$?_2%,J/-BV]X)(X=$Y_H1KUWE?(K\,3JJ=R,T\ZH%2\2=
MP)U*N5I53 !'J,&$V1S+IWR,)IN3"-@@014IA%9EI\AX>LLQS8F]=0_8#UV.
M?=C=Q.A+*,U-(A&#32U$$OAPV>>H7-K^>LK^^/Q&M_U[G#63G%:N8,B];N-.
MDG6#6VCXM;,^G:1V*N8>2I&R7&O#314N#D]]AZ-R.!*6C2Q#YUY&\K4?L_]
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MAE4V<_5CU(L)0^#V276QGIG*^E?C2T:._ 1UR^:1:AYG,31NP\V:#*5+.HU
M(BVI6N0 #4O&AB($4>)#D;/\5H,^[G6)CM^* H_@'\)WY28=XUOF]XKTFB'=
MN.'PB[XDWZ7A0Y;!NC+AAN/XG0RU;XG(L,K#/OHV>33_=,>E2F[:O<Z6##-]
MGCTA7<<\#R=JQDBU;B=93;GNY94JA":4U FOWIX$NW1SG3'S@9J$7<V%N0N>
M.](V;93=.O2@.Y,VWRARI!,W[5YC85(P#(:MMH[1#RJ8BE<3=XI6/)PY=5U
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MU_;FD7-7[PBK+T+A1^E!; ?'H03VWI,(P<WL14]?I>0Z<3SIK#_E'1ZGM11
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MEM@,&L*X<S%KW:BF]"6RZ!OCUHF)_X>]]XYJJNOV1@.(*"A(;T(0$)"J(*"
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MI)VJW.V4WXC/[V6[VBJM7L>D^"UWE\<6-O'QP! CW.[P%G5VU+AF0$FQZ,<
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MX'_8#U,@OW,)/U+P*NGJ<@.O$8J/IOH3+[VBJ@'#*O?LYA'@&NP\V=?:'4<
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M&VB[#9;P?(5T9;"HS/O#I>040X"(B+JCKZBV0%N*7582Y%RI=.?%YT:O+7X
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M&M=+HIR$X?=!Q4Z^2=/ %3:JVH.8^A-"#+$9YR, ->7Q?J J#N>. #,2'4<
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MNK7.VI6%WIPL&[8KD9R( _I?OT<_1 D/4S<NW5^(MT;,1&[&X,X;:YJTLSB
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MZV7':L3#FP%6U*.YI3$'G34;]W5=BHG6"HTUJ;BG%T89^,B[:Z<>SUO-C=F
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M=*.H+E*^-"=062R@X\+;UHN#2X4K.,2CM,8'?B:#42[]16[*L7,Z=>QX:'N
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M9 KNTR)#Q<\S]9[2[4<+L^(_KCJE;-SP!W#8+B7Q>1-&_ 0U-]2+J7K11?9
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ME]'?Q__BL>>6Q<"BCZCJC$G_BOOZDM:/(^6CHU_+M+F.%G<U[6?I3T^XBJO
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MMHAHIZ8YN$:?02IL&OHWB:E4$$?;X^?8WABW6'@6M<]U[M9.GNC&S-2"R<>
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M5W]S[W'R-R?%MG'%!KFQ0QK;9.$Q@XJWD* =)#EX,>ASFNR;) __+?><.M3
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MK3%:I\B#?1=5W@5U#[\?;G87Z1L?,R2^1[' !'D=ZYT;4D=#]VR,\J[%5U'
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MG5HK]>$.!58W>T:LOC<Z[X3W%YV<R#GX5F'FB9BCB%@HT,8$K [KQ @A4>[
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M?EOGYH4:VH]+/$T_?C&1 =!@<NRVRS%X?E/](P6;FI[CL;&!I)Z#/(7/BI?
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M$2:891.0?(R5 1#,^87'>GJIPRZQ.*;2J["+>A/,I:$(YF0 )JX!J0_2X?>
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M^K[2;-,:)Z?B53JO)O0^_N</3KL+(6_#ICA*6:?!8.98]3PX-A:TU0D#95'
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M^/LX]+<T[C:M3F?\>%>:,V45PNJAPSHF((X0(S.]ZBG^9O F;S73!#OMPV7
M%4TW(F63],9S,!!Y34T.N4K6[WB'9S,UC[Q0*(N5F2GD0O?/V>SH=0Z9?RZY
ML-/Z3Q_>$'&+T@P T&:<%C+$ $@B/[L1LR08@,022!H]*6$.QL7\+0>DCS$
MO>]V^\/W;-3_!\W0]VA#K2D.VL0&R! $;T.U[055ULHRMXO!"M-ABM2"27,K
MPJ&LMLAYE"Q,?WC'*;FM&/34D^S?"!)&8;BI^XF#*/QX1! \#)([V/(VS_Z[
M"_]0]+FZ-T\./X]]8/P1<M]8];63;!OKZ+IE>[7:TBF2H?Q3,182K"27;+A@
M34Z12W/$&[!UJ;_4KL 95W2J3"V)KT3=U7GQ_[#WWF%-;MO>Z*NH* H1Z34J
M*$H5:18@-D1$0$!ZB8J $#$B1<"0T%&J@(@40:1+B4@O$ND"(KW7)'0()-1
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ML&2S36;_7G6#$"^BXF/:SD'6<& R$]*(54##QN4A:_Q,WJ8H<H@7]1$IF'8
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M3<WKB=?I'!*73@V9[Y.'[ 79H!S;/)UL+863VP=4KGUDJ7)?2EY@_>9F#F]
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M++^0//,HKCC3@1+XJX2FT&GK@S8]"!7LE(.,Z_25<9N2WL+THI83#Y(^?PX
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MMPA64D%HK@?J;O>3XL28Z04#1W>O@*K\X=FV;]K*MF!O*UEJA7R7OA>NA*I
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M^-&3TIU$IW FJ5O!G:I,@3R).LW'UFHOHV/TJFW!G?I6?OG'W#A(->:M!P%
MY;YU;HV=&B,0Y&9 +S_ <+F']<'U.^+GGRK=OH]2(#^,(/6/@B="+8'4V,EA
ML_K!6D4,3 D+RU%]:AXTK%+'P'LNZ)&LE>*+6\!P/U$S-?X'NA 8?"UO\ZFE
MA(99/U3*8?LGL:KF9$B:0?8"A]Q&6R=>XOBWO#LNR,<$P.\^,9F>.E"&S9Y<
MQNH#"0"D)@% MMH4<A..! G\=I](H1.Y#0@=B\U7Z(40 "7$L'FRV7II?6KA
M,/JVXUA4BO6];]V2 QW*EUWBOWU6T.7\Q#8:(^\;].;XSA0V8VSV6A\BKFH
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ME03 G!L2_3,-0)R@" "\TOBI#,1I I:8N8).O%_S9@)1:0LL\ X! (LYGB,
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M E\^ H9982(J9D+SI.58*XQ<#3O*MR_=T2&SNE/%?_W:R;HU K)$79<W9LO
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MLHWVW4^B(6;(G2N]H"W<%,XN"UCB%(I<YLB _B(!@JN$BA(#-6_VSEF^7'S
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M^1A;5B5--]M#F>K:A&HMD>QR=::E*3.N82"ZMM66'^ETFZ)2?I)5]YH)'"M
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MYP*0=@' %6R\6.*S_O=24@^(8'OT((YX'E718I&&Y<XDV8 .8*2AM<RKGA>
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M&D&'?]CJ4A_2P"KYAF=9T\M#.D$41-WE^";8,XQ8[DEFIC6DH<:\)&;'M6
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M?Y#P5V57VZ8?E.X&/&0C.4-$U0*\ZP(X6&X:8I/Q]NN*L8";BUU"6E)$6 ?
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MGBPQ!N+REIY=&?[/RBK]E_V_-;(!J :F"(L*/RZ[:A&<L,76[RH\C7JK;>$
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MQ__K;<3_LO\_C?%B^K\!4$L#!!0    ( &!_853I7T1CO8T! %C8 0 3
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MW/Z!"7T9H8/U !QX2K',0S1YJ]J8L5.?;5-VD1-];IU^,F;6G1WJW??8;2[
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M0O*XN=;D498U9W!7QF*D+VE!P'9'6ZW!.D7VPU&\X/_IR4&:*$X)S.*D@[D
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M<F6B-'^0<[7\Y_:^!#S\FKO&(S\OU-W)7MD/KR$IDJ(MX8QUUAX&<?IX;*K
M^7/SNOJ20VEE[HOO$^K>2S6A83$3:TEAR<U15[/7:N:=+Q@DWO79:6#8Z=&#
M %"TZ3%H,@MEKD_%OH'#!%;+0IAJITQL'"+'R3R<P7+J>K#CG>QE]T4[,/.P
M7)R$]-X0M\UOW^FU<K<A(]E$2ODN?L,F<J)_8G:M"E02"A>-SK[%[JGRV%XS
M'A*BE'1MH\1\NXY'=+3[IWXBI+G3R^WX+YSU\#T?X2VMN:3@@ANE&GF=2>%
M:T"1^W"S$*;8_5"[KLAE._N_UGL!1XV56*W!TN\*94?H(6*<:LYI?AL.CIMP
MMF$O]A$4>#O8&S><7 #FV@"-3+4F*\CAP[X8=.2[ZQ<:+.PNM3]S+UOUKM/9
M!^.TIBP6 :+:Z0YF>&JW?"#6!(KSK4X/MC3M5-OP5:(H)L7:?[<MU/$IE5$E
MA6<*YW;$QHSOK?/^)'% 7QO=H%:>G0PX,-;)>8%/ROKG3,"3C&\3=GOOYP8N
M*\Y0LU5?!Y=,6_[Z@*I=R4<:=EGAY;_[!ADTLV,&BL26$WQ\U8L365ML^L37
M93YJM9ZHG0!VR2\8_U(582?V"&&@M=GJ.^Y^#(UIUH=.(S0.#0RI@.F,0V.'
MY_G:KD!@TZ1CP!U/"ZOR,YVS>Z7T[Q[L-3:N@GT-GQ 8X'M."&'!UC?@]549
M^(NT7"%,I:Q/;Q.[I2 8S[CZV2+$L?CQY.WL1\V9G_1_#%YZ>SEX_\RE_ING
M+1 [270J\L\Q!$]53/!>;5WP5*OF"AQ :2=]@U)4@#^O,$TC:P4DH&5_;7.R
MOL+(DS*:.6^UP!9?V7&*^SHX*E3%;,-+8D?O=827LR'40#[.TEC8J-/.>21U
MDKY!)J8+5-@I/'M'Q"U>2H6_59G:AS=-7D%V=V<_M ?OEH1'Y\/:#'+NGNTB
M4@IF<M\0Q+JW8<SHGPA -:7;B2U9T!3%1QUL!E,J#N.USDPW-WR,<QJRC3N@
MOO)6M&.'CQ5LCSY<$K*ST!8MOT( #M$*%,'B+:7F*3+(URV1^_]8!7^.IBI+
M?<>^><*F7/M7=!'-2 WL 0B']O"4P&RVS[O:>!;B\.=?^[3/='E?/)XG3XQ3
MZSQ08+A3MW/KDXHS1OM2'\D1TR!UAU:8OL+)Z0+SGO%D^02</>;E3\:N53 U
M^ G&="XJ;]O&IS)L15)WPFS,;K*A"[=Q>==O6@\B-T@%Y )1O0C=3M&+QS/F
MT;)GHJC;NK(&RU9+BME?7!9,CU.F#;]=OG39)HI=+9 [*H05_>5WX5<KS@AA
M2Y-HXAAAAC2/OTX*IDT?G.S3@I.MY7D.L8JS4QAXC]:G%\]GECB.LB7F7W,?
M_;0AYX9&ZFP<D!+I?FND4R<N-HP(@Z:A)_0L5CB#I @2Z<A;C(G53NMYSY.]
M[>-UO])/CBWN&-([8/ ?K]!(+#/_U+F-:C*)_@@.G"%,EPFDJN:%,"D>@E_9
MN6D>?,K^^J.'_M%U_X@E,:8Y\C%W=ZGMS%7CO#NU%=XFA]Y%UW[3KOXQ+]AL
MR5YD%/!4H(GN-+M ()5$+\AWM+[5K<+S[DXYR4!GV^*5>U[ZOTM2]8R/@5//
M)1RYOSH7E52VMS1Y:XE.SAJ>#L#_6!'JK?G_R<4*84>;I&%\(M!=_QR3?J!E
MP@XM3?M>HE(1>;7&VR.AK76/D7S,MV)#-\T_@9F;%_>(=%M,VBG(@9?7 T9Y
M9L]76M5'U@O<1X-F+UX\OG]&LZUX:V,:\L/*F]V+L*':J%+KS*NY!$5,KD]+
M?7WCC<'XI$0;BNK6/1"-;!(;__P2!N(Y5Z!* 7'O2,T%J=AP]BZZ0H_U+8'1
M<+?> TSO!A*PO=S]8$:7<T_YZ]"V&>T6HSS0)6B=NU- PS<6L)JYCNY<3QS%
MV;@-O%-Q^!*G(?*OCGO,<]>$,MGB!A<L1W#L92VQY8CGV]/_U87.\H0P?(\:
M-,8^A2OCZ25"6+TD*Y#K"KIP_,:[#:8.L,V13>VDIL_,M)E#;:5[W[(6.P_6
M&+38_.<3 D\:<0]D9"V1>%K-7$5HQ<E_S-[/CNW#ZS:1]#S912=RR;Z)CJ)N
MQ8YG\@U@]:*'?7>15VP^^)V4M]]$/G=/;$(("X6#5L35:6Y<!,Z$K;%: ;%S
M!+N&>,/J20M;<\S))*P@W#9G]<Z];UVN"88.#+$4*NL5GOZ*)&*'GY[L%<*:
M@C* (N:S7\Y6X%W$]5\$211H0&+H!UX42S!-0YG>WG((?Z[-ZD/?V8,HF#)"
MA42?7<\F--/Z"E+Q6@1.%!C^=+G4_AG7!92G4,H-BL@-,\N.5B7V=89MA7,?
M8][/FA]:RQ_ ?#C:W^(F0OEUKA*[%SP77'W?EB2W5)T<63M8RU#5:!VW,BB6
MLKK^R>MKCOOMN@&&T=]2V!_$82@<7P6?@HSX-7:$J9,N_'*!30#/'Q \Y+""
M>^+ ( I+G2.$A6<N)N%;DSRY+QC1YD4_4V]]E4%KX.FM$!FTOAF:-J5PIL R
MH(-97$)'$=2#,&$"%%&Z3U=05(T*1$:9U,P^*#&W]5R8.6:C]E^,2$XQC*?)
MW2.$O5_&:PEAJ^44(>SY6G;0D! F>1F,/0#0>$I#OKE]?_=UE09A?4:MK2:H
M^H_]OB51W5&Z?F6%R46E,&Y'+[Z%F,F+XL)[N%$@9$O^ O!L/?,)6^]A%;\(
M*1CK')G[?'&4L]MY.J]2_8MAF-^G'8;&U[%CG#+(YQZ>&+^ %$J4P4TCFB1[
MB-FEUM<[ R9R*Y?-GTPAG2SC93RC&V?ZKXV20[(U,WV_,=#!MYNM5^\;ND+2
M:2\8;I$O2EQ]]D29#$CRC$[\1,M#9!W7B09B'?HBGGJ_:J>DNVS32>>7V<%2
M*ICKH.70:AQ0U"> L8=8NH^P!\!SC-CLI8MS<NR2/"?]P:>!26R+82FK&N.'
MEKD#/6_N52KNLA]^Y8J"),Z_(>6I8(@&'"/ OM/4A; ((4P"FOEZ_LY^34CH
MW@94%FSB/TB\;)Q_VSTWXXYFH7WH^7*4O%CQ^X*! G KDB4SKS"SPJ"LID"6
MVX+WZ1[(-'5'(2R+ITFD\OS9E16<0<L@ZU73EB;4%M;8IF>%2>?)!7IFI_)R
MMEGA@X2P*-JT.9V8[ZR.&X+7A_<KR%GG.,D*=CAKDNHGY#<ZFK)ZG/4S=.^=
M??5DT%?92C/DQ/(!V'4%]SI^>[<4V,&Q;>5W="OT56,VWCCH::?$AP'_[?!(
ML#B?-Y< :4S7#UF#\86P8Q4CMPW.'H[VX)X&%=SYY5DLE7F$_$HYO*FH-['<
ML!D8J)9[/5'[BE7COT3VJ?MH=G];1N+-N[EY;W8?>0M/H\:2%0K@0#2))<5V
M$$@M<0]<N-::C0C#Y^$T)T+!&&95!A3"CM+/C'SZIBW*U;8G@@X^4G:JOK&%
MVH!KQLT)875#-TG1^&D:?>T%4,#82%O#&6 \O$;SL^9CU=!S,P&@Z['7^6KC
ML4T+36># .,3]^:+=JKO_R"U_ZG8$GR:PLD'([E>/'V -(#.G$Q4\@.)O>V)
M-Z-_/?2W2_=J:NC.^M3JH"@1K!3Z2?YHRUCS/=G))/2_,=F:=%9;")N:/ &6
M,>$W\;).:C',P/#^T:6_"GD\Q MTX'*0/O#LY<LE-#4&P_HV2]&V/7[[CI*2
M@=CUJ)4+L*V/<_Y_<FZ6E:X35WIK!YCU%(!&#F0X:":$L7;.XPM(@ >1:N8"
M^&9V&W]HU=L![H.H4G*P.N+@DM^T67WQQ!HUV3+33Y3"[2=GX)8'7FS,JHI
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M_4*+/5X\NZ/TM.U.YL'MQG'/#;KO/[[NK,>_1Z(7SD&,G'8)&P2F,X= ,\1
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M1D0$J9$F;Z:3@V!9#*<QO^66F"C=3O80@M.K8EQ^ZHJFFJK4O)^]G@LN"RH
M2&+WG$/0R_1V_ONP0# HQ]VZA&_2>PALN'9,L.PLD=YE/0JO MY/K'[*UK-F
M%>\X<ZM0ASVP*ZB:NT4PA%!$A%I/*_3 &R4ZV!YN['V+U[&ZP8R/VN2$;K42
M9'Y4\EXW5LW7TO&Y3WZ<@6><]ZFOWQS]W0ZUNQ#&@9 [S1SKS<^"Y-ICA 8B
M=H4XHW*0'4#3)#;+$%0PIYW5/IXMKESQTNB/J44T+VRK;[C>>3E$I_QP,HFG
M!A=(C0 4@70!UX0F&(2K-/O9ME5.VO)]/28MZ<J>E5]0GV3<%<VTRV=K]=]]
M;ZPG/HYX)$N0PECWT>1Y<O]N9Z0\I2[Y^V0\[:N*2%#L/6:? )#K7;2>ZZ\>
M.GW"9O>6M\0ATK\[D8?P5"1=@Z<FQD3PU(P8&ZP9^FLG+_;VWA]]IX")>L!Q
M.<:9.I%D&6 1 []I=+N];+?SY2D$XKV#+"X/$N'[!!]I#54L!SJ"ZDHF-:%9
M#ER_[]W.#@+UEF$G709"!NN EU_"J3?[?9AT/NK^?*YS:*]E]T:B[*8&V;O2
MU>NE3==>44/)_KJLKN;Y0[T3R1UAI5N_4MX/:;5KG+CV/-YL/+Y:]80DA)['
M"D##(3(--/-EY;+3.?7M_#I;M)9"GO^KOP4YMIO 0*LRCM_7KO*??"T\*Y*S
M-3E;0T&[T/['YCV_\>"V19YR$1WJ:$J?L\IXYP$F_V0/7 FGL^)>S;,'[S)
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M)H=XCJ%QZ7!+1\AD^]N.SB;C<X\CB#%WPH]5VX:(W<N'(8XX06LV*?,+.^,
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M'.7>9N\KWP/6/4#I%>OV!/[V&+][5Y6_U +"^K=O$O/1\-__X%,%#LYA1=2
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M%</KV(8/QLYI4F;[] D=W>CFI ]0PFUBMQM'G)987N*#>.!":Y@V)![LC7P
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M_1YRP=GRO%IO=D$!=8#Q+HA<P9+:9A1^,0]B2G*->Z7S'FDLGG,\5I 53O)
MFH4\J%S+&B@SL(G<ZH4?U=48>4Z=#):UOAX6<54@'=T]TII?NS>O*9K["E"W
M%60Q[-)H@;Y0#QTN4' ZD-O/D.?*I-,^A4D] '5@]ITYJ_T3,M?!$3)C7@'P
M'!%_LB.@@Z5"(Y>A@F6/]1G0)UU*"$>OO&OO1-CY[1%8],/Q"\K(.J.^>TG_
MOD&?"R9R\!SA:UP,!0)[-^5G-Z%$.+/&D.9?*:1NFHE7RS12>_DG2F[T34$;
MN:NE4V6-PO0471L+55A6/2_=JO82T_'GW=_3#^<1S57O]/1E9>2N$>8-3]II
M6-RRG5MXE9,MW7'P],+C<8$A+,W+\:OD.O=NS(,+G$\H&: AB+0+DA\EVSM
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M9J[A_K*3+>3_3WX5 !9 ?80(&VG77+A,X^:2T;YLF: O83]>_'C7=K=3[U_
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MY<DBL7K6=HEPG=(W4?CMRM++$-);_"$(*1-?%(!9#*!YTV<O#RPA[1 30B+
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MMJLJ\2M!^%@P?7\W>HV58_5S7(B590AAMW) 5&?(*SR\<SATHJ SB.E$%A*
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MD?BNDZZ)NOI.(/]!.3J"H#1!U/$6!GBNQ+.MSS<$F#_:0%0+!M0Y&N)ZF1
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MXD/>!_>W]X?J2G(;/#R\-T_DF;P=?^9Y@*OKX1/2'SY8Q!Z=D+OU9,AX/JW
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MI<XKZ_U:<ISO:UA:SB@A5G?SX%4)L)M!L"4T\!!EZ(;JK(0@S8'R#[VT%P$
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M4R"I-EK[F5IN49VN SQGKI5P+M]#S3V-P#^3T-41R3;\R]SQT(DN'D+>V&&
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M(2N P53]F03%7VPBKG%Y"/#M(D"[B!/B(3).T] <.6\R&,U7#SRJ_XT39^1
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MO+ _;*Y[&QC==VV9+[^Q^E#8KF^P K;=:'E"@M:2>XCOK&;0R9_?.:\UD(X
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M+A;NKPT=Q? T2.:&9AL3Q\WV 7%-7!,:')S2[_)Y",I0F2<D*G<,E!:D;2Y
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MA$_@ \L!ZCP^<(D/,-]9"%;["Y3O_E/HKHM'*<]NP'F] JGE<FV8FWAQQ_@
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MJ"U@!].OMVU<A_'$7='7(%3LT62$:Z)IXV_Z1HWB'RD#HX7&$HR<PQ"]FU[
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MBRJ(,F<5SAH]S^QS<:L9M]V1Y%KQX'1)9$YZJY7RL\*_8V]9=G$Y4>M\RG
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M2##FX,)8D*'$N"8MF9CDE,:?H)L&)J@^2D_997GTL<&,U>->JV-"$*XZL%T
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M5-(^($\/7>0Y%'JO##'KORF33A/\X=W8Y$=+BWQJ$GG718!&C$+6-JV.4*#
M2=_W)"DX)>U!7@8LRI<AW:Q+/U[*.=UNS=$K_?O8:.E-4&3.G'S96K(C-]6
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MKBYHS74?IO^Q5?QW2B76-9OVUN9(NDI^1=7.G=8]$!R!@P&[7HJ]P$W%AC!
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MDE0?:$8E*JX_"8YVJ7%*M/8"\023;&C:^7WOMY_(-_&KDU1"'+S6,-*$GRE
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M+YWE<\L;[ZB(7^I3GS919Y_#>G&;\8&D%&3=8H==RE16%TP *]H\\EL>I .
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MZ$@\58*YWC%KUG.?+O/HMW7EM53,C;;^<[5%:1^6#<4V"J/HL QU$$+J#/M
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MOJA6[5^@^@OT_,82^V=G0OVT\_Y>E"TRN*0G7H;FBI]H(4=XJ."S]T+9[L-
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M[E,*29+%$*6>![$7<YBJ7K9<_AHGB8WONX\04]N\R*\IM%M5>D%OMDP,#>C
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M%'^F(U>H#BJ4FECTG3">DM.;T$& 'OK88BLS^-A!N",V^%@C?#,0L!;=/(8
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M*W&=#TF?><=P*[2YV]$ []/^7+<H#LQO&P";/.&][D6G )H[:]T".9*']CQ
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ME2: M9+<PIMA!KN!I\@YF$/[B&J!07TZL!6Y(5(M-/B]%MNPS),%H!:.(>?
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M=NAAK]DV[(2")YJ&G;K;GN??2IL6DT(5+GK<=MJ^8(_YJBB?/G"^FH<X17Y
M A@DL>1W%'DP(\27OT9^1K, !ZE1[+'9<%/C]58V(+A-YQT#7$_SMENT!C<>
M.\)V662#X ?7")JSLULD1V+E,Q&UXF)S@(YPL,%#1N-><X6ZG&MQ5_^=OSH.
MP(LK_,#+YJPIQ-)8CL(0$J2ZA7M!!C$6 C(<>UF<<DJ)57O&O:-,C5FW0H('
M):7]_GP72/,]^5GPC+ /;Y#1 CH\DC."P/EN>W>DT7?8!Y7=MZL^?''O *P]
MA3WGB1">VCI#[D4I1$F2PC0,L=PY>RIP.,O\>%N=KJCPPNSKWS^:T?O]HCC=
M9LP!?7R\ JRM5EOA;V"Q%=DZSFH?R&:4< 9FKUU662+H-([J" ZN Z?V#35V
MI-01=?>$1AV[VG[W]3^+DN/E%VE(;@-#F\U=]=0L:8F7LBC#$<249A!AS"".
ML$J)]PA)/9;Y/#7=?AF,-S4KH189:)F[<=(;L<UW%"9HG]Z4.<9P8-HX"5^/
MP"D3',VW9H[Q'&EOUO^UM-J668!S9%]F\I31-F86*G5W9C:WC1Q151]37HKZ
M_&7KG)L++_-XXG-(A1= E"(&2>(1B$7DT2B.HQ SNT-<YS).[]#WFJ]XJ<HZ
M+C>GO\V!K_M#7O=3;F9MONHT#GUN<WXLTDYDT5;1"405G9J#:00.'93RSQ$;
M= ID9^$_)P?JMYA<E<4#+ZLGQ4_5Q5)'&3VH0>OH(OG034-E+\UBHA8)S E$
MC'.8(KE<1-1G09SX*<D2&]^?\<A3L_35Q*U5@5[>2JQ;:Q1*;#M:-P??C*X'
M@71@&FYEGNDELH9R(W<;W*-%'\"[: V84\XT'WU4+K0&Y27'V3_ I;?RX.AS
MGB91P#(,L7).():&,.-A"%'FD<!/DC".,XLF&SW%Z./?'('5/N3?I(&#=?UI
M%_[,P]-PCJ/S/%1?VP-ZE.N&]HV>A&X$I^EA&2;@33T)D)F;]?1C^O9 6W%Y
MTYU\Y#O^R!>%?FA3Y:MNUSD/$Y&*A,;09PA!%$84XL!7NWD4A\B/)?D9):5:
MC#DUZZP567]<':';$G26Y&:"NAFA.<9R8!([!:.DL+KO[B#]=WM@YKC'V>EQ
M1VYO9@S$;F<S\UM[Q%_SJEKHC>NEN.:4YX^8++AJG=9$>8M.]+?JKE:GL7SA
M5%>IG>,H3+B:A$S7#A0$PRPD,4R"*(EPX#$O3BP;GYTITD3MLZU6RM]4;O2J
M&PZVJ28O,E!T:T(LA"[=(BT2Y8RLGL#W5Y^^6'13.W>.3Y]5C3%E(WD5M]-T
M*<!6%Z"4:=V$\E^Z*2Q :=0F-K8ZC3<]%K'CXTW36 'E@T^77:2Y&X"/A9^?
M.<)X,>ENH'@6J.[HD7:K)./Y_+WFW;\5B[5\H\NG#_E"KACS($C\*!,,\CB(
M(4HRU9(NBF&:)%Y ,:4D-4I(.CC"U&SS6DBPD1+48II1W6$<CZ\O3M 9>-6P
M!<:85$XJO\=L7G'ZXVWQ^).\5UO,?T?J1UC_J(GD\%-'H8>32K4?_>D+>QZ:
MR,G[+*?SXEN^FGM9&H=^E$ _8!Y$?J9:CJ<,>HACN0U/O @9Q3WM>_C4/F!]
MBJV$ [\K\2QK<3R#S?!$HR<80Q]:F.)@?R*Q1V&WAP[= <8]5]BCVL[1P;YK
MSN_H,Z<1"JGOQQ!3+Y3;S#"#64:8*H:<9E[L!S[E\\H\=+G[<*N/=(1(91T-
MW;_A3H_^.1/Z,G4[G*IMAS-,ZYM!OLMG [Q:8YI#W^7>:^R]11>KU?J^KE;R
MZTKU/7V_JO+[IHSL!YR7?\.+-;\4=:V ^L(+LJI*3*LY8RGSF?QR$:/R&PZB
M"&+"0IC1%,=A'/.$^V91:N>*,KU@M"_K^WME-Q9"'>&UBH&U"EJJ"L!KW;@.
M2A-2.?"HM-,Q:WI+6]0WF#L=SIK)TPZAL69G8#;JJ &4'N#C$FPU48X%I0O0
MRJC?:O]"HX^T+1J-+&*>S_O"C#U!8\W/2&Z@BY??3+YLOYFFC/F1C^9'-[X?
M%Y ><?R<]?C1O#XN0.BZ?)P\KV]D'7_ .6L.6MZNRY+K\^#/$H7ZEWD:J/CJ
MQ(,Q4V$H(E'),UD*.0^Q+RA) [.*-.9#3FY#64O<]DZS#9\[B;#A+M,I;D/O
M/1O(WI^ K$<PG"D*CJ/@3@X[<OB;*0R[<6_&=_:CE L=G;6AK7?YBBZ*U;KD
M\S",4>:'"<Q2XD&$60+3)(P@\R,FLC1+""(V^]N#(TURL]N$K8%[CI6,#."J
MLV#;D<IAC*4 .!51"@5*,$01H3#E7@H3Y--(I )'@57Q S<8CU%:ID;WCB\8
MS)>P*M='.B)8@FI&T$Z@&M[6ES+.NA;]5DYW+'T2"J?D?'BT43GYI-(OJ?CT
M#?T8>//$C\N'=;7ZI )J_"9&/Z:I)R0'P$"D$40ARB!.,R1_39(TBWF(6&27
M17=DM.FY(/[7NE A)DV%?KF!NJA[1OV"RS\4?7ROQ?^7?_9C[U]]R_RW8[ '
M6<JRV/>@'RC8TY3"C#,&TTQ@FD18,$1M:-D1Z&,0\Y9J9J"6=@:TO,!WAZ\9
M0SM";6"./@+8 -DE!I@X)>MCXXU*UP:*OR1LDUOZ4?9G7KW%J[NKLGC,&6=O
MGFI'P$==+#M?WFJ:TI';6S]8[,4T\P6D\O\A0E1:>IXG[6J>!1D/.,->9L?D
M]D),C^"5 D LBJ^K.JXP;X4'>"/]7^UXI\?<F-'1L'@/S%*JU) &NQ5?I2%_
M_VOME_P!;)0 6RU,?,76_-4?1*>TUD.,4=FN/TPO2?",)_7-*>DV=KP4OR[+
M3>NT&_SM#5]RD5>K]]_H8JT*===E7%=7O*QPOI1_N"G>?\/WJ@^;:A7)JW6Y
M7%UWV_'05&Z4/03CA(?2.&,>5+X(Z*LV/9Z'/3^VVC,/+?#4++SG^JJCAZ[&
M.L.LU7D&-EHWU8]78*NW.@5L-:_[M]:ZG]5<9_#7QXSLI_12#+PT3.9]Z)'*
M,\XD.<X#&ECHD9.(QIF"W0RDD<;MMPC^7!3L:[Y8?+Q_D)L0==K\J5BMYG&
M8M]/0T@3)C<!@9";@ 1SB%F*/"^@@>=;Y5+N'V9J"TXKI=P?;^0$2E"[E>$
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M7@.Z!*P\/>Q)-I:+XDA _J$>VLA22I;16@UZ^FR0?ZG*K&HD8$RO0IW&]:;
MH:^NFU<B.@RM6<KP.E3G!M!%^G,<IF\EE"^/=+E\L\L7*YGG<QK$ 9>4P8 C
M;4.)@$,:IPE441JD$LLH4XYU4%Z,/S5*JXI]%#*"6DC7&B@O$6SG)P^X#,T_
M3I#TJ'YR5O$K:Y^\''/DRB=G%3JM>W+^LKXM(5??]>M1N/#*GK_%T4?Y:[W[
M"N=Z^R.12@2D*L4F;BZ C(<"Q@1CA'&&$^%TB-0YX]1>[8/ ^RS167U"Q&NI
M^[<!Z5X!.T/%*ZX#4\-+2+^4D%:%V?8"^^PW:0F-Y]Z37;..W(?2$H33GI2V
M-_:CH N1 ]HTV4B:R_RSS'=+$REGJK=5"7B?Y&:Q-E=_6N>+(L%W3F*!.8HQ
M9#C,(&89,C77"$09H90Q35:)DVO?CUA3([.]^& CET7YT.T:5(F,X%G23=$&
M\ZD6WXW*/*VD'=^-OSX#DV)+T%>M%-@K549K5VJ!4J_BID^=2^=,GWZ1]LJQ
MGD0;E8C]PGG,UIY'[U$.:+DLCNQO=]I4>M245OG(.4MB%20IE(&*](90*,W4
MG,"$(ZJP2(A,K0[56^:8&MEJ,<L.0C-SV%6%;1Y7;K9N-=P&;CME>H)L8/XS
M:)4>O[V,/>(S+B'D4 ;G>J3&JG#3!S&W^C7M6+25IKEPYWA59]I%?U%0IN/2
MGK4*#^U#;E:BL)P?UDM]?UZ6()X'12YKAB&-> @QES',>!9 0CE5H: QQJE3
M_<*."9WH<;0R#XV6Z\41=-Z0^Z]_(5&8_J-HRF9;/=T:?CLSTR>H Q/HAR,D
MW[6CYEXNT1(*OR44NR8=MZRB)00GI19M[^OKCS3)9.:+DYMBCE6#HGV5\V:J
MI22,*!HBB%$80VR\D"S-0BA$BF46I%)%L9LKTG;JJ5EG#<EG16'1QDL##N)?
M$?Q@O2BVKL@AH!Z8E#RBW,/3Z J89R>C]?0C^Q==83EU+3J/T+,X%N=%VM"A
ML\-'N9V3F$62JP0J&B00DY1 E@44$B00(5*("#L=]9V=96IT50O9:!/D6*_I
M+)9VU',U0D/O'6MP#@+.]$[;-/35QOWZ3ZI?#*#6>J.TD6+A.Z^G%1V_I9O.
MSC1NV:8V94]*-K5>W(\3+G3;-DF#7S=ZH1_D_4K6NWZ"$KV+"J"D20JQP R2
M+$M@B"*A_R\2B7"*Y'28>VK\4<D'M(!NO.&"MQV;#(3BP!Q32 V9$1M43=Q!
MH\?[##00'J#P4 _0O%*/R_RC$E(/8(YIJL\0O>,M"KO(-*BJCYOJS>'S;5U"
MF,HT%F$"@R+D@@4<LIA0*"(9XE2$*E/$K521S;0NK]HXQ8GV39<W\KM<N1;]
MM(+:CK!\PS<P4]7BEFTD:X%G^[[5S[/:<^@UQL(:(M]A%MT3CQUI80W%F6 +
M^WM[GDO+/)?R_DENJ/$#?C!NP?T4U8<M?[N3_Y)T\W[Q7<Y#A"+&%8$R8Q1B
MG!%M1(4Q1 'E@0FYR$CJ8D2Y"C U2TH_B(GC6;0KY)9GTP,".?19=2'Z#.R%
M!X7T+SAJNP9,:E-K(6; J ",#AZ/LWNBY_=XVU6(<8^[>T)T<OS==QSW\(.Z
MC,3-2MRMMOJ16^A-9UDY^)>-*5>"$I(EB<!0XD1 '*H0$AYIXRI.51P+%,08
MVWC=;":;IL?M6R5U<1*[V,M=%5R?@4)T>X][)^+M9.8;QX&)ZY<F> =A055/
MW3=V]F$+/C$<*7[AE]8'$7PS8GMJQ&.+3DM$0^<0HX4VV"K3C'&POL>=<@^\
MKL>YI9O-LRIK>.7O?CPM-OH/BY5A=</N^3P*$IRFF8(R-M:DDA0R%410!<*D
M$XA,95;6I//,$S0CX^+)-Z$GLCBLMB<.-\R[&7@P) >FXX;]J 4'+R0WQ1)+
MV4WE>B-]848ZT+,;RO9</1C:(Q&W5]2=>+P7<BVD[C;>: S?2\TFW?<;P*M#
MYG TGK]Y/EQ3F?O%X6K5G.W=#[GABUSF=ZLR%+FNT'-3%NBI_UZTH9C3-$62
M1A(B_7#J#XCBD(E40I(JBE :2LF<CB/&%7]J7Z%:N#*#[;<O;X%^<LI,-L=$
MMI$?@ZM<31-8W!&]54W5FRZKW-2@/^O6,@#,ZIZEAM$K$ REES#,P+Z,5H7$
M_JJR7<S@GJ^!UW ,Y]E0*DS!_S;P\EBZ\(:6HF=8DQ!%G@U=FM/-N]4M?5IL
MZ7*>!7$<2"Z@9$I C$S'OS!(H20QCD2LL/Z'F^/OPDS3\_4=! 6FWR+41,-+
M61VCG"Y :_>Y\ #7P+S>P,F(: CYM@,G]WBF=A3\1C1=F&O<F*9VA4^BFCHN
M'R9?9!\M''(BN,H(#+,$0YQR!6D<"<A5**)0<I*&S(TE;*>>'FU\N+MY<_?A
M[NO=NR_@YN-;\.7K_>W__9_W']Z^^_RESAYY]__\=O?U7WZS1QQ#MX< >&@/
MW=ELDD'BM%W1&37!Y'5BM%TA<4TX\12??2';^.L#W?YSO5L*4\R=;_>5R$PQ
M*KJ5\RP,@BB. DA)HB!.],)012B,8J80CJ3,D/)0JZ%#C*EMQ5\4 #!E&*HR
M>#G8:D7 GT83L"A4 7)?W,U<N-':>"G5T+5P=FPW_'(,S'T72S&4*U$H 4HM
MP*',7EU?;_#*"Y9 CE%IH4N4*516L(3+LI*"[6CN?K1WCT_+];,L&/OM0D^N
M'XXZ?3W,)$T#Q2!/D@CB+$A@QIFFS8"EFBPSS*2UUZQEGJE1XE[4JC!X):R]
M!Z<-TVZOF">D!F:K"R#U*)[0AI:]=\L3:B/YLGJCY^2WLL"DQ4O5=O=H/BD+
M%9H>*)O+K_ WL>.COK(JV<UN^[#>&,K^;:5'+ S?\H#ODU[U_,4AWF=S-%C]
MQJ0F50>!;>=^X3Q(M,F*%(:",M- *, P0YC!F*M 9#10*1'.WJ=74F9J;'_2
MF$/6'H4G(Z\?#]5K/3@._JK_ QZ'$;U79W.M2GUF1SXG4*B]_VV9!CJNG^J5
MU\Z_U^JU%!K?A_7*2W?6H_7:,EV7MJ]?73.CM@#T;S8[*1K'4G4&E@IP$C"9
M0$I0 '%$*,Q,VIM$&5<1#U"&7'U>]K-/[T![G\G^5$I?6*6TE%]_#\US8%LP
MKL]J1"P5$@4I##)$RWTF%5$&>49BR@.)",I<:E(-M!9C!,NWKD2C:M5PBV'I
MLQP&XJ']F#6ZGQKH5H*#AN0#I"KV &R0(@XV\[]*:0<'8"X5?' 9POVD[*TL
M*A27X>OOUQLE%_I+-J<R5G'*%$P+\E("0ZIW9)!BAB*:!BA"D>TAV?DIIK9C
MJJ3,36V34D+[PYX+(':?BET/S<#<4@E8Y>3,P'MOX-@?@ET/TDCG7^Y@.1U\
MM>/0<N9UX<;1CKO:!6^>='5<Z4YOMT47TL*H-][:[W1IXM?V(0=,R80$:0I3
M)#*(48I@QD@ :1*GH<@H8C2VLYB[)YN>@?QE]_A(-\^GW5I+)ZG<F&,C4VQ9
MVQ%%D?3M@P2B["59]!E;FI2%_1$2X'3)=\LR-I9)3G>Y-&/KNQ8;;91L%["X
MV3CX2J>K/8ETK&,WT_I;FX$9MQ2T[.0!&J(Z%T^T@,V>@_W!-Q(75S 6)7"+
MHK>5R)Z2(.WP:.'DC@%&XV8[19H<;7E'O^..?;+-NVI_OG]64410&.$,QHF0
M$,<HA!D6"90IRGC(9!IEU.UPX^)<TV/J0Y98?6[Q=[>]\F5<[7;&7K :F#D/
M(-5"#A)BUPF%UQWNY=E&W<]V*GV\>^V^H1]!E#%WO\KMPUH<:J?>_[G26\2'
MQ=,GJ1\F_7'Y)N<T#!%ADD(:1C'$4K,&)2*"+ ZB+(R(R-+$Q;UH/?/4=K8'
MR8PUMJX%=B,0>]SM"&40- <FF"INMQ0:'*2>@;W<X""X/\9QQLHK ]G//BHC
M.8-RS%#N _2(0ZM#VBYTD/VP>#0;W(]R^R++6.9T)<KZNOD\3K-,9C2%08P9
MQ(HRR%"DH-0_AI2CD%*K, E/\DR-W2J1P<?[#V7<$2_E= C5\K!(W1O0D:$?
MF@K/=L0^:H:]7QJY!2_K'%0A8K>OL50.T7?C+ME847JC+)U;2)\_H-M"_SS,
M,EZ(H#](7H02>ARV;W?SNY7^+M!"BK=T2VL7+8X(SQ0GD,<*02QX""D+$)0)
M"SA*98B8U7>N:Z*I?<"JYMX-88&1MM-9ZX9N^P?*)V9#?WEZPM6C*WH[%E>V
M1[\P^,A]TMM5/&V8WG%]OSW]^\5*D\X'/>9)0;6;Q_5FN_AWP4W524)1V5(_
M3O- 2!6',H(\U;L6G'$!"2,8$AK% B<\BH3CB6 _0:9W7&CJH;EM[WLN@=U>
M?WA8!^:<4@%8:'!2J;*HTJ4_JB8LMJ%-76A7"^'O). Z)+T>"_049=0S@NO@
M.CXPN'*T?MQ8E_1]O][4$2ISSH7I72!@AD/3_Q<GD&3&9D))'*4BPRAU2IPX
M,\?4C*0ZM.*I$M6-W<Z!:$==5T(S,"_5TA7]F&KY_+%-B_)>J>3</*/R1(NB
MQR30=JG;&YYOMO-?-:4\[AZKO$"&(QHFG,,8AP3B2*4PDR*$1' I BXQ4\CF
MO3X9>6IO<R6<W4M\BE/[JWN5]@._L)5<'C,B+VK;]H;JFQIOI_[7\9MY.NHH
M[^-%9>JW\/(%/<,--M_HJOINWZY7^7JY$&6ULY7XI!>^/HV[5_KC3U=\09=?
M]&_**FAO%SE?KO/=1GZ5/[9OM +_-8]1(GF0*IBDH818[T$@532$"4U#1CE*
M>&@5-SN4@%-C@E_D2JYS\/5![RJ?Y&Z[X/G,G$M>#M,99QWMK(/77)V!F:JI
MV@R\4*XX_VVJ9]S*>P7!04-P4!'\890$A98^8S$&6@"_(1R^A1PW\F,@B$\"
M1H::I]^7P33CO5OEVTWADM$"?9=ZAZ<W?$4%Z,7JF][R[5;;>Z6IJ_0DF]3"
M]<J<M:9A''+%)4Q3F4"<(@E)C"E$:10'*J5Z0J>FNE?(,C6^+]I6+_:ZS  _
M:*/_4>D#:*&0X159QESP6B&W[\(UJVCW"1AI;09F^V)9[AK+<MM<EEH5<+-?
MEBH4YK9S69PIW0.@7MG[&GE&)6H/P!USLH\A^]-OHP7Z=[I8FB0XO>O^0I?R
MLZ1+D[']"UVLYI1P%0NI8"#UUADC%4.:I3%,0A%'<1HIECG%^=E//4ERS?>B
MSP"MA8=JO8$Y-2_SIE( ?-,:N+.IY:+8DZ=_J,?@RB\-E&_.H%S+#GYI0[D7
M.;H!YIT++:<?G?K<8#G'=(XC]".VCUHCTYATO=07?2O<J3+?.D;CMP\RH7?E
MI:"@EG20N'P[4+R^#QU3COH.V*E__-Q;WC5\>]RO?Z[G>H_$,JH_W2'%!&(2
M4$AP)&"48B*I9 GG5N??/>>?VN=</W1HN.:X!G [MAD0QH'IIU=K7*W"ZW3&
M;6#W:HUQC0R3[8O; .B:MKC-87HF(151E/?JW0_^8$I"F6JU]ZM;FC^8_S6R
M(C]K,MTL3&R(^</-2KS\1>/*.:41#Q05$$F5:/(C"22Q8<"415AF@F+EU(MK
M !FG1I"EBL4I4:5D4;X;E#_G8&T:G^0/95: ^:&1!^R8_33 @MN1[RLOX\ $
M?5C!6K^B[+=9.2/TK/AO,PO>[*QJM<H_FL4]_MT[BW5VS\(:;B7\YFL-(.>X
MF5W# 7V2 S;@5#VRQ<YFI+TS1OG39I'+W^ER)^>8J9!1%<(8QQG$*F.0IE+
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M-5_T0>LU0-\M1;53*=PZQXWKYX(BBA%AD"4L-*V.0IA%^J<4(<(QCT,2.I5
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M+(O__4GU_:*NR!<E+&:80!(2"7$8,YCA$$&>*:H"HB^,E'UM^\[YIL8&E7"
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M6DC[TP=[M+M/:P;!<. W_Z@N0RWT;-^!#GQ=@\]#XFI_T#,(OB.=_7C"V>E
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M!16CD10R#B6SZEO<-='4=HZEK* I[,R<;?[-?I?3BFOWAM$76@-ST$6@>M1
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M8[9W^3R3,8M01B$6<:+_$R'()(^A2&26J(2$3#GMJ2Y/-37[P9R9-S9)6ES
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M-M9011DDA"204VKXF$4HQHD/![M-.S6B/6G0>EB4K>X4ZEZ.S1-_-RX-C^K
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M+).<BSA#LR>U*I;2O"ZK]6APGLXY[G-:]X^2RM!/N9P7LG*(A4&<8O.42IY
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M;[VDF-HW\.&;6BEF)1RF2.7Q$KA]@ 8'=N"OB%_YRCM0P0^L(L!J,GX]RXM
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M'X5FNE3;<D/G=?V\?V;()[5:/]N6D[8_DMWE/%E..>BJP3G+B,@0S A-S.[
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MCU)Q:X7M#AFF]G7X9 ;ZQK:%D^[,'_OBP")8W>:NA>G^6(P ]\"?C:LUFN]
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MG?1-7 RP#P%06P6:<)CE"JSW.O0-5?1;, >&'V<9AJ;^XQ#%K1IW34P)L)J
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MD<>21B053H>@7K-.[>MS*"6P8GJ6!_6#O/U;,AB0 W\^>F#H3$.],&FSD,V
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MG&+SJB4:4H8H3)*<$:8X)EGBFG!\//34OMA;Z=S3BT^@:G_=;@-@Z!.A1K#
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MQTPADF$E<J?]]\!R3HV^=B:FH:E%);.U% +0V-#KW6W[3V05!Z;/ *4O=L_
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MBA-$?I5/[(:>5NC$"8XC71.WJZ\5M'V7%^WB\;,Z[,:SD(F@+&0!%'JA#K%
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M3D+]9@A3II>8$F>*)PE2UJ'GP;WG1O@[\QS2S@_0NLS05V P,@7O+!N2?G^
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MJ_Q?6WFH_1,HGD4)XC"5IC4]2Q/(&$808YZI.$CBE%J=S4UJ]=SBZ:YVD-(
M--O91ZT@:BFA'ZU[H-SYYYCW-,E7PXYZ9S?A(U.W\;?.53ON2U'/[\X;L'=G
M%&VH5YD"ORE?DU@^;>;8E)-QE( VZ>#N1QU5P?P7^4.NMK()\ 0/42PS"6-B
MZI@$"R#+)(%Q&$6ICJ5C%5B5,9Z^_=S>%'7_Q$UMHOTN]PG<+I\G7(?&R#1:
M ]%8=SG6M?HF6>_G7X?,1/OTC@@Y[;N?!Z!G/_W$19/MDY\WN+O_W?.I83'X
M1QW6KXKV"X9"3@/%8AC%&8$8\1 2$2<:*41BS (DF5/)Y8N[SXVIVB_>UNS&
M@!<].35_%5)C^5"%.T)_<+E^JMO%=IIYNH6T+Y&V"ST'XS<RMS5VC;""/^FQ
MUXCLY0B31DXGG3N,<$Y_:(#4GJ3+]T;.Q>CXW'+-Z-NE20IX)Y]T.%2+/7S2
M<_Q9W6^,"G/Y_&[]2//5@D:95!1%D(M*22<SPE\$P8 G*(G#&,O(:L%\C1%S
MXPIC8]6QI;$2_%';Z:+A-W0^^JEB*I1'9A1W@-W$ :]$Z'HMP:$&3"<]>"5$
M+Y0*K[W7P'[7M-3+O\^MEK$Y4T4JB2(J$M,5AD,<*AW11(C!+!),)3PC$CF=
MIQ\/,3>J^O8@@3E\HBO'XXH3Z-E%*==A,CJQ&.,ZFN>UCODH?://XN"W,_3Q
M,-/V?C[KYE%WY_.?'-B_6?S/MNZ[6GQ;M[I5\I,L:S$J(UW^;?V6%@^:5G[D
M0HHWS[\7)IE]IVY^:S35ZAY9.YV9.$($!PR&*@@@3M(,D@QAJ *LUSR*A8PJ
MMW/.,<R<W[%HQTN3F[UI_305Y74W#_U;\S/7GH)M494)=1I^T)V/_^7807J,
M;X$=U;WVS(Y,E@=3NG.PJF%O12.-D[^:/QL_0>LH8,_@E]_K2?ZUTU]B[^\H
MPCMC3HC?;MAC&#IM\^P1H3[JM3WF6%XT"K_INU2*[ G%"$N4049E6-=^9DRD
M,(W2),4L263HU*7BS#AS"S./U/B,H4["]I> M6-D#W"-3*J#D+I6NO 0AS'%
M"W=CO:9\X:'#%P0,CSX^I"3\93/PME"J$4Y=9'&<BIAC&$2Q@CA.-#%P(XD3
MI%F0)$RIR/K<[\)8<R.'UCS3L\W8YU+CW _JY4-!CU"-3 R[@A0CTUS9>K,K
M:03O?2/G4A_N#<')*L2O0-*Q2-P*F]XR\?X[3%@H;N7*RU)QNTN&15A?9+5)
M>$\WY?.W#5T59H6X7A7O\H+K]>1VT^WHIS .$LH@2I2F5(H"2,*$0J[1UG#+
M$'/JMFAW&'U^:_'&>%!9#[KFN\5B+E-@%Y^-!.O(U'P>3[ W?*1MQ &(>8WN
M7,:?-.(; ,QA%#CD%L/([*WQ:576^YY?\N+/-\]OY(H_/-+-G]7R1K*8IS+B
M,*YT$L, 0\)3!%5&!6:Q"F64N:P;+PTXMQCQA;W & QV]@Y:1UY$W(ZP?.(X
M,DM= Z$S+=GBXI6++@XZ*0'90G#(.M;7#>V>RG0DU@KX_*Z_,>M-:>K,#*N9
MMB^+, TUOEA"QD-SQ$$1S"1CD 0LB!+"XCBB;IU4+XPX-[(YDI#:[FT&HC':
MM>7J)=255"$)> 1#_1/$(HD@Q5A!B37QXYB$.&"+E?QNWDA3XI[5N'=''@_Y
MW[M FUEHT0:F/.1!=M1+^/KQ:;UR[GER>2+LB-_KEWKTK0-F#F3VW^<NS.\N
M?9\'-,BUA,9SL]Q+HT[<.-<2A.,FNK87NF]"?J1%03](O<J\78G?WG_Y^@_*
M>;YJTTR)RCBF0D":9J;D3820,1UD9H((E88IXK&U,&7_4'-C_,I:4)D+M+W
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M*:CBK$R-NN<VX&;< _?$0!X=#EU8TF=(:Z?IQ:.QF+(C+QCTYNFYJJ/UK-'
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M.&TSJNW6RRM4FEG)((0::I<2(7+G0?JL'9WV,3=Z#K@G@?L![>=+_ ^OG0Y
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MRWP@<?\VJS/(>$$*<90'YNH-!T8'3G,.(5L=>1(NIC9)SGTI'#<QU )/M[O
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MA3HB+VKBDU/>2%2"HYA\#%RS]*U.#M411--M>Q6,QA;#)%BM4FT/@34]HR9
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MB_P+KL[#?$%;]SK9EFB<K]/9LHKM$PGI-3W_GS-&[KQ+&4$G4Y/(R5H-N03
MS!CQE27]\)YE?-Z-NJ*I&S T0>WC?AX=P&'22Y^;YA37"NEV->O;Y8AH.3,Y
M0$!-RV$Q =DK#+SDJ*3TD>4VC;*>)6O:2N(C070\P9S^>;]I4-'ZU+]ZR9'/
M_FU+.[X%8%3.1:(!,APS*(_DH"3'00BI59'!/LI//CD+X+9CRJOO87Y6V?[[
M<O4QG.'MNVH ?9'F9_.-R#>BN=URW',>3!WL9@HY<44+\"$4VH&TMIA"\:H-
MCPZE_&1.]%U0^%!='E6\79S<MRN^42R7=@FQ^.T\Q/G99M%7RB:_6WRHC%B1
M^?(ZK.?K!\N/T?M"1@L$GFJ#Q^#H0%%T7@6O:L1*VX?-PD=']PC+.!G+8!RH
M'UOPIV])?+SX^C6L?BQOM419KM;WM,2OY 3,SUI;&SL0<F2+9%\6'=]J\=I9
MGUD$:Y4"Q3U""-* 2,K(+(NPC7I#'\]JJ8^_\]0'1]MEXS:FM;2*%Z!%"R O
M0()30D&P+!>6H\>']8LCL6$ <2=C>^R"I8<*>6PA=1 "^'U>.R7,P]F;!3'H
M8E-=4INH9N,5<T&!P4SG5J851)D2:!&YUD8):WD3K#U!T+3X&EWP#^\ 1I!"
M!V#:Q#]*G5%[/9:#;!&R7AZO;EU;CJ^W_^BJ$ZNC-2H1),02$%32ADP57G.K
MC(J2;!8=7!,$CKF*:6$["JR6G<AXXL2//R[.+\)93?V[G@=OL$2M;(2<6*E%
MQ1$VW>VY$1EU,47[(1T6'SUX6LQ,)]_E6,SN0!/^_>.GU<;4_O%Z?G9V>W1<
M-X6.P:5Z_9 V7:9K1R(?H@9'W^;:YLA+FV#2\W1-ZU5/CKP&PNL BK\LOW[%
M5>72^_ -5]>S,X4NS'':3QII/UGD$*0H8+7CPDN1R1QN@L"MY$S;PK,;X!TN
MJA[PAJOS>9G3KU5._8K?ENOY^=52I+%:QUHU%+,&Y94'9ZV R&ST)AKDMLW5
M^C-$3=O>LQ_LC22V#A#XQW)U_CE\QM<A_1/SK?Y^LUY?8'[]X^\?_[;\CJM%
M9=W';\O%>DDT_K8@ KZMYNL;/>\LD\X9"P5+ *63AU#(M=.:IYR99ZI1.N8X
M]$_;2+0;7$\ A@FW0)V-^:&F(V[\/(:11^84<,_KE3]M6>\BAQ@RLN2KU3((
MP?34.^BEKQXB]]YKI[4B6UW5[,_9'N!P;4J$D$PHA@P(2Z9$#D1V80FL3\F*
ME#R&00F PP$QI4M[@,@>"GT/_DTL]C_"7_.O%U^O3W",B*YP$!8]G> 1P8N0
M(!-+. JC2AJ4WS5(\/=>/;'H]Q'<<@PN=F '#4F5>'N3IEZ24JH.?40KR<A#
M4H_!D&:,0=ALLY#&M/$(=R)S6D^Q=1R@G<0FKV#?RKARN;CK0L!-]^[S^DL_
M9B%F1Q97@5R* \63!:]"@,0-LMHQE&MU'XY/U+7O^.)I;U\; F!Y+&ETH/F>
M9MY-'#CGHAU:!$-K \6P=@/-#K1(GI8:@F)M\J!>IFU: [H]!!M)J4/</=AH
M7\D7K5V;ZG"+38K6+#!NJ_4!.05%AX5C=5_5#HZ2*ZG)N95M*G)VI71:M3@V
M4EX XJABVQ^6R_-P=@Q8IG3Q]6)3Q_JWU7*]_OMBA>&L+OAO8;ZXZH<7_III
MCLIZ*<$D3HO6M-^C*P)$E,H&&3.Q>@JL#B-_6J4Z+8 ;"+B+S.A]E_V6OKJS
M;)><B+XVGJ@&NR@,7*AS?Q7GV0932O1=X?H>^=,Z1)WB>G\![XYK?XGK!7ZN
MA#0V7^\S8.:L\P&U@Z(,K<QMYG,H"<DG9*%@R.HXT'V*PFF#:T=&YRAB.OW4
M^\L:A;"U1B&<W_S)<A'NURL<)Q__4.J.G*0_*C/'S]P?MZ@ZUIDO7M4ZUU3(
MF90<G$P2M'&1>70\F>;]"1K6V!]0M/WZQ^MP5D?:??R">$ZGW<6WVI;ULB4(
M.=VI* 5>VCH:D<XX;\B *TGGG),/ZN$ D+%KMY^AKINZ@.F0^F3!]UA"[>#B
MX\Z:[FBOWU?XWQ>X2#\NLXY53#$0IY0MGLPP7J,Q*"!GM EC$$JUJ>(90-S$
M>=JC(^)IR(TBGIX0MVU!5WDC*IELHHU@3:CC$D.&H!.#$GG@'IDTJ<T=[P#B
MND'<.(!X"G C2:=3P*UOC*ZK"''.M"7)H0 ?16W/%6--"U9@ [/6.65%;)/@
M.(2Z3B W%B0&0.X@^?2 N2<*>$P61K#:8,82&I1!!S%+#<YS+^A\X$SE-C [
MH#JOV>5J^^-S!#%T<6$Z:E:FMD4YIQ6PF VH5%L;J#HF)]/A8)0UFK6QYW[^
M KV=@-6R0&\7&4_>V_YQU5CP,A@L'/+&5_,<(2!** (E,T&4/&BNT<]<HK>3
MA)\MT=N%V5UHP]LZKT<U7CP5R:/"FF>.H+3)X+7E4)AF!F.D?]M<K#]-TT]4
MG+</YD866@?&W?9J+Y<C5X4A%!D<N5[D?WE=R 0645@GI(C8QK3[V0OS#@'=
MX:+J 6_/5'@QD1VO#5%RV=2T$CQ\#)[\,&UJJTF64B/4_5L4YAV$O9'$U@$"
M1ZK%X@%99"% #G7N0Y$%HK4!F+:9/+S$O6X3)OJ?PKP1<3T!&#K8 G?N*FX^
M_7_FN"*BOOQX6\?373J '+DPNH[U=)8VMA#D +(,1)%*@06F1!N(#Z-O6K/@
MF.&2L834$_3N7I ^7M_5UF89#=:&*\R2':V0$2<WF5,&+4_HC8NZ+0*'D-G)
ME?:(.!ERJSV*T'I"Y)O%MXOS]89C_$JO"RW)7Q,%7*I78,I8<,PG(+O:1(V8
M=&G3[/ 9HCI!V_A0> IT!\JEBUN>;8L1UU=6E5HC&- '#8K7GA:*V"6$]]H+
MQ@-71P.9Z.&>9UJ0[2.7;D$FKW<,62(YZ@*XL5 WPQRT)B/9&!DCF:BR4=O6
M9XCJQ(";!&3[R*4OD&VS>F^\M(\DQ\OQFN';@TEDF=>R/*Z!N3KRV@4'OC@/
M*7)GBXO$C\9(W)/R::^"CNAO'$&P/=A]6VX4;KYWF72YC1-WYNWXXEF0$;0-
M-3_)T?F 9&!;4[(BSU^G87U,QLA_V(GR3BS(H^#LY22*=D+O0E__$M9?:DXQ
M_:^F&G\/9_?.N=N\XAF312IG/!G5H4!=3#6J:X.UF(C+3##9IMOV8!*[RY-H
MB)V'%_!-Q-B!&AY<OV0,0^>BA(29@1(UT.4"+1/K^!SN<A!M,GU&+3-KYS--
MB<XF0NQ"?3XLS_C]^Y]S6H7FB24)7)=2QS<PB"77BP@7360A&MTFI7L;-1-[
M45/"[F#A]*#_-CS:ILCI=U&SG$&2Z@:E"T(H*4.2RG"AN7$/6[N/I?">(FEB
M#VA2#3>*F$9KPS%97>V?874Y<?PXA;*/7G?DRM?GESM2*>N0AF[.82U"H).R
MZ$U:681 OCX4[G3BP1!^VT3"=AZ[U"P<79"K8FLU1H[$@N!J\P0F(&"0=6*(
MCKY-;\ 1P]&3#@?:!4-[1J-WD5$'A^]N=\""><U4+D .EJ\-EPQXTFKULDT6
MIFG%_'^BT0UP<E T>A>A]83(+5'/J&2)AG9MQAJ0<@EI%2Y #+3$H%+V_Q.-
M'@T*.T2C=Y%+IQ"[#D<IRYQ'ZR"D2"9RY'1$.*[!!D7_6)ZD.UXL>I<P82>Q
MZ+$AMH]<.H#8K65=TS<W&I_\+NLT&1\Y^%AO?C*XJ#UP;DM43C'KV]PN/Z:E
M_]D AUAJ!_*^._3\$L[Q\W(U_S\;"5WG9@AA$3&"3,R!2D9#"'4F44W9*#KI
M8MOX B_3UDNSF?VD_RR8#A9%!^"J533+Q<?S9?KG=3E^8%8'DR"KJEM)FX*K
MR1A:,!,S.J9BFWNV1Z3T!)W#9;VE?&E_QG> G-UZ4J/Q 641I+V5 67(UW&N
MSFI@,I,*=R64-L6;/]DD@T..PG82ZP".SS/OPYWFNC/#'!.T94$R)VH@Q( 3
M5D-"7@)G6B;59HKQ<!I/:>+!3D#9:7K[WE([&3S6IK@SC3HF3>M1DC:V*B&"
MQ^RA%*>Y#3X5T:99X' :3VG\07L\[BRU#O"X+3A\O^GX9E4R(BM%%S!,D'4<
MN 2'UM,A8P,3M,6,;#-@<1A]TQ[0Q\-A VEUD3_R_/ZZWRS\?2VJ)LG^>5'-
MXW?E^NOU3#">O!<!@E<!ZG4C.!TX^*2#2I+I%-K<_(Y"_K1I [WHTA:R[D#-
M/K_H.L9IOKA87JRW+Y^+/^@WOJS?K=XN%Y]Q]9@=J$H4GOQ#;XH$Q7P=8E:G
MGS)DGO&"64T!_8,7-FT!?B^;XKCXZ&"[/#[3WBWNY*',=(J2E60@)'_5?-(5
MPB=*;IQS')UO4U3P F&#X&I.'ZYCRN?0,1Z?&MRHO_O7 O--FAPQOPZ&2,('
M<BQ#=&13J9S <V;!6FN\-J6P1LV>GJ-J$-[LZ>-M-,ETH-N>SI',092D90&-
M#.M51H80@@0>O:X*VB?5IB/Q8:FL[O3Q-8Y,^IP'\WZ%W\(\__;7-URLL>9P
MOCO_@JM?+E95!I<KWR,_==!C1\A#W9W\T?)-+R581PFN?PG?YN>7)]X50:^N
M"'DX>.(FCUKJ4F(J]4J^#AY4,D)0)@*&+%TL2#Y*F]U\(.&'ZK?'XKF=Q>&U
M4,;) #FK3':!X1 P:D"KI&!.,<':Y 8^0]34&:G'0]E#K3>6I$Y7[VV"9ZVT
MW]7#CZ0#MRVE$TW(4E8!<P:3''D#V28(/G""5JU!8DDQU68:Z42:L/9<OK5=
M'@COU9/"N]U\2#M:RFAH%R=&IHPO$+(7X%1RM,5E1A=? .BA-)RV5MP%<7<[
M91]-:J>K,O>O:-KEZ4=2FFWKE0[#<&V78R,IM<*+KD$<!8$%#<98J55,WL4V
M=UP3:LVK5_P1%A>%'G51Q\%<"_!*<#.99(GDZ8%AB?P\;4M->F'5\8\2M9?1
M#E&. UYUVCIP%_S<U8%CRZ"#*Y<-H^[K@^N5:(RDF[FI0^%KP\?:DU;0<:%X
MY"4PSYAM<ZWW-$U3)UX?'W8CRZD#Q-U?Q'VFW6PB)WWB18&4UM-""@?GO >N
MG;->%Q=SF_R> <1-G?$X'0;'EER?Q>Q#C*,1BMCW>LV1;+\C%:T?AF1=FQ$Y
MJ\!G K'BDD.0J6K!*%T2@A79JJ!]TDO$J]D)Z_O[3F0,)2@+3"92_44)B"%)
MD%';;"(SA;6ICMI*SFF;A[L@ZW&VPJ'2Z>&(#C\NJQ27J^OUS'SPI+K(<>>F
M;&I4R7L7!L&X9 4='-DWZO^ZA9C3-@,/@=>ADID07-6!NJ+Y*J:X7!6<GV.>
M!>M%)EL$>+U65U8'\!X+:)62-CP5B^&%X_3IIY^VO;8/6$;B=)\7<;_/_\*\
M=VCV[E^/8$P]2<Q(-M+[U?(;KLY_O#\+9)LM<DUR_K:9KWD;Y-)*NCIK6'L$
M)9,C>UYS0.[I9*'=ST.;*K$723O<3WSB!;>[Y,X%<X@R9?1@4QV:QTL&'S8C
MEX7E4:1@9:/3:0<JI[6*QL728]^PD;2ZUT)[!TH?/V-<C=0P[/DREF(HG.4:
M9C+,5!&345*G #/'=(C%&:W;5 Q.IY=N\>U\0&.<@Q("6632,/ .$;P1BH[;
M$()HXYJ^3%OO.F@7W S60?M)IGO-L__ETY:'C*M[6EX<O0PB3"YRG^D@0UT[
MN*(!E[P&35 RWEB1U)'WWUC*YVX4_BFP;ZK>N;:VZ"A!*N-K$5#MWUT01%$J
M$A),QC8I=D,I[%T1[8*AI]L&C"BE'NZ%GEK-ZQ\WS6(P9:E]#.""EJ!"LN"C
MXV M)P4K=0RI34;3 .)ZZ1$P)BJ&GH%[BJAGU-4%7;5-RT)9M#Z"XY*6E,A_
MB347O42/CEFL[L61+:X;XCK5=/L"8K#1M9]T.@#<6PQK_+(\RV^^?ELMOU]V
M[+N>EBZ$3U@LB,C)/LV)0\S1DSV9E<>4E&]43?H,49T";%\ +-M(HP-@O2ME
MGO"&0=>SGZ5)*90 )'A9\X04A*@$6"V$*989+=I :BLYT\966H/I< ET */?
M+U:+^7F-$BPR^5SUL^L-88LWVGM/TL[5=. 9 FH-9+)FC98L"]TF#/PT3=/&
M7UH#:B19=("J)SFU"5!5=ETOS$>K<K &M/$<E# )(G*$7$IDECB6E#RNL?60
MQ&D;AK3&7!M)]0S!MS>EK#XIAK5T0-?#7M5,-H<N0J(?&&M-RKG-O<;+M/72
M\6L*[W(_ ?4,N;^M:KLH9K/DMBC@M56ILM:"<R:#QFR%--GY<F2X;>CJU.+?
M$P5#0;:[2#H V*N4+KY>G-5V'+\B$9'F&SG1YV>X$=@BO_JZ7)U?]<E]<O$S
MP8761=32?5<'2"</,0H&$GD4.CBA3)N+M;%6T*EG,0YH)Q%S/_UAGES/GW@^
M<YQQ4Q(Y5<99VK%2021N0E$ETV$D2LQ'C@4359VZ)8U5Z*[B&"U%_Z!\YYOM
M-&/):G+'J_*7I/P+B[0[5( @G4V%A62Q3=O^NU1TZEV, YV]V=W!6?M<$M*W
MY3J<K6>9:&8NN5KY[.H<E Q>TS9 4J_:^D"N^O$3Q2YIF[:AWU0::3_1= "V
M'4_\VIOI&=^,SQPJH5VQD(4(M4;>0HC&@8RI("I-'GN;J[N1%S)MH[^^S+Q1
MA=YG/M+?ELO\K_D9+2V_H8<M/L_C&>Z=G_W<TT;(4!I,[$BI2M?O>_7X?5MR
M_8MAFJ=LP'(KZR#@?-F)U(7LDO?:,-_F7G4G,@_5FX->=INQ)UAA6AL)5I =
MHI*6$'5&8"ZDF&(V\F%/@V,RI9.\RG8X>Z@ &TIOQ';KQ])P>^=^O_S,MMJN
M86[X;EA,GFEDT8 WM2#)R'H;S208GWCDOD@,;9I,'%7GW5[./WP7O?Z:D@<]
MDXK69)O4Z?)1Q6H3,PB*)2"G72L5D^.QS:W)'L2>DO;;!7%/)W:VD6,7$R>N
M%[DLO\\7\W-\._^.CQC[^\4FZ'W'UKWJ*/!@]=XP(T1*$$G=@PI20S2"SH/"
M0]$B>8YM;JW'7,6T-]?'A_?1)7]RKLW'BZ]?P^K'LCSS._N79XSTXK8FQ-XL
MF,3.P,A"C#8#V;:);%Z1(=9T"!Y5#EY8F7D;/321G?$J_??%G';1TQOY]8\_
MPO]>KGXY"^M+<W#&K(A>FMHAG)P#Y9#VKF<*"IU9P?*2T;4IFSF([%.R/79!
MX3.S*!O+MH/+U6?.G[MKVV2O,VFLJ3WMC>49E)2\-E<1=  &PX-,$D6;&X(=
MB.RE\J0Y=!ZF1S:28]\0O5W8G^'K=<:?XB$5+<D XK6RM1I%GC'ZX(,55I.'
M\+!S<7N8;B-T6J@V \QP8!XLO0[ ^7:>R"2?+SZ_^KS">R431I8B-4K0115:
M2&$0.;<@G,#@E#:.-RI@>8JD;@%W.! >EK*,(I5)+PEJ;Z'7\^7_QG1=/"'*
M9E :0HH1*^D!@N8:Z+\@C19!/NS#M[5YT[V'3NMP'P,2A_&Q PVSR35_Q)[+
MI62&)JK(('DO:R2?$4-<(J4@HHXA9F;;9.D\0]2T^5['U#)C2692/;->G<\^
MT HN"U2Y<\&@%:!EC5BE+"%$KT :@=P&&Z,<U/"=GGH'3/350R#=>VTO"?W'
M,MKWY_F$^NB&Z"N$,X\Q.6D 9=:@A"=[4)%EJ+6QRLHDN!G4$&TX5*:T8@X0
MV4.A[\&_B<7^GSC__.4<\RM2..%F 4Z65&H7,U4J_+74X",M@ >5R(Y21I4P
M&@"VDC Q%/81Y'),KG9@G;RL,N^,1Y0):^9#!!M,G9$H%#A1,B3N8M1HD;4:
M+KD#E=/:+]/=(#639 <H?;B0/_'\M[_2V44F%_'F8OGZ[MA)[XK7M=K)U\(0
MG\#KR"$5Y2/7-K=*?=^%RFE]^798>31TMY'@ND@ >)I]?U]CN3A[.R\X\S';
MK((!J;4'Y9FN<ZP5?>84%NFM,&UF, VA;EH8MD/'X$O,/075@4Y\9N\2'V_8
M)G1R4<@Z;7@320O$P( *LHA6"<V<48T:70RB;UK7L0, [BVL+C3@-9-FTG+M
MZ(" G!TCCXK,Z:B2!Y=8*LSDK$R;0_>:@FXOQ_>6[Q,)Q3NQN@,]]6:1L3S-
MGJ?W6W16!:49^&P#N5.RT'[+M=F084)J+LA(;F3'[4?QM)['T739403:A79[
M9E=?ME@(T>E8$H.8F*@YA&0RB!PA1?+=F'!,-II%_A)E4]MUQT#(\"-V=V'U
M#K\[Y75W$TQG022CC;$0BY*@Z$ !QTT=6R*%Y+2Y?:..4[O3.K7EUQ=$QQ#H
MH5TNCN"6S&34RF6&@%B=+%%J2WF-(*2Q27JE6_5P?)ZNJ8_NOL"XJZ F;'Y1
MTP.>22V]U/Q(Y&?C)>0HR9_/FH-G0@ OUCKF@RCA@0^\-?/BI?=,V^ZBN?TW
M.JO[A4W= %ADT-[5&\]<0!'E$&1QP**2.6&PQI;#0#-4[S1K93$U9'9E<Y]S
M<,<I_9@]V!9'K'^9\7XJ8!ZRX:8&YC]&%\X(LXEW>7I;%A]E$O&.!792&^=5
M@))J27N=N>E3L""3<TQ'9C!-V)!@K$JBN];ZXVK7&6.,X,(8Z!R)"<5RB-(S
ML"8Q%Y7GOE%9Y_-TG5(MT"XX>A04'T\Z/5RE?OT6YJM- ^-':WET<,^LD5)H
MFT R7^\[:MR6\P(Y<.8RHM,/#9BQ[D]W(?.D2H8/0&([V74 S&NZ;Q?YMCH#
M26%(7GJPGI')J'R P 1MKQ2*-)E8ULC9WT[/M$[^\: V@C1.K\[\IB)_2\%]
MFP+S(6]L;%?OO.A)#,%HG9 R2RA6Q-K;B$',Y$.Z$J-6-B 7]O0-P><N=Q]+
MYT^2Q*=_X=EW_&.Y./^RGN7DG48;0 9FJRGBP1GE@9>$(FO/2B,F'4;W*1F2
MN^!PEZO[D:7;?>SI\7K_"\/JT[^6,U]*X$$;D.A+Y7 MQ$$%F+P6=5*05VV\
MG;W(/273\WC8W4>6IPI9PB#.2BC(8^:@[<8)Q C1A02QQ,*L]ZZP-OW#]B3X
ME,S8(\-V9WF>*'!_7UZL9A$U8X5,><-$K1B@#QZ#(_,^VB30HI5'S^Q\AMYI
MHV,]PW9G:9XJ:NEW9Y*1[QJBA^!K+PIG-42/""I@MEYX4?RQT^&?HW?: %W7
MJ-U5FB>(VE?E'%<WB_711"E" ,<*&?'$S5H(8R"&[&F/BCICM0/HWB-ZVB;S
MO>)W?[EV<-GZ0N*.5HI.BX"@2XVJDW\)4=@$-=TK%<N"X$=OGS0TT\'^U$#<
M53I]ICO\LER00CZOR_H5X_D>EZH/GS#")>FS1(UTZ5D?O 4LQB:.QDI(PI"?
M+) .PQ(L,.EU9H)I;UB3_;:=GL.G2-U]ZFV7VA0Q9>D1F.*D)+$N4XH,(C"6
M#48F<YO#[PF"IKUX' $+C^=)'<[X/L,V#S;GWK, MC]G?.W1L.?_$[CA3&$N
MZ$"51+C1UD)P7(+@)"%GN3 XJ!=+)SID&S]O >U",9' "8'02^86=S4.J0%5
MC"&A5,ZK)HM]EJPN]<DNN'BH3\830@<V[VU;C3_"^<5J?C['];OR=KGX_ E7
M7[>LC_-HT:8$6NJJB3T#;W,$)E).PA5I0QN0[4KIM$&(!KAK*JJ3..!&2"Q]
MZ8GC'WI'22!]RFQ27B<IR0'WF8%R4@+YY(+\<1.M4H8+;!.!:6="OUG0LRYN
MA\FSK$7AA.]<NPBJ),F*"SG5S)Y2O,O1I3;%S%N(Z?*HVP4#VTSG0QC>P0%W
M?PF;)G6NA%18MH Z*#JB90(G4W4!8HA)&I=UJQ&^#VF9'C$'B?=9N.S,Z^[0
M<J<=JL2B-%,, D^YMD-E-6]4093)1YF-8XUR[I^BJ"?D["[I9X&S)]LGA$\M
MQWIE_I=F=\[^C[B8+U=_+L]Q_>L%DG3552-#4L-.9<<AJ5S'$M6;2HNT)BZ#
M-M$S]K"-VM;ZMZ'OZPDH^TIVV9C-4T/GXO/%^EPP[N\L[/5RD6^:LZ/VRDH&
M(F, I2PI98X9N+<V%5+-(84AD'GA/=.[3.-"94RV3@R17S%M:'YF-<I'JQ,F
M,++V0 HFUI.[UMP8;3VYEC'& 2!Y^4W3YDF-#I.16=N!%5/O!,ZO[P3H;S;G
M<T&'B*)F%-3&ZT0XQ)RQVGFQ),F%#8W&;FRAIB=-<[C=>S"_.\3,U:8JF*.Q
M40!N>OL4$2"4DL$1<V(BFR^G-KEPV^F9UI@Y7,XO &</IG< G0<77M?=OX73
MF=?#-3 &BGD/7AL..I3,%1V\6;7QLK>2TQ=P]I'S\U&(/9C> 7(JY9<+69,D
M7O_X^V+^WQ>TGG5:S;]MA%-W6&0^8!TCJ[2H']!"8)IXY3(W-C ?&S6#&T1>
M3];0.%<XXTJD.YC=,1F328;+HL%HH>O\-@O>9P?6VL@",YR'=BDFVRB:WED?
M6?C/PFM/24SLBKU9S,_GX>QV&>]7\W0]I<*8J+W7"%&D38U$ J]0DJ<@.9?:
M9B:&7.X\]XZ>,+*O!)<-V#GU)4Y-??U_P^(BK'X($BC;OJ*2?9U5(B%;6SL5
M)P%1)P.>O%-ODK.)^P$ &?:VZ=VL4:'2@,5=@.;B[+GE**N9<2:!YLK7]@(,
MHJ<U!6Y-Y(8Y5]A@Q#S[JNE-F09P&8^YG5@RM^;>VYM1(E$F$;AR$$M-]3!.
M@D<9@'ET.7#OHVGCIC]!T+0U:6WCFOMQO3OP_!X2OOJZO%B<SU1*0BD6P%NL
M1?0QU9[W$5R12IB82VQ4V? 41=.;. >+^UD([<G[[C#T9D%/QO7YAW".'\]K
MJ^/WN$I55I]QEKTJ/A<$*:,$A:;0"8P90C2>.1-<L6T:;PRG<7K[J"W.1I-/
M!\A[OUHFQ+S^G?CX9KV^"(N$[TI=[RQ;C9IKVC2V#BZFOX7(M0/N)8LF*^%\
MF^;L3],TO2DU-K)&XG\'2+K/G3L7J0],1#[37#*N#((.B9$G05LD:%IGYD(%
MYA79$\<X&)\AL2=#JX4&&TLZ/<.N=M=8?UF>W5'.[\K'\V7ZYV:AGU;SSY_K
M78B6VD6I(<7":[T2AV"$ !>38:(P6]0Q,EUW)GS:2O^C0K2!)$\"N)]6H7;9
M_#7\6)-!B\E);J PP^J =T[>NM.@62I.Y%R<;5=R-9C,:<OWIP'EOE(Z"0C2
M]]:8+FJAQ9UU<O+[,V9K%'BC,AT2SD&P=$B48B.WV@0O!PWC;@#')TB>MJ!_
M&FB.(;WN8/H!,W[=Q,TVVO^.ZQ5D%$;0QA.ZT.Z3:"#2Q@-:'PN>I9Q=FP[2
M PD<!$%WNA <1S(= .YN]=_O8;[Z1SB[P)DP16&6"ABKO3",J2.&2@$C64E8
MF&2A32NHK>0, I,_)3 =SO4.H//KU6M_GR^J*__+<GW92,6C338'K#.&B#'(
M,[&(>5H0MUX90:MH=6!N)6C873 [)?R,P?HN$'27-7]?A,M^4)AK%>+F<IN3
M%YZ,]B"+H 6Q@N#JY*KLM8H8,GIWC+#4%M*&H>J$0PR'BJ,[?-V]R_ZM%$S5
M6+QS<K/H633)0K2>3FY+ZC?:[,FIUM86J0I1>.1PPQ8RA^'N)PDY'"JF[C"X
M]3;R0Q4?GY6(3IC(R5Y4M=[,DZLBHJT=1V5VDF$V1[[W>$CB,.R=5%"BC7@Z
MP=WM&JX65CO?W=3<;L+'?.:MLQ8# YF+(\.!S(7HC(:D>?;(I)2F791U"(7#
M4'=R(8K1A7,*H/OXA7B^KM$_S'R6'*GOD".4F,GA\=R"CU:!2UF1(H\H5;NK
MM>%T#@/@R04@&@FJ$QC>S96Y=K 3*>TD2@:O&.TF5\<S2Y7!*$OVJS"\]M$Y
M1IK2+A<;_(2#"/NQOCL$W34+PFKU8[[X?*F@WY5/7_"W_[Z8G__X9?GUVW)!
MOSRS(C&7HP>?:I\N[FC14A;@J@1II!7*MNN9M"?1PY#X<\0,1A9A!VC]6Y@O
MUG62'*[?+7[[ZYP6=S%??[D<:;A)L%$RJ)!4@NPR!U54G3!'V\^'$#,CXT+H
M-O<H+Y(V#'DG%2H85QP=X.O:);_JT3[SVAEKF8':U !4S :\"P*L52S+J$TH
M;<(##P@9AIV3B@P<PNK^D+(!NT69D$Q$B+[Z,'&C3#.#DIVMD^O1-IJ?MX68
M8?FZ)Q4+.)3E':#FMZ\1:YS^5US-OV]:7=X8CN_*XQ^^G8<X/Z,#>Z93(GLR
M*@AU"( 25H"W+(/V0?":O<=9F];G^U(\#'\G%34XBO"Z!&D]Y^LQ3X?\HY_5
M:%PJPBDG,C 32^W.0%K<"P;1H+;.NF0:.0([DSH,EB<55&@KK@[PN,D*O;R@
M^?5B13;F>UK-,F\VWNW5SKOR]\7\?#V3UHEB@P'KY69F)&VVD ,8'AABR:Q@
M&TVY$YG#<'A2 89V8CJ)CMNOP]EEG<>#[X_6@/NE%XS?CWNG);5MSYV+,S[%
M6L!06T<Y'X <AD(,0RNEEJ:$=HUMCM.>.UACL@F9=+$A4S8YVH79*M"124&.
MLQ38QM<\E?;<NV!@2'ON71C>P3&XI9&P%^A\=.0I%TL<\0$A2BS C<NR1.N<
M.,8%;)_MN7<2[\OMN7?A=7=HN=,B(ML4=- 2D.E(1WP*X(21$$2=2\R-%N(8
MR1<]-7(Z1-)#VW/OPO:I.ZT,[1MMO.*I!@]BC+3#F#3@$D:0Y%Q([HUDZ24;
MYR=HS[V39/=IS[T+F[O3/+>^A;<E$JD*D-/>4JQX<*74Z73D<UCFG#M*4>;;
MG1JO'+6Q[G@GUGY<[PX\=YI_6(_6.MH$2!P"%6V!H"0'%[+W/ M4YAAU0+TW
M7ME)W$,;K^S"^]TQY"\QM,#S$5J_/Q$)O\T".L=\M:IDI>?%&PA&:E A< B!
MOI08D[,B1%KV@--KEW?VI'(.PTQ3;A^ H<^U<\NG(]9M"*T9ET: D:$.1BB)
M5LCH2Z5+E@25I-K-I#V\;N/H-XSC*:A#I7$HRIJ6ELG$%*9B@1'9H&CS@(M9
M L\83(C,8VYUW[5_:=G1,Y,/ ]/AG)\40M<J>'[KO::TNMC,?-_$R6?%1Y&)
M1V!RML0>LB=]Y*K6-.E4,-K(W, 3[LF7]-FRY) C;1Q^=F!+WZV]G07CI&$Q
M@<^R>JG!@Y>D'J4OB 3RZ'V;<^HN%7VV$CE$B^S-X_WQL3P/9T>*:5W/T5W>
MF:,[6CSKN8>/'\L:O)2V<:R2@Y/!.G*E?&VB*PIX- J2+SZ1EZ730Y5\<G$L
M&6+,P@=PF$/M-:;I *6CU*94O%8Z.G:,2N9^XUB[8&!('&L7AG=R+#T:#>2C
MCA83 F,YD]6% 8+@CJPN+3A#%9QH<[VS]\BMH\:R=A+QD)%;N_"[0\Q<7;W3
MT5Q$U@Q,K8M6M*_ "TFVNE3,>AN-B&UB62<S<FLG.0\;N;4+TSN SA/3GW(.
M2I(ISW5-=%(N06"1UJ1"=IP)Q74;Y)S.R*V=Y#QLY-8.3.\ .5M"P]P%[E0*
M(.BDIA4H!I&A RF]T9RV%/F'/25<'#5\=<@A=2"ONT/+G?@P.N&Y%1DP65_9
MDL%QS2$*1AQ#G16V2UT[B82+G20]-.%B%[:?2L(%.IM** J<TS5 3 =YB-Z"
M\]P4R5.M)/CY$RYVDNP^"1>[L+D[S7-[KQ5=82B"!Q2E3F^I'4$],\"L$C(5
M'IWI+^'BJ.,?QSNQ]N-Z=^!Y=@H&2L-$#A$PU)4ETM5>L +2\4#;IWB';<9B
M#Z>Q)XVU)R3VGU*RBWPZ0-[=J_/;.]D/^"W\J$M=OROO5_-%FG\+9V\6?^)?
MYY_^A6??\8_EXOS+>E:;/W*CB*?!E=JH)4#D-H"E R!(AIADFXO4@\CNR6@?
M!Y_'D^*I0?:_,*P^_6LYR[X(;Y0"DQEQ5[)(UD0ND$7BV0<3Z929'JE7U/9T
M1D\ T'UD=I*X)*#AK,YZM)Y,7.$=&=(E,#)QK:,M2'SFLB:CMKL^W9W>/G-0
MCHO-G>76&3IG3D?#+2*0J6*KD4(:WV0%J2ATOEY'AS8],G;.0SA^F[N1D+03
MC_O,0WB5-OE\Z_?A1W74PB)?Y>)<]?[8)_W@Y6>.D'6P(^$C)1M<O6W]ZNIU
MX6Q]$VW&G"4/A<XN8P4H:QG$S#4A@F3I9,C2MU'RSQ!UJ$9YP.57-UR^[KE1
MDSMN N^?B,NOZ<__.4.!7MN<@:?J[ZM0(# 3 &WA5E@166I38KLGP=.ZLV.A
MZJ&N.H;T^FP9\*)VV%Q+-5%N5T\^AHK;MH@C*+JD@DE:>R"VT/')8AV 5--J
MI I2AN@U:W/=V5#176>MO2M#-LV&\;?[):80/*_%.K$&<#G+X)$VJM480_(J
MN5:=4 Z@NE^5MPN^'O5&.98<3U3O[9]4.OC1Q]!\+1-*GX.F3MY9X3-8:3@H
M+2Q$= &D3(*15\C)CS@UU?> V776'?YRL:J[F-[VYW*1+K^8<43K CKPJ<ZV
M35F0-^PTR*QKBR'M);8Q<(=2V*]*VP4W+UAQX\BG@]N*JRW],9R%%>GBJR7-
M6)$V&J8(#*&V]:Y)NU8D<LYUDLFP[!K-(=Q.S[2!A(:8.I3W4Z=R7*W@(J;E
M8L.0Z[-A1H>X$XH\%Z%KEDNPM:$#F1/66<:=<L8\1-#VY(TGWS#MW?W8F!B1
MFQUHE7?G7W#UV-+;JC!C5E'*Z"&Q+,FW+A&"%YF^#%P7SKUJ=&.S Y'3WL6W
MTC^MI-0! (?X'=?ZUOOHF6.1SFE2NBII!TX)!=:6Q%R2&+(ZAD7U')'37N$?
MR:@:34I]WO)O.H;6F=:$\LO!%'LX@%L>,H*K]Q)I(SEUCU]3TQ%OH10%U_7*
M06=R^I64N0[_2X2GX(LJ291&0T&?IVN4AKZ/GK[MRC?D&'@RM)>T]*!B4."+
MLZ"]RTR%I&-J,ZER,(G3.G<CXF=K.]_1A;2W(OJ.J[AL=T/U>+5[7\4_^:@F
M:JGA9?L+X#(DW82Q0#*X\>LM.!?H0S%1.$\0"">IG&ZN:C?O>?WCE[.P7M^B
M71B;@V$(IK; 4JF.O><A0?'.2^:E$*7-1< +A'6MB';!RM-WYX<+9$3U,PK"
MZNS!UV&-N4[D(L=V(Z_+B82O+LZ_+%>UN]'?:2^O-FM_]ZW^_/U96*Q?__CM
M+URE^1K?K^8)/X3%YSLJ67@3L9 QJ#2Q0VDE(2BO0&:GA9:<.]$F5;O]VJ:]
M^3H.SGN 10<^ZXL<N5W\^E6=GGU]'MZNV))EXKF1D*31H#C7X%A@$%U&HRL[
M4IMTL\-IG_8Z;TJ@CRO6$P#R!R2VSM,YYLW:-Q,R7OTKK/(3RY?$=!53!B\2
M[6/#:_:-<)"=+$[$X&QLD\<T\D*FO46<$.(M!=YG"L!C9G^\^/HUK'XLR_MK
M*C>_LW\JP,ZO:.*0[;*LXSAJ:)RQ)7E@#$E9&L' !YN !10Z(!="QY_'4=L4
M=BI)9DY0&3BO8T>%XA"+U&!0QQ"*=BRW3GUZ1%37#MHN&!GHH.TLB!X.ZEI3
MN>EF7)=PM:#+1CH! PM. #.I#H;WM;C2!S"DE55R+!;;R.U_BJ2)\326T!]=
M.XXA@0Z@=)?^J\8%PJ.1P4= GZL/)N@\9U& 9%Y$D[+0.C3!T&-:IE9&HPCY
M8=.APSC> 68^XB;MY;[E<-640K/L8RH&>,0,*F<D;\?2HD366D@F438*A3Q-
MU+0H.E3>#S7/2,SOXH[Q+F_>WE28L5H9:)VO$]1(,3.T$%DM.'..8Y B26^:
M*Z"W?0Q@:76 '<[Y#A01^:I?KRYB_KRH.^#*D5V_#Y<#CU\M\B99YC8>>"<!
M0NND([.0N*WSBH0'GPJ"-MIYKI61I4W#JT.H[D>5[0F:1QWXCB3!+M3=?:5-
M2WRWNFR/LEGJ>UQMUC[#Y)1"@<"<)^N"%V)H[3:6C!(\\9)=;!,6&4;?Q!@\
M&F*6S877(2@?AF]F7JO(#:TB<R1+@A'? C<)1/2!H7!USM(1P/B0KFE/Y4Y
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M_UR>_Q>>?\"T_+S8W%4P3,KD)*$$&>J<'83@,(+A43F1:A5I&P0V6](P$)]
M=*LOX7=P4=6,$9=FT._+U=6WZN_QF4/,@1-X4Y2;#%#R*AD/M:,@,J^RDZQ-
M]?%QUSELOYQ0(*UCF'2PB5Z=;7X'\W:^7+5SGBEO>:9SD 3 <W5Y+1E7/ &3
M.GK/I34/0VAC-<0=1-\PT)Y /*VA6#H V]YV_[MO]1?O7L)<W@[.DO!>1:&
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MK]?$W27[8LE[^&Q$*/XXQ47&_#_VO)?O[>;/Y2F^BNM-=O?,,OI/(D=4I#J
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M-D4/ ;SG"GCF*0LG8\Z=O8)M2^*1'K,#X/SP1W('T!U/FM=(4YUGQGN+IDA
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MW*;B[!R]&T/_&7)S\J5$FR$P0290S65VJDZ9L,D4XU Y-F3XRPA;F;BKT!'
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M,0=3?&W)JIF6@G1MFTC1[7UT")Q=1;P<C=\=H.5Q;?W[?(&;]CTS)04*<A9
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M<^:3Y'3.>8&P23I H< 9M&"4RJY(3-(/FG,[R*Q\: ?3&I>'LP9&D<#$"/J
MW\Y6Z4M8XZO/*]RD*MPEZ7+ZE&0Y8BA$A2 .84U7*$:!S=P%YJ6.>5#<:Q"L
M!F]K&@TWCN27K<4P=>SKY.QKI!_@[_."'],<%^E*R4I>RS3K#%_:-Y#;5D?Z
MFIK)G*.PSM=^0T.B7X\O,1TR&@ES.3YG.S"N'E'2F],DBV>V6$GFJJISGY."
M:%( :35Y]D:XV"@E\HE-35O)VLW;SM;RZ1=J%V>1&)(3SP&$,K$FX=41.)[(
M<M:9Q#P&3 ?-$^C S1Q-^,- M8,D^HKHRBQCE"$"+W5P5RW-":QFJR/S21:-
M/@_"4*N([L&S(G80Z./!W6VXVZ^Z^?VJ_WXHW&;O>2T<JX-!N "?18945.8I
M&\74($=M+(WS^U:#2IL5OW=SQ^TFJ0Z0=QTP>??/!>9?PDD@ _'C%V)_I443
M2[2"G%A]B\=4NWER(.^$\:*,+JQ-^OY3N^I2>^TH_WMO!2,)HP-@O?G/L\WK
M^^F79;Y-UVK]9?[MHNPE?,:9,H;V7Y#<CN+J;)L$L0ZLUB)EM%$D;]H$_ =O
ML9^7\=$AUT9,'>#O W['Q7FFY0T&SND@2<=E8I9#0E]["2M3^P<&8,7Z;*4P
MDLM&=^DC6^KGB7UT?(TCAA'3\?=XVTEITYWD R:<?Z^6Q!V*.!=62A]!ZAJB
MH=,!,5H!Z&*2T3#.7!M@/;>SJ5MJ-<37J$*9. CZZ_*$OK.LP[B^7\<#W_RH
M98*XKOGB\Z_QC%::H4 60L@0HBYU;IL$3TX-J,+).O!!D$X>$!(=O.#4+:X:
M *@=P[M"T8KX]7E#UB=<?9W19>TTV8J0-*L9<*4 G0,&.D:>F>1>\.<*AIY;
M8^J.4P?!RAYLG?JE9;5,B'E=;^2/9_%O1,CIS!!#C!0(PF%M>84</"8-PAH=
M3,!L[Z87/OS$\L!G#X*#/3HX[,W&KK3$I>I[59NJX>70#:D8DH5/=ED6D7B3
M K@ZF\HPYTQ6KJ1!P\ &+#4().[H0#(VD_O$S-=-O>8%.2FIH+FR$(-T=0 ,
M ^>%A<P\L\Y7:LWNF+FYU"#,^)>"F9V9W"=FSH_ NV\;<9T35= %RWT"L1DQ
M&UD!;U&3/\BD33$JJ;<W39Y8<%@<D;T4 .W)\9YA].8'KM)\?74\')>2\3J4
M4W'B7&8:8I8!&"(7P2&S>WA'#Z\Y#$S'%95NRO>)\;2QURYMN//8 >99JC8:
MH[L80ZFS$J."@"P"FAA$J5/6[\X+?Q X#W[X,(0<5Q!Y'$YV$2Q^D#N7D8!-
MN?Z-1\5_GY]^N?DK,UN"9E8C2![KY*;DP1>?P5HG,S-6Q]RF*\*>&Q\&RF.-
M/!].IEW$IU^?X:V>$G-<7\R)>;7(?RX7Z?R+6<Z">10&7/V',D)!+&0 ,!EY
M'1(30J/WCX$;' ;*XPQ7MY#1Q%?IY8C0S47PV]DB7\R?>'59B#WCP=O,#0/F
ML!*C,D3K'.2BF"PJH(A#+/MG%QH&G.,+4X_+X0ZNV_<K_!;F^4(5/W@ 4G&&
M:V_!!5X#[M9"X/6=T*CBK3&H;)LF=,_O;1C,CBO"W4@R?7:*_!LN<+G^] 57
MX1N>G<Y3'4IR>\N#6J<]_#DC-$P;L,&1VJ15N=;&H.3FD5)Y6PL/<'UZU8Q*
M,61>!0M>2](KL40(+FI@VI.BX4&HT";1^>E][5V\O/H<%O/_VLCE5[+]EB?S
M?-F']?T-F;TKO\T789'FX>0C?0?/ZPH?:"V(1OM@M8'$M:NV(@,?T$.Q/ H=
MO2;#L0F?QJ9DVN2Z$=%XKT)Y2I$?D1K<9,CNTD?RJ4]KI1(?VNQA%&-0,13F
M(EV"@:X^D3,$700X25B,#JWC;3K+M56,#V<#KJ]1SPI1&&E;6>D,2A'Q03@$
MQ*@5<L5<:!/H>&YG72NN;= R+$%S1Y%T8/O_%N:K?PLG9_AJO<;3-:G?W^<A
MDA]S7E8?JI;-[Q8?:JG]JHX$VQB?J\LO?PGK^;K^_D:VGS!]6<S_\PS7&U5P
MS904>4)&%P0FY$ .D 17L#ZRQJ2YSRF'-C-1#D+>M/G(#<'>'SB.Z.K^,ZS.
MWVEV;P8]['-;7>=/$W"8B]T%(PS*".0[1\*&M!"K+\VMCF@#RTFUL>3;7NQ_
MD !JIY_+SSTOA%*JZ. C!Z^T)F(9V; L!<C:.O2&(U.B";$/;J?K*WP;7-S5
M:OLSO\?>,3Z3&U8R>3Q**U %11VL[<%E4BC!.<QVT!7;MG=,,[R,(-3G>L-L
MP^&CZ0UCN'7.U#Z+:3.//6BHTQ\@6JV3*-RF8=-%7G1OF*TDOU-OF&W$,'6N
MQD.VPK]<%'HGGKS7RH&7WH%*D?2R534X'9.I/3RY<\\8/<^M<0S=8;82Y[(!
M;R?6/U<%BYOC8[(IDAL-TA<&RM>!JRDD$)[N[417>1#C=<N]M?2TGMFX=]+N
M/.T%#)>'@W&#,3 P5@4Z'-)!B#Q <%+Y+$1RS(P/AZDOECW$]Q (=N!ES_<&
MW: L1R8AFMH//D9%6JX20TSAP?,H[?'>&WL);>CML T'.X@[7KWF_'H2UNMW
MY>/I,OWC?.*$R)DN-UWG8]>Y8(5N.(\,'!%GG:"C8=K$"A_=TK3UX./=(N/R
MO@,0W=S_93?Z)+-T68+29*"K7*?*U>F9D16G63T+C68,W=_+Q+.$QA'R<E2.
M]X"9Y=>OR\6&@ O-R8,ED]P8X([L=#I7&7R=1BBU#3HB*F[:)&#>V\K$H\7W
ME.U=J.S%Z(F-E8]8&UB_>K? ]Y>KWZ0D<N6TE@)R))VKDD;P@M70@"<:5931
MA@'FRM.K3#RC>QPTC,S,#A3(W?OX]ZM,/YT"!J_)01=%UK'0%D*Q9-XS=);L
M>L9U&T7RZ):F[30RON4R#N\[ -'[\/,\;V#Y*OWGV7R%KW*>5[F$DTO:WBX^
MGL7U/,]#/3VS2!ZA3T: TS4%W5D%@6=!7$S"E:@%WE4Y8V7@;KO5OAX"=H3(
MW43<IO+J )!WV?9 R[%??KX/Y]40AICGH@&962'29"2J!(.0/2N)T1VGV_0A
MW&*3?47^Q@%A*QE-;6M56^#]_<CZUZ_S\^YWY>9ANTRYFM$N6,B20U1TRI3V
MM;R5S ;R:AQ]1VI^M[W7PS;83JOW%1+8#UX'DD$'2NXUIINYQG\CH_;=JDZR
MN6SD(*1CDKB'T5I0/OAJB18Z-,%FIZ12HE$IWM,;Z\N,&T>9C2F+_J#U ;]?
MYKW59LBG1!W>R!>]1VW,4G&LG8]S'3/NZ!_.DY-E:W-D'\E5CFT2>??;][2-
MZ X"S):2[ "W6S2<%4I+&P3P7-MT"UW R^3!!,%UH;-J69OBHW'[ C<K!&R#
MQC;RF=CB>[M(RZ]8#TVMFWTDI?X#AI,Z6>[5(K\ZV7P>YD_+&\:'Y%P+;B+H
MK&QM_4AGSF8&6I;H7(B"X9!!1*-L9MJV>N/;@X>74 >Z<!#1Y-BC,S(F8+6V
M0Z6:2V\W#9N$$9S\*WFW9^=H7?@';&_:UGUM=.#X<MD>;/X<; O\7%'>\.I=
MSSAF--Q8L-[5*9:E-I:S!9(-T29EC&M4Y;L/I)IU]CODM;H=[X^H%N6.37O1
MI7N^^#QR;<JSZ[2J5=F.P -5ZPO'5?0()AM-^,RNUC4I8 0$79(PV;49$C1%
M[4I0V8J"&= J5CODI)JF6D#(E+EG)82[QMA?MG9E&UP,JUW9AOD]UJZ@(+(S
M.2S%)D%7=Y;@HO*0@X\1M;,V#9K"_:)J5[82ZG.U*]MP^&AJ5^B.=L0$ 9HA
MN1>YSI+@W(++OD2!/LAAQ8$ONG9E*\GO-M=X"S'TG(,<BE%><4Z<DE@G0)->
M%DY!,*BR0.'#W6?-(\I!;B3.H=G)V_"V@TC XTX'TZS.OE1TDD3-W5:":# %
M@F:%.1:<P39I&/OE^!RXQF67NVM<WD^L:/Y]N?H'V7Z_AF_STW#RYD<Z.<N;
MK]=?9DPPXPMG(&5*H%Q,$&U]V3*2CH@S+DH^0,\\L41?YLR. ER.S\U]PSZ?
M1E,P?RY/<?T^_-R<EJ(-)FLEY%R[,XODP&=OH?C,I)(ZRM)&I]S<15]J9#_,
M[,WE#JZ@]ZOE-Z2;^?U)V+1\K!&K;_7:_A-/9X$(ER[5X8^B&G62@W<80&0R
M]H(IB+%-C<Q3N^HU)V8?!(TFA7Y4SUU&S;Q.F6YH$G<4N4Y^#'19L]HA2)$8
MO!:6#_*^]S9I>DUSV0= >W&[ S5TG?%POO^KEE#731A)LTIE0@V5VU! <6G!
M6Y*X(\->1UU8B:H)@ 9LKM<,E7TP-;9,.H#9<]E@7+" EDE2L&3@J=KX/WIR
M*)1,7DOI+?I^,_,F2#G9!UYCRJ*?:Z\Z"Z_G]:4/<WU&OD/E3-FH0ZP5*8J1
M7O:Q9K'&")H);Q5FGEV;!XQG-M9K9LD^"!M3%D?T"GO]T#Q?G/^%D9]?'U^@
MU;OK0)(.\^!JO4B1<P;)LPK)$L%ITDXN9">"YX:K-D=XB@=7QK0JPKGZ;$C$
M"IL@!!. 21.<8XY.S6&L]OX?7+?!Q; 'UVV8W^.#*Q?!*E_'40A9TUQ4[67&
M:P]%%XLWHC8!^,L]N&XEU.<>7+?A\-$\N!9/UIT4DIS5;$ A^:Y.Q0 2HXXF
M,!["_V\6N)7D=WIPW48,/3^X"H8R)%Y;7VE3W8<$,3G" 7*/3EN#=Z^P%_G@
MNI4XASZX;L/;#OS_Q[O5!!E*K,TV@\ZY!C)J/0TY&R*:ZBU&C'%0M[BM[9S]
MVD$=^,%UE[MK7-YW *('6I9(XP)*@\ UKZG@DH&K4V*018^6%1%+F_[AQ],.
M:BLA/]\.:AN.]X"9>UV*'#>*&;&IG*_1C5* ?DU#CEF%K(54\J_:#FHKV3[;
M#FH;1G<QT?6J>]&&-:\NR&">&:(]@;7<T?G)&KQ4FNYPQJ/QG%O;IA[HP>UT
MUS1J'\SLS_ .-,SC(521O<_*6A"663+\:I=H'25H43!P-(5XU&$NV8$[7>YC
MVHS#^PY =+OT-_\23L(BX<<OQ-?U3'H99?(&F- <E(D<8@DD=8N%I8PBI#8X
M>FI7?45X=A3\O4+$D:30Q76VV??[U3SAC+,D!&JD,X:B/ND5B"IQ",(HS>@'
M*;:Q>:[WT)=7-0Y>=N1P!_KFL?I(;^CNU3Q#EC:"<J8.,TXUVY(9Y:+7/O97
MFSI!SMD^J!F#]R,JF/;OHC?'S)U]_597&/ME]*DE6KV-#B;K,*^C*3N7HI)T
M(55(,F/ 23*K!%?9F225*6VFBTWQ.AHQ*IM+!E\VYT]Y")PY*)$QQU*2R-K4
MWA[?Z^@VN!CV.KH-\WM\'4UUUI-6Y*-ZST!9K2'XFHB2D^(:LRSXUQNEMI50
MGWL=W8;#1_,ZFFQ0VC,)W-=*2W)-Z<XGBR]DHW5TRB@<I&!?].OH5I+?Z75T
M&S'T_#K*G>>"6PZ)*S+WO%$094 @/\+DF+WPYCE3Z"6\CFXESJ&OH]OPM@-O
M[&+4<N72V\6WL]-/]'OG@PF=R9;.#,20$ZBDR"6H92C"\FBC"DSY1M6HC^RH
M+R]^]YMK5,YWBJ#+>N\@,Z+QY$S6]S\3&!TPQP&%0B^)'+Q;CMH00ST\E8XC
M\P% VD$ '4+IS8]OF,Y3];]>J%>K3$S*U+%F(M6$2UM#H5C;D"<N;/8JMGEU
M?WYO_4%K%Q0\ ZX]1=)%=/HN39LPZK\M3TA6)YOPV(8LKWB1M>D;ZAI6Y7R3
MQE ;P4GTA6OE\#!(>W![$]^&AP';_H+I$F\?YNM__$:FZ:4M\2&<XF7B0NU>
M*FHSDYJKIUP(X+1T(+30/&>?[;#LZ;U!]_@>)XZ+'P9Y(XFH#_@]^I3 O<M%
M!P%8B@.E7 +/N ;:!D8R:U.1;:IKCRI+8"\C?Q3>3QQ+>'5"G[,@*7S'ZT>C
M>P>1#(*9D4KX(BPXYPTH*^E/I1B(-3<]LN*-'M)_9O""?44S=Q3NLC6G.[#L
M!Q$V<XIG8>EH&86,5"M'\"$IX)S%Y!SW/K311X.VUU< 8C^PM9/+Q+KJX1?N
M-YOPWVJ^QLVKZ:;.7'+N()+)2"I=2@C2.K!1,FXYLBR'#-D<M%A?5]K^.FI\
M#A]1G?7M*:/7Y(^<4_#<,JWR"K8B[S"Y!8(</$U7&WB5ZTQ/PI"/A4-&NO^4
M4\HT<L.GR"VP+#I-+@0(M2F8H/L])O)HA'=2.?)K2J-!.,>76[ -+H;E%FS#
M_!YS"XP268KZZ"1XJ-U5-;B@/? 0A0ZNODH-LIY>5&[!5D)]+K=@&PX?36X!
M>JU5S 8TN;)TD"J';.UC8#%:=(P9/TCGO.C<@JTDOU-NP39BZ#FW0.?,C B%
M^%.GPPI1']65 RVR<Z;((*4=8%H?>V[!5N(<FENP#6\[</H?+PP5'IGG6H&5
M7!%WHH>(Y%IR9D@YJR)D:6/G'%7E]2YWU[B\[P!$#]3]Z8 H7+7ZG*L1>":A
M=@6#'$I(6CCOAF7#O>#*ZZV$_'SE]38<GWKD-Z[FN'[U;H&WG=D+%:J*U4I)
M#9YE!)6(1;XD"R[&S)Q-/)<XX'IZ>I7NJJNWDM^R"3,[4"6/Q\**R=H964#J
MP.EB-8QH*(SD;I6LI3$)VW0".:J'L'WNHW%XWP&('BNA*HE'8UD &XVKM<1D
MI6$*8*SRF=MBB,@F$-JG?&V"I[&MQ#VP?&T;WN\,H6^D"Y>D_LC0'ZGN>LCH
M4:-XR48FP"RJ]VD2>!<BY(B&914E;Y1".=Y(V F>Q/8!V?ARZ:=3\:,#;FU6
M=0PI)(Y$3>("O'<,?(Y2HM0RX?^OO6VDO+;A_9[*Z\WBYGCA1U_++GY0_Q'#
M&O_7?_M_4$L! A0#%     @ 8']A5'!A>+@D P  'PT  !D
M ( !     &EN;RTQ,C,Q,C R,7@Q,&ME>#(Q,2YH=&U02P$"% ,4    " !@
M?V%4P \>8"H$   /&0  &0              @ %; P  :6YO+3$R,S$R,#(Q
M>#$P:V5X,C,Q+FAT;5!+ 0(4 Q0    ( &!_851GM;$0< @  ,XK   9
M          "  ;P'  !I;F\M,3(S,3(P,C%X,3!K97@S,3$N:'1M4$L! A0#
M%     @ 8']A5&0""?=9"   F"L  !D              ( !8Q   &EN;RTQ
M,C,Q,C R,7@Q,&ME>#,Q,BYH=&U02P$"% ,4    " !@?V%4\A8MR7@%   7
M(   &0              @ 'S&   :6YO+3$R,S$R,#(Q>#$P:V5X,S(Q+FAT
M;5!+ 0(4 Q0    ( &!_85095[T+]C0    L"@ 9              "  :(>
M  !I;F\M,3(S,3(P,C%X,3!K97@Y.3$N:'1M4$L! A0#%     @ 8']A5##>
M]K#LX 0 ;%\M !               ( !SU,  &EN;RTR,#(Q,3(S,2YH=&U0
M2P$"% ,4    " !@?V%4@_+J\5D:  "D,0$ $               @ 'I- 4
M:6YO+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( &!_850X"YSL 3(  !P( @ 4
M              "  7!/!0!I;F\M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( &!_8510N*SIN:8   A/!P 4              "  :.!!0!I;F\M,C R
M,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( &!_853!(%7Q'BD& (<%!P 3
M          "  8XH!@!I;F\M,C R,3$R,S%?9S$N:G!G4$L! A0#%     @
M8']A5.;*9^!AKP, Y^,# !,              ( !W5$, &EN;RTR,#(Q,3(S
M,5]G,BYJ<&=02P$"% ,4    " !@?V%4PH5?BU78 @ 4*00 $P
M    @ %O 1  :6YO+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( &!_853I
M7T1CO8T! %C8 0 3              "  ?79$@!I;F\M,C R,3$R,S%?9S0N
M:G!G4$L! A0#%     @ 8']A5,N.@.*M<@$ \4H/ !0              ( !
MXV<4 &EN;RTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ 8']A5*#_00G+
MW   #AL* !0              ( !PMH5 &EN;RTR,#(Q,3(S,5]P<F4N>&UL
64$L%!@     0 !  ,@0  +^W%@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
